<SEC-DOCUMENT>0000059478-22-000250.txt : 20221101
<SEC-HEADER>0000059478-22-000250.hdr.sgml : 20221101
<ACCEPTANCE-DATETIME>20221101111621
ACCESSION NUMBER:		0000059478-22-000250
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		75
CONFORMED PERIOD OF REPORT:	20220930
FILED AS OF DATE:		20221101
DATE AS OF CHANGE:		20221101

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ELI LILLY & Co
		CENTRAL INDEX KEY:			0000059478
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				350470950
		STATE OF INCORPORATION:			IN
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-06351
		FILM NUMBER:		221349029

	BUSINESS ADDRESS:	
		STREET 1:		LILLY CORPORATE CTR
		STREET 2:		DROP CODE 1094
		CITY:			INDIANAPOLIS
		STATE:			IN
		ZIP:			46285
		BUSINESS PHONE:		3172762000

	MAIL ADDRESS:	
		STREET 1:		LILLY CORPORATE CENTER
		STREET 2:		DROP CODE 1094
		CITY:			INDIANAPOLIS
		STATE:			IN
		ZIP:			46285

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	LILLY ELI & CO
		DATE OF NAME CHANGE:	19941024
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>lly-20220930.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:1f63046d-a77a-465e-aed4-1fd7d331378a,g:f755fa79-e9ed-4360-88c0-9c62587f0bf5,d:5fed483d9c7e4f3cbba3a62c53226cd7--><html xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:lly="http://www.lilly.com/20220930" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:srt="http://fasb.org/srt/2022" xmlns:xlink="http://www.w3.org/1999/xlink" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>lly-20220930</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930" name="dei:AmendmentFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180L2ZyYWc6ZjA3ZDU1NzE1NmRmNGQ5N2EzYzgzZDUxMGI0NWIxNzQvdGFibGU6MDYwZDA0Mzk1MDFhNDAyNWJhODgzODY0ZDdjMDk2ZjEvdGFibGVyYW5nZTowNjBkMDQzOTUwMWE0MDI1YmE4ODM4NjRkN2MwOTZmMV8zLTEtMS0xLTE1OTU0MA_582a62c1-1ee7-48d5-940c-9bc41e37fa54">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180L2ZyYWc6ZjA3ZDU1NzE1NmRmNGQ5N2EzYzgzZDUxMGI0NWIxNzQvdGFibGU6MDYwZDA0Mzk1MDFhNDAyNWJhODgzODY0ZDdjMDk2ZjEvdGFibGVyYW5nZTowNjBkMDQzOTUwMWE0MDI1YmE4ODM4NjRkN2MwOTZmMV80LTEtMS0xLTE1OTU0MA_d1904b85-d2d2-4d0f-b9cb-92fb32c5a711">2022</ix:nonNumeric><ix:nonNumeric contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180L2ZyYWc6ZjA3ZDU1NzE1NmRmNGQ5N2EzYzgzZDUxMGI0NWIxNzQvdGFibGU6MDYwZDA0Mzk1MDFhNDAyNWJhODgzODY0ZDdjMDk2ZjEvdGFibGVyYW5nZTowNjBkMDQzOTUwMWE0MDI1YmE4ODM4NjRkN2MwOTZmMV81LTEtMS0xLTE1OTU0MA_eb986dfe-7a49-49a0-a37d-1798f409ef8a">Q3</ix:nonNumeric><ix:nonNumeric contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180L2ZyYWc6ZjA3ZDU1NzE1NmRmNGQ5N2EzYzgzZDUxMGI0NWIxNzQvdGFibGU6MDYwZDA0Mzk1MDFhNDAyNWJhODgzODY0ZDdjMDk2ZjEvdGFibGVyYW5nZTowNjBkMDQzOTUwMWE0MDI1YmE4ODM4NjRkN2MwOTZmMV82LTEtMS0xLTE1OTU0MA_3c9cc8c2-a16e-432e-92f2-c55e9d7a051d">0000059478</ix:nonNumeric><ix:nonNumeric contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930" name="dei:CurrentFiscalYearEndDate" format="ixt:date-month-day" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180L2ZyYWc6ZjA3ZDU1NzE1NmRmNGQ5N2EzYzgzZDUxMGI0NWIxNzQvdGFibGU6MDYwZDA0Mzk1MDFhNDAyNWJhODgzODY0ZDdjMDk2ZjEvdGFibGVyYW5nZTowNjBkMDQzOTUwMWE0MDI1YmE4ODM4NjRkN2MwOTZmMV83LTEtMS0xLTE1OTU0MA_c6179d16-4bd6-492e-8406-ea9ff242a47a">12/31</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="lly-20220930.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i71f35536970d471db55131eae57d8a56_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i928ac777ff9b4d2c901021ddb94de4b4_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A718NotesDueJune12025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i47d1aafe63fc4d6a8af84bd5fc7ec42a_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A1.625NotesDueJune22026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifbf789a7a75f4a94b1ecc8e7f5692048_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A2.125NotesDueJune32030Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i37d6cf7d3d9642f7887a8b59cb2a9056_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A625NotesDue2031Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia2c9b0358abd4ac1849fbad87ceaf6b2_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A500NotesDue2033Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib18e156e215841b180cc7996ffae9682_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A6.77NotesDueJanuary12036Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i80ad5b0231594dcca53dbf943886b1f2_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A1625NotesDue2043Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8e27869f09004f868cb336c53f59bddd_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A1700NotesDue2049Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i94f283ca5ff741c39e115f9c18564a88_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A1125NotesDue2051Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b0db4c7708642f7a34b06aae1404242_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A1375NotesDue2061Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i465e2cbbe1e444108f9f7bdae9a93ca5_I20221028"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-10-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i19fc0325c48543008ea71e1fdcf11d86_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="ie4fa4f6b472a4f269297591b44aba572_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i167ed8f67bef48c49e54fa466400cdaa_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i08ccb35f6ad24d7793c9c91b74ca2ea1_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0973ba0c1d894ceaa494709a13f814fb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3ff8d0839ef74b87b0394c920e9dfa82_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic9a5e6caa6224a1a95516222bf3644c0_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9fbf406305be444e87d56294647b476e_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iab7ebbcbace541c5b7a8ee0e0e859b97_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TrustForBenefitOfEmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i19336abc2d9f44a7a6562598fdd26074_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i880a0df9a6d245b9a11c009232dc11c9_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4d264417b4674277a12ca8c8f571f6da_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ice03038a88b14398a99843ecea77cf17_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i37f1eff7c147431d9904c45abe8087de_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i28729f1c595d49408f9bc75addee5dce_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieabf4a292fa6473cb378b3091605b996_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia0caea5b6e2742c49986260609ac8cb2_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d0c3b9efde1461b8e305f2507573310_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ied5972defca747b08dfeb7847dcbf9b1_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5e2b4f10aa894a52a243db283dd48374_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5d24641160994798813313583b8c5313_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TrustForBenefitOfEmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib38bda0500864764be978f7cbb680740_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7b19ed61f4414f2e89fb8677352c10c6_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6809dd88ee6440e8b81974c0682727a5_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id1796d16ca7c4cf0894522a6f064e12e_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia172fdb106784793868c32f3fe4a033a_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i13cf184e02084806adfd29b238e3b85d_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i044825e6cd0d4decafdaae3baf84a330_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TrustForBenefitOfEmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9cff35c3c8c34c0fb04c18abeacebca6_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i21c6412f9d1948d19b3452207237dadd_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i28fcba67335d4eeeb35e767ac7467d7b_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib48f338ea64a4a6ab71c4d7e3fd06673_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i55ef102ce6314f71bbad20789a340a44_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idb26ceb80a3d4067ad9572aeb3904905_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i97b74653944e4f17928c61ac64c196ad_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1b27ad5aed11494a84032093fe25e25c_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5c81da162e9a42e2a66c2c1a06d48dd5_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ice411cf446b842b893447accbe09511a_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8ebf10616d0b4419a14703502b215705_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i422ef8f62e714031b35d70b78011fe07_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TrustForBenefitOfEmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i405731ae56194b5ab8d7ef0f5a2a4501_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7890664142234b2cba495545e31cf06b_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i874cf6e76f6143ffbd4b62dbb7d9d39b_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9e4e65510f9e48218be4e6b56cc6a8e6_I20210531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id40dc90365d54458840dc95bd54da311_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i13a4d036feb14d029728aad2602198e3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i89632ef2fab645e59b17e0d04998f005_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i03ad855e73c7425c82de6d5bf47f2c5c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TrustForBenefitOfEmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0f26207c7675459eb15f8af1fa1954bd_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i475ce37d989c466ca8d104299897d8b5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idd150ac2b08f457b820ab337af8f787a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaae84e0e259740269afbdc32023935d8_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if4b3bbe2d1454aa7b635ddfa117d7690_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i53f6912753594605b21dd0402024a8d0_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0f7811d1ec7f49e2b3619fe9097a5c81_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i43c09d3fa78d4c5e896029e6ef10d475_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieb70d5cf9dee4eaa8c659c22eeb4ea9e_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i272cf8c25ebe4484a64e58f12187ad1b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibf8140dd5b59491da9ea91218accebc6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9d075318dc464943b61778b509358518_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib1b20bf098e647cbbe9a5c1797e3b7a9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TrustForBenefitOfEmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i016472e8315c436a845438f1b48dc880_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i39c60ea04aef49b0830a61d60786759c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9a1a2f4319ea49c8a9891d557b01b308_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i53fe950833774c68a3cffa46aff8f74b_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i78ac3ae89d8a4e4b9b5634d9c24f6a88_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i318f185707b94171a8496548525b0a43_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5fb9024f659a4c12b2ddd5ecc6dd8e7f_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i668d06cad6064c9488359f57b6460125_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1e65888bb572465d96d1a55aaa12d167_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i82811f99128e46738e63b2b2f09a72ef_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5fcc694940794a94a960d8f1f9315381_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if42877c131ac415eb21599c372b78f90_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i80d1b089c2a644458859200e15f563c8_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id3dd0ce52c8549c58e5d29bb1bb1c197_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1962268fe5e4415bbcb7e76b2f694425_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie24dcfd7665d4948a6b3ea63d1979c25_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CollaborationandOtherRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i28f16eccfa8b45c9b2f74cc6235732b4_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CollaborationandOtherRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3ebb89e75b934815a2a398afa3315ad4_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CollaborationandOtherRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0707295b42774a95baab2b522f5925a8_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CollaborationandOtherRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i34aeabd3620f4de8ad8c2efefc863807_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia0d2323337da484fb1444b8262ff7a7e_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i16836baff9c344308700232bb53196d6_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib6db6b88271640b7be37a4c3c9f838c6_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i46e52d8ad0e14ebf9fa7c9ecc503bbfa_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ChangeInAccountingEstimateByTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i72b37618b2b848e48b6d7a66628d0ea0_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ChangeInAccountingEstimateByTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i19f0f8e72ada412eb34eae9afa79a051_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ChangeInAccountingEstimateByTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7685d8873a9b40f5bab0b11fa36b225d_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ChangeInAccountingEstimateByTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i28a49a83c479441f905c7cffa76d0d1e_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrulicityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7ce64df6d312430cadd360079f217dd5_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrulicityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i345b235e6d564f1bb6f06b9ed8319a72_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrulicityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i89ca472eabec43fd814b3653fab15181_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrulicityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7bbccd7a5a8e4837a3a85f1a2b3d2ef1_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrulicityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i46a90cbffcd647a5801317b946ab5209_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrulicityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5546f63545a844a085ff12b7f2497571_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:JardianceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i348983749551494ba7808729a9dd6254_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:JardianceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idfba5b60fbbe4370bad16f003f72e3c1_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:JardianceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i669b22e2d64c487fb8bd01c345ab7f38_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:JardianceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4ab46b2a51674189a54630451735b250_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:JardianceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia28641f7c767406eacaa8089e13a2e77_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:JardianceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i233675fe0cc34caa880f2ae73fa95cad_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumalogMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i404df183ca794e64b829a2993c89673f_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumalogMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6069340928544f1d98e220d601c0ccf7_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumalogMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4b145726bc2c4ed78a3c2ec12b53c5c2_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumalogMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id28218d7550a4cf4be526f83ae1c7332_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumalogMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie59d14500008412ea099e2c09441a042_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumalogMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib99bd175ff46428092a6e96c970b94c5_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumulinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i644d2f1188e14878aaa508d910b54dde_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumulinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7cc0d4df5329427cb7da48ad36cb2efb_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumulinMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i02d6e02b9e20402bb506e5e37520efdb_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumulinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i40d7116b6c0a470195c3ab9234e5bb0e_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumulinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iec80f91e475941f1abdc131fd14d868d_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumulinMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i529518415079475fa56a8916e119480c_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:BasaglarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie34f0db27136443ca391ec67d20f46cc_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:BasaglarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id6f3b41d10de4dfb99b809554e15f4ca_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:BasaglarMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idcd8ed6a0f624997876200ae1a53d3ff_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:BasaglarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1981e978a66e4861b39ec95f950a699c_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:BasaglarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieef95d1c0c4643f8a5a104c9301c56f6_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:BasaglarMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7992fe4fc5774bd6aa8b55cf4d326364_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:MounjaroMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i47be57988ea94c92b33e106ae820b8f7_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:MounjaroMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i22fcf936becc4b56b4c435b41fdfd4c7_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:MounjaroMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i866b02b106bf4510aa3acc82ee4887a0_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:MounjaroMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i99914bb8f18546f78ea8cdcaa7af2939_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:MounjaroMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9094ecfcbf9c4d8bbe63fc38a5f24df0_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:MounjaroMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iceaf7dbcd2d8486cb982fc3658598e56_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherDiabetesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i05fc368927fd409998e10fd8a8626ff3_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherDiabetesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iadb96dab5219493a8a09e4ef5a30b381_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherDiabetesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i26f16b68de674d2592c2cd9ee9755295_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherDiabetesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib4a6a3281a6e41eda8915c8ed31cf4c4_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherDiabetesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib01598d835464cac82cecfbe826de92d_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherDiabetesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id8862697b08648bcb4c7b9ad3dff39c3_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:DiabetesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if00d7a9221f04fe68817babf35f51ebf_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:DiabetesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic1a606c172db416288ba0bbd8baa9966_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:DiabetesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9d79583b71134ad5b1affaf7d3c9e867_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:DiabetesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i74d4b85fd2a346fb93493d49de1c2bce_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:DiabetesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i42ad32bd431444b189dab3e866f14dce_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:DiabetesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c515dd1cd2b453686e3e31d8c9a32d3_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:VerzenioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id154bceb5f3a4af7bf7c046f1608e110_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:VerzenioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifb827f745b3b446f900ce979a433b71f_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:VerzenioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1f8a0004521c4a0ab278bcec0c67c5bd_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:VerzenioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaf75ab0eae484bb4b01f61ae25f750c5_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:VerzenioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6b3d0e422c9640ab9313c19640d9fd90_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:VerzenioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i46e236388c73464e81b03a5d53c0dd53_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CyramzaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5b6d4e4158744aaa95ee5bf00acb80cb_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CyramzaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4c1435377d2042d39e6953c271d4585b_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CyramzaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i176af1ca7219458c851326db4f5f0e18_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CyramzaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie4ca284b63654c0bbf5fc3646e324b1b_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CyramzaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i48871c7176154dbb971dc8a40b431eca_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CyramzaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifc30105eafd9459d81eaf411eb4da357_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ErbituxMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i84fe5c0fb05340ce93ab592130765d86_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ErbituxMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i75db1e7f9d154c588f6bfd88b08dacf2_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ErbituxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifb220bd49b9b4fee9a08cf2aba4811ff_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ErbituxMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if441e31221c74fb7b06ce4acda75a1ac_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ErbituxMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i74ebe2d40f834c6aaed2f9503f82b5c2_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ErbituxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i51fae75c655f4c9db22deca064e1d22a_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:AlimtaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i814e9ebeca8f4359b602b1c4116691fa_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:AlimtaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i093d47ca61034ea8b9f0303b73074f6e_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:AlimtaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5b8a2c0676cd456a958892b0fdc5f275_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:AlimtaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i01f53de517814e9fae0973ed84a89508_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:AlimtaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i91b98892233a42579bec90b2f1f07fad_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:AlimtaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i578736c37abd4751958301e188d9a111_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TYVYTMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic105c32b09d5439ab48f1ea47e388e5c_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TYVYTMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifc8fc5f6c1924a46b0d88ad7ea894f53_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TYVYTMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i326cec97451b4c0fa64fb496bcc0d262_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TYVYTMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id6f0f8b1cbb14fe5bc88c77765723cdc_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TYVYTMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9da960751fa245d8bf93fa1681ead439_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TYVYTMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4280b008d25146138bb9937941f505ac_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherOncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib83a82fddc51484f973f835759a83951_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherOncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7add942c6a224625b4aa726843340e48_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherOncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i010a412d535641f895d21d4765b984db_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherOncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9a1ab61d480a42babad1c189210b4f6f_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherOncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3d24e8995a5a4ced9875b8b9174e8096_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherOncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if7ca1b1b8ebc4b97a61e679591aa9aa4_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i98dec2ee927948db8ae6249a13fbc06a_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idacb7a7257294fe689d448659352e301_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i573f860cee384e44a092723fc9aaea21_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic45235af254e414c87819d6a61117897_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3490b47c9d914a7a80f4c441455b8ead_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id3ed2240ab2944e1a3695929ccce3c61_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TaltzMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iec46bce8b1474abc9815b6e1b2d7a169_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TaltzMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i800167f3776142a4bf399d8f51830c78_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TaltzMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia22b346dd2a54714a0f4ba483559b116_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TaltzMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0852df9f516e48b4a9af370971f46a78_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TaltzMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia60c521d441f43a2b5801e09809d0abe_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TaltzMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i16529d5d29744762b0746672c1ef5cbf_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2456bc73ed7d4b8b8bc891900fd86004_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i65843c3594444a24be3c2dd715fb25e8_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idef6b1951baa49b98d6da883dd4d89b9_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia1eb3846894a440d9b3b08cf8304da43_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i342e7e7b465546ffa22256042c6bf573_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id0dbce0c2a604a12ab2550f876430b73_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i32547c688b2942bb9648bd77d09fed5d_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic666c0215c174e0da07f4d1e09afbca8_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i24578a0bb60d41509dae6c91cf840cf4_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i797465f9dcae46679ecb0c162248cdbf_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i01bedd14598d4bef97fe5433a5abe2ec_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0bca0633651d410a8f37cdc991be5df2_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0952e420996041498b88ed77f880c508_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6386f383c2e5484da28e805bf356222b_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4d8dd9cfbda345988f0d1cea4fac4546_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icff9e13bc98e41938e743e7a4e4fd6de_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5adbec8a8b6b48f7a5d1e48f49bf3411_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i358dff328e02486cae97aaae267517fd_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:EmgalityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9c4b3d872761408cb58a702f02c9d3dd_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:EmgalityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i88720be3d2b447b38eacb349e966b957_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:EmgalityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i306f66892e60463a9440dd8625f955f2_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:EmgalityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i830b5f4dd99f475f892c9b95d9c74688_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:EmgalityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i04f1fa38b33d409c95edc1ca5dddc792_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:EmgalityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib3165ffc22844091b6dfdb6536ee8f81_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ZyprexaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i93ab8179e11b4f23a7909ff2a1a2042f_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ZyprexaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia17da4c4f6b642d596703193f6afe6b9_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ZyprexaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i870e9a03322b437eab5ad616b9b96c9f_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ZyprexaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i119d9834ae424e7fa424cf206e1fa0fa_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ZyprexaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9028e0822d8749e59ae82cba528438af_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ZyprexaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib6ab25c06067493bbca70a4e7597fdb8_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CymbaltaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i85be7a9452cb426a90fedddc2f455b01_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CymbaltaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2b6eac789003419ebceebcc13f624925_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CymbaltaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibd3368429e0140009581d9d510f8d8ff_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CymbaltaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i734fc13568954b75bd88b7375fbfa00d_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CymbaltaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i53769ba188564f8a86965473de7ac7a2_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CymbaltaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic8c180d54e944d17bbbf0438a4c8f563_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherNeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i31bc9c1361964102bc7f26ff4a6390ee_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherNeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icf97b2cc85a442f5bc488f333e264c43_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherNeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7434dc344c6b4a99973bac3fef8d4f3a_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherNeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3ed4e34eaaf642748b03cff5ec59a742_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherNeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifdd2b94511c147b0aa78edfbd1578f35_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherNeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i75c76b5ae8b04d0694593c6b670f2a70_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if373b9f49fe74bdbbcaeb90bdcf2de8e_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1f4a20a3083448aabf8de47a307ae3fc_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9aabeac82be44155a967c8ced0c3a972_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6d31ef68d52e4c1680dc7d71063a6777_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6cb7b465f1794abdb49eb28db9903a03_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0fe5df95a127467ea05981672b21cdba_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:COVID19AntibodiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib4b9aa980cc940d3870c8d9e4046840e_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:COVID19AntibodiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic89265df487544d48f864b30c7c12762_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:COVID19AntibodiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i136c9d207de14e89bbae2b72e3112e4a_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:COVID19AntibodiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic05b3db77dcf4e66b1e09c07f79fd579_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:COVID19AntibodiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i05b4b2fd75f8488cafa80162074dca18_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:COVID19AntibodiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i78e14fd2e59849538d2032aed3e9bb0c_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ForteoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic73ca51c96f5471cb91194277c299762_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ForteoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i29d5f03b98014ea7af366d7dbec08cc2_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ForteoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5b6529d5d56e42959333a8689a171264_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ForteoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i99005918fc524bff85805ac964cb5794_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ForteoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6ec8ff4aa32b406db0037636d5d11b91_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ForteoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id253637b6dc04f4593c5389197fd1ed5_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CialisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b5c45eac140477aa0acc064ef0011ea_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CialisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i57e0cd27dd3c4483afca4b02ab1ab2ea_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CialisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i71526b83a9b84d10a6e1ab1807ab8e18_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CialisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i04e727dddbbd447c91777ca002cf2367_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CialisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i01198f0de24240588ceb005e3647087b_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CialisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if0fe66e11e054c0a85bb68ff7d7f2857_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i347c502b181c4a13a94b72d8e2a383bf_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic32c291337714cc290c1dac418f4d40a_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4760c4e663814ba4816919d7cf1c133d_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0b57a14b81924b58a902d121891b42eb_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib28a57467090415586ea5d4a46d5a6ff_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3bfde2172ab44bdb98ffec5b7744d66c_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductTotalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4e976e03f8b7452b97fe7c6fa5a98acb_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductTotalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibb8a914c841d467289183242e217e8c8_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductTotalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i23b21b36e578436fa92bcc41739470c2_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductTotalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibe9720e656b242efa27c155f58ea5690_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductTotalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9af8cc7ddb614c4d8a4d4ce694795736_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductTotalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5ef4c6628ee44bfaba7f2e062c3984ca_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i553eac0570bc41a68be3130cb9383387_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib7200d1730974b7f929910230bd89187_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8bdc66e6dc0c4330955f23ef9a18d769_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie25d63c812ca4ba5bcb202b4ef3da925_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrulicityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i91615b3923a04f6a8fd92d711866d588_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrulicityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9623881a23db40a3b62885fe7a43e0c9_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrulicityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i46ce2dc33fb14a94972b38a4c73c48ee_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrulicityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9d256a84bdcc43939ac6114642c9df5a_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrulicityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idb96fc34e7f1409fb5661213f97e7f9d_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrulicityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i29b3721d52314523b933748df1c86126_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumalogMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i50fdff0f3f64436b8220edeb6c5da6b9_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumalogMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2bbcd6ec5faf46bc81ff607368bdd5ab_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumalogMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5f2bb68aeed244a48b9a5b9fe2b0b039_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumalogMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib6a78f62d5834a11a82558249ee89a7a_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumalogMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6afc7019eb204b20bc59d3a19fef7f74_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumalogMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1e18d072344643ada09a2e6559995804_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:JardianceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idb016f4e6a094b91ac0aee6fd832f15c_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:JardianceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1c01691865ed49fc84902886c99bbbdf_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:JardianceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia2d8d981e4314247892b22b49b01d418_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:JardianceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie65c118c7eb54da8b92e056d23b07e85_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:JardianceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i46099dfb95b0484ab5891f186d350f52_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:JardianceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3ad9a3d1e7704c9f8a4c92e4f18248ef_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumulinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib4c358f120c14431858d22fd921cdb1a_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumulinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i97453ba9a92b4601b70738c5fd865a63_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumulinMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9a4be59d818242b8a5d6e29a133e78b3_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumulinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i74ac58ad376e44179242350ff8091245_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumulinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4d442db3854641bb9c50b1533223b1bf_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumulinMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b84a7f78d3743f383680162b1a79677_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:BasaglarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if1fd51de24bf4269a3f10390a0eb16b8_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:BasaglarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1f95ba5af9c24c3eb20dc2c5a3979588_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:BasaglarMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9df6a30c7e76498dbe8e2c10556551c7_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:BasaglarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifc6cb890a5e04ad3ab5d2c0f4a2935cb_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:BasaglarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id065d1641c8b4bc19bda4f978edc7f70_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:BasaglarMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie9c6e93828454ef795aef5751d0352fd_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:MounjaroMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i844e2c3c4d3c4a4eb90a291b6edaa117_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:MounjaroMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8d0e3b68ad424288aedc96a1c3c5e2d2_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:MounjaroMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibd146a846a384a1cbb7ed3016e2cb317_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:MounjaroMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idea0b040a90e4c93ababd4c0d4f02647_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:MounjaroMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie993c12313da41f38573f6bc42f10868_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:MounjaroMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1ed26a3d9a8b45559192c48d5bb034d4_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherDiabetesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4cfbe889964e44e3a453aa644188647d_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherDiabetesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1414ede1c78a462e95bd1b8346592f8b_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherDiabetesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i20194883f2624f82b663260d5199fa21_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherDiabetesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i820e5b799761449bbbf32e97e1e019fa_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherDiabetesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iab636b5286134cd7875bd3dfdf73353a_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherDiabetesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1356cd272fa54029ba0f0c21fab222b4_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:DiabetesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i19fb57248d6f41d19ef8485870fa08f3_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:DiabetesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2a4c43c5e76a47ceb09387d84fc5d358_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:DiabetesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifc6e032f5a9d4001ba9413713acf7354_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:DiabetesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iabf6366b8c134597b8ac64603a6cb066_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:DiabetesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i44a3630aeb244ec2ab5204f6c1650459_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:DiabetesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i630ed70ef3804cddb8e7bd6a2c884284_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:VerzenioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id50357546429495db587cbaca50bd352_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:VerzenioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i20c536a6925e49838b17da59e54c92aa_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:VerzenioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if8fd3622c0c34f5f942c2bcf19a84b1b_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:VerzenioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i08e4bcea32b741f3ad619cb7789236d1_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:VerzenioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6ea3180802c144d4924a8a4b8a919abd_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:VerzenioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia0759c0458d14fac885984f8686a83c3_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CyramzaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i234acbdded404fc5bcf21a6ea711e9ef_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CyramzaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib28d65608ad54ff9b7e45a5c0298b338_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CyramzaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i98867991ccbb44078d309a9dd8539a71_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CyramzaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib811fbcdfc1241359475319e63db4106_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CyramzaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieb20b9b0be4f46bfb05c7b12f39a6a9e_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CyramzaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i64bc0872b6e94aa7bf69b1268d189134_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:AlimtaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id1a6ba9c9b6a42638bdfdbee6e6f2758_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:AlimtaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i07ddaa6f5dd549048da689638ae982f5_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:AlimtaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9571c6749464454692162cefb3bb7738_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:AlimtaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i546701dbe3cb400c84bc62c598271f8b_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:AlimtaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i70cb0ea9b68f4680b98801d50a608b14_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:AlimtaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i40507b3da3804796ace099350f243c27_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ErbituxMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i680ed22913654e2ead217f9b5989504b_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ErbituxMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0088a078fdd54003819037635cb52f70_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ErbituxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i27e99c349c3a48dcb14b9a15ed3dafe5_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ErbituxMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if0246564d9bc4f02a5441b1f2566bf51_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ErbituxMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic3c22691b22448eca997f30d1f1366e2_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ErbituxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0302245b5cc5492d85c394bdbd9a59c3_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TYVYTMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iab104518f25b49a4b922a68ba94e910b_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TYVYTMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6633f1ca883b4a32962bcd825ba66bfc_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TYVYTMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6761a6ec70464bd2bba2e8b31d7dfb55_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TYVYTMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i68cac27afeeb4c6ca2de0e2af5aeecd2_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TYVYTMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3a42a2407e7046519687e4401e714180_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TYVYTMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib89a61de2c8542719d727ea9b2e4d288_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherOncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie1753f6d5c4044468226ef9a5f59457c_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherOncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iffc444b9d88245d5a3bdb35b82ef0d55_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherOncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i85c317c4af504382b28dfedc3facb2dc_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherOncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6290305d31574c06901b06e6eacfd414_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherOncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7bf748b95e7a45cf9e722167434f1385_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherOncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i240fc921c5ef4622986756418d0b3d39_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5db5d222d3da4495a3cd1481fae9b1eb_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id3038a6b1fd04b43a1855095f482ffd4_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idf34cf4a2aae43eda96963b778a49168_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib71c38ea0818475aa548176344240c72_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7cc9d1bb283d475d915f7fcb4f945c8c_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i08907695f17c4fe487c0f59792752c89_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TaltzMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4d2d7d0cc9e04232b6d62adfc3777b93_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TaltzMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7453a607ad674e25bbab08ef19e88d3c_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TaltzMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iccd3059fecb04f1d94d0044c6e3c7e32_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TaltzMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3036c3ea47bd4c89bafa4bdba1320abf_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TaltzMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifea4d8eb21b94b0ca8248b42f02b49e9_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TaltzMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia4036604f9c945e1a19be8b3aa38e334_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i381560b71db64644aa7adbc056fac279_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5da2c0b8af014f4085d9e2a62f64ccc7_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9a1215ba2eae4c7da8010b728800b4d3_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ife8cad1b8c0f45d89f7c79beb6a9506c_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i681b00cc06e740d5afd240016ce29efc_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8cdc5308202645dfa9f06b53e46a162b_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6010298ee7bc433e8bebac5a5efc972e_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i659d2c39bfc34df8bd9f7d944a3822a2_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i61df0f1a279148aa9e8254f5980c32dc_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1e4c4171e5c3493aa1885a72fe4cfa14_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic9a4f1d7373649528e8dfb81328134a4_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibb0659e3898241ecbd83bdbf9dc59c78_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4e251958291a42a3a1c5447458b86d15_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8aaae8dc85e144a6a4bf886fd061d950_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2d035bb38a454213828a14551e6edea5_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i71c9047535fe473ba6d96eba16066ad6_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4cef6079bf0146839ee9f000bdcfe3c4_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaf50cba6df584b358ccfd1c552ac603a_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:EmgalityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ife6ede2d6f41458f8f350cd5f6ddeb17_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:EmgalityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0b7c20f1ff97494783d6f4579ff8f7f8_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:EmgalityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2892d650df3349fe9ae882f6ae942d58_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:EmgalityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibc4bdc96c6434cc8b53a24c987e9c41e_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:EmgalityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d73674530f248b5a702b835849253ef_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:EmgalityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibd5454cbe2de4d0ea429015722b20f15_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ZyprexaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id7ad299a8b764bb9813cbf2dcae42919_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ZyprexaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic3a68db7fa3b428995899c0bf854ba94_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ZyprexaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i006ca6ec8c3c4717aef2b19d419c92a3_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ZyprexaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib90b244e7d0040c68677396984559ec8_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ZyprexaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iedfe879bea3a496bb3766920c821c198_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ZyprexaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3f91e524972e42a98fc9b5abba31e458_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CymbaltaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic3c6fe2019a042c4909c317b26cdf477_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CymbaltaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iee5d9669f4b344499cebdffb37f32030_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CymbaltaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3f307f23d1de4f80bbe2e59ea610ff7f_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CymbaltaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i526c0b4d4b3140cfaf92e5209854bd78_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CymbaltaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i733173c6b1a342488769f27288f96647_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CymbaltaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i00d29df7fc444a888bd8f1ac7c7fcd63_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherNeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id5a61b3abda849d981158a33cc123750_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherNeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4894a69792984d28b5bd70bdcb925593_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherNeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2af7293d556c4ac189783fd3d7bfa089_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherNeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id7dd70175fc2484e9291653ca9b5bcd0_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherNeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaffd646b91554c9fbd55b7373a9ab9f2_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherNeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i177e8ff27d1b444d8032f9fd6e71b86e_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i20063c304d1142018b211b53b3a1c50b_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7a5789bb5ddb493385ae07bb301aa500_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c8cfb5bc4ac42dba8e3851f39bd2683_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib59bf69a9b284970b3b6642f7e4b795c_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i84bebc50684e4e1b90500bbb83bb79a6_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0e5b50746e074ddabe26161b8cf97195_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:COVID19AntibodiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2ce72c9f883a452ca19b57204999df16_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:COVID19AntibodiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie674d270134f4cffaff8f7a15471b73e_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:COVID19AntibodiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i62f7a17973be46d9bf4530c993775bef_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:COVID19AntibodiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifb238d01fbaa4761a5fe7a7c91587c74_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:COVID19AntibodiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic06f11244a5a4b88822809b3b3941ffe_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:COVID19AntibodiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifa18b54c7e0f4330b37b5256dc5dffac_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CialisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8a49509981cc41bbafe688a08ea538c6_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CialisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iac7de63087cb4fa28c15d4fe01f12460_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CialisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i80c0d99bb34b42e1adce6dce3134630a_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CialisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6dd390f6ff6a43b49662e266d7334459_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CialisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i51c31c17a15244248305698502760153_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CialisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3c39dd39688f4abb8ddb719a2260f6bf_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ForteoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i56ac4d65faa946aaaebabc3dc7ca99f9_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ForteoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i185dafd0ab80405eb3f78281a2098c9f_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ForteoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ice1d37ac1886488088492ea4c957a118_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ForteoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i33b45d6e796b4bab93b3906f52ced571_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ForteoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i606443bf75d84de3b93c88a5d2c2a9c5_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ForteoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i62be4d98bd454dbea6bd3764ddcdacb4_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i774d30363ab447e4b7b6985e99b6de0d_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i238722e1d54440828f51f9f11854afaf_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib4554ea5474043e5b51ccd4cca5610ae_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1a25265d56d04bc481727001f1d55ecc_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1fc264d1cb9b42cd927c0bbd387866cc_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i13e5988f996e48299f0ddef7dd648213_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductTotalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3b007283f3094ae08f3a1b5eca4a7fb8_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductTotalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5b6298a19c0a4c5da470fa7e5e3e967a_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductTotalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idcc7138275c74437be6ca40f1474b509_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductTotalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7efeaf621a9e448fa08571db01806cd3_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductTotalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7fe3dcab54b44eaf90f9f242c2fe0f52_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductTotalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i60c5eb8ff51d4d9fa0a74c53c73aa0dd_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if326645430854a2d9ac96495205c029f_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2783a40327b64633b6abee19f7b4ca30_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9ff1711a07ba45ffadc911d350d44f94_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i812f3d20a1af4d92924e0bbe1371c71e_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i973b61d370734fa5bcf42303b4a667df_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4cf771cc163e44ed8acdd62a65cc8b4c_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id0ffca9720f342dbbe64a17e04c55d84_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib92bd7160fd94961b7bba02ffbd18490_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i25019079a8464a91a3cf96012fcc0d52_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib37e987842e2478dab07f58a5f789a49_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if9ff4ce3b7704faaa359e30df99f2b54_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic678bb62bdef4faea88b4e3dfd6a7971_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib648672815904a56b3a3874c085884b6_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id085508ee8c24a36a655eea7d3096500_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4b2b1ef297534a4a801da2637a1d37e4_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib2c80ff08a384ec7a8c6dd07798b9efd_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">lly:OtherForeignCountriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i59dcfcfb04c94ad588f473c50147a921_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">lly:OtherForeignCountriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i20e09a0b7eb34ffbbc4057f306b92c3d_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">lly:OtherForeignCountriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3c8b51c823f54bb1a2efb0592f5476a3_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">lly:OtherForeignCountriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id1a51594b8b04df48cf5b7eff20f7e6d_I20210131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:PrevailTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i28f89248cda04bd08a5c9d722de7c1db_D20210101-20210131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:PrevailTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="right"><xbrli:measure>lly:right</xbrli:measure></xbrli:unit><xbrli:context id="ie6db4c7ca7af4463afc62347bd8b3a94_I20210122"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:PrevailTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i10a5ee4bd0c64813b300c5389565a056_D20210122-20210122"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:PrevailTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-22</xbrli:startDate><xbrli:endDate>2021-01-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3b190c0fcac94cb9b4d37191d35b87bb_D20220201-20220228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">lly:BioMarinPharmaceuticalIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-01</xbrli:startDate><xbrli:endDate>2022-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifa2b520f9b26403ca1dfc59f5150bb2a_D20210301-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">lly:RigelPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2a70d59a929b499ca4d9201b21544293_D20210101-20210131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">lly:PrecisionBiosciencesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieacc700b698842408fe2f8c736054aa3_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:AkouosAcquisitionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7d940f045f1243808212f82e48b91487_D20221001-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:AkouosAcquisitionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if142129c01ca4ea0b352f378c8bc9899_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:JardianceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i744124019ee24c83852d6d07406b514c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:JardianceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8a19b281bf8a4f059256a5bba91d053c_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrajentaBIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic00807c6a67343bd9b77d66d8f53542e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrajentaBIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie2eb6b846c0e477a94f57d35ebf60943_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:BasaglarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib6657690bf5241ba82f0d73292ac9ea7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:BasaglarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i91e1bea218144eab958a68c72b25b13d_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrajentaBIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9fe7212a81994bafa9e83b419cfb489f_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrajentaBIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4cbfd23e4f9c474bac8535d65c4695e8_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrajentaBIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i57c459014f2c4c2797423bd9e7eff879_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrajentaBIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idfc0a5f22fb44537835f6510caaa9fa5_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:RoyaltyAgreementTermsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i46a25e2e10224815a8f7d26777b2eb48_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsCapitalizedAsIntangibleAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i445e64ca4f7041e49970bead926a789e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsCapitalizedAsIntangibleAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i97f0fe2e404740069df426fbe933ed1d_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsSalesBasedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia361008dd9de45979f0de7611a5df845_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TYVYTMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsCapitalizedAsIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9f82e7316ae6411ea23d0347aa8ad8db_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TYVYTMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsCapitalizedAsIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8e3c0bf77cd749d8b6fec828c354954b_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsSuccessBasedRegulatoryAndSalesBasedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TYVYTMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">lly:InnoventBiologicsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic7d2b40b9fc943b9bfb247bb3c25f43f_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">lly:RocheMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:LebrikizumabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsDevelopmentAndRegulatoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id7f02cde7e1c419684772d2d99dda277_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">lly:RocheMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:LebrikizumabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsSalesBasedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9e48d839c4b14a2e953d735b3bb79f88_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:LebrikizumabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsDevelopmentAndRegulatoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id39a445d06074ecaa26735263645cb4e_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:LebrikizumabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsSalesBasedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iae28a429ac4b40e2a498a65c7eaaedc6_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:LebrikizumabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id7a3c615db604cd2baec39887078a8e2_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:BuyUsDollarSellEuroMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="eur"><xbrli:measure>iso4217:EUR</xbrli:measure></xbrli:unit><xbrli:context id="icbc49bb61efe4f65ba8c0e7f0093e86a_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:BuyEuroSellUsDollarMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i77c728fb616a42cc8c6b40e0bbdd95d4_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:BuyUSDollarSellChineseYuanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="cny"><xbrli:measure>iso4217:CNY</xbrli:measure></xbrli:unit><xbrli:context id="i80a649fe7dd9480994358ed2532d905d_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:BuyUSdollarSellJapaneseYenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="jpy"><xbrli:measure>iso4217:JPY</xbrli:measure></xbrli:unit><xbrli:context id="i04bcb23b9ae84c9c9a64aca2a3cc4a34_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:BuyBritishPoundandSellUSDollarsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="gbp"><xbrli:measure>iso4217:GBP</xbrli:measure></xbrli:unit><xbrli:context id="ifd62109e29474416b9bd4cb46c68e40f_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">lly:ForeignCurrencyDenominatedDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9e675ec6e62d42a9bc9b9a5e61226095_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">lly:ForeignCurrencyDenominatedDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5b6a7a49e6b543c7a9c9f34217259d0f_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:SwapU.S.DollarsToEuroMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5f4cbed09a8d4efbba96a84a21c4f229_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:SwapSwissFrancsToU.S.DollarsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i223b03ef72744bd2b0b10b131126e63e_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:SellEuroMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iea65a7fd63824506a3ca41c5d51257a3_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i788cd34fd44840639efca67d73c371ff_D20220915-20220915"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">lly:MaturityDate2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-09-15</xbrli:startDate><xbrli:endDate>2022-09-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d53c58f4c7d459489a11fd8bfd27153_I20220914"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">lly:MaturityDate2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2c071467da4c408bbfd8f27f707626e7_I20220915"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">lly:MaturityDate2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i17173f194d1742f38780c496d01c1177_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A050NotesDue2033Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">lly:ForeignCurrencyDenominatedDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iff7c9802a16c4e94a8b83d2c06fbfd30_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A1125NotesDue2051Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">lly:ForeignCurrencyDenominatedDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i11a8fe2e658c49ab879c662bd320fc8e_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A1375NotesDue2061Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">lly:ForeignCurrencyDenominatedDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iea81ed26b993414992722e426a530c04_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A1625NotesDue2043Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">lly:ForeignCurrencyDenominatedDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icdfd3853e3eb4a398286b232426b38b1_D20210901-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">lly:ForeignCurrencyDenominatedDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i96587d4174a14444becf7821313b1347_D20210901-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A395NotesDue2049Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">lly:ForeignCurrencyDenominatedDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i750c23289e514e58bf58ede4855592f4_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A395NotesDue2049Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">lly:ForeignCurrencyDenominatedDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ice18fb651f95409d813656a157f34daf_D20210901-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A415NotesDue2059Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">lly:ForeignCurrencyDenominatedDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i50894bb5721f4dd58072e6ce75ebf15d_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A415NotesDue2059Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">lly:ForeignCurrencyDenominatedDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ice022568bdf042618c2c002393cc3c5d_D20210901-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A3375NotesDue2029Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">lly:ForeignCurrencyDenominatedDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iccc6f8c08fc6454c849c681a4dbe3d01_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A3375NotesDue2029Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">lly:ForeignCurrencyDenominatedDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i65012aa62d474ff8af6d08eeb55d206a_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:HedgedFixedRateDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib627ecf64a434a6b8135da0ac7a5fdf7_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:HedgedFixedRateDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1d213f8c24344d22ada6f016432acea5_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:HedgedFixedRateDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i41a4fdad9bd748be972c155f2f3acedf_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:HedgedFixedRateDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic55d4cfd09d8486a8b6e1be77dcc5426_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i519d9df9a61b4cbf87c342e3496785cc_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7bcae384fb484b6aa3e84e7d484b69e9_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4cc8664469d846a2b0472f04c7e39442_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic1eb1816cd7241e7af47383c68f534c0_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if7cd0109836d43de86e2c830d47c9aec_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5f64e83e66774562be40774b52732fd5_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9ed2f279ccc74f238d18ee7977fea9e0_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaaffba52583d4dd09213c45974bda81f_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idb22c9f9ae5f42d5b5d0691a5daa1547_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i00fa96d219234882925d8b07dc0e9a2f_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5a4ce07ee9fd474a956ccb68a6af4713_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0803c43adcc2406c8d72a961bdbdb03a_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:HedgedFixedRateDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifa347bfa67994dfbad7418e0ab44ad66_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:HedgedFixedRateDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9300bb3fb0c149928c10ce50be156517_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:HedgedFixedRateDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i65cd935c26b44824a9d84d0554032fa4_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:HedgedFixedRateDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie32852c9ac004e18a40bd3c886375fa2_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie539446ea66443f18894fe65b477f3f2_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieb0755f46c634be3a274f37154dcd835_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib38ae8d2eee24da7b665b5ba4af2fc25_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iee72a06ebc24478d804a01c9c07503e0_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i847e2e726f374b8997cd2f409d0da50e_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i04964a8dc75f42aeb12d4f04a8c4b0eb_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i735c7ed5628e404298cd5de9565781a5_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i874a4fa6b8034fb7b972ede3e49e5375_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icc403fcb68ad44ae8c3d0f5675e78f2a_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic9cf169896e649948e7319fca615da6c_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i792ad77b79a7422690de67f74dc5988f_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia25fb80ee7f14608ad1bc42cf7dc3d85_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieb1b4d0ca2904d3699b0c20378d2d4de_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i909f721d549b4d17b64fd5ef7a64ed65_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ida76f129eae2411aac66cefe0c47c6fc_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic34ce18d9ac34702bf22cdc268d8fddc_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ice641419095d40b58b1ec413657e5350_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifab6a7669381463baa4bcac0c28cb1ec_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic8f3a57231c145049540a666d70b036f_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0bdbf4b6981d423b84e97332dcaf6c1a_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if1140c058291487fa611ebff0a87770b_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i78d99dff74e3423da8f09146d5ccfac9_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i047635964deb4302a146b6e33a2497a8_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2743696771f346c8b079973d11a7071f_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i33275a4d21e64200a487dc63563ca001_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0a4a874cc47f46a2a264722d13461f46_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5b78e10d989e462c8d6d0340d904cc92_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic182ac3c1369411e8483ee598bedbe15_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie5db88938a794a79995152d200739e71_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if975bb8107f649de87a30d9d0518813d_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i035b6f8bf7fd4eb2ade6d5c56da79b71_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i313d32c12b5e46a3b70bb355b88d33ae_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia62987f3e7a14b4cba45477046b24356_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i81cc2677a958476298d6e691a227d2ef_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibafa8194f14245d092cf8e3fef7acc20_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if5c5c6181311407dbfeb6b2bc5dabd45_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4cd5419a2b1e4f1dae5ad80e024ffbd8_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifa5439e6f71a449badc6db614afe1fc0_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia7e1bfc7167249e09fd9253c7056e6a4_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i184415738c194fc89b0a1a3ae91e05f6_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i99cd69cddcd1432eb41f86a6c107e126_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9351338d7d4b429093117dd87f8b02de_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i98487cf76fa84cba948c2fa763c08c17_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i921241c16da34890a377c6cc0f05bf9a_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib8c508d73f5d490c991f152f357c2edc_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4fcf6ea2160140fcb9374937bebdf459_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5892dce618474c3397f2f21748d154da_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i839d1d25f31e4a1e8f8686d85cd27d6f_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i66f937e8eb9d439fb99fc1eaf5bb8229_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8d540d6e9952406eae86fcb404c8aa3f_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iac853f32fb164d5dbb16b853b6478ad8_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4d0248c83e9f42aebdedbe45913091c1_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1f00b6f0d7a346a0bbf8ca789b9b4986_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id469158a1a2340c0b51dedb185916c2c_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2330a365ee524585810c28f7dc20e39e_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idb940b9eace84fd38c98429f0f9808ce_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib28917d514b84c3397d29e8e54a589da_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia4c3874a92684287bd36704e5ff16e8a_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i700bccbf1683474084361d2cee367dc8_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib7532b4a86304eaf897b92f1ef90f733_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:EquityMethodAndOtherInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic3b630730b424a6d8b697cf0362c83d2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0d06252e717445c989a037b2b13d0128_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6802f141d8af4b8aa65c6abe305eeed2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i124320eb89ce4dfa87c2f2083ad1e10b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2f37875c8bb94fed916b3375076f0703_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i52e3293fb124489e844061750e511c35_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i70cd211932aa44d4b6f18e4a94acaa15_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i47952f5ad6b1477c8890a2ebe950ab13_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iddfe43e26a024cd3b793575cebd70372_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic82b5cca8a0748c4ad44ff28aa5c8c63_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i19bcbbad1685404f997100cdd7ba2b51_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibb1ad2dc0cab41488bb60c7f417df54c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifb25438d52ac455ba62e9095554c8121_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iabe3e352015e443c90f93e7aee3a5340_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4d09607d938a418caf31b9504379627d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i70c1a238fafa4e82bb91738050707531_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i94da7f9a237b4f5d92545750475e0865_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iace537990e0345b984d5d9b511dbd56b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i122e96dd9f3645a1845a400915d238b3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2193cdcf640b46f79e5eb9ee0bdb3eb2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idb15d5720b2447969c89619f23a52bcd_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i83fbafd3b87749b69732c68f1032fe86_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if5e4829c2687480ba72b8c79c38602c5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5e0c7dd136f94803b44868029c626465_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i77a8bad9e7b643b3be999c26e7f341f3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3729e6381590490cad36d5c52a3a9a30_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i65d4f921c43e46389cd396c859835baa_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifea7137c64a940b98bfaf9336e0de8ed_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibb1fc1f870e44eb8b489ae050e35d2ec_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5843990a9b9642e089425093f642f011_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3d4a6fcb14b84769a71beaa7fadd7543_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib55c35900e8f4879bbab1c3db2b414e6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i514a63925c814a928a17a95e4d93d7cb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4e737ad3e2234f028bf65d35bf37f064_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie8e9125bc9f34767a3e05b3c767b3498_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib0e7cf4206ef42778711f85fddbfe12c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i37d081dc80d549d0b7cf06f3dd0f097c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iebaf7a78928c429596dc216106cd2f95_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4a82bacb2ac843e1b6f6f2fe0be9b508_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iddd8d40ea4024e44853ebae245c8ff89_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iee09e9df8cb24a98b446ff1b40b49036_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i76efc9c2d361426a8fabf8f468eae443_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i900be75d24cb4d0e8aaf431324f245f7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic0829e7b5687473690dec2d117e19409_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icdba688916644cc684b154cd319074ad_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i74870f5304a445feafaa0e95c37df511_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iec666b23a81840999cae844ee05abaf5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4dddf28fc04840efa98b6944bdadf64c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i89e7fea8ea92492693f830dd7afa0d55_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:EquityMethodAndOtherInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i49af86cdb4774f6da136e21a258b9f38_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9b96398a66a144a9aa05b43dea309d1a_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9eb05f2daf0940029ed9c6f6079b072c_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0cbd0bb84e934e18aa8a68f2ed4e3278_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5e03886140d04a0f90b726a0b8cb04a2_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie1da8e0f672e4bc390cd335a91d4cf83_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7cba691ea8004d118d604043b64cd431_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id1657a9a2856448687ac9aaada343dd5_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i020782910cc740779ffa9060458113ba_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8f69ca689c7e4d23aa1cab488bb7ed65_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1300d5f8c7d44be79cb93f333746c580_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaca361ecbf3749b7a324afc87754e17e_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5ac9d317ae404d2ebdc37459bd98e0c0_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib6a56ab1b3ed4c26b10443b11b7c0c23_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id7268bc376574172920167043f112985_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id872aa3055934897a2abffb3543add56_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idfd9f0975707442aa9a203b7a16441c5_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib2eb41ed3d014ed4b273125814f78a0d_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i79464644e1f741088bd241cb52754676_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i35a8009df6dc423f85c1ef726d565a66_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib616e3ba735b4f66ace91c9075e315e3_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7d14a5f5fcc44e8b974f3d717097b500_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7cf0b43a5a854904951946bba3c063dd_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie06f4bbec8ae497db6f7f77940abcf72_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idd5c8623b0274f569a6e9cb890fe814d_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id0faa86378a146a48b2256a18f02b7d5_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iec96867cd1734fb382b9a966a90c804e_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8d0b53a09fec472eab66541ef6214321_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1354c03ac64d49b996ad815decc0f6d7_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibc6aec644ba74dffa95a469f4848e6bc_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a65232f1fca4f95abbb3167ab435068_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i40ccf9cc0ff7401eab9722772af73854_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4aa9bedfa4ea4600ab40f4f731255ce9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6a47a49c720948c3b475ad8f3cf1ff16_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i024a1912186c40c1a4e62a542f42350c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i318612662ee348ca8f4c50e967285c42_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6b3448a25ab94a89aef263d03a2bd29a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i841d22572a894c128f4304c5a9d761b0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie51a0fafa7104530b58bfc8df0b750d4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0999361082eb4d43bc2fc7f00ef0bae3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8a94f32b7cb642279222210de17f03ed_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iab252218731740b9a75cb6728b7b9503_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5a6a92fb8f674015b49e7f493a12c723_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iee54e09047ba4b21a41fa3c8cc49cec2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icf2c03c7d41e4db1941ec3f47533b5ac_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i09f8de57c8924dc5916922a278ad4eb1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1339ff825ab84e1292a5f32205bb84fb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iddd7166aae2b440ab53a23a0b63e2aa9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic06c23f16f4443f78411fcbe2a43f013_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia6485e6d1b024de18d35df5658693713_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9674dda0210248f68699af728a2b7366_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i05396d0962d648b89a38691fab6227da_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i637a8ab6a8a7402880d7c301d82ac216_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i47903bc5967647c3ad861c42d533efb5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i22af614be29843faa74794b4926362d9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i62df949acd3f4b47ae7d10432a08e2ab_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i67750cd7b626486fa748e5b71374a667_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifea67e1feada4a8c8d0bf25c34910e9a_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i19f7d57c42aa4dde893b82e5f134cfc1_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0116b5022f7f41b494fd355fe823d76e_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8a97c43966fd4f6aaf5f8dfb7bba4701_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i238afcd7e9494cbb9f4c68c1cf1dcc2d_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6b0c929331c241cb98c2a4d85625e2e7_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i60435d86ecc44d56b9b471e301119ba4_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i146fcce3fad6486aa91cf7ba94fd98c8_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib414aaa5a0174c7fb17ac9898d399d32_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">lly:EmgalityPatentLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="patent"><xbrli:measure>lly:patent</xbrli:measure></xbrli:unit><xbrli:context id="if274934ece0041f487b43797bc8de648_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">lly:EmgalityPatentLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibcc5f2496e02449abe458e54c0a8a61f_I20221031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">lly:EmgalityPatentLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i58d8155218724e10a6956cdd38ca1bb1_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ByettaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="lawsuit"><xbrli:measure>lly:lawsuit</xbrli:measure></xbrli:unit><xbrli:context id="i03a0a6037fc44e39af8b9a0fc87cbcbb_D20090301-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ByettaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2009-03-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="plaintiff"><xbrli:measure>lly:plaintiff</xbrli:measure></xbrli:unit><xbrli:context id="iedfe8e594f2d4534ba3f7d18996055ec_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:UnfavorableRegulatoryActionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="site"><xbrli:measure>lly:site</xbrli:measure></xbrli:unit><xbrli:context id="i7b4e96e210ab4559a67ee97574922011_D20180701-20180731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">lly:EmployeeLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="brl"><xbrli:measure>iso4217:BRL</xbrli:measure></xbrli:unit><xbrli:context id="i983baf60b46f4dc0ab264f727cff1fd1_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">lly:EmployeeLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id52423032e6747898c41a944e3038420_D20190701-20190731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">lly:EmployeeLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i098637113ce84c2f8c583d5aac35942b_D20210601-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">lly:EmployeeLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i91a11e76b2844622ba08c167af2c1bbd_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">lly:EmployeeLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3fd1ac8f6fc9438cb71e216b3246793e_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumalogHumulinAndForteoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if2605d2b37d747e1b5887703c18e4963_D20210701-20210731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:InsulinMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="claim"><xbrli:measure>lly:claim</xbrli:measure></xbrli:unit><xbrli:context id="ia44884b555f84a8bb8c051329b5b483c_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icf1cf37660ed42919d552edbdc9ddf29_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib07a74d7836447719291eff28ad65a22_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia3f2ab912d2b47e7862abe56a92bb118_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic22b2460974b4792a24b9b75e0e598d3_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibb680e42808d41b587bffa2f35409a91_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib423da078b9740019ae03257a6ca1320_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0ddaa7c4639946b1a63ee163ebac9cda_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9e78a70b50b740909d4bd5980c556e3a_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i603b413215ff4ac0860f74b6a1be9294_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6105e19d65744395aeb2921c7555324a_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1ec1c7b3b72549149e283cdff33abeed_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifc51fbfd706a4f809013d42ddd4fef8c_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iad56c44530dd4208959b336f8d1fe8b1_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9b7795dc491c42cbb64812b2b99d2ac9_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ideb9d32d39e441f68ba01504bca2b03c_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iec456e1ce7794922919937b65a44561f_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2988484b109649f28736efa0418c49f9_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id29f7d92807d4933b0fb1e960563f81f_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3153def44849420f812d26d82e12f780_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i525ab1d53cfc40b99c19c64b4d032446_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4b3bb220bf604c6daaf72988d3e20703_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i24f2b962044749c5a2936c59a2f25aa9_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iab4358396efe4d7f92c5aab447052434_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5be060faaa5146e7a2bf742eb38f7bec_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i894ae4ccbe404068bbc052f007cea48c_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic74e9458c4f44462a21bfd6f33c8c50d_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9ed755da42e84ed28970211b57db0d80_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if779a9c74164409ab40929f3c1a22e08_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i15e5d118ed234a2f82b7b9a362d215d8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib7546d9d8f53446e8b4f3eed0a4210c4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if2ce5c439794420c8829fd223a835cd4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic63664fe4e074a5599837d8254019a8b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i13abcd536a74422a91f0be2e859c5f11_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieeda2eb9aa724c2eb2b08a110d5910ca_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1c0ca46f62b245baa26e2ca939e70c30_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i698e8cd8a6e44a719d0a96611610bdf4_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4b2bb6e433df4a26acb1d1cfbcc2ce7d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic15a6784d2e64c5b9176f90a12f6b997_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if4dbdc6b4ce3472bb83f35a58ba62009_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4084f6774b4344709f32500dfb758be3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i61189f333c704d8a9f0dffcd44fd0870_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4def4770d4c9484b9eafab55058f4c06_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if73a641a34fe4591b395573cedb1bea4_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i71a11ec78f2242498930e393cd63658b_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i314c9492fa9044c3a8d05e0fc3ad2e63_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaaff00acdddb497fb5b94bf8d2ff771d_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia0716cc08360439bb971180db7de8214_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1e81189c858b4d59b30b2380c8bf756b_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iafe03a1322e544acb123846499dfb8f0_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iedc64e6c0ae84f6f8f6f168b1b71f00f_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i02ba7e57b97e4c15aa93cdacb3f05447_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8d7550b247eb4a90ac3acd3ea2eab6ad_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if8458e6a1b9b4239b31d01e183c0368d_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i14e2a21089594bfda05e2f482a1a9fdb_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if60b1262bf5c4116ad9ba0e69b270a48_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i913335a3ccfe4b639f36db1017ae92af_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7c947211ed8b449b9617f0791f225696_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib98dca097ce342f1856252087101e534_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">lly:AccumulatedGainLossNetCashFlowHedgeAndForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if20e319a4c3045b8b0693a8773446ca4_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">lly:AccumulatedGainLossNetCashFlowHedgeAndForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i06f2cc53bd804ced906cc353bccf23bd_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">lly:AccumulatedGainLossNetCashFlowHedgeAndForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i562107a932c943419a75d588f68a7ede_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">lly:AccumulatedGainLossNetCashFlowHedgeAndForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i294aedf137cf40faaba28e6d98a540dc_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id04bc0ea75e7453daeb27bfa63e91d46_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id8fcac86ddf342cf954cceefebfd7779_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i741049a232dc40728bbe8ee225522d87_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yOC9mcmFnOmEyNTBjNDBjZWQ3ZDQwZjRhNWUyMTQwZDM3MWNiYjliL3RhYmxlOjU0ZWNlYTRkMjgzZDQ4NTJiZTI1Y2QyYWEzN2M0ZDU0L3RhYmxlcmFuZ2U6NTRlY2VhNGQyODNkNDg1MmJlMjVjZDJhYTM3YzRkNTRfMy0xNS0xLTEtMTU5NTQw_6d92fa6f-1acf-4170-82f2-aac697d0cb4d id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yOC9mcmFnOmEyNTBjNDBjZWQ3ZDQwZjRhNWUyMTQwZDM3MWNiYjliL3RhYmxlOjU0ZWNlYTRkMjgzZDQ4NTJiZTI1Y2QyYWEzN2M0ZDU0L3RhYmxlcmFuZ2U6NTRlY2VhNGQyODNkNDg1MmJlMjVjZDJhYTM3YzRkNTRfMTQtMTUtMS0xLTE1OTU0MA_2900ac5b-f4af-4b04-a084-997e5a9b4ef4 id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yOC9mcmFnOmEyNTBjNDBjZWQ3ZDQwZjRhNWUyMTQwZDM3MWNiYjliL3RhYmxlOjU0ZWNlYTRkMjgzZDQ4NTJiZTI1Y2QyYWEzN2M0ZDU0L3RhYmxlcmFuZ2U6NTRlY2VhNGQyODNkNDg1MmJlMjVjZDJhYTM3YzRkNTRfMTYtMTMtMS0xLTE1OTU0MA_79b6e3ff-9a51-48d4-a405-02f97d7823a6 id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yOC9mcmFnOmEyNTBjNDBjZWQ3ZDQwZjRhNWUyMTQwZDM3MWNiYjliL3RhYmxlOjU0ZWNlYTRkMjgzZDQ4NTJiZTI1Y2QyYWEzN2M0ZDU0L3RhYmxlcmFuZ2U6NTRlY2VhNGQyODNkNDg1MmJlMjVjZDJhYTM3YzRkNTRfMjUtMTMtMS0xLTE1OTU0MA_17f5a50e-d7d3-49ea-ac64-ce1a5539bebc id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yOC9mcmFnOmEyNTBjNDBjZWQ3ZDQwZjRhNWUyMTQwZDM3MWNiYjliL3RhYmxlOjU0ZWNlYTRkMjgzZDQ4NTJiZTI1Y2QyYWEzN2M0ZDU0L3RhYmxlcmFuZ2U6NTRlY2VhNGQyODNkNDg1MmJlMjVjZDJhYTM3YzRkNTRfMy0xMy0xLTEtMTU5NTQw_a0242d52-4853-4826-9c2a-9045ffce7d36 id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yOC9mcmFnOmEyNTBjNDBjZWQ3ZDQwZjRhNWUyMTQwZDM3MWNiYjliL3RhYmxlOjU0ZWNlYTRkMjgzZDQ4NTJiZTI1Y2QyYWEzN2M0ZDU0L3RhYmxlcmFuZ2U6NTRlY2VhNGQyODNkNDg1MmJlMjVjZDJhYTM3YzRkNTRfMTYtMTUtMS0xLTE1OTU0MA_8eb7f85c-86ce-4c28-8769-6fd6765ed5b0 id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yOC9mcmFnOmEyNTBjNDBjZWQ3ZDQwZjRhNWUyMTQwZDM3MWNiYjliL3RhYmxlOjU0ZWNlYTRkMjgzZDQ4NTJiZTI1Y2QyYWEzN2M0ZDU0L3RhYmxlcmFuZ2U6NTRlY2VhNGQyODNkNDg1MmJlMjVjZDJhYTM3YzRkNTRfMTQtMTMtMS0xLTE1OTU0MA_5ba3cacd-6990-4cb0-813c-c9d6994bcad2 id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yOC9mcmFnOmEyNTBjNDBjZWQ3ZDQwZjRhNWUyMTQwZDM3MWNiYjliL3RhYmxlOjU0ZWNlYTRkMjgzZDQ4NTJiZTI1Y2QyYWEzN2M0ZDU0L3RhYmxlcmFuZ2U6NTRlY2VhNGQyODNkNDg1MmJlMjVjZDJhYTM3YzRkNTRfMjUtMTUtMS0xLTE1OTU0MA_7af684c2-0888-4891-a471-aee7fb026ebd" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yOC9mcmFnOmEyNTBjNDBjZWQ3ZDQwZjRhNWUyMTQwZDM3MWNiYjliL3RleHRyZWdpb246YTI1MGM0MGNlZDdkNDBmNGE1ZTIxNDBkMzcxY2JiOWJfMjYx_2087051d-93f9-4e3e-80d6-ea5e9c10d8dd" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfMjAtMTUtMS0xLTE1OTU0MA_90b2c7b9-d4d4-47cb-960d-af52cb5f093c id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfMjItMTMtMS0xLTE1OTU0MA_04bc94f9-48f3-42e4-a934-3287c4031747 id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfOS0xNS0xLTEtMTU5NTQw_924c9fdc-7fe9-41c8-80cc-2c3895419a1d id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfMjUtMTUtMS0xLTE1OTU0MA_da8ad497-050f-4202-83f7-ba8bfce436f5 id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfMy0xNS0xLTEtMTU5NTQw_0c79c58d-ca29-449b-b8c0-a4ce0f3b7eda id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfMjUtMTMtMS0xLTE1OTU0MA_8ef29157-deac-4753-beeb-da0b17fe30c7 id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfNy0xMy0xLTEtMTU5NTQw_ac6aaddd-eafb-4ec4-accf-829f59b018fb id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfMTQtMTUtMS0xLTE1OTU0MA_47aac1d5-32f2-4222-a223-a804ecf08662 id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfMjItMTUtMS0xLTE1OTU0MA_30b3cfe7-2129-4339-a61e-be4bfad21855 id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfMy0xMy0xLTEtMTU5NTQw_d1cdfdda-f62e-426c-9a0c-ebd3749b728c id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfMTQtMTMtMS0xLTE1OTU0MA_96786cfe-52bc-495f-97eb-53dc1ce2f278 id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfOC0xMy0xLTEtMTU5NTQw_6f9cea00-98ea-47d7-83e7-d75d6037deda id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfMTYtMTUtMS0xLTE1OTU0MA_535791d1-15b8-498e-a925-9f7eddc75751 id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfMTYtMTMtMS0xLTE1OTU0MA_d0839666-32d6-4ae0-946a-a4c5686bf3ad id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfOC0xNS0xLTEtMTU5NTQw_5b19ff46-59ca-42cb-8ec4-ec729fa0feac id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfNy0xNS0xLTEtMTU5NTQw_86de006e-c527-4c64-8afd-d972d9acad45 id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfOS0xMy0xLTEtMTU5NTQw_3aeef466-3c5f-4743-b85a-183e218f075e id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfMjEtMTMtMS0xLTE1OTU0MA_8e9af476-2a91-410a-81c3-a243861cdf43 id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfMjAtMTMtMS0xLTE1OTU0MA_72afa8cd-b258-4119-8087-814775c285dd id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfMjEtMTUtMS0xLTE1OTU0MA_c8545f5f-37fb-4748-89c4-dbb910bf7e43" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RleHRyZWdpb246ZTAxODE5ZTcxMTNjNGY2YzkyNjFiNDYyYzIxODNiMjFfMTY0_9553bd20-e2be-4a9d-901f-d34e31f81e7e" order="1"></ix:relationship></ix:resources></ix:header></div><div id="i5fed483d9c7e4f3cbba3a62c53226cd7_1"></div><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%">UNITED STATES </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-weight:700;line-height:120%">Form <ix:nonNumeric contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xL2ZyYWc6N2FjMGRkOGIzNWQxNDhiNzlmYTVkMTUwOTYwZGFmZWIvdGV4dHJlZ2lvbjo3YWMwZGQ4YjM1ZDE0OGI3OWZhNWQxNTA5NjBkYWZlYl8yMDM2_73d5082c-d8c0-4f73-bd05-2f9a6414fe05">10-Q</ix:nonNumeric> </span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930" name="dei:DocumentQuarterlyReport" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xL2ZyYWc6N2FjMGRkOGIzNWQxNDhiNzlmYTVkMTUwOTYwZGFmZWIvdGV4dHJlZ2lvbjo3YWMwZGQ4YjM1ZDE0OGI3OWZhNWQxNTA5NjBkYWZlYl8yMDQx_103acb8c-ca70-4068-acc9-4530f68a6bba"><ix:nonNumeric contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xL2ZyYWc6N2FjMGRkOGIzNWQxNDhiNzlmYTVkMTUwOTYwZGFmZWIvdGV4dHJlZ2lvbjo3YWMwZGQ4YjM1ZDE0OGI3OWZhNWQxNTA5NjBkYWZlYl8yMDQx_87ed946d-d898-44d7-ae4d-ada2ac30381d">Quarterly</ix:nonNumeric></ix:nonNumeric> Report Pursuant to Section&#160;13 or 15(d) of the</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Securities Exchange Act of 1934</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xL2ZyYWc6N2FjMGRkOGIzNWQxNDhiNzlmYTVkMTUwOTYwZGFmZWIvdGV4dHJlZ2lvbjo3YWMwZGQ4YjM1ZDE0OGI3OWZhNWQxNTA5NjBkYWZlYl8yMTA_5776ee39-678b-4d2f-9d1e-7a5c35071614">September&#160;30, 2022</ix:nonNumeric></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COMMISSION FILE NUMBER <ix:nonNumeric contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xL2ZyYWc6N2FjMGRkOGIzNWQxNDhiNzlmYTVkMTUwOTYwZGFmZWIvdGV4dHJlZ2lvbjo3YWMwZGQ4YjM1ZDE0OGI3OWZhNWQxNTA5NjBkYWZlYl8yMDM1_22c99662-191c-4e79-9904-cd9149835d85">001-6351</ix:nonNumeric> </span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:22pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xL2ZyYWc6N2FjMGRkOGIzNWQxNDhiNzlmYTVkMTUwOTYwZGFmZWIvdGV4dHJlZ2lvbjo3YWMwZGQ4YjM1ZDE0OGI3OWZhNWQxNTA5NjBkYWZlYl8yMDQy_cc5f090c-cab8-4dc3-8289-5f068daef1f4">ELI LILLY AND COMPANY</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Exact name of Registrant as specified in its charter)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:47.948%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.560%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.192%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xL2ZyYWc6N2FjMGRkOGIzNWQxNDhiNzlmYTVkMTUwOTYwZGFmZWIvdGFibGU6ZjI0MWE4MmNiMTRkNDQwZDllNzFmMDkyMTQ1NTE5OTYvdGFibGVyYW5nZTpmMjQxYTgyY2IxNGQ0NDBkOWU3MWYwOTIxNDU1MTk5Nl8wLTAtMS0xLTE1OTU0MA_544edd58-36aa-4953-8559-944f5279d3a0">Indiana</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xL2ZyYWc6N2FjMGRkOGIzNWQxNDhiNzlmYTVkMTUwOTYwZGFmZWIvdGFibGU6ZjI0MWE4MmNiMTRkNDQwZDllNzFmMDkyMTQ1NTE5OTYvdGFibGVyYW5nZTpmMjQxYTgyY2IxNGQ0NDBkOWU3MWYwOTIxNDU1MTk5Nl8wLTItMS0xLTE1OTU0MA_18dc1a91-46f8-4a4b-b238-03a6332df688">35-0470950</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(State or other jurisdiction of</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(I.R.S. Employer</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">incorporation or organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Identification No.)</span></td></tr></table></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xL2ZyYWc6N2FjMGRkOGIzNWQxNDhiNzlmYTVkMTUwOTYwZGFmZWIvdGV4dHJlZ2lvbjo3YWMwZGQ4YjM1ZDE0OGI3OWZhNWQxNTA5NjBkYWZlYl8yMDM3_12745fad-11a6-4bd2-8050-e7644e0fb50c">Lilly Corporate Center</ix:nonNumeric>, <ix:nonNumeric contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xL2ZyYWc6N2FjMGRkOGIzNWQxNDhiNzlmYTVkMTUwOTYwZGFmZWIvdGV4dHJlZ2lvbjo3YWMwZGQ4YjM1ZDE0OGI3OWZhNWQxNTA5NjBkYWZlYl8yMDQz_2ab6411c-9a74-4238-948e-10e986fb63ed">Indianapolis</ix:nonNumeric>, <ix:nonNumeric contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xL2ZyYWc6N2FjMGRkOGIzNWQxNDhiNzlmYTVkMTUwOTYwZGFmZWIvdGV4dHJlZ2lvbjo3YWMwZGQ4YjM1ZDE0OGI3OWZhNWQxNTA5NjBkYWZlYl8yMDM4_6ef11003-a667-4a31-88b5-ad77a11e4b2b">Indiana</ix:nonNumeric> <ix:nonNumeric contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xL2ZyYWc6N2FjMGRkOGIzNWQxNDhiNzlmYTVkMTUwOTYwZGFmZWIvdGV4dHJlZ2lvbjo3YWMwZGQ4YjM1ZDE0OGI3OWZhNWQxNTA5NjBkYWZlYl8yMDQ2_53080333-60a1-48da-96c8-abf2f245efb0">46285</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Address and zip code of principal executive offices)</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Registrant's telephone number, including area code (<ix:nonNumeric contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xL2ZyYWc6N2FjMGRkOGIzNWQxNDhiNzlmYTVkMTUwOTYwZGFmZWIvdGV4dHJlZ2lvbjo3YWMwZGQ4YjM1ZDE0OGI3OWZhNWQxNTA5NjBkYWZlYl8yMDQ0_d89df568-cd87-4970-a2d0-1ac793463acc">317</ix:nonNumeric>)&#160;<ix:nonNumeric contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xL2ZyYWc6N2FjMGRkOGIzNWQxNDhiNzlmYTVkMTUwOTYwZGFmZWIvdGV4dHJlZ2lvbjo3YWMwZGQ4YjM1ZDE0OGI3OWZhNWQxNTA5NjBkYWZlYl8yMDM5_482405d2-915b-4844-86f0-bfe33594cc69">276-2000</ix:nonNumeric> </span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Securities registered pursuant to Section&#160;12(b) of the Exchange Act:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:32.282%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.313%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%;text-decoration:underline">Title of Each Class</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%;text-decoration:underline">Trading Symbols</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%;text-decoration:underline">Name of Each Exchange On Which Registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i71f35536970d471db55131eae57d8a56_D20220101-20220930" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xL2ZyYWc6N2FjMGRkOGIzNWQxNDhiNzlmYTVkMTUwOTYwZGFmZWIvdGFibGU6Y2UxN2EyYzQ3OWQ4NGQ0NTkyMTc5NDk3NGE2ZDJhMzUvdGFibGVyYW5nZTpjZTE3YTJjNDc5ZDg0ZDQ1OTIxNzk0OTc0YTZkMmEzNV8xLTAtMS0xLTE1OTU0MA_f71fb43d-9e49-4cda-814a-21e6f778f94e">Common Stock (no par value)</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i71f35536970d471db55131eae57d8a56_D20220101-20220930" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xL2ZyYWc6N2FjMGRkOGIzNWQxNDhiNzlmYTVkMTUwOTYwZGFmZWIvdGFibGU6Y2UxN2EyYzQ3OWQ4NGQ0NTkyMTc5NDk3NGE2ZDJhMzUvdGFibGVyYW5nZTpjZTE3YTJjNDc5ZDg0ZDQ1OTIxNzk0OTc0YTZkMmEzNV8xLTEtMS0xLTE1OTU0MA_4dfed371-b10d-493b-9463-99477b5265ec">LLY</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i71f35536970d471db55131eae57d8a56_D20220101-20220930" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xL2ZyYWc6N2FjMGRkOGIzNWQxNDhiNzlmYTVkMTUwOTYwZGFmZWIvdGFibGU6Y2UxN2EyYzQ3OWQ4NGQ0NTkyMTc5NDk3NGE2ZDJhMzUvdGFibGVyYW5nZTpjZTE3YTJjNDc5ZDg0ZDQ1OTIxNzk0OTc0YTZkMmEzNV8xLTItMS0xLTE1OTU0MA_97eda022-c29e-4a61-b940-00d36daaa181">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i928ac777ff9b4d2c901021ddb94de4b4_D20220101-20220930" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xL2ZyYWc6N2FjMGRkOGIzNWQxNDhiNzlmYTVkMTUwOTYwZGFmZWIvdGFibGU6Y2UxN2EyYzQ3OWQ4NGQ0NTkyMTc5NDk3NGE2ZDJhMzUvdGFibGVyYW5nZTpjZTE3YTJjNDc5ZDg0ZDQ1OTIxNzk0OTc0YTZkMmEzNV8yLTAtMS0xLTE1OTU0MA_b7df35ec-565b-4860-97d1-5bd49c0a8bac">7 1/8% Notes due 2025</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i928ac777ff9b4d2c901021ddb94de4b4_D20220101-20220930" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xL2ZyYWc6N2FjMGRkOGIzNWQxNDhiNzlmYTVkMTUwOTYwZGFmZWIvdGFibGU6Y2UxN2EyYzQ3OWQ4NGQ0NTkyMTc5NDk3NGE2ZDJhMzUvdGFibGVyYW5nZTpjZTE3YTJjNDc5ZDg0ZDQ1OTIxNzk0OTc0YTZkMmEzNV8yLTEtMS0xLTE1OTU0MA_de65a88d-e01d-4fbc-84cb-fb57e15ebc31">LLY25</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i928ac777ff9b4d2c901021ddb94de4b4_D20220101-20220930" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xL2ZyYWc6N2FjMGRkOGIzNWQxNDhiNzlmYTVkMTUwOTYwZGFmZWIvdGFibGU6Y2UxN2EyYzQ3OWQ4NGQ0NTkyMTc5NDk3NGE2ZDJhMzUvdGFibGVyYW5nZTpjZTE3YTJjNDc5ZDg0ZDQ1OTIxNzk0OTc0YTZkMmEzNV8yLTItMS0xLTE1OTU0MA_901b837b-1cbc-4215-87cc-22ae463a38fc">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i47d1aafe63fc4d6a8af84bd5fc7ec42a_D20220101-20220930" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xL2ZyYWc6N2FjMGRkOGIzNWQxNDhiNzlmYTVkMTUwOTYwZGFmZWIvdGFibGU6Y2UxN2EyYzQ3OWQ4NGQ0NTkyMTc5NDk3NGE2ZDJhMzUvdGFibGVyYW5nZTpjZTE3YTJjNDc5ZDg0ZDQ1OTIxNzk0OTc0YTZkMmEzNV8zLTAtMS0xLTE1OTU0MA_5da37923-32d2-4be4-b5e5-2c7377898110">1.625% Notes due 2026</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i47d1aafe63fc4d6a8af84bd5fc7ec42a_D20220101-20220930" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xL2ZyYWc6N2FjMGRkOGIzNWQxNDhiNzlmYTVkMTUwOTYwZGFmZWIvdGFibGU6Y2UxN2EyYzQ3OWQ4NGQ0NTkyMTc5NDk3NGE2ZDJhMzUvdGFibGVyYW5nZTpjZTE3YTJjNDc5ZDg0ZDQ1OTIxNzk0OTc0YTZkMmEzNV8zLTEtMS0xLTE1OTU0MA_f4eaed6d-249f-4cef-8ee0-54629ceeff1f">LLY26</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i47d1aafe63fc4d6a8af84bd5fc7ec42a_D20220101-20220930" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xL2ZyYWc6N2FjMGRkOGIzNWQxNDhiNzlmYTVkMTUwOTYwZGFmZWIvdGFibGU6Y2UxN2EyYzQ3OWQ4NGQ0NTkyMTc5NDk3NGE2ZDJhMzUvdGFibGVyYW5nZTpjZTE3YTJjNDc5ZDg0ZDQ1OTIxNzk0OTc0YTZkMmEzNV8zLTItMS0xLTE1OTU0MA_7c614c28-7332-464d-9027-5e638f6cc8ba">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ifbf789a7a75f4a94b1ecc8e7f5692048_D20220101-20220930" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xL2ZyYWc6N2FjMGRkOGIzNWQxNDhiNzlmYTVkMTUwOTYwZGFmZWIvdGFibGU6Y2UxN2EyYzQ3OWQ4NGQ0NTkyMTc5NDk3NGE2ZDJhMzUvdGFibGVyYW5nZTpjZTE3YTJjNDc5ZDg0ZDQ1OTIxNzk0OTc0YTZkMmEzNV80LTAtMS0xLTE1OTU0MA_46b96503-24b6-4a19-8510-753d303f604f">2.125% Notes due 2030</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ifbf789a7a75f4a94b1ecc8e7f5692048_D20220101-20220930" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xL2ZyYWc6N2FjMGRkOGIzNWQxNDhiNzlmYTVkMTUwOTYwZGFmZWIvdGFibGU6Y2UxN2EyYzQ3OWQ4NGQ0NTkyMTc5NDk3NGE2ZDJhMzUvdGFibGVyYW5nZTpjZTE3YTJjNDc5ZDg0ZDQ1OTIxNzk0OTc0YTZkMmEzNV80LTEtMS0xLTE1OTU0MA_0e404cc8-ac8c-4df3-b67c-f354b5fac456">LLY30</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ifbf789a7a75f4a94b1ecc8e7f5692048_D20220101-20220930" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xL2ZyYWc6N2FjMGRkOGIzNWQxNDhiNzlmYTVkMTUwOTYwZGFmZWIvdGFibGU6Y2UxN2EyYzQ3OWQ4NGQ0NTkyMTc5NDk3NGE2ZDJhMzUvdGFibGVyYW5nZTpjZTE3YTJjNDc5ZDg0ZDQ1OTIxNzk0OTc0YTZkMmEzNV80LTItMS0xLTE1OTU0MA_aef8cbe7-ee4c-40af-8ab0-53dfe96a5193">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i37d6cf7d3d9642f7887a8b59cb2a9056_D20220101-20220930" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xL2ZyYWc6N2FjMGRkOGIzNWQxNDhiNzlmYTVkMTUwOTYwZGFmZWIvdGFibGU6Y2UxN2EyYzQ3OWQ4NGQ0NTkyMTc5NDk3NGE2ZDJhMzUvdGFibGVyYW5nZTpjZTE3YTJjNDc5ZDg0ZDQ1OTIxNzk0OTc0YTZkMmEzNV81LTAtMS0xLTE1OTU0MA_913a9fed-3e04-4e4c-807c-67eab2803549">0.625% Notes due 2031</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i37d6cf7d3d9642f7887a8b59cb2a9056_D20220101-20220930" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xL2ZyYWc6N2FjMGRkOGIzNWQxNDhiNzlmYTVkMTUwOTYwZGFmZWIvdGFibGU6Y2UxN2EyYzQ3OWQ4NGQ0NTkyMTc5NDk3NGE2ZDJhMzUvdGFibGVyYW5nZTpjZTE3YTJjNDc5ZDg0ZDQ1OTIxNzk0OTc0YTZkMmEzNV81LTEtMS0xLTE1OTU0MA_ffc66a88-c114-447b-b7bc-5bf915ea4017">LLY31</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i37d6cf7d3d9642f7887a8b59cb2a9056_D20220101-20220930" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xL2ZyYWc6N2FjMGRkOGIzNWQxNDhiNzlmYTVkMTUwOTYwZGFmZWIvdGFibGU6Y2UxN2EyYzQ3OWQ4NGQ0NTkyMTc5NDk3NGE2ZDJhMzUvdGFibGVyYW5nZTpjZTE3YTJjNDc5ZDg0ZDQ1OTIxNzk0OTc0YTZkMmEzNV81LTItMS0xLTE1OTU0MA_c75a01b5-50fe-43de-8a36-42a017bff4c4">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia2c9b0358abd4ac1849fbad87ceaf6b2_D20220101-20220930" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xL2ZyYWc6N2FjMGRkOGIzNWQxNDhiNzlmYTVkMTUwOTYwZGFmZWIvdGFibGU6Y2UxN2EyYzQ3OWQ4NGQ0NTkyMTc5NDk3NGE2ZDJhMzUvdGFibGVyYW5nZTpjZTE3YTJjNDc5ZDg0ZDQ1OTIxNzk0OTc0YTZkMmEzNV82LTAtMS0xLTE1OTU0MA_9a5b992b-e8f8-4ab7-a40b-3246ba3fb5b5">0.500% Notes due 2033</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia2c9b0358abd4ac1849fbad87ceaf6b2_D20220101-20220930" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xL2ZyYWc6N2FjMGRkOGIzNWQxNDhiNzlmYTVkMTUwOTYwZGFmZWIvdGFibGU6Y2UxN2EyYzQ3OWQ4NGQ0NTkyMTc5NDk3NGE2ZDJhMzUvdGFibGVyYW5nZTpjZTE3YTJjNDc5ZDg0ZDQ1OTIxNzk0OTc0YTZkMmEzNV82LTEtMS0xLTE1OTU0MA_3606775e-049b-4974-81ad-61a808c92e70">LLY33</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia2c9b0358abd4ac1849fbad87ceaf6b2_D20220101-20220930" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xL2ZyYWc6N2FjMGRkOGIzNWQxNDhiNzlmYTVkMTUwOTYwZGFmZWIvdGFibGU6Y2UxN2EyYzQ3OWQ4NGQ0NTkyMTc5NDk3NGE2ZDJhMzUvdGFibGVyYW5nZTpjZTE3YTJjNDc5ZDg0ZDQ1OTIxNzk0OTc0YTZkMmEzNV82LTItMS0xLTE1OTU0MA_81c94f71-d34a-477c-a69c-2a7419c1d02e">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib18e156e215841b180cc7996ffae9682_D20220101-20220930" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xL2ZyYWc6N2FjMGRkOGIzNWQxNDhiNzlmYTVkMTUwOTYwZGFmZWIvdGFibGU6Y2UxN2EyYzQ3OWQ4NGQ0NTkyMTc5NDk3NGE2ZDJhMzUvdGFibGVyYW5nZTpjZTE3YTJjNDc5ZDg0ZDQ1OTIxNzk0OTc0YTZkMmEzNV83LTAtMS0xLTE1OTU0MA_158fa2e6-e28a-47c4-ac49-d1f6607bd5ac">6.77%&#160;Notes due 2036</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib18e156e215841b180cc7996ffae9682_D20220101-20220930" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xL2ZyYWc6N2FjMGRkOGIzNWQxNDhiNzlmYTVkMTUwOTYwZGFmZWIvdGFibGU6Y2UxN2EyYzQ3OWQ4NGQ0NTkyMTc5NDk3NGE2ZDJhMzUvdGFibGVyYW5nZTpjZTE3YTJjNDc5ZDg0ZDQ1OTIxNzk0OTc0YTZkMmEzNV83LTEtMS0xLTE1OTU0MA_41257b97-39d8-456d-bc21-65ea645cf931">LLY36</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib18e156e215841b180cc7996ffae9682_D20220101-20220930" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xL2ZyYWc6N2FjMGRkOGIzNWQxNDhiNzlmYTVkMTUwOTYwZGFmZWIvdGFibGU6Y2UxN2EyYzQ3OWQ4NGQ0NTkyMTc5NDk3NGE2ZDJhMzUvdGFibGVyYW5nZTpjZTE3YTJjNDc5ZDg0ZDQ1OTIxNzk0OTc0YTZkMmEzNV83LTItMS0xLTE1OTU0MA_4a030d73-4c31-42bd-a6b9-36acfdf550a7">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i80ad5b0231594dcca53dbf943886b1f2_D20220101-20220930" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xL2ZyYWc6N2FjMGRkOGIzNWQxNDhiNzlmYTVkMTUwOTYwZGFmZWIvdGFibGU6Y2UxN2EyYzQ3OWQ4NGQ0NTkyMTc5NDk3NGE2ZDJhMzUvdGFibGVyYW5nZTpjZTE3YTJjNDc5ZDg0ZDQ1OTIxNzk0OTc0YTZkMmEzNV84LTAtMS0xLTE1OTU0MA_edba796e-a498-4abb-8935-421196db3c36">1.625% Notes due 2043</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i80ad5b0231594dcca53dbf943886b1f2_D20220101-20220930" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xL2ZyYWc6N2FjMGRkOGIzNWQxNDhiNzlmYTVkMTUwOTYwZGFmZWIvdGFibGU6Y2UxN2EyYzQ3OWQ4NGQ0NTkyMTc5NDk3NGE2ZDJhMzUvdGFibGVyYW5nZTpjZTE3YTJjNDc5ZDg0ZDQ1OTIxNzk0OTc0YTZkMmEzNV84LTEtMS0xLTE1OTU0MA_922db86d-222b-42ec-835d-78124e46a67f">LLY43</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i80ad5b0231594dcca53dbf943886b1f2_D20220101-20220930" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xL2ZyYWc6N2FjMGRkOGIzNWQxNDhiNzlmYTVkMTUwOTYwZGFmZWIvdGFibGU6Y2UxN2EyYzQ3OWQ4NGQ0NTkyMTc5NDk3NGE2ZDJhMzUvdGFibGVyYW5nZTpjZTE3YTJjNDc5ZDg0ZDQ1OTIxNzk0OTc0YTZkMmEzNV84LTItMS0xLTE1OTU0MA_2dcab404-05b5-4a43-a6a0-b89253fa1ac0">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i8e27869f09004f868cb336c53f59bddd_D20220101-20220930" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xL2ZyYWc6N2FjMGRkOGIzNWQxNDhiNzlmYTVkMTUwOTYwZGFmZWIvdGFibGU6Y2UxN2EyYzQ3OWQ4NGQ0NTkyMTc5NDk3NGE2ZDJhMzUvdGFibGVyYW5nZTpjZTE3YTJjNDc5ZDg0ZDQ1OTIxNzk0OTc0YTZkMmEzNV85LTAtMS0xLTE1OTU0MA_1cbfcbaf-aa17-4a52-8496-a46348ba3912">1.700% Notes due 2049</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i8e27869f09004f868cb336c53f59bddd_D20220101-20220930" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xL2ZyYWc6N2FjMGRkOGIzNWQxNDhiNzlmYTVkMTUwOTYwZGFmZWIvdGFibGU6Y2UxN2EyYzQ3OWQ4NGQ0NTkyMTc5NDk3NGE2ZDJhMzUvdGFibGVyYW5nZTpjZTE3YTJjNDc5ZDg0ZDQ1OTIxNzk0OTc0YTZkMmEzNV85LTEtMS0xLTE1OTU0MA_fd675a67-017c-4ff7-98ea-cb86ef7aad4a">LLY49A</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i8e27869f09004f868cb336c53f59bddd_D20220101-20220930" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xL2ZyYWc6N2FjMGRkOGIzNWQxNDhiNzlmYTVkMTUwOTYwZGFmZWIvdGFibGU6Y2UxN2EyYzQ3OWQ4NGQ0NTkyMTc5NDk3NGE2ZDJhMzUvdGFibGVyYW5nZTpjZTE3YTJjNDc5ZDg0ZDQ1OTIxNzk0OTc0YTZkMmEzNV85LTItMS0xLTE1OTU0MA_1e055b99-3d08-4167-9e0c-2384224f0417">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i94f283ca5ff741c39e115f9c18564a88_D20220101-20220930" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xL2ZyYWc6N2FjMGRkOGIzNWQxNDhiNzlmYTVkMTUwOTYwZGFmZWIvdGFibGU6Y2UxN2EyYzQ3OWQ4NGQ0NTkyMTc5NDk3NGE2ZDJhMzUvdGFibGVyYW5nZTpjZTE3YTJjNDc5ZDg0ZDQ1OTIxNzk0OTc0YTZkMmEzNV8xMC0wLTEtMS0xNTk1NDA_192914d9-d26f-4adf-9b27-0acbb8c50b5c">1.125% Notes due 2051</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i94f283ca5ff741c39e115f9c18564a88_D20220101-20220930" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xL2ZyYWc6N2FjMGRkOGIzNWQxNDhiNzlmYTVkMTUwOTYwZGFmZWIvdGFibGU6Y2UxN2EyYzQ3OWQ4NGQ0NTkyMTc5NDk3NGE2ZDJhMzUvdGFibGVyYW5nZTpjZTE3YTJjNDc5ZDg0ZDQ1OTIxNzk0OTc0YTZkMmEzNV8xMC0xLTEtMS0xNTk1NDA_839eca65-ca4f-4c53-b7a0-b19ed493e5bf">LLY51</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i94f283ca5ff741c39e115f9c18564a88_D20220101-20220930" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xL2ZyYWc6N2FjMGRkOGIzNWQxNDhiNzlmYTVkMTUwOTYwZGFmZWIvdGFibGU6Y2UxN2EyYzQ3OWQ4NGQ0NTkyMTc5NDk3NGE2ZDJhMzUvdGFibGVyYW5nZTpjZTE3YTJjNDc5ZDg0ZDQ1OTIxNzk0OTc0YTZkMmEzNV8xMC0yLTEtMS0xNTk1NDA_23309646-379d-4e1b-9bc4-47bb5e26f63b">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9b0db4c7708642f7a34b06aae1404242_D20220101-20220930" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xL2ZyYWc6N2FjMGRkOGIzNWQxNDhiNzlmYTVkMTUwOTYwZGFmZWIvdGFibGU6Y2UxN2EyYzQ3OWQ4NGQ0NTkyMTc5NDk3NGE2ZDJhMzUvdGFibGVyYW5nZTpjZTE3YTJjNDc5ZDg0ZDQ1OTIxNzk0OTc0YTZkMmEzNV8xMS0wLTEtMS0xNTk1NDA_5702da64-e024-4859-9a1e-4046274ee5d2">1.375% Notes due 2061</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9b0db4c7708642f7a34b06aae1404242_D20220101-20220930" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xL2ZyYWc6N2FjMGRkOGIzNWQxNDhiNzlmYTVkMTUwOTYwZGFmZWIvdGFibGU6Y2UxN2EyYzQ3OWQ4NGQ0NTkyMTc5NDk3NGE2ZDJhMzUvdGFibGVyYW5nZTpjZTE3YTJjNDc5ZDg0ZDQ1OTIxNzk0OTc0YTZkMmEzNV8xMS0xLTEtMS0xNTk1NDA_5f72a643-8266-4c5e-9943-3d77ce8a58af">LLY61</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9b0db4c7708642f7a34b06aae1404242_D20220101-20220930" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xL2ZyYWc6N2FjMGRkOGIzNWQxNDhiNzlmYTVkMTUwOTYwZGFmZWIvdGFibGU6Y2UxN2EyYzQ3OWQ4NGQ0NTkyMTc5NDk3NGE2ZDJhMzUvdGFibGVyYW5nZTpjZTE3YTJjNDc5ZDg0ZDQ1OTIxNzk0OTc0YTZkMmEzNV8xMS0yLTEtMS0xNTk1NDA_cf504784-80e3-40fd-99b2-dd1ebd56b735">New York Stock Exchange</ix:nonNumeric></span></td></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the Registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports) and (2)&#160;has been subject to such filing requirements for the past 90 days.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xL2ZyYWc6N2FjMGRkOGIzNWQxNDhiNzlmYTVkMTUwOTYwZGFmZWIvdGV4dHJlZ2lvbjo3YWMwZGQ4YjM1ZDE0OGI3OWZhNWQxNTA5NjBkYWZlYl8yMDQ1_6a7ca5a9-5562-4b8b-bf6a-c02708e9a727">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:2pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit such files).</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xL2ZyYWc6N2FjMGRkOGIzNWQxNDhiNzlmYTVkMTUwOTYwZGFmZWIvdGV4dHJlZ2lvbjo3YWMwZGQ4YjM1ZDE0OGI3OWZhNWQxNTA5NjBkYWZlYl8yMDQw_35d85772-cc82-4125-8aa9-bbf7cafdb834">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:2pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:19.514%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.285%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.250%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.582%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xL2ZyYWc6N2FjMGRkOGIzNWQxNDhiNzlmYTVkMTUwOTYwZGFmZWIvdGFibGU6M2E1NDlmYmRjZTBkNGY4OWEwZjRlMWZmMTIxZmViMWEvdGFibGVyYW5nZTozYTU0OWZiZGNlMGQ0Zjg5YTBmNGUxZmYxMjFmZWIxYV8wLTAtMS0xLTE1OTU0MA_258f7f21-3480-4d34-a73e-6e3169c3d15f">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accelerated&#160;filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xL2ZyYWc6N2FjMGRkOGIzNWQxNDhiNzlmYTVkMTUwOTYwZGFmZWIvdGFibGU6M2E1NDlmYmRjZTBkNGY4OWEwZjRlMWZmMTIxZmViMWEvdGFibGVyYW5nZTozYTU0OWZiZGNlMGQ0Zjg5YTBmNGUxZmYxMjFmZWIxYV8xLTctMS0xLTE1OTU0MA_b8a371c6-c7f2-470e-b1ed-82ef822c4d9a">&#9744;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xL2ZyYWc6N2FjMGRkOGIzNWQxNDhiNzlmYTVkMTUwOTYwZGFmZWIvdGFibGU6M2E1NDlmYmRjZTBkNGY4OWEwZjRlMWZmMTIxZmViMWEvdGFibGVyYW5nZTozYTU0OWZiZGNlMGQ0Zjg5YTBmNGUxZmYxMjFmZWIxYV8yLTctMS0xLTE1OTU0MA_81a36563-09b5-4400-9d80-d9877eb1fe71">&#9744;</ix:nonNumeric></span></td></tr></table></div><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Yes </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930" name="dei:EntityShellCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xL2ZyYWc6N2FjMGRkOGIzNWQxNDhiNzlmYTVkMTUwOTYwZGFmZWIvdGV4dHJlZ2lvbjo3YWMwZGQ4YjM1ZDE0OGI3OWZhNWQxNTA5NjBkYWZlYl8yMDQ3_1270cc30-e5a9-4c62-a803-3855ce7db00a">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9746;</span></div><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The number of shares of common stock outstanding as of October&#160;28, 2022:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:47.948%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.560%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.192%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Class</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Number of Shares Outstanding</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i465e2cbbe1e444108f9f7bdae9a93ca5_I20221028" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xL2ZyYWc6N2FjMGRkOGIzNWQxNDhiNzlmYTVkMTUwOTYwZGFmZWIvdGFibGU6ZGRhMzY1NDUzNTc0NDAyN2I5MDY1MDEyMDc5N2NkYWUvdGFibGVyYW5nZTpkZGEzNjU0NTM1NzQ0MDI3YjkwNjUwMTIwNzk3Y2RhZV8xLTItMS0xLTE1OTU0MA_05c6a09b-a3e3-437f-ac0c-7bd4b6763e01">950,177,900</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i5fed483d9c7e4f3cbba3a62c53226cd7_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Eli Lilly and Company</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Form 10-Q</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the Quarter Ended September&#160;30, 2022 </span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Table of Contents</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:25.654%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:63.666%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.334%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Page</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5fed483d9c7e4f3cbba3a62c53226cd7_13">PART I. Financial Information</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5fed483d9c7e4f3cbba3a62c53226cd7_13">5</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5fed483d9c7e4f3cbba3a62c53226cd7_16">Item 1.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5fed483d9c7e4f3cbba3a62c53226cd7_16">Financial Statements</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5fed483d9c7e4f3cbba3a62c53226cd7_16">5</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5fed483d9c7e4f3cbba3a62c53226cd7_19">Consolidated Condensed Statements of Operations</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5fed483d9c7e4f3cbba3a62c53226cd7_19">5</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5fed483d9c7e4f3cbba3a62c53226cd7_22">Consolidated Condensed Statements of Comprehensive Income</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5fed483d9c7e4f3cbba3a62c53226cd7_22">6</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5fed483d9c7e4f3cbba3a62c53226cd7_25">Consolidated Condensed Balance Sheets</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5fed483d9c7e4f3cbba3a62c53226cd7_25">7</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5fed483d9c7e4f3cbba3a62c53226cd7_28">Consolidated Condensed Statements of Equity</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5fed483d9c7e4f3cbba3a62c53226cd7_28">8</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5fed483d9c7e4f3cbba3a62c53226cd7_34">Consolidated Condensed Statements of Cash Flows</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5fed483d9c7e4f3cbba3a62c53226cd7_34">10</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5fed483d9c7e4f3cbba3a62c53226cd7_37">Notes to Consolidated Condensed Financial Statements</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5fed483d9c7e4f3cbba3a62c53226cd7_37">11</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5fed483d9c7e4f3cbba3a62c53226cd7_82">Item 2.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5fed483d9c7e4f3cbba3a62c53226cd7_82">Management's Discussion and Analysis of Results of Operations and Financial Condition</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5fed483d9c7e4f3cbba3a62c53226cd7_82">37</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5fed483d9c7e4f3cbba3a62c53226cd7_85">Executive Overview</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5fed483d9c7e4f3cbba3a62c53226cd7_85">37</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5fed483d9c7e4f3cbba3a62c53226cd7_88">Revenue</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5fed483d9c7e4f3cbba3a62c53226cd7_88">45</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5fed483d9c7e4f3cbba3a62c53226cd7_94">Gross Margin, Costs, and Expenses</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5fed483d9c7e4f3cbba3a62c53226cd7_94">49</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5fed483d9c7e4f3cbba3a62c53226cd7_100">Financial Condition and Liquidity</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5fed483d9c7e4f3cbba3a62c53226cd7_100">50</a></span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5fed483d9c7e4f3cbba3a62c53226cd7_103">Critical Accounting Estimates</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5fed483d9c7e4f3cbba3a62c53226cd7_103">51</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5fed483d9c7e4f3cbba3a62c53226cd7_106">Available Information on our Website</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5fed483d9c7e4f3cbba3a62c53226cd7_106">51</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5fed483d9c7e4f3cbba3a62c53226cd7_109">Item 4.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5fed483d9c7e4f3cbba3a62c53226cd7_109">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5fed483d9c7e4f3cbba3a62c53226cd7_109">52</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5fed483d9c7e4f3cbba3a62c53226cd7_112">PART II. Other Information</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5fed483d9c7e4f3cbba3a62c53226cd7_112">53</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5fed483d9c7e4f3cbba3a62c53226cd7_115">Item 1.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5fed483d9c7e4f3cbba3a62c53226cd7_115">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5fed483d9c7e4f3cbba3a62c53226cd7_115">53</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5fed483d9c7e4f3cbba3a62c53226cd7_118">Item 1A.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5fed483d9c7e4f3cbba3a62c53226cd7_118">Risk Factors</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5fed483d9c7e4f3cbba3a62c53226cd7_118">53</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5fed483d9c7e4f3cbba3a62c53226cd7_121">Item 2.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5fed483d9c7e4f3cbba3a62c53226cd7_121">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5fed483d9c7e4f3cbba3a62c53226cd7_121">53</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5fed483d9c7e4f3cbba3a62c53226cd7_124">Item 6.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5fed483d9c7e4f3cbba3a62c53226cd7_124">Exhibits</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5fed483d9c7e4f3cbba3a62c53226cd7_124">54</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5fed483d9c7e4f3cbba3a62c53226cd7_127">Signatures</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5fed483d9c7e4f3cbba3a62c53226cd7_127">54</a></span></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="i5fed483d9c7e4f3cbba3a62c53226cd7_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-style:italic;font-weight:400;line-height:120%">Forward-Looking Statements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%">This Quarterly Report on Form 10-Q </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and our other publicly available documents include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 (Exchange Act), and are subject to the safe harbor created thereby under the Private Securities Litigation Reform Act of 1995. In particular, information appearing under "Management's Discussion and Analysis of Results of Operations and Financial Condition" includes forward-looking statements. Forward-looking statements include all statements that do not relate solely to historical or current facts, and generally can be identified by the use of words such as "may," "believe," "will," "expect," "project," "estimate," "intend," "anticipate," "plan," "continue," or similar expressions or future or conditional verbs. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forward-looking statements inherently involve many risks and uncertainties that could cause actual results to differ materially from those expressed in forward-looking statements. Where, in any forward-looking statement, we express an expectation or belief as to future results or events, it is based on management's current plans and expectations, expressed in good faith and believed to have a reasonable basis. However, we can give no assurance that any such expectation or belief will result or will be achieved or accomplished. Investors therefore should not place undue reliance on forward-looking statements. The following include some but not all of the factors that could cause actual results or events to differ materially from those anticipated:</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of the evolving COVID-19 pandemic or any future pandemic, epidemic, or similar public health threat and the global response thereto;</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">uncertainties related to our efforts to develop, manufacture, and distribute potential treatments for COVID-19;</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the significant costs and uncertainties in the pharmaceutical research and development process, including with respect to the timing and process of obtaining regulatory approvals;</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact and outcome of acquisitions and business development transactions and related integration costs;</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the expiration of intellectual property protection for certain of our products and competition from generic and/or biosimilar products;</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to protect and enforce patents and other intellectual property;</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in patent law or regulations related to data package exclusivity;</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">competitive developments affecting current products and our pipeline;</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">market uptake of recently launched products;</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">information technology system inadequacies, breaches, or operating failures;</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">unauthorized access, disclosure, misappropriation, or compromise of confidential information or other data stored in our information technology systems, networks, and facilities, or those of third parties with whom we share our data;</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">unexpected safety or efficacy concerns associated with our products;</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">litigation, investigations, or other similar proceedings involving past, current, or future products or commercial activities as we are largely self-insured;</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">issues with product supply and regulatory approvals stemming from manufacturing difficulties, disruptions, or shortages, including as a result of demand, labor shortages, third-party performance, or regulatory actions relating to our facilities;</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reliance on third-party relationships and outsourcing arrangements;</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory changes or other developments;</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory actions regarding currently marketed products; </span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">continued pricing pressures and the impact of actions of governmental and private payers affecting pricing of, reimbursement for, and access to pharmaceuticals;</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">devaluations in foreign currency exchange rates, changes in interest rates, and inflation;</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in tax law, tax rates, or events that differ from our assumptions related to tax positions; </span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">asset impairments and restructuring charges;</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of global macroeconomic conditions, trade disruptions, global disputes, unrest, war, or other costs, uncertainties and risks related to engaging in business in foreign jurisdictions; </span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in accounting and reporting standards promulgated by the Financial Accounting Standards Board and the Securities and Exchange Commission (SEC); and</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory compliance problems or government investigations.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%">More information on factors that could cause actual results or events to differ materially from those anticipated is included from time to time in our reports filed with the SEC, including in our Annual Report on </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000059478/000005947822000068/lly-20211231.htm">Form 10-K</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%"> for the year ended December&#160;31, 2021, particularly under the caption "Risk Factors." Investors should understand that it is not possible to predict or identify all such factors and should not consider the risks described above and under Part I, Item 1A, "Risk Factors" of our Annual Report on </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000059478/000005947822000068/lly-20211231.htm">Form 10-K</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%"> to be a complete statement of all potential risks and uncertainties.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%">All forward-looking statements speak only as of the date of this Quarterly Report on Form 10-Q and are expressly qualified in their entirety by the cautionary statements included in or incorporated by reference into this Quarterly Report on Form 10-Q. Except as is required by law, we expressly disclaim any obligation to publicly release any revisions to forward-looking statements to reflect events after the date of this Quarterly Report on Form 10-Q. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="i5fed483d9c7e4f3cbba3a62c53226cd7_13"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:16pt;font-weight:400;line-height:120%;text-decoration:underline">PART I. Financial Information</span></div><div id="i5fed483d9c7e4f3cbba3a62c53226cd7_16"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Item&#160;1. Financial Statements</span></div><div id="i5fed483d9c7e4f3cbba3a62c53226cd7_19"></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Condensed Statements of Operations</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ELI LILLY AND COMPANY AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars and shares in millions, except per-share data)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.613%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.206%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue (Note 2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19fc0325c48543008ea71e1fdcf11d86_D20220701-20220930" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xOS9mcmFnOjI4Y2NkODJiMTEwZDQzY2Y5ZjE3OWFlZTgwNzBiYmY0L3RhYmxlOmYzNmEyNjIyOTBjMzQ3ZmRhMzU4OTA1MDE2MGM2MDhhL3RhYmxlcmFuZ2U6ZjM2YTI2MjI5MGMzNDdmZGEzNTg5MDUwMTYwYzYwOGFfMi0xLTEtMS0xNTk1NDA_84b2baed-d6a5-43c8-9b22-b1720ffd84cc">6,941.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4fa4f6b472a4f269297591b44aba572_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xOS9mcmFnOjI4Y2NkODJiMTEwZDQzY2Y5ZjE3OWFlZTgwNzBiYmY0L3RhYmxlOmYzNmEyNjIyOTBjMzQ3ZmRhMzU4OTA1MDE2MGM2MDhhL3RhYmxlcmFuZ2U6ZjM2YTI2MjI5MGMzNDdmZGEzNTg5MDUwMTYwYzYwOGFfMi0zLTEtMS0xNTk1NDA_2e9d205c-5646-45ea-a8f1-00dea195e123">6,772.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xOS9mcmFnOjI4Y2NkODJiMTEwZDQzY2Y5ZjE3OWFlZTgwNzBiYmY0L3RhYmxlOmYzNmEyNjIyOTBjMzQ3ZmRhMzU4OTA1MDE2MGM2MDhhL3RhYmxlcmFuZ2U6ZjM2YTI2MjI5MGMzNDdmZGEzNTg5MDUwMTYwYzYwOGFfMi01LTEtMS0xNTk1NDA_17382a75-1af1-4741-92e1-29f6816e014e">21,239.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i167ed8f67bef48c49e54fa466400cdaa_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xOS9mcmFnOjI4Y2NkODJiMTEwZDQzY2Y5ZjE3OWFlZTgwNzBiYmY0L3RhYmxlOmYzNmEyNjIyOTBjMzQ3ZmRhMzU4OTA1MDE2MGM2MDhhL3RhYmxlcmFuZ2U6ZjM2YTI2MjI5MGMzNDdmZGEzNTg5MDUwMTYwYzYwOGFfMi03LTEtMS0xNTk1NDA_f14d0139-fe56-4a27-8f9a-40cb6b63c480">20,318.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs, expenses, and other:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19fc0325c48543008ea71e1fdcf11d86_D20220701-20220930" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xOS9mcmFnOjI4Y2NkODJiMTEwZDQzY2Y5ZjE3OWFlZTgwNzBiYmY0L3RhYmxlOmYzNmEyNjIyOTBjMzQ3ZmRhMzU4OTA1MDE2MGM2MDhhL3RhYmxlcmFuZ2U6ZjM2YTI2MjI5MGMzNDdmZGEzNTg5MDUwMTYwYzYwOGFfNC0xLTEtMS0xNTk1NDA_613d7d37-4cb7-418c-9328-7863400be6f6">1,579.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4fa4f6b472a4f269297591b44aba572_D20210701-20210930" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xOS9mcmFnOjI4Y2NkODJiMTEwZDQzY2Y5ZjE3OWFlZTgwNzBiYmY0L3RhYmxlOmYzNmEyNjIyOTBjMzQ3ZmRhMzU4OTA1MDE2MGM2MDhhL3RhYmxlcmFuZ2U6ZjM2YTI2MjI5MGMzNDdmZGEzNTg5MDUwMTYwYzYwOGFfNC0zLTEtMS0xNTk1NDA_f4d08199-fc25-4ff1-b97e-ef128b0b0d21">1,430.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xOS9mcmFnOjI4Y2NkODJiMTEwZDQzY2Y5ZjE3OWFlZTgwNzBiYmY0L3RhYmxlOmYzNmEyNjIyOTBjMzQ3ZmRhMzU4OTA1MDE2MGM2MDhhL3RhYmxlcmFuZ2U6ZjM2YTI2MjI5MGMzNDdmZGEzNTg5MDUwMTYwYzYwOGFfNC01LTEtMS0xNTk1NDA_10675cf5-06cf-43b2-8e6f-cb3244baaa08">5,081.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i167ed8f67bef48c49e54fa466400cdaa_D20210101-20210930" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xOS9mcmFnOjI4Y2NkODJiMTEwZDQzY2Y5ZjE3OWFlZTgwNzBiYmY0L3RhYmxlOmYzNmEyNjIyOTBjMzQ3ZmRhMzU4OTA1MDE2MGM2MDhhL3RhYmxlcmFuZ2U6ZjM2YTI2MjI5MGMzNDdmZGEzNTg5MDUwMTYwYzYwOGFfNC03LTEtMS0xNTk1NDA_f8bcac5c-a235-4a8f-bf87-c90345e34be9">5,262.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19fc0325c48543008ea71e1fdcf11d86_D20220701-20220930" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xOS9mcmFnOjI4Y2NkODJiMTEwZDQzY2Y5ZjE3OWFlZTgwNzBiYmY0L3RhYmxlOmYzNmEyNjIyOTBjMzQ3ZmRhMzU4OTA1MDE2MGM2MDhhL3RhYmxlcmFuZ2U6ZjM2YTI2MjI5MGMzNDdmZGEzNTg5MDUwMTYwYzYwOGFfNS0xLTEtMS0xNTk1NDA_a8fa6aeb-cf55-4189-920d-707e4caebbe8">1,802.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4fa4f6b472a4f269297591b44aba572_D20210701-20210930" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xOS9mcmFnOjI4Y2NkODJiMTEwZDQzY2Y5ZjE3OWFlZTgwNzBiYmY0L3RhYmxlOmYzNmEyNjIyOTBjMzQ3ZmRhMzU4OTA1MDE2MGM2MDhhL3RhYmxlcmFuZ2U6ZjM2YTI2MjI5MGMzNDdmZGEzNTg5MDUwMTYwYzYwOGFfNS0zLTEtMS0xNTk1NDA_d70a720b-459b-40df-9ea5-ecc8edc06707">1,705.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xOS9mcmFnOjI4Y2NkODJiMTEwZDQzY2Y5ZjE3OWFlZTgwNzBiYmY0L3RhYmxlOmYzNmEyNjIyOTBjMzQ3ZmRhMzU4OTA1MDE2MGM2MDhhL3RhYmxlcmFuZ2U6ZjM2YTI2MjI5MGMzNDdmZGEzNTg5MDUwMTYwYzYwOGFfNS01LTEtMS0xNTk1NDA_2a06c20f-888c-4cbc-91df-a48ea8ae00ff">5,194.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i167ed8f67bef48c49e54fa466400cdaa_D20210101-20210930" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xOS9mcmFnOjI4Y2NkODJiMTEwZDQzY2Y5ZjE3OWFlZTgwNzBiYmY0L3RhYmxlOmYzNmEyNjIyOTBjMzQ3ZmRhMzU4OTA1MDE2MGM2MDhhL3RhYmxlcmFuZ2U6ZjM2YTI2MjI5MGMzNDdmZGEzNTg5MDUwMTYwYzYwOGFfNS03LTEtMS0xNTk1NDA_7854caa1-7b76-464d-b7f4-c4101a2e27a2">5,032.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketing, selling, and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19fc0325c48543008ea71e1fdcf11d86_D20220701-20220930" decimals="-5" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xOS9mcmFnOjI4Y2NkODJiMTEwZDQzY2Y5ZjE3OWFlZTgwNzBiYmY0L3RhYmxlOmYzNmEyNjIyOTBjMzQ3ZmRhMzU4OTA1MDE2MGM2MDhhL3RhYmxlcmFuZ2U6ZjM2YTI2MjI5MGMzNDdmZGEzNTg5MDUwMTYwYzYwOGFfNi0xLTEtMS0xNTk1NDA_14213355-7ffb-439f-80f4-67242e82ed5d">1,614.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4fa4f6b472a4f269297591b44aba572_D20210701-20210930" decimals="-5" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xOS9mcmFnOjI4Y2NkODJiMTEwZDQzY2Y5ZjE3OWFlZTgwNzBiYmY0L3RhYmxlOmYzNmEyNjIyOTBjMzQ3ZmRhMzU4OTA1MDE2MGM2MDhhL3RhYmxlcmFuZ2U6ZjM2YTI2MjI5MGMzNDdmZGEzNTg5MDUwMTYwYzYwOGFfNi0zLTEtMS0xNTk1NDA_35072b4f-0452-4d41-8273-955eed100b0f">1,577.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930" decimals="-5" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xOS9mcmFnOjI4Y2NkODJiMTEwZDQzY2Y5ZjE3OWFlZTgwNzBiYmY0L3RhYmxlOmYzNmEyNjIyOTBjMzQ3ZmRhMzU4OTA1MDE2MGM2MDhhL3RhYmxlcmFuZ2U6ZjM2YTI2MjI5MGMzNDdmZGEzNTg5MDUwMTYwYzYwOGFfNi01LTEtMS0xNTk1NDA_67f8179b-9bdd-481b-82f9-f6bcd12659f9">4,797.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i167ed8f67bef48c49e54fa466400cdaa_D20210101-20210930" decimals="-5" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xOS9mcmFnOjI4Y2NkODJiMTEwZDQzY2Y5ZjE3OWFlZTgwNzBiYmY0L3RhYmxlOmYzNmEyNjIyOTBjMzQ3ZmRhMzU4OTA1MDE2MGM2MDhhL3RhYmxlcmFuZ2U6ZjM2YTI2MjI5MGMzNDdmZGEzNTg5MDUwMTYwYzYwOGFfNi03LTEtMS0xNTk1NDA_05d9ca06-addd-46cf-ab12-0e16beb9b4ac">4,839.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired in-process research and development and development milestones (Note 3)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19fc0325c48543008ea71e1fdcf11d86_D20220701-20220930" decimals="-5" name="lly:AcquiredInProcessResearchAndDevelopmentAndDevelopmentMilestones" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xOS9mcmFnOjI4Y2NkODJiMTEwZDQzY2Y5ZjE3OWFlZTgwNzBiYmY0L3RhYmxlOmYzNmEyNjIyOTBjMzQ3ZmRhMzU4OTA1MDE2MGM2MDhhL3RhYmxlcmFuZ2U6ZjM2YTI2MjI5MGMzNDdmZGEzNTg5MDUwMTYwYzYwOGFfNy0xLTEtMS0xNTk1NDA_8b459b38-3dde-4b01-86a3-b90670ef8e72">62.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4fa4f6b472a4f269297591b44aba572_D20210701-20210930" decimals="-5" name="lly:AcquiredInProcessResearchAndDevelopmentAndDevelopmentMilestones" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xOS9mcmFnOjI4Y2NkODJiMTEwZDQzY2Y5ZjE3OWFlZTgwNzBiYmY0L3RhYmxlOmYzNmEyNjIyOTBjMzQ3ZmRhMzU4OTA1MDE2MGM2MDhhL3RhYmxlcmFuZ2U6ZjM2YTI2MjI5MGMzNDdmZGEzNTg5MDUwMTYwYzYwOGFfNy0zLTEtMS0xNTk1NDA_930acb16-c7a4-46f2-b4ec-0c4ce1d82bd4">177.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930" decimals="-5" name="lly:AcquiredInProcessResearchAndDevelopmentAndDevelopmentMilestones" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xOS9mcmFnOjI4Y2NkODJiMTEwZDQzY2Y5ZjE3OWFlZTgwNzBiYmY0L3RhYmxlOmYzNmEyNjIyOTBjMzQ3ZmRhMzU4OTA1MDE2MGM2MDhhL3RhYmxlcmFuZ2U6ZjM2YTI2MjI5MGMzNDdmZGEzNTg5MDUwMTYwYzYwOGFfNy01LTEtMS0xNTk1NDA_814d2bcb-fad1-4171-8df7-5bf614293fde">668.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i167ed8f67bef48c49e54fa466400cdaa_D20210101-20210930" decimals="-5" name="lly:AcquiredInProcessResearchAndDevelopmentAndDevelopmentMilestones" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xOS9mcmFnOjI4Y2NkODJiMTEwZDQzY2Y5ZjE3OWFlZTgwNzBiYmY0L3RhYmxlOmYzNmEyNjIyOTBjMzQ3ZmRhMzU4OTA1MDE2MGM2MDhhL3RhYmxlcmFuZ2U6ZjM2YTI2MjI5MGMzNDdmZGEzNTg5MDUwMTYwYzYwOGFfNy03LTEtMS0xNTk1NDA_08faa181-0763-4f6c-9031-a7e1539d6611">532.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset impairment, restructuring, and other special charges (Note 5)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19fc0325c48543008ea71e1fdcf11d86_D20220701-20220930" decimals="-5" name="us-gaap:RestructuringSettlementAndImpairmentProvisions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xOS9mcmFnOjI4Y2NkODJiMTEwZDQzY2Y5ZjE3OWFlZTgwNzBiYmY0L3RhYmxlOmYzNmEyNjIyOTBjMzQ3ZmRhMzU4OTA1MDE2MGM2MDhhL3RhYmxlcmFuZ2U6ZjM2YTI2MjI5MGMzNDdmZGEzNTg5MDUwMTYwYzYwOGFfOC0xLTEtMS0xNTk1NDA_871cfb58-2491-43dc-b184-34f9c6cf822b">206.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4fa4f6b472a4f269297591b44aba572_D20210701-20210930" decimals="-5" name="us-gaap:RestructuringSettlementAndImpairmentProvisions" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xOS9mcmFnOjI4Y2NkODJiMTEwZDQzY2Y5ZjE3OWFlZTgwNzBiYmY0L3RhYmxlOmYzNmEyNjIyOTBjMzQ3ZmRhMzU4OTA1MDE2MGM2MDhhL3RhYmxlcmFuZ2U6ZjM2YTI2MjI5MGMzNDdmZGEzNTg5MDUwMTYwYzYwOGFfOC0zLTEtMS0xNTk1NDA_440c64be-a839-43d8-afea-b5abbee97a08">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930" decimals="-5" name="us-gaap:RestructuringSettlementAndImpairmentProvisions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xOS9mcmFnOjI4Y2NkODJiMTEwZDQzY2Y5ZjE3OWFlZTgwNzBiYmY0L3RhYmxlOmYzNmEyNjIyOTBjMzQ3ZmRhMzU4OTA1MDE2MGM2MDhhL3RhYmxlcmFuZ2U6ZjM2YTI2MjI5MGMzNDdmZGEzNTg5MDUwMTYwYzYwOGFfOC01LTEtMS0xNTk1NDA_3d999b88-4ddd-4fb1-bbaa-a10090f42bea">206.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i167ed8f67bef48c49e54fa466400cdaa_D20210101-20210930" decimals="-5" name="us-gaap:RestructuringSettlementAndImpairmentProvisions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xOS9mcmFnOjI4Y2NkODJiMTEwZDQzY2Y5ZjE3OWFlZTgwNzBiYmY0L3RhYmxlOmYzNmEyNjIyOTBjMzQ3ZmRhMzU4OTA1MDE2MGM2MDhhL3RhYmxlcmFuZ2U6ZjM2YTI2MjI5MGMzNDdmZGEzNTg5MDUwMTYwYzYwOGFfOC03LTEtMS0xNTk1NDA_6408657e-186f-4757-bc29-234f3692c156">211.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#8211;net, (income) expense (Note 11)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19fc0325c48543008ea71e1fdcf11d86_D20220701-20220930" decimals="-5" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xOS9mcmFnOjI4Y2NkODJiMTEwZDQzY2Y5ZjE3OWFlZTgwNzBiYmY0L3RhYmxlOmYzNmEyNjIyOTBjMzQ3ZmRhMzU4OTA1MDE2MGM2MDhhL3RhYmxlcmFuZ2U6ZjM2YTI2MjI5MGMzNDdmZGEzNTg5MDUwMTYwYzYwOGFfOS0xLTEtMS0xNTk1NDA_0a080a2b-b9ee-4570-bc4c-b4a3b0d6dc9c">111.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4fa4f6b472a4f269297591b44aba572_D20210701-20210930" decimals="-5" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xOS9mcmFnOjI4Y2NkODJiMTEwZDQzY2Y5ZjE3OWFlZTgwNzBiYmY0L3RhYmxlOmYzNmEyNjIyOTBjMzQ3ZmRhMzU4OTA1MDE2MGM2MDhhL3RhYmxlcmFuZ2U6ZjM2YTI2MjI5MGMzNDdmZGEzNTg5MDUwMTYwYzYwOGFfOS0zLTEtMS0xNTk1NDA_bf168203-185c-4fdc-8ed2-949d74015438">635.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930" decimals="-5" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xOS9mcmFnOjI4Y2NkODJiMTEwZDQzY2Y5ZjE3OWFlZTgwNzBiYmY0L3RhYmxlOmYzNmEyNjIyOTBjMzQ3ZmRhMzU4OTA1MDE2MGM2MDhhL3RhYmxlcmFuZ2U6ZjM2YTI2MjI5MGMzNDdmZGEzNTg5MDUwMTYwYzYwOGFfOS01LTEtMS0xNTk1NDA_da74eabf-5727-4eaa-92ef-c61d12d89473">580.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i167ed8f67bef48c49e54fa466400cdaa_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xOS9mcmFnOjI4Y2NkODJiMTEwZDQzY2Y5ZjE3OWFlZTgwNzBiYmY0L3RhYmxlOmYzNmEyNjIyOTBjMzQ3ZmRhMzU4OTA1MDE2MGM2MDhhL3RhYmxlcmFuZ2U6ZjM2YTI2MjI5MGMzNDdmZGEzNTg5MDUwMTYwYzYwOGFfOS03LTEtMS0xNTk1NDA_0c41ebaa-dad9-4452-984b-fec846c6f7fa">124.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19fc0325c48543008ea71e1fdcf11d86_D20220701-20220930" decimals="-5" name="lly:CostOfSalesOperatingExpensesAndOtherNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xOS9mcmFnOjI4Y2NkODJiMTEwZDQzY2Y5ZjE3OWFlZTgwNzBiYmY0L3RhYmxlOmYzNmEyNjIyOTBjMzQ3ZmRhMzU4OTA1MDE2MGM2MDhhL3RhYmxlcmFuZ2U6ZjM2YTI2MjI5MGMzNDdmZGEzNTg5MDUwMTYwYzYwOGFfMTAtMS0xLTEtMTU5NTQw_12970031-5dbe-4849-a3f4-8ffb277f515c">5,376.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4fa4f6b472a4f269297591b44aba572_D20210701-20210930" decimals="-5" name="lly:CostOfSalesOperatingExpensesAndOtherNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xOS9mcmFnOjI4Y2NkODJiMTEwZDQzY2Y5ZjE3OWFlZTgwNzBiYmY0L3RhYmxlOmYzNmEyNjIyOTBjMzQ3ZmRhMzU4OTA1MDE2MGM2MDhhL3RhYmxlcmFuZ2U6ZjM2YTI2MjI5MGMzNDdmZGEzNTg5MDUwMTYwYzYwOGFfMTAtMy0xLTEtMTU5NTQw_6cc08d87-8577-40d3-8162-b4bfa1f99ae9">5,527.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930" decimals="-5" name="lly:CostOfSalesOperatingExpensesAndOtherNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xOS9mcmFnOjI4Y2NkODJiMTEwZDQzY2Y5ZjE3OWFlZTgwNzBiYmY0L3RhYmxlOmYzNmEyNjIyOTBjMzQ3ZmRhMzU4OTA1MDE2MGM2MDhhL3RhYmxlcmFuZ2U6ZjM2YTI2MjI5MGMzNDdmZGEzNTg5MDUwMTYwYzYwOGFfMTAtNS0xLTEtMTU5NTQw_505cc220-bff5-4c8a-ba7f-c0f9d961bc6e">16,529.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i167ed8f67bef48c49e54fa466400cdaa_D20210101-20210930" decimals="-5" name="lly:CostOfSalesOperatingExpensesAndOtherNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xOS9mcmFnOjI4Y2NkODJiMTEwZDQzY2Y5ZjE3OWFlZTgwNzBiYmY0L3RhYmxlOmYzNmEyNjIyOTBjMzQ3ZmRhMzU4OTA1MDE2MGM2MDhhL3RhYmxlcmFuZ2U6ZjM2YTI2MjI5MGMzNDdmZGEzNTg5MDUwMTYwYzYwOGFfMTAtNy0xLTEtMTU5NTQw_a69242b6-87ed-45d0-9f4f-09653dc3dd7a">16,002.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income before income taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19fc0325c48543008ea71e1fdcf11d86_D20220701-20220930" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xOS9mcmFnOjI4Y2NkODJiMTEwZDQzY2Y5ZjE3OWFlZTgwNzBiYmY0L3RhYmxlOmYzNmEyNjIyOTBjMzQ3ZmRhMzU4OTA1MDE2MGM2MDhhL3RhYmxlcmFuZ2U6ZjM2YTI2MjI5MGMzNDdmZGEzNTg5MDUwMTYwYzYwOGFfMTEtMS0xLTEtMTU5NTQw_2eef83f2-97e8-4ef0-9ec0-103a268fbf7c">1,565.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4fa4f6b472a4f269297591b44aba572_D20210701-20210930" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xOS9mcmFnOjI4Y2NkODJiMTEwZDQzY2Y5ZjE3OWFlZTgwNzBiYmY0L3RhYmxlOmYzNmEyNjIyOTBjMzQ3ZmRhMzU4OTA1MDE2MGM2MDhhL3RhYmxlcmFuZ2U6ZjM2YTI2MjI5MGMzNDdmZGEzNTg5MDUwMTYwYzYwOGFfMTEtMy0xLTEtMTU5NTQw_aeb046cf-4b29-4557-8997-ab22bb920225">1,245.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xOS9mcmFnOjI4Y2NkODJiMTEwZDQzY2Y5ZjE3OWFlZTgwNzBiYmY0L3RhYmxlOmYzNmEyNjIyOTBjMzQ3ZmRhMzU4OTA1MDE2MGM2MDhhL3RhYmxlcmFuZ2U6ZjM2YTI2MjI5MGMzNDdmZGEzNTg5MDUwMTYwYzYwOGFfMTEtNS0xLTEtMTU5NTQw_97d34a5e-dce8-44a7-870d-73f5bcb10b3d">4,710.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i167ed8f67bef48c49e54fa466400cdaa_D20210101-20210930" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xOS9mcmFnOjI4Y2NkODJiMTEwZDQzY2Y5ZjE3OWFlZTgwNzBiYmY0L3RhYmxlOmYzNmEyNjIyOTBjMzQ3ZmRhMzU4OTA1MDE2MGM2MDhhL3RhYmxlcmFuZ2U6ZjM2YTI2MjI5MGMzNDdmZGEzNTg5MDUwMTYwYzYwOGFfMTEtNy0xLTEtMTU5NTQw_7f774311-61dc-4ef9-a174-7c15fecd6af8">4,315.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes (Note 7)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19fc0325c48543008ea71e1fdcf11d86_D20220701-20220930" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xOS9mcmFnOjI4Y2NkODJiMTEwZDQzY2Y5ZjE3OWFlZTgwNzBiYmY0L3RhYmxlOmYzNmEyNjIyOTBjMzQ3ZmRhMzU4OTA1MDE2MGM2MDhhL3RhYmxlcmFuZ2U6ZjM2YTI2MjI5MGMzNDdmZGEzNTg5MDUwMTYwYzYwOGFfMTItMS0xLTEtMTU5NTQw_6e1439d1-de64-4386-9f91-bcbf6791b807">113.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4fa4f6b472a4f269297591b44aba572_D20210701-20210930" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xOS9mcmFnOjI4Y2NkODJiMTEwZDQzY2Y5ZjE3OWFlZTgwNzBiYmY0L3RhYmxlOmYzNmEyNjIyOTBjMzQ3ZmRhMzU4OTA1MDE2MGM2MDhhL3RhYmxlcmFuZ2U6ZjM2YTI2MjI5MGMzNDdmZGEzNTg5MDUwMTYwYzYwOGFfMTItMy0xLTEtMTU5NTQw_6969386e-d191-4be3-9609-64ba670cddaa">135.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xOS9mcmFnOjI4Y2NkODJiMTEwZDQzY2Y5ZjE3OWFlZTgwNzBiYmY0L3RhYmxlOmYzNmEyNjIyOTBjMzQ3ZmRhMzU4OTA1MDE2MGM2MDhhL3RhYmxlcmFuZ2U6ZjM2YTI2MjI5MGMzNDdmZGEzNTg5MDUwMTYwYzYwOGFfMTItNS0xLTEtMTU5NTQw_19971751-8fac-441f-a382-ebacb1652bdb">402.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i167ed8f67bef48c49e54fa466400cdaa_D20210101-20210930" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xOS9mcmFnOjI4Y2NkODJiMTEwZDQzY2Y5ZjE3OWFlZTgwNzBiYmY0L3RhYmxlOmYzNmEyNjIyOTBjMzQ3ZmRhMzU4OTA1MDE2MGM2MDhhL3RhYmxlcmFuZ2U6ZjM2YTI2MjI5MGMzNDdmZGEzNTg5MDUwMTYwYzYwOGFfMTItNy0xLTEtMTU5NTQw_bb0754e4-3dee-4116-b570-59f9086ff5ab">460.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19fc0325c48543008ea71e1fdcf11d86_D20220701-20220930" decimals="-5" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xOS9mcmFnOjI4Y2NkODJiMTEwZDQzY2Y5ZjE3OWFlZTgwNzBiYmY0L3RhYmxlOmYzNmEyNjIyOTBjMzQ3ZmRhMzU4OTA1MDE2MGM2MDhhL3RhYmxlcmFuZ2U6ZjM2YTI2MjI5MGMzNDdmZGEzNTg5MDUwMTYwYzYwOGFfMTMtMS0xLTEtMTU5NTQw_58d9c5cb-4c5d-40be-a06d-2489d29adc4b">1,451.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4fa4f6b472a4f269297591b44aba572_D20210701-20210930" decimals="-5" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xOS9mcmFnOjI4Y2NkODJiMTEwZDQzY2Y5ZjE3OWFlZTgwNzBiYmY0L3RhYmxlOmYzNmEyNjIyOTBjMzQ3ZmRhMzU4OTA1MDE2MGM2MDhhL3RhYmxlcmFuZ2U6ZjM2YTI2MjI5MGMzNDdmZGEzNTg5MDUwMTYwYzYwOGFfMTMtMy0xLTEtMTU5NTQw_c6e26b7d-c614-4b1e-9f5b-889f1187c777">1,110.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930" decimals="-5" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xOS9mcmFnOjI4Y2NkODJiMTEwZDQzY2Y5ZjE3OWFlZTgwNzBiYmY0L3RhYmxlOmYzNmEyNjIyOTBjMzQ3ZmRhMzU4OTA1MDE2MGM2MDhhL3RhYmxlcmFuZ2U6ZjM2YTI2MjI5MGMzNDdmZGEzNTg5MDUwMTYwYzYwOGFfMTMtNS0xLTEtMTU5NTQw_6d3a5b51-fef7-4442-b0ae-e0b885eeddf5">4,307.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i167ed8f67bef48c49e54fa466400cdaa_D20210101-20210930" decimals="-5" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xOS9mcmFnOjI4Y2NkODJiMTEwZDQzY2Y5ZjE3OWFlZTgwNzBiYmY0L3RhYmxlOmYzNmEyNjIyOTBjMzQ3ZmRhMzU4OTA1MDE2MGM2MDhhL3RhYmxlcmFuZ2U6ZjM2YTI2MjI5MGMzNDdmZGEzNTg5MDUwMTYwYzYwOGFfMTMtNy0xLTEtMTU5NTQw_b9809708-0d2a-41f9-9bca-7ebbc7febc06">3,855.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings per share:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i19fc0325c48543008ea71e1fdcf11d86_D20220701-20220930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xOS9mcmFnOjI4Y2NkODJiMTEwZDQzY2Y5ZjE3OWFlZTgwNzBiYmY0L3RhYmxlOmYzNmEyNjIyOTBjMzQ3ZmRhMzU4OTA1MDE2MGM2MDhhL3RhYmxlcmFuZ2U6ZjM2YTI2MjI5MGMzNDdmZGEzNTg5MDUwMTYwYzYwOGFfMTgtMS0xLTEtMTU5NTQw_1788c234-9267-4223-8b6d-ad74cc709e5c">1.61</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie4fa4f6b472a4f269297591b44aba572_D20210701-20210930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xOS9mcmFnOjI4Y2NkODJiMTEwZDQzY2Y5ZjE3OWFlZTgwNzBiYmY0L3RhYmxlOmYzNmEyNjIyOTBjMzQ3ZmRhMzU4OTA1MDE2MGM2MDhhL3RhYmxlcmFuZ2U6ZjM2YTI2MjI5MGMzNDdmZGEzNTg5MDUwMTYwYzYwOGFfMTgtMy0xLTEtMTU5NTQw_44d673fa-a784-49b3-9a55-f65a3ef4135c">1.22</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xOS9mcmFnOjI4Y2NkODJiMTEwZDQzY2Y5ZjE3OWFlZTgwNzBiYmY0L3RhYmxlOmYzNmEyNjIyOTBjMzQ3ZmRhMzU4OTA1MDE2MGM2MDhhL3RhYmxlcmFuZ2U6ZjM2YTI2MjI5MGMzNDdmZGEzNTg5MDUwMTYwYzYwOGFfMTgtNS0xLTEtMTU5NTQw_ab48a2bc-46bb-46ec-ba3a-6fced6b4efc8">4.78</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i167ed8f67bef48c49e54fa466400cdaa_D20210101-20210930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xOS9mcmFnOjI4Y2NkODJiMTEwZDQzY2Y5ZjE3OWFlZTgwNzBiYmY0L3RhYmxlOmYzNmEyNjIyOTBjMzQ3ZmRhMzU4OTA1MDE2MGM2MDhhL3RhYmxlcmFuZ2U6ZjM2YTI2MjI5MGMzNDdmZGEzNTg5MDUwMTYwYzYwOGFfMTgtNy0xLTEtMTU5NTQw_e2fe351d-fd87-4ba1-ab7f-45d55f23330a">4.25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i19fc0325c48543008ea71e1fdcf11d86_D20220701-20220930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xOS9mcmFnOjI4Y2NkODJiMTEwZDQzY2Y5ZjE3OWFlZTgwNzBiYmY0L3RhYmxlOmYzNmEyNjIyOTBjMzQ3ZmRhMzU4OTA1MDE2MGM2MDhhL3RhYmxlcmFuZ2U6ZjM2YTI2MjI5MGMzNDdmZGEzNTg5MDUwMTYwYzYwOGFfMjAtMS0xLTEtMTU5NTQw_a40aefd9-b793-4ede-a8b5-9ee491bc0d74">1.61</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie4fa4f6b472a4f269297591b44aba572_D20210701-20210930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xOS9mcmFnOjI4Y2NkODJiMTEwZDQzY2Y5ZjE3OWFlZTgwNzBiYmY0L3RhYmxlOmYzNmEyNjIyOTBjMzQ3ZmRhMzU4OTA1MDE2MGM2MDhhL3RhYmxlcmFuZ2U6ZjM2YTI2MjI5MGMzNDdmZGEzNTg5MDUwMTYwYzYwOGFfMjAtMy0xLTEtMTU5NTQw_6489d081-a1d5-4648-aa7e-d1fde0d8b14c">1.22</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xOS9mcmFnOjI4Y2NkODJiMTEwZDQzY2Y5ZjE3OWFlZTgwNzBiYmY0L3RhYmxlOmYzNmEyNjIyOTBjMzQ3ZmRhMzU4OTA1MDE2MGM2MDhhL3RhYmxlcmFuZ2U6ZjM2YTI2MjI5MGMzNDdmZGEzNTg5MDUwMTYwYzYwOGFfMjAtNS0xLTEtMTU5NTQw_1cae5aec-ea4f-4289-8342-edb9c6e419be">4.76</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i167ed8f67bef48c49e54fa466400cdaa_D20210101-20210930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xOS9mcmFnOjI4Y2NkODJiMTEwZDQzY2Y5ZjE3OWFlZTgwNzBiYmY0L3RhYmxlOmYzNmEyNjIyOTBjMzQ3ZmRhMzU4OTA1MDE2MGM2MDhhL3RhYmxlcmFuZ2U6ZjM2YTI2MjI5MGMzNDdmZGEzNTg5MDUwMTYwYzYwOGFfMjAtNy0xLTEtMTU5NTQw_9459800a-920f-4ba4-a2ef-6c573174cb5d">4.23</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares used in calculation of earnings per share:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i19fc0325c48543008ea71e1fdcf11d86_D20220701-20220930" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xOS9mcmFnOjI4Y2NkODJiMTEwZDQzY2Y5ZjE3OWFlZTgwNzBiYmY0L3RhYmxlOmYzNmEyNjIyOTBjMzQ3ZmRhMzU4OTA1MDE2MGM2MDhhL3RhYmxlcmFuZ2U6ZjM2YTI2MjI5MGMzNDdmZGEzNTg5MDUwMTYwYzYwOGFfMjQtMS0xLTEtMTU5NTQw_a342be05-e5e0-4fb9-9cf0-bf15a8143672">900.7</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie4fa4f6b472a4f269297591b44aba572_D20210701-20210930" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xOS9mcmFnOjI4Y2NkODJiMTEwZDQzY2Y5ZjE3OWFlZTgwNzBiYmY0L3RhYmxlOmYzNmEyNjIyOTBjMzQ3ZmRhMzU4OTA1MDE2MGM2MDhhL3RhYmxlcmFuZ2U6ZjM2YTI2MjI5MGMzNDdmZGEzNTg5MDUwMTYwYzYwOGFfMjQtMy0xLTEtMTU5NTQw_45f2e109-295f-4292-b653-57a9576a5425">906.7</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xOS9mcmFnOjI4Y2NkODJiMTEwZDQzY2Y5ZjE3OWFlZTgwNzBiYmY0L3RhYmxlOmYzNmEyNjIyOTBjMzQ3ZmRhMzU4OTA1MDE2MGM2MDhhL3RhYmxlcmFuZ2U6ZjM2YTI2MjI5MGMzNDdmZGEzNTg5MDUwMTYwYzYwOGFfMjQtNS0xLTEtMTU5NTQw_be7c3387-beae-4102-b101-6b8c58663460">901.8</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i167ed8f67bef48c49e54fa466400cdaa_D20210101-20210930" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xOS9mcmFnOjI4Y2NkODJiMTEwZDQzY2Y5ZjE3OWFlZTgwNzBiYmY0L3RhYmxlOmYzNmEyNjIyOTBjMzQ3ZmRhMzU4OTA1MDE2MGM2MDhhL3RhYmxlcmFuZ2U6ZjM2YTI2MjI5MGMzNDdmZGEzNTg5MDUwMTYwYzYwOGFfMjQtNy0xLTEtMTU5NTQw_12a33f33-8b87-4de1-a2e6-1ffbea5b8339">907.7</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i19fc0325c48543008ea71e1fdcf11d86_D20220701-20220930" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xOS9mcmFnOjI4Y2NkODJiMTEwZDQzY2Y5ZjE3OWFlZTgwNzBiYmY0L3RhYmxlOmYzNmEyNjIyOTBjMzQ3ZmRhMzU4OTA1MDE2MGM2MDhhL3RhYmxlcmFuZ2U6ZjM2YTI2MjI5MGMzNDdmZGEzNTg5MDUwMTYwYzYwOGFfMjUtMS0xLTEtMTU5NTQw_18dcdabc-0a87-4da1-97d2-dde6115ab295">903.8</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie4fa4f6b472a4f269297591b44aba572_D20210701-20210930" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xOS9mcmFnOjI4Y2NkODJiMTEwZDQzY2Y5ZjE3OWFlZTgwNzBiYmY0L3RhYmxlOmYzNmEyNjIyOTBjMzQ3ZmRhMzU4OTA1MDE2MGM2MDhhL3RhYmxlcmFuZ2U6ZjM2YTI2MjI5MGMzNDdmZGEzNTg5MDUwMTYwYzYwOGFfMjUtMy0xLTEtMTU5NTQw_80fbbb1b-385c-462c-a772-a2b6929434e8">910.8</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xOS9mcmFnOjI4Y2NkODJiMTEwZDQzY2Y5ZjE3OWFlZTgwNzBiYmY0L3RhYmxlOmYzNmEyNjIyOTBjMzQ3ZmRhMzU4OTA1MDE2MGM2MDhhL3RhYmxlcmFuZ2U6ZjM2YTI2MjI5MGMzNDdmZGEzNTg5MDUwMTYwYzYwOGFfMjUtNS0xLTEtMTU5NTQw_35c97634-24cf-4189-8d10-a2e1a41b8118">904.5</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i167ed8f67bef48c49e54fa466400cdaa_D20210101-20210930" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xOS9mcmFnOjI4Y2NkODJiMTEwZDQzY2Y5ZjE3OWFlZTgwNzBiYmY0L3RhYmxlOmYzNmEyNjIyOTBjMzQ3ZmRhMzU4OTA1MDE2MGM2MDhhL3RhYmxlcmFuZ2U6ZjM2YTI2MjI5MGMzNDdmZGEzNTg5MDUwMTYwYzYwOGFfMjUtNy0xLTEtMTU5NTQw_4eb16921-f47a-45ae-9e75-e4218e04e70c">911.7</ix:nonFraction></span></td></tr></table></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See notes to consolidated condensed financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="i5fed483d9c7e4f3cbba3a62c53226cd7_22"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Condensed Statements of Comprehensive Income</span></div><div style="text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ELI LILLY AND COMPANY AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in millions)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.443%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.500%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19fc0325c48543008ea71e1fdcf11d86_D20220701-20220930" decimals="-5" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yMi9mcmFnOmFkY2U4MDk2NmRlYTQzMmM4YTY4MGZlMzYxMGFmYjU2L3RhYmxlOjFhNzM4NWIwZTEyMjRhYTliM2FiNTZlY2Y3Y2VhYzUyL3RhYmxlcmFuZ2U6MWE3Mzg1YjBlMTIyNGFhOWIzYWI1NmVjZjdjZWFjNTJfMi0xLTEtMS0xNTk1NDA_58d9c5cb-4c5d-40be-a06d-2489d29adc4b">1,451.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4fa4f6b472a4f269297591b44aba572_D20210701-20210930" decimals="-5" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yMi9mcmFnOmFkY2U4MDk2NmRlYTQzMmM4YTY4MGZlMzYxMGFmYjU2L3RhYmxlOjFhNzM4NWIwZTEyMjRhYTliM2FiNTZlY2Y3Y2VhYzUyL3RhYmxlcmFuZ2U6MWE3Mzg1YjBlMTIyNGFhOWIzYWI1NmVjZjdjZWFjNTJfMi0zLTEtMS0xNTk1NDA_c6e26b7d-c614-4b1e-9f5b-889f1187c777">1,110.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930" decimals="-5" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yMi9mcmFnOmFkY2U4MDk2NmRlYTQzMmM4YTY4MGZlMzYxMGFmYjU2L3RhYmxlOjFhNzM4NWIwZTEyMjRhYTliM2FiNTZlY2Y3Y2VhYzUyL3RhYmxlcmFuZ2U6MWE3Mzg1YjBlMTIyNGFhOWIzYWI1NmVjZjdjZWFjNTJfMi01LTEtMS0xNTk1NDA_87698447-ba66-4f71-89c1-b28a71c9e82a">4,307.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i167ed8f67bef48c49e54fa466400cdaa_D20210101-20210930" decimals="-5" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yMi9mcmFnOmFkY2U4MDk2NmRlYTQzMmM4YTY4MGZlMzYxMGFmYjU2L3RhYmxlOjFhNzM4NWIwZTEyMjRhYTliM2FiNTZlY2Y3Y2VhYzUyL3RhYmxlcmFuZ2U6MWE3Mzg1YjBlMTIyNGFhOWIzYWI1NmVjZjdjZWFjNTJfMi03LTEtMS0xNTk1NDA_912d99b5-d76a-4c0a-b3cd-69c00d2c8eed">3,855.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of tax (Note 10)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i19fc0325c48543008ea71e1fdcf11d86_D20220701-20220930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yMi9mcmFnOmFkY2U4MDk2NmRlYTQzMmM4YTY4MGZlMzYxMGFmYjU2L3RhYmxlOjFhNzM4NWIwZTEyMjRhYTliM2FiNTZlY2Y3Y2VhYzUyL3RhYmxlcmFuZ2U6MWE3Mzg1YjBlMTIyNGFhOWIzYWI1NmVjZjdjZWFjNTJfMy0xLTEtMS0xNTk1NDA_3492514b-29f6-4a97-b4ba-d4a886cd03bd">8.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4fa4f6b472a4f269297591b44aba572_D20210701-20210930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yMi9mcmFnOmFkY2U4MDk2NmRlYTQzMmM4YTY4MGZlMzYxMGFmYjU2L3RhYmxlOjFhNzM4NWIwZTEyMjRhYTliM2FiNTZlY2Y3Y2VhYzUyL3RhYmxlcmFuZ2U6MWE3Mzg1YjBlMTIyNGFhOWIzYWI1NmVjZjdjZWFjNTJfMy0zLTEtMS0xNTk1NDA_6bd78490-2767-4792-8223-3f77a669bcc7">114.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yMi9mcmFnOmFkY2U4MDk2NmRlYTQzMmM4YTY4MGZlMzYxMGFmYjU2L3RhYmxlOjFhNzM4NWIwZTEyMjRhYTliM2FiNTZlY2Y3Y2VhYzUyL3RhYmxlcmFuZ2U6MWE3Mzg1YjBlMTIyNGFhOWIzYWI1NmVjZjdjZWFjNTJfMy01LTEtMS0xNTk1NDA_46404f0d-dab3-4be2-8104-f9f3be52ab8b">47.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i167ed8f67bef48c49e54fa466400cdaa_D20210101-20210930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yMi9mcmFnOmFkY2U4MDk2NmRlYTQzMmM4YTY4MGZlMzYxMGFmYjU2L3RhYmxlOjFhNzM4NWIwZTEyMjRhYTliM2FiNTZlY2Y3Y2VhYzUyL3RhYmxlcmFuZ2U6MWE3Mzg1YjBlMTIyNGFhOWIzYWI1NmVjZjdjZWFjNTJfMy03LTEtMS0xNTk1NDA_0cbe9d9b-064d-4c6e-9258-7ad03c8bc524">323.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive income</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19fc0325c48543008ea71e1fdcf11d86_D20220701-20220930" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yMi9mcmFnOmFkY2U4MDk2NmRlYTQzMmM4YTY4MGZlMzYxMGFmYjU2L3RhYmxlOjFhNzM4NWIwZTEyMjRhYTliM2FiNTZlY2Y3Y2VhYzUyL3RhYmxlcmFuZ2U6MWE3Mzg1YjBlMTIyNGFhOWIzYWI1NmVjZjdjZWFjNTJfNC0xLTEtMS0xNTk1NDA_d0c29698-24ec-4a7b-92b3-b5188c7deeb1">1,443.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4fa4f6b472a4f269297591b44aba572_D20210701-20210930" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yMi9mcmFnOmFkY2U4MDk2NmRlYTQzMmM4YTY4MGZlMzYxMGFmYjU2L3RhYmxlOjFhNzM4NWIwZTEyMjRhYTliM2FiNTZlY2Y3Y2VhYzUyL3RhYmxlcmFuZ2U6MWE3Mzg1YjBlMTIyNGFhOWIzYWI1NmVjZjdjZWFjNTJfNC0zLTEtMS0xNTk1NDA_966b1a16-2188-439b-aea5-86ccceca6fe0">1,224.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yMi9mcmFnOmFkY2U4MDk2NmRlYTQzMmM4YTY4MGZlMzYxMGFmYjU2L3RhYmxlOjFhNzM4NWIwZTEyMjRhYTliM2FiNTZlY2Y3Y2VhYzUyL3RhYmxlcmFuZ2U6MWE3Mzg1YjBlMTIyNGFhOWIzYWI1NmVjZjdjZWFjNTJfNC01LTEtMS0xNTk1NDA_4f365400-8e9d-4a7f-884c-23f8ba2c1acb">4,354.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i167ed8f67bef48c49e54fa466400cdaa_D20210101-20210930" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yMi9mcmFnOmFkY2U4MDk2NmRlYTQzMmM4YTY4MGZlMzYxMGFmYjU2L3RhYmxlOjFhNzM4NWIwZTEyMjRhYTliM2FiNTZlY2Y3Y2VhYzUyL3RhYmxlcmFuZ2U6MWE3Mzg1YjBlMTIyNGFhOWIzYWI1NmVjZjdjZWFjNTJfNC03LTEtMS0xNTk1NDA_7a232746-1a31-451a-934c-5845fc79dcf3">4,179.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See notes to consolidated condensed financial statements.</span></div><div style="margin-top:9pt"><span><br/></span></div><div style="margin-top:9pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="i5fed483d9c7e4f3cbba3a62c53226cd7_25"></div><hr style="page-break-after:always"/><div style="min-height:27pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Condensed Balance Sheets</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ELI LILLY AND COMPANY AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in millions)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.424%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.281%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.512%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.283%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Current Assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents (Note 6)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08ccb35f6ad24d7793c9c91b74ca2ea1_I20220930" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yNS9mcmFnOjhlOTlhYzhjMjM5YzRmZjg5YmQ2ZTM0YzZjMzBjM2UzL3RhYmxlOjdjMDlhN2RjNGUzNDQ5MjViNGY1Yjg3ZDBmN2Y3NzYwL3RhYmxlcmFuZ2U6N2MwOWE3ZGM0ZTM0NDkyNWI0ZjViODdkMGY3Zjc3NjBfMy0xLTEtMS0xNTk1NDA_258622be-3365-4a96-91d9-ab61a14403bd">2,617.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0973ba0c1d894ceaa494709a13f814fb_I20211231" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yNS9mcmFnOjhlOTlhYzhjMjM5YzRmZjg5YmQ2ZTM0YzZjMzBjM2UzL3RhYmxlOjdjMDlhN2RjNGUzNDQ5MjViNGY1Yjg3ZDBmN2Y3NzYwL3RhYmxlcmFuZ2U6N2MwOWE3ZGM0ZTM0NDkyNWI0ZjViODdkMGY3Zjc3NjBfMy0zLTEtMS0xNTk1NDA_01c2ae74-7f55-4da1-9d57-e13534decca7">3,818.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments (Note 6)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08ccb35f6ad24d7793c9c91b74ca2ea1_I20220930" decimals="-5" name="us-gaap:ShortTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yNS9mcmFnOjhlOTlhYzhjMjM5YzRmZjg5YmQ2ZTM0YzZjMzBjM2UzL3RhYmxlOjdjMDlhN2RjNGUzNDQ5MjViNGY1Yjg3ZDBmN2Y3NzYwL3RhYmxlcmFuZ2U6N2MwOWE3ZGM0ZTM0NDkyNWI0ZjViODdkMGY3Zjc3NjBfNC0xLTEtMS0xNTk1NDA_ecc6984c-df33-40de-8131-7c5e04c1b75e">124.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0973ba0c1d894ceaa494709a13f814fb_I20211231" decimals="-5" name="us-gaap:ShortTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yNS9mcmFnOjhlOTlhYzhjMjM5YzRmZjg5YmQ2ZTM0YzZjMzBjM2UzL3RhYmxlOjdjMDlhN2RjNGUzNDQ5MjViNGY1Yjg3ZDBmN2Y3NzYwL3RhYmxlcmFuZ2U6N2MwOWE3ZGM0ZTM0NDkyNWI0ZjViODdkMGY3Zjc3NjBfNC0zLTEtMS0xNTk1NDA_f11fce4a-1f0d-43a2-aac0-2a037605ca5a">90.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net of allowances of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="i08ccb35f6ad24d7793c9c91b74ca2ea1_I20220930" decimals="-5" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yNS9mcmFnOjhlOTlhYzhjMjM5YzRmZjg5YmQ2ZTM0YzZjMzBjM2UzL3RhYmxlOjdjMDlhN2RjNGUzNDQ5MjViNGY1Yjg3ZDBmN2Y3NzYwL3RhYmxlcmFuZ2U6N2MwOWE3ZGM0ZTM0NDkyNWI0ZjViODdkMGY3Zjc3NjBfNS0wLTEtMS0xNTk1NDAvdGV4dHJlZ2lvbjoxYzg5YmU1NWM2ZWI0NWIyYjdjYjlkMGQzZWMxMmI4OF80Nw_b19a986a-77cb-4977-8e85-31f22483c306">17.7</ix:nonFraction> (2022)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> and $<ix:nonFraction unitRef="usd" contextRef="i0973ba0c1d894ceaa494709a13f814fb_I20211231" decimals="-5" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yNS9mcmFnOjhlOTlhYzhjMjM5YzRmZjg5YmQ2ZTM0YzZjMzBjM2UzL3RhYmxlOjdjMDlhN2RjNGUzNDQ5MjViNGY1Yjg3ZDBmN2Y3NzYwL3RhYmxlcmFuZ2U6N2MwOWE3ZGM0ZTM0NDkyNWI0ZjViODdkMGY3Zjc3NjBfNS0wLTEtMS0xNTk1NDAvdGV4dHJlZ2lvbjoxYzg5YmU1NWM2ZWI0NWIyYjdjYjlkMGQzZWMxMmI4OF82Mg_c63e1ac1-475f-4b86-8273-c6e2ce081463">22.5</ix:nonFraction> (2021)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08ccb35f6ad24d7793c9c91b74ca2ea1_I20220930" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yNS9mcmFnOjhlOTlhYzhjMjM5YzRmZjg5YmQ2ZTM0YzZjMzBjM2UzL3RhYmxlOjdjMDlhN2RjNGUzNDQ5MjViNGY1Yjg3ZDBmN2Y3NzYwL3RhYmxlcmFuZ2U6N2MwOWE3ZGM0ZTM0NDkyNWI0ZjViODdkMGY3Zjc3NjBfNS0xLTEtMS0xNTk1NDA_ab5f6710-3431-4d52-9859-e91ab0a14690">6,715.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0973ba0c1d894ceaa494709a13f814fb_I20211231" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yNS9mcmFnOjhlOTlhYzhjMjM5YzRmZjg5YmQ2ZTM0YzZjMzBjM2UzL3RhYmxlOjdjMDlhN2RjNGUzNDQ5MjViNGY1Yjg3ZDBmN2Y3NzYwL3RhYmxlcmFuZ2U6N2MwOWE3ZGM0ZTM0NDkyNWI0ZjViODdkMGY3Zjc3NjBfNS0zLTEtMS0xNTk1NDA_7bd80223-a9c3-4e22-82d9-4ae6d749a617">6,672.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08ccb35f6ad24d7793c9c91b74ca2ea1_I20220930" decimals="-5" name="us-gaap:OtherReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yNS9mcmFnOjhlOTlhYzhjMjM5YzRmZjg5YmQ2ZTM0YzZjMzBjM2UzL3RhYmxlOjdjMDlhN2RjNGUzNDQ5MjViNGY1Yjg3ZDBmN2Y3NzYwL3RhYmxlcmFuZ2U6N2MwOWE3ZGM0ZTM0NDkyNWI0ZjViODdkMGY3Zjc3NjBfNi0xLTEtMS0xNTk1NDA_0afe3dcd-2806-44d6-ae8b-0fd486f6130b">1,609.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0973ba0c1d894ceaa494709a13f814fb_I20211231" decimals="-5" name="us-gaap:OtherReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yNS9mcmFnOjhlOTlhYzhjMjM5YzRmZjg5YmQ2ZTM0YzZjMzBjM2UzL3RhYmxlOjdjMDlhN2RjNGUzNDQ5MjViNGY1Yjg3ZDBmN2Y3NzYwL3RhYmxlcmFuZ2U6N2MwOWE3ZGM0ZTM0NDkyNWI0ZjViODdkMGY3Zjc3NjBfNi0zLTEtMS0xNTk1NDA_f19b2b00-7b22-4c1f-adb3-eb30d05cebae">1,454.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08ccb35f6ad24d7793c9c91b74ca2ea1_I20220930" decimals="-5" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yNS9mcmFnOjhlOTlhYzhjMjM5YzRmZjg5YmQ2ZTM0YzZjMzBjM2UzL3RhYmxlOjdjMDlhN2RjNGUzNDQ5MjViNGY1Yjg3ZDBmN2Y3NzYwL3RhYmxlcmFuZ2U6N2MwOWE3ZGM0ZTM0NDkyNWI0ZjViODdkMGY3Zjc3NjBfNy0xLTEtMS0xNTk1NDA_12310145-a3d9-418a-8225-fcebb251b589">3,831.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0973ba0c1d894ceaa494709a13f814fb_I20211231" decimals="-5" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yNS9mcmFnOjhlOTlhYzhjMjM5YzRmZjg5YmQ2ZTM0YzZjMzBjM2UzL3RhYmxlOjdjMDlhN2RjNGUzNDQ5MjViNGY1Yjg3ZDBmN2Y3NzYwL3RhYmxlcmFuZ2U6N2MwOWE3ZGM0ZTM0NDkyNWI0ZjViODdkMGY3Zjc3NjBfNy0zLTEtMS0xNTk1NDA_e2eb9067-78a5-4492-a0c2-ff451113d3f5">3,886.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08ccb35f6ad24d7793c9c91b74ca2ea1_I20220930" decimals="-5" name="us-gaap:PrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yNS9mcmFnOjhlOTlhYzhjMjM5YzRmZjg5YmQ2ZTM0YzZjMzBjM2UzL3RhYmxlOjdjMDlhN2RjNGUzNDQ5MjViNGY1Yjg3ZDBmN2Y3NzYwL3RhYmxlcmFuZ2U6N2MwOWE3ZGM0ZTM0NDkyNWI0ZjViODdkMGY3Zjc3NjBfOC0xLTEtMS0xNTk1NDA_b767a778-61a5-4263-8907-6cf9f455fe1c">2,741.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0973ba0c1d894ceaa494709a13f814fb_I20211231" decimals="-5" name="us-gaap:PrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yNS9mcmFnOjhlOTlhYzhjMjM5YzRmZjg5YmQ2ZTM0YzZjMzBjM2UzL3RhYmxlOjdjMDlhN2RjNGUzNDQ5MjViNGY1Yjg3ZDBmN2Y3NzYwL3RhYmxlcmFuZ2U6N2MwOWE3ZGM0ZTM0NDkyNWI0ZjViODdkMGY3Zjc3NjBfOC0zLTEtMS0xNTk1NDA_f9f8c975-c9f8-48e5-8fcd-a6223da95da2">2,530.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08ccb35f6ad24d7793c9c91b74ca2ea1_I20220930" decimals="-5" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yNS9mcmFnOjhlOTlhYzhjMjM5YzRmZjg5YmQ2ZTM0YzZjMzBjM2UzL3RhYmxlOjdjMDlhN2RjNGUzNDQ5MjViNGY1Yjg3ZDBmN2Y3NzYwL3RhYmxlcmFuZ2U6N2MwOWE3ZGM0ZTM0NDkyNWI0ZjViODdkMGY3Zjc3NjBfOS0xLTEtMS0xNTk1NDA_487d1f4c-a662-4d7c-bbb5-6a3584ea94a9">17,639.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0973ba0c1d894ceaa494709a13f814fb_I20211231" decimals="-5" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yNS9mcmFnOjhlOTlhYzhjMjM5YzRmZjg5YmQ2ZTM0YzZjMzBjM2UzL3RhYmxlOjdjMDlhN2RjNGUzNDQ5MjViNGY1Yjg3ZDBmN2Y3NzYwL3RhYmxlcmFuZ2U6N2MwOWE3ZGM0ZTM0NDkyNWI0ZjViODdkMGY3Zjc3NjBfOS0zLTEtMS0xNTk1NDA_e25e2846-7a93-42e7-bf53-4e9483207b71">18,452.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments (Note 6)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08ccb35f6ad24d7793c9c91b74ca2ea1_I20220930" decimals="-5" name="us-gaap:LongTermInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yNS9mcmFnOjhlOTlhYzhjMjM5YzRmZjg5YmQ2ZTM0YzZjMzBjM2UzL3RhYmxlOjdjMDlhN2RjNGUzNDQ5MjViNGY1Yjg3ZDBmN2Y3NzYwL3RhYmxlcmFuZ2U6N2MwOWE3ZGM0ZTM0NDkyNWI0ZjViODdkMGY3Zjc3NjBfMTAtMS0xLTEtMTU5NTQw_d02b5002-7f0a-4246-b2d3-adbc85598ab0">2,574.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0973ba0c1d894ceaa494709a13f814fb_I20211231" decimals="-5" name="us-gaap:LongTermInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yNS9mcmFnOjhlOTlhYzhjMjM5YzRmZjg5YmQ2ZTM0YzZjMzBjM2UzL3RhYmxlOjdjMDlhN2RjNGUzNDQ5MjViNGY1Yjg3ZDBmN2Y3NzYwL3RhYmxlcmFuZ2U6N2MwOWE3ZGM0ZTM0NDkyNWI0ZjViODdkMGY3Zjc3NjBfMTAtMy0xLTEtMTU5NTQw_db9a907b-fd01-4b39-a4d1-6860b5de6fd9">3,212.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08ccb35f6ad24d7793c9c91b74ca2ea1_I20220930" decimals="-5" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yNS9mcmFnOjhlOTlhYzhjMjM5YzRmZjg5YmQ2ZTM0YzZjMzBjM2UzL3RhYmxlOjdjMDlhN2RjNGUzNDQ5MjViNGY1Yjg3ZDBmN2Y3NzYwL3RhYmxlcmFuZ2U6N2MwOWE3ZGM0ZTM0NDkyNWI0ZjViODdkMGY3Zjc3NjBfMTEtMS0xLTEtMTU5NTQw_2449ff88-41a8-4515-bf37-fc0dcb15a504">3,891.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0973ba0c1d894ceaa494709a13f814fb_I20211231" decimals="-5" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yNS9mcmFnOjhlOTlhYzhjMjM5YzRmZjg5YmQ2ZTM0YzZjMzBjM2UzL3RhYmxlOjdjMDlhN2RjNGUzNDQ5MjViNGY1Yjg3ZDBmN2Y3NzYwL3RhYmxlcmFuZ2U6N2MwOWE3ZGM0ZTM0NDkyNWI0ZjViODdkMGY3Zjc3NjBfMTEtMy0xLTEtMTU5NTQw_a9b095b2-2468-40f5-8ff3-8c40277c9562">3,892.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other intangibles, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08ccb35f6ad24d7793c9c91b74ca2ea1_I20220930" decimals="-5" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yNS9mcmFnOjhlOTlhYzhjMjM5YzRmZjg5YmQ2ZTM0YzZjMzBjM2UzL3RhYmxlOjdjMDlhN2RjNGUzNDQ5MjViNGY1Yjg3ZDBmN2Y3NzYwL3RhYmxlcmFuZ2U6N2MwOWE3ZGM0ZTM0NDkyNWI0ZjViODdkMGY3Zjc3NjBfMTItMS0xLTEtMTU5NTQw_7f0bb81c-6fae-484f-a08b-5bbc315de246">7,124.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0973ba0c1d894ceaa494709a13f814fb_I20211231" decimals="-5" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yNS9mcmFnOjhlOTlhYzhjMjM5YzRmZjg5YmQ2ZTM0YzZjMzBjM2UzL3RhYmxlOjdjMDlhN2RjNGUzNDQ5MjViNGY1Yjg3ZDBmN2Y3NzYwL3RhYmxlcmFuZ2U6N2MwOWE3ZGM0ZTM0NDkyNWI0ZjViODdkMGY3Zjc3NjBfMTItMy0xLTEtMTU5NTQw_c53ab72a-f910-4179-8eb1-77fd6f556736">7,691.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08ccb35f6ad24d7793c9c91b74ca2ea1_I20220930" decimals="-5" name="us-gaap:DeferredIncomeTaxAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yNS9mcmFnOjhlOTlhYzhjMjM5YzRmZjg5YmQ2ZTM0YzZjMzBjM2UzL3RhYmxlOjdjMDlhN2RjNGUzNDQ5MjViNGY1Yjg3ZDBmN2Y3NzYwL3RhYmxlcmFuZ2U6N2MwOWE3ZGM0ZTM0NDkyNWI0ZjViODdkMGY3Zjc3NjBfMTMtMS0xLTEtMTU5NTQw_5b0311aa-6873-4375-a34c-678aff44af5b">2,384.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0973ba0c1d894ceaa494709a13f814fb_I20211231" decimals="-5" name="us-gaap:DeferredIncomeTaxAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yNS9mcmFnOjhlOTlhYzhjMjM5YzRmZjg5YmQ2ZTM0YzZjMzBjM2UzL3RhYmxlOjdjMDlhN2RjNGUzNDQ5MjViNGY1Yjg3ZDBmN2Y3NzYwL3RhYmxlcmFuZ2U6N2MwOWE3ZGM0ZTM0NDkyNWI0ZjViODdkMGY3Zjc3NjBfMTMtMy0xLTEtMTU5NTQw_b35d82df-9a8a-49ef-9600-44d0a3efd5ad">2,489.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net of accumulated depreciation of</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> $<ix:nonFraction unitRef="usd" contextRef="i08ccb35f6ad24d7793c9c91b74ca2ea1_I20220930" decimals="-5" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yNS9mcmFnOjhlOTlhYzhjMjM5YzRmZjg5YmQ2ZTM0YzZjMzBjM2UzL3RhYmxlOjdjMDlhN2RjNGUzNDQ5MjViNGY1Yjg3ZDBmN2Y3NzYwL3RhYmxlcmFuZ2U6N2MwOWE3ZGM0ZTM0NDkyNWI0ZjViODdkMGY3Zjc3NjBfMTQtMC0xLTEtMTU5NTQwL3RleHRyZWdpb246MjVhYmU4OTliZDE2NDVmNjg1NzlmYzI5NzE1ZjcxN2JfNjM_37543d0e-594d-4d87-b91f-24c9527fea65">10,074.0</ix:nonFraction> (2022) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">and $<ix:nonFraction unitRef="usd" contextRef="i0973ba0c1d894ceaa494709a13f814fb_I20211231" decimals="-5" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yNS9mcmFnOjhlOTlhYzhjMjM5YzRmZjg5YmQ2ZTM0YzZjMzBjM2UzL3RhYmxlOjdjMDlhN2RjNGUzNDQ5MjViNGY1Yjg3ZDBmN2Y3NzYwL3RhYmxlcmFuZ2U6N2MwOWE3ZGM0ZTM0NDkyNWI0ZjViODdkMGY3Zjc3NjBfMTQtMC0xLTEtMTU5NTQwL3RleHRyZWdpb246MjVhYmU4OTliZDE2NDVmNjg1NzlmYzI5NzE1ZjcxN2JfNzc_4f13a435-2b19-460f-a2a6-d1605042b529">9,976.7</ix:nonFraction> (2021)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08ccb35f6ad24d7793c9c91b74ca2ea1_I20220930" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yNS9mcmFnOjhlOTlhYzhjMjM5YzRmZjg5YmQ2ZTM0YzZjMzBjM2UzL3RhYmxlOjdjMDlhN2RjNGUzNDQ5MjViNGY1Yjg3ZDBmN2Y3NzYwL3RhYmxlcmFuZ2U6N2MwOWE3ZGM0ZTM0NDkyNWI0ZjViODdkMGY3Zjc3NjBfMTQtMS0xLTEtMTU5NTQw_213ce0f8-6fd8-4311-a364-0f5407540896">9,311.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0973ba0c1d894ceaa494709a13f814fb_I20211231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yNS9mcmFnOjhlOTlhYzhjMjM5YzRmZjg5YmQ2ZTM0YzZjMzBjM2UzL3RhYmxlOjdjMDlhN2RjNGUzNDQ5MjViNGY1Yjg3ZDBmN2Y3NzYwL3RhYmxlcmFuZ2U6N2MwOWE3ZGM0ZTM0NDkyNWI0ZjViODdkMGY3Zjc3NjBfMTQtMy0xLTEtMTU5NTQw_0414288a-182c-42a7-ab08-1a91a27c5615">8,985.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08ccb35f6ad24d7793c9c91b74ca2ea1_I20220930" decimals="-5" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yNS9mcmFnOjhlOTlhYzhjMjM5YzRmZjg5YmQ2ZTM0YzZjMzBjM2UzL3RhYmxlOjdjMDlhN2RjNGUzNDQ5MjViNGY1Yjg3ZDBmN2Y3NzYwL3RhYmxlcmFuZ2U6N2MwOWE3ZGM0ZTM0NDkyNWI0ZjViODdkMGY3Zjc3NjBfMTUtMS0xLTEtMTU5NTQw_5ed6a90d-7bc6-47fc-9c3f-dba9c9afb7dc">4,535.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0973ba0c1d894ceaa494709a13f814fb_I20211231" decimals="-5" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yNS9mcmFnOjhlOTlhYzhjMjM5YzRmZjg5YmQ2ZTM0YzZjMzBjM2UzL3RhYmxlOjdjMDlhN2RjNGUzNDQ5MjViNGY1Yjg3ZDBmN2Y3NzYwL3RhYmxlcmFuZ2U6N2MwOWE3ZGM0ZTM0NDkyNWI0ZjViODdkMGY3Zjc3NjBfMTUtMy0xLTEtMTU5NTQw_c7d6b30f-fae9-469f-a365-4fda19a83677">4,082.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08ccb35f6ad24d7793c9c91b74ca2ea1_I20220930" decimals="-5" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yNS9mcmFnOjhlOTlhYzhjMjM5YzRmZjg5YmQ2ZTM0YzZjMzBjM2UzL3RhYmxlOjdjMDlhN2RjNGUzNDQ5MjViNGY1Yjg3ZDBmN2Y3NzYwL3RhYmxlcmFuZ2U6N2MwOWE3ZGM0ZTM0NDkyNWI0ZjViODdkMGY3Zjc3NjBfMTYtMS0xLTEtMTU5NTQw_689c1831-07b9-4dbe-b846-098b7f969a0b">47,461.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0973ba0c1d894ceaa494709a13f814fb_I20211231" decimals="-5" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yNS9mcmFnOjhlOTlhYzhjMjM5YzRmZjg5YmQ2ZTM0YzZjMzBjM2UzL3RhYmxlOjdjMDlhN2RjNGUzNDQ5MjViNGY1Yjg3ZDBmN2Y3NzYwL3RhYmxlcmFuZ2U6N2MwOWE3ZGM0ZTM0NDkyNWI0ZjViODdkMGY3Zjc3NjBfMTYtMy0xLTEtMTU5NTQw_b3c5f9f9-9fd3-441c-901e-bd917b861063">48,806.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities and Equity</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Current Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term borrowings and current maturities of long-term debt</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08ccb35f6ad24d7793c9c91b74ca2ea1_I20220930" decimals="-5" name="us-gaap:DebtCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yNS9mcmFnOjhlOTlhYzhjMjM5YzRmZjg5YmQ2ZTM0YzZjMzBjM2UzL3RhYmxlOjdjMDlhN2RjNGUzNDQ5MjViNGY1Yjg3ZDBmN2Y3NzYwL3RhYmxlcmFuZ2U6N2MwOWE3ZGM0ZTM0NDkyNWI0ZjViODdkMGY3Zjc3NjBfMTktMS0xLTEtMTU5NTQw_ff2dfb2b-44d7-428e-a06c-ebe3af4d930e">1,744.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0973ba0c1d894ceaa494709a13f814fb_I20211231" decimals="-5" name="us-gaap:DebtCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yNS9mcmFnOjhlOTlhYzhjMjM5YzRmZjg5YmQ2ZTM0YzZjMzBjM2UzL3RhYmxlOjdjMDlhN2RjNGUzNDQ5MjViNGY1Yjg3ZDBmN2Y3NzYwL3RhYmxlcmFuZ2U6N2MwOWE3ZGM0ZTM0NDkyNWI0ZjViODdkMGY3Zjc3NjBfMTktMy0xLTEtMTU5NTQw_cf946d35-5928-4872-9b5a-0ebebcfc1f05">1,538.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08ccb35f6ad24d7793c9c91b74ca2ea1_I20220930" decimals="-5" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yNS9mcmFnOjhlOTlhYzhjMjM5YzRmZjg5YmQ2ZTM0YzZjMzBjM2UzL3RhYmxlOjdjMDlhN2RjNGUzNDQ5MjViNGY1Yjg3ZDBmN2Y3NzYwL3RhYmxlcmFuZ2U6N2MwOWE3ZGM0ZTM0NDkyNWI0ZjViODdkMGY3Zjc3NjBfMjAtMS0xLTEtMTU5NTQw_954fcb33-4191-48bb-99a8-4b9629c58657">1,683.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0973ba0c1d894ceaa494709a13f814fb_I20211231" decimals="-5" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yNS9mcmFnOjhlOTlhYzhjMjM5YzRmZjg5YmQ2ZTM0YzZjMzBjM2UzL3RhYmxlOjdjMDlhN2RjNGUzNDQ5MjViNGY1Yjg3ZDBmN2Y3NzYwL3RhYmxlcmFuZ2U6N2MwOWE3ZGM0ZTM0NDkyNWI0ZjViODdkMGY3Zjc3NjBfMjAtMy0xLTEtMTU5NTQw_5b49cf70-0aef-416c-975b-821fbc2f8fbf">1,670.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08ccb35f6ad24d7793c9c91b74ca2ea1_I20220930" decimals="-5" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yNS9mcmFnOjhlOTlhYzhjMjM5YzRmZjg5YmQ2ZTM0YzZjMzBjM2UzL3RhYmxlOjdjMDlhN2RjNGUzNDQ5MjViNGY1Yjg3ZDBmN2Y3NzYwL3RhYmxlcmFuZ2U6N2MwOWE3ZGM0ZTM0NDkyNWI0ZjViODdkMGY3Zjc3NjBfMjEtMS0xLTEtMTU5NTQw_e19513ed-0f2a-422d-b91d-8b64eb3e9d40">984.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0973ba0c1d894ceaa494709a13f814fb_I20211231" decimals="-5" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yNS9mcmFnOjhlOTlhYzhjMjM5YzRmZjg5YmQ2ZTM0YzZjMzBjM2UzL3RhYmxlOjdjMDlhN2RjNGUzNDQ5MjViNGY1Yjg3ZDBmN2Y3NzYwL3RhYmxlcmFuZ2U6N2MwOWE3ZGM0ZTM0NDkyNWI0ZjViODdkMGY3Zjc3NjBfMjEtMy0xLTEtMTU5NTQw_5d192ac0-a27d-433d-b1a6-5bb5f3f2cd2b">958.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales rebates and discounts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08ccb35f6ad24d7793c9c91b74ca2ea1_I20220930" decimals="-5" name="lly:SalesRebatesAndDiscounts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yNS9mcmFnOjhlOTlhYzhjMjM5YzRmZjg5YmQ2ZTM0YzZjMzBjM2UzL3RhYmxlOjdjMDlhN2RjNGUzNDQ5MjViNGY1Yjg3ZDBmN2Y3NzYwL3RhYmxlcmFuZ2U6N2MwOWE3ZGM0ZTM0NDkyNWI0ZjViODdkMGY3Zjc3NjBfMjItMS0xLTEtMTU5NTQw_4d908b33-c4c7-4482-9bd8-31a66f6e71fa">8,568.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0973ba0c1d894ceaa494709a13f814fb_I20211231" decimals="-5" name="lly:SalesRebatesAndDiscounts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yNS9mcmFnOjhlOTlhYzhjMjM5YzRmZjg5YmQ2ZTM0YzZjMzBjM2UzL3RhYmxlOjdjMDlhN2RjNGUzNDQ5MjViNGY1Yjg3ZDBmN2Y3NzYwL3RhYmxlcmFuZ2U6N2MwOWE3ZGM0ZTM0NDkyNWI0ZjViODdkMGY3Zjc3NjBfMjItMy0xLTEtMTU5NTQw_8eff446a-5b64-4c73-b09e-b2abc41f0de0">6,845.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08ccb35f6ad24d7793c9c91b74ca2ea1_I20220930" decimals="-5" name="us-gaap:DividendsPayableCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yNS9mcmFnOjhlOTlhYzhjMjM5YzRmZjg5YmQ2ZTM0YzZjMzBjM2UzL3RhYmxlOjdjMDlhN2RjNGUzNDQ5MjViNGY1Yjg3ZDBmN2Y3NzYwL3RhYmxlcmFuZ2U6N2MwOWE3ZGM0ZTM0NDkyNWI0ZjViODdkMGY3Zjc3NjBfMjMtMS0xLTEtMTU5NTQw_eb03c580-9581-41db-a876-67f2d5b6a4c5">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0973ba0c1d894ceaa494709a13f814fb_I20211231" decimals="-5" name="us-gaap:DividendsPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yNS9mcmFnOjhlOTlhYzhjMjM5YzRmZjg5YmQ2ZTM0YzZjMzBjM2UzL3RhYmxlOjdjMDlhN2RjNGUzNDQ5MjViNGY1Yjg3ZDBmN2Y3NzYwL3RhYmxlcmFuZ2U6N2MwOWE3ZGM0ZTM0NDkyNWI0ZjViODdkMGY3Zjc3NjBfMjMtMy0xLTEtMTU5NTQw_effe50b6-40cd-4ead-a898-e5c73a7d302d">885.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08ccb35f6ad24d7793c9c91b74ca2ea1_I20220930" decimals="-5" name="us-gaap:TaxesPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yNS9mcmFnOjhlOTlhYzhjMjM5YzRmZjg5YmQ2ZTM0YzZjMzBjM2UzL3RhYmxlOjdjMDlhN2RjNGUzNDQ5MjViNGY1Yjg3ZDBmN2Y3NzYwL3RhYmxlcmFuZ2U6N2MwOWE3ZGM0ZTM0NDkyNWI0ZjViODdkMGY3Zjc3NjBfMjQtMS0xLTEtMTU5NTQw_91ab8558-880a-4404-b810-128448e6b45f">685.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0973ba0c1d894ceaa494709a13f814fb_I20211231" decimals="-5" name="us-gaap:TaxesPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yNS9mcmFnOjhlOTlhYzhjMjM5YzRmZjg5YmQ2ZTM0YzZjMzBjM2UzL3RhYmxlOjdjMDlhN2RjNGUzNDQ5MjViNGY1Yjg3ZDBmN2Y3NzYwL3RhYmxlcmFuZ2U6N2MwOWE3ZGM0ZTM0NDkyNWI0ZjViODdkMGY3Zjc3NjBfMjQtMy0xLTEtMTU5NTQw_fb66bc51-7140-4992-a237-cfba4951acf9">126.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08ccb35f6ad24d7793c9c91b74ca2ea1_I20220930" decimals="-5" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yNS9mcmFnOjhlOTlhYzhjMjM5YzRmZjg5YmQ2ZTM0YzZjMzBjM2UzL3RhYmxlOjdjMDlhN2RjNGUzNDQ5MjViNGY1Yjg3ZDBmN2Y3NzYwL3RhYmxlcmFuZ2U6N2MwOWE3ZGM0ZTM0NDkyNWI0ZjViODdkMGY3Zjc3NjBfMjUtMS0xLTEtMTU5NTQw_6d0bd9c0-70fc-4a65-a63f-964d21b26333">1,986.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0973ba0c1d894ceaa494709a13f814fb_I20211231" decimals="-5" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yNS9mcmFnOjhlOTlhYzhjMjM5YzRmZjg5YmQ2ZTM0YzZjMzBjM2UzL3RhYmxlOjdjMDlhN2RjNGUzNDQ5MjViNGY1Yjg3ZDBmN2Y3NzYwL3RhYmxlcmFuZ2U6N2MwOWE3ZGM0ZTM0NDkyNWI0ZjViODdkMGY3Zjc3NjBfMjUtMy0xLTEtMTU5NTQw_3913dbb5-0b1b-48e8-b669-9dd7fee45f64">3,027.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08ccb35f6ad24d7793c9c91b74ca2ea1_I20220930" decimals="-5" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yNS9mcmFnOjhlOTlhYzhjMjM5YzRmZjg5YmQ2ZTM0YzZjMzBjM2UzL3RhYmxlOjdjMDlhN2RjNGUzNDQ5MjViNGY1Yjg3ZDBmN2Y3NzYwL3RhYmxlcmFuZ2U6N2MwOWE3ZGM0ZTM0NDkyNWI0ZjViODdkMGY3Zjc3NjBfMjYtMS0xLTEtMTU5NTQw_07f6f68b-cf9c-40a9-a102-373630c1ae79">15,652.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0973ba0c1d894ceaa494709a13f814fb_I20211231" decimals="-5" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yNS9mcmFnOjhlOTlhYzhjMjM5YzRmZjg5YmQ2ZTM0YzZjMzBjM2UzL3RhYmxlOjdjMDlhN2RjNGUzNDQ5MjViNGY1Yjg3ZDBmN2Y3NzYwL3RhYmxlcmFuZ2U6N2MwOWE3ZGM0ZTM0NDkyNWI0ZjViODdkMGY3Zjc3NjBfMjYtMy0xLTEtMTU5NTQw_9952a1da-616c-4a13-b7bf-89d69b907ab8">15,052.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08ccb35f6ad24d7793c9c91b74ca2ea1_I20220930" decimals="-5" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yNS9mcmFnOjhlOTlhYzhjMjM5YzRmZjg5YmQ2ZTM0YzZjMzBjM2UzL3RhYmxlOjdjMDlhN2RjNGUzNDQ5MjViNGY1Yjg3ZDBmN2Y3NzYwL3RhYmxlcmFuZ2U6N2MwOWE3ZGM0ZTM0NDkyNWI0ZjViODdkMGY3Zjc3NjBfMjgtMS0xLTEtMTU5NTQw_2375d25b-5e7c-45b6-87fb-40c0d3ff9593">14,143.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0973ba0c1d894ceaa494709a13f814fb_I20211231" decimals="-5" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yNS9mcmFnOjhlOTlhYzhjMjM5YzRmZjg5YmQ2ZTM0YzZjMzBjM2UzL3RhYmxlOjdjMDlhN2RjNGUzNDQ5MjViNGY1Yjg3ZDBmN2Y3NzYwL3RhYmxlcmFuZ2U6N2MwOWE3ZGM0ZTM0NDkyNWI0ZjViODdkMGY3Zjc3NjBfMjgtMy0xLTEtMTU5NTQw_9364e45a-ca83-48de-8185-5195dd23c1f8">15,346.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued retirement benefits (Note 8)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08ccb35f6ad24d7793c9c91b74ca2ea1_I20220930" decimals="-5" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yNS9mcmFnOjhlOTlhYzhjMjM5YzRmZjg5YmQ2ZTM0YzZjMzBjM2UzL3RhYmxlOjdjMDlhN2RjNGUzNDQ5MjViNGY1Yjg3ZDBmN2Y3NzYwL3RhYmxlcmFuZ2U6N2MwOWE3ZGM0ZTM0NDkyNWI0ZjViODdkMGY3Zjc3NjBfMjktMS0xLTEtMTU5NTQw_84f3e680-f348-4b2c-b8c0-d7d2f3a7b188">1,832.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0973ba0c1d894ceaa494709a13f814fb_I20211231" decimals="-5" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yNS9mcmFnOjhlOTlhYzhjMjM5YzRmZjg5YmQ2ZTM0YzZjMzBjM2UzL3RhYmxlOjdjMDlhN2RjNGUzNDQ5MjViNGY1Yjg3ZDBmN2Y3NzYwL3RhYmxlcmFuZ2U6N2MwOWE3ZGM0ZTM0NDkyNWI0ZjViODdkMGY3Zjc3NjBfMjktMy0xLTEtMTU5NTQw_4d5b2baa-6c52-4034-8937-bf54598c3105">1,954.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term income taxes payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08ccb35f6ad24d7793c9c91b74ca2ea1_I20220930" decimals="-5" name="us-gaap:AccruedIncomeTaxesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yNS9mcmFnOjhlOTlhYzhjMjM5YzRmZjg5YmQ2ZTM0YzZjMzBjM2UzL3RhYmxlOjdjMDlhN2RjNGUzNDQ5MjViNGY1Yjg3ZDBmN2Y3NzYwL3RhYmxlcmFuZ2U6N2MwOWE3ZGM0ZTM0NDkyNWI0ZjViODdkMGY3Zjc3NjBfMzAtMS0xLTEtMTU5NTQw_3a3cec52-0ed0-44f3-8b86-18246f9232f4">3,641.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0973ba0c1d894ceaa494709a13f814fb_I20211231" decimals="-5" name="us-gaap:AccruedIncomeTaxesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yNS9mcmFnOjhlOTlhYzhjMjM5YzRmZjg5YmQ2ZTM0YzZjMzBjM2UzL3RhYmxlOjdjMDlhN2RjNGUzNDQ5MjViNGY1Yjg3ZDBmN2Y3NzYwL3RhYmxlcmFuZ2U6N2MwOWE3ZGM0ZTM0NDkyNWI0ZjViODdkMGY3Zjc3NjBfMzAtMy0xLTEtMTU5NTQw_8e4123d4-043f-4d9c-9faa-7c6d3f10c301">3,920.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08ccb35f6ad24d7793c9c91b74ca2ea1_I20220930" decimals="-5" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yNS9mcmFnOjhlOTlhYzhjMjM5YzRmZjg5YmQ2ZTM0YzZjMzBjM2UzL3RhYmxlOjdjMDlhN2RjNGUzNDQ5MjViNGY1Yjg3ZDBmN2Y3NzYwL3RhYmxlcmFuZ2U6N2MwOWE3ZGM0ZTM0NDkyNWI0ZjViODdkMGY3Zjc3NjBfMzEtMS0xLTEtMTU5NTQw_716b9b2e-60e2-4313-83e5-7c7522fc48ec">171.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0973ba0c1d894ceaa494709a13f814fb_I20211231" decimals="-5" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yNS9mcmFnOjhlOTlhYzhjMjM5YzRmZjg5YmQ2ZTM0YzZjMzBjM2UzL3RhYmxlOjdjMDlhN2RjNGUzNDQ5MjViNGY1Yjg3ZDBmN2Y3NzYwL3RhYmxlcmFuZ2U6N2MwOWE3ZGM0ZTM0NDkyNWI0ZjViODdkMGY3Zjc3NjBfMzEtMy0xLTEtMTU5NTQw_0c8cc5fd-214f-4d35-ad7c-e854c8d8ff30">1,733.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08ccb35f6ad24d7793c9c91b74ca2ea1_I20220930" decimals="-5" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yNS9mcmFnOjhlOTlhYzhjMjM5YzRmZjg5YmQ2ZTM0YzZjMzBjM2UzL3RhYmxlOjdjMDlhN2RjNGUzNDQ5MjViNGY1Yjg3ZDBmN2Y3NzYwL3RhYmxlcmFuZ2U6N2MwOWE3ZGM0ZTM0NDkyNWI0ZjViODdkMGY3Zjc3NjBfMzItMS0xLTEtMTU5NTQw_17fb9f7c-9f28-4952-9bb0-3de3f0152828">1,852.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0973ba0c1d894ceaa494709a13f814fb_I20211231" decimals="-5" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yNS9mcmFnOjhlOTlhYzhjMjM5YzRmZjg5YmQ2ZTM0YzZjMzBjM2UzL3RhYmxlOjdjMDlhN2RjNGUzNDQ5MjViNGY1Yjg3ZDBmN2Y3NzYwL3RhYmxlcmFuZ2U6N2MwOWE3ZGM0ZTM0NDkyNWI0ZjViODdkMGY3Zjc3NjBfMzItMy0xLTEtMTU5NTQw_7143a679-23bf-4c13-a98f-63c79fd198f9">1,644.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08ccb35f6ad24d7793c9c91b74ca2ea1_I20220930" decimals="-5" name="us-gaap:LiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yNS9mcmFnOjhlOTlhYzhjMjM5YzRmZjg5YmQ2ZTM0YzZjMzBjM2UzL3RhYmxlOjdjMDlhN2RjNGUzNDQ5MjViNGY1Yjg3ZDBmN2Y3NzYwL3RhYmxlcmFuZ2U6N2MwOWE3ZGM0ZTM0NDkyNWI0ZjViODdkMGY3Zjc3NjBfMzMtMS0xLTEtMTU5NTQw_5e4ffb82-2719-495f-bb32-824705e9d184">21,642.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0973ba0c1d894ceaa494709a13f814fb_I20211231" decimals="-5" name="us-gaap:LiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yNS9mcmFnOjhlOTlhYzhjMjM5YzRmZjg5YmQ2ZTM0YzZjMzBjM2UzL3RhYmxlOjdjMDlhN2RjNGUzNDQ5MjViNGY1Yjg3ZDBmN2Y3NzYwL3RhYmxlcmFuZ2U6N2MwOWE3ZGM0ZTM0NDkyNWI0ZjViODdkMGY3Zjc3NjBfMzMtMy0xLTEtMTU5NTQw_926495a8-349c-41e3-a1f0-0f47cf0e52af">24,598.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Commitments and Contingencies (Note 9)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i08ccb35f6ad24d7793c9c91b74ca2ea1_I20220930" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yNS9mcmFnOjhlOTlhYzhjMjM5YzRmZjg5YmQ2ZTM0YzZjMzBjM2UzL3RhYmxlOjdjMDlhN2RjNGUzNDQ5MjViNGY1Yjg3ZDBmN2Y3NzYwL3RhYmxlcmFuZ2U6N2MwOWE3ZGM0ZTM0NDkyNWI0ZjViODdkMGY3Zjc3NjBfMzQtMS0xLTEtMTU5NTQw_ed2c349c-8615-40f3-b30d-93b05b4cee01"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i0973ba0c1d894ceaa494709a13f814fb_I20211231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yNS9mcmFnOjhlOTlhYzhjMjM5YzRmZjg5YmQ2ZTM0YzZjMzBjM2UzL3RhYmxlOjdjMDlhN2RjNGUzNDQ5MjViNGY1Yjg3ZDBmN2Y3NzYwL3RhYmxlcmFuZ2U6N2MwOWE3ZGM0ZTM0NDkyNWI0ZjViODdkMGY3Zjc3NjBfMzQtMy0xLTEtMTU5NTQw_2ee68847-370e-4e54-94f0-08b48156ba8e"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Eli Lilly and Company Shareholders' Equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08ccb35f6ad24d7793c9c91b74ca2ea1_I20220930" decimals="-5" name="us-gaap:CommonStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yNS9mcmFnOjhlOTlhYzhjMjM5YzRmZjg5YmQ2ZTM0YzZjMzBjM2UzL3RhYmxlOjdjMDlhN2RjNGUzNDQ5MjViNGY1Yjg3ZDBmN2Y3NzYwL3RhYmxlcmFuZ2U6N2MwOWE3ZGM0ZTM0NDkyNWI0ZjViODdkMGY3Zjc3NjBfMzYtMS0xLTEtMTU5NTQw_6f945256-6a20-49dc-ab4a-6f42cd913251">594.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0973ba0c1d894ceaa494709a13f814fb_I20211231" decimals="-5" name="us-gaap:CommonStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yNS9mcmFnOjhlOTlhYzhjMjM5YzRmZjg5YmQ2ZTM0YzZjMzBjM2UzL3RhYmxlOjdjMDlhN2RjNGUzNDQ5MjViNGY1Yjg3ZDBmN2Y3NzYwL3RhYmxlcmFuZ2U6N2MwOWE3ZGM0ZTM0NDkyNWI0ZjViODdkMGY3Zjc3NjBfMzYtMy0xLTEtMTU5NTQw_9d547d3c-c16e-47a8-b0d0-faaf4ba786bf">596.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08ccb35f6ad24d7793c9c91b74ca2ea1_I20220930" decimals="-5" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yNS9mcmFnOjhlOTlhYzhjMjM5YzRmZjg5YmQ2ZTM0YzZjMzBjM2UzL3RhYmxlOjdjMDlhN2RjNGUzNDQ5MjViNGY1Yjg3ZDBmN2Y3NzYwL3RhYmxlcmFuZ2U6N2MwOWE3ZGM0ZTM0NDkyNWI0ZjViODdkMGY3Zjc3NjBfMzctMS0xLTEtMTU5NTQw_30d4db3f-7b5a-4463-8464-28b1b04af3b7">6,829.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0973ba0c1d894ceaa494709a13f814fb_I20211231" decimals="-5" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yNS9mcmFnOjhlOTlhYzhjMjM5YzRmZjg5YmQ2ZTM0YzZjMzBjM2UzL3RhYmxlOjdjMDlhN2RjNGUzNDQ5MjViNGY1Yjg3ZDBmN2Y3NzYwL3RhYmxlcmFuZ2U6N2MwOWE3ZGM0ZTM0NDkyNWI0ZjViODdkMGY3Zjc3NjBfMzctMy0xLTEtMTU5NTQw_0a2fce72-e720-4219-83e7-6cb98505cb5e">6,833.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retained earnings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08ccb35f6ad24d7793c9c91b74ca2ea1_I20220930" decimals="-5" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yNS9mcmFnOjhlOTlhYzhjMjM5YzRmZjg5YmQ2ZTM0YzZjMzBjM2UzL3RhYmxlOjdjMDlhN2RjNGUzNDQ5MjViNGY1Yjg3ZDBmN2Y3NzYwL3RhYmxlcmFuZ2U6N2MwOWE3ZGM0ZTM0NDkyNWI0ZjViODdkMGY3Zjc3NjBfMzgtMS0xLTEtMTU5NTQw_4356b3df-1ebf-4a4d-83c5-97c3221e488e">10,006.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0973ba0c1d894ceaa494709a13f814fb_I20211231" decimals="-5" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yNS9mcmFnOjhlOTlhYzhjMjM5YzRmZjg5YmQ2ZTM0YzZjMzBjM2UzL3RhYmxlOjdjMDlhN2RjNGUzNDQ5MjViNGY1Yjg3ZDBmN2Y3NzYwL3RhYmxlcmFuZ2U6N2MwOWE3ZGM0ZTM0NDkyNWI0ZjViODdkMGY3Zjc3NjBfMzgtMy0xLTEtMTU5NTQw_f525ed5f-f563-4f8e-ae59-f9ff003f83d0">8,958.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee benefit trust</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i08ccb35f6ad24d7793c9c91b74ca2ea1_I20220930" decimals="-5" name="us-gaap:CommonStockSharesHeldInEmployeeTrust" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yNS9mcmFnOjhlOTlhYzhjMjM5YzRmZjg5YmQ2ZTM0YzZjMzBjM2UzL3RhYmxlOjdjMDlhN2RjNGUzNDQ5MjViNGY1Yjg3ZDBmN2Y3NzYwL3RhYmxlcmFuZ2U6N2MwOWE3ZGM0ZTM0NDkyNWI0ZjViODdkMGY3Zjc3NjBfMzktMS0xLTEtMTU5NTQw_41d7b892-cd4c-4d63-847c-8ae7104e5ff5">3,013.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0973ba0c1d894ceaa494709a13f814fb_I20211231" decimals="-5" name="us-gaap:CommonStockSharesHeldInEmployeeTrust" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yNS9mcmFnOjhlOTlhYzhjMjM5YzRmZjg5YmQ2ZTM0YzZjMzBjM2UzL3RhYmxlOjdjMDlhN2RjNGUzNDQ5MjViNGY1Yjg3ZDBmN2Y3NzYwL3RhYmxlcmFuZ2U6N2MwOWE3ZGM0ZTM0NDkyNWI0ZjViODdkMGY3Zjc3NjBfMzktMy0xLTEtMTU5NTQw_8aa14d69-63ef-4579-b5cf-9f17a80df6c9">3,013.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss (Note 10)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i08ccb35f6ad24d7793c9c91b74ca2ea1_I20220930" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yNS9mcmFnOjhlOTlhYzhjMjM5YzRmZjg5YmQ2ZTM0YzZjMzBjM2UzL3RhYmxlOjdjMDlhN2RjNGUzNDQ5MjViNGY1Yjg3ZDBmN2Y3NzYwL3RhYmxlcmFuZ2U6N2MwOWE3ZGM0ZTM0NDkyNWI0ZjViODdkMGY3Zjc3NjBfNDAtMS0xLTEtMTU5NTQw_be175668-fed2-4d93-b0a3-7b998489cb07">4,295.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0973ba0c1d894ceaa494709a13f814fb_I20211231" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yNS9mcmFnOjhlOTlhYzhjMjM5YzRmZjg5YmQ2ZTM0YzZjMzBjM2UzL3RhYmxlOjdjMDlhN2RjNGUzNDQ5MjViNGY1Yjg3ZDBmN2Y3NzYwL3RhYmxlcmFuZ2U6N2MwOWE3ZGM0ZTM0NDkyNWI0ZjViODdkMGY3Zjc3NjBfNDAtMy0xLTEtMTU5NTQw_c48df100-2831-4414-a2d9-74efbb7b6414">4,343.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of common stock in treasury</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i08ccb35f6ad24d7793c9c91b74ca2ea1_I20220930" decimals="-5" name="us-gaap:TreasuryStockCommonValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yNS9mcmFnOjhlOTlhYzhjMjM5YzRmZjg5YmQ2ZTM0YzZjMzBjM2UzL3RhYmxlOjdjMDlhN2RjNGUzNDQ5MjViNGY1Yjg3ZDBmN2Y3NzYwL3RhYmxlcmFuZ2U6N2MwOWE3ZGM0ZTM0NDkyNWI0ZjViODdkMGY3Zjc3NjBfNDEtMS0xLTEtMTU5NTQw_9da404ad-22a5-41ab-acaa-fe21d3bf090b">50.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0973ba0c1d894ceaa494709a13f814fb_I20211231" decimals="-5" name="us-gaap:TreasuryStockCommonValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yNS9mcmFnOjhlOTlhYzhjMjM5YzRmZjg5YmQ2ZTM0YzZjMzBjM2UzL3RhYmxlOjdjMDlhN2RjNGUzNDQ5MjViNGY1Yjg3ZDBmN2Y3NzYwL3RhYmxlcmFuZ2U6N2MwOWE3ZGM0ZTM0NDkyNWI0ZjViODdkMGY3Zjc3NjBfNDEtMy0xLTEtMTU5NTQw_661952f6-67c9-4250-aa42-fd386e53977b">52.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Eli Lilly and Company shareholders' equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08ccb35f6ad24d7793c9c91b74ca2ea1_I20220930" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yNS9mcmFnOjhlOTlhYzhjMjM5YzRmZjg5YmQ2ZTM0YzZjMzBjM2UzL3RhYmxlOjdjMDlhN2RjNGUzNDQ5MjViNGY1Yjg3ZDBmN2Y3NzYwL3RhYmxlcmFuZ2U6N2MwOWE3ZGM0ZTM0NDkyNWI0ZjViODdkMGY3Zjc3NjBfNDItMS0xLTEtMTU5NTQw_f5846b84-be1f-4976-ac40-6226ea648a2b">10,070.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0973ba0c1d894ceaa494709a13f814fb_I20211231" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yNS9mcmFnOjhlOTlhYzhjMjM5YzRmZjg5YmQ2ZTM0YzZjMzBjM2UzL3RhYmxlOjdjMDlhN2RjNGUzNDQ5MjViNGY1Yjg3ZDBmN2Y3NzYwL3RhYmxlcmFuZ2U6N2MwOWE3ZGM0ZTM0NDkyNWI0ZjViODdkMGY3Zjc3NjBfNDItMy0xLTEtMTU5NTQw_ff9c930e-a404-4170-8b92-38cbfc993039">8,979.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08ccb35f6ad24d7793c9c91b74ca2ea1_I20220930" decimals="-5" name="us-gaap:MinorityInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yNS9mcmFnOjhlOTlhYzhjMjM5YzRmZjg5YmQ2ZTM0YzZjMzBjM2UzL3RhYmxlOjdjMDlhN2RjNGUzNDQ5MjViNGY1Yjg3ZDBmN2Y3NzYwL3RhYmxlcmFuZ2U6N2MwOWE3ZGM0ZTM0NDkyNWI0ZjViODdkMGY3Zjc3NjBfNDMtMS0xLTEtMTU5NTQw_1dd22c49-06ff-4fe7-ad48-6e6fc8568d67">95.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0973ba0c1d894ceaa494709a13f814fb_I20211231" decimals="-5" name="us-gaap:MinorityInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yNS9mcmFnOjhlOTlhYzhjMjM5YzRmZjg5YmQ2ZTM0YzZjMzBjM2UzL3RhYmxlOjdjMDlhN2RjNGUzNDQ5MjViNGY1Yjg3ZDBmN2Y3NzYwL3RhYmxlcmFuZ2U6N2MwOWE3ZGM0ZTM0NDkyNWI0ZjViODdkMGY3Zjc3NjBfNDMtMy0xLTEtMTU5NTQw_4d889854-6640-4a18-89bf-513e478707de">175.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08ccb35f6ad24d7793c9c91b74ca2ea1_I20220930" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yNS9mcmFnOjhlOTlhYzhjMjM5YzRmZjg5YmQ2ZTM0YzZjMzBjM2UzL3RhYmxlOjdjMDlhN2RjNGUzNDQ5MjViNGY1Yjg3ZDBmN2Y3NzYwL3RhYmxlcmFuZ2U6N2MwOWE3ZGM0ZTM0NDkyNWI0ZjViODdkMGY3Zjc3NjBfNDQtMS0xLTEtMTU5NTQw_5d8111d7-420a-4d73-98fb-4648d03a68bb">10,165.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0973ba0c1d894ceaa494709a13f814fb_I20211231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yNS9mcmFnOjhlOTlhYzhjMjM5YzRmZjg5YmQ2ZTM0YzZjMzBjM2UzL3RhYmxlOjdjMDlhN2RjNGUzNDQ5MjViNGY1Yjg3ZDBmN2Y3NzYwL3RhYmxlcmFuZ2U6N2MwOWE3ZGM0ZTM0NDkyNWI0ZjViODdkMGY3Zjc3NjBfNDQtMy0xLTEtMTU5NTQw_dc289584-7b58-418a-b3f1-57669e605413">9,154.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and equity</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08ccb35f6ad24d7793c9c91b74ca2ea1_I20220930" decimals="-5" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yNS9mcmFnOjhlOTlhYzhjMjM5YzRmZjg5YmQ2ZTM0YzZjMzBjM2UzL3RhYmxlOjdjMDlhN2RjNGUzNDQ5MjViNGY1Yjg3ZDBmN2Y3NzYwL3RhYmxlcmFuZ2U6N2MwOWE3ZGM0ZTM0NDkyNWI0ZjViODdkMGY3Zjc3NjBfNDUtMS0xLTEtMTU5NTQw_a3b4d9e9-1e46-4533-bdf9-dd21360c131b">47,461.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0973ba0c1d894ceaa494709a13f814fb_I20211231" decimals="-5" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yNS9mcmFnOjhlOTlhYzhjMjM5YzRmZjg5YmQ2ZTM0YzZjMzBjM2UzL3RhYmxlOjdjMDlhN2RjNGUzNDQ5MjViNGY1Yjg3ZDBmN2Y3NzYwL3RhYmxlcmFuZ2U6N2MwOWE3ZGM0ZTM0NDkyNWI0ZjViODdkMGY3Zjc3NjBfNDUtMy0xLTEtMTU5NTQw_40fb6377-8608-4b12-bf8b-d003a00a08f1">48,806.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See notes to consolidated condensed financial statements.</span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><div id="i5fed483d9c7e4f3cbba3a62c53226cd7_28"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Condensed Statements of Equity</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ELI LILLY AND COMPANY AND SUBSIDIARIES</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:24.668%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.927%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.781%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.927%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.074%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.927%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.856%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.927%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.781%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.276%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="45" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Equity of Eli Lilly and Company Shareholders</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:18pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%"><br/></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">(Dollars in millions, except per-share data, and shares in thousands)</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Retained<br/>Earnings</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Employee Benefit Trust</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Loss</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Common Stock in Treasury</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Noncontrolling Interests</span></td></tr><tr style="height:11pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Balance at July 1, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3ff8d0839ef74b87b0394c920e9dfa82_I20210630" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yOC9mcmFnOmEyNTBjNDBjZWQ3ZDQwZjRhNWUyMTQwZDM3MWNiYjliL3RhYmxlOjU0ZWNlYTRkMjgzZDQ4NTJiZTI1Y2QyYWEzN2M0ZDU0L3RhYmxlcmFuZ2U6NTRlY2VhNGQyODNkNDg1MmJlMjVjZDJhYTM3YzRkNTRfMy0xLTEtMS0xNTk1NDA_d99130da-dfa5-4730-b181-c58b7e189e14">957,038</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ff8d0839ef74b87b0394c920e9dfa82_I20210630" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yOC9mcmFnOmEyNTBjNDBjZWQ3ZDQwZjRhNWUyMTQwZDM3MWNiYjliL3RhYmxlOjU0ZWNlYTRkMjgzZDQ4NTJiZTI1Y2QyYWEzN2M0ZDU0L3RhYmxlcmFuZ2U6NTRlY2VhNGQyODNkNDg1MmJlMjVjZDJhYTM3YzRkNTRfMy0zLTEtMS0xNTk1NDA_8a21183e-9e62-4214-8ea3-eaf9bfd9b255">598.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9a5e6caa6224a1a95516222bf3644c0_I20210630" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yOC9mcmFnOmEyNTBjNDBjZWQ3ZDQwZjRhNWUyMTQwZDM3MWNiYjliL3RhYmxlOjU0ZWNlYTRkMjgzZDQ4NTJiZTI1Y2QyYWEzN2M0ZDU0L3RhYmxlcmFuZ2U6NTRlY2VhNGQyODNkNDg1MmJlMjVjZDJhYTM3YzRkNTRfMy01LTEtMS0xNTk1NDA_d6b5ac1c-e96a-472c-bb49-c9be4b954f46">6,669.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fbf406305be444e87d56294647b476e_I20210630" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yOC9mcmFnOmEyNTBjNDBjZWQ3ZDQwZjRhNWUyMTQwZDM3MWNiYjliL3RhYmxlOjU0ZWNlYTRkMjgzZDQ4NTJiZTI1Y2QyYWEzN2M0ZDU0L3RhYmxlcmFuZ2U6NTRlY2VhNGQyODNkNDg1MmJlMjVjZDJhYTM3YzRkNTRfMy03LTEtMS0xNTk1NDA_f4eecd7b-57d8-4ca5-8452-f0f41731dd00">8,530.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iab7ebbcbace541c5b7a8ee0e0e859b97_I20210630" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yOC9mcmFnOmEyNTBjNDBjZWQ3ZDQwZjRhNWUyMTQwZDM3MWNiYjliL3RhYmxlOjU0ZWNlYTRkMjgzZDQ4NTJiZTI1Y2QyYWEzN2M0ZDU0L3RhYmxlcmFuZ2U6NTRlY2VhNGQyODNkNDg1MmJlMjVjZDJhYTM3YzRkNTRfMy05LTEtMS0xNTk1NDA_17125689-6af3-4986-ab90-256a19eef300">3,013.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i19336abc2d9f44a7a6562598fdd26074_I20210630" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yOC9mcmFnOmEyNTBjNDBjZWQ3ZDQwZjRhNWUyMTQwZDM3MWNiYjliL3RhYmxlOjU0ZWNlYTRkMjgzZDQ4NTJiZTI1Y2QyYWEzN2M0ZDU0L3RhYmxlcmFuZ2U6NTRlY2VhNGQyODNkNDg1MmJlMjVjZDJhYTM3YzRkNTRfMy0xMS0xLTEtMTU5NTQw_7fa55e07-b2c9-48c0-bfe6-7a08f6ccee19">6,287.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i880a0df9a6d245b9a11c009232dc11c9_I20210630" decimals="-3" name="us-gaap:TreasuryStockCommonShares" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yOC9mcmFnOmEyNTBjNDBjZWQ3ZDQwZjRhNWUyMTQwZDM3MWNiYjliL3RhYmxlOjU0ZWNlYTRkMjgzZDQ4NTJiZTI1Y2QyYWEzN2M0ZDU0L3RhYmxlcmFuZ2U6NTRlY2VhNGQyODNkNDg1MmJlMjVjZDJhYTM3YzRkNTRfMy0xMy0xLTEtMTU5NTQw_a0242d52-4853-4826-9c2a-9045ffce7d36">463</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i880a0df9a6d245b9a11c009232dc11c9_I20210630" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yOC9mcmFnOmEyNTBjNDBjZWQ3ZDQwZjRhNWUyMTQwZDM3MWNiYjliL3RhYmxlOjU0ZWNlYTRkMjgzZDQ4NTJiZTI1Y2QyYWEzN2M0ZDU0L3RhYmxlcmFuZ2U6NTRlY2VhNGQyODNkNDg1MmJlMjVjZDJhYTM3YzRkNTRfMy0xNS0xLTEtMTU5NTQw_6d92fa6f-1acf-4170-82f2-aac697d0cb4d">52.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d264417b4674277a12ca8c8f571f6da_I20210630" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yOC9mcmFnOmEyNTBjNDBjZWQ3ZDQwZjRhNWUyMTQwZDM3MWNiYjliL3RhYmxlOjU0ZWNlYTRkMjgzZDQ4NTJiZTI1Y2QyYWEzN2M0ZDU0L3RhYmxlcmFuZ2U6NTRlY2VhNGQyODNkNDg1MmJlMjVjZDJhYTM3YzRkNTRfMy0xNy0xLTEtMTU5NTQw_a9acd5e2-5aec-4ba5-9339-48e3f1e2a6d4">219.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net income (loss) </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice03038a88b14398a99843ecea77cf17_D20210701-20210930" decimals="-5" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yOC9mcmFnOmEyNTBjNDBjZWQ3ZDQwZjRhNWUyMTQwZDM3MWNiYjliL3RhYmxlOjU0ZWNlYTRkMjgzZDQ4NTJiZTI1Y2QyYWEzN2M0ZDU0L3RhYmxlcmFuZ2U6NTRlY2VhNGQyODNkNDg1MmJlMjVjZDJhYTM3YzRkNTRfNC03LTEtMS0xNTk1NDA_9334433b-71f0-482b-b0ed-efc85667419e">1,110.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i37f1eff7c147431d9904c45abe8087de_D20210701-20210930" decimals="-5" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yOC9mcmFnOmEyNTBjNDBjZWQ3ZDQwZjRhNWUyMTQwZDM3MWNiYjliL3RhYmxlOjU0ZWNlYTRkMjgzZDQ4NTJiZTI1Y2QyYWEzN2M0ZDU0L3RhYmxlcmFuZ2U6NTRlY2VhNGQyODNkNDg1MmJlMjVjZDJhYTM3YzRkNTRfNC0xNy0xLTEtMTU5NTQw_b302ceb9-0483-4553-b3b0-a7bbfd98d89a">22.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other comprehensive income, net of tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28729f1c595d49408f9bc75addee5dce_D20210701-20210930" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yOC9mcmFnOmEyNTBjNDBjZWQ3ZDQwZjRhNWUyMTQwZDM3MWNiYjliL3RhYmxlOjU0ZWNlYTRkMjgzZDQ4NTJiZTI1Y2QyYWEzN2M0ZDU0L3RhYmxlcmFuZ2U6NTRlY2VhNGQyODNkNDg1MmJlMjVjZDJhYTM3YzRkNTRfNS0xMS0xLTEtMTU5NTQw_b5d34ff5-fdb6-4175-bd8f-8acb0e98fca3">114.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Issuance of stock under employee stock plans, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ieabf4a292fa6473cb378b3091605b996_D20210701-20210930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yOC9mcmFnOmEyNTBjNDBjZWQ3ZDQwZjRhNWUyMTQwZDM3MWNiYjliL3RhYmxlOjU0ZWNlYTRkMjgzZDQ4NTJiZTI1Y2QyYWEzN2M0ZDU0L3RhYmxlcmFuZ2U6NTRlY2VhNGQyODNkNDg1MmJlMjVjZDJhYTM3YzRkNTRfMTAtMS0xLTEtMTU5NTQw_4a6e22e0-78b9-4cd9-9fd5-351b6a9d0265">14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieabf4a292fa6473cb378b3091605b996_D20210701-20210930" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yOC9mcmFnOmEyNTBjNDBjZWQ3ZDQwZjRhNWUyMTQwZDM3MWNiYjliL3RhYmxlOjU0ZWNlYTRkMjgzZDQ4NTJiZTI1Y2QyYWEzN2M0ZDU0L3RhYmxlcmFuZ2U6NTRlY2VhNGQyODNkNDg1MmJlMjVjZDJhYTM3YzRkNTRfMTAtMy0xLTEtMTU5NTQw_cb5228b7-d2a3-4faa-9075-9e8f7c1e1068">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia0caea5b6e2742c49986260609ac8cb2_D20210701-20210930" decimals="-5" sign="-" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yOC9mcmFnOmEyNTBjNDBjZWQ3ZDQwZjRhNWUyMTQwZDM3MWNiYjliL3RhYmxlOjU0ZWNlYTRkMjgzZDQ4NTJiZTI1Y2QyYWEzN2M0ZDU0L3RhYmxlcmFuZ2U6NTRlY2VhNGQyODNkNDg1MmJlMjVjZDJhYTM3YzRkNTRfMTAtNS0xLTEtMTU5NTQw_5b574dac-02ce-4c68-af74-aed5fe5c9acb">1.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0caea5b6e2742c49986260609ac8cb2_D20210701-20210930" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yOC9mcmFnOmEyNTBjNDBjZWQ3ZDQwZjRhNWUyMTQwZDM3MWNiYjliL3RhYmxlOjU0ZWNlYTRkMjgzZDQ4NTJiZTI1Y2QyYWEzN2M0ZDU0L3RhYmxlcmFuZ2U6NTRlY2VhNGQyODNkNDg1MmJlMjVjZDJhYTM3YzRkNTRfMTEtNS0xLTEtMTU5NTQw_a99ec9e9-a57b-434c-bba8-14bb40e0e4cd">90.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ice03038a88b14398a99843ecea77cf17_D20210701-20210930" decimals="-5" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yOC9mcmFnOmEyNTBjNDBjZWQ3ZDQwZjRhNWUyMTQwZDM3MWNiYjliL3RhYmxlOjU0ZWNlYTRkMjgzZDQ4NTJiZTI1Y2QyYWEzN2M0ZDU0L3RhYmxlcmFuZ2U6NTRlY2VhNGQyODNkNDg1MmJlMjVjZDJhYTM3YzRkNTRfMTMtNy0xLTEtMTU5NTQw_500b1be3-576d-4c65-bf20-4f56891e467a">0.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37f1eff7c147431d9904c45abe8087de_D20210701-20210930" decimals="-5" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yOC9mcmFnOmEyNTBjNDBjZWQ3ZDQwZjRhNWUyMTQwZDM3MWNiYjliL3RhYmxlOjU0ZWNlYTRkMjgzZDQ4NTJiZTI1Y2QyYWEzN2M0ZDU0L3RhYmxlcmFuZ2U6NTRlY2VhNGQyODNkNDg1MmJlMjVjZDJhYTM3YzRkNTRfMTMtMTctMS0xLTE1OTU0MA_bc57a8e6-dc10-4b1a-b0c9-05210e9c61e2">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Balance at September&#160;30, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5d0c3b9efde1461b8e305f2507573310_I20210930" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yOC9mcmFnOmEyNTBjNDBjZWQ3ZDQwZjRhNWUyMTQwZDM3MWNiYjliL3RhYmxlOjU0ZWNlYTRkMjgzZDQ4NTJiZTI1Y2QyYWEzN2M0ZDU0L3RhYmxlcmFuZ2U6NTRlY2VhNGQyODNkNDg1MmJlMjVjZDJhYTM3YzRkNTRfMTQtMS0xLTEtMTU5NTQw_ab54cf97-2781-4f63-b704-ce2ff1d7dbe5">957,052</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d0c3b9efde1461b8e305f2507573310_I20210930" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yOC9mcmFnOmEyNTBjNDBjZWQ3ZDQwZjRhNWUyMTQwZDM3MWNiYjliL3RhYmxlOjU0ZWNlYTRkMjgzZDQ4NTJiZTI1Y2QyYWEzN2M0ZDU0L3RhYmxlcmFuZ2U6NTRlY2VhNGQyODNkNDg1MmJlMjVjZDJhYTM3YzRkNTRfMTQtMy0xLTEtMTU5NTQw_11f051ef-b549-4ebe-974b-408b5096316c">598.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied5972defca747b08dfeb7847dcbf9b1_I20210930" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yOC9mcmFnOmEyNTBjNDBjZWQ3ZDQwZjRhNWUyMTQwZDM3MWNiYjliL3RhYmxlOjU0ZWNlYTRkMjgzZDQ4NTJiZTI1Y2QyYWEzN2M0ZDU0L3RhYmxlcmFuZ2U6NTRlY2VhNGQyODNkNDg1MmJlMjVjZDJhYTM3YzRkNTRfMTQtNS0xLTEtMTU5NTQw_482df404-ec88-40d0-abc2-87feb99b0eb8">6,758.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e2b4f10aa894a52a243db283dd48374_I20210930" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yOC9mcmFnOmEyNTBjNDBjZWQ3ZDQwZjRhNWUyMTQwZDM3MWNiYjliL3RhYmxlOjU0ZWNlYTRkMjgzZDQ4NTJiZTI1Y2QyYWEzN2M0ZDU0L3RhYmxlcmFuZ2U6NTRlY2VhNGQyODNkNDg1MmJlMjVjZDJhYTM3YzRkNTRfMTQtNy0xLTEtMTU5NTQw_1836dd86-4f61-4760-9272-7bb7b5e860ad">9,639.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5d24641160994798813313583b8c5313_I20210930" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yOC9mcmFnOmEyNTBjNDBjZWQ3ZDQwZjRhNWUyMTQwZDM3MWNiYjliL3RhYmxlOjU0ZWNlYTRkMjgzZDQ4NTJiZTI1Y2QyYWEzN2M0ZDU0L3RhYmxlcmFuZ2U6NTRlY2VhNGQyODNkNDg1MmJlMjVjZDJhYTM3YzRkNTRfMTQtOS0xLTEtMTU5NTQw_f957e044-1a01-42c5-b1dc-fa79bc20b841">3,013.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib38bda0500864764be978f7cbb680740_I20210930" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yOC9mcmFnOmEyNTBjNDBjZWQ3ZDQwZjRhNWUyMTQwZDM3MWNiYjliL3RhYmxlOjU0ZWNlYTRkMjgzZDQ4NTJiZTI1Y2QyYWEzN2M0ZDU0L3RhYmxlcmFuZ2U6NTRlY2VhNGQyODNkNDg1MmJlMjVjZDJhYTM3YzRkNTRfMTQtMTEtMS0xLTE1OTU0MA_93816949-4939-4059-99fa-6aa33d993e70">6,172.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7b19ed61f4414f2e89fb8677352c10c6_I20210930" decimals="-3" name="us-gaap:TreasuryStockCommonShares" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yOC9mcmFnOmEyNTBjNDBjZWQ3ZDQwZjRhNWUyMTQwZDM3MWNiYjliL3RhYmxlOjU0ZWNlYTRkMjgzZDQ4NTJiZTI1Y2QyYWEzN2M0ZDU0L3RhYmxlcmFuZ2U6NTRlY2VhNGQyODNkNDg1MmJlMjVjZDJhYTM3YzRkNTRfMTQtMTMtMS0xLTE1OTU0MA_5ba3cacd-6990-4cb0-813c-c9d6994bcad2">463</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7b19ed61f4414f2e89fb8677352c10c6_I20210930" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yOC9mcmFnOmEyNTBjNDBjZWQ3ZDQwZjRhNWUyMTQwZDM3MWNiYjliL3RhYmxlOjU0ZWNlYTRkMjgzZDQ4NTJiZTI1Y2QyYWEzN2M0ZDU0L3RhYmxlcmFuZ2U6NTRlY2VhNGQyODNkNDg1MmJlMjVjZDJhYTM3YzRkNTRfMTQtMTUtMS0xLTE1OTU0MA_2900ac5b-f4af-4b04-a084-997e5a9b4ef4">52.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6809dd88ee6440e8b81974c0682727a5_I20210930" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yOC9mcmFnOmEyNTBjNDBjZWQ3ZDQwZjRhNWUyMTQwZDM3MWNiYjliL3RhYmxlOjU0ZWNlYTRkMjgzZDQ4NTJiZTI1Y2QyYWEzN2M0ZDU0L3RhYmxlcmFuZ2U6NTRlY2VhNGQyODNkNDg1MmJlMjVjZDJhYTM3YzRkNTRfMTQtMTctMS0xLTE1OTU0MA_a9aff882-9ca0-4a01-a9c9-5793cd0734c9">197.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Balance at July 1, 2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id1796d16ca7c4cf0894522a6f064e12e_I20220630" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yOC9mcmFnOmEyNTBjNDBjZWQ3ZDQwZjRhNWUyMTQwZDM3MWNiYjliL3RhYmxlOjU0ZWNlYTRkMjgzZDQ4NTJiZTI1Y2QyYWEzN2M0ZDU0L3RhYmxlcmFuZ2U6NTRlY2VhNGQyODNkNDg1MmJlMjVjZDJhYTM3YzRkNTRfMTYtMS0xLTEtMTU5NTQw_52cdcd29-2525-4ae3-b4d7-2ba5f9c69e58">950,619</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1796d16ca7c4cf0894522a6f064e12e_I20220630" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yOC9mcmFnOmEyNTBjNDBjZWQ3ZDQwZjRhNWUyMTQwZDM3MWNiYjliL3RhYmxlOjU0ZWNlYTRkMjgzZDQ4NTJiZTI1Y2QyYWEzN2M0ZDU0L3RhYmxlcmFuZ2U6NTRlY2VhNGQyODNkNDg1MmJlMjVjZDJhYTM3YzRkNTRfMTYtMy0xLTEtMTU5NTQw_c7933550-6abf-4f37-bdc4-439f9acf1ae4">594.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia172fdb106784793868c32f3fe4a033a_I20220630" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yOC9mcmFnOmEyNTBjNDBjZWQ3ZDQwZjRhNWUyMTQwZDM3MWNiYjliL3RhYmxlOjU0ZWNlYTRkMjgzZDQ4NTJiZTI1Y2QyYWEzN2M0ZDU0L3RhYmxlcmFuZ2U6NTRlY2VhNGQyODNkNDg1MmJlMjVjZDJhYTM3YzRkNTRfMTYtNS0xLTEtMTU5NTQw_e0dcc718-e876-40e3-865d-74e304b026f9">6,746.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13cf184e02084806adfd29b238e3b85d_I20220630" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yOC9mcmFnOmEyNTBjNDBjZWQ3ZDQwZjRhNWUyMTQwZDM3MWNiYjliL3RhYmxlOjU0ZWNlYTRkMjgzZDQ4NTJiZTI1Y2QyYWEzN2M0ZDU0L3RhYmxlcmFuZ2U6NTRlY2VhNGQyODNkNDg1MmJlMjVjZDJhYTM3YzRkNTRfMTYtNy0xLTEtMTU5NTQw_95b3a5c3-92d3-46d8-a0f1-cd1e3723aab2">8,556.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i044825e6cd0d4decafdaae3baf84a330_I20220630" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yOC9mcmFnOmEyNTBjNDBjZWQ3ZDQwZjRhNWUyMTQwZDM3MWNiYjliL3RhYmxlOjU0ZWNlYTRkMjgzZDQ4NTJiZTI1Y2QyYWEzN2M0ZDU0L3RhYmxlcmFuZ2U6NTRlY2VhNGQyODNkNDg1MmJlMjVjZDJhYTM3YzRkNTRfMTYtOS0xLTEtMTU5NTQw_421097d9-14fe-47d2-82c0-b453d549a435">3,013.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9cff35c3c8c34c0fb04c18abeacebca6_I20220630" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yOC9mcmFnOmEyNTBjNDBjZWQ3ZDQwZjRhNWUyMTQwZDM3MWNiYjliL3RhYmxlOjU0ZWNlYTRkMjgzZDQ4NTJiZTI1Y2QyYWEzN2M0ZDU0L3RhYmxlcmFuZ2U6NTRlY2VhNGQyODNkNDg1MmJlMjVjZDJhYTM3YzRkNTRfMTYtMTEtMS0xLTE1OTU0MA_922f799c-ed71-4cf6-873c-182b55de97e1">4,287.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i21c6412f9d1948d19b3452207237dadd_I20220630" decimals="-3" name="us-gaap:TreasuryStockCommonShares" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yOC9mcmFnOmEyNTBjNDBjZWQ3ZDQwZjRhNWUyMTQwZDM3MWNiYjliL3RhYmxlOjU0ZWNlYTRkMjgzZDQ4NTJiZTI1Y2QyYWEzN2M0ZDU0L3RhYmxlcmFuZ2U6NTRlY2VhNGQyODNkNDg1MmJlMjVjZDJhYTM3YzRkNTRfMTYtMTMtMS0xLTE1OTU0MA_79b6e3ff-9a51-48d4-a405-02f97d7823a6">450</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i21c6412f9d1948d19b3452207237dadd_I20220630" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yOC9mcmFnOmEyNTBjNDBjZWQ3ZDQwZjRhNWUyMTQwZDM3MWNiYjliL3RhYmxlOjU0ZWNlYTRkMjgzZDQ4NTJiZTI1Y2QyYWEzN2M0ZDU0L3RhYmxlcmFuZ2U6NTRlY2VhNGQyODNkNDg1MmJlMjVjZDJhYTM3YzRkNTRfMTYtMTUtMS0xLTE1OTU0MA_8eb7f85c-86ce-4c28-8769-6fd6765ed5b0">50.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28fcba67335d4eeeb35e767ac7467d7b_I20220630" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yOC9mcmFnOmEyNTBjNDBjZWQ3ZDQwZjRhNWUyMTQwZDM3MWNiYjliL3RhYmxlOjU0ZWNlYTRkMjgzZDQ4NTJiZTI1Y2QyYWEzN2M0ZDU0L3RhYmxlcmFuZ2U6NTRlY2VhNGQyODNkNDg1MmJlMjVjZDJhYTM3YzRkNTRfMTYtMTctMS0xLTE1OTU0MA_35553261-2932-45e5-b75b-26a9b8a401f7">114.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib48f338ea64a4a6ab71c4d7e3fd06673_D20220701-20220930" decimals="-5" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yOC9mcmFnOmEyNTBjNDBjZWQ3ZDQwZjRhNWUyMTQwZDM3MWNiYjliL3RhYmxlOjU0ZWNlYTRkMjgzZDQ4NTJiZTI1Y2QyYWEzN2M0ZDU0L3RhYmxlcmFuZ2U6NTRlY2VhNGQyODNkNDg1MmJlMjVjZDJhYTM3YzRkNTRfMTctNy0xLTEtMTU5NTQw_14ca4ec0-2a9e-440a-b653-8d3cb5cf460a">1,451.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i55ef102ce6314f71bbad20789a340a44_D20220701-20220930" decimals="-5" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yOC9mcmFnOmEyNTBjNDBjZWQ3ZDQwZjRhNWUyMTQwZDM3MWNiYjliL3RhYmxlOjU0ZWNlYTRkMjgzZDQ4NTJiZTI1Y2QyYWEzN2M0ZDU0L3RhYmxlcmFuZ2U6NTRlY2VhNGQyODNkNDg1MmJlMjVjZDJhYTM3YzRkNTRfMTctMTctMS0xLTE1OTU0MA_111cfb83-128b-4931-b704-03735487bcbe">15.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other comprehensive loss, net of tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb26ceb80a3d4067ad9572aeb3904905_D20220701-20220930" decimals="-5" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yOC9mcmFnOmEyNTBjNDBjZWQ3ZDQwZjRhNWUyMTQwZDM3MWNiYjliL3RhYmxlOjU0ZWNlYTRkMjgzZDQ4NTJiZTI1Y2QyYWEzN2M0ZDU0L3RhYmxlcmFuZ2U6NTRlY2VhNGQyODNkNDg1MmJlMjVjZDJhYTM3YzRkNTRfMTgtMTEtMS0xLTE1OTU0MA_ac8af636-3dee-4504-82aa-5287e0932a31">8.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Issuance of stock under employee stock plans, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i97b74653944e4f17928c61ac64c196ad_D20220701-20220930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yOC9mcmFnOmEyNTBjNDBjZWQ3ZDQwZjRhNWUyMTQwZDM3MWNiYjliL3RhYmxlOjU0ZWNlYTRkMjgzZDQ4NTJiZTI1Y2QyYWEzN2M0ZDU0L3RhYmxlcmFuZ2U6NTRlY2VhNGQyODNkNDg1MmJlMjVjZDJhYTM3YzRkNTRfMjItMS0xLTEtMTU5NTQw_cbed6caa-260e-4cf6-bf22-4b4865463975">8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1b27ad5aed11494a84032093fe25e25c_D20220701-20220930" decimals="-5" sign="-" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yOC9mcmFnOmEyNTBjNDBjZWQ3ZDQwZjRhNWUyMTQwZDM3MWNiYjliL3RhYmxlOjU0ZWNlYTRkMjgzZDQ4NTJiZTI1Y2QyYWEzN2M0ZDU0L3RhYmxlcmFuZ2U6NTRlY2VhNGQyODNkNDg1MmJlMjVjZDJhYTM3YzRkNTRfMjItNS0xLTEtMTU5NTQw_dbb85e96-a511-4c5c-b3a8-522111227c0f">2.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b27ad5aed11494a84032093fe25e25c_D20220701-20220930" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yOC9mcmFnOmEyNTBjNDBjZWQ3ZDQwZjRhNWUyMTQwZDM3MWNiYjliL3RhYmxlOjU0ZWNlYTRkMjgzZDQ4NTJiZTI1Y2QyYWEzN2M0ZDU0L3RhYmxlcmFuZ2U6NTRlY2VhNGQyODNkNDg1MmJlMjVjZDJhYTM3YzRkNTRfMjMtNS0xLTEtMTU5NTQw_793dabe7-3c23-40ba-8b7c-01c5fbeae239">85.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib48f338ea64a4a6ab71c4d7e3fd06673_D20220701-20220930" decimals="-5" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yOC9mcmFnOmEyNTBjNDBjZWQ3ZDQwZjRhNWUyMTQwZDM3MWNiYjliL3RhYmxlOjU0ZWNlYTRkMjgzZDQ4NTJiZTI1Y2QyYWEzN2M0ZDU0L3RhYmxlcmFuZ2U6NTRlY2VhNGQyODNkNDg1MmJlMjVjZDJhYTM3YzRkNTRfMjQtNy0xLTEtMTU5NTQw_3052b3ea-5816-42a7-8c61-a84aff3ded87">1.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i55ef102ce6314f71bbad20789a340a44_D20220701-20220930" decimals="-5" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yOC9mcmFnOmEyNTBjNDBjZWQ3ZDQwZjRhNWUyMTQwZDM3MWNiYjliL3RhYmxlOjU0ZWNlYTRkMjgzZDQ4NTJiZTI1Y2QyYWEzN2M0ZDU0L3RhYmxlcmFuZ2U6NTRlY2VhNGQyODNkNDg1MmJlMjVjZDJhYTM3YzRkNTRfMjQtMTctMS0xLTE1OTU0MA_16605fdf-9003-4867-b015-ad4fd8ac69af">3.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Balance at September&#160;30, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5c81da162e9a42e2a66c2c1a06d48dd5_I20220930" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yOC9mcmFnOmEyNTBjNDBjZWQ3ZDQwZjRhNWUyMTQwZDM3MWNiYjliL3RhYmxlOjU0ZWNlYTRkMjgzZDQ4NTJiZTI1Y2QyYWEzN2M0ZDU0L3RhYmxlcmFuZ2U6NTRlY2VhNGQyODNkNDg1MmJlMjVjZDJhYTM3YzRkNTRfMjUtMS0xLTEtMTU5NTQw_5f20c68a-bb7e-4c4b-b690-31acc3a6dc64">950,627</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c81da162e9a42e2a66c2c1a06d48dd5_I20220930" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yOC9mcmFnOmEyNTBjNDBjZWQ3ZDQwZjRhNWUyMTQwZDM3MWNiYjliL3RhYmxlOjU0ZWNlYTRkMjgzZDQ4NTJiZTI1Y2QyYWEzN2M0ZDU0L3RhYmxlcmFuZ2U6NTRlY2VhNGQyODNkNDg1MmJlMjVjZDJhYTM3YzRkNTRfMjUtMy0xLTEtMTU5NTQw_3c594ee2-1ec7-4dfa-911c-0548180b2f69">594.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice411cf446b842b893447accbe09511a_I20220930" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yOC9mcmFnOmEyNTBjNDBjZWQ3ZDQwZjRhNWUyMTQwZDM3MWNiYjliL3RhYmxlOjU0ZWNlYTRkMjgzZDQ4NTJiZTI1Y2QyYWEzN2M0ZDU0L3RhYmxlcmFuZ2U6NTRlY2VhNGQyODNkNDg1MmJlMjVjZDJhYTM3YzRkNTRfMjUtNS0xLTEtMTU5NTQw_2a7f82f0-e187-410b-8956-11f19497c65e">6,829.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ebf10616d0b4419a14703502b215705_I20220930" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yOC9mcmFnOmEyNTBjNDBjZWQ3ZDQwZjRhNWUyMTQwZDM3MWNiYjliL3RhYmxlOjU0ZWNlYTRkMjgzZDQ4NTJiZTI1Y2QyYWEzN2M0ZDU0L3RhYmxlcmFuZ2U6NTRlY2VhNGQyODNkNDg1MmJlMjVjZDJhYTM3YzRkNTRfMjUtNy0xLTEtMTU5NTQw_c293efd4-0b90-4e97-b6f9-5d3574699496">10,006.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i422ef8f62e714031b35d70b78011fe07_I20220930" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yOC9mcmFnOmEyNTBjNDBjZWQ3ZDQwZjRhNWUyMTQwZDM3MWNiYjliL3RhYmxlOjU0ZWNlYTRkMjgzZDQ4NTJiZTI1Y2QyYWEzN2M0ZDU0L3RhYmxlcmFuZ2U6NTRlY2VhNGQyODNkNDg1MmJlMjVjZDJhYTM3YzRkNTRfMjUtOS0xLTEtMTU5NTQw_0aca80ce-bca5-4fac-9dab-71b90961a7d1">3,013.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i405731ae56194b5ab8d7ef0f5a2a4501_I20220930" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yOC9mcmFnOmEyNTBjNDBjZWQ3ZDQwZjRhNWUyMTQwZDM3MWNiYjliL3RhYmxlOjU0ZWNlYTRkMjgzZDQ4NTJiZTI1Y2QyYWEzN2M0ZDU0L3RhYmxlcmFuZ2U6NTRlY2VhNGQyODNkNDg1MmJlMjVjZDJhYTM3YzRkNTRfMjUtMTEtMS0xLTE1OTU0MA_2e3dcb2f-de3e-4493-8c47-c1a091b32532">4,295.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7890664142234b2cba495545e31cf06b_I20220930" decimals="-3" name="us-gaap:TreasuryStockCommonShares" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yOC9mcmFnOmEyNTBjNDBjZWQ3ZDQwZjRhNWUyMTQwZDM3MWNiYjliL3RhYmxlOjU0ZWNlYTRkMjgzZDQ4NTJiZTI1Y2QyYWEzN2M0ZDU0L3RhYmxlcmFuZ2U6NTRlY2VhNGQyODNkNDg1MmJlMjVjZDJhYTM3YzRkNTRfMjUtMTMtMS0xLTE1OTU0MA_17f5a50e-d7d3-49ea-ac64-ce1a5539bebc">450</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7890664142234b2cba495545e31cf06b_I20220930" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yOC9mcmFnOmEyNTBjNDBjZWQ3ZDQwZjRhNWUyMTQwZDM3MWNiYjliL3RhYmxlOjU0ZWNlYTRkMjgzZDQ4NTJiZTI1Y2QyYWEzN2M0ZDU0L3RhYmxlcmFuZ2U6NTRlY2VhNGQyODNkNDg1MmJlMjVjZDJhYTM3YzRkNTRfMjUtMTUtMS0xLTE1OTU0MA_7af684c2-0888-4891-a471-aee7fb026ebd">50.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i874cf6e76f6143ffbd4b62dbb7d9d39b_I20220930" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yOC9mcmFnOmEyNTBjNDBjZWQ3ZDQwZjRhNWUyMTQwZDM3MWNiYjliL3RhYmxlOjU0ZWNlYTRkMjgzZDQ4NTJiZTI1Y2QyYWEzN2M0ZDU0L3RhYmxlcmFuZ2U6NTRlY2VhNGQyODNkNDg1MmJlMjVjZDJhYTM3YzRkNTRfMjUtMTctMS0xLTE1OTU0MA_9b67932d-c29d-44d6-9029-00b1aaa98c37">95.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> <ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yOC9mcmFnOmEyNTBjNDBjZWQ3ZDQwZjRhNWUyMTQwZDM3MWNiYjliL3RleHRyZWdpb246YTI1MGM0MGNlZDdkNDBmNGE1ZTIxNDBkMzcxY2JiOWJfMjYx_2087051d-93f9-4e3e-80d6-ea5e9c10d8dd" footnoteRole="http://www.xbrl.org/2003/role/footnote">As of September&#160;30, 2022, there was $<ix:nonFraction unitRef="usd" contextRef="i08ccb35f6ad24d7793c9c91b74ca2ea1_I20220930" decimals="-7" name="us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yOC9mcmFnOmEyNTBjNDBjZWQ3ZDQwZjRhNWUyMTQwZDM3MWNiYjliL3RleHRyZWdpb246YTI1MGM0MGNlZDdkNDBmNGE1ZTIxNDBkMzcxY2JiOWJfMTI2_392aac4e-3a4d-409a-9955-2d5861d0f0a4">3.25</ix:nonFraction> billion remaining under our $<ix:nonFraction unitRef="usd" contextRef="i9e4e65510f9e48218be4e6b56cc6a8e6_I20210531" decimals="INF" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yOC9mcmFnOmEyNTBjNDBjZWQ3ZDQwZjRhNWUyMTQwZDM3MWNiYjliL3RleHRyZWdpb246YTI1MGM0MGNlZDdkNDBmNGE1ZTIxNDBkMzcxY2JiOWJfMTQ5_7e916f3f-df34-4731-a795-e9ef2c8472bc">5.00</ix:nonFraction> billion share repurchase program authorized in May 2021.</ix:footnote> </span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See notes to consolidated condensed financial statements.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><div id="i5fed483d9c7e4f3cbba3a62c53226cd7_31"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:24.668%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.927%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.781%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.927%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.074%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.927%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.856%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.927%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.781%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.276%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="45" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Equity of Eli Lilly and Company Shareholders</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:17pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%"><br/></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">(Dollars in millions, except per-share data, and shares in thousands)</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Retained<br/>Earnings</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Employee Benefit Trust</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Loss</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Common Stock in Treasury</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Noncontrolling Interests</span></td></tr><tr style="height:11pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Balance at January 1, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id40dc90365d54458840dc95bd54da311_I20201231" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfMy0xLTEtMS0xNTk1NDA_2132fa1b-70fd-4e4f-a01f-ffd6b0c714a2">957,077</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id40dc90365d54458840dc95bd54da311_I20201231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfMy0zLTEtMS0xNTk1NDA_49513b36-23c6-4302-bc8a-3e7dce9e4f9e">598.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13a4d036feb14d029728aad2602198e3_I20201231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfMy01LTEtMS0xNTk1NDA_24489339-2366-4003-a9ac-0a475443ec09">6,778.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89632ef2fab645e59b17e0d04998f005_I20201231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfMy03LTEtMS0xNTk1NDA_7bf3ad30-99af-4e23-a5db-56723fa12009">7,830.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i03ad855e73c7425c82de6d5bf47f2c5c_I20201231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfMy05LTEtMS0xNTk1NDA_97801844-2f7b-4d80-bb1b-ea229c3d9330">3,013.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0f26207c7675459eb15f8af1fa1954bd_I20201231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfMy0xMS0xLTEtMTU5NTQw_45563e87-5a11-412c-8815-eb21c40cb120">6,496.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i475ce37d989c466ca8d104299897d8b5_I20201231" decimals="-3" name="us-gaap:TreasuryStockCommonShares" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfMy0xMy0xLTEtMTU5NTQw_d1cdfdda-f62e-426c-9a0c-ebd3749b728c">487</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i475ce37d989c466ca8d104299897d8b5_I20201231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfMy0xNS0xLTEtMTU5NTQw_0c79c58d-ca29-449b-b8c0-a4ce0f3b7eda">55.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd150ac2b08f457b820ab337af8f787a_I20201231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfMy0xNy0xLTEtMTU5NTQw_66e66eb1-ec42-4ada-8619-68e242132c1b">183.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaae84e0e259740269afbdc32023935d8_D20210101-20210930" decimals="-5" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfNC03LTEtMS0xNTk1NDA_e666f04c-429b-4790-a01b-808f5cc00ecf">3,855.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4b3bbe2d1454aa7b635ddfa117d7690_D20210101-20210930" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfNC0xNy0xLTEtMTU5NTQw_b6af0d50-8257-4a5b-9d1d-90d9faea180c">25.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other comprehensive income, net of tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53f6912753594605b21dd0402024a8d0_D20210101-20210930" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfNS0xMS0xLTEtMTU5NTQw_15e3426b-e712-410b-886e-979d782b8d05">323.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash dividends declared per share: $<ix:nonFraction unitRef="usdPerShare" contextRef="i167ed8f67bef48c49e54fa466400cdaa_D20210101-20210930" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfNi0wLTEtMS0xNTk1NDAvdGV4dHJlZ2lvbjo2ZTk0NmE3YzUyMzM0ZjRkODAzOTg4ZWIyOWQ5MjkwNl8zOQ_264e7906-d7fe-4127-a93f-53fff8e375aa">1.70</ix:nonFraction> </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaae84e0e259740269afbdc32023935d8_D20210101-20210930" decimals="-5" name="us-gaap:Dividends" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfNi03LTEtMS0xNTk1NDA_20d6bbec-76c2-4d04-a885-ae1b096b0b58">1,542.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Retirement of treasury shares</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i0f7811d1ec7f49e2b3619fe9097a5c81_D20210101-20210930" decimals="-3" name="us-gaap:TreasuryStockSharesRetired" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfNy0xLTEtMS0xNTk1NDA_679f571e-3b8e-441e-b62c-bef0449b53d0">2,467</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0f7811d1ec7f49e2b3619fe9097a5c81_D20210101-20210930" decimals="-5" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfNy0zLTEtMS0xNTk1NDA_6634d471-c170-433b-892b-f6f91955369f">1.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaae84e0e259740269afbdc32023935d8_D20210101-20210930" decimals="-5" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfNy03LTEtMS0xNTk1NDA_05ec5219-eae0-4cb0-b3bc-4e0ebcca3bdd">498.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i43c09d3fa78d4c5e896029e6ef10d475_D20210101-20210930" decimals="-3" name="us-gaap:TreasuryStockSharesRetired" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfNy0xMy0xLTEtMTU5NTQw_ac6aaddd-eafb-4ec4-accf-829f59b018fb">2,467</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43c09d3fa78d4c5e896029e6ef10d475_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfNy0xNS0xLTEtMTU5NTQw_86de006e-c527-4c64-8afd-d972d9acad45">500.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Purchase of treasury shares </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i43c09d3fa78d4c5e896029e6ef10d475_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfOC0xMy0xLTEtMTU5NTQw_6f9cea00-98ea-47d7-83e7-d75d6037deda">2,467</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i43c09d3fa78d4c5e896029e6ef10d475_D20210101-20210930" decimals="-5" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfOC0xNS0xLTEtMTU5NTQw_5b19ff46-59ca-42cb-8ec4-ec729fa0feac">500.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Issuance of stock under employee stock plans, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0f7811d1ec7f49e2b3619fe9097a5c81_D20210101-20210930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfOS0xLTEtMS0xNTk1NDA_ab343927-0015-46ea-b510-e6333f0c1ad8">2,442</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f7811d1ec7f49e2b3619fe9097a5c81_D20210101-20210930" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfOS0zLTEtMS0xNTk1NDA_522291f5-add3-4599-a7f5-cb942110c57c">1.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieb70d5cf9dee4eaa8c659c22eeb4ea9e_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfOS01LTEtMS0xNTk1NDA_747e7374-e678-4bd6-af94-1fc5da0850ed">287.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i43c09d3fa78d4c5e896029e6ef10d475_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfOS0xMy0xLTEtMTU5NTQw_3aeef466-3c5f-4743-b85a-183e218f075e">24</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43c09d3fa78d4c5e896029e6ef10d475_D20210101-20210930" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfOS0xNS0xLTEtMTU5NTQw_924c9fdc-7fe9-41c8-80cc-2c3895419a1d">3.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb70d5cf9dee4eaa8c659c22eeb4ea9e_D20210101-20210930" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfMTAtNS0xLTEtMTU5NTQw_0ca3d1f2-d08b-4f97-a61b-c64ee132f2bd">267.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieb70d5cf9dee4eaa8c659c22eeb4ea9e_D20210101-20210930" decimals="-5" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfMTMtNS0xLTEtMTU5NTQw_8d18c9f1-80ac-4c14-9ad0-8db4ee8e60b0">0.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaae84e0e259740269afbdc32023935d8_D20210101-20210930" decimals="-5" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfMTMtNy0xLTEtMTU5NTQw_4462113d-c8c5-4da1-bee2-1f3244e3b67c">5.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if4b3bbe2d1454aa7b635ddfa117d7690_D20210101-20210930" decimals="-5" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfMTMtMTctMS0xLTE1OTU0MA_50b230a8-b9fd-4ed9-a8d8-5d0be38f1d7b">11.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Balance at September&#160;30, 2021</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5d0c3b9efde1461b8e305f2507573310_I20210930" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfMTQtMS0xLTEtMTU5NTQw_3e600aec-3f0e-47ad-a44f-0061634fd80c">957,052</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d0c3b9efde1461b8e305f2507573310_I20210930" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfMTQtMy0xLTEtMTU5NTQw_42f8db68-04fd-4974-960b-80ceccdfe146">598.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied5972defca747b08dfeb7847dcbf9b1_I20210930" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfMTQtNS0xLTEtMTU5NTQw_81633402-28b7-4825-b5b7-6af580ef37f0">6,758.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e2b4f10aa894a52a243db283dd48374_I20210930" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfMTQtNy0xLTEtMTU5NTQw_1836dd86-4f61-4760-9272-7bb7b5e860ad">9,639.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5d24641160994798813313583b8c5313_I20210930" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfMTQtOS0xLTEtMTU5NTQw_a0d8388b-c177-44f6-87f3-6df9302cc370">3,013.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib38bda0500864764be978f7cbb680740_I20210930" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfMTQtMTEtMS0xLTE1OTU0MA_30d30615-9381-44eb-9012-907d0f4a9c0d">6,172.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7b19ed61f4414f2e89fb8677352c10c6_I20210930" decimals="-3" name="us-gaap:TreasuryStockCommonShares" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfMTQtMTMtMS0xLTE1OTU0MA_96786cfe-52bc-495f-97eb-53dc1ce2f278">463</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7b19ed61f4414f2e89fb8677352c10c6_I20210930" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfMTQtMTUtMS0xLTE1OTU0MA_47aac1d5-32f2-4222-a223-a804ecf08662">52.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6809dd88ee6440e8b81974c0682727a5_I20210930" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfMTQtMTctMS0xLTE1OTU0MA_6e9724f4-a4eb-4b56-a3dc-86a277367c9a">197.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Balance at January 1, 2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i272cf8c25ebe4484a64e58f12187ad1b_I20211231" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfMTYtMS0xLTEtMTU5NTQw_002454a9-5cd6-4f01-94d5-75379d7bc199">954,116</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i272cf8c25ebe4484a64e58f12187ad1b_I20211231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfMTYtMy0xLTEtMTU5NTQw_0b7c2b3a-07a8-4b4a-90d8-0e708bbf10f9">596.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf8140dd5b59491da9ea91218accebc6_I20211231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfMTYtNS0xLTEtMTU5NTQw_9bba381a-13d6-494e-839e-38fee9507482">6,833.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d075318dc464943b61778b509358518_I20211231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfMTYtNy0xLTEtMTU5NTQw_9a0e730b-50ca-4d3b-ac16-d02e04f9bde5">8,958.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib1b20bf098e647cbbe9a5c1797e3b7a9_I20211231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfMTYtOS0xLTEtMTU5NTQw_2193abb6-63f7-4178-b852-58b7a88037af">3,013.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i016472e8315c436a845438f1b48dc880_I20211231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfMTYtMTEtMS0xLTE1OTU0MA_5ee7737e-cf3e-43c3-8600-6ff064b2d889">4,343.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i39c60ea04aef49b0830a61d60786759c_I20211231" decimals="-3" name="us-gaap:TreasuryStockCommonShares" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfMTYtMTMtMS0xLTE1OTU0MA_d0839666-32d6-4ae0-946a-a4c5686bf3ad">463</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i39c60ea04aef49b0830a61d60786759c_I20211231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfMTYtMTUtMS0xLTE1OTU0MA_535791d1-15b8-498e-a925-9f7eddc75751">52.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a1a2f4319ea49c8a9891d557b01b308_I20211231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfMTYtMTctMS0xLTE1OTU0MA_e563bd3d-bf63-4cdb-8bdc-c615ce3a888c">175.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53fe950833774c68a3cffa46aff8f74b_D20220101-20220930" decimals="-5" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfMTctNy0xLTEtMTU5NTQw_1488f5b1-e72b-42ae-a6a5-54c34666b7f0">4,307.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i78ac3ae89d8a4e4b9b5634d9c24f6a88_D20220101-20220930" decimals="-5" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfMTctMTctMS0xLTE1OTU0MA_668f5da5-cd08-4bac-bbb8-61dc5dc13db8">63.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other comprehensive income, net of tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i318f185707b94171a8496548525b0a43_D20220101-20220930" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfMTgtMTEtMS0xLTE1OTU0MA_2ae23a72-97f8-46ac-ac5d-bda0c1a083b7">47.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash dividends declared per share: $<ix:nonFraction unitRef="usdPerShare" contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfMTktMC0xLTEtMTU5NTQwL3RleHRyZWdpb246OTA0ZjZjMzVjZWM2NDE5NWI3ZjgxMjEzMTY2ZTE0YjhfMzk_04551d09-5ce0-4264-b8c4-2f3305475ce9">1.96</ix:nonFraction> </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i53fe950833774c68a3cffa46aff8f74b_D20220101-20220930" decimals="-5" name="us-gaap:Dividends" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfMTktNy0xLTEtMTU5NTQw_5bea35f8-dc32-4f00-b577-3a633eb5fb8d">1,765.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Retirement of treasury shares</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i5fb9024f659a4c12b2ddd5ecc6dd8e7f_D20220101-20220930" decimals="-3" name="us-gaap:TreasuryStockSharesRetired" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfMjAtMS0xLTEtMTU5NTQw_3c5243b1-f8e1-46ea-965a-2132168277ba">5,607</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5fb9024f659a4c12b2ddd5ecc6dd8e7f_D20220101-20220930" decimals="-5" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfMjAtMy0xLTEtMTU5NTQw_2539f052-6bd7-4354-bb2d-681a9b76c79e">3.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i53fe950833774c68a3cffa46aff8f74b_D20220101-20220930" decimals="-5" name="us-gaap:TreasuryStockRetiredCostMethodAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfMjAtNy0xLTEtMTU5NTQw_745a80a5-1a69-42c6-b6d4-0533f56e2900">1,496.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i668d06cad6064c9488359f57b6460125_D20220101-20220930" decimals="-3" name="us-gaap:TreasuryStockSharesRetired" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfMjAtMTMtMS0xLTE1OTU0MA_72afa8cd-b258-4119-8087-814775c285dd">5,607</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i668d06cad6064c9488359f57b6460125_D20220101-20220930" decimals="-5" sign="-" name="us-gaap:TreasuryStockRetiredCostMethodAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfMjAtMTUtMS0xLTE1OTU0MA_90b2c7b9-d4d4-47cb-960d-af52cb5f093c">1,500.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Purchase of treasury shares</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i668d06cad6064c9488359f57b6460125_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfMjEtMTMtMS0xLTE1OTU0MA_8e9af476-2a91-410a-81c3-a243861cdf43">5,607</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i668d06cad6064c9488359f57b6460125_D20220101-20220930" decimals="-5" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfMjEtMTUtMS0xLTE1OTU0MA_c8545f5f-37fb-4748-89c4-dbb910bf7e43">1,500.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Issuance of stock under employee stock plans, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5fb9024f659a4c12b2ddd5ecc6dd8e7f_D20220101-20220930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfMjItMS0xLTEtMTU5NTQw_fac55b76-b054-47f6-a788-aa8c5e06a9c4">2,118</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5fb9024f659a4c12b2ddd5ecc6dd8e7f_D20220101-20220930" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfMjItMy0xLTEtMTU5NTQw_db2b2906-739a-4b47-8f3e-03022e2495d0">1.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1e65888bb572465d96d1a55aaa12d167_D20220101-20220930" decimals="-5" sign="-" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfMjItNS0xLTEtMTU5NTQw_70c88f5d-6ad0-4bf4-8108-30a01e218cad">282.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i668d06cad6064c9488359f57b6460125_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfMjItMTMtMS0xLTE1OTU0MA_04bc94f9-48f3-42e4-a934-3287c4031747">13</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i668d06cad6064c9488359f57b6460125_D20220101-20220930" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfMjItMTUtMS0xLTE1OTU0MA_30b3cfe7-2129-4339-a61e-be4bfad21855">2.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e65888bb572465d96d1a55aaa12d167_D20220101-20220930" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfMjMtNS0xLTEtMTU5NTQw_64053464-fa17-41d1-afbf-9592f2033a17">278.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53fe950833774c68a3cffa46aff8f74b_D20220101-20220930" decimals="-5" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfMjQtNy0xLTEtMTU5NTQw_bad7e069-fcfc-431e-b524-dfc9eda39d0b">3.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i78ac3ae89d8a4e4b9b5634d9c24f6a88_D20220101-20220930" decimals="-5" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfMjQtMTctMS0xLTE1OTU0MA_071d8009-b60e-44d6-beb2-633a460171d0">16.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Balance at September&#160;30, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5c81da162e9a42e2a66c2c1a06d48dd5_I20220930" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfMjUtMS0xLTEtMTU5NTQw_ed8e396f-8fa5-483e-91c7-3849a10db72c">950,627</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c81da162e9a42e2a66c2c1a06d48dd5_I20220930" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfMjUtMy0xLTEtMTU5NTQw_f8276910-2b59-49de-8393-db14d519ce5c">594.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice411cf446b842b893447accbe09511a_I20220930" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfMjUtNS0xLTEtMTU5NTQw_4fb65594-0089-4ee0-b65c-06b622fa0fed">6,829.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ebf10616d0b4419a14703502b215705_I20220930" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfMjUtNy0xLTEtMTU5NTQw_5d85fa14-fa1e-40f8-9ad9-72d2adb9120a">10,006.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i422ef8f62e714031b35d70b78011fe07_I20220930" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfMjUtOS0xLTEtMTU5NTQw_67618d32-1f03-47a0-8024-fce4cf6d5902">3,013.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i405731ae56194b5ab8d7ef0f5a2a4501_I20220930" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfMjUtMTEtMS0xLTE1OTU0MA_850d9ab0-8b71-4991-b214-659011ddcdfb">4,295.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7890664142234b2cba495545e31cf06b_I20220930" decimals="-3" name="us-gaap:TreasuryStockCommonShares" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfMjUtMTMtMS0xLTE1OTU0MA_8ef29157-deac-4753-beeb-da0b17fe30c7">450</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7890664142234b2cba495545e31cf06b_I20220930" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfMjUtMTUtMS0xLTE1OTU0MA_da8ad497-050f-4202-83f7-ba8bfce436f5">50.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i874cf6e76f6143ffbd4b62dbb7d9d39b_I20220930" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfMjUtMTctMS0xLTE1OTU0MA_2b347a9e-dd04-46fb-8d13-754797bf19ac">95.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:12pt;margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> <ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RleHRyZWdpb246ZTAxODE5ZTcxMTNjNGY2YzkyNjFiNDYyYzIxODNiMjFfMTY0_9553bd20-e2be-4a9d-901f-d34e31f81e7e" footnoteRole="http://www.xbrl.org/2003/role/footnote">As of September&#160;30, 2022, there was $<ix:nonFraction unitRef="usd" contextRef="i08ccb35f6ad24d7793c9c91b74ca2ea1_I20220930" decimals="-7" name="us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RleHRyZWdpb246ZTAxODE5ZTcxMTNjNGY2YzkyNjFiNDYyYzIxODNiMjFfMzE_392aac4e-3a4d-409a-9955-2d5861d0f0a4">3.25</ix:nonFraction> billion remaining under our $<ix:nonFraction unitRef="usd" contextRef="i9e4e65510f9e48218be4e6b56cc6a8e6_I20210531" decimals="INF" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RleHRyZWdpb246ZTAxODE5ZTcxMTNjNGY2YzkyNjFiNDYyYzIxODNiMjFfNTQ_7e916f3f-df34-4731-a795-e9ef2c8472bc">5.00</ix:nonFraction> billion share repurchase program authorized in May 2021. </ix:footnote></span></div><div style="margin-bottom:12pt;margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See notes to consolidated condensed financial statements.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><div id="i5fed483d9c7e4f3cbba3a62c53226cd7_34"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Condensed Statements of Cash Flows</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ELI LILLY AND COMPANY AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in millions)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.145%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.911%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.914%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash Flows from Operating Activities</span></td><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930" decimals="-5" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zNC9mcmFnOmUxYWRjYjRiOGNhYTQzYTM5OWY1ZjExNzc3OTQ0YjI2L3RhYmxlOjg5MzlmNDA0NzJkMTQ2ZGViZTg3MzJlMTg4NTU5ZTE0L3RhYmxlcmFuZ2U6ODkzOWY0MDQ3MmQxNDZkZWJlODczMmUxODg1NTllMTRfMy0xLTEtMS0xNTk1NDA_87698447-ba66-4f71-89c1-b28a71c9e82a">4,307.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i167ed8f67bef48c49e54fa466400cdaa_D20210101-20210930" decimals="-5" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zNC9mcmFnOmUxYWRjYjRiOGNhYTQzYTM5OWY1ZjExNzc3OTQ0YjI2L3RhYmxlOjg5MzlmNDA0NzJkMTQ2ZGViZTg3MzJlMTg4NTU5ZTE0L3RhYmxlcmFuZ2U6ODkzOWY0MDQ3MmQxNDZkZWJlODczMmUxODg1NTllMTRfMy0zLTEtMS0xNTk1NDA_912d99b5-d76a-4c0a-b3cd-69c00d2c8eed">3,855.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjustments to Reconcile Net Income to Cash Flows from Operating Activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zNC9mcmFnOmUxYWRjYjRiOGNhYTQzYTM5OWY1ZjExNzc3OTQ0YjI2L3RhYmxlOjg5MzlmNDA0NzJkMTQ2ZGViZTg3MzJlMTg4NTU5ZTE0L3RhYmxlcmFuZ2U6ODkzOWY0MDQ3MmQxNDZkZWJlODczMmUxODg1NTllMTRfNi0xLTEtMS0xNTk1NDA_b9cc748a-9363-4b7b-acb2-159869e22b9f">1,147.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i167ed8f67bef48c49e54fa466400cdaa_D20210101-20210930" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zNC9mcmFnOmUxYWRjYjRiOGNhYTQzYTM5OWY1ZjExNzc3OTQ0YjI2L3RhYmxlOjg5MzlmNDA0NzJkMTQ2ZGViZTg3MzJlMTg4NTU5ZTE0L3RhYmxlcmFuZ2U6ODkzOWY0MDQ3MmQxNDZkZWJlODczMmUxODg1NTllMTRfNi0zLTEtMS0xNTk1NDA_9d7d1f9d-c79a-45eb-b5f7-11fbd7b7ea47">1,101.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in deferred income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930" decimals="-5" name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zNC9mcmFnOmUxYWRjYjRiOGNhYTQzYTM5OWY1ZjExNzc3OTQ0YjI2L3RhYmxlOjg5MzlmNDA0NzJkMTQ2ZGViZTg3MzJlMTg4NTU5ZTE0L3RhYmxlcmFuZ2U6ODkzOWY0MDQ3MmQxNDZkZWJlODczMmUxODg1NTllMTRfNy0xLTEtMS0xNTk1NDA_764e659f-8406-4ad2-a060-e1d8421b2f97">2,195.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i167ed8f67bef48c49e54fa466400cdaa_D20210101-20210930" decimals="-5" name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zNC9mcmFnOmUxYWRjYjRiOGNhYTQzYTM5OWY1ZjExNzc3OTQ0YjI2L3RhYmxlOjg5MzlmNDA0NzJkMTQ2ZGViZTg3MzJlMTg4NTU5ZTE0L3RhYmxlcmFuZ2U6ODkzOWY0MDQ3MmQxNDZkZWJlODczMmUxODg1NTllMTRfNy0zLTEtMS0xNTk1NDA_87aef963-a7a1-4268-9d2e-d9f86dec1340">709.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt extinguishment loss (Note 6)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930" decimals="-5" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zNC9mcmFnOmUxYWRjYjRiOGNhYTQzYTM5OWY1ZjExNzc3OTQ0YjI2L3RhYmxlOjg5MzlmNDA0NzJkMTQ2ZGViZTg3MzJlMTg4NTU5ZTE0L3RhYmxlcmFuZ2U6ODkzOWY0MDQ3MmQxNDZkZWJlODczMmUxODg1NTllMTRfOC0xLTEtMS0xNTk1NDA_328a2c13-40c1-486c-9761-5b3e0b35c0a0">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i167ed8f67bef48c49e54fa466400cdaa_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zNC9mcmFnOmUxYWRjYjRiOGNhYTQzYTM5OWY1ZjExNzc3OTQ0YjI2L3RhYmxlOjg5MzlmNDA0NzJkMTQ2ZGViZTg3MzJlMTg4NTU5ZTE0L3RhYmxlcmFuZ2U6ODkzOWY0MDQ3MmQxNDZkZWJlODczMmUxODg1NTllMTRfOC0zLTEtMS0xNTk1NDA_569e5a6f-b822-41b5-953f-f9ef17228704">405.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zNC9mcmFnOmUxYWRjYjRiOGNhYTQzYTM5OWY1ZjExNzc3OTQ0YjI2L3RhYmxlOjg5MzlmNDA0NzJkMTQ2ZGViZTg3MzJlMTg4NTU5ZTE0L3RhYmxlcmFuZ2U6ODkzOWY0MDQ3MmQxNDZkZWJlODczMmUxODg1NTllMTRfOS0xLTEtMS0xNTk1NDA_82ab231b-3959-45a5-8912-96f848fc2b13">278.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i167ed8f67bef48c49e54fa466400cdaa_D20210101-20210930" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zNC9mcmFnOmUxYWRjYjRiOGNhYTQzYTM5OWY1ZjExNzc3OTQ0YjI2L3RhYmxlOjg5MzlmNDA0NzJkMTQ2ZGViZTg3MzJlMTg4NTU5ZTE0L3RhYmxlcmFuZ2U6ODkzOWY0MDQ3MmQxNDZkZWJlODczMmUxODg1NTllMTRfOS0zLTEtMS0xNTk1NDA_f133a8dc-8f7b-4aca-897f-9e1c38bdc39c">267.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment (gains) losses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930" decimals="-5" sign="-" name="us-gaap:GainLossOnInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zNC9mcmFnOmUxYWRjYjRiOGNhYTQzYTM5OWY1ZjExNzc3OTQ0YjI2L3RhYmxlOjg5MzlmNDA0NzJkMTQ2ZGViZTg3MzJlMTg4NTU5ZTE0L3RhYmxlcmFuZ2U6ODkzOWY0MDQ3MmQxNDZkZWJlODczMmUxODg1NTllMTRfMTEtMS0xLTEtMTU5NTQw_ec4b44eb-a340-48b1-b0af-46349619b1e5">676.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i167ed8f67bef48c49e54fa466400cdaa_D20210101-20210930" decimals="-5" name="us-gaap:GainLossOnInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zNC9mcmFnOmUxYWRjYjRiOGNhYTQzYTM5OWY1ZjExNzc3OTQ0YjI2L3RhYmxlOjg5MzlmNDA0NzJkMTQ2ZGViZTg3MzJlMTg4NTU5ZTE0L3RhYmxlcmFuZ2U6ODkzOWY0MDQ3MmQxNDZkZWJlODczMmUxODg1NTllMTRfMTEtMy0xLTEtMTU5NTQw_97a67122-077c-4352-ac30-90f9b59e1868">271.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired in-process research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930" decimals="-5" name="lly:AcquiredInProcessResearchAndDevelopment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zNC9mcmFnOmUxYWRjYjRiOGNhYTQzYTM5OWY1ZjExNzc3OTQ0YjI2L3RhYmxlOjg5MzlmNDA0NzJkMTQ2ZGViZTg3MzJlMTg4NTU5ZTE0L3RhYmxlcmFuZ2U6ODkzOWY0MDQ3MmQxNDZkZWJlODczMmUxODg1NTllMTRfMTItMS0xLTEtMTU5NTQw_dcc1f7f6-af8e-4c78-aa45-9ce768437fb3">252.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i167ed8f67bef48c49e54fa466400cdaa_D20210101-20210930" decimals="-5" name="lly:AcquiredInProcessResearchAndDevelopment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zNC9mcmFnOmUxYWRjYjRiOGNhYTQzYTM5OWY1ZjExNzc3OTQ0YjI2L3RhYmxlOjg5MzlmNDA0NzJkMTQ2ZGViZTg3MzJlMTg4NTU5ZTE0L3RhYmxlcmFuZ2U6ODkzOWY0MDQ3MmQxNDZkZWJlODczMmUxODg1NTllMTRfMTItMy0xLTEtMTU5NTQw_5c23604b-5a24-410e-b04f-04d7914c0171">498.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other changes in operating assets and liabilities, net of acquisitions and divestitures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zNC9mcmFnOmUxYWRjYjRiOGNhYTQzYTM5OWY1ZjExNzc3OTQ0YjI2L3RhYmxlOjg5MzlmNDA0NzJkMTQ2ZGViZTg3MzJlMTg4NTU5ZTE0L3RhYmxlcmFuZ2U6ODkzOWY0MDQ3MmQxNDZkZWJlODczMmUxODg1NTllMTRfMTMtMS0xLTEtMTU5NTQw_0db44160-12aa-4dd2-82a3-81f847e73113">821.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i167ed8f67bef48c49e54fa466400cdaa_D20210101-20210930" decimals="-5" name="us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zNC9mcmFnOmUxYWRjYjRiOGNhYTQzYTM5OWY1ZjExNzc3OTQ0YjI2L3RhYmxlOjg5MzlmNDA0NzJkMTQ2ZGViZTg3MzJlMTg4NTU5ZTE0L3RhYmxlcmFuZ2U6ODkzOWY0MDQ3MmQxNDZkZWJlODczMmUxODg1NTllMTRfMTMtMy0xLTEtMTU5NTQw_5f6110da-05b6-4d87-afea-962318793b33">548.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-cash operating activities, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930" decimals="-5" name="us-gaap:OtherOperatingActivitiesCashFlowStatement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zNC9mcmFnOmUxYWRjYjRiOGNhYTQzYTM5OWY1ZjExNzc3OTQ0YjI2L3RhYmxlOjg5MzlmNDA0NzJkMTQ2ZGViZTg3MzJlMTg4NTU5ZTE0L3RhYmxlcmFuZ2U6ODkzOWY0MDQ3MmQxNDZkZWJlODczMmUxODg1NTllMTRfMTQtMS0xLTEtMTU5NTQw_288b8c65-33ef-4727-a892-c3f2cde4f247">217.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i167ed8f67bef48c49e54fa466400cdaa_D20210101-20210930" decimals="-5" name="us-gaap:OtherOperatingActivitiesCashFlowStatement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zNC9mcmFnOmUxYWRjYjRiOGNhYTQzYTM5OWY1ZjExNzc3OTQ0YjI2L3RhYmxlOjg5MzlmNDA0NzJkMTQ2ZGViZTg3MzJlMTg4NTU5ZTE0L3RhYmxlcmFuZ2U6ODkzOWY0MDQ3MmQxNDZkZWJlODczMmUxODg1NTllMTRfMTQtMy0xLTEtMTU5NTQw_04e1b5bd-99da-47e9-97ff-c13da12b6387">504.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Cash Provided by Operating Activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930" decimals="-5" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zNC9mcmFnOmUxYWRjYjRiOGNhYTQzYTM5OWY1ZjExNzc3OTQ0YjI2L3RhYmxlOjg5MzlmNDA0NzJkMTQ2ZGViZTg3MzJlMTg4NTU5ZTE0L3RhYmxlcmFuZ2U6ODkzOWY0MDQ3MmQxNDZkZWJlODczMmUxODg1NTllMTRfMTUtMS0xLTEtMTU5NTQw_6bb08335-ddfb-4a04-bfcc-447a014d0496">5,504.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i167ed8f67bef48c49e54fa466400cdaa_D20210101-20210930" decimals="-5" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zNC9mcmFnOmUxYWRjYjRiOGNhYTQzYTM5OWY1ZjExNzc3OTQ0YjI2L3RhYmxlOjg5MzlmNDA0NzJkMTQ2ZGViZTg3MzJlMTg4NTU5ZTE0L3RhYmxlcmFuZ2U6ODkzOWY0MDQ3MmQxNDZkZWJlODczMmUxODg1NTllMTRfMTUtMy0xLTEtMTU5NTQw_f383a937-0b7d-44dc-a557-f5b1f767e627">5,104.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash Flows from Investing Activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net purchases of property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930" decimals="-5" name="us-gaap:PaymentsToAcquireProductiveAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zNC9mcmFnOmUxYWRjYjRiOGNhYTQzYTM5OWY1ZjExNzc3OTQ0YjI2L3RhYmxlOjg5MzlmNDA0NzJkMTQ2ZGViZTg3MzJlMTg4NTU5ZTE0L3RhYmxlcmFuZ2U6ODkzOWY0MDQ3MmQxNDZkZWJlODczMmUxODg1NTllMTRfMTctMS0xLTEtMTU5NTQw_ca5d5be9-6d35-47d9-9943-2beaa3ecad9c">1,353.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i167ed8f67bef48c49e54fa466400cdaa_D20210101-20210930" decimals="-5" name="us-gaap:PaymentsToAcquireProductiveAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zNC9mcmFnOmUxYWRjYjRiOGNhYTQzYTM5OWY1ZjExNzc3OTQ0YjI2L3RhYmxlOjg5MzlmNDA0NzJkMTQ2ZGViZTg3MzJlMTg4NTU5ZTE0L3RhYmxlcmFuZ2U6ODkzOWY0MDQ3MmQxNDZkZWJlODczMmUxODg1NTllMTRfMTctMy0xLTEtMTU5NTQw_5e9b2339-93ad-42d8-9132-14a123a8ab14">1,018.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sales and maturities of short-term investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930" decimals="-5" name="us-gaap:ProceedsFromSaleOfShortTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zNC9mcmFnOmUxYWRjYjRiOGNhYTQzYTM5OWY1ZjExNzc3OTQ0YjI2L3RhYmxlOjg5MzlmNDA0NzJkMTQ2ZGViZTg3MzJlMTg4NTU5ZTE0L3RhYmxlcmFuZ2U6ODkzOWY0MDQ3MmQxNDZkZWJlODczMmUxODg1NTllMTRfMTgtMS0xLTEtMTU5NTQw_40c8c0cc-1be7-4e46-a0db-c61e697604bb">83.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i167ed8f67bef48c49e54fa466400cdaa_D20210101-20210930" decimals="-5" name="us-gaap:ProceedsFromSaleOfShortTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zNC9mcmFnOmUxYWRjYjRiOGNhYTQzYTM5OWY1ZjExNzc3OTQ0YjI2L3RhYmxlOjg5MzlmNDA0NzJkMTQ2ZGViZTg3MzJlMTg4NTU5ZTE0L3RhYmxlcmFuZ2U6ODkzOWY0MDQ3MmQxNDZkZWJlODczMmUxODg1NTllMTRfMTgtMy0xLTEtMTU5NTQw_a4b5ab83-a00f-416f-ae12-62df96c82992">46.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of short-term investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930" decimals="-5" name="us-gaap:PaymentsToAcquireShortTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zNC9mcmFnOmUxYWRjYjRiOGNhYTQzYTM5OWY1ZjExNzc3OTQ0YjI2L3RhYmxlOjg5MzlmNDA0NzJkMTQ2ZGViZTg3MzJlMTg4NTU5ZTE0L3RhYmxlcmFuZ2U6ODkzOWY0MDQ3MmQxNDZkZWJlODczMmUxODg1NTllMTRfMTktMS0xLTEtMTU5NTQw_62d74910-481b-40a4-8d64-e96ed1b818c8">65.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i167ed8f67bef48c49e54fa466400cdaa_D20210101-20210930" decimals="-5" name="us-gaap:PaymentsToAcquireShortTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zNC9mcmFnOmUxYWRjYjRiOGNhYTQzYTM5OWY1ZjExNzc3OTQ0YjI2L3RhYmxlOjg5MzlmNDA0NzJkMTQ2ZGViZTg3MzJlMTg4NTU5ZTE0L3RhYmxlcmFuZ2U6ODkzOWY0MDQ3MmQxNDZkZWJlODczMmUxODg1NTllMTRfMTktMy0xLTEtMTU5NTQw_74557a09-80f4-473f-aa1a-6dec572a31ca">27.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sales of noncurrent investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930" decimals="-5" name="us-gaap:ProceedsFromSaleOfLongtermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zNC9mcmFnOmUxYWRjYjRiOGNhYTQzYTM5OWY1ZjExNzc3OTQ0YjI2L3RhYmxlOjg5MzlmNDA0NzJkMTQ2ZGViZTg3MzJlMTg4NTU5ZTE0L3RhYmxlcmFuZ2U6ODkzOWY0MDQ3MmQxNDZkZWJlODczMmUxODg1NTllMTRfMjAtMS0xLTEtMTU5NTQw_3434e9b9-5b67-4077-b746-975240c17351">251.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i167ed8f67bef48c49e54fa466400cdaa_D20210101-20210930" decimals="-5" name="us-gaap:ProceedsFromSaleOfLongtermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zNC9mcmFnOmUxYWRjYjRiOGNhYTQzYTM5OWY1ZjExNzc3OTQ0YjI2L3RhYmxlOjg5MzlmNDA0NzJkMTQ2ZGViZTg3MzJlMTg4NTU5ZTE0L3RhYmxlcmFuZ2U6ODkzOWY0MDQ3MmQxNDZkZWJlODczMmUxODg1NTllMTRfMjAtMy0xLTEtMTU5NTQw_f4fef672-2df4-43b0-a0f7-bcd950718d5c">537.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of noncurrent investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930" decimals="-5" name="us-gaap:PaymentsToAcquireLongtermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zNC9mcmFnOmUxYWRjYjRiOGNhYTQzYTM5OWY1ZjExNzc3OTQ0YjI2L3RhYmxlOjg5MzlmNDA0NzJkMTQ2ZGViZTg3MzJlMTg4NTU5ZTE0L3RhYmxlcmFuZ2U6ODkzOWY0MDQ3MmQxNDZkZWJlODczMmUxODg1NTllMTRfMjEtMS0xLTEtMTU5NTQw_9bf78d1b-6c1e-45bf-8e24-30fa8d8de78d">474.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i167ed8f67bef48c49e54fa466400cdaa_D20210101-20210930" decimals="-5" name="us-gaap:PaymentsToAcquireLongtermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zNC9mcmFnOmUxYWRjYjRiOGNhYTQzYTM5OWY1ZjExNzc3OTQ0YjI2L3RhYmxlOjg5MzlmNDA0NzJkMTQ2ZGViZTg3MzJlMTg4NTU5ZTE0L3RhYmxlcmFuZ2U6ODkzOWY0MDQ3MmQxNDZkZWJlODczMmUxODg1NTllMTRfMjEtMy0xLTEtMTU5NTQw_75173681-dd0d-4f28-9f64-82e68bbf1f44">710.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for acquisitions, net of cash acquired (Note 3)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zNC9mcmFnOmUxYWRjYjRiOGNhYTQzYTM5OWY1ZjExNzc3OTQ0YjI2L3RhYmxlOjg5MzlmNDA0NzJkMTQ2ZGViZTg3MzJlMTg4NTU5ZTE0L3RhYmxlcmFuZ2U6ODkzOWY0MDQ3MmQxNDZkZWJlODczMmUxODg1NTllMTRfMjItMS0xLTEtMTU5NTQw_177676c3-2202-4fa7-a902-2e4cf7a37549">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i167ed8f67bef48c49e54fa466400cdaa_D20210101-20210930" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zNC9mcmFnOmUxYWRjYjRiOGNhYTQzYTM5OWY1ZjExNzc3OTQ0YjI2L3RhYmxlOjg5MzlmNDA0NzJkMTQ2ZGViZTg3MzJlMTg4NTU5ZTE0L3RhYmxlcmFuZ2U6ODkzOWY0MDQ3MmQxNDZkZWJlODczMmUxODg1NTllMTRfMjItMy0xLTEtMTU5NTQw_e1fd174b-e2d1-41fc-9455-45f9c24728a3">747.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of in-process research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930" decimals="-5" name="lly:PurchasedInProcessResearchAndDevelopment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zNC9mcmFnOmUxYWRjYjRiOGNhYTQzYTM5OWY1ZjExNzc3OTQ0YjI2L3RhYmxlOjg5MzlmNDA0NzJkMTQ2ZGViZTg3MzJlMTg4NTU5ZTE0L3RhYmxlcmFuZ2U6ODkzOWY0MDQ3MmQxNDZkZWJlODczMmUxODg1NTllMTRfMjQtMS0xLTEtMTU5NTQw_b503ab4d-f58f-4069-9818-d2c83c572b70">574.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i167ed8f67bef48c49e54fa466400cdaa_D20210101-20210930" decimals="-5" name="lly:PurchasedInProcessResearchAndDevelopment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zNC9mcmFnOmUxYWRjYjRiOGNhYTQzYTM5OWY1ZjExNzc3OTQ0YjI2L3RhYmxlOjg5MzlmNDA0NzJkMTQ2ZGViZTg3MzJlMTg4NTU5ZTE0L3RhYmxlcmFuZ2U6ODkzOWY0MDQ3MmQxNDZkZWJlODczMmUxODg1NTllMTRfMjQtMy0xLTEtMTU5NTQw_1a617613-4c4d-40f3-a2fa-e891430a0c03">460.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other investing activities, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930" decimals="-5" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zNC9mcmFnOmUxYWRjYjRiOGNhYTQzYTM5OWY1ZjExNzc3OTQ0YjI2L3RhYmxlOjg5MzlmNDA0NzJkMTQ2ZGViZTg3MzJlMTg4NTU5ZTE0L3RhYmxlcmFuZ2U6ODkzOWY0MDQ3MmQxNDZkZWJlODczMmUxODg1NTllMTRfMjUtMS0xLTEtMTU5NTQw_3c8796b1-f1b6-4c64-a938-6142f6b5d666">268.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i167ed8f67bef48c49e54fa466400cdaa_D20210101-20210930" decimals="-5" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zNC9mcmFnOmUxYWRjYjRiOGNhYTQzYTM5OWY1ZjExNzc3OTQ0YjI2L3RhYmxlOjg5MzlmNDA0NzJkMTQ2ZGViZTg3MzJlMTg4NTU5ZTE0L3RhYmxlcmFuZ2U6ODkzOWY0MDQ3MmQxNDZkZWJlODczMmUxODg1NTllMTRfMjUtMy0xLTEtMTU5NTQw_3ee7f4b3-234c-4fba-b5fe-ee78439318dd">2.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Cash Used for Investing Activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zNC9mcmFnOmUxYWRjYjRiOGNhYTQzYTM5OWY1ZjExNzc3OTQ0YjI2L3RhYmxlOjg5MzlmNDA0NzJkMTQ2ZGViZTg3MzJlMTg4NTU5ZTE0L3RhYmxlcmFuZ2U6ODkzOWY0MDQ3MmQxNDZkZWJlODczMmUxODg1NTllMTRfMjYtMS0xLTEtMTU5NTQw_a627cbdc-b668-4f21-925f-cd14613cc17d">2,401.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i167ed8f67bef48c49e54fa466400cdaa_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zNC9mcmFnOmUxYWRjYjRiOGNhYTQzYTM5OWY1ZjExNzc3OTQ0YjI2L3RhYmxlOjg5MzlmNDA0NzJkMTQ2ZGViZTg3MzJlMTg4NTU5ZTE0L3RhYmxlcmFuZ2U6ODkzOWY0MDQ3MmQxNDZkZWJlODczMmUxODg1NTllMTRfMjYtMy0xLTEtMTU5NTQw_12d7c113-8444-4b2b-915e-8ef9a7e90b16">2,383.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash Flows from Financing Activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends paid</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930" decimals="-5" name="us-gaap:PaymentsOfDividends" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zNC9mcmFnOmUxYWRjYjRiOGNhYTQzYTM5OWY1ZjExNzc3OTQ0YjI2L3RhYmxlOjg5MzlmNDA0NzJkMTQ2ZGViZTg3MzJlMTg4NTU5ZTE0L3RhYmxlcmFuZ2U6ODkzOWY0MDQ3MmQxNDZkZWJlODczMmUxODg1NTllMTRfMjgtMS0xLTEtMTU5NTQw_2daf73e0-0adb-465b-b461-da3b89a3cb06">2,651.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i167ed8f67bef48c49e54fa466400cdaa_D20210101-20210930" decimals="-5" name="us-gaap:PaymentsOfDividends" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zNC9mcmFnOmUxYWRjYjRiOGNhYTQzYTM5OWY1ZjExNzc3OTQ0YjI2L3RhYmxlOjg5MzlmNDA0NzJkMTQ2ZGViZTg3MzJlMTg4NTU5ZTE0L3RhYmxlcmFuZ2U6ODkzOWY0MDQ3MmQxNDZkZWJlODczMmUxODg1NTllMTRfMjgtMy0xLTEtMTU5NTQw_b734ad7f-5df0-431d-8cf8-9d7b067f6371">2,313.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net change in short-term borrowings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930" decimals="-5" name="us-gaap:ProceedsFromShortTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zNC9mcmFnOmUxYWRjYjRiOGNhYTQzYTM5OWY1ZjExNzc3OTQ0YjI2L3RhYmxlOjg5MzlmNDA0NzJkMTQ2ZGViZTg3MzJlMTg4NTU5ZTE0L3RhYmxlcmFuZ2U6ODkzOWY0MDQ3MmQxNDZkZWJlODczMmUxODg1NTllMTRfMjktMS0xLTEtMTU5NTQw_0b92accc-d1a4-4611-9c38-36ef0f1c866a">1,741.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i167ed8f67bef48c49e54fa466400cdaa_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:ProceedsFromShortTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zNC9mcmFnOmUxYWRjYjRiOGNhYTQzYTM5OWY1ZjExNzc3OTQ0YjI2L3RhYmxlOjg5MzlmNDA0NzJkMTQ2ZGViZTg3MzJlMTg4NTU5ZTE0L3RhYmxlcmFuZ2U6ODkzOWY0MDQ3MmQxNDZkZWJlODczMmUxODg1NTllMTRfMjktMy0xLTEtMTU5NTQw_9cf07f1b-dfc4-4c80-93cf-d3aac87aed91">1.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from issuance of long-term debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zNC9mcmFnOmUxYWRjYjRiOGNhYTQzYTM5OWY1ZjExNzc3OTQ0YjI2L3RhYmxlOjg5MzlmNDA0NzJkMTQ2ZGViZTg3MzJlMTg4NTU5ZTE0L3RhYmxlcmFuZ2U6ODkzOWY0MDQ3MmQxNDZkZWJlODczMmUxODg1NTllMTRfMzAtMS0xLTEtMTU5NTQw_b707055a-6256-4816-aa37-c3b84c53640d">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i167ed8f67bef48c49e54fa466400cdaa_D20210101-20210930" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zNC9mcmFnOmUxYWRjYjRiOGNhYTQzYTM5OWY1ZjExNzc3OTQ0YjI2L3RhYmxlOjg5MzlmNDA0NzJkMTQ2ZGViZTg3MzJlMTg4NTU5ZTE0L3RhYmxlcmFuZ2U6ODkzOWY0MDQ3MmQxNDZkZWJlODczMmUxODg1NTllMTRfMzAtMy0xLTEtMTU5NTQw_4fbebe53-dbe3-46b7-866c-623447a9cb6d">2,410.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repayments of long-term debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930" decimals="-5" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zNC9mcmFnOmUxYWRjYjRiOGNhYTQzYTM5OWY1ZjExNzc3OTQ0YjI2L3RhYmxlOjg5MzlmNDA0NzJkMTQ2ZGViZTg3MzJlMTg4NTU5ZTE0L3RhYmxlcmFuZ2U6ODkzOWY0MDQ3MmQxNDZkZWJlODczMmUxODg1NTllMTRfMzEtMS0xLTEtMTU5NTQw_fd21dd0d-8e21-4001-8765-84806aa5e6da">1,560.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i167ed8f67bef48c49e54fa466400cdaa_D20210101-20210930" decimals="-5" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zNC9mcmFnOmUxYWRjYjRiOGNhYTQzYTM5OWY1ZjExNzc3OTQ0YjI2L3RhYmxlOjg5MzlmNDA0NzJkMTQ2ZGViZTg3MzJlMTg4NTU5ZTE0L3RhYmxlcmFuZ2U6ODkzOWY0MDQ3MmQxNDZkZWJlODczMmUxODg1NTllMTRfMzEtMy0xLTEtMTU5NTQw_50c48fb5-0621-4f3a-ba04-a0f7765632dd">1,905.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930" decimals="-5" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zNC9mcmFnOmUxYWRjYjRiOGNhYTQzYTM5OWY1ZjExNzc3OTQ0YjI2L3RhYmxlOjg5MzlmNDA0NzJkMTQ2ZGViZTg3MzJlMTg4NTU5ZTE0L3RhYmxlcmFuZ2U6ODkzOWY0MDQ3MmQxNDZkZWJlODczMmUxODg1NTllMTRfMzItMS0xLTEtMTU5NTQw_9f31c2fa-6849-4968-92d0-450b156e1d41">1,500.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i167ed8f67bef48c49e54fa466400cdaa_D20210101-20210930" decimals="-5" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zNC9mcmFnOmUxYWRjYjRiOGNhYTQzYTM5OWY1ZjExNzc3OTQ0YjI2L3RhYmxlOjg5MzlmNDA0NzJkMTQ2ZGViZTg3MzJlMTg4NTU5ZTE0L3RhYmxlcmFuZ2U6ODkzOWY0MDQ3MmQxNDZkZWJlODczMmUxODg1NTllMTRfMzItMy0xLTEtMTU5NTQw_d85bb1cc-71a5-4c31-86ed-c2114e83e792">500.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other financing activities, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930" decimals="-5" sign="-" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zNC9mcmFnOmUxYWRjYjRiOGNhYTQzYTM5OWY1ZjExNzc3OTQ0YjI2L3RhYmxlOjg5MzlmNDA0NzJkMTQ2ZGViZTg3MzJlMTg4NTU5ZTE0L3RhYmxlcmFuZ2U6ODkzOWY0MDQ3MmQxNDZkZWJlODczMmUxODg1NTllMTRfMzQtMS0xLTEtMTU5NTQw_3b3c2ed5-5e87-44cf-8e2b-fc522b40f82f">295.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i167ed8f67bef48c49e54fa466400cdaa_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zNC9mcmFnOmUxYWRjYjRiOGNhYTQzYTM5OWY1ZjExNzc3OTQ0YjI2L3RhYmxlOjg5MzlmNDA0NzJkMTQ2ZGViZTg3MzJlMTg4NTU5ZTE0L3RhYmxlcmFuZ2U6ODkzOWY0MDQ3MmQxNDZkZWJlODczMmUxODg1NTllMTRfMzQtMy0xLTEtMTU5NTQw_38bbeaf7-b915-436b-896c-0da49d08ba69">295.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Cash Used for Financing Activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zNC9mcmFnOmUxYWRjYjRiOGNhYTQzYTM5OWY1ZjExNzc3OTQ0YjI2L3RhYmxlOjg5MzlmNDA0NzJkMTQ2ZGViZTg3MzJlMTg4NTU5ZTE0L3RhYmxlcmFuZ2U6ODkzOWY0MDQ3MmQxNDZkZWJlODczMmUxODg1NTllMTRfMzUtMS0xLTEtMTU5NTQw_bac41b47-a144-414b-8a24-914f32a3d386">4,265.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i167ed8f67bef48c49e54fa466400cdaa_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zNC9mcmFnOmUxYWRjYjRiOGNhYTQzYTM5OWY1ZjExNzc3OTQ0YjI2L3RhYmxlOjg5MzlmNDA0NzJkMTQ2ZGViZTg3MzJlMTg4NTU5ZTE0L3RhYmxlcmFuZ2U6ODkzOWY0MDQ3MmQxNDZkZWJlODczMmUxODg1NTllMTRfMzUtMy0xLTEtMTU5NTQw_4f302acd-0901-4703-a1ad-9c60a2cd4eaf">2,604.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930" decimals="-5" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zNC9mcmFnOmUxYWRjYjRiOGNhYTQzYTM5OWY1ZjExNzc3OTQ0YjI2L3RhYmxlOjg5MzlmNDA0NzJkMTQ2ZGViZTg3MzJlMTg4NTU5ZTE0L3RhYmxlcmFuZ2U6ODkzOWY0MDQ3MmQxNDZkZWJlODczMmUxODg1NTllMTRfMzYtMS0xLTEtMTU5NTQw_2e450789-c04d-4f1c-8538-dfe6887b2591">39.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i167ed8f67bef48c49e54fa466400cdaa_D20210101-20210930" decimals="-5" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zNC9mcmFnOmUxYWRjYjRiOGNhYTQzYTM5OWY1ZjExNzc3OTQ0YjI2L3RhYmxlOjg5MzlmNDA0NzJkMTQ2ZGViZTg3MzJlMTg4NTU5ZTE0L3RhYmxlcmFuZ2U6ODkzOWY0MDQ3MmQxNDZkZWJlODczMmUxODg1NTllMTRfMzYtMy0xLTEtMTU5NTQw_1811339c-0279-44cc-a072-6fefee97a6cc">15.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net decrease in cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930" decimals="-5" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zNC9mcmFnOmUxYWRjYjRiOGNhYTQzYTM5OWY1ZjExNzc3OTQ0YjI2L3RhYmxlOjg5MzlmNDA0NzJkMTQ2ZGViZTg3MzJlMTg4NTU5ZTE0L3RhYmxlcmFuZ2U6ODkzOWY0MDQ3MmQxNDZkZWJlODczMmUxODg1NTllMTRfMzgtMS0xLTEtMTU5NTQw_a28bb36e-7195-40e0-a77f-b14351a55465">1,201.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i167ed8f67bef48c49e54fa466400cdaa_D20210101-20210930" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zNC9mcmFnOmUxYWRjYjRiOGNhYTQzYTM5OWY1ZjExNzc3OTQ0YjI2L3RhYmxlOjg5MzlmNDA0NzJkMTQ2ZGViZTg3MzJlMTg4NTU5ZTE0L3RhYmxlcmFuZ2U6ODkzOWY0MDQ3MmQxNDZkZWJlODczMmUxODg1NTllMTRfMzgtMy0xLTEtMTU5NTQw_39368642-1b38-4577-a7ee-0f931466ca29">131.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents at January&#160;1</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0973ba0c1d894ceaa494709a13f814fb_I20211231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zNC9mcmFnOmUxYWRjYjRiOGNhYTQzYTM5OWY1ZjExNzc3OTQ0YjI2L3RhYmxlOjg5MzlmNDA0NzJkMTQ2ZGViZTg3MzJlMTg4NTU5ZTE0L3RhYmxlcmFuZ2U6ODkzOWY0MDQ3MmQxNDZkZWJlODczMmUxODg1NTllMTRfMzktMS0xLTEtMTU5NTQw_4138cde0-d05c-46d1-b55b-3ec64c5b13ec">3,818.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82811f99128e46738e63b2b2f09a72ef_I20201231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zNC9mcmFnOmUxYWRjYjRiOGNhYTQzYTM5OWY1ZjExNzc3OTQ0YjI2L3RhYmxlOjg5MzlmNDA0NzJkMTQ2ZGViZTg3MzJlMTg4NTU5ZTE0L3RhYmxlcmFuZ2U6ODkzOWY0MDQ3MmQxNDZkZWJlODczMmUxODg1NTllMTRfMzktMy0xLTEtMTU5NTQw_803f4814-4572-421f-84d7-fd69fc65f552">3,657.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash and Cash Equivalents at September 30</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08ccb35f6ad24d7793c9c91b74ca2ea1_I20220930" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zNC9mcmFnOmUxYWRjYjRiOGNhYTQzYTM5OWY1ZjExNzc3OTQ0YjI2L3RhYmxlOjg5MzlmNDA0NzJkMTQ2ZGViZTg3MzJlMTg4NTU5ZTE0L3RhYmxlcmFuZ2U6ODkzOWY0MDQ3MmQxNDZkZWJlODczMmUxODg1NTllMTRfNDAtMS0xLTEtMTU5NTQw_eed9b77a-2738-4fbd-94c1-1605e4fd8402">2,617.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5fcc694940794a94a960d8f1f9315381_I20210930" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zNC9mcmFnOmUxYWRjYjRiOGNhYTQzYTM5OWY1ZjExNzc3OTQ0YjI2L3RhYmxlOjg5MzlmNDA0NzJkMTQ2ZGViZTg3MzJlMTg4NTU5ZTE0L3RhYmxlcmFuZ2U6ODkzOWY0MDQ3MmQxNDZkZWJlODczMmUxODg1NTllMTRfNDAtMy0xLTEtMTU5NTQw_9b1f9dbb-af91-4ae6-bde0-d3b4eeee6877">3,788.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See notes to consolidated condensed financial statements.</span></div><div style="margin-top:9pt"><span><br/></span></div><div style="margin-top:9pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><div id="i5fed483d9c7e4f3cbba3a62c53226cd7_37"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Condensed Financial Statements</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Tables present dollars in millions, except per-share data)</span></div><div id="i5fed483d9c7e4f3cbba3a62c53226cd7_40"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 1: <ix:nonNumeric contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180MC9mcmFnOjY1MTIyYTE5YjI4ZjQ1MzNhMjNhNzYyMmI4NDg4MGQ5L3RleHRyZWdpb246NjUxMjJhMTliMjhmNDUzM2EyM2E3NjIyYjg0ODgwZDlfNDE2Nw_fef486b7-2bf9-4243-b1bf-ccb3fd9bb9e8" continuedAt="i791f6c3d34404365a97e68b9ae7ec7aa" escape="true">Basis of Presentation and Implementation of New Financial Accounting Standard </ix:nonNumeric></span></div><ix:continuation id="i791f6c3d34404365a97e68b9ae7ec7aa"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have prepared the accompanying unaudited consolidated condensed financial statements in accordance with the requirements of Form 10-Q and, therefore, they do not include all information and footnotes necessary for a fair presentation of financial position, results of operations, and cash flows in conformity with accounting principles generally accepted in the United States (GAAP). In our opinion, the consolidated condensed financial statements reflect all adjustments (including those that are normal and recurring) that are necessary for a fair presentation of the results of operations for the periods shown. In preparing financial statements in conformity with GAAP, we must make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, expenses, and related disclosures at the date of the financial statements and during the reporting period. Actual results could differ from those estimates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information included in this Quarterly Report on Form 10-Q should be read in conjunction with our consolidated financial statements and accompanying notes included in our Annual Report on </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000059478/000005947822000068/lly-20211231.htm">Form 10-K</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the year ended December&#160;31, 2021. We issue our financial statements by filing them with the Securities and Exchange Commission and have evaluated subsequent events up to the time of the filing of this Quarterly Report on Form 10-Q.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain reclassifications have been made to prior periods in the consolidated condensed financial statements and accompanying notes to conform with the current presentation.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All per-share amounts, unless otherwise noted in the footnotes, are presented on a diluted basis; that is, based on the weighted-average number of common shares outstanding plus the effect of incremental shares from our stock-based compensation programs.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate as a single operating segment engaged in the discovery, development, manufacturing, marketing, and sales of pharmaceutical products worldwide. A global research and development organization and a supply chain organization are responsible for the discovery, development, manufacturing, and supply of our products. Regional commercial organizations market, distribute, and sell the products. The business is also supported by global corporate staff functions. Our determination that we operate as a single segment is consistent with the financial information regularly reviewed by the chief operating decision maker for purposes of evaluating performance, allocating resources, setting incentive compensation targets, and planning and forecasting for future periods.</span></div><ix:nonNumeric contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180MC9mcmFnOjY1MTIyYTE5YjI4ZjQ1MzNhMjNhNzYyMmI4NDg4MGQ5L3RleHRyZWdpb246NjUxMjJhMTliMjhmNDUzM2EyM2E3NjIyYjg0ODgwZDlfNDE3NA_c48d06ff-5e0b-4653-8b6c-1453156fde1e" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development Expenses and Acquired In-Process Research and Development (IPR&amp;D) and Development Milestones</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are expensed as incurred. Research and development costs consist of expenses incurred in performing research and development activities, including but not limited to, compensation and benefits, facilities and overhead expense, clinical trial expense, and fees paid to contract research organizations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquired IPR&amp;D and development milestones include the initial costs of externally developed IPR&amp;D projects, acquired directly in a transaction other than a business combination, that do not have an alternative future use. Additionally, milestone payment obligations related to these transactions that are incurred prior to regulatory approval of the compound are expensed when the event triggering an obligation to pay the milestone occurs.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180MC9mcmFnOjY1MTIyYTE5YjI4ZjQ1MzNhMjNhNzYyMmI4NDg4MGQ5L3RleHRyZWdpb246NjUxMjJhMTliMjhmNDUzM2EyM2E3NjIyYjg0ODgwZDlfNDE2MA_e539ef21-51c4-4a56-93ea-59e5c9426eb5" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Implementation of New Financial Accounting Standard</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounting Standards Update 2021-01, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reference Rate Reform</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, provides for temporary optional expedients and exceptions in applying current GAAP to contracts, hedging relationships, and other transactions affected by the transition from the use of the London Interbank Offered Rate (LIBOR) to an alternative reference rate. The standard is currently applicable to contracts entered into before January 1, 2023. We adopted the standard in the first quarter of 2022. The adoption did not have a material impact on our consolidated condensed financial statements.</span></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><div id="i5fed483d9c7e4f3cbba3a62c53226cd7_43"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 2: <ix:nonNumeric contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RleHRyZWdpb246MzBhNDczMzUyMjFjNDA4Yjg4MjFiMDVmZmU0MmMzNTdfMzYxMA_932f7981-0408-4c83-94a4-8b2a8211708a" continuedAt="i9b6734e2ae1b41aa8072f418713c62dc" escape="true">Revenue</ix:nonNumeric></span></div><ix:continuation id="i9b6734e2ae1b41aa8072f418713c62dc" continuedAt="i7c5afb1018314c73b9913adea27862c1"><ix:nonNumeric contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RleHRyZWdpb246MzBhNDczMzUyMjFjNDA4Yjg4MjFiMDVmZmU0MmMzNTdfMzYyNg_6ed514c1-a15c-4ee4-b5b9-6c21ca4f5357" continuedAt="i9bf5f888dbb34effbbdcbb5ca4c84cd0" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our revenue recognized in our consolidated condensed statements of operations:</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.613%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.206%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if42877c131ac415eb21599c372b78f90_D20220701-20220930" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjA3OWI2OTMzNGFkNDQ5YTBhODFiNGY3ZGZlMDkzN2M0L3RhYmxlcmFuZ2U6MDc5YjY5MzM0YWQ0NDlhMGE4MWI0ZjdkZmUwOTM3YzRfMi0xLTEtMS0xNTk1NDA_7cb2a4c7-1716-45c9-8edc-e1709c8521c6">6,119.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80d1b089c2a644458859200e15f563c8_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjA3OWI2OTMzNGFkNDQ5YTBhODFiNGY3ZGZlMDkzN2M0L3RhYmxlcmFuZ2U6MDc5YjY5MzM0YWQ0NDlhMGE4MWI0ZjdkZmUwOTM3YzRfMi0zLTEtMS0xNTk1NDA_831ad7c4-6e8a-446d-90a9-8755ba774bc5">6,189.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3dd0ce52c8549c58e5d29bb1bb1c197_D20220101-20220930" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjA3OWI2OTMzNGFkNDQ5YTBhODFiNGY3ZGZlMDkzN2M0L3RhYmxlcmFuZ2U6MDc5YjY5MzM0YWQ0NDlhMGE4MWI0ZjdkZmUwOTM3YzRfMi01LTEtMS0xNTk1NDA_7f49393a-0299-45f2-a53f-487e0e7b7fc7">19,123.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1962268fe5e4415bbcb7e76b2f694425_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjA3OWI2OTMzNGFkNDQ5YTBhODFiNGY3ZGZlMDkzN2M0L3RhYmxlcmFuZ2U6MDc5YjY5MzM0YWQ0NDlhMGE4MWI0ZjdkZmUwOTM3YzRfMi03LTEtMS0xNTk1NDA_beeb036d-b623-4bdb-abb4-d6bf219bff19">18,579.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration and other revenue</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie24dcfd7665d4948a6b3ea63d1979c25_D20220701-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjA3OWI2OTMzNGFkNDQ5YTBhODFiNGY3ZGZlMDkzN2M0L3RhYmxlcmFuZ2U6MDc5YjY5MzM0YWQ0NDlhMGE4MWI0ZjdkZmUwOTM3YzRfMy0xLTEtMS0xNTk1NDA_91e45130-eaf7-493d-8c3f-a3da24660c94">822.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28f16eccfa8b45c9b2f74cc6235732b4_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjA3OWI2OTMzNGFkNDQ5YTBhODFiNGY3ZGZlMDkzN2M0L3RhYmxlcmFuZ2U6MDc5YjY5MzM0YWQ0NDlhMGE4MWI0ZjdkZmUwOTM3YzRfMy0zLTEtMS0xNTk1NDA_f2b10dfd-d1df-4bd2-8e47-05df82f43ef9">583.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ebb89e75b934815a2a398afa3315ad4_D20220101-20220930" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjA3OWI2OTMzNGFkNDQ5YTBhODFiNGY3ZGZlMDkzN2M0L3RhYmxlcmFuZ2U6MDc5YjY5MzM0YWQ0NDlhMGE4MWI0ZjdkZmUwOTM3YzRfMy01LTEtMS0xNTk1NDA_7b426d53-c29a-46a8-a041-cf93af6fe19d">2,116.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0707295b42774a95baab2b522f5925a8_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjA3OWI2OTMzNGFkNDQ5YTBhODFiNGY3ZGZlMDkzN2M0L3RhYmxlcmFuZ2U6MDc5YjY5MzM0YWQ0NDlhMGE4MWI0ZjdkZmUwOTM3YzRfMy03LTEtMS0xNTk1NDA_ac06b230-7599-445e-a758-572f515f5955">1,739.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19fc0325c48543008ea71e1fdcf11d86_D20220701-20220930" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjA3OWI2OTMzNGFkNDQ5YTBhODFiNGY3ZGZlMDkzN2M0L3RhYmxlcmFuZ2U6MDc5YjY5MzM0YWQ0NDlhMGE4MWI0ZjdkZmUwOTM3YzRfNC0xLTEtMS0xNTk1NDA_12e03f10-98cf-4b8e-b958-bc063c635ef8">6,941.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4fa4f6b472a4f269297591b44aba572_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjA3OWI2OTMzNGFkNDQ5YTBhODFiNGY3ZGZlMDkzN2M0L3RhYmxlcmFuZ2U6MDc5YjY5MzM0YWQ0NDlhMGE4MWI0ZjdkZmUwOTM3YzRfNC0zLTEtMS0xNTk1NDA_159989f0-4305-48b1-9340-a92b751ddf73">6,772.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjA3OWI2OTMzNGFkNDQ5YTBhODFiNGY3ZGZlMDkzN2M0L3RhYmxlcmFuZ2U6MDc5YjY5MzM0YWQ0NDlhMGE4MWI0ZjdkZmUwOTM3YzRfNC01LTEtMS0xNTk1NDA_c7f53c2a-97d3-40c1-8e71-3bc264a49ee2">21,239.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i167ed8f67bef48c49e54fa466400cdaa_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjA3OWI2OTMzNGFkNDQ5YTBhODFiNGY3ZGZlMDkzN2M0L3RhYmxlcmFuZ2U6MDc5YjY5MzM0YWQ0NDlhMGE4MWI0ZjdkZmUwOTM3YzRfNC03LTEtMS0xNTk1NDA_ca22ca5b-9b12-4f38-baf1-ba66e3eb63d3">20,318.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div style="margin-top:1pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Collaboration and other revenue associated with prior period transfers of intellectual property was $<ix:nonFraction unitRef="usd" contextRef="i34aeabd3620f4de8ad8c2efefc863807_D20220701-20220930" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RleHRyZWdpb246MzBhNDczMzUyMjFjNDA4Yjg4MjFiMDVmZmU0MmMzNTdfMjM3_f0f2f02c-15ad-4db8-8741-6bed5024e2b6">43.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ia0d2323337da484fb1444b8262ff7a7e_D20220101-20220930" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RleHRyZWdpb246MzBhNDczMzUyMjFjNDA4Yjg4MjFiMDVmZmU0MmMzNTdfMjQ0_73540d04-9c94-44c7-8a94-e0acf37c1b39">130.9</ix:nonFraction> million during the three and nine months ended September&#160;30, 2022, respectively, and $<ix:nonFraction unitRef="usd" contextRef="i16836baff9c344308700232bb53196d6_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RleHRyZWdpb246MzBhNDczMzUyMjFjNDA4Yjg4MjFiMDVmZmU0MmMzNTdfMjk2_74bd2027-e5ee-42ef-9a3c-077af228cbba">62.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ib6db6b88271640b7be37a4c3c9f838c6_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RleHRyZWdpb246MzBhNDczMzUyMjFjNDA4Yjg4MjFiMDVmZmU0MmMzNTdfMzAz_cbd103f3-7e5a-4006-a81f-8fb363caa85a">136.1</ix:nonFraction> million during the three and nine months ended September&#160;30, 2021, respectively.</span></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize revenue primarily from two different types of contracts, product sales to customers (net product revenue) and collaborations and other arrangements. Revenue recognized from collaborations and other arrangements includes our share of profits from the collaborations, as well as royalties, upfront and milestone payments we receive under these types of contracts. See Note 4 for additional information related to our collaborations and other arrangements. Collaboration and other revenue disclosed above includes the revenue from the Jardiance</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trajenta</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> families of products resulting from our collaboration with Boehringer Ingelheim discussed in Note 4. Substantially all of the remainder of collaboration and other revenue is related to contracts accounted for as contracts with customers.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Adjustments to Revenue</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjustments to increase revenue recognized as a result of changes in estimates for our most significant United States (U.S.) sales returns, rebates, and discounts liability balances for products shipped in previous periods were <ix:nonFraction unitRef="number" contextRef="i46e52d8ad0e14ebf9fa7c9ecc503bbfa_D20220701-20220930" decimals="2" name="lly:RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RleHRyZWdpb246MzBhNDczMzUyMjFjNDA4Yjg4MjFiMDVmZmU0MmMzNTdfMzI5ODUzNDg4NzE4MA_5b451c14-f56c-4b09-ab4d-34d0986e41c2">3</ix:nonFraction> percent of U.S. revenue for the three months ended September&#160;30, 2022 and less than <ix:nonFraction unitRef="number" contextRef="i72b37618b2b848e48b6d7a66628d0ea0_D20220101-20220930" decimals="2" name="lly:RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RleHRyZWdpb246MzBhNDczMzUyMjFjNDA4Yjg4MjFiMDVmZmU0MmMzNTdfMTQxMA_0eb796ed-9b9f-4506-8b44-40e03e988f78"><ix:nonFraction unitRef="number" contextRef="i19f0f8e72ada412eb34eae9afa79a051_D20210701-20210930" decimals="2" name="lly:RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RleHRyZWdpb246MzBhNDczMzUyMjFjNDA4Yjg4MjFiMDVmZmU0MmMzNTdfMTQxMA_6e78608c-d607-4a0e-84f2-ca135f08d9c7"><ix:nonFraction unitRef="number" contextRef="i7685d8873a9b40f5bab0b11fa36b225d_D20210101-20210930" decimals="2" name="lly:RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RleHRyZWdpb246MzBhNDczMzUyMjFjNDA4Yjg4MjFiMDVmZmU0MmMzNTdfMTQxMA_7e029b78-43ca-4f60-bc29-bad0fcf3e363">1</ix:nonFraction></ix:nonFraction></ix:nonFraction> percent of U.S. revenue during the nine months ended September&#160;30, 2022 and the three and nine months ended September&#160;30, 2021. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Contract Liabilities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our contract liabilities result from arrangements where we have received payment in advance of performance under the contract and do not include sales returns, rebates, and discounts. Changes in contract liabilities are generally due to either receipt of additional advance payments or our performance under the contract. </span></div><ix:nonNumeric contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930" name="us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RleHRyZWdpb246MzBhNDczMzUyMjFjNDA4Yjg4MjFiMDVmZmU0MmMzNTdfMzYyOA_78254a29-9a46-45f0-a0cb-93d522524262" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes contract liability balances:</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.274%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.276%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08ccb35f6ad24d7793c9c91b74ca2ea1_I20220930" decimals="-5" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjQxNzkzNmNkMjI4MTQwYmU4ZWY0NWY3MjdmZjM5OGMzL3RhYmxlcmFuZ2U6NDE3OTM2Y2QyMjgxNDBiZThlZjQ1ZjcyN2ZmMzk4YzNfMS0xLTEtMS0xNTk1NDA_d65e19dc-0f22-425e-9ad6-e5dd69a060fc">232.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0973ba0c1d894ceaa494709a13f814fb_I20211231" decimals="-5" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjQxNzkzNmNkMjI4MTQwYmU4ZWY0NWY3MjdmZjM5OGMzL3RhYmxlcmFuZ2U6NDE3OTM2Y2QyMjgxNDBiZThlZjQ1ZjcyN2ZmMzk4YzNfMS0zLTEtMS0xNTk1NDA_fecc1ef7-53ac-41e6-ac8d-b31aa7ad7f68">262.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended September&#160;30, 2022 and 2021, revenue recognized from contract liabilities as of the beginning of the respective year was not material. Revenue expected to be recognized in the future from contract liabilities as the related performance obligations are satisfied is not expected to be material in any one year.</span></div></ix:continuation><div style="margin-bottom:12pt;margin-top:12pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i7c5afb1018314c73b9913adea27862c1" continuedAt="i8a87bd7f728c4956b4f7b4a382aa7a0a"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Disaggregation of Revenue</span></div><ix:continuation id="i9bf5f888dbb34effbbdcbb5ca4c84cd0" continuedAt="ia7ddf8304b894ea5ae7ce70c55fcc02c"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes revenue by product for the three months ended September&#160;30, 2022 and 2021:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.133%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.577%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outside U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outside U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue&#8212;to unaffiliated customers:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diabetes:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Trulicity</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28a49a83c479441f905c7cffa76d0d1e_D20220701-20220930" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfNS0xLTEtMS0xNTk1NDA_0a0e8bf5-a577-4900-b278-d7a04ee80107">1,418.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ce64df6d312430cadd360079f217dd5_D20220701-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfNS0yLTEtMS0xNTk1NDA_1a2199b9-12bd-47bf-ae8a-6c6a69218f5a">432.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i345b235e6d564f1bb6f06b9ed8319a72_D20220701-20220930" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfNS0zLTEtMS0xNTk1NDA_c321a335-fcb5-4a1d-9b4d-5f42b3cae5b9">1,850.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89ca472eabec43fd814b3653fab15181_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfNS01LTEtMS0xNTk1NDA_4dadfefb-6ae4-4196-95d1-5af313320aa4">1,201.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7bbccd7a5a8e4837a3a85f1a2b3d2ef1_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfNS02LTEtMS0xNTk1NDA_09157d41-c628-48ef-bf42-57976969f325">398.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46a90cbffcd647a5801317b946ab5209_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfNS03LTEtMS0xNTk1NDA_d980fd01-6e83-48ff-aa9c-7000ff03be32">1,600.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Jardiance</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5546f63545a844a085ff12b7f2497571_D20220701-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfNi0xLTEtMS0xNTk1NDA_1fcf3759-c56c-4c17-831e-88fc29de45a6">350.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i348983749551494ba7808729a9dd6254_D20220701-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfNi0yLTEtMS0xNTk1NDA_45a007c0-bd08-45bb-a63e-e154e3b3b4cc">222.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfba5b60fbbe4370bad16f003f72e3c1_D20220701-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfNi0zLTEtMS0xNTk1NDA_4b4062e7-4dbf-476d-b7d9-c49ae88fb823">573.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i669b22e2d64c487fb8bd01c345ab7f38_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfNi01LTEtMS0xNTk1NDA_8b429d89-4e05-479b-920e-bdb91cf04f68">221.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ab46b2a51674189a54630451735b250_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfNi02LTEtMS0xNTk1NDA_416e5a77-2473-428d-b4ba-9abd5f7e7ed5">169.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia28641f7c767406eacaa8089e13a2e77_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfNi03LTEtMS0xNTk1NDA_a6146567-ce3d-4baa-8cc0-7c8b22aba394">390.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Humalog</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; (2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i233675fe0cc34caa880f2ae73fa95cad_D20220701-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfNy0xLTEtMS0xNTk1NDA_d8c05d8a-7bfe-4a08-809f-8bee6eca013b">248.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i404df183ca794e64b829a2993c89673f_D20220701-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfNy0yLTEtMS0xNTk1NDA_a425bba8-99ae-4d14-8303-e5eea1502902">198.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6069340928544f1d98e220d601c0ccf7_D20220701-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfNy0zLTEtMS0xNTk1NDA_5ab1e631-5e58-4f75-a0df-d43c4b15221a">447.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b145726bc2c4ed78a3c2ec12b53c5c2_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfNy01LTEtMS0xNTk1NDA_ef942622-abcd-4639-8d77-6ac8e8a0402a">347.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id28218d7550a4cf4be526f83ae1c7332_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfNy02LTEtMS0xNTk1NDA_03219981-3fac-4a71-b859-0bf2fc9a5c4f">279.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie59d14500008412ea099e2c09441a042_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfNy03LTEtMS0xNTk1NDA_59269390-f54a-4272-a172-208b9ae465df">626.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Humulin</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib99bd175ff46428092a6e96c970b94c5_D20220701-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfOC0xLTEtMS0xNTk1NDA_ef8255d3-ba3a-4fe4-8d53-a7c538c10f08">169.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i644d2f1188e14878aaa508d910b54dde_D20220701-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfOC0yLTEtMS0xNTk1NDA_d767dbdb-d458-411d-9060-53fea646da55">68.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7cc0d4df5329427cb7da48ad36cb2efb_D20220701-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfOC0zLTEtMS0xNTk1NDA_545ab11e-e529-4b1e-8c2d-d5f998327755">238.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02d6e02b9e20402bb506e5e37520efdb_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfOC01LTEtMS0xNTk1NDA_704ddbb1-ea70-4a79-b949-8e824af7ebe0">193.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40d7116b6c0a470195c3ab9234e5bb0e_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfOC02LTEtMS0xNTk1NDA_d73b78ed-eec6-4af8-aa8e-7aa015e64068">93.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec80f91e475941f1abdc131fd14d868d_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfOC03LTEtMS0xNTk1NDA_e2256e80-7d98-4239-9df7-3cf70d782bad">286.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Basaglar</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i529518415079475fa56a8916e119480c_D20220701-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfOS0xLTEtMS0xNTk1NDA_0fd4e0cf-7cbe-4944-818b-8ce1563cb87e">124.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie34f0db27136443ca391ec67d20f46cc_D20220701-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfOS0yLTEtMS0xNTk1NDA_31691ed2-0cb3-496c-9d57-42567e4ffd19">68.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6f3b41d10de4dfb99b809554e15f4ca_D20220701-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfOS0zLTEtMS0xNTk1NDA_f5a63c3a-96cf-4c8e-978e-398f3ff81c82">193.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idcd8ed6a0f624997876200ae1a53d3ff_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfOS01LTEtMS0xNTk1NDA_117389a1-ff79-41cc-9127-c5112b157bf9">114.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1981e978a66e4861b39ec95f950a699c_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfOS02LTEtMS0xNTk1NDA_d6155f67-733f-4420-b723-607036c04867">78.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieef95d1c0c4643f8a5a104c9301c56f6_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfOS03LTEtMS0xNTk1NDA_f749cbc3-4bf9-40a9-9045-7be859795e51">192.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Mounjaro</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7992fe4fc5774bd6aa8b55cf4d326364_D20220701-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMTAtMS0xLTEtMTg5NTI3_8255f582-07e7-413b-8f1b-697aebc72623">97.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47be57988ea94c92b33e106ae820b8f7_D20220701-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMTAtMi0xLTEtMTg5NTMw_00c4b87b-fccc-4654-800e-4d61aa4fc78a">90.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22fcf936becc4b56b4c435b41fdfd4c7_D20220701-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMTAtMy0xLTEtMTg5NTMz_1a17e772-77e8-424a-b3a8-99bc44d20c89">187.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i866b02b106bf4510aa3acc82ee4887a0_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMTAtNS0xLTEtMTg5NTM2_69604ef1-fb87-4640-af77-034a6a0db5ea">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99914bb8f18546f78ea8cdcaa7af2939_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMTAtNi0xLTEtMTg5NTQz_3ade9baa-dfc0-491a-8c02-258606dc14cc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9094ecfcbf9c4d8bbe63fc38a5f24df0_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMTAtNy0xLTEtMTg5NTUw_fb5ffaf4-fc18-4729-9c50-d4c48f4a9343">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other diabetes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iceaf7dbcd2d8486cb982fc3658598e56_D20220701-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMTAtMS0xLTEtMTU5NTQw_5a99f14f-a3eb-4586-a551-935e24cd4316">79.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05fc368927fd409998e10fd8a8626ff3_D20220701-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMTAtMi0xLTEtMTU5NTQw_34167a83-898e-4991-8e01-cda06cf1b704">94.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iadb96dab5219493a8a09e4ef5a30b381_D20220701-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMTAtMy0xLTEtMTU5NTQw_ace0b04b-86fb-4754-8362-1ff7ca2a5ea6">173.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26f16b68de674d2592c2cd9ee9755295_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMTAtNS0xLTEtMTU5NTQw_3f38029c-f3ba-449d-beb0-1c07de26c128">65.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4a6a3281a6e41eda8915c8ed31cf4c4_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMTAtNi0xLTEtMTU5NTQw_a751d592-9242-4989-a1f9-324525142cd6">112.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib01598d835464cac82cecfbe826de92d_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMTAtNy0xLTEtMTU5NTQw_eb3e62c9-f150-41d5-8b49-0125b7996564">177.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total diabetes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8862697b08648bcb4c7b9ad3dff39c3_D20220701-20220930" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMTEtMS0xLTEtMTU5NTQw_9d99bd9f-beb1-41a1-96bb-397628572fd8">2,488.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if00d7a9221f04fe68817babf35f51ebf_D20220701-20220930" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMTEtMi0xLTEtMTU5NTQw_b425fd58-6cbf-429b-b6eb-098318981878">1,174.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1a606c172db416288ba0bbd8baa9966_D20220701-20220930" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMTEtMy0xLTEtMTU5NTQw_50dee3e7-ab7f-476a-9f1a-44ec81c342c0">3,662.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d79583b71134ad5b1affaf7d3c9e867_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMTEtNS0xLTEtMTU5NTQw_b6662909-18d3-492e-a0ef-055e21944738">2,143.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74d4b85fd2a346fb93493d49de1c2bce_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMTEtNi0xLTEtMTU5NTQw_c983a16c-6278-49dd-b11e-d5a0cb1ee3e9">1,131.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42ad32bd431444b189dab3e866f14dce_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMTEtNy0xLTEtMTU5NTQw_cf24845e-71e1-48db-a723-30807d75527f">3,274.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oncology:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Verzenio</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c515dd1cd2b453686e3e31d8c9a32d3_D20220701-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMTQtMS0xLTEtMTU5NTQw_e069ea93-cd38-4c38-b992-e533125625d9">414.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id154bceb5f3a4af7bf7c046f1608e110_D20220701-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMTQtMi0xLTEtMTU5NTQw_2de77508-96e1-4f18-87f4-307ed27cf4a0">202.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb827f745b3b446f900ce979a433b71f_D20220701-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMTQtMy0xLTEtMTU5NTQw_90b049e2-586b-47ce-9e23-2a66d21a6b97">617.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f8a0004521c4a0ab278bcec0c67c5bd_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMTQtNS0xLTEtMTU5NTQw_41af130e-c1ea-4564-8900-daf733b5847d">199.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf75ab0eae484bb4b01f61ae25f750c5_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMTQtNi0xLTEtMTU5NTQw_e87e7d23-008a-4a6f-baf7-d27291162c54">135.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b3d0e422c9640ab9313c19640d9fd90_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMTQtNy0xLTEtMTU5NTQw_97860e17-ba67-4bbd-bd88-851e365440b3">335.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Cyramza</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46e236388c73464e81b03a5d53c0dd53_D20220701-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMTUtMS0xLTEtMTU5NTQw_a0e70550-a289-48de-9173-910bd3533c20">87.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b6d4e4158744aaa95ee5bf00acb80cb_D20220701-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMTUtMi0xLTEtMTU5NTQw_9a5d3133-6e39-4844-84fa-3543c50ea269">144.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c1435377d2042d39e6953c271d4585b_D20220701-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMTUtMy0xLTEtMTU5NTQw_547eed38-1637-4bb0-96d7-3d6b7b2b83bc">232.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i176af1ca7219458c851326db4f5f0e18_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMTUtNS0xLTEtMTU5NTQw_ef4c93db-fa39-455f-b988-fb25c2b566f7">84.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4ca284b63654c0bbf5fc3646e324b1b_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMTUtNi0xLTEtMTU5NTQw_c2e46eb6-79f6-4e02-8130-7f4e6ae38029">168.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48871c7176154dbb971dc8a40b431eca_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMTUtNy0xLTEtMTU5NTQw_35b4bdb8-c6a3-47a5-81ce-b9cccf2f2883">253.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Erbitux</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc30105eafd9459d81eaf411eb4da357_D20220701-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMTctMS0xLTEtMTg5ODM0_cbcb7a5f-830c-41ab-a693-93520437ecbe">126.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84fe5c0fb05340ce93ab592130765d86_D20220701-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMTctMi0xLTEtMTg5ODM0_a03d3848-0b20-4d31-8513-39008743b95f">18.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75db1e7f9d154c588f6bfd88b08dacf2_D20220701-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMTctMy0xLTEtMTg5ODM0_d5c0c9dd-5cfc-4f6d-9a11-c714c7907dc1">144.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb220bd49b9b4fee9a08cf2aba4811ff_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMTctNS0xLTEtMTg5ODM0_4aa752af-408e-483d-97a7-6121f91d106b">114.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if441e31221c74fb7b06ce4acda75a1ac_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMTctNi0xLTEtMTg5ODM0_6df77aae-22e4-46f8-ac1a-6250a2c21fe2">20.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74ebe2d40f834c6aaed2f9503f82b5c2_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMTctNy0xLTEtMTg5ODM0_6a36e185-5ee4-4985-a13b-b101f56933ad">134.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Alimta</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51fae75c655f4c9db22deca064e1d22a_D20220701-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMTYtMS0xLTEtMTU5NTQw_008998d3-636a-47ac-98d6-abb4776e490a">64.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i814e9ebeca8f4359b602b1c4116691fa_D20220701-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMTYtMi0xLTEtMTU5NTQw_2f8e2d9e-70d2-4996-99ca-902541697733">54.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i093d47ca61034ea8b9f0303b73074f6e_D20220701-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMTYtMy0xLTEtMTU5NTQw_f5b1ff49-0ed6-42ff-82f9-9557ec1dad79">119.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b8a2c0676cd456a958892b0fdc5f275_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMTYtNS0xLTEtMTU5NTQw_658bca63-6a3a-4b70-9f15-b79f6cd0632c">297.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01f53de517814e9fae0973ed84a89508_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMTYtNi0xLTEtMTU5NTQw_f9ccac0c-976b-4085-a8a9-a7ed24d35244">159.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91b98892233a42579bec90b2f1f07fad_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMTYtNy0xLTEtMTU5NTQw_6fff5085-50a8-400c-a933-ec49cc7f7619">457.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Tyvyt</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i578736c37abd4751958301e188d9a111_D20220701-20220930" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMTgtMS0xLTEtMTU5NTQw_c2b50857-bdbe-42bf-b4f4-61c3da66822e">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic105c32b09d5439ab48f1ea47e388e5c_D20220701-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMTgtMi0xLTEtMTU5NTQw_7cd0c5a8-1419-44f5-a7b7-bcbb4af3d433">76.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc8fc5f6c1924a46b0d88ad7ea894f53_D20220701-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMTgtMy0xLTEtMTU5NTQw_dffb5a95-e891-48a9-a689-abb5c7e30b8f">76.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i326cec97451b4c0fa64fb496bcc0d262_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMTgtNS0xLTEtMTU5NTQw_8fe7e548-688b-46b3-a0c7-af6fa6954001">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6f0f8b1cbb14fe5bc88c77765723cdc_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMTgtNi0xLTEtMTU5NTQw_7d371912-8da9-4688-b513-e8225a93b469">125.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9da960751fa245d8bf93fa1681ead439_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMTgtNy0xLTEtMTU5NTQw_c37672f7-0a32-4eec-a93a-db53ea961956">125.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other oncology</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4280b008d25146138bb9937941f505ac_D20220701-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMTktMS0xLTEtMTU5NTQw_771d4ba2-7381-4a38-b5fb-9cd908d128f3">39.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib83a82fddc51484f973f835759a83951_D20220701-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMTktMi0xLTEtMTU5NTQw_1a94ecd5-7153-462b-a9c6-0bb2bc805a21">62.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7add942c6a224625b4aa726843340e48_D20220701-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMTktMy0xLTEtMTU5NTQw_0f863038-dd11-4964-bd8c-b8fb3ec61ba2">102.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i010a412d535641f895d21d4765b984db_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMTktNS0xLTEtMTU5NTQw_3b3ce568-b14b-404d-a467-e6d8521fd535">35.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a1ab61d480a42babad1c189210b4f6f_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMTktNi0xLTEtMTU5NTQw_667f8e4f-545e-4583-8bf6-fdaa6d165c36">65.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d24e8995a5a4ced9875b8b9174e8096_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMTktNy0xLTEtMTU5NTQw_9a0a5031-2d6f-4026-a508-b22b91f65eb3">100.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total oncology</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7ca1b1b8ebc4b97a61e679591aa9aa4_D20220701-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMjAtMS0xLTEtMTU5NTQw_baa6c5e9-cc3c-4079-ba64-1bf89df4d6e6">732.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98dec2ee927948db8ae6249a13fbc06a_D20220701-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMjAtMi0xLTEtMTU5NTQw_3dc52c54-71ba-4422-a2ef-751c1b81edd1">560.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idacb7a7257294fe689d448659352e301_D20220701-20220930" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMjAtMy0xLTEtMTU5NTQw_544235f5-6797-4de9-a4d2-b6b9a58f1718">1,293.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i573f860cee384e44a092723fc9aaea21_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMjAtNS0xLTEtMTU5NTQw_ca75517a-c1c9-4dfe-9d59-26c6c87a57d1">730.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic45235af254e414c87819d6a61117897_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMjAtNi0xLTEtMTU5NTQw_9679b0de-f48b-4fb9-b293-c46ba1331ade">675.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3490b47c9d914a7a80f4c441455b8ead_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMjAtNy0xLTEtMTU5NTQw_589cc164-6ff6-4f93-b74f-60482aaf352e">1,406.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Immunology:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Taltz</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3ed2240ab2944e1a3695929ccce3c61_D20220701-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMjMtMS0xLTEtMTU5NTQw_0830681a-f057-4aee-86f5-6791461a3846">493.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec46bce8b1474abc9815b6e1b2d7a169_D20220701-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMjMtMi0xLTEtMTU5NTQw_e2297c6f-9a44-4e35-ada7-f2e73020a633">186.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i800167f3776142a4bf399d8f51830c78_D20220701-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMjMtMy0xLTEtMTU5NTQw_137072df-c045-4937-8754-4bd0ad4db73e">679.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia22b346dd2a54714a0f4ba483559b116_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMjMtNS0xLTEtMTU5NTQw_c32ea69c-4566-46a7-a983-5778aa7bb7b5">422.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0852df9f516e48b4a9af370971f46a78_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMjMtNi0xLTEtMTU5NTQw_dc0aaf75-cbb0-44ef-ba19-a57f93b60d8d">170.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia60c521d441f43a2b5801e09809d0abe_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMjMtNy0xLTEtMTU5NTQw_dadaba69-0e03-41d5-ba60-88fed39d1579">593.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Olumiant</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; (3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16529d5d29744762b0746672c1ef5cbf_D20220701-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMjQtMS0xLTEtMTU5NTQw_50b999b2-f31a-41f5-8415-e5aca82bc315">22.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2456bc73ed7d4b8b8bc891900fd86004_D20220701-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMjQtMi0xLTEtMTU5NTQw_5b4a0366-f77b-4317-8dbb-d09afc7fce7e">160.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65843c3594444a24be3c2dd715fb25e8_D20220701-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMjQtMy0xLTEtMTU5NTQw_257580ce-899d-4d9b-ab06-7b681acb7802">182.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idef6b1951baa49b98d6da883dd4d89b9_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMjQtNS0xLTEtMTU5NTQw_26e2b0c3-c706-449d-86a1-0941b2c6e40c">194.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1eb3846894a440d9b3b08cf8304da43_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMjQtNi0xLTEtMTU5NTQw_7f39255d-1753-4e20-8646-5b6010d5bb5b">212.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i342e7e7b465546ffa22256042c6bf573_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMjQtNy0xLTEtMTU5NTQw_64568da7-872d-4490-bbf2-bebf62cdca4f">406.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other immunology</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0dbce0c2a604a12ab2550f876430b73_D20220701-20220930" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMjUtMS0xLTEtMTU5NTQw_e5b3fd3a-aa09-4caf-90d1-51c3a7bd466c">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32547c688b2942bb9648bd77d09fed5d_D20220701-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMjUtMi0xLTEtMTU5NTQw_9fadcc39-0896-4434-bb80-61bc1bd82107">3.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic666c0215c174e0da07f4d1e09afbca8_D20220701-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMjUtMy0xLTEtMTU5NTQw_82840e44-5947-4878-bcc6-565b79cab370">3.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24578a0bb60d41509dae6c91cf840cf4_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMjUtNS0xLTEtMTU5NTQw_095cc759-d686-4964-a679-46b98946033d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i797465f9dcae46679ecb0c162248cdbf_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMjUtNi0xLTEtMTU5NTQw_be09041e-57b0-43ee-b41b-cb85903b5a21">4.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01bedd14598d4bef97fe5433a5abe2ec_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMjUtNy0xLTEtMTU5NTQw_f4b7064f-b241-48a0-b064-0e6721d8a44a">4.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total immunology</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bca0633651d410a8f37cdc991be5df2_D20220701-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMjYtMS0xLTEtMTU5NTQw_77d4aa5f-7606-426e-9162-d519fb860bf1">516.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0952e420996041498b88ed77f880c508_D20220701-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMjYtMi0xLTEtMTU5NTQw_e9e7b637-6efc-421e-bec8-2dacd3f3521e">349.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6386f383c2e5484da28e805bf356222b_D20220701-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMjYtMy0xLTEtMTU5NTQw_1bc8f1fc-9d20-490f-864a-30c2b71145e1">866.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d8dd9cfbda345988f0d1cea4fac4546_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMjYtNS0xLTEtMTU5NTQw_b01d6266-b78a-4379-9bc0-fcfe47e68409">616.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icff9e13bc98e41938e743e7a4e4fd6de_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMjYtNi0xLTEtMTU5NTQw_d4182dd0-43a7-486a-8bc1-c47dc10ad1af">388.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5adbec8a8b6b48f7a5d1e48f49bf3411_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMjYtNy0xLTEtMTU5NTQw_35717df8-0dcd-4782-b080-1f21092ebd04">1,004.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neuroscience:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Emgality</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i358dff328e02486cae97aaae267517fd_D20220701-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMjktMS0xLTEtMTU5NTQw_8967f1e2-4625-4893-a0c4-2f543d39af2d">114.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c4b3d872761408cb58a702f02c9d3dd_D20220701-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMjktMi0xLTEtMTU5NTQw_befa0c0c-a1dc-40c3-8369-cffc7d5e1ee5">54.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88720be3d2b447b38eacb349e966b957_D20220701-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMjktMy0xLTEtMTU5NTQw_8ee494a4-a31d-4595-8d27-08873bef5193">168.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i306f66892e60463a9440dd8625f955f2_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMjktNS0xLTEtMTU5NTQw_c51a5040-112c-4cf6-a2e6-dea3609e2f95">99.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i830b5f4dd99f475f892c9b95d9c74688_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMjktNi0xLTEtMTU5NTQw_a1ce6726-10fb-41ba-aeb2-500152ff68c4">40.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04f1fa38b33d409c95edc1ca5dddc792_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMjktNy0xLTEtMTU5NTQw_32a8996b-1635-4f14-9bbf-798c243c78d5">140.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Zyprexa</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3165ffc22844091b6dfdb6536ee8f81_D20220701-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMzAtMS0xLTEtMTU5NTQw_560db19e-bd9a-4b62-a91b-9536f09d0e72">8.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93ab8179e11b4f23a7909ff2a1a2042f_D20220701-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMzAtMi0xLTEtMTU5NTQw_64ae06ae-b854-405e-ad14-642010136a75">73.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia17da4c4f6b642d596703193f6afe6b9_D20220701-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMzAtMy0xLTEtMTU5NTQw_ab5c4348-1e7e-4b8b-93a7-69d8e5158abf">81.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i870e9a03322b437eab5ad616b9b96c9f_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMzAtNS0xLTEtMTU5NTQw_e04efa83-7f5f-434b-9e23-a60e1458723e">13.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i119d9834ae424e7fa424cf206e1fa0fa_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMzAtNi0xLTEtMTU5NTQw_f3dae17b-3259-47bb-ae80-452ce0416c7a">88.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9028e0822d8749e59ae82cba528438af_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMzAtNy0xLTEtMTU5NTQw_b76c7e98-774b-4dc1-a816-50b4e7a108eb">101.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Cymbalta</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6ab25c06067493bbca70a4e7597fdb8_D20220701-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMzEtMS0xLTEtMTU5NTQw_a7af9985-6940-4b9f-9315-032dd66a34a7">7.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85be7a9452cb426a90fedddc2f455b01_D20220701-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMzEtMi0xLTEtMTU5NTQw_ad99c188-31f1-49d4-82c1-fd460b314ca9">54.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b6eac789003419ebceebcc13f624925_D20220701-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMzEtMy0xLTEtMTU5NTQw_40a7a521-b55b-430a-8278-3bf5163ad5c4">62.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd3368429e0140009581d9d510f8d8ff_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMzEtNS0xLTEtMTU5NTQw_c2357e65-39cb-435f-862c-4aa87032718d">7.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i734fc13568954b75bd88b7375fbfa00d_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMzEtNi0xLTEtMTU5NTQw_2737e1c9-60a5-438b-98f5-d2c8e956d29f">125.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53769ba188564f8a86965473de7ac7a2_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMzEtNy0xLTEtMTU5NTQw_3caf55c9-ac07-4833-82f7-b93449a6e5d7">132.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other neuroscience</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8c180d54e944d17bbbf0438a4c8f563_D20220701-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMzMtMS0xLTEtMTU5NTQw_bf6d0e00-4fee-46af-b567-65b296a42b67">16.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31bc9c1361964102bc7f26ff4a6390ee_D20220701-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMzMtMi0xLTEtMTU5NTQw_162173ef-fc97-43b3-9c37-e122f2132b45">44.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf97b2cc85a442f5bc488f333e264c43_D20220701-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMzMtMy0xLTEtMTU5NTQw_366c4be6-d347-43d9-ab7f-95b0b50139b9">60.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7434dc344c6b4a99973bac3fef8d4f3a_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMzMtNS0xLTEtMTU5NTQw_59d648e5-e908-4777-ba0d-d290ded228af">24.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ed4e34eaaf642748b03cff5ec59a742_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMzMtNi0xLTEtMTU5NTQw_14801ce0-8a85-4c5d-b273-23b59535068c">51.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifdd2b94511c147b0aa78edfbd1578f35_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMzMtNy0xLTEtMTU5NTQw_98f63d11-caca-45fb-8d9b-9b52390a9f67">76.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total neuroscience</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75c76b5ae8b04d0694593c6b670f2a70_D20220701-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMzQtMS0xLTEtMTU5NTQw_089e8a8d-bcbb-4507-95b5-f188b6e4da93">145.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if373b9f49fe74bdbbcaeb90bdcf2de8e_D20220701-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMzQtMi0xLTEtMTU5NTQw_aa962b8e-92b2-4d7e-9852-fb025339841d">227.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f4a20a3083448aabf8de47a307ae3fc_D20220701-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMzQtMy0xLTEtMTU5NTQw_8d188003-97ae-455e-9a08-7eeb0bff9748">373.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9aabeac82be44155a967c8ced0c3a972_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMzQtNS0xLTEtMTU5NTQw_c96669b8-52ce-4837-9b04-7dd519f55dc0">144.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d31ef68d52e4c1680dc7d71063a6777_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMzQtNi0xLTEtMTU5NTQw_d4724dbb-e2a0-4f6b-9df7-fef5c124aa39">305.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cb7b465f1794abdb49eb28db9903a03_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMzQtNy0xLTEtMTU5NTQw_f4fd061b-510c-41ed-8f74-f2164e8e6c40">450.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">COVID-19 antibodies</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0fe5df95a127467ea05981672b21cdba_D20220701-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMzktMS0xLTEtMTg5ODQ0_3ac039e5-b096-4982-9fb4-378136d0ced2">386.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4b9aa980cc940d3870c8d9e4046840e_D20220701-20220930" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMzktMi0xLTEtMTg5ODQ0_8c158368-7148-4a58-b873-4cd8f2a2f7e2">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic89265df487544d48f864b30c7c12762_D20220701-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMzktMy0xLTEtMTg5ODQ0_71e40ea7-c487-4757-9800-7bafda958193">386.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i136c9d207de14e89bbae2b72e3112e4a_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMzktNS0xLTEtMTg5ODQ0_d5af7875-149b-442c-8710-94ebf0d1fd20">215.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic05b3db77dcf4e66b1e09c07f79fd579_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMzktNi0xLTEtMTg5ODQ0_e795a3c8-c7f0-4056-9013-7c278317fa67">1.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05b4b2fd75f8488cafa80162074dca18_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMzktNy0xLTEtMTg5ODQ0_68157132-4443-4e9f-95c1-d21929f2a3b7">217.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Forteo</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78e14fd2e59849538d2032aed3e9bb0c_D20220701-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfNDAtMS0xLTEtMTg5ODU2_82afa443-ae00-4d17-9ac7-bd7485cc4e11">112.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic73ca51c96f5471cb91194277c299762_D20220701-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfNDAtMi0xLTEtMTg5ODU2_1abef22b-0ded-4d80-93c6-4c7b1c531843">64.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29d5f03b98014ea7af366d7dbec08cc2_D20220701-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfNDAtMy0xLTEtMTg5ODU2_c1b32467-a42b-4b3a-9ec5-d312c34430cf">177.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b6529d5d56e42959333a8689a171264_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfNDAtNS0xLTEtMTg5ODU2_85c89292-5642-42e1-9658-fceb79e3828a">109.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99005918fc524bff85805ac964cb5794_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfNDAtNi0xLTEtMTg5ODU2_2a89c97d-2750-4da2-b177-3640dc13e2dc">91.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ec8ff4aa32b406db0037636d5d11b91_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfNDAtNy0xLTEtMTg5ODU2_facfc698-fc04-49af-bb00-5b0b2593d797">200.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Cialis</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id253637b6dc04f4593c5389197fd1ed5_D20220701-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMzgtMS0xLTEtMTU5NTQw_1720fbd3-7d60-4fbf-865e-5af8fdce5f1f">8.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b5c45eac140477aa0acc064ef0011ea_D20220701-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMzgtMi0xLTEtMTU5NTQw_4b4840d8-4b80-415f-8dd8-32096ab164e0">107.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57e0cd27dd3c4483afca4b02ab1ab2ea_D20220701-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMzgtMy0xLTEtMTU5NTQw_76e3f28e-af56-4a81-be9d-ca0f83620ce0">115.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i71526b83a9b84d10a6e1ab1807ab8e18_D20210701-20210930" decimals="-5" sign="-" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMzgtNS0xLTEtMTU5NTQw_f022107b-baf5-4b6b-bb62-e1cabad8fa34">6.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04e727dddbbd447c91777ca002cf2367_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMzgtNi0xLTEtMTU5NTQw_10342b0c-bfbf-4eb4-8b34-30977ee43ff1">137.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01198f0de24240588ceb005e3647087b_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMzgtNy0xLTEtMTU5NTQw_e24217b2-5baa-4c6b-9461-08c731010070">130.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0fe66e11e054c0a85bb68ff7d7f2857_D20220701-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfNDEtMS0xLTEtMTU5NTQw_2cdfa985-29ee-4f37-a429-ff25d7c6071c">30.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i347c502b181c4a13a94b72d8e2a383bf_D20220701-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfNDEtMi0xLTEtMTU5NTQw_c16ee405-5e27-40eb-a8bb-2bb188633c30">35.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic32c291337714cc290c1dac418f4d40a_D20220701-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfNDEtMy0xLTEtMTU5NTQw_25dec1dc-a949-44ce-b519-9f6823bdc69b">66.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4760c4e663814ba4816919d7cf1c133d_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfNDEtNS0xLTEtMTU5NTQw_ae0548ac-6608-4708-af7f-6160ac8b001f">36.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b57a14b81924b58a902d121891b42eb_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfNDEtNi0xLTEtMTU5NTQw_fae2249b-e12d-4dc9-8c9b-46d04fe62d9d">52.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib28a57467090415586ea5d4a46d5a6ff_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfNDEtNy0xLTEtMTU5NTQw_c8286fcc-052e-4195-b64f-26eaeb84d91d">88.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3bfde2172ab44bdb98ffec5b7744d66c_D20220701-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfNDItMS0xLTEtMTU5NTQw_c4c276fe-f52c-4bb8-941b-9006a1ba6cf3">538.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e976e03f8b7452b97fe7c6fa5a98acb_D20220701-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfNDItMi0xLTEtMTU5NTQw_ab281325-aa88-4edc-a928-62f9ee2e8ac4">207.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb8a914c841d467289183242e217e8c8_D20220701-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfNDItMy0xLTEtMTU5NTQw_c1372e67-c2c5-4b5d-936e-89d76f7cc1da">746.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23b21b36e578436fa92bcc41739470c2_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfNDItNS0xLTEtMTU5NTQw_3b02b59e-955c-4e54-8c30-7609a14b04b1">354.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe9720e656b242efa27c155f58ea5690_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfNDItNi0xLTEtMTU5NTQw_06ec6791-c558-4e7f-b1c3-4f6e4064dd99">282.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9af8cc7ddb614c4d8a4d4ce694795736_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfNDItNy0xLTEtMTU5NTQw_bd6b51b4-dfdb-4ef3-80e7-1ee168d043ed">637.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ef4c6628ee44bfaba7f2e062c3984ca_D20220701-20220930" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfNDMtMS0xLTEtMTU5NTQw_36d2d49b-a03a-402f-8870-b74fd2142958">4,422.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i553eac0570bc41a68be3130cb9383387_D20220701-20220930" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfNDMtMi0xLTEtMTU5NTQw_6d3f2eaa-477b-45aa-ad0b-d2e593013d29">2,519.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19fc0325c48543008ea71e1fdcf11d86_D20220701-20220930" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfNDMtMy0xLTEtMTU5NTQw_7a6111b5-5456-4a75-b85e-f449c909d6c9">6,941.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7200d1730974b7f929910230bd89187_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfNDMtNS0xLTEtMTU5NTQw_930cff6b-fa4e-4b50-8808-24330c9ad2b7">3,989.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8bdc66e6dc0c4330955f23ef9a18d769_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfNDMtNi0xLTEtMTU5NTQw_cdcf29b5-0707-4a98-a656-321aa03a343f">2,783.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4fa4f6b472a4f269297591b44aba572_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfNDMtNy0xLTEtMTU5NTQw_cd4c6a4e-adc6-4b3f-aa23-70ff34b66eb2">6,772.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Numbers may not add due to rounding.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Jardiance revenue includes Glyxambi</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Synjardy</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">and Trijardy</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> XR. </span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Humalog revenue includes insulin lispro. </span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Olumiant revenue includes sales for baricitinib that were made pursuant to Emergency Use Authorization (EUA) or similar regulatory authorizations.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">COVID-19 antibodies include sales for bamlanivimab administered alone, for bamlanivimab and etesevimab administered together, and for bebtelovimab and were made pursuant to EUAs or similar regulatory authorizations.</span></div></ix:continuation></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i8a87bd7f728c4956b4f7b4a382aa7a0a" continuedAt="ib7361aaef70b4b8fa3c69ad4809e4450"><ix:continuation id="ia7ddf8304b894ea5ae7ce70c55fcc02c" continuedAt="i112884bde4f449e382ba04acb79a007c"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes revenue by product for the nine months ended September&#160;30, 2022 and 2021:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.133%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.577%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outside U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outside U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue&#8212;to unaffiliated customers:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diabetes:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Trulicity</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie25d63c812ca4ba5bcb202b4ef3da925_D20220101-20220930" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfNS0xLTEtMS0xNTk1NDA_78f7c6bc-53e5-42c4-8e6f-369bee45a702">4,162.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91615b3923a04f6a8fd92d711866d588_D20220101-20220930" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfNS0yLTEtMS0xNTk1NDA_f867169a-8cdc-4b4b-ad2e-7ae8ce771bf9">1,341.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9623881a23db40a3b62885fe7a43e0c9_D20220101-20220930" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfNS0zLTEtMS0xNTk1NDA_f9ebcd49-bc95-41e2-a637-fcd13893f83d">5,503.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46ce2dc33fb14a94972b38a4c73c48ee_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfNS01LTEtMS0xNTk1NDA_d9357e3f-a140-4be6-869d-6725de106ea3">3,465.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d256a84bdcc43939ac6114642c9df5a_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfNS02LTEtMS0xNTk1NDA_07603271-9bbc-4458-8ef3-31812afafdc4">1,122.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb96fc34e7f1409fb5661213f97e7f9d_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfNS03LTEtMS0xNTk1NDA_3262ba04-7f0f-430f-88bb-cfd59fc91394">4,588.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Humalog</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29b3721d52314523b933748df1c86126_D20220101-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfNi0xLTEtMS0xNTk1NDA_4e97100c-6d9e-4b42-a6b4-9281d12c89d2">855.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50fdff0f3f64436b8220edeb6c5da6b9_D20220101-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfNi0yLTEtMS0xNTk1NDA_191ce3f9-8adf-44ba-aa10-bafd4e89b835">656.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bbcd6ec5faf46bc81ff607368bdd5ab_D20220101-20220930" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfNi0zLTEtMS0xNTk1NDA_314f2181-a085-4dce-8fa0-58e41ce454f6">1,512.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f2bb68aeed244a48b9a5b9fe2b0b039_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfNi01LTEtMS0xNTk1NDA_9c67c148-0208-444e-89c5-563f8d84e047">1,009.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6a78f62d5834a11a82558249ee89a7a_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfNi02LTEtMS0xNTk1NDA_8c93613c-4e26-430f-b8e4-3fd4afd4bca6">842.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6afc7019eb204b20bc59d3a19fef7f74_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfNi03LTEtMS0xNTk1NDA_8191ab00-1b6f-41f9-a8d6-e7ad1136a125">1,851.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Jardiance</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e18d072344643ada09a2e6559995804_D20220101-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfNy0xLTEtMS0xNTk1NDA_2029b5b6-f677-46d0-8252-8915b807e55f">831.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb016f4e6a094b91ac0aee6fd832f15c_D20220101-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfNy0yLTEtMS0xNTk1NDA_8a27f5df-9a0f-407d-9bfc-a282cdf5a0e1">622.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c01691865ed49fc84902886c99bbbdf_D20220101-20220930" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfNy0zLTEtMS0xNTk1NDA_cb373d45-18c4-40fb-bb86-e9d14a320f3a">1,453.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2d8d981e4314247892b22b49b01d418_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfNy01LTEtMS0xNTk1NDA_8cc9ca82-3ef7-4a0d-8bd5-5a4ea9e955e5">566.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie65c118c7eb54da8b92e056d23b07e85_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfNy02LTEtMS0xNTk1NDA_f26c63fc-a0e4-42b7-8a71-21244b727bb3">492.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46099dfb95b0484ab5891f186d350f52_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfNy03LTEtMS0xNTk1NDA_70ca7508-c330-4dc2-95ef-5b171312bb25">1,058.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Humulin</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ad9a3d1e7704c9f8a4c92e4f18248ef_D20220101-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfOC0xLTEtMS0xNTk1NDA_00d765a6-e520-48ad-9f0c-a33a20fe91ed">562.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4c358f120c14431858d22fd921cdb1a_D20220101-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfOC0yLTEtMS0xNTk1NDA_7348fdbe-cea7-4e55-bcad-71095de37c50">223.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97453ba9a92b4601b70738c5fd865a63_D20220101-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfOC0zLTEtMS0xNTk1NDA_e2811bc0-5b34-4a0f-8df4-2026c523050e">785.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a4be59d818242b8a5d6e29a133e78b3_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfOC01LTEtMS0xNTk1NDA_4bf79573-94d0-4f2a-ab2e-c43f60f53746">633.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74ac58ad376e44179242350ff8091245_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfOC02LTEtMS0xNTk1NDA_76a5202e-4615-4ec4-99c0-14bf221c19c5">290.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d442db3854641bb9c50b1533223b1bf_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfOC03LTEtMS0xNTk1NDA_849b745e-00dd-4fb1-80df-ec298c532e4d">923.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Basaglar</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b84a7f78d3743f383680162b1a79677_D20220101-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfOS0xLTEtMS0xNTk1NDA_5adc3df3-376b-4f63-8a1c-18c0eb84801f">339.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1fd51de24bf4269a3f10390a0eb16b8_D20220101-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfOS0yLTEtMS0xNTk1NDA_bc8b7b5b-7aba-4d58-94ed-61b1bd68e367">218.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f95ba5af9c24c3eb20dc2c5a3979588_D20220101-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfOS0zLTEtMS0xNTk1NDA_11a1b9ff-2de8-493b-989f-355beeaf0e2b">558.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9df6a30c7e76498dbe8e2c10556551c7_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfOS01LTEtMS0xNTk1NDA_a9f3c5fa-5c69-4356-88be-49889c5a8b3f">423.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc6cb890a5e04ad3ab5d2c0f4a2935cb_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfOS02LTEtMS0xNTk1NDA_423620b9-1c16-42b8-87a5-b57c86dceb50">226.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id065d1641c8b4bc19bda4f978edc7f70_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfOS03LTEtMS0xNTk1NDA_ce835c8b-bb9d-4ca6-af69-991834fa4bc4">650.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Mounjaro</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9c6e93828454ef795aef5751d0352fd_D20220101-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMTAtMS0xLTEtMTg5NTU2_b263dd4a-d009-4717-aa7c-765bc613ba3d">109.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i844e2c3c4d3c4a4eb90a291b6edaa117_D20220101-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMTAtMi0xLTEtMTg5NTU5_ef04d445-3a87-42d9-983f-f71f06ea12cd">93.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d0e3b68ad424288aedc96a1c3c5e2d2_D20220101-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMTAtMy0xLTEtMTg5NTYy_fad2afec-0f97-4a73-9967-bd21e86d2bcc">203.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd146a846a384a1cbb7ed3016e2cb317_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMTAtNS0xLTEtMTg5NTY1_f1e746f9-8f1c-435d-8ea4-f56ea71f1235">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idea0b040a90e4c93ababd4c0d4f02647_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMTAtNi0xLTEtMTg5NTcy_0e54ba4a-3ab6-433c-9362-64f9ad86d975">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie993c12313da41f38573f6bc42f10868_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMTAtNy0xLTEtMTg5NTc5_1573663c-598c-4a5a-8426-f3e528222106">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other diabetes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ed26a3d9a8b45559192c48d5bb034d4_D20220101-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMTAtMS0xLTEtMTU5NTQw_9eebadc7-e2dd-4ff6-9757-a1cbc244549a">195.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cfbe889964e44e3a453aa644188647d_D20220101-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMTAtMi0xLTEtMTU5NTQw_d91c4ecb-f2dd-4775-bcea-dd9f8913deb0">276.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1414ede1c78a462e95bd1b8346592f8b_D20220101-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMTAtMy0xLTEtMTU5NTQw_c6c7a97f-a239-41be-9b53-faaa8ff25109">472.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20194883f2624f82b663260d5199fa21_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMTAtNS0xLTEtMTU5NTQw_d86144ec-142c-4709-be8a-e49ae2a040dc">185.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i820e5b799761449bbbf32e97e1e019fa_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMTAtNi0xLTEtMTU5NTQw_7d9e2052-ecdb-4055-94a9-b2287dc200d6">302.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab636b5286134cd7875bd3dfdf73353a_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMTAtNy0xLTEtMTU5NTQw_54996cc7-c9cc-4897-a7be-0c25eb5efb56">488.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total diabetes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1356cd272fa54029ba0f0c21fab222b4_D20220101-20220930" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMTEtMS0xLTEtMTU5NTQw_68778c5e-1a3b-4eda-9cfa-9a7300b6e342">7,057.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19fb57248d6f41d19ef8485870fa08f3_D20220101-20220930" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMTEtMi0xLTEtMTU5NTQw_95358171-7207-4b47-9a61-44cdef026f72">3,431.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a4c43c5e76a47ceb09387d84fc5d358_D20220101-20220930" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMTEtMy0xLTEtMTU5NTQw_02a093a9-b99a-45ff-a708-0e75cc307561">10,489.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc6e032f5a9d4001ba9413713acf7354_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMTEtNS0xLTEtMTU5NTQw_99e215c7-7077-4ecc-9863-46656418e352">6,284.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabf6366b8c134597b8ac64603a6cb066_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMTEtNi0xLTEtMTU5NTQw_b772e530-7522-4cb6-9a4b-4a45abd4bdcf">3,276.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44a3630aeb244ec2ab5204f6c1650459_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMTEtNy0xLTEtMTU5NTQw_83da6114-3ea7-43f6-b461-f6737d4a1efc">9,560.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oncology:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Verzenio</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i630ed70ef3804cddb8e7bd6a2c884284_D20220101-20220930" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMTQtMS0xLTEtMTU5NTQw_6d34a77f-8ec5-4c24-bc5c-7b5834e8e748">1,100.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id50357546429495db587cbaca50bd352_D20220101-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMTQtMi0xLTEtMTU5NTQw_1c68d4f4-8093-4ec0-9529-9e4e7501be18">575.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20c536a6925e49838b17da59e54c92aa_D20220101-20220930" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMTQtMy0xLTEtMTU5NTQw_9bede702-2b65-435e-878c-e753d652c795">1,675.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8fd3622c0c34f5f942c2bcf19a84b1b_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMTQtNS0xLTEtMTU5NTQw_81cfc482-4d67-4f67-9360-6b2ac4f69366">582.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08e4bcea32b741f3ad619cb7789236d1_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMTQtNi0xLTEtMTU5NTQw_28a4ad81-4c7f-4a41-a9f7-03ea4c729c1b">363.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ea3180802c144d4924a8a4b8a919abd_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMTQtNy0xLTEtMTU5NTQw_61a50161-29e5-4a7b-828a-56e401cb2d66">945.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Cyramza</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0759c0458d14fac885984f8686a83c3_D20220101-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMTYtMS0xLTEtMTg5ODcz_09943eef-4d04-42fc-abb8-123256cf513d">259.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i234acbdded404fc5bcf21a6ea711e9ef_D20220101-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMTYtMi0xLTEtMTg5ODcz_75d5dc1a-40bb-473e-9784-6dd0ce642bee">434.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib28d65608ad54ff9b7e45a5c0298b338_D20220101-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMTYtMy0xLTEtMTg5ODcz_228265e0-bba2-4a9e-b79f-8950634447b6">693.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98867991ccbb44078d309a9dd8539a71_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMTYtNS0xLTEtMTg5ODcz_05dedfbf-9c60-4ae2-ad1e-114c5eabeb0b">266.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib811fbcdfc1241359475319e63db4106_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMTYtNi0xLTEtMTg5ODcz_c7fd8e86-3aaa-428c-95f3-19abd31c4213">496.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb20b9b0be4f46bfb05c7b12f39a6a9e_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMTYtNy0xLTEtMTg5ODcz_6cfd3129-2b99-4295-bf5a-3f9cd635c1ad">762.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Alimta</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64bc0872b6e94aa7bf69b1268d189134_D20220101-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMTUtMS0xLTEtMTU5NTQw_9e452868-a984-406b-a2c7-95c8f6d4add8">490.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1a6ba9c9b6a42638bdfdbee6e6f2758_D20220101-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMTUtMi0xLTEtMTU5NTQw_55088cd5-938e-4b10-955f-025453af8e44">200.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07ddaa6f5dd549048da689638ae982f5_D20220101-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMTUtMy0xLTEtMTU5NTQw_36e6a5a1-2443-4576-a596-1070445ca1db">691.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9571c6749464454692162cefb3bb7738_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMTUtNS0xLTEtMTU5NTQw_384bf604-3f03-41f6-a2cd-90ceb022ef9d">911.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i546701dbe3cb400c84bc62c598271f8b_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMTUtNi0xLTEtMTU5NTQw_1a674613-abf5-4c24-97eb-54e01023d3d8">714.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70cb0ea9b68f4680b98801d50a608b14_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMTUtNy0xLTEtMTU5NTQw_dcc8dcea-ec27-4cf4-b5df-e8e4596da607">1,626.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Erbitux</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40507b3da3804796ace099350f243c27_D20220101-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMTctMS0xLTEtMTU5NTQw_4655b855-be03-40a9-bfb6-55802404e5a4">361.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i680ed22913654e2ead217f9b5989504b_D20220101-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMTctMi0xLTEtMTU5NTQw_fad0f39a-54f4-4c56-85be-3614512d2b04">47.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0088a078fdd54003819037635cb52f70_D20220101-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMTctMy0xLTEtMTU5NTQw_cb8ab5bf-cd75-4e83-8ee2-88f9656ade25">408.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27e99c349c3a48dcb14b9a15ed3dafe5_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMTctNS0xLTEtMTU5NTQw_746df41d-a5d6-479b-994c-ef88cb2a48bc">357.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0246564d9bc4f02a5441b1f2566bf51_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMTctNi0xLTEtMTU5NTQw_12cf1918-9117-400f-b35f-2884cd95979d">45.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3c22691b22448eca997f30d1f1366e2_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMTctNy0xLTEtMTU5NTQw_64961947-4df9-467d-a715-be43889fc82d">403.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Tyvyt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0302245b5cc5492d85c394bdbd9a59c3_D20220101-20220930" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMTgtMS0xLTEtMTU5NTQw_cc4c44ca-2a22-4d11-86ba-464533ca76af">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab104518f25b49a4b922a68ba94e910b_D20220101-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMTgtMi0xLTEtMTU5NTQw_af0994c6-c648-4b7d-82ee-8f1972e444a4">235.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6633f1ca883b4a32962bcd825ba66bfc_D20220101-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMTgtMy0xLTEtMTU5NTQw_e0a86df6-6300-4357-90bd-48dc6a115ee0">235.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6761a6ec70464bd2bba2e8b31d7dfb55_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMTgtNS0xLTEtMTU5NTQw_b4cabb1f-f6f9-47aa-8420-70ce2b8f5a94">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68cac27afeeb4c6ca2de0e2af5aeecd2_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMTgtNi0xLTEtMTU5NTQw_ae4c7127-fc5d-421f-beaf-c68b55cab49d">340.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a42a2407e7046519687e4401e714180_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMTgtNy0xLTEtMTU5NTQw_035251c1-2596-483b-bfe5-5ec2455ef786">340.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other oncology</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib89a61de2c8542719d727ea9b2e4d288_D20220101-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMTktMS0xLTEtMTU5NTQw_d1954928-0d68-436a-b652-b8f4b43c336d">124.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1753f6d5c4044468226ef9a5f59457c_D20220101-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMTktMi0xLTEtMTU5NTQw_d5afd4d1-6da6-496e-8e0f-2ddf9931b1ef">186.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffc444b9d88245d5a3bdb35b82ef0d55_D20220101-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMTktMy0xLTEtMTU5NTQw_bdfc72d6-c0a0-4d00-9cfd-5a5c91d2c5a4">310.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85c317c4af504382b28dfedc3facb2dc_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMTktNS0xLTEtMTU5NTQw_27f30563-5d83-492f-9890-653dad2fdebf">83.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6290305d31574c06901b06e6eacfd414_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMTktNi0xLTEtMTU5NTQw_430358fb-1e2e-40f3-919d-b3d16bf185e6">169.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7bf748b95e7a45cf9e722167434f1385_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMTktNy0xLTEtMTU5NTQw_47730d60-9fe8-4567-ba6c-421b2883efd5">253.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total oncology</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i240fc921c5ef4622986756418d0b3d39_D20220101-20220930" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMjAtMS0xLTEtMTU5NTQw_b76b1790-9c2d-4393-a4c4-1dd489a1d3f0">2,335.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5db5d222d3da4495a3cd1481fae9b1eb_D20220101-20220930" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMjAtMi0xLTEtMTU5NTQw_d98bb26f-8708-4478-859d-fc50d47e4d1e">1,679.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3038a6b1fd04b43a1855095f482ffd4_D20220101-20220930" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMjAtMy0xLTEtMTU5NTQw_b9a08008-cef8-44af-985f-21c664d06f00">4,015.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf34cf4a2aae43eda96963b778a49168_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMjAtNS0xLTEtMTU5NTQw_ed797912-125b-4f4a-aa8e-f857787ec7f2">2,201.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib71c38ea0818475aa548176344240c72_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMjAtNi0xLTEtMTU5NTQw_4654c914-0650-4861-b47f-422d9e58cada">2,130.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7cc9d1bb283d475d915f7fcb4f945c8c_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMjAtNy0xLTEtMTU5NTQw_dc4cf420-6e48-42d4-911d-2ecaca404342">4,332.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Immunology:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Taltz</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08907695f17c4fe487c0f59792752c89_D20220101-20220930" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMjMtMS0xLTEtMTU5NTQw_7170280b-4102-49f8-8f6c-27a5d09a5424">1,212.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d2d7d0cc9e04232b6d62adfc3777b93_D20220101-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMjMtMi0xLTEtMTU5NTQw_037c63eb-a53f-48a3-93e6-05c59f8fa181">561.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7453a607ad674e25bbab08ef19e88d3c_D20220101-20220930" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMjMtMy0xLTEtMTU5NTQw_90de6c5f-36a3-491b-bf87-80b0910ab151">1,774.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccd3059fecb04f1d94d0044c6e3c7e32_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMjMtNS0xLTEtMTU5NTQw_4815ccb4-fc7a-4228-8bbe-81a4cdfb4d0f">1,071.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3036c3ea47bd4c89bafa4bdba1320abf_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMjMtNi0xLTEtMTU5NTQw_3589a551-23f3-4fb5-a75e-ce83e5303093">493.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifea4d8eb21b94b0ca8248b42f02b49e9_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMjMtNy0xLTEtMTU5NTQw_3af34f47-3d64-411d-aa4b-fd0846638dc8">1,565.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Olumiant</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4036604f9c945e1a19be8b3aa38e334_D20220101-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMjQtMS0xLTEtMTU5NTQw_f2338a2d-334b-488e-8454-5c8fa3aabc6d">104.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i381560b71db64644aa7adbc056fac279_D20220101-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMjQtMi0xLTEtMTU5NTQw_3b095cd8-e776-41b7-83a4-56c231624b5c">520.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5da2c0b8af014f4085d9e2a62f64ccc7_D20220101-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMjQtMy0xLTEtMTU5NTQw_0df76049-ccad-4122-b1a1-eae0338220ed">624.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a1215ba2eae4c7da8010b728800b4d3_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMjQtNS0xLTEtMTU5NTQw_a3ded4d3-5609-4fa3-a38a-aa000fef4537">236.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife8cad1b8c0f45d89f7c79beb6a9506c_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMjQtNi0xLTEtMTU5NTQw_8a7fef6a-7192-4e4f-bbde-8f108239dd41">572.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i681b00cc06e740d5afd240016ce29efc_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMjQtNy0xLTEtMTU5NTQw_0e645580-44b6-4123-bb51-2c0d05b45c34">809.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other immunology</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8cdc5308202645dfa9f06b53e46a162b_D20220101-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMjUtMS0xLTEtMTU5NTQw_84eff3e8-f7a9-45e5-b5a4-7e930c0354d6">0.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6010298ee7bc433e8bebac5a5efc972e_D20220101-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMjUtMi0xLTEtMTU5NTQw_dbff1416-bdfa-4649-9dde-32101d8f32d3">12.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i659d2c39bfc34df8bd9f7d944a3822a2_D20220101-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMjUtMy0xLTEtMTU5NTQw_a3bf93f1-ec60-48a2-88a2-911f67889c4c">12.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61df0f1a279148aa9e8254f5980c32dc_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMjUtNS0xLTEtMTU5NTQw_a2d5afe6-fb45-42a9-a57b-121984acfbf8">15.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e4c4171e5c3493aa1885a72fe4cfa14_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMjUtNi0xLTEtMTU5NTQw_e82df984-0ab3-4cda-932f-df2805c2afaf">14.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9a4f1d7373649528e8dfb81328134a4_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMjUtNy0xLTEtMTU5NTQw_bac4c98a-62f5-44d8-b79e-864d331ebbec">29.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total immunology</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb0659e3898241ecbd83bdbf9dc59c78_D20220101-20220930" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMjYtMS0xLTEtMTU5NTQw_322295e6-f0a1-4117-bf6c-23b22e8051fa">1,317.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e251958291a42a3a1c5447458b86d15_D20220101-20220930" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMjYtMi0xLTEtMTU5NTQw_3b945b74-f88c-455c-b295-8cce5ce019f8">1,093.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8aaae8dc85e144a6a4bf886fd061d950_D20220101-20220930" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMjYtMy0xLTEtMTU5NTQw_2a1b4de2-78f1-4358-94f5-0e85ec10895e">2,411.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d035bb38a454213828a14551e6edea5_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMjYtNS0xLTEtMTU5NTQw_bf15046f-bd16-41b8-9a5f-3d03b05e718c">1,323.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71c9047535fe473ba6d96eba16066ad6_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMjYtNi0xLTEtMTU5NTQw_ddb39170-32cc-4211-b1c9-271ee3933363">1,080.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cef6079bf0146839ee9f000bdcfe3c4_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMjYtNy0xLTEtMTU5NTQw_d5844e8d-7abe-44f0-b189-b56d4ef1cc00">2,404.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neuroscience:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Emgality</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf50cba6df584b358ccfd1c552ac603a_D20220101-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMjktMS0xLTEtMTU5NTQw_308f3405-b807-43c5-b079-9b53b9ce1c94">330.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife6ede2d6f41458f8f350cd5f6ddeb17_D20220101-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMjktMi0xLTEtMTU5NTQw_12a2d764-0b04-49ab-b36a-d06ff1fe8340">144.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b7c20f1ff97494783d6f4579ff8f7f8_D20220101-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMjktMy0xLTEtMTU5NTQw_66b2cf61-0883-49b8-8cc3-19c42c885acf">475.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2892d650df3349fe9ae882f6ae942d58_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMjktNS0xLTEtMTU5NTQw_f2fa058b-7488-4f61-a64a-f8fa583457e5">313.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc4bdc96c6434cc8b53a24c987e9c41e_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMjktNi0xLTEtMTU5NTQw_3454f956-24d2-48a7-8a2d-b04c804ac919">102.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d73674530f248b5a702b835849253ef_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMjktNy0xLTEtMTU5NTQw_8765ed08-e070-4308-9f0f-367204ab3919">415.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Zyprexa</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd5454cbe2de4d0ea429015722b20f15_D20220101-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMzAtMS0xLTEtMTU5NTQw_a45535e3-b672-4bc1-8551-d783e45a7da8">26.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7ad299a8b764bb9813cbf2dcae42919_D20220101-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMzAtMi0xLTEtMTU5NTQw_98b61161-64fb-4843-a541-2c35f32b06a7">235.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3a68db7fa3b428995899c0bf854ba94_D20220101-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMzAtMy0xLTEtMTU5NTQw_27530aab-c6b1-4264-90b9-872e0b87c681">261.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i006ca6ec8c3c4717aef2b19d419c92a3_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMzAtNS0xLTEtMTU5NTQw_cf9ab302-ff9b-4004-b925-3de48c55b160">28.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib90b244e7d0040c68677396984559ec8_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMzAtNi0xLTEtMTU5NTQw_7d00e1e3-02ca-4f0e-930f-9f409f4aa72a">264.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedfe879bea3a496bb3766920c821c198_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMzAtNy0xLTEtMTU5NTQw_8323e1b4-bdca-4a0b-a930-4fc4f2df5d63">292.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Cymbalta</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f91e524972e42a98fc9b5abba31e458_D20220101-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMzEtMS0xLTEtMTU5NTQw_eafd4191-eaf5-4990-bdbb-aaf97378e6f1">25.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3c6fe2019a042c4909c317b26cdf477_D20220101-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMzEtMi0xLTEtMTU5NTQw_021cd889-11c2-4ce1-9d12-d5f5b217448c">194.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee5d9669f4b344499cebdffb37f32030_D20220101-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMzEtMy0xLTEtMTU5NTQw_1b415956-8aa6-4f0a-9859-2a5f0d137fec">219.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f307f23d1de4f80bbe2e59ea610ff7f_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMzEtNS0xLTEtMTU5NTQw_26a269cb-9d2c-41ad-865f-dc1e3fdcb92a">30.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i526c0b4d4b3140cfaf92e5209854bd78_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMzEtNi0xLTEtMTU5NTQw_f184166e-77fa-41cc-a27f-2f86abde8c08">454.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i733173c6b1a342488769f27288f96647_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMzEtNy0xLTEtMTU5NTQw_625e4818-16b5-44e8-bf09-d39441263f9e">484.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other neuroscience</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00d29df7fc444a888bd8f1ac7c7fcd63_D20220101-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMzMtMS0xLTEtMTU5NTQw_c2416596-e2c0-495e-8182-f65f0142c472">62.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5a61b3abda849d981158a33cc123750_D20220101-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMzMtMi0xLTEtMTU5NTQw_d030dd11-a637-4d5a-99f0-d394fce76db8">142.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4894a69792984d28b5bd70bdcb925593_D20220101-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMzMtMy0xLTEtMTU5NTQw_cc24c286-506d-4492-ab7d-1327d7c2bb52">204.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2af7293d556c4ac189783fd3d7bfa089_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMzMtNS0xLTEtMTU5NTQw_05c7f402-9405-4ada-9f53-5e46a10da191">81.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7dd70175fc2484e9291653ca9b5bcd0_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMzMtNi0xLTEtMTU5NTQw_1ff1c493-5cbe-4f08-b556-4b3804047aac">154.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaffd646b91554c9fbd55b7373a9ab9f2_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMzMtNy0xLTEtMTU5NTQw_899bd158-7165-49f4-82b2-7b6596cb6875">235.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total neuroscience</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i177e8ff27d1b444d8032f9fd6e71b86e_D20220101-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMzQtMS0xLTEtMTU5NTQw_be398c11-6894-431e-9e28-0ee67b4475fa">444.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20063c304d1142018b211b53b3a1c50b_D20220101-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMzQtMi0xLTEtMTU5NTQw_8e7429f4-d1a6-47a4-b6a1-00587456c0e2">716.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a5789bb5ddb493385ae07bb301aa500_D20220101-20220930" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMzQtMy0xLTEtMTU5NTQw_f91f288f-acb2-4b3e-85f1-5a1d73cb38d7">1,160.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c8cfb5bc4ac42dba8e3851f39bd2683_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMzQtNS0xLTEtMTU5NTQw_32d83a4e-1114-4e6a-8108-d5c53edfb38a">453.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib59bf69a9b284970b3b6642f7e4b795c_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMzQtNi0xLTEtMTU5NTQw_431ac662-ce23-4ac6-ba0d-9f78b9786908">974.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84bebc50684e4e1b90500bbb83bb79a6_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMzQtNy0xLTEtMTU5NTQw_cbd4c88d-c298-4d52-a99d-52477d083eea">1,427.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">COVID-19 antibodies</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e5b50746e074ddabe26161b8cf97195_D20220101-20220930" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMzctMS0xLTEtMTU5NTQw_5aa3a9b2-3e1c-4f33-99f7-7a72796a434b">1,970.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ce72c9f883a452ca19b57204999df16_D20220101-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMzctMi0xLTEtMTU5NTQw_6e16a7c5-f921-4f65-a876-31902fff3d34">14.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie674d270134f4cffaff8f7a15471b73e_D20220101-20220930" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMzctMy0xLTEtMTU5NTQw_7a9a30a8-9c8c-485a-bfb7-42874b8658e5">1,985.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62f7a17973be46d9bf4530c993775bef_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMzctNS0xLTEtMTU5NTQw_2d5a706e-a578-469f-a69f-6219045e347c">949.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb238d01fbaa4761a5fe7a7c91587c74_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMzctNi0xLTEtMTU5NTQw_0a7b29ef-0cbe-4090-936f-d321c82d74ed">226.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic06f11244a5a4b88822809b3b3941ffe_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMzctNy0xLTEtMTU5NTQw_d3fac61e-40f3-4c74-868b-7e1273c87a02">1,176.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Cialis</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa18b54c7e0f4330b37b5256dc5dffac_D20220101-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMzgtMS0xLTEtMTU5NTQw_f6758b03-d34a-4919-92eb-f2ca9590795a">25.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a49509981cc41bbafe688a08ea538c6_D20220101-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMzgtMi0xLTEtMTU5NTQw_86893191-cf05-42b1-8797-7d9848b02abc">454.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac7de63087cb4fa28c15d4fe01f12460_D20220101-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMzgtMy0xLTEtMTU5NTQw_dd613df6-183f-410e-add4-309494740e73">480.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i80c0d99bb34b42e1adce6dce3134630a_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMzgtNS0xLTEtMTU5NTQw_1a856c7c-f1aa-4213-b67c-03d95d46c5da">3.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6dd390f6ff6a43b49662e266d7334459_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMzgtNi0xLTEtMTU5NTQw_4aed1679-c9cf-4d83-a8dc-cafbbdd71721">541.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51c31c17a15244248305698502760153_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMzgtNy0xLTEtMTU5NTQw_c4884def-b052-4a85-af44-e0510efa7ce7">538.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Forteo</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c39dd39688f4abb8ddb719a2260f6bf_D20220101-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMzktMS0xLTEtMTU5NTQw_b9ad8ddb-a960-4578-b59d-fe3855a2aad9">261.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56ac4d65faa946aaaebabc3dc7ca99f9_D20220101-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMzktMi0xLTEtMTU5NTQw_6226f064-40a0-4192-aa5a-ad55e7c70e77">191.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i185dafd0ab80405eb3f78281a2098c9f_D20220101-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMzktMy0xLTEtMTU5NTQw_fcf3196b-a9ea-468a-b614-74f71b8aeef3">453.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice1d37ac1886488088492ea4c957a118_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMzktNS0xLTEtMTU5NTQw_52a5a948-bac9-4bd4-b974-fe6b7f9d24e8">330.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33b45d6e796b4bab93b3906f52ced571_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMzktNi0xLTEtMTU5NTQw_5a4de6ff-7d0f-4a84-8e47-ddb5998f90c4">287.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i606443bf75d84de3b93c88a5d2c2a9c5_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMzktNy0xLTEtMTU5NTQw_f719b0af-37e2-4069-88db-a82c09493c0d">617.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62be4d98bd454dbea6bd3764ddcdacb4_D20220101-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfNDAtMS0xLTEtMTU5NTQw_6ba9d7e5-aa81-4bbf-a522-9702171e5628">119.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i774d30363ab447e4b7b6985e99b6de0d_D20220101-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfNDAtMi0xLTEtMTU5NTQw_c9d2ddfc-a807-4a7f-abd7-1682156006c5">125.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i238722e1d54440828f51f9f11854afaf_D20220101-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfNDAtMy0xLTEtMTU5NTQw_1bf029e8-7051-40f5-bcb3-c8fd0c16f192">244.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4554ea5474043e5b51ccd4cca5610ae_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfNDAtNS0xLTEtMTU5NTQw_b0efffcb-c735-4c5a-916f-72c626bc80a3">96.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a25265d56d04bc481727001f1d55ecc_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfNDAtNi0xLTEtMTU5NTQw_c742b6f4-9f5d-487c-989b-9afb04d35af6">164.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1fc264d1cb9b42cd927c0bbd387866cc_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfNDAtNy0xLTEtMTU5NTQw_65a7826e-3d20-4a60-bf44-61163cafa545">260.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13e5988f996e48299f0ddef7dd648213_D20220101-20220930" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfNDEtMS0xLTEtMTU5NTQw_dfc87ea7-b2cf-4b6c-b3af-cd7054a6ca8f">2,377.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b007283f3094ae08f3a1b5eca4a7fb8_D20220101-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfNDEtMi0xLTEtMTU5NTQw_935de9a4-b15d-4677-87ce-59467bff3f19">786.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b6298a19c0a4c5da470fa7e5e3e967a_D20220101-20220930" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfNDEtMy0xLTEtMTU5NTQw_b246ea30-eda0-4771-b21d-dc81c5ef75a8">3,163.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idcc7138275c74437be6ca40f1474b509_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfNDEtNS0xLTEtMTU5NTQw_ce57a28b-7964-4566-b132-c2a5f727a8f7">1,373.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7efeaf621a9e448fa08571db01806cd3_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfNDEtNi0xLTEtMTU5NTQw_ac883ad5-414a-439b-939f-eceb98fb8966">1,220.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fe3dcab54b44eaf90f9f242c2fe0f52_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfNDEtNy0xLTEtMTU5NTQw_ba66f90c-6765-47fc-bfdb-9dca322733c0">2,593.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60c5eb8ff51d4d9fa0a74c53c73aa0dd_D20220101-20220930" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfNDItMS0xLTEtMTU5NTQw_f7b95b53-67a9-4e1e-9d54-11edea30b950">13,531.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if326645430854a2d9ac96495205c029f_D20220101-20220930" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfNDItMi0xLTEtMTU5NTQw_d9e090eb-f8ef-4af5-9ea1-fe546ef35914">7,708.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfNDItMy0xLTEtMTU5NTQw_5c289ad6-b9d0-4de9-a767-912454043fd8">21,239.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2783a40327b64633b6abee19f7b4ca30_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfNDItNS0xLTEtMTU5NTQw_b734da01-1a15-4bfd-b067-7404be20971b">11,635.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ff1711a07ba45ffadc911d350d44f94_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfNDItNi0xLTEtMTU5NTQw_a4c93317-7d6c-410a-872b-399af12dee02">8,683.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i167ed8f67bef48c49e54fa466400cdaa_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfNDItNy0xLTEtMTU5NTQw_7af87305-39ea-4021-beb7-4f04fe13d67e">20,318.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Numbers may not add due to rounding.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Humalog revenue includes insulin lispro.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Jardiance revenue includes Glyxambi,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Synjardy,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">and Trijardy XR.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Olumiant revenue includes sales for baricitinib that were made pursuant to EUA or similar regulatory authorizations.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">COVID-19 antibodies include sales for bamlanivimab administered alone, for bamlanivimab and etesevimab administered together, and for bebtelovimab and were made pursuant to EUAs or similar regulatory authorizations.</span></div></ix:continuation></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ib7361aaef70b4b8fa3c69ad4809e4450"><ix:continuation id="i112884bde4f449e382ba04acb79a007c"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes revenue by geographical area:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.613%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.206%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue&#8212;to unaffiliated customers</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ef4c6628ee44bfaba7f2e062c3984ca_D20220701-20220930" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjE3ZWUzZDMzZjVjNDRkMWU4ZjgxYjZkOGYxZDRkODdiL3RhYmxlcmFuZ2U6MTdlZTNkMzNmNWM0NGQxZThmODFiNmQ4ZjFkNGQ4N2JfMy0xLTEtMS0xNTk1NDA_e494795c-195e-4e17-acc0-c4d87fd013a0">4,422.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7200d1730974b7f929910230bd89187_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjE3ZWUzZDMzZjVjNDRkMWU4ZjgxYjZkOGYxZDRkODdiL3RhYmxlcmFuZ2U6MTdlZTNkMzNmNWM0NGQxZThmODFiNmQ4ZjFkNGQ4N2JfMy0zLTEtMS0xNTk1NDA_c1810556-5ea1-4f39-b1b4-9505f760d904">3,989.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60c5eb8ff51d4d9fa0a74c53c73aa0dd_D20220101-20220930" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjE3ZWUzZDMzZjVjNDRkMWU4ZjgxYjZkOGYxZDRkODdiL3RhYmxlcmFuZ2U6MTdlZTNkMzNmNWM0NGQxZThmODFiNmQ4ZjFkNGQ4N2JfMy01LTEtMS0xNTk1NDA_8ed50024-bfcb-4b87-904c-5493d51273b3">13,531.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2783a40327b64633b6abee19f7b4ca30_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjE3ZWUzZDMzZjVjNDRkMWU4ZjgxYjZkOGYxZDRkODdiL3RhYmxlcmFuZ2U6MTdlZTNkMzNmNWM0NGQxZThmODFiNmQ4ZjFkNGQ4N2JfMy03LTEtMS0xNTk1NDA_37b2118d-2c3f-47df-bac7-c96fca7f5488">11,635.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i812f3d20a1af4d92924e0bbe1371c71e_D20220701-20220930" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjE3ZWUzZDMzZjVjNDRkMWU4ZjgxYjZkOGYxZDRkODdiL3RhYmxlcmFuZ2U6MTdlZTNkMzNmNWM0NGQxZThmODFiNmQ4ZjFkNGQ4N2JfNC0xLTEtMS0xNTk1NDA_b35a54cb-bbc5-4a76-9c86-7b2a5f8b3a0a">1,056.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i973b61d370734fa5bcf42303b4a667df_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjE3ZWUzZDMzZjVjNDRkMWU4ZjgxYjZkOGYxZDRkODdiL3RhYmxlcmFuZ2U6MTdlZTNkMzNmNWM0NGQxZThmODFiNmQ4ZjFkNGQ4N2JfNC0zLTEtMS0xNTk1NDA_04403aaa-5c93-4628-a577-8849b48afedf">1,098.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cf771cc163e44ed8acdd62a65cc8b4c_D20220101-20220930" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjE3ZWUzZDMzZjVjNDRkMWU4ZjgxYjZkOGYxZDRkODdiL3RhYmxlcmFuZ2U6MTdlZTNkMzNmNWM0NGQxZThmODFiNmQ4ZjFkNGQ4N2JfNC01LTEtMS0xNTk1NDA_b1a7b8e1-f2d1-453c-a420-adcba0497d55">3,224.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0ffca9720f342dbbe64a17e04c55d84_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjE3ZWUzZDMzZjVjNDRkMWU4ZjgxYjZkOGYxZDRkODdiL3RhYmxlcmFuZ2U6MTdlZTNkMzNmNWM0NGQxZThmODFiNmQ4ZjFkNGQ4N2JfNC03LTEtMS0xNTk1NDA_1b417717-307e-4f96-9ed7-20094b2b2832">3,629.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib92bd7160fd94961b7bba02ffbd18490_D20220701-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjE3ZWUzZDMzZjVjNDRkMWU4ZjgxYjZkOGYxZDRkODdiL3RhYmxlcmFuZ2U6MTdlZTNkMzNmNWM0NGQxZThmODFiNmQ4ZjFkNGQ4N2JfNS0xLTEtMS0xNTk1NDA_2c9f2b01-887f-4033-a1da-91eb83104354">487.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25019079a8464a91a3cf96012fcc0d52_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjE3ZWUzZDMzZjVjNDRkMWU4ZjgxYjZkOGYxZDRkODdiL3RhYmxlcmFuZ2U6MTdlZTNkMzNmNWM0NGQxZThmODFiNmQ4ZjFkNGQ4N2JfNS0zLTEtMS0xNTk1NDA_52023aa9-af64-4fa6-bb1e-90562938225e">595.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib37e987842e2478dab07f58a5f789a49_D20220101-20220930" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjE3ZWUzZDMzZjVjNDRkMWU4ZjgxYjZkOGYxZDRkODdiL3RhYmxlcmFuZ2U6MTdlZTNkMzNmNWM0NGQxZThmODFiNmQ4ZjFkNGQ4N2JfNS01LTEtMS0xNTk1NDA_c5edc270-7a0d-4379-8d2e-7b30cb33a916">1,352.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9ff4ce3b7704faaa359e30df99f2b54_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjE3ZWUzZDMzZjVjNDRkMWU4ZjgxYjZkOGYxZDRkODdiL3RhYmxlcmFuZ2U6MTdlZTNkMzNmNWM0NGQxZThmODFiNmQ4ZjFkNGQ4N2JfNS03LTEtMS0xNTk1NDA_648df1d2-ec98-483e-9066-e540213dc338">1,832.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic678bb62bdef4faea88b4e3dfd6a7971_D20220701-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjE3ZWUzZDMzZjVjNDRkMWU4ZjgxYjZkOGYxZDRkODdiL3RhYmxlcmFuZ2U6MTdlZTNkMzNmNWM0NGQxZThmODFiNmQ4ZjFkNGQ4N2JfNi0xLTEtMS0xNTk1NDA_481185cb-e19d-4fe4-9b55-f335452f974b">343.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib648672815904a56b3a3874c085884b6_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjE3ZWUzZDMzZjVjNDRkMWU4ZjgxYjZkOGYxZDRkODdiL3RhYmxlcmFuZ2U6MTdlZTNkMzNmNWM0NGQxZThmODFiNmQ4ZjFkNGQ4N2JfNi0zLTEtMS0xNTk1NDA_c0605c90-d2c2-493f-ac20-eb22c98cfa57">400.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id085508ee8c24a36a655eea7d3096500_D20220101-20220930" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjE3ZWUzZDMzZjVjNDRkMWU4ZjgxYjZkOGYxZDRkODdiL3RhYmxlcmFuZ2U6MTdlZTNkMzNmNWM0NGQxZThmODFiNmQ4ZjFkNGQ4N2JfNi01LTEtMS0xNTk1NDA_c7458d53-fe69-44d1-8ba0-43882a9d94df">1,102.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b2b1ef297534a4a801da2637a1d37e4_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjE3ZWUzZDMzZjVjNDRkMWU4ZjgxYjZkOGYxZDRkODdiL3RhYmxlcmFuZ2U6MTdlZTNkMzNmNWM0NGQxZThmODFiNmQ4ZjFkNGQ4N2JfNi03LTEtMS0xNTk1NDA_f8ffdb9e-a949-4c29-b9af-516ea72b450d">1,285.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other foreign countries</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2c80ff08a384ec7a8c6dd07798b9efd_D20220701-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjE3ZWUzZDMzZjVjNDRkMWU4ZjgxYjZkOGYxZDRkODdiL3RhYmxlcmFuZ2U6MTdlZTNkMzNmNWM0NGQxZThmODFiNmQ4ZjFkNGQ4N2JfNy0xLTEtMS0xNTk1NDA_5e100b96-21c6-4c0d-a597-de4acdab4d52">632.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59dcfcfb04c94ad588f473c50147a921_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjE3ZWUzZDMzZjVjNDRkMWU4ZjgxYjZkOGYxZDRkODdiL3RhYmxlcmFuZ2U6MTdlZTNkMzNmNWM0NGQxZThmODFiNmQ4ZjFkNGQ4N2JfNy0zLTEtMS0xNTk1NDA_a945ddd6-e144-4647-b9ec-0127f970c063">689.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20e09a0b7eb34ffbbc4057f306b92c3d_D20220101-20220930" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjE3ZWUzZDMzZjVjNDRkMWU4ZjgxYjZkOGYxZDRkODdiL3RhYmxlcmFuZ2U6MTdlZTNkMzNmNWM0NGQxZThmODFiNmQ4ZjFkNGQ4N2JfNy01LTEtMS0xNTk1NDA_e2d90996-5bac-4bb9-9b36-f894c73a19c7">2,029.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c8b51c823f54bb1a2efb0592f5476a3_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjE3ZWUzZDMzZjVjNDRkMWU4ZjgxYjZkOGYxZDRkODdiL3RhYmxlcmFuZ2U6MTdlZTNkMzNmNWM0NGQxZThmODFiNmQ4ZjFkNGQ4N2JfNy03LTEtMS0xNTk1NDA_6e30a109-699d-47f3-9c3d-9590872718f6">1,936.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19fc0325c48543008ea71e1fdcf11d86_D20220701-20220930" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjE3ZWUzZDMzZjVjNDRkMWU4ZjgxYjZkOGYxZDRkODdiL3RhYmxlcmFuZ2U6MTdlZTNkMzNmNWM0NGQxZThmODFiNmQ4ZjFkNGQ4N2JfOC0xLTEtMS0xNTk1NDA_f8f0b6e6-9cba-4307-b2be-39893593c9fb">6,941.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4fa4f6b472a4f269297591b44aba572_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjE3ZWUzZDMzZjVjNDRkMWU4ZjgxYjZkOGYxZDRkODdiL3RhYmxlcmFuZ2U6MTdlZTNkMzNmNWM0NGQxZThmODFiNmQ4ZjFkNGQ4N2JfOC0zLTEtMS0xNTk1NDA_326ddb93-9840-4cb9-b7ef-3ca94ed85232">6,772.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjE3ZWUzZDMzZjVjNDRkMWU4ZjgxYjZkOGYxZDRkODdiL3RhYmxlcmFuZ2U6MTdlZTNkMzNmNWM0NGQxZThmODFiNmQ4ZjFkNGQ4N2JfOC01LTEtMS0xNTk1NDA_bf893bbf-e7c6-4f13-917f-b0ac4b0ab7f0">21,239.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i167ed8f67bef48c49e54fa466400cdaa_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjE3ZWUzZDMzZjVjNDRkMWU4ZjgxYjZkOGYxZDRkODdiL3RhYmxlcmFuZ2U6MTdlZTNkMzNmNWM0NGQxZThmODFiNmQ4ZjFkNGQ4N2JfOC03LTEtMS0xNTk1NDA_a2778e51-db16-45da-907f-c4e990974baf">20,318.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Numbers may not add due to rounding.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Revenue is attributed to the countries based on the location of the customer.</span></div></ix:continuation></ix:continuation><div style="margin-top:6pt"><span><br/></span></div><div id="i5fed483d9c7e4f3cbba3a62c53226cd7_49"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note&#160;3:&#160;<ix:nonNumeric contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930" name="us-gaap:AssetAcquisitionTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180OS9mcmFnOmVkZDg1Zjg2YWYyNjQ0MGU5ZWZhMDdiM2U3YmE5ODY0L3RleHRyZWdpb246ZWRkODVmODZhZjI2NDQwZTllZmEwN2IzZTdiYTk4NjRfNTM4OA_9c9d5dc2-2183-457b-ba18-d6a3c679b6a2" continuedAt="ic4a6a0b7b6854ae39bc00c0e3afbf068" escape="true"><ix:nonNumeric contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930" name="us-gaap:BusinessCombinationDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180OS9mcmFnOmVkZDg1Zjg2YWYyNjQ0MGU5ZWZhMDdiM2U3YmE5ODY0L3RleHRyZWdpb246ZWRkODVmODZhZjI2NDQwZTllZmEwN2IzZTdiYTk4NjRfNTM4OA_b088c754-96b4-4a83-8614-5eba5465b419" continuedAt="i332885803b5f46c8bd7bc737b6c88549" escape="true">Acquisitions</ix:nonNumeric></ix:nonNumeric></span></div><ix:continuation id="ic4a6a0b7b6854ae39bc00c0e3afbf068" continuedAt="i79ca4b26995a420b9671af6ce640942b"><ix:continuation id="i332885803b5f46c8bd7bc737b6c88549" continuedAt="ida4a1d9320294c6c802da257ee40cd25"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We engage in various forms of business development activities to enhance our product pipeline, including acquisitions, collaborations, investments, and licensing arrangements. In connection with these arrangements, our partners may be entitled to future royalties and/or commercial milestones based on sales should products be approved for commercialization and/or milestones based on the successful progress of compounds through the development process.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, we completed the acquisition of Prevail Therapeutics Inc. (Prevail). This transaction, as further discussed below in Acquisition of a Business, was accounted for as a business combination under the acquisition method of accounting. <ix:nonNumeric contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930" name="us-gaap:BusinessCombinationsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180OS9mcmFnOmVkZDg1Zjg2YWYyNjQ0MGU5ZWZhMDdiM2U3YmE5ODY0L3RleHRyZWdpb246ZWRkODVmODZhZjI2NDQwZTllZmEwN2IzZTdiYTk4NjRfNTM4Mg_566b54f7-348e-45d8-adfd-16d9cd26da4c" continuedAt="i85d462e013914613971ca6381af3c5a7" escape="true">Under this method, the assets acquired and liabilities assumed were recorded at their respective fair values as of the acquisition date in our consolidated condensed financial statements. The determination of estimated fair value required management to make significant estimates and assumptions. The excess of the purchase price over the fair value of the acquired net assets, where applicable, has been recorded as goodwill. The results of operations of this acquisition is included in our consolidated condensed financial statements from the date of acquisition.</ix:nonNumeric></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also acquired assets in development which are further discussed below in Asset Acquisitions. <ix:continuation id="i85d462e013914613971ca6381af3c5a7">Upon each acquisition, the cost allocated to acquired IPR&amp;D is immediately expensed if the compound has no alternative future use. Milestone payment obligations incurred prior to regulatory approval of the compound are expensed when the event triggering an obligation to pay the milestone occurs.</ix:continuation> We recognized acquired IPR&amp;D and development milestone charges of $<ix:nonFraction unitRef="usd" contextRef="i19fc0325c48543008ea71e1fdcf11d86_D20220701-20220930" decimals="-5" name="lly:AcquiredInProcessResearchAndDevelopmentAndDevelopmentMilestones" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180OS9mcmFnOmVkZDg1Zjg2YWYyNjQ0MGU5ZWZhMDdiM2U3YmE5ODY0L3RleHRyZWdpb246ZWRkODVmODZhZjI2NDQwZTllZmEwN2IzZTdiYTk4NjRfMTc1NQ_8b459b38-3dde-4b01-86a3-b90670ef8e72">62.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930" decimals="-5" name="lly:AcquiredInProcessResearchAndDevelopmentAndDevelopmentMilestones" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180OS9mcmFnOmVkZDg1Zjg2YWYyNjQ0MGU5ZWZhMDdiM2U3YmE5ODY0L3RleHRyZWdpb246ZWRkODVmODZhZjI2NDQwZTllZmEwN2IzZTdiYTk4NjRfMTc2Mg_814d2bcb-fad1-4171-8df7-5bf614293fde">668.4</ix:nonFraction> million for the three and nine months ended September&#160;30, 2022, respectively, and $<ix:nonFraction unitRef="usd" contextRef="ie4fa4f6b472a4f269297591b44aba572_D20210701-20210930" decimals="-5" name="lly:AcquiredInProcessResearchAndDevelopmentAndDevelopmentMilestones" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180OS9mcmFnOmVkZDg1Zjg2YWYyNjQ0MGU5ZWZhMDdiM2U3YmE5ODY0L3RleHRyZWdpb246ZWRkODVmODZhZjI2NDQwZTllZmEwN2IzZTdiYTk4NjRfMTgxMQ_930acb16-c7a4-46f2-b4ec-0c4ce1d82bd4">177.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i167ed8f67bef48c49e54fa466400cdaa_D20210101-20210930" decimals="-5" name="lly:AcquiredInProcessResearchAndDevelopmentAndDevelopmentMilestones" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180OS9mcmFnOmVkZDg1Zjg2YWYyNjQ0MGU5ZWZhMDdiM2U3YmE5ODY0L3RleHRyZWdpb246ZWRkODVmODZhZjI2NDQwZTllZmEwN2IzZTdiYTk4NjRfMTgxOA_08faa181-0763-4f6c-9031-a7e1539d6611">532.4</ix:nonFraction> million for the three and nine months ended September&#160;30, 2021, respectively. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Acquisition of a Business</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Prevail Acquisition</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Overview of Transaction</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, we acquired all shares of Prevail for a purchase price that included $<ix:nonFraction unitRef="usdPerShare" contextRef="id1a51594b8b04df48cf5b7eff20f7e6d_I20210131" decimals="INF" name="us-gaap:BusinessAcquisitionSharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180OS9mcmFnOmVkZDg1Zjg2YWYyNjQ0MGU5ZWZhMDdiM2U3YmE5ODY0L3RleHRyZWdpb246ZWRkODVmODZhZjI2NDQwZTllZmEwN2IzZTdiYTk4NjRfMjAyMA_6f244deb-9d0b-474c-99fb-f51b8fffa448">22.50</ix:nonFraction> per share in cash (or an aggregate of $<ix:nonFraction unitRef="usd" contextRef="i28f89248cda04bd08a5c9d722de7c1db_D20210101-20210131" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180OS9mcmFnOmVkZDg1Zjg2YWYyNjQ0MGU5ZWZhMDdiM2U3YmE5ODY0L3RleHRyZWdpb246ZWRkODVmODZhZjI2NDQwZTllZmEwN2IzZTdiYTk4NjRfMjA2MQ_645d971d-3cd1-4fdc-87fb-8e286f6e284c">747.4</ix:nonFraction>&#160;million, net of cash acquired) plus <ix:nonFraction unitRef="right" contextRef="i28f89248cda04bd08a5c9d722de7c1db_D20210101-20210131" decimals="INF" name="lly:BusinessCombinationConsiderationTransferredNumberOfContingentValueRights" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180OS9mcmFnOmVkZDg1Zjg2YWYyNjQ0MGU5ZWZhMDdiM2U3YmE5ODY0L3RleHRyZWdpb246ZWRkODVmODZhZjI2NDQwZTllZmEwN2IzZTdiYTk4NjRfMjA5Mg_aa7d0c8c-64b4-4d7e-82ae-bd200b947af6">one</ix:nonFraction> non-tradable contingent value right (CVR) per share. The CVR entitles Prevail stockholders up to an additional $<ix:nonFraction unitRef="usdPerShare" contextRef="id1a51594b8b04df48cf5b7eff20f7e6d_I20210131" decimals="INF" name="lly:BusinessAcquisitionContingentValueRightAdditionalPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180OS9mcmFnOmVkZDg1Zjg2YWYyNjQ0MGU5ZWZhMDdiM2U3YmE5ODY0L3RleHRyZWdpb246ZWRkODVmODZhZjI2NDQwZTllZmEwN2IzZTdiYTk4NjRfMjIwNg_f4c96899-c61c-4e25-9cbc-4d4b5a039966">4.00</ix:nonFraction> per share in cash (or an aggregate of approximately $<ix:nonFraction unitRef="usd" contextRef="id1a51594b8b04df48cf5b7eff20f7e6d_I20210131" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180OS9mcmFnOmVkZDg1Zjg2YWYyNjQ0MGU5ZWZhMDdiM2U3YmE5ODY0L3RleHRyZWdpb246ZWRkODVmODZhZjI2NDQwZTllZmEwN2IzZTdiYTk4NjRfMjI2MQ_933609d8-ce89-48bc-a35b-0ffd528363ad">160</ix:nonFraction>&#160;million) payable, subject to certain terms and conditions, upon the first regulatory approval of a Prevail product in one of the following countries: U.S., Japan, United Kingdom, Germany, France, Italy, or Spain. To achieve the full value of the CVR, such regulatory approval must occur by December 31, 2024. If such regulatory approval occurs after December 31, 2024, the value of the CVR will be reduced by approximately <ix:nonFraction unitRef="usdPerShare" contextRef="id1a51594b8b04df48cf5b7eff20f7e6d_I20210131" decimals="3" name="lly:BusinessAcquisitionContingentValueRightRegulatoryApprovalDelayMonthlyReduction" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180OS9mcmFnOmVkZDg1Zjg2YWYyNjQ0MGU5ZWZhMDdiM2U3YmE5ODY0L3RleHRyZWdpb246ZWRkODVmODZhZjI2NDQwZTllZmEwN2IzZTdiYTk4NjRfMjY3OA_690a7673-9b2f-4993-87ad-3dbbf8c0e150">8.3</ix:nonFraction> cents per month until December 1, 2028, at which point the CVR will expire without payment.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the agreement, we acquired potentially disease-modifying AAV9-based gene therapies for patients with neurodegenerative diseases. The acquisition established a new modality for drug discovery and development, extending our research efforts through the creation of a gene therapy program that is being anchored by Prevail's portfolio of assets. The lead gene therapies in clinical development that we acquired were PR001 for patients with Parkinson's disease with GBA1 mutations and neuronopathic Gaucher disease and PR006 for patients with frontotemporal dementia with GRN mutations. Both PR001 and PR006 were granted Fast Track designation from the U.S. Food and Drug Administration (FDA). </span></div></ix:continuation></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i79ca4b26995a420b9671af6ce640942b" continuedAt="if80b203fcde347c0938caeef136b6e9a"><ix:continuation id="ida4a1d9320294c6c802da257ee40cd25" continuedAt="iee6f84e6979e404791cade9f5002e52c"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Assets Acquired and Liabilities Assumed</span></div><ix:nonNumeric contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930" name="us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180OS9mcmFnOmVkZDg1Zjg2YWYyNjQ0MGU5ZWZhMDdiM2U3YmE5ODY0L3RleHRyZWdpb246ZWRkODVmODZhZjI2NDQwZTllZmEwN2IzZTdiYTk4NjRfNTM4Mw_44d6e0ee-dbf4-4a3a-b21c-845be5d49516" continuedAt="iae3d512978a044fabebff17c3aa0bb87" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the amounts recognized for assets acquired and liabilities assumed as of the acquisition date:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:79.016%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.784%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value at January 22, 2021</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6db4c7ca7af4463afc62347bd8b3a94_I20210122" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180OS9mcmFnOmVkZDg1Zjg2YWYyNjQ0MGU5ZWZhMDdiM2U3YmE5ODY0L3RhYmxlOjNlMDE0MGU5YTIxMjQ0NWJiMzljMWI4MWY2ZWIxMGY4L3RhYmxlcmFuZ2U6M2UwMTQwZTlhMjEyNDQ1YmIzOWMxYjgxZjZlYjEwZjhfMS0xLTEtMS0xNTk1NDA_58807b48-29be-4d10-a0b2-17298c13efaa">90.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired IPR&amp;D</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6db4c7ca7af4463afc62347bd8b3a94_I20210122" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180OS9mcmFnOmVkZDg1Zjg2YWYyNjQ0MGU5ZWZhMDdiM2U3YmE5ODY0L3RhYmxlOjNlMDE0MGU5YTIxMjQ0NWJiMzljMWI4MWY2ZWIxMGY4L3RhYmxlcmFuZ2U6M2UwMTQwZTlhMjEyNDQ1YmIzOWMxYjgxZjZlYjEwZjhfMi0xLTEtMS0xNTk1NDA_db4146de-1491-4d4a-bf18-705b2b325b85">824.0</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6db4c7ca7af4463afc62347bd8b3a94_I20210122" decimals="-5" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180OS9mcmFnOmVkZDg1Zjg2YWYyNjQ0MGU5ZWZhMDdiM2U3YmE5ODY0L3RhYmxlOjNlMDE0MGU5YTIxMjQ0NWJiMzljMWI4MWY2ZWIxMGY4L3RhYmxlcmFuZ2U6M2UwMTQwZTlhMjEyNDQ1YmIzOWMxYjgxZjZlYjEwZjhfMy0xLTEtMS0xNTk1NDA_7518ab8b-58df-47b7-b570-af626e5a5e5d">126.8</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie6db4c7ca7af4463afc62347bd8b3a94_I20210122" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180OS9mcmFnOmVkZDg1Zjg2YWYyNjQ0MGU5ZWZhMDdiM2U3YmE5ODY0L3RhYmxlOjNlMDE0MGU5YTIxMjQ0NWJiMzljMWI4MWY2ZWIxMGY4L3RhYmxlcmFuZ2U6M2UwMTQwZTlhMjEyNDQ1YmIzOWMxYjgxZjZlYjEwZjhfNC0xLTEtMS0xNTk1NDA_771f6ac2-5610-47c2-b998-3169ded53077">106.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets and liabilities, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie6db4c7ca7af4463afc62347bd8b3a94_I20210122" decimals="-5" sign="-" name="lly:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180OS9mcmFnOmVkZDg1Zjg2YWYyNjQ0MGU5ZWZhMDdiM2U3YmE5ODY0L3RhYmxlOjNlMDE0MGU5YTIxMjQ0NWJiMzljMWI4MWY2ZWIxMGY4L3RhYmxlcmFuZ2U6M2UwMTQwZTlhMjEyNDQ1YmIzOWMxYjgxZjZlYjEwZjhfNS0xLTEtMS0xNTk1NDA_a0484e4d-414f-48da-8763-6a56fbd2d0df">31.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition date fair value of consideration transferred </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6db4c7ca7af4463afc62347bd8b3a94_I20210122" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180OS9mcmFnOmVkZDg1Zjg2YWYyNjQ0MGU5ZWZhMDdiM2U3YmE5ODY0L3RhYmxlOjNlMDE0MGU5YTIxMjQ0NWJiMzljMWI4MWY2ZWIxMGY4L3RhYmxlcmFuZ2U6M2UwMTQwZTlhMjEyNDQ1YmIzOWMxYjgxZjZlYjEwZjhfNi0xLTEtMS0xNTk1NDA_0cc12a80-9b70-4f37-bd64-ec50299eb884">903.8</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash acquired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i10a5ee4bd0c64813b300c5389565a056_D20210122-20210122" decimals="-5" name="us-gaap:CashAcquiredFromAcquisition" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180OS9mcmFnOmVkZDg1Zjg2YWYyNjQ0MGU5ZWZhMDdiM2U3YmE5ODY0L3RhYmxlOjNlMDE0MGU5YTIxMjQ0NWJiMzljMWI4MWY2ZWIxMGY4L3RhYmxlcmFuZ2U6M2UwMTQwZTlhMjEyNDQ1YmIzOWMxYjgxZjZlYjEwZjhfOC0xLTEtMS0xNTk1NDA_1a79c54a-800b-454d-8e0f-bb3d3d9cf90e">90.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of CVR liability</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie6db4c7ca7af4463afc62347bd8b3a94_I20210122" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180OS9mcmFnOmVkZDg1Zjg2YWYyNjQ0MGU5ZWZhMDdiM2U3YmE5ODY0L3RhYmxlOjNlMDE0MGU5YTIxMjQ0NWJiMzljMWI4MWY2ZWIxMGY4L3RhYmxlcmFuZ2U6M2UwMTQwZTlhMjEyNDQ1YmIzOWMxYjgxZjZlYjEwZjhfOS0xLTEtMS0xNTk1NDA_cca5af70-b6b3-41a5-a994-fb0e3d134546">65.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid, net of cash acquired</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28f89248cda04bd08a5c9d722de7c1db_D20210101-20210131" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180OS9mcmFnOmVkZDg1Zjg2YWYyNjQ0MGU5ZWZhMDdiM2U3YmE5ODY0L3RhYmxlOjNlMDE0MGU5YTIxMjQ0NWJiMzljMWI4MWY2ZWIxMGY4L3RhYmxlcmFuZ2U6M2UwMTQwZTlhMjEyNDQ1YmIzOWMxYjgxZjZlYjEwZjhfMTAtMS0xLTEtMTU5NTQw_645d971d-3cd1-4fdc-87fb-8e286f6e284c">747.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Acquired IPR&amp;D intangibles primarily relate to PR001. In the third quarter of 2022, we impaired the intangible asset related to PR001. See Note 5 for additional information.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The goodwill recognized from this acquisition is not deductible for tax purposes. </span></div></ix:nonNumeric><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"><ix:continuation id="iae3d512978a044fabebff17c3aa0bb87" continuedAt="i2bebdf1948ef426997642cf00c12249f">(3) </ix:continuation></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:continuation id="i2bebdf1948ef426997642cf00c12249f">See Note 6 for a discussion on the estimation of the CVR liability.</ix:continuation> </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are unable to provide the results of operations for the three and nine months ended September&#160;30, 2022 and 2021 attributable to Prevail as those operations were substantially integrated into our legacy business.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pro forma information has not been included as this acquisition did not have a material impact on our consolidated condensed statements of operations for the three and nine months ended September&#160;30, 2021.</span></div><div style="margin-top:6pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Asset Acquisitions</span></div><ix:nonNumeric contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930" name="us-gaap:ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180OS9mcmFnOmVkZDg1Zjg2YWYyNjQ0MGU5ZWZhMDdiM2U3YmE5ODY0L3RleHRyZWdpb246ZWRkODVmODZhZjI2NDQwZTllZmEwN2IzZTdiYTk4NjRfNTM5NA_05d2cd9a-ce90-45b6-8093-3723db29a26e" continuedAt="ic690359283f84e42bd0f9322b4d832c5" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our significant asset acquisitions during the nine months ended September&#160;30, 2022 and 2021:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:26.531%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.104%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.916%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Counterparty</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Compound(s), Therapy or Asset</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Acquisition Month</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Phase of Development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Acquired IPR&amp;D Expense</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BioMarin Pharmaceutical Inc.</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Priority Review Voucher</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Not applicable</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b190c0fcac94cb9b4d37191d35b87bb_D20220201-20220228" decimals="-5" name="lly:PaymentsForAssetAcquisitions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180OS9mcmFnOmVkZDg1Zjg2YWYyNjQ0MGU5ZWZhMDdiM2U3YmE5ODY0L3RhYmxlOmQzYjJkZDUwNzFlNzRiZTZhZWJmMGJhNWFlYjQ1YWQ0L3RhYmxlcmFuZ2U6ZDNiMmRkNTA3MWU3NGJlNmFlYmYwYmE1YWViNDVhZDRfMS02LTEtMS0xNTk1NDA_863e82e8-4b04-40e1-bf47-c8f31648e415">110.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rigel Pharmaceuticals, Inc.</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R552, a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor, for the potential treatment of autoimmune and inflammatory diseases</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase I</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa2b520f9b26403ca1dfc59f5150bb2a_D20210301-20210331" decimals="-5" name="lly:PaymentsForAssetAcquisitions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180OS9mcmFnOmVkZDg1Zjg2YWYyNjQ0MGU5ZWZhMDdiM2U3YmE5ODY0L3RhYmxlOmQzYjJkZDUwNzFlNzRiZTZhZWJmMGJhNWFlYjQ1YWQ0L3RhYmxlcmFuZ2U6ZDNiMmRkNTA3MWU3NGJlNmFlYmYwYmE1YWViNDVhZDRfMy02LTEtMS0xNTk1NDA_ae271ce7-8708-4774-a62a-edc05567b11c">125.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Precision Biosciences, Inc. </span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Potential in vivo therapies for genetic disorders</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2021</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a70d59a929b499ca4d9201b21544293_D20210101-20210131" decimals="-5" name="lly:PaymentsForAssetAcquisitions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180OS9mcmFnOmVkZDg1Zjg2YWYyNjQ0MGU5ZWZhMDdiM2U3YmE5ODY0L3RhYmxlOmQzYjJkZDUwNzFlNzRiZTZhZWJmMGJhNWFlYjQ1YWQ0L3RhYmxlcmFuZ2U6ZDNiMmRkNTA3MWU3NGJlNmFlYmYwYmE1YWViNDVhZDRfNC02LTEtMS0xNTk1NDA_9765f2d6-d196-430b-9962-1014523454dd">107.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="padding-left:9pt;text-indent:-9pt"><ix:continuation id="ic690359283f84e42bd0f9322b4d832c5" continuedAt="i4d31b2f1b0134117bf6f5ffdac4e7b0e"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span></ix:continuation><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:continuation id="i4d31b2f1b0134117bf6f5ffdac4e7b0e">The phase of development presented is as of the date of the arrangement and represents the phase of development of the most advanced asset acquired, where applicable.</ix:continuation> </span></div><div style="padding-left:9pt;text-indent:-9pt"><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our acquisition of Petra Pharma Corporation (Petra), we were required to make milestone payments to Petra shareholders contingent upon the occurrence of certain future events linked to the success of the mutant-selective PI3K</span><span style="color:#000000;font-family:'Book Antiqua',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#945;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> inhibitor. In the second quarter of 2022, we entered into agreements with substantially all Petra shareholders to acquire their rights to receive any future milestone payments in exchange for a one-time payment. As a result of these agreements, we recognized a charge of $<ix:nonFraction unitRef="usd" contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930" decimals="-5" name="lly:PaymentsForAssetAcquisitions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180OS9mcmFnOmVkZDg1Zjg2YWYyNjQ0MGU5ZWZhMDdiM2U3YmE5ODY0L3RleHRyZWdpb246ZWRkODVmODZhZjI2NDQwZTllZmEwN2IzZTdiYTk4NjRfNTA2NA_becd547d-bff8-40b6-8fcd-5b41bf6b3d7b">333.8</ix:nonFraction>&#160;million as a development milestone during the nine months ended September&#160;30, 2022. Any remaining contingent milestones payments linked to the success of the mutant-selective PI3K&#945; are not expected to be material. We recognized no other significant development milestones during the three and nine months ended September&#160;30, 2022 and 2021.</span></div></ix:continuation></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:continuation id="if80b203fcde347c0938caeef136b6e9a" continuedAt="i6bfdb0d50a4342a1bf004caaee3991cd"><ix:continuation id="iee6f84e6979e404791cade9f5002e52c" continuedAt="i5392492144ef471382a6490f6b4ea5c0">Subsequent Event - Akouos, Inc. (Akouos) Acquisition</ix:continuation></ix:continuation></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i6bfdb0d50a4342a1bf004caaee3991cd"><ix:continuation id="i5392492144ef471382a6490f6b4ea5c0">On October 17, 2022, we entered into a definitive agreement to acquire Akouos. Pursuant to the terms of the agreement, we have commenced a tender offer to acquire all outstanding shares of Akouos for a purchase price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ieacc700b698842408fe2f8c736054aa3_I20221231" decimals="INF" name="us-gaap:BusinessAcquisitionSharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180OS9mcmFnOmVkZDg1Zjg2YWYyNjQ0MGU5ZWZhMDdiM2U3YmE5ODY0L3RleHRyZWdpb246ZWRkODVmODZhZjI2NDQwZTllZmEwN2IzZTdiYTk4NjRfMzI5ODUzNDg5NTU2MA_dea851e6-3eb9-4e84-ab22-60afe15d8fd4">12.50</ix:nonFraction> per share in cash (an aggregate of approximately $<ix:nonFraction unitRef="usd" contextRef="i7d940f045f1243808212f82e48b91487_D20221001-20221231" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180OS9mcmFnOmVkZDg1Zjg2YWYyNjQ0MGU5ZWZhMDdiM2U3YmE5ODY0L3RleHRyZWdpb246ZWRkODVmODZhZjI2NDQwZTllZmEwN2IzZTdiYTk4NjRfMzI5ODUzNDg5NTU2OA_48817f80-3aff-4262-bb7f-9452924fa23c">487</ix:nonFraction>&#160;million), payable at closing, plus <ix:nonFraction unitRef="right" contextRef="i7d940f045f1243808212f82e48b91487_D20221001-20221231" decimals="INF" name="lly:BusinessCombinationConsiderationTransferredNumberOfContingentValueRights" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180OS9mcmFnOmVkZDg1Zjg2YWYyNjQ0MGU5ZWZhMDdiM2U3YmE5ODY0L3RleHRyZWdpb246ZWRkODVmODZhZjI2NDQwZTllZmEwN2IzZTdiYTk4NjRfMzI5ODUzNDg5NTYwMg_a6298565-022d-4050-befe-0451b3175c02">one</ix:nonFraction> non-tradable CVR per share that will entitle the holder to receive up to an additional $<ix:nonFraction unitRef="usdPerShare" contextRef="ieacc700b698842408fe2f8c736054aa3_I20221231" decimals="INF" name="lly:BusinessAcquisitionContingentValueRightAdditionalPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180OS9mcmFnOmVkZDg1Zjg2YWYyNjQ0MGU5ZWZhMDdiM2U3YmE5ODY0L3RleHRyZWdpb246ZWRkODVmODZhZjI2NDQwZTllZmEwN2IzZTdiYTk4NjRfMzI5ODUzNDg5NTU4Mg_7f4c5933-1d83-45f0-bc0a-3a778944d759">3.00</ix:nonFraction> per CVR in cash (an aggregate of up to approximately $<ix:nonFraction unitRef="usd" contextRef="ieacc700b698842408fe2f8c736054aa3_I20221231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180OS9mcmFnOmVkZDg1Zjg2YWYyNjQ0MGU5ZWZhMDdiM2U3YmE5ODY0L3RleHRyZWdpb246ZWRkODVmODZhZjI2NDQwZTllZmEwN2IzZTdiYTk4NjRfMzI5ODUzNDg5NTU4OQ_428d1249-58fb-4a3b-8759-3f6d0b0315b5">123</ix:nonFraction>&#160;million) upon the achievement of certain specified milestones. The acquisition will expand our gene therapy portfolio to include potential treatments for hearing loss and other inner ear conditions. The acquisition is not subject to any financing condition and is expected to close in the fourth quarter of 2022, subject to customary closing conditions, including receipt of required antitrust clearance and the tender of a majority of the outstanding shares of Akouos's common stock.</ix:continuation></ix:continuation> </span></div><div style="margin-top:6pt"><span><br/></span></div><div id="i5fed483d9c7e4f3cbba3a62c53226cd7_52"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 4: <ix:nonNumeric contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN181Mi9mcmFnOmIxNmQ0YjlkMmM5MzQ4ODZiZjM3YTgxYThjM2FiODM0L3RleHRyZWdpb246YjE2ZDRiOWQyYzkzNDg4NmJmMzdhODFhOGMzYWI4MzRfMTA3NTc_2f88cd9c-8e4f-4d20-88b6-307bd28c5de8" continuedAt="i42589800df9b409f80be60e460bea592" escape="true">Collaborations and Other Arrangements</ix:nonNumeric></span></div><ix:continuation id="i42589800df9b409f80be60e460bea592" continuedAt="i37308c9518cf4ab5bd2f67e52edd2bbd"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We often enter into collaborative and other similar arrangements to develop and commercialize drug candidates. Collaborative activities may include research and development, marketing and selling (including promotional activities and physician detailing), manufacturing, and distribution. These arrangements often require milestone as well as royalty or profit-share payments, contingent upon the occurrence of certain future events linked to the success of the asset in development, as well as expense reimbursements from or payments to the collaboration partner. See Note 2 for amounts of collaboration and other revenue recognized from these types of arrangements. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating expenses for costs incurred pursuant to these arrangements are reported in their respective expense line item, net of any payments due to or reimbursements due from our collaboration partners, with such reimbursements being recognized at the time the party becomes obligated to pay. Each collaboration is unique in nature, and our more significant arrangements are discussed below. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Boehringer Ingelheim Diabetes Collaboration</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and Boehringer Ingelheim have a global agreement to jointly develop and commercialize a portfolio of diabetes compounds. Currently included in the collaboration are Boehringer Ingelheim's oral diabetes products: Jardiance, Glyxambi, Synjardy, Trijardy XR, Trajenta, and Jentadueto</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as well as our basal insulin, Basaglar. Glyxambi, Synjardy, and Trijardy XR are included in the Jardiance product family. Jentadueto is included in the Trajenta product family. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the regulatory approvals of Jardiance, Trajenta, and Basaglar in the U.S., Europe, and Japan, milestone payments made for Jardiance and Trajenta were capitalized as intangible assets and are being amortized to cost of sales, and milestone payments received for Basaglar were recorded as contract liabilities and are being amortized to collaboration and other revenue. The milestones pertaining to Jardiance and Trajenta are being amortized through their respective term under the collaboration, which, depending on country or region, is determined based on the latest to occur of (a) a defined number of years following launch date, (b) the expiration of the compound patent, or (c) the expiration of marketing authorization exclusivity. The milestones pertaining to Basaglar are being amortized through 2029. <ix:nonNumeric contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930" name="us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN181Mi9mcmFnOmIxNmQ0YjlkMmM5MzQ4ODZiZjM3YTgxYThjM2FiODM0L3RleHRyZWdpb246YjE2ZDRiOWQyYzkzNDg4NmJmMzdhODFhOGMzYWI4MzRfMTA3NDk_78f77876-c203-4d20-9203-7cacc98da862" continuedAt="i1768c6828f5b4a75bb4f355d4c46cc3a" escape="true">The table below summarizes the net milestones capitalized with respect to the Jardiance and Trajenta families of products and the net milestones deferred with respect to Basaglar as of September&#160;30, 2022 and December&#160;31, 2021: </ix:nonNumeric></span></div><ix:continuation id="i1768c6828f5b4a75bb4f355d4c46cc3a" continuedAt="i7885d94a1add4d3e9f555862d2649742"><div style="margin-top:6pt;padding-left:9pt;text-indent:-9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.812%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.443%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.445%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Milestones Capitalized (Deferred)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jardiance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if142129c01ca4ea0b352f378c8bc9899_I20220930" decimals="-5" name="lly:CollaborativeArrangementRightsAndObligationsRightsObligations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN181Mi9mcmFnOmIxNmQ0YjlkMmM5MzQ4ODZiZjM3YTgxYThjM2FiODM0L3RhYmxlOjA3MjlmMmMyMWEyNDQ2MGQ5NzIwYTI0ZDgwMzVhYmYxL3RhYmxlcmFuZ2U6MDcyOWYyYzIxYTI0NDYwZDk3MjBhMjRkODAzNWFiZjFfMi0xLTEtMS0xNTk1NDA_7c5f2ab0-39c4-4a24-a141-bc0fc8e243f1">121.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i744124019ee24c83852d6d07406b514c_I20211231" decimals="-5" name="lly:CollaborativeArrangementRightsAndObligationsRightsObligations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN181Mi9mcmFnOmIxNmQ0YjlkMmM5MzQ4ODZiZjM3YTgxYThjM2FiODM0L3RhYmxlOjA3MjlmMmMyMWEyNDQ2MGQ5NzIwYTI0ZDgwMzVhYmYxL3RhYmxlcmFuZ2U6MDcyOWYyYzIxYTI0NDYwZDk3MjBhMjRkODAzNWFiZjFfMi0yLTEtMS0xNTk1NDA_cfdca453-350a-48f7-982a-fcfe59c2edf4">136.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trajenta</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a19b281bf8a4f059256a5bba91d053c_I20220930" decimals="-5" name="lly:CollaborativeArrangementRightsAndObligationsRightsObligations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN181Mi9mcmFnOmIxNmQ0YjlkMmM5MzQ4ODZiZjM3YTgxYThjM2FiODM0L3RhYmxlOjA3MjlmMmMyMWEyNDQ2MGQ5NzIwYTI0ZDgwMzVhYmYxL3RhYmxlcmFuZ2U6MDcyOWYyYzIxYTI0NDYwZDk3MjBhMjRkODAzNWFiZjFfMy0xLTEtMS0xNTk1NDA_08154d56-bd1b-45a6-a7bf-04bae21e3727">69.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic00807c6a67343bd9b77d66d8f53542e_I20211231" decimals="-5" name="lly:CollaborativeArrangementRightsAndObligationsRightsObligations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN181Mi9mcmFnOmIxNmQ0YjlkMmM5MzQ4ODZiZjM3YTgxYThjM2FiODM0L3RhYmxlOjA3MjlmMmMyMWEyNDQ2MGQ5NzIwYTI0ZDgwMzVhYmYxL3RhYmxlcmFuZ2U6MDcyOWYyYzIxYTI0NDYwZDk3MjBhMjRkODAzNWFiZjFfMy0yLTEtMS0xNTk1NDA_79a754c3-684f-4b05-a429-21d6d2e535ed">88.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basaglar</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie2eb6b846c0e477a94f57d35ebf60943_I20220930" decimals="-5" sign="-" name="lly:CollaborativeArrangementRightsAndObligationsRightsObligations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN181Mi9mcmFnOmIxNmQ0YjlkMmM5MzQ4ODZiZjM3YTgxYThjM2FiODM0L3RhYmxlOjA3MjlmMmMyMWEyNDQ2MGQ5NzIwYTI0ZDgwMzVhYmYxL3RhYmxlcmFuZ2U6MDcyOWYyYzIxYTI0NDYwZDk3MjBhMjRkODAzNWFiZjFfNC0xLTEtMS0xNTk1NDA_cf91d070-eef0-44fa-a9b7-0169329da805">135.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib6657690bf5241ba82f0d73292ac9ea7_I20211231" decimals="-5" sign="-" name="lly:CollaborativeArrangementRightsAndObligationsRightsObligations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN181Mi9mcmFnOmIxNmQ0YjlkMmM5MzQ4ODZiZjM3YTgxYThjM2FiODM0L3RhYmxlOjA3MjlmMmMyMWEyNDQ2MGQ5NzIwYTI0ZDgwMzVhYmYxL3RhYmxlcmFuZ2U6MDcyOWYyYzIxYTI0NDYwZDk3MjBhMjRkODAzNWFiZjFfNC0yLTEtMS0xNTk1NDA_447b4005-69d8-40b2-94f4-db759d560cf3">149.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">This represents the amounts that have been capitalized (deferred) from the start of this collaboration through the end of the reporting period, net of amount amortized. </span></div></ix:continuation></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i37308c9518cf4ab5bd2f67e52edd2bbd" continuedAt="i1607506c39164692869697afa4f7ea2d"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the Jardiance product family, we and Boehringer Ingelheim share equally the ongoing development and commercialization costs in the most significant markets, and we record our portion of the development and commercialization costs as research and development expense and marketing, selling, and administrative expense, respectively. We receive a royalty on net sales of Boehringer Ingelheim's products in the most significant markets and recognize the royalty as collaboration and other revenue. Boehringer Ingelheim is entitled to potential performance payments depending on the net sales of the Jardiance product family; therefore, our reported revenue for Jardiance may be reduced by any potential performance payments we make related to this product family. The royalty received by us related to the Jardiance product family may also be increased or decreased depending on whether net sales for this product family exceed or fall below certain thresholds. We pay to Boehringer Ingelheim a royalty on net sales for Basaglar in the U.S. We record our sales of Basaglar to third parties as net product revenue with the royalty payments made to Boehringer Ingelheim recorded as cost of sales.</span></div><ix:continuation id="i7885d94a1add4d3e9f555862d2649742" continuedAt="if04031cc01bd4a95ac0b4852d726204a"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our collaboration and other revenue recognized with respect to the Jardiance and Trajenta families of products and net product revenue recognized with respect to Basaglar:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.613%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.206%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jardiance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfba5b60fbbe4370bad16f003f72e3c1_D20220701-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN181Mi9mcmFnOmIxNmQ0YjlkMmM5MzQ4ODZiZjM3YTgxYThjM2FiODM0L3RhYmxlOmRjNWFmNjFjMDJjNTQ2NDFhYjdkNjc3ODI1N2E5YzA0L3RhYmxlcmFuZ2U6ZGM1YWY2MWMwMmM1NDY0MWFiN2Q2Nzc4MjU3YTljMDRfMi0xLTEtMS0xNTk1NDA_4b4062e7-4dbf-476d-b7d9-c49ae88fb823">573.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia28641f7c767406eacaa8089e13a2e77_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN181Mi9mcmFnOmIxNmQ0YjlkMmM5MzQ4ODZiZjM3YTgxYThjM2FiODM0L3RhYmxlOmRjNWFmNjFjMDJjNTQ2NDFhYjdkNjc3ODI1N2E5YzA0L3RhYmxlcmFuZ2U6ZGM1YWY2MWMwMmM1NDY0MWFiN2Q2Nzc4MjU3YTljMDRfMi0zLTEtMS0xNTk1NDA_a6146567-ce3d-4baa-8cc0-7c8b22aba394">390.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c01691865ed49fc84902886c99bbbdf_D20220101-20220930" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN181Mi9mcmFnOmIxNmQ0YjlkMmM5MzQ4ODZiZjM3YTgxYThjM2FiODM0L3RhYmxlOmRjNWFmNjFjMDJjNTQ2NDFhYjdkNjc3ODI1N2E5YzA0L3RhYmxlcmFuZ2U6ZGM1YWY2MWMwMmM1NDY0MWFiN2Q2Nzc4MjU3YTljMDRfMi01LTEtMS0xNTk1NDA_cb373d45-18c4-40fb-bb86-e9d14a320f3a">1,453.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46099dfb95b0484ab5891f186d350f52_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN181Mi9mcmFnOmIxNmQ0YjlkMmM5MzQ4ODZiZjM3YTgxYThjM2FiODM0L3RhYmxlOmRjNWFmNjFjMDJjNTQ2NDFhYjdkNjc3ODI1N2E5YzA0L3RhYmxlcmFuZ2U6ZGM1YWY2MWMwMmM1NDY0MWFiN2Q2Nzc4MjU3YTljMDRfMi03LTEtMS0xNTk1NDA_70ca7508-c330-4dc2-95ef-5b171312bb25">1,058.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basaglar</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6f3b41d10de4dfb99b809554e15f4ca_D20220701-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN181Mi9mcmFnOmIxNmQ0YjlkMmM5MzQ4ODZiZjM3YTgxYThjM2FiODM0L3RhYmxlOmRjNWFmNjFjMDJjNTQ2NDFhYjdkNjc3ODI1N2E5YzA0L3RhYmxlcmFuZ2U6ZGM1YWY2MWMwMmM1NDY0MWFiN2Q2Nzc4MjU3YTljMDRfMy0xLTEtMS0xNTk1NDA_f5a63c3a-96cf-4c8e-978e-398f3ff81c82">193.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieef95d1c0c4643f8a5a104c9301c56f6_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN181Mi9mcmFnOmIxNmQ0YjlkMmM5MzQ4ODZiZjM3YTgxYThjM2FiODM0L3RhYmxlOmRjNWFmNjFjMDJjNTQ2NDFhYjdkNjc3ODI1N2E5YzA0L3RhYmxlcmFuZ2U6ZGM1YWY2MWMwMmM1NDY0MWFiN2Q2Nzc4MjU3YTljMDRfMy0zLTEtMS0xNTk1NDA_f749cbc3-4bf9-40a9-9045-7be859795e51">192.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f95ba5af9c24c3eb20dc2c5a3979588_D20220101-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN181Mi9mcmFnOmIxNmQ0YjlkMmM5MzQ4ODZiZjM3YTgxYThjM2FiODM0L3RhYmxlOmRjNWFmNjFjMDJjNTQ2NDFhYjdkNjc3ODI1N2E5YzA0L3RhYmxlcmFuZ2U6ZGM1YWY2MWMwMmM1NDY0MWFiN2Q2Nzc4MjU3YTljMDRfMy01LTEtMS0xNTk1NDA_11a1b9ff-2de8-493b-989f-355beeaf0e2b">558.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id065d1641c8b4bc19bda4f978edc7f70_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN181Mi9mcmFnOmIxNmQ0YjlkMmM5MzQ4ODZiZjM3YTgxYThjM2FiODM0L3RhYmxlOmRjNWFmNjFjMDJjNTQ2NDFhYjdkNjc3ODI1N2E5YzA0L3RhYmxlcmFuZ2U6ZGM1YWY2MWMwMmM1NDY0MWFiN2Q2Nzc4MjU3YTljMDRfMy03LTEtMS0xNTk1NDA_ce835c8b-bb9d-4ca6-af69-991834fa4bc4">650.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trajenta</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91e1bea218144eab958a68c72b25b13d_D20220701-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN181Mi9mcmFnOmIxNmQ0YjlkMmM5MzQ4ODZiZjM3YTgxYThjM2FiODM0L3RhYmxlOmRjNWFmNjFjMDJjNTQ2NDFhYjdkNjc3ODI1N2E5YzA0L3RhYmxlcmFuZ2U6ZGM1YWY2MWMwMmM1NDY0MWFiN2Q2Nzc4MjU3YTljMDRfNC0xLTEtMS0xNTk1NDA_e1ddd021-8863-4d52-87c7-21043d1d2d01">103.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fe7212a81994bafa9e83b419cfb489f_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN181Mi9mcmFnOmIxNmQ0YjlkMmM5MzQ4ODZiZjM3YTgxYThjM2FiODM0L3RhYmxlOmRjNWFmNjFjMDJjNTQ2NDFhYjdkNjc3ODI1N2E5YzA0L3RhYmxlcmFuZ2U6ZGM1YWY2MWMwMmM1NDY0MWFiN2Q2Nzc4MjU3YTljMDRfNC0zLTEtMS0xNTk1NDA_38c0a24d-a730-4496-b8f8-5919446b8f00">96.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cbfd23e4f9c474bac8535d65c4695e8_D20220101-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN181Mi9mcmFnOmIxNmQ0YjlkMmM5MzQ4ODZiZjM3YTgxYThjM2FiODM0L3RhYmxlOmRjNWFmNjFjMDJjNTQ2NDFhYjdkNjc3ODI1N2E5YzA0L3RhYmxlcmFuZ2U6ZGM1YWY2MWMwMmM1NDY0MWFiN2Q2Nzc4MjU3YTljMDRfNC01LTEtMS0xNTk1NDA_63f9b6e9-36d6-40c9-bd8d-27168e12376d">293.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57c459014f2c4c2797423bd9e7eff879_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN181Mi9mcmFnOmIxNmQ0YjlkMmM5MzQ4ODZiZjM3YTgxYThjM2FiODM0L3RhYmxlOmRjNWFmNjFjMDJjNTQ2NDFhYjdkNjc3ODI1N2E5YzA0L3RhYmxlcmFuZ2U6ZGM1YWY2MWMwMmM1NDY0MWFiN2Q2Nzc4MjU3YTljMDRfNC03LTEtMS0xNTk1NDA_67e2a83d-773e-46af-90d5-440415a399aa">279.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div></ix:continuation><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Olumiant</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a worldwide license and collaboration agreement with Incyte Corporation (Incyte), which provides us the development and commercialization rights to baricitinib, branded and trademarked as Olumiant, and certain follow-on compounds, for the treatment of inflammatory and autoimmune diseases and COVID-19. Incyte has the right to receive tiered, double digit royalty payments on worldwide net sales with rates ranging up to <ix:nonFraction unitRef="number" contextRef="idfc0a5f22fb44537835f6510caaa9fa5_D20220101-20220930" decimals="2" name="lly:CollaborativeArrangementRightsAndObligationsPercent" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN181Mi9mcmFnOmIxNmQ0YjlkMmM5MzQ4ODZiZjM3YTgxYThjM2FiODM0L3RleHRyZWdpb246YjE2ZDRiOWQyYzkzNDg4NmJmMzdhODFhOGMzYWI4MzRfNDY4NQ_52dc7c2d-ce3b-484e-8820-da8deb37ac53">20</ix:nonFraction> percent. Incyte has the right to receive an additional royalty ranging up to the low teens on worldwide net sales for the treatment of COVID-19 that exceed a specified aggregate worldwide net sales threshold. The agreement calls for payments by us to Incyte associated with certain development, success-based regulatory, and sales-based milestones. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the regulatory approvals of Olumiant in the U.S., Europe, and Japan, as well as achievement of a sales-based milestone, milestone payments of $<ix:nonFraction unitRef="usd" contextRef="i46a25e2e10224815a8f7d26777b2eb48_I20220930" decimals="-5" name="lly:CollaborativeArrangementRightsAndObligationsRightsObligations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN181Mi9mcmFnOmIxNmQ0YjlkMmM5MzQ4ODZiZjM3YTgxYThjM2FiODM0L3RleHRyZWdpb246YjE2ZDRiOWQyYzkzNDg4NmJmMzdhODFhOGMzYWI4MzRfNTE5MQ_fa58c009-cddb-453c-b9ad-ccec3892dbd5">330.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i445e64ca4f7041e49970bead926a789e_I20211231" decimals="-5" name="lly:CollaborativeArrangementRightsAndObligationsRightsObligations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN181Mi9mcmFnOmIxNmQ0YjlkMmM5MzQ4ODZiZjM3YTgxYThjM2FiODM0L3RleHRyZWdpb246YjE2ZDRiOWQyYzkzNDg4NmJmMzdhODFhOGMzYWI4MzRfNTE5OA_d0840c62-9cc7-4622-b373-a0656d5f6900">260.0</ix:nonFraction> million were capitalized as intangible assets as of September&#160;30, 2022 and December&#160;31, 2021, respectively, and are being amortized to cost of sales through the term of the collaboration. This represents the cumulative amounts that have been capitalized from the start of this collaboration through the end of each reporting period.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2022, Incyte is eligible to receive up to $<ix:nonFraction unitRef="usd" contextRef="i97f0fe2e404740069df426fbe933ed1d_I20220930" decimals="-5" name="lly:CollaborativeArrangementRightsAndObligationsRightsObligations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN181Mi9mcmFnOmIxNmQ0YjlkMmM5MzQ4ODZiZjM3YTgxYThjM2FiODM0L3RleHRyZWdpb246YjE2ZDRiOWQyYzkzNDg4NmJmMzdhODFhOGMzYWI4MzRfNTU0MQ_dd7e39fd-0976-4f85-9a1c-db6ffbeaaf75">100.0</ix:nonFraction>&#160;million of additional payments from us in potential sales-based milestones.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record our sales of Olumiant, including sales of baricitinib that were made pursuant to EUA or similar regulatory authorizations, to third parties as net product revenue with the royalty payments made to Incyte recorded as cost of sales. <ix:continuation id="if04031cc01bd4a95ac0b4852d726204a" continuedAt="ib45ada16e894467ba256f4720108241b">The following table summarizes our net product revenue recognized with respect to Olumiant:</ix:continuation></span></div><div style="margin-top:6pt;text-align:center"><ix:continuation id="ib45ada16e894467ba256f4720108241b" continuedAt="i29d0279936634dd4a8516c55644e400d"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.613%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.206%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Olumiant</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65843c3594444a24be3c2dd715fb25e8_D20220701-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN181Mi9mcmFnOmIxNmQ0YjlkMmM5MzQ4ODZiZjM3YTgxYThjM2FiODM0L3RhYmxlOmJhZTliNGI0MzhjZjRjY2Y5MDE2NTI3M2YyOTlkNmUzL3RhYmxlcmFuZ2U6YmFlOWI0YjQzOGNmNGNjZjkwMTY1MjczZjI5OWQ2ZTNfMi0xLTEtMS0xNTk1NDA_257580ce-899d-4d9b-ab06-7b681acb7802">182.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i342e7e7b465546ffa22256042c6bf573_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN181Mi9mcmFnOmIxNmQ0YjlkMmM5MzQ4ODZiZjM3YTgxYThjM2FiODM0L3RhYmxlOmJhZTliNGI0MzhjZjRjY2Y5MDE2NTI3M2YyOTlkNmUzL3RhYmxlcmFuZ2U6YmFlOWI0YjQzOGNmNGNjZjkwMTY1MjczZjI5OWQ2ZTNfMi0zLTEtMS0xNTk1NDA_64568da7-872d-4490-bbf2-bebf62cdca4f">406.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5da2c0b8af014f4085d9e2a62f64ccc7_D20220101-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN181Mi9mcmFnOmIxNmQ0YjlkMmM5MzQ4ODZiZjM3YTgxYThjM2FiODM0L3RhYmxlOmJhZTliNGI0MzhjZjRjY2Y5MDE2NTI3M2YyOTlkNmUzL3RhYmxlcmFuZ2U6YmFlOWI0YjQzOGNmNGNjZjkwMTY1MjczZjI5OWQ2ZTNfMi01LTEtMS0xNTk1NDA_0df76049-ccad-4122-b1a1-eae0338220ed">624.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i681b00cc06e740d5afd240016ce29efc_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN181Mi9mcmFnOmIxNmQ0YjlkMmM5MzQ4ODZiZjM3YTgxYThjM2FiODM0L3RhYmxlOmJhZTliNGI0MzhjZjRjY2Y5MDE2NTI3M2YyOTlkNmUzL3RhYmxlcmFuZ2U6YmFlOWI0YjQzOGNmNGNjZjkwMTY1MjczZjI5OWQ2ZTNfMi03LTEtMS0xNTk1NDA_0e645580-44b6-4123-bb51-2c0d05b45c34">809.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i1607506c39164692869697afa4f7ea2d" continuedAt="ibad8abd71c984a5394a588f0ecc207a1"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COVID-19 Antibodies</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a worldwide license and collaboration agreement with AbCellera Biologics Inc. (AbCellera) to co-develop therapeutic antibodies for the potential prevention and treatment of COVID-19, including bamlanivimab and bebtelovimab, for which we hold development and commercialization rights. AbCellera has the right to receive tiered royalty payments on worldwide net sales of bamlanivimab and bebtelovimab with percentages ranging in the mid-teens to mid-twenties. Royalty payments made to AbCellera are recorded as cost of sales.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a license and collaboration agreement with Shanghai Junshi Biosciences Co., Ltd. (Junshi Biosciences) to co-develop therapeutic antibodies for the potential prevention and treatment of COVID-19, including etesevimab, for which we hold development and commercialization rights outside of mainland China and the Special Administrative Regions of Hong Kong and Macau, and for which Junshi Biosciences currently maintains all rights in mainland China and the Special Administrative Regions of Hong Kong and Macau. Junshi Biosciences has the right to receive royalty payments in the mid-teens on our net sales of etesevimab. Junshi Biosciences received certain development, success-based regulatory and sales-based milestones. Capitalized regulatory and sales-based milestones were fully amortized to cost of sales as of September&#160;30, 2022. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to EUAs or similar regulatory authorizations, we recognized net product revenue associated with our sales of our COVID-19 antibodies of $<ix:nonFraction unitRef="usd" contextRef="ic89265df487544d48f864b30c7c12762_D20220701-20220930" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN181Mi9mcmFnOmIxNmQ0YjlkMmM5MzQ4ODZiZjM3YTgxYThjM2FiODM0L3RleHRyZWdpb246YjE2ZDRiOWQyYzkzNDg4NmJmMzdhODFhOGMzYWI4MzRfNzE0NjgyNTU5MjY4OQ_84c24c47-9b52-4830-9028-647017123355">386.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ie674d270134f4cffaff8f7a15471b73e_D20220101-20220930" decimals="-7" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN181Mi9mcmFnOmIxNmQ0YjlkMmM5MzQ4ODZiZjM3YTgxYThjM2FiODM0L3RleHRyZWdpb246YjE2ZDRiOWQyYzkzNDg4NmJmMzdhODFhOGMzYWI4MzRfNzE0NjgyNTU5MjcwMg_2b20ced1-1fef-4ea4-92ae-675404e43394">1.99</ix:nonFraction> billion for the three and nine months ended September&#160;30, 2022, respectively, and $<ix:nonFraction unitRef="usd" contextRef="i05b4b2fd75f8488cafa80162074dca18_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN181Mi9mcmFnOmIxNmQ0YjlkMmM5MzQ4ODZiZjM3YTgxYThjM2FiODM0L3RleHRyZWdpb246YjE2ZDRiOWQyYzkzNDg4NmJmMzdhODFhOGMzYWI4MzRfNzUyOQ_68157132-4443-4e9f-95c1-d21929f2a3b7">217.1</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="ic06f11244a5a4b88822809b3b3941ffe_D20210101-20210930" decimals="-7" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN181Mi9mcmFnOmIxNmQ0YjlkMmM5MzQ4ODZiZjM3YTgxYThjM2FiODM0L3RleHRyZWdpb246YjE2ZDRiOWQyYzkzNDg4NmJmMzdhODFhOGMzYWI4MzRfNTQ5NzU1ODI2MDE4_ce62e567-a21b-4e98-8737-7351a6a6f471">1.18</ix:nonFraction> billion for the three and nine months ended September&#160;30, 2021, respectively. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Sintilimab Injection</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a collaboration agreement with Innovent Biologics, Inc. (Innovent) to jointly develop and commercialize sintilimab injection in China, where it is branded and trademarked as Tyvyt. In connection with regulatory approvals for Tyvyt in China, milestone payments of $<ix:nonFraction unitRef="usd" contextRef="ia361008dd9de45979f0de7611a5df845_I20220930" decimals="-5" name="lly:CollaborativeArrangementRightsAndObligationsRightsObligations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN181Mi9mcmFnOmIxNmQ0YjlkMmM5MzQ4ODZiZjM3YTgxYThjM2FiODM0L3RleHRyZWdpb246YjE2ZDRiOWQyYzkzNDg4NmJmMzdhODFhOGMzYWI4MzRfODI2Ng_4cea3fff-5730-4da4-817c-c951866d375d">120.0</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i9f82e7316ae6411ea23d0347aa8ad8db_I20211231" decimals="-5" name="lly:CollaborativeArrangementRightsAndObligationsRightsObligations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN181Mi9mcmFnOmIxNmQ0YjlkMmM5MzQ4ODZiZjM3YTgxYThjM2FiODM0L3RleHRyZWdpb246YjE2ZDRiOWQyYzkzNDg4NmJmMzdhODFhOGMzYWI4MzRfODI3Mw_7a723e72-ba2a-4889-8d0d-4b4545b3cbdf">40.0</ix:nonFraction>&#160;million were capitalized as intangible assets as of September&#160;30, 2022 and December&#160;31, 2021, respectively, and are being amortized to cost of sales through the term of the collaboration. This represents the cumulative amounts that have been capitalized from the start of this collaboration through the end of each reporting period. As of September&#160;30, 2022, Innovent is eligible to receive up to $<ix:nonFraction unitRef="usd" contextRef="i8e3c0bf77cd749d8b6fec828c354954b_I20220930" decimals="-5" name="lly:CollaborativeArrangementRightsAndObligationsRightsObligations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN181Mi9mcmFnOmIxNmQ0YjlkMmM5MzQ4ODZiZjM3YTgxYThjM2FiODM0L3RleHRyZWdpb246YjE2ZDRiOWQyYzkzNDg4NmJmMzdhODFhOGMzYWI4MzRfODY2NA_897e055d-5e0a-4dcc-a5a8-c57f56ac373d">115.0</ix:nonFraction>&#160;million in success-based regulatory and sales-based milestones.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record our sales of Tyvyt to third parties as net product revenue, with payments made to Innovent for its portion of the gross margin reported as cost of sales. We report as collaboration and other revenue our portion of the gross margin for Tyvyt sales made by Innovent to third parties. <ix:continuation id="i29d0279936634dd4a8516c55644e400d" continuedAt="i6347470199ed462697a9c005688aec57">The following table summarizes our revenue recognized in China with respect to Tyvyt:</ix:continuation></span></div><div style="margin-top:6pt;text-align:center"><ix:continuation id="i6347470199ed462697a9c005688aec57"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.613%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.206%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tyvyt</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc8fc5f6c1924a46b0d88ad7ea894f53_D20220701-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN181Mi9mcmFnOmIxNmQ0YjlkMmM5MzQ4ODZiZjM3YTgxYThjM2FiODM0L3RhYmxlOjhjZDYxOTA4MTdlMjQ4NmM4ZDkyNzRhNWFjMzE5MzY0L3RhYmxlcmFuZ2U6OGNkNjE5MDgxN2UyNDg2YzhkOTI3NGE1YWMzMTkzNjRfMi0xLTEtMS0xNTk1NDA_dffb5a95-e891-48a9-a689-abb5c7e30b8f">76.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9da960751fa245d8bf93fa1681ead439_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN181Mi9mcmFnOmIxNmQ0YjlkMmM5MzQ4ODZiZjM3YTgxYThjM2FiODM0L3RhYmxlOjhjZDYxOTA4MTdlMjQ4NmM4ZDkyNzRhNWFjMzE5MzY0L3RhYmxlcmFuZ2U6OGNkNjE5MDgxN2UyNDg2YzhkOTI3NGE1YWMzMTkzNjRfMi0zLTEtMS0xNTk1NDA_c37672f7-0a32-4eec-a93a-db53ea961956">125.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6633f1ca883b4a32962bcd825ba66bfc_D20220101-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN181Mi9mcmFnOmIxNmQ0YjlkMmM5MzQ4ODZiZjM3YTgxYThjM2FiODM0L3RhYmxlOjhjZDYxOTA4MTdlMjQ4NmM4ZDkyNzRhNWFjMzE5MzY0L3RhYmxlcmFuZ2U6OGNkNjE5MDgxN2UyNDg2YzhkOTI3NGE1YWMzMTkzNjRfMi01LTEtMS0xNTk1NDA_e0a86df6-6300-4357-90bd-48dc6a115ee0">235.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a42a2407e7046519687e4401e714180_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN181Mi9mcmFnOmIxNmQ0YjlkMmM5MzQ4ODZiZjM3YTgxYThjM2FiODM0L3RhYmxlOjhjZDYxOTA4MTdlMjQ4NmM4ZDkyNzRhNWFjMzE5MzY0L3RhYmxlcmFuZ2U6OGNkNjE5MDgxN2UyNDg2YzhkOTI3NGE1YWMzMTkzNjRfMi03LTEtMS0xNTk1NDA_035251c1-2596-483b-bfe5-5ec2455ef786">340.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, we obtained an exclusive license for sintilimab injection from Innovent for geographies outside of China, which was subsequently terminated and rights have reverted to Innovent in October 2022.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Lebrikizumab</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a worldwide license agreement with F. Hoffmann-La Roche Ltd and Genentech, Inc. (collectively, Roche), which provides us the worldwide development and commercialization rights to lebrikizumab. Roche has the right to receive tiered royalty payments on future worldwide net sales ranging in percentages from high single digits to high teens if the product is successfully commercialized. As of September&#160;30, 2022, Roche is eligible to receive up to $<ix:nonFraction unitRef="usd" contextRef="ic7d2b40b9fc943b9bfb247bb3c25f43f_I20220930" decimals="-5" name="lly:CollaborativeArrangementRightsAndObligationsRightsObligations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN181Mi9mcmFnOmIxNmQ0YjlkMmM5MzQ4ODZiZjM3YTgxYThjM2FiODM0L3RleHRyZWdpb246YjE2ZDRiOWQyYzkzNDg4NmJmMzdhODFhOGMzYWI4MzRfOTY3OQ_1dd06fe1-611c-4c8a-9fc1-0304b156891f">180.0</ix:nonFraction>&#160;million of payments from us contingent upon the achievement of success-based regulatory milestones and up to $<ix:nonFraction unitRef="usd" contextRef="id7f02cde7e1c419684772d2d99dda277_I20220930" decimals="-7" name="lly:CollaborativeArrangementRightsAndObligationsRightsObligations" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN181Mi9mcmFnOmIxNmQ0YjlkMmM5MzQ4ODZiZjM3YTgxYThjM2FiODM0L3RleHRyZWdpb246YjE2ZDRiOWQyYzkzNDg4NmJmMzdhODFhOGMzYWI4MzRfOTc4Mw_5b09a2e2-6a19-45bb-8c28-a89c6a5ad3d2">1.03</ix:nonFraction> billion in a series of sales-based milestones, contingent upon the commercial success of lebrikizumab.</span></div></ix:continuation><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ibad8abd71c984a5394a588f0ecc207a1">We have a license agreement with Almirall, S.A. (Almirall), under which Almirall licensed the rights to develop and commercialize lebrikizumab for the treatment or prevention of dermatology indications, including, but not limited to, atopic dermatitis in Europe. We have the right to receive tiered royalty payments on future net sales in Europe ranging in percentages from low double digits to low twenties if the product is successfully commercialized. As of September&#160;30, 2022, we are eligible to receive additional payments of $<ix:nonFraction unitRef="usd" contextRef="i9e48d839c4b14a2e953d735b3bb79f88_I20220930" decimals="-5" name="lly:CollaborativeArrangementRightsAndObligationsRightsObligations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN181Mi9mcmFnOmIxNmQ0YjlkMmM5MzQ4ODZiZjM3YTgxYThjM2FiODM0L3RleHRyZWdpb246YjE2ZDRiOWQyYzkzNDg4NmJmMzdhODFhOGMzYWI4MzRfMTAzOTY_abe0622e-8118-47c2-ae5e-fba10e22f7af">85.0</ix:nonFraction>&#160;million from Almirall contingent upon the achievement of success-based regulatory milestones and up to $<ix:nonFraction unitRef="usd" contextRef="id39a445d06074ecaa26735263645cb4e_I20220930" decimals="-7" name="lly:CollaborativeArrangementRightsAndObligationsRightsObligations" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN181Mi9mcmFnOmIxNmQ0YjlkMmM5MzQ4ODZiZjM3YTgxYThjM2FiODM0L3RleHRyZWdpb246YjE2ZDRiOWQyYzkzNDg4NmJmMzdhODFhOGMzYWI4MzRfMTA0OTQ_8f138dcc-b845-4cf3-b29f-ec17c2281664">1.25</ix:nonFraction>&#160;billion in a series of sales-based milestones, contingent upon the commercial success of lebrikizumab. There were <ix:nonFraction unitRef="usd" contextRef="iae28a429ac4b40e2a498a65c7eaaedc6_I20220930" decimals="INF" name="us-gaap:ContractWithCustomerLiability" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN181Mi9mcmFnOmIxNmQ0YjlkMmM5MzQ4ODZiZjM3YTgxYThjM2FiODM0L3RleHRyZWdpb246YjE2ZDRiOWQyYzkzNDg4NmJmMzdhODFhOGMzYWI4MzRfMzI5ODUzNDg5NTkzNQ_ef166288-ac09-4915-b8a3-ff370612e89e">no</ix:nonFraction> remaining contract liabilities as of September&#160;30, 2022. As of December&#160;31, 2021, contract liabilities were not material. During the three and nine months ended September&#160;30, 2022 and 2021, collaboration and other revenue recognized was not material.</ix:continuation> </span></div><div style="margin-top:6pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><div id="i5fed483d9c7e4f3cbba3a62c53226cd7_58"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 5: <ix:nonNumeric contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930" name="us-gaap:RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN181OC9mcmFnOjdhMjU0OTU2YzMzNTQ1Y2Y4M2YzNGQyMTZiNzAwM2IyL3RleHRyZWdpb246N2EyNTQ5NTZjMzM1NDVjZjgzZjM0ZDIxNmI3MDAzYjJfMTQ1OQ_36fb74c1-3feb-4aa2-a9d1-776a73faf563" continuedAt="icd765b037a83457d970e625a5f8d3f75" escape="true">Asset Impairment, Restructuring, and Other Special Charges</ix:nonNumeric></span></div><ix:continuation id="icd765b037a83457d970e625a5f8d3f75"><ix:nonNumeric contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930" name="us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN181OC9mcmFnOjdhMjU0OTU2YzMzNTQ1Y2Y4M2YzNGQyMTZiNzAwM2IyL3RleHRyZWdpb246N2EyNTQ5NTZjMzM1NDVjZjgzZjM0ZDIxNmI3MDAzYjJfMTQ2Mw_30eb621b-b403-49a9-b4f2-cf6793535fbf" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of the charges included in asset impairment, restructuring, and other special charges in our consolidated condensed statements of operations are described below. </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.613%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.206%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Severance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19fc0325c48543008ea71e1fdcf11d86_D20220701-20220930" decimals="-5" name="us-gaap:SeveranceCosts1" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN181OC9mcmFnOjdhMjU0OTU2YzMzNTQ1Y2Y4M2YzNGQyMTZiNzAwM2IyL3RhYmxlOjMzZWJjYzY5ZmUzMzQ5Njc4OTEwNTYwMGIxODAxOTNhL3RhYmxlcmFuZ2U6MzNlYmNjNjlmZTMzNDk2Nzg5MTA1NjAwYjE4MDE5M2FfMi0xLTEtMS0xNTk1NDA_380697ba-892c-49de-98d4-b56752660ac8">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4fa4f6b472a4f269297591b44aba572_D20210701-20210930" decimals="-5" name="us-gaap:SeveranceCosts1" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN181OC9mcmFnOjdhMjU0OTU2YzMzNTQ1Y2Y4M2YzNGQyMTZiNzAwM2IyL3RhYmxlOjMzZWJjYzY5ZmUzMzQ5Njc4OTEwNTYwMGIxODAxOTNhL3RhYmxlcmFuZ2U6MzNlYmNjNjlmZTMzNDk2Nzg5MTA1NjAwYjE4MDE5M2FfMi0zLTEtMS0xNTk1NDA_2782df8a-3172-459a-a984-388835739f8e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930" decimals="-5" name="us-gaap:SeveranceCosts1" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN181OC9mcmFnOjdhMjU0OTU2YzMzNTQ1Y2Y4M2YzNGQyMTZiNzAwM2IyL3RhYmxlOjMzZWJjYzY5ZmUzMzQ5Njc4OTEwNTYwMGIxODAxOTNhL3RhYmxlcmFuZ2U6MzNlYmNjNjlmZTMzNDk2Nzg5MTA1NjAwYjE4MDE5M2FfMi01LTEtMS0xNTk1NDA_4961dac5-007a-46db-9323-8f4e563cee79">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i167ed8f67bef48c49e54fa466400cdaa_D20210101-20210930" decimals="-5" name="us-gaap:SeveranceCosts1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN181OC9mcmFnOjdhMjU0OTU2YzMzNTQ1Y2Y4M2YzNGQyMTZiNzAwM2IyL3RhYmxlOjMzZWJjYzY5ZmUzMzQ5Njc4OTEwNTYwMGIxODAxOTNhL3RhYmxlcmFuZ2U6MzNlYmNjNjlmZTMzNDk2Nzg5MTA1NjAwYjE4MDE5M2FfMi03LTEtMS0xNTk1NDA_d03c8e32-2bdd-4e53-a743-aa601fb53597">11.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset impairment and other special charges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19fc0325c48543008ea71e1fdcf11d86_D20220701-20220930" decimals="-5" name="lly:AssetImpairmentChargesRecoveriesAndOtherSpecialCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN181OC9mcmFnOjdhMjU0OTU2YzMzNTQ1Y2Y4M2YzNGQyMTZiNzAwM2IyL3RhYmxlOjMzZWJjYzY5ZmUzMzQ5Njc4OTEwNTYwMGIxODAxOTNhL3RhYmxlcmFuZ2U6MzNlYmNjNjlmZTMzNDk2Nzg5MTA1NjAwYjE4MDE5M2FfMy0xLTEtMS0xNTk1NDA_c701641e-aa73-4776-9ea8-73bd44204eeb">206.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4fa4f6b472a4f269297591b44aba572_D20210701-20210930" decimals="-5" name="lly:AssetImpairmentChargesRecoveriesAndOtherSpecialCharges" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN181OC9mcmFnOjdhMjU0OTU2YzMzNTQ1Y2Y4M2YzNGQyMTZiNzAwM2IyL3RhYmxlOjMzZWJjYzY5ZmUzMzQ5Njc4OTEwNTYwMGIxODAxOTNhL3RhYmxlcmFuZ2U6MzNlYmNjNjlmZTMzNDk2Nzg5MTA1NjAwYjE4MDE5M2FfMy0zLTEtMS0xNTk1NDA_38836c07-2dc0-4a68-96b1-789c0ddce6d4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930" decimals="-5" name="lly:AssetImpairmentChargesRecoveriesAndOtherSpecialCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN181OC9mcmFnOjdhMjU0OTU2YzMzNTQ1Y2Y4M2YzNGQyMTZiNzAwM2IyL3RhYmxlOjMzZWJjYzY5ZmUzMzQ5Njc4OTEwNTYwMGIxODAxOTNhL3RhYmxlcmFuZ2U6MzNlYmNjNjlmZTMzNDk2Nzg5MTA1NjAwYjE4MDE5M2FfMy01LTEtMS0xNTk1NDA_4a7fc6a4-00eb-48e0-9be6-7541e73b4e57">206.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i167ed8f67bef48c49e54fa466400cdaa_D20210101-20210930" decimals="-5" name="lly:AssetImpairmentChargesRecoveriesAndOtherSpecialCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN181OC9mcmFnOjdhMjU0OTU2YzMzNTQ1Y2Y4M2YzNGQyMTZiNzAwM2IyL3RhYmxlOjMzZWJjYzY5ZmUzMzQ5Njc4OTEwNTYwMGIxODAxOTNhL3RhYmxlcmFuZ2U6MzNlYmNjNjlmZTMzNDk2Nzg5MTA1NjAwYjE4MDE5M2FfMy03LTEtMS0xNTk1NDA_22f520ff-4c8a-4171-8bec-3ed929512e3f">200.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total asset impairment, restructuring, and other special charges</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19fc0325c48543008ea71e1fdcf11d86_D20220701-20220930" decimals="-5" name="us-gaap:RestructuringSettlementAndImpairmentProvisions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN181OC9mcmFnOjdhMjU0OTU2YzMzNTQ1Y2Y4M2YzNGQyMTZiNzAwM2IyL3RhYmxlOjMzZWJjYzY5ZmUzMzQ5Njc4OTEwNTYwMGIxODAxOTNhL3RhYmxlcmFuZ2U6MzNlYmNjNjlmZTMzNDk2Nzg5MTA1NjAwYjE4MDE5M2FfNC0xLTEtMS0xNTk1NDA_871cfb58-2491-43dc-b184-34f9c6cf822b">206.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4fa4f6b472a4f269297591b44aba572_D20210701-20210930" decimals="-5" name="us-gaap:RestructuringSettlementAndImpairmentProvisions" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN181OC9mcmFnOjdhMjU0OTU2YzMzNTQ1Y2Y4M2YzNGQyMTZiNzAwM2IyL3RhYmxlOjMzZWJjYzY5ZmUzMzQ5Njc4OTEwNTYwMGIxODAxOTNhL3RhYmxlcmFuZ2U6MzNlYmNjNjlmZTMzNDk2Nzg5MTA1NjAwYjE4MDE5M2FfNC0zLTEtMS0xNTk1NDA_440c64be-a839-43d8-afea-b5abbee97a08">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930" decimals="-5" name="us-gaap:RestructuringSettlementAndImpairmentProvisions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN181OC9mcmFnOjdhMjU0OTU2YzMzNTQ1Y2Y4M2YzNGQyMTZiNzAwM2IyL3RhYmxlOjMzZWJjYzY5ZmUzMzQ5Njc4OTEwNTYwMGIxODAxOTNhL3RhYmxlcmFuZ2U6MzNlYmNjNjlmZTMzNDk2Nzg5MTA1NjAwYjE4MDE5M2FfNC01LTEtMS0xNTk1NDA_3d999b88-4ddd-4fb1-bbaa-a10090f42bea">206.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i167ed8f67bef48c49e54fa466400cdaa_D20210101-20210930" decimals="-5" name="us-gaap:RestructuringSettlementAndImpairmentProvisions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN181OC9mcmFnOjdhMjU0OTU2YzMzNTQ1Y2Y4M2YzNGQyMTZiNzAwM2IyL3RhYmxlOjMzZWJjYzY5ZmUzMzQ5Njc4OTEwNTYwMGIxODAxOTNhL3RhYmxlcmFuZ2U6MzNlYmNjNjlmZTMzNDk2Nzg5MTA1NjAwYjE4MDE5M2FfNC03LTEtMS0xNTk1NDA_6408657e-186f-4757-bc29-234f3692c156">211.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Asset impairment, restructuring, and other special charges recognized during the three and nine months ended September 30, 2022 were primarily related to an intangible asset impairment for GBA1 Gene Therapy (PR001), acquired in the Prevail acquisition, as a result of changes in key assumptions used in the valuation due to delays in estimated launch timing.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Asset impairment, restructuring, and other special charges recognized during the nine months ended September&#160;30, 2021 were primarily related to an intangible asset impairment of $<ix:nonFraction unitRef="usd" contextRef="i167ed8f67bef48c49e54fa466400cdaa_D20210101-20210930" decimals="-5" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN181OC9mcmFnOjdhMjU0OTU2YzMzNTQ1Y2Y4M2YzNGQyMTZiNzAwM2IyL3RleHRyZWdpb246N2EyNTQ5NTZjMzM1NDVjZjgzZjM0ZDIxNmI3MDAzYjJfNTUy_a6a138de-a385-482a-9695-61f4d5e3e137">108.1</ix:nonFraction>&#160;million resulting from the sale of the rights to Qbrexza</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, as well as acquisition and integration costs associated with the acquisition of Prevail. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized a net inventory impairment charge related to our COVID-19 antibodies of $<ix:nonFraction unitRef="usd" contextRef="i167ed8f67bef48c49e54fa466400cdaa_D20210101-20210930" decimals="-5" name="us-gaap:InventoryWriteDown" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN181OC9mcmFnOjdhMjU0OTU2YzMzNTQ1Y2Y4M2YzNGQyMTZiNzAwM2IyL3RleHRyZWdpb246N2EyNTQ5NTZjMzM1NDVjZjgzZjM0ZDIxNmI3MDAzYjJfMzI5ODUzNDg5MTA1NQ_588cbba9-1f4c-4fa0-bc05-1cf0e9111c12">435.1</ix:nonFraction>&#160;million during the nine months ended September&#160;30, 2021 in cost of sales in our consolidated condensed statements of operations. As part of our response to the COVID-19 pandemic, and at the request of the U.S. and international governments, we invested in large-scale manufacturing of COVID-19 antibodies at risk, in order to ensure rapid access to patients around the world. As the COVID-19 pandemic evolved during 2021, we incurred a net inventory impairment charge primarily due to the combination of changes to demand from U.S. and international governments, including changes to our agreement with the U.S. government, and near-term expiry dates of COVID-19 antibodies.</span></div></ix:continuation><div style="margin-top:6pt"><span><br/></span></div><div id="i5fed483d9c7e4f3cbba3a62c53226cd7_61"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 6: <ix:nonNumeric contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RleHRyZWdpb246OGRmOTEwZDdhYjFhNDFmMThlODU5ZTE4OTQxY2E4MDhfMTUxNjc_c5b9d29e-47f2-4819-a809-42a93bda0875" continuedAt="i22eac50db1234c699d1d6d1c48247d51" escape="true">Financial Instruments</ix:nonNumeric></span></div><ix:continuation id="i22eac50db1234c699d1d6d1c48247d51" continuedAt="i272d0faec1534fd68944863c239a84ec"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject us to credit risk consist principally of trade receivables and interest-bearing investments. Wholesale distributors of life science products account for a substantial portion of our trade receivables; collateral is generally not required. We seek to mitigate the risk associated with this concentration through our ongoing credit-review procedures and insurance. A large portion of our cash is held by a few major financial institutions. We monitor our exposures with these institutions and do not expect any of these institutions to fail to meet their obligations. In accordance with documented corporate risk-management policies, we monitor the amount of credit exposure to any one financial institution or corporate issuer. We are exposed to credit-related losses in the event of nonperformance by counterparties to risk-management instruments but do not expect any counterparties to fail to meet their obligations given their investment grade credit ratings.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider all highly liquid investments with a maturity of three months or less from the date of purchase to be cash equivalents. The cost of these investments approximates fair value.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our equity investments are accounted for using three different methods depending on the type of equity investment:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Investments in companies over which we have significant influence but not a controlling interest are accounted for using the equity method, with our share of earnings or losses reported in other-net, (income) expense. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">For equity investments that do not have readily determinable fair values, we measure these investments at cost, less any impairment, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investment of the same issuer. Any change in recorded value is recorded in other-net, (income) expense. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our public equity investments are measured and carried at fair value. Any change in fair value is recognized in other-net, (income) expense. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We review equity investments other than public equity investments for indications of impairment and observable price changes on a regular basis.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i272d0faec1534fd68944863c239a84ec" continuedAt="i3620a190ca6c48c9bbbe0ac45245a2a4"><ix:nonNumeric contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930" name="us-gaap:DerivativesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RleHRyZWdpb246OGRmOTEwZDdhYjFhNDFmMThlODU5ZTE4OTQxY2E4MDhfMTUxNzM_083e67c0-6517-4e27-bc90-3f30344102df" continuedAt="i37426f726b8c48eba19a89cf7a4aa0b4" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our derivative activities are initiated within the guidelines of documented corporate risk-management policies and are intended to offset losses and gains on the assets, liabilities, and transactions being hedged. Management reviews the correlation and effectiveness of our derivatives on a quarterly basis.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For derivative instruments that are designated and qualify as fair value hedges, the derivative instrument is marked to market, with gains and losses recognized currently in income to offset the respective losses and gains recognized on the underlying exposure. For derivative instruments that are designated and qualify as cash flow hedges, gains and losses are reported as a component of accumulated other comprehensive loss and reclassified into earnings in the same period the hedged transaction affects earnings. For derivative and non-derivative instruments that are designated and qualify as net investment hedges, the foreign currency translation gains or losses due to spot rate fluctuations are reported as a component of accumulated other comprehensive loss. Derivative contracts that are not designated as hedging instruments are recorded at fair value with the gain or loss recognized in earnings during the period of change.</span></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i37426f726b8c48eba19a89cf7a4aa0b4">We may enter into foreign currency forward or option contracts to reduce the effect of fluctuating currency exchange rates (principally the euro, British pound, Chinese yuan, and Japanese yen). Foreign currency derivatives used for hedging are put in place using the same or like currencies and duration as the underlying exposures. Forward and option contracts are principally used to manage exposures arising from subsidiary trade and loan payables and receivables denominated in foreign currencies. These contracts are recorded at fair value with the gain or loss recognized in other&#8211;net, (income) expense. We may enter into foreign currency forward and option contracts and currency swaps as fair value hedges of firm commitments. Forward contracts generally have maturities not exceeding 12 months.</ix:continuation> At September&#160;30, 2022, we had outstanding foreign currency forward commitments to purchase <ix:nonFraction unitRef="usd" contextRef="id7a3c615db604cd2baec39887078a8e2_I20220930" decimals="-7" name="us-gaap:DerivativeLiabilityNotionalAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RleHRyZWdpb246OGRmOTEwZDdhYjFhNDFmMThlODU5ZTE4OTQxY2E4MDhfNDQyOQ_a74c6b7d-e01b-4fff-899d-93fdfa5fcc31">1.69</ix:nonFraction> billion U.S. dollars and sell <ix:nonFraction unitRef="eur" contextRef="id7a3c615db604cd2baec39887078a8e2_I20220930" decimals="-7" name="us-gaap:DerivativeAssetNotionalAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RleHRyZWdpb246OGRmOTEwZDdhYjFhNDFmMThlODU5ZTE4OTQxY2E4MDhfNDQ1NA_10b3bc07-0b02-4799-8b4e-6c7ea350c6d4">1.71</ix:nonFraction> billion euro; commitments to purchase <ix:nonFraction unitRef="eur" contextRef="icbc49bb61efe4f65ba8c0e7f0093e86a_I20220930" decimals="-7" name="us-gaap:DerivativeLiabilityNotionalAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RleHRyZWdpb246OGRmOTEwZDdhYjFhNDFmMThlODU5ZTE4OTQxY2E4MDhfNDQ4Nw_cc0d41a1-e5b0-4b89-8ece-06b439ee1596">2.24</ix:nonFraction> billion euro and sell <ix:nonFraction unitRef="usd" contextRef="icbc49bb61efe4f65ba8c0e7f0093e86a_I20220930" decimals="-7" name="us-gaap:DerivativeAssetNotionalAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RleHRyZWdpb246OGRmOTEwZDdhYjFhNDFmMThlODU5ZTE4OTQxY2E4MDhfNDUwNA_bf5baa84-61a7-4aa3-943a-cdb2b32ef617">2.24</ix:nonFraction>&#160;billion U.S. dollars; commitments to purchase <ix:nonFraction unitRef="usd" contextRef="i77c728fb616a42cc8c6b40e0bbdd95d4_I20220930" decimals="-5" name="us-gaap:DerivativeLiabilityNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RleHRyZWdpb246OGRmOTEwZDdhYjFhNDFmMThlODU5ZTE4OTQxY2E4MDhfNDU0NQ_0c46b301-a1d9-4ac4-9236-2758227b2a36">239.5</ix:nonFraction> million U.S. dollars and sell <ix:nonFraction unitRef="cny" contextRef="i77c728fb616a42cc8c6b40e0bbdd95d4_I20220930" decimals="-7" name="us-gaap:DerivativeAssetNotionalAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RleHRyZWdpb246OGRmOTEwZDdhYjFhNDFmMThlODU5ZTE4OTQxY2E4MDhfNDU3MA_2954e008-0049-4aed-a058-ca48833de239">1.63</ix:nonFraction> billion Chinese yuan; commitments to purchase <ix:nonFraction unitRef="usd" contextRef="i80a649fe7dd9480994358ed2532d905d_I20220930" decimals="-5" name="us-gaap:DerivativeLiabilityNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RleHRyZWdpb246OGRmOTEwZDdhYjFhNDFmMThlODU5ZTE4OTQxY2E4MDhfNDYxMQ_b5308860-f970-4a43-a307-7417551accf7">82.1</ix:nonFraction>&#160;million U.S. dollars and sell <ix:nonFraction unitRef="jpy" contextRef="i80a649fe7dd9480994358ed2532d905d_I20220930" decimals="-7" name="us-gaap:DerivativeAssetNotionalAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RleHRyZWdpb246OGRmOTEwZDdhYjFhNDFmMThlODU5ZTE4OTQxY2E4MDhfNDYzNg_78be03b4-0d03-4ba4-9113-d2d8ea320b6c">11.86</ix:nonFraction> billion Japanese yen; and commitments to purchase <ix:nonFraction unitRef="gbp" contextRef="i04bcb23b9ae84c9c9a64aca2a3cc4a34_I20220930" decimals="-5" name="us-gaap:DerivativeLiabilityNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RleHRyZWdpb246OGRmOTEwZDdhYjFhNDFmMThlODU5ZTE4OTQxY2E4MDhfNDY4MQ_0ba8459b-6759-4c70-a770-bcdcd8d741e8">182.1</ix:nonFraction> million British pounds and sell <ix:nonFraction unitRef="usd" contextRef="i04bcb23b9ae84c9c9a64aca2a3cc4a34_I20220930" decimals="-5" name="us-gaap:DerivativeAssetNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RleHRyZWdpb246OGRmOTEwZDdhYjFhNDFmMThlODU5ZTE4OTQxY2E4MDhfNDcwOA_cc4644b0-58d3-42a5-8ae5-aae578f05aff">206.9</ix:nonFraction>&#160;million U.S. dollars, which all have settlement dates within <ix:nonNumeric contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930" name="us-gaap:MaximumRemainingMaturityOfForeignCurrencyDerivatives1" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RleHRyZWdpb246OGRmOTEwZDdhYjFhNDFmMThlODU5ZTE4OTQxY2E4MDhfNDc2NA_a682fe0f-96b5-453c-9736-9aab3a483f2d">180</ix:nonNumeric> days.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign currency exchange risk is also managed through the use of foreign currency debt, cross-currency interest rate swaps, and foreign currency forward contracts. Our foreign currency-denominated notes had carrying amounts of $<ix:nonFraction unitRef="usd" contextRef="ifd62109e29474416b9bd4cb46c68e40f_I20220930" decimals="-7" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RleHRyZWdpb246OGRmOTEwZDdhYjFhNDFmMThlODU5ZTE4OTQxY2E4MDhfNDk5Ng_1f3244f1-a7d5-4d3a-aae9-770af8f74064">6.23</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="i9e675ec6e62d42a9bc9b9a5e61226095_I20211231" decimals="-7" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RleHRyZWdpb246OGRmOTEwZDdhYjFhNDFmMThlODU5ZTE4OTQxY2E4MDhfNTAwMw_b5fb8667-238a-4aba-bc32-b45eabce2aa6">7.90</ix:nonFraction>&#160;billion as of September&#160;30, 2022 and December&#160;31, 2021, respectively, of which $<ix:nonFraction unitRef="usd" contextRef="i08ccb35f6ad24d7793c9c91b74ca2ea1_I20220930" decimals="-7" name="us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTax" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RleHRyZWdpb246OGRmOTEwZDdhYjFhNDFmMThlODU5ZTE4OTQxY2E4MDhfNTA0Ng_b8b0af48-04d0-4d19-90be-7b2c8e0c91c9">4.94</ix:nonFraction>&#160;billion and $<ix:nonFraction unitRef="usd" contextRef="i0973ba0c1d894ceaa494709a13f814fb_I20211231" decimals="-7" name="us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTax" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RleHRyZWdpb246OGRmOTEwZDdhYjFhNDFmMThlODU5ZTE4OTQxY2E4MDhfNTA1Mw_02423f90-bbe6-4b31-b670-0b1665f70c3a">5.79</ix:nonFraction> billion have been designated as, and are effective as, economic hedges of net investments in certain of our foreign operations as of September&#160;30, 2022 and December&#160;31, 2021, respectively. At September&#160;30, 2022, we had outstanding cross-currency swaps with notional amounts of $<ix:nonFraction unitRef="usd" contextRef="i5b6a7a49e6b543c7a9c9f34217259d0f_I20220930" decimals="-7" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RleHRyZWdpb246OGRmOTEwZDdhYjFhNDFmMThlODU5ZTE4OTQxY2E4MDhfNTI3OA_343b1e68-7452-4b3a-844c-c8ec49513718">1.56</ix:nonFraction> billion swapping U.S. dollars to euro and $<ix:nonFraction unitRef="usd" contextRef="i5f4cbed09a8d4efbba96a84a21c4f229_I20220930" decimals="-7" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RleHRyZWdpb246OGRmOTEwZDdhYjFhNDFmMThlODU5ZTE4OTQxY2E4MDhfNTMxNQ_cfa93c94-d8df-479c-aa9c-0481091d5af0">1.00</ix:nonFraction>&#160;billion swapping Swiss francs to U.S. dollars which have settlement dates ranging through 2028. Our cross-currency interest rate swaps, for which a majority convert a portion of our U.S. dollar-denominated fixed-rate debt to foreign-denominated fixed-rate debt, have also been designated as, and are effective as, economic hedges of net investments. At September&#160;30, 2022, we had outstanding foreign currency forward contracts to sell <ix:nonFraction unitRef="eur" contextRef="i223b03ef72744bd2b0b10b131126e63e_I20220930" decimals="-7" name="us-gaap:DerivativeAssetNotionalAmount" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RleHRyZWdpb246OGRmOTEwZDdhYjFhNDFmMThlODU5ZTE4OTQxY2E4MDhfNTcyOQ_fa195d7c-17a4-46ce-badc-403e77c1c4af">1.34</ix:nonFraction> billion euro with settlement dates ranging through 2023, which have been designated as, and are effective as, economic hedges of net investments.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, our operations are exposed to fluctuations in interest rates which can vary the costs of financing, investing, and operating. We seek to address a portion of these risks through a controlled program of risk management that includes the use of derivative financial instruments. The objective of controlling these risks is to limit the impact of fluctuations in interest rates on earnings. Our primary interest-rate risk exposure results from changes in short-term U.S. dollar interest rates. In an effort to manage interest-rate exposures, we strive to achieve an acceptable balance between fixed- and floating-rate debt and investment positions and may enter into interest rate swaps or collars to help maintain that balance.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest rate swaps or collars that convert our fixed-rate debt to a floating rate are designated as fair value hedges of the underlying instruments. Interest rate swaps or collars that convert floating-rate debt to a fixed rate are designated as cash flow hedges. Interest expense on the debt is adjusted to include the payments made or received under the swap agreements. Cash proceeds from or payments to counterparties resulting from the termination of interest rate swaps are classified as operating activities in our consolidated condensed statements of cash flows. At September&#160;30, 2022, substantially all of our total long-term debt is at a fixed rate. We have converted approximately <ix:nonFraction unitRef="number" contextRef="i08ccb35f6ad24d7793c9c91b74ca2ea1_I20220930" decimals="2" name="lly:DescriptionOfDerivativeActivityVolumePercent" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RleHRyZWdpb246OGRmOTEwZDdhYjFhNDFmMThlODU5ZTE4OTQxY2E4MDhfNzMxNQ_c27361a5-c64b-408f-acaa-b2836a5cc3c5">10</ix:nonFraction> percent of our long-term fixed-rate notes to floating rates through the use of interest rate swaps.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i3620a190ca6c48c9bbbe0ac45245a2a4" continuedAt="ie2d1b96979184c80ab5eb2a40bb0da95"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also may enter into forward-starting interest rate swaps, which we designate as cash flow hedges, as part of any anticipated future debt issuances in order to reduce the risk of cash flow volatility from future changes in interest rates. The change in fair value of these instruments is recorded as part of other comprehensive income (loss) and, upon completion of a debt issuance and termination of the swap, is amortized to interest expense over the life of the underlying debt. As of September&#160;30, 2022, the total notional amounts of forward-starting interest rate contracts in designated cash flow hedging instruments were $<ix:nonFraction unitRef="usd" contextRef="iea65a7fd63824506a3ca41c5d51257a3_I20220930" decimals="-7" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RleHRyZWdpb246OGRmOTEwZDdhYjFhNDFmMThlODU5ZTE4OTQxY2E4MDhfODAxNw_0f465d2c-ee23-41d4-b53d-487c29e7e8fc">1.75</ix:nonFraction> billion, which have settlement dates ranging between 2023 and 2025.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective September 15, 2022, we increased our <ix:nonNumeric contextRef="i788cd34fd44840639efca67d73c371ff_D20220915-20220915" name="us-gaap:DebtInstrumentTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RleHRyZWdpb246OGRmOTEwZDdhYjFhNDFmMThlODU5ZTE4OTQxY2E4MDhfMzI5ODUzNDkwMzAxNw_ce7d2d87-4026-482f-97b8-93cb1c592998">364-day</ix:nonNumeric> credit facility from $<ix:nonFraction unitRef="usd" contextRef="i5d53c58f4c7d459489a11fd8bfd27153_I20220914" decimals="-7" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RleHRyZWdpb246OGRmOTEwZDdhYjFhNDFmMThlODU5ZTE4OTQxY2E4MDhfMzI5ODUzNDkwMjk1NQ_03c38822-6492-4c38-93c1-a50755127fa1">2.00</ix:nonFraction>&#160;billion to $<ix:nonFraction unitRef="usd" contextRef="i2c071467da4c408bbfd8f27f707626e7_I20220915" decimals="-7" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RleHRyZWdpb246OGRmOTEwZDdhYjFhNDFmMThlODU5ZTE4OTQxY2E4MDhfMzI5ODUzNDkwMjk3MA_59e876b1-ba17-4119-aa39-c2d44605e198">4.00</ix:nonFraction>&#160;billion, which will expire in September 2023, and is available to support our commercial paper program. We have not drawn against the $<ix:nonFraction unitRef="usd" contextRef="i2c071467da4c408bbfd8f27f707626e7_I20220915" decimals="-7" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RleHRyZWdpb246OGRmOTEwZDdhYjFhNDFmMThlODU5ZTE4OTQxY2E4MDhfMzI5ODUzNDkwMjk4NQ_3b24ed1c-d1d4-4ebd-a28a-94b6d7e89ddc">4.00</ix:nonFraction>&#160;billion <ix:nonNumeric contextRef="i788cd34fd44840639efca67d73c371ff_D20220915-20220915" name="us-gaap:DebtInstrumentTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RleHRyZWdpb246OGRmOTEwZDdhYjFhNDFmMThlODU5ZTE4OTQxY2E4MDhfMzI5ODUzNDkwMzAxOA_694da09d-cb8c-4113-9beb-2dffa4b64e6f">364-day</ix:nonNumeric> credit facility as of September 30, 2022.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2021, we issued euro-denominated notes consisting of &#8364;<ix:nonFraction unitRef="eur" contextRef="i17173f194d1742f38780c496d01c1177_I20210930" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RleHRyZWdpb246OGRmOTEwZDdhYjFhNDFmMThlODU5ZTE4OTQxY2E4MDhfMzI5ODUzNDkwMTE5OA_fabf239f-6312-44b9-9ce8-43bbc6b59362">600.0</ix:nonFraction>&#160;million of <ix:nonFraction unitRef="number" contextRef="i17173f194d1742f38780c496d01c1177_I20210930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RleHRyZWdpb246OGRmOTEwZDdhYjFhNDFmMThlODU5ZTE4OTQxY2E4MDhfMzI5ODUzNDkwMTIxNA_a89528c5-914f-4899-b7f3-320697f05b06">0.50</ix:nonFraction> percent fixed-rate notes due in September 2033, with interest to be paid annually. The net proceeds from the offering have been, and will continue to be, used to fund, in whole or in part, eligible projects designed to advance one or more of our environmental, social, and governance objectives.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2021, we issued euro-denominated notes consisting of &#8364;<ix:nonFraction unitRef="eur" contextRef="iff7c9802a16c4e94a8b83d2c06fbfd30_I20210930" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RleHRyZWdpb246OGRmOTEwZDdhYjFhNDFmMThlODU5ZTE4OTQxY2E4MDhfMzI5ODUzNDkwMDU5Mg_e09fb3a2-d8d3-496f-ae95-6f9d425edad8">500.0</ix:nonFraction>&#160;million of <ix:nonFraction unitRef="number" contextRef="iff7c9802a16c4e94a8b83d2c06fbfd30_I20210930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RleHRyZWdpb246OGRmOTEwZDdhYjFhNDFmMThlODU5ZTE4OTQxY2E4MDhfMzI5ODUzNDkwMDYwOA_ffb64c0c-3315-4943-b496-0acaf2271454">1.125</ix:nonFraction> percent fixed-rate notes due in September 2051 and &#8364;<ix:nonFraction unitRef="eur" contextRef="i11a8fe2e658c49ab879c662bd320fc8e_I20210930" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RleHRyZWdpb246OGRmOTEwZDdhYjFhNDFmMThlODU5ZTE4OTQxY2E4MDhfMzI5ODUzNDkwMDYxNQ_8c2421ec-6805-49f0-abfc-907a2d70ae19">700.0</ix:nonFraction>&#160;million of <ix:nonFraction unitRef="number" contextRef="i11a8fe2e658c49ab879c662bd320fc8e_I20210930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RleHRyZWdpb246OGRmOTEwZDdhYjFhNDFmMThlODU5ZTE4OTQxY2E4MDhfMzI5ODUzNDkwMDYzMQ_95d377da-b023-432b-a5c5-3cd13eafd92a">1.375</ix:nonFraction> percent fixed-rate notes due in September 2061, with interest to be paid annually, and British pound-denominated notes consisting of &#163;<ix:nonFraction unitRef="gbp" contextRef="iea81ed26b993414992722e426a530c04_I20210930" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RleHRyZWdpb246OGRmOTEwZDdhYjFhNDFmMThlODU5ZTE4OTQxY2E4MDhfMzI5ODUzNDkwMDYzOA_ecaafde3-786f-4832-a0d2-e47e6084fa99">250.0</ix:nonFraction>&#160;million of <ix:nonFraction unitRef="number" contextRef="iea81ed26b993414992722e426a530c04_I20210930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RleHRyZWdpb246OGRmOTEwZDdhYjFhNDFmMThlODU5ZTE4OTQxY2E4MDhfMzI5ODUzNDkwMDY1NA_9bac2bf5-3734-43f3-8c9c-c37e9ed447a6">1.625</ix:nonFraction> percent fixed-rate notes due in September 2043, with interest to be paid annually. We paid $<ix:nonFraction unitRef="usd" contextRef="icdfd3853e3eb4a398286b232426b38b1_D20210901-20210930" decimals="-7" name="us-gaap:PaymentsOfDebtExtinguishmentCosts" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RleHRyZWdpb246OGRmOTEwZDdhYjFhNDFmMThlODU5ZTE4OTQxY2E4MDhfMzI5ODUzNDkwMDY2MQ_01f5fe97-07e9-40cd-a008-d0e4dd747414">1.91</ix:nonFraction>&#160;billion of the net cash proceeds from the offering to purchase and redeem certain higher interest rate U.S. dollar-denominated notes with an aggregate principal amount of $<ix:nonFraction unitRef="usd" contextRef="icdfd3853e3eb4a398286b232426b38b1_D20210901-20210930" decimals="-7" name="us-gaap:ExtinguishmentOfDebtAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RleHRyZWdpb246OGRmOTEwZDdhYjFhNDFmMThlODU5ZTE4OTQxY2E4MDhfMzI5ODUzNDkwMDY3Ng_77656b80-9cdf-43ef-8295-52415607ddc0">1.50</ix:nonFraction>&#160;billion, resulting in a debt extinguishment loss of $<ix:nonFraction unitRef="usd" contextRef="icdfd3853e3eb4a398286b232426b38b1_D20210901-20210930" decimals="-5" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RleHRyZWdpb246OGRmOTEwZDdhYjFhNDFmMThlODU5ZTE4OTQxY2E4MDhfMzI5ODUzNDkwMDY5MQ_3f663fd6-62a2-4a6d-8eaa-a65c832b3eb8">405.2</ix:nonFraction>&#160;million. This loss was included in other net, (income) expense in our consolidated condensed statement of operations during the three and nine months ended September 30, 2021. The $<ix:nonFraction unitRef="usd" contextRef="icdfd3853e3eb4a398286b232426b38b1_D20210901-20210930" decimals="-7" name="us-gaap:ExtinguishmentOfDebtAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RleHRyZWdpb246OGRmOTEwZDdhYjFhNDFmMThlODU5ZTE4OTQxY2E4MDhfMzI5ODUzNDkwMDcwNw_a500e631-12ca-44b6-af36-97afec4dfb37">1.50</ix:nonFraction>&#160;billion principal amount of higher interest rate U.S. dollar-denominated notes that were redeemed primarily included $<ix:nonFraction unitRef="usd" contextRef="i96587d4174a14444becf7821313b1347_D20210901-20210930" decimals="-5" name="us-gaap:ExtinguishmentOfDebtAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RleHRyZWdpb246OGRmOTEwZDdhYjFhNDFmMThlODU5ZTE4OTQxY2E4MDhfMzI5ODUzNDkwMDcyMg_702426dc-cd70-47c9-9146-873f2a3501c3">541.8</ix:nonFraction>&#160;million of <ix:nonFraction unitRef="number" contextRef="i750c23289e514e58bf58ede4855592f4_I20210930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RleHRyZWdpb246OGRmOTEwZDdhYjFhNDFmMThlODU5ZTE4OTQxY2E4MDhfMzI5ODUzNDkwMDczOA_047fb137-f65c-4028-8748-262cfe831471">3.95</ix:nonFraction> percent notes due 2049, $<ix:nonFraction unitRef="usd" contextRef="ice18fb651f95409d813656a157f34daf_D20210901-20210930" decimals="-5" name="us-gaap:ExtinguishmentOfDebtAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RleHRyZWdpb246OGRmOTEwZDdhYjFhNDFmMThlODU5ZTE4OTQxY2E4MDhfMzI5ODUzNDkwMDc0NA_bca6857f-0b81-4779-8dd1-291d63c94b48">408.7</ix:nonFraction>&#160;million of <ix:nonFraction unitRef="number" contextRef="i50894bb5721f4dd58072e6ce75ebf15d_I20210930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RleHRyZWdpb246OGRmOTEwZDdhYjFhNDFmMThlODU5ZTE4OTQxY2E4MDhfMzI5ODUzNDkwMDc2MA_62d97da8-c395-40b2-b7a6-f90739a6cb1a">4.15</ix:nonFraction> percent notes due 2059, and $<ix:nonFraction unitRef="usd" contextRef="ice022568bdf042618c2c002393cc3c5d_D20210901-20210930" decimals="-5" name="us-gaap:ExtinguishmentOfDebtAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RleHRyZWdpb246OGRmOTEwZDdhYjFhNDFmMThlODU5ZTE4OTQxY2E4MDhfMzI5ODUzNDkwMDc2Ng_6feda03f-fc2e-4783-822a-9b435148eb37">219.4</ix:nonFraction>&#160;million of <ix:nonFraction unitRef="number" contextRef="iccc6f8c08fc6454c849c681a4dbe3d01_I20210930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RleHRyZWdpb246OGRmOTEwZDdhYjFhNDFmMThlODU5ZTE4OTQxY2E4MDhfMzI5ODUzNDkwMDc4Mg_46ae064e-e5b3-4fa2-b782-46ae301f6c8b">3.375</ix:nonFraction> percent notes due 2029. We used the remaining net proceeds from the offering to prefund certain 2022 debt maturities and for general corporate purposes.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The Effect of Risk-Management Instruments on the Consolidated Condensed Statements of Operations</span></div><ix:nonNumeric contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930" name="us-gaap:ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RleHRyZWdpb246OGRmOTEwZDdhYjFhNDFmMThlODU5ZTE4OTQxY2E4MDhfMTUxMDk_30459d61-6677-4ad8-8dba-ecb15fc493c8" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following effects of risk-management instruments were recognized in other&#8211;net, (income) expense:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.800%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.157%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.157%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.157%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.160%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value hedges:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect from hedged fixed-rate debt</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i65012aa62d474ff8af6d08eeb55d206a_D20220701-20220930" decimals="-5" name="us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOmY2M2E4OTNjOGY5MzQ0M2ViOTA2ZDYwZWNjMWRhMzJiL3RhYmxlcmFuZ2U6ZjYzYTg5M2M4ZjkzNDQzZWI5MDZkNjBlY2MxZGEzMmJfMy0xLTEtMS0xNTk1NDA_f7e28d6f-0f64-4fb1-9f5d-f00ca3de4b58">62.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib627ecf64a434a6b8135da0ac7a5fdf7_D20210701-20210930" decimals="-5" name="us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOmY2M2E4OTNjOGY5MzQ0M2ViOTA2ZDYwZWNjMWRhMzJiL3RhYmxlcmFuZ2U6ZjYzYTg5M2M4ZjkzNDQzZWI5MDZkNjBlY2MxZGEzMmJfMy0zLTEtMS0xNTk1NDA_40c651de-326e-477f-8354-547f965a0334">10.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1d213f8c24344d22ada6f016432acea5_D20220101-20220930" decimals="-5" name="us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOmY2M2E4OTNjOGY5MzQ0M2ViOTA2ZDYwZWNjMWRhMzJiL3RhYmxlcmFuZ2U6ZjYzYTg5M2M4ZjkzNDQzZWI5MDZkNjBlY2MxZGEzMmJfMy01LTEtMS0xNTk1NDA_496be9f4-9bd5-4012-8cc5-bdb0502bfaa3">215.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i41a4fdad9bd748be972c155f2f3acedf_D20210101-20210930" decimals="-5" name="us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOmY2M2E4OTNjOGY5MzQ0M2ViOTA2ZDYwZWNjMWRhMzJiL3RhYmxlcmFuZ2U6ZjYzYTg5M2M4ZjkzNDQzZWI5MDZkNjBlY2MxZGEzMmJfMy03LTEtMS0xNTk1NDA_eb181ae3-ffba-4a20-a5f7-3c49c81ac772">60.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect from interest rate contracts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic55d4cfd09d8486a8b6e1be77dcc5426_D20220701-20220930" decimals="-5" sign="-" name="us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOmY2M2E4OTNjOGY5MzQ0M2ViOTA2ZDYwZWNjMWRhMzJiL3RhYmxlcmFuZ2U6ZjYzYTg5M2M4ZjkzNDQzZWI5MDZkNjBlY2MxZGEzMmJfNC0xLTEtMS0xNTk1NDA_07fc5259-89e6-4bc6-b021-d086c6e94a2a">62.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i519d9df9a61b4cbf87c342e3496785cc_D20210701-20210930" decimals="-5" sign="-" name="us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOmY2M2E4OTNjOGY5MzQ0M2ViOTA2ZDYwZWNjMWRhMzJiL3RhYmxlcmFuZ2U6ZjYzYTg5M2M4ZjkzNDQzZWI5MDZkNjBlY2MxZGEzMmJfNC0zLTEtMS0xNTk1NDA_751aaf20-0bb2-464e-ae8c-c294a7f06e88">10.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7bcae384fb484b6aa3e84e7d484b69e9_D20220101-20220930" decimals="-5" sign="-" name="us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOmY2M2E4OTNjOGY5MzQ0M2ViOTA2ZDYwZWNjMWRhMzJiL3RhYmxlcmFuZ2U6ZjYzYTg5M2M4ZjkzNDQzZWI5MDZkNjBlY2MxZGEzMmJfNC01LTEtMS0xNTk1NDA_5aeac55d-65ff-4c3d-873b-be05ab82e2dd">215.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cc8664469d846a2b0472f04c7e39442_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOmY2M2E4OTNjOGY5MzQ0M2ViOTA2ZDYwZWNjMWRhMzJiL3RhYmxlcmFuZ2U6ZjYzYTg5M2M4ZjkzNDQzZWI5MDZkNjBlY2MxZGEzMmJfNC03LTEtMS0xNTk1NDA_a703e13a-35d7-422d-8d7b-a0ddbe49efc4">60.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flow hedges:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective portion of losses on interest rate contracts reclassified from accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic55d4cfd09d8486a8b6e1be77dcc5426_D20220701-20220930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOmY2M2E4OTNjOGY5MzQ0M2ViOTA2ZDYwZWNjMWRhMzJiL3RhYmxlcmFuZ2U6ZjYzYTg5M2M4ZjkzNDQzZWI5MDZkNjBlY2MxZGEzMmJfNi0xLTEtMS0xNTk1NDA_deec1bc1-e224-4ddc-b5b8-535d47d558c9">4.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i519d9df9a61b4cbf87c342e3496785cc_D20210701-20210930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOmY2M2E4OTNjOGY5MzQ0M2ViOTA2ZDYwZWNjMWRhMzJiL3RhYmxlcmFuZ2U6ZjYzYTg5M2M4ZjkzNDQzZWI5MDZkNjBlY2MxZGEzMmJfNi0zLTEtMS0xNTk1NDA_27a2de22-f375-4abb-8d67-1a70d53868dc">4.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7bcae384fb484b6aa3e84e7d484b69e9_D20220101-20220930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOmY2M2E4OTNjOGY5MzQ0M2ViOTA2ZDYwZWNjMWRhMzJiL3RhYmxlcmFuZ2U6ZjYzYTg5M2M4ZjkzNDQzZWI5MDZkNjBlY2MxZGEzMmJfNi01LTEtMS0xNTk1NDA_2081da8d-0d6d-4f45-aaea-f2c570fcbaaf">12.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cc8664469d846a2b0472f04c7e39442_D20210101-20210930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOmY2M2E4OTNjOGY5MzQ0M2ViOTA2ZDYwZWNjMWRhMzJiL3RhYmxlcmFuZ2U6ZjYzYTg5M2M4ZjkzNDQzZWI5MDZkNjBlY2MxZGEzMmJfNi03LTEtMS0xNTk1NDA_2c1682bd-562f-46aa-8fc3-768ec6328ace">12.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency interest rate swaps</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1eb1816cd7241e7af47383c68f534c0_D20220701-20220930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOmY2M2E4OTNjOGY5MzQ0M2ViOTA2ZDYwZWNjMWRhMzJiL3RhYmxlcmFuZ2U6ZjYzYTg5M2M4ZjkzNDQzZWI5MDZkNjBlY2MxZGEzMmJfNy0xLTEtMS0xNTk1NDA_9d72c7a5-5f9e-4df6-ae38-aece61fa2fcb">33.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7cd0109836d43de86e2c830d47c9aec_D20210701-20210930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOmY2M2E4OTNjOGY5MzQ0M2ViOTA2ZDYwZWNjMWRhMzJiL3RhYmxlcmFuZ2U6ZjYzYTg5M2M4ZjkzNDQzZWI5MDZkNjBlY2MxZGEzMmJfNy0zLTEtMS0xNTk1NDA_7859894c-8a1c-41e6-88d3-68b247684a74">10.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f64e83e66774562be40774b52732fd5_D20220101-20220930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOmY2M2E4OTNjOGY5MzQ0M2ViOTA2ZDYwZWNjMWRhMzJiL3RhYmxlcmFuZ2U6ZjYzYTg5M2M4ZjkzNDQzZWI5MDZkNjBlY2MxZGEzMmJfNy01LTEtMS0xNTk1NDA_9952a76f-c00c-4375-9adf-f73464f36a14">75.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ed2f279ccc74f238d18ee7977fea9e0_D20210101-20210930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOmY2M2E4OTNjOGY5MzQ0M2ViOTA2ZDYwZWNjMWRhMzJiL3RhYmxlcmFuZ2U6ZjYzYTg5M2M4ZjkzNDQzZWI5MDZkNjBlY2MxZGEzMmJfNy03LTEtMS0xNTk1NDA_75f0bbca-be3b-4cfb-bcc0-55d6d52f0f01">58.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (gains) losses on foreign currency exchange contracts not designated as hedging instruments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaaffba52583d4dd09213c45974bda81f_D20220701-20220930" decimals="-5" sign="-" name="us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOmY2M2E4OTNjOGY5MzQ0M2ViOTA2ZDYwZWNjMWRhMzJiL3RhYmxlcmFuZ2U6ZjYzYTg5M2M4ZjkzNDQzZWI5MDZkNjBlY2MxZGEzMmJfOC0xLTEtMS0xNTk1NDA_45ad136c-ec3b-4b58-9265-6dcfcbf87432">129.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb22c9f9ae5f42d5b5d0691a5daa1547_D20210701-20210930" decimals="-5" sign="-" name="us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOmY2M2E4OTNjOGY5MzQ0M2ViOTA2ZDYwZWNjMWRhMzJiL3RhYmxlcmFuZ2U6ZjYzYTg5M2M4ZjkzNDQzZWI5MDZkNjBlY2MxZGEzMmJfOC0zLTEtMS0xNTk1NDA_feea260b-9edd-4420-8f6a-004a68ebd262">50.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00fa96d219234882925d8b07dc0e9a2f_D20220101-20220930" decimals="-5" sign="-" name="us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOmY2M2E4OTNjOGY5MzQ0M2ViOTA2ZDYwZWNjMWRhMzJiL3RhYmxlcmFuZ2U6ZjYzYTg5M2M4ZjkzNDQzZWI5MDZkNjBlY2MxZGEzMmJfOC01LTEtMS0xNTk1NDA_edd95548-5100-4323-a726-ef27ed518838">280.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a4ce07ee9fd474a956ccb68a6af4713_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOmY2M2E4OTNjOGY5MzQ0M2ViOTA2ZDYwZWNjMWRhMzJiL3RhYmxlcmFuZ2U6ZjYzYTg5M2M4ZjkzNDQzZWI5MDZkNjBlY2MxZGEzMmJfOC03LTEtMS0xNTk1NDA_899dca17-35aa-4d2f-8658-642ad5f08d4f">110.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19fc0325c48543008ea71e1fdcf11d86_D20220701-20220930" decimals="-5" sign="-" name="lly:DerivativeInstrumentsGainLossRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOmY2M2E4OTNjOGY5MzQ0M2ViOTA2ZDYwZWNjMWRhMzJiL3RhYmxlcmFuZ2U6ZjYzYTg5M2M4ZjkzNDQzZWI5MDZkNjBlY2MxZGEzMmJfOS0xLTEtMS0xNTk1NDA_26ee518e-1941-4c09-b6a5-0c2fe576c581">166.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4fa4f6b472a4f269297591b44aba572_D20210701-20210930" decimals="-5" sign="-" name="lly:DerivativeInstrumentsGainLossRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOmY2M2E4OTNjOGY5MzQ0M2ViOTA2ZDYwZWNjMWRhMzJiL3RhYmxlcmFuZ2U6ZjYzYTg5M2M4ZjkzNDQzZWI5MDZkNjBlY2MxZGEzMmJfOS0zLTEtMS0xNTk1NDA_739481e3-e83a-4ca5-abd9-415495b69ef0">65.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930" decimals="-5" sign="-" name="lly:DerivativeInstrumentsGainLossRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOmY2M2E4OTNjOGY5MzQ0M2ViOTA2ZDYwZWNjMWRhMzJiL3RhYmxlcmFuZ2U6ZjYzYTg5M2M4ZjkzNDQzZWI5MDZkNjBlY2MxZGEzMmJfOS01LTEtMS0xNTk1NDA_031e8542-3748-4884-b7af-152aaaf951fe">368.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i167ed8f67bef48c49e54fa466400cdaa_D20210101-20210930" decimals="-5" sign="-" name="lly:DerivativeInstrumentsGainLossRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOmY2M2E4OTNjOGY5MzQ0M2ViOTA2ZDYwZWNjMWRhMzJiL3RhYmxlcmFuZ2U6ZjYzYTg5M2M4ZjkzNDQzZWI5MDZkNjBlY2MxZGEzMmJfOS03LTEtMS0xNTk1NDA_97ebec2e-25a4-4154-8eee-716bbe3cb9b0">181.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended September&#160;30, 2022 and 2021, the amortization of losses related to the portion of our risk management hedging instruments, fair value hedges, and cash flow hedges that was excluded from the assessment of effectiveness was not material.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ie2d1b96979184c80ab5eb2a40bb0da95" continuedAt="i51161b7126f64961b8d320046e8e9f6c"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The Effect of Risk-Management Instruments on Other Comprehensive Income (Loss)</span></div><ix:nonNumeric contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930" name="us-gaap:ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RleHRyZWdpb246OGRmOTEwZDdhYjFhNDFmMThlODU5ZTE4OTQxY2E4MDhfMTUxNjk_af7c9e84-70f2-4f2d-b46f-c00a40254ce4" escape="true"><ix:nonNumeric contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930" name="us-gaap:ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RleHRyZWdpb246OGRmOTEwZDdhYjFhNDFmMThlODU5ZTE4OTQxY2E4MDhfMTUxODk_228ac172-3acf-4d55-9fbf-db92983ef792" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective portion of risk-management instruments that was recognized in other comprehensive income (loss) is as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.613%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.206%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment hedges:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency-denominated notes</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0803c43adcc2406c8d72a961bdbdb03a_D20220701-20220930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOmQ4YWMyOTIzMWExMjRmZTRhMzI5NWJhOGNmMTgzZGQ5L3RhYmxlcmFuZ2U6ZDhhYzI5MjMxYTEyNGZlNGEzMjk1YmE4Y2YxODNkZDlfMy0xLTEtMS0xNTk1NDA_8ada233f-b314-42ff-a8c1-c7626a18e18d">435.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa347bfa67994dfbad7418e0ab44ad66_D20210701-20210930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOmQ4YWMyOTIzMWExMjRmZTRhMzI5NWJhOGNmMTgzZGQ5L3RhYmxlcmFuZ2U6ZDhhYzI5MjMxYTEyNGZlNGEzMjk1YmE4Y2YxODNkZDlfMy0zLTEtMS0xNTk1NDA_dd5e03a5-f1b0-4c63-b06d-296d73176244">119.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9300bb3fb0c149928c10ce50be156517_D20220101-20220930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOmQ4YWMyOTIzMWExMjRmZTRhMzI5NWJhOGNmMTgzZGQ5L3RhYmxlcmFuZ2U6ZDhhYzI5MjMxYTEyNGZlNGEzMjk1YmE4Y2YxODNkZDlfMy01LTEtMS0xNTk1NDA_ea03d8bc-cc9d-43bc-bdbb-278a93295c5d">822.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65cd935c26b44824a9d84d0554032fa4_D20210101-20210930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOmQ4YWMyOTIzMWExMjRmZTRhMzI5NWJhOGNmMTgzZGQ5L3RhYmxlcmFuZ2U6ZDhhYzI5MjMxYTEyNGZlNGEzMjk1YmE4Y2YxODNkZDlfMy03LTEtMS0xNTk1NDA_e0b9d6aa-0e2a-4fa9-bfb0-d102ea25b064">268.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency interest rate swaps</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie32852c9ac004e18a40bd3c886375fa2_D20220701-20220930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOmQ4YWMyOTIzMWExMjRmZTRhMzI5NWJhOGNmMTgzZGQ5L3RhYmxlcmFuZ2U6ZDhhYzI5MjMxYTEyNGZlNGEzMjk1YmE4Y2YxODNkZDlfNC0xLTEtMS0xNTk1NDA_c41fbcd4-8d83-4050-9bea-1f227220f00a">92.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie539446ea66443f18894fe65b477f3f2_D20210701-20210930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOmQ4YWMyOTIzMWExMjRmZTRhMzI5NWJhOGNmMTgzZGQ5L3RhYmxlcmFuZ2U6ZDhhYzI5MjMxYTEyNGZlNGEzMjk1YmE4Y2YxODNkZDlfNC0zLTEtMS0xNTk1NDA_048d8537-f679-4fa0-85af-c34f3f2b9be8">66.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb0755f46c634be3a274f37154dcd835_D20220101-20220930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOmQ4YWMyOTIzMWExMjRmZTRhMzI5NWJhOGNmMTgzZGQ5L3RhYmxlcmFuZ2U6ZDhhYzI5MjMxYTEyNGZlNGEzMjk1YmE4Y2YxODNkZDlfNC01LTEtMS0xNTk1NDA_dfdd2151-8699-4f50-a371-65c0f73a14b3">171.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib38ae8d2eee24da7b665b5ba4af2fc25_D20210101-20210930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOmQ4YWMyOTIzMWExMjRmZTRhMzI5NWJhOGNmMTgzZGQ5L3RhYmxlcmFuZ2U6ZDhhYzI5MjMxYTEyNGZlNGEzMjk1YmE4Y2YxODNkZDlfNC03LTEtMS0xNTk1NDA_efb63077-67bf-4515-a6db-2f7fd81f422b">170.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forward contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee72a06ebc24478d804a01c9c07503e0_D20220701-20220930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOmQ4YWMyOTIzMWExMjRmZTRhMzI5NWJhOGNmMTgzZGQ5L3RhYmxlcmFuZ2U6ZDhhYzI5MjMxYTEyNGZlNGEzMjk1YmE4Y2YxODNkZDlfNS0xLTEtMS0xNTk1NDA_0907f90c-cb5f-400a-ba6b-147a64dbdf37">107.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i847e2e726f374b8997cd2f409d0da50e_D20210701-20210930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOmQ4YWMyOTIzMWExMjRmZTRhMzI5NWJhOGNmMTgzZGQ5L3RhYmxlcmFuZ2U6ZDhhYzI5MjMxYTEyNGZlNGEzMjk1YmE4Y2YxODNkZDlfNS0zLTEtMS0xNTk1NDA_29d30dc8-c02f-451c-a952-9092e948fc6f">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04964a8dc75f42aeb12d4f04a8c4b0eb_D20220101-20220930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOmQ4YWMyOTIzMWExMjRmZTRhMzI5NWJhOGNmMTgzZGQ5L3RhYmxlcmFuZ2U6ZDhhYzI5MjMxYTEyNGZlNGEzMjk1YmE4Y2YxODNkZDlfNS01LTEtMS0xNTk1NDA_a5a07281-e177-4764-b709-6a94347197e5">121.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i735c7ed5628e404298cd5de9565781a5_D20210101-20210930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOmQ4YWMyOTIzMWExMjRmZTRhMzI5NWJhOGNmMTgzZGQ5L3RhYmxlcmFuZ2U6ZDhhYzI5MjMxYTEyNGZlNGEzMjk1YmE4Y2YxODNkZDlfNS03LTEtMS0xNTk1NDA_1783236e-7f89-4fb1-80e3-5d415876b230">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flow hedges:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward-starting interest rate swaps</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i874a4fa6b8034fb7b972ede3e49e5375_D20220701-20220930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOmQ4YWMyOTIzMWExMjRmZTRhMzI5NWJhOGNmMTgzZGQ5L3RhYmxlcmFuZ2U6ZDhhYzI5MjMxYTEyNGZlNGEzMjk1YmE4Y2YxODNkZDlfNy0xLTEtMS0xNTk1NDA_8ef7bfed-ecbe-45f5-a075-60517430e066">57.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc403fcb68ad44ae8c3d0f5675e78f2a_D20210701-20210930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOmQ4YWMyOTIzMWExMjRmZTRhMzI5NWJhOGNmMTgzZGQ5L3RhYmxlcmFuZ2U6ZDhhYzI5MjMxYTEyNGZlNGEzMjk1YmE4Y2YxODNkZDlfNy0zLTEtMS0xNTk1NDA_5bfb10b8-46fd-4378-a2fd-6705949223e7">19.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9cf169896e649948e7319fca615da6c_D20220101-20220930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOmQ4YWMyOTIzMWExMjRmZTRhMzI5NWJhOGNmMTgzZGQ5L3RhYmxlcmFuZ2U6ZDhhYzI5MjMxYTEyNGZlNGEzMjk1YmE4Y2YxODNkZDlfNy01LTEtMS0xNTk1NDA_50bdee4f-f2a3-415b-86e0-46b280e4ec5b">337.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i792ad77b79a7422690de67f74dc5988f_D20210101-20210930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOmQ4YWMyOTIzMWExMjRmZTRhMzI5NWJhOGNmMTgzZGQ5L3RhYmxlcmFuZ2U6ZDhhYzI5MjMxYTEyNGZlNGEzMjk1YmE4Y2YxODNkZDlfNy03LTEtMS0xNTk1NDA_ed88540e-2eda-47af-a347-b3432e3c2e17">149.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency interest rate swaps</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie32852c9ac004e18a40bd3c886375fa2_D20220701-20220930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOmQ4YWMyOTIzMWExMjRmZTRhMzI5NWJhOGNmMTgzZGQ5L3RhYmxlcmFuZ2U6ZDhhYzI5MjMxYTEyNGZlNGEzMjk1YmE4Y2YxODNkZDlfOC0xLTEtMS0xNTk1NDA_881e6419-f1ab-45f1-8519-d30cc48be0d2">19.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie539446ea66443f18894fe65b477f3f2_D20210701-20210930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOmQ4YWMyOTIzMWExMjRmZTRhMzI5NWJhOGNmMTgzZGQ5L3RhYmxlcmFuZ2U6ZDhhYzI5MjMxYTEyNGZlNGEzMjk1YmE4Y2YxODNkZDlfOC0zLTEtMS0xNTk1NDA_068058f8-7d3d-4ccc-a2aa-1bd84a03fe93">3.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb0755f46c634be3a274f37154dcd835_D20220101-20220930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOmQ4YWMyOTIzMWExMjRmZTRhMzI5NWJhOGNmMTgzZGQ5L3RhYmxlcmFuZ2U6ZDhhYzI5MjMxYTEyNGZlNGEzMjk1YmE4Y2YxODNkZDlfOC01LTEtMS0xNTk1NDA_556f17c3-68c7-4d1c-ab01-9229419f0ea1">38.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib38ae8d2eee24da7b665b5ba4af2fc25_D20210101-20210930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOmQ4YWMyOTIzMWExMjRmZTRhMzI5NWJhOGNmMTgzZGQ5L3RhYmxlcmFuZ2U6ZDhhYzI5MjMxYTEyNGZlNGEzMjk1YmE4Y2YxODNkZDlfOC03LTEtMS0xNTk1NDA_6d80bf62-6bb6-4a2a-aa78-bffb042c7d8a">22.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the next 12&#160;months, we expect to reclassify $<ix:nonFraction unitRef="usd" contextRef="i08ccb35f6ad24d7793c9c91b74ca2ea1_I20220930" decimals="-5" sign="-" name="us-gaap:InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RleHRyZWdpb246OGRmOTEwZDdhYjFhNDFmMThlODU5ZTE4OTQxY2E4MDhfODc3MQ_cc02ee53-2444-4fa4-9307-1ae16614df16">16.7</ix:nonFraction>&#160;million of pretax net losses on cash flow hedges from accumulated other comprehensive loss to other&#8211;net, (income) expense. During the three and nine months ended September&#160;30, 2022 and 2021, the amounts excluded from the assessment of hedge effectiveness recognized in other comprehensive income (loss) were not material.</span></div></ix:continuation><div style="margin-top:9pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i51161b7126f64961b8d320046e8e9f6c" continuedAt="i81a1014c662b4c0a83dff086461700ef"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value of Financial Instruments</span></div><ix:nonNumeric contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RleHRyZWdpb246OGRmOTEwZDdhYjFhNDFmMThlODU5ZTE4OTQxY2E4MDhfMTUxMTg_8c519f20-07b4-4979-970c-a1817df9b732" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize certain fair value information at September&#160;30, 2022 and December&#160;31, 2021 for assets and liabilities measured at fair value on a recurring basis, as well as the carrying amount and amortized cost of certain other investments:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:34.624%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.466%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.714%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices in Active Markets for Identical Assets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Other<br/>Observable Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia25fb80ee7f14608ad1bc42cf7dc3d85_I20220930" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMy0xLTEtMS0xNTk1NDA_170efdd2-271a-472e-a1fd-0e5db5f1eb2c">1,246.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb1b4d0ca2904d3699b0c20378d2d4de_I20220930" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMy0zLTEtMS0xNTk1NDA_cf4ac1dc-54d9-438d-a3a9-d509b2db1389">1,246.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i909f721d549b4d17b64fd5ef7a64ed65_I20220930" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMy01LTEtMS0xNTk1NDA_76e28b35-7962-4a4d-81bb-c2a7e1b86e75">1,239.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida76f129eae2411aac66cefe0c47c6fc_I20220930" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMy03LTEtMS0xNTk1NDA_74cf33c2-091c-4dc6-af1d-50073c278e6b">7.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic34ce18d9ac34702bf22cdc268d8fddc_I20220930" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMy05LTEtMS0xNTk1NDA_5234a2e4-073c-49a9-929c-c76431a66b80">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice641419095d40b58b1ec413657e5350_I20220930" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMy0xMS0xLTEtMTU5NTQw_4f6ca784-8d50-441e-97f9-624c2e4bddac">1,246.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term investments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifab6a7669381463baa4bcac0c28cb1ec_I20220930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfNi0xLTEtMS0xNTk1NDA_30c10619-e70d-4924-8576-408b3384afd1">43.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8f3a57231c145049540a666d70b036f_I20220930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfNi0zLTEtMS0xNTk1NDA_6c7e25e5-e196-4019-9910-9a46acd1fe9a">43.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bdbf4b6981d423b84e97332dcaf6c1a_I20220930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfNi01LTEtMS0xNTk1NDA_e95852ef-2150-4460-96d5-df7dd02cd1c9">43.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1140c058291487fa611ebff0a87770b_I20220930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfNi03LTEtMS0xNTk1NDA_7a8defb7-caba-4e2f-af41-4fca2c8d2dfa">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78d99dff74e3423da8f09146d5ccfac9_I20220930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfNi05LTEtMS0xNTk1NDA_b048abc3-724b-4299-99f4-0e5db8b9110b">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i047635964deb4302a146b6e33a2497a8_I20220930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfNi0xMS0xLTEtMTU5NTQw_530f232d-70f6-446d-8429-0270e04c02dc">43.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2743696771f346c8b079973d11a7071f_I20220930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfNy0xLTEtMS0xNTk1NDA_052d25d3-5810-4ec2-b834-e709b357e3de">51.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33275a4d21e64200a487dc63563ca001_I20220930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfNy0zLTEtMS0xNTk1NDA_3e135d91-f69e-4dad-a13e-e2b15b3c3399">51.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a4a874cc47f46a2a264722d13461f46_I20220930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfNy01LTEtMS0xNTk1NDA_754dc1ae-d820-4afd-8d9b-97429fd3224b">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b78e10d989e462c8d6d0340d904cc92_I20220930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfNy03LTEtMS0xNTk1NDA_33403580-2a0c-43fe-b168-fc6e2fbfad72">51.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic182ac3c1369411e8483ee598bedbe15_I20220930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfNy05LTEtMS0xNTk1NDA_25e41940-af39-4cb4-aee3-3a2090439889">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5db88938a794a79995152d200739e71_I20220930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfNy0xMS0xLTEtMTU5NTQw_bfb58401-b833-4ebe-9ed9-5cc87c5afa3d">51.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if975bb8107f649de87a30d9d0518813d_I20220930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfOS0xLTEtMS0xNTk1NDA_f5dc5b67-6257-423e-b9bb-a359f20d9c1c">3.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i035b6f8bf7fd4eb2ade6d5c56da79b71_I20220930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfOS0zLTEtMS0xNTk1NDA_62c20e37-31ec-4725-b18a-1bac93ee5e7a">3.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i313d32c12b5e46a3b70bb355b88d33ae_I20220930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfOS01LTEtMS0xNTk1NDA_d681c21b-5ac0-434f-9eb6-c46ce72a7632">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia62987f3e7a14b4cba45477046b24356_I20220930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfOS03LTEtMS0xNTk1NDA_c5c302ef-e225-4bd5-84cf-2b29c818f545">3.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81cc2677a958476298d6e691a227d2ef_I20220930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfOS05LTEtMS0xNTk1NDA_13665a64-fc20-4dc7-a36a-7b63f395c683">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibafa8194f14245d092cf8e3fef7acc20_I20220930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfOS0xMS0xLTEtMTU5NTQw_90b91c05-9116-449d-ad0e-8b815dffc699">3.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5c5c6181311407dbfeb6b2bc5dabd45_I20220930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMTAtMS0xLTEtMTU5NTQw_655c3b21-9340-4c2d-94f0-a83cfc66d1f7">27.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cd5419a2b1e4f1dae5ad80e024ffbd8_I20220930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMTAtMy0xLTEtMTU5NTQw_5362c58b-b06e-4e49-958a-e7cb4b853572">27.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa5439e6f71a449badc6db614afe1fc0_I20220930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMTAtNS0xLTEtMTU5NTQw_6f85d79f-bca6-44c5-82d2-4cfd7bf4fd08">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7e1bfc7167249e09fd9253c7056e6a4_I20220930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMTAtNy0xLTEtMTU5NTQw_83a8514f-05a2-4242-893b-05fb9e3b34db">14.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i184415738c194fc89b0a1a3ae91e05f6_I20220930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMTAtOS0xLTEtMTU5NTQw_03eee07c-6243-4f36-9b5b-1e290e847a13">12.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99cd69cddcd1432eb41f86a6c107e126_I20220930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMTAtMTEtMS0xLTE1OTU0MA_1c009b28-7a56-4655-aa0d-9dc0a09be431">27.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term investments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia25fb80ee7f14608ad1bc42cf7dc3d85_I20220930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMTItMS0xLTEtMTU5NTQw_8c9fa782-80ad-44f5-b3dc-09784bd399a7">124.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncurrent investments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifab6a7669381463baa4bcac0c28cb1ec_I20220930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMTUtMS0xLTEtMTU5NTQw_4f823aca-1097-4ad5-97ae-fdff8e8fc161">131.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8f3a57231c145049540a666d70b036f_I20220930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMTUtMy0xLTEtMTU5NTQw_77e928af-9068-4fa5-8b1a-69b9a853ce55">148.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bdbf4b6981d423b84e97332dcaf6c1a_I20220930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMTUtNS0xLTEtMTU5NTQw_ddfa3ae4-10f1-44bf-85c9-d383008ad0aa">131.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1140c058291487fa611ebff0a87770b_I20220930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMTUtNy0xLTEtMTU5NTQw_e7483636-af60-4210-9bda-9fe45a5d47c4">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78d99dff74e3423da8f09146d5ccfac9_I20220930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMTUtOS0xLTEtMTU5NTQw_a2e639ef-7940-42d6-9901-835994db0016">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i047635964deb4302a146b6e33a2497a8_I20220930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMTUtMTEtMS0xLTE1OTU0MA_eeedb3d3-15cc-415f-8f04-751577dad833">131.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2743696771f346c8b079973d11a7071f_I20220930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMTctMS0xLTEtMTU5NTQw_3e4935bf-3fff-429c-80f9-04ca0d240a88">206.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33275a4d21e64200a487dc63563ca001_I20220930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMTctMy0xLTEtMTU5NTQw_3a8e0db3-9cd8-45a7-97f2-cfea141b3f9e">232.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a4a874cc47f46a2a264722d13461f46_I20220930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMTctNS0xLTEtMTU5NTQw_a0e12a97-0adb-48af-9231-76f57b931744">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b78e10d989e462c8d6d0340d904cc92_I20220930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMTctNy0xLTEtMTU5NTQw_e4b6dce1-f351-4c15-ad3d-9ca8bda89b82">206.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic182ac3c1369411e8483ee598bedbe15_I20220930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMTctOS0xLTEtMTU5NTQw_237d224d-90b4-4756-bce8-3a42084e7e1e">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5db88938a794a79995152d200739e71_I20220930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMTctMTEtMS0xLTE1OTU0MA_f3105b3b-383d-4e1c-a067-e9dd9ece33e7">206.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9351338d7d4b429093117dd87f8b02de_I20220930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMTgtMS0xLTEtMTU5NTQw_b6810022-f21d-46cd-b78a-e1c90023a85a">143.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98487cf76fa84cba948c2fa763c08c17_I20220930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMTgtMy0xLTEtMTU5NTQw_e1b71066-7247-4bd3-9785-ff5d464a2cbd">156.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i921241c16da34890a377c6cc0f05bf9a_I20220930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMTgtNS0xLTEtMTU5NTQw_91f8ac2a-d7ef-4aec-b737-64ecf554b6c7">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8c508d73f5d490c991f152f357c2edc_I20220930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMTgtNy0xLTEtMTU5NTQw_bcbd68c1-7006-4713-948c-68c05b6c9c11">143.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fcf6ea2160140fcb9374937bebdf459_I20220930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMTgtOS0xLTEtMTU5NTQw_df7a88ff-de03-4b12-95d6-30eb7d45e8be">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5892dce618474c3397f2f21748d154da_I20220930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMTgtMTEtMS0xLTE1OTU0MA_63dc4ef0-f59a-4ac3-af4a-4efcfbefee01">143.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if975bb8107f649de87a30d9d0518813d_I20220930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMTktMS0xLTEtMTU5NTQw_00bb232e-3f9e-492d-8852-39fa209c29ec">43.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i035b6f8bf7fd4eb2ade6d5c56da79b71_I20220930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMTktMy0xLTEtMTU5NTQw_78f53150-12e4-4128-8201-ce9f46292ed8">45.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i313d32c12b5e46a3b70bb355b88d33ae_I20220930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMTktNS0xLTEtMTU5NTQw_90ad37c5-85a5-49b7-b7a9-2516c044a82f">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia62987f3e7a14b4cba45477046b24356_I20220930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMTktNy0xLTEtMTU5NTQw_337140b6-4036-4440-91a4-520f6c52cc7d">43.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81cc2677a958476298d6e691a227d2ef_I20220930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMTktOS0xLTEtMTU5NTQw_9f352256-cbf6-494b-bf6b-42fb4eadfdf7">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibafa8194f14245d092cf8e3fef7acc20_I20220930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMTktMTEtMS0xLTE1OTU0MA_06039997-5311-44ab-9897-d7774104aca5">43.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i839d1d25f31e4a1e8f8686d85cd27d6f_I20220930" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMjAtMS0xLTEtMTU5NTQw_a978486d-6469-4731-a897-bc81703c9538">152.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66f937e8eb9d439fb99fc1eaf5bb8229_I20220930" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMjAtMy0xLTEtMTU5NTQw_c61d361a-f168-4771-a0a5-63f9d93e8afb">96.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d540d6e9952406eae86fcb404c8aa3f_I20220930" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMjAtNS0xLTEtMTU5NTQw_59f6c1fa-eaae-421c-baac-26a07a8a8df9">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac853f32fb164d5dbb16b853b6478ad8_I20220930" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMjAtNy0xLTEtMTU5NTQw_66d96170-cb32-4695-aafa-ea428c262282">39.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d0248c83e9f42aebdedbe45913091c1_I20220930" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMjAtOS0xLTEtMTU5NTQw_08491453-b555-48d9-9d2c-f5bfe431e8bd">113.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f00b6f0d7a346a0bbf8ca789b9b4986_I20220930" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMjAtMTEtMS0xLTE1OTU0MA_ae0e8a05-1354-4c22-ba19-f8244b2dddef">152.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id469158a1a2340c0b51dedb185916c2c_I20220930" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMjEtMS0xLTEtMTU5NTQw_deeb4aa8-eeb0-414b-a3a0-d86e3e1c4b05">549.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2330a365ee524585810c28f7dc20e39e_I20220930" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMjEtMy0xLTEtMTU5NTQw_f4fa3e8b-597c-4675-a1ee-fa981aa22eba">416.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb940b9eace84fd38c98429f0f9808ce_I20220930" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMjEtNS0xLTEtMTU5NTQw_ca7f6c7a-476d-4396-a753-7d810ecda772">549.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib28917d514b84c3397d29e8e54a589da_I20220930" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMjEtNy0xLTEtMTU5NTQw_b6f663a8-89fa-495e-ac7a-60c38a461325">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4c3874a92684287bd36704e5ff16e8a_I20220930" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMjEtOS0xLTEtMTU5NTQw_cc1ddcd6-f30f-499d-a748-69e8cc826391">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i700bccbf1683474084361d2cee367dc8_I20220930" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMjEtMTEtMS0xLTE1OTU0MA_b827dbfd-5d6f-4daf-8ebb-691b6612c340">549.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity investments without readily determinable fair values</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia25fb80ee7f14608ad1bc42cf7dc3d85_I20220930" decimals="-5" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMjItMS0xLTEtMTU5NTQw_43cf3cab-66bc-410a-815d-0db050aa205b">583.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity method investments</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7532b4a86304eaf897b92f1ef90f733_I20220930" decimals="-5" name="us-gaap:OtherLongTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMjMtMS0xLTEtMTU5NTQw_0e8d0aab-2aca-45db-b861-610cbb6dfc1a">764.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncurrent investments</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia25fb80ee7f14608ad1bc42cf7dc3d85_I20220930" decimals="-5" name="us-gaap:LongTermInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMjQtMS0xLTEtMTU5NTQw_ceea8f95-4c9c-473c-9381-a572a8716b92">2,574.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3b630730b424a6d8b697cf0362c83d2_I20211231" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMjctMS0xLTEtMTU5NTQw_7b66aac1-5e07-4766-b62d-f2d335009b63">2,379.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d06252e717445c989a037b2b13d0128_I20211231" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMjctMy0xLTEtMTU5NTQw_0dbc3d35-107a-4fb6-a6db-8ab9a1fbf94e">2,379.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6802f141d8af4b8aa65c6abe305eeed2_I20211231" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMjctNS0xLTEtMTU5NTQw_2467fa7e-f467-41ab-bd5c-7b6ee9e5b6cc">2,361.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i124320eb89ce4dfa87c2f2083ad1e10b_I20211231" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMjctNy0xLTEtMTU5NTQw_e9ca3d15-ce0a-4578-b6af-74402e255acc">18.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f37875c8bb94fed916b3375076f0703_I20211231" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMjctOS0xLTEtMTU5NTQw_1f815554-d81c-4187-91a3-b86b238069f3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52e3293fb124489e844061750e511c35_I20211231" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMjctMTEtMS0xLTE1OTU0MA_e256ec1c-7bcc-436f-88d0-73c5fb6c3cb4">2,379.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term investments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70cd211932aa44d4b6f18e4a94acaa15_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMzAtMS0xLTEtMTU5NTQw_c0da060b-b885-453b-ae08-f6ba6607790c">25.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47952f5ad6b1477c8890a2ebe950ab13_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMzAtMy0xLTEtMTU5NTQw_1100363e-6803-4544-976c-fb8ae6ea81cf">25.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iddfe43e26a024cd3b793575cebd70372_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMzAtNS0xLTEtMTU5NTQw_421764a3-8a3b-46f1-ace1-ae0f5ccc3cc5">25.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic82b5cca8a0748c4ad44ff28aa5c8c63_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMzAtNy0xLTEtMTU5NTQw_18bb5c48-352d-4382-961b-64103c434c69">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19bcbbad1685404f997100cdd7ba2b51_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMzAtOS0xLTEtMTU5NTQw_a9166f0a-1aeb-4cec-8635-8f0dbc18e355">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb1ad2dc0cab41488bb60c7f417df54c_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMzAtMTEtMS0xLTE1OTU0MA_4889383f-c53b-4aaf-a727-f8c740d6bd93">25.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb25438d52ac455ba62e9095554c8121_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMzEtMS0xLTEtMTU5NTQw_2cad25b6-ee2b-4be4-922b-ca87f6302be4">43.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabe3e352015e443c90f93e7aee3a5340_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMzEtMy0xLTEtMTU5NTQw_52209efd-b5d5-488f-a728-e16b4a341a5a">43.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d09607d938a418caf31b9504379627d_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMzEtNS0xLTEtMTU5NTQw_2044d514-8d2a-42b4-aaee-83dbbf2bc194">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70c1a238fafa4e82bb91738050707531_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMzEtNy0xLTEtMTU5NTQw_48e6f4de-f6d0-48c7-8bf8-d65fb435960c">43.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94da7f9a237b4f5d92545750475e0865_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMzEtOS0xLTEtMTU5NTQw_0387427d-5688-4a9f-8513-3db44bf13f13">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iace537990e0345b984d5d9b511dbd56b_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMzEtMTEtMS0xLTE1OTU0MA_ddb7535a-79ad-41a1-8028-5238d3eaa7e2">43.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i122e96dd9f3645a1845a400915d238b3_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMzItMS0xLTEtMTU5NTQw_4a9755d6-1970-4c49-a26b-2f96abe30c17">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2193cdcf640b46f79e5eb9ee0bdb3eb2_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMzItMy0xLTEtMTU5NTQw_968a280b-6dfe-49ea-8996-8171f0ba60d2">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb15d5720b2447969c89619f23a52bcd_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMzItNS0xLTEtMTU5NTQw_4bb90297-c356-45c8-9a40-66fc5dc9e3d9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83fbafd3b87749b69732c68f1032fe86_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMzItNy0xLTEtMTU5NTQw_9431e545-5966-4707-9c0c-c892fa07d563">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5e4829c2687480ba72b8c79c38602c5_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMzItOS0xLTEtMTU5NTQw_53f4bbc9-a0f8-43b3-80ef-1c4747e2322f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e0c7dd136f94803b44868029c626465_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMzItMTEtMS0xLTE1OTU0MA_21f0e55a-d8a9-4231-8d6b-71693a9361d2">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77a8bad9e7b643b3be999c26e7f341f3_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMzMtMS0xLTEtMTU5NTQw_6ef467e6-6bec-4457-9999-ed448e96fa78">6.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3729e6381590490cad36d5c52a3a9a30_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMzMtMy0xLTEtMTU5NTQw_bc0c326f-5d34-4b0e-8f3b-530d7b55417d">6.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65d4f921c43e46389cd396c859835baa_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMzMtNS0xLTEtMTU5NTQw_fe9752cc-d4f5-4125-9759-093427290636">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifea7137c64a940b98bfaf9336e0de8ed_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMzMtNy0xLTEtMTU5NTQw_0cd4dba2-48f3-4ac3-a17e-a844b4aa9585">6.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb1fc1f870e44eb8b489ae050e35d2ec_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMzMtOS0xLTEtMTU5NTQw_b34f0e66-9494-4c18-8c85-c649a7749463">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5843990a9b9642e089425093f642f011_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMzMtMTEtMS0xLTE1OTU0MA_19f2a45a-3903-414b-bc1f-f9b46120e90b">6.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d4a6fcb14b84769a71beaa7fadd7543_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMzQtMS0xLTEtMTU5NTQw_bbd695a7-43e1-47aa-8426-a73e14e4140d">14.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib55c35900e8f4879bbab1c3db2b414e6_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMzQtMy0xLTEtMTU5NTQw_4f332b60-d353-403c-b638-2d42cbcc726e">14.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i514a63925c814a928a17a95e4d93d7cb_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMzQtNS0xLTEtMTU5NTQw_6e73d3d1-890b-4ece-ba14-28fa22ac6d35">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e737ad3e2234f028bf65d35bf37f064_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMzQtNy0xLTEtMTU5NTQw_df349d80-9897-4b76-b9cc-7c5cfc836467">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8e9125bc9f34767a3e05b3c767b3498_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMzQtOS0xLTEtMTU5NTQw_9cd8843e-e6f3-44ae-acc0-4c612e6dc78b">14.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0e7cf4206ef42778711f85fddbfe12c_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMzQtMTEtMS0xLTE1OTU0MA_84661a8f-36b9-416e-8bf4-17b53ea56a91">14.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term investments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3b630730b424a6d8b697cf0362c83d2_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMzYtMS0xLTEtMTU5NTQw_a1311ae5-10fe-420c-a7e9-178fa9e5e494">90.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncurrent investments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70cd211932aa44d4b6f18e4a94acaa15_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMzktMS0xLTEtMTU5NTQw_15d66309-3d4f-4f49-abc4-eb1330c14607">137.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47952f5ad6b1477c8890a2ebe950ab13_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMzktMy0xLTEtMTU5NTQw_fe7d663f-4f6a-4d1f-9e54-34ed4130ae72">136.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iddfe43e26a024cd3b793575cebd70372_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMzktNS0xLTEtMTU5NTQw_69e75e5e-d4bb-4e0a-9c94-b5f82f911162">137.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic82b5cca8a0748c4ad44ff28aa5c8c63_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMzktNy0xLTEtMTU5NTQw_ddcd1559-d70f-4d48-9409-d74db71cf56b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19bcbbad1685404f997100cdd7ba2b51_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMzktOS0xLTEtMTU5NTQw_6e712349-8bf7-4309-896e-f5650e62a9e7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb1ad2dc0cab41488bb60c7f417df54c_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMzktMTEtMS0xLTE1OTU0MA_b55c9a85-870a-4bd9-a2f2-0efd372b7297">137.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb25438d52ac455ba62e9095554c8121_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfNDAtMS0xLTEtMTU5NTQw_9de13d7e-0e0f-4a2f-af06-a6c84ccb4588">235.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabe3e352015e443c90f93e7aee3a5340_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfNDAtMy0xLTEtMTU5NTQw_319ad318-d462-40de-b52f-9714e3100bd4">232.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d09607d938a418caf31b9504379627d_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfNDAtNS0xLTEtMTU5NTQw_ed893770-c64a-4eff-aa20-8542c474a054">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70c1a238fafa4e82bb91738050707531_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfNDAtNy0xLTEtMTU5NTQw_0057f2b7-d6d0-4974-9749-e94009453be8">235.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94da7f9a237b4f5d92545750475e0865_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfNDAtOS0xLTEtMTU5NTQw_71e41d7a-b672-4263-a7a5-994a9e9f7f4c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iace537990e0345b984d5d9b511dbd56b_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfNDAtMTEtMS0xLTE1OTU0MA_8b3486fb-70b4-4456-8250-34073e4aa89b">235.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i122e96dd9f3645a1845a400915d238b3_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfNDEtMS0xLTEtMTU5NTQw_53fe74f9-f8d7-42b4-9afb-6fb9f7bbc2b6">109.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2193cdcf640b46f79e5eb9ee0bdb3eb2_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfNDEtMy0xLTEtMTU5NTQw_3aa812ff-adfc-4eb1-9951-66c05d711224">108.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb15d5720b2447969c89619f23a52bcd_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfNDEtNS0xLTEtMTU5NTQw_c5014f5c-26e0-4957-a321-8c117536ad26">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83fbafd3b87749b69732c68f1032fe86_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfNDEtNy0xLTEtMTU5NTQw_2a512c98-0933-4e70-80a6-666b5f66bce2">109.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5e4829c2687480ba72b8c79c38602c5_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfNDEtOS0xLTEtMTU5NTQw_2cf65041-9992-4987-906b-efa0d10d7c05">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e0c7dd136f94803b44868029c626465_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfNDEtMTEtMS0xLTE1OTU0MA_7ddec577-50c1-42e6-9764-7cb61a987502">109.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77a8bad9e7b643b3be999c26e7f341f3_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfNDItMS0xLTEtMTU5NTQw_c6ec8f93-6aec-4720-a531-22fb6fb38030">23.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3729e6381590490cad36d5c52a3a9a30_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfNDItMy0xLTEtMTU5NTQw_408b5c13-68ae-451f-b783-5f190843a3c5">23.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65d4f921c43e46389cd396c859835baa_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfNDItNS0xLTEtMTU5NTQw_12486ee3-0f84-4d73-a39f-011c522d1c62">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifea7137c64a940b98bfaf9336e0de8ed_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfNDItNy0xLTEtMTU5NTQw_d0c68b71-0a25-498b-87c8-d5d82386e23b">23.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb1fc1f870e44eb8b489ae050e35d2ec_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfNDItOS0xLTEtMTU5NTQw_d4c91593-5ee7-40c7-bd37-549f7fd6aede">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5843990a9b9642e089425093f642f011_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfNDItMTEtMS0xLTE1OTU0MA_f43e31f5-5d4f-4601-90a5-6f245ac2b14a">23.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37d081dc80d549d0b7cf06f3dd0f097c_I20211231" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfNDMtMS0xLTEtMTU5NTQw_c27e376e-c098-4bbf-a860-8d10b104fc45">108.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebaf7a78928c429596dc216106cd2f95_I20211231" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfNDMtMy0xLTEtMTU5NTQw_6fc87c01-6efe-4949-9de4-b7ba6e85c61e">22.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a82bacb2ac843e1b6f6f2fe0be9b508_I20211231" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfNDMtNS0xLTEtMTU5NTQw_64426407-62cc-4ce5-8bd8-2e1bd520a816">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iddd8d40ea4024e44853ebae245c8ff89_I20211231" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfNDMtNy0xLTEtMTU5NTQw_461d6cc0-c4a8-4f21-ac5a-aab383791e52">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee09e9df8cb24a98b446ff1b40b49036_I20211231" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfNDMtOS0xLTEtMTU5NTQw_1a1d9ffa-324d-46aa-98e7-b103c32ed0cb">108.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76efc9c2d361426a8fabf8f468eae443_I20211231" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfNDMtMTEtMS0xLTE1OTU0MA_51023642-42a9-4daf-828d-c13b9640b9ef">108.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i900be75d24cb4d0e8aaf431324f245f7_I20211231" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfNDQtMS0xLTEtMTU5NTQw_d6163976-f1e6-46e1-a57a-c5a5384560b5">1,279.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0829e7b5687473690dec2d117e19409_I20211231" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfNDQtMy0xLTEtMTU5NTQw_37ed1f2b-2553-434a-9a38-94cf9064822d">487.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdba688916644cc684b154cd319074ad_I20211231" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfNDQtNS0xLTEtMTU5NTQw_66d6b23e-834a-4a90-bc92-826cf0c93afa">1,279.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74870f5304a445feafaa0e95c37df511_I20211231" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfNDQtNy0xLTEtMTU5NTQw_fc360f18-9e6a-4ac0-bce3-2d65f108c76e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec666b23a81840999cae844ee05abaf5_I20211231" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfNDQtOS0xLTEtMTU5NTQw_c07932cc-717a-49c5-be6c-d06aa60b62ac">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4dddf28fc04840efa98b6944bdadf64c_I20211231" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfNDQtMTEtMS0xLTE1OTU0MA_ff317ec6-c800-44f2-8a1d-ae36d8af4ce2">1,279.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity investments without readily determinable fair values</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3b630730b424a6d8b697cf0362c83d2_I20211231" decimals="-5" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfNDUtMS0xLTEtMTU5NTQw_6a77511b-20ea-4d06-9057-064a5f628f72">548.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity method investments</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89e7fea8ea92492693f830dd7afa0d55_I20211231" decimals="-5" name="us-gaap:OtherLongTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfNDYtMS0xLTEtMTU5NTQw_5d9bcb86-8e21-4517-8e47-2fa2d674c981">771.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncurrent investments</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3b630730b424a6d8b697cf0362c83d2_I20211231" decimals="-5" name="us-gaap:LongTermInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfNDctMS0xLTEtMTU5NTQw_2102108b-a17f-4cba-ba25-7847b199c60c">3,212.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">For available-for-sale debt securities, amounts disclosed represent the securities' amortized cost.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Fair value disclosures are not applicable for equity method investments and investments accounted for under the measurement alternative for equity investments.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:11pt"><ix:continuation id="i81a1014c662b4c0a83dff086461700ef" continuedAt="if70a84d3b8e9487ea97fe69a98293411"><ix:nonNumeric contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RleHRyZWdpb246OGRmOTEwZDdhYjFhNDFmMThlODU5ZTE4OTQxY2E4MDhfMTUxNjQ_9cf34e74-a993-46a9-8fb7-348a8e1f7585" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:38.870%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.320%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.320%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.320%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.320%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.322%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices in Active Markets for Identical Assets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Other Observable Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Short-term commercial paper borrowings</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 30, 2022</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia25fb80ee7f14608ad1bc42cf7dc3d85_I20220930" decimals="-5" name="us-gaap:CommercialPaper" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjcyZmFiYWVlZWVhODRmZTdiN2E3NjI2ZTAwNzM2ODg2L3RhYmxlcmFuZ2U6NzJmYWJhZWVlZWE4NGZlN2I3YTc2MjZlMDA3MzY4ODZfMy0xLTEtMS0xNTk1NDA_7420c4f6-cf56-4f12-bad4-5a53445716fd">1,741.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i909f721d549b4d17b64fd5ef7a64ed65_I20220930" decimals="-5" name="us-gaap:CommercialPaper" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjcyZmFiYWVlZWVhODRmZTdiN2E3NjI2ZTAwNzM2ODg2L3RhYmxlcmFuZ2U6NzJmYWJhZWVlZWE4NGZlN2I3YTc2MjZlMDA3MzY4ODZfMy0zLTEtMS0xNTk1NDA_48d1e888-4a78-41b2-8575-3184a47b5b45">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ida76f129eae2411aac66cefe0c47c6fc_I20220930" decimals="-5" name="us-gaap:CommercialPaper" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjcyZmFiYWVlZWVhODRmZTdiN2E3NjI2ZTAwNzM2ODg2L3RhYmxlcmFuZ2U6NzJmYWJhZWVlZWE4NGZlN2I3YTc2MjZlMDA3MzY4ODZfMy01LTEtMS0xNTk1NDA_b88c5560-aa75-4b1f-8c2a-232eab6d23f7">1,738.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic34ce18d9ac34702bf22cdc268d8fddc_I20220930" decimals="-5" name="us-gaap:CommercialPaper" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjcyZmFiYWVlZWVhODRmZTdiN2E3NjI2ZTAwNzM2ODg2L3RhYmxlcmFuZ2U6NzJmYWJhZWVlZWE4NGZlN2I3YTc2MjZlMDA3MzY4ODZfMy03LTEtMS0xNTk1NDA_7a4cc1b6-b1c6-495a-ae98-04e8ae4f9fae">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ice641419095d40b58b1ec413657e5350_I20220930" decimals="-5" name="us-gaap:CommercialPaper" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjcyZmFiYWVlZWVhODRmZTdiN2E3NjI2ZTAwNzM2ODg2L3RhYmxlcmFuZ2U6NzJmYWJhZWVlZWE4NGZlN2I3YTc2MjZlMDA3MzY4ODZfMy05LTEtMS0xNTk1NDA_2c2af7bf-92d5-4a21-9fa7-7fb4c3947d94">1,738.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3b630730b424a6d8b697cf0362c83d2_I20211231" decimals="-5" name="us-gaap:CommercialPaper" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjcyZmFiYWVlZWVhODRmZTdiN2E3NjI2ZTAwNzM2ODg2L3RhYmxlcmFuZ2U6NzJmYWJhZWVlZWE4NGZlN2I3YTc2MjZlMDA3MzY4ODZfNC0xLTEtMS0xNTk1NDA_025c32dc-423b-4e5f-955e-380391d3d409">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6802f141d8af4b8aa65c6abe305eeed2_I20211231" decimals="-5" name="us-gaap:CommercialPaper" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjcyZmFiYWVlZWVhODRmZTdiN2E3NjI2ZTAwNzM2ODg2L3RhYmxlcmFuZ2U6NzJmYWJhZWVlZWE4NGZlN2I3YTc2MjZlMDA3MzY4ODZfNC0zLTEtMS0xNTk1NDA_3a4f749f-fc88-45b4-b3e9-24998a15bb87">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i124320eb89ce4dfa87c2f2083ad1e10b_I20211231" decimals="-5" name="us-gaap:CommercialPaper" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjcyZmFiYWVlZWVhODRmZTdiN2E3NjI2ZTAwNzM2ODg2L3RhYmxlcmFuZ2U6NzJmYWJhZWVlZWE4NGZlN2I3YTc2MjZlMDA3MzY4ODZfNC01LTEtMS0xNTk1NDA_546cb3b4-8d82-4d9b-83fb-b37859df70e9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f37875c8bb94fed916b3375076f0703_I20211231" decimals="-5" name="us-gaap:CommercialPaper" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjcyZmFiYWVlZWVhODRmZTdiN2E3NjI2ZTAwNzM2ODg2L3RhYmxlcmFuZ2U6NzJmYWJhZWVlZWE4NGZlN2I3YTc2MjZlMDA3MzY4ODZfNC03LTEtMS0xNTk1NDA_8ee8caf3-bdf4-4424-b31b-421b1224d2d9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52e3293fb124489e844061750e511c35_I20211231" decimals="-5" name="us-gaap:CommercialPaper" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjcyZmFiYWVlZWVhODRmZTdiN2E3NjI2ZTAwNzM2ODg2L3RhYmxlcmFuZ2U6NzJmYWJhZWVlZWE4NGZlN2I3YTc2MjZlMDA3MzY4ODZfNC05LTEtMS0xNTk1NDA_7df4475d-7590-4e02-b1e6-271976608ede">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Long-term debt, including current portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 30, 2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia25fb80ee7f14608ad1bc42cf7dc3d85_I20220930" decimals="-5" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjcyZmFiYWVlZWVhODRmZTdiN2E3NjI2ZTAwNzM2ODg2L3RhYmxlcmFuZ2U6NzJmYWJhZWVlZWE4NGZlN2I3YTc2MjZlMDA3MzY4ODZfNi0xLTEtMS0xNTk1NDA_d62b2cfe-dc1a-4374-bd46-a55cfcc379f3">14,147.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i909f721d549b4d17b64fd5ef7a64ed65_I20220930" decimals="-5" name="us-gaap:LongTermDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjcyZmFiYWVlZWVhODRmZTdiN2E3NjI2ZTAwNzM2ODg2L3RhYmxlcmFuZ2U6NzJmYWJhZWVlZWE4NGZlN2I3YTc2MjZlMDA3MzY4ODZfNi0zLTEtMS0xNTk1NDA_10d5c607-7b6c-4243-b863-c2dcaae216b6">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ida76f129eae2411aac66cefe0c47c6fc_I20220930" decimals="-5" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjcyZmFiYWVlZWVhODRmZTdiN2E3NjI2ZTAwNzM2ODg2L3RhYmxlcmFuZ2U6NzJmYWJhZWVlZWE4NGZlN2I3YTc2MjZlMDA3MzY4ODZfNi01LTEtMS0xNTk1NDA_70b5fdf3-9fc1-4290-bd75-44b912f10b37">11,848.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic34ce18d9ac34702bf22cdc268d8fddc_I20220930" decimals="-5" name="us-gaap:LongTermDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjcyZmFiYWVlZWVhODRmZTdiN2E3NjI2ZTAwNzM2ODg2L3RhYmxlcmFuZ2U6NzJmYWJhZWVlZWE4NGZlN2I3YTc2MjZlMDA3MzY4ODZfNi03LTEtMS0xNTk1NDA_ff95524b-e84f-4008-97ef-2a9e3c150d63">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ice641419095d40b58b1ec413657e5350_I20220930" decimals="-5" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjcyZmFiYWVlZWVhODRmZTdiN2E3NjI2ZTAwNzM2ODg2L3RhYmxlcmFuZ2U6NzJmYWJhZWVlZWE4NGZlN2I3YTc2MjZlMDA3MzY4ODZfNi05LTEtMS0xNTk1NDA_34707b5d-0cc8-4966-b228-a657e42af3b8">11,848.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic3b630730b424a6d8b697cf0362c83d2_I20211231" decimals="-5" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjcyZmFiYWVlZWVhODRmZTdiN2E3NjI2ZTAwNzM2ODg2L3RhYmxlcmFuZ2U6NzJmYWJhZWVlZWE4NGZlN2I3YTc2MjZlMDA3MzY4ODZfNy0xLTEtMS0xNTk1NDA_2b9e2e9d-7c11-4a8a-ac3a-18ac3d4dac90">16,884.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6802f141d8af4b8aa65c6abe305eeed2_I20211231" decimals="-5" name="us-gaap:LongTermDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjcyZmFiYWVlZWVhODRmZTdiN2E3NjI2ZTAwNzM2ODg2L3RhYmxlcmFuZ2U6NzJmYWJhZWVlZWE4NGZlN2I3YTc2MjZlMDA3MzY4ODZfNy0zLTEtMS0xNTk1NDA_09d7cbb5-d425-407d-abd5-daf856309fb4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i124320eb89ce4dfa87c2f2083ad1e10b_I20211231" decimals="-5" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjcyZmFiYWVlZWVhODRmZTdiN2E3NjI2ZTAwNzM2ODg2L3RhYmxlcmFuZ2U6NzJmYWJhZWVlZWE4NGZlN2I3YTc2MjZlMDA3MzY4ODZfNy01LTEtMS0xNTk1NDA_c8f22544-7716-4e98-a73e-0b08ced8dc96">18,157.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f37875c8bb94fed916b3375076f0703_I20211231" decimals="-5" name="us-gaap:LongTermDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjcyZmFiYWVlZWVhODRmZTdiN2E3NjI2ZTAwNzM2ODg2L3RhYmxlcmFuZ2U6NzJmYWJhZWVlZWE4NGZlN2I3YTc2MjZlMDA3MzY4ODZfNy03LTEtMS0xNTk1NDA_434d68d6-5d65-4d5e-bff7-3638f8705a88">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i52e3293fb124489e844061750e511c35_I20211231" decimals="-5" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjcyZmFiYWVlZWVhODRmZTdiN2E3NjI2ZTAwNzM2ODg2L3RhYmxlcmFuZ2U6NzJmYWJhZWVlZWE4NGZlN2I3YTc2MjZlMDA3MzY4ODZfNy05LTEtMS0xNTk1NDA_a78bfa23-a816-4245-b199-c78a9bd93809">18,157.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span><br/></span></div><div><ix:continuation id="if70a84d3b8e9487ea97fe69a98293411" continuedAt="i69c07437f434411caf87c5d63a2351cb"><ix:nonNumeric contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930" name="us-gaap:FairValueByBalanceSheetGroupingTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RleHRyZWdpb246OGRmOTEwZDdhYjFhNDFmMThlODU5ZTE4OTQxY2E4MDhfMTUxMjU_1236d36a-e08a-4940-96ed-a206440b1a5f" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:37.870%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.517%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.517%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.517%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.517%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.522%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices in Active Markets for Identical Assets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Other Observable Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk-management instruments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest rate contracts designated as fair value hedges:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i49af86cdb4774f6da136e21a258b9f38_I20220930" decimals="-5" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfOC0xLTEtMS0xNTk1NDA_458a107c-8eea-400b-a657-4a0ff904219c">140.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b96398a66a144a9aa05b43dea309d1a_I20220930" decimals="-5" name="us-gaap:DerivativeLiabilitiesNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfOC0zLTEtMS0xNTk1NDA_3c2c8659-be59-40fa-b529-3cc9c6818c50">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9eb05f2daf0940029ed9c6f6079b072c_I20220930" decimals="-5" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfOC01LTEtMS0xNTk1NDA_bd5d7c80-fb2a-4011-b95d-1b181930c010">140.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cbd0bb84e934e18aa8a68f2ed4e3278_I20220930" decimals="-5" name="us-gaap:DerivativeLiabilitiesNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfOC03LTEtMS0xNTk1NDA_8c46a2ad-b135-4b31-bfa5-f2f58be6dc64">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e03886140d04a0f90b726a0b8cb04a2_I20220930" decimals="-5" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfOC05LTEtMS0xNTk1NDA_8bd8e3b3-e776-4f74-9f05-dc9e9f141d1c">140.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest rate contracts designated as cash flow hedges:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1da8e0f672e4bc390cd335a91d4cf83_I20220930" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfMTItMS0xLTEtMTU5NTQw_dd57b20d-a74f-471c-99f6-8a7149749b93">355.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7cba691ea8004d118d604043b64cd431_I20220930" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfMTItMy0xLTEtMTU5NTQw_58e7a805-65fb-4e70-b417-727798ba8336">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1657a9a2856448687ac9aaada343dd5_I20220930" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfMTItNS0xLTEtMTU5NTQw_57ceef84-3fe3-46de-ad91-c9b62812e074">355.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i020782910cc740779ffa9060458113ba_I20220930" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfMTItNy0xLTEtMTU5NTQw_242c5ee9-a6c5-47ae-bc3a-fb17e62ed2a9">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f69ca689c7e4d23aa1cab488bb7ed65_I20220930" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfMTItOS0xLTEtMTU5NTQw_cab06653-49d3-4d64-a9d9-83ce5314f2a3">355.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cross-currency interest rate contracts designated as net investment hedges:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1300d5f8c7d44be79cb93f333746c580_I20220930" decimals="-5" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfMTUtMS0xLTEtMTU5NTQw_22e1f2f2-1e6c-42b2-ba3a-17acb986d6ad">81.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaca361ecbf3749b7a324afc87754e17e_I20220930" decimals="-5" name="us-gaap:DerivativeAssetsCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfMTUtMy0xLTEtMTU5NTQw_490ee643-f78c-48e4-9a9f-e0a1cbc14e98">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ac9d317ae404d2ebdc37459bd98e0c0_I20220930" decimals="-5" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfMTUtNS0xLTEtMTU5NTQw_78af148b-8a72-4cc9-8391-b3bbc42f15e9">81.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6a56ab1b3ed4c26b10443b11b7c0c23_I20220930" decimals="-5" name="us-gaap:DerivativeAssetsCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfMTUtNy0xLTEtMTU5NTQw_b54fa0cf-6abb-4ef0-a3db-ff471554b1bc">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7268bc376574172920167043f112985_I20220930" decimals="-5" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfMTUtOS0xLTEtMTU5NTQw_453b9670-6638-4ae0-9088-6b1158b6a484">81.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1300d5f8c7d44be79cb93f333746c580_I20220930" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfMTYtMS0xLTEtMTU5NTQw_ebdf50ae-a827-4b98-b760-613c9438eaa8">116.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaca361ecbf3749b7a324afc87754e17e_I20220930" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfMTYtMy0xLTEtMTU5NTQw_9e27aa07-70a0-44fb-a605-0e79a35b8fee">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ac9d317ae404d2ebdc37459bd98e0c0_I20220930" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfMTYtNS0xLTEtMTU5NTQw_d79fea84-482e-413c-ba99-842ed843cfd9">116.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6a56ab1b3ed4c26b10443b11b7c0c23_I20220930" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfMTYtNy0xLTEtMTU5NTQw_19332f46-9c44-491f-a98d-0aa5ba060b83">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7268bc376574172920167043f112985_I20220930" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfMTYtOS0xLTEtMTU5NTQw_7e20ae77-589b-47c0-89e9-fa96c848500c">116.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cross-currency interest rate contracts designated as cash flow hedges:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id872aa3055934897a2abffb3543add56_I20220930" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfMjAtMS0xLTEtMTU5NTQw_322b03c2-a902-4e01-8414-dc789221f7b3">8.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfd9f0975707442aa9a203b7a16441c5_I20220930" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfMjAtMy0xLTEtMTU5NTQw_1d3e6a0d-572b-4c76-9a66-2ed3d74705df">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2eb41ed3d014ed4b273125814f78a0d_I20220930" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfMjAtNS0xLTEtMTU5NTQw_aef1fa34-da10-42bb-ab0c-3951d152889e">8.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79464644e1f741088bd241cb52754676_I20220930" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfMjAtNy0xLTEtMTU5NTQw_93bc179c-7728-47a6-b89c-a9105457fb44">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35a8009df6dc423f85c1ef726d565a66_I20220930" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfMjAtOS0xLTEtMTU5NTQw_42a55421-ee80-4a33-b659-64ba86119db7">8.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id872aa3055934897a2abffb3543add56_I20220930" decimals="-5" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfMjEtMS0xLTEtMTU5NTQw_c363b830-0837-4e83-a387-ed9a16b84915">12.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfd9f0975707442aa9a203b7a16441c5_I20220930" decimals="-5" name="us-gaap:DerivativeLiabilitiesNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfMjEtMy0xLTEtMTU5NTQw_aa85cf5a-507e-4e24-9be3-f79ad22f66fa">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib2eb41ed3d014ed4b273125814f78a0d_I20220930" decimals="-5" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfMjEtNS0xLTEtMTU5NTQw_e51dd8d9-ef2c-4045-8cf7-ff180aaef8fa">12.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79464644e1f741088bd241cb52754676_I20220930" decimals="-5" name="us-gaap:DerivativeLiabilitiesNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfMjEtNy0xLTEtMTU5NTQw_27ebc35b-1998-4036-afd2-bd6b12d89ea4">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i35a8009df6dc423f85c1ef726d565a66_I20220930" decimals="-5" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfMjEtOS0xLTEtMTU5NTQw_b51103a3-95d7-424a-9274-1804e5eecfb1">12.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign exchange contracts designated as net investment hedges:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib616e3ba735b4f66ace91c9075e315e3_I20220930" decimals="-5" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfMjMtMS0xLTEtMTU5NTQw_3c67fe3d-379c-49cb-b9fe-2c92be70cbee">108.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d14a5f5fcc44e8b974f3d717097b500_I20220930" decimals="-5" name="us-gaap:DerivativeAssetsCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfMjMtMy0xLTEtMTU5NTQw_29cd5751-904d-4024-8d1e-20e27e2c3403">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7cf0b43a5a854904951946bba3c063dd_I20220930" decimals="-5" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfMjMtNS0xLTEtMTU5NTQw_419d7262-2984-4541-a997-45292104b17e">108.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie06f4bbec8ae497db6f7f77940abcf72_I20220930" decimals="-5" name="us-gaap:DerivativeAssetsCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfMjMtNy0xLTEtMTU5NTQw_f03efa66-b48c-4f00-a2cf-3eae3b20eee9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd5c8623b0274f569a6e9cb890fe814d_I20220930" decimals="-5" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfMjMtOS0xLTEtMTU5NTQw_36bbdbae-cf70-4c04-898a-e2f63ee18621">108.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib616e3ba735b4f66ace91c9075e315e3_I20220930" decimals="-5" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfMjQtMS0xLTEtMTkzNDEz_076b24bf-65b5-41f5-a7c4-a3e96ec78f00">2.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d14a5f5fcc44e8b974f3d717097b500_I20220930" decimals="-5" name="us-gaap:DerivativeLiabilitiesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfMjQtMy0xLTEtMTkzNDI3_c51231dc-48c5-4320-957a-8698b6877907">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7cf0b43a5a854904951946bba3c063dd_I20220930" decimals="-5" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfMjQtNS0xLTEtMTkzNDQw_a0e929d0-4d82-4022-bdbe-6c8c242d63f8">2.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie06f4bbec8ae497db6f7f77940abcf72_I20220930" decimals="-5" name="us-gaap:DerivativeLiabilitiesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfMjQtNy0xLTEtMTkzNDUx_acc3f89d-a9d6-45a2-99ab-1a658503186d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idd5c8623b0274f569a6e9cb890fe814d_I20220930" decimals="-5" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfMjQtOS0xLTEtMTkzNDU5_910d3f44-e0c1-437c-a1cc-a3d03f00f7e6">2.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign exchange contracts not designated as hedging instruments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0faa86378a146a48b2256a18f02b7d5_I20220930" decimals="-5" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfMjUtMS0xLTEtMTU5NTQw_c1ce4a22-4048-4e66-958a-e5fcb6eb2431">48.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec96867cd1734fb382b9a966a90c804e_I20220930" decimals="-5" name="us-gaap:DerivativeAssetsCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfMjUtMy0xLTEtMTU5NTQw_70306229-3d77-49c6-9e24-823876c48528">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d0b53a09fec472eab66541ef6214321_I20220930" decimals="-5" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfMjUtNS0xLTEtMTU5NTQw_2f215724-f9de-4e5d-86e0-08bb6dc6c70d">48.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1354c03ac64d49b996ad815decc0f6d7_I20220930" decimals="-5" name="us-gaap:DerivativeAssetsCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfMjUtNy0xLTEtMTU5NTQw_bab00712-5d23-4f4e-8bd1-afb3c3cbf3bd">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc6aec644ba74dffa95a469f4848e6bc_I20220930" decimals="-5" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfMjUtOS0xLTEtMTU5NTQw_c6862c6f-4407-4d85-8438-9d3223841264">48.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id0faa86378a146a48b2256a18f02b7d5_I20220930" decimals="-5" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfMjYtMS0xLTEtMTU5NTQw_7d2604a2-9b3d-40e6-9bd2-64e0a2c09aa7">93.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec96867cd1734fb382b9a966a90c804e_I20220930" decimals="-5" name="us-gaap:DerivativeLiabilitiesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfMjYtMy0xLTEtMTU5NTQw_9fc9ed45-d004-4eb3-ba6a-1775e77d8531">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8d0b53a09fec472eab66541ef6214321_I20220930" decimals="-5" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfMjYtNS0xLTEtMTU5NTQw_053940e5-47ac-4261-adcf-247d072cfff1">93.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1354c03ac64d49b996ad815decc0f6d7_I20220930" decimals="-5" name="us-gaap:DerivativeLiabilitiesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfMjYtNy0xLTEtMTU5NTQw_4fcf2bac-7145-46c9-8760-e4e4a03c9587">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibc6aec644ba74dffa95a469f4848e6bc_I20220930" decimals="-5" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfMjYtOS0xLTEtMTU5NTQw_3c8b48a8-9362-44d5-a394-3910de794eec">93.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent consideration liability:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia25fb80ee7f14608ad1bc42cf7dc3d85_I20220930" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfMzEtMS0xLTEtMTU5NTQw_a454c479-b41d-4f7e-a863-9b67a1e1b97c">42.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i909f721d549b4d17b64fd5ef7a64ed65_I20220930" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfMzEtMy0xLTEtMTU5NTQw_dab904da-6fb0-4d2b-8e46-5ff134a993ba">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida76f129eae2411aac66cefe0c47c6fc_I20220930" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfMzEtNS0xLTEtMTU5NTQw_cbae7742-04e8-4363-a60a-a6758557c5e4">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic34ce18d9ac34702bf22cdc268d8fddc_I20220930" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfMzEtNy0xLTEtMTU5NTQw_b841238f-51cb-4aac-8384-aeff066ddc2b">42.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ice641419095d40b58b1ec413657e5350_I20220930" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfMzEtOS0xLTEtMTU5NTQw_337496d2-9905-448b-821d-30774d7d1d91">42.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk-management instruments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest rate contracts designated as fair value hedges:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other receivables</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a65232f1fca4f95abbb3167ab435068_I20211231" decimals="-5" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfMzYtMS0xLTEtMTU5NTQw_195b3f84-4bed-410a-8639-e544a1b13819">4.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40ccf9cc0ff7401eab9722772af73854_I20211231" decimals="-5" name="us-gaap:DerivativeAssetsCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfMzYtMy0xLTEtMTU5NTQw_b0805d62-c47a-43df-b8fb-b2f222781eb1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4aa9bedfa4ea4600ab40f4f731255ce9_I20211231" decimals="-5" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfMzYtNS0xLTEtMTU5NTQw_40c5ea8c-6acb-4401-a7ed-8908804f41c9">4.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a47a49c720948c3b475ad8f3cf1ff16_I20211231" decimals="-5" name="us-gaap:DerivativeAssetsCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfMzYtNy0xLTEtMTU5NTQw_6feccb88-17e0-4e30-a902-73b0f20dc399">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i024a1912186c40c1a4e62a542f42350c_I20211231" decimals="-5" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfMzYtOS0xLTEtMTU5NTQw_f9da8fe1-542a-44e3-86f8-c4cc8bfbf9d2">4.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a65232f1fca4f95abbb3167ab435068_I20211231" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfMzctMS0xLTEtMTU5NTQw_702c5be3-298d-4de9-a7b6-efe750261277">78.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40ccf9cc0ff7401eab9722772af73854_I20211231" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfMzctMy0xLTEtMTU5NTQw_0bd23237-d998-4adc-9bb2-7f8b45437b17">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4aa9bedfa4ea4600ab40f4f731255ce9_I20211231" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfMzctNS0xLTEtMTU5NTQw_beb31b67-0a26-4dea-b222-cf250671cfa7">78.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a47a49c720948c3b475ad8f3cf1ff16_I20211231" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfMzctNy0xLTEtMTU5NTQw_a20c48d6-e999-4249-b5e1-5de5ddab3c9f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i024a1912186c40c1a4e62a542f42350c_I20211231" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfMzctOS0xLTEtMTU5NTQw_475a7dd8-a682-425c-b578-4ac9f9ee364c">78.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3a65232f1fca4f95abbb3167ab435068_I20211231" decimals="-5" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfMzktMS0xLTEtMTU5NTQw_2345edfb-29e7-40cc-8c45-9a5fb16e7a96">7.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40ccf9cc0ff7401eab9722772af73854_I20211231" decimals="-5" name="us-gaap:DerivativeLiabilitiesNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfMzktMy0xLTEtMTU5NTQw_54c0ae5d-4ebd-4cdd-8771-a21ecd0debba">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4aa9bedfa4ea4600ab40f4f731255ce9_I20211231" decimals="-5" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfMzktNS0xLTEtMTU5NTQw_00c322f4-1993-4e4c-adab-b5171fe83939">7.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a47a49c720948c3b475ad8f3cf1ff16_I20211231" decimals="-5" name="us-gaap:DerivativeLiabilitiesNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfMzktNy0xLTEtMTU5NTQw_308c6d03-3d42-43f0-91c8-464a1e037031">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i024a1912186c40c1a4e62a542f42350c_I20211231" decimals="-5" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfMzktOS0xLTEtMTU5NTQw_d7a73612-0090-44cb-8650-8b6301153b76">7.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest rate contracts designated as cash flow hedges:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i318612662ee348ca8f4c50e967285c42_I20211231" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfNDEtMS0xLTEtMTU5NTQw_917b7e63-9c66-4cbe-a2ba-0a05b33173fb">49.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b3448a25ab94a89aef263d03a2bd29a_I20211231" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfNDEtMy0xLTEtMTU5NTQw_00327ed6-0618-4511-8450-fd99d0855b47">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i841d22572a894c128f4304c5a9d761b0_I20211231" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfNDEtNS0xLTEtMTU5NTQw_81eb4109-b8d2-478a-883d-dbb63601a4d6">49.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie51a0fafa7104530b58bfc8df0b750d4_I20211231" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfNDEtNy0xLTEtMTU5NTQw_8f4b0654-943a-4599-ad40-84f822e9c1d8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0999361082eb4d43bc2fc7f00ef0bae3_I20211231" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfNDEtOS0xLTEtMTU5NTQw_60039a2b-bdf9-42d9-995b-44b0b7308935">49.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i318612662ee348ca8f4c50e967285c42_I20211231" decimals="-5" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfNDItMS0xLTEtMTU5NTQw_d47a46f8-49dd-4078-902d-2f9779a4bbd0">31.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b3448a25ab94a89aef263d03a2bd29a_I20211231" decimals="-5" name="us-gaap:DerivativeLiabilitiesNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfNDItMy0xLTEtMTU5NTQw_f5fbe6a4-1584-43f3-a48d-eefc3dcef4c8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i841d22572a894c128f4304c5a9d761b0_I20211231" decimals="-5" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfNDItNS0xLTEtMTU5NTQw_176a13ce-2a0d-4a95-8a2b-4a423e4e2f10">31.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie51a0fafa7104530b58bfc8df0b750d4_I20211231" decimals="-5" name="us-gaap:DerivativeLiabilitiesNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfNDItNy0xLTEtMTU5NTQw_219e1619-a0f5-44aa-acef-6d9e990e3d47">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0999361082eb4d43bc2fc7f00ef0bae3_I20211231" decimals="-5" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfNDItOS0xLTEtMTU5NTQw_a95a4bc5-66ef-488a-97fb-25f60cf77f9b">31.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cross-currency interest rate contracts designated as net investment hedges:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a94f32b7cb642279222210de17f03ed_I20211231" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfNDUtMS0xLTEtMTU5NTQw_02897dc0-1425-4404-bbb3-106c18765a50">31.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab252218731740b9a75cb6728b7b9503_I20211231" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfNDUtMy0xLTEtMTU5NTQw_408933ea-01e8-48d6-9296-f809cb500bdd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a6a92fb8f674015b49e7f493a12c723_I20211231" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfNDUtNS0xLTEtMTU5NTQw_29d4b28f-a95b-48d2-8f91-b467d51af740">31.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee54e09047ba4b21a41fa3c8cc49cec2_I20211231" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfNDUtNy0xLTEtMTU5NTQw_73b2b14e-1ac8-43f2-a758-1317b01eee79">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf2c03c7d41e4db1941ec3f47533b5ac_I20211231" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfNDUtOS0xLTEtMTU5NTQw_51cff681-efa0-470a-841d-615888177fcb">31.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8a94f32b7cb642279222210de17f03ed_I20211231" decimals="-5" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfNDYtMS0xLTEtMTU5NTQw_aaf65246-76f2-4489-9052-46905345cf8e">1.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab252218731740b9a75cb6728b7b9503_I20211231" decimals="-5" name="us-gaap:DerivativeLiabilitiesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfNDYtMy0xLTEtMTU5NTQw_a0278670-f225-4e35-b8e0-6cc186705f5a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5a6a92fb8f674015b49e7f493a12c723_I20211231" decimals="-5" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfNDYtNS0xLTEtMTU5NTQw_9742dacc-dcc1-42bd-a5f3-b15ebffd65e3">1.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee54e09047ba4b21a41fa3c8cc49cec2_I20211231" decimals="-5" name="us-gaap:DerivativeLiabilitiesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfNDYtNy0xLTEtMTU5NTQw_659aac83-3f23-4f40-b405-18d21242290e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icf2c03c7d41e4db1941ec3f47533b5ac_I20211231" decimals="-5" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfNDYtOS0xLTEtMTU5NTQw_83417eee-68cb-496e-b74d-5f873ab1e22a">1.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cross-currency interest rate contracts designated as cash flow hedges:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09f8de57c8924dc5916922a278ad4eb1_I20211231" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfNDktMS0xLTEtMTU5NTQw_9b37ebf6-5a55-4a58-954c-cb957e1d7001">33.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1339ff825ab84e1292a5f32205bb84fb_I20211231" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfNDktMy0xLTEtMTU5NTQw_a1425879-238d-4785-b0e5-50b10586d791">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iddd7166aae2b440ab53a23a0b63e2aa9_I20211231" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfNDktNS0xLTEtMTU5NTQw_92564f90-5f65-47e3-b196-c0c5d5911a29">33.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic06c23f16f4443f78411fcbe2a43f013_I20211231" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfNDktNy0xLTEtMTU5NTQw_f548e4cc-715c-4114-a162-3be09cf3f950">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6485e6d1b024de18d35df5658693713_I20211231" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfNDktOS0xLTEtMTU5NTQw_813e35ca-491b-4823-b2f7-d887a95854b1">33.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i09f8de57c8924dc5916922a278ad4eb1_I20211231" decimals="-5" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfNTAtMS0xLTEtMTU5NTQw_e9d349c3-961b-4583-a904-0f5e3c7e0023">1.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1339ff825ab84e1292a5f32205bb84fb_I20211231" decimals="-5" name="us-gaap:DerivativeLiabilitiesNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfNTAtMy0xLTEtMTU5NTQw_c8c7c961-faa8-4d2a-b814-a2461de9becb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iddd7166aae2b440ab53a23a0b63e2aa9_I20211231" decimals="-5" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfNTAtNS0xLTEtMTU5NTQw_1b99872b-28ce-47dd-ac6c-b82b08275635">1.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic06c23f16f4443f78411fcbe2a43f013_I20211231" decimals="-5" name="us-gaap:DerivativeLiabilitiesNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfNTAtNy0xLTEtMTU5NTQw_858eca8f-8a4d-4a7a-9b91-c65637099667">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia6485e6d1b024de18d35df5658693713_I20211231" decimals="-5" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfNTAtOS0xLTEtMTU5NTQw_e74e45b5-f654-460b-a5e0-91c4df806c49">1.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign exchange contracts not designated as hedging instruments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9674dda0210248f68699af728a2b7366_I20211231" decimals="-5" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfNTItMS0xLTEtMTU5NTQw_a9b0cb44-1e16-4364-b2aa-dc206796df41">9.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05396d0962d648b89a38691fab6227da_I20211231" decimals="-5" name="us-gaap:DerivativeAssetsCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfNTItMy0xLTEtMTU5NTQw_42e63e7d-0796-40fe-9a02-7f231569f3d9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i637a8ab6a8a7402880d7c301d82ac216_I20211231" decimals="-5" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfNTItNS0xLTEtMTU5NTQw_493600d2-6bfe-4c94-8df7-31aaa9debfad">9.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47903bc5967647c3ad861c42d533efb5_I20211231" decimals="-5" name="us-gaap:DerivativeAssetsCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfNTItNy0xLTEtMTU5NTQw_97d07676-b86b-4f5b-8ca1-36c00b747282">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22af614be29843faa74794b4926362d9_I20211231" decimals="-5" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfNTItOS0xLTEtMTU5NTQw_d83d8859-efbb-4768-9e5f-373d7c668e82">9.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9674dda0210248f68699af728a2b7366_I20211231" decimals="-5" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfNTMtMS0xLTEtMTU5NTQw_f313140b-25f3-47d2-9903-34254c7891fe">35.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05396d0962d648b89a38691fab6227da_I20211231" decimals="-5" name="us-gaap:DerivativeLiabilitiesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfNTMtMy0xLTEtMTU5NTQw_678f0086-bb4a-4545-83af-07b09c223ad8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i637a8ab6a8a7402880d7c301d82ac216_I20211231" decimals="-5" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfNTMtNS0xLTEtMTU5NTQw_ac2d072f-8ad2-4e4d-9bea-65d9a6fd2b2f">35.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47903bc5967647c3ad861c42d533efb5_I20211231" decimals="-5" name="us-gaap:DerivativeLiabilitiesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfNTMtNy0xLTEtMTU5NTQw_a1828f81-f9b2-4ffd-90a9-7b0c4e2e3ac1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i22af614be29843faa74794b4926362d9_I20211231" decimals="-5" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfNTMtOS0xLTEtMTU5NTQw_cd7b2b48-874a-4b7b-9b88-eea51378640a">35.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent consideration liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic3b630730b424a6d8b697cf0362c83d2_I20211231" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfNTYtMS0xLTEtMTU5NTQw_90fecfdc-c5d0-4fb1-af0a-e713a3f4d323">70.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6802f141d8af4b8aa65c6abe305eeed2_I20211231" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfNTYtMy0xLTEtMTU5NTQw_7b158f4d-f4b4-4984-9a2c-6daf3b115547">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i124320eb89ce4dfa87c2f2083ad1e10b_I20211231" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfNTYtNS0xLTEtMTU5NTQw_e4a927e1-ca5b-4995-a608-b10f14caf1ff">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2f37875c8bb94fed916b3375076f0703_I20211231" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfNTYtNy0xLTEtMTU5NTQw_28112ff9-cc87-4a90-92cd-2a6cd75442e2">70.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i52e3293fb124489e844061750e511c35_I20211231" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfNTYtOS0xLTEtMTU5NTQw_e816fe41-013d-4fa3-8f42-ee1697c3d840">70.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:nonNumeric></ix:continuation></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i69c07437f434411caf87c5d63a2351cb" continuedAt="i0580b0c8eb2543f7a8cb29921b6585ba"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk-management instruments above are disclosed on a gross basis. There are various rights of setoff associated with certain of the risk-management instruments above that are subject to enforceable master netting arrangements or similar agreements. Although various rights of setoff and master netting arrangements or similar agreements may exist with the individual counterparties to the risk-management instruments above, individually, these financial rights are not material.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine our Level 1 and Level 2 fair value measurements based on a market approach using quoted market values, significant other observable inputs for identical or comparable assets or liabilities, or discounted cash flow analyses. Level 3 fair value measurements for other investment securities are determined using unobservable inputs, including the investments' cost adjusted for impairments and price changes from orderly transactions. Fair values are not readily available for certain equity investments measured under the measurement alternative. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2022, we had approximately $<ix:nonFraction unitRef="usd" contextRef="i08ccb35f6ad24d7793c9c91b74ca2ea1_I20220930" decimals="-6" name="us-gaap:FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RleHRyZWdpb246OGRmOTEwZDdhYjFhNDFmMThlODU5ZTE4OTQxY2E4MDhfMTA2Njc_4d1d6cb8-c65c-4dac-bd5f-f1074917dfbb">854</ix:nonFraction> million of unfunded commitments to invest in venture capital funds, which we anticipate will be paid over a period of up to <ix:nonNumeric contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930" name="lly:FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RleHRyZWdpb246OGRmOTEwZDdhYjFhNDFmMThlODU5ZTE4OTQxY2E4MDhfMTA3ODY_c0b48292-becb-48a7-bdeb-620ef39ad735">10</ix:nonNumeric> years. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contingent consideration liability relates to our liability arising in connection with the CVR issued as a result of the Prevail acquisition. The fair value of the CVR liability was estimated using a discounted cash flow analysis and Level 3 inputs, including projections representative of a market participant's view of the expected cash payment associated with the first potential regulatory approval of a Prevail compound in the applicable countries based on probabilities of technical success, timing of the potential approval events for the compounds, and an estimated discount rate. See Note 3 for additional information related to the CVR arrangement. </span></div><ix:nonNumeric contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RleHRyZWdpb246OGRmOTEwZDdhYjFhNDFmMThlODU5ZTE4OTQxY2E4MDhfMTUxMDc_8195e1d3-627d-4380-a914-1bab3363b2db" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes the contractual maturities of our investments in debt securities measured at fair value as of September&#160;30, 2022:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:40.162%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.060%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.060%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.060%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.060%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.062%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maturities by Period</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less&#160;Than<br/>1 Year</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1-5<br/>Years</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">6-10<br/>Years</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">More&#160;Than<br/>10 Years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of debt securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08ccb35f6ad24d7793c9c91b74ca2ea1_I20220930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOmIyMDQ2NGYwYTg3NDRmNTE4NmY0ZTY4MmIwNmZiZWJlL3RhYmxlcmFuZ2U6YjIwNDY0ZjBhODc0NGY1MTg2ZjRlNjgyYjA2ZmJlYmVfMi0xLTEtMS0xNTk1NDA_b9dc3d8b-4db6-4ba5-b0d4-8b5002df5e24">622.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08ccb35f6ad24d7793c9c91b74ca2ea1_I20220930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOmIyMDQ2NGYwYTg3NDRmNTE4NmY0ZTY4MmIwNmZiZWJlL3RhYmxlcmFuZ2U6YjIwNDY0ZjBhODc0NGY1MTg2ZjRlNjgyYjA2ZmJlYmVfMi0zLTEtMS0xNTk1NDA_872c587f-8a3e-4ab4-9cfb-2a4740153aa4">97.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08ccb35f6ad24d7793c9c91b74ca2ea1_I20220930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOmIyMDQ2NGYwYTg3NDRmNTE4NmY0ZTY4MmIwNmZiZWJlL3RhYmxlcmFuZ2U6YjIwNDY0ZjBhODc0NGY1MTg2ZjRlNjgyYjA2ZmJlYmVfMi01LTEtMS0xNTk1NDA_eae1fcb3-6f93-441e-8c6e-773ba30e70a7">197.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08ccb35f6ad24d7793c9c91b74ca2ea1_I20220930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOmIyMDQ2NGYwYTg3NDRmNTE4NmY0ZTY4MmIwNmZiZWJlL3RhYmxlcmFuZ2U6YjIwNDY0ZjBhODc0NGY1MTg2ZjRlNjgyYjA2ZmJlYmVfMi03LTEtMS0xNTk1NDA_a8569ec8-bc0a-4b58-8d66-da4429ca1a33">121.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08ccb35f6ad24d7793c9c91b74ca2ea1_I20220930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOmIyMDQ2NGYwYTg3NDRmNTE4NmY0ZTY4MmIwNmZiZWJlL3RhYmxlcmFuZ2U6YjIwNDY0ZjBhODc0NGY1MTg2ZjRlNjgyYjA2ZmJlYmVfMi05LTEtMS0xNTk1NDA_4a30bdbb-dee8-4fb4-a28c-7adb4d192156">205.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net gains (losses) recognized in our consolidated condensed statements of operations for equity securities were $(<ix:nonFraction unitRef="usd" contextRef="i19fc0325c48543008ea71e1fdcf11d86_D20220701-20220930" decimals="-5" sign="-" name="us-gaap:EquitySecuritiesFvNiGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RleHRyZWdpb246OGRmOTEwZDdhYjFhNDFmMThlODU5ZTE4OTQxY2E4MDhfMTE2OTQ_8f0a0b99-1ff4-4ac8-8531-70c7ebd1dd6f">123.3</ix:nonFraction>)&#160;million and $(<ix:nonFraction unitRef="usd" contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930" decimals="-5" sign="-" name="us-gaap:EquitySecuritiesFvNiGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RleHRyZWdpb246OGRmOTEwZDdhYjFhNDFmMThlODU5ZTE4OTQxY2E4MDhfMTE3MDE_eb576f1c-f504-4904-89ff-727ba1432122">667.6</ix:nonFraction>)&#160;million for the three and nine months ended September&#160;30, 2022, respectively, and $(<ix:nonFraction unitRef="usd" contextRef="ie4fa4f6b472a4f269297591b44aba572_D20210701-20210930" decimals="-5" sign="-" name="us-gaap:EquitySecuritiesFvNiGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RleHRyZWdpb246OGRmOTEwZDdhYjFhNDFmMThlODU5ZTE4OTQxY2E4MDhfMTE3NTA_2bb44b70-0646-4de6-8b8f-88101b95cec8">246.8</ix:nonFraction>)&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i167ed8f67bef48c49e54fa466400cdaa_D20210101-20210930" decimals="-5" name="us-gaap:EquitySecuritiesFvNiGainLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RleHRyZWdpb246OGRmOTEwZDdhYjFhNDFmMThlODU5ZTE4OTQxY2E4MDhfMTE3NTc_4a4d3e33-c128-44a6-ab68-0d7e5da2a7aa">270.1</ix:nonFraction>&#160;million for the three and nine months ended September&#160;30, 2021, respectively. The net gains (losses) recognized for the three and nine months ended September&#160;30, 2022 and 2021 on equity securities sold during the respective periods were not material.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We adjust our equity investments without readily determinable fair values based upon changes in the equity instruments' values resulting from observable price changes in orderly transactions for an identical or similar investment of the same issuer. Downward adjustments resulting from an impairment are recorded based upon impairment considerations, including the financial condition and near term prospects of the issuer, general market conditions, and industry specific factors. Adjustments recorded for the three and nine months ended September&#160;30, 2022 and 2021 were not material.</span></div><ix:nonNumeric contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930" name="us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RleHRyZWdpb246OGRmOTEwZDdhYjFhNDFmMThlODU5ZTE4OTQxY2E4MDhfMTUxNzg_54b52b0d-743c-45a2-b58d-52f1f154cd39" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the amount of unrealized gains and losses in accumulated other comprehensive loss and the fair value of available-for-sale securities in an unrealized gain or loss position follows:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:66.249%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.859%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.860%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gross gains</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08ccb35f6ad24d7793c9c91b74ca2ea1_I20220930" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjA4MmY3YTI1MmU1ZjRlYjRhNTZkZDU5M2YxMzEyMGZjL3RhYmxlcmFuZ2U6MDgyZjdhMjUyZTVmNGViNGE1NmRkNTkzZjEzMTIwZmNfMS0xLTEtMS0xNTk1NDA_78bb3a83-371d-4dda-8a45-2f0d8b9b1022">0.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0973ba0c1d894ceaa494709a13f814fb_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjA4MmY3YTI1MmU1ZjRlYjRhNTZkZDU5M2YxMzEyMGZjL3RhYmxlcmFuZ2U6MDgyZjdhMjUyZTVmNGViNGE1NmRkNTkzZjEzMTIwZmNfMS0zLTEtMS0xNTk1NDA_d7865bfd-e2ba-4d45-8973-8bd1df337ff6">9.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gross losses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08ccb35f6ad24d7793c9c91b74ca2ea1_I20220930" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjA4MmY3YTI1MmU1ZjRlYjRhNTZkZDU5M2YxMzEyMGZjL3RhYmxlcmFuZ2U6MDgyZjdhMjUyZTVmNGViNGE1NmRkNTkzZjEzMTIwZmNfMi0xLTEtMS0xNTk1NDA_7716b38b-927f-4600-b2e9-a5de79a6c7b5">51.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0973ba0c1d894ceaa494709a13f814fb_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjA4MmY3YTI1MmU1ZjRlYjRhNTZkZDU5M2YxMzEyMGZjL3RhYmxlcmFuZ2U6MDgyZjdhMjUyZTVmNGViNGE1NmRkNTkzZjEzMTIwZmNfMi0zLTEtMS0xNTk1NDA_d13aca1f-0646-4b11-b367-d224022e1dd5">5.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of securities in an unrealized gain position</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08ccb35f6ad24d7793c9c91b74ca2ea1_I20220930" decimals="-5" name="lly:DebtSecuritiesAvailableforsaleUnrealizedGainPosition" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjA4MmY3YTI1MmU1ZjRlYjRhNTZkZDU5M2YxMzEyMGZjL3RhYmxlcmFuZ2U6MDgyZjdhMjUyZTVmNGViNGE1NmRkNTkzZjEzMTIwZmNfMy0xLTEtMS0xNTk1NDA_e6afa47d-02f3-4ee3-bc7a-a1799604434c">13.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0973ba0c1d894ceaa494709a13f814fb_I20211231" decimals="-5" name="lly:DebtSecuritiesAvailableforsaleUnrealizedGainPosition" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjA4MmY3YTI1MmU1ZjRlYjRhNTZkZDU5M2YxMzEyMGZjL3RhYmxlcmFuZ2U6MDgyZjdhMjUyZTVmNGViNGE1NmRkNTkzZjEzMTIwZmNfMy0zLTEtMS0xNTk1NDA_fe856a80-2c92-451b-9066-c79017d564cf">250.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of securities in an unrealized loss position</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08ccb35f6ad24d7793c9c91b74ca2ea1_I20220930" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjA4MmY3YTI1MmU1ZjRlYjRhNTZkZDU5M2YxMzEyMGZjL3RhYmxlcmFuZ2U6MDgyZjdhMjUyZTVmNGViNGE1NmRkNTkzZjEzMTIwZmNfNC0xLTEtMS0xNTk1NDA_78b75982-8cd5-47bd-b2cb-c38c52f28428">578.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0973ba0c1d894ceaa494709a13f814fb_I20211231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjA4MmY3YTI1MmU1ZjRlYjRhNTZkZDU5M2YxMzEyMGZjL3RhYmxlcmFuZ2U6MDgyZjdhMjUyZTVmNGViNGE1NmRkNTkzZjEzMTIwZmNfNC0zLTEtMS0xNTk1NDA_005f2639-e344-435c-9630-378f3b52c417">290.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We periodically assess our investment in available-for-sale securities for impairment losses and credit losses. The amount of credit losses are determined by comparing the difference between the present value of future cash flows expected to be collected on these securities and the amortized cost. Factors considered in assessing credit losses include the position in the capital structure, vintage and amount of collateral, delinquency rates, current credit support, and geographic concentration. Impairment and credit losses related to available-for-sale securities were not material for the three and nine months ended September&#160;30, 2022 and 2021.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i0580b0c8eb2543f7a8cb29921b6585ba"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2022, the available-for-sale securities in an unrealized loss position include primarily fixed-rate debt securities of varying maturities, which are sensitive to changes in the yield curve and other market conditions. Approximately <ix:nonFraction unitRef="number" contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930" decimals="2" name="lly:DebtSecuritiesAvailableForSaleUnrealizedLossPositionQualitativeDisclosureOtherPercentageOfNonperformingAssets" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RleHRyZWdpb246OGRmOTEwZDdhYjFhNDFmMThlODU5ZTE4OTQxY2E4MDhfMTM1NTc_c2127107-d222-4181-bc82-39af6a9b7cb6">95</ix:nonFraction> percent&#160;of the fixed-rate debt securities in a loss position are investment-grade debt securities. As of September&#160;30, 2022, we do not intend to sell, and it is not more likely than not that we will be required to sell, the securities in a loss position before the market values recover or the underlying cash flows have been received, and there is no indication of a material default on interest or principal payments for our debt securities.</span></div><ix:nonNumeric contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930" name="us-gaap:GainLossOnInvestmentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RleHRyZWdpb246OGRmOTEwZDdhYjFhNDFmMThlODU5ZTE4OTQxY2E4MDhfMTUxMjk_d53f54cd-0846-4d0c-a453-e9182f065ed0" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Activity related to our available-for-sale securities was as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.613%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.206%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19fc0325c48543008ea71e1fdcf11d86_D20220701-20220930" decimals="-5" name="lly:ProceedsfromSaleofEquityandAvailableforSaleSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjYxNGZlZGYwZjc2ZTQwOTc5ZDgwOTc0YmM0ODc3Y2U5L3RhYmxlcmFuZ2U6NjE0ZmVkZjBmNzZlNDA5NzlkODA5NzRiYzQ4NzdjZTlfMi0xLTEtMS0xNTk1NDA_bfcbc4cc-9a0d-4242-bd13-db7902cd263e">50.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4fa4f6b472a4f269297591b44aba572_D20210701-20210930" decimals="-5" name="lly:ProceedsfromSaleofEquityandAvailableforSaleSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjYxNGZlZGYwZjc2ZTQwOTc5ZDgwOTc0YmM0ODc3Y2U5L3RhYmxlcmFuZ2U6NjE0ZmVkZjBmNzZlNDA5NzlkODA5NzRiYzQ4NzdjZTlfMi0zLTEtMS0xNTk1NDA_c69e90ca-bacd-40f8-a7fb-3b246b8d301d">49.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930" decimals="-5" name="lly:ProceedsfromSaleofEquityandAvailableforSaleSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjYxNGZlZGYwZjc2ZTQwOTc5ZDgwOTc0YmM0ODc3Y2U5L3RhYmxlcmFuZ2U6NjE0ZmVkZjBmNzZlNDA5NzlkODA5NzRiYzQ4NzdjZTlfMi01LTEtMS0xNTk1NDA_67ddab9b-d464-4e7e-a19f-c86f401e63e0">115.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i167ed8f67bef48c49e54fa466400cdaa_D20210101-20210930" decimals="-5" name="lly:ProceedsfromSaleofEquityandAvailableforSaleSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjYxNGZlZGYwZjc2ZTQwOTc5ZDgwOTc0YmM0ODc3Y2U5L3RhYmxlcmFuZ2U6NjE0ZmVkZjBmNzZlNDA5NzlkODA5NzRiYzQ4NzdjZTlfMi03LTEtMS0xNTk1NDA_70857a31-7d04-4515-8db0-c0d9de976179">137.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Realized gross gains on sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19fc0325c48543008ea71e1fdcf11d86_D20220701-20220930" decimals="-5" name="lly:AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjYxNGZlZGYwZjc2ZTQwOTc5ZDgwOTc0YmM0ODc3Y2U5L3RhYmxlcmFuZ2U6NjE0ZmVkZjBmNzZlNDA5NzlkODA5NzRiYzQ4NzdjZTlfMy0xLTEtMS0xNTk1NDA_0ee4a37b-1b18-4c7f-a4ff-f5a2ca628f81">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4fa4f6b472a4f269297591b44aba572_D20210701-20210930" decimals="-5" name="lly:AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjYxNGZlZGYwZjc2ZTQwOTc5ZDgwOTc0YmM0ODc3Y2U5L3RhYmxlcmFuZ2U6NjE0ZmVkZjBmNzZlNDA5NzlkODA5NzRiYzQ4NzdjZTlfMy0zLTEtMS0xNTk1NDA_181e2eff-aa2a-40ae-9cd0-87365340e6df">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930" decimals="-5" name="lly:AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjYxNGZlZGYwZjc2ZTQwOTc5ZDgwOTc0YmM0ODc3Y2U5L3RhYmxlcmFuZ2U6NjE0ZmVkZjBmNzZlNDA5NzlkODA5NzRiYzQ4NzdjZTlfMy01LTEtMS0xNTk1NDA_a4084db9-d5b2-40ab-a7e6-27ba3c7017db">0.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i167ed8f67bef48c49e54fa466400cdaa_D20210101-20210930" decimals="-5" name="lly:AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjYxNGZlZGYwZjc2ZTQwOTc5ZDgwOTc0YmM0ODc3Y2U5L3RhYmxlcmFuZ2U6NjE0ZmVkZjBmNzZlNDA5NzlkODA5NzRiYzQ4NzdjZTlfMy03LTEtMS0xNTk1NDA_2e4bb8bb-6619-4ce0-986e-3d8258673716">2.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Realized gross losses on sales</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19fc0325c48543008ea71e1fdcf11d86_D20220701-20220930" decimals="-5" name="lly:AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjYxNGZlZGYwZjc2ZTQwOTc5ZDgwOTc0YmM0ODc3Y2U5L3RhYmxlcmFuZ2U6NjE0ZmVkZjBmNzZlNDA5NzlkODA5NzRiYzQ4NzdjZTlfNC0xLTEtMS0xNTk1NDA_493453ef-6c00-4a69-afe7-7803c4f4272e">7.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4fa4f6b472a4f269297591b44aba572_D20210701-20210930" decimals="-5" name="lly:AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjYxNGZlZGYwZjc2ZTQwOTc5ZDgwOTc0YmM0ODc3Y2U5L3RhYmxlcmFuZ2U6NjE0ZmVkZjBmNzZlNDA5NzlkODA5NzRiYzQ4NzdjZTlfNC0zLTEtMS0xNTk1NDA_e34a78d3-71a4-45e4-910d-7771596bf60c">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930" decimals="-5" name="lly:AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjYxNGZlZGYwZjc2ZTQwOTc5ZDgwOTc0YmM0ODc3Y2U5L3RhYmxlcmFuZ2U6NjE0ZmVkZjBmNzZlNDA5NzlkODA5NzRiYzQ4NzdjZTlfNC01LTEtMS0xNTk1NDA_3da89a97-911b-4877-9510-38345ea87350">9.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i167ed8f67bef48c49e54fa466400cdaa_D20210101-20210930" decimals="-5" name="lly:AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjYxNGZlZGYwZjc2ZTQwOTc5ZDgwOTc0YmM0ODc3Y2U5L3RhYmxlcmFuZ2U6NjE0ZmVkZjBmNzZlNDA5NzlkODA5NzRiYzQ4NzdjZTlfNC03LTEtMS0xNTk1NDA_ad957c67-3630-48eb-9e9c-e01c0c32a3df">1.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Realized gains and losses on sales of available-for-sale investments are computed based upon specific identification of the initial cost adjusted for any other-than-temporary declines in fair value that were recorded in earnings.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounts Receivable Factoring Arrangements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into accounts receivable factoring agreements with financial institutions to sell certain of our non-U.S. accounts receivable. These transactions are accounted for as sales and result in a reduction in accounts receivable because the agreements transfer effective control over, and risk related to, the receivables to the buyers. Our factoring agreements do not allow for recourse in the event of uncollectibility, and we do not retain any interest in the underlying accounts receivable once sold. We derecognized $<ix:nonFraction unitRef="usd" contextRef="i08ccb35f6ad24d7793c9c91b74ca2ea1_I20220930" decimals="-5" name="us-gaap:TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RleHRyZWdpb246OGRmOTEwZDdhYjFhNDFmMThlODU5ZTE4OTQxY2E4MDhfMTQ4NTU_d461a7a3-cf80-45a2-b935-0ca765dd766f">356.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i0973ba0c1d894ceaa494709a13f814fb_I20211231" decimals="-5" name="us-gaap:TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RleHRyZWdpb246OGRmOTEwZDdhYjFhNDFmMThlODU5ZTE4OTQxY2E4MDhfMTQ4NjI_3c509b7e-cf02-4800-bc5e-abc722a8c242">550.5</ix:nonFraction> million&#160;of accounts receivable as of September&#160;30, 2022 and December&#160;31, 2021, respectively, under these factoring arrangements. The costs of factoring such accounts receivable on our consolidated condensed results of operations for the three and nine months ended September&#160;30, 2022 and 2021&#160;were&#160;not material.</span></div></ix:continuation><div style="margin-top:6pt"><span><br/></span></div><div id="i5fed483d9c7e4f3cbba3a62c53226cd7_64"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 7: <ix:nonNumeric contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182NC9mcmFnOmMzYjIwOWNjM2ExMjQ2OWE4NmQ5NTdhYTRkZGUyMmE4L3RleHRyZWdpb246YzNiMjA5Y2MzYTEyNDY5YTg2ZDk1N2FhNGRkZTIyYThfMTMwMw_4da865fa-c18e-49b7-bd05-bde2e642708c" continuedAt="i8b9605b0eade4b6c9df79e0034f776f4" escape="true">Income Taxes </ix:nonNumeric></span></div><ix:continuation id="i8b9605b0eade4b6c9df79e0034f776f4" continuedAt="i41f95466915c4c0986c5f382c4331b2e"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective tax rates were <ix:nonFraction unitRef="number" contextRef="i19fc0325c48543008ea71e1fdcf11d86_D20220701-20220930" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182NC9mcmFnOmMzYjIwOWNjM2ExMjQ2OWE4NmQ5NTdhYTRkZGUyMmE4L3RleHRyZWdpb246YzNiMjA5Y2MzYTEyNDY5YTg2ZDk1N2FhNGRkZTIyYThfNTY_09741c81-4db5-421b-913c-1f9342c8166f">7.3</ix:nonFraction> percent and <ix:nonFraction unitRef="number" contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182NC9mcmFnOmMzYjIwOWNjM2ExMjQ2OWE4NmQ5NTdhYTRkZGUyMmE4L3RleHRyZWdpb246YzNiMjA5Y2MzYTEyNDY5YTg2ZDk1N2FhNGRkZTIyYThfNjM_204ae19b-fe42-4b04-a332-f083899a2403">8.6</ix:nonFraction> percent for the three and nine months ended September&#160;30, 2022, respectively, reflecting the favorable tax impact of the implementation of a provision in the Tax Cuts and Jobs Act (2017 Tax Act) that requires capitalization and amortization of research and development expenses for tax purposes starting in 2022, net investment losses on equity securities, and an intangible asset impairment charge. We expect our effective tax rate to be approximately <ix:nonFraction unitRef="number" contextRef="i62df949acd3f4b47ae7d10432a08e2ab_D20220101-20221231" decimals="2" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182NC9mcmFnOmMzYjIwOWNjM2ExMjQ2OWE4NmQ5NTdhYTRkZGUyMmE4L3RleHRyZWdpb246YzNiMjA5Y2MzYTEyNDY5YTg2ZDk1N2FhNGRkZTIyYThfNTQy_18580e2a-b740-4700-b29a-a2bb08e7e56a">13</ix:nonFraction> percent to <ix:nonFraction unitRef="number" contextRef="i67750cd7b626486fa748e5b71374a667_D20220101-20221231" decimals="2" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182NC9mcmFnOmMzYjIwOWNjM2ExMjQ2OWE4NmQ5NTdhYTRkZGUyMmE4L3RleHRyZWdpb246YzNiMjA5Y2MzYTEyNDY5YTg2ZDk1N2FhNGRkZTIyYThfNTQ4_7ceba8cc-230d-4a04-8485-1d1cf712d502">14</ix:nonFraction> percent for 2022 if the capitalization and amortization of research and development expenses provision of the 2017 Tax Act is deferred or repealed by the U.S. Congress effective for 2022.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective tax rate was <ix:nonFraction unitRef="number" contextRef="ie4fa4f6b472a4f269297591b44aba572_D20210701-20210930" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182NC9mcmFnOmMzYjIwOWNjM2ExMjQ2OWE4NmQ5NTdhYTRkZGUyMmE4L3RleHRyZWdpb246YzNiMjA5Y2MzYTEyNDY5YTg2ZDk1N2FhNGRkZTIyYThfNzYw_58733c71-1992-4699-afb8-e653abf947a3">10.9</ix:nonFraction> percent for the three months ended September&#160;30, 2021, reflecting the favorable tax impact of a debt extinguishment loss and of net investment losses on equity securities, partially offset by a net discrete tax detriment. The effective tax rate was <ix:nonFraction unitRef="number" contextRef="i167ed8f67bef48c49e54fa466400cdaa_D20210101-20210930" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182NC9mcmFnOmMzYjIwOWNjM2ExMjQ2OWE4NmQ5NTdhYTRkZGUyMmE4L3RleHRyZWdpb246YzNiMjA5Y2MzYTEyNDY5YTg2ZDk1N2FhNGRkZTIyYThfMjc0ODc3OTA3Mjc5NA_64cf953c-f539-4d84-a573-a47b34d0e185">10.7</ix:nonFraction> percent for the nine months ended September&#160;30, 2021, reflecting the favorable tax impact of a net discrete tax benefit, a debt extinguishment loss, and a net inventory impairment charge related to our COVID-19 antibodies. </span></div></ix:continuation><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i41f95466915c4c0986c5f382c4331b2e">The U.S. examination of tax years 2016-2018 began in the fourth quarter of 2019 and remains ongoing. The resolution of this audit period will likely extend beyond the next 12 months.</ix:continuation> </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><div id="i5fed483d9c7e4f3cbba3a62c53226cd7_67"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 8: <ix:nonNumeric contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182Ny9mcmFnOjc2ODNiYjQ2MzFiMTQ0MTJiMDk2YzNkYmNmOTZiMTFlL3RleHRyZWdpb246NzY4M2JiNDYzMWIxNDQxMmIwOTZjM2RiY2Y5NmIxMWVfMTM3_1c8712a1-f795-4abf-992b-0ac5987fbd6a" continuedAt="i0bcd190fbaea4ce79aa8bbcf90cd3509" escape="true">Retirement Benefits</ix:nonNumeric></span></div><ix:continuation id="i0bcd190fbaea4ce79aa8bbcf90cd3509"><ix:nonNumeric contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930" name="us-gaap:ScheduleOfNetBenefitCostsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182Ny9mcmFnOjc2ODNiYjQ2MzFiMTQ0MTJiMDk2YzNkYmNmOTZiMTFlL3RleHRyZWdpb246NzY4M2JiNDYzMWIxNDQxMmIwOTZjM2RiY2Y5NmIxMWVfMTQw_8042c4cc-a70c-4f01-8248-31be639cb51f" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net pension and retiree health benefit (income) cost included the following components:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.613%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.206%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Defined Benefit Pension Plans</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Components of net periodic benefit cost:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifea67e1feada4a8c8d0bf25c34910e9a_D20220701-20220930" decimals="-5" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182Ny9mcmFnOjc2ODNiYjQ2MzFiMTQ0MTJiMDk2YzNkYmNmOTZiMTFlL3RhYmxlOjdhMGMwNmMxMTE0NTRlZmU4ZTc3YWM0MDhmYTQ1NTdmL3RhYmxlcmFuZ2U6N2EwYzA2YzExMTQ1NGVmZThlNzdhYzQwOGZhNDU1N2ZfNC0xLTEtMS0xNTk1NDA_2d091511-32e1-48de-899c-0d41867dc013">87.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19f7d57c42aa4dde893b82e5f134cfc1_D20210701-20210930" decimals="-5" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182Ny9mcmFnOjc2ODNiYjQ2MzFiMTQ0MTJiMDk2YzNkYmNmOTZiMTFlL3RhYmxlOjdhMGMwNmMxMTE0NTRlZmU4ZTc3YWM0MDhmYTQ1NTdmL3RhYmxlcmFuZ2U6N2EwYzA2YzExMTQ1NGVmZThlNzdhYzQwOGZhNDU1N2ZfNC0zLTEtMS0xNTk1NDA_b0d3754d-b275-4904-bd17-baa279f27785">92.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0116b5022f7f41b494fd355fe823d76e_D20220101-20220930" decimals="-5" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182Ny9mcmFnOjc2ODNiYjQ2MzFiMTQ0MTJiMDk2YzNkYmNmOTZiMTFlL3RhYmxlOjdhMGMwNmMxMTE0NTRlZmU4ZTc3YWM0MDhmYTQ1NTdmL3RhYmxlcmFuZ2U6N2EwYzA2YzExMTQ1NGVmZThlNzdhYzQwOGZhNDU1N2ZfNC01LTEtMS0xNTk1NDA_1270c886-5b81-46b4-86d3-c161d36f5f4c">264.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a97c43966fd4f6aaf5f8dfb7bba4701_D20210101-20210930" decimals="-5" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182Ny9mcmFnOjc2ODNiYjQ2MzFiMTQ0MTJiMDk2YzNkYmNmOTZiMTFlL3RhYmxlOjdhMGMwNmMxMTE0NTRlZmU4ZTc3YWM0MDhmYTQ1NTdmL3RhYmxlcmFuZ2U6N2EwYzA2YzExMTQ1NGVmZThlNzdhYzQwOGZhNDU1N2ZfNC03LTEtMS0xNTk1NDA_a289693d-c14d-45c1-8b22-d2b3288482fc">277.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifea67e1feada4a8c8d0bf25c34910e9a_D20220701-20220930" decimals="-5" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182Ny9mcmFnOjc2ODNiYjQ2MzFiMTQ0MTJiMDk2YzNkYmNmOTZiMTFlL3RhYmxlOjdhMGMwNmMxMTE0NTRlZmU4ZTc3YWM0MDhmYTQ1NTdmL3RhYmxlcmFuZ2U6N2EwYzA2YzExMTQ1NGVmZThlNzdhYzQwOGZhNDU1N2ZfNS0xLTEtMS0xNTk1NDA_6af69744-5fdd-44a5-b4e7-996cae1b298a">98.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19f7d57c42aa4dde893b82e5f134cfc1_D20210701-20210930" decimals="-5" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182Ny9mcmFnOjc2ODNiYjQ2MzFiMTQ0MTJiMDk2YzNkYmNmOTZiMTFlL3RhYmxlOjdhMGMwNmMxMTE0NTRlZmU4ZTc3YWM0MDhmYTQ1NTdmL3RhYmxlcmFuZ2U6N2EwYzA2YzExMTQ1NGVmZThlNzdhYzQwOGZhNDU1N2ZfNS0zLTEtMS0xNTk1NDA_f003af34-46e5-48f2-a7ce-bb728393949f">84.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0116b5022f7f41b494fd355fe823d76e_D20220101-20220930" decimals="-5" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182Ny9mcmFnOjc2ODNiYjQ2MzFiMTQ0MTJiMDk2YzNkYmNmOTZiMTFlL3RhYmxlOjdhMGMwNmMxMTE0NTRlZmU4ZTc3YWM0MDhmYTQ1NTdmL3RhYmxlcmFuZ2U6N2EwYzA2YzExMTQ1NGVmZThlNzdhYzQwOGZhNDU1N2ZfNS01LTEtMS0xNTk1NDA_d0899d1f-4d82-4800-bb9c-d31a07cd8edf">299.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a97c43966fd4f6aaf5f8dfb7bba4701_D20210101-20210930" decimals="-5" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182Ny9mcmFnOjc2ODNiYjQ2MzFiMTQ0MTJiMDk2YzNkYmNmOTZiMTFlL3RhYmxlOjdhMGMwNmMxMTE0NTRlZmU4ZTc3YWM0MDhmYTQ1NTdmL3RhYmxlcmFuZ2U6N2EwYzA2YzExMTQ1NGVmZThlNzdhYzQwOGZhNDU1N2ZfNS03LTEtMS0xNTk1NDA_630c584b-2cc1-4279-9c6b-c4c253956a06">253.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifea67e1feada4a8c8d0bf25c34910e9a_D20220701-20220930" decimals="-5" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182Ny9mcmFnOjc2ODNiYjQ2MzFiMTQ0MTJiMDk2YzNkYmNmOTZiMTFlL3RhYmxlOjdhMGMwNmMxMTE0NTRlZmU4ZTc3YWM0MDhmYTQ1NTdmL3RhYmxlcmFuZ2U6N2EwYzA2YzExMTQ1NGVmZThlNzdhYzQwOGZhNDU1N2ZfNi0xLTEtMS0xNTk1NDA_6ba39726-929b-48f2-9c83-872d1bc37987">235.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i19f7d57c42aa4dde893b82e5f134cfc1_D20210701-20210930" decimals="-5" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182Ny9mcmFnOjc2ODNiYjQ2MzFiMTQ0MTJiMDk2YzNkYmNmOTZiMTFlL3RhYmxlOjdhMGMwNmMxMTE0NTRlZmU4ZTc3YWM0MDhmYTQ1NTdmL3RhYmxlcmFuZ2U6N2EwYzA2YzExMTQ1NGVmZThlNzdhYzQwOGZhNDU1N2ZfNi0zLTEtMS0xNTk1NDA_1a9cf00b-7436-4fe4-bada-6e60d20b8ff0">237.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0116b5022f7f41b494fd355fe823d76e_D20220101-20220930" decimals="-5" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182Ny9mcmFnOjc2ODNiYjQ2MzFiMTQ0MTJiMDk2YzNkYmNmOTZiMTFlL3RhYmxlOjdhMGMwNmMxMTE0NTRlZmU4ZTc3YWM0MDhmYTQ1NTdmL3RhYmxlcmFuZ2U6N2EwYzA2YzExMTQ1NGVmZThlNzdhYzQwOGZhNDU1N2ZfNi01LTEtMS0xNTk1NDA_bdd9f46a-7357-4dda-97cc-014f240b8071">711.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8a97c43966fd4f6aaf5f8dfb7bba4701_D20210101-20210930" decimals="-5" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182Ny9mcmFnOjc2ODNiYjQ2MzFiMTQ0MTJiMDk2YzNkYmNmOTZiMTFlL3RhYmxlOjdhMGMwNmMxMTE0NTRlZmU4ZTc3YWM0MDhmYTQ1NTdmL3RhYmxlcmFuZ2U6N2EwYzA2YzExMTQ1NGVmZThlNzdhYzQwOGZhNDU1N2ZfNi03LTEtMS0xNTk1NDA_6ceeae2f-86ec-45f7-94ed-12dd3f26fd8e">712.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of prior service cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifea67e1feada4a8c8d0bf25c34910e9a_D20220701-20220930" decimals="-5" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182Ny9mcmFnOjc2ODNiYjQ2MzFiMTQ0MTJiMDk2YzNkYmNmOTZiMTFlL3RhYmxlOjdhMGMwNmMxMTE0NTRlZmU4ZTc3YWM0MDhmYTQ1NTdmL3RhYmxlcmFuZ2U6N2EwYzA2YzExMTQ1NGVmZThlNzdhYzQwOGZhNDU1N2ZfNy0xLTEtMS0xNTk1NDA_79f7701a-4e75-4ad6-841e-3c300f94aad8">0.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19f7d57c42aa4dde893b82e5f134cfc1_D20210701-20210930" decimals="-5" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182Ny9mcmFnOjc2ODNiYjQ2MzFiMTQ0MTJiMDk2YzNkYmNmOTZiMTFlL3RhYmxlOjdhMGMwNmMxMTE0NTRlZmU4ZTc3YWM0MDhmYTQ1NTdmL3RhYmxlcmFuZ2U6N2EwYzA2YzExMTQ1NGVmZThlNzdhYzQwOGZhNDU1N2ZfNy0zLTEtMS0xNTk1NDA_4d01de6d-f33d-4125-b650-2465d8233962">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0116b5022f7f41b494fd355fe823d76e_D20220101-20220930" decimals="-5" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182Ny9mcmFnOjc2ODNiYjQ2MzFiMTQ0MTJiMDk2YzNkYmNmOTZiMTFlL3RhYmxlOjdhMGMwNmMxMTE0NTRlZmU4ZTc3YWM0MDhmYTQ1NTdmL3RhYmxlcmFuZ2U6N2EwYzA2YzExMTQ1NGVmZThlNzdhYzQwOGZhNDU1N2ZfNy01LTEtMS0xNTk1NDA_bbcd8f96-9617-4756-a8ca-93860fd077ac">1.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a97c43966fd4f6aaf5f8dfb7bba4701_D20210101-20210930" decimals="-5" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182Ny9mcmFnOjc2ODNiYjQ2MzFiMTQ0MTJiMDk2YzNkYmNmOTZiMTFlL3RhYmxlOjdhMGMwNmMxMTE0NTRlZmU4ZTc3YWM0MDhmYTQ1NTdmL3RhYmxlcmFuZ2U6N2EwYzA2YzExMTQ1NGVmZThlNzdhYzQwOGZhNDU1N2ZfNy03LTEtMS0xNTk1NDA_d09315bc-a246-4761-8dcf-d026058a8514">3.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognized actuarial loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifea67e1feada4a8c8d0bf25c34910e9a_D20220701-20220930" decimals="-5" sign="-" name="us-gaap:DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182Ny9mcmFnOjc2ODNiYjQ2MzFiMTQ0MTJiMDk2YzNkYmNmOTZiMTFlL3RhYmxlOjdhMGMwNmMxMTE0NTRlZmU4ZTc3YWM0MDhmYTQ1NTdmL3RhYmxlcmFuZ2U6N2EwYzA2YzExMTQ1NGVmZThlNzdhYzQwOGZhNDU1N2ZfOC0xLTEtMS0xNTk1NDA_b56420f5-b92a-4a74-a84f-db8f87c32552">85.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19f7d57c42aa4dde893b82e5f134cfc1_D20210701-20210930" decimals="-5" sign="-" name="us-gaap:DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182Ny9mcmFnOjc2ODNiYjQ2MzFiMTQ0MTJiMDk2YzNkYmNmOTZiMTFlL3RhYmxlOjdhMGMwNmMxMTE0NTRlZmU4ZTc3YWM0MDhmYTQ1NTdmL3RhYmxlcmFuZ2U6N2EwYzA2YzExMTQ1NGVmZThlNzdhYzQwOGZhNDU1N2ZfOC0zLTEtMS0xNTk1NDA_67aa935d-0b6b-4e66-9ab9-4385e1182ba1">121.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0116b5022f7f41b494fd355fe823d76e_D20220101-20220930" decimals="-5" sign="-" name="us-gaap:DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182Ny9mcmFnOjc2ODNiYjQ2MzFiMTQ0MTJiMDk2YzNkYmNmOTZiMTFlL3RhYmxlOjdhMGMwNmMxMTE0NTRlZmU4ZTc3YWM0MDhmYTQ1NTdmL3RhYmxlcmFuZ2U6N2EwYzA2YzExMTQ1NGVmZThlNzdhYzQwOGZhNDU1N2ZfOC01LTEtMS0xNTk1NDA_17d0dd71-107c-44a9-a8ee-8324ff5a143f">256.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a97c43966fd4f6aaf5f8dfb7bba4701_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182Ny9mcmFnOjc2ODNiYjQ2MzFiMTQ0MTJiMDk2YzNkYmNmOTZiMTFlL3RhYmxlOjdhMGMwNmMxMTE0NTRlZmU4ZTc3YWM0MDhmYTQ1NTdmL3RhYmxlcmFuZ2U6N2EwYzA2YzExMTQ1NGVmZThlNzdhYzQwOGZhNDU1N2ZfOC03LTEtMS0xNTk1NDA_89bf223b-a162-4be6-9096-7103e7c89cda">366.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic benefit cost</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifea67e1feada4a8c8d0bf25c34910e9a_D20220701-20220930" decimals="-5" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182Ny9mcmFnOjc2ODNiYjQ2MzFiMTQ0MTJiMDk2YzNkYmNmOTZiMTFlL3RhYmxlOjdhMGMwNmMxMTE0NTRlZmU4ZTc3YWM0MDhmYTQ1NTdmL3RhYmxlcmFuZ2U6N2EwYzA2YzExMTQ1NGVmZThlNzdhYzQwOGZhNDU1N2ZfMTAtMS0xLTEtMTU5NTQw_d222aaa8-4de2-464e-ad36-89f18ffdc09e">36.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19f7d57c42aa4dde893b82e5f134cfc1_D20210701-20210930" decimals="-5" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182Ny9mcmFnOjc2ODNiYjQ2MzFiMTQ0MTJiMDk2YzNkYmNmOTZiMTFlL3RhYmxlOjdhMGMwNmMxMTE0NTRlZmU4ZTc3YWM0MDhmYTQ1NTdmL3RhYmxlcmFuZ2U6N2EwYzA2YzExMTQ1NGVmZThlNzdhYzQwOGZhNDU1N2ZfMTAtMy0xLTEtMTU5NTQw_2c71567a-37d1-44d3-a00b-549332be76a7">62.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0116b5022f7f41b494fd355fe823d76e_D20220101-20220930" decimals="-5" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182Ny9mcmFnOjc2ODNiYjQ2MzFiMTQ0MTJiMDk2YzNkYmNmOTZiMTFlL3RhYmxlOjdhMGMwNmMxMTE0NTRlZmU4ZTc3YWM0MDhmYTQ1NTdmL3RhYmxlcmFuZ2U6N2EwYzA2YzExMTQ1NGVmZThlNzdhYzQwOGZhNDU1N2ZfMTAtNS0xLTEtMTU5NTQw_b0b9ea53-a34e-4cc9-a7a2-e52a6e61d7cf">110.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a97c43966fd4f6aaf5f8dfb7bba4701_D20210101-20210930" decimals="-5" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182Ny9mcmFnOjc2ODNiYjQ2MzFiMTQ0MTJiMDk2YzNkYmNmOTZiMTFlL3RhYmxlOjdhMGMwNmMxMTE0NTRlZmU4ZTc3YWM0MDhmYTQ1NTdmL3RhYmxlcmFuZ2U6N2EwYzA2YzExMTQ1NGVmZThlNzdhYzQwOGZhNDU1N2ZfMTAtNy0xLTEtMTU5NTQw_c3a020f8-bc63-4fc4-ab1e-08f0c7f02b32">188.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.613%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.206%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Retiree Health Benefit Plans</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Components of net periodic benefit income:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i238afcd7e9494cbb9f4c68c1cf1dcc2d_D20220701-20220930" decimals="-5" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182Ny9mcmFnOjc2ODNiYjQ2MzFiMTQ0MTJiMDk2YzNkYmNmOTZiMTFlL3RhYmxlOjBhZjE5OWIyY2U1YTQ5ODA4ZTVlYThlMDdjNmE2YmZkL3RhYmxlcmFuZ2U6MGFmMTk5YjJjZTVhNDk4MDhlNWVhOGUwN2M2YTZiZmRfNC0xLTEtMS0xNTk1NDA_7b659c1c-bbe9-425c-8caa-6edcc81ad9f8">11.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b0c929331c241cb98c2a4d85625e2e7_D20210701-20210930" decimals="-5" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182Ny9mcmFnOjc2ODNiYjQ2MzFiMTQ0MTJiMDk2YzNkYmNmOTZiMTFlL3RhYmxlOjBhZjE5OWIyY2U1YTQ5ODA4ZTVlYThlMDdjNmE2YmZkL3RhYmxlcmFuZ2U6MGFmMTk5YjJjZTVhNDk4MDhlNWVhOGUwN2M2YTZiZmRfNC0zLTEtMS0xNTk1NDA_1ee08aff-fd66-4527-b92f-171c895057f3">12.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60435d86ecc44d56b9b471e301119ba4_D20220101-20220930" decimals="-5" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182Ny9mcmFnOjc2ODNiYjQ2MzFiMTQ0MTJiMDk2YzNkYmNmOTZiMTFlL3RhYmxlOjBhZjE5OWIyY2U1YTQ5ODA4ZTVlYThlMDdjNmE2YmZkL3RhYmxlcmFuZ2U6MGFmMTk5YjJjZTVhNDk4MDhlNWVhOGUwN2M2YTZiZmRfNC01LTEtMS0xNTk1NDA_03baa210-7659-4b21-a32c-9fcb2dc8e7a1">35.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i146fcce3fad6486aa91cf7ba94fd98c8_D20210101-20210930" decimals="-5" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182Ny9mcmFnOjc2ODNiYjQ2MzFiMTQ0MTJiMDk2YzNkYmNmOTZiMTFlL3RhYmxlOjBhZjE5OWIyY2U1YTQ5ODA4ZTVlYThlMDdjNmE2YmZkL3RhYmxlcmFuZ2U6MGFmMTk5YjJjZTVhNDk4MDhlNWVhOGUwN2M2YTZiZmRfNC03LTEtMS0xNTk1NDA_dfaa4e37-9742-4f4d-86fb-f3f3b338ce5a">37.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i238afcd7e9494cbb9f4c68c1cf1dcc2d_D20220701-20220930" decimals="-5" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182Ny9mcmFnOjc2ODNiYjQ2MzFiMTQ0MTJiMDk2YzNkYmNmOTZiMTFlL3RhYmxlOjBhZjE5OWIyY2U1YTQ5ODA4ZTVlYThlMDdjNmE2YmZkL3RhYmxlcmFuZ2U6MGFmMTk5YjJjZTVhNDk4MDhlNWVhOGUwN2M2YTZiZmRfNS0xLTEtMS0xNTk1NDA_5e9dce56-a7a7-454f-8c5c-fe9a11d638ed">9.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b0c929331c241cb98c2a4d85625e2e7_D20210701-20210930" decimals="-5" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182Ny9mcmFnOjc2ODNiYjQ2MzFiMTQ0MTJiMDk2YzNkYmNmOTZiMTFlL3RhYmxlOjBhZjE5OWIyY2U1YTQ5ODA4ZTVlYThlMDdjNmE2YmZkL3RhYmxlcmFuZ2U6MGFmMTk5YjJjZTVhNDk4MDhlNWVhOGUwN2M2YTZiZmRfNS0zLTEtMS0xNTk1NDA_4c0b4229-63c5-4de5-9668-6973b9de3436">8.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60435d86ecc44d56b9b471e301119ba4_D20220101-20220930" decimals="-5" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182Ny9mcmFnOjc2ODNiYjQ2MzFiMTQ0MTJiMDk2YzNkYmNmOTZiMTFlL3RhYmxlOjBhZjE5OWIyY2U1YTQ5ODA4ZTVlYThlMDdjNmE2YmZkL3RhYmxlcmFuZ2U6MGFmMTk5YjJjZTVhNDk4MDhlNWVhOGUwN2M2YTZiZmRfNS01LTEtMS0xNTk1NDA_79221b18-8d5e-4e89-8c41-c71302047af2">28.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i146fcce3fad6486aa91cf7ba94fd98c8_D20210101-20210930" decimals="-5" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182Ny9mcmFnOjc2ODNiYjQ2MzFiMTQ0MTJiMDk2YzNkYmNmOTZiMTFlL3RhYmxlOjBhZjE5OWIyY2U1YTQ5ODA4ZTVlYThlMDdjNmE2YmZkL3RhYmxlcmFuZ2U6MGFmMTk5YjJjZTVhNDk4MDhlNWVhOGUwN2M2YTZiZmRfNS03LTEtMS0xNTk1NDA_190cdb00-ffd0-4447-9151-e314e71cbf4a">24.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i238afcd7e9494cbb9f4c68c1cf1dcc2d_D20220701-20220930" decimals="-5" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182Ny9mcmFnOjc2ODNiYjQ2MzFiMTQ0MTJiMDk2YzNkYmNmOTZiMTFlL3RhYmxlOjBhZjE5OWIyY2U1YTQ5ODA4ZTVlYThlMDdjNmE2YmZkL3RhYmxlcmFuZ2U6MGFmMTk5YjJjZTVhNDk4MDhlNWVhOGUwN2M2YTZiZmRfNi0xLTEtMS0xNTk1NDA_5e20d3b0-e504-4cd8-bbba-6febad47b954">38.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6b0c929331c241cb98c2a4d85625e2e7_D20210701-20210930" decimals="-5" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182Ny9mcmFnOjc2ODNiYjQ2MzFiMTQ0MTJiMDk2YzNkYmNmOTZiMTFlL3RhYmxlOjBhZjE5OWIyY2U1YTQ5ODA4ZTVlYThlMDdjNmE2YmZkL3RhYmxlcmFuZ2U6MGFmMTk5YjJjZTVhNDk4MDhlNWVhOGUwN2M2YTZiZmRfNi0zLTEtMS0xNTk1NDA_33531405-5355-4e13-ab49-59dfffcffecd">36.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i60435d86ecc44d56b9b471e301119ba4_D20220101-20220930" decimals="-5" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182Ny9mcmFnOjc2ODNiYjQ2MzFiMTQ0MTJiMDk2YzNkYmNmOTZiMTFlL3RhYmxlOjBhZjE5OWIyY2U1YTQ5ODA4ZTVlYThlMDdjNmE2YmZkL3RhYmxlcmFuZ2U6MGFmMTk5YjJjZTVhNDk4MDhlNWVhOGUwN2M2YTZiZmRfNi01LTEtMS0xNTk1NDA_bbe145c7-cff3-4935-881c-0d39f4e98c80">114.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i146fcce3fad6486aa91cf7ba94fd98c8_D20210101-20210930" decimals="-5" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182Ny9mcmFnOjc2ODNiYjQ2MzFiMTQ0MTJiMDk2YzNkYmNmOTZiMTFlL3RhYmxlOjBhZjE5OWIyY2U1YTQ5ODA4ZTVlYThlMDdjNmE2YmZkL3RhYmxlcmFuZ2U6MGFmMTk5YjJjZTVhNDk4MDhlNWVhOGUwN2M2YTZiZmRfNi03LTEtMS0xNTk1NDA_3aa119d3-74c2-4a5e-889e-4a61b2d3523c">109.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of prior service benefit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i238afcd7e9494cbb9f4c68c1cf1dcc2d_D20220701-20220930" decimals="-5" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182Ny9mcmFnOjc2ODNiYjQ2MzFiMTQ0MTJiMDk2YzNkYmNmOTZiMTFlL3RhYmxlOjBhZjE5OWIyY2U1YTQ5ODA4ZTVlYThlMDdjNmE2YmZkL3RhYmxlcmFuZ2U6MGFmMTk5YjJjZTVhNDk4MDhlNWVhOGUwN2M2YTZiZmRfNy0xLTEtMS0xNTk1NDA_b0039838-d99b-4511-b9ee-7d15005dd77d">13.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6b0c929331c241cb98c2a4d85625e2e7_D20210701-20210930" decimals="-5" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182Ny9mcmFnOjc2ODNiYjQ2MzFiMTQ0MTJiMDk2YzNkYmNmOTZiMTFlL3RhYmxlOjBhZjE5OWIyY2U1YTQ5ODA4ZTVlYThlMDdjNmE2YmZkL3RhYmxlcmFuZ2U6MGFmMTk5YjJjZTVhNDk4MDhlNWVhOGUwN2M2YTZiZmRfNy0zLTEtMS0xNTk1NDA_fced5d52-4240-4409-ac21-c381b98ddb20">14.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i60435d86ecc44d56b9b471e301119ba4_D20220101-20220930" decimals="-5" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182Ny9mcmFnOjc2ODNiYjQ2MzFiMTQ0MTJiMDk2YzNkYmNmOTZiMTFlL3RhYmxlOjBhZjE5OWIyY2U1YTQ5ODA4ZTVlYThlMDdjNmE2YmZkL3RhYmxlcmFuZ2U6MGFmMTk5YjJjZTVhNDk4MDhlNWVhOGUwN2M2YTZiZmRfNy01LTEtMS0xNTk1NDA_42a2821c-2674-4e97-9067-c041f2b8238d">41.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i146fcce3fad6486aa91cf7ba94fd98c8_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182Ny9mcmFnOjc2ODNiYjQ2MzFiMTQ0MTJiMDk2YzNkYmNmOTZiMTFlL3RhYmxlOjBhZjE5OWIyY2U1YTQ5ODA4ZTVlYThlMDdjNmE2YmZkL3RhYmxlcmFuZ2U6MGFmMTk5YjJjZTVhNDk4MDhlNWVhOGUwN2M2YTZiZmRfNy03LTEtMS0xNTk1NDA_9c76e13a-df82-4ce2-ae22-c31d846b7b08">44.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognized actuarial loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i238afcd7e9494cbb9f4c68c1cf1dcc2d_D20220701-20220930" decimals="-5" sign="-" name="us-gaap:DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182Ny9mcmFnOjc2ODNiYjQ2MzFiMTQ0MTJiMDk2YzNkYmNmOTZiMTFlL3RhYmxlOjBhZjE5OWIyY2U1YTQ5ODA4ZTVlYThlMDdjNmE2YmZkL3RhYmxlcmFuZ2U6MGFmMTk5YjJjZTVhNDk4MDhlNWVhOGUwN2M2YTZiZmRfOC0xLTEtMS0xNTk1NDA_e0784215-c079-4775-a5b2-742e92fbc4cc">0.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b0c929331c241cb98c2a4d85625e2e7_D20210701-20210930" decimals="-5" sign="-" name="us-gaap:DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182Ny9mcmFnOjc2ODNiYjQ2MzFiMTQ0MTJiMDk2YzNkYmNmOTZiMTFlL3RhYmxlOjBhZjE5OWIyY2U1YTQ5ODA4ZTVlYThlMDdjNmE2YmZkL3RhYmxlcmFuZ2U6MGFmMTk5YjJjZTVhNDk4MDhlNWVhOGUwN2M2YTZiZmRfOC0zLTEtMS0xNTk1NDA_47d99cdf-0375-4cba-b0aa-05328f552da9">0.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60435d86ecc44d56b9b471e301119ba4_D20220101-20220930" decimals="-5" sign="-" name="us-gaap:DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182Ny9mcmFnOjc2ODNiYjQ2MzFiMTQ0MTJiMDk2YzNkYmNmOTZiMTFlL3RhYmxlOjBhZjE5OWIyY2U1YTQ5ODA4ZTVlYThlMDdjNmE2YmZkL3RhYmxlcmFuZ2U6MGFmMTk5YjJjZTVhNDk4MDhlNWVhOGUwN2M2YTZiZmRfOC01LTEtMS0xNTk1NDA_21e03264-275f-49f8-96ef-ab83786c7f3e">0.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i146fcce3fad6486aa91cf7ba94fd98c8_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182Ny9mcmFnOjc2ODNiYjQ2MzFiMTQ0MTJiMDk2YzNkYmNmOTZiMTFlL3RhYmxlOjBhZjE5OWIyY2U1YTQ5ODA4ZTVlYThlMDdjNmE2YmZkL3RhYmxlcmFuZ2U6MGFmMTk5YjJjZTVhNDk4MDhlNWVhOGUwN2M2YTZiZmRfOC03LTEtMS0xNTk1NDA_07011895-c6b7-4421-b55c-bceab32fdfa8">2.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic benefit income</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i238afcd7e9494cbb9f4c68c1cf1dcc2d_D20220701-20220930" decimals="-5" sign="-" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182Ny9mcmFnOjc2ODNiYjQ2MzFiMTQ0MTJiMDk2YzNkYmNmOTZiMTFlL3RhYmxlOjBhZjE5OWIyY2U1YTQ5ODA4ZTVlYThlMDdjNmE2YmZkL3RhYmxlcmFuZ2U6MGFmMTk5YjJjZTVhNDk4MDhlNWVhOGUwN2M2YTZiZmRfMTAtMS0xLTEtMTU5NTQw_7842c229-76a1-41f9-91c7-5bc773be8c6d">30.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6b0c929331c241cb98c2a4d85625e2e7_D20210701-20210930" decimals="-5" sign="-" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182Ny9mcmFnOjc2ODNiYjQ2MzFiMTQ0MTJiMDk2YzNkYmNmOTZiMTFlL3RhYmxlOjBhZjE5OWIyY2U1YTQ5ODA4ZTVlYThlMDdjNmE2YmZkL3RhYmxlcmFuZ2U6MGFmMTk5YjJjZTVhNDk4MDhlNWVhOGUwN2M2YTZiZmRfMTAtMy0xLTEtMTU5NTQw_6119dc87-bc16-4d11-a6f8-22537b1fe836">30.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i60435d86ecc44d56b9b471e301119ba4_D20220101-20220930" decimals="-5" sign="-" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182Ny9mcmFnOjc2ODNiYjQ2MzFiMTQ0MTJiMDk2YzNkYmNmOTZiMTFlL3RhYmxlOjBhZjE5OWIyY2U1YTQ5ODA4ZTVlYThlMDdjNmE2YmZkL3RhYmxlcmFuZ2U6MGFmMTk5YjJjZTVhNDk4MDhlNWVhOGUwN2M2YTZiZmRfMTAtNS0xLTEtMTU5NTQw_639edd6f-88e4-4b6c-bab9-5a0e961e527c">91.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i146fcce3fad6486aa91cf7ba94fd98c8_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182Ny9mcmFnOjc2ODNiYjQ2MzFiMTQ0MTJiMDk2YzNkYmNmOTZiMTFlL3RhYmxlOjBhZjE5OWIyY2U1YTQ5ODA4ZTVlYThlMDdjNmE2YmZkL3RhYmxlcmFuZ2U6MGFmMTk5YjJjZTVhNDk4MDhlNWVhOGUwN2M2YTZiZmRfMTAtNy0xLTEtMTU5NTQw_172a5a38-69a0-4b77-a7f5-9ff66dded603">90.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:6pt"><span><br/></span></div><div id="i5fed483d9c7e4f3cbba3a62c53226cd7_70"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 9: <ix:nonNumeric contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183MC9mcmFnOjNjOWJjNzRiOGMyODRlZTQ4NThjMTM0MDBiMTE4Zjk1L3RleHRyZWdpb246M2M5YmM3NGI4YzI4NGVlNDg1OGMxMzQwMGIxMThmOTVfMjU1Mjg_816570e0-3745-4ff8-b916-414dbcfea259" continuedAt="i52889ec5ff384d31a9395d774eb8548f" escape="true">Contingencies</ix:nonNumeric></span></div><ix:continuation id="i52889ec5ff384d31a9395d774eb8548f" continuedAt="ic6d9a033f0be4f6ba6989be13d6d66ad"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are involved in various lawsuits, claims, government investigations and other legal proceedings that arise in the ordinary course of business. These claims or proceedings can involve various types of parties, including governments, competitors, customers, suppliers, service providers, licensees, employees, or shareholders, among others. These matters may involve patent infringement, antitrust, securities, pricing, sales and marketing practices, environmental, commercial, contractual rights, licensing obligations, health and safety matters, consumer fraud, employment matters, product liability and insurance coverage, among others. The resolution of these matters often develops over a long period of time and expectations can change as a result of new findings, rulings, appeals or settlement arrangements. Legal proceedings that are significant or that we believe could become significant or material are described below. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe the legal proceedings in which we are named as defendants are without merit and we are defending against them vigorously. It is not possible to determine the final outcome of these matters, and we cannot reasonably estimate the maximum potential exposure or the range of possible loss in excess of amounts accrued for any of these matters; however, we believe that the resolution of all such matters will not have a material adverse effect on our consolidated financial position or liquidity, but could possibly be material to our consolidated results of operations in any one accounting period.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930" name="us-gaap:CommitmentsAndContingenciesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183MC9mcmFnOjNjOWJjNzRiOGMyODRlZTQ4NThjMTM0MDBiMTE4Zjk1L3RleHRyZWdpb246M2M5YmM3NGI4YzI4NGVlNDg1OGMxMzQwMGIxMThmOTVfMjU1Mjc_94d35f0a-1f1c-40a2-a374-cb9a1db87e4c" continuedAt="i114efd4796cb4b0892c0d74f5d87e89e" escape="true">Litigation accruals, environmental liabilities, and the related estimated insurance recoverables are reflected on a gross basis as liabilities and assets, respectively, on our consolidated condensed balance sheets. With respect to the product liability claims currently asserted against us, we have accrued for our estimated exposures to the extent they are both probable and reasonably estimable based on the information available to us. We accrue for certain product liability claims incurred but not filed to the extent we can formulate a reasonable estimate of their costs. We estimate these expenses based primarily on historical claims experience and data regarding product usage. Legal defense costs expected to be incurred in connection with significant product liability loss contingencies are accrued when both probable and reasonably estimable.</ix:nonNumeric></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i114efd4796cb4b0892c0d74f5d87e89e">Because of the nature of pharmaceutical products, it is possible that we could become subject to large numbers of additional product liability and related claims in the future. Due to a very restrictive market for litigation liability insurance, we are self-insured for litigation liability losses for all our currently and previously marketed products.</ix:continuation> </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ic6d9a033f0be4f6ba6989be13d6d66ad" continuedAt="i21ea1be77e034af49bfdae98dea849af"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Patent Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Alimta European Patent Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In Europe, Alimta (pemetrexed) was protected by a patent through June 2021. A number of legal proceedings that were initiated prior to patent expiration are ongoing. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Emgality Patent Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a named defendant in litigation filed by Teva Pharmaceuticals International GMBH and Teva Pharmaceuticals USA, Inc. (collectively, Teva) in the U.S. District Court for the District of Massachusetts seeking a ruling that various claims in <ix:nonFraction unitRef="patent" contextRef="ib414aaa5a0174c7fb17ac9898d399d32_I20220930" decimals="INF" name="lly:LossContingencyNumberOfPatents" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183MC9mcmFnOjNjOWJjNzRiOGMyODRlZTQ4NThjMTM0MDBiMTE4Zjk1L3RleHRyZWdpb246M2M5YmM3NGI4YzI4NGVlNDg1OGMxMzQwMGIxMThmOTVfMzI3MA_8e971b18-a9a6-4aef-8669-427d64636547">three</ix:nonFraction> different Teva patents would be infringed by our launch and continued sales of Emgality for the prevention of migraine in adults. Trial began in October 2022. In June 2021, we were named as a defendant in a second litigation filed by Teva in the U.S. District Court for the District of Massachusetts seeking a ruling that <ix:nonFraction unitRef="patent" contextRef="if274934ece0041f487b43797bc8de648_I20210630" decimals="INF" name="lly:LossContingencyNumberOfPatents" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183MC9mcmFnOjNjOWJjNzRiOGMyODRlZTQ4NThjMTM0MDBiMTE4Zjk1L3RleHRyZWdpb246M2M5YmM3NGI4YzI4NGVlNDg1OGMxMzQwMGIxMThmOTVfMzYyMQ_e7472257-8527-43b9-811f-30e96ee28ad1">two</ix:nonFraction> of Teva's patents, which are directed toward use of the active ingredient in Emgality to treat migraine, would be infringed by our continued sales of Emgality. We challenged these <ix:nonFraction unitRef="patent" contextRef="ibcc5f2496e02449abe458e54c0a8a61f_I20221031" decimals="INF" name="lly:LossContingencyNumberOfPatents" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183MC9mcmFnOjNjOWJjNzRiOGMyODRlZTQ4NThjMTM0MDBiMTE4Zjk1L3RleHRyZWdpb246M2M5YmM3NGI4YzI4NGVlNDg1OGMxMzQwMGIxMThmOTVfMzI5ODUzNDkxMzc1Nw_ffd61f4e-01d0-4ed4-8e24-921cab76ceb3">two</ix:nonFraction> patents by filing requests for Inter Partes Review with the Patent Trial and Appeal Board (PTAB) and in October 2022, the PTAB granted our requests.The corresponding district court litigation is stayed while this PTAB proceeding is ongoing.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Jardiance Patent Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2018, Boehringer Ingelheim, our partner in marketing and development of Jardiance, initiated U.S. patent litigation in the U.S. District Court of Delaware alleging infringement arising from submissions of Abbreviated New Drug Applications (ANDA) by a number of generic companies seeking approval to market generic versions of Jardiance, Glyxambi, and Synjardy in accordance with the procedures set out in the Drug Price Competition and Patent Term Restoration Act of 1984 (the Hatch-Waxman Act). Particularly with respect to Jardiance, the generic companies' ANDAs seek approval to market generic versions of Jardiance prior to the expiration of the relevant patents, and allege that certain patents, including in some allegations the compound patent, are invalid or would not be infringed. We are not a party to this litigation. This litigation has been stayed. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Taltz Patent Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2021, we petitioned the High Court of Ireland to declare invalid a patent that Novartis Pharma AG (Novartis) purchased from Genentech, Inc. in 2020. Novartis responded by filing a claim against us alleging patent infringement related to our commercialization of Taltz and seeking damages for past infringement and an injunction against future infringement. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2021, Novartis petitioned the Court of Rome Intellectual Property Division for a preliminary injunction (PI) against us related to our commercialization of Taltz in Italy. In May 2021, We commenced patent revocation proceedings against Novartis before the Court of Milan&#8217;s IP Division where we also sought a declaration of non-infringement. Novartis counter-claimed for patent infringement and sought a permanent injunction. A hearing on the PI request before the Court of Rome Intellectual Property Division took place in May 2022 and in July 2022, the court rejected Novartis' request.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2021, Novartis petitioned the Swiss Federal Patent Court for a PI and a permanent injunction in main infringement proceedings against us related to our commercialization of Taltz in Switzerland. We petitioned the court to revoke the patent and for a declaration of non-infringement. In April 2022, Novartis withdrew its PI request.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2022, we commenced an action in the Hague District Court asking for a judgment that a Novartis Dutch patent is not infringed by our commercialization of Taltz in the Netherlands and is invalid. In October 2022, Novartis filed a counterclaim for infringement and sought a permanent injunction.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2022, we entered into a settlement and mutual release agreement with Novartis, which resolves the above-described disputes. Without any admission of liability or wrongdoing, we and Novartis have agreed to mutual releases for past claims and mutual covenants not to sue the other in relation to Taltz and the patents Novartis purchased from Genentech. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i21ea1be77e034af49bfdae98dea849af" continuedAt="ie638f5bd5e9f476193a7dbaa06514ac3"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Zyprexa Canada Patent Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in the mid-2000s, several generic companies in Canada challenged the validity of our Zyprexa compound patent. In 2012, the Canadian Federal Court of Appeals denied our appeal of a lower court's decision that certain patent claims were invalid for lack of utility. In 2013, Apotex Inc. and Apotex Pharmachem Inc. (collectively, Apotex) brought claims against us in the Ontario Superior Court of Justice at Toronto for damages related to our enforcement of the Zyprexa compound patent under Canadian regulations governing patented drugs. Apotex seeks compensation based on novel legal theories under the Statute of Monopolies, Trademark Act, and common law. In March 2021, the Ontario Superior Court granted our motion for summary judgment, thereby dismissing Apotex's case. Apotex appealed that ruling to the Court of Appeal for Ontario in April 2021. In August 2022, the Court dismissed the appeal and in October 2022, Apotex appealed the decision. This matter is ongoing.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product Liability Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Byetta&#174; Product Liability</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have been named as a defendant in over <ix:nonFraction unitRef="lawsuit" contextRef="i58d8155218724e10a6956cdd38ca1bb1_I20220930" decimals="0" name="us-gaap:LossContingencyPendingClaimsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183MC9mcmFnOjNjOWJjNzRiOGMyODRlZTQ4NThjMTM0MDBiMTE4Zjk1L3RleHRyZWdpb246M2M5YmM3NGI4YzI4NGVlNDg1OGMxMzQwMGIxMThmOTVfNzE4NA_c911cb99-3c7e-4e9d-8a5e-5f4a3ac54ad6">500</ix:nonFraction> Byetta product liability lawsuits in the U.S. that were first initiated in March 2009 and involved over <ix:nonFraction unitRef="plaintiff" contextRef="i03a0a6037fc44e39af8b9a0fc87cbcbb_D20090301-20220930" decimals="0" name="us-gaap:LossContingencyNumberOfPlaintiffs" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183MC9mcmFnOjNjOWJjNzRiOGMyODRlZTQ4NThjMTM0MDBiMTE4Zjk1L3RleHRyZWdpb246M2M5YmM3NGI4YzI4NGVlNDg1OGMxMzQwMGIxMThmOTVfNzI5MQ_a72efacc-c27f-4e6e-8f0e-a546adfee6ab">800</ix:nonFraction> plaintiffs. These lawsuits have been filed in various state and federal jurisdictions, including California state court (coordinated in Los Angeles County Superior Court), and various federal courts, the majority of which are coordinated in a multi-district litigation (MDL) in the U.S. District Court for the Southern District of California. The majority of these suits contain allegations that Byetta caused or contributed to the plaintiffs' cancer (primarily pancreatic cancer or thyroid cancer). The federal MDL and coordinated California state trial courts granted summary judgment in our favor on claims pertaining to pancreatic cancer, and the plaintiffs have dismissed Lilly from their appeal of the MDL ruling (the parties still await the order of judgment in the Los Angeles County Superior Court). Most of the MDL and state court lawsuits have been dismissed as of November 2022.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Environmental Proceedings</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Comprehensive Environmental Response, Compensation, and Liability Act, commonly known as "Superfund," we have been designated as one of several potentially responsible parties with respect to the cleanup of fewer than <ix:nonFraction unitRef="site" contextRef="iedfe8e594f2d4534ba3f7d18996055ec_I20220930" decimals="0" name="lly:LossContingencyNumberOfSitesJointlyAndSeverallyLiableForCleanup" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183MC9mcmFnOjNjOWJjNzRiOGMyODRlZTQ4NThjMTM0MDBiMTE4Zjk1L3RleHRyZWdpb246M2M5YmM3NGI4YzI4NGVlNDg1OGMxMzQwMGIxMThmOTVfOTQwMQ_5089f719-62ae-4612-80e7-43f34070b9d0">10</ix:nonFraction> sites. Under Superfund, each responsible party may be jointly and severally liable for the entire amount of the cleanup.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Matters</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">340B Litigation and Investigations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are the plaintiff in a lawsuit filed in January 2021 in the U.S. District Court for the Southern District of Indiana against the U.S. Department of Health and Human Services (HHS), the Secretary of HHS, the Health Resources and Services Administration (HRSA), and the Administrator of HRSA. The lawsuit challenges the HHS's December 30, 2020 advisory opinion stating that drug manufacturers are required to deliver discounts under the 340B program to all contract pharmacies. We seek a declaratory judgment that the defendants violated the Administrative Procedures Act and the U.S. Constitution, a preliminary injunction enjoining implementation of the administrative dispute resolution process created by defendants and, with it, their application of the advisory opinion, and other related relief. In March 2021, the court entered an order preliminarily enjoining the government's enforcement of the administrative dispute resolution process against us. In May 2021, HRSA notified us that it determined that our policy was contrary to the 340B statute. In response, in May 2021, we filed a motion for preliminary injunction and temporary restraining order requesting that the U.S. District Court for the Southern District of Indiana enjoin defendants from taking any action against us relating to the 340B drug pricing program until after the court issues a final judgment on the aforementioned litigation. In May 2021, the court denied our motion for a temporary restraining order but deferred resolution of our motion for preliminary injunction. In June 2021, the defendants withdrew the HHS December 30, 2020 advisory opinion. In July 2021, the court held oral argument on the parties' cross motions for summary judgment, the defendants' motion to dismiss, and our motion for preliminary injunction related to HRSA's May 2021 enforcement letter. In October 2021, the court denied the defendants' motion to dismiss, and granted in part and denied in part the parties' cross motions for summary judgment. Both parties filed notices of appeal related to the court's summary judgment order. Oral argument took place in October 2022 in the U.S. Court of Appeals for the Seventh Circuit. This matter is ongoing.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, we, along with other pharmaceutical manufacturers, were named as a defendant in a petition currently pending before the HHS Administrative Dispute Resolution Panel. Petitioner seeks declaratory and other injunctive relief related to the 340B program. As described above, the U.S. District Court for the Southern District of Indiana has entered a preliminary injunction enjoining the government's enforcement of this administrative dispute resolution process against us. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ie638f5bd5e9f476193a7dbaa06514ac3" continuedAt="i17ff402873de46eba0376eb4da6d0c18"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2021, we, along with Sanofi-Aventis U.S., LLC (Sanofi), Novo Nordisk Inc. (Novo Nordisk), and AstraZeneca Pharmaceuticals LP, were named as a defendant in a purported class action lawsuit filed in the U.S. District Court for the Western District of New York by Mosaic Health, Inc. alleging antitrust and unjust enrichment claims related to the defendants' 340B distribution programs. We, with Sanofi and Novo Nordisk, filed a motion to dismiss the lawsuit, which was granted in September 2022. In October 2022, the plaintiffs filed a motion for leave to amend their complaint. This matter is ongoing.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We received a civil investigative subpoena in February 2021 from the Office of the Attorney General for the State of Vermont relating to the sale of pharmaceutical products to Vermont covered entities under the 340B program. We are cooperating with this subpoena. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Branchburg Manufacturing Facility</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, we received a subpoena from the U.S. Department of Justice requesting the production of certain documents relating to our manufacturing site in Branchburg, New Jersey. We are cooperating with the subpoena.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Brazil Litigation &#8211; Cosmopolis Facility</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Labor Attorney Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">First initiated in 2008, our subsidiary in Brazil, Eli Lilly do Brasil Limitada (Lilly Brasil), is named in a Public Civil Action brought by the Labor Public Attorney (LPA) for the 15th Region in the Labor Court of Paulinia, State of Sao Paulo, Brazil, (the Labor Court) alleging possible harm to employees and former employees caused by alleged exposure to soil and groundwater contaminants at a former Lilly Brasil manufacturing facility in Cosmopolis, Brazil, operated by the company between 1977 and 2003. In May 2014, the Labor Court judge ruled against Lilly Brasil, ordering it to undertake several remedial and compensatory actions including health coverage for a class of individuals and certain of their children. In July 2018, the appeals court (TRT) generally affirmed our appeal of the Labor Court's ruling, which included a liquidated award of <ix:nonFraction unitRef="brl" contextRef="i7b4e96e210ab4559a67ee97574922011_D20180701-20180731" decimals="-6" name="us-gaap:LossContingencyDamagesAwardedValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183MC9mcmFnOjNjOWJjNzRiOGMyODRlZTQ4NThjMTM0MDBiMTE4Zjk1L3RleHRyZWdpb246M2M5YmM3NGI4YzI4NGVlNDg1OGMxMzQwMGIxMThmOTVfMTQyMTE_d6c1f2d4-f081-4c9e-87e4-c8521a4db76d">300</ix:nonFraction> million Brazilian real, which, when adjusted for inflation and the addition of pre and post judgment interest using the current Central Bank of Brazil's special system of clearance and custody rate, is approximately <ix:nonFraction unitRef="brl" contextRef="i983baf60b46f4dc0ab264f727cff1fd1_D20220101-20220930" decimals="-9" name="us-gaap:LossContingencyDamagesAwardedValue" format="ixt-sec:numwordsen" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183MC9mcmFnOjNjOWJjNzRiOGMyODRlZTQ4NThjMTM0MDBiMTE4Zjk1L3RleHRyZWdpb246M2M5YmM3NGI4YzI4NGVlNDg1OGMxMzQwMGIxMThmOTVfMTQ0MjI_9d1ce226-be24-4fb7-88e3-a7c4b947c95a">one</ix:nonFraction> billion Brazilian real (approximately $<ix:nonFraction unitRef="usd" contextRef="i983baf60b46f4dc0ab264f727cff1fd1_D20220101-20220930" decimals="-6" name="us-gaap:LossContingencyDamagesAwardedValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183MC9mcmFnOjNjOWJjNzRiOGMyODRlZTQ4NThjMTM0MDBiMTE4Zjk1L3RleHRyZWdpb246M2M5YmM3NGI4YzI4NGVlNDg1OGMxMzQwMGIxMThmOTVfMTQ0NjM_26784162-b13d-444b-a14d-98a5f9b6b865">185</ix:nonFraction>&#160;million as of September&#160;30, 2022). In August 2019, Lilly Brasil filed an appeal to the superior labor court (TST) and in June 2021, the TRT published its decision on the admissibility of Lilly Brasil's appeal, allowing the majority of the elements, which were allowed to proceed in June 2021; elements not proceeding are subject to an interlocutory appeal to the TST that was filed in June 2021. In September 2019, the TRT stayed a number of elements of its trial court decision pending the determination of Lilly Brasil's appeal to the TST.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2019 and September 2020, the LPA filed applications in the Labor Court for enforcement of certain remedies granted by the TRT in its July 2018 decision, requested restrictions on Lilly Brasil&#8217;s assets in Brazil, and required Lilly Brasil and Antibi&#243;ticos do Brasil Ltda. (ABL) to submit a list of potential beneficiaries of the Public Civil Action. In July 2019, the Labor Court issued a ruling requiring a freeze of Lilly Brasil&#8217;s immovable property or, alternatively, a security deposit or lien of <ix:nonFraction unitRef="brl" contextRef="id52423032e6747898c41a944e3038420_D20190701-20190731" decimals="-6" name="us-gaap:LossContingencyDamagesAwardedValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183MC9mcmFnOjNjOWJjNzRiOGMyODRlZTQ4NThjMTM0MDBiMTE4Zjk1L3RleHRyZWdpb246M2M5YmM3NGI4YzI4NGVlNDg1OGMxMzQwMGIxMThmOTVfMTU0OTI_05a6deee-589b-4dc5-a6ac-d95a9c2c06f6">500</ix:nonFraction> million Brazilian real, which ruling was subsequently limited in scope and the security was reduced to <ix:nonFraction unitRef="brl" contextRef="i098637113ce84c2f8c583d5aac35942b_D20210601-20210630" decimals="-6" name="us-gaap:LossContingencyDamagesAwardedValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183MC9mcmFnOjNjOWJjNzRiOGMyODRlZTQ4NThjMTM0MDBiMTE4Zjk1L3RleHRyZWdpb246M2M5YmM3NGI4YzI4NGVlNDg1OGMxMzQwMGIxMThmOTVfMTU1OTA_a0d249b9-eaa1-45da-818b-3b500a445068">100</ix:nonFraction> million Brazilian real. ABL and LPA appealed the June 2021 Labor Court ruling to the TST, which appeal is under review. The Labor Court is currently assessing the status of Lilly Brasil&#8217;s and ABL&#8217;s compliance with such portion of the July 2018 TRT decision and an inspection in the industrial plant is expected. These matters are ongoing.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Individual Former Employee Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lilly Brasil is also named in over <ix:nonFraction unitRef="lawsuit" contextRef="i91a11e76b2844622ba08c167af2c1bbd_I20220930" decimals="0" name="us-gaap:LossContingencyPendingClaimsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183MC9mcmFnOjNjOWJjNzRiOGMyODRlZTQ4NThjMTM0MDBiMTE4Zjk1L3RleHRyZWdpb246M2M5YmM3NGI4YzI4NGVlNDg1OGMxMzQwMGIxMThmOTVfMTU5OTc_c00515b3-d3eb-4b3d-87f9-0186af61fd07">20</ix:nonFraction> pending lawsuits filed in the Labor Court by individual former employees making similar claims. These individual lawsuits are at various stages in the litigation process.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Puerto Rico Tax Matter</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2013, the Municipality of Carolina in Puerto Rico (Municipality) filed a lawsuit against us alleging noncompliance with respect to a contract with the Municipality and seeking a declaratory judgment. In December 2020, the Puerto Rico Appellate Court (AP) reversed the summary judgment previously granted by the Court of First Instance (CFI) in our favor, dismissing the Municipality's complaint in its entirety. The AP remanded the case to the CFI for trial on the merits. The trial began in May 2022; however, the Municipality filed a new motion requesting the CFI to award damages. The request was denied by the CFI in our favor and the Municipality filed for revision at the AP, which we opposed, staying the case. This matter is ongoing. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i17ff402873de46eba0376eb4da6d0c18" continuedAt="i29abc795a0f74b6d97f622965ea5cdaf"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Eastern District of Pennsylvania Pricing (Average Manufacturer Price) Inquiry</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2014, we, along with another pharmaceutical manufacturer, were named as co-defendants in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">United States et al. ex rel. Streck v. Takeda Pharm. Am., Inc., et al.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which was filed in November 2014 and unsealed in the U.S. District Court for the Northern District of Illinois. The complaint alleges that the defendants should have treated certain credits from distributors as retroactive price increases and included such increases in calculating average manufacturer prices. Following a trial in August 2022, the jury returned a verdict in favor of the plaintiff. The case is proceeding with post-trial motions after which the court will enter final judgment in the case. This matter is ongoing.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Health Choice Alliance </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are named as a defendant in <ix:nonFraction unitRef="lawsuit" contextRef="i3fd1ac8f6fc9438cb71e216b3246793e_I20220930" decimals="INF" name="us-gaap:LossContingencyPendingClaimsNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183MC9mcmFnOjNjOWJjNzRiOGMyODRlZTQ4NThjMTM0MDBiMTE4Zjk1L3RleHRyZWdpb246M2M5YmM3NGI4YzI4NGVlNDg1OGMxMzQwMGIxMThmOTVfMTc1OTg_f42a9182-bf94-43fd-98b7-772f35b286c5">two</ix:nonFraction> lawsuits filed in Texas and New Jersey state courts in October 2019 seeking damages under the Texas Medicaid Fraud Prevention Act and New Jersey Medicaid False Claims Act, respectively, for certain patient support programs related to our products Humalog, Humulin, and Forteo. The Texas state court action has been stayed. The New Jersey state court action was dismissed with prejudice pending an ongoing appeal before the Appellate Division of the New Jersey Superior Court. This matter is ongoing.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Pricing Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2017 and February 2018, we, along with Sanofi and Novo Nordisk, were named as defendants in a consolidated purported class action lawsuit, In re. Insulin Pricing Litigation and in MSP Recovery Claims, Series, LLC et al. v. Sanofi Aventis U.S. LLC et al., both filed in the U.S. District Court for the District of New Jersey. The cases relate to insulin pricing and seek damages or other relief under various theories, including state consumer protection laws, common law fraud, unjust enrichment, and the Federal Racketeer Influenced and Corrupt Organization Act (federal RICO Act). In both cases, the court dismissed claims under the federal RICO Act and certain state laws. In April 2021, the plaintiffs in In re. Insulin Pricing Litigation amended their complaint to allege additional state law claims for civil conspiracy and violations of state RICO statutes. The court allowed the Arizona RICO statute and certain state civil conspiracy law claims to proceed. Additionally in 2020, we, along with Sanofi, Novo Nordisk, CVS, Express Scripts, and Optum, have been sued in a putative class action, FWK Holdings, LLC v. Novo Nordisk Inc., et al., filed in the same court, for alleged violations of the federal RICO Act as well as the New Jersey RICO Act and antitrust law. The same group of defendants, along with Medco Health and United Health Group, also have been sued in other purported class actions in the same court, Rochester Drug Co-Operative Inc. v. Eli Lilly &amp; Co. et al. and Value Drug Co. v. Eli Lilly &amp; Co. et al., which were both initiated in March 2020, with the plaintiffs seeking damages for alleged violations of the federal RICO Act. In September 2020, the U.S. District Court for the District of New Jersey granted plaintiffs' motion to consolidate FWK Holdings, LLC v. Novo Nordisk Inc., et al., Rochester Drug Co-Operative Inc. v. Eli Lilly &amp; Co. et al., and Value Drug Co. v. Eli Lilly &amp; Co. et al. In July 2021, the U.S. District Court for the District of New Jersey dismissed the <ix:nonFraction unitRef="claim" contextRef="if2605d2b37d747e1b5887703c18e4963_D20210701-20210731" decimals="INF" name="lly:LitigationClaimsDismissedNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183MC9mcmFnOjNjOWJjNzRiOGMyODRlZTQ4NThjMTM0MDBiMTE4Zjk1L3RleHRyZWdpb246M2M5YmM3NGI4YzI4NGVlNDg1OGMxMzQwMGIxMThmOTVfMjAxODI_b508d386-d4a9-4d74-8d63-16450171d9c7">three</ix:nonFraction> antitrust claims alleged by plaintiffs in the consolidated litigation and denied dismissal of the federal RICO Act claims.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, the Minnesota Attorney General's Office initiated litigation against us, Sanofi, and Novo Nordisk, State of Minnesota v. Sanofi-Aventis U.S. LLC et al., in the U.S. District Court for the District of New Jersey, seeking damages for unjust enrichment, violations of various Minnesota state consumer protection laws, and the federal RICO Act. In March 2021, the U.S. District Court for the District of New Jersey dismissed with prejudice the Minnesota Attorney General's federal RICO claims and false advertising claims under state law; the consumer fraud and other related state law claims remain ongoing. Additionally, in May 2019, the Kentucky Attorney General's Office filed a complaint against us, Sanofi, and Novo Nordisk, Commonwealth of Kentucky v. Novo Nordisk, Inc. et al., in Kentucky state court, alleging violations of the Kentucky consumer protection law, false advertising, and unjust enrichment.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021, the Mississippi Attorney General's Office initiated litigation against us, Sanofi, Novo Nordisk, Evernorth/ESI, CVS/Caremark, and United/Optum in the Hinds County, Mississippi Chancery Court, alleging state law consumer protection, unjust enrichment, and civil conspiracy claims. After the case was removed to federal court, we, along with the other defendants, filed a motion to dismiss the lawsuit, which was denied. This matter is ongoing.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2022, the state of Arkansas filed suit against us Sanofi, Novo Nordisk, ESI, CVS/Caremark/Aetna, and Optum, asserting state law consumer protection, civil conspiracy, and unjust enrichment claims. The case has been removed to federal court and is ongoing.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2022, the County of Albany, New York filed a suit against us, Sanofi, Novo Nordisk, Evernorth/ESI, CVS/Caremark and United/Optum asserting violations of federal RICO statute and state law claims for deceptive trade practices, unjust enrichment, and civil conspiracy. This matter is ongoing.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i29abc795a0f74b6d97f622965ea5cdaf"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2022, the State of Montana filed a suit against us, Sanofi, Novo Nordisk, Evernorth/ESI, Medco Health Solutions, CVS/Caremark and Optum asserting violations of the Montana Unfair Practices and Consumer Protection Act, unjust enrichment, and civil conspiracy. This matter is ongoing.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Investigations, Subpoenas, and Inquiries</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the pricing and sale of our insulin and other products, we have been subject to various investigations and received subpoenas, civil investigative demand requests, information requests, interrogatories, and other inquiries from various governmental entities. These include subpoenas from the New York and Vermont Attorney General Offices, civil investigative demands from the Washington, New Mexico, Colorado, Illinois, Ohio Attorney General Offices, the Department of Justice and the Federal Trade Commission, as well as information requests from the Mississippi, Washington D.C., California, Florida, Hawaii, and Nevada Attorney General Offices. In January 2022, the Michigan Attorney General filed a petition in Michigan state court seeking authorization to investigate Lilly for potential violations of the Michigan Consumer Protection Act (MCPA), and a complaint seeking a declaratory judgment that the Attorney General has authority to investigate Lilly's sale of insulin under the MCPA. The court authorized the proposed investigation and the issuance of civil investigative subpoenas. In April 2022, the parties entered into a stipulation providing that the State will not issue any civil investigative subpoena to us under the MCPA until the declaratory judgment action is resolved. In July 2022, the court dismissed the case in its entirety. The Michigan Attorney General filed a notice of appeal and an application to obtain review by the Michigan Supreme Court, which remain pending. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We received a request in January 2019 from the House of Representatives' Committee on Oversight and Reform seeking commercial information and business records related to the pricing of insulin products, among other issues. We also received similar requests from the Senate Finance Committee and the Senate Committee on Health, Education, Labor, and Pensions, and separate requests from the House Committee on Energy and Commerce majority and minority members. In January 2021, the Senate Finance Committee released a report summarizing the findings of its investigation. In December 2021 the House of Representatives' Committee on Oversight and Reform majority and minority staffs released separate reports with findings from their investigations into drug pricing, including of insulin products.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are cooperating with all of the aforementioned investigations, subpoenas, and inquiries.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Research Corporation Technologies, Inc.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2016, we were named as a defendant in litigation filed by Research Corporation Technologies, Inc. (RCT) in the U.S. District Court for the District of Arizona. RCT is seeking damages for breach of contract, unjust enrichment, and conversion related to processes used to manufacture certain products, including Humalog and Humulin. In October 2021, the court issued a summary judgment decision finding in favor of RCT on certain issues, including with respect to a disputed royalty. Both parties filed motions for reconsideration, which were denied. We filed supplemental summary judgment motions. A trial date has not been set. Potential damages payable under the litigation, if finally awarded after an appeal, could be material but are not currently reasonably estimable. This matter is ongoing.</span></div></ix:continuation><div style="margin-top:6pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><div id="i5fed483d9c7e4f3cbba3a62c53226cd7_73"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 10: <ix:nonNumeric contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930" name="us-gaap:ComprehensiveIncomeNoteTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RleHRyZWdpb246ZTE0MjlmY2IyNjYyNDg4ZDk5MTllMTg4MGNiZTMyMTNfMTI1Ng_4177cc75-a543-4e1f-95ea-f932e4ab8da9" continuedAt="ife5293ddf23a4ace82a22a273c0270aa" escape="true">Other Comprehensive Income (Loss)</ix:nonNumeric></span></div><ix:continuation id="ife5293ddf23a4ace82a22a273c0270aa" continuedAt="i5522e96d15c7416b8ed82fcd2588116a"><ix:nonNumeric contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930" name="us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RleHRyZWdpb246ZTE0MjlmY2IyNjYyNDg4ZDk5MTllMTg4MGNiZTMyMTNfMTI1NA_1a2821d3-38b3-400c-bedd-744bdd5e1a5e" continuedAt="i3587bacca65548d4a7335757e1648b25" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the activity related to each component of other comprehensive income (loss) during the three months ended September&#160;30, 2022 and 2021:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.601%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Amounts presented net of taxes)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Foreign Currency Translation Gains&#160;(Losses)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Unrealized Net Gains (Losses) on&#160;Securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Defined Benefit Pension and Retiree&#160;Health Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Effective Portion of Cash&#160;Flow Hedges</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Loss</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at July 1, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia44884b555f84a8bb8c051329b5b483c_I20220630" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmI0OWI3ZGUzOGIzYTRjZGE4OGU1ZDkxMzcwMDI5NmJlL3RhYmxlcmFuZ2U6YjQ5YjdkZTM4YjNhNGNkYTg4ZTVkOTEzNzAwMjk2YmVfMi0xLTEtMS0xNTk1NDA_61537d92-f2a1-4b69-a3f9-24b3bc3738a2">1,844.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icf1cf37660ed42919d552edbdc9ddf29_I20220630" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmI0OWI3ZGUzOGIzYTRjZGE4OGU1ZDkxMzcwMDI5NmJlL3RhYmxlcmFuZ2U6YjQ5YjdkZTM4YjNhNGNkYTg4ZTVkOTEzNzAwMjk2YmVfMi0zLTEtMS0xNTk1NDA_69a279ca-9089-47c0-b87e-d86d691a3181">27.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib07a74d7836447719291eff28ad65a22_I20220630" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmI0OWI3ZGUzOGIzYTRjZGE4OGU1ZDkxMzcwMDI5NmJlL3RhYmxlcmFuZ2U6YjQ5YjdkZTM4YjNhNGNkYTg4ZTVkOTEzNzAwMjk2YmVfMi01LTEtMS0xNTk1NDA_db7d1beb-6363-4f7f-a9d9-b2d18039afa9">2,443.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3f2ab912d2b47e7862abe56a92bb118_I20220630" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmI0OWI3ZGUzOGIzYTRjZGE4OGU1ZDkxMzcwMDI5NmJlL3RhYmxlcmFuZ2U6YjQ5YjdkZTM4YjNhNGNkYTg4ZTVkOTEzNzAwMjk2YmVfMi03LTEtMS0xNTk1NDA_343b9422-190c-462f-8ead-daf5eeaab408">27.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic22b2460974b4792a24b9b75e0e598d3_I20220630" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmI0OWI3ZGUzOGIzYTRjZGE4OGU1ZDkxMzcwMDI5NmJlL3RhYmxlcmFuZ2U6YjQ5YjdkZTM4YjNhNGNkYTg4ZTVkOTEzNzAwMjk2YmVfMi0xMS0xLTEtMTU5NTQw_fd980611-5e52-4a97-a798-2655f95c571e">4,287.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibb680e42808d41b587bffa2f35409a91_D20220701-20220930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmI0OWI3ZGUzOGIzYTRjZGE4OGU1ZDkxMzcwMDI5NmJlL3RhYmxlcmFuZ2U6YjQ5YjdkZTM4YjNhNGNkYTg4ZTVkOTEzNzAwMjk2YmVfNC0xLTEtMS0xNTk1NDA_cbc2ec7d-665e-4d72-abcf-0680f8743a62">165.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib423da078b9740019ae03257a6ca1320_D20220701-20220930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmI0OWI3ZGUzOGIzYTRjZGE4OGU1ZDkxMzcwMDI5NmJlL3RhYmxlcmFuZ2U6YjQ5YjdkZTM4YjNhNGNkYTg4ZTVkOTEzNzAwMjk2YmVfNC0zLTEtMS0xNTk1NDA_dd7e584d-274c-4035-a1ad-3bd934deec3d">24.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ddaa7c4639946b1a63ee163ebac9cda_D20220701-20220930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmI0OWI3ZGUzOGIzYTRjZGE4OGU1ZDkxMzcwMDI5NmJlL3RhYmxlcmFuZ2U6YjQ5YjdkZTM4YjNhNGNkYTg4ZTVkOTEzNzAwMjk2YmVfNC01LTEtMS0xNTk1NDA_c4468f3b-2c88-45f9-a4e2-213f55b53fe2">47.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e78a70b50b740909d4bd5980c556e3a_D20220701-20220930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmI0OWI3ZGUzOGIzYTRjZGE4OGU1ZDkxMzcwMDI5NmJlL3RhYmxlcmFuZ2U6YjQ5YjdkZTM4YjNhNGNkYTg4ZTVkOTEzNzAwMjk2YmVfNC03LTEtMS0xNTk1NDA_591568af-3056-4f1f-88f7-e568a0207664">63.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i19fc0325c48543008ea71e1fdcf11d86_D20220701-20220930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmI0OWI3ZGUzOGIzYTRjZGE4OGU1ZDkxMzcwMDI5NmJlL3RhYmxlcmFuZ2U6YjQ5YjdkZTM4YjNhNGNkYTg4ZTVkOTEzNzAwMjk2YmVfNC0xMS0xLTEtMTU5NTQw_c31fdf97-1486-4381-9437-328a9ca94800">79.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net amount reclassified from accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb680e42808d41b587bffa2f35409a91_D20220701-20220930" decimals="-5" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmI0OWI3ZGUzOGIzYTRjZGE4OGU1ZDkxMzcwMDI5NmJlL3RhYmxlcmFuZ2U6YjQ5YjdkZTM4YjNhNGNkYTg4ZTVkOTEzNzAwMjk2YmVfNS0xLTEtMS0xNTk1NDA_c14fa024-aa18-4392-a0f1-db43693c837a">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib423da078b9740019ae03257a6ca1320_D20220701-20220930" decimals="-5" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmI0OWI3ZGUzOGIzYTRjZGE4OGU1ZDkxMzcwMDI5NmJlL3RhYmxlcmFuZ2U6YjQ5YjdkZTM4YjNhNGNkYTg4ZTVkOTEzNzAwMjk2YmVfNS0zLTEtMS0xNTk1NDA_a4adb628-3aa8-4ae0-aa97-fc39db7ac531">13.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ddaa7c4639946b1a63ee163ebac9cda_D20220701-20220930" decimals="-5" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmI0OWI3ZGUzOGIzYTRjZGE4OGU1ZDkxMzcwMDI5NmJlL3RhYmxlcmFuZ2U6YjQ5YjdkZTM4YjNhNGNkYTg4ZTVkOTEzNzAwMjk2YmVfNS01LTEtMS0xNTk1NDA_c08f6e8b-84f8-4d36-abc4-42478db731bb">57.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e78a70b50b740909d4bd5980c556e3a_D20220701-20220930" decimals="-5" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmI0OWI3ZGUzOGIzYTRjZGE4OGU1ZDkxMzcwMDI5NmJlL3RhYmxlcmFuZ2U6YjQ5YjdkZTM4YjNhNGNkYTg4ZTVkOTEzNzAwMjk2YmVfNS03LTEtMS0xNTk1NDA_b3f01a8b-6d38-4402-93a0-821e676bc7a1">0.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19fc0325c48543008ea71e1fdcf11d86_D20220701-20220930" decimals="-5" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmI0OWI3ZGUzOGIzYTRjZGE4OGU1ZDkxMzcwMDI5NmJlL3RhYmxlcmFuZ2U6YjQ5YjdkZTM4YjNhNGNkYTg4ZTVkOTEzNzAwMjk2YmVfNS0xMS0xLTEtMTU5NTQw_088704fe-f523-48bf-8ae4-4b227e58c298">71.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibb680e42808d41b587bffa2f35409a91_D20220701-20220930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmI0OWI3ZGUzOGIzYTRjZGE4OGU1ZDkxMzcwMDI5NmJlL3RhYmxlcmFuZ2U6YjQ5YjdkZTM4YjNhNGNkYTg4ZTVkOTEzNzAwMjk2YmVfNi0xLTEtMS0xNTk1NDA_3b62616a-2821-459a-a310-620633bc58e9">165.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib423da078b9740019ae03257a6ca1320_D20220701-20220930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmI0OWI3ZGUzOGIzYTRjZGE4OGU1ZDkxMzcwMDI5NmJlL3RhYmxlcmFuZ2U6YjQ5YjdkZTM4YjNhNGNkYTg4ZTVkOTEzNzAwMjk2YmVfNi0zLTEtMS0xNTk1NDA_dc860762-cab1-407d-9227-4d943555d204">11.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ddaa7c4639946b1a63ee163ebac9cda_D20220701-20220930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmI0OWI3ZGUzOGIzYTRjZGE4OGU1ZDkxMzcwMDI5NmJlL3RhYmxlcmFuZ2U6YjQ5YjdkZTM4YjNhNGNkYTg4ZTVkOTEzNzAwMjk2YmVfNi01LTEtMS0xNTk1NDA_7ac26987-d230-4727-8f9c-6cc3a1627cec">105.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e78a70b50b740909d4bd5980c556e3a_D20220701-20220930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmI0OWI3ZGUzOGIzYTRjZGE4OGU1ZDkxMzcwMDI5NmJlL3RhYmxlcmFuZ2U6YjQ5YjdkZTM4YjNhNGNkYTg4ZTVkOTEzNzAwMjk2YmVfNi03LTEtMS0xNTk1NDA_fd9706f0-f0af-4046-b6c4-7bfe7b4b4acc">63.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i19fc0325c48543008ea71e1fdcf11d86_D20220701-20220930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmI0OWI3ZGUzOGIzYTRjZGE4OGU1ZDkxMzcwMDI5NmJlL3RhYmxlcmFuZ2U6YjQ5YjdkZTM4YjNhNGNkYTg4ZTVkOTEzNzAwMjk2YmVfNi0xMS0xLTEtMTU5NTQw_40cb76f4-eb16-4abc-9dad-92674aae60e4">8.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September&#160;30, 2022</span></div></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i603b413215ff4ac0860f74b6a1be9294_I20220930" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmI0OWI3ZGUzOGIzYTRjZGE4OGU1ZDkxMzcwMDI5NmJlL3RhYmxlcmFuZ2U6YjQ5YjdkZTM4YjNhNGNkYTg4ZTVkOTEzNzAwMjk2YmVfOC0xLTEtMS0xNTk1NDA_5d3103f5-2c11-4a4b-b0bc-675cd4e76e01">2,009.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6105e19d65744395aeb2921c7555324a_I20220930" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmI0OWI3ZGUzOGIzYTRjZGE4OGU1ZDkxMzcwMDI5NmJlL3RhYmxlcmFuZ2U6YjQ5YjdkZTM4YjNhNGNkYTg4ZTVkOTEzNzAwMjk2YmVfOC0zLTEtMS0xNTk1NDA_1a11a6ab-46f7-46ba-9882-ee81f6991b2d">39.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1ec1c7b3b72549149e283cdff33abeed_I20220930" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmI0OWI3ZGUzOGIzYTRjZGE4OGU1ZDkxMzcwMDI5NmJlL3RhYmxlcmFuZ2U6YjQ5YjdkZTM4YjNhNGNkYTg4ZTVkOTEzNzAwMjk2YmVfOC01LTEtMS0xNTk1NDA_eb9fe125-efd8-45bc-9d1f-26432a65fe4b">2,338.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc51fbfd706a4f809013d42ddd4fef8c_I20220930" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmI0OWI3ZGUzOGIzYTRjZGE4OGU1ZDkxMzcwMDI5NmJlL3RhYmxlcmFuZ2U6YjQ5YjdkZTM4YjNhNGNkYTg4ZTVkOTEzNzAwMjk2YmVfOC03LTEtMS0xNTk1NDA_fa96315f-e4ce-4976-91c5-8d39001ad233">91.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iad56c44530dd4208959b336f8d1fe8b1_I20220930" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmI0OWI3ZGUzOGIzYTRjZGE4OGU1ZDkxMzcwMDI5NmJlL3RhYmxlcmFuZ2U6YjQ5YjdkZTM4YjNhNGNkYTg4ZTVkOTEzNzAwMjk2YmVfOC0xMS0xLTEtMTU5NTQw_0792feed-da8e-462b-b629-002325c41dda">4,295.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.601%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Amounts presented net of taxes)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Foreign Currency Translation Gains&#160;(Losses)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Unrealized Net Gains (Losses) on&#160;Securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Defined Benefit Pension and Retiree&#160;Health Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Effective Portion of Cash&#160;Flow Hedges</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Loss</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at July 1, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9b7795dc491c42cbb64812b2b99d2ac9_I20210630" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOjU0MGYzNDkzN2Y1NDQ5NWI4YzRjZjllMzUyMjZjMjY3L3RhYmxlcmFuZ2U6NTQwZjM0OTM3ZjU0NDk1YjhjNGNmOWUzNTIyNmMyNjdfMi0xLTEtMS0xNTk1NDA_9f17f11a-0fc5-43a5-8540-fc6678ec4e5c">1,516.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ideb9d32d39e441f68ba01504bca2b03c_I20210630" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOjU0MGYzNDkzN2Y1NDQ5NWI4YzRjZjllMzUyMjZjMjY3L3RhYmxlcmFuZ2U6NTQwZjM0OTM3ZjU0NDk1YjhjNGNmOWUzNTIyNmMyNjdfMi0zLTEtMS0xNTk1NDA_51706b6e-854b-47d9-9a42-09fa39f7bae1">9.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iec456e1ce7794922919937b65a44561f_I20210630" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOjU0MGYzNDkzN2Y1NDQ5NWI4YzRjZjllMzUyMjZjMjY3L3RhYmxlcmFuZ2U6NTQwZjM0OTM3ZjU0NDk1YjhjNGNmOWUzNTIyNmMyNjdfMi01LTEtMS0xNTk1NDA_0e6d56b0-e95e-4911-8028-5eae3b51a9e7">4,569.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2988484b109649f28736efa0418c49f9_I20210630" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOjU0MGYzNDkzN2Y1NDQ5NWI4YzRjZjllMzUyMjZjMjY3L3RhYmxlcmFuZ2U6NTQwZjM0OTM3ZjU0NDk1YjhjNGNmOWUzNTIyNmMyNjdfMi03LTEtMS0xNTk1NDA_5e978c74-5638-4781-a4ff-865cc813ebaf">210.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id29f7d92807d4933b0fb1e960563f81f_I20210630" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOjU0MGYzNDkzN2Y1NDQ5NWI4YzRjZjllMzUyMjZjMjY3L3RhYmxlcmFuZ2U6NTQwZjM0OTM3ZjU0NDk1YjhjNGNmOWUzNTIyNmMyNjdfMi0xMS0xLTEtMTU5NTQw_37377391-9ecb-4afc-9492-6c1eadf7fe84">6,287.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3153def44849420f812d26d82e12f780_D20210701-20210930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOjU0MGYzNDkzN2Y1NDQ5NWI4YzRjZjllMzUyMjZjMjY3L3RhYmxlcmFuZ2U6NTQwZjM0OTM3ZjU0NDk1YjhjNGNmOWUzNTIyNmMyNjdfNC0xLTEtMS0xNTk1NDA_bc8a8610-333e-4734-8c68-4bb9f7eac143">8.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i525ab1d53cfc40b99c19c64b4d032446_D20210701-20210930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOjU0MGYzNDkzN2Y1NDQ5NWI4YzRjZjllMzUyMjZjMjY3L3RhYmxlcmFuZ2U6NTQwZjM0OTM3ZjU0NDk1YjhjNGNmOWUzNTIyNmMyNjdfNC0zLTEtMS0xNTk1NDA_69c003da-0998-4b7f-8fa6-c4c56181b78e">2.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b3bb220bf604c6daaf72988d3e20703_D20210701-20210930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOjU0MGYzNDkzN2Y1NDQ5NWI4YzRjZjllMzUyMjZjMjY3L3RhYmxlcmFuZ2U6NTQwZjM0OTM3ZjU0NDk1YjhjNGNmOWUzNTIyNmMyNjdfNC01LTEtMS0xNTk1NDA_db3bdeb5-0335-4d31-8f22-8dfdbf73f86c">18.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24f2b962044749c5a2936c59a2f25aa9_D20210701-20210930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOjU0MGYzNDkzN2Y1NDQ5NWI4YzRjZjllMzUyMjZjMjY3L3RhYmxlcmFuZ2U6NTQwZjM0OTM3ZjU0NDk1YjhjNGNmOWUzNTIyNmMyNjdfNC03LTEtMS0xNTk1NDA_8fcdde21-f197-47a8-bd3f-ed07e15a6bf7">16.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4fa4f6b472a4f269297591b44aba572_D20210701-20210930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOjU0MGYzNDkzN2Y1NDQ5NWI4YzRjZjllMzUyMjZjMjY3L3RhYmxlcmFuZ2U6NTQwZjM0OTM3ZjU0NDk1YjhjNGNmOWUzNTIyNmMyNjdfNC0xMS0xLTEtMTU5NTQw_343b68c5-27eb-4a31-b338-3ed735373f5a">25.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net amount reclassified from accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3153def44849420f812d26d82e12f780_D20210701-20210930" decimals="-5" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOjU0MGYzNDkzN2Y1NDQ5NWI4YzRjZjllMzUyMjZjMjY3L3RhYmxlcmFuZ2U6NTQwZjM0OTM3ZjU0NDk1YjhjNGNmOWUzNTIyNmMyNjdfNS0xLTEtMS0xNTk1NDA_2a329ba9-7e50-447e-bffc-c4a69fd434f6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i525ab1d53cfc40b99c19c64b4d032446_D20210701-20210930" decimals="-5" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOjU0MGYzNDkzN2Y1NDQ5NWI4YzRjZjllMzUyMjZjMjY3L3RhYmxlcmFuZ2U6NTQwZjM0OTM3ZjU0NDk1YjhjNGNmOWUzNTIyNmMyNjdfNS0zLTEtMS0xNTk1NDA_b36cff12-8b7c-4afa-b308-583098de3ea4">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b3bb220bf604c6daaf72988d3e20703_D20210701-20210930" decimals="-5" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOjU0MGYzNDkzN2Y1NDQ5NWI4YzRjZjllMzUyMjZjMjY3L3RhYmxlcmFuZ2U6NTQwZjM0OTM3ZjU0NDk1YjhjNGNmOWUzNTIyNmMyNjdfNS01LTEtMS0xNTk1NDA_7731c7aa-8612-4961-b098-63eb8bfaf2ff">86.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24f2b962044749c5a2936c59a2f25aa9_D20210701-20210930" decimals="-5" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOjU0MGYzNDkzN2Y1NDQ5NWI4YzRjZjllMzUyMjZjMjY3L3RhYmxlcmFuZ2U6NTQwZjM0OTM3ZjU0NDk1YjhjNGNmOWUzNTIyNmMyNjdfNS03LTEtMS0xNTk1NDA_6e152849-6097-4be8-91ea-75fa17567af1">3.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4fa4f6b472a4f269297591b44aba572_D20210701-20210930" decimals="-5" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOjU0MGYzNDkzN2Y1NDQ5NWI4YzRjZjllMzUyMjZjMjY3L3RhYmxlcmFuZ2U6NTQwZjM0OTM3ZjU0NDk1YjhjNGNmOWUzNTIyNmMyNjdfNS0xMS0xLTEtMTU5NTQw_32339359-20c1-45a6-b833-49beea1c1a68">89.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3153def44849420f812d26d82e12f780_D20210701-20210930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOjU0MGYzNDkzN2Y1NDQ5NWI4YzRjZjllMzUyMjZjMjY3L3RhYmxlcmFuZ2U6NTQwZjM0OTM3ZjU0NDk1YjhjNGNmOWUzNTIyNmMyNjdfNi0xLTEtMS0xNTk1NDA_8d330736-566f-4748-af15-275f24a2ecc5">8.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i525ab1d53cfc40b99c19c64b4d032446_D20210701-20210930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOjU0MGYzNDkzN2Y1NDQ5NWI4YzRjZjllMzUyMjZjMjY3L3RhYmxlcmFuZ2U6NTQwZjM0OTM3ZjU0NDk1YjhjNGNmOWUzNTIyNmMyNjdfNi0zLTEtMS0xNTk1NDA_974c590f-756c-4fa5-b790-400ffac0b535">2.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b3bb220bf604c6daaf72988d3e20703_D20210701-20210930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOjU0MGYzNDkzN2Y1NDQ5NWI4YzRjZjllMzUyMjZjMjY3L3RhYmxlcmFuZ2U6NTQwZjM0OTM3ZjU0NDk1YjhjNGNmOWUzNTIyNmMyNjdfNi01LTEtMS0xNTk1NDA_14730f10-7bc8-4e8d-835f-7b995f65368e">104.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24f2b962044749c5a2936c59a2f25aa9_D20210701-20210930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOjU0MGYzNDkzN2Y1NDQ5NWI4YzRjZjllMzUyMjZjMjY3L3RhYmxlcmFuZ2U6NTQwZjM0OTM3ZjU0NDk1YjhjNGNmOWUzNTIyNmMyNjdfNi03LTEtMS0xNTk1NDA_30b23c77-6fe2-4c9c-af28-6395045b5f29">20.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4fa4f6b472a4f269297591b44aba572_D20210701-20210930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOjU0MGYzNDkzN2Y1NDQ5NWI4YzRjZjllMzUyMjZjMjY3L3RhYmxlcmFuZ2U6NTQwZjM0OTM3ZjU0NDk1YjhjNGNmOWUzNTIyNmMyNjdfNi0xMS0xLTEtMTU5NTQw_08c98961-b86f-4677-8189-af10d0ee5c84">114.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September&#160;30, 2021</span></div></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iab4358396efe4d7f92c5aab447052434_I20210930" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOjU0MGYzNDkzN2Y1NDQ5NWI4YzRjZjllMzUyMjZjMjY3L3RhYmxlcmFuZ2U6NTQwZjM0OTM3ZjU0NDk1YjhjNGNmOWUzNTIyNmMyNjdfOC0xLTEtMS0xNTk1NDA_7b757b75-7371-4b9d-ac7a-2f1cdb45fb2e">1,524.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5be060faaa5146e7a2bf742eb38f7bec_I20210930" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOjU0MGYzNDkzN2Y1NDQ5NWI4YzRjZjllMzUyMjZjMjY3L3RhYmxlcmFuZ2U6NTQwZjM0OTM3ZjU0NDk1YjhjNGNmOWUzNTIyNmMyNjdfOC0zLTEtMS0xNTk1NDA_2b6b1d47-7f8a-468f-884d-6bf3a2292ee7">6.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i894ae4ccbe404068bbc052f007cea48c_I20210930" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOjU0MGYzNDkzN2Y1NDQ5NWI4YzRjZjllMzUyMjZjMjY3L3RhYmxlcmFuZ2U6NTQwZjM0OTM3ZjU0NDk1YjhjNGNmOWUzNTIyNmMyNjdfOC01LTEtMS0xNTk1NDA_b37da8f5-807c-42b1-b506-fc8dfe381b72">4,465.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic74e9458c4f44462a21bfd6f33c8c50d_I20210930" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOjU0MGYzNDkzN2Y1NDQ5NWI4YzRjZjllMzUyMjZjMjY3L3RhYmxlcmFuZ2U6NTQwZjM0OTM3ZjU0NDk1YjhjNGNmOWUzNTIyNmMyNjdfOC03LTEtMS0xNTk1NDA_d4efb03b-9397-40f6-bbee-979fe8e73da5">190.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9ed755da42e84ed28970211b57db0d80_I20210930" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOjU0MGYzNDkzN2Y1NDQ5NWI4YzRjZjllMzUyMjZjMjY3L3RhYmxlcmFuZ2U6NTQwZjM0OTM3ZjU0NDk1YjhjNGNmOWUzNTIyNmMyNjdfOC0xMS0xLTEtMTU5NTQw_f375035b-ffa1-4002-b006-f4d6d33aa64c">6,172.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the activity related to each component of other comprehensive income (loss) during the nine months ended September&#160;30, 2022 and 2021: </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.601%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Amounts presented net of taxes)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Foreign Currency Translation Gains&#160;(Losses)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Unrealized Net Gains (Losses) on&#160;Securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Defined Benefit Pension and Retiree&#160;Health Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Effective Portion of Cash&#160;Flow Hedges</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Loss</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January 1, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if779a9c74164409ab40929f3c1a22e08_I20211231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmJhMWE1ZDZiZDA3YTRhN2E5MmJlMzY4ZDI1NWZkNTM3L3RhYmxlcmFuZ2U6YmExYTVkNmJkMDdhNGE3YTkyYmUzNjhkMjU1ZmQ1MzdfMS0xLTEtMS0xNTk1NDA_c57d548c-63b2-4e4c-8797-1863e9f2985c">1,550.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15e5d118ed234a2f82b7b9a362d215d8_I20211231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmJhMWE1ZDZiZDA3YTRhN2E5MmJlMzY4ZDI1NWZkNTM3L3RhYmxlcmFuZ2U6YmExYTVkNmJkMDdhNGE3YTkyYmUzNjhkMjU1ZmQ1MzdfMS0zLTEtMS0xNTk1NDA_e16a6b1c-4be5-4d8b-9098-1d40eec27402">3.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib7546d9d8f53446e8b4f3eed0a4210c4_I20211231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmJhMWE1ZDZiZDA3YTRhN2E5MmJlMzY4ZDI1NWZkNTM3L3RhYmxlcmFuZ2U6YmExYTVkNmJkMDdhNGE3YTkyYmUzNjhkMjU1ZmQ1MzdfMS01LTEtMS0xNTk1NDA_3e788ceb-98ed-421e-a00e-fab504a1fe6d">2,583.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if2ce5c439794420c8829fd223a835cd4_I20211231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmJhMWE1ZDZiZDA3YTRhN2E5MmJlMzY4ZDI1NWZkNTM3L3RhYmxlcmFuZ2U6YmExYTVkNmJkMDdhNGE3YTkyYmUzNjhkMjU1ZmQ1MzdfMS03LTEtMS0xNTk1NDA_3cc16d4d-e794-44ff-ab6d-7768cfdf83d9">213.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic63664fe4e074a5599837d8254019a8b_I20211231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmJhMWE1ZDZiZDA3YTRhN2E5MmJlMzY4ZDI1NWZkNTM3L3RhYmxlcmFuZ2U6YmExYTVkNmJkMDdhNGE3YTkyYmUzNjhkMjU1ZmQ1MzdfMS05LTEtMS0xNTk1NDA_7d55d54f-0b88-4df8-85ee-b72af38d492d">4,343.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i13abcd536a74422a91f0be2e859c5f11_D20220101-20220930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmJhMWE1ZDZiZDA3YTRhN2E5MmJlMzY4ZDI1NWZkNTM3L3RhYmxlcmFuZ2U6YmExYTVkNmJkMDdhNGE3YTkyYmUzNjhkMjU1ZmQ1MzdfMy0xLTEtMS0xNTk1NDA_4d50c7d3-123d-4020-a141-6e06010277e1">459.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieeda2eb9aa724c2eb2b08a110d5910ca_D20220101-20220930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmJhMWE1ZDZiZDA3YTRhN2E5MmJlMzY4ZDI1NWZkNTM3L3RhYmxlcmFuZ2U6YmExYTVkNmJkMDdhNGE3YTkyYmUzNjhkMjU1ZmQ1MzdfMy0zLTEtMS0xNTk1NDA_c6f62673-eae2-4982-b1dc-26d018ba39ac">55.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c0ca46f62b245baa26e2ca939e70c30_D20220101-20220930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmJhMWE1ZDZiZDA3YTRhN2E5MmJlMzY4ZDI1NWZkNTM3L3RhYmxlcmFuZ2U6YmExYTVkNmJkMDdhNGE3YTkyYmUzNjhkMjU1ZmQ1MzdfMy01LTEtMS0xNTk1NDA_1d6a8cf2-3ffa-4a8b-adbe-86525531a476">72.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i698e8cd8a6e44a719d0a96611610bdf4_D20220101-20220930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmJhMWE1ZDZiZDA3YTRhN2E5MmJlMzY4ZDI1NWZkNTM3L3RhYmxlcmFuZ2U6YmExYTVkNmJkMDdhNGE3YTkyYmUzNjhkMjU1ZmQ1MzdfMy03LTEtMS0xNTk1NDA_3ee4aca4-1af3-4241-a3ad-15fa974c7eb0">297.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmJhMWE1ZDZiZDA3YTRhN2E5MmJlMzY4ZDI1NWZkNTM3L3RhYmxlcmFuZ2U6YmExYTVkNmJkMDdhNGE3YTkyYmUzNjhkMjU1ZmQ1MzdfMy05LTEtMS0xNTk1NDA_f7cf9943-aa76-4bdf-b722-c3e1eaed20c4">145.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net amount reclassified from accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13abcd536a74422a91f0be2e859c5f11_D20220101-20220930" decimals="-5" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmJhMWE1ZDZiZDA3YTRhN2E5MmJlMzY4ZDI1NWZkNTM3L3RhYmxlcmFuZ2U6YmExYTVkNmJkMDdhNGE3YTkyYmUzNjhkMjU1ZmQ1MzdfNC0xLTEtMS0xNTk1NDA_e23bba7b-34de-48f1-9b60-8e15a22b59f6">0.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieeda2eb9aa724c2eb2b08a110d5910ca_D20220101-20220930" decimals="-5" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmJhMWE1ZDZiZDA3YTRhN2E5MmJlMzY4ZDI1NWZkNTM3L3RhYmxlcmFuZ2U6YmExYTVkNmJkMDdhNGE3YTkyYmUzNjhkMjU1ZmQ1MzdfNC0zLTEtMS0xNTk1NDA_9190dfd0-0744-4be9-8d39-1d232d9a7b8d">12.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c0ca46f62b245baa26e2ca939e70c30_D20220101-20220930" decimals="-5" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmJhMWE1ZDZiZDA3YTRhN2E5MmJlMzY4ZDI1NWZkNTM3L3RhYmxlcmFuZ2U6YmExYTVkNmJkMDdhNGE3YTkyYmUzNjhkMjU1ZmQ1MzdfNC01LTEtMS0xNTk1NDA_852c1882-c146-48a5-9450-2a666a131665">172.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i698e8cd8a6e44a719d0a96611610bdf4_D20220101-20220930" decimals="-5" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmJhMWE1ZDZiZDA3YTRhN2E5MmJlMzY4ZDI1NWZkNTM3L3RhYmxlcmFuZ2U6YmExYTVkNmJkMDdhNGE3YTkyYmUzNjhkMjU1ZmQ1MzdfNC03LTEtMS0xNTk1NDA_11893604-2bfe-48e3-81ff-2b84fa6a9b37">6.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930" decimals="-5" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmJhMWE1ZDZiZDA3YTRhN2E5MmJlMzY4ZDI1NWZkNTM3L3RhYmxlcmFuZ2U6YmExYTVkNmJkMDdhNGE3YTkyYmUzNjhkMjU1ZmQ1MzdfNC05LTEtMS0xNTk1NDA_43bf1dac-bccf-4c22-84b0-f7f40c953855">192.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i13abcd536a74422a91f0be2e859c5f11_D20220101-20220930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmJhMWE1ZDZiZDA3YTRhN2E5MmJlMzY4ZDI1NWZkNTM3L3RhYmxlcmFuZ2U6YmExYTVkNmJkMDdhNGE3YTkyYmUzNjhkMjU1ZmQ1MzdfNS0xLTEtMS0xNTk1NDA_9622fa05-3684-45e2-8cf0-a244e7a249f4">459.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieeda2eb9aa724c2eb2b08a110d5910ca_D20220101-20220930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmJhMWE1ZDZiZDA3YTRhN2E5MmJlMzY4ZDI1NWZkNTM3L3RhYmxlcmFuZ2U6YmExYTVkNmJkMDdhNGE3YTkyYmUzNjhkMjU1ZmQ1MzdfNS0zLTEtMS0xNTk1NDA_a849d495-a915-48e5-9b20-7bfed9449537">43.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c0ca46f62b245baa26e2ca939e70c30_D20220101-20220930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmJhMWE1ZDZiZDA3YTRhN2E5MmJlMzY4ZDI1NWZkNTM3L3RhYmxlcmFuZ2U6YmExYTVkNmJkMDdhNGE3YTkyYmUzNjhkMjU1ZmQ1MzdfNS01LTEtMS0xNTk1NDA_048e54b6-f1b0-4d53-91cf-412483723899">245.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i698e8cd8a6e44a719d0a96611610bdf4_D20220101-20220930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmJhMWE1ZDZiZDA3YTRhN2E5MmJlMzY4ZDI1NWZkNTM3L3RhYmxlcmFuZ2U6YmExYTVkNmJkMDdhNGE3YTkyYmUzNjhkMjU1ZmQ1MzdfNS03LTEtMS0xNTk1NDA_6a7da4af-c3b0-438f-ba1d-f8da68a1e393">304.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmJhMWE1ZDZiZDA3YTRhN2E5MmJlMzY4ZDI1NWZkNTM3L3RhYmxlcmFuZ2U6YmExYTVkNmJkMDdhNGE3YTkyYmUzNjhkMjU1ZmQ1MzdfNS05LTEtMS0xNTk1NDA_79e6ae06-d612-4dc9-ab64-0b6d4d858ce1">47.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September&#160;30, 2022</span></div></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i603b413215ff4ac0860f74b6a1be9294_I20220930" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmJhMWE1ZDZiZDA3YTRhN2E5MmJlMzY4ZDI1NWZkNTM3L3RhYmxlcmFuZ2U6YmExYTVkNmJkMDdhNGE3YTkyYmUzNjhkMjU1ZmQ1MzdfNy0xLTEtMS0xNTk1NDA_e2817971-3ce0-4f62-8b72-ec9911ed1219">2,009.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6105e19d65744395aeb2921c7555324a_I20220930" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmJhMWE1ZDZiZDA3YTRhN2E5MmJlMzY4ZDI1NWZkNTM3L3RhYmxlcmFuZ2U6YmExYTVkNmJkMDdhNGE3YTkyYmUzNjhkMjU1ZmQ1MzdfNy0zLTEtMS0xNTk1NDA_a3b04b31-bbaf-4aa0-9a03-66bce2b7d63e">39.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1ec1c7b3b72549149e283cdff33abeed_I20220930" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmJhMWE1ZDZiZDA3YTRhN2E5MmJlMzY4ZDI1NWZkNTM3L3RhYmxlcmFuZ2U6YmExYTVkNmJkMDdhNGE3YTkyYmUzNjhkMjU1ZmQ1MzdfNy01LTEtMS0xNTk1NDA_2ea540f9-5c8b-4ece-8733-2bd315bdaa84">2,338.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc51fbfd706a4f809013d42ddd4fef8c_I20220930" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmJhMWE1ZDZiZDA3YTRhN2E5MmJlMzY4ZDI1NWZkNTM3L3RhYmxlcmFuZ2U6YmExYTVkNmJkMDdhNGE3YTkyYmUzNjhkMjU1ZmQ1MzdfNy03LTEtMS0xNTk1NDA_a7d3d5b8-ef0b-4c72-ac84-9259e1ecdca6">91.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iad56c44530dd4208959b336f8d1fe8b1_I20220930" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmJhMWE1ZDZiZDA3YTRhN2E5MmJlMzY4ZDI1NWZkNTM3L3RhYmxlcmFuZ2U6YmExYTVkNmJkMDdhNGE3YTkyYmUzNjhkMjU1ZmQ1MzdfNy05LTEtMS0xNTk1NDA_672abccd-1b4a-49ea-ae6b-39bf34e1fe61">4,295.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.601%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Amounts presented net of taxes)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Foreign Currency Translation Gains&#160;(Losses)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Unrealized Net Gains (Losses) on&#160;Securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Defined Benefit Pension and Retiree&#160;Health Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Effective Portion of Cash&#160;Flow Hedges</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Loss</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January 1, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4b2bb6e433df4a26acb1d1cfbcc2ce7d_I20201231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOjZkZDI3YTI5ZjA1YzQ0YjRhMWMxOWQ2MTQ5MWFiMDRiL3RhYmxlcmFuZ2U6NmRkMjdhMjlmMDVjNDRiNGExYzE5ZDYxNDkxYWIwNGJfMS0xLTEtMS0xNTk1NDA_97951402-5497-4828-9561-5cab17c2bda8">1,427.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic15a6784d2e64c5b9176f90a12f6b997_I20201231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOjZkZDI3YTI5ZjA1YzQ0YjRhMWMxOWQ2MTQ5MWFiMDRiL3RhYmxlcmFuZ2U6NmRkMjdhMjlmMDVjNDRiNGExYzE5ZDYxNDkxYWIwNGJfMS0zLTEtMS0xNTk1NDA_882fb8f0-8666-4ad8-b77b-3848ee4f03b4">14.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if4dbdc6b4ce3472bb83f35a58ba62009_I20201231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOjZkZDI3YTI5ZjA1YzQ0YjRhMWMxOWQ2MTQ5MWFiMDRiL3RhYmxlcmFuZ2U6NmRkMjdhMjlmMDVjNDRiNGExYzE5ZDYxNDkxYWIwNGJfMS01LTEtMS0xNTk1NDA_c2f6e5ff-e854-4806-9340-0995d612e927">4,751.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4084f6774b4344709f32500dfb758be3_I20201231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOjZkZDI3YTI5ZjA1YzQ0YjRhMWMxOWQ2MTQ5MWFiMDRiL3RhYmxlcmFuZ2U6NmRkMjdhMjlmMDVjNDRiNGExYzE5ZDYxNDkxYWIwNGJfMS03LTEtMS0xNTk1NDA_2da41502-b2ab-44ee-8b0f-30b72625c205">332.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i61189f333c704d8a9f0dffcd44fd0870_I20201231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOjZkZDI3YTI5ZjA1YzQ0YjRhMWMxOWQ2MTQ5MWFiMDRiL3RhYmxlcmFuZ2U6NmRkMjdhMjlmMDVjNDRiNGExYzE5ZDYxNDkxYWIwNGJfMS05LTEtMS0xNTk1NDA_0b6c8abd-2f26-4669-9d7d-4924fbdb1bf2">6,496.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4def4770d4c9484b9eafab55058f4c06_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOjZkZDI3YTI5ZjA1YzQ0YjRhMWMxOWQ2MTQ5MWFiMDRiL3RhYmxlcmFuZ2U6NmRkMjdhMjlmMDVjNDRiNGExYzE5ZDYxNDkxYWIwNGJfMy0xLTEtMS0xNTk1NDA_d44c05f9-6f7a-4c53-af68-0eda7919903d">96.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if73a641a34fe4591b395573cedb1bea4_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOjZkZDI3YTI5ZjA1YzQ0YjRhMWMxOWQ2MTQ5MWFiMDRiL3RhYmxlcmFuZ2U6NmRkMjdhMjlmMDVjNDRiNGExYzE5ZDYxNDkxYWIwNGJfMy0zLTEtMS0xNTk1NDA_51e782a8-6f25-47c7-99d9-cdc918d27e6e">8.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71a11ec78f2242498930e393cd63658b_D20210101-20210930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOjZkZDI3YTI5ZjA1YzQ0YjRhMWMxOWQ2MTQ5MWFiMDRiL3RhYmxlcmFuZ2U6NmRkMjdhMjlmMDVjNDRiNGExYzE5ZDYxNDkxYWIwNGJfMy01LTEtMS0xNTk1NDA_bcd0bbc9-ec9d-4c48-a74b-68fb8571e331">27.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i314c9492fa9044c3a8d05e0fc3ad2e63_D20210101-20210930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOjZkZDI3YTI5ZjA1YzQ0YjRhMWMxOWQ2MTQ5MWFiMDRiL3RhYmxlcmFuZ2U6NmRkMjdhMjlmMDVjNDRiNGExYzE5ZDYxNDkxYWIwNGJfMy03LTEtMS0xNTk1NDA_8156c0cb-ba75-44a2-b9a5-dc9d6f619b07">132.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i167ed8f67bef48c49e54fa466400cdaa_D20210101-20210930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOjZkZDI3YTI5ZjA1YzQ0YjRhMWMxOWQ2MTQ5MWFiMDRiL3RhYmxlcmFuZ2U6NmRkMjdhMjlmMDVjNDRiNGExYzE5ZDYxNDkxYWIwNGJfMy05LTEtMS0xNTk1NDA_b6d2e3de-b539-42d4-aadb-0ad48f908c1e">54.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net amount reclassified from accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4def4770d4c9484b9eafab55058f4c06_D20210101-20210930" decimals="-5" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOjZkZDI3YTI5ZjA1YzQ0YjRhMWMxOWQ2MTQ5MWFiMDRiL3RhYmxlcmFuZ2U6NmRkMjdhMjlmMDVjNDRiNGExYzE5ZDYxNDkxYWIwNGJfNC0xLTEtMS0xNTk1NDA_df117ee3-063e-4522-8a2b-590a65911b29">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if73a641a34fe4591b395573cedb1bea4_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOjZkZDI3YTI5ZjA1YzQ0YjRhMWMxOWQ2MTQ5MWFiMDRiL3RhYmxlcmFuZ2U6NmRkMjdhMjlmMDVjNDRiNGExYzE5ZDYxNDkxYWIwNGJfNC0zLTEtMS0xNTk1NDA_fc963b77-b32c-41b6-88c2-94026c36effd">0.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71a11ec78f2242498930e393cd63658b_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOjZkZDI3YTI5ZjA1YzQ0YjRhMWMxOWQ2MTQ5MWFiMDRiL3RhYmxlcmFuZ2U6NmRkMjdhMjlmMDVjNDRiNGExYzE5ZDYxNDkxYWIwNGJfNC01LTEtMS0xNTk1NDA_3a98660b-8435-4d58-a6ce-92f902d62686">258.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i314c9492fa9044c3a8d05e0fc3ad2e63_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOjZkZDI3YTI5ZjA1YzQ0YjRhMWMxOWQ2MTQ5MWFiMDRiL3RhYmxlcmFuZ2U6NmRkMjdhMjlmMDVjNDRiNGExYzE5ZDYxNDkxYWIwNGJfNC03LTEtMS0xNTk1NDA_bfaa1d27-e9e4-443a-9975-36ed67113289">9.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i167ed8f67bef48c49e54fa466400cdaa_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOjZkZDI3YTI5ZjA1YzQ0YjRhMWMxOWQ2MTQ5MWFiMDRiL3RhYmxlcmFuZ2U6NmRkMjdhMjlmMDVjNDRiNGExYzE5ZDYxNDkxYWIwNGJfNC05LTEtMS0xNTk1NDA_f029ff4d-e8ee-4af2-aa01-c0569e36d6fc">269.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4def4770d4c9484b9eafab55058f4c06_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOjZkZDI3YTI5ZjA1YzQ0YjRhMWMxOWQ2MTQ5MWFiMDRiL3RhYmxlcmFuZ2U6NmRkMjdhMjlmMDVjNDRiNGExYzE5ZDYxNDkxYWIwNGJfNS0xLTEtMS0xNTk1NDA_f142a863-e7ef-441c-ba12-31bddcf20883">96.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if73a641a34fe4591b395573cedb1bea4_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOjZkZDI3YTI5ZjA1YzQ0YjRhMWMxOWQ2MTQ5MWFiMDRiL3RhYmxlcmFuZ2U6NmRkMjdhMjlmMDVjNDRiNGExYzE5ZDYxNDkxYWIwNGJfNS0zLTEtMS0xNTk1NDA_fc325872-d51f-4c45-ae5b-77c883cf97bd">8.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71a11ec78f2242498930e393cd63658b_D20210101-20210930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOjZkZDI3YTI5ZjA1YzQ0YjRhMWMxOWQ2MTQ5MWFiMDRiL3RhYmxlcmFuZ2U6NmRkMjdhMjlmMDVjNDRiNGExYzE5ZDYxNDkxYWIwNGJfNS01LTEtMS0xNTk1NDA_31a06a9d-b27b-4cec-b8b2-6bbe0a72a142">285.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i314c9492fa9044c3a8d05e0fc3ad2e63_D20210101-20210930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOjZkZDI3YTI5ZjA1YzQ0YjRhMWMxOWQ2MTQ5MWFiMDRiL3RhYmxlcmFuZ2U6NmRkMjdhMjlmMDVjNDRiNGExYzE5ZDYxNDkxYWIwNGJfNS03LTEtMS0xNTk1NDA_8f52c74d-d777-4d3c-9078-604c6e660b15">142.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i167ed8f67bef48c49e54fa466400cdaa_D20210101-20210930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOjZkZDI3YTI5ZjA1YzQ0YjRhMWMxOWQ2MTQ5MWFiMDRiL3RhYmxlcmFuZ2U6NmRkMjdhMjlmMDVjNDRiNGExYzE5ZDYxNDkxYWIwNGJfNS05LTEtMS0xNTk1NDA_1a7b6916-95a3-4664-b1be-77f3cddfc826">323.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September&#160;30, 2021</span></div></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iab4358396efe4d7f92c5aab447052434_I20210930" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOjZkZDI3YTI5ZjA1YzQ0YjRhMWMxOWQ2MTQ5MWFiMDRiL3RhYmxlcmFuZ2U6NmRkMjdhMjlmMDVjNDRiNGExYzE5ZDYxNDkxYWIwNGJfNy0xLTEtMS0xNTk1NDA_df686e57-acf0-4aae-8f8d-89339b78fb83">1,524.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5be060faaa5146e7a2bf742eb38f7bec_I20210930" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOjZkZDI3YTI5ZjA1YzQ0YjRhMWMxOWQ2MTQ5MWFiMDRiL3RhYmxlcmFuZ2U6NmRkMjdhMjlmMDVjNDRiNGExYzE5ZDYxNDkxYWIwNGJfNy0zLTEtMS0xNTk1NDA_1562e3d0-3bb8-4ee8-8ee0-5bae8ee51810">6.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i894ae4ccbe404068bbc052f007cea48c_I20210930" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOjZkZDI3YTI5ZjA1YzQ0YjRhMWMxOWQ2MTQ5MWFiMDRiL3RhYmxlcmFuZ2U6NmRkMjdhMjlmMDVjNDRiNGExYzE5ZDYxNDkxYWIwNGJfNy01LTEtMS0xNTk1NDA_080fc4e5-2651-4b0d-b0b2-3f8acc562924">4,465.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic74e9458c4f44462a21bfd6f33c8c50d_I20210930" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOjZkZDI3YTI5ZjA1YzQ0YjRhMWMxOWQ2MTQ5MWFiMDRiL3RhYmxlcmFuZ2U6NmRkMjdhMjlmMDVjNDRiNGExYzE5ZDYxNDkxYWIwNGJfNy03LTEtMS0xNTk1NDA_c699214d-26ae-4453-a649-8b55feb4304b">190.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9ed755da42e84ed28970211b57db0d80_I20210930" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOjZkZDI3YTI5ZjA1YzQ0YjRhMWMxOWQ2MTQ5MWFiMDRiL3RhYmxlcmFuZ2U6NmRkMjdhMjlmMDVjNDRiNGExYzE5ZDYxNDkxYWIwNGJfNy05LTEtMS0xNTk1NDA_6b796905-b78a-40b3-a04d-9f8a7c2593f2">6,172.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i5522e96d15c7416b8ed82fcd2588116a"><ix:continuation id="i3587bacca65548d4a7335757e1648b25"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tax effects on the net activity related to each component of other comprehensive income (loss) were as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.613%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.206%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Tax benefit (expense) </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation gains/losses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibb680e42808d41b587bffa2f35409a91_D20220701-20220930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmFhYWFkZDkyNDk1NzQ2NTM4ZTYyOWNhYmVmOTIyNDUwL3RhYmxlcmFuZ2U6YWFhYWRkOTI0OTU3NDY1MzhlNjI5Y2FiZWY5MjI0NTBfMi0xLTEtMS0xNTk1NDA_9288aeb5-bc35-4821-b372-845cc812a74b">133.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3153def44849420f812d26d82e12f780_D20210701-20210930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmFhYWFkZDkyNDk1NzQ2NTM4ZTYyOWNhYmVmOTIyNDUwL3RhYmxlcmFuZ2U6YWFhYWRkOTI0OTU3NDY1MzhlNjI5Y2FiZWY5MjI0NTBfMi0zLTEtMS0xNTk1NDA_a5ffecc2-9b51-46ac-af7b-fee5b950b93f">39.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i13abcd536a74422a91f0be2e859c5f11_D20220101-20220930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmFhYWFkZDkyNDk1NzQ2NTM4ZTYyOWNhYmVmOTIyNDUwL3RhYmxlcmFuZ2U6YWFhYWRkOTI0OTU3NDY1MzhlNjI5Y2FiZWY5MjI0NTBfMi01LTEtMS0xNTk1NDA_effcd36c-4bc5-413d-902e-1975903a5dbc">234.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4def4770d4c9484b9eafab55058f4c06_D20210101-20210930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmFhYWFkZDkyNDk1NzQ2NTM4ZTYyOWNhYmVmOTIyNDUwL3RhYmxlcmFuZ2U6YWFhYWRkOTI0OTU3NDY1MzhlNjI5Y2FiZWY5MjI0NTBfMi03LTEtMS0xNTk1NDA_cf738574-2c69-4fb7-897e-f429ae685e23">92.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized net gains/losses on securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib423da078b9740019ae03257a6ca1320_D20220701-20220930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmFhYWFkZDkyNDk1NzQ2NTM4ZTYyOWNhYmVmOTIyNDUwL3RhYmxlcmFuZ2U6YWFhYWRkOTI0OTU3NDY1MzhlNjI5Y2FiZWY5MjI0NTBfMy0xLTEtMS0xNTk1NDA_adc9b647-288e-4693-b5fd-7dd97abcc7c9">3.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i525ab1d53cfc40b99c19c64b4d032446_D20210701-20210930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmFhYWFkZDkyNDk1NzQ2NTM4ZTYyOWNhYmVmOTIyNDUwL3RhYmxlcmFuZ2U6YWFhYWRkOTI0OTU3NDY1MzhlNjI5Y2FiZWY5MjI0NTBfMy0zLTEtMS0xNTk1NDA_891e3a1c-8491-4d56-a658-a73f2948d075">0.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieeda2eb9aa724c2eb2b08a110d5910ca_D20220101-20220930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmFhYWFkZDkyNDk1NzQ2NTM4ZTYyOWNhYmVmOTIyNDUwL3RhYmxlcmFuZ2U6YWFhYWRkOTI0OTU3NDY1MzhlNjI5Y2FiZWY5MjI0NTBfMy01LTEtMS0xNTk1NDA_b1fb0281-e508-477b-bbc4-f0903d8ca148">13.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if73a641a34fe4591b395573cedb1bea4_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmFhYWFkZDkyNDk1NzQ2NTM4ZTYyOWNhYmVmOTIyNDUwL3RhYmxlcmFuZ2U6YWFhYWRkOTI0OTU3NDY1MzhlNjI5Y2FiZWY5MjI0NTBfMy03LTEtMS0xNTk1NDA_2d52efac-cc89-410f-a00b-9f4d7f605ae7">3.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Defined benefit pension and retiree health benefit plans</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0ddaa7c4639946b1a63ee163ebac9cda_D20220701-20220930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmFhYWFkZDkyNDk1NzQ2NTM4ZTYyOWNhYmVmOTIyNDUwL3RhYmxlcmFuZ2U6YWFhYWRkOTI0OTU3NDY1MzhlNjI5Y2FiZWY5MjI0NTBfNC0xLTEtMS0xNTk1NDA_f3500220-7318-4848-bc45-1c25ece78cb8">22.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4b3bb220bf604c6daaf72988d3e20703_D20210701-20210930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmFhYWFkZDkyNDk1NzQ2NTM4ZTYyOWNhYmVmOTIyNDUwL3RhYmxlcmFuZ2U6YWFhYWRkOTI0OTU3NDY1MzhlNjI5Y2FiZWY5MjI0NTBfNC0zLTEtMS0xNTk1NDA_c0679b86-78ff-4695-8681-9e8c61bd9da9">28.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1c0ca46f62b245baa26e2ca939e70c30_D20220101-20220930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmFhYWFkZDkyNDk1NzQ2NTM4ZTYyOWNhYmVmOTIyNDUwL3RhYmxlcmFuZ2U6YWFhYWRkOTI0OTU3NDY1MzhlNjI5Y2FiZWY5MjI0NTBfNC01LTEtMS0xNTk1NDA_08c99a23-2aac-45a4-b919-842288032819">73.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i71a11ec78f2242498930e393cd63658b_D20210101-20210930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmFhYWFkZDkyNDk1NzQ2NTM4ZTYyOWNhYmVmOTIyNDUwL3RhYmxlcmFuZ2U6YWFhYWRkOTI0OTU3NDY1MzhlNjI5Y2FiZWY5MjI0NTBfNC03LTEtMS0xNTk1NDA_4e681248-c5d8-4faf-b1e8-fd0f254e2154">79.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective portion of cash flow hedges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9e78a70b50b740909d4bd5980c556e3a_D20220701-20220930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmFhYWFkZDkyNDk1NzQ2NTM4ZTYyOWNhYmVmOTIyNDUwL3RhYmxlcmFuZ2U6YWFhYWRkOTI0OTU3NDY1MzhlNjI5Y2FiZWY5MjI0NTBfNS0xLTEtMS0xNTk1NDA_d196d5d1-d157-4ec3-a972-9a43fec9dd9d">16.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i24f2b962044749c5a2936c59a2f25aa9_D20210701-20210930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmFhYWFkZDkyNDk1NzQ2NTM4ZTYyOWNhYmVmOTIyNDUwL3RhYmxlcmFuZ2U6YWFhYWRkOTI0OTU3NDY1MzhlNjI5Y2FiZWY5MjI0NTBfNS0zLTEtMS0xNTk1NDA_2f573e2c-37b5-4711-86c5-3a6b173c0498">5.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i698e8cd8a6e44a719d0a96611610bdf4_D20220101-20220930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmFhYWFkZDkyNDk1NzQ2NTM4ZTYyOWNhYmVmOTIyNDUwL3RhYmxlcmFuZ2U6YWFhYWRkOTI0OTU3NDY1MzhlNjI5Y2FiZWY5MjI0NTBfNS01LTEtMS0xNTk1NDA_7a1f9e17-3ca1-424e-a357-8dbda5994062">80.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i314c9492fa9044c3a8d05e0fc3ad2e63_D20210101-20210930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmFhYWFkZDkyNDk1NzQ2NTM4ZTYyOWNhYmVmOTIyNDUwL3RhYmxlcmFuZ2U6YWFhYWRkOTI0OTU3NDY1MzhlNjI5Y2FiZWY5MjI0NTBfNS03LTEtMS0xNTk1NDA_f1841f57-2300-4e86-9a53-bca575b58a79">37.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit (expense) for income taxes allocated to other comprehensive income (loss) items</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i19fc0325c48543008ea71e1fdcf11d86_D20220701-20220930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmFhYWFkZDkyNDk1NzQ2NTM4ZTYyOWNhYmVmOTIyNDUwL3RhYmxlcmFuZ2U6YWFhYWRkOTI0OTU3NDY1MzhlNjI5Y2FiZWY5MjI0NTBfNi0xLTEtMS0xNTk1NDA_b0afe6a4-7541-4944-a2d7-1fe08a907f67">169.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie4fa4f6b472a4f269297591b44aba572_D20210701-20210930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmFhYWFkZDkyNDk1NzQ2NTM4ZTYyOWNhYmVmOTIyNDUwL3RhYmxlcmFuZ2U6YWFhYWRkOTI0OTU3NDY1MzhlNjI5Y2FiZWY5MjI0NTBfNi0zLTEtMS0xNTk1NDA_54b09372-a85d-4dce-9258-21a58b740a97">71.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmFhYWFkZDkyNDk1NzQ2NTM4ZTYyOWNhYmVmOTIyNDUwL3RhYmxlcmFuZ2U6YWFhYWRkOTI0OTU3NDY1MzhlNjI5Y2FiZWY5MjI0NTBfNi01LTEtMS0xNTk1NDA_95d8e0c0-f5d8-4739-a772-b658fe2818d4">375.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i167ed8f67bef48c49e54fa466400cdaa_D20210101-20210930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmFhYWFkZDkyNDk1NzQ2NTM4ZTYyOWNhYmVmOTIyNDUwL3RhYmxlcmFuZ2U6YWFhYWRkOTI0OTU3NDY1MzhlNjI5Y2FiZWY5MjI0NTBfNi03LTEtMS0xNTk1NDA_9c096cdb-f645-4bac-8c07-275cf8aa1352">206.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except for the tax effects of foreign currency translation gains and losses related to our foreign currency-denominated notes, cross-currency interest rate swaps, and other foreign currency exchange contracts designated as net investment hedges (see Note 6), income taxes were not provided for foreign currency translation. Generally, the assets and liabilities of foreign operations are translated into U.S. dollars using the current exchange rate. For those operations, changes in exchange rates generally do not affect cash flows; therefore, resulting translation adjustments are made in shareholders' equity rather than in the consolidated condensed statements of operations.</span></div><ix:nonNumeric contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930" name="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RleHRyZWdpb246ZTE0MjlmY2IyNjYyNDg4ZDk5MTllMTg4MGNiZTMyMTNfMTI0Ng_7fce3647-7646-46f0-b874-b42e629c05a1" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reclassifications out of accumulated other comprehensive loss were as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.718%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.830%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Details about Accumulated Other Comprehensive Loss Components</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Affected Line Item in the Consolidated Condensed Statements of Operations</span></td></tr><tr style="height:6pt"><td colspan="30" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of retirement benefit items:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior service benefits, net</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaaff00acdddb497fb5b94bf8d2ff771d_D20220701-20220930" decimals="-5" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmEwNDg1MGU2OTU2MjQ2ZTg4NDNjOWQzMjQ1ZGFiZDk4L3RhYmxlcmFuZ2U6YTA0ODUwZTY5NTYyNDZlODg0M2M5ZDMyNDVkYWJkOThfNC0yLTEtMS0xNTk1NDA_75d52764-47c2-4aed-9811-e009dae7063b">13.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia0716cc08360439bb971180db7de8214_D20210701-20210930" decimals="-5" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmEwNDg1MGU2OTU2MjQ2ZTg4NDNjOWQzMjQ1ZGFiZDk4L3RhYmxlcmFuZ2U6YTA0ODUwZTY5NTYyNDZlODg0M2M5ZDMyNDVkYWJkOThfNC00LTEtMS0xNTk1NDA_7757718b-97b7-430d-8469-2655b7c55f79">13.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1e81189c858b4d59b30b2380c8bf756b_D20220101-20220930" decimals="-5" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmEwNDg1MGU2OTU2MjQ2ZTg4NDNjOWQzMjQ1ZGFiZDk4L3RhYmxlcmFuZ2U6YTA0ODUwZTY5NTYyNDZlODg0M2M5ZDMyNDVkYWJkOThfNC02LTEtMS0xNTk1NDA_ab068766-f7f2-4015-aca9-d0926ab6f17a">39.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iafe03a1322e544acb123846499dfb8f0_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmEwNDg1MGU2OTU2MjQ2ZTg4NDNjOWQzMjQ1ZGFiZDk4L3RhYmxlcmFuZ2U6YTA0ODUwZTY5NTYyNDZlODg0M2M5ZDMyNDVkYWJkOThfNC04LTEtMS0xNTk1NDA_4c80be46-a6d8-4fb5-a83b-021447ab5122">41.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#8211;net, (income) expense</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actuarial losses, net</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedc64e6c0ae84f6f8f6f168b1b71f00f_D20220701-20220930" decimals="-5" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmEwNDg1MGU2OTU2MjQ2ZTg4NDNjOWQzMjQ1ZGFiZDk4L3RhYmxlcmFuZ2U6YTA0ODUwZTY5NTYyNDZlODg0M2M5ZDMyNDVkYWJkOThfNS0yLTEtMS0xNTk1NDA_b8c61d10-6692-415c-acb7-4a5f3bc9cdc1">85.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02ba7e57b97e4c15aa93cdacb3f05447_D20210701-20210930" decimals="-5" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmEwNDg1MGU2OTU2MjQ2ZTg4NDNjOWQzMjQ1ZGFiZDk4L3RhYmxlcmFuZ2U6YTA0ODUwZTY5NTYyNDZlODg0M2M5ZDMyNDVkYWJkOThfNS00LTEtMS0xNTk1NDA_4aa3e2da-7c6b-4b72-b2f6-621b543f2042">122.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d7550b247eb4a90ac3acd3ea2eab6ad_D20220101-20220930" decimals="-5" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmEwNDg1MGU2OTU2MjQ2ZTg4NDNjOWQzMjQ1ZGFiZDk4L3RhYmxlcmFuZ2U6YTA0ODUwZTY5NTYyNDZlODg0M2M5ZDMyNDVkYWJkOThfNS02LTEtMS0xNTk1NDA_acc4c432-ea31-4b2a-af8a-cd9d50eaab77">257.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8458e6a1b9b4239b31d01e183c0368d_D20210101-20210930" decimals="-5" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmEwNDg1MGU2OTU2MjQ2ZTg4NDNjOWQzMjQ1ZGFiZDk4L3RhYmxlcmFuZ2U6YTA0ODUwZTY5NTYyNDZlODg0M2M5ZDMyNDVkYWJkOThfNS04LTEtMS0xNTk1NDA_3323a627-a909-48fd-8e7d-0bb12bf616ab">368.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#8211;net, (income) expense</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total before tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14e2a21089594bfda05e2f482a1a9fdb_D20220701-20220930" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmEwNDg1MGU2OTU2MjQ2ZTg4NDNjOWQzMjQ1ZGFiZDk4L3RhYmxlcmFuZ2U6YTA0ODUwZTY5NTYyNDZlODg0M2M5ZDMyNDVkYWJkOThfNi0yLTEtMS0xNTk1NDA_e4cca648-b540-4e36-bc46-c09b2a81efe5">72.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if60b1262bf5c4116ad9ba0e69b270a48_D20210701-20210930" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmEwNDg1MGU2OTU2MjQ2ZTg4NDNjOWQzMjQ1ZGFiZDk4L3RhYmxlcmFuZ2U6YTA0ODUwZTY5NTYyNDZlODg0M2M5ZDMyNDVkYWJkOThfNi00LTEtMS0xNTk1NDA_753a8d8b-c928-4c94-bf34-6b0fed64423d">108.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i913335a3ccfe4b639f36db1017ae92af_D20220101-20220930" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmEwNDg1MGU2OTU2MjQ2ZTg4NDNjOWQzMjQ1ZGFiZDk4L3RhYmxlcmFuZ2U6YTA0ODUwZTY5NTYyNDZlODg0M2M5ZDMyNDVkYWJkOThfNi02LTEtMS0xNTk1NDA_6b167d15-d4ac-4f22-9f2f-443e5d6874be">218.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c947211ed8b449b9617f0791f225696_D20210101-20210930" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmEwNDg1MGU2OTU2MjQ2ZTg4NDNjOWQzMjQ1ZGFiZDk4L3RhYmxlcmFuZ2U6YTA0ODUwZTY5NTYyNDZlODg0M2M5ZDMyNDVkYWJkOThfNi04LTEtMS0xNTk1NDA_0350ef29-18de-4d39-86a2-c8ceb299f6e7">327.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax benefit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i14e2a21089594bfda05e2f482a1a9fdb_D20220701-20220930" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmEwNDg1MGU2OTU2MjQ2ZTg4NDNjOWQzMjQ1ZGFiZDk4L3RhYmxlcmFuZ2U6YTA0ODUwZTY5NTYyNDZlODg0M2M5ZDMyNDVkYWJkOThfNy0yLTEtMS0xNTk1NDA_c69e305a-591a-4070-9ec3-f9a8f7a02bc0">15.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if60b1262bf5c4116ad9ba0e69b270a48_D20210701-20210930" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmEwNDg1MGU2OTU2MjQ2ZTg4NDNjOWQzMjQ1ZGFiZDk4L3RhYmxlcmFuZ2U6YTA0ODUwZTY5NTYyNDZlODg0M2M5ZDMyNDVkYWJkOThfNy00LTEtMS0xNTk1NDA_2f77d614-038e-490f-b2ef-544ac03182a9">22.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i913335a3ccfe4b639f36db1017ae92af_D20220101-20220930" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmEwNDg1MGU2OTU2MjQ2ZTg4NDNjOWQzMjQ1ZGFiZDk4L3RhYmxlcmFuZ2U6YTA0ODUwZTY5NTYyNDZlODg0M2M5ZDMyNDVkYWJkOThfNy02LTEtMS0xNTk1NDA_202a3d38-09bf-4207-8bf8-1aff1296d1b1">45.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7c947211ed8b449b9617f0791f225696_D20210101-20210930" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmEwNDg1MGU2OTU2MjQ2ZTg4NDNjOWQzMjQ1ZGFiZDk4L3RhYmxlcmFuZ2U6YTA0ODUwZTY5NTYyNDZlODg0M2M5ZDMyNDVkYWJkOThfNy04LTEtMS0xNTk1NDA_a640bf6f-a7d1-4129-81f4-869a47fac787">68.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net of tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14e2a21089594bfda05e2f482a1a9fdb_D20220701-20220930" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmEwNDg1MGU2OTU2MjQ2ZTg4NDNjOWQzMjQ1ZGFiZDk4L3RhYmxlcmFuZ2U6YTA0ODUwZTY5NTYyNDZlODg0M2M5ZDMyNDVkYWJkOThfOC0yLTEtMS0xNTk1NDA_078cf349-6ae2-4264-ba2d-cc2dc7023f74">57.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if60b1262bf5c4116ad9ba0e69b270a48_D20210701-20210930" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmEwNDg1MGU2OTU2MjQ2ZTg4NDNjOWQzMjQ1ZGFiZDk4L3RhYmxlcmFuZ2U6YTA0ODUwZTY5NTYyNDZlODg0M2M5ZDMyNDVkYWJkOThfOC00LTEtMS0xNTk1NDA_43f1f17d-5e6e-4e0d-9275-01fc78827701">86.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i913335a3ccfe4b639f36db1017ae92af_D20220101-20220930" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmEwNDg1MGU2OTU2MjQ2ZTg4NDNjOWQzMjQ1ZGFiZDk4L3RhYmxlcmFuZ2U6YTA0ODUwZTY5NTYyNDZlODg0M2M5ZDMyNDVkYWJkOThfOC02LTEtMS0xNTk1NDA_024f976b-b13d-4afb-a727-247f62c054ae">172.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c947211ed8b449b9617f0791f225696_D20210101-20210930" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmEwNDg1MGU2OTU2MjQ2ZTg4NDNjOWQzMjQ1ZGFiZDk4L3RhYmxlcmFuZ2U6YTA0ODUwZTY5NTYyNDZlODg0M2M5ZDMyNDVkYWJkOThfOC04LTEtMS0xNTk1NDA_ee56cd72-d540-4e2e-a6aa-7aa4b9663e61">258.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net of tax</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib98dca097ce342f1856252087101e534_D20220701-20220930" decimals="-5" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmEwNDg1MGU2OTU2MjQ2ZTg4NDNjOWQzMjQ1ZGFiZDk4L3RhYmxlcmFuZ2U6YTA0ODUwZTY5NTYyNDZlODg0M2M5ZDMyNDVkYWJkOThfMTAtMi0xLTEtMTU5NTQw_f2d3ab8e-1b2b-4ff5-a7c3-5f627d0d4f55">13.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if20e319a4c3045b8b0693a8773446ca4_D20210701-20210930" decimals="-5" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmEwNDg1MGU2OTU2MjQ2ZTg4NDNjOWQzMjQ1ZGFiZDk4L3RhYmxlcmFuZ2U6YTA0ODUwZTY5NTYyNDZlODg0M2M5ZDMyNDVkYWJkOThfMTAtNC0xLTEtMTU5NTQw_cae01196-fe0d-48f1-a0a1-d5308a3751c6">3.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06f2cc53bd804ced906cc353bccf23bd_D20220101-20220930" decimals="-5" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmEwNDg1MGU2OTU2MjQ2ZTg4NDNjOWQzMjQ1ZGFiZDk4L3RhYmxlcmFuZ2U6YTA0ODUwZTY5NTYyNDZlODg0M2M5ZDMyNDVkYWJkOThfMTAtNi0xLTEtMTU5NTQw_0b895ae1-2a9b-4f7c-8d41-9911ac8e0f19">19.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i562107a932c943419a75d588f68a7ede_D20210101-20210930" decimals="-5" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmEwNDg1MGU2OTU2MjQ2ZTg4NDNjOWQzMjQ1ZGFiZDk4L3RhYmxlcmFuZ2U6YTA0ODUwZTY5NTYyNDZlODg0M2M5ZDMyNDVkYWJkOThfMTAtOC0xLTEtMTU5NTQw_ea3bc79b-cd71-4dcc-b0cc-66f387200de8">10.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#8211;net, (income) expense</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total reclassifications, net of tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i294aedf137cf40faaba28e6d98a540dc_D20220701-20220930" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmEwNDg1MGU2OTU2MjQ2ZTg4NDNjOWQzMjQ1ZGFiZDk4L3RhYmxlcmFuZ2U6YTA0ODUwZTY5NTYyNDZlODg0M2M5ZDMyNDVkYWJkOThfMTItMi0xLTEtMTU5NTQw_9c895380-89ef-4bd2-9085-faf91a1e9dd5">71.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id04bc0ea75e7453daeb27bfa63e91d46_D20210701-20210930" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmEwNDg1MGU2OTU2MjQ2ZTg4NDNjOWQzMjQ1ZGFiZDk4L3RhYmxlcmFuZ2U6YTA0ODUwZTY5NTYyNDZlODg0M2M5ZDMyNDVkYWJkOThfMTItNC0xLTEtMTU5NTQw_dafea8ca-30c7-42dd-b875-a96517caeeaf">89.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8fcac86ddf342cf954cceefebfd7779_D20220101-20220930" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmEwNDg1MGU2OTU2MjQ2ZTg4NDNjOWQzMjQ1ZGFiZDk4L3RhYmxlcmFuZ2U6YTA0ODUwZTY5NTYyNDZlODg0M2M5ZDMyNDVkYWJkOThfMTItNi0xLTEtMTU5NTQw_a52dcf8c-cf09-42ec-bb83-f8eb0ca6ac84">192.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i741049a232dc40728bbe8ee225522d87_D20210101-20210930" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmEwNDg1MGU2OTU2MjQ2ZTg4NDNjOWQzMjQ1ZGFiZDk4L3RhYmxlcmFuZ2U6YTA0ODUwZTY5NTYyNDZlODg0M2M5ZDMyNDVkYWJkOThfMTItOC0xLTEtMTU5NTQw_2d74a895-ec3d-48e4-aea1-6e52b6e3c7db">269.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div id="i5fed483d9c7e4f3cbba3a62c53226cd7_79"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 11: <ix:nonNumeric contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930" name="us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183OS9mcmFnOjRlODJmYzU4OGU5ZTQ1OWY4NThhZGYzYjAwN2ZhNjIxL3RleHRyZWdpb246NGU4MmZjNTg4ZTllNDU5Zjg1OGFkZjNiMDA3ZmE2MjFfMTAw_a4436a0b-790b-4f5c-89ef-5fc4fe3b6d4c" continuedAt="ic9967df7dda640d38cf70f17b7e0c2c9" escape="true">Other&#8211;Net, (Income) Expense</ix:nonNumeric></span></div><ix:continuation id="ic9967df7dda640d38cf70f17b7e0c2c9"><ix:nonNumeric contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930" name="us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183OS9mcmFnOjRlODJmYzU4OGU5ZTQ1OWY4NThhZGYzYjAwN2ZhNjIxL3RleHRyZWdpb246NGU4MmZjNTg4ZTllNDU5Zjg1OGFkZjNiMDA3ZmE2MjFfMTEw_ad46a46a-9b7c-457d-899a-6c782493986f" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other&#8211;net, (income) expense consisted of the following:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.613%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.206%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19fc0325c48543008ea71e1fdcf11d86_D20220701-20220930" decimals="-5" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183OS9mcmFnOjRlODJmYzU4OGU5ZTQ1OWY4NThhZGYzYjAwN2ZhNjIxL3RhYmxlOjJjYTIxZTlmZWFjNzRmMWQ4ZDQ2MjEzMGY2NThlYTdkL3RhYmxlcmFuZ2U6MmNhMjFlOWZlYWM3NGYxZDhkNDYyMTMwZjY1OGVhN2RfMi0xLTEtMS0xNTk1NDA_33cda92a-e46e-4aea-842b-df4b67ecd84e">81.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4fa4f6b472a4f269297591b44aba572_D20210701-20210930" decimals="-5" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183OS9mcmFnOjRlODJmYzU4OGU5ZTQ1OWY4NThhZGYzYjAwN2ZhNjIxL3RhYmxlOjJjYTIxZTlmZWFjNzRmMWQ4ZDQ2MjEzMGY2NThlYTdkL3RhYmxlcmFuZ2U6MmNhMjFlOWZlYWM3NGYxZDhkNDYyMTMwZjY1OGVhN2RfMi0zLTEtMS0xNTk1NDA_1eabc783-52db-4890-bb75-8406c7ee6a31">83.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930" decimals="-5" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183OS9mcmFnOjRlODJmYzU4OGU5ZTQ1OWY4NThhZGYzYjAwN2ZhNjIxL3RhYmxlOjJjYTIxZTlmZWFjNzRmMWQ4ZDQ2MjEzMGY2NThlYTdkL3RhYmxlcmFuZ2U6MmNhMjFlOWZlYWM3NGYxZDhkNDYyMTMwZjY1OGVhN2RfMi01LTEtMS0xNTk1NDA_ada27b2f-3ec8-422a-aed1-25eb5ee50ea0">247.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i167ed8f67bef48c49e54fa466400cdaa_D20210101-20210930" decimals="-5" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183OS9mcmFnOjRlODJmYzU4OGU5ZTQ1OWY4NThhZGYzYjAwN2ZhNjIxL3RhYmxlOjJjYTIxZTlmZWFjNzRmMWQ4ZDQ2MjEzMGY2NThlYTdkL3RhYmxlcmFuZ2U6MmNhMjFlOWZlYWM3NGYxZDhkNDYyMTMwZjY1OGVhN2RfMi03LTEtMS0xNTk1NDA_54fa630a-3f4d-4f04-9577-1077a69f6f70">258.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i19fc0325c48543008ea71e1fdcf11d86_D20220701-20220930" decimals="-5" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183OS9mcmFnOjRlODJmYzU4OGU5ZTQ1OWY4NThhZGYzYjAwN2ZhNjIxL3RhYmxlOjJjYTIxZTlmZWFjNzRmMWQ4ZDQ2MjEzMGY2NThlYTdkL3RhYmxlcmFuZ2U6MmNhMjFlOWZlYWM3NGYxZDhkNDYyMTMwZjY1OGVhN2RfMy0xLTEtMS0xNTk1NDA_75826add-d709-499e-939b-c541790eaed8">20.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie4fa4f6b472a4f269297591b44aba572_D20210701-20210930" decimals="-5" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183OS9mcmFnOjRlODJmYzU4OGU5ZTQ1OWY4NThhZGYzYjAwN2ZhNjIxL3RhYmxlOjJjYTIxZTlmZWFjNzRmMWQ4ZDQ2MjEzMGY2NThlYTdkL3RhYmxlcmFuZ2U6MmNhMjFlOWZlYWM3NGYxZDhkNDYyMTMwZjY1OGVhN2RfMy0zLTEtMS0xNTk1NDA_f798d748-7f48-4a5f-bb59-23fd9c334244">7.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930" decimals="-5" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183OS9mcmFnOjRlODJmYzU4OGU5ZTQ1OWY4NThhZGYzYjAwN2ZhNjIxL3RhYmxlOjJjYTIxZTlmZWFjNzRmMWQ4ZDQ2MjEzMGY2NThlYTdkL3RhYmxlcmFuZ2U6MmNhMjFlOWZlYWM3NGYxZDhkNDYyMTMwZjY1OGVhN2RfMy01LTEtMS0xNTk1NDA_d3294d53-2ec1-4008-afb9-ebd49ab57ae6">37.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i167ed8f67bef48c49e54fa466400cdaa_D20210101-20210930" decimals="-5" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183OS9mcmFnOjRlODJmYzU4OGU5ZTQ1OWY4NThhZGYzYjAwN2ZhNjIxL3RhYmxlOjJjYTIxZTlmZWFjNzRmMWQ4ZDQ2MjEzMGY2NThlYTdkL3RhYmxlcmFuZ2U6MmNhMjFlOWZlYWM3NGYxZDhkNDYyMTMwZjY1OGVhN2RfMy03LTEtMS0xNTk1NDA_7af8f4a4-f340-41e1-8ffc-1f0c48f342d9">18.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment (gains) losses on equity securities (Note 6)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19fc0325c48543008ea71e1fdcf11d86_D20220701-20220930" decimals="-5" sign="-" name="us-gaap:EquitySecuritiesFvNiGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183OS9mcmFnOjRlODJmYzU4OGU5ZTQ1OWY4NThhZGYzYjAwN2ZhNjIxL3RhYmxlOjJjYTIxZTlmZWFjNzRmMWQ4ZDQ2MjEzMGY2NThlYTdkL3RhYmxlcmFuZ2U6MmNhMjFlOWZlYWM3NGYxZDhkNDYyMTMwZjY1OGVhN2RfNC0xLTEtMS0xNTk1NDA_5cd0ac3d-1d37-4f83-919d-48c80bd2ec13">123.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4fa4f6b472a4f269297591b44aba572_D20210701-20210930" decimals="-5" sign="-" name="us-gaap:EquitySecuritiesFvNiGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183OS9mcmFnOjRlODJmYzU4OGU5ZTQ1OWY4NThhZGYzYjAwN2ZhNjIxL3RhYmxlOjJjYTIxZTlmZWFjNzRmMWQ4ZDQ2MjEzMGY2NThlYTdkL3RhYmxlcmFuZ2U6MmNhMjFlOWZlYWM3NGYxZDhkNDYyMTMwZjY1OGVhN2RfNC0zLTEtMS0xNTk1NDA_8dca2ddf-db58-412d-8364-95935d1ba64c">246.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930" decimals="-5" sign="-" name="us-gaap:EquitySecuritiesFvNiGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183OS9mcmFnOjRlODJmYzU4OGU5ZTQ1OWY4NThhZGYzYjAwN2ZhNjIxL3RhYmxlOjJjYTIxZTlmZWFjNzRmMWQ4ZDQ2MjEzMGY2NThlYTdkL3RhYmxlcmFuZ2U6MmNhMjFlOWZlYWM3NGYxZDhkNDYyMTMwZjY1OGVhN2RfNC01LTEtMS0xNTk1NDA_2ffa2442-aa70-42f4-b1f5-332bdd49c2c8">667.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i167ed8f67bef48c49e54fa466400cdaa_D20210101-20210930" decimals="-5" name="us-gaap:EquitySecuritiesFvNiGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183OS9mcmFnOjRlODJmYzU4OGU5ZTQ1OWY4NThhZGYzYjAwN2ZhNjIxL3RhYmxlOjJjYTIxZTlmZWFjNzRmMWQ4ZDQ2MjEzMGY2NThlYTdkL3RhYmxlcmFuZ2U6MmNhMjFlOWZlYWM3NGYxZDhkNDYyMTMwZjY1OGVhN2RfNC03LTEtMS0xNTk1NDA_1ef5aaec-a5b2-49d9-b2e6-fc4bfd34c928">270.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retirement benefit plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i19fc0325c48543008ea71e1fdcf11d86_D20220701-20220930" decimals="-5" sign="-" name="us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183OS9mcmFnOjRlODJmYzU4OGU5ZTQ1OWY4NThhZGYzYjAwN2ZhNjIxL3RhYmxlOjJjYTIxZTlmZWFjNzRmMWQ4ZDQ2MjEzMGY2NThlYTdkL3RhYmxlcmFuZ2U6MmNhMjFlOWZlYWM3NGYxZDhkNDYyMTMwZjY1OGVhN2RfNS0xLTEtMS0xNTk1NDA_696c9a51-3037-4c44-9707-e7a4fe5990e2">92.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie4fa4f6b472a4f269297591b44aba572_D20210701-20210930" decimals="-5" sign="-" name="us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183OS9mcmFnOjRlODJmYzU4OGU5ZTQ1OWY4NThhZGYzYjAwN2ZhNjIxL3RhYmxlOjJjYTIxZTlmZWFjNzRmMWQ4ZDQ2MjEzMGY2NThlYTdkL3RhYmxlcmFuZ2U6MmNhMjFlOWZlYWM3NGYxZDhkNDYyMTMwZjY1OGVhN2RfNS0zLTEtMS0xNTk1NDA_108e730a-fa82-4d4a-b646-a497cd3bfe47">72.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930" decimals="-5" sign="-" name="us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183OS9mcmFnOjRlODJmYzU4OGU5ZTQ1OWY4NThhZGYzYjAwN2ZhNjIxL3RhYmxlOjJjYTIxZTlmZWFjNzRmMWQ4ZDQ2MjEzMGY2NThlYTdkL3RhYmxlcmFuZ2U6MmNhMjFlOWZlYWM3NGYxZDhkNDYyMTMwZjY1OGVhN2RfNS01LTEtMS0xNTk1NDA_6dd8f318-1931-4704-811b-5f43ab62d832">280.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i167ed8f67bef48c49e54fa466400cdaa_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183OS9mcmFnOjRlODJmYzU4OGU5ZTQ1OWY4NThhZGYzYjAwN2ZhNjIxL3RhYmxlOjJjYTIxZTlmZWFjNzRmMWQ4ZDQ2MjEzMGY2NThlYTdkL3RhYmxlcmFuZ2U6MmNhMjFlOWZlYWM3NGYxZDhkNDYyMTMwZjY1OGVhN2RfNS03LTEtMS0xNTk1NDA_ddc5eef9-547b-40ff-9889-d15cff937812">217.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt extinguishment loss (Note 6)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19fc0325c48543008ea71e1fdcf11d86_D20220701-20220930" decimals="-5" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183OS9mcmFnOjRlODJmYzU4OGU5ZTQ1OWY4NThhZGYzYjAwN2ZhNjIxL3RhYmxlOjJjYTIxZTlmZWFjNzRmMWQ4ZDQ2MjEzMGY2NThlYTdkL3RhYmxlcmFuZ2U6MmNhMjFlOWZlYWM3NGYxZDhkNDYyMTMwZjY1OGVhN2RfNi0xLTEtMS0xNTk1NDA_e112022d-6846-40ce-b958-29278337cd5d">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4fa4f6b472a4f269297591b44aba572_D20210701-20210930" decimals="-5" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183OS9mcmFnOjRlODJmYzU4OGU5ZTQ1OWY4NThhZGYzYjAwN2ZhNjIxL3RhYmxlOjJjYTIxZTlmZWFjNzRmMWQ4ZDQ2MjEzMGY2NThlYTdkL3RhYmxlcmFuZ2U6MmNhMjFlOWZlYWM3NGYxZDhkNDYyMTMwZjY1OGVhN2RfNi0zLTEtMS0xNTk1NDA_94ed0a9f-b016-4c6b-8256-c4dbca145a96">405.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930" decimals="-5" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183OS9mcmFnOjRlODJmYzU4OGU5ZTQ1OWY4NThhZGYzYjAwN2ZhNjIxL3RhYmxlOjJjYTIxZTlmZWFjNzRmMWQ4ZDQ2MjEzMGY2NThlYTdkL3RhYmxlcmFuZ2U6MmNhMjFlOWZlYWM3NGYxZDhkNDYyMTMwZjY1OGVhN2RfNi01LTEtMS0xNTk1NDA_6bb402b6-31d7-426c-9be9-1aaec0b9e87c">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i167ed8f67bef48c49e54fa466400cdaa_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183OS9mcmFnOjRlODJmYzU4OGU5ZTQ1OWY4NThhZGYzYjAwN2ZhNjIxL3RhYmxlOjJjYTIxZTlmZWFjNzRmMWQ4ZDQ2MjEzMGY2NThlYTdkL3RhYmxlcmFuZ2U6MmNhMjFlOWZlYWM3NGYxZDhkNDYyMTMwZjY1OGVhN2RfNi03LTEtMS0xNTk1NDA_963519da-bc95-4b28-aa75-075fdb0bcf67">405.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (income) expense </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19fc0325c48543008ea71e1fdcf11d86_D20220701-20220930" decimals="-5" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183OS9mcmFnOjRlODJmYzU4OGU5ZTQ1OWY4NThhZGYzYjAwN2ZhNjIxL3RhYmxlOjJjYTIxZTlmZWFjNzRmMWQ4ZDQ2MjEzMGY2NThlYTdkL3RhYmxlcmFuZ2U6MmNhMjFlOWZlYWM3NGYxZDhkNDYyMTMwZjY1OGVhN2RfNy0xLTEtMS0xNTk1NDA_50be6c14-aff6-4757-847e-cfa0831e1bbb">18.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie4fa4f6b472a4f269297591b44aba572_D20210701-20210930" decimals="-5" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183OS9mcmFnOjRlODJmYzU4OGU5ZTQ1OWY4NThhZGYzYjAwN2ZhNjIxL3RhYmxlOjJjYTIxZTlmZWFjNzRmMWQ4ZDQ2MjEzMGY2NThlYTdkL3RhYmxlcmFuZ2U6MmNhMjFlOWZlYWM3NGYxZDhkNDYyMTMwZjY1OGVhN2RfNy0zLTEtMS0xNTk1NDA_522898d9-cf62-4b08-adbb-ed7883066ea3">20.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930" decimals="-5" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183OS9mcmFnOjRlODJmYzU4OGU5ZTQ1OWY4NThhZGYzYjAwN2ZhNjIxL3RhYmxlOjJjYTIxZTlmZWFjNzRmMWQ4ZDQ2MjEzMGY2NThlYTdkL3RhYmxlcmFuZ2U6MmNhMjFlOWZlYWM3NGYxZDhkNDYyMTMwZjY1OGVhN2RfNy01LTEtMS0xNTk1NDA_2cea1b0b-fb10-4879-86b7-123df7461cc5">17.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i167ed8f67bef48c49e54fa466400cdaa_D20210101-20210930" decimals="-5" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183OS9mcmFnOjRlODJmYzU4OGU5ZTQ1OWY4NThhZGYzYjAwN2ZhNjIxL3RhYmxlOjJjYTIxZTlmZWFjNzRmMWQ4ZDQ2MjEzMGY2NThlYTdkL3RhYmxlcmFuZ2U6MmNhMjFlOWZlYWM3NGYxZDhkNDYyMTMwZjY1OGVhN2RfNy03LTEtMS0xNTk1NDA_06289573-41b0-4298-95dc-9abd1048b93c">34.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#8211;net, (income) expense</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19fc0325c48543008ea71e1fdcf11d86_D20220701-20220930" decimals="-5" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183OS9mcmFnOjRlODJmYzU4OGU5ZTQ1OWY4NThhZGYzYjAwN2ZhNjIxL3RhYmxlOjJjYTIxZTlmZWFjNzRmMWQ4ZDQ2MjEzMGY2NThlYTdkL3RhYmxlcmFuZ2U6MmNhMjFlOWZlYWM3NGYxZDhkNDYyMTMwZjY1OGVhN2RfOC0xLTEtMS0xNTk1NDA_f98b9603-2aa7-4cc7-9928-490f2e31db3b">111.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4fa4f6b472a4f269297591b44aba572_D20210701-20210930" decimals="-5" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183OS9mcmFnOjRlODJmYzU4OGU5ZTQ1OWY4NThhZGYzYjAwN2ZhNjIxL3RhYmxlOjJjYTIxZTlmZWFjNzRmMWQ4ZDQ2MjEzMGY2NThlYTdkL3RhYmxlcmFuZ2U6MmNhMjFlOWZlYWM3NGYxZDhkNDYyMTMwZjY1OGVhN2RfOC0zLTEtMS0xNTk1NDA_08fb8c9e-ea3f-490c-ae48-abadbe691982">635.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930" decimals="-5" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183OS9mcmFnOjRlODJmYzU4OGU5ZTQ1OWY4NThhZGYzYjAwN2ZhNjIxL3RhYmxlOjJjYTIxZTlmZWFjNzRmMWQ4ZDQ2MjEzMGY2NThlYTdkL3RhYmxlcmFuZ2U6MmNhMjFlOWZlYWM3NGYxZDhkNDYyMTMwZjY1OGVhN2RfOC01LTEtMS0xNTk1NDA_56cd7490-bc22-41e8-8cc1-e23a9679190e">580.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i167ed8f67bef48c49e54fa466400cdaa_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183OS9mcmFnOjRlODJmYzU4OGU5ZTQ1OWY4NThhZGYzYjAwN2ZhNjIxL3RhYmxlOjJjYTIxZTlmZWFjNzRmMWQ4ZDQ2MjEzMGY2NThlYTdkL3RhYmxlcmFuZ2U6MmNhMjFlOWZlYWM3NGYxZDhkNDYyMTMwZjY1OGVhN2RfOC03LTEtMS0xNTk1NDA_dcd3636f-bd7d-474a-92e7-b4e1736f410b">124.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><div id="i5fed483d9c7e4f3cbba3a62c53226cd7_82"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Item&#160;2. Management's Discussion and Analysis of Results of Operations and Financial Condition</span></div><div id="i5fed483d9c7e4f3cbba3a62c53226cd7_85"></div><div><span><br/></span></div><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Results of Operations</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Tables present dollars in millions, except per-share data)</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management's discussion and analysis of results of operations and financial condition is intended to assist the reader in understanding and assessing significant changes and trends related to the results of operations and financial position of our consolidated company. This discussion and analysis should be read in conjunction with the consolidated condensed financial statements and accompanying footnotes in Part I, Item 1 of this Quarterly Report on Form 10-Q. Certain statements in this Part I, Item 2 of this Quarterly Report on Form 10-Q constitute forward-looking statements. Various risks and uncertainties, including those discussed in "Forward-Looking Statements" in this Quarterly Report on Form 10-Q and "Risk Factors" in Part I, Item 1A of our Annual Report on </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000059478/000005947822000068/lly-20211231.htm">Form 10-K</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the year ended December&#160;31, 2021, may cause our actual results, financial position, and cash generated from operations to differ materially from these forward-looking statements.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Executive Overview</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This section provides an overview of our financial results, recent product and late-stage pipeline developments, and other matters affecting our company and the pharmaceutical industry. Earnings per share (EPS) data are presented on a diluted basis.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COVID-19 Pandemic</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In response to the COVID-19 pandemic, we have focused on maintaining a supply of our medicines; reducing the strain on the medical system; developing treatments for COVID-19; protecting the health, safety, and well-being of our employees; supporting our communities; and ensuring affordability of and access to our medicines, particularly insulin. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have received various regulatory authorizations, including Emergency Use Authorizations (EUA), for our COVID-19 therapies. We supplied the United States (U.S.) government approximately 810,000 doses of bebtelovimab during the nine months ended September 30, 2022. Beginning in the third quarter of 2022 and in collaboration with the U.S. government, we have made bebtelovimab commercially available for purchase by U.S. states/territories, hospitals, and certain other providers. We do not anticipate any further U.S. government orders. The U.S. Food and Drug Administration (FDA) has revised, and may in the future revise, any EUA for our COVID-19 therapies in response to the prevalence of variants against which our therapies have varying degrees of efficacy, including the new BQ variants. Based on early data, we do not believe that bebtelovimab will neutralize against the new BQ variants. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic has, and may continue to, adversely impact our business and operations. Strain on global transportation, logistics, manufacturing, and labor markets, including as aggravated by the pandemic and global unrest, the focus of resources on COVID-19, protective measures implemented to control the spread of COVID-19, and an increase in overall demand in our industry for certain resources and medicines, resulting in changed buying patterns, increased costs, and constrained supply, have negatively impacted and may continue to negatively impact the development, manufacturing, supply, distribution, and sales of our medicines. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The degree to which the COVID-19 pandemic and related challenges impact the development, manufacturing, supply, distribution, and sale of our medicines will depend on developments that are highly uncertain and beyond our knowledge or control. </span></div><div style="margin-top:6pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product Supply </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Continued strong demand for Trulicity</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in U.S. and international markets, partially due to the ongoing limited availability of competitor therapies, has challenged, and is expected to continue to challenge, our ability to meet demand in most international markets. In the U.S., as demand for Trulicity has continued to exceed historical levels, we anticipate tight supplies will persist until additional manufacturing capacity is operationalized, and U.S. wholesalers may experience intermittent restocking delays of Trulicity orders. Outside the U.S., we have implemented certain actions to minimize the impact to existing patients, but we expect to experience intermittent disruptions in our supply of Trulicity in international markets. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the uptake of Mounjaro</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for type 2 diabetes following its launch in the U.S. has been very strong. We continue to carefully monitor demand, incretin competitor availability, and supply with a focus on access for Type 2 diabetes patients.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We anticipate that additional internal and contracted manufacturing capacity will become fully operational around the world in the next several years, with significant expansion in 2023, as part of our ongoing efforts to meet the significant demand for our incretin medicines.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See "Risk Factors" in Part I, Item 1A of our Annual Report on </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000059478/000005947822000068/lly-20211231.htm">Form 10-K</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the year ended December&#160;31, 2021 for additional information on risk factors that could impact our business and operations.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Results</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our key operating results:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:33.357%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.923%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.923%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.791%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.923%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.923%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.795%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended <br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percent Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percent Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,941.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,772.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">21,239.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,318.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross margin</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,362.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,342.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">16,157.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,055.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross margin as a percent of revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">77.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">76.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,802.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,705.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,194.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,032.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketing, selling, and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,614.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,577.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,797.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,839.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired in-process research and development (IPR&amp;D) and development milestones</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">62.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(65)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">668.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">532.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset impairment, restructuring, and other special charges</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">206.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NM</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">206.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#8211;net, (income) expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">111.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">635.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(83)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">580.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NM</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,451.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,110.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,307.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,855.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EPS - diluted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.61</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4.76</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13</span></td></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">NM - not meaningful</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue increased for the three and nine months ended September&#160;30, 2022, driven by increased volume, partially offset by lower realized prices and the unfavorable impact of foreign exchange rates. Research and development expenses increased for the three and nine months ended September&#160;30, 2022, primarily driven by higher development expenses for late-stage assets, partially offset by lower development expenses for COVID-19 antibodies and the favorable impact of foreign exchange rates. Marketing, selling, and administrative expenses increased for the three months ended September&#160;30, 2022, primarily driven by increased costs associated with the launch of Mounjaro, partially offset by the favorable impact of foreign exchange rates. Marketing, selling, and administrative expenses decreased for the nine months ended September&#160;30, 2022, primarily driven by the favorable impact of foreign exchange rates as well as reduced marketing costs in the first half of 2022, partially offset by increased costs associated with the launch of Mounjaro. </span></div><div style="margin-top:6pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following highlighted items also affect comparisons of our financial results for the three and nine months ended September&#160;30, 2022 and 2021:</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022 </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquired IPR&amp;D and Development Milestones (See Note 3 to the consolidated condensed financial statements)</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We recognized $62.4 million and $668.4 million of acquired IPR&amp;D and development milestones for the three and nine months ended September&#160;30, 2022, respectively. The charges for the nine months ended September&#160;30, 2022 included the buy-out of substantially all future obligations that were contingent upon the occurrence of certain events linked to the success of our mutant-selective PI3k&#945; inhibitor and a purchase of a Priority Review Voucher. </span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Asset Impairment, Restructuring, and Other Special Charges (See Note 5 to the consolidated condensed financial statements)</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We recognized charges of $206.5 million for the three and nine months ended September&#160;30, 2022, primarily related to an intangible asset impairment for GBA1 Gene Therapy (PR001) due to changes in estimated launch timing.</span></div><div style="margin-top:6pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other-Net, (Income) Expense (See Note 11 to the consolidated condensed financial statements)</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We recognized $123.3 million and $667.6 million of net investment losses on equity securities for the three and nine months ended September&#160;30, 2022, respectively. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021 </span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of Sales (See Note 5 to the consolidated condensed financial statements)</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We recognized a net inventory impairment charge related to our COVID-19 antibodies of $435.1 million for the nine months ended September&#160;30, 2021. As part of our response to the COVID-19 pandemic, and at the request of the U.S. and international governments, we invested in large-scale manufacturing of COVID-19 antibodies at risk, in order to ensure rapid access to patients around the world. As the COVID-19 pandemic evolved during 2021, we incurred a net inventory impairment charge primarily due to the combination of changes to demand from U.S. and international governments, including changes to our agreement with the U.S. government, and near-term expiry dates of COVID-19 antibodies. </span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquired IPR&amp;D and Development Milestones (See Note 3 to the consolidated condensed financial statements)</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We recognized $177.6 million and $532.4 million of acquired IPR&amp;D and development milestones for the three and nine months ended September&#160;30, 2021, respectively. The charges for the nine months ended September&#160;30, 2021 included acquired IPR&amp;D charges resulting from business development transactions with Rigel Pharmaceuticals, Inc. (Rigel) and Precision Biosciences, Inc. (Precision).</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Asset Impairment, Restructuring, and Other Special Charges (See Note 5 to the consolidated condensed financial statements)</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We recognized charges of $211.6 million for the nine months ended September&#160;30, 2021, primarily related to an intangible asset impairment resulting from the sale of the rights to Qbrexza</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, as well as acquisition and integration costs associated with the acquisition of Prevail Therapeutics Inc. (Prevail). </span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other-Net, (Income) Expense (See Note 11 to the consolidated condensed financial statements)</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We recognized a debt extinguishment loss of $405.2 million related to the repurchase of debt for the three and nine months ended September&#160;30, 2021.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We recognized $246.8 million of net investment losses on equity securities for the three months ended September&#160;30, 2021. We recognized $270.1 million of net investment gains on equity securities for the nine months ended September&#160;30, 2021. </span></div><div style="margin-top:6pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Late-Stage Pipeline</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our long-term success depends on our ability to continually discover or acquire, develop, and commercialize innovative new medicines. We currently have approximately 45 new medicine candidates in clinical development or under regulatory review, and a larger number of projects in the discovery phase.</span></div><div style="margin-bottom:8pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following certain new molecular entities (NMEs) are currently in Phase II or Phase III clinical trials or have been submitted for regulatory review or have received regulatory approval in the U.S., Europe, or Japan. The following table reflects the status of these NMEs, including certain other developments since our Annual Report on </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000059478/000005947822000068/lly-20211231.htm">Form 10-K</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the year ended December&#160;31, 2021. </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.373%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.539%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Compound</span></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Indication</span></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Status </span></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Developments</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="12" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Diabetes</span></td><td colspan="3" style="display:none"></td></tr><tr style="height:35pt"><td colspan="3" rowspan="5" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tirzepatide (Mounjaro)</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Type 2 diabetes</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Approved</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Approved in the U.S. in the second quarter of 2022 and in Europe and Japan in the third quarter of 2022.</span></td><td colspan="3" style="display:none"></td></tr><tr style="height:35pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Heart failure with preserved ejection fraction</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase III</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase III trials are ongoing.</span></td><td colspan="3" style="display:none"></td></tr><tr style="height:45pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Obesity</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase III</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted FDA Fast Track designation</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> in October 2022. Announced in the second quarter of 2022 that the initial Phase III trial met co-primary and all key secondary endpoints. Phase III trials are ongoing.</span></div></td><td colspan="3" style="display:none"></td></tr><tr style="height:24pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Obstructive sleep apnea</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase III</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase III trial initiated in the third quarter of 2022.</span></td><td colspan="3" style="display:none"></td></tr><tr style="height:24pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonalcoholic steatohepatitis </span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II trial is ongoing. </span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basal Insulin-Fc</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Type 1 and 2 diabetes</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase III</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase III trials initiated in the first, second, and third quarters of 2022. </span></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" rowspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Orforglipron (GLP-1R NPA)</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Obesity</span></td><td colspan="3" rowspan="2" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II</span></td><td colspan="3" rowspan="2" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II trials are ongoing.</span></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Type 2 diabetes</span></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" rowspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retatrutide (GGG Tri-Agonist)</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Obesity</span></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II</span></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II trials are ongoing. </span></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Type 2 diabetes</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="12" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Immunology</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Lebrikizumab</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Atopic dermatitis</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Submitted</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted FDA Fast Track designation</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Submitted in the U.S. in the third quarter of 2022 and in Europe in October 2022. Phase III trials are ongoing. </span></div></td><td colspan="3" style="display:none"></td></tr><tr style="height:24pt"><td colspan="3" rowspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mirikizumab</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ulcerative colitis</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Submitted</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Submitted in the U.S. in first quarter of 2022 and in Europe and Japan in the second quarter of 2022.</span></div></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Crohn's Disease</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase III</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase III trials are ongoing. </span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ANGPTL3 siRNA</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardiovascular disease</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II trial initiated in the third quarter of 2022.</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BTLA MAB Agonist</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Systemic lupus erythematosus</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II trial initiated in the second quarter of 2022.</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CXCR1/2 Ligands Monoclonal Antibody</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hidradenitis suppurativa</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II trial is ongoing.</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Peresolimab (PD-1 MAB Agonist)</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Rheumatoid arthritis</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Phase II</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Phase II trial is ongoing.</span></td><td colspan="3" style="display:none"></td></tr><tr style="height:24pt"><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rezpegaldesleukin (IL-2 Conjugate)</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Systemic lupus erythematosus</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Phase II trial is ongoing.</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.373%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.539%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Compound</span></td><td colspan="3" style="background-color:#d8d8d8;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Indication</span></td><td colspan="3" style="background-color:#d8d8d8;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Status </span></td><td colspan="3" style="background-color:#d8d8d8;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Developments</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="12" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Neuroscience</span></td><td colspan="3" style="display:none"></td></tr><tr style="height:54pt"><td colspan="3" rowspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Donanemab</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Early Alzheimer's disease</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Submitted</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted FDA Breakthrough Therapy designation</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Submitted in the U.S. in the second quarter of 2022. Received Priority Review designation under the accelerated approval pathway. Phase III trials are ongoing.</span></div></td><td colspan="3" style="display:none"></td></tr><tr style="height:24pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preclinical Alzheimer's disease</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase III</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase III trial is ongoing.</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remternetug</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Early Alzheimer's disease</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase III</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase III trial initiated in the third quarter of 2022.</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Solanezumab</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preclinical Alzheimer's disease</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase III</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase III trial is ongoing. </span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GBA1 Gene Therapy (PR001)</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Parkinson's disease </span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted FDA Fast Track designation</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Phase II trial is ongoing. </span></div></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GRN Gene Therapy (PR006)</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Frontotemporal dementia</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted FDA Fast Track designation</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Phase II trial is ongoing. </span></div></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">O-GlcNAcase Inh</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alzheimer's disease</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II trial is ongoing.</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SSTR4 Agonist</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pain</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II trials are ongoing.</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TRPA1 Antagonist</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pain</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II trials are ongoing.</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PACAP38 Antibody</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Migraine</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In the third quarter of 2022 based on the results of the Phase II trial, we discontinued development.</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="12" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Oncology</span></td><td colspan="3" style="display:none"></td></tr><tr style="height:65pt"><td colspan="3" rowspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selpercatinib (Retevmo</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">)</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lung cancer</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Approved</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase III trials are ongoing. In the third quarter of 2022, the FDA granted accelerated approval in tumor-agnostic RET fusion-positive advanced or metastatic solid tumors and traditional approval in locally advanced or metastatic RET fusion-positive non-small cell lung cancer.</span></div></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thyroid cancer</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Approved</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase III trial is ongoing.</span></td><td colspan="3" style="display:none"></td></tr><tr style="height:45pt"><td colspan="3" rowspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pirtobrutinib (LOXO-305)</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mantle cell lymphoma</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Submitted</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Submitted in the U.S. in second quarter of 2022. Received Priority Review designation under the accelerated approval pathway. Phase III trial is ongoing.</span></div></td><td colspan="3" style="display:none"></td></tr><tr style="height:24pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chronic lymphocytic leukemia</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase III</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase III trials are ongoing.</span></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">B-cell malignancies</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II trial is ongoing.</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Imlunestrant</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ER+HER2- metastatic breast cancer</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase III</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase III trial is ongoing.</span></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Fast Track designation is designed to facilitate the development and expedite the review of medicines to treat serious conditions and fill an unmet medical need.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In collaboration with Almirall, S.A. in Europe. </span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Breakthrough Therapy designation is designed to expedite the development and review of potential medicines that are intended to treat a serious condition where preliminary clinical evidence indicates that the treatment may demonstrate substantial improvement over available therapy on a clinically significant endpoint. </span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Continued approval may be contingent on verification and description of clinical benefit in confirmatory Phase III trials.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our pipeline also contains several new indication line extension (NILEX) products. The following certain NILEX products for use in the indication described are currently in Phase II or Phase III clinical trials or have been submitted for regulatory review or have received regulatory approval in the U.S., Europe, or Japan. The following table reflects the status of these NILEX products, including certain other developments since our Annual Report on </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000059478/000005947822000068/lly-20211231.htm">Form 10-K</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the year ended December&#160;31, 2021. </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.373%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.539%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Compound</span></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:1pt solid #000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Indication</span></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:1pt solid #000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Status</span></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Developments</span></td></tr><tr><td colspan="12" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Diabetes</span></td></tr><tr style="height:35pt"><td colspan="3" rowspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Empagliflozin (Jardiance</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Heart failure with preserved ejection fraction</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Approved</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Approved in the U.S. and Europe in the first quarter of 2022 and in Japan in the second quarter of 2022.</span></div></td></tr><tr style="height:45pt"><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chronic kidney disease</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase III</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted FDA Fast Track designation</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. In the first quarter of 2022 the Independent Data Monitoring Committee recommended stopping the Phase III trial early due to clear positive efficacy.</span></div></td></tr><tr><td colspan="12" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Immunology</span></td></tr><tr style="height:24pt"><td colspan="3" rowspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Baricitinib (Olumiant</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">)</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alopecia areata</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Approved</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Approved in the U.S., Europe, and Japan in the second quarter of 2022. </span></div></td></tr><tr style="height:15pt"><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">COVID-19</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Approved</span></div></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Approved in the U.S. in the second quarter of 2022.</span></td></tr><tr><td colspan="12" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Oncology</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Abemaciclib (Verzenio</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">)</span></div></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Prostate cancer</span></div></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Phase III</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase III trials are ongoing.</span></div></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In collaboration with Boehringer Ingelheim. </span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Fast Track designation is designed to facilitate the development and expedite the review of medicines to treat serious conditions and fill an unmet medical need.</span></div><div style="margin-top:15pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Matters</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Patent Matters</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We depend on patents or other forms of intellectual property protection for most of our revenue, cash flows, and earnings. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the June 2021 loss of patent exclusivity for Alimta</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Europe and Japan, we faced, and expect to continue to face, generic competition that has rapidly and severely eroded revenue, and we expect will continue to erode revenue from current levels. In addition, as a result of the entry of multiple generics in the U.S. following the loss of patent and pediatric exclusivity in May 2022, we began facing, and expect to continue to face, additional generic competition that has eroded revenue, and we expect will continue to rapidly and severely erode revenue from current levels. This decline in revenue has had and will have a material adverse effect on our consolidated results of operations and cash flows. See Note 9 to the consolidated condensed financial statements for a description of legal proceedings currently pending regarding certain of our patents.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our compound patents for Humalog</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (insulin lispro) have expired in the U.S. and major international markets, and we have also introduced lower-priced versions of Humalog as part of our insulin affordability solutions. A competitor has a similar version of insulin lispro in the U.S. and in certain European markets. Due to the impact of competition and pricing pressure in the U.S. and some international markets, we expect that lower revenue due to realized price decline will continue over time.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our formulation and use patents for Forteo</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> have expired in major markets. We expect further decline in revenue as a result of the entry of generic and biosimilar competition due to the loss of patent exclusivity in major markets. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Foreign Currency Exchange Rates</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a global company, we face foreign currency risk exposure from fluctuating currency exchange rates, primarily the U.S. dollar against the euro, Japanese yen, and Chinese yuan. While we seek to manage a portion of these exposures through hedging and other risk management techniques, significant fluctuations in currency rates can have a material impact, either positive or negative, on our consolidated results of operations in any given period. During the three and nine months ended September&#160;30, 2022, revenue was unfavorably impacted by 4 percent and 3 percent, respectively, due to foreign exchange rates. While there is uncertainty in the future movements in foreign exchange rates, fluctuations in these rates have, and we currently expect in the near-term future will, adversely impact our consolidated results of operations and cash flows.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Trends Affecting Pharmaceutical Pricing, Reimbursement, and Access </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Global concern over access to and affordability of pharmaceutical products continues to drive regulatory and legislative debate and action, as well as worldwide cost containment efforts by governmental authorities. Such measures include the use of mandated discounts, price reporting requirements, mandated reference prices, restrictive formularies, changes to available intellectual property protections, as well as other efforts. In August 2022, the U.S. government enacted the Inflation Reduction Act (IRA). Among other measures, the IRA will allow the U.S. Department of Health and Human Services to effectively set prices for certain single-source drugs and biologics reimbursed under Medicare Part B and Part D. Generally, these government prices apply nine (medicines approved under a New Drug Application) or thirteen (medicines approved under a Biologics License Application) years following initial FDA approval and will be capped at a statutory ceiling price that is likely to represent a significant discount from average prices to wholesalers and direct purchasers. It is too soon to tell how the U.S. government will set these prices as the law specifies a ceiling price, but not a minimum or floor price. One or more significant Lilly products may be selected, which would have the effect of accelerating revenue erosion prior to patent expiry. The effect of reducing prices and reimbursement for certain of our products could significantly impact our business and consolidated results of operations.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other of the IRA&#8217;s provisions provide for penalties on drug manufacturers that increase prices of certain Medicare Part B and Part D medicines at a rate greater than the rate of inflation and replace the Part D coverage gap discount program with a new manufacturer discounting program. Manufacturers that fail to comply with the IRA may be subject to various penalties, including civil monetary penalties. The IRA takes effect progressively starting in 2023, with the first government set prices effective in 2026. The IRA may meaningfully influence our and pharmaceutical industry business strategies. In particular it may reduce the attractiveness of investment in small molecule innovation. Provisions of the IRA may be subject to legal challenges or other reformation, and the full effect of the IRA on our business and the pharmaceutical industry remains uncertain. Additional policies, regulations, legislation, or enforcement, including those proposed and/or pursued by the U.S. Congress and executive branch of the U.S. administration and other regulatory authorities worldwide, could adversely impact our business and consolidated results of operations. </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidation of private payors in the U.S. has also significantly impacted the market for pharmaceuticals by increasing payor leverage in negotiating manufacturer price concessions and pharmacy reimbursement rates. Furthermore, restrictive or unfavorable pricing, coverage, or reimbursement determinations for our medicines or product candidates by governments, regulatory agencies, courts, or private payers, such as the Centers for Medicare &amp; Medicaid Services' National Coverage Determination for monoclonal antibodies for the treatment of Alzheimer's Disease, may adversely impact our business and consolidated results of operations. We expect that these actions may intensify and could particularly affect certain products, such as insulin, as governments manage and emerge from the COVID-19 pandemic, which could adversely affect our business. In addition, we are engaged in litigation and investigations related to our 340B program and access to insulin that, if resolved adversely to us, could negatively impact our business and consolidated results of operations. It is not currently possible to predict the overall potential adverse impact to us or the general pharmaceutical industry of continued cost containment efforts worldwide. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Evolving regulatory priorities have also intensified governmental scrutiny of our operations and our industry, including with respect to current Good Manufacturing Practices, quality assurance, and similar regulations, and increased focus on business combinations in our industry. Any regulatory issues concerning these matters could lead to regulatory and legal actions, product recalls and seizures, fines and penalties, interruption of production leading to product shortages, import bans or denials of import certifications, delays or denials in the approvals of new products or supplemental approvals of current products pending resolution of the issues, impediments to the completion of business combinations, and reputational harm, any of which would adversely affect our business.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See "Business - Regulations and Private Payer Actions Affecting Pharmaceutical Pricing, Reimbursement, and Access" in Part I, Item 1 and "Risk Factors" in Part I, Item 1A of our Annual Report on </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000059478/000005947822000068/lly-20211231.htm">Form 10-K</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the year ended December&#160;31, 2021. See also Note 9 to the consolidated condensed financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Tax Matters</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to income taxes and various other taxes in the U.S. and in many foreign jurisdictions; therefore, changes in both domestic and international tax laws or regulations have affected and may affect our effective tax rate, results of operations, and cash flows. In 2017, the U.S. enacted the Tax Cuts and Jobs Act (the 2017 Tax Act), which contains a provision that requires capitalization and amortization of research and development expenses for tax purposes starting in 2022. Previously, these expenses could be deducted in the year incurred. The implementation of this provision has increased, and is expected to continue to increase, our 2022 cash payments of income taxes and subsequently decrease our cash payments of income taxes moderately over the five-year amortization period. We expect the implementation of this provision to impact our 2022 cash payments of income taxes by up to $1.50 billion. For the three and nine months ended September&#160;30, 2022, the implementation of this provision favorably impacted other tax items that decreased our effective tax rate by approximately 4 percentage points. If this provision of the 2017 Tax Act is deferred or repealed by the U.S. Congress effective for 2022, we expect our effective tax rate to be approximately 13 percent to 14 percent for 2022.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. and countries around the world are actively considering and enacting tax law changes. Tax proposals have been introduced by the U.S. Congress and the U.S. administration containing significant changes, including increases to the tax rates at which both domestic and foreign income of U.S. companies would be taxed. In addition, tax authorities in the U.S. and other jurisdictions in which we do business routinely examine our tax returns and are intensifying their scrutiny and examinations of profit allocations among jurisdictions. Further, actions taken with respect to tax-related matters by associations, such as the Organisation for Economic Co-operation and Development and the European Commission, could influence tax laws in countries in which we operate. Changes to existing tax law and increased scrutiny by tax authorities in the U.S. and other jurisdictions could adversely impact our future consolidated results of operations and cash flows.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquisitions</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We opportunistically invest in external research and technologies that we believe complement and strengthen our own efforts. These investments can take many forms, including acquisitions, collaborations, investments, and licensing arrangements. We view our business development activity as a way to enhance our pipeline and strengthen our business. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 3 to the consolidated condensed financial statements for further discussion regarding our recent acquisitions.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><div id="i5fed483d9c7e4f3cbba3a62c53226cd7_88"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Revenue</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our revenue activity by region:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:26.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.508%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percent Change</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percent Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,422.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,989.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13,531.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,635.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outside U.S.</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,519.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,783.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,708.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,683.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,941.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,772.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">21,239.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,318.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></td></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Numbers may not add due to rounding.</span></div><div><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following are components of the change in revenue compared with the prior year:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:26.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.742%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.742%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.742%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.742%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.744%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022 vs. 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022 vs. 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outside U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outside U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volume</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Price</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange rates</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Percent change</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Numbers may not add due to rounding.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S. for the three and nine months ended September&#160;30, 2022, the increase in volume was primarily driven by COVID-19 antibodies, Trulicity, Verzenio, Jardiance, Taltz</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and Mounjaro, partially offset by decreased volume for Alimta, resulting from the entry of multiple generics in the second quarter of 2022, and for Olumiant, due to the decline in utilization for COVID-19 treatment. In the U.S. for the three and nine months ended September&#160;30, 2022, the decrease in realized prices was primarily driven by Humalog, due to a list price reduction of insulin lispro injection and unfavorable segment mix, and by Trulicity, due to unfavorable segment mix and higher contracted rebates. In the U.S. for the three months ended September 30, 2022, the decrease in realized prices for Trulicity was partially offset by changes to estimates for rebates and discounts.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outside the U.S. for the three and nine months ended September&#160;30, 2022, the increase in volume was primarily driven by Verzenio, Trulicity, Tyvyt</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Jardiance, and Taltz, partially offset by Alimta and Cymbalta</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> resulting from generic competition. Additionally outside the U.S. for the three and nine months ended September&#160;30, 2022, we recognized revenue related to a sales collaboration agreement for the right to sell and distribute Mounjaro in Japan. Outside the U.S. for the nine months ended September&#160;30, 2022, the increase in volume was also partially offset by decreased sales of COVID-19 antibodies and the sale of the rights to Cialis</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in China in the second quarter of 2021. Outside the U.S. for the three and nine months ended September&#160;30, 2022, the decrease in realized prices was primarily driven by the impact of government pricing in China from the National Reimbursement Drug List (NRDL) formulary for certain products, particularly Tyvyt and Verzenio, and volume-based procurement (VBP) for Humalog. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our revenue activity by product for the three months ended September&#160;30, 2022 and 2021: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:37.225%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.651%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" rowspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td></tr><tr style="height:20pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Product</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S. </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outside U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percent Change</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trulicity</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,418.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">432.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,850.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,600.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Taltz</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">493.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">186.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">679.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">593.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Verzenio</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">414.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">202.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">617.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">335.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jardiance</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">350.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">222.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">573.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">390.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Humalog</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">248.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">198.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">447.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">626.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">COVID-19 antibodies</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">386.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">386.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Humulin</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">169.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">68.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">238.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">286.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cyramza</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">87.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">144.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">232.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basaglar</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">124.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">68.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">193.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mounjaro</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">97.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">90.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">187.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NM</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Olumiant</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">22.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">160.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">182.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">406.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(55)</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forteo</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">112.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">64.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">177.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emgality</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">114.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">54.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">168.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Erbitux</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">126.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">18.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">144.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alimta</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">64.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">54.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">119.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">457.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(74)</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cialis</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">107.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">115.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Zyprexa</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">73.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">81.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tyvyt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">76.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">76.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39)</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cymbalta</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">54.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">62.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53)</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other products</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">166.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">240.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">406.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">447.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,422.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,519.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,941.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,772.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Numbers may not add due to rounding.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">NM - not meaningful</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Jardiance revenue includes Glyxambi</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Synjardy</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, and Trijardy</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> XR. </span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Humalog revenue includes insulin lispro. </span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">COVID-19 antibodies include sales for bamlanivimab administered alone, for bamlanivimab and etesevimab administered together, and for bebtelovimab and were made pursuant to EUAs or similar regulatory authorizations.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Olumiant revenue includes sales for baricitinib that were made pursuant to EUA or similar regulatory authorizations.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"> </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our revenue activity by product for the nine months ended September&#160;30, 2022 and 2021:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:37.191%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.534%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.685%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td><td colspan="3" rowspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:20pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Product</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outside U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percent Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trulicity</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,162.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,341.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,503.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,588.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">COVID-19 antibodies</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,970.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,985.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,176.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Taltz</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,212.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">561.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,774.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,565.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Verzenio</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,100.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">575.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,675.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">945.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Humalog</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">855.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">656.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,512.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,851.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jardiance</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">831.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">622.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,453.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,058.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Humulin</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">562.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">223.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">785.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">923.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cyramza</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">259.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">434.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">693.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">762.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alimta</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">490.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">200.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">691.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,626.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(58)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Olumiant</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">104.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">520.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">624.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">809.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basaglar</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">339.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">218.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">558.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">650.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cialis</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">25.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">454.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">480.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">538.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emgality</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">330.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">144.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">475.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">415.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forteo</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">261.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">191.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">453.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">617.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Erbitux</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">361.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">47.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">408.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">403.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Zyprexa</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">26.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">235.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">261.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">292.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tyvyt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">235.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">235.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">340.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cymbalta</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">25.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">194.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">219.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">484.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(55)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mounjaro</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">109.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">93.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">203.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NM</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other products</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">501.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">743.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,244.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,267.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13,531.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,708.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">21,239.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,318.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Numbers may not add due to rounding.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">NM - not meaningful</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">COVID-19 antibodies include sales for bamlanivimab administered alone, for bamlanivimab and etesevimab administered together, and for bebtelovimab and were made pursuant to EUAs or similar regulatory authorizations.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Humalog revenue includes insulin lispro. </span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Jardiance revenue includes Glyxambi,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Synjardy, and Trijardy XR. </span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Olumiant revenue includes sales for baricitinib that were made pursuant to EUA or similar regulatory authorizations.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"> </span></div><div><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue of Trulicity, a treatment for type 2 diabetes and to reduce the risk of major adverse cardiovascular events in adult patients with type 2 diabetes and established cardiovascular disease or multiple cardiovascular risk factors, increased 18 percent in the U.S. during the three months ended September&#160;30, 2022, driven by increased demand, partially offset by lower realized prices. The lower realized prices in the U.S. for the three months ended September&#160;30, 2022 were due to unfavorable segment mix and higher contracted rebates, partially offset by changes to estimates for rebates and discounts. Revenue in the U.S. increased 20 percent during the nine months ended September&#160;30, 2022, driven by increased demand, partially offset by lower realized prices due to unfavorable segment mix and higher contracted rebates. Revenue outside the U.S. increased 8 percent and 19 percent during the three and nine months ended September&#160;30, 2022, respectively, driven by increased demand, partially offset by the unfavorable impact of foreign exchange rates and, to a lesser extent, lower realized prices.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue of COVID-19 antibodies, treatments for mild to moderate COVID-19 for higher-risk patients and for post-exposure prophylaxis in certain individuals for the prevention of SARS-CoV-2 infection, was $386.6&#160;million and $1.97&#160;billion in the U.S. during the three and nine months ended September&#160;30, 2022, respectively. Revenue outside the U.S. was not material during the three and nine months ended September&#160;30, 2022. The availability of superior or competitive therapies, including therapies that can be administered more easily, or preventative measures, such as vaccines, coupled with the unpredictable nature of pandemics, have and could further negatively impact or eliminate demand for these COVID-19 antibodies. The FDA has revised, and may in the future revise, any EUA for our COVID-19 antibodies in response to the prevalence of variants against which our antibodies have varying degrees of efficacy, including the new BQ variants. Based on early data, we do not believe that bebtelovimab will neutralize against the new BQ variants. We supplied the U.S. government approximately 810,000 doses of bebtelovimab during the nine months ended September 30, 2022. Beginning in the third quarter of 2022 and in collaboration with the U.S. government, we have made bebtelovimab commercially available for purchase by U.S. states/territories, hospitals, and certain other providers. We do not anticipate any further U.S. government orders. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue of Taltz, a treatment for moderate-to-severe plaque psoriasis, active psoriatic arthritis, ankylosing spondylitis, and active non-radiographic axial spondyloarthritis, increased 17 percent and 13 percent in the U.S. during the three and nine months ended September&#160;30, 2022, respectively, driven by increased demand, partially offset by lower realized prices. Revenue outside the U.S. increased 9 percent and 14 percent during the three and nine months ended September&#160;30, 2022, respectively, driven by increased volume, partially offset by unfavorable impact of foreign exchange rates and lower realized prices.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue of Verzenio, a treatment for HR+, HER2- metastatic breast cancer and high risk early breast cancer, increased $215.1&#160;million and $518.4&#160;million in the U.S. during the three and nine months ended September&#160;30, 2022, respectively, primarily driven by increased demand. Revenue outside the U.S. increased 49 percent and 58 percent during the three and nine months ended September&#160;30, 2022, respectively, driven by increased demand, partially offset by lower realized prices due to the impact of the NRDL formulary in China and the unfavorable impact of foreign exchange rates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue of Humalog, an injectable human insulin analog for the treatment of diabetes, decreased 29 percent and 15 percent in the U.S. during the three and nine months ended September&#160;30, 2022, respectively, driven by lower realized prices due to a list price reduction of insulin lispro injection and unfavorable segment mix. Revenue outside the U.S. decreased 29 percent and 22 percent during the three and nine months ended September&#160;30, 2022, respectively, driven by lower realized prices due to the impact of VBP in China and the unfavorable impact of foreign exchange rates. Due to the impact of competition and pricing pressure in the U.S. and some international markets, we expect that lower revenue due to realized price decline will continue over time. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue of Jardiance, a treatment for type 2 diabetes, to reduce the risk of cardiovascular death in adult patients with type 2 diabetes and established cardiovascular disease, and to reduce the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure, regardless of left ventricular ejection fraction, increased 59 percent and 47 percent in the U.S. during the three and nine months ended September&#160;30, 2022, respectively, primarily driven by increased demand. The increase in revenue in the U.S. during the three months ended September&#160;30, 2022 was also driven by changes to estimates for rebates and discounts. Revenue outside the U.S. increased 31 percent and 26 percent during the three and nine months ended September&#160;30, 2022, respectively, primarily driven by increased demand, partially offset by the unfavorable impact of foreign exchange rates. See Note 4 to the consolidated condensed financial statements for information regarding our collaboration with Boehringer Ingelheim involving Jardiance.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue of Alimta, a treatment for various cancers, decreased 78 percent and 46 percent in the U.S. during the three and nine months ended September&#160;30, 2022, respectively, primarily driven by decreased demand due to the entry of multiple generics in the second quarter of 2022. Revenue outside the U.S. decreased 66 percent and 72 percent during the three and nine months ended September&#160;30, 2022, respectively, largely driven by decreased demand due to generic competition. Following the June 2021 loss of patent exclusivity for Alimta in Europe and Japan, we faced, and expect to continue to face, generic competition that has rapidly and severely eroded revenue, and we expect will continue to erode revenue from current levels. In addition, as a result of the entry of multiple generics in the U.S. following the loss of patent and pediatric exclusivity in May 2022, we began facing, and expect to continue to face, additional generic competition that has eroded revenue, and we expect will continue to rapidly and severely erode revenue from current levels. See "Executive Overview - Other Matters- Patent Matters" for additional information.</span></div><div style="margin-top:6pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><div id="i5fed483d9c7e4f3cbba3a62c53226cd7_94"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Gross Margin, Costs, and Expenses</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross margin as a percent of revenue decreased 1.6 percentage points to 77.3 percent and increased 2.0 percentage points to 76.1 percent for the three and nine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">months ended September&#160;30, 2022, respectively. The decrease in the gross margin percent for the three months ended September&#160;30, 2022 was primarily driven by a benefit in the gross margin for the three months ended September&#160;30, 2021 due to the partial reversal of inventory impairment charges related to our COVID-19 antibodies that were recognized in the first and second quarters of 2021. The partial reversal of inventory impairment charges related to our COVID-19 antibodies was driven by an unexpected increase in our COVID-19 antibodies sales as the COVID-19 pandemic evolved during the third quarter of 2021. The increase in gross margin percent for the nine months ended September&#160;30, 2022 was primarily driven by a net inventory impairment charge related to our COVID-19 antibodies recognized in 2021. Additionally, for the three and nine months ended September&#160;30, 2022, lower realized prices and increased expenses due to inflation and logistics costs were offset by favorable product mix, including the impact of lower sales of Olumiant for the treatment of COVID-19, and the favorable impact of foreign exchange rates. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses increased 6 percent to $1.80 billion and 3 percent to $5.19 billion for the three and nine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">months ended September&#160;30, 2022, respectively, primarily driven by higher development expenses for late-stage assets, partially offset by lower development expenses for COVID-19 antibodies and the favorable impact of foreign exchange rates. </span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketing, selling, and administrative expenses </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">increased</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2 percent to $1.61 billion for the three months ended September&#160;30, 2022, primarily driven by increased costs associated with the launch of Mounjaro, partially offset by the favorable impact of foreign exchange rates. </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketing, selling, and administrative expenses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> decreased 1 percent to $4.80 billion for the nine months ended September&#160;30, 2022, primarily driven by the favorable impact of foreign exchange rates as well as reduced marketing costs in the first half of 2022, partially offset by increased costs associated with the launch of Mounjaro. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We plan to take compensatory actions to improve retention and address wage inflation which will impact our costs and consolidated results of operations. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized $62.4 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$668.4 million of acquired IPR&amp;D and development milestones for the three and nine months ended September&#160;30, 2022, respectively. The charges for the nine months ended September&#160;30, 2022 included the buy-out of substantially all future obligations that were contingent upon the occurrence of certain events linked to the success of our mutant-selective PI3k&#945; inhibitor and a purchase of a Priority Review Voucher. We recognized $177.6 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$532.4 million of acquired IPR&amp;D and development milestones for the three and nine months ended September&#160;30, 2021, respectively. The charges for the nine months ended September&#160;30, 2021 included acquired IPR&amp;D charges from business development transactions with Rigel and Precision. See Note 3 to the consolidated condensed financial statements for additional information.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized asset impairment, restructuring, and other special charges of $206.5 million for the three and nine months ended September&#160;30, 2022, primarily related to an intangible asset impairment for GBA1 Gene Therapy (PR001) due to changes in estimated launch timing. There were no asset impairment, restructuring, and other special charges recognized for the three months ended September&#160;30, 2021. We recognized asset impairment, restructuring, and other special charges of $211.6 million for the nine months ended September&#160;30, 2021, primarily related to an intangible asset impairment resulting from the sale of the rights to Qbrexza, as well as acquisition and integration costs associated with the acquisition of Prevail. See Note 5 to the consolidated condensed financial statements for additional information.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other&#8211;net, (income) expense was expense of $111.0 million and $580.9 million for the three and nine months ended September&#160;30, 2022, respectively, compared with expense of $635.9 million and $124.3 million for the three and nine months ended September&#160;30, 2021, respectively. The decrease in other expense for the three months ended September&#160;30, 2022 was primarily driven by a debt extinguishment loss of $405.2 million related to the repurchase of debt in 2021, as well as lower net investment losses on equity securities in 2022 compared to 2021. The increase in other expense for the nine months ended September&#160;30, 2022 was primarily driven by net investment losses on equity securities in 2022 compared with net investment gains on equity securities in 2021, partially offset by a debt extinguishment loss of $405.2 million related to the repurchase of debt in 2021.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective tax rates were 7.3 percent and 8.6 percent for the three and nine months ended September&#160;30, 2022, respectively, reflecting the favorable tax impact of the implementation of a provision in the 2017 Tax Act that requires capitalization and amortization of research and development expenses for tax purposes starting in 2022, net investment losses on equity securities, and an intangible asset impairment charge. We expect our effective tax rate to be approximately 13 percent to 14 percent for 2022 if the capitalization and amortization of research and development expenses provision of the 2017 Tax Act is deferred or repealed by the U.S. Congress effective for 2022.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective tax rate was 10.9 percent for the three months ended September&#160;30, 2021, reflecting the favorable tax impact of a debt extinguishment loss and of net investment losses on equity securities, partially offset by a net discrete tax detriment. The effective tax rate was 10.7 percent for the nine months ended September&#160;30, 2021, reflecting the favorable tax impact of a net discrete tax benefit, a debt extinguishment loss, and a net inventory impairment charge related to our COVID-19 antibodies. </span></div><div style="margin-top:6pt"><span><br/></span></div><div id="i5fed483d9c7e4f3cbba3a62c53226cd7_100"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Financial Condition and Liquidity</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe our available cash and cash equivalents, together with our ability to generate operating cash flow and our access to short-term and long-term borrowings, are sufficient to fund our existing and planned capital requirements. For a discussion of our capital requirements, see "Management's Discussion and Analysis of Results of Operations and Financial Condition" in Part II, Item 7 of our Annual Report on </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000059478/000005947822000068/lly-20211231.htm">Form 10-K</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the year ended December&#160;31, 2021.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We plan to invest more than $2 billion over several years in two new facilities in Lebanon, Indiana to manufacture existing and future products and more than $1 billion over several years in a new facility in Concord, North Carolina to manufacture parenteral (injectable) products and devices. We plan to invest more than 400 million euro over several years in a new facility in Limerick, Ireland to expand our manufacturing network for biologic active ingredients. These investments, and other capital investments that support our operations, will result in capital expenditures being higher than recent historical levels for the next several years.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents decreased to $2.62 billion as of September&#160;30, 2022, compared with $3.82 billion as of December&#160;31, 2021. Refer to the consolidated condensed statements of cash flows for additional information on the significant sources and uses of cash for the nine months ended September&#160;30, 2022 and 2021. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to our cash and cash equivalents, we held total investments of $2.70 billion and $3.30 billion as of September&#160;30, 2022 and December&#160;31, 2021, respectively. See Note 6 to the consolidated condensed financial statements for additional information. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2022, total debt was $15.89 billion, a decrease of $996.3 million compared with $16.88&#160;billion as of December&#160;31, 2021. See Note 6 to the consolidated condensed financial statements for additional information. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2022, we had a total of $7.26 billion of unused committed bank credit facilities, $7.00 billion of which is available to support our commercial paper program. We believe that amounts accessible through existing commercial paper markets should be adequate to fund short-term borrowing needs. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September&#160;30, 2022, we repurchased $1.50 billion of shares under our $5.00&#160;billion share repurchase program authorized in May 2021. As of September&#160;30, 2022, we had $3.25 billion remaining under this program. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September&#160;30, 2022, we paid dividends of $2.65&#160;billion, or $2.94 per share, to our shareholders. In October 2022, we declared a dividend for the fourth quarter of 2022 of $0.98 per share on outstanding common stock. The dividend of approximately $882 million is payable on December 9, 2022 to shareholders of record at the close of business on November 15, 2022.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See "Executive Overview - Other Matters - Patent Matters" for information regarding recent losses of patent protection.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Both domestically and abroad, we continue to monitor the potential impacts of the economic environment; the creditworthiness of our wholesalers and other customers, including foreign government-backed agencies and suppliers; the uncertain impact of health care legislation; various international government funding levels; and fluctuations in interest rates, foreign currency exchange rates (see "Executive Overview - Other Matters - Foreign Currency Exchange Rates"), and fair values of equity securities.</span></div><div style="margin-top:6pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><div id="i5fed483d9c7e4f3cbba3a62c53226cd7_103"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Critical Accounting Estimates</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a discussion of our critical accounting estimates, refer to "Management's Discussion and Analysis of Results of Operations and Financial Condition" in Part II, Item 7 and the notes to our consolidated financial statements in Part II, Item 8 of our Annual Report on </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000059478/000005947822000068/lly-20211231.htm">Form 10-K</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the year ended December&#160;31, 2021. See also Note 1 to the consolidated condensed financial statements. There have been no material changes to our critical accounting estimates since our Annual Report on </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000059478/000005947822000068/lly-20211231.htm">Form 10-K</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the year ended December&#160;31, 2021. </span></div><div style="margin-bottom:12pt;margin-top:6pt"><span><br/></span></div><div id="i5fed483d9c7e4f3cbba3a62c53226cd7_106"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Available Information on our Website</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We make available through our company website, free of charge, our company filings with the Securities and Exchange Commission (SEC) as soon as reasonably practicable after we electronically file them with, or furnish them to, the SEC. The reports we make available include annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, proxy statements, registration statements, and any amendments to those documents.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The website link to our SEC filings is </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">investor.lilly.com/financial-information/sec-filings</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We routinely post important information for investors in the &#8220;Investors&#8221; section of our website, www.lilly.com. We may use our website as a means of disclosing material, non-public information and for complying with our disclosure obligations under Regulation FD. Accordingly, investors should monitor the &#8220;Investors&#8221; section of our website, in addition to following our press releases, filings with the SEC, public conference calls, presentations, and webcasts. We may also use social media channels to communicate with investors and the public about our business, products and other matters, and those communications could be deemed to be material information. The information contained on, or that may be accessed through, our website or social media channels, is not incorporated by reference into, and is not a part of, this Quarterly Report on Form 10-Q.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><div id="i5fed483d9c7e4f3cbba3a62c53226cd7_109"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Item&#160;4. Controls and Procedures</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:23.78pt">Evaluation of Disclosure Controls and Procedures</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Under applicable Securities and Exchange Commission (SEC) regulations, management of a reporting company, with the participation of the principal executive officer and principal financial officer, must periodically evaluate the company's "disclosure controls and procedures," which are defined generally as controls and other procedures of a reporting company designed to ensure that information required to be disclosed by the reporting company in its periodic reports filed with the SEC (such as this Quarterly Report on Form&#160;10-Q) is recorded, processed, summarized, and reported on a timely basis.</span></div><div style="margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, with the participation of David A. Ricks, president and chief executive officer, and Anat Ashkenazi, executive vice president and chief financial officer, evaluated our disclosure controls and procedures (as such terms are defined in our Annual Report on </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000059478/000005947822000068/lly-20211231.htm">Form 10-K</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the year ended December&#160;31, 2021) as of September&#160;30, 2022, and concluded that they were effective.</span></div><div style="margin-bottom:12pt;margin-top:6pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:23.78pt">Changes in Internal Controls</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. During the third quarter of 2022, there were no changes in our internal control over financial reporting that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><div id="i5fed483d9c7e4f3cbba3a62c53226cd7_112"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:16pt;font-weight:400;line-height:120%;text-decoration:underline">PART II. Other Information</span></div><div id="i5fed483d9c7e4f3cbba3a62c53226cd7_115"></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Item&#160;1. Legal Proceedings</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a party to various currently pending legal actions, government investigations, and environmental proceedings. See Note 9 to the consolidated condensed financial statements for information on various legal proceedings. </span></div><div style="margin-bottom:9pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Item should be read in conjunction with "Legal Proceedings" in Part I, Item 3 of our Annual Report on </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000059478/000005947822000068/lly-20211231.htm">Form 10-K</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the year ended December&#160;31, 2021.</span></div><div style="margin-bottom:9pt;margin-top:6pt"><span><br/></span></div><div id="i5fed483d9c7e4f3cbba3a62c53226cd7_118"></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Item&#160;1A. Risk Factors</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our material risk factors are disclosed in "Risk Factors" in Part I, Item 1A of our Annual Report on </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000059478/000005947822000068/lly-20211231.htm">Form 10-K</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the year ended December&#160;31, 2021. There have been no material changes from the risk factors previously disclosed in our Annual Report on </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000059478/000005947822000068/lly-20211231.htm">Form 10-K</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the year ended December&#160;31, 2021. </span></div><div style="margin-bottom:9pt;margin-top:6pt"><span><br/></span></div><div id="i5fed483d9c7e4f3cbba3a62c53226cd7_121"></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Item&#160;2. Unregistered Sales of Equity Securities and Use of Proceeds</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information relating to the principal market for our common stock and related shareholder matters is described in "Management's Discussion and Analysis of Results of Operations and Financial Condition" in Part II, Item 7 and in "Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters" in Part III, Item 12 of our Annual Report on </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000059478/000005947822000068/lly-20211231.htm">Form 10-K</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the year ended December&#160;31, 2021. </span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity related to repurchases of our equity securities during the three months ended September&#160;30, 2022:</span></div><div style="margin-bottom:6pt;margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:23.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.589%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.735%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.427%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.017%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Period</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Number of<br/>Shares Purchased<br/>(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Average&#160;Price Paid&#160;<br/>per Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total&#160;Number of Shares<br/>Purchased&#160;as Part of<br/>Publicly Announced<br/>Plans or Programs<br/>(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Approximate Dollar Value of Shares that May Yet Be Purchased Under the Plans or Programs <br/>(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,250.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,250.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,250.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September&#160;30, 2022, we did not repurchase any shares under our $5.00 billion share repurchase program authorized in May 2021.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><div id="i5fed483d9c7e4f3cbba3a62c53226cd7_124"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Item&#160;6. Exhibits</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following documents are filed as a part of this Quarterly Report:</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:16.323%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.145%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:77.232%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Description</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EXHIBIT 3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/59478/000005947822000138/articlesofincorporationlly.htm">Amended Articles of Incorporation are incorporated by reference to Exhibit 3.1 to the Company's Current Report on Form 8-K filed on May 4, 2022</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EXHIBIT 3.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/59478/000005947822000138/bylaws.htm">Bylaws, as amended, are incorporated by reference to Exhibit 3.2 to the Company's Current Report on Form 8-K filed on May 4, 2022</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EXHIBIT 10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="lly-093022x10qexhibit101.htm">Form of Performance Award under the 2002 Lilly Stock Plan (with non-compete)</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EXHIBIT 10.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="lly-093022x10qexhibit102.htm">Form of Shareholder Value Award under the 2002 Lilly Stock Plan (with non-compete)</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EXHIBIT 10.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="lly-093022x10qexhibit103.htm">Form of Relative Value Award under the 2002 Lilly Stock Plan (with non-compete)</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EXHIBIT&#160;31.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="lly-09302022x10qxexhibit311.htm">Rule&#160;13a-14(a) Certification of David A. Ricks, Chair, President, and Chief Executive Officer</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EXHIBIT 31.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="lly-09302022x10qxexhibit312.htm">Rule&#160;13a-14(a) Certification of Anat Ashkenazi, </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="lly-09302022x10qxexhibit312.htm">Executive</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="lly-09302022x10qxexhibit312.htm"> Vice President and Chief Financial Officer</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EXHIBIT 32.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="lly-09302022x10qxexhibit32.htm">Section 1350 Certification</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EXHIBIT 101.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interactive Data Files (embedded within the Inline XBRL document)</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EXHIBIT 104.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)</span></td></tr></table><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Indicates management contract or compensatory plan.</span></div><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term debt instruments under which the total amount of securities authorized does not exceed 10 percent of our consolidated assets are not filed as exhibits to this Quarterly Report. We will furnish a copy of these agreements to the Securities and Exchange Commission upon request.</span></div><div style="margin-top:6pt"><span><br/></span></div><div id="i5fed483d9c7e4f3cbba3a62c53226cd7_127"></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Signatures</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.747%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:74.486%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">ELI LILLY AND COMPANY</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Registrant)</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 1, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Anat Ashkenazi</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anat Ashkenazi</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President and Chief Financial Officer</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 1, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Donald A. Zakrowski</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Donald A. Zakrowski</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Vice President, Finance, and Chief Accounting Officer</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>lly-093022x10qexhibit101.htm
<DESCRIPTION>EX-10.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i373e57c4e04c430f9ea6c63f129e5150_76"></div><div style="min-height:77.76pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Exhibit 10.1 Form of Performance Award under the 2002 Lilly Stock Plan (with non-compete)</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:24pt;font-weight:400;line-height:100%">Eli Lilly and Company</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:24pt;font-weight:400;line-height:100%">Performance Award Agreement</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:18pt;font-weight:400;line-height:100%">(for Executive Officers)</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Performance Award has been granted on &#91;&#8226;&#93; (&#8220;Grant Date&#8221;) by Eli Lilly and Company, an Indiana corporation, with its principal offices in Indianapolis, Indiana (&#8220;Lilly&#8221; or the &#8220;Company&#8221;), to the Eligible Individual who has received this Performance Award Agreement (the &#8220;Grantee&#8221;).</font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-right:39.6pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:400;line-height:100%">Performance Levels&#58;</font></div><div style="padding-right:39.6pt"><font><br></font></div><div style="padding-right:39.6pt"><img alt="a101performancelevel.jpg" src="a101performancelevel.jpg" style="height:184px;margin-bottom:5pt;vertical-align:text-bottom;width:601px"></div><div style="text-indent:13.5pt"><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:400;line-height:100%">Performance Period&#58;</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:16pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:14pt;font-weight:400;line-height:100%">January 1, 2022 &#8211; December 31, 2023</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:400;line-height:100%">Service Vesting Date&#58;</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:16pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:14pt;font-weight:400;line-height:100%">February 1, 2025</font></div><div><font><br></font></div><div style="height:63.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:396pt;text-indent:36pt"><img alt="lillyfooter1.jpg" src="lillyfooter1.jpg" style="height:55px;margin-bottom:5pt;vertical-align:text-bottom;width:101px"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:77.76pt;width:100%"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Eli Lilly and Company Performance Award Agreement (Executive Officer)</font></div></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:400;line-height:100%">Table of Contents</font></div><div style="padding-right:1.8pt;text-align:right"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:93.564%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.236%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 1.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Grant of Performance Award</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 2.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Vesting</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 3.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Impact of Certain Employment Status Changes</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 4.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Change in Control</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 5.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Settlement</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 6.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Rights of the Grantee</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 7.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Prohibition Against Transfer</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 8.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Responsibility for Taxes</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 9.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 409A Compliance</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 10.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Grantee&#8217;s Acknowledgments</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 11.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Data Privacy</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 12.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Restrictive Covenants, Remedies, and Additional Terms and Conditions</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">12</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 13.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Governing Law and Choice of Venue</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">15</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 14.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Miscellaneous Provisions</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">15</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 15.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Compensation Recovery</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">16</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 16.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Award Subject to Acknowledgement of Acceptance</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">17</font></div></td></tr></table></div><div style="padding-left:76.5pt;text-indent:-64.5pt"><font><br></font></div><div style="margin-bottom:3pt;margin-top:12pt"><font><br></font></div><div style="height:63.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Page 2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:77.76pt;width:100%"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Eli Lilly and Company Performance Award Agreement (Executive Officer)</font></div></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 1.&#160;&#160;&#160;&#160;Grant of Performance Award</font></div><div style="margin-top:6pt;padding-left:22.3pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Eli Lilly and Company, an Indiana corporation (&#8220;Lilly&#8221; or the &#8220;Company&#8221;), has granted to the Eligible Individual who has received this Performance Award Agreement (the &#8220;Grantee&#8221;) a Performance-Based Award (the &#8220;Performance Award&#8221; or the &#8220;Award&#8221;) with respect to the target number of shares of Lilly Common Stock (the &#8220;Shares&#8221;) that the Grantee may view by logging on to the Merrill Lynch website at </font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">http&#58;&#47;&#47;myequity.lilly.com</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (the &#34;Target Number of Shares&#34;).   </font></div><div style="margin-top:6pt;padding-left:22.3pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Award is made pursuant to and subject to the terms and conditions set forth in the Amended and Restated 2002 Lilly Stock Plan (the &#8220;Plan&#8221;) and to the terms and conditions set forth in this Performance Award Agreement, including all appendices, exhibits and addenda hereto (the &#8220;Award Agreement&#8221;).  In the event of any conflict between the terms of the Plan and this Award Agreement, the terms of the Plan shall govern except with respect to the provisions described in Section 12 below (in which case, the terms of the Award Agreement shall govern). </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Any capitalized terms used but not defined in this Award Agreement shall have the meanings set forth in the Plan.  </font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 2.&#160;&#160;&#160;&#160;Vesting</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">As soon as reasonably practicable following the end of the Performance Period, the Committee shall determine the number of units eligible to vest (&#8220;Performance Units&#8221;) based on the actual cumulative Earnings Per Share (&#34;EPS&#34;) for the Performance Period and using the Non-GAAP EPS (as adjusted to the extent determined by the Committee) for the year immediately prior to the commencement of the Performance Period as a reference point (as shown on page 1 of this document) (&#8220;EPS Growth&#8221;), the corresponding payout multiple and the Target Number of Shares.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.&#160;&#160;&#160;&#160;The actual cumulative EPS for the Performance Period shall be computed using the following procedures&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">i.&#160;&#160;&#160;&#160;A determination of adjusted consolidated net income ascertained from the Company's audited consolidated financial statements shall be made for each fiscal year in the Performance Period in accordance with accounting principles currently applicable in the United States (&#34;US GAAP&#34;), adjusted to the extent deemed appropriate by the Committee for any unusual items deemed significant by the Committee.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ii.&#160;&#160;&#160;&#160;The number of shares of outstanding Lilly Common Stock used to compute consolidated EPS shall be determined as of the end of each fiscal year in the Performance Period on a diluted basis or its equivalent in accordance with US GAAP.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">iii.&#160;&#160;&#160;&#160;To calculate consolidated EPS for each fiscal year in the Performance Period, the adjusted consolidated net income shall be divided by the number of shares of outstanding Lilly Common Stock as computed in accordance with subsection (ii) above and the quotient rounded to the nearest cent.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">iv.&#160;&#160;&#160;&#160;To determine the cumulative EPS for the Performance Period, the EPS amounts for each fiscal year as determined above shall be added.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.&#160;&#160;&#160;&#160;The payout multiple corresponding to the EPS Growth (as shown on page 1 of this document) shall then be applied to the Target Number of Shares.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">c.&#160;&#160;&#160;&#160;The number of Performance Units under this Performance Award will be the number resulting from the calculation described in subsection (b) above. </font></div><div style="height:63.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Page 3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:77.76pt;width:100%"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Eli Lilly and Company Performance Award Agreement (Executive Officer)</font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">d.&#160;&#160;&#160;&#160;In the event the Grantee&#8217;s Service is terminated prior to the Service Vesting Date for any reason or in any circumstance other than as described in Section 3 below, the Award, including any accrued Dividend Equivalent Rights, shall be forfeited.  </font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 3.&#160;&#160;&#160;&#160;Impact of Certain Employment Status Changes </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Unless the Committee determines, in its sole discretion, that such treatment is not advisable after consideration of Applicable Laws, the number of Shares that are eligible to vest upon a change in employment status of the Grantee during the Performance Period will be as follows&#58; </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Leaves of Absence</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In the event the Grantee is on an approved leave of absence during the Performance Period, the number of Shares eligible to vest shall be the number determined in accordance with Section 2 above.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Retirement&#59; Death&#59; Disability</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Except as otherwise provided below (including Section 12), in the event the Grantee&#8217;s Service is terminated (i) on or following the Retirement Vesting Date (A) due to the Grantee&#8217;s Retirement or (B) due to the Grantee&#8217;s Qualifying Termination (as defined below) on a date that the Grantee is eligible for Retirement, (ii) due to the Grantee&#8217;s death, or (iii) by reason of Grantee&#8217;s Disability, the number of Shares eligible to vest shall be the number determined in accordance with Section 2 above.  For the avoidance of any doubt, the Award shall be forfeited in the event the Grantee&#8217;s Service is terminated prior to the Retirement Vesting Date due to the Grantee&#8217;s Retirement.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;Retirement&#8221; means retirement as a &#8220;retiree,&#8221; which is a person who is (A) a retired employee under The Lilly Retirement Plan&#59; (B) a retired employee under the retirement plan or program of an Affiliate&#59; (C) a retired employee under a retirement program specifically approved by the Committee&#59; (D) required to retire under local law, to the extent authorized by the Company to address such local requirements or (E) otherwise determined to be a retired employee in the sole discretion of the Company.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;Retirement Vesting Date&#8221; means the date that is on or following December 31 immediately following the commencement of the Performance Period.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;Disability&#8221; for purposes of this Award Agreement means that the Grantee would qualify to receive benefit payments under the long-term disability plan or policy, as it may be amended from time to time, of the Company or the Affiliate that employs the Grantee (the &#8220;Employer&#8221;).  If the Company or the Employer does not have a long-term disability plan or policy, &#8220;Disability&#8221; means that the Grantee is unable to carry out the responsibilities and functions of the position held by the Grantee by reason of any medically determined physical or mental impairment for a period of at least ninety (90) consecutive days as determined by the Company or Employer.  The Grantee shall not be considered to have incurred a Disability unless he or she furnishes proof of such impairment sufficient to satisfy the Company as it determines in its sole discretion.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">c.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Qualifying Termination</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Except as otherwise provided in section 3(b), in the event the Grantee&#8217;s employment is subject to a Qualifying Termination (as defined below), the Performance Units shall vest, provided that if the Qualifying Termination occurs prior to the last day of the Performance Period, the number of Shares eligible to vest shall be the number determined in accordance with Section 2 above, reduced proportionally for the portion of the total days during the Performance Period in which the Grantee was not in active Service.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">For purposes of this Award Agreement, a &#8220;Qualifying Termination&#8221; means the termination of the Grantee's Service under any one of the following circumstances&#58;</font></div><div style="height:63.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Page 4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:77.76pt;width:100%"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Eli Lilly and Company Performance Award Agreement (Executive Officer)</font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">i.&#160;&#160;&#160;&#160;due to a plant closing or reduction in workforce (as defined below)&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ii.&#160;&#160;&#160;&#160;as a result of the Grantee&#8217;s failure to locate a position within the Company or an Affiliate following the placement of the Grantee on reallocation or medical reassignment in the United States (or equivalent as determined by the Committee).</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;Plant closing&#8221; means the closing of a plant site or other corporate location that directly results in termination of the Grantee&#8217;s Service. </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;Reduction in workforce&#8221; means the elimination of a work group, functional or business unit or other broadly applicable reduction in job positions that directly results in termination of the Grantee&#8217;s Service.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">d.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Post-Performance Period Retirement.</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Notwithstanding Section 3(b), in the event the Grantee's Service is terminated due to Retirement subsequent to the last day of the Performance Period but prior to the Service Vesting Date, the Performance Units, if any, shall continue to accrue Dividend Equivalent Rights and the Performance Units and Dividend Equivalent Rights shall vest on the Service Vesting Date.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A Grantee who has not received a year-end individual performance rating and (i) is on final written warning (or equivalent as determined by the Committee) for unsatisfactory performance and elects to retire in lieu of a termination of employment&#59; or (ii) elects to retire in lieu of termination of employment because of an immediately terminable offense (e.g., absence of three days without notice, insubordination, violation of substance abuse policy, possession of firearms, misconduct) will not be considered to have terminated due to Retirement as described herein.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">e.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Demotions, Disciplinary Actions and Misconduct</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Company may, in its sole discretion, cancel this Performance Award or reduce the number of Performance Units, prorated according to time or other measure as determined appropriate by the Company, if during any period prior to the Service Vesting Date the Grantee has been (i)&#160;subject to disciplinary action by the Company or (ii) determined to have committed a material violation of law or Company policy or to have failed to properly manage or monitor the conduct of an employee who has committed a material violation of law or Company policy whereby, in either case, such conduct causes significant harm to the Company, as determined in the sole discretion of the Company.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">f.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Final Written Warning</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If the Grantee is placed on final written warning (or its equivalent as determined by the Committee) at any time subsequent to the last day of the Performance Period but prior to the Service Vesting Date, the Grantee shall forfeit the Performance Units and Dividend Equivalent Rights scheduled to vest on the Service Vesting Date to the extent the Award is the next subsequent Award (when compared to other Awards held by the Grantee) that is scheduled to vest following the date that the Grantee is placed on final written warning (it being understood that all other Awards, if any, that are scheduled to vest on the Service Vesting Date shall also be forfeited).</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Committee&#8217;s determination as to whether (1) a leave of absence or a transfer of employment between Lilly and an Affiliate or between Affiliates constitutes a termination of Service, (2) the Grantee&#8217;s Service has been terminated by reason of Disability or Retirement, (3) the Grantee is eligible for Retirement, (4) the Grantee&#8217;s Service has been terminated as a direct result of either a plant closing or a reduction in force, and (5) the Grantee's service has been terminated as a result of the failure to locate a position within the Company or an Affiliate following reallocation or medical reassignment shall be final and binding on the Grantee.  </font></div><div style="height:63.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Page 5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:77.76pt;width:100%"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Eli Lilly and Company Performance Award Agreement (Executive Officer)</font></div></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 4.&#160;&#160;&#160;&#160;Change in Control</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:115%">The provisions of Section 13.2 of the Plan apply to this Award with the following modifications&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.&#160;&#160;&#160;&#160;The only Change in Control event that shall result in a benefit under this Section 4 shall be the consummation of a merger, share exchange, or consolidation of the Company, as defined in Section 2.6(c) of the Plan (a &#8220;Transaction&#8221;).</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.&#160;&#160;&#160;&#160;In the event of a Transaction that occurs prior to the last day of the Performance Period, the Grantee will be credited with an award of Restricted Stock Units equal to the number of Performance Units, to be calculated in a manner consistent with Section 2, but the cumulative EPS shall equal the Company&#8217;s cumulative EPS expected results (as determined by the Company&#8217;s last approved forecast prior to the consummation of the Transaction, not considering the impact of the Transaction) (the &#8220;Credited RSU Award&#8221;).  The Credited RSU Award shall be eligible to vest on the last day of the Performance Period, subject to the Grantee&#8217;s continued Service through the last day of the Performance Period, except as provided below&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">i.&#160;&#160;&#160;&#160;In the event that the Credited RSU Award is not converted, assumed, substituted, continued or replaced by a successor or surviving corporation, or a parent or subsidiary thereof, in connection with a Transaction, then immediately prior to the Transaction, the Credited RSU Award shall vest automatically in full.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-9pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ii.&#160;&#160;&#160;&#160;In the event that the Credited RSU Award is converted, assumed, substituted, continued or replaced by a successor or surviving corporation, or a parent or subsidiary thereof, in connection with the Transaction and the Grantee is subject to a Covered Termination (as defined below) prior to the last day of the Performance Period, then immediately as of the date of the Covered Termination, the Credited RSU Award shall vest automatically in full. </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">For purposes of this Award Agreement, &#8220;Covered Termination&#8221; shall mean a termination of Service as described in Sections 3(b) and (c), Grantee&#8217;s termination of Service without Cause or the Grantee&#8217;s resignation for Good Reason.  &#8220;Cause&#8221; and &#8220;Good Reason&#8221; shall have the meanings ascribed to them in the Eli Lilly and Company 2007 Change in Control Severance Pay Plan for Select Employees (as amended from time to time) or any successor plan or arrangement thereto.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">c.&#160;&#160;&#160;&#160;The following shall apply in the event of a Transaction that occurs subsequent to the last day of the Performance Period but prior to the Service Vesting Date&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">i.&#160;&#160;&#160;&#160;In the event that the Performance Units are not converted, assumed, substituted, continued or replaced by a successor or surviving corporation, or a parent or subsidiary thereof, in connection with a Transaction, then immediately prior to the Transaction, the Performance Units shall vest automatically in full.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-9pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ii.&#160;&#160;&#160;&#160;In the event that the Performance Units are converted, assumed, substituted, continued or replaced by a successor or surviving corporation, or a parent or subsidiary thereof, in connection with the Transaction and the Grantee is subject to a Covered Termination prior to the Service Vesting Date, then immediately as of the date of the Covered Termination, the Performance Units shall vest automatically in full.</font></div><div style="height:63.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Page 6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:77.76pt;width:100%"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Eli Lilly and Company Performance Award Agreement (Executive Officer)</font></div></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 5.&#160;&#160;&#160;&#160;Settlement  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.&#160;&#160;&#160;&#160;Except as provided below, a vested Award shall be paid to the Grantee as soon as practicable, but in no event later than sixty (60) days following the Service Vesting Date, including if the Award vests pursuant to Sections 3(b) or 3(c). </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.&#160;&#160;&#160;&#160;If the Award vests pursuant to Section 3(b)(ii) or (iii) subsequent to the last day of the Performance Period, the Award shall be paid to the Grantee no later than sixty (60) days following the date of the Grantee&#8217;s termination of Service under Section 3(b)(ii) or (iii), provided that if the Award is considered an item of nonqualified deferred compensation subject to Section 409A of the Code (&#8220;NQ Deferred Compensation&#8221;), the Award shall be paid within sixty (60) days following the date the Grantee experiences a &#8220;separation from service&#8221; within the meaning of Section 409A of the Code (a &#8220;409A Separation&#8221;), provided that if the Grantee is a &#8220;specified employee&#8221; within the meaning of Section 409A of the Code as of the payment date, the Award shall instead be paid on the earliest of (i) the first day following the six (6) month anniversary of the Grantee&#8217;s Section 409A Separation and (ii) the date of the Grantee&#8217;s death, as applicable.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">c.&#160;&#160;&#160;&#160;If the Award vests pursuant to Section 4(b)(i) or Section 4(c)(i), the Award shall be paid to the Grantee immediately prior to the Transaction, provided that if the Award is considered NQ Deferred Compensation and the Transaction does not constitute a &#8220;change in control event&#8221; under Section 409A of the Code (a &#8220;409A CIC&#8221;), then the Award shall be paid in cash (calculated based on the value of the Shares established for the consideration to be paid to holders of Shares in the Transaction) on the Service Vesting Date.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">d.&#160;&#160;&#160;&#160;If the Award vests pursuant to Section 4(b)(ii) or Section 4(c)(ii), the Award shall be paid to the Grantee as soon as practicable, but in no event later than sixty (60) days following the date the Grantee is subject to a Covered Termination, provided that if the Award is NQ Deferred Compensation, (i) the Award shall be paid within sixty (60) days following the date the Grantee experiences a 409A Separation, and (ii)&#160;if the Grantee is a &#8220;specified employee&#8221; within the meaning of Section 409A of the Code as of the payment date, the Award shall instead be paid on the earliest of (1) the first day following the six (6) month anniversary of the Grantee&#8217;s Section 409A Separation and (2) the date of the Grantee&#8217;s death.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">e.&#160;&#160;&#160;&#160;At the time of settlement provided in this Section 5, Lilly shall issue or transfer Shares or the cash equivalent, as contemplated under Section 5(f) below, to the Grantee.  In the event the Grantee is entitled to a fractional Share, the fraction may be paid in cash or rounded, in the Committee&#8217;s discretion.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">f.&#160;&#160;&#160;&#160;At any time prior to the Service Vesting Date or until the Performance Units are paid in accordance with this Section 5, the Committee may, if it so elects, determine to pay part or all of the Performance Units in cash in lieu of issuing or transferring Shares.  The amount of cash shall be calculated based on the Fair Market Value of the Shares on the last day of the Restriction Period in the case of payment pursuant to Section 5(a) and on the date of payment in the case of a payment pursuant to Section 5(d).</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">g.&#160;&#160;&#160;&#160;Dividend Equivalent Rights, if any, that accrue hereunder shall be settled in cash.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">h.&#160;&#160;&#160;&#160;In the event of the death of the Grantee, the payments described above shall be made to the successor of the Grantee.</font></div><div style="height:63.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Page 7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:77.76pt;width:100%"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Eli Lilly and Company Performance Award Agreement (Executive Officer)</font></div></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 6.&#160;&#160;&#160;&#160;Rights of the Grantee</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">No Shareholder Rights</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Performance Award does not entitle the Grantee to any rights of a shareholder of Lilly until such time as the Performance Award is settled and Shares are issued or transferred to the Grantee.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Dividend Equivalent Rights</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  On each date that the Company pays a cash dividend to holders of Shares during the period commencing on the date the number of Performance Units are determined continuing through the date the Performance Units are settled, the Grantee shall be credited with Dividend Equivalent Rights in an amount equal to the total number of Performance Units, multiplied by the dollar amount of the cash dividend paid per Share by the Company on such date.  Dividend Equivalent Rights shall accrue in an account denominated in U.S. dollars and shall not accrue interest or other credits prior to being paid.  The Dividend Equivalent Rights shall be subject to the same vesting conditions and restrictions as the Performance Units to which the Dividend Equivalent Rights relate, and the Dividend Equivalent Rights shall be forfeited in the event that the Performance Units with respect to which such Dividend Equivalent Rights were credited are forfeited.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">c.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">No Trust&#59; Grantee&#8217;s Rights Unsecured.</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Neither this Award Agreement nor any action in accordance with this Award Agreement shall be construed to create a trust of any kind.  The right of the Grantee to receive payments of cash or Shares pursuant to this Award Agreement shall be an unsecured claim against the general assets of the Company.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 7.&#160;&#160;&#160;&#160;Prohibition Against Transfer</font></div><div style="margin-top:6pt;padding-left:22.3pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The right of a Grantee to receive payments of Shares and&#47;or cash under this Award may not be transferred except to a duly appointed guardian of the estate of the Grantee or to a successor of the Grantee by will or the applicable laws of descent and distribution and then only subject to the provisions of this Award Agreement.  A Grantee may not assign, sell, pledge, or otherwise transfer Shares or cash to which he or she may be entitled hereunder prior to transfer or payment thereof to the Grantee, and any such attempted assignment, sale, pledge or transfer shall be void.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 8.&#160;&#160;&#160;&#160;Responsibility for Taxes</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.&#160;&#160;&#160;&#160;Regardless of any action Lilly and&#47;or the Employer takes with respect to any or all income tax (including federal, state, local and non-U.S. tax), social insurance, payroll tax, fringe benefits tax, payment on account or other tax related items related to the Grantee&#8217;s participation in the Plan and legally applicable to the Grantee (&#8220;Tax Related Items&#8221;), the Grantee acknowledges that the ultimate liability for all Tax Related Items is and remains the Grantee&#8217;s responsibility and may exceed the amount actually withheld by Lilly or the Employer.  The Grantee further acknowledges that Lilly and the Employer (i)&#160;make no representations or undertakings regarding the treatment of any Tax Related Items in connection with any aspect of the Award, including the grant of the Performance Award, the vesting of the Performance Award, the transfer and issuance of any Shares, the receipt of any cash payment pursuant to the Award, the accrual and payment of Dividend Equivalent Rights, the receipt of any dividends and the sale of any Shares acquired pursuant to this Award&#59; and (ii)&#160;do not commit to and are under no obligation to structure the terms of the grant or any aspect of the Award to reduce or eliminate the Grantee&#8217;s liability for Tax Related Items or achieve any particular tax result.  Furthermore, if the Grantee becomes subject to Tax Related Items in more than one jurisdiction, the Grantee acknowledges that the Company and&#47;or the Employer (or </font></div><div style="height:63.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Page 8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:77.76pt;width:100%"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Eli Lilly and Company Performance Award Agreement (Executive Officer)</font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">former employer, as applicable) may be required to withhold or account for Tax Related Items in more than one jurisdiction.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.&#160;&#160;&#160;&#160;Prior to the applicable taxable or tax withholding event, as applicable, the Grantee shall pay or make adequate arrangements satisfactory to Lilly and&#47;or the Employer to satisfy all Tax Related Items.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">i.&#160;&#160;&#160;&#160;If the Performance Award is paid to the Grantee in cash in lieu of Shares, the Grantee authorizes the Company and&#47;or the Employer, or their respective agents, at their discretion, to satisfy any obligation for Tax Related Items by withholding from the cash amount paid to the Grantee pursuant to the Award or from the Grantee&#8217;s wages or other cash compensation paid to the Grantee by the Company and&#47;or the Employer.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ii.&#160;&#160;&#160;&#160;If the Performance Award is paid to the Grantee in Shares and the Grantee is not subject to the short-swing profit rules of Section 16(b) of the Exchange Act, the Grantee authorizes Lilly and&#47;or the Employer, or their respective agents, at their discretion, to (A) withhold from the Grantee&#8217;s wages or other cash compensation paid to the Grantee by the Company and&#47;or the Employer, (B) arrange for the sale of Shares to be issued upon settlement of the Award (on the Grantee&#8217;s behalf and at the Grantee&#8217;s direction pursuant to this authorization or such other authorization as the Grantee may be required to provide to Lilly or its designated broker in order for such sale to be effectuated) and withhold from the proceeds of such sale, (C)&#160;withhold in Shares otherwise issuable to the Grantee pursuant to this Award, and&#47;or (D) apply any other method of withholding determined by the Company and, to the extent required by Applicable Laws or the Plan, approved by the Committee.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">iii.&#160;&#160;&#160;&#160;If the Performance Award is paid to the Grantee in Shares and the Grantee is subject to the short-swing profit rules of Section 16(b) of the Exchange Act, Lilly will withhold in Shares otherwise issuable to the Grantee pursuant to this Award, unless the use of such withholding method is prevented by Applicable Laws or has materially adverse accounting or tax consequences, in which case the withholding obligation for Tax Related Items may be satisfied by one or a combination of the methods set forth in Section 8(b)(ii)(A) and (B) above.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">c.&#160;&#160;&#160;&#160;Depending on the withholding method, Lilly and&#47;or the Employer may withhold or account for Tax Related Items by considering applicable statutory or other withholding rates, including minimum or maximum rates in the jurisdiction(s) applicable to the Grantee.  In the event of over-withholding, the Grantee may receive a refund of any over-withheld amount in cash (without interest and without entitlement to the equivalent amount in Shares).  If the obligation for Tax Related Items is satisfied by withholding Shares, for tax purposes, the Grantee will be deemed to have been issued the full number of Shares to which he or she is entitled pursuant to this Award, notwithstanding that a number of Shares are withheld to satisfy the obligation for Tax Related Items.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">d.&#160;&#160;&#160;&#160;Lilly may refuse to deliver Shares or any cash payment to the Grantee if the Grantee fails to comply with the Grantee&#8217;s obligation in connection with the Tax Related Items as described in this Section 8. </font></div><div style="text-align:justify"><font><br></font></div><div style="height:63.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Page 9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:77.76pt;width:100%"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Eli Lilly and Company Performance Award Agreement (Executive Officer)</font></div></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 9.&#160;&#160;&#160;&#160;Section 409A Compliance</font></div><div style="padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">To the extent applicable, it is intended that this Award comply with the requirements of Section 409A of the U.S. Internal Revenue Code of 1986, as amended and the Treasury Regulations and other guidance issued thereunder (&#8220;Section 409A&#8221;) and this Award shall be interpreted and applied by the Committee in a manner consistent with this intent in order to avoid the imposition of any additional tax under Section 409A.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 10.&#160;&#160;&#160;&#160;Grantee&#8217;s Acknowledgments</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In accepting this Award, the Grantee acknowledges, understands and agrees that&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.&#160;&#160;&#160;&#160;the Plan is established voluntarily by Lilly, it is discretionary in nature and it may be modified, amended, suspended or terminated by Lilly at any time, as provided in the Plan&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.&#160;&#160;&#160;&#160;the Award is voluntary and occasional and does not create any contractual or other right to receive future Performance-Based Awards, or benefits in lieu thereof, even if Performance-Based Awards have been granted in the past&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">c.&#160;&#160;&#160;&#160;all decisions with respect to future Performance-Based Awards or other awards, if any, will be at the sole discretion of the Committee&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">d.&#160;&#160;&#160;&#160;the Grantee&#8217;s participation in the Plan is voluntary&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">e.&#160;&#160;&#160;&#160;the Award and any Shares subject to the Award are not intended to replace any pension rights or compensation&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">f.&#160;&#160;&#160;&#160;the Award and any Shares subject to the Award, and the income and value of same, are not part of normal or expected compensation for any purpose, including but not limited to, calculating any severance, resignation, termination, redundancy, dismissal, end of service payments, bonuses, long-service awards, holiday pay, leave pay, pension or welfare or retirement benefits or similar mandatory payments&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">g.&#160;&#160;&#160;&#160;neither the Award nor any provision of this Award Agreement, the Plan or the policies adopted pursuant to the Plan, confer upon the Grantee any right with respect to employment or continuation of current employment, and in the event that the Grantee is not an employee of Lilly or any subsidiary of Lilly, the Award shall not be interpreted to form an employment contract or relationship with Lilly or any Affiliate&#59; </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">h.&#160;&#160;&#160;&#160;the future value of the underlying Shares is unknown, indeterminable and cannot be predicted with certainty&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">i.&#160;&#160;&#160;&#160;no claim or entitlement to compensation or damages shall arise from forfeiture of the Award resulting from the Grantee ceasing to provide employment or other services to Lilly or the Employer (for any reason whatsoever, whether or not later found to be invalid or in breach of local labor laws in the jurisdiction where the Grantee is employed or the terms of Grantee&#8217;s employment agreement, if any)&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">j.&#160;&#160;&#160;&#160;for purposes of the Award, the Grantee&#8217;s employment will be considered terminated as of the date he or she is no longer actively providing services to the Company or an Affiliate and the Grantee&#8217;s right, if any, to earn and be paid any portion of the Award and any Dividend Equivalent Rights after such termination of employment&#160;or services (regardless of the reason for such termination&#160;and whether or not such termination is later found to be invalid or in breach of employment laws in the jurisdiction where the Grantee is employed or the terms of the Grantee&#8217;s employment agreement, if any)&#160;will be measured by the date the Grantee ceases to&#160;actively&#160;provide services and will not be extended by any notice period (e.g., active&#160;service would not include any contractual notice period or any&#160;period of </font></div><div style="height:63.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Page 10</font></div></div></div><hr style="page-break-after:always"><div style="min-height:77.76pt;width:100%"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Eli Lilly and Company Performance Award Agreement (Executive Officer)</font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;garden leave&#8221; or similar period&#160;mandated under employment laws in the jurisdiction where the Grantee is employed or the terms of the Grantee&#8217;s employment agreement, if any)&#59; the Committee shall have the exclusive discretion to determine when the Grantee is no longer actively&#160;providing services&#160;for purposes of the Award (including whether the Grantee may still be considered&#160;to be actively&#160;providing services&#160;while on a leave of absence) in accordance with Section 409A&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">k.&#160;&#160;&#160;&#160;unless otherwise provided in the Plan or by the Committee in its discretion, the Award and the benefits evidenced by this Award Agreement do not create any entitlement to have the Award or any such benefits transferred to, or assumed by, another company nor to be exchanged, cashed out or substituted for, in connection with any corporate transaction affecting the Shares&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">l.&#160;&#160;&#160;&#160;the Grantee is solely responsible for investigating and complying with any laws applicable to him or her in connection with the Award&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">m.&#160;&#160;&#160;&#160;the Company has communicated share ownership guidelines that apply to the Grantee, and the Grantee understands and agrees that those guidelines may impact any shares of Lilly Stock that may be issued pursuant to this Award.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 11.&#160;&#160;&#160;&#160;Data Privacy</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">a.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">Data Collection and Usage</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">.  The Company and the Employer may collect, process and use certain personal information about the Grantee, and persons closely associated with the Grantee, including, but not limited to, the Grantee&#8217;s name, home address and telephone number, email address, date of birth, social insurance number, passport or other identification number (e.g., resident registration number), salary, nationality, job title, any shares of stock or directorships held in the Company, details of all Performance Awards or any other entitlement to shares of stock awarded, canceled, exercised, vested, unvested or outstanding in the Grantee&#8217;s favor (&#8220;Data&#8221;), for the purposes of implementing, administering and managing the Plan.  The legal basis, where required, for the processing of Data is the Grantee&#8217;s consent.  Where required under Applicable Laws, Data may also be disclosed to certain securities or other regulatory authorities where the Company&#8217;s securities are listed or traded or regulatory filings are made and the legal basis, where required, for such disclosure are the Applicable Laws.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">b.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">Stock Plan Administration Service Providers</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">.  The Company transfers Data to Bank of America Merrill Lynch and&#47;or its affiliated companies (&#8220;Merrill Lynch&#8221;), an independent service provider, which is assisting the Company with the implementation, administration and management of the Plan.  In the future, the Company may select a different service provider and share Data with such other provider serving in a similar manner.  The Grantee may be asked to agree on separate terms and data processing practices with the service provider, with such agreement being a condition to the ability to participate in the Plan.  The Company may also transfer Data to KPMG, an independent service provider, which is also assisting the Company with certain aspects of the implementation, administration and management of the Plan.  In the future, the Company may select a different service provider and share Data with such other provider serving in a similar manner.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">c.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">International Data Transfers</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">.  The Company and its service providers are based in the United States.  The Grantee&#8217;s country or jurisdiction may have different data privacy laws and protections than the United States.  The Company&#8217;s legal basis, where required, for the transfer of Data is Grantee&#8217;s consent.</font></div><div style="height:63.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Page 11</font></div></div></div><hr style="page-break-after:always"><div style="min-height:77.76pt;width:100%"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Eli Lilly and Company Performance Award Agreement (Executive Officer)</font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">d.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">Data Retention</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">.  The Company will hold and use the Data only as long as is necessary to implement, administer and manage the Grantee&#8217;s participation in the Plan, or as required to comply with legal or regulatory obligations, including under tax and security laws.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">e.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">Voluntariness and Consequences of Consent Denial or Withdrawal</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">.  Participation in the Plan is voluntary and the Grantee is providing the consents herein on a purely voluntary basis.  If the Grantee does not consent, or if the Grantee later seeks to revoke the Grantee&#8217;s consent, the Grantee&#8217;s salary from or employment and career with the Employer will not be affected&#59; the only consequence of refusing or withdrawing the Grantee&#8217;s consent is that the Company would not be able to grant this Award or other awards to the Grantee or administer or maintain such awards.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">f.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">Data Subject Rights</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">. The Grantee understands that data subject rights regarding the processing of Data vary depending on Applicable Laws and that, depending on where the Grantee is based and subject to the conditions set out in such Applicable Laws, the Grantee may have, without limitation, the right to (i) inquire whether and what kind of Data the Company holds about the Grantee and how it is processed, and to access or request copies of such Data, (ii) request the correction or supplementation of Data about the Grantee that is inaccurate, incomplete or out-of-date in light of the purposes underlying the processing, (iii) obtain the erasure of Data no longer necessary for the purposes underlying the processing, (iv) request the Company to restrict the processing of the Grantee&#8217;s Data in certain situations where the Grantee feels its processing is inappropriate, (v) object, in certain circumstances, to the processing of Data for legitimate interests, and to (vi) request portability of the Grantee&#8217;s Data that the Grantee has actively or passively provided to the Company or the Employer (which does not include data derived or inferred from the collected data), where the processing of such Data is based on consent or the Grantee&#8217;s employment and is carried out by automated means.  In case of concerns, the Grantee understands that he or she may also have the right to lodge a complaint with the competent local data protection authority.  Further, to receive clarification of, or to exercise any of, the Grantee&#8217;s rights, the Grantee understands that he or she should contact his or her local human resources representative.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">g.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">Declaration of Consent</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">.  By accepting the Award and indicating consent via the Company&#8217;s online acceptance procedure, the Grantee is declaring that he or she agrees with the data processing practices described herein and consents to the collection, processing and use of Data by the Company and the transfer of Data to the recipients mentioned above, including recipients located in countries which do not adduce an adequate level of protection from a European (or other non-U.S.) data protection law perspective, for the purposes described above.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 12.&#160;&#160;&#160;&#160;Restrictive Covenants, Remedies, and Additional Terms and Conditions</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Restrictive Covenants</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In consideration of the Grantee&#8217;s receipt of the Award from Lilly, the Grantee agrees that during the Grantee&#8217;s employment with Lilly or an Affiliate that the Grantee provided services to or had access to confidential information concerning (&#8220;Covered Affiliate&#8221;) and for twelve (12) months immediately following the end of the Grantee&#8217;s employment (regardless of reason), the Grantee will not directly or indirectly, on a worldwide basis, engage in any of the following activities&#58;</font></div><div style="margin-bottom:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">i.&#160;&#160;&#160;&#160;Work for, advise, manage, act as an agent, employee or consultant for, or otherwise provide any services, in a Competitively-Sensitive Capacity, to&#58; (a) any person or entity engaged in research, development, production, sale, or distribution of a product or service competitive with or substantially similar to any product or service in research, development or design, or </font></div><div style="height:63.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Page 12</font></div></div></div><hr style="page-break-after:always"><div style="min-height:77.76pt;width:100%"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Eli Lilly and Company Performance Award Agreement (Executive Officer)</font></div></div><div style="margin-bottom:6pt;padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">manufactured, produced, sold, or distributed by Lilly or a Covered Affiliate&#59; or (b) any person or entity that otherwise competes or intends to compete with Lilly or a Covered Affiliate.    </font></div><div style="margin-bottom:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ii.&#160;&#160;&#160;&#160;Directly or indirectly solicit, urge, divert, induce, or seek to induce any of Lilly&#8217;s (or Covered Affiliate&#8217;s) independent contractors, subcontractors, business partners, distributors, brokers, consultants, sales representatives, customers, vendors, suppliers or any other person with whom Lilly or Covered Affiliate has a business relationship and with whom the Grantee interacted during the Grantee&#8217;s employment with Lilly or Covered Affiliate to terminate their relationship with, or representation of, Lilly or Covered Affiliate or to cancel, withdraw, reduce, limit or in any manner modify any such person's business with, or representation of, Lilly or a Covered Affiliate. </font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Grantee acknowledges and agrees that any Lilly Affiliate is an intended third-party beneficiary of this Award Agreement, which may be enforced by Lilly or any such Affiliate, either singularly or jointly.</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">For purposes of this Award Agreement, &#8220;Competitively-Sensitive Capacity&#8221; means&#58; (A)&#160;the same or similar capacity or function in which the Grantee worked for Lilly or a Covered Affiliate at any time during the two (2) years immediately preceding the end of the Grantee&#8217;s employment&#59; (B)&#160;any officer, director, executive or senior management capacity or function&#59; (C)&#160;any research and development capacity or function&#59; (D)&#160;any sales management or business development management capacity or function&#59; (E)&#160;any ownership capacity (except the Grantee may own as a passive investment up to 2% of any publicly traded securities)&#59; and&#47;or (F)&#160;any other capacity or function in which there is a material risk that the Grantee likely would inevitably use or disclose trade secrets and&#47;or confidential information Lilly or a Covered Affiliate.  For purposes of clarity, if a competing business has multiple divisions, lines or segments, some of which are not competitive with the business of Lilly, including its Covered Affiliates, nothing in this Award Agreement will prohibit the Grantee from being employed by, working for or assisting only that division, line or segment of such competing business that is not competitive with the business of Lilly or a Covered Affiliate, provided the Grantee is not involved in a Competitively-Sensitive Capacity in the research, development, manufacture, provision or sale of any products that compete with any products of Lilly or a Covered Affiliate.</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Grantee and Lilly acknowledge and agree that the worldwide geographic scope of the foregoing covenants is reasonable and necessary given, among other things, that&#58; (a)&#160;absent the restrictions, the Grantee could utilize Lilly&#8217;s (or its Affiliates) trade secrets and&#47;or confidential information and compete with Lilly or Affiliate from virtually anywhere&#59; and (b)&#160;such scope is the only way for Lilly and its Affiliates to protect their trade secrets and confidential information.  In the event the Grantee violates any of the restrictive covenants contained herein, their duration will automatically be extended by the length of time during which the Grantee was in violation of any of the restrictive covenants.</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Grantee acknowledges and agrees that during the course of the Grantee&#8217;s employment with Lilly or a Covered Affiliate, the Grantee will become intimately familiar with confidential information and trade secrets key to its unique competitive advantage.  The Grantee also acknowledges and agrees that Lilly&#8217;s (and Covered Affiliate&#8217;s) confidential information and trade secrets will retain continuing vitality throughout and beyond the one-year restricted period.  And the Grantee acknowledges and agrees that, should the Grantee leave Lilly or Covered Affiliate and, near the Grantee&#8217;s departure from Lilly or Covered Affiliate, work with another person or entity that engages in business activities similar to those of Lilly and&#47;or </font></div><div style="height:63.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Page 13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:77.76pt;width:100%"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Eli Lilly and Company Performance Award Agreement (Executive Officer)</font></div></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Covered Affiliate, it would be highly likely, if not inevitable, that the Grantee would rely on confidential information of Lilly and&#47;or Covered Affiliate in the course of the Grantee&#8217;s work, either consciously or subconsciously, harming Lilly and any Covered Affiliates.  For these and other reasons, the Grantee agrees that the restrictions above are reasonably necessary to protect Lilly&#8217;s and its Covered Affiliate&#8217;s legitimate business interests, and do so by creating a specific amount of time after the Grantee&#8217;s employment ends during which the Grantee will not be able to engage or prepare to engage in the activities above.</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Grantee and Lilly further acknowledge and agree that if any particular covenant or provision is determined to be unreasonable or unenforceable for any reason, including, without limitation, the time period, geographic area, and&#47;or scope of activity covered by any restrictive covenant, such covenant or provision will automatically be deemed reformed so that the contested covenant or provision will have the closest effect permitted by applicable law to the original form and will be given effect and enforced as so reformed to whatever extent would be reasonable and enforceable under applicable law.  Any court interpreting any restrictive covenant provision of this Award Agreement will, if necessary, reform any such provision to make it enforceable under applicable law.</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Award Agreement is intended, among other things, to supplement (and not supersede) all applicable statutes protecting trade secrets and the duties the Grantee owes to Lilly and&#47;or Covered Affiliates under the common law, as well as any other non-competition, non-solicitation, or confidentiality provisions that the Grantee agreed to in the past, including those in the Grantee&#8217;s Employee Confidentiality and Invention Agreement, each of which remains in full force and effect, or that the Grantee agrees to in the future.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Grantee acknowledges that a breach by the Grantee of this Award Agreement will give rise to irreparable injury to Lilly and Covered Affiliates and money damages will not be adequate relief for such injury.  As a result, the Grantee agrees that Lilly (including any third-party beneficiary) will be entitled to obtain equitable or injunctive relief without having to post any bond or other security to restrain or prohibit any such breach or threatened breach, in addition to any other remedies which may be available, including the recovery of monetary damages from the Grantee.</font></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Remedies</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:700;line-height:100%">  </font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If the Company determines that the Grantee has violated any applicable provisions of this Section 12, in addition to injunctive relief and damages, the Grantee agrees and covenants that&#58; (i) the Award shall be immediately rescinded&#59; (ii) the Grantee shall automatically forfeit any rights the Grantee may have with respect to the Award as of the date of such determination, including the rights to continue to be eligible to vest or receive a payment under the Award&#59; and (iii) the foregoing remedies set forth in this Section 12 shall not be Lilly&#8217;s exclusive remedies.  Lilly reserves all other rights and remedies available to it at law or in equity.</font><font style="color:#c00000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In addition, the Company reserves the right to impose other requirements on the Award and any Shares acquired under the Plan, to the extent the Company determines it is necessary or advisable for legal or administrative reasons, and to require the Grantee to execute any additional agreements or undertakings that may be necessary to accomplish the foregoing.  Without limitation to the foregoing, the Grantee agrees that the Performance Award and any benefits or proceeds the Grantee may receive hereunder shall be subject to forfeiture and&#47;or repayment to the Company to the extent required to comply with any requirements imposed under Applicable Laws or any compensation recovery policy of the Company that reflects the provisions of Applicable Laws.</font></div><div style="height:63.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Page 14</font></div></div></div><hr style="page-break-after:always"><div style="min-height:77.76pt;width:100%"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Eli Lilly and Company Performance Award Agreement (Executive Officer)</font></div></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 13.&#160;&#160;&#160;&#160;Governing Law and Choice of Venue</font></div><div style="padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The validity, construction, and enforcement of this Award Agreement shall be governed by the laws of the State of Indiana, U.S.A. without regard to laws that might cause other law to govern under applicable principles of conflict of laws or cause the application of substantive law of any jurisdiction other than Indiana.  For purposes of litigating any dispute that arises under this Award Agreement, the parties hereby submit to and consent to the jurisdiction and venue of the State of Indiana, and agree that such litigation shall be conducted exclusively in the courts having appropriate subject matter jurisdiction in Marion</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">County, Indiana, or the federal courts for the United States for the Southern District of Indiana, and no other courts, where this Award is granted and&#47;or to be performed.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 14.&#160;&#160;&#160;&#160;Miscellaneous Provisions</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Notices and Electronic Delivery and Participation</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Any notice to be given by the Grantee or successor Grantee shall be in writing, and any notice shall be deemed to have been given or made only upon receipt thereof by the Corporate Secretary of Lilly at Lilly Corporate Center, Indianapolis, Indiana 46285, U.S.A.  Any notice or communication by Lilly in writing shall be deemed to have been given in the case of the Grantee if mailed or delivered to the Grantee at any address specified in writing to Lilly by the Grantee and, in the case of any successor Grantee, at the address specified in writing to Lilly by the successor Grantee.  In addition, Lilly may, in its sole discretion, decide to deliver any documents related to the Award and participation in the Plan by electronic means or request the Grantee&#8217;s consent to participate in the Plan by electronic means.  By accepting this Award, the Grantee hereby consents to receive such documents by electronic delivery and agrees to participate in the Plan through an on-line or electronic system established and maintained by Lilly or a third party designated by Lilly.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Language</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Grantee acknowledges that he or she is proficient in the English language or has consulted with an advisor who is sufficiently proficient in English, so as to allow the Grantee to understand the terms and conditions of this Award Agreement.  If the Grantee has received this Award Agreement or any other document related to the Plan translated into a language other than English and if the meaning of the translated version is different from the English version, the English version will control.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:13pt;font-weight:400;line-height:100%">c.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Waiver.</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:13pt;font-style:italic;font-weight:700;line-height:100%">  </font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The waiver by Lilly of any provision of this Award Agreement at any time or for any purpose shall not operate as or be construed to be a waiver of the same or any other provision of this Award Agreement at any subsequent time or for any other purpose.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:13pt;font-weight:400;line-height:100%">d.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Severability and Section Headings</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If one or more of the provisions of this Award Agreement shall be held invalid, illegal or unenforceable in any respect, the validity, legality and enforceability of the remaining provisions shall not in any way be affected or impaired thereby and the invalid, illegal or unenforceable provisions shall be deemed null and void&#59; however, to the extent permissible by law, any provisions which could be deemed null and void shall first be construed, interpreted or revised retroactively to permit this Award Agreement to be construed so as to foster the intent of this Award Agreement and the Plan.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The section headings in this Award Agreement are for convenience of reference only and shall not be deemed a part of, or germane to, the interpretation or construction of this instrument.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:13pt;font-weight:400;line-height:100%">e.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">No Advice Regarding Grant</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Lilly is not providing any tax, legal or financial advice, nor is Lilly making any recommendations regarding the Grantee&#8217;s participation in </font></div><div style="height:63.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Page 15</font></div></div></div><hr style="page-break-after:always"><div style="min-height:77.76pt;width:100%"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Eli Lilly and Company Performance Award Agreement (Executive Officer)</font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the Plan or the Grantee&#8217;s acquisition or sale of the underlying Shares.  The Grantee should consult with his or her own personal tax, legal and financial advisors regarding the Grantee&#8217;s participation in the Plan before taking any action related to the Plan.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 15.&#160;&#160;&#160;&#160;Compensation Recovery</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:22.3pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">At any time during the three years following the date on which the number of Performance Units subject to the Award has been determined under Section 2 above, the Company reserves the right to and, in appropriate cases, will seek restitution of all or part of any Shares that have been issued or cash that has been paid pursuant to this Award if&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.&#160;&#160;&#160;&#160;(i)&#160;&#160;&#160;&#160;the number of Shares or the amount of the cash payment was calculated based, directly or indirectly, upon the achievement of financial results that were subsequently the subject of a restatement of all or a portion of the Company&#8217;s financial statements&#59; and </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)&#160;&#160;&#160;&#160;the Grantee engaged in intentional misconduct that caused or partially caused the need for such a restatement&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii)&#160;&#160;&#160;&#160;the number of Shares or the amount of cash payment that would have been issued or paid to the Grantee had the financial results been properly reported would have been lower than the number of Shares actually issued or the amount of cash actually paid&#59; or </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.&#160;&#160;&#160;&#160;the Grantee has been determined to have committed a material violation of law or Company policy or to have failed to properly manage or monitor the conduct of an employee who has committed a material violation of law or Company policy whereby, in either case, such misconduct causes significant harm to the company.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:22.5pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Furthermore, in the event the number of Shares issued or cash paid pursuant to this Award is determined to have been based on materially inaccurate financial statements or other Company performance measures or on calculation errors (without any misconduct on the part of the Grantee), the Company reserves the right to and, in appropriate cases, will (A) seek restitution of the Shares or cash paid pursuant to this Award to the extent that the number of Shares issued or the amount paid exceeded the number of Shares that would have been issued or the amount that would have been paid had the inaccuracy or error not occurred, or (B) issue additional Shares or make additional payment to the extent that the number of Shares issued or the amount paid was less than the correct amount.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:22.5pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Section 15 is not intended to limit the Company&#8217;s power to take such action as it deems necessary to remedy any misconduct, prevent its reoccurrence and, if appropriate, based on all relevant facts and circumstances, punish the wrongdoer in a manner it deems appropriate.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:63.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Page 16</font></div></div></div><hr style="page-break-after:always"><div style="min-height:77.76pt;width:100%"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Eli Lilly and Company Performance Award Agreement (Executive Officer)</font></div></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 16.&#160;&#160;&#160;&#160;Award Subject to Acknowledgement of Acceptance</font></div><div style="margin-top:6pt;padding-left:22.3pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notwithstanding any provisions of this Award Agreement, the Award is subject to acknowledgement of acceptance by the Grantee prior to 4&#58;00 PM (EDT) &#91;&#8226;&#93;, through the website of Merrill Lynch, the Company&#8217;s stock plan administrator.  If the Grantee does not acknowledge acceptance of the Award prior to 4&#58;00 PM (EDT) &#91;&#8226;&#93;, the Award will be cancelled, subject to the Committee&#8217;s discretion for unforeseen circumstances. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">IN WITNESS WHEREOF, Lilly has caused this Award Agreement to be executed in Indianapolis, Indiana, by its proper officer.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:288pt;text-align:justify"><font><br></font></div><div style="padding-left:288pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ELI LILLY AND COMPANY</font></div><div style="padding-left:288pt;text-align:justify"><font><br></font></div><div style="padding-left:288pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:288pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58; _________________________</font></div><div style="padding-left:288pt"><font><br></font></div><div style="height:63.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Page 17</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>lly-093022x10qexhibit102.htm
<DESCRIPTION>EX-10.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i4580a532ef31450da59a11d4d2741ff5_97"></div><div style="min-height:77.76pt;width:100%"><div><font><br></font></div></div><div style="padding-right:39.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Exhibit 10.2 Form of Shareholder Value Award under the 2002 Lilly Stock Plan (with non-compete)</font></div><div style="padding-left:19.8pt;padding-right:19.8pt;text-align:center"><font><br></font></div><div style="padding-right:39.6pt"><font><br></font></div><div style="padding-right:39.6pt"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:24pt;font-weight:400;line-height:100%">Eli Lilly and Company</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:24pt;font-weight:400;line-height:100%">Shareholder Value Award Agreement</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:24pt;font-weight:400;line-height:100%">(for Executive Officers)</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Shareholder Value Award has been granted on &#91;&#8226;&#93; (&#8220;Grant Date&#8221;) by Eli Lilly and Company, an Indiana corporation, with its principal offices in Indianapolis, Indiana (&#8220;Lilly&#8221; or the &#8220;Company&#8221;), to the Eligible Individual who has received this Shareholder Value Award Agreement (the &#8220;Grantee&#8221;).</font></div><div style="padding-right:39.6pt"><font><br></font></div><div style="padding-right:39.6pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:400;line-height:100%">Lilly Stock Price Performance Levels&#58;</font></div><div style="padding-right:39.6pt"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.379%"><tr><td style="width:1.0%"></td><td style="width:14.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.809%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.627%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.720%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:700;line-height:100%">No Payout</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Level 1</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Level 2</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Level 3</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Level 4</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Level 5</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Level 6</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Final Lilly Stock Price</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#60; $246.99</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$246.99 &#8211;</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$280.85</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.65pt;padding-right:6.65pt;text-align:center"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$280.86</font></div><div style="padding-left:6.65pt;padding-right:6.65pt;text-align:center"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:11pt;font-weight:400;line-height:100%">-</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$314.71</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.65pt;padding-right:6.65pt;text-align:center"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$314.72</font></div><div style="padding-left:6.65pt;padding-right:6.65pt;text-align:center"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:11pt;font-weight:400;line-height:100%">-</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$348.58</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.65pt;padding-right:6.65pt;text-align:center"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$348.59</font></div><div style="padding-left:6.65pt;padding-right:6.65pt;text-align:center"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:11pt;font-weight:400;line-height:100%">-</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$382.45</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.65pt;padding-right:6.65pt;text-align:center"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$382.46</font></div><div style="padding-left:6.65pt;padding-right:6.65pt;text-align:center"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:11pt;font-weight:400;line-height:100%">-</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$416.32</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#62;$416.32</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Percent of Target</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:11pt;font-weight:700;line-height:100%">0%</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:11pt;font-weight:700;line-height:100%">50%</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:11pt;font-weight:700;line-height:100%">75%</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:11pt;font-weight:700;line-height:100%">100%</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:11pt;font-weight:700;line-height:100%">125%</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:11pt;font-weight:700;line-height:100%">150%</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:11pt;font-weight:700;line-height:100%">175%</font></td></tr></table></div><div style="padding-left:19.8pt;padding-right:19.8pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:400;line-height:100%">Performance Period&#58; &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:14pt;font-weight:400;line-height:100%">January 1, 2022 &#8211; December 31, 2024</font></div><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:49.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:396pt;text-indent:36pt"><img alt="lillyfooter.jpg" src="lillyfooter.jpg" style="height:51px;margin-bottom:5pt;vertical-align:text-bottom;width:101px"></div></div></div><hr style="page-break-after:always"><div style="min-height:77.76pt;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Eli Lilly and Company Shareholder Value Award Agreement (Executive Officer)</font></div><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:400;line-height:100%">Table of Contents</font></div><div><font><br></font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:93.745%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.055%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 1.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Grant of Shareholder Value Award</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Vesting</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 3.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Impact of Certain Employment Status Changes</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 4.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Change in Control</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 5.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Settlement</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 6.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Rights of the Grantee</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 7.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Prohibition Against Transfer</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 8.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Responsibility for Taxes</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 9.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 409A Compliance</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 10.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Grantee&#8217;s Acknowledgment</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 11.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Data Privacy</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 12.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Restrictive Covenants, Remedies, and Additional Terms and Conditions</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 13.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Governing Law and Choice of Venue</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">12</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 14.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Miscellaneous Provisions</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">12</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 15.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Compensation Recovery</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">13</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 16.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Award Subject to Acknowledgement of Acceptance</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">14</font></div></td></tr></table></div><div style="padding-left:23.75pt"><font><br></font></div><div><font><br></font></div><div style="height:49.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Page 2</font></div></div></div><div id="i4580a532ef31450da59a11d4d2741ff5_100"></div><hr style="page-break-after:always"><div style="min-height:92.16pt;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Eli Lilly and Company Shareholder Value Award Agreement (Executive Officer) </font></div><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 1.&#160;&#160;&#160;&#160;Grant of Shareholder Value Award</font></div><div style="margin-top:6pt;padding-left:22.3pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Eli Lilly and Company, an Indiana corporation (&#8220;Lilly&#8221; or the &#8220;Company&#8221;), has granted to the Eligible Individual who has received this Shareholder Value Award Agreement (the &#8220;Grantee&#8221;) a Performance-Based Award (the &#8220;Shareholder Value Award&#8221; or the &#8220;Award&#8221;) with respect to the target number of shares of Lilly Common Stock (the &#8220;Shares&#8221;) that the Grantee may view by logging on to the Merrill Lynch website at </font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">http&#58;&#47;&#47;myequity.lilly.com</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (the &#34;Target Number of Shares&#34;).</font></div><div style="margin-top:6pt;padding-left:22.3pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Award is made pursuant to and subject to the terms and conditions set forth in the Amended and Restated 2002 Lilly Stock Plan (the &#8220;Plan&#8221;) and to the terms and conditions set forth in this Shareholder Value Award Agreement, including all appendices, exhibits and addenda hereto (the &#8220;Award Agreement&#8221;).  In the event of any conflict between the terms of the Plan and this Award Agreement, the terms of the Plan shall govern except with respect to the provisions described in Section 12 below (in which case, the terms of the Award Agreement shall govern). </font></div><div style="padding-left:22.5pt;text-align:justify"><font><br></font></div><div style="padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Any capitalized terms used but not defined in this Award Agreement shall have the meanings set forth in the Plan.  </font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 2.&#160;&#160;&#160;&#160;Vesting</font></div><div style="padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">As soon as reasonably practicable following the end of the Performance Period, the Committee shall determine the number of Shares that are eligible to vest which shall be equal to the product of (i) the Target Number of Shares, multiplied by (ii)&#160;the Percent of Target, where&#58;  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Percent of Target</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean the percentage set forth in the Lilly Stock Price Performance Levels table set forth on the first page of this document representing the attainment level of the Final Lilly Stock Price measured against the performance goal attainment levels set forth in the table.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Final Lilly Stock Price</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean the average of the closing price of a share of Lilly Common Stock on the New York Stock Exchange for each trading day in the last two months of the Performance Period, rounded to the nearest cent. </font></div><div style="margin-top:6pt;padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In the event the Grantee&#8217;s Service is terminated prior to the end of the Performance Period for any reason or in any circumstance other than as described in Section 3 below, the Award shall be forfeited.  </font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 3.&#160;&#160;&#160;&#160;Impact of Certain Employment Status Changes</font></div><div style="margin-top:6pt;padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Unless the Committee determines, in its sole discretion, that such treatment is not advisable after consideration of Applicable Laws, the number of Shares that are eligible to vest upon a change in employment status of the Grantee during the Performance Period will be as follows&#58; </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Leaves of Absence</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In the event the Grantee is on an approved leave of absence during the Performance Period, the number of Shares eligible to vest shall be the number determined in accordance with Section 2 above.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Retirement&#59; Death&#59; Disability</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Except as otherwise provided below (including Section 12), in the event the Grantee&#8217;s Service is terminated (i) on or following the Retirement Vesting Date (A) due to the Grantee&#8217;s Retirement or (B) due to the Grantee&#8217;s Qualifying Termination (as defined below) on a date that the Grantee is eligible for Retirement, (ii) due to the Grantee&#8217;s death, or (iii) by reason of Grantee&#8217;s Disability, the number of Shares eligible to vest shall be the number determined in accordance with Section 2 above.  For the avoidance of any doubt, the Award shall be forfeited in the event the Grantee&#8217;s Service is terminated prior to the Retirement Vesting Date due to the Grantee&#8217;s Retirement.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;Retirement&#8221; means retirement as a &#8220;retiree,&#8221; which is a person who is (A) a retired employee under The Lilly Retirement Plan&#59; (B) a retired employee under the retirement plan or program of an Affiliate&#59; (C) a retired employee under a retirement program </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Page 2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:92.16pt;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Eli Lilly and Company Shareholder Value Award Agreement (Executive Officer)</font></div><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">specifically approved by the Committee&#59; (D) required to retire under local law, to the extent authorized by the Company to address such local requirements or (E) otherwise determined to be a retired employee in the sole discretion of the Company.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;Retirement Vesting Date&#8221; means the date that is on or following December 31 immediately following the commencement of the Performance Period.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;Disability&#8221; for purposes of this Award Agreement means that the Grantee would qualify to receive benefit payments under the long-term disability plan or policy, as it may be amended from time to time, of the Company or the Affiliate that employs the Grantee (the &#8220;Employer&#8221;).  If the Company or the Employer does not have a long-term disability plan or policy, &#8220;Disability&#8221; means that the Grantee is unable to carry out the responsibilities and functions of the position held by the Grantee by reason of any medically determined physical or mental impairment for a period of at least ninety (90) consecutive days as determined by the Company or Employer.  The Grantee shall not be considered to have incurred a Disability unless he or she furnishes proof of such impairment sufficient to satisfy the Company as it determines in its sole discretion.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">c.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Qualifying Termination</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Except as otherwise provided in section 3(b), in the event the Grantee&#8217;s employment is subject to a Qualifying Termination (as defined below), the number of Shares eligible to vest shall be the number determined in accordance with Section 2 above, reduced proportionally for the portion of the total days during the Performance Period in which the Grantee was not in active Service.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">For purposes of this Award Agreement, a &#8220;Qualifying Termination&#8221; means the termination of the Grantee's Service under any one of the following circumstances&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">i.&#160;&#160;&#160;&#160;due to a plant closing or reduction in workforce (as defined below)&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ii.&#160;&#160;&#160;&#160;as a result of the Grantee&#8217;s failure to locate a position within the Company or an Affiliate following the placement of the Grantee on reallocation or medical reassignment in the United States (or equivalent as determined by the Committee).</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;Plant closing&#8221; means the closing of a plant site or other corporate location that directly results in termination of the Grantee&#8217;s Service. </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;Reduction in workforce&#8221; means the elimination of a work group, functional or business unit or other broadly applicable reduction in job positions that directly results in termination of the Grantee&#8217;s Service.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">d.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Demotions, Disciplinary Actions and Misconduct</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Committee may, in its sole discretion, cancel this Shareholder Value Award or reduce the number of Shares eligible to vest, prorated according to time or other measure as determined appropriate by the Committee, if during any portion of the Performance Period the Grantee has been (i)&#160;subject to disciplinary action by the Company or (ii) determined to have committed a material violation of law or Company policy or to have failed to properly manage or monitor the conduct of an employee who has committed a material violation of law or Company policy whereby, in either case, such conduct causes significant harm to the Company, as determined in the sole discretion of the Company.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Committee&#8217;s determination as to whether (1) a leave of absence or a transfer of employment between Lilly and an Affiliate or between Affiliates constitutes a termination of Service, (2) the Grantee&#8217;s Service has been terminated by reason of Disability or Retirement, (3) the Grantee is eligible for Retirement, (4) the Grantee&#8217;s Service has been terminated as a direct result of either a plant closing or a reduction in force, and (5) the Grantee's service has been terminated as a result of the failure to locate a position within the Company or an Affiliate following reallocation or medical reassignment shall be final and binding on the Grantee.  </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Page 3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:92.16pt;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Eli Lilly and Company Shareholder Value Award Agreement (Executive Officer)</font></div><div><font><br></font></div></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 4.&#160;&#160;&#160;&#160;Change in Control</font></div><div style="margin-bottom:12pt;padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:115%">The provisions of Section 13.2 of the Plan apply to this Award with the following modifications&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.&#160;&#160;&#160;&#160;The only Change in Control event that shall result in a benefit under this Section 4 shall be the consummation of a merger, share exchange, or consolidation of the Company, as defined in Section 2.6(c) of the Plan (a &#8220;Transaction&#8221;).</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.&#160;&#160;&#160;&#160;In the event of a Transaction that occurs prior to the end of the Performance Period, the Grantee will be credited with an award of Restricted Stock Units equal to the number of Shares eligible to vest, calculated in a manner consistent with Section 2, but the Final Lilly Stock Price shall be equal to the value of Shares established for the consideration to be paid to holders of Shares in the Transaction (the &#8220;Credited RSU Award&#8221;).  The Credited RSU Award shall be eligible to vest on the last day of the Performance Period, subject to the Grantee&#8217;s continued Service through the last day of the Performance Period, except as provided below&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">i.&#160;&#160;&#160;&#160;In the event that the Credited RSU Award is not converted, assumed, substituted, continued or replaced by a successor or surviving corporation, or a parent or subsidiary thereof, in connection with a Transaction, then immediately prior to the Transaction, the Credited RSU Award shall vest automatically in full.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ii.&#160;&#160;&#160;&#160;In the event that the Credited RSU Award is converted, assumed, substituted, continued or replaced by a successor or surviving corporation, or a parent or subsidiary thereof, in connection with the Transaction and the Grantee is subject to a Covered Termination (as defined below) prior to the end of the Performance Period, then immediately as of the date of the Covered Termination, the Credited RSU Award shall vest automatically in full. </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">For purposes of this Award Agreement, &#8220;Covered Termination&#8221; shall mean a termination of Service as described in Sections 3(b) and (c), Grantee&#8217;s termination of Service without Cause or the Grantee&#8217;s resignation for Good Reason.  &#8220;Cause&#8221; and &#8220;Good Reason&#8221; shall have the meanings ascribed to them in the Eli Lilly and Company 2007 Change in Control Severance Pay Plan for Select Employees (as amended from time to time) or any successor plan or arrangement thereto.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">c.&#160;&#160;&#160;&#160;If the Grantee is entitled to receive stock of the acquiring entity or successor to the Company as a result of the application of this Section 4, then references to Shares in this Award Agreement shall be read to mean stock of the successor or surviving corporation, or a parent or subsidiary thereof, as and when applicable.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Page 4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:92.16pt;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Eli Lilly and Company Shareholder Value Award Agreement (Executive Officer)</font></div><div><font><br></font></div></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 5.&#160;&#160;&#160;&#160;Settlement  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.&#160;&#160;&#160;&#160;Except as provided below, the Award shall be paid to the Grantee as soon as practicable, but in no event later than sixty (60) days, following the last day of the Performance Period.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.&#160;&#160;&#160;&#160;If the Award vests pursuant to Section 4(b)(i), the Award shall be paid to the Grantee immediately prior to the Transaction, provided that if the Award is considered an item of non-qualified deferred compensation subject to Section 409A of the Code (&#8220;NQ Deferred Compensation&#8221;) and the Transaction does not constitute a &#8220;change in control event,&#8221; within the meaning of the U.S. Treasury Regulations (a &#8220;409A CIC&#8221;), then the Award shall be paid in cash (calculated based on the value of the Shares established for the consideration to be paid to holders of Shares in the Transaction) on the earliest of (i) the date that the Grantee experiences a &#8220;separation from service&#8221; within the meaning of Section 409A of the Code (a &#8220;Section 409A Separation&#8221;), provided that if the Grantee is a &#8220;specified employee&#8221; within the meaning of Section 409A of the Code as of the payment date, the Award shall instead be paid on the first day following the six (6) month anniversary of the Grantee&#8217;s Section 409A Separation, (ii) the date of the Grantee&#8217;s death and (iii) the date set forth in Section 5(a) above.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">c.&#160;&#160;&#160;&#160;If the Award vests pursuant to Section 4(b)(ii), the Award shall be paid to the Grantee as soon as practicable, but in no event later than sixty (60) days, following the date the Grantee is subject to a Covered Termination, provided that if the Award is NQ Deferred Compensation, (i) the Award shall be paid within sixty (60) days following the date the Grantee experiences a Section 409A Separation, and (ii)&#160;if the Grantee is a &#8220;specified employee&#8221; within the meaning of Section 409A of the Code as of the payment date, the Award shall instead be paid on the earliest of (1) the first day following the six (6) month anniversary of the Grantee&#8217;s Section 409A Separation, and (2) the date of the Grantee&#8217;s death.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">d.&#160;&#160;&#160;&#160;At the time of settlement provided in this Section 5,</font><font style="color:#0000ff;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Lilly shall issue or transfer Shares or the cash equivalent, as contemplated under Section 5(e) below, to the Grantee.  In the event the Grantee is entitled to a fractional Share, the fraction may be paid in cash or rounded, in the Committee&#8217;s discretion.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">e.&#160;&#160;&#160;&#160;At any time prior to the end of the Performance Period or until the Award is paid in accordance with this Section 5, the Committee may, if it so elects, determine to pay part or all of the Award in cash in lieu of issuing or transferring Shares.  The amount of cash shall be calculated based on the Fair Market Value of the Shares on the last day of the Performance Period in the case of payment pursuant to Section 5(a) and on the date of payment in the case of a payment pursuant to Section 5(c). </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">f.&#160;&#160;&#160;&#160;In the event of the death of the Grantee, the payments described above shall be made to the successor of the Grantee.  </font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 6.&#160;&#160;&#160;&#160;Rights of the Grantee</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">No Shareholder Rights</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Shareholder Value Award does not entitle the Grantee to any rights of a shareholder of Lilly until such time as the Shareholder Value Award is settled and Shares are issued or transferred to the Grantee.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">No Trust&#59; Grantee&#8217;s Rights Unsecured.</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Neither this Award Agreement nor any action in accordance with this Award Agreement shall be construed to create a trust of any kind.  The right of the Grantee to receive payments of cash or Shares pursuant to this Award Agreement shall be an unsecured claim against the general assets of the Company.</font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Page 5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:92.16pt;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Eli Lilly and Company Shareholder Value Award Agreement (Executive Officer)</font></div><div><font><br></font></div></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 7.&#160;&#160;&#160;&#160;Prohibition Against Transfer</font></div><div style="margin-top:6pt;padding-left:22.3pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The right of a Grantee to receive payments of Shares and&#47;or cash under this Award may not be transferred except to a duly appointed guardian of the estate of the Grantee or to a successor of the Grantee by will or the applicable laws of descent and distribution and then only subject to the provisions of this Award Agreement.  A Grantee may not assign, sell, pledge, or otherwise transfer Shares or cash to which he or she may be entitled hereunder prior to transfer or payment thereof to the Grantee, and any such attempted assignment, sale, pledge or transfer shall be void.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 8.&#160;&#160;&#160;&#160;Responsibility for Taxes</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.&#160;&#160;&#160;&#160;Regardless of any action Lilly and&#47;or the Employer takes with respect to any or all income tax (including federal, state, local and non-U.S. tax), social insurance, payroll tax, fringe benefits tax, payment on account or other tax related items related to the Grantee&#8217;s participation in the Plan and legally applicable to the Grantee (&#8220;Tax Related Items&#8221;), the Grantee acknowledges that the ultimate liability for all Tax Related Items is and remains the Grantee&#8217;s responsibility and may exceed the amount actually withheld by Lilly or the Employer.  The Grantee further acknowledges that Lilly and the Employer (i)&#160;make no representations or undertakings regarding the treatment of any Tax Related Items in connection with any aspect of the Award, including the grant of the Shareholder Value Award, the vesting of the Shareholder Value Award, the transfer and issuance of any Shares, the receipt of any cash payment pursuant to the Award, the receipt of any dividends and the sale of any Shares acquired pursuant to this Award&#59; and (ii)&#160;do not commit to and are under no obligation to structure the terms of the grant or any aspect of the Award to reduce or eliminate the Grantee&#8217;s liability for Tax Related Items or achieve any particular tax result.  Furthermore, if the Grantee becomes subject to Tax Related Items in more than one jurisdiction, the Grantee acknowledges that the Company and&#47;or the Employer (or former employer, as applicable) may be required to withhold or account for Tax Related Items in more than one jurisdiction.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.&#160;&#160;&#160;&#160;Prior to the applicable taxable or tax withholding event, as applicable, the Grantee shall pay or make adequate arrangements satisfactory to Lilly and&#47;or the Employer to satisfy all Tax Related Items.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">i.&#160;&#160;&#160;&#160;If the Shareholder Value Award is paid to the Grantee in cash in lieu of Shares, the Grantee authorizes the Company and&#47;or the Employer, or their respective agents, at their discretion, to satisfy any obligation for Tax Related Items by withholding from the cash amount paid to the Grantee pursuant to the Award or from the Grantee&#8217;s wages or other cash compensation paid to the Grantee by the Company and&#47;or the Employer.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ii.&#160;&#160;&#160;&#160;If the Shareholder Value Award is paid to the Grantee in Shares and the Grantee is not subject to the short-swing profit rules of Section 16(b) of the Exchange Act, the Grantee authorizes Lilly and&#47;or the Employer, or their respective agents, at their discretion, to (A) withhold from the Grantee&#8217;s wages or other cash compensation paid to the Grantee by the Company and&#47;or the Employer, (B) arrange for the sale of Shares to be issued upon settlement of the Award (on the Grantee&#8217;s behalf and at the Grantee&#8217;s direction pursuant to this authorization or such other authorization as the Grantee may be required to provide to Lilly or its designated broker in order for such sale to be effectuated) and withhold from the proceeds of such sale, (C) withhold in Shares otherwise issuable to the Grantee pursuant to this Award, and&#47;or (D) apply any other method of withholding determined by the Company and, to the extent required by Applicable Laws or the Plan, approved by the Committee.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">iii.&#160;&#160;&#160;&#160;If the Shareholder Value Award is paid to the Grantee in Shares and the Grantee is subject to the short-swing profit rules of Section 16(b) of the Exchange Act, Lilly </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Page 6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:92.16pt;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Eli Lilly and Company Shareholder Value Award Agreement (Executive Officer)</font></div><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">will withhold in Shares otherwise issuable to the Grantee pursuant to this Award, unless the use of such withholding method is prevented by Applicable Laws or has materially adverse accounting or tax consequences, in which case the withholding obligation for Tax Related Items may be satisfied by one or a combination of the methods set forth in Section 8(b)(ii)(A) and (B) above.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">c.&#160;&#160;&#160;&#160;Depending on the withholding method, Lilly and&#47;or the Employer may withhold or account for Tax Related Items by considering applicable statutory or other withholding rates, including minimum or maximum rates in the jurisdiction(s) applicable to the Grantee.  In the event of over-withholding, the Grantee may receive a refund of any over-withheld amount in cash (without interest and without entitlement to the equivalent amount in Shares).  If the obligation for Tax Related Items is satisfied by withholding Shares, for tax purposes, the Grantee will be deemed to have been issued the full number of Shares to which he or she is entitled pursuant to this Award, notwithstanding that a number of Shares are withheld to satisfy the obligation for Tax Related Items.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">d.&#160;&#160;&#160;&#160;Lilly may refuse to deliver Shares or any cash payment to the Grantee if the Grantee fails to comply with the Grantee&#8217;s obligation in connection with the Tax Related Items as described in this Section 8. </font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:400;line-height:100%">Section 9.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 409A Compliance</font></div><div style="padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">To the extent applicable, it is intended that this Award comply with the requirements of Section 409A of the U.S. Internal Revenue Code of 1986, as amended and the Treasury Regulations and other guidance issued thereunder (&#8220;Section 409A&#8221;) and this Award shall be interpreted and applied by the Committee in a manner consistent with this intent in order to avoid the imposition of any additional tax under Section 409A.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 10.&#160;&#160;&#160;&#160;Grantee&#8217;s Acknowledgment</font></div><div style="padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In accepting this Award, the Grantee acknowledges, understands and agrees that&#58;</font></div><div style="padding-left:22.5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.&#160;&#160;&#160;&#160;the Plan is established voluntarily by Lilly, it is discretionary in nature and it may be modified, amended, suspended or terminated by Lilly at any time, as provided in the Plan&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.&#160;&#160;&#160;&#160;the Award is voluntary and occasional and does not create any contractual or other right to receive future Performance-Based Awards, or benefits in lieu thereof, even if Performance-Based Awards have been granted in the past&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">c.&#160;&#160;&#160;&#160;all decisions with respect to future Performance-Based Awards or other awards, if any, will be at the sole discretion of the Committee&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">d.&#160;&#160;&#160;&#160;the Grantee&#8217;s participation in the Plan is voluntary&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">e.&#160;&#160;&#160;&#160;the Award and any Shares subject to the Award are not intended to replace any pension rights or compensation&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">f.&#160;&#160;&#160;&#160;the Award and any Shares subject to the Award, and the income and value of same, are not part of normal or expected compensation for any purpose, including but not limited to, calculating any severance, resignation, termination, redundancy, dismissal, end of service payments, bonuses, long-service awards, holiday pay, leave pay, pension or welfare or retirement benefits or similar mandatory payments&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">g.&#160;&#160;&#160;&#160;neither the Award nor any provision of this Award Agreement, the Plan or the policies adopted pursuant to the Plan, confer upon the Grantee any right with respect to employment or continuation of current employment, and in the event that the Grantee is not an employee of Lilly or any subsidiary of Lilly, the Award shall not be interpreted to form an employment contract or relationship with Lilly or any Affiliate&#59; </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Page 7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:92.16pt;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Eli Lilly and Company Shareholder Value Award Agreement (Executive Officer)</font></div><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">h.&#160;&#160;&#160;&#160;the future value of the underlying Shares is unknown, indeterminable and cannot be predicted with certainty&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">i.&#160;&#160;&#160;&#160;no claim or entitlement to compensation or damages shall arise from forfeiture of the Award resulting from the Grantee ceasing to provide employment or other services to Lilly or the Employer (for any reason whatsoever, whether or not later found to be invalid or in breach of local labor laws in the jurisdiction where the Grantee is employed or the terms of Grantee&#8217;s employment agreement, if any)&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">j.&#160;&#160;&#160;&#160;for purposes of the Award, the Grantee&#8217;s employment will be considered terminated as of the date he or she is no longer actively providing services to the Company or an Affiliate and the Grantee&#8217;s right, if any, to earn and be paid any portion of the Award after such termination of employment&#160;or services (regardless of the reason for such termination&#160;and whether or not such termination is later found to be invalid or in breach of employment laws in the jurisdiction where the Grantee is employed or the terms of the Grantee&#8217;s employment agreement, if any)&#160;will be measured by the date the Grantee ceases to&#160;actively&#160;provide services and will not be extended by any notice period (e.g., active&#160;service would not include any contractual notice period or any&#160;period of &#8220;garden leave&#8221; or similar period&#160;mandated under employment laws in the jurisdiction where the Grantee is employed or the terms of the Grantee&#8217;s employment agreement, if any)&#59; the Committee shall have the exclusive discretion to determine when the Grantee is no longer actively&#160;providing services&#160;for purposes of the Award (including whether the Grantee may still be considered&#160;to be actively&#160;providing services&#160;while on a leave of absence) in accordance with Section 409A&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">k.&#160;&#160;&#160;&#160;unless otherwise provided in the Plan or by the Committee in its discretion, the Award and the benefits evidenced by this Award Agreement do not create any entitlement to have the Award or any such benefits transferred to, or assumed by, another company nor to be exchanged, cashed out or substituted for, in connection with any corporate transaction affecting the Shares&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">l.&#160;&#160;&#160;&#160;the Grantee is solely responsible for investigating and complying with any laws applicable to him or her in connection with the Award&#59; and </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">m.&#160;&#160;&#160;&#160;the Company has communicated share ownership guidelines that apply to the Grantee, and the Grantee understands and agrees that those guidelines may impact any Shares subject to, or issued pursuant to the Award.   </font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:400;line-height:100%">Section 11.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Data Privacy</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">a.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">Data Collection and Usage</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">.  The Company and the Employer may collect, process and use certain personal information about the Grantee, and persons closely associated with the Grantee, including, but not limited to, the Grantee&#8217;s name, home address and telephone number, email address, date of birth, social insurance number, passport or other identification number (e.g., resident registration number), salary, nationality, job title, any shares of stock or directorships held in the Company, details of all Shareholder Value Awards or any other entitlement to shares of stock awarded, canceled, exercised, vested, unvested or outstanding in the Grantee&#8217;s favor (&#8220;Data&#8221;), for the purposes of implementing, administering and managing the Plan.  The legal basis, where required, for the processing of Data is the Grantee&#8217;s consent.  Where required under Applicable Laws, Data may also be disclosed to certain securities or other regulatory authorities where the Company&#8217;s securities are listed or traded or regulatory filings are made and the legal basis, where required, for such disclosure are the Applicable Laws.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">b.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">Stock Plan Administration Service Providers</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">.  The Company transfers Data to Bank of America Merrill Lynch and&#47;or its affiliated companies (&#8220;Merrill Lynch&#8221;), an independent service provider, which is assisting the Company with the implementation, administration </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Page 8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:92.16pt;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Eli Lilly and Company Shareholder Value Award Agreement (Executive Officer)</font></div><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">and management of the Plan.  In the future, the Company may select a different service provider and share Data with such other provider serving in a similar manner.  The Grantee may be asked to agree on separate terms and data processing practices with the service provider, with such agreement being a condition to the ability to participate in the Plan.  The Company may also transfer Data to KPMG, an independent service provider, which is also assisting the Company with certain aspects of the implementation, administration and management of the Plan.  In the future, the Company may select a different service provider and share Data with such other provider serving in a similar manner.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">c.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">International Data Transfers</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">.  The Company and its service providers are based in the United States.  The Grantee&#8217;s country or jurisdiction may have different data privacy laws and protections than the United States.  The Company&#8217;s legal basis, where required, for the transfer of Data is Grantee&#8217;s consent.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">d.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">Data Retention</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">.  The Company will hold and use the Data only as long as is necessary to implement, administer and manage the Grantee&#8217;s participation in the Plan, or as required to comply with legal or regulatory obligations, including under tax and security laws.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">e.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">Voluntariness and Consequences of Consent Denial or Withdrawal</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">.  Participation in the Plan is voluntary and the Grantee is providing the consents herein on a purely voluntary basis.  If the Grantee does not consent, or if the Grantee later seeks to revoke the Grantee&#8217;s consent, the Grantee&#8217;s salary from or employment and career with the Employer will not be affected&#59; the only consequence of refusing or withdrawing the Grantee&#8217;s consent is that the Company would not be able to grant this Award or other awards to the Grantee or administer or maintain such awards.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">f.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">Data Subject Rights</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">. The Grantee understands that data subject rights regarding the processing of Data vary depending on Applicable Laws and that, depending on where the Grantee is based and subject to the conditions set out in such Applicable Laws, the Grantee may have, without limitation, the right to (i) inquire whether and what kind of Data the Company holds about the Grantee and how it is processed, and to access or request copies of such Data, (ii) request the correction or supplementation of Data about the Grantee that is inaccurate, incomplete or out-of-date in light of the purposes underlying the processing, (iii) obtain the erasure of Data no longer necessary for the purposes underlying the processing, (iv) request the Company to restrict the processing of the Grantee&#8217;s Data in certain situations where the Grantee feels its processing is inappropriate, (v) object, in certain circumstances, to the processing of Data for legitimate interests, and to (vi) request portability of the Grantee&#8217;s Data that the Grantee has actively or passively provided to the Company or the Employer (which does not include data derived or inferred from the collected data), where the processing of such Data is based on consent or the Grantee&#8217;s employment and is carried out by automated means.  In case of concerns, the Grantee understands that he or she may also have the right to lodge a complaint with the competent local data protection authority.  Further, to receive clarification of, or to exercise any of, the Grantee&#8217;s rights, the Grantee understands that he or she should contact his or her local human resources representative.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">g.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">Declaration of Consent</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">.  By accepting the Award and indicating consent via the Company&#8217;s online acceptance procedure, the Grantee is declaring that he or she agrees with the data processing practices described herein and consents to the collection, processing and use of Data by the Company and the transfer of Data to the recipients mentioned above, including recipients located in countries which do not adduce an adequate level of protection from a European (or other non-U.S.) data protection law perspective, for the purposes described above.</font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Page 9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:92.16pt;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Eli Lilly and Company Shareholder Value Award Agreement (Executive Officer)</font></div><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 12.&#160;&#160;&#160;&#160;Restrictive Covenants, Remedies, and Additional Terms and Conditions</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Restrictive Covenants</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In consideration of the Grantee&#8217;s receipt of the Award from Lilly, the Grantee agrees that during the Grantee&#8217;s employment with Lilly or an Affiliate that the Grantee provided services to or had access to confidential information concerning (&#8220;Covered Affiliate&#8221;) and for twelve (12) months immediately following the end of the Grantee&#8217;s employment (regardless of reason), the Grantee will not directly or indirectly, on a worldwide basis, engage in any of the following activities&#58;</font></div><div style="margin-bottom:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">i.&#160;&#160;&#160;&#160;Work for, advise, manage, act as an agent, employee or consultant for, or otherwise provide any services, in a Competitively-Sensitive Capacity, to&#58; (a) any person or entity engaged in research, development, production, sale, or distribution of a product or service competitive with or substantially similar to any product or service in research, development or design, or manufactured, produced, sold, or distributed by Lilly or a Covered Affiliate&#59; or (b) any person or entity that otherwise competes or intends to compete with Lilly or a Covered Affiliate.</font></div><div style="margin-bottom:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ii.&#160;&#160;&#160;&#160;Directly or indirectly solicit, urge, divert, induce, or seek to induce any of Lilly&#8217;s (or Covered Affiliate&#8217;s) independent contractors, subcontractors, business partners, distributors, brokers, consultants, sales representatives, customers, vendors, suppliers or any other person with whom Lilly or Covered Affiliate has a business relationship and with whom the Grantee interacted during the Grantee&#8217;s employment with Lilly or Covered Affiliate to terminate their relationship with, or representation of, Lilly or Covered Affiliate or to cancel, withdraw, reduce, limit or in any manner modify any such person's business with, or representation of, Lilly or a Covered Affiliate.</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Grantee acknowledges and agrees that any Lilly Affiliate is an intended third-party beneficiary of this Award Agreement, which may be enforced by Lilly or any such Affiliate, either singularly or jointly.</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">For purposes of this Award Agreement, &#8220;Competitively-Sensitive Capacity&#8221; means&#58; (A)&#160;the same or similar capacity or function in which the Grantee worked for Lilly or a Covered Affiliate at any time during the two (2) years immediately preceding the end of the Grantee&#8217;s employment&#59; (B)&#160;any officer, director, executive or senior management capacity or function&#59; (C)&#160;any research and development capacity or function&#59; (D)&#160;any sales management or business development management capacity or function&#59; (E)&#160;any ownership capacity (except the Grantee may own as a passive investment up to 2% of any publicly traded securities)&#59; and&#47;or (F)&#160;any other capacity or function in which there is a material risk that the Grantee likely would inevitably use or disclose trade secrets and&#47;or confidential information Lilly or a Covered Affiliate.  For purposes of clarity, if a competing business has multiple divisions, lines or segments, some of which are not competitive with the business of Lilly, including its Covered Affiliates, nothing in this Award Agreement will prohibit the Grantee from being employed by, working for or assisting only that division, line or segment of such competing business that is not competitive with the business of Lilly or a Covered Affiliate, provided the Grantee is not involved in a Competitively-Sensitive Capacity in the research, development, manufacture, provision or sale of any products that compete with any products of Lilly or a Covered Affiliate.</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Grantee and Lilly acknowledge and agree that the worldwide geographic scope of the foregoing covenants is reasonable and necessary given, among other things, that&#58; (a)&#160;absent the restrictions, the Grantee could utilize Lilly&#8217;s (or its Affiliates) trade secrets and&#47;or confidential information and compete with Lilly or Affiliate from virtually anywhere&#59; and (b)&#160;such scope is the only way for Lilly and its Affiliates to protect their trade secrets and confidential information.  In the event the Grantee violates any of the </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Page 10</font></div></div></div><hr style="page-break-after:always"><div style="min-height:92.16pt;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Eli Lilly and Company Shareholder Value Award Agreement (Executive Officer)</font></div><div><font><br></font></div></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">restrictive covenants contained herein, their duration will automatically be extended by the length of time during which the Grantee was in violation of any of the restrictive covenants.</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Grantee acknowledges and agrees that during the course of Grantee&#8217;s employment with Lilly or a Covered Affiliate, the Grantee will become intimately familiar with confidential information and trade secrets key to its unique competitive advantage.  The Grantee also acknowledges and agrees that Lilly&#8217;s (and Covered Affiliate&#8217;s) confidential information and trade secrets will retain continuing vitality throughout and beyond the one-year restricted period.  And the Grantee acknowledges and agrees that, should the Grantee leave Lilly or Covered Affiliate and, near the Grantee&#8217;s departure from Lilly or Covered Affiliate, work with another person or entity that engages in business activities similar to those of Lilly and&#47;or Covered Affiliate, it would be highly likely, if not inevitable, that the Grantee would rely on confidential information of Lilly and&#47;or Covered Affiliate in the course of the Grantee&#8217;s work, either consciously or subconsciously, harming Lilly and any Covered Affiliates.  For these and other reasons, the Grantee agrees that the restrictions above are reasonably necessary to protect Lilly&#8217;s and its Covered Affiliate&#8217;s legitimate business interests, and do so by creating a specific amount of time after the Grantee&#8217;s employment ends during which the Grantee will not be able to engage or prepare to engage in the activities above.</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Grantee and Lilly further acknowledge and agree that if any particular covenant or provision is determined to be unreasonable or unenforceable for any reason, including, without limitation, the time period, geographic area, and&#47;or scope of activity covered by any restrictive covenant, such covenant or provision will automatically be deemed reformed so that the contested covenant or provision will have the closest effect permitted by applicable law to the original form and will be given effect and enforced as so reformed to whatever extent would be reasonable and enforceable under applicable law.  Any court interpreting any restrictive covenant provision of this Award Agreement will, if necessary, reform any such provision to make it enforceable under applicable law.</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Award Agreement is intended, among other things, to supplement (and not supersede) all applicable statutes protecting trade secrets and the duties the Grantee owes to Lilly and&#47;or Covered Affiliates under the common law, as well as any other non-competition, non-solicitation, or confidentiality provisions that the Grantee agreed to in the past, including those in the Grantee&#8217;s Employee Confidentiality and Invention Agreement, each of which remains in full force and effect, or that the Grantee agrees to in the future.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Grantee acknowledges that a breach by the Grantee of this Award Agreement will give rise to irreparable injury to Lilly and Covered Affiliates and money damages will not be adequate relief for such injury.  As a result, the Grantee agrees that Lilly (including any third party beneficiary) will be entitled to obtain equitable or injunctive relief without having to post any bond or other security to restrain or prohibit any such breach or threatened breach, in addition to any other remedies which may be available, including the recovery of monetary damages from the Grantee.</font></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Remedies</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If the Company determines that the Grantee has violated any applicable provisions of this Section 12, in addition to injunctive relief and damages, the Grantee agrees and covenants that&#58; (i) the Award shall be immediately rescinded&#59; (ii) the Grantee shall automatically forfeit any rights the Grantee may have with respect to the Award as of the date of such determination, including the rights to continue to be eligible to vest or receive a payment under the Award&#59; and (iii) the foregoing remedies set forth in this Section 12 shall not be Lilly&#8217;s exclusive remedies.  Lilly reserves all other rights and remedies available to it at law or in equity. </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Page 11</font></div></div></div><hr style="page-break-after:always"><div style="min-height:92.16pt;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Eli Lilly and Company Shareholder Value Award Agreement (Executive Officer)</font></div><div><font><br></font></div></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In addition, the Company reserves the right to impose other requirements on the Award and any Shares acquired under the Plan, to the extent the Company determines it is necessary or advisable for legal or administrative reasons, and to require the Grantee to execute any additional agreements or undertakings that may be necessary to accomplish the foregoing.  Without limitation to the foregoing, the Grantee agrees that the Shareholder Value Award and any benefits or proceeds the Grantee may receive hereunder shall be subject to forfeiture and&#47;or repayment to the Company to the extent required to comply with any requirements imposed under Applicable Laws or any compensation recovery policy of the Company that reflects the provisions of Applicable Laws.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-align:justify;text-indent:-72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 13.&#160;&#160;&#160;&#160;Governing Law and Choice of Venue</font></div><div style="margin-top:6pt;padding-left:22.3pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The validity, construction, and enforcement of this Award Agreement shall be governed by the laws of the State of Indiana, U.S.A. without regard to laws that might cause other law to govern under applicable principles of conflict of laws or cause the application of substantive law of any jurisdiction other than Indiana.  For purposes of litigating any dispute that arises under this Award Agreement, the parties hereby submit to and consent to the jurisdiction and venue of the State of Indiana, and agree that such litigation shall be conducted exclusively in the courts having appropriate subject matter jurisdiction in of Marion</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">County, Indiana, or the federal courts for the United States for the Southern District of Indiana, and no other courts, where this Award is granted and&#47;or to be performed.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 14.&#160;&#160;&#160;&#160;Miscellaneous Provisions</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Notices and Electronic Delivery and Participation</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Any notice to be given by the Grantee or successor Grantee shall be in writing, and any notice shall be deemed to have been given or made only upon receipt thereof by the Corporate Secretary of Lilly at Lilly Corporate Center, Indianapolis, Indiana 46285, U.S.A.  Any notice or communication by Lilly in writing shall be deemed to have been given in the case of the Grantee if mailed or delivered to the Grantee at any address specified in writing to Lilly by the Grantee and, in the case of any successor Grantee, at the address specified in writing to Lilly by the successor Grantee.  In addition, Lilly may, in its sole discretion, decide to deliver any documents related to the Award and participation in the Plan by electronic means or request the Grantee&#8217;s consent to participate in the Plan by electronic means.  By accepting this Award, the Grantee hereby consents to receive such documents by electronic delivery and agrees to participate in the Plan through an on-line or electronic system established and maintained by Lilly or a third party designated by Lilly.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Language</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Grantee acknowledges that he or she is proficient in the English language, or has consulted with an advisor who is sufficiently proficient in English, so as to allow the Grantee to understand the terms and conditions of this Award Agreement.  If the Grantee has received this Award Agreement or any other document related to the Plan translated into a language other than English and if the meaning of the translated version is different than the English version, the English version will control.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:13pt;font-weight:400;line-height:100%">c.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Waiver.</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:13pt;font-style:italic;font-weight:700;line-height:100%">  </font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The waiver by Lilly of any provision of this Award Agreement at any time or for any purpose shall not operate as or be construed to be a waiver of the same or any other provision of this Award Agreement at any subsequent time or for any other purpose.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:13pt;font-weight:400;line-height:100%">d.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Severability and Section Headings</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If one or more of the provisions of this Award Agreement shall be held invalid, illegal or unenforceable in any respect, the validity, legality and enforceability of the remaining provisions shall not in any way be affected or impaired thereby and the invalid, illegal or unenforceable provisions shall be deemed null and void&#59; however, to the extent permissible by law, any provisions which could be deemed null and void shall first be construed, interpreted or revised retroactively to </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Page 12</font></div></div></div><hr style="page-break-after:always"><div style="min-height:92.16pt;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Eli Lilly and Company Shareholder Value Award Agreement (Executive Officer)</font></div><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">permit this Award Agreement to be construed so as to foster the intent of this Award Agreement and the Plan.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The section headings in this Award Agreement are for convenience of reference only and shall not be deemed a part of, or germane to, the interpretation or construction of this instrument.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:13pt;font-weight:400;line-height:100%">e.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">No Advice Regarding Grant</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Lilly is not providing any tax, legal or financial advice, nor is Lilly making any recommendations regarding the Grantee&#8217;s participation in the Plan or the Grantee&#8217;s acquisition or sale of the underlying Shares.  The Grantee should consult with his or her own personal tax, legal and financial advisors regarding the Grantee&#8217;s participation in the Plan before taking any action related to the Plan.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 15.&#160;&#160;&#160;&#160;Compensation Recovery</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">At any time during the three years following the date on which the number of Shares eligible to vest under this Award has been determined under Section 2 above, the Company reserves the right to and, in appropriate cases, will seek restitution of all or part of any Shares that have been issued or cash that has been paid pursuant to this Award if&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.&#160;&#160;&#160;&#160;(i) the number of Shares or the amount of the cash payment was calculated based, directly or indirectly, upon the achievement of financial results that were subsequently the subject of a restatement of all or a portion of the Company&#8217;s financial statements, (ii) the Grantee engaged in intentional misconduct that caused or partially caused the need for such a restatement&#59; and (iii) the number of Shares or the amount of cash payment that would have been issued or paid to the Grantee had the financial results been properly reported would have been lower than the number of Shares actually issued or the amount of cash actually paid&#59; or</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.&#160;&#160;&#160;&#160;the Grantee has been determined to have committed a material violation of law or Company policy or to have failed to properly manage or monitor the conduct of an employee who has committed a material violation of law or Company policy whereby, in either case, such misconduct causes significant harm to the company.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Furthermore, in the event the number of Shares issued or cash paid pursuant to this Award is determined to have been based on materially inaccurate financial statements or other Company performance measures or on calculation errors (without any misconduct on the part of the Grantee), the Company reserves the right to and, in appropriate cases, will (A) seek restitution of the Shares or cash paid pursuant to this Award to the extent that the number of Shares issued or the amount paid exceeded the number of Shares that would have been issued or the amount that would have been paid had the inaccuracy or error not occurred, or (B) issue additional Shares or make additional payment to the extent that the number of Shares issued or the amount paid was less than the correct amount.</font></div><div style="padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Section 15 is not intended to limit the Company&#8217;s power to take such action as it deems necessary to remedy any misconduct, prevent its reoccurrence and, if appropriate, based on all relevant facts and circumstances, punish the wrongdoer in a manner it deems appropriate.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Page 13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:92.16pt;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Eli Lilly and Company Shareholder Value Award Agreement (Executive Officer)</font></div><div><font><br></font></div></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 16.&#160;&#160;&#160;&#160;Award Subject to Acknowledgement of Acceptance</font></div><div style="margin-top:6pt;padding-left:22.3pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notwithstanding any provisions of this Award Agreement, the Award is subject to acknowledgement of acceptance by the Grantee prior to 4&#58;00 PM (EDT) &#91;&#8226;&#93;, through the website of Merrill Lynch, the Company&#8217;s stock plan administrator.  If the Grantee does not acknowledge acceptance of the Award prior to 4&#58;00 PM (EDT) &#91;&#8226;&#93;, the Award will be cancelled, subject to the Committee&#8217;s discretion for unforeseen circumstances. </font></div><div style="padding-left:18pt;text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">IN WITNESS WHEREOF, Lilly has caused this Award Agreement to be executed in Indianapolis, Indiana, by its proper officer.</font></div><div style="padding-left:22.5pt;text-align:justify"><font><br></font></div><div style="padding-left:274.5pt;text-align:justify;text-indent:13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ELI LILLY AND COMPANY</font></div><div style="padding-left:288pt;text-align:justify"><font><br></font></div><div style="padding-left:288pt;text-align:justify"><font><br></font></div><div style="padding-left:288pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58; _________________________</font></div><div style="padding-left:288pt"><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Page 14</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>4
<FILENAME>lly-093022x10qexhibit103.htm
<DESCRIPTION>EX-10.3
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ic134c9c6dae44d1c8861d41d7772d550_97"></div><div style="min-height:77.76pt;width:100%"><div><font><br></font></div></div><div style="padding-right:39.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Exhibit 10.3 Form of Relative Value Award under the 2002 Lilly Stock Plan (with non-compete)</font></div><div style="padding-left:19.8pt;padding-right:19.8pt;text-align:center"><font><br></font></div><div style="padding-right:39.6pt"><font><br></font></div><div style="padding-right:39.6pt"><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:24pt;font-weight:400;line-height:100%">Eli Lilly and Company</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:24pt;font-weight:400;line-height:100%">Relative Value Award Agreement</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:24pt;font-weight:400;line-height:100%">(for Executive Officers)</font></div><div style="text-align:center"><font><br></font></div><div style="padding-left:18pt;padding-right:9pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Relative Value Award has been granted on &#91;&#8226;&#93; (&#8220;Grant Date&#8221;) by Eli Lilly and Company, an Indiana corporation, with its principal offices in Indianapolis, Indiana (&#8220;Lilly&#8221; or the &#8220;Company&#8221;), to the Eligible Individual who has received this Relative Value Award Agreement (the &#8220;Grantee&#8221;).</font></div><div style="padding-left:18pt;padding-right:39.6pt"><font><br></font></div><div style="padding-left:18pt;padding-right:39.6pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:400;line-height:100%">Lilly Relative Total Shareholder Return Performance Levels&#58;</font></div><div style="padding-left:18pt;padding-right:39.6pt"><font><br></font></div><div style="padding-left:17.61pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.666%"><tr><td style="width:1.0%"></td><td style="width:10.968%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.796%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.658%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.658%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.796%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.796%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.796%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.658%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.658%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.796%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.658%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.658%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.804%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#d9d9d9;border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 2.37pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Absolute Percentage Point (pp) Difference from Peer Median TSR</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:-2.7pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">&#60;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> -30pp</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:1.35pt;padding-right:1.35pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">-24.0 pp</font></div><div style="padding-right:-0.5pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">to</font></div><div style="padding-right:-0.55pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">-29.9 pp</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:-0.65pt;text-align:center;text-indent:-0.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">-18.0 pp</font></div><div style="padding-right:-0.65pt;text-align:center;text-indent:-0.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">to</font></div><div style="padding-right:-0.65pt;text-align:center;text-indent:-0.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">-23.9 pp</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:-0.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">-12.0 pp</font></div><div style="padding-right:-0.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">to</font></div><div style="padding-right:-0.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">-17.9 pp</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:-0.6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">-6.0 pp</font></div><div style="padding-right:-0.6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">to</font></div><div style="padding-right:-0.6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">-11.9 pp</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:-0.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">-0.01 pp</font></div><div style="padding-right:-0.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">to</font></div><div style="padding-right:-0.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">-5.9 pp</font></div></td><td colspan="3" style="background-color:#d9d9d9;border-left:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Peer Median</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">to</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">+5.9 pp</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">+6.0 pp</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">to</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">+11.9 pp</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">+12.0 pp</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">to</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">+17.9 pp</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">+18.0 pp</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">to</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">+23.9 pp</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">+24.0 pp</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">to</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">+29.9 pp</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">&#62;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> +30 pp</font></div></td></tr><tr><td colspan="3" style="background-color:#d9d9d9;border-bottom:0.75pt solid #000000;border-left:0.75pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 2.37pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Payout Multiple</font></td><td colspan="3" style="background-color:#f2f2f2;border-bottom:0.75pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">0.0</font></td><td colspan="3" style="background-color:#f2f2f2;border-bottom:0.75pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">0.25</font></td><td colspan="3" style="background-color:#f2f2f2;border-bottom:0.75pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">0.40</font></td><td colspan="3" style="background-color:#f2f2f2;border-bottom:0.75pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">0.55</font></td><td colspan="3" style="background-color:#f2f2f2;border-bottom:0.75pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">0.70</font></td><td colspan="3" style="background-color:#f2f2f2;border-bottom:0.75pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">0.85</font></td><td colspan="3" style="background-color:#d9d9d9;border-bottom:0.75pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.00</font></td><td colspan="3" style="background-color:#f2f2f2;border-bottom:0.75pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.15</font></td><td colspan="3" style="background-color:#f2f2f2;border-bottom:0.75pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.30</font></td><td colspan="3" style="background-color:#f2f2f2;border-bottom:0.75pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.45</font></td><td colspan="3" style="background-color:#f2f2f2;border-bottom:0.75pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.60</font></td><td colspan="3" style="background-color:#f2f2f2;border-bottom:0.75pt solid #000000;border-left:0.5pt solid #000000;border-right:0.75pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.75</font></td></tr></table></div><div style="padding-left:13.5pt;padding-right:18pt"><font><br></font></div><div style="padding-left:13.5pt;padding-right:39.6pt"><font><br></font></div><div style="padding-left:18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:400;line-height:100%">Performance Period&#58; &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:14pt;font-weight:400;line-height:100%">January 1, 2022 &#8211; December 31, 2024</font></div><div style="padding-left:128.25pt;padding-right:128.25pt;text-align:center;text-indent:-198pt"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:49.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:432pt;text-indent:36pt"><img alt="lillyfooter2.jpg" src="lillyfooter2.jpg" style="height:53px;margin-bottom:5pt;vertical-align:text-bottom;width:101px"></div></div></div><hr style="page-break-after:always"><div style="min-height:77.76pt;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Eli Lilly and Company Relative Value Award Agreement</font></div><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:400;line-height:100%">Table of Contents</font></div><div><font><br></font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:94.038%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.762%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 1.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Grant of Relative Value Award</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Vesting</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 3.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Impact of Certain Employment Status Changes</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 4.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Change in Control</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 5.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Settlement</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 6.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Rights of the Grantee</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 7.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Prohibition Against Transfer</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 8.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Responsibility for Taxes</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 9.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 409A Compliance</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 10.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Grantee&#8217;s Acknowledgment</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 11.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Data Privacy</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 12.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Restrictive Covenants, Remedies, and Additional Terms and Conditions</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">12</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 13.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Governing Law and Choice of Venue</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">15</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 14.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Miscellaneous Provisions</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">15</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 15.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Compensation Recovery</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">16</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 16.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Award Subject to Acknowledgement of Acceptance</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">16</font></div></td></tr></table></div><div style="padding-left:23.75pt"><font><br></font></div><div><font><br></font></div><div style="height:49.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Page 2</font></div></div></div><div id="ic134c9c6dae44d1c8861d41d7772d550_100"></div><hr style="page-break-after:always"><div style="min-height:92.16pt;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Eli Lilly and Company Relative Value Award</font></div><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 1.&#160;&#160;&#160;&#160;Grant of Relative Value Award</font></div><div style="margin-top:6pt;padding-left:22.3pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Eli Lilly and Company, an Indiana corporation (&#8220;Lilly&#8221; or the &#8220;Company&#8221;), has granted to the Eligible Individual who has received this Relative Value Award Agreement (the &#8220;Grantee&#8221;) a Performance-Based Award (the &#8220;Relative Value Award&#8221; or the &#8220;Award&#8221;) with respect to the target number of shares of Lilly Common Stock (the &#8220;Shares&#8221;) that the Grantee may view by logging on to the Merrill Lynch website at </font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">http&#58;&#47;&#47;myequity.lilly.com</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. (the &#34;Target Number of Shares&#34;).</font></div><div style="margin-top:6pt;padding-left:22.3pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Award is made pursuant to and subject to the terms and conditions set forth in the Amended and Restated 2002 Lilly Stock Plan (the &#8220;Plan&#8221;) and to the terms and conditions set forth in this Relative Value Award Agreement, including all appendices, exhibits and addenda hereto (the &#8220;Award Agreement&#8221;).  In the event of any conflict between the terms of the Plan and this Award Agreement, the terms of the Plan shall govern except with respect to the provisions described in Section 12 below (in which case, the terms of the Award Agreement shall govern). </font></div><div style="padding-left:22.5pt;text-align:justify"><font><br></font></div><div style="padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Any capitalized terms used but not defined in this Award Agreement shall have the meanings set forth in the Plan.  </font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 2.&#160;&#160;&#160;&#160;Vesting</font></div><div style="padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">As soon as reasonably practicable following the end of the Performance Period, the Committee shall determine the number of Shares that are eligible to vest which shall be equal to the product of (i) the Target Number of Shares, multiplied by (ii)&#160;the Payout Multiple, where&#58;  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;padding-right:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Payout Multiple</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean the payout multiple set forth in the Lilly Relative Total Shareholder Return Performance Levels table set forth on the first page of this document, representing the attainment level of Lilly&#8217;s rTSR, measured against the performance goal attainment levels set forth in the table.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;padding-right:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Final Lilly Stock Price</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean the average of the closing price of a share of Lilly Common Stock on the New York Stock Exchange for each trading day in the last two months of the Performance Period, rounded to the nearest cent. </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;padding-right:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">c.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Total Shareholder Return</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">TSR</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean the quotient of (i) the Final Lilly Stock Price or Final Peer Stock Price, as applicable, minus the corresponding Beginning Stock Price, including the impact of Dividend reinvestment on each ex-dividend date, if any, paid by the applicable issuer during the Performance Period, divided by (ii) the corresponding Beginning Stock Price.   </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;padding-right:72pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The stock prices and cash dividend payments reflected in the calculation of TSR shall be adjusted to reflect stock splits during the Performance Period and dividends shall be assumed to be reinvested in the relevant issuer&#8217;s shares for purposes of the calculation of TSR.   </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">d.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Relative Total Shareholder Return</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">rTSR</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean the comparison between Lilly&#8217;s TSR and the TSR of the Peer Group over the Performance Period, measured as the absolute percentage point difference in the performance of the Company&#8217;s TSR compared to the Peer Group&#8217;s median TSR.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">e.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Beginning Stock Price</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean the average closing price of a share of Lilly Common Stock on the New York Stock Exchange or a share of each Peer Group company&#8217;s stock, as applicable, for each trading day in the two month period immediately preceding the Performance Period, rounded to the nearest cent.   </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">f.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Final Peer Stock Price</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean the average of the closing price of a share of each Peer Group company&#8217;s stock, on Nasdaq, the New York Stock Exchange, or other market where an independent share price can be </font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Page 3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:92.16pt;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Eli Lilly and Company Relative Value Award Agreement</font></div><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;padding-right:72pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">determined, for each trading day in the last two months of the Performance Period, rounded to the nearest cent.   </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">g.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Dividend</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean ordinary or extraordinary cash dividends paid by Lilly or a Peer Group company to its shareholders of record at any time during the Performance Period.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">h.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Peer Group</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean all companies identified and most recently approved by the Committee as a member of the Company&#8217;s Peer Group in effect as of the Grant Date.  Companies that are members of the Peer Group at the beginning of the Performance Period that subsequently cease to be traded on a market where an independent share price can be determined shall be excluded from the Peer Group.   </font></div><div style="margin-top:6pt;padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In the event the Grantee&#8217;s Service is terminated prior to the end of the Performance Period for any reason or in any circumstance other than as described in Section 3 below, the Award shall be forfeited.  </font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 3.&#160;&#160;&#160;&#160;Impact of Certain Employment Status Changes</font></div><div style="margin-top:6pt;padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Unless the Committee determines, in its sole discretion, that such treatment is not advisable after consideration of Applicable Laws, the number of Shares that are eligible to vest upon a change in employment status of the Grantee during the Performance Period will be as follows&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Leaves of Absence</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In the event the Grantee is on an approved leave of absence during the Performance Period, the number of Shares eligible to vest shall be the number determined in accordance with Section 2 above.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Retirement&#59; Death&#59; Disability</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Except as otherwise provided below (including Section 12), in the event the Grantee&#8217;s Service is terminated (i) on or following the Retirement Vesting Date (A) due to the Grantee&#8217;s Retirement or (B) due to the Grantee&#8217;s Qualifying Termination (as defined below) on a date that the Grantee is eligible for Retirement, (ii) due to the Grantee&#8217;s death, or (iii) by reason of Grantee&#8217;s Disability, the number of Shares eligible to vest shall be the number determined in accordance with Section 2 above.  For the avoidance of any doubt, the Award shall be forfeited in the event the Grantee&#8217;s Service is terminated prior to the Retirement Vesting Date due to the Grantee&#8217;s Retirement. </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;Retirement&#8221; means retirement as a &#8220;retiree,&#8221; which is a person who is (A) a retired employee under The Lilly Retirement Plan&#59; (B) a retired employee under the retirement plan or program of an Affiliate&#59; (C) a retired employee under a retirement program specifically approved by the Committee&#59; (D) required to retire under local law, to the extent authorized by the Company to address such local requirements or (E) otherwise determined to be a retired employee in the sole discretion of the Company.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;Retirement Vesting Date&#8221; means the date that is on or following December 31 immediately following the commencement of the Performance Period.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;Disability&#8221; for purposes of this Award Agreement means that the Grantee would qualify to receive benefit payments under the long-term disability plan or policy, as it may be amended from time to time, of the Company or the Affiliate that employs the Grantee (the &#8220;Employer&#8221;).  If the Company or the Employer does not have a long-term disability plan or policy, &#8220;Disability&#8221; means that the Grantee is unable to carry out the responsibilities and functions of the position held by the Grantee by reason of any medically determined physical or mental impairment for a period of at least ninety (90) consecutive days as determined by the Company or Employer.  The Grantee shall not be considered to have incurred a Disability unless he or she furnishes proof of such impairment sufficient to satisfy the Company as it determines in its sole discretion.  </font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Page 4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:92.16pt;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Eli Lilly and Company Relative Value Award Agreement</font></div><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">c.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Qualifying Termination</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Except as otherwise provided in section 3(b), in the event the Grantee&#8217;s employment is subject to a Qualifying Termination (as defined below), the number of Shares eligible to vest shall be the number determined in accordance with Section 2 above, reduced proportionally for the portion of the total days during the Performance Period in which the Grantee was not in active Service.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">For purposes of this Award Agreement, a &#8220;Qualifying Termination&#8221; means the termination of the Grantee's Service under any one of the following circumstances&#58;  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">i.&#160;&#160;&#160;&#160;due to a plant closing or reduction in workforce (as defined below)&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ii.&#160;&#160;&#160;&#160;as a result of the Grantee&#8217;s failure to locate a position within the Company or an Affiliate following the placement of the Grantee on reallocation or medical reassignment in the United States (or equivalent as determined by the Committee).</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;Plant closing&#8221; means the closing of a plant site or other corporate location that directly results in termination of the Grantee&#8217;s Service. </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;Reduction in workforce&#8221; means the elimination of a work group, functional or business unit or other broadly applicable reduction in job positions that directly results in termination of the Grantee&#8217;s Service.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">d.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Demotions, Disciplinary Actions and Misconduct</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Committee may, in its sole discretion, cancel this Relative Value Award or reduce the number of Shares eligible to vest, prorated according to time or other measure as determined appropriate by the Committee, if during any portion of the Performance Period the Grantee has been (i) subject to disciplinary action by the Company or (ii) determined to have committed a material violation of law or Company policy or to have failed to properly manage or monitor the conduct of an employee who has committed a material violation of law or Company policy whereby, in either case, such conduct causes significant harm to the Company, as determined in the sole discretion of the Company.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Committee&#8217;s determination as to whether (1) a leave of absence or a transfer of employment between Lilly and an Affiliate or between Affiliates constitutes a termination of Service, (2) the Grantee&#8217;s Service has been terminated by reason of Disability or Retirement, (3) the Grantee is eligible for Retirement, (4) the Grantee&#8217;s Service has been terminated as a result a direct result of either a plant closing or a reduction in force and (5) the Grantee&#8217;s Service has been terminated of as a result of the failure to locate a position within the Company or an Affiliate following reallocation or medical reassignment shall be final and binding on the Grantee.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Page 5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:92.16pt;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Eli Lilly and Company Relative Value Award Agreement</font></div><div><font><br></font></div></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 4.&#160;&#160;&#160;&#160;Change in Control</font></div><div style="margin-bottom:12pt;padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:115%">The provisions of Section 13.2 of the Plan apply to this Award with the following modifications&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.&#160;&#160;&#160;&#160;The only Change in Control event that shall result in a benefit under this Section 4 shall be the consummation of a merger, share exchange, or consolidation of the Company, as defined in Section 2.6(c) of the Plan (a &#8220;Transaction&#8221;).</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.&#160;&#160;&#160;&#160;In the event of a Transaction that occurs prior to the end of the Performance Period, the Grantee will be credited with an award of Restricted Stock Units equal to the number of Shares eligible to vest, calculated in a manner consistent with Section 2, but the Final Lilly Stock Price shall be equal to the value of Shares established for the consideration to be paid to holders of Shares in the Transaction and the Final Peer Stock Price shall be equal to the closing price of a share of each Peer Group company&#8217;s stock, on Nasdaq, the New York Stock Exchange, or other market where an independent share price can be determined, on the date the Transaction closes (or if such day is not a trading date, the first trading date immediately preceding such date) (the &#8220;Credited RSU Award&#8221;).  The Credited RSU Award shall be eligible to vest on the last day of the Performance Period, subject to the Grantee&#8217;s continued Service through the last day of the Performance Period, except as provided below&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">i.&#160;&#160;&#160;&#160;In the event that the Credited RSU Award is not converted, assumed, substituted, continued or replaced by a successor or surviving corporation, or a parent or subsidiary thereof, in connection with a Transaction, then immediately prior to the Transaction, the Credited RSU Award shall vest automatically in full.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ii.&#160;&#160;&#160;&#160;In the event that the Credited RSU Award is converted, assumed, substituted, continued or replaced by a successor or surviving corporation, or a parent or subsidiary thereof, in connection with the Transaction and the Grantee is subject to a Covered Termination (as defined below) prior to the end of the Performance Period, then immediately as of the date of the Covered Termination, the Credited RSU Award shall vest automatically in full. </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">For purposes of this Award Agreement, &#8220;Covered Termination&#8221; shall mean a termination of Service as described in Sections 3(b) and (c), Grantee&#8217;s termination of Service without Cause or the Grantee&#8217;s resignation for Good Reason.  &#8220;Cause&#8221; and &#8220;Good Reason&#8221; shall have the meanings ascribed to them in the Eli Lilly and Company 2007 Change in Control Severance Pay Plan for Select Employees (as amended from time to time) or any successor plan or arrangement thereto.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:13pt;font-weight:400;line-height:100%">c.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If the Grantee is entitled to receive stock of the acquiring entity or successor to the Company as a result of the application of this Section 4, then references to Shares in this Award Agreement shall be read to mean stock of the successor or surviving corporation, or a parent or subsidiary thereof, as and when applicable.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 5.&#160;&#160;&#160;&#160;Settlement  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.&#160;&#160;&#160;&#160;Except as provided below, the Award shall be paid to the Grantee as soon as practicable, but in no event later than sixty (60) days, following the last day of the Performance Period.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.&#160;&#160;&#160;&#160;If the Award vests pursuant to Section 4(b)(i), the Award shall be paid to the Grantee immediately prior to the Transaction, provided that if the Award is considered an item of non-qualified deferred compensation subject to Section 409A of the Code (&#8220;NQ Deferred Compensation&#8221;) and the Transaction does not constitute a &#8220;change in control event,&#8221; within the meaning of the U.S. Treasury Regulations (a &#8220;409A CIC&#8221;), then the Award shall be paid in cash (calculated based on the value of the Shares established for the consideration to be paid to holders of Shares in the Transaction) on the earliest of (i) the date that the Grantee experiences a &#8220;separation from service&#8221; within the meaning of </font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Page 6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:92.16pt;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Eli Lilly and Company Relative Value Award Agreement</font></div><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 409A of the Code (a &#8220;Section 409A Separation&#8221;), provided that if the Grantee is a &#8220;specified employee&#8221; within the meaning of Section 409A of the Code as of the payment date, the Award shall instead be paid on the first day following the six (6) month anniversary of the Grantee&#8217;s Section 409A Separation, (ii) the date of the Grantee&#8217;s death and (iii) the date set forth in Section 5(a) above.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">c.&#160;&#160;&#160;&#160;If the Award vests pursuant to Section 4(b)(ii), the Award shall be paid to the Grantee as soon as practicable, but in no event later than sixty (60) days, following the date the Grantee is subject to a Covered Termination, provided that if the Award is NQ Deferred Compensation, (i) the Award shall be paid within sixty (60) days following the date the Grantee experiences a Section 409A Separation, and (ii)&#160;if the Grantee is a &#8220;specified employee&#8221; within the meaning of Section 409A of the Code as of the payment date, the Award shall instead be paid on the earliest of (1) the first day following the six (6) month anniversary of the Grantee&#8217;s Section 409A Separation and (2) the date of the Grantee&#8217;s death.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">d.&#160;&#160;&#160;&#160;At the time of settlement provided in this Section 5,</font><font style="color:#0000ff;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Lilly shall issue or transfer Shares or the cash equivalent, as contemplated under Section 5(e) below, to the Grantee.  In the event the Grantee is entitled to a fractional Share, the fraction may be paid in cash or rounded, in the Committee&#8217;s discretion.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">e.&#160;&#160;&#160;&#160;At any time prior to the end of the Performance Period or until the Award is paid in accordance with this Section 5, the Committee may, if it so elects, determine to pay part or all of the Award in cash in lieu of issuing or transferring Shares.  The amount of cash shall be calculated based on the Fair Market Value of the Shares on the last day of the Performance Period in the case of payment pursuant to Section 5(a) and on the date of payment in the case of a payment pursuant to Section 5(c). </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">f.&#160;&#160;&#160;&#160;In the event of the death of the Grantee, the payments described above shall be made to the successor of the Grantee.  </font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 6.&#160;&#160;&#160;&#160;Rights of the Grantee</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">No Shareholder Rights</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Relative Value Award does not entitle the Grantee to any rights of a shareholder of Lilly until such time as the Relative Value Award is settled and Shares are issued or transferred to the Grantee.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">No Trust&#59; Grantee&#8217;s Rights Unsecured.</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Neither this Award Agreement nor any action in accordance with this Award Agreement shall be construed to create a trust of any kind.  The right of the Grantee to receive payments of cash or Shares pursuant to this Award Agreement shall be an unsecured claim against the general assets of the Company.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 7.&#160;&#160;&#160;&#160;Prohibition Against Transfer</font></div><div style="margin-top:6pt;padding-left:22.3pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The right of a Grantee to receive payments of Shares and&#47;or cash under this Award may not be transferred except to a duly appointed guardian of the estate of the Grantee or to a successor of the Grantee by will or the applicable laws of descent and distribution and then only subject to the provisions of this Award Agreement.  A Grantee may not assign, sell, pledge, or otherwise transfer Shares or cash to which he or she may be entitled hereunder prior to transfer or payment thereof to the Grantee, and any such attempted assignment, sale, pledge or transfer shall be void.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Page 7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:92.16pt;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Eli Lilly and Company Relative Value Award Agreement</font></div><div><font><br></font></div></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 8.&#160;&#160;&#160;&#160;Responsibility for Taxes</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.&#160;&#160;&#160;&#160;Regardless of any action Lilly and&#47;or the Employer takes with respect to any or all income tax (including federal, state, local and non-U.S. tax), social insurance, payroll tax, fringe benefits tax, payment on account or other tax related items related to the Grantee&#8217;s participation in the Plan and legally applicable to the Grantee (&#8220;Tax Related Items&#8221;), the Grantee acknowledges that the ultimate liability for all Tax Related Items is and remains the Grantee&#8217;s responsibility and may exceed the amount actually withheld by Lilly or the Employer.  The Grantee further acknowledges that Lilly and the Employer (i)&#160;make no representations or undertakings regarding the treatment of any Tax Related Items in connection with any aspect of the Award, including the grant of the Relative Value Award, the vesting of the Relative Value Award, the transfer and issuance of any Shares, the receipt of any cash payment pursuant to the Award, the receipt of any dividends and the sale of any Shares acquired pursuant to this Award&#59; and (ii)&#160;do not commit to and are under no obligation to structure the terms of the grant or any aspect of the Award to reduce or eliminate the Grantee&#8217;s liability for Tax Related Items or achieve any particular tax result.  Furthermore, if the Grantee becomes subject to Tax Related Items in more than one jurisdiction, the Grantee acknowledges that the Company and&#47;or the Employer (or former employer, as applicable) may be required to withhold or account for Tax Related Items in more than one jurisdiction.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.&#160;&#160;&#160;&#160;Prior to the applicable taxable or tax withholding event, as applicable, the Grantee shall pay or make adequate arrangements satisfactory to Lilly and&#47;or the Employer to satisfy all Tax Related Items.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">i.&#160;&#160;&#160;&#160;If the Relative Value Award is paid to the Grantee in cash in lieu of Shares, the Grantee authorizes the Company and&#47;or the Employer, or their respective agents, at their discretion, to satisfy any obligation for Tax Related Items by withholding from the cash amount paid to the Grantee pursuant to the Award or from the Grantee&#8217;s wages or other cash compensation paid to the Grantee by the Company and&#47;or the Employer.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ii.&#160;&#160;&#160;&#160;If the Relative Value Award is paid to the Grantee in Shares and the Grantee is not subject to the short-swing profit rules of Section 16(b) of the Exchange Act, the Grantee authorizes Lilly and&#47;or the Employer, or their respective agents, at their discretion, to (A) withhold from the Grantee&#8217;s wages or other cash compensation paid to the Grantee by the Company and&#47;or the Employer, (B) arrange for the sale of Shares to be issued upon settlement of the Award (on the Grantee&#8217;s behalf and at the Grantee&#8217;s direction pursuant to this authorization or such other authorization as the Grantee may be required to provide to Lilly or its designated broker in order for such sale to be effectuated) and withhold from the proceeds of such sale, (C) withhold in Shares otherwise issuable to the Grantee pursuant to this Award, and&#47;or (D) apply any other method of withholding determined by the Company and, to the extent required by Applicable Laws or the Plan, approved by the Committee.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">iii.&#160;&#160;&#160;&#160;If the Relative Value Award is paid to the Grantee in Shares and the Grantee is subject to the short-swing profit rules of Section 16(b) of the Exchange Act, Lilly will withhold in Shares otherwise issuable to the Grantee pursuant to this Award, unless the use of such withholding method is prevented by Applicable Laws or has materially adverse accounting or tax consequences, in which case the withholding obligation for Tax Related Items may be satisfied by one or a combination of the methods set forth in Section 8(b)(ii)(A) and (B) above.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">c.&#160;&#160;&#160;&#160;Depending on the withholding method, Lilly and&#47;or the Employer may withhold or account for Tax Related Items by considering applicable statutory or other withholding rates, including minimum or maximum rates in the jurisdiction(s) applicable to the Grantee.  In the event of over-withholding, the Grantee may receive a refund of any over-</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Page 8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:92.16pt;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Eli Lilly and Company Relative Value Award Agreement</font></div><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">withheld amount in cash (without interest and without entitlement to the equivalent amount in Shares).  If the obligation for Tax Related Items is satisfied by withholding Shares, for tax purposes, the Grantee will be deemed to have been issued the full number of Shares to which he or she is entitled pursuant to this Award, notwithstanding that a number of Shares are withheld to satisfy the obligation for Tax Related Items.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">d.&#160;&#160;&#160;&#160;Lilly may refuse to deliver Shares or any cash payment to the Grantee if the Grantee fails to comply with the Grantee&#8217;s obligation in connection with the Tax Related Items as described in this Section 8. </font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:400;line-height:100%">Section 9.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 409A Compliance</font></div><div style="padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">To the extent applicable, it is intended that this Award comply with the requirements of Section 409A of the U.S. Internal Revenue Code of 1986, as amended and the Treasury Regulations and other guidance issued thereunder (&#8220;Section 409A&#8221;) and this Award shall be interpreted and applied by the Committee in a manner consistent with this intent in order to avoid the imposition of any additional tax under Section 409A.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 10.&#160;&#160;&#160;&#160;Grantee&#8217;s Acknowledgment</font></div><div style="padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In accepting this Award, the Grantee acknowledges, understands and agrees that&#58;</font></div><div style="padding-left:22.5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.&#160;&#160;&#160;&#160;the Plan is established voluntarily by Lilly, it is discretionary in nature and it may be modified, amended, suspended or terminated by Lilly at any time, as provided in the Plan&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.&#160;&#160;&#160;&#160;the Award is voluntary and occasional and does not create any contractual or other right to receive future Performance-Based Awards, or benefits in lieu thereof, even if Performance-Based Awards have been granted in the past&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">c.&#160;&#160;&#160;&#160;all decisions with respect to future Performance-Based Awards or other awards, if any, will be at the sole discretion of the Committee&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">d.&#160;&#160;&#160;&#160;the Grantee&#8217;s participation in the Plan is voluntary&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">e.&#160;&#160;&#160;&#160;the Award and any Shares subject to the Award are not intended to replace any pension rights or compensation&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">f.&#160;&#160;&#160;&#160;the Award and any Shares subject to the Award, and the income and value of same, are not part of normal or expected compensation for any purpose, including but not limited to, calculating any severance, resignation, termination, redundancy, dismissal, end of service payments, bonuses, long-service awards, holiday pay, leave pay, pension or welfare or retirement benefits or similar mandatory payments&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">g.&#160;&#160;&#160;&#160;unless otherwise agreed with Lilly, the Award and any Shares subject to the Award, and the income and value of same, are not granted as consideration for, or in connection with, the service the Grantee may provide as a director of an Affiliate&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">h.&#160;&#160;&#160;&#160;neither the Award nor any provision of this Award Agreement, the Plan or the policies adopted pursuant to the Plan, confer upon the Grantee any right with respect to employment or continuation of current employment, and in the event that the Grantee is not an employee of Lilly or any subsidiary of Lilly, the Award shall not be interpreted to form an employment contract or relationship with Lilly or any Affiliate&#59; </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">i.&#160;&#160;&#160;&#160;the future value of the underlying Shares is unknown, indeterminable and cannot be predicted with certainty&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">j.&#160;&#160;&#160;&#160;no claim or entitlement to compensation or damages shall arise from forfeiture of the Award resulting from the Grantee ceasing to provide employment or other services to Lilly or the Employer (for any reason whatsoever, whether or not later found to be invalid or in </font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Page 9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:92.16pt;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Eli Lilly and Company Relative Value Award Agreement</font></div><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">breach of local labor laws in the jurisdiction where the Grantee is employed or the terms of Grantee&#8217;s employment agreement, if any)&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">k.&#160;&#160;&#160;&#160;for purposes of the Award, the Grantee&#8217;s employment will be considered terminated as of the date he or she is no longer actively providing services to the Company or an Affiliate and the Grantee&#8217;s right, if any, to earn and be paid any portion of the Award after such termination of employment&#160;or services (regardless of the reason for such termination&#160;and whether or not such termination is later found to be invalid or in breach of employment laws in the jurisdiction where the Grantee is employed or the terms of the Grantee&#8217;s employment agreement, if any)&#160;will be measured by the date the Grantee ceases to&#160;actively&#160;provide services and will not be extended by any notice period (e.g., active&#160;service would not include any contractual notice period or any&#160;period of &#8220;garden leave&#8221; or similar period&#160;mandated under employment laws in the jurisdiction where the Grantee is employed or the terms of the Grantee&#8217;s employment agreement, if any)&#59; the Committee shall have the exclusive discretion to determine when the Grantee is no longer actively&#160;providing services&#160;for purposes of the Award (including whether the Grantee may still be considered&#160;to be actively&#160;providing services&#160;while on a leave of absence) in accordance with Section 409A&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">l.&#160;&#160;&#160;&#160;unless otherwise provided in the Plan or by the Committee in its discretion, the Award and the benefits evidenced by this Award Agreement do not create any entitlement to have the Award or any such benefits transferred to, or assumed by, another company nor to be exchanged, cashed out or substituted for, in connection with any corporate transaction affecting the Shares&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">m.&#160;&#160;&#160;&#160;the Grantee is solely responsible for investigating and complying with any laws applicable to him or her in connection with the Award&#59; and </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">n.&#160;&#160;&#160;&#160;neither the Company, the Employer nor any Affiliate shall be liable for any foreign exchange rate fluctuation between the Grantee&#8217;s local currency and the United States Dollar that may affect the value of the Award or any amounts due to the Grantee pursuant to the settlement of the Award or the subsequent sale of any Shares acquired upon settlement.   </font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:400;line-height:100%">Section 11.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Data Privacy</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">a.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">Data Collection and Usage</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">.  The Company and the Employer may collect, process and use certain personal information about the Grantee, and persons closely associated with the Grantee, including, but not limited to, the Grantee&#8217;s name, home address and telephone number, email address, date of birth, social insurance number, passport or other identification number (e.g., resident registration number), salary, nationality, job title, any shares of stock or directorships held in the Company, details of all Relative Value Awards or any other entitlement to shares of stock awarded, canceled, exercised, vested, unvested or outstanding in the Grantee&#8217;s favor (&#8220;Data&#8221;), for the purposes of implementing, administering and managing the Plan.  The legal basis, where required, for the processing of Data is the Grantee&#8217;s consent.  Where required under Applicable Laws, Data may also be disclosed to certain securities or other regulatory authorities where the Company&#8217;s securities are listed or traded or regulatory filings are made and the legal basis, where required, for such disclosure are the Applicable Laws.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">b.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">Stock Plan Administration Service Providers</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">.  The Company transfers Data to Bank of America Merrill Lynch and&#47;or its affiliated companies (&#8220;Merrill Lynch&#8221;), an independent service provider, which is assisting the Company with the implementation, administration and management of the Plan.  In the future, the Company may select a different service provider and share Data with such other provider serving in a similar manner.  The Grantee may be asked to agree on separate terms and data processing practices with the service provider, with such agreement being a condition to the ability to participate in the Plan.  The </font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Page 10</font></div></div></div><hr style="page-break-after:always"><div style="min-height:92.16pt;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Eli Lilly and Company Relative Value Award Agreement</font></div><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Company may also transfer Data to KPMG, an independent service provider, which is also assisting the Company with certain aspects of the implementation, administration and management of the Plan.  In the future, the Company may select a different service provider and share Data with such other provider serving in a similar manner.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">c.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">International Data Transfers</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">.  The Company and its service providers are based in the United States.  The Grantee&#8217;s country or jurisdiction may have different data privacy laws and protections than the United States.  The Company&#8217;s legal basis, where required, for the transfer of Data is Grantee&#8217;s consent.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">d.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">Data Retention</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">.  The Company will hold and use the Data only as long as is necessary to implement, administer and manage the Grantee&#8217;s participation in the Plan, or as required to comply with legal or regulatory obligations, including under tax and security laws.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">e.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">Voluntariness and Consequences of Consent Denial or Withdrawal</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">.  Participation in the Plan is voluntary and the Grantee is providing the consents herein on a purely voluntary basis.  If the Grantee does not consent, or if the Grantee later seeks to revoke the Grantee&#8217;s consent, the Grantee&#8217;s salary from or employment and career with the Employer will not be affected&#59; the only consequence of refusing or withdrawing the Grantee&#8217;s consent is that the Company would not be able to grant this Award or other awards to the Grantee or administer or maintain such awards.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">f.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">Data Subject Rights</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">. The Grantee understands that data subject rights regarding the processing of Data vary depending on Applicable Laws and that, depending on where the Grantee is based and subject to the conditions set out in such Applicable Laws, the Grantee may have, without limitation, the right to (i) inquire whether and what kind of Data the Company holds about the Grantee and how it is processed, and to access or request copies of such Data, (ii) request the correction or supplementation of Data about the Grantee that is inaccurate, incomplete or out-of-date in light of the purposes underlying the processing, (iii) obtain the erasure of Data no longer necessary for the purposes underlying the processing, (iv) request the Company to restrict the processing of the Grantee&#8217;s Data in certain situations where the Grantee feels its processing is inappropriate, (v) object, in certain circumstances, to the processing of Data for legitimate interests, and to (vi) request portability of the Grantee&#8217;s Data that the Grantee has actively or passively provided to the Company or the Employer (which does not include data derived or inferred from the collected data), where the processing of such Data is based on consent or the Grantee&#8217;s employment and is carried out by automated means.  In case of concerns, the Grantee understands that he or she may also have the right to lodge a complaint with the competent local data protection authority.  Further, to receive clarification of, or to exercise any of, the Grantee&#8217;s rights, the Grantee understands that he or she should contact his or her local human resources representative.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">g.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">Declaration of Consent</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">.  By accepting the Award and indicating consent via the Company&#8217;s online acceptance procedure, the Grantee is declaring that he or she agrees with the data processing practices described herein and consents to the collection, processing and use of Data by the Company and the transfer of Data to the recipients mentioned above, including recipients located in countries which do not adduce an adequate level of protection from a European (or other non-U.S.) data protection law perspective, for the purposes described above.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Page 11</font></div></div></div><hr style="page-break-after:always"><div style="min-height:92.16pt;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Eli Lilly and Company Relative Value Award Agreement</font></div><div><font><br></font></div></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 12.&#160;&#160;&#160;&#160;Restrictive Covenants, Remedies, and Additional Terms and Conditions</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Restrictive Covenants</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In consideration of the Grantee&#8217;s receipt of the Award from Lilly, the Grantee agrees that during the Grantee&#8217;s employment with Lilly or an Affiliate that the Grantee provided services to or had access to confidential information concerning (&#8220;Covered Affiliate&#8221;) and for twelve (12) months immediately following the end of the Grantee&#8217;s employment (regardless of reason), the Grantee will not directly or indirectly, on a worldwide basis, engage in any of the following activities&#58;</font></div><div style="margin-bottom:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">i.&#160;&#160;&#160;&#160;Work for, advise, manage, act as an agent, employee or consultant for, or otherwise provide any services, in a Competitively-Sensitive Capacity, to&#58; (a) any person or entity engaged in research, development, production, sale, or distribution of a product or service competitive with or substantially similar to any product or service in research, development or design, or manufactured, produced, sold, or distributed by Lilly or a Covered Affiliate&#59; or (b) any person or entity that otherwise competes or intends to compete with Lilly or a Covered Affiliate.    </font></div><div style="margin-bottom:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ii.&#160;&#160;&#160;&#160;Directly or indirectly solicit, urge, divert, induce, or seek to induce any of Lilly&#8217;s (or Covered Affiliate&#8217;s) independent contractors, subcontractors, business partners, distributors, brokers, consultants, sales representatives, customers, vendors, suppliers or any other person with whom Lilly or Covered Affiliate has a business relationship and with whom the Grantee interacted during the Grantee&#8217;s employment with Lilly or Covered Affiliate to terminate their relationship with, or representation of, Lilly or Covered Affiliate or to cancel, withdraw, reduce, limit or in any manner modify any such person's business with, or representation of, Lilly or a Covered Affiliate. </font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Grantee acknowledges and agrees that any Lilly Affiliate is an intended third-party beneficiary of this Award Agreement, which may be enforced by Lilly or any such Affiliate, either singularly or jointly.</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">For purposes of this Award Agreement, &#8220;Competively-Sensitive Capacity&#8221; means&#58; (A)&#160;the same or similar capacity or function in which the Grantee worked for Lilly or a Covered Affiliate at any time during the two (2) years immediately preceding the end of the Grantee&#8217;s employment&#59; (B)&#160;any officer, director, executive or senior management capacity or function&#59; (C)&#160;any research and development capacity or function&#59; (D)&#160;any sales management or business development management capacity or function&#59; (E)&#160;any ownership capacity (except the Grantee may own as a passive investment up to 2% of any publicly traded securities)&#59; and&#47;or (F)&#160;any other capacity or function in which there is a material risk that the Grantee likely would inevitably use or disclose trade secrets and&#47;or confidential information Lilly or a Covered Affiliate.  For purposes of clarity, if a competing business has multiple divisions, lines or segments, some of which are not competitive with the business of Lilly, including its Covered Affiliates, nothing in this Award Agreement will prohibit the Grantee from being employed by, working for or assisting only that division, line or segment of such competing business that is not competitive with the business of Lilly or a Covered Affiliate, provided the Grantee is not involved in a Competitively-Sensitive Capacity in the research, development, manufacture, provision or sale of any products that compete with any products of Lilly or a Covered Affiliate.</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Grantee and Lilly acknowledge and agree that the worldwide geographic scope of the foregoing covenants is reasonable and necessary given, among other things, that&#58; (a)&#160;absent the restrictions, the Grantee could utilize Lilly&#8217;s (or its Affiliates) trade secrets and&#47;or confidential information and compete with Lilly or Affiliate from virtually anywhere&#59; and (b)&#160;such scope is the only way for Lilly and its Affiliates to protect their trade secrets and confidential information.  In the event the Grantee violates any of the restrictive covenants contained herein, their duration will automatically be extended by </font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Page 12</font></div></div></div><hr style="page-break-after:always"><div style="min-height:92.16pt;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Eli Lilly and Company Relative Value Award Agreement</font></div><div><font><br></font></div></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the length of time during which the Grantee was in violation of any of the restrictive covenants.</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Grantee acknowledges and agrees that during the course of the Grantee&#8217;s employment with Lilly or a Covered Affiliate, the Grantee will become intimately familiar with confidential information and trade secrets key to its unique competitive advantage.  The Grantee also acknowledges and agrees that Lilly&#8217;s (and Covered Affiliate&#8217;s) confidential information and trade secrets will retain continuing vitality throughout and beyond the one-year restricted period.  And the Grantee acknowledges and agrees that, should the Grantee leave Lilly or Covered Affiliate and, near the Grantee&#8217;s departure from Lilly or Covered Affiliate, work with another person or entity that engages in business activities similar to those of Lilly and&#47;or Covered Affiliate, it would be highly likely, if not inevitable, that the Grantee would rely on confidential information of Lilly and&#47;or Covered Affiliate in the course of the Grantee&#8217;s work, either consciously or subconsciously, harming Lilly and any Covered Affiliates.  For these and other reasons, the Grantee agrees that the restrictions above are reasonably necessary to protect Lilly&#8217;s and its Covered Affiliate&#8217;s legitimate business interests, and do so by creating a specific amount of time after the Grantee&#8217;s employment ends during which the Grantee will not be able to engage or prepare to engage in the activities above.</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Grantee and Lilly further acknowledge and agree that if any particular covenant or provision is determined to be unreasonable or unenforceable for any reason, including, without limitation, the time period, geographic area, and&#47;or scope of activity covered by any restrictive covenant, such covenant or provision will automatically be deemed reformed so that the contested covenant or provision will have the closest effect permitted by applicable law to the original form and will be given effect and enforced as so reformed to whatever extent would be reasonable and enforceable under applicable law.  Any court interpreting any restrictive covenant provision of this Award Agreement will, if necessary, reform any such provision to make it enforceable under applicable law.</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Award Agreement is intended, among other things, to supplement (and not supersede) all applicable statutes protecting trade secrets and the duties the Grantee owes to Lilly and&#47;or Covered Affiliates under the common law, as well as any other non-competition, non-solicitation, or confidentiality provisions that the Grantee agreed to in the past, including those in the Grantee&#8217;s Employee Confidentiality and Invention Agreement, each of which remains in full force and effect, or that the Grantee agrees to in the future.</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Grantee acknowledges that a breach by the Grantee of this Award Agreement will give rise to irreparable injury to Lilly and Covered Affiliates and money damages will not be adequate relief for such injury.  As a result, the Grantee agrees that Lilly (including any third party beneficiary) will be entitled to obtain equitable or injunctive relief without having to post any bond or other security to restrain or prohibit any such breach or threatened breach, in addition to any other remedies which may be available, including the recovery of monetary damages from the Grantee.</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Remedies</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:700;line-height:100%">  </font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If the Company determines that the Grantee has violated any applicable provisions of this Section 12, in addition to injunctive relief and damages, the Grantee agrees and covenants that&#58; (i) the Award shall be immediately rescinded&#59; (ii) the Grantee shall automatically forfeit any rights the Grantee may have with respect to the Award as of the date of such determination, including the rights to continue to be eligible to vest or receive a payment under the Award&#59; and (iii) the foregoing remedies set forth in this Section 12 shall not be Lilly&#8217;s exclusive remedies.  Lilly reserves all other rights and remedies available to it at law or in equity.</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">c.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Country-Specific Conditions</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In addition, the Award shall be subject to any special terms and conditions set forth in any Appendix to this Award Agreement for the Grantee&#8217;s </font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Page 13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:92.16pt;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Eli Lilly and Company Relative Value Award Agreement</font></div><div><font><br></font></div></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">country.  Moreover, if the Grantee relocates to one of the countries included in the Appendix, the special terms and conditions for such country will apply to the Grantee, to the extent the Company determines that the application of such terms and conditions is necessary or advisable for legal or administrative reasons.  The Appendix constitutes part of this Award Agreement.</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">d.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Insider Trading &#47; Market Abuse Laws</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The Grantee may be subject to insider trading restrictions and&#47;or market abuse laws in applicable jurisdictions, including but not limited to the United States and the Grantee&#8217;s country of residence, which may affect the Grantee&#8217;s ability to directly or indirectly, for the Grantee or for a third party, acquire or sell, or attempt to sell, or otherwise dispose of Shares, rights to acquire Shares (e.g., the Relative Value Award) under the Plan during such times as the Grantee is considered to have &#8220;inside information&#8221; regarding the Company (as determined under the laws or regulations in the applicable jurisdictions).&#160; Any restrictions under these laws or regulations are separate from and in addition to any restrictions that may be imposed under any applicable Company insider trading policy.&#160; The Grantee acknowledges that it is his or her responsibility to comply with any applicable restrictions, and the Grantee should consult with his or her personal legal advisor on this matter.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">e.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Imposition of Other Requirements</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Company reserves the right to impose other requirements on the Award and any Shares acquired under the Plan, to the extent the Company determines it is necessary or advisable for legal or administrative reasons, and to require the Grantee to execute any additional agreements or undertakings that may be necessary to accomplish the foregoing.  Without limitation to the foregoing, the Grantee agrees that the Relative Value Award and any benefits or proceeds the Grantee may receive hereunder shall be subject to forfeiture and&#47;or repayment to the Company to the extent required to comply with any requirements imposed under Applicable Laws or any compensation recovery policy of the Company that reflects the provisions of Applicable Laws.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Page 14</font></div></div></div><hr style="page-break-after:always"><div style="min-height:92.16pt;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Eli Lilly and Company Relative Value Award Agreement</font></div><div><font><br></font></div></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 13.&#160;&#160;&#160;&#160;Governing Law and Choice of Venue</font></div><div style="margin-top:6pt;padding-left:22.3pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The validity, construction, and enforcement of this Award Agreement shall be governed by the laws of the State of Indiana, U.S.A. without regard to laws that might cause other law to govern under applicable principles of conflict of laws or cause the application of substantive law of any jurisdiction other than Indiana.  For purposes of litigating any dispute that arises under this Award Agreement, the parties hereby submit to and consent to the jurisdiction and venue of the State of Indiana, and agree that such litigation shall be conducted exclusively in the courts having appropriate subject matter jurisdiction in Marion</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">County, Indiana, or the federal courts for the United States for the Southern District of Indiana, and no other courts, where this Award is granted and&#47;or to be performed.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 14.&#160;&#160;&#160;&#160;Miscellaneous Provisions</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Notices and Electronic Delivery and Participation</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Any notice to be given by the Grantee or successor Grantee shall be in writing, and any notice shall be deemed to have been given or made only upon receipt thereof by the Corporate Secretary of Lilly at Lilly Corporate Center, Indianapolis, Indiana 46285, U.S.A.  Any notice or communication by Lilly in writing shall be deemed to have been given in the case of the Grantee if mailed or delivered to the Grantee at any address specified in writing to Lilly by the Grantee and, in the case of any successor Grantee, at the address specified in writing to Lilly by the successor Grantee.  In addition, Lilly may, in its sole discretion, decide to deliver any documents related to the Award and participation in the Plan by electronic means or request the Grantee&#8217;s consent to participate in the Plan by electronic means.  By accepting this Award, the Grantee hereby consents to receive such documents by electronic delivery and agrees to participate in the Plan through an on-line or electronic system established and maintained by Lilly or a third party designated by Lilly.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Language</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Grantee acknowledges that he or she is proficient in the English language, or has consulted with an advisor who is sufficiently proficient in English, so as to allow the Grantee to understand the terms and conditions of this Award Agreement.  If the Grantee has received this Award Agreement or any other document related to the Plan translated into a language other than English and if the meaning of the translated version is different than the English version, the English version will control.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:13pt;font-weight:400;line-height:100%">c.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Waiver.</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:13pt;font-style:italic;font-weight:700;line-height:100%">  </font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The waiver by Lilly of any provision of this Award Agreement at any time or for any purpose shall not operate as or be construed to be a waiver of the same or any other provision of this Award Agreement at any subsequent time or for any other purpose.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:13pt;font-weight:400;line-height:100%">d.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Severability and Section Headings</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If one or more of the provisions of this Award Agreement shall be held invalid, illegal or unenforceable in any respect, the validity, legality and enforceability of the remaining provisions shall not in any way be affected or impaired thereby and the invalid, illegal or unenforceable provisions shall be deemed null and void&#59; however, to the extent permissible by law, any provisions which could be deemed null and void shall first be construed, interpreted or revised retroactively to permit this Award Agreement to be construed so as to foster the intent of this Award Agreement and the Plan.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The section headings in this Award Agreement are for convenience of reference only and shall not be deemed a part of, or germane to, the interpretation or construction of this instrument.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:13pt;font-weight:400;line-height:100%">e.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">No Advice Regarding Grant</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Lilly is not providing any tax, legal or financial advice, nor is Lilly making any recommendations regarding the Grantee&#8217;s participation in the Plan or the Grantee&#8217;s acquisition or sale of the underlying Shares.  The Grantee should consult with his or her own personal tax, legal and financial advisors regarding the Grantee&#8217;s participation in the Plan before taking any action related to the Plan.</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Page 15</font></div></div></div><hr style="page-break-after:always"><div style="min-height:92.16pt;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Eli Lilly and Company Relative Value Award Agreement</font></div><div><font><br></font></div></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 15.&#160;&#160;&#160;&#160;Compensation Recovery</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">At any time during the three years following the date on which the number of Shares eligible to vest under this Award has been determined under Section 2 above, the Company reserves the right to and, in appropriate cases, will seek restitution of all or part of any Shares that have been issued or cash that has been paid pursuant to this Award if&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.&#160;&#160;&#160;&#160;(i) the number of Shares or the amount of the cash payment was calculated based, directly or indirectly, upon the achievement of financial results that were subsequently the subject of a restatement of all or a portion of the Company&#8217;s financial statements, (ii) the Grantee engaged in intentional misconduct that caused or partially caused the need for such a restatement&#59; and (iii) the number of Shares or the amount of cash payment that would have been issued or paid to the Grantee had the financial results been properly reported would have been lower than the number of Shares actually issued or the amount of cash actually paid&#59; or</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.&#160;&#160;&#160;&#160;the Grantee has been determined to have committed a material violation of law or Company policy or to have failed to properly manage or monitor the conduct of an employee who has committed a material violation of law or Company policy whereby, in either case, such misconduct causes significant harm to the company.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Furthermore, in the event the number of Shares issued or cash paid pursuant to this Award is determined to have been based on materially inaccurate financial statements or other Company performance measures or on calculation errors (without any misconduct on the part of the Grantee), the Company reserves the right to and, in appropriate cases, will (A) seek restitution of the Shares or cash paid pursuant to this Award to the extent that the number of Shares issued or the amount paid exceeded the number of Shares that would have been issued or the amount that would have been paid had the inaccuracy or error not occurred, or (B) issue additional Shares or make additional payment to the extent that the number of Shares issued or the amount paid was less than the correct amount.</font></div><div style="padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Section 15 is not intended to limit the Company&#8217;s power to take such action as it deems necessary to remedy any misconduct, prevent its reoccurrence and, if appropriate, based on all relevant facts and circumstances, punish the wrongdoer in a manner it deems appropriate.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 16.&#160;&#160;&#160;&#160;Award Subject to Acknowledgement of Acceptance</font></div><div style="margin-top:6pt;padding-left:22.3pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notwithstanding any provisions of this Award Agreement, the Award is subject to acknowledgement of acceptance by the Grantee prior to 4&#58;00 PM (EDT) &#91;&#8226;&#93;, through the website of Merrill Lynch, the Company&#8217;s stock plan administrator.  If the Grantee does not acknowledge acceptance of the Award prior to 4&#58;00 PM (EDT) &#91;&#8226;&#93;, the Award will be cancelled, subject to the Committee&#8217;s discretion for unforeseen circumstances. </font></div><div style="padding-left:18pt;text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">IN WITNESS WHEREOF, Lilly has caused this Award Agreement to be executed in Indianapolis, Indiana, by its proper officer.</font></div><div style="padding-left:22.5pt;text-align:justify"><font><br></font></div><div style="padding-left:274.5pt;text-align:justify;text-indent:13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ELI LILLY AND COMPANY</font></div><div style="padding-left:288pt;text-align:justify"><font><br></font></div><div style="padding-left:288pt;text-align:justify"><font><br></font></div><div style="padding-left:288pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58; _________________________</font></div><div><font><br></font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Page 16</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>5
<FILENAME>lly-09302022x10qxexhibit311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ic40e639684cc400b86fe562cabab9ae9_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:14pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EXHIBIT 31.1 Rule 13a-14(a) Certification of David A. Ricks, Chair, President, and Chief Executive Officer</font></div><div style="margin-top:14pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATIONS</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, David A. Ricks, Chair, President, and Chief Executive Officer, certify that&#58;</font></div><div style="margin-top:9pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">I have reviewed this report on Form 10-Q of Eli Lilly and Company&#59;</font></div><div style="margin-top:9pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:9pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:9pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.11pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.11pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.11pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:9pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s Board of Directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.11pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize, and report financial information&#59; and</font></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.11pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:57.456%"><tr><td style="width:1.0%"></td><td style="width:9.078%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.989%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:83.633%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 1, 2022</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; David A. Ricks</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">David A. Ricks</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chair, President, and Chief Executive Officer</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>6
<FILENAME>lly-09302022x10qxexhibit312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="iceda03473f054a0889468b9ad4229b49_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:14pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EXHIBIT 31.2 Rule 13a-14(a) Certification of Anat Ashkenazi, Executive Vice President and Chief Financial Officer</font></div><div style="margin-top:14pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATIONS</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Anat Ashkenazi, Executive Vice President and Chief Financial Officer, certify that&#58;</font></div><div style="margin-top:9pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">I have reviewed this report on Form 10-Q of Eli Lilly and Company&#59;</font></div><div style="margin-top:9pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:9pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:9pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.11pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.11pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.11pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:9pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s Board of Directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.11pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize, and report financial information&#59; and</font></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.11pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:57.456%"><tr><td style="width:1.0%"></td><td style="width:9.078%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.989%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:83.633%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 1, 2022</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Anat Ashkenazi</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anat Ashkenazi</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President and Chief Financial Officer</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32
<SEQUENCE>7
<FILENAME>lly-09302022x10qxexhibit32.htm
<DESCRIPTION>EX-32
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ifab87982fb4542dba310a601e6e68546_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EXHIBIT 32. Section 1350 Certification</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a)&#160;and (b)&#160;of section 1350, chapter 63 of title 18, United States Code), each of the undersigned officers of Eli Lilly and Company, an Indiana corporation (the &#34;Company&#34;), does hereby certify that, to the best of their knowledge&#58;</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Quarterly Report on Form 10-Q for the quarter ended September&#160;30, 2022 (the &#34;Form 10-Q&#34;) of the Company fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934 and information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:4.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.706%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.995%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 1, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; David A. Ricks</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">David A. Ricks</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chair, President, and Chief Executive Officer</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 1, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Anat Ashkenazi</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anat Ashkenazi</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President and Chief Financial Officer</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>lly-20220930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:1f63046d-a77a-465e-aed4-1fd7d331378a,g:f755fa79-e9ed-4360-88c0-9c62587f0bf5-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:lly="http://www.lilly.com/20220930" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.lilly.com/20220930">
  <xs:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2022" schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lly-20220930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lly-20220930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lly-20220930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lly-20220930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.lilly.com/role/CoverPage">
        <link:definition>0000001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedCondensedStatementsofOperationsUnaudited" roleURI="http://www.lilly.com/role/ConsolidatedCondensedStatementsofOperationsUnaudited">
        <link:definition>0000002 - Statement - Consolidated Condensed Statements of Operations (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedCondensedStatementsofComprehensiveIncomeUnaudited" roleURI="http://www.lilly.com/role/ConsolidatedCondensedStatementsofComprehensiveIncomeUnaudited">
        <link:definition>0000003 - Statement - Consolidated Condensed Statements of Comprehensive Income (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedCondensedBalanceSheets" roleURI="http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets">
        <link:definition>0000004 - Statement - Consolidated Condensed Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedCondensedBalanceSheetsParenthetical" roleURI="http://www.lilly.com/role/ConsolidatedCondensedBalanceSheetsParenthetical">
        <link:definition>0000005 - Statement - Consolidated Condensed Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedCondensedStatementsofEquity" roleURI="http://www.lilly.com/role/ConsolidatedCondensedStatementsofEquity">
        <link:definition>0000006 - Statement - Consolidated Condensed Statements of Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedCondensedStatementsofEquityParenthetical" roleURI="http://www.lilly.com/role/ConsolidatedCondensedStatementsofEquityParenthetical">
        <link:definition>0000007 - Statement - Consolidated Condensed Statements of Equity (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedCondensedStatementsofCashFlows" roleURI="http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows">
        <link:definition>0000008 - Statement - Consolidated Condensed Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandImplementationofNewFinancialAccountingStandard" roleURI="http://www.lilly.com/role/BasisofPresentationandImplementationofNewFinancialAccountingStandard">
        <link:definition>0000009 - Disclosure - Basis of Presentation and Implementation of New Financial Accounting Standard</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Revenue" roleURI="http://www.lilly.com/role/Revenue">
        <link:definition>0000010 - Disclosure - Revenue</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Acquisitions" roleURI="http://www.lilly.com/role/Acquisitions">
        <link:definition>0000011 - Disclosure - Acquisitions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationsandOtherArrangements" roleURI="http://www.lilly.com/role/CollaborationsandOtherArrangements">
        <link:definition>0000012 - Disclosure - Collaborations and Other Arrangements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AssetImpairmentRestructuringandOtherSpecialCharges" roleURI="http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialCharges">
        <link:definition>0000013 - Disclosure - Asset Impairment, Restructuring, and Other Special Charges</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstruments" roleURI="http://www.lilly.com/role/FinancialInstruments">
        <link:definition>0000014 - Disclosure - Financial Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.lilly.com/role/IncomeTaxes">
        <link:definition>0000015 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RetirementBenefits" roleURI="http://www.lilly.com/role/RetirementBenefits">
        <link:definition>0000016 - Disclosure - Retirement Benefits</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Contingencies" roleURI="http://www.lilly.com/role/Contingencies">
        <link:definition>0000017 - Disclosure - Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherComprehensiveIncomeLoss" roleURI="http://www.lilly.com/role/OtherComprehensiveIncomeLoss">
        <link:definition>0000018 - Disclosure - Other Comprehensive Income (Loss)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherNetIncomeExpense" roleURI="http://www.lilly.com/role/OtherNetIncomeExpense">
        <link:definition>0000019 - Disclosure - Other&#8211;Net, (Income) Expense</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandImplementationofNewFinancialAccountingStandardPolicies" roleURI="http://www.lilly.com/role/BasisofPresentationandImplementationofNewFinancialAccountingStandardPolicies">
        <link:definition>0000020 - Disclosure - Basis of Presentation and Implementation of New Financial Accounting Standard (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueTables" roleURI="http://www.lilly.com/role/RevenueTables">
        <link:definition>0000021 - Disclosure - Revenue (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsTables" roleURI="http://www.lilly.com/role/AcquisitionsTables">
        <link:definition>0000022 - Disclosure - Acquisitions (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationsandOtherArrangementsTables" roleURI="http://www.lilly.com/role/CollaborationsandOtherArrangementsTables">
        <link:definition>0000023 - Disclosure - Collaborations and Other Arrangements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AssetImpairmentRestructuringandOtherSpecialChargesTables" roleURI="http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialChargesTables">
        <link:definition>0000024 - Disclosure - Asset Impairment, Restructuring, and Other Special Charges (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsTables" roleURI="http://www.lilly.com/role/FinancialInstrumentsTables">
        <link:definition>0000025 - Disclosure - Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RetirementBenefitsTables" roleURI="http://www.lilly.com/role/RetirementBenefitsTables">
        <link:definition>0000026 - Disclosure - Retirement Benefits (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherComprehensiveIncomeLossTables" roleURI="http://www.lilly.com/role/OtherComprehensiveIncomeLossTables">
        <link:definition>0000027 - Disclosure - Other Comprehensive Income (Loss) (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherNetIncomeExpenseTables" roleURI="http://www.lilly.com/role/OtherNetIncomeExpenseTables">
        <link:definition>0000028 - Disclosure - Other&#8211;Net, (Income) Expense (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueSummaryofRevenueRecognizedDetails" roleURI="http://www.lilly.com/role/RevenueSummaryofRevenueRecognizedDetails">
        <link:definition>0000029 - Disclosure - Revenue (Summary of Revenue Recognized) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueAdjustmentstoRevenueDetails" roleURI="http://www.lilly.com/role/RevenueAdjustmentstoRevenueDetails">
        <link:definition>0000030 - Disclosure - Revenue (Adjustments to Revenue) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueContractLiabilitiesDetails" roleURI="http://www.lilly.com/role/RevenueContractLiabilitiesDetails">
        <link:definition>0000031 - Disclosure - Revenue (Contract Liabilities) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueDisaggregationofRevenuebyProductDetails" roleURI="http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails">
        <link:definition>0000032 - Disclosure - Revenue (Disaggregation of Revenue by Product) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueDisaggregationofRevenuebyGeographicalAreaDetails" roleURI="http://www.lilly.com/role/RevenueDisaggregationofRevenuebyGeographicalAreaDetails">
        <link:definition>0000033 - Disclosure - Revenue (Disaggregation of Revenue by Geographical Area) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsNarrativeDetails" roleURI="http://www.lilly.com/role/AcquisitionsNarrativeDetails">
        <link:definition>0000034 - Disclosure - Acquisitions (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails" roleURI="http://www.lilly.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails">
        <link:definition>0000035 - Disclosure - Acquisitions (Assets Acquired and Liabilities Assumed) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsAssetAcquisitionsDetails" roleURI="http://www.lilly.com/role/AcquisitionsAssetAcquisitionsDetails">
        <link:definition>0000036 - Disclosure - Acquisitions (Asset Acquisitions) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationsandOtherArrangementsDetails" roleURI="http://www.lilly.com/role/CollaborationsandOtherArrangementsDetails">
        <link:definition>0000037 - Disclosure - Collaborations and Other Arrangements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AssetImpairmentRestructuringandOtherSpecialChargesDetails" roleURI="http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialChargesDetails">
        <link:definition>0000038 - Disclosure - Asset Impairment, Restructuring, and Other Special Charges (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsNarrativeDetails" roleURI="http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails">
        <link:definition>0000039 - Disclosure - Financial Instruments (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsEffectofRiskManagementInstrumentsDetails" roleURI="http://www.lilly.com/role/FinancialInstrumentsEffectofRiskManagementInstrumentsDetails">
        <link:definition>0000040 - Disclosure - Financial Instruments (Effect of Risk-Management Instruments) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsFairValueofFinancialInstrumentsDetails" roleURI="http://www.lilly.com/role/FinancialInstrumentsFairValueofFinancialInstrumentsDetails">
        <link:definition>0000041 - Disclosure - Financial Instruments (Fair Value of Financial Instruments) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsRiskManagementInstrumentsDetails" roleURI="http://www.lilly.com/role/FinancialInstrumentsRiskManagementInstrumentsDetails">
        <link:definition>0000042 - Disclosure - Financial Instruments (Risk Management Instruments) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsContractualMaturitiesDetails" roleURI="http://www.lilly.com/role/FinancialInstrumentsContractualMaturitiesDetails">
        <link:definition>0000043 - Disclosure - Financial Instruments (Contractual Maturities) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsUnrealizedGainsandLossesDetails" roleURI="http://www.lilly.com/role/FinancialInstrumentsUnrealizedGainsandLossesDetails">
        <link:definition>0000044 - Disclosure - Financial Instruments (Unrealized Gains and Losses) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsRealizedGainsandLossesDetails" roleURI="http://www.lilly.com/role/FinancialInstrumentsRealizedGainsandLossesDetails">
        <link:definition>0000045 - Disclosure - Financial Instruments (Realized Gains and Losses) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDetails" roleURI="http://www.lilly.com/role/IncomeTaxesDetails">
        <link:definition>0000046 - Disclosure - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RetirementBenefitsComponentsofNetPeriodicBenefitCostDetails" roleURI="http://www.lilly.com/role/RetirementBenefitsComponentsofNetPeriodicBenefitCostDetails">
        <link:definition>0000047 - Disclosure - Retirement Benefits (Components of Net Periodic Benefit Cost) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ContingenciesDetails" roleURI="http://www.lilly.com/role/ContingenciesDetails">
        <link:definition>0000048 - Disclosure - Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherComprehensiveIncomeLossAOCIDetails" roleURI="http://www.lilly.com/role/OtherComprehensiveIncomeLossAOCIDetails">
        <link:definition>0000049 - Disclosure - Other Comprehensive Income (Loss) (AOCI) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherComprehensiveIncomeLossTaxEffectDetails" roleURI="http://www.lilly.com/role/OtherComprehensiveIncomeLossTaxEffectDetails">
        <link:definition>0000050 - Disclosure - Other Comprehensive Income (Loss) (Tax Effect) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherComprehensiveIncomeLossReclassificationDetails" roleURI="http://www.lilly.com/role/OtherComprehensiveIncomeLossReclassificationDetails">
        <link:definition>0000051 - Disclosure - Other Comprehensive Income (Loss) (Reclassification) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherNetIncomeExpenseDetails" roleURI="http://www.lilly.com/role/OtherNetIncomeExpenseDetails">
        <link:definition>0000052 - Disclosure - Other&#8211;Net, (Income) Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="lly_MounjaroMember" abstract="true" name="MounjaroMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_A6.77NotesDueJanuary12036Member" abstract="true" name="A6.77NotesDueJanuary12036Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_BioMarinPharmaceuticalIncMember" abstract="true" name="BioMarinPharmaceuticalIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_HumulinMember" abstract="true" name="HumulinMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_CyramzaMember" abstract="true" name="CyramzaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_A1125NotesDue2051Member" abstract="true" name="A1125NotesDue2051Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_OlumiantMember" abstract="true" name="OlumiantMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_PaymentsForAssetAcquisitions" abstract="false" name="PaymentsForAssetAcquisitions" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lly_BuyUSDollarSellChineseYuanMember" abstract="true" name="BuyUSDollarSellChineseYuanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_EmgalityMember" abstract="true" name="EmgalityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_OtherOncologyMember" abstract="true" name="OtherOncologyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_JardianceMember" abstract="true" name="JardianceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_AlimtaMember" abstract="true" name="AlimtaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_LitigationClaimsDismissedNumber" abstract="false" name="LitigationClaimsDismissedNumber" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="lly_MaturityDate2023Member" abstract="true" name="MaturityDate2023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_OtherDiabetesMember" abstract="true" name="OtherDiabetesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_BuyUsDollarSellEuroMember" abstract="true" name="BuyUsDollarSellEuroMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_TaltzMember" abstract="true" name="TaltzMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_A1375NotesDue2061Member" abstract="true" name="A1375NotesDue2061Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_PurchasedInProcessResearchAndDevelopment" abstract="false" name="PurchasedInProcessResearchAndDevelopment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lly_BuyBritishPoundandSellUSDollarsMember" abstract="true" name="BuyBritishPoundandSellUSDollarsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_BusinessAcquisitionContingentValueRightAdditionalPricePerShare" abstract="false" name="BusinessAcquisitionContingentValueRightAdditionalPricePerShare" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="lly_A500NotesDue2033Member" abstract="true" name="A500NotesDue2033Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_PrecisionBiosciencesIncMember" abstract="true" name="PrecisionBiosciencesIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_DebtSecuritiesAvailableForSaleUnrealizedLossPositionQualitativeDisclosureOtherPercentageOfNonperformingAssets" abstract="false" name="DebtSecuritiesAvailableForSaleUnrealizedLossPositionQualitativeDisclosureOtherPercentageOfNonperformingAssets" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="lly_AcquiredInProcessResearchAndDevelopmentAndDevelopmentMilestones" abstract="false" name="AcquiredInProcessResearchAndDevelopmentAndDevelopmentMilestones" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lly_TYVYTMember" abstract="true" name="TYVYTMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_BusinessAcquisitionContingentValueRightRegulatoryApprovalDelayMonthlyReduction" abstract="false" name="BusinessAcquisitionContingentValueRightRegulatoryApprovalDelayMonthlyReduction" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="lly_AccumulatedGainLossNetCashFlowHedgeAndForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" abstract="true" name="AccumulatedGainLossNetCashFlowHedgeAndForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_A1700NotesDue2049Member" abstract="true" name="A1700NotesDue2049Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_RocheMember" abstract="true" name="RocheMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_BuyEuroSellUsDollarMember" abstract="true" name="BuyEuroSellUsDollarMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_HumalogMember" abstract="true" name="HumalogMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_DerivativeInstrumentsGainLossRecognized" abstract="false" name="DerivativeInstrumentsGainLossRecognized" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lly_AkouosAcquisitionMember" abstract="true" name="AkouosAcquisitionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_SwapU.S.DollarsToEuroMember" abstract="true" name="SwapU.S.DollarsToEuroMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_BusinessCombinationConsiderationTransferredNumberOfContingentValueRights" abstract="false" name="BusinessCombinationConsiderationTransferredNumberOfContingentValueRights" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lly_A3375NotesDue2029Member" abstract="true" name="A3375NotesDue2029Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain" abstract="false" name="AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lly_AssetImpairmentChargesRecoveriesAndOtherSpecialCharges" abstract="false" name="AssetImpairmentChargesRecoveriesAndOtherSpecialCharges" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lly_PrevailTherapeuticsIncMember" abstract="true" name="PrevailTherapeuticsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_A050NotesDue2033Member" abstract="true" name="A050NotesDue2033Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss" abstract="false" name="AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lly_CymbaltaMember" abstract="true" name="CymbaltaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_A2.125NotesDueJune32030Member" abstract="true" name="A2.125NotesDueJune32030Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_ImmunologyMember" abstract="true" name="ImmunologyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_AcquiredInProcessResearchAndDevelopment" abstract="false" name="AcquiredInProcessResearchAndDevelopment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lly_SalesRebatesAndDiscounts" abstract="false" name="SalesRebatesAndDiscounts" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lly_ErbituxMember" abstract="true" name="ErbituxMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_BasaglarMember" abstract="true" name="BasaglarMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_CollaborativeArrangementRightsAndObligationsPercent" abstract="false" name="CollaborativeArrangementRightsAndObligationsPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="lly_A1.625NotesDueJune22026Member" abstract="true" name="A1.625NotesDueJune22026Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_ForteoMember" abstract="true" name="ForteoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_A718NotesDueJune12025Member" abstract="true" name="A718NotesDueJune12025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_A1625NotesDue2043Member" abstract="true" name="A1625NotesDue2043Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_OtherProductTotalMember" abstract="true" name="OtherProductTotalMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_DiabetesMember" abstract="true" name="DiabetesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_MarketableSecuritiesMember" abstract="true" name="MarketableSecuritiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_SwapSwissFrancsToU.S.DollarsMember" abstract="true" name="SwapSwissFrancsToU.S.DollarsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_ProductLiabilityMember" abstract="true" name="ProductLiabilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_TrajentaBIMember" abstract="true" name="TrajentaBIMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_CostOfSalesOperatingExpensesAndOtherNet" abstract="false" name="CostOfSalesOperatingExpensesAndOtherNet" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lly_LossContingencyNumberOfSitesJointlyAndSeverallyLiableForCleanup" abstract="false" name="LossContingencyNumberOfSitesJointlyAndSeverallyLiableForCleanup" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="lly_EmployeeLitigationMember" abstract="true" name="EmployeeLitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_LebrikizumabMember" abstract="true" name="LebrikizumabMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_OtherProductMember" abstract="true" name="OtherProductMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_LossContingencyNumberOfPatents" abstract="false" name="LossContingencyNumberOfPatents" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="lly_MilestonePaymentsSalesBasedMember" abstract="true" name="MilestonePaymentsSalesBasedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_EquityMethodAndOtherInvestmentsMember" abstract="true" name="EquityMethodAndOtherInvestmentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_InsulinMember" abstract="true" name="InsulinMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_ProceedsfromSaleofEquityandAvailableforSaleSecurities" abstract="false" name="ProceedsfromSaleofEquityandAvailableforSaleSecurities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lly_A395NotesDue2049Member" abstract="true" name="A395NotesDue2049Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_FairValueHedgeAbstract" abstract="true" name="FairValueHedgeAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lly_ByettaMember" abstract="true" name="ByettaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_OtherForeignCountriesMember" abstract="true" name="OtherForeignCountriesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_DescriptionOfDerivativeActivityVolumePercent" abstract="false" name="DescriptionOfDerivativeActivityVolumePercent" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="lly_MilestonePaymentsCapitalizedAsIntangibleAssetsMember" abstract="true" name="MilestonePaymentsCapitalizedAsIntangibleAssetsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_MilestonePaymentsDevelopmentAndRegulatoryMember" abstract="true" name="MilestonePaymentsDevelopmentAndRegulatoryMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_OtherEquitySecuritiesMember" abstract="true" name="OtherEquitySecuritiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember" abstract="true" name="MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_BuyUSdollarSellJapaneseYenMember" abstract="true" name="BuyUSdollarSellJapaneseYenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_DebtSecuritiesAvailableforsaleUnrealizedGainPosition" abstract="false" name="DebtSecuritiesAvailableforsaleUnrealizedGainPosition" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lly_HumalogHumulinAndForteoMember" abstract="true" name="HumalogHumulinAndForteoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_ZyprexaMember" abstract="true" name="ZyprexaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_CollaborationandOtherRevenueMember" abstract="true" name="CollaborationandOtherRevenueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_OtherImmunologyMember" abstract="true" name="OtherImmunologyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_HedgedFixedRateDebtMember" abstract="true" name="HedgedFixedRateDebtMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_InnoventBiologicsIncMember" abstract="true" name="InnoventBiologicsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_ForeignCurrencyDenominatedDebtMember" abstract="true" name="ForeignCurrencyDenominatedDebtMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod" abstract="false" name="FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="lly_RigelPharmaceuticalsIncMember" abstract="true" name="RigelPharmaceuticalsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_OncologyMember" abstract="true" name="OncologyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_OtherNeuroscienceMember" abstract="true" name="OtherNeuroscienceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_CashFlowHedgeAbstract" abstract="true" name="CashFlowHedgeAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lly_A415NotesDue2059Member" abstract="true" name="A415NotesDue2059Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_NeuroscienceMember" abstract="true" name="NeuroscienceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_SellEuroMember" abstract="true" name="SellEuroMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_CollaborativeArrangementRightsAndObligationsRightsObligations" abstract="false" name="CollaborativeArrangementRightsAndObligationsRightsObligations" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lly_CialisMember" abstract="true" name="CialisMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent" abstract="false" name="RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="lly_VerzenioMember" abstract="true" name="VerzenioMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_MilestonePaymentsSuccessBasedRegulatoryAndSalesBasedMember" abstract="true" name="MilestonePaymentsSuccessBasedRegulatoryAndSalesBasedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_EmgalityPatentLitigationMember" abstract="true" name="EmgalityPatentLitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_A625NotesDue2031Member" abstract="true" name="A625NotesDue2031Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_COVID19AntibodiesMember" abstract="true" name="COVID19AntibodiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_TrulicityMember" abstract="true" name="TrulicityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>9
<FILENAME>lly-20220930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:1f63046d-a77a-465e-aed4-1fd7d331378a,g:f755fa79-e9ed-4360-88c0-9c62587f0bf5-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.lilly.com/role/ConsolidatedCondensedStatementsofOperationsUnaudited" xlink:type="simple" xlink:href="lly-20220930.xsd#ConsolidatedCondensedStatementsofOperationsUnaudited"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/ConsolidatedCondensedStatementsofOperationsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2be14191-c026-44e6-96db-a67d8127ea61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_a04ac68d-9ca6-4793-8b23-735f31509c81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2be14191-c026-44e6-96db-a67d8127ea61" xlink:to="loc_us-gaap_Revenues_a04ac68d-9ca6-4793-8b23-735f31509c81" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CostOfSalesOperatingExpensesAndOtherNet_572cd1c8-b7dc-4ef6-aa4e-37120abd3bbf" xlink:href="lly-20220930.xsd#lly_CostOfSalesOperatingExpensesAndOtherNet"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2be14191-c026-44e6-96db-a67d8127ea61" xlink:to="loc_lly_CostOfSalesOperatingExpensesAndOtherNet_572cd1c8-b7dc-4ef6-aa4e-37120abd3bbf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CostOfSalesOperatingExpensesAndOtherNet_a3108c3d-0bbe-468b-9a12-9a5009973103" xlink:href="lly-20220930.xsd#lly_CostOfSalesOperatingExpensesAndOtherNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AcquiredInProcessResearchAndDevelopmentAndDevelopmentMilestones_a284d4f0-d10d-49e4-bf79-51fc9ccdc7f5" xlink:href="lly-20220930.xsd#lly_AcquiredInProcessResearchAndDevelopmentAndDevelopmentMilestones"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_lly_CostOfSalesOperatingExpensesAndOtherNet_a3108c3d-0bbe-468b-9a12-9a5009973103" xlink:to="loc_lly_AcquiredInProcessResearchAndDevelopmentAndDevelopmentMilestones_a284d4f0-d10d-49e4-bf79-51fc9ccdc7f5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringSettlementAndImpairmentProvisions_c87fcf76-daf2-4af2-9920-e0e1ee24a2d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringSettlementAndImpairmentProvisions"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_lly_CostOfSalesOperatingExpensesAndOtherNet_a3108c3d-0bbe-468b-9a12-9a5009973103" xlink:to="loc_us-gaap_RestructuringSettlementAndImpairmentProvisions_c87fcf76-daf2-4af2-9920-e0e1ee24a2d7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_16dd6a5f-b2cc-4709-a900-5d8f3075e448" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_lly_CostOfSalesOperatingExpensesAndOtherNet_a3108c3d-0bbe-468b-9a12-9a5009973103" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_16dd6a5f-b2cc-4709-a900-5d8f3075e448" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_359e7c93-4dc4-4083-b6b0-dfe980d81e26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_lly_CostOfSalesOperatingExpensesAndOtherNet_a3108c3d-0bbe-468b-9a12-9a5009973103" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_359e7c93-4dc4-4083-b6b0-dfe980d81e26" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_78adabe9-f2fb-44aa-98fb-d69c11b73ba1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_lly_CostOfSalesOperatingExpensesAndOtherNet_a3108c3d-0bbe-468b-9a12-9a5009973103" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_78adabe9-f2fb-44aa-98fb-d69c11b73ba1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_20827f08-96c1-47e1-bf3c-fb2d5e71d2c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_lly_CostOfSalesOperatingExpensesAndOtherNet_a3108c3d-0bbe-468b-9a12-9a5009973103" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_20827f08-96c1-47e1-bf3c-fb2d5e71d2c1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_66f0b129-e969-46ab-9a49-2c8fe4331eb5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_80001a5d-6fba-4d04-be7f-d8f33adb4f37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_66f0b129-e969-46ab-9a49-2c8fe4331eb5" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_80001a5d-6fba-4d04-be7f-d8f33adb4f37" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_8d9455fa-09f3-4504-b6a4-6317ed885b1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_66f0b129-e969-46ab-9a49-2c8fe4331eb5" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_8d9455fa-09f3-4504-b6a4-6317ed885b1d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/ConsolidatedCondensedStatementsofComprehensiveIncomeUnaudited" xlink:type="simple" xlink:href="lly-20220930.xsd#ConsolidatedCondensedStatementsofComprehensiveIncomeUnaudited"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/ConsolidatedCondensedStatementsofComprehensiveIncomeUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_c8ab922a-6920-4166-b15c-9269b125efb9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_aab1d6db-a654-426f-ba1c-a235e1742e4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_c8ab922a-6920-4166-b15c-9269b125efb9" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_aab1d6db-a654-426f-ba1c-a235e1742e4c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_b91244cb-a808-4239-a692-e5bddf740191" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_c8ab922a-6920-4166-b15c-9269b125efb9" xlink:to="loc_us-gaap_NetIncomeLoss_b91244cb-a808-4239-a692-e5bddf740191" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets" xlink:type="simple" xlink:href="lly-20220930.xsd#ConsolidatedCondensedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_93f53c7e-1176-458a-8072-d388c03957f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_289ec657-6025-486f-bf44-69e622a6b56b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_93f53c7e-1176-458a-8072-d388c03957f1" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_289ec657-6025-486f-bf44-69e622a6b56b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesHeldInEmployeeTrust_db4b5932-26c7-4f36-af5a-ac73e17b9b90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesHeldInEmployeeTrust"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_93f53c7e-1176-458a-8072-d388c03957f1" xlink:to="loc_us-gaap_CommonStockSharesHeldInEmployeeTrust_db4b5932-26c7-4f36-af5a-ac73e17b9b90" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonValue_a3e4f349-3c0b-4293-8cb4-9f18a0a1f961" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonValue"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_93f53c7e-1176-458a-8072-d388c03957f1" xlink:to="loc_us-gaap_TreasuryStockCommonValue_a3e4f349-3c0b-4293-8cb4-9f18a0a1f961" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_b5efa4ef-4361-4e04-9c6c-8779589c774f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_93f53c7e-1176-458a-8072-d388c03957f1" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_b5efa4ef-4361-4e04-9c6c-8779589c774f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_e4189975-99bc-44bd-b708-9f8e1b897789" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_93f53c7e-1176-458a-8072-d388c03957f1" xlink:to="loc_us-gaap_CommonStockValue_e4189975-99bc-44bd-b708-9f8e1b897789" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_b1ecbda0-d42e-4133-80b8-43a170733e75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_93f53c7e-1176-458a-8072-d388c03957f1" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_b1ecbda0-d42e-4133-80b8-43a170733e75" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_66aab189-c7de-42fa-aff4-aff9028ac0a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_8c3f6923-8d1d-49b6-82d3-6200b8d3d4e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_66aab189-c7de-42fa-aff4-aff9028ac0a7" xlink:to="loc_us-gaap_StockholdersEquity_8c3f6923-8d1d-49b6-82d3-6200b8d3d4e3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_2ecad008-913c-4e7b-b248-3ffa37f39d21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_66aab189-c7de-42fa-aff4-aff9028ac0a7" xlink:to="loc_us-gaap_MinorityInterest_2ecad008-913c-4e7b-b248-3ffa37f39d21" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_5681cc61-5f91-4507-8ceb-c359331fc6d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_97981df4-4d8a-4d7e-9dee-1265a44b9c93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_5681cc61-5f91-4507-8ceb-c359331fc6d8" xlink:to="loc_us-gaap_AccountsPayableCurrent_97981df4-4d8a-4d7e-9dee-1265a44b9c93" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_9d35439c-e9b8-4702-b0d7-745655be080a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_5681cc61-5f91-4507-8ceb-c359331fc6d8" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_9d35439c-e9b8-4702-b0d7-745655be080a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_SalesRebatesAndDiscounts_fc5bc6cf-fb4e-4197-9b89-496efd952c15" xlink:href="lly-20220930.xsd#lly_SalesRebatesAndDiscounts"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_5681cc61-5f91-4507-8ceb-c359331fc6d8" xlink:to="loc_lly_SalesRebatesAndDiscounts_fc5bc6cf-fb4e-4197-9b89-496efd952c15" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableCurrent_7b35d36c-6a16-4315-a29c-9ace9cd0639a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsPayableCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_5681cc61-5f91-4507-8ceb-c359331fc6d8" xlink:to="loc_us-gaap_DividendsPayableCurrent_7b35d36c-6a16-4315-a29c-9ace9cd0639a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent_62399217-69a4-48e2-9ed7-50e06493a90b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_5681cc61-5f91-4507-8ceb-c359331fc6d8" xlink:to="loc_us-gaap_TaxesPayableCurrent_62399217-69a4-48e2-9ed7-50e06493a90b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_9002df85-03e7-4a65-afec-7d03b1510ed9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_5681cc61-5f91-4507-8ceb-c359331fc6d8" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_9002df85-03e7-4a65-afec-7d03b1510ed9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrent_032b59ba-40b4-4e2a-9bea-96a0322e0561" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_5681cc61-5f91-4507-8ceb-c359331fc6d8" xlink:to="loc_us-gaap_DebtCurrent_032b59ba-40b4-4e2a-9bea-96a0322e0561" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_0090a76e-1405-4b0f-8f27-eb29c98e869e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_e75a40f1-36e0-4c55-b572-efb31b16ff38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_0090a76e-1405-4b0f-8f27-eb29c98e869e" xlink:to="loc_us-gaap_LiabilitiesCurrent_e75a40f1-36e0-4c55-b572-efb31b16ff38" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_0de27bd5-d700-485b-84bc-abc56239b8bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_0090a76e-1405-4b0f-8f27-eb29c98e869e" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_0de27bd5-d700-485b-84bc-abc56239b8bc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_eae92376-088c-41d7-9d07-8fbf0d424598" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_0090a76e-1405-4b0f-8f27-eb29c98e869e" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_eae92376-088c-41d7-9d07-8fbf0d424598" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_e9cf4db9-3b71-4ba2-ac3c-a9c31e90044d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_0090a76e-1405-4b0f-8f27-eb29c98e869e" xlink:to="loc_us-gaap_CommitmentsAndContingencies_e9cf4db9-3b71-4ba2-ac3c-a9c31e90044d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_45e808f5-5d13-4a56-a3f7-005753e38a65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_f9330a84-0529-479a-8eb0-4571b4585bbe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_45e808f5-5d13-4a56-a3f7-005753e38a65" xlink:to="loc_us-gaap_AssetsCurrent_f9330a84-0529-479a-8eb0-4571b4585bbe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments_1f28806f-3119-45f3-9f0d-3a703ff84cba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermInvestments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_45e808f5-5d13-4a56-a3f7-005753e38a65" xlink:to="loc_us-gaap_LongTermInvestments_1f28806f-3119-45f3-9f0d-3a703ff84cba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_b517881d-0a8b-477b-9fd2-fd25e931bfd8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_45e808f5-5d13-4a56-a3f7-005753e38a65" xlink:to="loc_us-gaap_Goodwill_b517881d-0a8b-477b-9fd2-fd25e931bfd8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_620eef1c-eca8-48b9-9a2e-c7a4599f04a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_45e808f5-5d13-4a56-a3f7-005753e38a65" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_620eef1c-eca8-48b9-9a2e-c7a4599f04a7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_c53c3fb3-fcf4-4e21-82a8-246645e63389" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_45e808f5-5d13-4a56-a3f7-005753e38a65" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_c53c3fb3-fcf4-4e21-82a8-246645e63389" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_6b1ca860-eae5-41bc-a99d-fe2674921f28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_45e808f5-5d13-4a56-a3f7-005753e38a65" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_6b1ca860-eae5-41bc-a99d-fe2674921f28" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_fab154d4-2e12-4e7f-9ace-31d29b1bc278" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_45e808f5-5d13-4a56-a3f7-005753e38a65" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_fab154d4-2e12-4e7f-9ace-31d29b1bc278" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_52cc6586-c6d6-4ece-abb6-1280611f33da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesNoncurrent_529e5749-bead-4524-8aba-a2849560dc3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedIncomeTaxesNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_52cc6586-c6d6-4ece-abb6-1280611f33da" xlink:to="loc_us-gaap_AccruedIncomeTaxesNoncurrent_529e5749-bead-4524-8aba-a2849560dc3a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_9862712a-72cf-4f87-96ff-3cc93e2da8ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_52cc6586-c6d6-4ece-abb6-1280611f33da" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_9862712a-72cf-4f87-96ff-3cc93e2da8ba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_862e4440-2ab6-4fa3-98c6-c1b98289c8bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_52cc6586-c6d6-4ece-abb6-1280611f33da" xlink:to="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_862e4440-2ab6-4fa3-98c6-c1b98289c8bd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_2d083308-dfa9-4790-b980-1a622182c54b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_52cc6586-c6d6-4ece-abb6-1280611f33da" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_2d083308-dfa9-4790-b980-1a622182c54b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_2ec134f4-3822-4fd5-bd75-430ea2731b39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_52cc6586-c6d6-4ece-abb6-1280611f33da" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_2ec134f4-3822-4fd5-bd75-430ea2731b39" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_62f50ef2-4ad0-4467-88c5-d8d9c6b584b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_5d6b2eef-9770-4237-a216-0a442b38a289" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_62f50ef2-4ad0-4467-88c5-d8d9c6b584b7" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_5d6b2eef-9770-4237-a216-0a442b38a289" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_748a7a37-71f3-44c1-8a9c-f98ea30a4fe6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_62f50ef2-4ad0-4467-88c5-d8d9c6b584b7" xlink:to="loc_us-gaap_ShortTermInvestments_748a7a37-71f3-44c1-8a9c-f98ea30a4fe6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_cbadf2ef-ecc9-47d7-879d-ba93d890bf71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_62f50ef2-4ad0-4467-88c5-d8d9c6b584b7" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_cbadf2ef-ecc9-47d7-879d-ba93d890bf71" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_aea2d2a0-460c-407a-9362-96f719c58617" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_62f50ef2-4ad0-4467-88c5-d8d9c6b584b7" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_aea2d2a0-460c-407a-9362-96f719c58617" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_a2d6efbc-84f7-471d-b437-a7c3200f8238" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_62f50ef2-4ad0-4467-88c5-d8d9c6b584b7" xlink:to="loc_us-gaap_InventoryNet_a2d6efbc-84f7-471d-b437-a7c3200f8238" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_e193eaaf-fdf6-4ba9-9e39-6c22029fa84b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_62f50ef2-4ad0-4467-88c5-d8d9c6b584b7" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_e193eaaf-fdf6-4ba9-9e39-6c22029fa84b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows" xlink:type="simple" xlink:href="lly-20220930.xsd#ConsolidatedCondensedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a204229b-41e3-4524-8d38-070aaf1d8c20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_f8483d7c-97c2-4b93-9887-96a02cf56e34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a204229b-41e3-4524-8d38-070aaf1d8c20" xlink:to="loc_us-gaap_NetIncomeLoss_f8483d7c-97c2-4b93-9887-96a02cf56e34" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_2937969f-3d0c-4a56-b9e2-0767c758a931" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a204229b-41e3-4524-8d38-070aaf1d8c20" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_2937969f-3d0c-4a56-b9e2-0767c758a931" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_7bca6132-3f4e-47c2-a0f5-ec025f64aaeb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a204229b-41e3-4524-8d38-070aaf1d8c20" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_7bca6132-3f4e-47c2-a0f5-ec025f64aaeb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_10f9e601-315f-4bca-961d-3a97dff25160" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a204229b-41e3-4524-8d38-070aaf1d8c20" xlink:to="loc_us-gaap_ShareBasedCompensation_10f9e601-315f-4bca-961d-3a97dff25160" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AcquiredInProcessResearchAndDevelopment_7b7c8e62-642f-4e6c-8de2-cc345f2703bd" xlink:href="lly-20220930.xsd#lly_AcquiredInProcessResearchAndDevelopment"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a204229b-41e3-4524-8d38-070aaf1d8c20" xlink:to="loc_lly_AcquiredInProcessResearchAndDevelopment_7b7c8e62-642f-4e6c-8de2-cc345f2703bd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_c5163fb2-806e-471c-bb40-43d34ea8c8fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a204229b-41e3-4524-8d38-070aaf1d8c20" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_c5163fb2-806e-471c-bb40-43d34ea8c8fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_161605cf-3e75-450b-a69d-9ce616780e88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a204229b-41e3-4524-8d38-070aaf1d8c20" xlink:to="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_161605cf-3e75-450b-a69d-9ce616780e88" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestments_ac3cea93-7ff9-4377-8b3c-5493b03e5de3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnInvestments"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a204229b-41e3-4524-8d38-070aaf1d8c20" xlink:to="loc_us-gaap_GainLossOnInvestments_ac3cea93-7ff9-4377-8b3c-5493b03e5de3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_e1aa202b-5320-427c-a894-610bc3d7b1da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a204229b-41e3-4524-8d38-070aaf1d8c20" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_e1aa202b-5320-427c-a894-610bc3d7b1da" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ecba4dfe-64db-454c-ae2d-1845d514c4b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_ac6ee666-d2bb-4a75-8bef-207d6efbce6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ecba4dfe-64db-454c-ae2d-1845d514c4b7" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_ac6ee666-d2bb-4a75-8bef-207d6efbce6f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromShortTermDebt_bf4d8cfb-1464-40af-a0e6-edc0c05d27f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromShortTermDebt"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ecba4dfe-64db-454c-ae2d-1845d514c4b7" xlink:to="loc_us-gaap_ProceedsFromShortTermDebt_bf4d8cfb-1464-40af-a0e6-edc0c05d27f4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_58f793ed-22a6-40a0-a0de-117a52fe59ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ecba4dfe-64db-454c-ae2d-1845d514c4b7" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_58f793ed-22a6-40a0-a0de-117a52fe59ca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_7e7762cb-e66e-4821-8954-081e93823233" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ecba4dfe-64db-454c-ae2d-1845d514c4b7" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_7e7762cb-e66e-4821-8954-081e93823233" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividends_d9c476b7-2fca-4389-ac73-e983dbb8d93f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDividends"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ecba4dfe-64db-454c-ae2d-1845d514c4b7" xlink:to="loc_us-gaap_PaymentsOfDividends_d9c476b7-2fca-4389-ac73-e983dbb8d93f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_331e1480-31cc-432c-b2f3-e88f6622fcc7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ecba4dfe-64db-454c-ae2d-1845d514c4b7" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_331e1480-31cc-432c-b2f3-e88f6622fcc7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0241eacf-827a-4832-a540-9a04893cad23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments_fa529c6e-8e71-495a-9d31-b596eecd3463" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfShortTermInvestments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0241eacf-827a-4832-a540-9a04893cad23" xlink:to="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments_fa529c6e-8e71-495a-9d31-b596eecd3463" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments_e820c514-bef6-437f-9f5f-1ab0337021fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireShortTermInvestments"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0241eacf-827a-4832-a540-9a04893cad23" xlink:to="loc_us-gaap_PaymentsToAcquireShortTermInvestments_e820c514-bef6-437f-9f5f-1ab0337021fb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfLongtermInvestments_e854e096-3ae4-41db-b835-9ff1b6d4c7a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfLongtermInvestments"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0241eacf-827a-4832-a540-9a04893cad23" xlink:to="loc_us-gaap_ProceedsFromSaleOfLongtermInvestments_e854e096-3ae4-41db-b835-9ff1b6d4c7a4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_fcd6d7fb-d548-4e5d-aadf-46633677dcb8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0241eacf-827a-4832-a540-9a04893cad23" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_fcd6d7fb-d548-4e5d-aadf-46633677dcb8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireLongtermInvestments_1c6e268b-fa83-4045-9c65-efc89d46fbc1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireLongtermInvestments"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0241eacf-827a-4832-a540-9a04893cad23" xlink:to="loc_us-gaap_PaymentsToAcquireLongtermInvestments_1c6e268b-fa83-4045-9c65-efc89d46fbc1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_PurchasedInProcessResearchAndDevelopment_8e7b0aa1-ab06-4c8a-8e26-29710839ffc9" xlink:href="lly-20220930.xsd#lly_PurchasedInProcessResearchAndDevelopment"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0241eacf-827a-4832-a540-9a04893cad23" xlink:to="loc_lly_PurchasedInProcessResearchAndDevelopment_8e7b0aa1-ab06-4c8a-8e26-29710839ffc9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_2a2935a4-8bb6-4655-a268-1cc054dab472" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0241eacf-827a-4832-a540-9a04893cad23" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_2a2935a4-8bb6-4655-a268-1cc054dab472" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets_00aaf3b8-cfae-423a-baf1-4ec7a204edfe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireProductiveAssets"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0241eacf-827a-4832-a540-9a04893cad23" xlink:to="loc_us-gaap_PaymentsToAcquireProductiveAssets_00aaf3b8-cfae-423a-baf1-4ec7a204edfe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_bdc2f62a-5fe3-4432-b714-8f8c8b893c6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1ed3d1f4-6539-4584-8f61-9a78057e7a71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_bdc2f62a-5fe3-4432-b714-8f8c8b893c6d" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1ed3d1f4-6539-4584-8f61-9a78057e7a71" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f063d24d-1818-469d-8ce0-2e30385a059c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_bdc2f62a-5fe3-4432-b714-8f8c8b893c6d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f063d24d-1818-469d-8ce0-2e30385a059c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_e441f839-52d3-41e3-a6e0-e7cd82da95a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_bdc2f62a-5fe3-4432-b714-8f8c8b893c6d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_e441f839-52d3-41e3-a6e0-e7cd82da95a5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_49f639e8-abfb-43e8-ab13-700c0f76b4b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_bdc2f62a-5fe3-4432-b714-8f8c8b893c6d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_49f639e8-abfb-43e8-ab13-700c0f76b4b9" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="simple" xlink:href="lly-20220930.xsd#AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_ed2f3003-7837-4d77-bd20-b7978915431a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_ea6b64f5-14b0-4928-bf98-dfb96e895bfd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_ed2f3003-7837-4d77-bd20-b7978915431a" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_ea6b64f5-14b0-4928-bf98-dfb96e895bfd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_a0596034-e530-4e52-8a3a-1d3e884505b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_ed2f3003-7837-4d77-bd20-b7978915431a" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_a0596034-e530-4e52-8a3a-1d3e884505b7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_6bd2ee04-975a-4f09-b5d7-9f3c51e4f8b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_ed2f3003-7837-4d77-bd20-b7978915431a" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_6bd2ee04-975a-4f09-b5d7-9f3c51e4f8b7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet_925670e0-7ea8-47c9-a8a4-23ed4dd469ae" xlink:href="lly-20220930.xsd#lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_ed2f3003-7837-4d77-bd20-b7978915431a" xlink:to="loc_lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet_925670e0-7ea8-47c9-a8a4-23ed4dd469ae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_fc256d5d-2324-4813-aabb-9d459a6af411" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_ed2f3003-7837-4d77-bd20-b7978915431a" xlink:to="loc_us-gaap_Goodwill_fc256d5d-2324-4813-aabb-9d459a6af411" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialChargesDetails" xlink:type="simple" xlink:href="lly-20220930.xsd#AssetImpairmentRestructuringandOtherSpecialChargesDetails"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialChargesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringSettlementAndImpairmentProvisions_3334173a-665d-445d-b5b3-4efe26debdeb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringSettlementAndImpairmentProvisions"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1_efe177c7-055b-4f94-bfc6-dc9aa9b2f68a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeveranceCosts1"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_RestructuringSettlementAndImpairmentProvisions_3334173a-665d-445d-b5b3-4efe26debdeb" xlink:to="loc_us-gaap_SeveranceCosts1_efe177c7-055b-4f94-bfc6-dc9aa9b2f68a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AssetImpairmentChargesRecoveriesAndOtherSpecialCharges_483444b0-30fe-4bba-bab6-bf18f39b568f" xlink:href="lly-20220930.xsd#lly_AssetImpairmentChargesRecoveriesAndOtherSpecialCharges"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_RestructuringSettlementAndImpairmentProvisions_3334173a-665d-445d-b5b3-4efe26debdeb" xlink:to="loc_lly_AssetImpairmentChargesRecoveriesAndOtherSpecialCharges_483444b0-30fe-4bba-bab6-bf18f39b568f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/FinancialInstrumentsEffectofRiskManagementInstrumentsDetails" xlink:type="simple" xlink:href="lly-20220930.xsd#FinancialInstrumentsEffectofRiskManagementInstrumentsDetails"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/FinancialInstrumentsEffectofRiskManagementInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lly_DerivativeInstrumentsGainLossRecognized_a1d9c7a6-e502-4006-b783-245d13c3bb2f" xlink:href="lly-20220930.xsd#lly_DerivativeInstrumentsGainLossRecognized"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_28cebed9-ff94-4385-a7fa-33b02554a863" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_lly_DerivativeInstrumentsGainLossRecognized_a1d9c7a6-e502-4006-b783-245d13c3bb2f" xlink:to="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_28cebed9-ff94-4385-a7fa-33b02554a863" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_11bcde0a-13b7-4ff8-ac24-dfea4c7e8fba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_lly_DerivativeInstrumentsGainLossRecognized_a1d9c7a6-e502-4006-b783-245d13c3bb2f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_11bcde0a-13b7-4ff8-ac24-dfea4c7e8fba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_82084d8b-8bbe-42df-bd03-dd74084b697c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_lly_DerivativeInstrumentsGainLossRecognized_a1d9c7a6-e502-4006-b783-245d13c3bb2f" xlink:to="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_82084d8b-8bbe-42df-bd03-dd74084b697c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1_bd832fa3-928e-4750-b246-4379a0dbc0c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_lly_DerivativeInstrumentsGainLossRecognized_a1d9c7a6-e502-4006-b783-245d13c3bb2f" xlink:to="loc_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1_bd832fa3-928e-4750-b246-4379a0dbc0c3" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/FinancialInstrumentsFairValueofFinancialInstrumentsDetails" xlink:type="simple" xlink:href="lly-20220930.xsd#FinancialInstrumentsFairValueofFinancialInstrumentsDetails"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/FinancialInstrumentsFairValueofFinancialInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments_56078c0c-53a7-467c-ac0a-6b6032165638" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermInvestments"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLongTermInvestments_c758d9e7-8be2-4ff9-9348-525b9a24003c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLongTermInvestments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermInvestments_56078c0c-53a7-467c-ac0a-6b6032165638" xlink:to="loc_us-gaap_OtherLongTermInvestments_c758d9e7-8be2-4ff9-9348-525b9a24003c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_cc2e580a-0d69-4941-86f9-a1bf9a988ba1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermInvestments_56078c0c-53a7-467c-ac0a-6b6032165638" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_cc2e580a-0d69-4941-86f9-a1bf9a988ba1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_78b0257f-2840-4f71-8b41-d74d07ea41c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermInvestments_56078c0c-53a7-467c-ac0a-6b6032165638" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_78b0257f-2840-4f71-8b41-d74d07ea41c9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_5983e6d2-b6c6-4aaf-bafc-e1421816312d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermInvestments_56078c0c-53a7-467c-ac0a-6b6032165638" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_5983e6d2-b6c6-4aaf-bafc-e1421816312d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/FinancialInstrumentsContractualMaturitiesDetails" xlink:type="simple" xlink:href="lly-20220930.xsd#FinancialInstrumentsContractualMaturitiesDetails"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/FinancialInstrumentsContractualMaturitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e4fa7887-25b6-42af-995d-affd592b72fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_159a0043-959c-4116-8aee-7e114cea334b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e4fa7887-25b6-42af-995d-affd592b72fe" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_159a0043-959c-4116-8aee-7e114cea334b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_9f486386-9343-407f-980d-d48569a3ab43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e4fa7887-25b6-42af-995d-affd592b72fe" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_9f486386-9343-407f-980d-d48569a3ab43" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_fe12e542-1309-4c5c-837f-672406440748" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e4fa7887-25b6-42af-995d-affd592b72fe" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_fe12e542-1309-4c5c-837f-672406440748" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue_ca15a18d-1181-4370-b35e-cf8572de81fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e4fa7887-25b6-42af-995d-affd592b72fe" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue_ca15a18d-1181-4370-b35e-cf8572de81fc" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/RetirementBenefitsComponentsofNetPeriodicBenefitCostDetails" xlink:type="simple" xlink:href="lly-20220930.xsd#RetirementBenefitsComponentsofNetPeriodicBenefitCostDetails"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/RetirementBenefitsComponentsofNetPeriodicBenefitCostDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_70cb48ea-35b5-47a7-bc23-efbb56736412" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_30bd1f4b-0c63-4bca-8225-4790545c5537" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_70cb48ea-35b5-47a7-bc23-efbb56736412" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_30bd1f4b-0c63-4bca-8225-4790545c5537" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_b3c0d29f-bb74-42a3-8bc5-025d944c3b7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_70cb48ea-35b5-47a7-bc23-efbb56736412" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_b3c0d29f-bb74-42a3-8bc5-025d944c3b7f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_ff65fb7b-9285-41f3-af02-84632796bcc5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_70cb48ea-35b5-47a7-bc23-efbb56736412" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_ff65fb7b-9285-41f3-af02-84632796bcc5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_1216e9e0-d838-4445-a601-e3946e401497" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_70cb48ea-35b5-47a7-bc23-efbb56736412" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_1216e9e0-d838-4445-a601-e3946e401497" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit_c278fb66-bc7e-45fc-9a56-35a141eca474" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_70cb48ea-35b5-47a7-bc23-efbb56736412" xlink:to="loc_us-gaap_DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit_c278fb66-bc7e-45fc-9a56-35a141eca474" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/OtherComprehensiveIncomeLossAOCIDetails" xlink:type="simple" xlink:href="lly-20220930.xsd#OtherComprehensiveIncomeLossAOCIDetails"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/OtherComprehensiveIncomeLossAOCIDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_197a245f-a539-41cb-a4c3-9fcaad628fc7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_69ddeddf-46fd-4b98-9b9e-b8f3aea0312d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_197a245f-a539-41cb-a4c3-9fcaad628fc7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_69ddeddf-46fd-4b98-9b9e-b8f3aea0312d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_8716c2b8-2fac-4040-a2cc-df4ebebb30c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_197a245f-a539-41cb-a4c3-9fcaad628fc7" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_8716c2b8-2fac-4040-a2cc-df4ebebb30c8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/OtherNetIncomeExpenseDetails" xlink:type="simple" xlink:href="lly-20220930.xsd#OtherNetIncomeExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/OtherNetIncomeExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_91392fe1-9756-45bc-87c8-077ec49da082" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_1b67ddaf-ef93-4713-bfb7-781f5097369c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_91392fe1-9756-45bc-87c8-077ec49da082" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_1b67ddaf-ef93-4713-bfb7-781f5097369c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_6d6f0d27-fd5c-444e-9360-f2da5a175918" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_91392fe1-9756-45bc-87c8-077ec49da082" xlink:to="loc_us-gaap_InterestExpense_6d6f0d27-fd5c-444e-9360-f2da5a175918" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_0de1fdd7-b2e0-45f3-9cf3-4fdb63e28aaf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_91392fe1-9756-45bc-87c8-077ec49da082" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLoss_0de1fdd7-b2e0-45f3-9cf3-4fdb63e28aaf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_6631d186-14dd-4105-8cbe-572e1d963c86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_91392fe1-9756-45bc-87c8-077ec49da082" xlink:to="loc_us-gaap_InvestmentIncomeInterest_6631d186-14dd-4105-8cbe-572e1d963c86" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent_22d31a4b-36f9-438d-91c9-c355f1b5e71f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_91392fe1-9756-45bc-87c8-077ec49da082" xlink:to="loc_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent_22d31a4b-36f9-438d-91c9-c355f1b5e71f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_48ac056b-653b-44d1-adee-ef306b34a078" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_91392fe1-9756-45bc-87c8-077ec49da082" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_48ac056b-653b-44d1-adee-ef306b34a078" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>10
<FILENAME>lly-20220930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:1f63046d-a77a-465e-aed4-1fd7d331378a,g:f755fa79-e9ed-4360-88c0-9c62587f0bf5-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.lilly.com/role/CoverPage" xlink:type="simple" xlink:href="lly-20220930.xsd#CoverPage"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/CoverPage" xlink:type="extended" id="i47504e9b36ab4a0fa2fd097cbe701062_CoverPage">
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems_663bb69d-ca95-4b75-b907-b5ccb28d5446" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_50a81e89-8691-43a2-81bb-bad2dcf26b49" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_663bb69d-ca95-4b75-b907-b5ccb28d5446" xlink:to="loc_dei_DocumentType_50a81e89-8691-43a2-81bb-bad2dcf26b49" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_7f642852-70d5-4c6c-9e87-c61cdec8c84f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_663bb69d-ca95-4b75-b907-b5ccb28d5446" xlink:to="loc_dei_DocumentQuarterlyReport_7f642852-70d5-4c6c-9e87-c61cdec8c84f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_4ff9db29-c65f-4456-88e2-29c4c9dc53d0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_663bb69d-ca95-4b75-b907-b5ccb28d5446" xlink:to="loc_dei_DocumentTransitionReport_4ff9db29-c65f-4456-88e2-29c4c9dc53d0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_456b6f28-4207-4b80-af52-d982ececfd88" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_663bb69d-ca95-4b75-b907-b5ccb28d5446" xlink:to="loc_dei_DocumentPeriodEndDate_456b6f28-4207-4b80-af52-d982ececfd88" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_1c019e2d-62f0-408e-812c-297d326d65d2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_663bb69d-ca95-4b75-b907-b5ccb28d5446" xlink:to="loc_dei_EntityFileNumber_1c019e2d-62f0-408e-812c-297d326d65d2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_6c465f87-3415-4d39-a2ae-c1bd522507e0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_663bb69d-ca95-4b75-b907-b5ccb28d5446" xlink:to="loc_dei_EntityRegistrantName_6c465f87-3415-4d39-a2ae-c1bd522507e0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_b7d373af-f1e0-42ac-bd32-f50860ca174c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_663bb69d-ca95-4b75-b907-b5ccb28d5446" xlink:to="loc_dei_EntityIncorporationStateCountryCode_b7d373af-f1e0-42ac-bd32-f50860ca174c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_d72749bd-e5e6-46af-a961-a26a212afc61" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_663bb69d-ca95-4b75-b907-b5ccb28d5446" xlink:to="loc_dei_EntityTaxIdentificationNumber_d72749bd-e5e6-46af-a961-a26a212afc61" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_9ed10252-eebd-440a-b316-43637819a582" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_663bb69d-ca95-4b75-b907-b5ccb28d5446" xlink:to="loc_dei_EntityAddressAddressLine1_9ed10252-eebd-440a-b316-43637819a582" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_eb7a662d-ad57-41d9-b8d7-abd82c8b529b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_663bb69d-ca95-4b75-b907-b5ccb28d5446" xlink:to="loc_dei_EntityAddressCityOrTown_eb7a662d-ad57-41d9-b8d7-abd82c8b529b" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_a48d10b9-9a93-4b58-96f6-bc03a380ed03" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_663bb69d-ca95-4b75-b907-b5ccb28d5446" xlink:to="loc_dei_EntityAddressStateOrProvince_a48d10b9-9a93-4b58-96f6-bc03a380ed03" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_cd1b91fd-c55a-4162-91b3-f057a666c916" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_663bb69d-ca95-4b75-b907-b5ccb28d5446" xlink:to="loc_dei_EntityAddressPostalZipCode_cd1b91fd-c55a-4162-91b3-f057a666c916" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_8d9ace8e-4245-41c2-8ab8-9f5923ab0e5a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_663bb69d-ca95-4b75-b907-b5ccb28d5446" xlink:to="loc_dei_CityAreaCode_8d9ace8e-4245-41c2-8ab8-9f5923ab0e5a" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_072f48b2-3e21-48c3-b7b6-59ddb078cbb9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_663bb69d-ca95-4b75-b907-b5ccb28d5446" xlink:to="loc_dei_LocalPhoneNumber_072f48b2-3e21-48c3-b7b6-59ddb078cbb9" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_ad02fb14-ae03-4651-a28e-eb70801a598d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_663bb69d-ca95-4b75-b907-b5ccb28d5446" xlink:to="loc_dei_Security12bTitle_ad02fb14-ae03-4651-a28e-eb70801a598d" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_50ac939f-7d22-41d6-b39f-e7b718378553" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_663bb69d-ca95-4b75-b907-b5ccb28d5446" xlink:to="loc_dei_TradingSymbol_50ac939f-7d22-41d6-b39f-e7b718378553" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_f1586f9e-7ab4-4f46-b9aa-fc08a721cccd" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_663bb69d-ca95-4b75-b907-b5ccb28d5446" xlink:to="loc_dei_SecurityExchangeName_f1586f9e-7ab4-4f46-b9aa-fc08a721cccd" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_910b31c0-f586-47b0-bddb-e7043238341d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_663bb69d-ca95-4b75-b907-b5ccb28d5446" xlink:to="loc_dei_EntityCurrentReportingStatus_910b31c0-f586-47b0-bddb-e7043238341d" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_91a91b0e-0c78-440a-8d83-75b6f98512be" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_663bb69d-ca95-4b75-b907-b5ccb28d5446" xlink:to="loc_dei_EntityInteractiveDataCurrent_91a91b0e-0c78-440a-8d83-75b6f98512be" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_579ccb8e-86dc-4934-bd6f-e43fe15e8dc7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_663bb69d-ca95-4b75-b907-b5ccb28d5446" xlink:to="loc_dei_EntityFilerCategory_579ccb8e-86dc-4934-bd6f-e43fe15e8dc7" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_f30c286d-fbfa-442a-8b02-cda9ee270316" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_663bb69d-ca95-4b75-b907-b5ccb28d5446" xlink:to="loc_dei_EntitySmallBusiness_f30c286d-fbfa-442a-8b02-cda9ee270316" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_5ec038ea-1e28-4bc1-a542-f1b76582d25e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_663bb69d-ca95-4b75-b907-b5ccb28d5446" xlink:to="loc_dei_EntityEmergingGrowthCompany_5ec038ea-1e28-4bc1-a542-f1b76582d25e" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_77e45310-274c-4040-8706-09edaffff907" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_663bb69d-ca95-4b75-b907-b5ccb28d5446" xlink:to="loc_dei_EntityShellCompany_77e45310-274c-4040-8706-09edaffff907" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_d962d8ee-0cf6-4c50-88a9-77039364fb75" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_663bb69d-ca95-4b75-b907-b5ccb28d5446" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_d962d8ee-0cf6-4c50-88a9-77039364fb75" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_1a8e26b7-e4d8-4e31-90db-62a94e8d55d4" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_663bb69d-ca95-4b75-b907-b5ccb28d5446" xlink:to="loc_dei_AmendmentFlag_1a8e26b7-e4d8-4e31-90db-62a94e8d55d4" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_72d5d61c-0115-46e5-82f1-496becd6839d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_663bb69d-ca95-4b75-b907-b5ccb28d5446" xlink:to="loc_dei_DocumentFiscalYearFocus_72d5d61c-0115-46e5-82f1-496becd6839d" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_9f5ba0c3-e3f3-48bf-a42f-69fd1fe35f9f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_663bb69d-ca95-4b75-b907-b5ccb28d5446" xlink:to="loc_dei_DocumentFiscalPeriodFocus_9f5ba0c3-e3f3-48bf-a42f-69fd1fe35f9f" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_68aedcd0-c7d5-4f66-8136-6763bd167142" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_663bb69d-ca95-4b75-b907-b5ccb28d5446" xlink:to="loc_dei_EntityCentralIndexKey_68aedcd0-c7d5-4f66-8136-6763bd167142" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_6eb9c86e-df2d-4acd-bd5d-22d263f29204" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_663bb69d-ca95-4b75-b907-b5ccb28d5446" xlink:to="loc_dei_CurrentFiscalYearEndDate_6eb9c86e-df2d-4acd-bd5d-22d263f29204" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable_9e2376c9-79f3-409e-a1dc-5d1cdb1c2fad" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_DocumentInformationLineItems_663bb69d-ca95-4b75-b907-b5ccb28d5446" xlink:to="loc_dei_DocumentInformationTable_9e2376c9-79f3-409e-a1dc-5d1cdb1c2fad" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_59ffacc9-4e66-4f3b-ae84-456dc6a05bcf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_DocumentInformationTable_9e2376c9-79f3-409e-a1dc-5d1cdb1c2fad" xlink:to="loc_us-gaap_StatementClassOfStockAxis_59ffacc9-4e66-4f3b-ae84-456dc6a05bcf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_59ffacc9-4e66-4f3b-ae84-456dc6a05bcf_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_59ffacc9-4e66-4f3b-ae84-456dc6a05bcf" xlink:to="loc_us-gaap_ClassOfStockDomain_59ffacc9-4e66-4f3b-ae84-456dc6a05bcf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_1dc3d308-dfe7-4e80-989b-ae75f81ff455" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_59ffacc9-4e66-4f3b-ae84-456dc6a05bcf" xlink:to="loc_us-gaap_ClassOfStockDomain_1dc3d308-dfe7-4e80-989b-ae75f81ff455" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_54cc28e9-9a15-4def-bc89-c6043a711799" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1dc3d308-dfe7-4e80-989b-ae75f81ff455" xlink:to="loc_us-gaap_CommonClassAMember_54cc28e9-9a15-4def-bc89-c6043a711799" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A718NotesDueJune12025Member_d8275590-66e2-432d-bbb5-ce1faa36d480" xlink:href="lly-20220930.xsd#lly_A718NotesDueJune12025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1dc3d308-dfe7-4e80-989b-ae75f81ff455" xlink:to="loc_lly_A718NotesDueJune12025Member_d8275590-66e2-432d-bbb5-ce1faa36d480" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1.625NotesDueJune22026Member_a77bad25-47ed-4d64-886b-4fea83ecb9f3" xlink:href="lly-20220930.xsd#lly_A1.625NotesDueJune22026Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1dc3d308-dfe7-4e80-989b-ae75f81ff455" xlink:to="loc_lly_A1.625NotesDueJune22026Member_a77bad25-47ed-4d64-886b-4fea83ecb9f3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A2.125NotesDueJune32030Member_8acd9df9-a2cf-417d-9658-21fb54d83a6d" xlink:href="lly-20220930.xsd#lly_A2.125NotesDueJune32030Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1dc3d308-dfe7-4e80-989b-ae75f81ff455" xlink:to="loc_lly_A2.125NotesDueJune32030Member_8acd9df9-a2cf-417d-9658-21fb54d83a6d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A625NotesDue2031Member_bf48e6dd-4b65-489e-8e31-10b7dc77a67f" xlink:href="lly-20220930.xsd#lly_A625NotesDue2031Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1dc3d308-dfe7-4e80-989b-ae75f81ff455" xlink:to="loc_lly_A625NotesDue2031Member_bf48e6dd-4b65-489e-8e31-10b7dc77a67f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A500NotesDue2033Member_60bfe2b1-b154-4d5b-8b73-2aa25dd7e248" xlink:href="lly-20220930.xsd#lly_A500NotesDue2033Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1dc3d308-dfe7-4e80-989b-ae75f81ff455" xlink:to="loc_lly_A500NotesDue2033Member_60bfe2b1-b154-4d5b-8b73-2aa25dd7e248" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A6.77NotesDueJanuary12036Member_56652fbc-5e67-4f72-be5e-45c95b3155f1" xlink:href="lly-20220930.xsd#lly_A6.77NotesDueJanuary12036Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1dc3d308-dfe7-4e80-989b-ae75f81ff455" xlink:to="loc_lly_A6.77NotesDueJanuary12036Member_56652fbc-5e67-4f72-be5e-45c95b3155f1" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1625NotesDue2043Member_6546c0ba-f261-46c4-b3b4-dd95f412f8ee" xlink:href="lly-20220930.xsd#lly_A1625NotesDue2043Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1dc3d308-dfe7-4e80-989b-ae75f81ff455" xlink:to="loc_lly_A1625NotesDue2043Member_6546c0ba-f261-46c4-b3b4-dd95f412f8ee" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1700NotesDue2049Member_c04eacc8-e05e-4d61-b91d-4e1bcd3cc1ca" xlink:href="lly-20220930.xsd#lly_A1700NotesDue2049Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1dc3d308-dfe7-4e80-989b-ae75f81ff455" xlink:to="loc_lly_A1700NotesDue2049Member_c04eacc8-e05e-4d61-b91d-4e1bcd3cc1ca" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1125NotesDue2051Member_954a371d-9842-4e82-975a-79386b217475" xlink:href="lly-20220930.xsd#lly_A1125NotesDue2051Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1dc3d308-dfe7-4e80-989b-ae75f81ff455" xlink:to="loc_lly_A1125NotesDue2051Member_954a371d-9842-4e82-975a-79386b217475" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1375NotesDue2061Member_fb345301-ceb4-4798-9c1c-85f28563351d" xlink:href="lly-20220930.xsd#lly_A1375NotesDue2061Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1dc3d308-dfe7-4e80-989b-ae75f81ff455" xlink:to="loc_lly_A1375NotesDue2061Member_fb345301-ceb4-4798-9c1c-85f28563351d" xlink:type="arc" order="10"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/ConsolidatedCondensedStatementsofEquity" xlink:type="simple" xlink:href="lly-20220930.xsd#ConsolidatedCondensedStatementsofEquity"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/ConsolidatedCondensedStatementsofEquity" xlink:type="extended" id="if276f415c37847dcb7620d5b40d1b5d8_ConsolidatedCondensedStatementsofEquity">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_d4f5613d-6d3f-4895-a58d-4ad2339b1cd9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f3e11bbd-91ae-4393-aca3-99c1ad0f7712" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d4f5613d-6d3f-4895-a58d-4ad2339b1cd9" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f3e11bbd-91ae-4393-aca3-99c1ad0f7712" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_c9a2508d-ed4c-4969-b4ce-e22faea04a88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f3e11bbd-91ae-4393-aca3-99c1ad0f7712" xlink:to="loc_us-gaap_CommonStockSharesIssued_c9a2508d-ed4c-4969-b4ce-e22faea04a88" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_fd11850c-a80b-404f-ab4b-c87690ef909e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f3e11bbd-91ae-4393-aca3-99c1ad0f7712" xlink:to="loc_us-gaap_TreasuryStockCommonShares_fd11850c-a80b-404f-ab4b-c87690ef909e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3e334697-cb17-412a-8863-00b40cac35a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f3e11bbd-91ae-4393-aca3-99c1ad0f7712" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3e334697-cb17-412a-8863-00b40cac35a9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_b7d14ff9-e415-421e-9bea-eb90d31dafa3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f3e11bbd-91ae-4393-aca3-99c1ad0f7712" xlink:to="loc_us-gaap_ProfitLoss_b7d14ff9-e415-421e-9bea-eb90d31dafa3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_c97f8e46-3259-4853-9f4b-d8b3af7327bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f3e11bbd-91ae-4393-aca3-99c1ad0f7712" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_c97f8e46-3259-4853-9f4b-d8b3af7327bc" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Dividends_ec2d2940-c154-4c5c-8889-4182522bef2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Dividends"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f3e11bbd-91ae-4393-aca3-99c1ad0f7712" xlink:to="loc_us-gaap_Dividends_ec2d2940-c154-4c5c-8889-4182522bef2f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesRetired_1e7a6536-7761-4230-b498-e70e88766626" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockSharesRetired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f3e11bbd-91ae-4393-aca3-99c1ad0f7712" xlink:to="loc_us-gaap_TreasuryStockSharesRetired_1e7a6536-7761-4230-b498-e70e88766626" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockRetiredCostMethodAmount_68d729f2-237c-44ee-8ae4-a1df1dcab6fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockRetiredCostMethodAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f3e11bbd-91ae-4393-aca3-99c1ad0f7712" xlink:to="loc_us-gaap_TreasuryStockRetiredCostMethodAmount_68d729f2-237c-44ee-8ae4-a1df1dcab6fe" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_e7cda99e-083c-4086-b9b2-1e789ac1d295" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f3e11bbd-91ae-4393-aca3-99c1ad0f7712" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_e7cda99e-083c-4086-b9b2-1e789ac1d295" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_2311e70f-4963-4181-ab93-9cefb59e9f45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f3e11bbd-91ae-4393-aca3-99c1ad0f7712" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_2311e70f-4963-4181-ab93-9cefb59e9f45" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_0e08ebd4-9fd4-44db-a170-8fe26aeb7283" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f3e11bbd-91ae-4393-aca3-99c1ad0f7712" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_0e08ebd4-9fd4-44db-a170-8fe26aeb7283" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_91c60a48-94fa-4663-842d-53c1b11ec663" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f3e11bbd-91ae-4393-aca3-99c1ad0f7712" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_91c60a48-94fa-4663-842d-53c1b11ec663" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_622f3ea2-c01e-4366-8efe-b52059ac05d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f3e11bbd-91ae-4393-aca3-99c1ad0f7712" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_622f3ea2-c01e-4366-8efe-b52059ac05d7" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOther_cb904d20-ca3e-4f05-9922-e089f2de708d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f3e11bbd-91ae-4393-aca3-99c1ad0f7712" xlink:to="loc_us-gaap_StockholdersEquityOther_cb904d20-ca3e-4f05-9922-e089f2de708d" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_a0d616d4-139e-45ba-8710-97689c77a117" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_dafefc71-69d6-4c2f-9eaf-ba2ad1d95a7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_80bc5423-9bff-4395-870f-eb465560ebfc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_79369ac0-965b-4268-b9b2-584063ca3195" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_d4f5613d-6d3f-4895-a58d-4ad2339b1cd9" xlink:to="loc_us-gaap_StatementTable_79369ac0-965b-4268-b9b2-584063ca3195" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_3e45009f-a686-4f63-966d-e57b78d87839" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_79369ac0-965b-4268-b9b2-584063ca3195" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_3e45009f-a686-4f63-966d-e57b78d87839" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_3e45009f-a686-4f63-966d-e57b78d87839_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_3e45009f-a686-4f63-966d-e57b78d87839" xlink:to="loc_us-gaap_EquityComponentDomain_3e45009f-a686-4f63-966d-e57b78d87839_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_d695ccdf-e900-4e07-a042-f73afa72c339" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_3e45009f-a686-4f63-966d-e57b78d87839" xlink:to="loc_us-gaap_EquityComponentDomain_d695ccdf-e900-4e07-a042-f73afa72c339" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_65d02275-8b84-4417-b6c9-b595088588ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_d695ccdf-e900-4e07-a042-f73afa72c339" xlink:to="loc_us-gaap_CommonStockMember_65d02275-8b84-4417-b6c9-b595088588ff" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_f84e46f3-0652-4bcc-936a-3cc03cb5e9c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_d695ccdf-e900-4e07-a042-f73afa72c339" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_f84e46f3-0652-4bcc-936a-3cc03cb5e9c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_d9a9dab2-ac5d-4ed1-90a0-5f31b58db862" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_d695ccdf-e900-4e07-a042-f73afa72c339" xlink:to="loc_us-gaap_RetainedEarningsMember_d9a9dab2-ac5d-4ed1-90a0-5f31b58db862" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrustForBenefitOfEmployeesMember_14c76391-f976-46cc-804a-7d32e5e6e59d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TrustForBenefitOfEmployeesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_d695ccdf-e900-4e07-a042-f73afa72c339" xlink:to="loc_us-gaap_TrustForBenefitOfEmployeesMember_14c76391-f976-46cc-804a-7d32e5e6e59d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_fcadc3b4-5d73-4eb3-b4f8-58c1a21bdaf8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_d695ccdf-e900-4e07-a042-f73afa72c339" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_fcadc3b4-5d73-4eb3-b4f8-58c1a21bdaf8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember_86a188c3-3c75-4a30-81dc-541ff1c151bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_d695ccdf-e900-4e07-a042-f73afa72c339" xlink:to="loc_us-gaap_TreasuryStockCommonMember_86a188c3-3c75-4a30-81dc-541ff1c151bc" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_2a68e8fe-f08f-4aee-a2ce-515d54dfe64a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_d695ccdf-e900-4e07-a042-f73afa72c339" xlink:to="loc_us-gaap_NoncontrollingInterestMember_2a68e8fe-f08f-4aee-a2ce-515d54dfe64a" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/RevenueSummaryofRevenueRecognizedDetails" xlink:type="simple" xlink:href="lly-20220930.xsd#RevenueSummaryofRevenueRecognizedDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/RevenueSummaryofRevenueRecognizedDetails" xlink:type="extended" id="i25eb4d8d50184085b9aeaa6d838ebeec_RevenueSummaryofRevenueRecognizedDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_514b86bd-3011-4469-9181-85aa9bfed66b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_79215baa-a05f-4b06-ac05-3bcc35e3b4b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_514b86bd-3011-4469-9181-85aa9bfed66b" xlink:to="loc_us-gaap_Revenues_79215baa-a05f-4b06-ac05-3bcc35e3b4b1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_4773a452-0c0a-4965-bc57-e72ae7c17b49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_514b86bd-3011-4469-9181-85aa9bfed66b" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_4773a452-0c0a-4965-bc57-e72ae7c17b49" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_400ca3b4-06ce-4139-b721-aa962a33de00" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_4773a452-0c0a-4965-bc57-e72ae7c17b49" xlink:to="loc_srt_ProductOrServiceAxis_400ca3b4-06ce-4139-b721-aa962a33de00" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_400ca3b4-06ce-4139-b721-aa962a33de00_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_400ca3b4-06ce-4139-b721-aa962a33de00" xlink:to="loc_srt_ProductsAndServicesDomain_400ca3b4-06ce-4139-b721-aa962a33de00_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_168fb72d-5f74-44cd-a695-b531e42b2370" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_400ca3b4-06ce-4139-b721-aa962a33de00" xlink:to="loc_srt_ProductsAndServicesDomain_168fb72d-5f74-44cd-a695-b531e42b2370" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_3f7aae95-4341-4eec-a9de-5275bfbdaaec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_168fb72d-5f74-44cd-a695-b531e42b2370" xlink:to="loc_us-gaap_ProductMember_3f7aae95-4341-4eec-a9de-5275bfbdaaec" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CollaborationandOtherRevenueMember_9dbb1a70-e7c2-4bd7-8fdd-d3bf220b672a" xlink:href="lly-20220930.xsd#lly_CollaborationandOtherRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_168fb72d-5f74-44cd-a695-b531e42b2370" xlink:to="loc_lly_CollaborationandOtherRevenueMember_9dbb1a70-e7c2-4bd7-8fdd-d3bf220b672a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_386673df-59c5-47e9-96ed-f38d6d05b1ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_168fb72d-5f74-44cd-a695-b531e42b2370" xlink:to="loc_us-gaap_RoyaltyMember_386673df-59c5-47e9-96ed-f38d6d05b1ec" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/RevenueAdjustmentstoRevenueDetails" xlink:type="simple" xlink:href="lly-20220930.xsd#RevenueAdjustmentstoRevenueDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/RevenueAdjustmentstoRevenueDetails" xlink:type="extended" id="i13b7503cd87949e39c25f262ea6e4251_RevenueAdjustmentstoRevenueDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateLineItems_90810cfd-6d0f-48c3-a28d-245c04fe05a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInAccountingEstimateLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent_0fb31fb1-e67e-4e04-86a0-2aa6da5ee81f" xlink:href="lly-20220930.xsd#lly_RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ChangeInAccountingEstimateLineItems_90810cfd-6d0f-48c3-a28d-245c04fe05a4" xlink:to="loc_lly_RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent_0fb31fb1-e67e-4e04-86a0-2aa6da5ee81f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfChangeInAccountingEstimateTable_5b7aa423-a849-457b-b8df-595a2be8920d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfChangeInAccountingEstimateTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ChangeInAccountingEstimateLineItems_90810cfd-6d0f-48c3-a28d-245c04fe05a4" xlink:to="loc_us-gaap_ScheduleOfChangeInAccountingEstimateTable_5b7aa423-a849-457b-b8df-595a2be8920d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_525eb263-5de1-444c-a554-a4b36304f481" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfChangeInAccountingEstimateTable_5b7aa423-a849-457b-b8df-595a2be8920d" xlink:to="loc_srt_StatementGeographicalAxis_525eb263-5de1-444c-a554-a4b36304f481" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_525eb263-5de1-444c-a554-a4b36304f481_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_525eb263-5de1-444c-a554-a4b36304f481" xlink:to="loc_srt_SegmentGeographicalDomain_525eb263-5de1-444c-a554-a4b36304f481_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_83eb2484-e5cb-4f16-81c2-56e1407311e4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_525eb263-5de1-444c-a554-a4b36304f481" xlink:to="loc_srt_SegmentGeographicalDomain_83eb2484-e5cb-4f16-81c2-56e1407311e4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_feec730e-4bca-4e3e-bcc7-89ac29173f74" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_83eb2484-e5cb-4f16-81c2-56e1407311e4" xlink:to="loc_country_US_feec730e-4bca-4e3e-bcc7-89ac29173f74" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_f686fee8-01c8-42c4-aa90-ea60cf06c8a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInAccountingEstimateByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfChangeInAccountingEstimateTable_5b7aa423-a849-457b-b8df-595a2be8920d" xlink:to="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_f686fee8-01c8-42c4-aa90-ea60cf06c8a3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_f686fee8-01c8-42c4-aa90-ea60cf06c8a3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInAccountingEstimateTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_f686fee8-01c8-42c4-aa90-ea60cf06c8a3" xlink:to="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_f686fee8-01c8-42c4-aa90-ea60cf06c8a3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_9cea77b9-d2c7-462e-89e9-85357d54370a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInAccountingEstimateTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_f686fee8-01c8-42c4-aa90-ea60cf06c8a3" xlink:to="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_9cea77b9-d2c7-462e-89e9-85357d54370a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesReturnsAndAllowancesMember_4378d874-407c-49f0-95bf-66887250f55e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesReturnsAndAllowancesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_9cea77b9-d2c7-462e-89e9-85357d54370a" xlink:to="loc_us-gaap_SalesReturnsAndAllowancesMember_4378d874-407c-49f0-95bf-66887250f55e" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails" xlink:type="simple" xlink:href="lly-20220930.xsd#RevenueDisaggregationofRevenuebyProductDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails" xlink:type="extended" id="i927a42c01d6f45bca1c09e1f936c1b8d_RevenueDisaggregationofRevenuebyProductDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_cc66c5d5-5804-40ca-ac99-28eb0d89ae7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_d9287941-341c-4695-81c9-a90d841270b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_cc66c5d5-5804-40ca-ac99-28eb0d89ae7d" xlink:to="loc_us-gaap_Revenues_d9287941-341c-4695-81c9-a90d841270b8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_6fa2293f-f99a-48a6-8c78-bfeda3070338" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_cc66c5d5-5804-40ca-ac99-28eb0d89ae7d" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_6fa2293f-f99a-48a6-8c78-bfeda3070338" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_6718f0ee-6631-48cb-a3e0-895c403a3d53" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_6fa2293f-f99a-48a6-8c78-bfeda3070338" xlink:to="loc_srt_ProductOrServiceAxis_6718f0ee-6631-48cb-a3e0-895c403a3d53" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_6718f0ee-6631-48cb-a3e0-895c403a3d53_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_6718f0ee-6631-48cb-a3e0-895c403a3d53" xlink:to="loc_srt_ProductsAndServicesDomain_6718f0ee-6631-48cb-a3e0-895c403a3d53_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_e1e31312-a68d-4590-85ad-67ee5cbf776a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_6718f0ee-6631-48cb-a3e0-895c403a3d53" xlink:to="loc_srt_ProductsAndServicesDomain_e1e31312-a68d-4590-85ad-67ee5cbf776a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DiabetesMember_07f5d614-5f44-4537-8e25-580bc3f35cd4" xlink:href="lly-20220930.xsd#lly_DiabetesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e1e31312-a68d-4590-85ad-67ee5cbf776a" xlink:to="loc_lly_DiabetesMember_07f5d614-5f44-4537-8e25-580bc3f35cd4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_TrulicityMember_fe5510e1-000a-4be6-9990-a787def64de0" xlink:href="lly-20220930.xsd#lly_TrulicityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_DiabetesMember_07f5d614-5f44-4537-8e25-580bc3f35cd4" xlink:to="loc_lly_TrulicityMember_fe5510e1-000a-4be6-9990-a787def64de0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_JardianceMember_9b7f8955-e9ee-4e98-818f-03eb5353bc94" xlink:href="lly-20220930.xsd#lly_JardianceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_DiabetesMember_07f5d614-5f44-4537-8e25-580bc3f35cd4" xlink:to="loc_lly_JardianceMember_9b7f8955-e9ee-4e98-818f-03eb5353bc94" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_HumalogMember_9fe76c02-93a9-42db-a04b-29ddb595f98f" xlink:href="lly-20220930.xsd#lly_HumalogMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_DiabetesMember_07f5d614-5f44-4537-8e25-580bc3f35cd4" xlink:to="loc_lly_HumalogMember_9fe76c02-93a9-42db-a04b-29ddb595f98f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_HumulinMember_ce10f3ae-13a9-43f0-8cb8-1405b0e37743" xlink:href="lly-20220930.xsd#lly_HumulinMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_DiabetesMember_07f5d614-5f44-4537-8e25-580bc3f35cd4" xlink:to="loc_lly_HumulinMember_ce10f3ae-13a9-43f0-8cb8-1405b0e37743" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BasaglarMember_353c61a4-8683-4e97-b08b-3402091b4e1c" xlink:href="lly-20220930.xsd#lly_BasaglarMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_DiabetesMember_07f5d614-5f44-4537-8e25-580bc3f35cd4" xlink:to="loc_lly_BasaglarMember_353c61a4-8683-4e97-b08b-3402091b4e1c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MounjaroMember_ad0bebdc-5d41-4ffe-ae2e-9059cf007f2e" xlink:href="lly-20220930.xsd#lly_MounjaroMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_DiabetesMember_07f5d614-5f44-4537-8e25-580bc3f35cd4" xlink:to="loc_lly_MounjaroMember_ad0bebdc-5d41-4ffe-ae2e-9059cf007f2e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OtherDiabetesMember_827827fd-155a-40b1-9b8e-747b9d3b34b8" xlink:href="lly-20220930.xsd#lly_OtherDiabetesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_DiabetesMember_07f5d614-5f44-4537-8e25-580bc3f35cd4" xlink:to="loc_lly_OtherDiabetesMember_827827fd-155a-40b1-9b8e-747b9d3b34b8" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OncologyMember_7e287428-01e4-4b27-8c8b-66f8e2a953fc" xlink:href="lly-20220930.xsd#lly_OncologyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e1e31312-a68d-4590-85ad-67ee5cbf776a" xlink:to="loc_lly_OncologyMember_7e287428-01e4-4b27-8c8b-66f8e2a953fc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_VerzenioMember_8859e150-dad7-44c6-b0d1-26bb1f8d785f" xlink:href="lly-20220930.xsd#lly_VerzenioMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_OncologyMember_7e287428-01e4-4b27-8c8b-66f8e2a953fc" xlink:to="loc_lly_VerzenioMember_8859e150-dad7-44c6-b0d1-26bb1f8d785f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CyramzaMember_bd02c411-6cfb-4027-9083-506bc23a0ef6" xlink:href="lly-20220930.xsd#lly_CyramzaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_OncologyMember_7e287428-01e4-4b27-8c8b-66f8e2a953fc" xlink:to="loc_lly_CyramzaMember_bd02c411-6cfb-4027-9083-506bc23a0ef6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ErbituxMember_f0674908-f91d-4f00-a741-d2b061f26957" xlink:href="lly-20220930.xsd#lly_ErbituxMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_OncologyMember_7e287428-01e4-4b27-8c8b-66f8e2a953fc" xlink:to="loc_lly_ErbituxMember_f0674908-f91d-4f00-a741-d2b061f26957" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AlimtaMember_bc7abe43-1b2e-4fec-9d44-d30a23dbe17d" xlink:href="lly-20220930.xsd#lly_AlimtaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_OncologyMember_7e287428-01e4-4b27-8c8b-66f8e2a953fc" xlink:to="loc_lly_AlimtaMember_bc7abe43-1b2e-4fec-9d44-d30a23dbe17d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_TYVYTMember_e8e84b2b-962f-42e3-95db-758c09aa7e61" xlink:href="lly-20220930.xsd#lly_TYVYTMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_OncologyMember_7e287428-01e4-4b27-8c8b-66f8e2a953fc" xlink:to="loc_lly_TYVYTMember_e8e84b2b-962f-42e3-95db-758c09aa7e61" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OtherOncologyMember_02a6e829-517e-4dad-ab08-6f02b9bb9aa4" xlink:href="lly-20220930.xsd#lly_OtherOncologyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_OncologyMember_7e287428-01e4-4b27-8c8b-66f8e2a953fc" xlink:to="loc_lly_OtherOncologyMember_02a6e829-517e-4dad-ab08-6f02b9bb9aa4" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ImmunologyMember_1a2e23e0-39f7-456c-84d3-ea6be717a82e" xlink:href="lly-20220930.xsd#lly_ImmunologyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e1e31312-a68d-4590-85ad-67ee5cbf776a" xlink:to="loc_lly_ImmunologyMember_1a2e23e0-39f7-456c-84d3-ea6be717a82e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_TaltzMember_31e1f3ad-9a37-47fb-9321-9f7df75b7d4e" xlink:href="lly-20220930.xsd#lly_TaltzMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_ImmunologyMember_1a2e23e0-39f7-456c-84d3-ea6be717a82e" xlink:to="loc_lly_TaltzMember_31e1f3ad-9a37-47fb-9321-9f7df75b7d4e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OlumiantMember_76161c32-5546-4384-aabd-f5d8e4add712" xlink:href="lly-20220930.xsd#lly_OlumiantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_ImmunologyMember_1a2e23e0-39f7-456c-84d3-ea6be717a82e" xlink:to="loc_lly_OlumiantMember_76161c32-5546-4384-aabd-f5d8e4add712" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OtherImmunologyMember_c61f2102-78f2-447d-93b7-a124f37eb3b5" xlink:href="lly-20220930.xsd#lly_OtherImmunologyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_ImmunologyMember_1a2e23e0-39f7-456c-84d3-ea6be717a82e" xlink:to="loc_lly_OtherImmunologyMember_c61f2102-78f2-447d-93b7-a124f37eb3b5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_NeuroscienceMember_d5a6f8c3-df3f-4b32-91d8-c868009e51d1" xlink:href="lly-20220930.xsd#lly_NeuroscienceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e1e31312-a68d-4590-85ad-67ee5cbf776a" xlink:to="loc_lly_NeuroscienceMember_d5a6f8c3-df3f-4b32-91d8-c868009e51d1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_EmgalityMember_a82efc61-3af0-482e-921d-e4f80293d679" xlink:href="lly-20220930.xsd#lly_EmgalityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_NeuroscienceMember_d5a6f8c3-df3f-4b32-91d8-c868009e51d1" xlink:to="loc_lly_EmgalityMember_a82efc61-3af0-482e-921d-e4f80293d679" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ZyprexaMember_02a0a2ca-4c9e-4fa8-8676-e557c49a5e51" xlink:href="lly-20220930.xsd#lly_ZyprexaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_NeuroscienceMember_d5a6f8c3-df3f-4b32-91d8-c868009e51d1" xlink:to="loc_lly_ZyprexaMember_02a0a2ca-4c9e-4fa8-8676-e557c49a5e51" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CymbaltaMember_38d776c9-caa5-42eb-8cef-268c74e5024c" xlink:href="lly-20220930.xsd#lly_CymbaltaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_NeuroscienceMember_d5a6f8c3-df3f-4b32-91d8-c868009e51d1" xlink:to="loc_lly_CymbaltaMember_38d776c9-caa5-42eb-8cef-268c74e5024c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OtherNeuroscienceMember_0832a463-15ee-40f2-8868-5fcef86d4917" xlink:href="lly-20220930.xsd#lly_OtherNeuroscienceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_NeuroscienceMember_d5a6f8c3-df3f-4b32-91d8-c868009e51d1" xlink:to="loc_lly_OtherNeuroscienceMember_0832a463-15ee-40f2-8868-5fcef86d4917" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OtherProductTotalMember_dd01e253-e4b3-431e-8e59-d994b4b8ec02" xlink:href="lly-20220930.xsd#lly_OtherProductTotalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e1e31312-a68d-4590-85ad-67ee5cbf776a" xlink:to="loc_lly_OtherProductTotalMember_dd01e253-e4b3-431e-8e59-d994b4b8ec02" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_COVID19AntibodiesMember_cdfcd4fd-026a-4772-bec3-19634d7ea501" xlink:href="lly-20220930.xsd#lly_COVID19AntibodiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_OtherProductTotalMember_dd01e253-e4b3-431e-8e59-d994b4b8ec02" xlink:to="loc_lly_COVID19AntibodiesMember_cdfcd4fd-026a-4772-bec3-19634d7ea501" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ForteoMember_fa42e216-8d6e-46eb-a326-ae478c7c2bce" xlink:href="lly-20220930.xsd#lly_ForteoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_OtherProductTotalMember_dd01e253-e4b3-431e-8e59-d994b4b8ec02" xlink:to="loc_lly_ForteoMember_fa42e216-8d6e-46eb-a326-ae478c7c2bce" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CialisMember_15c41593-6f30-45d6-89d9-04348355a198" xlink:href="lly-20220930.xsd#lly_CialisMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_OtherProductTotalMember_dd01e253-e4b3-431e-8e59-d994b4b8ec02" xlink:to="loc_lly_CialisMember_15c41593-6f30-45d6-89d9-04348355a198" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OtherProductMember_af065bb4-c702-49b9-b66a-3fa37c97a221" xlink:href="lly-20220930.xsd#lly_OtherProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_OtherProductTotalMember_dd01e253-e4b3-431e-8e59-d994b4b8ec02" xlink:to="loc_lly_OtherProductMember_af065bb4-c702-49b9-b66a-3fa37c97a221" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_f038f5c2-a2ef-497d-83da-2b1fbb35184d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_6fa2293f-f99a-48a6-8c78-bfeda3070338" xlink:to="loc_srt_StatementGeographicalAxis_f038f5c2-a2ef-497d-83da-2b1fbb35184d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_f038f5c2-a2ef-497d-83da-2b1fbb35184d_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_f038f5c2-a2ef-497d-83da-2b1fbb35184d" xlink:to="loc_srt_SegmentGeographicalDomain_f038f5c2-a2ef-497d-83da-2b1fbb35184d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_960832e6-2d42-4555-a0a2-28b3c8105096" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_f038f5c2-a2ef-497d-83da-2b1fbb35184d" xlink:to="loc_srt_SegmentGeographicalDomain_960832e6-2d42-4555-a0a2-28b3c8105096" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_c34cea8e-50a4-470f-bd36-2c76292ce16d" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_960832e6-2d42-4555-a0a2-28b3c8105096" xlink:to="loc_country_US_c34cea8e-50a4-470f-bd36-2c76292ce16d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_fd94195a-0d67-4839-8fa3-ed0a0f3fa9b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_960832e6-2d42-4555-a0a2-28b3c8105096" xlink:to="loc_us-gaap_NonUsMember_fd94195a-0d67-4839-8fa3-ed0a0f3fa9b3" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/RevenueDisaggregationofRevenuebyGeographicalAreaDetails" xlink:type="simple" xlink:href="lly-20220930.xsd#RevenueDisaggregationofRevenuebyGeographicalAreaDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/RevenueDisaggregationofRevenuebyGeographicalAreaDetails" xlink:type="extended" id="i7d070b9cdea64fec962d4700ea7059c6_RevenueDisaggregationofRevenuebyGeographicalAreaDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_ae9f083f-921d-45bb-bb43-cfb341dec8b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_f77b64dd-1d83-498f-bb87-310a22ea266d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_ae9f083f-921d-45bb-bb43-cfb341dec8b7" xlink:to="loc_us-gaap_Revenues_f77b64dd-1d83-498f-bb87-310a22ea266d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_a950338f-42cb-42b6-84e6-25a0ce44b0c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_ae9f083f-921d-45bb-bb43-cfb341dec8b7" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_a950338f-42cb-42b6-84e6-25a0ce44b0c8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_2bd709b6-8e02-4814-85fb-7de3f836538a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_a950338f-42cb-42b6-84e6-25a0ce44b0c8" xlink:to="loc_srt_StatementGeographicalAxis_2bd709b6-8e02-4814-85fb-7de3f836538a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_2bd709b6-8e02-4814-85fb-7de3f836538a_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_2bd709b6-8e02-4814-85fb-7de3f836538a" xlink:to="loc_srt_SegmentGeographicalDomain_2bd709b6-8e02-4814-85fb-7de3f836538a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_e8456c22-0122-4601-82cd-41c8e7d40260" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_2bd709b6-8e02-4814-85fb-7de3f836538a" xlink:to="loc_srt_SegmentGeographicalDomain_e8456c22-0122-4601-82cd-41c8e7d40260" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_b68cd15e-93df-45b9-8cf4-c1ec7e90abb1" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_e8456c22-0122-4601-82cd-41c8e7d40260" xlink:to="loc_country_US_b68cd15e-93df-45b9-8cf4-c1ec7e90abb1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember_2d23bee1-c4b5-47bf-b54b-eb6c55cae5d7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EuropeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_e8456c22-0122-4601-82cd-41c8e7d40260" xlink:to="loc_srt_EuropeMember_2d23bee1-c4b5-47bf-b54b-eb6c55cae5d7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_JP_e26a93aa-6f45-4095-b2f7-aa7bede04ad5" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_JP"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_e8456c22-0122-4601-82cd-41c8e7d40260" xlink:to="loc_country_JP_e26a93aa-6f45-4095-b2f7-aa7bede04ad5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CN_7ab79495-a482-4645-880c-4f29018a634e" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CN"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_e8456c22-0122-4601-82cd-41c8e7d40260" xlink:to="loc_country_CN_7ab79495-a482-4645-880c-4f29018a634e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OtherForeignCountriesMember_629d9de4-93d9-417c-af48-c3fb9e1c39eb" xlink:href="lly-20220930.xsd#lly_OtherForeignCountriesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_e8456c22-0122-4601-82cd-41c8e7d40260" xlink:to="loc_lly_OtherForeignCountriesMember_629d9de4-93d9-417c-af48-c3fb9e1c39eb" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/AcquisitionsNarrativeDetails" xlink:type="simple" xlink:href="lly-20220930.xsd#AcquisitionsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/AcquisitionsNarrativeDetails" xlink:type="extended" id="ie52310b283a3468a95b631347be7401f_AcquisitionsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_99321e59-a98b-4704-83dc-77613c70cbe2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AcquiredInProcessResearchAndDevelopmentAndDevelopmentMilestones_93bbb501-e52b-4b1a-af59-7134d15e4902" xlink:href="lly-20220930.xsd#lly_AcquiredInProcessResearchAndDevelopmentAndDevelopmentMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_99321e59-a98b-4704-83dc-77613c70cbe2" xlink:to="loc_lly_AcquiredInProcessResearchAndDevelopmentAndDevelopmentMilestones_93bbb501-e52b-4b1a-af59-7134d15e4902" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_1f8d57ed-e749-4e19-918d-6bb0fca396d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionSharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_99321e59-a98b-4704-83dc-77613c70cbe2" xlink:to="loc_us-gaap_BusinessAcquisitionSharePrice_1f8d57ed-e749-4e19-918d-6bb0fca396d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_8d8d78ff-1a7f-4fb7-9b4f-7dd279d125a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_99321e59-a98b-4704-83dc-77613c70cbe2" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_8d8d78ff-1a7f-4fb7-9b4f-7dd279d125a0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BusinessCombinationConsiderationTransferredNumberOfContingentValueRights_9201994c-5fed-4fd4-af8e-9fc8b3fd2470" xlink:href="lly-20220930.xsd#lly_BusinessCombinationConsiderationTransferredNumberOfContingentValueRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_99321e59-a98b-4704-83dc-77613c70cbe2" xlink:to="loc_lly_BusinessCombinationConsiderationTransferredNumberOfContingentValueRights_9201994c-5fed-4fd4-af8e-9fc8b3fd2470" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BusinessAcquisitionContingentValueRightAdditionalPricePerShare_4aeece1d-ce31-4137-a9ab-7fccc86ebe30" xlink:href="lly-20220930.xsd#lly_BusinessAcquisitionContingentValueRightAdditionalPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_99321e59-a98b-4704-83dc-77613c70cbe2" xlink:to="loc_lly_BusinessAcquisitionContingentValueRightAdditionalPricePerShare_4aeece1d-ce31-4137-a9ab-7fccc86ebe30" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_b26fc4e7-d055-40af-aea1-2196e7cae143" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_99321e59-a98b-4704-83dc-77613c70cbe2" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_b26fc4e7-d055-40af-aea1-2196e7cae143" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BusinessAcquisitionContingentValueRightRegulatoryApprovalDelayMonthlyReduction_70e13fce-ec58-4f95-aa5c-3f9e9532c574" xlink:href="lly-20220930.xsd#lly_BusinessAcquisitionContingentValueRightRegulatoryApprovalDelayMonthlyReduction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_99321e59-a98b-4704-83dc-77613c70cbe2" xlink:to="loc_lly_BusinessAcquisitionContingentValueRightRegulatoryApprovalDelayMonthlyReduction_70e13fce-ec58-4f95-aa5c-3f9e9532c574" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_PaymentsForAssetAcquisitions_f176bf21-1654-4986-b627-dc14bf459409" xlink:href="lly-20220930.xsd#lly_PaymentsForAssetAcquisitions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_99321e59-a98b-4704-83dc-77613c70cbe2" xlink:to="loc_lly_PaymentsForAssetAcquisitions_f176bf21-1654-4986-b627-dc14bf459409" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_6eb187cb-e03b-45ff-b500-fbe7276040d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_99321e59-a98b-4704-83dc-77613c70cbe2" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_6eb187cb-e03b-45ff-b500-fbe7276040d7" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_9f18d728-22fd-4459-aa14-4c34cc8fa253" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_99321e59-a98b-4704-83dc-77613c70cbe2" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_9f18d728-22fd-4459-aa14-4c34cc8fa253" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_a94e5cff-c534-4db9-a801-5a3c6233f003" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_9f18d728-22fd-4459-aa14-4c34cc8fa253" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_a94e5cff-c534-4db9-a801-5a3c6233f003" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a94e5cff-c534-4db9-a801-5a3c6233f003_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_a94e5cff-c534-4db9-a801-5a3c6233f003" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a94e5cff-c534-4db9-a801-5a3c6233f003_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ec795f65-08ef-48b8-998e-57f0e0029a7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_a94e5cff-c534-4db9-a801-5a3c6233f003" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ec795f65-08ef-48b8-998e-57f0e0029a7f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_PrevailTherapeuticsIncMember_e3422d24-6701-4b82-b7ec-d6cc6bc0b26d" xlink:href="lly-20220930.xsd#lly_PrevailTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ec795f65-08ef-48b8-998e-57f0e0029a7f" xlink:to="loc_lly_PrevailTherapeuticsIncMember_e3422d24-6701-4b82-b7ec-d6cc6bc0b26d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AkouosAcquisitionMember_294414aa-97aa-46b3-9c6a-c1bff14c32ff" xlink:href="lly-20220930.xsd#lly_AkouosAcquisitionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ec795f65-08ef-48b8-998e-57f0e0029a7f" xlink:to="loc_lly_AkouosAcquisitionMember_294414aa-97aa-46b3-9c6a-c1bff14c32ff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_36af5a6c-c6f5-4723-a88b-7ca382d5a063" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_9f18d728-22fd-4459-aa14-4c34cc8fa253" xlink:to="loc_srt_StatementScenarioAxis_36af5a6c-c6f5-4723-a88b-7ca382d5a063" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_36af5a6c-c6f5-4723-a88b-7ca382d5a063_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_36af5a6c-c6f5-4723-a88b-7ca382d5a063" xlink:to="loc_srt_ScenarioUnspecifiedDomain_36af5a6c-c6f5-4723-a88b-7ca382d5a063_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_b28130cd-5bf1-4c48-95cd-846ae75c3cd0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_36af5a6c-c6f5-4723-a88b-7ca382d5a063" xlink:to="loc_srt_ScenarioUnspecifiedDomain_b28130cd-5bf1-4c48-95cd-846ae75c3cd0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_ce4cb0da-d5c5-4931-b499-42c3012b17b1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_b28130cd-5bf1-4c48-95cd-846ae75c3cd0" xlink:to="loc_srt_ScenarioForecastMember_ce4cb0da-d5c5-4931-b499-42c3012b17b1" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="simple" xlink:href="lly-20220930.xsd#AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="extended" id="ibc03d85f7d574c0fad2615056ea59623_AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_1c898ee7-950a-40e7-823a-eeb606793986" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_04e50ae4-f83a-4e8c-bf92-0ca238f038f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1c898ee7-950a-40e7-823a-eeb606793986" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_04e50ae4-f83a-4e8c-bf92-0ca238f038f0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_f28bec4a-7754-4fd7-be08-0623a8edb3df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1c898ee7-950a-40e7-823a-eeb606793986" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_f28bec4a-7754-4fd7-be08-0623a8edb3df" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_47257f8b-d88d-4207-b8a3-fe85abc31904" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1c898ee7-950a-40e7-823a-eeb606793986" xlink:to="loc_us-gaap_Goodwill_47257f8b-d88d-4207-b8a3-fe85abc31904" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_07abbb71-e1f8-473c-ae2c-569894f0beff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1c898ee7-950a-40e7-823a-eeb606793986" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_07abbb71-e1f8-473c-ae2c-569894f0beff" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet_cb403367-4114-4dfb-bbb6-3d7ebaa77d37" xlink:href="lly-20220930.xsd#lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1c898ee7-950a-40e7-823a-eeb606793986" xlink:to="loc_lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet_cb403367-4114-4dfb-bbb6-3d7ebaa77d37" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_6aed2e08-48cb-494a-b977-4be0b93d9ce8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1c898ee7-950a-40e7-823a-eeb606793986" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_6aed2e08-48cb-494a-b977-4be0b93d9ce8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAcquiredFromAcquisition_19b30659-2aed-4092-af3f-645e297751cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAcquiredFromAcquisition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1c898ee7-950a-40e7-823a-eeb606793986" xlink:to="loc_us-gaap_CashAcquiredFromAcquisition_19b30659-2aed-4092-af3f-645e297751cd" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability_f3151577-a9d3-4b41-88a6-4e804853d2c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1c898ee7-950a-40e7-823a-eeb606793986" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability_f3151577-a9d3-4b41-88a6-4e804853d2c9" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_f6800c58-a08a-47a4-9dd3-dda0667d7f14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1c898ee7-950a-40e7-823a-eeb606793986" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_f6800c58-a08a-47a4-9dd3-dda0667d7f14" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_03972954-e924-4651-89c4-03cba14c111a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1c898ee7-950a-40e7-823a-eeb606793986" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_03972954-e924-4651-89c4-03cba14c111a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_39766ab2-2f0b-4bc5-8f12-3d05fb963083" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_03972954-e924-4651-89c4-03cba14c111a" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_39766ab2-2f0b-4bc5-8f12-3d05fb963083" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_39766ab2-2f0b-4bc5-8f12-3d05fb963083_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_39766ab2-2f0b-4bc5-8f12-3d05fb963083" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_39766ab2-2f0b-4bc5-8f12-3d05fb963083_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a52a759a-54e3-4c7b-ab4c-7326267cb521" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_39766ab2-2f0b-4bc5-8f12-3d05fb963083" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a52a759a-54e3-4c7b-ab4c-7326267cb521" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_PrevailTherapeuticsIncMember_39e018c8-de32-4d62-b26e-be45ab7ce49b" xlink:href="lly-20220930.xsd#lly_PrevailTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a52a759a-54e3-4c7b-ab4c-7326267cb521" xlink:to="loc_lly_PrevailTherapeuticsIncMember_39e018c8-de32-4d62-b26e-be45ab7ce49b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/AcquisitionsAssetAcquisitionsDetails" xlink:type="simple" xlink:href="lly-20220930.xsd#AcquisitionsAssetAcquisitionsDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/AcquisitionsAssetAcquisitionsDetails" xlink:type="extended" id="i7bde64d5d6f34b0f8eb2db5cf6a2b6dc_AcquisitionsAssetAcquisitionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_b60b8eb7-e2ee-4776-aef5-edf698d948c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_PaymentsForAssetAcquisitions_faee0236-4c83-4abd-95c4-c23c3a8c93de" xlink:href="lly-20220930.xsd#lly_PaymentsForAssetAcquisitions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b60b8eb7-e2ee-4776-aef5-edf698d948c2" xlink:to="loc_lly_PaymentsForAssetAcquisitions_faee0236-4c83-4abd-95c4-c23c3a8c93de" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionTable_e199436e-e4ec-4fe5-a5b6-ace264c825f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b60b8eb7-e2ee-4776-aef5-edf698d948c2" xlink:to="loc_us-gaap_AssetAcquisitionTable_e199436e-e4ec-4fe5-a5b6-ace264c825f3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_9a896f9b-d6b5-484d-8287-eed544790637" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AssetAcquisitionTable_e199436e-e4ec-4fe5-a5b6-ace264c825f3" xlink:to="loc_us-gaap_AssetAcquisitionAxis_9a896f9b-d6b5-484d-8287-eed544790637" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_9a896f9b-d6b5-484d-8287-eed544790637_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AssetAcquisitionAxis_9a896f9b-d6b5-484d-8287-eed544790637" xlink:to="loc_us-gaap_AssetAcquisitionDomain_9a896f9b-d6b5-484d-8287-eed544790637_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_72476664-ad97-4734-bd8a-8cf53b1d160e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AssetAcquisitionAxis_9a896f9b-d6b5-484d-8287-eed544790637" xlink:to="loc_us-gaap_AssetAcquisitionDomain_72476664-ad97-4734-bd8a-8cf53b1d160e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BioMarinPharmaceuticalIncMember_707271e9-9db7-4817-9993-e3761550db9d" xlink:href="lly-20220930.xsd#lly_BioMarinPharmaceuticalIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_72476664-ad97-4734-bd8a-8cf53b1d160e" xlink:to="loc_lly_BioMarinPharmaceuticalIncMember_707271e9-9db7-4817-9993-e3761550db9d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_RigelPharmaceuticalsIncMember_20a8eddf-8054-4d0c-94a8-b759dcc429b5" xlink:href="lly-20220930.xsd#lly_RigelPharmaceuticalsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_72476664-ad97-4734-bd8a-8cf53b1d160e" xlink:to="loc_lly_RigelPharmaceuticalsIncMember_20a8eddf-8054-4d0c-94a8-b759dcc429b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_PrecisionBiosciencesIncMember_d28feca0-b226-4b3f-81e5-baf9d34e422d" xlink:href="lly-20220930.xsd#lly_PrecisionBiosciencesIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_72476664-ad97-4734-bd8a-8cf53b1d160e" xlink:to="loc_lly_PrecisionBiosciencesIncMember_d28feca0-b226-4b3f-81e5-baf9d34e422d" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/CollaborationsandOtherArrangementsDetails" xlink:type="simple" xlink:href="lly-20220930.xsd#CollaborationsandOtherArrangementsDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/CollaborationsandOtherArrangementsDetails" xlink:type="extended" id="i1fe19f59430d4f69b63b47ec12afd3bb_CollaborationsandOtherArrangementsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_89c6607d-b434-4571-aa93-d959bb15496e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CollaborativeArrangementRightsAndObligationsRightsObligations_d66f588f-45f2-4bd4-913f-67dc3068c62a" xlink:href="lly-20220930.xsd#lly_CollaborativeArrangementRightsAndObligationsRightsObligations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_89c6607d-b434-4571-aa93-d959bb15496e" xlink:to="loc_lly_CollaborativeArrangementRightsAndObligationsRightsObligations_d66f588f-45f2-4bd4-913f-67dc3068c62a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_5b0dd65d-48e8-41bd-9c47-f28c814c0fc9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_89c6607d-b434-4571-aa93-d959bb15496e" xlink:to="loc_us-gaap_Revenues_5b0dd65d-48e8-41bd-9c47-f28c814c0fc9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CollaborativeArrangementRightsAndObligationsPercent_07674011-0cdf-4ed9-98d1-00893e7874d3" xlink:href="lly-20220930.xsd#lly_CollaborativeArrangementRightsAndObligationsPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_89c6607d-b434-4571-aa93-d959bb15496e" xlink:to="loc_lly_CollaborativeArrangementRightsAndObligationsPercent_07674011-0cdf-4ed9-98d1-00893e7874d3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_172bf556-3607-4766-8882-b13356827efd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_89c6607d-b434-4571-aa93-d959bb15496e" xlink:to="loc_us-gaap_ContractWithCustomerLiability_172bf556-3607-4766-8882-b13356827efd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_afb1537d-c3cb-4bbd-9f2a-4ad2df31819b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_89c6607d-b434-4571-aa93-d959bb15496e" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_afb1537d-c3cb-4bbd-9f2a-4ad2df31819b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_0786455d-24f1-4665-8cf1-136fb73fbe99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_afb1537d-c3cb-4bbd-9f2a-4ad2df31819b" xlink:to="loc_us-gaap_TypeOfArrangementAxis_0786455d-24f1-4665-8cf1-136fb73fbe99" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0786455d-24f1-4665-8cf1-136fb73fbe99_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_0786455d-24f1-4665-8cf1-136fb73fbe99" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0786455d-24f1-4665-8cf1-136fb73fbe99_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b8e77768-56a8-49d6-b378-7da670854141" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_0786455d-24f1-4665-8cf1-136fb73fbe99" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b8e77768-56a8-49d6-b378-7da670854141" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember_a7b30151-22f3-4f4a-8ece-8975aedb798f" xlink:href="lly-20220930.xsd#lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b8e77768-56a8-49d6-b378-7da670854141" xlink:to="loc_lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember_a7b30151-22f3-4f4a-8ece-8975aedb798f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyAgreementTermsMember_c3b75ba4-bca1-4afb-b42d-828bf73215c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyAgreementTermsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b8e77768-56a8-49d6-b378-7da670854141" xlink:to="loc_us-gaap_RoyaltyAgreementTermsMember_c3b75ba4-bca1-4afb-b42d-828bf73215c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MilestonePaymentsCapitalizedAsIntangibleAssetsMember_575be92b-6ced-47b6-900a-8732a025e420" xlink:href="lly-20220930.xsd#lly_MilestonePaymentsCapitalizedAsIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b8e77768-56a8-49d6-b378-7da670854141" xlink:to="loc_lly_MilestonePaymentsCapitalizedAsIntangibleAssetsMember_575be92b-6ced-47b6-900a-8732a025e420" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MilestonePaymentsSalesBasedMember_2af6d978-570a-4525-be87-b58e12529ca5" xlink:href="lly-20220930.xsd#lly_MilestonePaymentsSalesBasedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b8e77768-56a8-49d6-b378-7da670854141" xlink:to="loc_lly_MilestonePaymentsSalesBasedMember_2af6d978-570a-4525-be87-b58e12529ca5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MilestonePaymentsSuccessBasedRegulatoryAndSalesBasedMember_c8c1e098-03cf-4bf0-bcff-87d5af5262ab" xlink:href="lly-20220930.xsd#lly_MilestonePaymentsSuccessBasedRegulatoryAndSalesBasedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b8e77768-56a8-49d6-b378-7da670854141" xlink:to="loc_lly_MilestonePaymentsSuccessBasedRegulatoryAndSalesBasedMember_c8c1e098-03cf-4bf0-bcff-87d5af5262ab" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MilestonePaymentsDevelopmentAndRegulatoryMember_3260e713-615b-4714-a89f-0521f1f8a27d" xlink:href="lly-20220930.xsd#lly_MilestonePaymentsDevelopmentAndRegulatoryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b8e77768-56a8-49d6-b378-7da670854141" xlink:to="loc_lly_MilestonePaymentsDevelopmentAndRegulatoryMember_3260e713-615b-4714-a89f-0521f1f8a27d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_039cd5e0-fdb9-4a41-9869-f1c7709f3c85" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_afb1537d-c3cb-4bbd-9f2a-4ad2df31819b" xlink:to="loc_srt_ProductOrServiceAxis_039cd5e0-fdb9-4a41-9869-f1c7709f3c85" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_039cd5e0-fdb9-4a41-9869-f1c7709f3c85_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_039cd5e0-fdb9-4a41-9869-f1c7709f3c85" xlink:to="loc_srt_ProductsAndServicesDomain_039cd5e0-fdb9-4a41-9869-f1c7709f3c85_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_6b5ff927-235f-4c9d-8f44-c6fe8434adea" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_039cd5e0-fdb9-4a41-9869-f1c7709f3c85" xlink:to="loc_srt_ProductsAndServicesDomain_6b5ff927-235f-4c9d-8f44-c6fe8434adea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_JardianceMember_757fbda9-52a2-42a6-b71a-9b2fcf4ea20f" xlink:href="lly-20220930.xsd#lly_JardianceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_6b5ff927-235f-4c9d-8f44-c6fe8434adea" xlink:to="loc_lly_JardianceMember_757fbda9-52a2-42a6-b71a-9b2fcf4ea20f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BasaglarMember_236944f0-b617-452e-928e-eb25c5eec4aa" xlink:href="lly-20220930.xsd#lly_BasaglarMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_6b5ff927-235f-4c9d-8f44-c6fe8434adea" xlink:to="loc_lly_BasaglarMember_236944f0-b617-452e-928e-eb25c5eec4aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_TrajentaBIMember_cb8756c1-76f5-4c4e-a2c1-22f024426ffe" xlink:href="lly-20220930.xsd#lly_TrajentaBIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_6b5ff927-235f-4c9d-8f44-c6fe8434adea" xlink:to="loc_lly_TrajentaBIMember_cb8756c1-76f5-4c4e-a2c1-22f024426ffe" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OlumiantMember_3059031e-7ee5-42f2-8fe2-0f5474c3ddf0" xlink:href="lly-20220930.xsd#lly_OlumiantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_6b5ff927-235f-4c9d-8f44-c6fe8434adea" xlink:to="loc_lly_OlumiantMember_3059031e-7ee5-42f2-8fe2-0f5474c3ddf0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_COVID19AntibodiesMember_b5a2c8ba-7d44-45e0-9285-db0988cc8a07" xlink:href="lly-20220930.xsd#lly_COVID19AntibodiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_6b5ff927-235f-4c9d-8f44-c6fe8434adea" xlink:to="loc_lly_COVID19AntibodiesMember_b5a2c8ba-7d44-45e0-9285-db0988cc8a07" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_TYVYTMember_427804ae-5071-425a-8bca-14da94f4c863" xlink:href="lly-20220930.xsd#lly_TYVYTMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_6b5ff927-235f-4c9d-8f44-c6fe8434adea" xlink:to="loc_lly_TYVYTMember_427804ae-5071-425a-8bca-14da94f4c863" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_LebrikizumabMember_89fdec69-397c-45dc-be2b-77157eefabbf" xlink:href="lly-20220930.xsd#lly_LebrikizumabMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_6b5ff927-235f-4c9d-8f44-c6fe8434adea" xlink:to="loc_lly_LebrikizumabMember_89fdec69-397c-45dc-be2b-77157eefabbf" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_79a61833-21d7-47aa-8247-2f994467a715" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_afb1537d-c3cb-4bbd-9f2a-4ad2df31819b" xlink:to="loc_dei_LegalEntityAxis_79a61833-21d7-47aa-8247-2f994467a715" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_79a61833-21d7-47aa-8247-2f994467a715_default" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_79a61833-21d7-47aa-8247-2f994467a715" xlink:to="loc_dei_EntityDomain_79a61833-21d7-47aa-8247-2f994467a715_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_71db1caa-e83e-4e5a-837a-dc9c05108fa4" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_79a61833-21d7-47aa-8247-2f994467a715" xlink:to="loc_dei_EntityDomain_71db1caa-e83e-4e5a-837a-dc9c05108fa4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_InnoventBiologicsIncMember_b986ee84-811c-4659-b3b9-bf4a25f4da32" xlink:href="lly-20220930.xsd#lly_InnoventBiologicsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_71db1caa-e83e-4e5a-837a-dc9c05108fa4" xlink:to="loc_lly_InnoventBiologicsIncMember_b986ee84-811c-4659-b3b9-bf4a25f4da32" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_RocheMember_72cb499e-c37a-4fd2-a118-d0dc026b3c25" xlink:href="lly-20220930.xsd#lly_RocheMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_71db1caa-e83e-4e5a-837a-dc9c05108fa4" xlink:to="loc_lly_RocheMember_72cb499e-c37a-4fd2-a118-d0dc026b3c25" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails" xlink:type="simple" xlink:href="lly-20220930.xsd#FinancialInstrumentsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails" xlink:type="extended" id="i7c7811ff647041fabf37ccd8f579e926_FinancialInstrumentsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_42a2a3f6-0ee0-40f2-9b1a-a964cd143b00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityNotionalAmount_0cbad97e-1d3d-4eb2-8f9e-97ad6b738cb7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilityNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_42a2a3f6-0ee0-40f2-9b1a-a964cd143b00" xlink:to="loc_us-gaap_DerivativeLiabilityNotionalAmount_0cbad97e-1d3d-4eb2-8f9e-97ad6b738cb7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetNotionalAmount_d4cac38a-e81a-4d4c-9f82-111b8e2fc914" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_42a2a3f6-0ee0-40f2-9b1a-a964cd143b00" xlink:to="loc_us-gaap_DerivativeAssetNotionalAmount_d4cac38a-e81a-4d4c-9f82-111b8e2fc914" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1_98dad97f-ba9b-497d-aeea-1f7729e71b24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_42a2a3f6-0ee0-40f2-9b1a-a964cd143b00" xlink:to="loc_us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1_98dad97f-ba9b-497d-aeea-1f7729e71b24" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_728dc34e-0eeb-49be-ad03-528c49ba7e72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_42a2a3f6-0ee0-40f2-9b1a-a964cd143b00" xlink:to="loc_us-gaap_LongTermDebt_728dc34e-0eeb-49be-ad03-528c49ba7e72" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTax_13292def-1386-477d-b1db-c83d548e67cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_42a2a3f6-0ee0-40f2-9b1a-a964cd143b00" xlink:to="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTax_13292def-1386-477d-b1db-c83d548e67cd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_86cc7d3d-f982-4022-9279-a275813ea394" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_42a2a3f6-0ee0-40f2-9b1a-a964cd143b00" xlink:to="loc_us-gaap_DerivativeNotionalAmount_86cc7d3d-f982-4022-9279-a275813ea394" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DescriptionOfDerivativeActivityVolumePercent_7c98b834-47b6-4864-af34-4dda40b2c15d" xlink:href="lly-20220930.xsd#lly_DescriptionOfDerivativeActivityVolumePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_42a2a3f6-0ee0-40f2-9b1a-a964cd143b00" xlink:to="loc_lly_DescriptionOfDerivativeActivityVolumePercent_7c98b834-47b6-4864-af34-4dda40b2c15d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_ddbc3472-31dd-4821-9842-32e26f768250" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_42a2a3f6-0ee0-40f2-9b1a-a964cd143b00" xlink:to="loc_us-gaap_DebtInstrumentTerm_ddbc3472-31dd-4821-9842-32e26f768250" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_55b40cd4-6f2d-4f5a-8f33-bca3b9e030fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_42a2a3f6-0ee0-40f2-9b1a-a964cd143b00" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_55b40cd4-6f2d-4f5a-8f33-bca3b9e030fe" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_31a95aca-df81-4afc-ae33-4bcce27acd84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_42a2a3f6-0ee0-40f2-9b1a-a964cd143b00" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_31a95aca-df81-4afc-ae33-4bcce27acd84" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_f6a95f9d-b7b1-435a-bdbf-cc161a25ca9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_42a2a3f6-0ee0-40f2-9b1a-a964cd143b00" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_f6a95f9d-b7b1-435a-bdbf-cc161a25ca9a" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts_4b1f72a4-7bd3-4953-bdab-2bdbaf80870b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDebtExtinguishmentCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_42a2a3f6-0ee0-40f2-9b1a-a964cd143b00" xlink:to="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts_4b1f72a4-7bd3-4953-bdab-2bdbaf80870b" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExtinguishmentOfDebtAmount_8e3075ca-1dbc-4748-92b1-ef9f3fbe0e63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ExtinguishmentOfDebtAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_42a2a3f6-0ee0-40f2-9b1a-a964cd143b00" xlink:to="loc_us-gaap_ExtinguishmentOfDebtAmount_8e3075ca-1dbc-4748-92b1-ef9f3fbe0e63" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_cdc6cc2b-ecbe-4a00-915c-19a5603f99b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_42a2a3f6-0ee0-40f2-9b1a-a964cd143b00" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_cdc6cc2b-ecbe-4a00-915c-19a5603f99b2" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet_9f6f1a77-7487-430c-86c3-7db2212b8739" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_42a2a3f6-0ee0-40f2-9b1a-a964cd143b00" xlink:to="loc_us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet_9f6f1a77-7487-430c-86c3-7db2212b8739" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments_468284c3-a9ca-45a1-be53-187dfe3745d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_42a2a3f6-0ee0-40f2-9b1a-a964cd143b00" xlink:to="loc_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments_468284c3-a9ca-45a1-be53-187dfe3745d6" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod_bcf59191-3f39-442b-b571-b99b6a15bfde" xlink:href="lly-20220930.xsd#lly_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_42a2a3f6-0ee0-40f2-9b1a-a964cd143b00" xlink:to="loc_lly_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod_bcf59191-3f39-442b-b571-b99b6a15bfde" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_366e7fc7-ce64-484d-971f-00cb7ba253cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_42a2a3f6-0ee0-40f2-9b1a-a964cd143b00" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLoss_366e7fc7-ce64-484d-971f-00cb7ba253cd" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DebtSecuritiesAvailableForSaleUnrealizedLossPositionQualitativeDisclosureOtherPercentageOfNonperformingAssets_71a1d50a-4226-404b-92ee-6907f0ba095a" xlink:href="lly-20220930.xsd#lly_DebtSecuritiesAvailableForSaleUnrealizedLossPositionQualitativeDisclosureOtherPercentageOfNonperformingAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_42a2a3f6-0ee0-40f2-9b1a-a964cd143b00" xlink:to="loc_lly_DebtSecuritiesAvailableForSaleUnrealizedLossPositionQualitativeDisclosureOtherPercentageOfNonperformingAssets_71a1d50a-4226-404b-92ee-6907f0ba095a" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized_0cf229fa-54bf-4dc7-bb9a-bf984a2490df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_42a2a3f6-0ee0-40f2-9b1a-a964cd143b00" xlink:to="loc_us-gaap_TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized_0cf229fa-54bf-4dc7-bb9a-bf984a2490df" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_85a73397-674e-40d3-8d6b-b7658e1e5848" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_42a2a3f6-0ee0-40f2-9b1a-a964cd143b00" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_85a73397-674e-40d3-8d6b-b7658e1e5848" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_4f62d6d7-04ad-46bf-99db-cc3b3e789811" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_85a73397-674e-40d3-8d6b-b7658e1e5848" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_4f62d6d7-04ad-46bf-99db-cc3b3e789811" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_4f62d6d7-04ad-46bf-99db-cc3b3e789811_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_4f62d6d7-04ad-46bf-99db-cc3b3e789811" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_4f62d6d7-04ad-46bf-99db-cc3b3e789811_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_8957fa1e-a3f8-4918-9d54-15c722f2ccf8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_4f62d6d7-04ad-46bf-99db-cc3b3e789811" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_8957fa1e-a3f8-4918-9d54-15c722f2ccf8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BuyUsDollarSellEuroMember_ca89151e-9f6d-43b6-a161-ac27b5f9ecb8" xlink:href="lly-20220930.xsd#lly_BuyUsDollarSellEuroMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_8957fa1e-a3f8-4918-9d54-15c722f2ccf8" xlink:to="loc_lly_BuyUsDollarSellEuroMember_ca89151e-9f6d-43b6-a161-ac27b5f9ecb8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BuyEuroSellUsDollarMember_3fb82bd7-472f-4564-9f17-1da899d1c962" xlink:href="lly-20220930.xsd#lly_BuyEuroSellUsDollarMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_8957fa1e-a3f8-4918-9d54-15c722f2ccf8" xlink:to="loc_lly_BuyEuroSellUsDollarMember_3fb82bd7-472f-4564-9f17-1da899d1c962" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BuyUSDollarSellChineseYuanMember_8173bf14-f84c-4ecf-be64-14e0b6b3322b" xlink:href="lly-20220930.xsd#lly_BuyUSDollarSellChineseYuanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_8957fa1e-a3f8-4918-9d54-15c722f2ccf8" xlink:to="loc_lly_BuyUSDollarSellChineseYuanMember_8173bf14-f84c-4ecf-be64-14e0b6b3322b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BuyUSdollarSellJapaneseYenMember_8d3dc1a8-c879-4c18-899b-e258ad6347c6" xlink:href="lly-20220930.xsd#lly_BuyUSdollarSellJapaneseYenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_8957fa1e-a3f8-4918-9d54-15c722f2ccf8" xlink:to="loc_lly_BuyUSdollarSellJapaneseYenMember_8d3dc1a8-c879-4c18-899b-e258ad6347c6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BuyBritishPoundandSellUSDollarsMember_8f77e475-13c8-48e0-996e-2448531b2f39" xlink:href="lly-20220930.xsd#lly_BuyBritishPoundandSellUSDollarsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_8957fa1e-a3f8-4918-9d54-15c722f2ccf8" xlink:to="loc_lly_BuyBritishPoundandSellUSDollarsMember_8f77e475-13c8-48e0-996e-2448531b2f39" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_SwapU.S.DollarsToEuroMember_77d04127-3c31-4052-8b86-349b9c789291" xlink:href="lly-20220930.xsd#lly_SwapU.S.DollarsToEuroMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_8957fa1e-a3f8-4918-9d54-15c722f2ccf8" xlink:to="loc_lly_SwapU.S.DollarsToEuroMember_77d04127-3c31-4052-8b86-349b9c789291" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_SwapSwissFrancsToU.S.DollarsMember_ad396926-911f-44ea-a0d5-031c7f535c39" xlink:href="lly-20220930.xsd#lly_SwapSwissFrancsToU.S.DollarsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_8957fa1e-a3f8-4918-9d54-15c722f2ccf8" xlink:to="loc_lly_SwapSwissFrancsToU.S.DollarsMember_ad396926-911f-44ea-a0d5-031c7f535c39" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_SellEuroMember_25416dbd-4251-49f9-a472-3a962352a819" xlink:href="lly-20220930.xsd#lly_SellEuroMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_8957fa1e-a3f8-4918-9d54-15c722f2ccf8" xlink:to="loc_lly_SellEuroMember_25416dbd-4251-49f9-a472-3a962352a819" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_36436fc6-fbd8-4d18-871b-6407ef8be4f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateSwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_8957fa1e-a3f8-4918-9d54-15c722f2ccf8" xlink:to="loc_us-gaap_InterestRateSwapMember_36436fc6-fbd8-4d18-871b-6407ef8be4f5" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_8d19370b-dbdc-4fa9-8f65-95ce93e86c3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_85a73397-674e-40d3-8d6b-b7658e1e5848" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_8d19370b-dbdc-4fa9-8f65-95ce93e86c3b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_8d19370b-dbdc-4fa9-8f65-95ce93e86c3b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_8d19370b-dbdc-4fa9-8f65-95ce93e86c3b" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_8d19370b-dbdc-4fa9-8f65-95ce93e86c3b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_98d45780-31c9-41b9-95fb-2e927c52f395" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_8d19370b-dbdc-4fa9-8f65-95ce93e86c3b" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_98d45780-31c9-41b9-95fb-2e927c52f395" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ForeignCurrencyDenominatedDebtMember_84700694-a6f0-4f09-9389-497851db30bc" xlink:href="lly-20220930.xsd#lly_ForeignCurrencyDenominatedDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_98d45780-31c9-41b9-95fb-2e927c52f395" xlink:to="loc_lly_ForeignCurrencyDenominatedDebtMember_84700694-a6f0-4f09-9389-497851db30bc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_c2329908-35ff-458a-b125-2f53fbd83203" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_85a73397-674e-40d3-8d6b-b7658e1e5848" xlink:to="loc_us-gaap_HedgingDesignationAxis_c2329908-35ff-458a-b125-2f53fbd83203" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_c2329908-35ff-458a-b125-2f53fbd83203_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_c2329908-35ff-458a-b125-2f53fbd83203" xlink:to="loc_us-gaap_HedgingDesignationDomain_c2329908-35ff-458a-b125-2f53fbd83203_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_bb6ef92c-e459-4317-a722-5c49249ee494" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_c2329908-35ff-458a-b125-2f53fbd83203" xlink:to="loc_us-gaap_HedgingDesignationDomain_bb6ef92c-e459-4317-a722-5c49249ee494" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_570cc07b-b71b-490b-b36d-6426d3b7e5a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_bb6ef92c-e459-4317-a722-5c49249ee494" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_570cc07b-b71b-490b-b36d-6426d3b7e5a7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_81648f29-8186-4148-ba5c-5c022e27706a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_85a73397-674e-40d3-8d6b-b7658e1e5848" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_81648f29-8186-4148-ba5c-5c022e27706a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_81648f29-8186-4148-ba5c-5c022e27706a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_81648f29-8186-4148-ba5c-5c022e27706a" xlink:to="loc_us-gaap_HedgingRelationshipDomain_81648f29-8186-4148-ba5c-5c022e27706a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_fa158429-5536-4aef-bee9-d7e5f365803b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_81648f29-8186-4148-ba5c-5c022e27706a" xlink:to="loc_us-gaap_HedgingRelationshipDomain_fa158429-5536-4aef-bee9-d7e5f365803b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_329756ee-55c0-4ac9-a0ec-ad116a463944" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_fa158429-5536-4aef-bee9-d7e5f365803b" xlink:to="loc_us-gaap_CashFlowHedgingMember_329756ee-55c0-4ac9-a0ec-ad116a463944" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_28a99abd-c4f4-4c98-a835-2cacbc153855" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_85a73397-674e-40d3-8d6b-b7658e1e5848" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_28a99abd-c4f4-4c98-a835-2cacbc153855" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_28a99abd-c4f4-4c98-a835-2cacbc153855_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_28a99abd-c4f4-4c98-a835-2cacbc153855" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_28a99abd-c4f4-4c98-a835-2cacbc153855_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_8583be1d-4a48-4134-a349-4c132eb1709b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_28a99abd-c4f4-4c98-a835-2cacbc153855" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_8583be1d-4a48-4134-a349-4c132eb1709b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MaturityDate2023Member_89f779fa-fc94-47e8-b7fe-f4dcc0f57bda" xlink:href="lly-20220930.xsd#lly_MaturityDate2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_8583be1d-4a48-4134-a349-4c132eb1709b" xlink:to="loc_lly_MaturityDate2023Member_89f779fa-fc94-47e8-b7fe-f4dcc0f57bda" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_8a9ccf21-7104-473a-9888-088fa0b2dea7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_85a73397-674e-40d3-8d6b-b7658e1e5848" xlink:to="loc_us-gaap_DebtInstrumentAxis_8a9ccf21-7104-473a-9888-088fa0b2dea7" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_8a9ccf21-7104-473a-9888-088fa0b2dea7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_8a9ccf21-7104-473a-9888-088fa0b2dea7" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_8a9ccf21-7104-473a-9888-088fa0b2dea7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_b09e75b1-06e9-4124-a6d4-1272a096a2cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_8a9ccf21-7104-473a-9888-088fa0b2dea7" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_b09e75b1-06e9-4124-a6d4-1272a096a2cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A050NotesDue2033Member_725a9156-9b21-44ac-a5ce-09cf0d6715e1" xlink:href="lly-20220930.xsd#lly_A050NotesDue2033Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b09e75b1-06e9-4124-a6d4-1272a096a2cd" xlink:to="loc_lly_A050NotesDue2033Member_725a9156-9b21-44ac-a5ce-09cf0d6715e1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1125NotesDue2051Member_2d85e283-eb5c-49d2-aaf2-3bb6275ca33d" xlink:href="lly-20220930.xsd#lly_A1125NotesDue2051Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b09e75b1-06e9-4124-a6d4-1272a096a2cd" xlink:to="loc_lly_A1125NotesDue2051Member_2d85e283-eb5c-49d2-aaf2-3bb6275ca33d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1375NotesDue2061Member_dfac8fc9-4016-4252-a083-15d7666e50d3" xlink:href="lly-20220930.xsd#lly_A1375NotesDue2061Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b09e75b1-06e9-4124-a6d4-1272a096a2cd" xlink:to="loc_lly_A1375NotesDue2061Member_dfac8fc9-4016-4252-a083-15d7666e50d3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1625NotesDue2043Member_3c09c48d-8267-4ef8-9dd0-882142655605" xlink:href="lly-20220930.xsd#lly_A1625NotesDue2043Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b09e75b1-06e9-4124-a6d4-1272a096a2cd" xlink:to="loc_lly_A1625NotesDue2043Member_3c09c48d-8267-4ef8-9dd0-882142655605" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A395NotesDue2049Member_33a46f02-3581-4a15-9072-00ab8dcbbd21" xlink:href="lly-20220930.xsd#lly_A395NotesDue2049Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b09e75b1-06e9-4124-a6d4-1272a096a2cd" xlink:to="loc_lly_A395NotesDue2049Member_33a46f02-3581-4a15-9072-00ab8dcbbd21" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A415NotesDue2059Member_036e6cda-33ec-434c-b042-632d0e1a4169" xlink:href="lly-20220930.xsd#lly_A415NotesDue2059Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b09e75b1-06e9-4124-a6d4-1272a096a2cd" xlink:to="loc_lly_A415NotesDue2059Member_036e6cda-33ec-434c-b042-632d0e1a4169" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A3375NotesDue2029Member_91ac2093-6090-4ef9-854c-d93848c949fd" xlink:href="lly-20220930.xsd#lly_A3375NotesDue2029Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b09e75b1-06e9-4124-a6d4-1272a096a2cd" xlink:to="loc_lly_A3375NotesDue2029Member_91ac2093-6090-4ef9-854c-d93848c949fd" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/FinancialInstrumentsEffectofRiskManagementInstrumentsDetails" xlink:type="simple" xlink:href="lly-20220930.xsd#FinancialInstrumentsEffectofRiskManagementInstrumentsDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/FinancialInstrumentsEffectofRiskManagementInstrumentsDetails" xlink:type="extended" id="i94576988f98a4926937c2dbc5f0aab8a_FinancialInstrumentsEffectofRiskManagementInstrumentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8ea31f4e-44f5-4f1b-9a54-30757539ba63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_FairValueHedgeAbstract_8c568ac7-4871-40f3-b200-c1d4e4637238" xlink:href="lly-20220930.xsd#lly_FairValueHedgeAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8ea31f4e-44f5-4f1b-9a54-30757539ba63" xlink:to="loc_lly_FairValueHedgeAbstract_8c568ac7-4871-40f3-b200-c1d4e4637238" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1_105eeadb-bfd3-4cfc-b9b7-9c4ba684671a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_FairValueHedgeAbstract_8c568ac7-4871-40f3-b200-c1d4e4637238" xlink:to="loc_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1_105eeadb-bfd3-4cfc-b9b7-9c4ba684671a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_35abee40-38ea-4675-a117-5ee5ba391847" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_FairValueHedgeAbstract_8c568ac7-4871-40f3-b200-c1d4e4637238" xlink:to="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_35abee40-38ea-4675-a117-5ee5ba391847" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CashFlowHedgeAbstract_6866c12f-6936-47c2-ac13-339948483f19" xlink:href="lly-20220930.xsd#lly_CashFlowHedgeAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8ea31f4e-44f5-4f1b-9a54-30757539ba63" xlink:to="loc_lly_CashFlowHedgeAbstract_6866c12f-6936-47c2-ac13-339948483f19" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_d9c781c3-9495-41b5-9304-94946a56551b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_CashFlowHedgeAbstract_6866c12f-6936-47c2-ac13-339948483f19" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_d9c781c3-9495-41b5-9304-94946a56551b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_643dfd22-5b69-448f-919f-3b517aade94f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8ea31f4e-44f5-4f1b-9a54-30757539ba63" xlink:to="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_643dfd22-5b69-448f-919f-3b517aade94f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DerivativeInstrumentsGainLossRecognized_2201d31e-10a6-4fa7-99eb-644550de3d6a" xlink:href="lly-20220930.xsd#lly_DerivativeInstrumentsGainLossRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8ea31f4e-44f5-4f1b-9a54-30757539ba63" xlink:to="loc_lly_DerivativeInstrumentsGainLossRecognized_2201d31e-10a6-4fa7-99eb-644550de3d6a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_87add630-6600-4877-ab6d-d382f6cd26c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8ea31f4e-44f5-4f1b-9a54-30757539ba63" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_87add630-6600-4877-ab6d-d382f6cd26c3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_edf0b470-9b30-4a53-a0d4-9742ae598ff9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8ea31f4e-44f5-4f1b-9a54-30757539ba63" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_edf0b470-9b30-4a53-a0d4-9742ae598ff9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_240f47c4-ef5d-48ce-bc34-f4d4eea1ca3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8ea31f4e-44f5-4f1b-9a54-30757539ba63" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_240f47c4-ef5d-48ce-bc34-f4d4eea1ca3f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_8efe27b1-a330-41a7-b852-6f3c24e49e15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_240f47c4-ef5d-48ce-bc34-f4d4eea1ca3f" xlink:to="loc_us-gaap_HedgingDesignationAxis_8efe27b1-a330-41a7-b852-6f3c24e49e15" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_8efe27b1-a330-41a7-b852-6f3c24e49e15_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_8efe27b1-a330-41a7-b852-6f3c24e49e15" xlink:to="loc_us-gaap_HedgingDesignationDomain_8efe27b1-a330-41a7-b852-6f3c24e49e15_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_e668208e-7ec2-4bf3-b0cc-60853e45f24d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_8efe27b1-a330-41a7-b852-6f3c24e49e15" xlink:to="loc_us-gaap_HedgingDesignationDomain_e668208e-7ec2-4bf3-b0cc-60853e45f24d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_5ec22594-f48e-4f8e-acea-efb3405451b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_e668208e-7ec2-4bf3-b0cc-60853e45f24d" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_5ec22594-f48e-4f8e-acea-efb3405451b3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_8d65e9c4-cbdc-4889-81ad-1f57cf20e66c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NondesignatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_e668208e-7ec2-4bf3-b0cc-60853e45f24d" xlink:to="loc_us-gaap_NondesignatedMember_8d65e9c4-cbdc-4889-81ad-1f57cf20e66c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_97c8413c-caf2-48c6-adf9-93aa6c53dcba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_240f47c4-ef5d-48ce-bc34-f4d4eea1ca3f" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_97c8413c-caf2-48c6-adf9-93aa6c53dcba" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_97c8413c-caf2-48c6-adf9-93aa6c53dcba_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_97c8413c-caf2-48c6-adf9-93aa6c53dcba" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_97c8413c-caf2-48c6-adf9-93aa6c53dcba_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_4b7e9fae-50af-4375-8d68-52b9fa5a9b96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_97c8413c-caf2-48c6-adf9-93aa6c53dcba" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_4b7e9fae-50af-4375-8d68-52b9fa5a9b96" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_HedgedFixedRateDebtMember_bd24cd46-02e7-4efc-aacb-feeb7f81c54f" xlink:href="lly-20220930.xsd#lly_HedgedFixedRateDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_4b7e9fae-50af-4375-8d68-52b9fa5a9b96" xlink:to="loc_lly_HedgedFixedRateDebtMember_bd24cd46-02e7-4efc-aacb-feeb7f81c54f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateContractMember_c95f789f-0d50-485e-830b-fd5e0de13da3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_4b7e9fae-50af-4375-8d68-52b9fa5a9b96" xlink:to="loc_us-gaap_InterestRateContractMember_c95f789f-0d50-485e-830b-fd5e0de13da3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CrossCurrencyInterestRateContractMember_dd766351-c71d-4e2d-8ffc-7b5b96bad6e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CrossCurrencyInterestRateContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_4b7e9fae-50af-4375-8d68-52b9fa5a9b96" xlink:to="loc_us-gaap_CrossCurrencyInterestRateContractMember_dd766351-c71d-4e2d-8ffc-7b5b96bad6e0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_fba979b1-8c68-4ba4-b40f-0574541a3115" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_4b7e9fae-50af-4375-8d68-52b9fa5a9b96" xlink:to="loc_us-gaap_ForeignExchangeContractMember_fba979b1-8c68-4ba4-b40f-0574541a3115" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_05fa338a-7408-43a1-9945-35fe0888e2f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateSwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_4b7e9fae-50af-4375-8d68-52b9fa5a9b96" xlink:to="loc_us-gaap_InterestRateSwapMember_05fa338a-7408-43a1-9945-35fe0888e2f7" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/FinancialInstrumentsFairValueofFinancialInstrumentsDetails" xlink:type="simple" xlink:href="lly-20220930.xsd#FinancialInstrumentsFairValueofFinancialInstrumentsDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/FinancialInstrumentsFairValueofFinancialInstrumentsDetails" xlink:type="extended" id="i33e91efd4ac54a2abf07a4d037d71844_FinancialInstrumentsFairValueofFinancialInstrumentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_462f9b62-e494-4ed5-b670-2837457d452c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_52d5af92-c890-4c5b-af2b-15c8af38178f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_462f9b62-e494-4ed5-b670-2837457d452c" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_52d5af92-c890-4c5b-af2b-15c8af38178f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_8abffb36-0b31-4c2e-bcda-9474b2dab9b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_462f9b62-e494-4ed5-b670-2837457d452c" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_8abffb36-0b31-4c2e-bcda-9474b2dab9b3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_a33c4b9d-9374-4fb5-88f7-a0428cc7ca02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_462f9b62-e494-4ed5-b670-2837457d452c" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_a33c4b9d-9374-4fb5-88f7-a0428cc7ca02" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_f65bf90f-9aae-4d3e-bacc-c7434a5aed85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_462f9b62-e494-4ed5-b670-2837457d452c" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_f65bf90f-9aae-4d3e-bacc-c7434a5aed85" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_91e700a3-3d4e-4ffa-8647-f56d3fe74609" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_462f9b62-e494-4ed5-b670-2837457d452c" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_91e700a3-3d4e-4ffa-8647-f56d3fe74609" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLongTermInvestments_20f434b0-62c8-4a51-967a-b2a282e886f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLongTermInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_462f9b62-e494-4ed5-b670-2837457d452c" xlink:to="loc_us-gaap_OtherLongTermInvestments_20f434b0-62c8-4a51-967a-b2a282e886f6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments_1491b2a5-fda3-4b6e-b223-bfde4324e9f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_462f9b62-e494-4ed5-b670-2837457d452c" xlink:to="loc_us-gaap_LongTermInvestments_1491b2a5-fda3-4b6e-b223-bfde4324e9f3" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaper_64484a5c-143b-4a00-a560-3f519c7fad1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaper"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_462f9b62-e494-4ed5-b670-2837457d452c" xlink:to="loc_us-gaap_CommercialPaper_64484a5c-143b-4a00-a560-3f519c7fad1e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_d5603dae-342a-4d14-a85f-a4d7b3c4437f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_462f9b62-e494-4ed5-b670-2837457d452c" xlink:to="loc_us-gaap_LongTermDebt_d5603dae-342a-4d14-a85f-a4d7b3c4437f" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_11bc4c71-67c0-43ec-9b9a-c7cc6d929674" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_462f9b62-e494-4ed5-b670-2837457d452c" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_11bc4c71-67c0-43ec-9b9a-c7cc6d929674" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_acd56928-a98d-48c7-ae50-68fe30601b82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_11bc4c71-67c0-43ec-9b9a-c7cc6d929674" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_acd56928-a98d-48c7-ae50-68fe30601b82" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_acd56928-a98d-48c7-ae50-68fe30601b82_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_acd56928-a98d-48c7-ae50-68fe30601b82" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_acd56928-a98d-48c7-ae50-68fe30601b82_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_519f5cda-316b-435b-85b0-f08b0593521c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_acd56928-a98d-48c7-ae50-68fe30601b82" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_519f5cda-316b-435b-85b0-f08b0593521c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_fbc486ab-4248-4950-93dd-909f0fbd9c32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_519f5cda-316b-435b-85b0-f08b0593521c" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_fbc486ab-4248-4950-93dd-909f0fbd9c32" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_23386bcb-b55f-4ecb-b047-770bcd9249fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_519f5cda-316b-435b-85b0-f08b0593521c" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_23386bcb-b55f-4ecb-b047-770bcd9249fd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember_37c885d2-60ea-463e-abd6-281073287088" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_519f5cda-316b-435b-85b0-f08b0593521c" xlink:to="loc_us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember_37c885d2-60ea-463e-abd6-281073287088" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_821c1e34-e0d8-410a-ba98-d6aabddcef65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_519f5cda-316b-435b-85b0-f08b0593521c" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_821c1e34-e0d8-410a-ba98-d6aabddcef65" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_62f1229d-4b2d-453b-93d9-43dff96ec3af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_11bc4c71-67c0-43ec-9b9a-c7cc6d929674" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_62f1229d-4b2d-453b-93d9-43dff96ec3af" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_62f1229d-4b2d-453b-93d9-43dff96ec3af_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_62f1229d-4b2d-453b-93d9-43dff96ec3af" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_62f1229d-4b2d-453b-93d9-43dff96ec3af_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c92c7cc5-ff1a-4bbc-892a-c71c559b8c71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_62f1229d-4b2d-453b-93d9-43dff96ec3af" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c92c7cc5-ff1a-4bbc-892a-c71c559b8c71" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_4388bcaf-4323-42a0-9d46-ac960845fe5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c92c7cc5-ff1a-4bbc-892a-c71c559b8c71" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_4388bcaf-4323-42a0-9d46-ac960845fe5a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_be3a37cb-e4fd-4ed5-9e6b-5ebd7f01ed70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c92c7cc5-ff1a-4bbc-892a-c71c559b8c71" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_be3a37cb-e4fd-4ed5-9e6b-5ebd7f01ed70" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_241de72f-35df-4b93-be31-8f778f01e46e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c92c7cc5-ff1a-4bbc-892a-c71c559b8c71" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_241de72f-35df-4b93-be31-8f778f01e46e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_f4029da5-e37c-4089-967c-31fe93022ddf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_11bc4c71-67c0-43ec-9b9a-c7cc6d929674" xlink:to="loc_us-gaap_FinancialInstrumentAxis_f4029da5-e37c-4089-967c-31fe93022ddf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f4029da5-e37c-4089-967c-31fe93022ddf_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_f4029da5-e37c-4089-967c-31fe93022ddf" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f4029da5-e37c-4089-967c-31fe93022ddf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_158334df-a401-4bdc-8185-d3a614e00d7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_f4029da5-e37c-4089-967c-31fe93022ddf" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_158334df-a401-4bdc-8185-d3a614e00d7b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_40272f64-9fa8-4536-8389-1b3f4e232247" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_158334df-a401-4bdc-8185-d3a614e00d7b" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_40272f64-9fa8-4536-8389-1b3f4e232247" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_48a03932-753a-4244-ae9c-d4461d30f454" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_158334df-a401-4bdc-8185-d3a614e00d7b" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_48a03932-753a-4244-ae9c-d4461d30f454" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MortgageBackedSecuritiesMember_59f38323-1922-4cd3-ac8b-afddcfad4dac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MortgageBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_158334df-a401-4bdc-8185-d3a614e00d7b" xlink:to="loc_us-gaap_MortgageBackedSecuritiesMember_59f38323-1922-4cd3-ac8b-afddcfad4dac" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_780d0736-6afc-47e6-bb2d-d8ca74c8f3ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_158334df-a401-4bdc-8185-d3a614e00d7b" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_780d0736-6afc-47e6-bb2d-d8ca74c8f3ed" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherDebtSecuritiesMember_c23b5c1d-a8b3-47b2-8d78-0cde03a12324" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_158334df-a401-4bdc-8185-d3a614e00d7b" xlink:to="loc_us-gaap_OtherDebtSecuritiesMember_c23b5c1d-a8b3-47b2-8d78-0cde03a12324" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OtherEquitySecuritiesMember_78b73ce5-0164-441e-b4b8-4a28c021fca8" xlink:href="lly-20220930.xsd#lly_OtherEquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_158334df-a401-4bdc-8185-d3a614e00d7b" xlink:to="loc_lly_OtherEquitySecuritiesMember_78b73ce5-0164-441e-b4b8-4a28c021fca8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MarketableSecuritiesMember_fbb155d4-43bc-4e45-be6b-92078dd239cd" xlink:href="lly-20220930.xsd#lly_MarketableSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_158334df-a401-4bdc-8185-d3a614e00d7b" xlink:to="loc_lly_MarketableSecuritiesMember_fbb155d4-43bc-4e45-be6b-92078dd239cd" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_EquityMethodAndOtherInvestmentsMember_d3650ca6-59f0-4561-92f1-635f18a51437" xlink:href="lly-20220930.xsd#lly_EquityMethodAndOtherInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_158334df-a401-4bdc-8185-d3a614e00d7b" xlink:to="loc_lly_EquityMethodAndOtherInvestmentsMember_d3650ca6-59f0-4561-92f1-635f18a51437" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/FinancialInstrumentsRiskManagementInstrumentsDetails" xlink:type="simple" xlink:href="lly-20220930.xsd#FinancialInstrumentsRiskManagementInstrumentsDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/FinancialInstrumentsRiskManagementInstrumentsDetails" xlink:type="extended" id="i00a6acc76e114756bc85a5427f935f80_FinancialInstrumentsRiskManagementInstrumentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b66fa097-2e16-44c4-bf80-a7a29dc8790d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsCurrent_ba509ab6-d100-4986-9fe1-62948870a72b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b66fa097-2e16-44c4-bf80-a7a29dc8790d" xlink:to="loc_us-gaap_DerivativeAssetsCurrent_ba509ab6-d100-4986-9fe1-62948870a72b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsNoncurrent_52dbbf42-4f87-479f-bf73-8a865e3af099" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b66fa097-2e16-44c4-bf80-a7a29dc8790d" xlink:to="loc_us-gaap_DerivativeAssetsNoncurrent_52dbbf42-4f87-479f-bf73-8a865e3af099" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent_8fa02b65-8237-43f5-9eaa-534e7146e4ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b66fa097-2e16-44c4-bf80-a7a29dc8790d" xlink:to="loc_us-gaap_DerivativeLiabilitiesCurrent_8fa02b65-8237-43f5-9eaa-534e7146e4ac" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_003b239c-08b9-4d03-b0ff-cc992ce76b8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b66fa097-2e16-44c4-bf80-a7a29dc8790d" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent_003b239c-08b9-4d03-b0ff-cc992ce76b8c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_ed99dfa3-5839-4ab0-820d-a74758e2f189" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b66fa097-2e16-44c4-bf80-a7a29dc8790d" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_ed99dfa3-5839-4ab0-820d-a74758e2f189" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b190457a-1633-469d-ac2e-6d294c9c255a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b66fa097-2e16-44c4-bf80-a7a29dc8790d" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b190457a-1633-469d-ac2e-6d294c9c255a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_1f7a444b-ee85-4e33-bceb-ec6043930e71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b190457a-1633-469d-ac2e-6d294c9c255a" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_1f7a444b-ee85-4e33-bceb-ec6043930e71" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_1f7a444b-ee85-4e33-bceb-ec6043930e71_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_1f7a444b-ee85-4e33-bceb-ec6043930e71" xlink:to="loc_us-gaap_HedgingRelationshipDomain_1f7a444b-ee85-4e33-bceb-ec6043930e71_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_5db872bd-8cc2-4bf7-aae5-e9e9e1c53210" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_1f7a444b-ee85-4e33-bceb-ec6043930e71" xlink:to="loc_us-gaap_HedgingRelationshipDomain_5db872bd-8cc2-4bf7-aae5-e9e9e1c53210" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueHedgingMember_96d73363-bca4-4167-8e14-7e0e303893c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_5db872bd-8cc2-4bf7-aae5-e9e9e1c53210" xlink:to="loc_us-gaap_FairValueHedgingMember_96d73363-bca4-4167-8e14-7e0e303893c4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_0835ef90-361f-4342-99ed-69d786b67dd6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_5db872bd-8cc2-4bf7-aae5-e9e9e1c53210" xlink:to="loc_us-gaap_CashFlowHedgingMember_0835ef90-361f-4342-99ed-69d786b67dd6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_958a15e2-0b63-47b6-b8ae-d0c4791ea5fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_5db872bd-8cc2-4bf7-aae5-e9e9e1c53210" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_958a15e2-0b63-47b6-b8ae-d0c4791ea5fa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_ef86978c-826b-4ebc-ad8c-fb3b421da83d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b190457a-1633-469d-ac2e-6d294c9c255a" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_ef86978c-826b-4ebc-ad8c-fb3b421da83d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_ef86978c-826b-4ebc-ad8c-fb3b421da83d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_ef86978c-826b-4ebc-ad8c-fb3b421da83d" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_ef86978c-826b-4ebc-ad8c-fb3b421da83d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_d0b7e93f-3a43-411c-9ac7-77f98cff20cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_ef86978c-826b-4ebc-ad8c-fb3b421da83d" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_d0b7e93f-3a43-411c-9ac7-77f98cff20cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_188ab044-3b39-4345-ab4b-44d6f9253f26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_d0b7e93f-3a43-411c-9ac7-77f98cff20cc" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_188ab044-3b39-4345-ab4b-44d6f9253f26" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_75938125-5d99-489f-add4-56d4debac366" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_d0b7e93f-3a43-411c-9ac7-77f98cff20cc" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_75938125-5d99-489f-add4-56d4debac366" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_49ff8af4-ed13-4bde-9dd1-378a449ff563" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_d0b7e93f-3a43-411c-9ac7-77f98cff20cc" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_49ff8af4-ed13-4bde-9dd1-378a449ff563" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_d068c9d5-ad89-4531-a712-0df2347c3c48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b190457a-1633-469d-ac2e-6d294c9c255a" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_d068c9d5-ad89-4531-a712-0df2347c3c48" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_d068c9d5-ad89-4531-a712-0df2347c3c48_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_d068c9d5-ad89-4531-a712-0df2347c3c48" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_d068c9d5-ad89-4531-a712-0df2347c3c48_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_6b89593d-e838-45d6-878d-ef1c43c6b8b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_d068c9d5-ad89-4531-a712-0df2347c3c48" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_6b89593d-e838-45d6-878d-ef1c43c6b8b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateContractMember_ec3c99f3-59d7-4c8b-a785-15aaed3368f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_6b89593d-e838-45d6-878d-ef1c43c6b8b9" xlink:to="loc_us-gaap_InterestRateContractMember_ec3c99f3-59d7-4c8b-a785-15aaed3368f9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CrossCurrencyInterestRateContractMember_0ba48a6b-8fca-4700-a897-16f7eb6518a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CrossCurrencyInterestRateContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_6b89593d-e838-45d6-878d-ef1c43c6b8b9" xlink:to="loc_us-gaap_CrossCurrencyInterestRateContractMember_0ba48a6b-8fca-4700-a897-16f7eb6518a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_bf870393-d431-4b89-84b1-74d164975dfc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_6b89593d-e838-45d6-878d-ef1c43c6b8b9" xlink:to="loc_us-gaap_ForeignExchangeContractMember_bf870393-d431-4b89-84b1-74d164975dfc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_c440302f-14cd-4ff9-a6b2-a1a03c30f8d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b190457a-1633-469d-ac2e-6d294c9c255a" xlink:to="loc_us-gaap_HedgingDesignationAxis_c440302f-14cd-4ff9-a6b2-a1a03c30f8d6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_c440302f-14cd-4ff9-a6b2-a1a03c30f8d6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_c440302f-14cd-4ff9-a6b2-a1a03c30f8d6" xlink:to="loc_us-gaap_HedgingDesignationDomain_c440302f-14cd-4ff9-a6b2-a1a03c30f8d6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_a09d32cf-f87c-4224-81da-9abd5510d649" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_c440302f-14cd-4ff9-a6b2-a1a03c30f8d6" xlink:to="loc_us-gaap_HedgingDesignationDomain_a09d32cf-f87c-4224-81da-9abd5510d649" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_143018c2-8bb1-4391-9a70-f3a7c8d95e1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_a09d32cf-f87c-4224-81da-9abd5510d649" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_143018c2-8bb1-4391-9a70-f3a7c8d95e1b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_26cc8d87-969a-41dd-bac1-f8b46bf4d84e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NondesignatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_a09d32cf-f87c-4224-81da-9abd5510d649" xlink:to="loc_us-gaap_NondesignatedMember_26cc8d87-969a-41dd-bac1-f8b46bf4d84e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5e24def9-a1c0-46ab-b4e5-115ab7ab5f10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b190457a-1633-469d-ac2e-6d294c9c255a" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5e24def9-a1c0-46ab-b4e5-115ab7ab5f10" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5e24def9-a1c0-46ab-b4e5-115ab7ab5f10_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5e24def9-a1c0-46ab-b4e5-115ab7ab5f10" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5e24def9-a1c0-46ab-b4e5-115ab7ab5f10_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c2628717-4e0d-48b9-acef-b8398c9c3ee0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5e24def9-a1c0-46ab-b4e5-115ab7ab5f10" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c2628717-4e0d-48b9-acef-b8398c9c3ee0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_c9249920-0447-46fe-9f30-7b190b842f8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c2628717-4e0d-48b9-acef-b8398c9c3ee0" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_c9249920-0447-46fe-9f30-7b190b842f8c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_d936955e-6807-4374-bca4-9df2d4693020" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c2628717-4e0d-48b9-acef-b8398c9c3ee0" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_d936955e-6807-4374-bca4-9df2d4693020" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_d2198b9c-edf5-4289-bb66-cfacd330c9f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c2628717-4e0d-48b9-acef-b8398c9c3ee0" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_d2198b9c-edf5-4289-bb66-cfacd330c9f1" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/IncomeTaxesDetails" xlink:type="simple" xlink:href="lly-20220930.xsd#IncomeTaxesDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/IncomeTaxesDetails" xlink:type="extended" id="i45314f31240845acb8781c17cbe8f38c_IncomeTaxesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_f27e753f-9923-47a6-bc86-b5a933313b2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_a39ba2e8-7d0d-473f-a863-81d2e6106a20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_f27e753f-9923-47a6-bc86-b5a933313b2f" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_a39ba2e8-7d0d-473f-a863-81d2e6106a20" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_443322cb-6b87-4e0f-87fb-b5beb8325309" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_f27e753f-9923-47a6-bc86-b5a933313b2f" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_443322cb-6b87-4e0f-87fb-b5beb8325309" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_c73c768c-5ea9-4cf9-a68e-991a78d9dd0d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_443322cb-6b87-4e0f-87fb-b5beb8325309" xlink:to="loc_srt_StatementScenarioAxis_c73c768c-5ea9-4cf9-a68e-991a78d9dd0d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_c73c768c-5ea9-4cf9-a68e-991a78d9dd0d_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_c73c768c-5ea9-4cf9-a68e-991a78d9dd0d" xlink:to="loc_srt_ScenarioUnspecifiedDomain_c73c768c-5ea9-4cf9-a68e-991a78d9dd0d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_6d1d73ec-10d8-4fab-8141-58cddad03755" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_c73c768c-5ea9-4cf9-a68e-991a78d9dd0d" xlink:to="loc_srt_ScenarioUnspecifiedDomain_6d1d73ec-10d8-4fab-8141-58cddad03755" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_87737e21-accc-46be-b93a-36222807f319" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_6d1d73ec-10d8-4fab-8141-58cddad03755" xlink:to="loc_srt_ScenarioForecastMember_87737e21-accc-46be-b93a-36222807f319" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_504e981a-297d-46f6-a043-6f6c2291e26b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_443322cb-6b87-4e0f-87fb-b5beb8325309" xlink:to="loc_srt_RangeAxis_504e981a-297d-46f6-a043-6f6c2291e26b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_504e981a-297d-46f6-a043-6f6c2291e26b_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_504e981a-297d-46f6-a043-6f6c2291e26b" xlink:to="loc_srt_RangeMember_504e981a-297d-46f6-a043-6f6c2291e26b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d0da3675-212a-440e-9eb9-0e1968c715de" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_504e981a-297d-46f6-a043-6f6c2291e26b" xlink:to="loc_srt_RangeMember_d0da3675-212a-440e-9eb9-0e1968c715de" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_e523e5cc-a87a-4e13-ac2f-04421f2e5d63" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_d0da3675-212a-440e-9eb9-0e1968c715de" xlink:to="loc_srt_MinimumMember_e523e5cc-a87a-4e13-ac2f-04421f2e5d63" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_565b02ad-674c-4ea9-bf57-32bc5af4ae8e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_d0da3675-212a-440e-9eb9-0e1968c715de" xlink:to="loc_srt_MaximumMember_565b02ad-674c-4ea9-bf57-32bc5af4ae8e" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/RetirementBenefitsComponentsofNetPeriodicBenefitCostDetails" xlink:type="simple" xlink:href="lly-20220930.xsd#RetirementBenefitsComponentsofNetPeriodicBenefitCostDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/RetirementBenefitsComponentsofNetPeriodicBenefitCostDetails" xlink:type="extended" id="ifcb828cbe7e14671a91284308c0966f6_RetirementBenefitsComponentsofNetPeriodicBenefitCostDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_2cb2af1e-5712-451f-a1eb-f9e998065b1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_e8751cac-0f6e-4504-b28e-743c895a5e29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_2cb2af1e-5712-451f-a1eb-f9e998065b1a" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_e8751cac-0f6e-4504-b28e-743c895a5e29" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_9d6e8b66-22b8-4b2e-b2f3-055fefa1ec8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_2cb2af1e-5712-451f-a1eb-f9e998065b1a" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_9d6e8b66-22b8-4b2e-b2f3-055fefa1ec8b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_47070be2-1668-4c4c-a2c0-8c951f48912b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_2cb2af1e-5712-451f-a1eb-f9e998065b1a" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_47070be2-1668-4c4c-a2c0-8c951f48912b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_ea56b77c-9de6-47bb-bd7a-d5097025fe21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_2cb2af1e-5712-451f-a1eb-f9e998065b1a" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_ea56b77c-9de6-47bb-bd7a-d5097025fe21" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit_4f955a86-9c9a-42bc-8756-efb48e857676" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_2cb2af1e-5712-451f-a1eb-f9e998065b1a" xlink:to="loc_us-gaap_DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit_4f955a86-9c9a-42bc-8756-efb48e857676" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_4be39af5-0974-4d52-940c-cc225d349398" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_2cb2af1e-5712-451f-a1eb-f9e998065b1a" xlink:to="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_4be39af5-0974-4d52-940c-cc225d349398" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_59b10cb9-2224-48bb-803a-90b7a7e70eda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_2cb2af1e-5712-451f-a1eb-f9e998065b1a" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_59b10cb9-2224-48bb-803a-90b7a7e70eda" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_ce276b6e-a2c3-46e5-93ad-3bd47a50e231" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_59b10cb9-2224-48bb-803a-90b7a7e70eda" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_ce276b6e-a2c3-46e5-93ad-3bd47a50e231" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_ce276b6e-a2c3-46e5-93ad-3bd47a50e231_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_ce276b6e-a2c3-46e5-93ad-3bd47a50e231" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_ce276b6e-a2c3-46e5-93ad-3bd47a50e231_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_cfd91e2a-f022-4646-b3f8-1aa6a99317a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_ce276b6e-a2c3-46e5-93ad-3bd47a50e231" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_cfd91e2a-f022-4646-b3f8-1aa6a99317a2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_ce885b37-2480-4674-b3f5-9354bc782db7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_cfd91e2a-f022-4646-b3f8-1aa6a99317a2" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_ce885b37-2480-4674-b3f5-9354bc782db7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_2ee73ae4-5c74-4b7a-b740-c40f4eb57b94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_cfd91e2a-f022-4646-b3f8-1aa6a99317a2" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_2ee73ae4-5c74-4b7a-b740-c40f4eb57b94" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/ContingenciesDetails" xlink:type="simple" xlink:href="lly-20220930.xsd#ContingenciesDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/ContingenciesDetails" xlink:type="extended" id="i5fcd6e6c375b4fd3ae2b27e7b5c56df1_ContingenciesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_20b7d726-83ac-4226-b33d-478fac1a9789" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_LossContingencyNumberOfPatents_670e97d8-6a7d-45c6-ab6c-5c7ce703554b" xlink:href="lly-20220930.xsd#lly_LossContingencyNumberOfPatents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_20b7d726-83ac-4226-b33d-478fac1a9789" xlink:to="loc_lly_LossContingencyNumberOfPatents_670e97d8-6a7d-45c6-ab6c-5c7ce703554b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber_2dd4aa0f-c12e-42fb-a4dc-fd5c1d9b293d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_20b7d726-83ac-4226-b33d-478fac1a9789" xlink:to="loc_us-gaap_LossContingencyPendingClaimsNumber_2dd4aa0f-c12e-42fb-a4dc-fd5c1d9b293d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNumberOfPlaintiffs_5b811670-eb75-4ddb-bd89-1c13b8700998" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNumberOfPlaintiffs"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_20b7d726-83ac-4226-b33d-478fac1a9789" xlink:to="loc_us-gaap_LossContingencyNumberOfPlaintiffs_5b811670-eb75-4ddb-bd89-1c13b8700998" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_LossContingencyNumberOfSitesJointlyAndSeverallyLiableForCleanup_4dfcc7ce-81a0-410a-942a-1f62be715c5c" xlink:href="lly-20220930.xsd#lly_LossContingencyNumberOfSitesJointlyAndSeverallyLiableForCleanup"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_20b7d726-83ac-4226-b33d-478fac1a9789" xlink:to="loc_lly_LossContingencyNumberOfSitesJointlyAndSeverallyLiableForCleanup_4dfcc7ce-81a0-410a-942a-1f62be715c5c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesAwardedValue_740fdd90-f384-40db-b24e-4f6763a02c5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyDamagesAwardedValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_20b7d726-83ac-4226-b33d-478fac1a9789" xlink:to="loc_us-gaap_LossContingencyDamagesAwardedValue_740fdd90-f384-40db-b24e-4f6763a02c5f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_LitigationClaimsDismissedNumber_4b479d18-cf9b-429c-94c1-7ec08398c9ed" xlink:href="lly-20220930.xsd#lly_LitigationClaimsDismissedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_20b7d726-83ac-4226-b33d-478fac1a9789" xlink:to="loc_lly_LitigationClaimsDismissedNumber_4b479d18-cf9b-429c-94c1-7ec08398c9ed" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_eb28ce4c-84c5-4a40-b74c-8335ec487b15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_20b7d726-83ac-4226-b33d-478fac1a9789" xlink:to="loc_us-gaap_LossContingenciesTable_eb28ce4c-84c5-4a40-b74c-8335ec487b15" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_73ff64d7-b28d-4894-acdb-a81a9232faf8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_eb28ce4c-84c5-4a40-b74c-8335ec487b15" xlink:to="loc_srt_LitigationCaseAxis_73ff64d7-b28d-4894-acdb-a81a9232faf8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_73ff64d7-b28d-4894-acdb-a81a9232faf8_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_73ff64d7-b28d-4894-acdb-a81a9232faf8" xlink:to="loc_srt_LitigationCaseTypeDomain_73ff64d7-b28d-4894-acdb-a81a9232faf8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_d5dd8b45-9303-4083-9f3e-dc2885d43ec0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_73ff64d7-b28d-4894-acdb-a81a9232faf8" xlink:to="loc_srt_LitigationCaseTypeDomain_d5dd8b45-9303-4083-9f3e-dc2885d43ec0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_EmgalityPatentLitigationMember_3db88e87-61be-45e6-9a6b-e1bf517aa1c5" xlink:href="lly-20220930.xsd#lly_EmgalityPatentLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_d5dd8b45-9303-4083-9f3e-dc2885d43ec0" xlink:to="loc_lly_EmgalityPatentLitigationMember_3db88e87-61be-45e6-9a6b-e1bf517aa1c5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_EmployeeLitigationMember_0a53c331-bac3-4bda-8c90-5e926ae98e9e" xlink:href="lly-20220930.xsd#lly_EmployeeLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_d5dd8b45-9303-4083-9f3e-dc2885d43ec0" xlink:to="loc_lly_EmployeeLitigationMember_0a53c331-bac3-4bda-8c90-5e926ae98e9e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_a69f1262-1bea-4709-a9a7-97560517611f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_eb28ce4c-84c5-4a40-b74c-8335ec487b15" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_a69f1262-1bea-4709-a9a7-97560517611f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_a69f1262-1bea-4709-a9a7-97560517611f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_a69f1262-1bea-4709-a9a7-97560517611f" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_a69f1262-1bea-4709-a9a7-97560517611f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_3ef83a4a-bd26-437c-979b-1f51fd2d0d3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_a69f1262-1bea-4709-a9a7-97560517611f" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_3ef83a4a-bd26-437c-979b-1f51fd2d0d3b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_48c3939a-de18-4603-8448-a87b4300e35a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_3ef83a4a-bd26-437c-979b-1f51fd2d0d3b" xlink:to="loc_us-gaap_SubsequentEventMember_48c3939a-de18-4603-8448-a87b4300e35a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_45b2ca5b-575f-4636-9136-42a394abfe67" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_eb28ce4c-84c5-4a40-b74c-8335ec487b15" xlink:to="loc_srt_ProductOrServiceAxis_45b2ca5b-575f-4636-9136-42a394abfe67" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_45b2ca5b-575f-4636-9136-42a394abfe67_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_45b2ca5b-575f-4636-9136-42a394abfe67" xlink:to="loc_srt_ProductsAndServicesDomain_45b2ca5b-575f-4636-9136-42a394abfe67_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_d8823e78-3372-4b78-8d8f-7e5960bc6577" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_45b2ca5b-575f-4636-9136-42a394abfe67" xlink:to="loc_srt_ProductsAndServicesDomain_d8823e78-3372-4b78-8d8f-7e5960bc6577" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ByettaMember_b088ce44-717e-4479-bb1a-b6b67b4f9bd8" xlink:href="lly-20220930.xsd#lly_ByettaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d8823e78-3372-4b78-8d8f-7e5960bc6577" xlink:to="loc_lly_ByettaMember_b088ce44-717e-4479-bb1a-b6b67b4f9bd8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_HumalogHumulinAndForteoMember_beb0bb24-a7e6-4597-a677-4344240b6f42" xlink:href="lly-20220930.xsd#lly_HumalogHumulinAndForteoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d8823e78-3372-4b78-8d8f-7e5960bc6577" xlink:to="loc_lly_HumalogHumulinAndForteoMember_beb0bb24-a7e6-4597-a677-4344240b6f42" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_InsulinMember_12d832fe-9a82-44c3-9cad-c0127b134c19" xlink:href="lly-20220930.xsd#lly_InsulinMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d8823e78-3372-4b78-8d8f-7e5960bc6577" xlink:to="loc_lly_InsulinMember_12d832fe-9a82-44c3-9cad-c0127b134c19" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_134bab10-e3e4-4f0c-b2bf-bd26f9a346fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_eb28ce4c-84c5-4a40-b74c-8335ec487b15" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_134bab10-e3e4-4f0c-b2bf-bd26f9a346fd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_134bab10-e3e4-4f0c-b2bf-bd26f9a346fd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_134bab10-e3e4-4f0c-b2bf-bd26f9a346fd" xlink:to="loc_us-gaap_LossContingencyNatureDomain_134bab10-e3e4-4f0c-b2bf-bd26f9a346fd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_f650ff05-643d-4aa1-b62b-2e44a5a99b99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_134bab10-e3e4-4f0c-b2bf-bd26f9a346fd" xlink:to="loc_us-gaap_LossContingencyNatureDomain_f650ff05-643d-4aa1-b62b-2e44a5a99b99" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ProductLiabilityMember_4521f93c-d34b-46cb-bcab-5211b7b4cc7f" xlink:href="lly-20220930.xsd#lly_ProductLiabilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_f650ff05-643d-4aa1-b62b-2e44a5a99b99" xlink:to="loc_lly_ProductLiabilityMember_4521f93c-d34b-46cb-bcab-5211b7b4cc7f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnfavorableRegulatoryActionMember_aa82378d-0358-47a1-b8cd-fb63e29b3531" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnfavorableRegulatoryActionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_f650ff05-643d-4aa1-b62b-2e44a5a99b99" xlink:to="loc_us-gaap_UnfavorableRegulatoryActionMember_aa82378d-0358-47a1-b8cd-fb63e29b3531" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_0e9b13cd-4ffc-467b-a9e0-39e5d2c08daa" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_eb28ce4c-84c5-4a40-b74c-8335ec487b15" xlink:to="loc_srt_StatementGeographicalAxis_0e9b13cd-4ffc-467b-a9e0-39e5d2c08daa" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_0e9b13cd-4ffc-467b-a9e0-39e5d2c08daa_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_0e9b13cd-4ffc-467b-a9e0-39e5d2c08daa" xlink:to="loc_srt_SegmentGeographicalDomain_0e9b13cd-4ffc-467b-a9e0-39e5d2c08daa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_2cba47d1-e42f-4d3d-9fca-f330b3175f2a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_0e9b13cd-4ffc-467b-a9e0-39e5d2c08daa" xlink:to="loc_srt_SegmentGeographicalDomain_2cba47d1-e42f-4d3d-9fca-f330b3175f2a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_BR_39c34011-4d41-47c0-801a-d6a1cfff065f" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_BR"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_2cba47d1-e42f-4d3d-9fca-f330b3175f2a" xlink:to="loc_country_BR_39c34011-4d41-47c0-801a-d6a1cfff065f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/OtherComprehensiveIncomeLossAOCIDetails" xlink:type="simple" xlink:href="lly-20220930.xsd#OtherComprehensiveIncomeLossAOCIDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/OtherComprehensiveIncomeLossAOCIDetails" xlink:type="extended" id="ia881ebd7d21b4d428802970a78d5e7f2_OtherComprehensiveIncomeLossAOCIDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_061c7dac-ac39-4b7c-804a-411d5a7325f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_99805ae0-b1b4-422d-9790-526868b4cf59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_061c7dac-ac39-4b7c-804a-411d5a7325f8" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_99805ae0-b1b4-422d-9790-526868b4cf59" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b93c4b38-0090-4961-a465-de9d7693c6d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_99805ae0-b1b4-422d-9790-526868b4cf59" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b93c4b38-0090-4961-a465-de9d7693c6d2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_b4a9e65a-eeef-427a-ae76-fa164391e03c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_99805ae0-b1b4-422d-9790-526868b4cf59" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_b4a9e65a-eeef-427a-ae76-fa164391e03c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_46d138bc-eb8f-490e-9287-8982e26da634" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_99805ae0-b1b4-422d-9790-526868b4cf59" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_46d138bc-eb8f-490e-9287-8982e26da634" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_815f2711-28e6-4acb-8823-936632f5167f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_99805ae0-b1b4-422d-9790-526868b4cf59" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_815f2711-28e6-4acb-8823-936632f5167f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_72c1b9ed-aa53-47a6-bd6e-f24b97f50907" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_b3fbb330-031e-47fa-a570-b9fb8f4ffd37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_061c7dac-ac39-4b7c-804a-411d5a7325f8" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_b3fbb330-031e-47fa-a570-b9fb8f4ffd37" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_72d270a8-de26-44ec-bfdf-6cad8232e16b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_b3fbb330-031e-47fa-a570-b9fb8f4ffd37" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_72d270a8-de26-44ec-bfdf-6cad8232e16b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_72d270a8-de26-44ec-bfdf-6cad8232e16b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_72d270a8-de26-44ec-bfdf-6cad8232e16b" xlink:to="loc_us-gaap_EquityComponentDomain_72d270a8-de26-44ec-bfdf-6cad8232e16b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_2d6613fb-7fe3-4412-94ba-2159af24ca87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_72d270a8-de26-44ec-bfdf-6cad8232e16b" xlink:to="loc_us-gaap_EquityComponentDomain_2d6613fb-7fe3-4412-94ba-2159af24ca87" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_8fb886c2-7f90-46df-b0ab-507119ebcbe3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_2d6613fb-7fe3-4412-94ba-2159af24ca87" xlink:to="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_8fb886c2-7f90-46df-b0ab-507119ebcbe3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_c9f52f96-3da1-4e0f-b609-a2f5e717d7e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_8fb886c2-7f90-46df-b0ab-507119ebcbe3" xlink:to="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_c9f52f96-3da1-4e0f-b609-a2f5e717d7e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember_e2bbd132-67cd-46aa-9b47-7d92c4922f8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_8fb886c2-7f90-46df-b0ab-507119ebcbe3" xlink:to="loc_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember_e2bbd132-67cd-46aa-9b47-7d92c4922f8b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_814f1855-2b16-4a0a-a469-92b8646c8f01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_8fb886c2-7f90-46df-b0ab-507119ebcbe3" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_814f1855-2b16-4a0a-a469-92b8646c8f01" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember_52ae1ca3-81e9-44a6-9665-b2f5623e01b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_8fb886c2-7f90-46df-b0ab-507119ebcbe3" xlink:to="loc_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember_52ae1ca3-81e9-44a6-9665-b2f5623e01b9" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/OtherComprehensiveIncomeLossTaxEffectDetails" xlink:type="simple" xlink:href="lly-20220930.xsd#OtherComprehensiveIncomeLossTaxEffectDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/OtherComprehensiveIncomeLossTaxEffectDetails" xlink:type="extended" id="i930123d5c3764ff585fffcfbe3fd95c2_OtherComprehensiveIncomeLossTaxEffectDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_9d78f3b8-e99c-4d8a-9ecd-e8cea5534281" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTax_2666f2ed-596a-48d5-82f2-ab0bd0f0f9cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_9d78f3b8-e99c-4d8a-9ecd-e8cea5534281" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossTax_2666f2ed-596a-48d5-82f2-ab0bd0f0f9cb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_9d705111-b4c6-4af7-bb27-608d63a6a708" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_9d78f3b8-e99c-4d8a-9ecd-e8cea5534281" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_9d705111-b4c6-4af7-bb27-608d63a6a708" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_caae0706-8791-4c98-b799-b649acc1b002" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_9d705111-b4c6-4af7-bb27-608d63a6a708" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_caae0706-8791-4c98-b799-b649acc1b002" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_caae0706-8791-4c98-b799-b649acc1b002_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_caae0706-8791-4c98-b799-b649acc1b002" xlink:to="loc_us-gaap_EquityComponentDomain_caae0706-8791-4c98-b799-b649acc1b002_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_42f8c945-2fcf-4d2f-bd57-1af4ef65a4db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_caae0706-8791-4c98-b799-b649acc1b002" xlink:to="loc_us-gaap_EquityComponentDomain_42f8c945-2fcf-4d2f-bd57-1af4ef65a4db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_840362f1-5d3d-4763-8fcd-aad558d97112" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_42f8c945-2fcf-4d2f-bd57-1af4ef65a4db" xlink:to="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_840362f1-5d3d-4763-8fcd-aad558d97112" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember_90938f9f-72c4-4688-a4b1-f491445163f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_42f8c945-2fcf-4d2f-bd57-1af4ef65a4db" xlink:to="loc_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember_90938f9f-72c4-4688-a4b1-f491445163f6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_99b35180-4706-4d8d-a5f0-a676893a774e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_42f8c945-2fcf-4d2f-bd57-1af4ef65a4db" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_99b35180-4706-4d8d-a5f0-a676893a774e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember_b649192a-3e7a-4a25-8b98-17836ac73fd5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_42f8c945-2fcf-4d2f-bd57-1af4ef65a4db" xlink:to="loc_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember_b649192a-3e7a-4a25-8b98-17836ac73fd5" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/OtherComprehensiveIncomeLossReclassificationDetails" xlink:type="simple" xlink:href="lly-20220930.xsd#OtherComprehensiveIncomeLossReclassificationDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/OtherComprehensiveIncomeLossReclassificationDetails" xlink:type="extended" id="iebbbc2be16c74d92b09d4f23d3f2b459_OtherComprehensiveIncomeLossReclassificationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_a9606c7c-0b5e-45dd-8151-83b5377d7f56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_1905c47e-0197-46f6-ab3d-3e9dee8b0fd0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_a9606c7c-0b5e-45dd-8151-83b5377d7f56" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_1905c47e-0197-46f6-ab3d-3e9dee8b0fd0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_f836a768-d064-4626-9d51-efe795be1b50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_a9606c7c-0b5e-45dd-8151-83b5377d7f56" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_f836a768-d064-4626-9d51-efe795be1b50" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_8fa4a6e3-350b-435c-9cf0-b42de241eb0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_a9606c7c-0b5e-45dd-8151-83b5377d7f56" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_8fa4a6e3-350b-435c-9cf0-b42de241eb0f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_bc05aee7-31b0-454b-8b38-c1341ca73060" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_a9606c7c-0b5e-45dd-8151-83b5377d7f56" xlink:to="loc_us-gaap_ProfitLoss_bc05aee7-31b0-454b-8b38-c1341ca73060" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_49536301-82ab-42ad-be4e-e6323ed50e3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_a9606c7c-0b5e-45dd-8151-83b5377d7f56" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_49536301-82ab-42ad-be4e-e6323ed50e3d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_8b87a143-1252-42b2-aff1-8c2a3d5ffceb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_49536301-82ab-42ad-be4e-e6323ed50e3d" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_8b87a143-1252-42b2-aff1-8c2a3d5ffceb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_8b87a143-1252-42b2-aff1-8c2a3d5ffceb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_8b87a143-1252-42b2-aff1-8c2a3d5ffceb" xlink:to="loc_us-gaap_EquityComponentDomain_8b87a143-1252-42b2-aff1-8c2a3d5ffceb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_e1ded240-d0cb-4e3f-abee-d3e343b830fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_8b87a143-1252-42b2-aff1-8c2a3d5ffceb" xlink:to="loc_us-gaap_EquityComponentDomain_e1ded240-d0cb-4e3f-abee-d3e343b830fb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_cc3211bd-c7ec-45d6-9bcd-624365fc211a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_e1ded240-d0cb-4e3f-abee-d3e343b830fb" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_cc3211bd-c7ec-45d6-9bcd-624365fc211a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember_4f778847-609a-4d14-9db0-5e060f45ae87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_cc3211bd-c7ec-45d6-9bcd-624365fc211a" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember_4f778847-609a-4d14-9db0-5e060f45ae87" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember_5fe0b448-008c-4d0b-bcba-65cc2c97dc90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_cc3211bd-c7ec-45d6-9bcd-624365fc211a" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember_5fe0b448-008c-4d0b-bcba-65cc2c97dc90" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AccumulatedGainLossNetCashFlowHedgeAndForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_6c647e1d-1ed7-44c3-a539-6a95e6fbe43f" xlink:href="lly-20220930.xsd#lly_AccumulatedGainLossNetCashFlowHedgeAndForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_e1ded240-d0cb-4e3f-abee-d3e343b830fb" xlink:to="loc_lly_AccumulatedGainLossNetCashFlowHedgeAndForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_6c647e1d-1ed7-44c3-a539-6a95e6fbe43f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_be3520b5-2399-43e8-9e6a-7e3a4b69fdc6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_49536301-82ab-42ad-be4e-e6323ed50e3d" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_be3520b5-2399-43e8-9e6a-7e3a4b69fdc6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_be3520b5-2399-43e8-9e6a-7e3a4b69fdc6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_be3520b5-2399-43e8-9e6a-7e3a4b69fdc6" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_be3520b5-2399-43e8-9e6a-7e3a4b69fdc6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_5097c6ce-f70a-4219-a29c-10f39b879985" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_be3520b5-2399-43e8-9e6a-7e3a4b69fdc6" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_5097c6ce-f70a-4219-a29c-10f39b879985" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_4cddcc75-f895-4cca-8963-53c5c6844828" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_5097c6ce-f70a-4219-a29c-10f39b879985" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_4cddcc75-f895-4cca-8963-53c5c6844828" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>11
<FILENAME>lly-20220930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:1f63046d-a77a-465e-aed4-1fd7d331378a,g:f755fa79-e9ed-4360-88c0-9c62587f0bf5-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_a234c411-6cd2-4d1a-a2a7-66102084298f_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less&#160;Than 1 Year</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_d0f8ceef-47bc-4338-a95e-017a92676a49_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_OlumiantMember_8fecc1c2-9cbc-468c-996e-1851bfebf6d7_terseLabel_en-US" xlink:label="lab_lly_OlumiantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Olumiant&#174;</link:label>
    <link:label id="lab_lly_OlumiantMember_label_en-US" xlink:label="lab_lly_OlumiantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Olumiant [Member]</link:label>
    <link:label id="lab_lly_OlumiantMember_documentation_en-US" xlink:label="lab_lly_OlumiantMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Olumiant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OlumiantMember" xlink:href="lly-20220930.xsd#lly_OlumiantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_OlumiantMember" xlink:to="lab_lly_OlumiantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_7dbd158a-bc26-438a-92f2-249f9fd3e269_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net amount reclassified from accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:to="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0504e04a-2995-4e82-9a77-80683939d75f_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Shareholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_a39dbd35-a26b-4af8-ac89-d686eeddd8e2_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_00b3de5a-acfd-4295-a763-75738279abd7_verboseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total reclassifications, net of tax</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyPendingClaimsNumber_2b2e56a2-1b8d-4670-959c-dbd360adea6d_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyPendingClaimsNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of pending lawsuits</link:label>
    <link:label id="lab_us-gaap_LossContingencyPendingClaimsNumber_label_en-US" xlink:label="lab_us-gaap_LossContingencyPendingClaimsNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Pending Claims, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyPendingClaimsNumber" xlink:to="lab_us-gaap_LossContingencyPendingClaimsNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock_9f37e799-79a4-4b58-ab1a-9273e9c6e8bd_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of asset acquisitions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Research and Development Assets Acquired Other than Through Business Combination [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock" xlink:to="lab_us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_99fc803f-59e4-4ce7-ad07-6c0314f50cde_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_LebrikizumabMember_359c1a49-41fe-4c26-9968-5789d0990f28_terseLabel_en-US" xlink:label="lab_lly_LebrikizumabMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lebrikizumab</link:label>
    <link:label id="lab_lly_LebrikizumabMember_label_en-US" xlink:label="lab_lly_LebrikizumabMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lebrikizumab [Member]</link:label>
    <link:label id="lab_lly_LebrikizumabMember_documentation_en-US" xlink:label="lab_lly_LebrikizumabMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lebrikizumab [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_LebrikizumabMember" xlink:href="lly-20220930.xsd#lly_LebrikizumabMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_LebrikizumabMember" xlink:to="lab_lly_LebrikizumabMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_14fd9ebf-3fb7-455e-b7b9-d3eecc53e044_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_NeuroscienceMember_2042bc04-7d8d-4cad-b176-a3ea2d85a42a_terseLabel_en-US" xlink:label="lab_lly_NeuroscienceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Neuroscience</link:label>
    <link:label id="lab_lly_NeuroscienceMember_label_en-US" xlink:label="lab_lly_NeuroscienceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Neuroscience [Member]</link:label>
    <link:label id="lab_lly_NeuroscienceMember_documentation_en-US" xlink:label="lab_lly_NeuroscienceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue to unaffiliated customers, Neuroscience</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_NeuroscienceMember" xlink:href="lly-20220930.xsd#lly_NeuroscienceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_NeuroscienceMember" xlink:to="lab_lly_NeuroscienceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnInvestments_433c4888-2bd9-4e41-800f-9540dc42c99e_negatedLabel_en-US" xlink:label="lab_us-gaap_GainLossOnInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net investment (gains) losses</link:label>
    <link:label id="lab_us-gaap_GainLossOnInvestments_label_en-US" xlink:label="lab_us-gaap_GainLossOnInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnInvestments" xlink:to="lab_us-gaap_GainLossOnInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_OtherDiabetesMember_3ebb579f-116a-405b-b984-f16a907d2372_terseLabel_en-US" xlink:label="lab_lly_OtherDiabetesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other diabetes</link:label>
    <link:label id="lab_lly_OtherDiabetesMember_label_en-US" xlink:label="lab_lly_OtherDiabetesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Diabetes [Member]</link:label>
    <link:label id="lab_lly_OtherDiabetesMember_documentation_en-US" xlink:label="lab_lly_OtherDiabetesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Diabetes [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OtherDiabetesMember" xlink:href="lly-20220930.xsd#lly_OtherDiabetesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_OtherDiabetesMember" xlink:to="lab_lly_OtherDiabetesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_f67dce3e-1189-4fe7-99d9-60f6f130625d_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsPolicy" xlink:to="lab_us-gaap_BusinessCombinationsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_db12cb69-ed07-4ebc-a216-024ab4b90724_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_6d1ee27b-dc72-46c6-abe3-7d4a6e65df24_negatedLabel_en-US" xlink:label="lab_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect from interest rate contracts</link:label>
    <link:label id="lab_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_label_en-US" xlink:label="lab_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" xlink:to="lab_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_262bc02f-7753-4bd0-89c6-d623236e028a_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of credit facility, maximum borrowing capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_56175a43-889a-4533-a53d-bbe656eea493_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent_ba718f57-6a72-45e4-b28f-0bba35457fc1_terseLabel_en-US" xlink:label="lab_lly_RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, information used to determine revenue recognized, change in accounting estimate, percent (less than)</link:label>
    <link:label id="lab_lly_RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent_label_en-US" xlink:label="lab_lly_RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Information Used To Determine Revenue Recognized, Change In Accounting Estimate, Percent</link:label>
    <link:label id="lab_lly_RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent_documentation_en-US" xlink:label="lab_lly_RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Information Used To Determine Revenue Recognized, Change In Accounting Estimate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent" xlink:href="lly-20220930.xsd#lly_RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent" xlink:to="lab_lly_RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockSharesRetired_3e91a439-09d7-40f5-8761-45a85c0603a1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesRetired" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement of treasury shares (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesRetired_label_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesRetired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares, Retired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesRetired" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockSharesRetired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockSharesRetired" xlink:to="lab_us-gaap_TreasuryStockSharesRetired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyDamagesAwardedValue_e4224ccd-7d89-4f6a-b851-80df52a5a415_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesAwardedValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Damages awarded, value</link:label>
    <link:label id="lab_us-gaap_LossContingencyDamagesAwardedValue_label_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesAwardedValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Damages Awarded, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesAwardedValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyDamagesAwardedValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyDamagesAwardedValue" xlink:to="lab_us-gaap_LossContingencyDamagesAwardedValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_0fde812d-ee5a-434e-83c9-f2cf7108c69c_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency exchange contracts</link:label>
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_label_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Exchange Contract [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignExchangeContractMember" xlink:to="lab_us-gaap_ForeignExchangeContractMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_89c985db-3265-422f-9dd8-5ca9a9e6c7fb_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6-10 Years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_39061abd-0bc9-4364-84ee-203b9d2bab61_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of other&#8211;net, (income) expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Other Nonoperating Income (Expense) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_82139d5a-3f93-43d5-b2cb-e3f2f547a542_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_86079e02-3651-4e67-a4bb-8ffd8887f065_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyNumberOfPlaintiffs_46ae7d91-398f-47d5-9b31-b36e984af4b2_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of plaintiffs</link:label>
    <link:label id="lab_us-gaap_LossContingencyNumberOfPlaintiffs_label_en-US" xlink:label="lab_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number of Plaintiffs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNumberOfPlaintiffs"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:to="lab_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_CashFlowHedgeAbstract_0fc7684f-fdc5-466b-b9a2-6c0e4fc2aabd_terseLabel_en-US" xlink:label="lab_lly_CashFlowHedgeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flow hedges:</link:label>
    <link:label id="lab_lly_CashFlowHedgeAbstract_label_en-US" xlink:label="lab_lly_CashFlowHedgeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow Hedge [Abstract]</link:label>
    <link:label id="lab_lly_CashFlowHedgeAbstract_documentation_en-US" xlink:label="lab_lly_CashFlowHedgeAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow Hedge [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CashFlowHedgeAbstract" xlink:href="lly-20220930.xsd#lly_CashFlowHedgeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_CashFlowHedgeAbstract" xlink:to="lab_lly_CashFlowHedgeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_9a761ba7-cb52-4aad-a870-147999716947_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other investing activities, net</link:label>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for (Proceeds from) Other Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:to="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_95bd38b3-081c-4bd6-806e-56aab126cf5b_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_RigelPharmaceuticalsIncMember_b54841f7-dac3-48a5-996c-9499b42ac46e_terseLabel_en-US" xlink:label="lab_lly_RigelPharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rigel Pharmaceuticals, Inc.</link:label>
    <link:label id="lab_lly_RigelPharmaceuticalsIncMember_label_en-US" xlink:label="lab_lly_RigelPharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rigel Pharmaceuticals, Inc. [Member]</link:label>
    <link:label id="lab_lly_RigelPharmaceuticalsIncMember_documentation_en-US" xlink:label="lab_lly_RigelPharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rigel Pharmaceuticals, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_RigelPharmaceuticalsIncMember" xlink:href="lly-20220930.xsd#lly_RigelPharmaceuticalsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_RigelPharmaceuticalsIncMember" xlink:to="lab_lly_RigelPharmaceuticalsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_MarketableSecuritiesMember_6b1f95f8-c45b-4eee-8350-a13da1a53a0b_terseLabel_en-US" xlink:label="lab_lly_MarketableSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable equity securities</link:label>
    <link:label id="lab_lly_MarketableSecuritiesMember_label_en-US" xlink:label="lab_lly_MarketableSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities [Member]</link:label>
    <link:label id="lab_lly_MarketableSecuritiesMember_documentation_en-US" xlink:label="lab_lly_MarketableSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MarketableSecuritiesMember" xlink:href="lly-20220930.xsd#lly_MarketableSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_MarketableSecuritiesMember" xlink:to="lab_lly_MarketableSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_08919980-aed4-4880-941f-a3de18ce2e7d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stated interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionTable_2992293d-671f-4fc8-a9a3-581ea56bab00_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionTable" xlink:to="lab_us-gaap_AssetAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_9da28eaa-4f60-41f3-be56-d8fa14200809_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_1af6dd95-065f-4f2f-ad51-5229dcf5120c_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Axis]</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_3ef1ef54-3a40-4054-bf7c-3c59e3d64cd6_totalLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net periodic benefit cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Net Periodic Benefit Cost (Credit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:to="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_43abc85c-43a6-446b-b23e-af24adccc082_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of treasury shares</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value, Acquired, Cost Method</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:to="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_55b856ec-6f85-4cf0-8760-16e7335c1322_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_2995b63e-f36c-4351-8a98-9bf981fdf05b_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_dd4cd869-56c3-469a-8ba0-90e039f92fad_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_72f81287-0841-44d8-8bd1-48f0ed800a0c_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1-5 Years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentInformationLineItems_4137f0ea-58d8-437e-a0c2-b9d8c5401cd4_terseLabel_en-US" xlink:label="lab_dei_DocumentInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:label id="lab_dei_DocumentInformationLineItems_label_en-US" xlink:label="lab_dei_DocumentInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationLineItems" xlink:to="lab_dei_DocumentInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_8deb8f6e-1623-430b-8a51-7138d2cc2807_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_a8a0390a-13af-4a86-a563-f5fee2617d33_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of prior service cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Amortization of Prior Service Cost (Credit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:to="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_475b4f2c-b869-46d8-85f9-2eea423dc57d_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_69b46084-f4fb-4e38-b5aa-356b2d0432f7_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementScenarioAxis_b6e9eb66-6895-49d6-82b0-8a5c198aa245_terseLabel_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:label id="lab_srt_StatementScenarioAxis_label_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockCommonValue_8a9245d8-088c-4b29-94a3-5bef10af8b0e_negatedLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonValue" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of common stock in treasury</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonValue_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Common, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonValue" xlink:to="lab_us-gaap_TreasuryStockCommonValue" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_AssetImpairmentChargesRecoveriesAndOtherSpecialCharges_ed2f1f26-0ddf-47fc-a147-702252e1cea2_terseLabel_en-US" xlink:label="lab_lly_AssetImpairmentChargesRecoveriesAndOtherSpecialCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset impairment and other special charges</link:label>
    <link:label id="lab_lly_AssetImpairmentChargesRecoveriesAndOtherSpecialCharges_label_en-US" xlink:label="lab_lly_AssetImpairmentChargesRecoveriesAndOtherSpecialCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Impairment Charges (Recoveries) And Other Special Charges</link:label>
    <link:label id="lab_lly_AssetImpairmentChargesRecoveriesAndOtherSpecialCharges_documentation_en-US" xlink:label="lab_lly_AssetImpairmentChargesRecoveriesAndOtherSpecialCharges" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Impairment Charges (Recoveries) And Other Special Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AssetImpairmentChargesRecoveriesAndOtherSpecialCharges" xlink:href="lly-20220930.xsd#lly_AssetImpairmentChargesRecoveriesAndOtherSpecialCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_AssetImpairmentChargesRecoveriesAndOtherSpecialCharges" xlink:to="lab_lly_AssetImpairmentChargesRecoveriesAndOtherSpecialCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_763b138b-846e-454a-bff2-dc74fdd54d81_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionSharePrice_88d0d2fb-f8d3-45df-900e-7d6613711949_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionSharePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business acquisition, share price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionSharePrice_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionSharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Share Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionSharePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionSharePrice" xlink:to="lab_us-gaap_BusinessAcquisitionSharePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_3d101374-3a68-46d5-8aa1-74c86fa98bda_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationDomain" xlink:to="lab_us-gaap_HedgingDesignationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_f486fccb-9474-4857-be64-dd19b7d99b59_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:to="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_EmployeeLitigationMember_496c3817-9949-4ce3-bd4e-b5f41e32e64b_terseLabel_en-US" xlink:label="lab_lly_EmployeeLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Litigation</link:label>
    <link:label id="lab_lly_EmployeeLitigationMember_label_en-US" xlink:label="lab_lly_EmployeeLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Litigation [Member]</link:label>
    <link:label id="lab_lly_EmployeeLitigationMember_documentation_en-US" xlink:label="lab_lly_EmployeeLitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Litigation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_EmployeeLitigationMember" xlink:href="lly-20220930.xsd#lly_EmployeeLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_EmployeeLitigationMember" xlink:to="lab_lly_EmployeeLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrent_a92a7cd1-fa8b-44b4-a2bc-338c05eee81b_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrent" xlink:to="lab_us-gaap_LiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_a3a8e960-e670-4839-a77d-a98d335a2a84_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_5c64e6aa-2216-4ab1-beb1-45847f911c2f_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_5749dc20-9793-41ba-9485-a0968d83093d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quoted Prices in Active Markets for Identical Assets (Level 1)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod_7527efe6-50a2-4d84-b06a-9ab02dbb4f7f_terseLabel_en-US" xlink:label="lab_lly_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alternative investments, unfunded commitments, payment period</link:label>
    <link:label id="lab_lly_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod_label_en-US" xlink:label="lab_lly_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Investments, Entities That Calculate Net Asset Value Per Share, Unfunded Commitments, Payment Period</link:label>
    <link:label id="lab_lly_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod_documentation_en-US" xlink:label="lab_lly_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Investments, Entities That Calculate Net Asset Value Per Share, Unfunded Commitments, Payment Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod" xlink:href="lly-20220930.xsd#lly_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod" xlink:to="lab_lly_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_36d26541-9e09-49cc-a370-18a163bf44f7_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Pension and Retiree&#160;Health Benefit Plans</link:label>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Defined Benefit Plans Adjustment Including Portion Attributable to Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:to="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_037eb0a9-9811-4bbe-8617-dfc3805c2de5_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by Operating Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_d7bfd5c8-9abc-47aa-a5e8-025598ed249b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary the contractual maturities of our investments in debt securities measured at fair value</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_InnoventBiologicsIncMember_e9f2fe92-ee3b-4b5d-9dc3-dfab14fc83ff_terseLabel_en-US" xlink:label="lab_lly_InnoventBiologicsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Innovent Biologics, Inc.</link:label>
    <link:label id="lab_lly_InnoventBiologicsIncMember_label_en-US" xlink:label="lab_lly_InnoventBiologicsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Innovent Biologics, Inc. [Member]</link:label>
    <link:label id="lab_lly_InnoventBiologicsIncMember_documentation_en-US" xlink:label="lab_lly_InnoventBiologicsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Innovent Biologics, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_InnoventBiologicsIncMember" xlink:href="lly-20220930.xsd#lly_InnoventBiologicsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_InnoventBiologicsIncMember" xlink:to="lab_lly_InnoventBiologicsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_OtherNeuroscienceMember_ef53ec98-7baa-47ac-9fbc-af9ea7aadd9e_terseLabel_en-US" xlink:label="lab_lly_OtherNeuroscienceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other neuroscience</link:label>
    <link:label id="lab_lly_OtherNeuroscienceMember_label_en-US" xlink:label="lab_lly_OtherNeuroscienceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Neuroscience [Member]</link:label>
    <link:label id="lab_lly_OtherNeuroscienceMember_documentation_en-US" xlink:label="lab_lly_OtherNeuroscienceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Neuroscience [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OtherNeuroscienceMember" xlink:href="lly-20220930.xsd#lly_OtherNeuroscienceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_OtherNeuroscienceMember" xlink:to="lab_lly_OtherNeuroscienceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_ae644560-4ad6-4d11-9c05-201803ea2ca9_terseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs, expenses, and other:</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract" xlink:to="lab_us-gaap_CostsAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent_35e1ce3a-ed89-4c43-bf89-0bc48022d1c7_terseLabel_en-US" xlink:label="lab_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement benefit plans</link:label>
    <link:label id="lab_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent_label_en-US" xlink:label="lab_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Periodic Defined Benefits Expense (Reversal of Expense), Excluding Service Cost Component</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent" xlink:to="lab_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet_3ff12e5b-9044-414a-9dd8-8f2269c7e9d8_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pretax net losses on cash flow hedges expected to be reclassified during the next 12 months</link:label>
    <link:label id="lab_us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet_label_en-US" xlink:label="lab_us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet" xlink:to="lab_us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ChangeInAccountingEstimateByTypeAxis_6c75d301-820c-4fc7-aac1-2207c33d2f0c_terseLabel_en-US" xlink:label="lab_us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Accounting Estimate by Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ChangeInAccountingEstimateByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Accounting Estimate by Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInAccountingEstimateByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:to="lab_us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_TrulicityMember_d592ec64-841e-443e-802f-8886ad0bda39_terseLabel_en-US" xlink:label="lab_lly_TrulicityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trulicity&#174;</link:label>
    <link:label id="lab_lly_TrulicityMember_label_en-US" xlink:label="lab_lly_TrulicityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trulicity [Member]</link:label>
    <link:label id="lab_lly_TrulicityMember_documentation_en-US" xlink:label="lab_lly_TrulicityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trulicity [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_TrulicityMember" xlink:href="lly-20220930.xsd#lly_TrulicityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_TrulicityMember" xlink:to="lab_lly_TrulicityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LegalEntityAxis_1793316a-426a-4183-9d22-3b85830ef924_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_label_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_0b922d95-f291-4834-abf7-3b96442c9244_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ChangeInAccountingEstimateTypeDomain_b774c277-8575-41f8-8d46-805d2e196ccc_terseLabel_en-US" xlink:label="lab_us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Accounting Estimate, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ChangeInAccountingEstimateTypeDomain_label_en-US" xlink:label="lab_us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Accounting Estimate, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInAccountingEstimateTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:to="lab_us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_ByettaMember_6b5a8283-936a-476a-ad13-64aae74a1471_terseLabel_en-US" xlink:label="lab_lly_ByettaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Byetta</link:label>
    <link:label id="lab_lly_ByettaMember_label_en-US" xlink:label="lab_lly_ByettaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Byetta [Member]</link:label>
    <link:label id="lab_lly_ByettaMember_documentation_en-US" xlink:label="lab_lly_ByettaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Byetta</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ByettaMember" xlink:href="lly-20220930.xsd#lly_ByettaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_ByettaMember" xlink:to="lab_lly_ByettaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_ec4ef4ca-a480-4652-85d1-672a48637ed0_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective portion of losses on interest rate contracts reclassified from accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_064208df-e419-45c0-814c-bd2ecebddd77_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f1f9a5d7-4aa2-49de-becf-4f09fa592c4b_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flows from Investing Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_OtherForeignCountriesMember_aaf50c81-5256-4a68-892d-0a6c90c8fda0_terseLabel_en-US" xlink:label="lab_lly_OtherForeignCountriesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other foreign countries</link:label>
    <link:label id="lab_lly_OtherForeignCountriesMember_label_en-US" xlink:label="lab_lly_OtherForeignCountriesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Foreign Countries [Member]</link:label>
    <link:label id="lab_lly_OtherForeignCountriesMember_documentation_en-US" xlink:label="lab_lly_OtherForeignCountriesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Foreign Countries [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OtherForeignCountriesMember" xlink:href="lly-20220930.xsd#lly_OtherForeignCountriesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_OtherForeignCountriesMember" xlink:to="lab_lly_OtherForeignCountriesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_0f5f572a-242c-44d2-8b02-86f89af6566b_terseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued retirement benefits (Note 8)</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability, Defined Benefit Plan, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" xlink:to="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_f68a5dd6-10b9-4150-b44d-351c14475f16_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_CollaborativeArrangementRightsAndObligationsRightsObligations_2cf94d7c-5f25-43cb-a4a1-3859b9d66de8_terseLabel_en-US" xlink:label="lab_lly_CollaborativeArrangementRightsAndObligationsRightsObligations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential achievements</link:label>
    <link:label id="lab_lly_CollaborativeArrangementRightsAndObligationsRightsObligations_label_en-US" xlink:label="lab_lly_CollaborativeArrangementRightsAndObligationsRightsObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Rights (Obligations)</link:label>
    <link:label id="lab_lly_CollaborativeArrangementRightsAndObligationsRightsObligations_documentation_en-US" xlink:label="lab_lly_CollaborativeArrangementRightsAndObligationsRightsObligations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Terms or rights and obligations under collaborative arrangements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CollaborativeArrangementRightsAndObligationsRightsObligations" xlink:href="lly-20220930.xsd#lly_CollaborativeArrangementRightsAndObligationsRightsObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_CollaborativeArrangementRightsAndObligationsRightsObligations" xlink:to="lab_lly_CollaborativeArrangementRightsAndObligationsRightsObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_8ae94fec-7bcc-4063-9c6b-6b1e781a6c25_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of reclassifications out of accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilitiesCurrent_ff618e34-0d5a-4d03-b58c-ee422af7527e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilitiesCurrent" xlink:to="lab_us-gaap_DerivativeLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_1426f787-bbcd-4fe7-8fc5-355a8a98976e_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_61097236-1a34-4a82-bce2-e8ab97d6b5e1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_01dae180-f15d-428c-89b6-35545c46d891_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of significant milestones and revenue recognized</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_BasaglarMember_3a7ef6cd-3993-4cb2-8702-466b3763541d_terseLabel_en-US" xlink:label="lab_lly_BasaglarMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basaglar&#174;</link:label>
    <link:label id="lab_lly_BasaglarMember_e73e90a5-cd01-4a00-a304-8b5bbb003a1b_verboseLabel_en-US" xlink:label="lab_lly_BasaglarMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basaglar</link:label>
    <link:label id="lab_lly_BasaglarMember_label_en-US" xlink:label="lab_lly_BasaglarMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basaglar [Member]</link:label>
    <link:label id="lab_lly_BasaglarMember_documentation_en-US" xlink:label="lab_lly_BasaglarMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basaglar [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BasaglarMember" xlink:href="lly-20220930.xsd#lly_BasaglarMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_BasaglarMember" xlink:to="lab_lly_BasaglarMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_8f1ce547-fd50-4f89-ab70-995c54754b15_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_76d2d67d-fd17-42b5-87ba-1b80df237937_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfChangeInAccountingEstimateTable_0f9b0246-2582-49c9-a7a5-b3be6167fec6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfChangeInAccountingEstimateTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Change in Accounting Estimate [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfChangeInAccountingEstimateTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfChangeInAccountingEstimateTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Change in Accounting Estimate [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfChangeInAccountingEstimateTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfChangeInAccountingEstimateTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfChangeInAccountingEstimateTable" xlink:to="lab_us-gaap_ScheduleOfChangeInAccountingEstimateTable" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_BusinessAcquisitionContingentValueRightRegulatoryApprovalDelayMonthlyReduction_20ab858c-5f05-43f1-ab44-944fae1ff8f2_terseLabel_en-US" xlink:label="lab_lly_BusinessAcquisitionContingentValueRightRegulatoryApprovalDelayMonthlyReduction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent value right, monthly reduction (in cents per share)</link:label>
    <link:label id="lab_lly_BusinessAcquisitionContingentValueRightRegulatoryApprovalDelayMonthlyReduction_label_en-US" xlink:label="lab_lly_BusinessAcquisitionContingentValueRightRegulatoryApprovalDelayMonthlyReduction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Contingent Value Right, Regulatory Approval Delay, Monthly Reduction</link:label>
    <link:label id="lab_lly_BusinessAcquisitionContingentValueRightRegulatoryApprovalDelayMonthlyReduction_documentation_en-US" xlink:label="lab_lly_BusinessAcquisitionContingentValueRightRegulatoryApprovalDelayMonthlyReduction" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Contingent Value Right, Covenant, Regulatory Approval Occurs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BusinessAcquisitionContingentValueRightRegulatoryApprovalDelayMonthlyReduction" xlink:href="lly-20220930.xsd#lly_BusinessAcquisitionContingentValueRightRegulatoryApprovalDelayMonthlyReduction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_BusinessAcquisitionContingentValueRightRegulatoryApprovalDelayMonthlyReduction" xlink:to="lab_lly_BusinessAcquisitionContingentValueRightRegulatoryApprovalDelayMonthlyReduction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeveranceCosts1_1f44d58b-4405-4d59-a31d-6e8197b796a4_terseLabel_en-US" xlink:label="lab_us-gaap_SeveranceCosts1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Severance</link:label>
    <link:label id="lab_us-gaap_SeveranceCosts1_label_en-US" xlink:label="lab_us-gaap_SeveranceCosts1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Severance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeveranceCosts1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeveranceCosts1" xlink:to="lab_us-gaap_SeveranceCosts1" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet_344c6a24-c4d4-44aa-ba06-0d1ed064934d_terseLabel_en-US" xlink:label="lab_lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets and liabilities, net</link:label>
    <link:label id="lab_lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet_label_en-US" xlink:label="lab_lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Assets (Liabilities), Net</link:label>
    <link:label id="lab_lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet_documentation_en-US" xlink:label="lab_lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Assets (Liabilities), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet" xlink:href="lly-20220930.xsd#lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet" xlink:to="lab_lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionAxis_e3b0fa05-141c-43f6-8d54-c5ad12aca17c_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionAxis" xlink:to="lab_us-gaap_AssetAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_c4603659-fab4-4dad-b9a2-e9f0b0e4534c_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember_58e9b4e0-5077-462d-a61e-f955db882833_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective portion of cash flow hedges</link:label>
    <link:label id="lab_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Gain (Loss), Cash Flow Hedge, Including Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember" xlink:to="lab_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_25d3a02a-056b-4075-aec3-126e1dc96668_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_AccumulatedGainLossNetCashFlowHedgeAndForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_b6001daf-ecd9-4269-ab72-1f9afb73a1a7_terseLabel_en-US" xlink:label="lab_lly_AccumulatedGainLossNetCashFlowHedgeAndForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other, net of tax</link:label>
    <link:label id="lab_lly_AccumulatedGainLossNetCashFlowHedgeAndForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_label_en-US" xlink:label="lab_lly_AccumulatedGainLossNetCashFlowHedgeAndForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Gain (Loss), Net, Cash Flow Hedge And Foreign Currency Adjustment, Including Portion Attributable To Noncontrolling Interest [Member]</link:label>
    <link:label id="lab_lly_AccumulatedGainLossNetCashFlowHedgeAndForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_documentation_en-US" xlink:label="lab_lly_AccumulatedGainLossNetCashFlowHedgeAndForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Gain (Loss), Net, Cash Flow Hedge And Foreign Currency Adjustment, Including Portion Attributable To Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AccumulatedGainLossNetCashFlowHedgeAndForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:href="lly-20220930.xsd#lly_AccumulatedGainLossNetCashFlowHedgeAndForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_AccumulatedGainLossNetCashFlowHedgeAndForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:to="lab_lly_AccumulatedGainLossNetCashFlowHedgeAndForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_9ba3091c-d923-4505-bb81-e69f8b77d707_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_4ae79ac8-c563-4fec-b73c-7f233897d8c0_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective portion of risk-management instruments that was recognized in other comprehensive income (loss), cash flow hedges</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_LossContingencyNumberOfPatents_795a1034-32a1-464a-a570-198b02c96b76_terseLabel_en-US" xlink:label="lab_lly_LossContingencyNumberOfPatents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of patents</link:label>
    <link:label id="lab_lly_LossContingencyNumberOfPatents_label_en-US" xlink:label="lab_lly_LossContingencyNumberOfPatents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number Of Patents</link:label>
    <link:label id="lab_lly_LossContingencyNumberOfPatents_documentation_en-US" xlink:label="lab_lly_LossContingencyNumberOfPatents" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number Of Patents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_LossContingencyNumberOfPatents" xlink:href="lly-20220930.xsd#lly_LossContingencyNumberOfPatents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_LossContingencyNumberOfPatents" xlink:to="lab_lly_LossContingencyNumberOfPatents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_66450b60-de1f-409c-bdb5-ddd28a32e3e1_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_6a6955e1-85de-4287-8be3-766ddd5caf63_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of amounts recorded for contract liabilities</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:to="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_de2e23e2-9c6e-415a-9c81-7ab74af0b66a_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock_1b9de6be-5553-45a1-85b8-a87a995b1b04_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Impairment, Restructuring, and Other Special Charges</link:label>
    <link:label id="lab_us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring, Impairment, and Other Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock" xlink:to="lab_us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_PrecisionBiosciencesIncMember_540beb0f-62cc-4104-a3a0-f4faf5d51de9_terseLabel_en-US" xlink:label="lab_lly_PrecisionBiosciencesIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Precision Biosciences, Inc.</link:label>
    <link:label id="lab_lly_PrecisionBiosciencesIncMember_label_en-US" xlink:label="lab_lly_PrecisionBiosciencesIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Precision Biosciences, Inc. [Member]</link:label>
    <link:label id="lab_lly_PrecisionBiosciencesIncMember_documentation_en-US" xlink:label="lab_lly_PrecisionBiosciencesIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Precision Biosciences, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_PrecisionBiosciencesIncMember" xlink:href="lly-20220930.xsd#lly_PrecisionBiosciencesIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_PrecisionBiosciencesIncMember" xlink:to="lab_lly_PrecisionBiosciencesIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_5b957b19-bb97-4146-9527-c228ff541146_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of components of other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_b6c3d830-fb9d-4654-b247-4b4ee26c05f2_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringSettlementAndImpairmentProvisions_9c429dd8-8dcf-47cf-97d3-ca4eafb0b3b8_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringSettlementAndImpairmentProvisions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset impairment, restructuring, and other special charges (Note 5)</link:label>
    <link:label id="lab_us-gaap_RestructuringSettlementAndImpairmentProvisions_736c0fe7-eae5-40e6-b960-984382825a6e_totalLabel_en-US" xlink:label="lab_us-gaap_RestructuringSettlementAndImpairmentProvisions" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total asset impairment, restructuring, and other special charges</link:label>
    <link:label id="lab_us-gaap_RestructuringSettlementAndImpairmentProvisions_label_en-US" xlink:label="lab_us-gaap_RestructuringSettlementAndImpairmentProvisions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring, Settlement and Impairment Provisions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringSettlementAndImpairmentProvisions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringSettlementAndImpairmentProvisions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringSettlementAndImpairmentProvisions" xlink:to="lab_us-gaap_RestructuringSettlementAndImpairmentProvisions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_fa49b780-d84a-473e-a325-17df2af821c3_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings per share:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_f1ac9841-a681-410a-974d-1b8cd406672e_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNi" xlink:to="lab_us-gaap_EquitySecuritiesFvNi" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestRateSwapMember_a9b59754-ac74-4cf0-9047-314a60ebbedb_terseLabel_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forward-starting interest rate swaps</link:label>
    <link:label id="lab_us-gaap_InterestRateSwapMember_label_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Swap [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateSwapMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestRateSwapMember" xlink:to="lab_us-gaap_InterestRateSwapMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_TaltzMember_facbb068-3556-4357-a3c2-1850865c20bd_terseLabel_en-US" xlink:label="lab_lly_TaltzMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taltz&#174;</link:label>
    <link:label id="lab_lly_TaltzMember_label_en-US" xlink:label="lab_lly_TaltzMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taltz [Member]</link:label>
    <link:label id="lab_lly_TaltzMember_documentation_en-US" xlink:label="lab_lly_TaltzMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taltz [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_TaltzMember" xlink:href="lly-20220930.xsd#lly_TaltzMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_TaltzMember" xlink:to="lab_lly_TaltzMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_f7edce88-7a3f-4a43-bafb-0c595ad36653_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Used for Financing Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermInvestments_8ae223b0-2fad-4bd1-bf44-1081a1318154_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments (Note 6)</link:label>
    <link:label id="lab_us-gaap_LongTermInvestments_2e184cfa-6ae8-46ea-b882-ba7a699e8bef_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermInvestments" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncurrent investments</link:label>
    <link:label id="lab_us-gaap_LongTermInvestments_label_en-US" xlink:label="lab_us-gaap_LongTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermInvestments" xlink:to="lab_us-gaap_LongTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_dc6a0312-462a-448f-b211-0c406bfa61df_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock repurchase program, authorized amount</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Authorized Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_66eccdcf-d0eb-40ce-bba0-7e0fbe3a89f9_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee compensation</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_2915bcf7-c176-49cd-bd0d-629925b71148_terseLabel_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset-backed securities</link:label>
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset-Backed Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetBackedSecuritiesMember" xlink:to="lab_us-gaap_AssetBackedSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_580f3742-bc28-4569-ac12-82dbe204a771_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2bbf74fd-f552-4db8-9691-9e73419f77de_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total before tax</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_a568b57c-e300-462d-af07-96fa182963ed_negatedLabel_en-US" xlink:label="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (gains) losses on foreign currency exchange contracts not designated as hedging instruments</link:label>
    <link:label id="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_label_en-US" xlink:label="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:to="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A395NotesDue2049Member_aee33cd4-5267-4759-aade-c1545ed32066_terseLabel_en-US" xlink:label="lab_lly_A395NotesDue2049Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.95% Notes Due 2049</link:label>
    <link:label id="lab_lly_A395NotesDue2049Member_label_en-US" xlink:label="lab_lly_A395NotesDue2049Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.95% Notes Due 2049 [Member]</link:label>
    <link:label id="lab_lly_A395NotesDue2049Member_documentation_en-US" xlink:label="lab_lly_A395NotesDue2049Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.95% Notes Due 2049 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A395NotesDue2049Member" xlink:href="lly-20220930.xsd#lly_A395NotesDue2049Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A395NotesDue2049Member" xlink:to="lab_lly_A395NotesDue2049Member" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_VerzenioMember_18d05b27-eb59-4682-b407-7970196fc56d_terseLabel_en-US" xlink:label="lab_lly_VerzenioMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Verzenio&#174;</link:label>
    <link:label id="lab_lly_VerzenioMember_label_en-US" xlink:label="lab_lly_VerzenioMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Verzenio [Member]</link:label>
    <link:label id="lab_lly_VerzenioMember_documentation_en-US" xlink:label="lab_lly_VerzenioMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Verzenio [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_VerzenioMember" xlink:href="lly-20220930.xsd#lly_VerzenioMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_VerzenioMember" xlink:to="lab_lly_VerzenioMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_2f9be36e-aba5-48d9-9686-7800f4a7c65c_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Translation Gains&#160;(Losses)</link:label>
    <link:label id="lab_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Foreign Currency Adjustment Including Portion Attributable to Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:to="lab_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanInterestCost_4bb5f5bb-ad02-44be-abd7-0395f81c3874_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanInterestCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanInterestCost_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanInterestCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Interest Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanInterestCost" xlink:to="lab_us-gaap_DefinedBenefitPlanInterestCost" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A415NotesDue2059Member_0ea6870e-c1df-448f-8e67-873ab4f5d931_terseLabel_en-US" xlink:label="lab_lly_A415NotesDue2059Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.15% Notes Due 2059</link:label>
    <link:label id="lab_lly_A415NotesDue2059Member_label_en-US" xlink:label="lab_lly_A415NotesDue2059Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.15% Notes Due 2059 [Member]</link:label>
    <link:label id="lab_lly_A415NotesDue2059Member_documentation_en-US" xlink:label="lab_lly_A415NotesDue2059Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.15% Notes Due 2059 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A415NotesDue2059Member" xlink:href="lly-20220930.xsd#lly_A415NotesDue2059Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A415NotesDue2059Member" xlink:to="lab_lly_A415NotesDue2059Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_fd22ecc0-5e69-4f50-9fb3-e88f45d5da0c_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss), net of tax</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_fbc4a3c1-9de3-40f1-9f0a-fd62da5fb9b9_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective portion of risk-management instruments that was recognized in other comprehensive income (loss), net investment hedges</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_82a41c6b-4c3e-47d6-b148-454fec8d8e5f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt extinguishment loss (Note 6)</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_ae7462b1-1584-4bdf-afda-f72fb0f4eacb_negatedLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on extinguishment of debt</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_label_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxContingencyTable_2c68b1eb-2869-49da-8d62-2fe9b85ec545_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxContingencyTable_label_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxContingencyTable" xlink:to="lab_us-gaap_IncomeTaxContingencyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_058fad4d-7fe5-4b47-b937-101064cf9e6b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of effects of risk-management instruments were recognized in other&#8211;net, (income) expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Derivatives Instruments Statements of Financial Performance and Financial Position, Location [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_7f8ac585-3232-47c3-8fde-8ed8baa89035_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss) before reclassifications</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), before Reclassifications, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_f8e8461d-4e5e-4d55-940c-20afd44359ee_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to acquire businesses</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock_c0f709b1-4054-41f5-a9dd-f73fa109df77_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of fair value, by balance sheet grouping</link:label>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByBalanceSheetGroupingTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:to="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_f0a96d3a-dbe2-47cb-9153-93ee3d2d9a69_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_label_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeContractTypeDomain" xlink:to="lab_us-gaap_DerivativeContractTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetInvestmentHedgingMember_d24ba4e8-08d7-4a2c-b0fe-53cb02171874_terseLabel_en-US" xlink:label="lab_us-gaap_NetInvestmentHedgingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Investment Hedges</link:label>
    <link:label id="lab_us-gaap_NetInvestmentHedgingMember_label_en-US" xlink:label="lab_us-gaap_NetInvestmentHedgingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Investment Hedging [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetInvestmentHedgingMember" xlink:to="lab_us-gaap_NetInvestmentHedgingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_a672fe63-30ec-4573-8273-a3e35367d34c_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_country_CN_a87b582c-e531-440e-86c9-81191748c8f3_terseLabel_en-US" xlink:label="lab_country_CN" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">China</link:label>
    <link:label id="lab_country_CN_label_en-US" xlink:label="lab_country_CN" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CHINA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_CN" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CN"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_CN" xlink:to="lab_country_CN" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_EquityMethodAndOtherInvestmentsMember_c1ae3dfa-b043-4562-aa69-40540af5d25d_verboseLabel_en-US" xlink:label="lab_lly_EquityMethodAndOtherInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity method investments</link:label>
    <link:label id="lab_lly_EquityMethodAndOtherInvestmentsMember_label_en-US" xlink:label="lab_lly_EquityMethodAndOtherInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method And Other Investments [Member]</link:label>
    <link:label id="lab_lly_EquityMethodAndOtherInvestmentsMember_documentation_en-US" xlink:label="lab_lly_EquityMethodAndOtherInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method and Other Investments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_EquityMethodAndOtherInvestmentsMember" xlink:href="lly-20220930.xsd#lly_EquityMethodAndOtherInvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_EquityMethodAndOtherInvestmentsMember" xlink:to="lab_lly_EquityMethodAndOtherInvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_0cb5bc58-ea95-44d3-bc02-6d091adecd2d_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_59965089-0794-41f5-870f-974b8b55e6dc_terseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_84e0fa5b-db2a-4b28-a327-7db9895a882b_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_5cfc44df-9f71-4532-9eda-c662307ad6ca_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_f7d79f76-548a-4dff-9390-f5b9842271a6_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_279d079a-bd57-4256-b316-62068754ed21_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_OtherOncologyMember_40c11958-4ea5-46a5-aa08-4d32f6d1fb26_terseLabel_en-US" xlink:label="lab_lly_OtherOncologyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other oncology</link:label>
    <link:label id="lab_lly_OtherOncologyMember_label_en-US" xlink:label="lab_lly_OtherOncologyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Oncology [Member]</link:label>
    <link:label id="lab_lly_OtherOncologyMember_documentation_en-US" xlink:label="lab_lly_OtherOncologyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Oncology [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OtherOncologyMember" xlink:href="lly-20220930.xsd#lly_OtherOncologyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_OtherOncologyMember" xlink:to="lab_lly_OtherOncologyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterest_ac0ca8b5-0d0f-4acc-ad4d-9af9172f20fb_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_label_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest" xlink:to="lab_us-gaap_MinorityInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_43581086-7d95-4f5e-a317-c5994e762f3c_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_ff45f47d-60ba-481b-9bbe-6b566bc7592a_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RoyaltyMember_fc547647-b768-4954-bf38-6f75883dbd11_terseLabel_en-US" xlink:label="lab_us-gaap_RoyaltyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and other revenue associated with prior period transfers of intellectual property</link:label>
    <link:label id="lab_us-gaap_RoyaltyMember_label_en-US" xlink:label="lab_us-gaap_RoyaltyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyMember" xlink:to="lab_us-gaap_RoyaltyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWriteDown_9d297fb4-3ebb-4bff-af7c-85cb8692d220_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWriteDown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory write-down</link:label>
    <link:label id="lab_us-gaap_InventoryWriteDown_label_en-US" xlink:label="lab_us-gaap_InventoryWriteDown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Write-down</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWriteDown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWriteDown" xlink:to="lab_us-gaap_InventoryWriteDown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_82ad1682-a11d-48c2-b3fe-1676ced7c489_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired IPR&amp;D</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_539650f4-2e49-40a7-902e-a54fb696cd42_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_country_BR_a740912e-710b-446d-859b-31b4758daf84_terseLabel_en-US" xlink:label="lab_country_BR" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Brazil</link:label>
    <link:label id="lab_country_BR_label_en-US" xlink:label="lab_country_BR" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BRAZIL</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_BR" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_BR"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_BR" xlink:to="lab_country_BR" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockCommonMember_4d7ebd94-d5d9-4617-bb8e-98690a663e9a_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock in Treasury</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonMember_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Common [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonMember" xlink:to="lab_us-gaap_TreasuryStockCommonMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionPlansDefinedBenefitMember_c638a427-6088-4523-8eee-bec87f2fe287_verboseLabel_en-US" xlink:label="lab_us-gaap_PensionPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Pension Plans</link:label>
    <link:label id="lab_us-gaap_PensionPlansDefinedBenefitMember_label_en-US" xlink:label="lab_us-gaap_PensionPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionPlansDefinedBenefitMember" xlink:to="lab_us-gaap_PensionPlansDefinedBenefitMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_c6c64d98-2218-4ca9-b738-fd9b878cdac9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_155963de-96eb-4632-9a97-b95458f3e4c2_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_label_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:to="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_91ad99b3-2798-4d86-9fff-3f15f355f810_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_76293c2d-b9da-4694-a61b-0b2a5645e588_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_HedgedFixedRateDebtMember_8069d073-67b1-4ae9-aedb-99d0485e850f_terseLabel_en-US" xlink:label="lab_lly_HedgedFixedRateDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency-denominated notes</link:label>
    <link:label id="lab_lly_HedgedFixedRateDebtMember_label_en-US" xlink:label="lab_lly_HedgedFixedRateDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedged Fixed Rate Debt [Member]</link:label>
    <link:label id="lab_lly_HedgedFixedRateDebtMember_documentation_en-US" xlink:label="lab_lly_HedgedFixedRateDebtMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedged Fixed-Rate Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_HedgedFixedRateDebtMember" xlink:href="lly-20220930.xsd#lly_HedgedFixedRateDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_HedgedFixedRateDebtMember" xlink:to="lab_lly_HedgedFixedRateDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_2349e4f2-df29-4447-b83b-ad4720114b56_periodStartLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_587bfec5-8c50-4c71-a6fa-6e0df32062c8_periodEndLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Common, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonShares" xlink:to="lab_us-gaap_TreasuryStockCommonShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_14303b9a-0151-42f8-a8d2-50cff012c3fd_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_AcquiredInProcessResearchAndDevelopment_66a66516-8de9-4b30-be12-555fab4a634e_terseLabel_en-US" xlink:label="lab_lly_AcquiredInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired in-process research and development</link:label>
    <link:label id="lab_lly_AcquiredInProcessResearchAndDevelopment_label_en-US" xlink:label="lab_lly_AcquiredInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired In-process Research And Development</link:label>
    <link:label id="lab_lly_AcquiredInProcessResearchAndDevelopment_documentation_en-US" xlink:label="lab_lly_AcquiredInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The amount of EXPENSE related to research and development assets that are acquired in a business combination (pre-141R) and/or licensing arrangement that have no alternative future use and are therefore written off in the period of acquisition (INCOME STATEMENT)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AcquiredInProcessResearchAndDevelopment" xlink:href="lly-20220930.xsd#lly_AcquiredInProcessResearchAndDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_AcquiredInProcessResearchAndDevelopment" xlink:to="lab_lly_AcquiredInProcessResearchAndDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_319203dd-9da8-456a-9fc9-89e6d2db214e_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireShortTermInvestments_573bd3e4-1229-4a3f-9c2a-9913371c94d4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of short-term investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Short-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_f5a6aa8c-8fe8-40bd-b8c9-8da0d4fbdac2_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of Derivative Risk Management</link:label>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesPolicyTextBlock" xlink:to="lab_us-gaap_DerivativesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_2991824a-2abd-4649-a843-79451475c5b6_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective income tax rate, percentage</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_eb844bb1-f2bd-4f78-8e35-287ae4764ced_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilityNotionalAmount_f8756527-e988-449a-86fe-b3e467b0de2f_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative liability, notional amount</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilityNotionalAmount_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Notional Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityNotionalAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilityNotionalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilityNotionalAmount" xlink:to="lab_us-gaap_DerivativeLiabilityNotionalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_9bbdff26-22d3-498c-8b98-4266f9682013_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_c76b5828-4fb9-4594-b2ca-b20d9781e97d_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition date fair value of consideration transferred</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_FairValueHedgeAbstract_1c4f8c18-ffbd-4862-83f7-de241b5ee0db_terseLabel_en-US" xlink:label="lab_lly_FairValueHedgeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value hedges:</link:label>
    <link:label id="lab_lly_FairValueHedgeAbstract_label_en-US" xlink:label="lab_lly_FairValueHedgeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hedge [Abstract]</link:label>
    <link:label id="lab_lly_FairValueHedgeAbstract_documentation_en-US" xlink:label="lab_lly_FairValueHedgeAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hedge [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_FairValueHedgeAbstract" xlink:href="lly-20220930.xsd#lly_FairValueHedgeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_FairValueHedgeAbstract" xlink:to="lab_lly_FairValueHedgeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Revenues_f661bb05-e281-41e7-8f10-69eb132cac60_verboseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue (Note 2)</link:label>
    <link:label id="lab_us-gaap_Revenues_2ae35656-a303-4b5a-930f-ada0090d1eae_terseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_Revenues_label_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_ab3ea61d-b459-429e-b8aa-979261a2c7e6_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember_3782bd3d-24a4-4ad4-b98e-b16ba0a875cd_terseLabel_en-US" xlink:label="lab_lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments, Development and Regulatory, Capitalized (Deferred), Cumulative</link:label>
    <link:label id="lab_lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember_label_en-US" xlink:label="lab_lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments, Development and Regulatory, Capitalized (Deferred), Cumulative [Member]</link:label>
    <link:label id="lab_lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember_documentation_en-US" xlink:label="lab_lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments, Development and Regulatory, Capitalized, Cumulative [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember" xlink:href="lly-20220930.xsd#lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember" xlink:to="lab_lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDebtExtinguishmentCosts_53457dfb-500f-45e7-a910-4c987bd4610d_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment for debt extinguishment</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDebtExtinguishmentCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment for Debt Extinguishment or Debt Prepayment Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDebtExtinguishmentCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:to="lab_us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_AlimtaMember_9515e2dc-1a35-416e-b088-3fb700014928_terseLabel_en-US" xlink:label="lab_lly_AlimtaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alimta&#174;</link:label>
    <link:label id="lab_lly_AlimtaMember_label_en-US" xlink:label="lab_lly_AlimtaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alimta [Member]</link:label>
    <link:label id="lab_lly_AlimtaMember_documentation_en-US" xlink:label="lab_lly_AlimtaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alimta [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AlimtaMember" xlink:href="lly-20220930.xsd#lly_AlimtaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_AlimtaMember" xlink:to="lab_lly_AlimtaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_8dd78a29-606c-4381-9eee-ac47f6184e46_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems_7b6ec034-464f-4207-9542-c3957155f083_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_SwapSwissFrancsToU.S.DollarsMember_4b7f660f-7d88-47fa-a6d6-21a5eed046e0_terseLabel_en-US" xlink:label="lab_lly_SwapSwissFrancsToU.S.DollarsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Swap Swiss Francs to U.S. Dollars</link:label>
    <link:label id="lab_lly_SwapSwissFrancsToU.S.DollarsMember_label_en-US" xlink:label="lab_lly_SwapSwissFrancsToU.S.DollarsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Swap Swiss Francs To U.S. Dollars [Member]</link:label>
    <link:label id="lab_lly_SwapSwissFrancsToU.S.DollarsMember_documentation_en-US" xlink:label="lab_lly_SwapSwissFrancsToU.S.DollarsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Swap Swiss Francs To U.S. Dollars [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_SwapSwissFrancsToU.S.DollarsMember" xlink:href="lly-20220930.xsd#lly_SwapSwissFrancsToU.S.DollarsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_SwapSwissFrancsToU.S.DollarsMember" xlink:to="lab_lly_SwapSwissFrancsToU.S.DollarsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_c1dd5fc7-5bac-4290-9b12-90a0b95e1ffb_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Eli Lilly and Company shareholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_13643881-1739-4d65-ab57-a1b017ce32f5_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at January&#160;1</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_511e566f-6cb8-4079-9dd1-1188e2c6a86f_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents at September 30</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_4af9f769-fc10-4a41-9e0d-4a042dcdf781_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseCurrent" xlink:to="lab_us-gaap_PrepaidExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_ErbituxMember_5ad85df7-80cb-4ff6-9a2c-f7eb64b52082_terseLabel_en-US" xlink:label="lab_lly_ErbituxMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Erbitux&#174;</link:label>
    <link:label id="lab_lly_ErbituxMember_label_en-US" xlink:label="lab_lly_ErbituxMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Erbitux [Member]</link:label>
    <link:label id="lab_lly_ErbituxMember_documentation_en-US" xlink:label="lab_lly_ErbituxMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Erbitux [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ErbituxMember" xlink:href="lly-20220930.xsd#lly_ErbituxMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_ErbituxMember" xlink:to="lab_lly_ErbituxMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_5bfa30b1-3d43-4514-8563-1ee18c21a35d_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A718NotesDueJune12025Member_2c9ed6fd-d86e-4436-bc6a-313fb5ff4b05_terseLabel_en-US" xlink:label="lab_lly_A718NotesDueJune12025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">7 1/8% Notes due 2025</link:label>
    <link:label id="lab_lly_A718NotesDueJune12025Member_label_en-US" xlink:label="lab_lly_A718NotesDueJune12025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">7 1/8% Notes Due June&#160;1, 2025 [Member]</link:label>
    <link:label id="lab_lly_A718NotesDueJune12025Member_documentation_en-US" xlink:label="lab_lly_A718NotesDueJune12025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">7 1/8% Notes Due June&#160;1, 2025 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A718NotesDueJune12025Member" xlink:href="lly-20220930.xsd#lly_A718NotesDueJune12025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A718NotesDueJune12025Member" xlink:to="lab_lly_A718NotesDueJune12025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized_faad9bb9-eae3-4bd2-a6a0-f2cf8e7df68a_terseLabel_en-US" xlink:label="lab_us-gaap_TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of receivable derecognized</link:label>
    <link:label id="lab_us-gaap_TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized_label_en-US" xlink:label="lab_us-gaap_TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transfer of Financial Assets Accounted for as Sales, Amount Derecognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized" xlink:to="lab_us-gaap_TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A500NotesDue2033Member_c053ab6b-2918-4cfa-9690-625f8d92105e_terseLabel_en-US" xlink:label="lab_lly_A500NotesDue2033Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.500% Notes due 2033</link:label>
    <link:label id="lab_lly_A500NotesDue2033Member_label_en-US" xlink:label="lab_lly_A500NotesDue2033Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">.500% Notes Due 2033 [Member]</link:label>
    <link:label id="lab_lly_A500NotesDue2033Member_documentation_en-US" xlink:label="lab_lly_A500NotesDue2033Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">.500% Notes Due 2033 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A500NotesDue2033Member" xlink:href="lly-20220930.xsd#lly_A500NotesDue2033Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A500NotesDue2033Member" xlink:to="lab_lly_A500NotesDue2033Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_2cccc79d-287a-4f02-a6f6-718dc3ac3369_terseLabel_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion at Fair Value Measurement</link:label>
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion at Fair Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:to="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDividends_fd7cb790-2759-4b17-bf3c-aaacdf91a3f1_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDividends" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends paid</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDividends_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDividends" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Dividends</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividends" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDividends"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDividends" xlink:to="lab_us-gaap_PaymentsOfDividends" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_e6cb79c5-8676-4d00-8658-577f7135b62d_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfShortTermInvestments_1b2b548b-f0e2-4063-a17b-577dbff4db61_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sales and maturities of short-term investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Short-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:to="lab_us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_744a6ff5-0177-4b85-8675-a11736e0dbca_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_192e2265-676a-4688-9fe9-badb62a1e4e9_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_f2968c70-99f9-42bf-8f8f-fc5fc29aca1f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of common stock</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_bb8f87e4-f6ec-49ad-925d-01939ef2c4bb_negatedLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration liability, other noncurrent liabilities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaper_ba67a4e2-ce0d-4aa7-94da-d9710d3922b7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaper" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term commercial paper borrowings</link:label>
    <link:label id="lab_us-gaap_CommercialPaper_label_en-US" xlink:label="lab_us-gaap_CommercialPaper" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaper" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaper"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaper" xlink:to="lab_us-gaap_CommercialPaper" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_CostOfSalesOperatingExpensesAndOtherNet_35472b88-50c7-4398-aef6-019351becbb8_totalLabel_en-US" xlink:label="lab_lly_CostOfSalesOperatingExpensesAndOtherNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs, expenses, and other</link:label>
    <link:label id="lab_lly_CostOfSalesOperatingExpensesAndOtherNet_label_en-US" xlink:label="lab_lly_CostOfSalesOperatingExpensesAndOtherNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost Of Sales, Operating Expenses, And Other-net</link:label>
    <link:label id="lab_lly_CostOfSalesOperatingExpensesAndOtherNet_documentation_en-US" xlink:label="lab_lly_CostOfSalesOperatingExpensesAndOtherNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost Of Sales, Operating Expenses, And Other-net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CostOfSalesOperatingExpensesAndOtherNet" xlink:href="lly-20220930.xsd#lly_CostOfSalesOperatingExpensesAndOtherNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_CostOfSalesOperatingExpensesAndOtherNet" xlink:to="lab_lly_CostOfSalesOperatingExpensesAndOtherNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_9066804d-70e3-46b1-b134-13a1ae2dca80_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_BuyUSDollarSellChineseYuanMember_7fa0c07b-db37-4677-9fb6-ec96b594f94c_terseLabel_en-US" xlink:label="lab_lly_BuyUSDollarSellChineseYuanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buy US Dollar Sell Chinese Yuan</link:label>
    <link:label id="lab_lly_BuyUSDollarSellChineseYuanMember_label_en-US" xlink:label="lab_lly_BuyUSDollarSellChineseYuanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buy US Dollar Sell Chinese Yuan [Member]</link:label>
    <link:label id="lab_lly_BuyUSDollarSellChineseYuanMember_documentation_en-US" xlink:label="lab_lly_BuyUSDollarSellChineseYuanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buy US Dollar Sell Chinese Yuan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BuyUSDollarSellChineseYuanMember" xlink:href="lly-20220930.xsd#lly_BuyUSDollarSellChineseYuanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_BuyUSDollarSellChineseYuanMember" xlink:to="lab_lly_BuyUSDollarSellChineseYuanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_ImmunologyMember_5b8c446e-c6eb-4782-abdd-7fb2d60abb35_terseLabel_en-US" xlink:label="lab_lly_ImmunologyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Immunology</link:label>
    <link:label id="lab_lly_ImmunologyMember_label_en-US" xlink:label="lab_lly_ImmunologyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Immunology [Member]</link:label>
    <link:label id="lab_lly_ImmunologyMember_documentation_en-US" xlink:label="lab_lly_ImmunologyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Immunology [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ImmunologyMember" xlink:href="lly-20220930.xsd#lly_ImmunologyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_ImmunologyMember" xlink:to="lab_lly_ImmunologyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_360fe98b-0d84-4e75-9a6d-ca28c82f0a63_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_ProductLiabilityMember_7a78cd6f-e482-4374-9078-591f96c429d8_terseLabel_en-US" xlink:label="lab_lly_ProductLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Liability</link:label>
    <link:label id="lab_lly_ProductLiabilityMember_label_en-US" xlink:label="lab_lly_ProductLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Liability [Member]</link:label>
    <link:label id="lab_lly_ProductLiabilityMember_documentation_en-US" xlink:label="lab_lly_ProductLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ProductLiabilityMember" xlink:href="lly-20220930.xsd#lly_ProductLiabilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_ProductLiabilityMember" xlink:to="lab_lly_ProductLiabilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_3844c7ea-299c-4d9a-92f2-1b7a46023902_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_5f10febc-30a6-4b64-9809-fd1ba40b8d9a_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_0b7561f3-01fc-4676-aa7e-99d45cbfb4f7_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfLongtermInvestments_f19e85b1-617c-4831-8797-417917b15088_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfLongtermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sales of noncurrent investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfLongtermInvestments_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfLongtermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Long-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfLongtermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfLongtermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfLongtermInvestments" xlink:to="lab_us-gaap_ProceedsFromSaleOfLongtermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionDomain_828c6ea9-f24f-4ca6-8365-624b64cff4e5_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Domain]</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionDomain_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionDomain" xlink:to="lab_us-gaap_AssetAcquisitionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_9e68ee63-8c43-4ade-9632-3e0791f7b826_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of treasury shares (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_label_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares, Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockSharesAcquired" xlink:to="lab_us-gaap_TreasuryStockSharesAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_22fdd6a0-407c-4548-876b-f19a8e121363_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Domain]</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_9b59bb83-117e-49ba-b53c-9752cdee5b21_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesReturnsAndAllowancesMember_2600953c-1bbf-4f8b-9844-28ed03ba5c3f_terseLabel_en-US" xlink:label="lab_us-gaap_SalesReturnsAndAllowancesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales returns, rebates, and discounts</link:label>
    <link:label id="lab_us-gaap_SalesReturnsAndAllowancesMember_label_en-US" xlink:label="lab_us-gaap_SalesReturnsAndAllowancesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Returns and Allowances [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesReturnsAndAllowancesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesReturnsAndAllowancesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesReturnsAndAllowancesMember" xlink:to="lab_us-gaap_SalesReturnsAndAllowancesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_4d45c929-c24a-4f12-a916-a2bd8999dd5d_terseLabel_en-US" xlink:label="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Including Portion Attributable to Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:to="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement_cc5b046e-81d5-4d34-af65-4a4730388cdb_terseLabel_en-US" xlink:label="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-cash operating activities, net</link:label>
    <link:label id="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement_label_en-US" xlink:label="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Operating Activities, Cash Flow Statement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:to="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_92ec2f5f-244e-4c43-9a19-c2cd900f1517_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net of allowances of $17.7 (2022) and $22.5 (2021)</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_755e3f16-6047-43ef-9fb3-c628442078d1_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_bdc99c90-c9f9-4cca-ab20-7f8222670cb9_terseLabel_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_label_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseTypeDomain_f46be302-a6f5-446b-9d45-644d1e3a7b34_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case Type [Domain]</link:label>
    <link:label id="lab_srt_LitigationCaseTypeDomain_label_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseTypeDomain" xlink:to="lab_srt_LitigationCaseTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_0e8f89b4-71e6-4d0f-9bfa-0ccaa54c3754_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_40d1ff0c-2fa6-435d-91e4-2f7178381d87_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flows from Operating Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_391f90dd-c7e2-4545-ad15-70d0cec43909_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_LitigationClaimsDismissedNumber_133f9efb-5461-4b0e-a2e8-bb317c846da0_terseLabel_en-US" xlink:label="lab_lly_LitigationClaimsDismissedNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of claims dismissed</link:label>
    <link:label id="lab_lly_LitigationClaimsDismissedNumber_label_en-US" xlink:label="lab_lly_LitigationClaimsDismissedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation, Claims Dismissed, Number</link:label>
    <link:label id="lab_lly_LitigationClaimsDismissedNumber_documentation_en-US" xlink:label="lab_lly_LitigationClaimsDismissedNumber" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation, Claims Dismissed, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_LitigationClaimsDismissedNumber" xlink:href="lly-20220930.xsd#lly_LitigationClaimsDismissedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_LitigationClaimsDismissedNumber" xlink:to="lab_lly_LitigationClaimsDismissedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain_b9a8b30f-5d69-43be-9683-d0f83f3de12d_terseLabel_en-US" xlink:label="lab_lly_AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Realized gross gains on sales</link:label>
    <link:label id="lab_lly_AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain_label_en-US" xlink:label="lab_lly_AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available for Sale Securities and Equity Securities, FV-NI, Realized Gain</link:label>
    <link:label id="lab_lly_AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain_documentation_en-US" xlink:label="lab_lly_AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available for Sale Securities and Equity Securities, FV-NI, Realized Gain</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain" xlink:href="lly-20220930.xsd#lly_AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain" xlink:to="lab_lly_AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_ab6cf999-4d2a-4071-ab25-2304e0f92444_negatedLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other&#8211;net, (income) expense (Note 11)</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_241482ee-bb97-4abb-a23a-5d323d742433_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other&#8211;net, (income) expense</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_d2222310-5337-4a16-a937-437740a61944_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_12b9ffb3-2e66-4be9-b49a-50a09c80f563_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketing, selling, and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesTable_4655ba04-4825-4eb1-a821-335f36a4e8a0_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable" xlink:to="lab_us-gaap_LossContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_26b8e7db-8b21-4e3e-b90b-4e81153d478e_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gross losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductMember_2379b9cc-e511-4848-895c-e29e1e74b2a4_terseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net product revenue</link:label>
    <link:label id="lab_us-gaap_ProductMember_label_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember" xlink:to="lab_us-gaap_ProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_0836cba6-20b1-4342-bfde-2cf9b4a77e32_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_4d3b82f3-a21c-4db4-bbd5-03299ca34790_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss) Note [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNoteTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_OtherProductTotalMember_e1cd667c-3f9a-4510-9bf0-7cd14e5a53eb_terseLabel_en-US" xlink:label="lab_lly_OtherProductTotalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_lly_OtherProductTotalMember_label_en-US" xlink:label="lab_lly_OtherProductTotalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Product, Total [Member]</link:label>
    <link:label id="lab_lly_OtherProductTotalMember_documentation_en-US" xlink:label="lab_lly_OtherProductTotalMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Product, Total [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OtherProductTotalMember" xlink:href="lly-20220930.xsd#lly_OtherProductTotalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_OtherProductTotalMember" xlink:to="lab_lly_OtherProductTotalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireProductiveAssets_3028ec03-eb22-4aad-9ccd-87b063cbf29f_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireProductiveAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireProductiveAssets_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Productive Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireProductiveAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireProductiveAssets" xlink:to="lab_us-gaap_PaymentsToAcquireProductiveAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_40e2428a-7bef-4d57-b7ea-ab94ebf702ae_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_2b14362f-eae6-438d-bdb4-69f9e105e8c1_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_fb971dc0-e6ee-48c9-9893-7e84f82b1615_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Implementation of New Financial Accounting Standard</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_10bd7cae-e25c-4067-b0e7-eddf9c816f33_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity investments without readily determinable fair values</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities without Readily Determinable Fair Value, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:to="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentInformationTable_bca8ce85-41e9-4302-808e-3ef7b074e4f3_terseLabel_en-US" xlink:label="lab_dei_DocumentInformationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Table]</link:label>
    <link:label id="lab_dei_DocumentInformationTable_label_en-US" xlink:label="lab_dei_DocumentInformationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationTable" xlink:to="lab_dei_DocumentInformationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_ef49162a-d3a5-493d-a171-035ce504cfcd_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_ProceedsfromSaleofEquityandAvailableforSaleSecurities_c74f1aec-25b1-4605-9c80-0a33293c9dad_terseLabel_en-US" xlink:label="lab_lly_ProceedsfromSaleofEquityandAvailableforSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sales</link:label>
    <link:label id="lab_lly_ProceedsfromSaleofEquityandAvailableforSaleSecurities_label_en-US" xlink:label="lab_lly_ProceedsfromSaleofEquityandAvailableforSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Equity and Available for Sale Securities</link:label>
    <link:label id="lab_lly_ProceedsfromSaleofEquityandAvailableforSaleSecurities_documentation_en-US" xlink:label="lab_lly_ProceedsfromSaleofEquityandAvailableforSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Equity and Available for Sale Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ProceedsfromSaleofEquityandAvailableforSaleSecurities" xlink:href="lly-20220930.xsd#lly_ProceedsfromSaleofEquityandAvailableforSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_ProceedsfromSaleofEquityandAvailableforSaleSecurities" xlink:to="lab_lly_ProceedsfromSaleofEquityandAvailableforSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember_1f1538ea-bd3b-4727-8444-11764fc2ce97_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Net Gains (Losses) on&#160;Securities</link:label>
    <link:label id="lab_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember_1f819169-cf8d-40c6-8aaf-bb8c4f0d5593_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized net gains/losses on securities</link:label>
    <link:label id="lab_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Including Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember" xlink:to="lab_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_CollaborativeArrangementRightsAndObligationsPercent_8b81d780-5ed5-4b8b-84eb-560d0b057fe0_terseLabel_en-US" xlink:label="lab_lly_CollaborativeArrangementRightsAndObligationsPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangement, rights and obligations, percentage (up to)</link:label>
    <link:label id="lab_lly_CollaborativeArrangementRightsAndObligationsPercent_label_en-US" xlink:label="lab_lly_CollaborativeArrangementRightsAndObligationsPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations Percent</link:label>
    <link:label id="lab_lly_CollaborativeArrangementRightsAndObligationsPercent_documentation_en-US" xlink:label="lab_lly_CollaborativeArrangementRightsAndObligationsPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of rights and obligations under the collaborative arrangements, including but not limited to - percent share in various revenues and costs, percent interest earned on related party notes.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CollaborativeArrangementRightsAndObligationsPercent" xlink:href="lly-20220930.xsd#lly_CollaborativeArrangementRightsAndObligationsPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_CollaborativeArrangementRightsAndObligationsPercent" xlink:to="lab_lly_CollaborativeArrangementRightsAndObligationsPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e3f56dc0-1d1a-4125-802c-bd26566a4bc8_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income to Cash Flows from Operating Activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_1b88647f-460a-48a9-8f6f-7a8c786a07b4_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes (Note 7)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_35b2e95b-c665-47d7-b1e5-747817508cba_negatedNetLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax benefit</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_2fc8337a-3336-46eb-9cbf-d9070fe26d82_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5205a684-ff2c-42c6-b0ab-4a870a22e5da_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_f98234fc-dafa-4365-bdbd-45f8af0544e7_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromShortTermDebt_e8f037ea-0d54-42fe-a0bb-caa9d4b64516_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromShortTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change in short-term borrowings</link:label>
    <link:label id="lab_us-gaap_ProceedsFromShortTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromShortTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Short-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromShortTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromShortTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromShortTermDebt" xlink:to="lab_us-gaap_ProceedsFromShortTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_53607d3e-3c45-4566-ba39-700f000b8cb5_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_07548d19-414e-4521-a4d4-0b48653be7c8_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_4e4d5947-9312-471b-915c-aa494d5264eb_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_eeefad47-b845-414b-a76a-4e269509ce55_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_HumalogHumulinAndForteoMember_5be4967d-6694-435c-8944-bc07e8957ec9_terseLabel_en-US" xlink:label="lab_lly_HumalogHumulinAndForteoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Humalog, Humulin and Forteo</link:label>
    <link:label id="lab_lly_HumalogHumulinAndForteoMember_label_en-US" xlink:label="lab_lly_HumalogHumulinAndForteoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Humalog, Humulin, And Forteo [Member]</link:label>
    <link:label id="lab_lly_HumalogHumulinAndForteoMember_documentation_en-US" xlink:label="lab_lly_HumalogHumulinAndForteoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Humalog, Humulin, And Forteo</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_HumalogHumulinAndForteoMember" xlink:href="lly-20220930.xsd#lly_HumalogHumulinAndForteoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_HumalogHumulinAndForteoMember" xlink:to="lab_lly_HumalogHumulinAndForteoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_c7e6baa4-5050-4106-867f-4eba65a8dd20_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of sales</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_PurchasedInProcessResearchAndDevelopment_54685e9c-64e8-48ba-928d-423cc3bc1560_negatedTerseLabel_en-US" xlink:label="lab_lly_PurchasedInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of in-process research and development</link:label>
    <link:label id="lab_lly_PurchasedInProcessResearchAndDevelopment_label_en-US" xlink:label="lab_lly_PurchasedInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchased In-process Research And Development</link:label>
    <link:label id="lab_lly_PurchasedInProcessResearchAndDevelopment_documentation_en-US" xlink:label="lab_lly_PurchasedInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The amount of CASH paid for research and development assets that are acquired in a business combination (pre-141R) and/or licensing arrangement that have no alternative future use and are therefore, written off in the period of acquisition (CASH FLOWS).</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_PurchasedInProcessResearchAndDevelopment" xlink:href="lly-20220930.xsd#lly_PurchasedInProcessResearchAndDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_PurchasedInProcessResearchAndDevelopment" xlink:to="lab_lly_PurchasedInProcessResearchAndDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_CyramzaMember_a94d5ced-9d4b-4ec6-b570-d73496fb15cb_terseLabel_en-US" xlink:label="lab_lly_CyramzaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cyramza&#174;</link:label>
    <link:label id="lab_lly_CyramzaMember_label_en-US" xlink:label="lab_lly_CyramzaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cyramza [Member]</link:label>
    <link:label id="lab_lly_CyramzaMember_documentation_en-US" xlink:label="lab_lly_CyramzaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cyramza [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CyramzaMember" xlink:href="lly-20220930.xsd#lly_CyramzaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_CyramzaMember" xlink:to="lab_lly_CyramzaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_218a2d20-6f31-4c57-a3cb-d71957474d9d_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A2.125NotesDueJune32030Member_882ad0d9-d656-410c-915d-5c862dc96348_terseLabel_en-US" xlink:label="lab_lly_A2.125NotesDueJune32030Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.125% Notes due 2030</link:label>
    <link:label id="lab_lly_A2.125NotesDueJune32030Member_label_en-US" xlink:label="lab_lly_A2.125NotesDueJune32030Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.125% Notes Due June 3, 2030 [Member]</link:label>
    <link:label id="lab_lly_A2.125NotesDueJune32030Member_documentation_en-US" xlink:label="lab_lly_A2.125NotesDueJune32030Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.125% Notes Due June 3, 2030 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A2.125NotesDueJune32030Member" xlink:href="lly-20220930.xsd#lly_A2.125NotesDueJune32030Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A2.125NotesDueJune32030Member" xlink:to="lab_lly_A2.125NotesDueJune32030Member" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_MilestonePaymentsSalesBasedMember_aa8b0e2a-dcb2-4a53-ae72-c0619a821d92_terseLabel_en-US" xlink:label="lab_lly_MilestonePaymentsSalesBasedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments, Sales-based</link:label>
    <link:label id="lab_lly_MilestonePaymentsSalesBasedMember_label_en-US" xlink:label="lab_lly_MilestonePaymentsSalesBasedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments, Sales-based [Member]</link:label>
    <link:label id="lab_lly_MilestonePaymentsSalesBasedMember_documentation_en-US" xlink:label="lab_lly_MilestonePaymentsSalesBasedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments, Sales-based [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MilestonePaymentsSalesBasedMember" xlink:href="lly-20220930.xsd#lly_MilestonePaymentsSalesBasedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_MilestonePaymentsSalesBasedMember" xlink:to="lab_lly_MilestonePaymentsSalesBasedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_a56c7504-d58c-46cb-8c15-fcbd23c963f4_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyNatureDomain_bf1de118-d61c-4b5d-85fe-5bf7d1daea9f_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNatureDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Nature [Domain]</link:label>
    <link:label id="lab_us-gaap_LossContingencyNatureDomain_label_en-US" xlink:label="lab_us-gaap_LossContingencyNatureDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Nature [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNatureDomain" xlink:to="lab_us-gaap_LossContingencyNatureDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_DiabetesMember_52f41333-bfa5-4ece-ba23-5304fa693e73_terseLabel_en-US" xlink:label="lab_lly_DiabetesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diabetes</link:label>
    <link:label id="lab_lly_DiabetesMember_label_en-US" xlink:label="lab_lly_DiabetesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diabetes [Member]</link:label>
    <link:label id="lab_lly_DiabetesMember_documentation_en-US" xlink:label="lab_lly_DiabetesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diabetes [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DiabetesMember" xlink:href="lly-20220930.xsd#lly_DiabetesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_DiabetesMember" xlink:to="lab_lly_DiabetesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_670a8bd5-3319-4c48-bd7a-89253a9a1b88_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems" xlink:to="lab_us-gaap_LossContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5e86ad1b-f13b-453a-95eb-8fabc49f8f0b_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangements and Non-collaborative Arrangement Transactions [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_OtherProductMember_954c4dc4-1601-4d16-93a2-550941cae4fc_terseLabel_en-US" xlink:label="lab_lly_OtherProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_lly_OtherProductMember_label_en-US" xlink:label="lab_lly_OtherProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Product [Member]</link:label>
    <link:label id="lab_lly_OtherProductMember_documentation_en-US" xlink:label="lab_lly_OtherProductMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OtherProductMember" xlink:href="lly-20220930.xsd#lly_OtherProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_OtherProductMember" xlink:to="lab_lly_OtherProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit_c9d8ed35-131d-4006-917b-5be4369e919b_negatedLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recognized actuarial loss</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Actuarial Gain (Loss), Immediate Recognition as Component in Net Periodic Benefit (Cost) Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit" xlink:to="lab_us-gaap_DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_BuyBritishPoundandSellUSDollarsMember_41d88cd2-5f0c-42a9-9143-74c0a42e475b_terseLabel_en-US" xlink:label="lab_lly_BuyBritishPoundandSellUSDollarsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buy British Pounds and Sell U.S. Dollars</link:label>
    <link:label id="lab_lly_BuyBritishPoundandSellUSDollarsMember_label_en-US" xlink:label="lab_lly_BuyBritishPoundandSellUSDollarsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buy British Pound and Sell US Dollars [Member]</link:label>
    <link:label id="lab_lly_BuyBritishPoundandSellUSDollarsMember_documentation_en-US" xlink:label="lab_lly_BuyBritishPoundandSellUSDollarsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buy British Pound and Sell US Dollars [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BuyBritishPoundandSellUSDollarsMember" xlink:href="lly-20220930.xsd#lly_BuyBritishPoundandSellUSDollarsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_BuyBritishPoundandSellUSDollarsMember" xlink:to="lab_lly_BuyBritishPoundandSellUSDollarsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss_5a6dbfb5-fba0-4d26-b9e4-d8e62bebf951_terseLabel_en-US" xlink:label="lab_lly_AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Realized gross losses on sales</link:label>
    <link:label id="lab_lly_AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss_label_en-US" xlink:label="lab_lly_AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available for sale Securities and Equity Securities, FV-NI, Realized Loss</link:label>
    <link:label id="lab_lly_AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss_documentation_en-US" xlink:label="lab_lly_AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available for sale Securities and Equity Securities, FV-NI, Realized Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss" xlink:href="lly-20220930.xsd#lly_AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss" xlink:to="lab_lly_AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_6fc2bd24-159e-491d-b00a-d551403493b3_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_a1e6d86f-6419-49f4-8a13-3fc442a7cdef_terseLabel_en-US" xlink:label="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying Amount</link:label>
    <link:label id="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reported Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:to="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_64fa6a0d-79a9-493f-b2b6-35b9a0f6ff3f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTax_b3b62a0f-bc31-4d46-a9d3-902e7cc3d9df_terseLabel_en-US" xlink:label="lab_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives used in net investment hedge, net of tax</link:label>
    <link:label id="lab_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTax_label_en-US" xlink:label="lab_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives used in Net Investment Hedge, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTax" xlink:to="lab_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_902533ba-7fc9-46d1-a137-852f5371a516_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_01ad6d75-6640-46a4-afab-8a4951192a77_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_c4838067-5419-492b-930a-3acd5362ce2a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of effective portion of risk-management instruments that was recognized in other comprehensive income (loss), cash flow hedges</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember_7f7a9fe5-b375-4c15-8811-339717c8cc38_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actuarial losses, net</link:label>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Defined Benefit Plans Adjustment, Net Gain (Loss) Including Portion Attributable to Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember" xlink:to="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_40e39486-e807-4ce6-8340-5fa628c4ae5d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of effective portion of risk-management instruments that was recognized in other comprehensive income (loss), net investment hedges</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Net Investment Hedges in Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A050NotesDue2033Member_7764a0fb-89f3-417c-8d40-3b60ad7b3ec4_terseLabel_en-US" xlink:label="lab_lly_A050NotesDue2033Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.50% Notes Due 2033</link:label>
    <link:label id="lab_lly_A050NotesDue2033Member_label_en-US" xlink:label="lab_lly_A050NotesDue2033Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.50% Notes Due 2033 [Member]</link:label>
    <link:label id="lab_lly_A050NotesDue2033Member_documentation_en-US" xlink:label="lab_lly_A050NotesDue2033Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.50% Notes Due 2033 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A050NotesDue2033Member" xlink:href="lly-20220930.xsd#lly_A050NotesDue2033Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A050NotesDue2033Member" xlink:to="lab_lly_A050NotesDue2033Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_68980380-7d74-4b5e-b3b9-b94a947176e7_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_249631f1-bf05-43e8-805e-0859dc09e529_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_BusinessAcquisitionContingentValueRightAdditionalPricePerShare_8903ee16-8c9e-456a-b422-9d886e4f890e_terseLabel_en-US" xlink:label="lab_lly_BusinessAcquisitionContingentValueRightAdditionalPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent value right, additional price per share (up to) (in dollars per share)</link:label>
    <link:label id="lab_lly_BusinessAcquisitionContingentValueRightAdditionalPricePerShare_label_en-US" xlink:label="lab_lly_BusinessAcquisitionContingentValueRightAdditionalPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Contingent Value Right, Additional Price Per Share</link:label>
    <link:label id="lab_lly_BusinessAcquisitionContingentValueRightAdditionalPricePerShare_documentation_en-US" xlink:label="lab_lly_BusinessAcquisitionContingentValueRightAdditionalPricePerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Contingent Value Right, Additional Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BusinessAcquisitionContingentValueRightAdditionalPricePerShare" xlink:href="lly-20220930.xsd#lly_BusinessAcquisitionContingentValueRightAdditionalPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_BusinessAcquisitionContingentValueRightAdditionalPricePerShare" xlink:to="lab_lly_BusinessAcquisitionContingentValueRightAdditionalPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_4dfad847-03d1-4bd3-af06-895967dbe8f6_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of long-term debt</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_5896ffad-389e-4e52-9e61-101f20e4379a_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_d2d89e13-739b-4504-97e9-f33f1c360e25_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_566e8210-b070-4b84-ad4d-7ad3c51daa4a_terseLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of the fair value of available-for-sale securities in an unrealized gain or loss position</link:label>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain (Loss) on Investments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock" xlink:to="lab_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanTypeDomain_bbd2deb6-e280-41e0-8a79-64a8611c4258_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Domain]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanTypeDomain_label_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanTypeDomain" xlink:to="lab_us-gaap_RetirementPlanTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_21ade83e-785b-459a-a248-3a6cbe936db5_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionTextBlock_3eb26026-8621-46ab-be53-def46b7f46e8_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionTextBlock_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionTextBlock" xlink:to="lab_us-gaap_AssetAcquisitionTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowHedgingMember_85e770d3-b240-41b0-9553-6668df5bfffc_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowHedgingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow Hedging</link:label>
    <link:label id="lab_us-gaap_CashFlowHedgingMember_label_en-US" xlink:label="lab_us-gaap_CashFlowHedgingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow Hedging [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowHedgingMember" xlink:to="lab_us-gaap_CashFlowHedgingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f07d0e83-f3b8-46ca-91f0-955544f491e6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_de60829c-1f53-40be-9f86-c7e3f01cf81e_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of securities in an unrealized loss position</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_bf5eb7a3-30ab-425c-a93c-fd81cc8f3666_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_b27e7050-7fb4-4b2e-90b7-ffc55d07044c_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Used for Investing Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueHedgingMember_1af44919-0263-4eeb-b5fa-2898ec618c60_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueHedgingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hedging</link:label>
    <link:label id="lab_us-gaap_FairValueHedgingMember_label_en-US" xlink:label="lab_us-gaap_FairValueHedgingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hedging [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueHedgingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueHedgingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueHedgingMember" xlink:to="lab_us-gaap_FairValueHedgingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_5c3aec3f-c5c4-40e4-9089-6480e698fa75_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, face amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_PaymentsForAssetAcquisitions_ddd82db9-985f-42f4-b4ab-1f6b6f56ab4a_terseLabel_en-US" xlink:label="lab_lly_PaymentsForAssetAcquisitions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired IPR&amp;D Expense</link:label>
    <link:label id="lab_lly_PaymentsForAssetAcquisitions_label_en-US" xlink:label="lab_lly_PaymentsForAssetAcquisitions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Asset Acquisitions</link:label>
    <link:label id="lab_lly_PaymentsForAssetAcquisitions_documentation_en-US" xlink:label="lab_lly_PaymentsForAssetAcquisitions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Asset Acquisitions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_PaymentsForAssetAcquisitions" xlink:href="lly-20220930.xsd#lly_PaymentsForAssetAcquisitions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_PaymentsForAssetAcquisitions" xlink:to="lab_lly_PaymentsForAssetAcquisitions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_9a5dd6c0-1bc0-417b-8e95-e4d42f9ba4c8_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss), net of tax (Note 10)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_d404d02d-7777-4ea0-aa7b-fb77e8092621_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_6a0b33b5-2fd2-4a1f-8f2c-3a7b935a2240_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of stock under employee stock plans, net</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_80bff988-035d-4301-8be0-d5fc8f50f369_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_f5a58d8f-3986-42f8-9beb-77bb05208de5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary certain fair value information, liabilities</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseAxis_6ee28fd9-3a10-417d-ac18-5ade09aacea2_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:label id="lab_srt_LitigationCaseAxis_label_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseAxis" xlink:to="lab_srt_LitigationCaseAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_CymbaltaMember_2881187c-1a21-4617-b7fe-fb1204351054_terseLabel_en-US" xlink:label="lab_lly_CymbaltaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cymbalta&#174;</link:label>
    <link:label id="lab_lly_CymbaltaMember_label_en-US" xlink:label="lab_lly_CymbaltaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cymbalta [Member]</link:label>
    <link:label id="lab_lly_CymbaltaMember_documentation_en-US" xlink:label="lab_lly_CymbaltaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cymbalta [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CymbaltaMember" xlink:href="lly-20220930.xsd#lly_CymbaltaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_CymbaltaMember" xlink:to="lab_lly_CymbaltaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_09d29938-a5cd-458c-90f7-7f52f2328ed5_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gross gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_f785059e-6a90-42b6-859f-5c0593f4f507_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_7f0b912b-be1a-4294-b8a1-0afd6554fc27_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_911feab7-c3cd-416f-882a-a9758bd90efd_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_858a12e8-3aa1-486d-996e-a647f72d0028_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other noncurrent assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_MilestonePaymentsCapitalizedAsIntangibleAssetsMember_390819aa-61a3-4090-b413-59e584c01294_terseLabel_en-US" xlink:label="lab_lly_MilestonePaymentsCapitalizedAsIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments, Capitalized as Intangible Assets</link:label>
    <link:label id="lab_lly_MilestonePaymentsCapitalizedAsIntangibleAssetsMember_label_en-US" xlink:label="lab_lly_MilestonePaymentsCapitalizedAsIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments, Capitalized As Intangible Assets [Member]</link:label>
    <link:label id="lab_lly_MilestonePaymentsCapitalizedAsIntangibleAssetsMember_documentation_en-US" xlink:label="lab_lly_MilestonePaymentsCapitalizedAsIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments, Capitalized As Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MilestonePaymentsCapitalizedAsIntangibleAssetsMember" xlink:href="lly-20220930.xsd#lly_MilestonePaymentsCapitalizedAsIntangibleAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_MilestonePaymentsCapitalizedAsIntangibleAssetsMember" xlink:to="lab_lly_MilestonePaymentsCapitalizedAsIntangibleAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CrossCurrencyInterestRateContractMember_77e84db3-27ae-40bb-a262-bb4f348d0fb9_terseLabel_en-US" xlink:label="lab_us-gaap_CrossCurrencyInterestRateContractMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cross-currency interest rate swaps</link:label>
    <link:label id="lab_us-gaap_CrossCurrencyInterestRateContractMember_label_en-US" xlink:label="lab_us-gaap_CrossCurrencyInterestRateContractMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cross Currency Interest Rate Contract [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CrossCurrencyInterestRateContractMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CrossCurrencyInterestRateContractMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CrossCurrencyInterestRateContractMember" xlink:to="lab_us-gaap_CrossCurrencyInterestRateContractMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_2529d794-f945-4177-b8d5-4cd720ac71e2_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_444dfd45-ca5c-4be3-9d66-547edbc0d4d3_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_country_JP_a4ebfe18-480b-45f4-b9fc-a5569a494040_terseLabel_en-US" xlink:label="lab_country_JP" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Japan</link:label>
    <link:label id="lab_country_JP_label_en-US" xlink:label="lab_country_JP" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">JAPAN</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_JP" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_JP"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_JP" xlink:to="lab_country_JP" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_7d220415-817a-4f40-b94b-0978ddd5b7b2_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of stock under employee stock plans, net (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_6cc72501-e758-4af5-8962-709c24fccd4f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of the amounts recognized for assets acquired and liabilities assumed</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_f18ec3bb-cc8c-4dee-a2dc-cc27f8618e16_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_7d0e0db9-f157-4c0f-a28d-b6519dc4c858_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Table]</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_32b59cc1-da2b-4c97-8d1a-d8a9755b0ec8_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityOther_4187c780-9df7-4b52-8c12-92bf53f73b2f_negatedLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityOther" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityOther_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityOther" xlink:to="lab_us-gaap_StockholdersEquityOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b9bbcb41-337c-4ff9-a183-d1d837d40967_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability_bdd9f6e9-54a7-49fb-b417-8ee88abfd20e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of CVR liability</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Contingent Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3f330168-4781-4a2b-b0fa-bdb11e2cc515_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange rate changes on cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_70ca41d1-63c6-4aae-b6b4-ac09a0a82ce5_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net of accumulated depreciation of $10,074.0 (2022) and $9,976.7 (2021)</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract_610f16f0-c73b-4c7e-bd04-87ecb389dc79_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract" xlink:to="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_9575c00f-c69b-4aeb-92f5-06c22e74c695_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of long-term debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_bbfebbb1-3ca6-4fe3-a496-66a55ba55dc1_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent value right, additional price per share, aggregate amount</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_b3ff43ea-e97e-4ea1-afc4-cf3f2d3e3e94_terseLabel_en-US" xlink:label="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other&#8211;Net, (Income) Expense</link:label>
    <link:label id="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income and Other Expense Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:to="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Dividends_a8cfb26c-270b-4531-8229-8125ee539677_negatedLabel_en-US" xlink:label="lab_us-gaap_Dividends" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash dividends declared</link:label>
    <link:label id="lab_us-gaap_Dividends_label_en-US" xlink:label="lab_us-gaap_Dividends" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Dividends" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Dividends"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Dividends" xlink:to="lab_us-gaap_Dividends" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain_379c213c-2dac-4744-b06e-ee7921c17bfa_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_3187d0fe-4d70-48f5-a663-c0336895f144_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowances for doubtful accounts</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_85e5a818-4092-4331-80a6-62afafb6e37f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other&#8211;net, (income) expense</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_dcf060e0-9339-4aaf-9123-8ee07bd8468d_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (income) expense</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_affcdbcd-15d5-480d-85a9-0f66ad4abe6d_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, including current portion</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_ad82cfc6-0d92-4128-979b-2d7f29f57a0f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, including current portion</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A1700NotesDue2049Member_bb01303d-ae77-44a0-8892-a3343ffb6c14_terseLabel_en-US" xlink:label="lab_lly_A1700NotesDue2049Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.700% Notes due 2049</link:label>
    <link:label id="lab_lly_A1700NotesDue2049Member_label_en-US" xlink:label="lab_lly_A1700NotesDue2049Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.700% Notes Due 2049 [Member]</link:label>
    <link:label id="lab_lly_A1700NotesDue2049Member_documentation_en-US" xlink:label="lab_lly_A1700NotesDue2049Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.700% Notes due 2049 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1700NotesDue2049Member" xlink:href="lly-20220930.xsd#lly_A1700NotesDue2049Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A1700NotesDue2049Member" xlink:to="lab_lly_A1700NotesDue2049Member" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_AcquiredInProcessResearchAndDevelopmentAndDevelopmentMilestones_0b5164b8-ad73-4936-9c2f-f2fd6cb0baf9_terseLabel_en-US" xlink:label="lab_lly_AcquiredInProcessResearchAndDevelopmentAndDevelopmentMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired in-process research and development and development milestones (Note 3)</link:label>
    <link:label id="lab_lly_AcquiredInProcessResearchAndDevelopmentAndDevelopmentMilestones_fd3cb041-9f2f-48cf-a069-30de8e1d5903_verboseLabel_en-US" xlink:label="lab_lly_AcquiredInProcessResearchAndDevelopmentAndDevelopmentMilestones" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired in-process research and development and development milestones</link:label>
    <link:label id="lab_lly_AcquiredInProcessResearchAndDevelopmentAndDevelopmentMilestones_label_en-US" xlink:label="lab_lly_AcquiredInProcessResearchAndDevelopmentAndDevelopmentMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired In-Process Research And Development And Development Milestones</link:label>
    <link:label id="lab_lly_AcquiredInProcessResearchAndDevelopmentAndDevelopmentMilestones_documentation_en-US" xlink:label="lab_lly_AcquiredInProcessResearchAndDevelopmentAndDevelopmentMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired In-Process Research And Development And Development Milestones</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AcquiredInProcessResearchAndDevelopmentAndDevelopmentMilestones" xlink:href="lly-20220930.xsd#lly_AcquiredInProcessResearchAndDevelopmentAndDevelopmentMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_AcquiredInProcessResearchAndDevelopmentAndDevelopmentMilestones" xlink:to="lab_lly_AcquiredInProcessResearchAndDevelopmentAndDevelopmentMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_1bc5b66f-23ab-402b-8fb8-0451143f61eb_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_2837d268-dc7e-4d4b-b77e-3297a476fc3c_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_f694fb56-cc5a-4c2a-a196-aba74fc79c23_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss (Note 10)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_MaturityDate2023Member_9feab043-52e7-4997-8815-9953ca1076df_terseLabel_en-US" xlink:label="lab_lly_MaturityDate2023Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturity Date 2023</link:label>
    <link:label id="lab_lly_MaturityDate2023Member_label_en-US" xlink:label="lab_lly_MaturityDate2023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturity Date 2023 [Member]</link:label>
    <link:label id="lab_lly_MaturityDate2023Member_documentation_en-US" xlink:label="lab_lly_MaturityDate2023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturity Date 2023 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MaturityDate2023Member" xlink:href="lly-20220930.xsd#lly_MaturityDate2023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_MaturityDate2023Member" xlink:to="lab_lly_MaturityDate2023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonClassAMember_8e898fd3-bb19-401a-b6c6-b79b3470f67a_terseLabel_en-US" xlink:label="lab_us-gaap_CommonClassAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock (no par value)</link:label>
    <link:label id="lab_us-gaap_CommonClassAMember_label_en-US" xlink:label="lab_us-gaap_CommonClassAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Class A [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonClassAMember" xlink:to="lab_us-gaap_CommonClassAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_a959da0f-0586-46e9-84f2-336de52e624b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_a0128ad3-a44c-4908-8880-121c9e53e397_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents (Note 6)</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_DebtSecuritiesAvailableForSaleUnrealizedLossPositionQualitativeDisclosureOtherPercentageOfNonperformingAssets_b4bf5ab3-3244-4102-aba6-cd7f46866ded_terseLabel_en-US" xlink:label="lab_lly_DebtSecuritiesAvailableForSaleUnrealizedLossPositionQualitativeDisclosureOtherPercentageOfNonperformingAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale, percentage of nonperforming assets</link:label>
    <link:label id="lab_lly_DebtSecuritiesAvailableForSaleUnrealizedLossPositionQualitativeDisclosureOtherPercentageOfNonperformingAssets_label_en-US" xlink:label="lab_lly_DebtSecuritiesAvailableForSaleUnrealizedLossPositionQualitativeDisclosureOtherPercentageOfNonperformingAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position, Qualitative Disclosure, Other, Percentage of Nonperforming Assets</link:label>
    <link:label id="lab_lly_DebtSecuritiesAvailableForSaleUnrealizedLossPositionQualitativeDisclosureOtherPercentageOfNonperformingAssets_documentation_en-US" xlink:label="lab_lly_DebtSecuritiesAvailableForSaleUnrealizedLossPositionQualitativeDisclosureOtherPercentageOfNonperformingAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities, available-for-sale, unrealized loss position, qualitative disclosure, other, percentage of nonperforming assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DebtSecuritiesAvailableForSaleUnrealizedLossPositionQualitativeDisclosureOtherPercentageOfNonperformingAssets" xlink:href="lly-20220930.xsd#lly_DebtSecuritiesAvailableForSaleUnrealizedLossPositionQualitativeDisclosureOtherPercentageOfNonperformingAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_DebtSecuritiesAvailableForSaleUnrealizedLossPositionQualitativeDisclosureOtherPercentageOfNonperformingAssets" xlink:to="lab_lly_DebtSecuritiesAvailableForSaleUnrealizedLossPositionQualitativeDisclosureOtherPercentageOfNonperformingAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiGainLoss_e089d89d-cb89-48b9-8fc8-db8649891124_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity securities, net unrealized gains (losses)</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiGainLoss_abae7e2e-170e-4ad2-80b2-7e9246289957_negatedLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net investment (gains) losses on equity securities (Note 6)</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiGainLoss_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:to="lab_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_7113312a-4846-4ef9-a4f1-6f4cafab4ab3_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_5b0b5e78-5076-4b7d-8c6e-f4b3b423c539_terseLabel_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Designated as Hedging Instrument</link:label>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_label_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:to="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxesPayableCurrent_86da0500-4fda-4544-94f6-89539ef9f568_terseLabel_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes payable</link:label>
    <link:label id="lab_us-gaap_TaxesPayableCurrent_label_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxesPayableCurrent" xlink:to="lab_us-gaap_TaxesPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_OtherImmunologyMember_bafa4253-a73d-4d1b-a772-3b003082ef4d_terseLabel_en-US" xlink:label="lab_lly_OtherImmunologyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other immunology</link:label>
    <link:label id="lab_lly_OtherImmunologyMember_label_en-US" xlink:label="lab_lly_OtherImmunologyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Immunology [Member]</link:label>
    <link:label id="lab_lly_OtherImmunologyMember_documentation_en-US" xlink:label="lab_lly_OtherImmunologyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Immunology [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OtherImmunologyMember" xlink:href="lly-20220930.xsd#lly_OtherImmunologyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_OtherImmunologyMember" xlink:to="lab_lly_OtherImmunologyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_c47702a4-a4d4-4ed6-92f2-89d0dee60985_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_00a9d1ea-13ec-4362-82e1-9bc50b73704d_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_a297bbaf-9dfe-4683-a51c-167a0583ac25_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Basis [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Basis [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis" xlink:to="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_a90aabdf-041a-4670-a9eb-9e7a8edb99a1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of net pension and retiree health benefit (income) cost</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Net Benefit Costs [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNetBenefitCostsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareDeclared_b2383c1e-e2d1-4255-ab71-77197db2d77c_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash dividend declared per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareDeclared_label_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Dividends, Per Share, Declared</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockDividendsPerShareDeclared" xlink:to="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_9cb6c90b-1338-4a76-bbbd-302a92f36be0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary certain fair value information, assets</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A1625NotesDue2043Member_dc88d711-ff8b-475f-bd9b-d12ca388288a_terseLabel_en-US" xlink:label="lab_lly_A1625NotesDue2043Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.625% Notes due 2043</link:label>
    <link:label id="lab_lly_A1625NotesDue2043Member_label_en-US" xlink:label="lab_lly_A1625NotesDue2043Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.625% Notes Due 2043 [Member]</link:label>
    <link:label id="lab_lly_A1625NotesDue2043Member_documentation_en-US" xlink:label="lab_lly_A1625NotesDue2043Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.625% Notes Due 2043</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1625NotesDue2043Member" xlink:href="lly-20220930.xsd#lly_A1625NotesDue2043Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A1625NotesDue2043Member" xlink:to="lab_lly_A1625NotesDue2043Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssetNotionalAmount_51f0e2b6-7e0d-49a9-bd6d-9d6628460bd1_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssetNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative asset, notional amount</link:label>
    <link:label id="lab_us-gaap_DerivativeAssetNotionalAmount_label_en-US" xlink:label="lab_us-gaap_DerivativeAssetNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Notional Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetNotionalAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetNotionalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssetNotionalAmount" xlink:to="lab_us-gaap_DerivativeAssetNotionalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLongTermInvestments_b3603b90-6506-48b0-bd1c-5191c6106112_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherLongTermInvestments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity method investments</link:label>
    <link:label id="lab_us-gaap_OtherLongTermInvestments_label_en-US" xlink:label="lab_us-gaap_OtherLongTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Long-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLongTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLongTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLongTermInvestments" xlink:to="lab_us-gaap_OtherLongTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_COVID19AntibodiesMember_2e020e3f-c2fc-46ee-9b2e-2cfbcdff98be_terseLabel_en-US" xlink:label="lab_lly_COVID19AntibodiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COVID-19 antibodies</link:label>
    <link:label id="lab_lly_COVID19AntibodiesMember_label_en-US" xlink:label="lab_lly_COVID19AntibodiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COVID-19 Antibodies [Member]</link:label>
    <link:label id="lab_lly_COVID19AntibodiesMember_documentation_en-US" xlink:label="lab_lly_COVID19AntibodiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COVID-19 Antibodies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_COVID19AntibodiesMember" xlink:href="lly-20220930.xsd#lly_COVID19AntibodiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_COVID19AntibodiesMember" xlink:to="lab_lly_COVID19AntibodiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_BioMarinPharmaceuticalIncMember_dd761de8-cb5f-4091-b7d1-a5b9a1c67c90_terseLabel_en-US" xlink:label="lab_lly_BioMarinPharmaceuticalIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BioMarin Pharmaceutical Inc.</link:label>
    <link:label id="lab_lly_BioMarinPharmaceuticalIncMember_label_en-US" xlink:label="lab_lly_BioMarinPharmaceuticalIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BioMarin Pharmaceutical Inc [Member]</link:label>
    <link:label id="lab_lly_BioMarinPharmaceuticalIncMember_documentation_en-US" xlink:label="lab_lly_BioMarinPharmaceuticalIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BioMarin Pharmaceutical Inc</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BioMarinPharmaceuticalIncMember" xlink:href="lly-20220930.xsd#lly_BioMarinPharmaceuticalIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_BioMarinPharmaceuticalIncMember" xlink:to="lab_lly_BioMarinPharmaceuticalIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_2aaf789f-e199-4cdb-8911-241a25f84b9f_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_a17c4e12-b21a-4b76-a75c-dc40d5ef6b12_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Defined Benefit Plans Disclosures [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Defined Benefit Plans Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_d69bb890-2bf6-4bfb-b464-3bafdb3e8f5f_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation and Implementation of New Financial Accounting Standard</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_DebtSecuritiesAvailableforsaleUnrealizedGainPosition_2851b15e-887a-4b24-bce4-afc73afa9d6d_terseLabel_en-US" xlink:label="lab_lly_DebtSecuritiesAvailableforsaleUnrealizedGainPosition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of securities in an unrealized gain position</link:label>
    <link:label id="lab_lly_DebtSecuritiesAvailableforsaleUnrealizedGainPosition_label_en-US" xlink:label="lab_lly_DebtSecuritiesAvailableforsaleUnrealizedGainPosition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Gain Position</link:label>
    <link:label id="lab_lly_DebtSecuritiesAvailableforsaleUnrealizedGainPosition_documentation_en-US" xlink:label="lab_lly_DebtSecuritiesAvailableforsaleUnrealizedGainPosition" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Gain Position</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DebtSecuritiesAvailableforsaleUnrealizedGainPosition" xlink:href="lly-20220930.xsd#lly_DebtSecuritiesAvailableforsaleUnrealizedGainPosition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_DebtSecuritiesAvailableforsaleUnrealizedGainPosition" xlink:to="lab_lly_DebtSecuritiesAvailableforsaleUnrealizedGainPosition" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermInvestments_8d5d2e06-d7c5-48ef-8d11-21c0696d989b_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments (Note 6)</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestments" xlink:to="lab_us-gaap_ShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssetsNoncurrent_c54e6844-6c7c-4895-9e98-04cadaef2deb_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other noncurrent assets</link:label>
    <link:label id="lab_us-gaap_DerivativeAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_DerivativeAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssetsNoncurrent" xlink:to="lab_us-gaap_DerivativeAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination and Asset Acquisition [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxContingencyLineItems_d00f57dc-3b72-4820-abce-ae7aa93d67be_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxContingencyLineItems_label_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems" xlink:to="lab_us-gaap_IncomeTaxContingencyLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_d77c67fd-2bad-46a6-983c-101ec1e15dba_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. government and agency securities</link:label>
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government Agencies Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_ForeignCurrencyDenominatedDebtMember_7df5ba1f-243d-4874-8867-da007b71ff68_terseLabel_en-US" xlink:label="lab_lly_ForeignCurrencyDenominatedDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Denominated Debt</link:label>
    <link:label id="lab_lly_ForeignCurrencyDenominatedDebtMember_label_en-US" xlink:label="lab_lly_ForeignCurrencyDenominatedDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Denominated Debt [Member]</link:label>
    <link:label id="lab_lly_ForeignCurrencyDenominatedDebtMember_documentation_en-US" xlink:label="lab_lly_ForeignCurrencyDenominatedDebtMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Denominated Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ForeignCurrencyDenominatedDebtMember" xlink:href="lly-20220930.xsd#lly_ForeignCurrencyDenominatedDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_ForeignCurrencyDenominatedDebtMember" xlink:to="lab_lly_ForeignCurrencyDenominatedDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3966bcaf-6c49-44fa-8f34-dfd1675d1b5d_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_0dc80a6d-8407-4374-9be6-cc9b011c9408_terseLabel_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimate of Fair Value Measurement</link:label>
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimate of Fair Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:to="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A625NotesDue2031Member_06214b5d-bccf-4169-8462-b002a56c8cc5_terseLabel_en-US" xlink:label="lab_lly_A625NotesDue2031Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.625% Notes due 2031</link:label>
    <link:label id="lab_lly_A625NotesDue2031Member_label_en-US" xlink:label="lab_lly_A625NotesDue2031Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">.625% Notes Due 2031 [Member]</link:label>
    <link:label id="lab_lly_A625NotesDue2031Member_documentation_en-US" xlink:label="lab_lly_A625NotesDue2031Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">.625% Notes due 2031 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A625NotesDue2031Member" xlink:href="lly-20220930.xsd#lly_A625NotesDue2031Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A625NotesDue2031Member" xlink:to="lab_lly_A625NotesDue2031Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5c784045-e880-4206-8256-96a4f2959d75_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_EmgalityPatentLitigationMember_f6875998-9f92-48b5-b1e4-2ed3ebd449ad_terseLabel_en-US" xlink:label="lab_lly_EmgalityPatentLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Emgality Patent Litigation</link:label>
    <link:label id="lab_lly_EmgalityPatentLitigationMember_label_en-US" xlink:label="lab_lly_EmgalityPatentLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Emgality Patent Litigation [Member]</link:label>
    <link:label id="lab_lly_EmgalityPatentLitigationMember_documentation_en-US" xlink:label="lab_lly_EmgalityPatentLitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Emgality Patent Litigation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_EmgalityPatentLitigationMember" xlink:href="lly-20220930.xsd#lly_EmgalityPatentLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_EmgalityPatentLitigationMember" xlink:to="lab_lly_EmgalityPatentLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ChangeInAccountingEstimateLineItems_375f9821-3db5-4f21-8821-693b32f18120_terseLabel_en-US" xlink:label="lab_us-gaap_ChangeInAccountingEstimateLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Accounting Estimate [Line Items]</link:label>
    <link:label id="lab_us-gaap_ChangeInAccountingEstimateLineItems_label_en-US" xlink:label="lab_us-gaap_ChangeInAccountingEstimateLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Accounting Estimate [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInAccountingEstimateLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ChangeInAccountingEstimateLineItems" xlink:to="lab_us-gaap_ChangeInAccountingEstimateLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_7308283f-0c01-40ca-a959-3968c1a8a311_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares used in calculation of earnings per share:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_a54648e7-cd79-4904-9596-f5dbb003167d_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_AkouosAcquisitionMember_bcd82b7f-1595-4d9f-876b-9455d739c680_terseLabel_en-US" xlink:label="lab_lly_AkouosAcquisitionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Akouos Acquisition</link:label>
    <link:label id="lab_lly_AkouosAcquisitionMember_label_en-US" xlink:label="lab_lly_AkouosAcquisitionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Akouos Acquisition [Member]</link:label>
    <link:label id="lab_lly_AkouosAcquisitionMember_documentation_en-US" xlink:label="lab_lly_AkouosAcquisitionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Akouos Acquisition [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AkouosAcquisitionMember" xlink:href="lly-20220930.xsd#lly_AkouosAcquisitionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_AkouosAcquisitionMember" xlink:to="lab_lly_AkouosAcquisitionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_660d19f7-3302-4ca9-8279-7d6a9973b594_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember_9a9565a2-721a-45ff-8889-55d9b2802314_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior service benefits, net</link:label>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Defined Benefit Plans Adjustment, Net Prior Service Including Portion Attributable to Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember" xlink:to="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_SellEuroMember_f3aa8d21-d54d-4da6-a527-60579434ff18_terseLabel_en-US" xlink:label="lab_lly_SellEuroMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sell Euro</link:label>
    <link:label id="lab_lly_SellEuroMember_label_en-US" xlink:label="lab_lly_SellEuroMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sell Euro [Member]</link:label>
    <link:label id="lab_lly_SellEuroMember_documentation_en-US" xlink:label="lab_lly_SellEuroMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sell Euro [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_SellEuroMember" xlink:href="lly-20220930.xsd#lly_SellEuroMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_SellEuroMember" xlink:to="lab_lly_SellEuroMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A1125NotesDue2051Member_7307b854-1764-4049-a9ac-7d56e9ea1444_terseLabel_en-US" xlink:label="lab_lly_A1125NotesDue2051Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.125% Notes due 2051</link:label>
    <link:label id="lab_lly_A1125NotesDue2051Member_label_en-US" xlink:label="lab_lly_A1125NotesDue2051Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.125% Notes Due 2051 [Member]</link:label>
    <link:label id="lab_lly_A1125NotesDue2051Member_documentation_en-US" xlink:label="lab_lly_A1125NotesDue2051Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.125% Notes Due 2051</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1125NotesDue2051Member" xlink:href="lly-20220930.xsd#lly_A1125NotesDue2051Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A1125NotesDue2051Member" xlink:to="lab_lly_A1125NotesDue2051Member" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A1.625NotesDueJune22026Member_fa8d70ca-3bff-4c2c-8695-610182f00a4b_terseLabel_en-US" xlink:label="lab_lly_A1.625NotesDueJune22026Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.625% Notes due 2026</link:label>
    <link:label id="lab_lly_A1.625NotesDueJune22026Member_label_en-US" xlink:label="lab_lly_A1.625NotesDueJune22026Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.625% Notes Due June 2, 2026 [Member]</link:label>
    <link:label id="lab_lly_A1.625NotesDueJune22026Member_documentation_en-US" xlink:label="lab_lly_A1.625NotesDueJune22026Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.625% Notes Due June 2, 2026 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1.625NotesDueJune22026Member" xlink:href="lly-20220930.xsd#lly_A1.625NotesDueJune22026Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A1.625NotesDueJune22026Member" xlink:to="lab_lly_A1.625NotesDueJune22026Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_bbbe5e87-8131-41f1-9c1c-2cfb0b5a748f_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_label_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingRelationshipDomain" xlink:to="lab_us-gaap_HedgingRelationshipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_02d0f67d-9f8e-4663-91fb-9b057488d3e0_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationAxis" xlink:to="lab_us-gaap_HedgingDesignationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_InsulinMember_0db6a920-4b1c-4b9a-bdc8-66b62759c074_terseLabel_en-US" xlink:label="lab_lly_InsulinMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insulin</link:label>
    <link:label id="lab_lly_InsulinMember_label_en-US" xlink:label="lab_lly_InsulinMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insulin [Member]</link:label>
    <link:label id="lab_lly_InsulinMember_documentation_en-US" xlink:label="lab_lly_InsulinMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insulin</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_InsulinMember" xlink:href="lly-20220930.xsd#lly_InsulinMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_InsulinMember" xlink:to="lab_lly_InsulinMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_92dd2c93-a2ea-40f3-9ac9-18a42756ef5e_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_428f6f7d-84b6-4ed5-910f-2f413d60a862_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eli Lilly and Company Shareholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_9c9e636c-6b6a-4225-995e-76815a9cadc0_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_727ae484-2ec6-4e42-8cb5-894348e98a44_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S.</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesHeldInEmployeeTrust_8b7525a8-3e40-4bfa-8731-dc6696d5473e_negatedLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesHeldInEmployeeTrust" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee benefit trust</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesHeldInEmployeeTrust_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesHeldInEmployeeTrust" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Held in Employee Trust</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesHeldInEmployeeTrust" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesHeldInEmployeeTrust"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesHeldInEmployeeTrust" xlink:to="lab_us-gaap_CommonStockSharesHeldInEmployeeTrust" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_9e303986-4f71-4d4c-b8c9-18bdaee4b4ac_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies (Note 9)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_0c4b8f1f-0065-462b-9bb2-0d471f39710b_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TrustForBenefitOfEmployeesMember_3631883e-4da9-4ea8-b89d-fcd865293867_terseLabel_en-US" xlink:label="lab_us-gaap_TrustForBenefitOfEmployeesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Benefit Trust</link:label>
    <link:label id="lab_us-gaap_TrustForBenefitOfEmployeesMember_label_en-US" xlink:label="lab_us-gaap_TrustForBenefitOfEmployeesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trust for Benefit of Employees [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrustForBenefitOfEmployeesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TrustForBenefitOfEmployeesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TrustForBenefitOfEmployeesMember" xlink:to="lab_us-gaap_TrustForBenefitOfEmployeesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_901d9bcb-64be-41f2-99d2-71b5e6d8735e_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, notional amount</link:label>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_label_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Notional Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeNotionalAmount" xlink:to="lab_us-gaap_DerivativeNotionalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_TYVYTMember_d6d7c5c9-851c-4c29-8245-3f04e7eb950a_terseLabel_en-US" xlink:label="lab_lly_TYVYTMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tyvyt&#174;</link:label>
    <link:label id="lab_lly_TYVYTMember_label_en-US" xlink:label="lab_lly_TYVYTMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TYVYT [Member]</link:label>
    <link:label id="lab_lly_TYVYTMember_documentation_en-US" xlink:label="lab_lly_TYVYTMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TYVYT</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_TYVYTMember" xlink:href="lly-20220930.xsd#lly_TYVYTMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_TYVYTMember" xlink:to="lab_lly_TYVYTMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanServiceCost_c32156d7-5577-4289-9569-a6cc3d4c3027_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanServiceCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanServiceCost_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanServiceCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Service Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanServiceCost" xlink:to="lab_us-gaap_DefinedBenefitPlanServiceCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtCurrent_41679818-2c96-4ddb-a3dc-744d01bbcc05_terseLabel_en-US" xlink:label="lab_us-gaap_DebtCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term borrowings and current maturities of long-term debt</link:label>
    <link:label id="lab_us-gaap_DebtCurrent_label_en-US" xlink:label="lab_us-gaap_DebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtCurrent" xlink:to="lab_us-gaap_DebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_84f398c2-5a26-484c-9feb-48862861579c_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Noncurrent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_7db1f4f1-ebe7-4ed7-b8c2-84c97f1e8646_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_01ea3a08-cc5b-4739-a0e4-ec22e9f6454d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Unobservable Inputs (Level 3)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_ba6e1227-7241-417b-a2f7-a565e5f995a0_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncurrent investments</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireLongtermInvestments_08fc3173-107a-4bfa-a40c-6afa386fdee0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireLongtermInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of noncurrent investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireLongtermInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireLongtermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Long-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireLongtermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireLongtermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireLongtermInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireLongtermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_83373eee-3023-455f-bf29-cf84e4b8fc55_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities [Abstract]</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_LossContingencyNumberOfSitesJointlyAndSeverallyLiableForCleanup_e5683e4f-f093-4e56-97bf-7cec8c18c21b_terseLabel_en-US" xlink:label="lab_lly_LossContingencyNumberOfSitesJointlyAndSeverallyLiableForCleanup" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of sites jointly and severally liable for cleanup (fewer than)</link:label>
    <link:label id="lab_lly_LossContingencyNumberOfSitesJointlyAndSeverallyLiableForCleanup_label_en-US" xlink:label="lab_lly_LossContingencyNumberOfSitesJointlyAndSeverallyLiableForCleanup" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number Of Sites Jointly And Severally Liable For Cleanup</link:label>
    <link:label id="lab_lly_LossContingencyNumberOfSitesJointlyAndSeverallyLiableForCleanup_documentation_en-US" xlink:label="lab_lly_LossContingencyNumberOfSitesJointlyAndSeverallyLiableForCleanup" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number Of Sites Jointly And Severally Liable For Cleanup</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_LossContingencyNumberOfSitesJointlyAndSeverallyLiableForCleanup" xlink:href="lly-20220930.xsd#lly_LossContingencyNumberOfSitesJointlyAndSeverallyLiableForCleanup"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_LossContingencyNumberOfSitesJointlyAndSeverallyLiableForCleanup" xlink:to="lab_lly_LossContingencyNumberOfSitesJointlyAndSeverallyLiableForCleanup" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_a2b61547-df2e-4a72-8a64-112b6e8d67aa_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in deferred income taxes</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Deferred Income Taxes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:to="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_c7aab75a-04bb-4864-abb0-ef83da46055a_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAcquiredFromAcquisition_60c5083b-27b4-4c11-802a-5838bc4da5a1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_CashAcquiredFromAcquisition" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash acquired</link:label>
    <link:label id="lab_us-gaap_CashAcquiredFromAcquisition_label_en-US" xlink:label="lab_us-gaap_CashAcquiredFromAcquisition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Acquired from Acquisition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAcquiredFromAcquisition" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAcquiredFromAcquisition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAcquiredFromAcquisition" xlink:to="lab_us-gaap_CashAcquiredFromAcquisition" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_OncologyMember_90edc745-b5b3-4b6f-bc41-265c7c3358db_terseLabel_en-US" xlink:label="lab_lly_OncologyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oncology</link:label>
    <link:label id="lab_lly_OncologyMember_label_en-US" xlink:label="lab_lly_OncologyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oncology [Member]</link:label>
    <link:label id="lab_lly_OncologyMember_documentation_en-US" xlink:label="lab_lly_OncologyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue to unaffiliated customers, Oncology</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OncologyMember" xlink:href="lly-20220930.xsd#lly_OncologyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_OncologyMember" xlink:to="lab_lly_OncologyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_e2761d7d-dc93-45da-bac1-4a0b0d86ab76_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interests</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember" xlink:to="lab_us-gaap_NoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssetsCurrent_d5bbf965-ea1a-4789-b960-5c86e326403d_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other receivables</link:label>
    <link:label id="lab_us-gaap_DerivativeAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_DerivativeAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssetsCurrent" xlink:to="lab_us-gaap_DerivativeAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioForecastMember_08c7c811-4c57-4093-aa05-57f61ec94bec_terseLabel_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast</link:label>
    <link:label id="lab_srt_ScenarioForecastMember_label_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioForecastMember" xlink:to="lab_srt_ScenarioForecastMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_MilestonePaymentsSuccessBasedRegulatoryAndSalesBasedMember_4f9e33d9-0c8a-4673-beb5-09d0038c4118_terseLabel_en-US" xlink:label="lab_lly_MilestonePaymentsSuccessBasedRegulatoryAndSalesBasedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments, Success-based Regulatory and Sales-based</link:label>
    <link:label id="lab_lly_MilestonePaymentsSuccessBasedRegulatoryAndSalesBasedMember_label_en-US" xlink:label="lab_lly_MilestonePaymentsSuccessBasedRegulatoryAndSalesBasedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments, Success-based Regulatory And Sales-based [Member]</link:label>
    <link:label id="lab_lly_MilestonePaymentsSuccessBasedRegulatoryAndSalesBasedMember_documentation_en-US" xlink:label="lab_lly_MilestonePaymentsSuccessBasedRegulatoryAndSalesBasedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments, Success-based Regulatory And Sales-based</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MilestonePaymentsSuccessBasedRegulatoryAndSalesBasedMember" xlink:href="lly-20220930.xsd#lly_MilestonePaymentsSuccessBasedRegulatoryAndSalesBasedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_MilestonePaymentsSuccessBasedRegulatoryAndSalesBasedMember" xlink:to="lab_lly_MilestonePaymentsSuccessBasedRegulatoryAndSalesBasedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_EmgalityMember_4e6d2e18-3666-4716-86e9-7005c0b1b6ee_terseLabel_en-US" xlink:label="lab_lly_EmgalityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Emgality&#174;</link:label>
    <link:label id="lab_lly_EmgalityMember_label_en-US" xlink:label="lab_lly_EmgalityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Emgality [Member]</link:label>
    <link:label id="lab_lly_EmgalityMember_documentation_en-US" xlink:label="lab_lly_EmgalityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Emgality [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_EmgalityMember" xlink:href="lly-20220930.xsd#lly_EmgalityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_EmgalityMember" xlink:to="lab_lly_EmgalityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_MilestonePaymentsDevelopmentAndRegulatoryMember_a72326df-f97d-42f0-8cbc-2ec2a54b3a77_terseLabel_en-US" xlink:label="lab_lly_MilestonePaymentsDevelopmentAndRegulatoryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments, Development and Regulatory</link:label>
    <link:label id="lab_lly_MilestonePaymentsDevelopmentAndRegulatoryMember_label_en-US" xlink:label="lab_lly_MilestonePaymentsDevelopmentAndRegulatoryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments, Development and Regulatory [Member]</link:label>
    <link:label id="lab_lly_MilestonePaymentsDevelopmentAndRegulatoryMember_documentation_en-US" xlink:label="lab_lly_MilestonePaymentsDevelopmentAndRegulatoryMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments, Development and Regulatory [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MilestonePaymentsDevelopmentAndRegulatoryMember" xlink:href="lly-20220930.xsd#lly_MilestonePaymentsDevelopmentAndRegulatoryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_MilestonePaymentsDevelopmentAndRegulatoryMember" xlink:to="lab_lly_MilestonePaymentsDevelopmentAndRegulatoryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivablesNetCurrentAbstract_a15367d7-3406-4c79-9159-06f7231008a8_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivablesNetCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables, Net, Current [Abstract]</link:label>
    <link:label id="lab_us-gaap_ReceivablesNetCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_ReceivablesNetCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables, Net, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesNetCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesNetCurrentAbstract" xlink:to="lab_us-gaap_ReceivablesNetCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_033d0ab1-5835-4b47-9f6f-f91db139e3cf_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember_38991fcc-4aef-4a92-8c04-998decbf71da_terseLabel_en-US" xlink:label="lab_us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost</link:label>
    <link:label id="lab_us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion at Other than Fair Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember" xlink:to="lab_us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_4ec3a3de-ace9-443f-8020-84f2b7046e46_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, term</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTerm" xlink:to="lab_us-gaap_DebtInstrumentTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_a43bd7c5-7609-4afe-860b-6e5dd322a9ac_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangements and Non-collaborative Arrangements [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_9548d1f0-2332-4a9e-8771-3899f84d19a2_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</link:label>
    <link:label id="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_label_en-US" xlink:label="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems" xlink:to="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1_c1b97c5b-cd04-4302-a4be-c7259caa4224_negatedLabel_en-US" xlink:label="lab_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect from hedged fixed-rate debt</link:label>
    <link:label id="lab_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1_label_en-US" xlink:label="lab_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Unrealized Gain (Loss) on Hedged Item in Fair Value Hedge</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" xlink:to="lab_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_bbc1fe07-3c87-4286-99fb-a910f4343fa3_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ExtinguishmentOfDebtAmount_79061be1-d881-4a9a-81b8-7cad1d67a8e5_terseLabel_en-US" xlink:label="lab_us-gaap_ExtinguishmentOfDebtAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Extinguishment of debt, amount</link:label>
    <link:label id="lab_us-gaap_ExtinguishmentOfDebtAmount_label_en-US" xlink:label="lab_us-gaap_ExtinguishmentOfDebtAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Extinguishment of Debt, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExtinguishmentOfDebtAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ExtinguishmentOfDebtAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ExtinguishmentOfDebtAmount" xlink:to="lab_us-gaap_ExtinguishmentOfDebtAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_60468e67-8983-4aa5-983c-da505441c842_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock repurchase program, remaining authorized amount</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Remaining Authorized Repurchase Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A6.77NotesDueJanuary12036Member_21a7a810-745e-4004-8d9e-c032f4cc583a_terseLabel_en-US" xlink:label="lab_lly_A6.77NotesDueJanuary12036Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.77%&#160;Notes due 2036</link:label>
    <link:label id="lab_lly_A6.77NotesDueJanuary12036Member_label_en-US" xlink:label="lab_lly_A6.77NotesDueJanuary12036Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.77%&#160;Notes Due January&#160;1, 2036 [Member]</link:label>
    <link:label id="lab_lly_A6.77NotesDueJanuary12036Member_documentation_en-US" xlink:label="lab_lly_A6.77NotesDueJanuary12036Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.77%&#160;Notes Due January&#160;1, 2036 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A6.77NotesDueJanuary12036Member" xlink:href="lly-20220930.xsd#lly_A6.77NotesDueJanuary12036Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A6.77NotesDueJanuary12036Member" xlink:to="lab_lly_A6.77NotesDueJanuary12036Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonUsMember_e4184e15-7bcd-4069-bb8a-62001fe4b166_terseLabel_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outside U.S.</link:label>
    <link:label id="lab_us-gaap_NonUsMember_label_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-US [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonUsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonUsMember" xlink:to="lab_us-gaap_NonUsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_SalesRebatesAndDiscounts_e3e97dd1-729b-4578-abe1-903314be06e5_terseLabel_en-US" xlink:label="lab_lly_SalesRebatesAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales rebates and discounts</link:label>
    <link:label id="lab_lly_SalesRebatesAndDiscounts_label_en-US" xlink:label="lab_lly_SalesRebatesAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Rebates And Discounts</link:label>
    <link:label id="lab_lly_SalesRebatesAndDiscounts_documentation_en-US" xlink:label="lab_lly_SalesRebatesAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Rebates And Discounts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_SalesRebatesAndDiscounts" xlink:href="lly-20220930.xsd#lly_SalesRebatesAndDiscounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_SalesRebatesAndDiscounts" xlink:to="lab_lly_SalesRebatesAndDiscounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5f43752b-f11c-41b2-8304-3731891cf050_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NondesignatedMember_55c4323d-2bfe-45fc-a8a8-a0ba7f1403a8_terseLabel_en-US" xlink:label="lab_us-gaap_NondesignatedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Not Designated as Hedging Instrument</link:label>
    <link:label id="lab_us-gaap_NondesignatedMember_label_en-US" xlink:label="lab_us-gaap_NondesignatedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Not Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NondesignatedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NondesignatedMember" xlink:to="lab_us-gaap_NondesignatedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_35674613-f1cc-4d60-84dd-f92f196f6542_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for acquisitions, net of cash acquired (Note 3)</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_f45fe1a0-c52b-4d60-8bc7-d5c4cee8f5c6_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid, net of cash acquired</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Net of Cash Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_09fae707-1f7e-4f88-9d25-612dea9dab4c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Other Observable Inputs (Level 2)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_ed794a7d-a049-427d-96c0-b8e3c3f2862d_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_DerivativeInstrumentsGainLossRecognized_631f2405-9cdd-4806-ab86-2d72bdb21ea2_negatedTotalLabel_en-US" xlink:label="lab_lly_DerivativeInstrumentsGainLossRecognized" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_lly_DerivativeInstrumentsGainLossRecognized_label_en-US" xlink:label="lab_lly_DerivativeInstrumentsGainLossRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) Recognized</link:label>
    <link:label id="lab_lly_DerivativeInstrumentsGainLossRecognized_documentation_en-US" xlink:label="lab_lly_DerivativeInstrumentsGainLossRecognized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DerivativeInstrumentsGainLossRecognized" xlink:href="lly-20220930.xsd#lly_DerivativeInstrumentsGainLossRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_DerivativeInstrumentsGainLossRecognized" xlink:to="lab_lly_DerivativeInstrumentsGainLossRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_CialisMember_d00700b1-db92-422e-a4bb-f9d35047a329_terseLabel_en-US" xlink:label="lab_lly_CialisMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cialis&#174;</link:label>
    <link:label id="lab_lly_CialisMember_label_en-US" xlink:label="lab_lly_CialisMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cialis [Member]</link:label>
    <link:label id="lab_lly_CialisMember_documentation_en-US" xlink:label="lab_lly_CialisMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cialis [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CialisMember" xlink:href="lly-20220930.xsd#lly_CialisMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_CialisMember" xlink:to="lab_lly_CialisMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_d70bc002-082a-4ccf-a0d6-5190af7a3442_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other intangibles, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_c92615b9-6439-4ae7-9cda-b5a83ce56242_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_OtherEquitySecuritiesMember_2264d03d-7ad6-40b6-b2db-d9807533eea6_terseLabel_en-US" xlink:label="lab_lly_OtherEquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other securities, noncurrent investments</link:label>
    <link:label id="lab_lly_OtherEquitySecuritiesMember_label_en-US" xlink:label="lab_lly_OtherEquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Equity Securities [Member]</link:label>
    <link:label id="lab_lly_OtherEquitySecuritiesMember_documentation_en-US" xlink:label="lab_lly_OtherEquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Equity Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OtherEquitySecuritiesMember" xlink:href="lly-20220930.xsd#lly_OtherEquitySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_OtherEquitySecuritiesMember" xlink:to="lab_lly_OtherEquitySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_e447e318-bde2-43c7-aca3-07e6c348621e_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue_2127feca-054a-4555-9bb8-e3959a9d2686_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">More&#160;Than 10 Years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 10</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesNoncurrent_5e30a135-5858-4914-bf09-59d0d50b25c0_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term income taxes payable</link:label>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesNoncurrent_label_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Income Taxes, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedIncomeTaxesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:to="lab_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_CollaborationandOtherRevenueMember_a71acc18-50b8-4934-a825-64ebc31dca6d_verboseLabel_en-US" xlink:label="lab_lly_CollaborationandOtherRevenueMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and other revenue</link:label>
    <link:label id="lab_lly_CollaborationandOtherRevenueMember_label_en-US" xlink:label="lab_lly_CollaborationandOtherRevenueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and Other Revenue [Member]</link:label>
    <link:label id="lab_lly_CollaborationandOtherRevenueMember_documentation_en-US" xlink:label="lab_lly_CollaborationandOtherRevenueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and Other Revenue [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CollaborationandOtherRevenueMember" xlink:href="lly-20220930.xsd#lly_CollaborationandOtherRevenueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_CollaborationandOtherRevenueMember" xlink:to="lab_lly_CollaborationandOtherRevenueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_91fe8099-ef84-46b3-ba8b-f4b78e50aec5_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_216fc75c-5c84-4897-8e34-d3bd85af1345_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RoyaltyAgreementTermsMember_1f5d8320-9576-4e6d-bdf6-1a04cc98cca6_terseLabel_en-US" xlink:label="lab_us-gaap_RoyaltyAgreementTermsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Agreement Terms</link:label>
    <link:label id="lab_us-gaap_RoyaltyAgreementTermsMember_label_en-US" xlink:label="lab_us-gaap_RoyaltyAgreementTermsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Agreement Terms [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyAgreementTermsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyAgreementTermsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyAgreementTermsMember" xlink:to="lab_us-gaap_RoyaltyAgreementTermsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_2271d515-e09f-4f8d-b265-9f2d3d64d48e_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossTax_a5682a52-8dfe-456f-8d3c-312d324ed2ab_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefit (expense) for income taxes allocated to other comprehensive income (loss) items</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_4bab0ce4-a8eb-48d6-b754-491d1698012c_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other financing activities, net</link:label>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from (Payments for) Other Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:to="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_8ae76b7c-fd2d-4c19-825c-844a96a57e3a_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract liabilities</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_662b7efc-eea1-4abb-84f8-1d3bb93dca1e_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining contract liabilities</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_BusinessCombinationConsiderationTransferredNumberOfContingentValueRights_ad934292-ec05-471f-bd26-b85370257869_terseLabel_en-US" xlink:label="lab_lly_BusinessCombinationConsiderationTransferredNumberOfContingentValueRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration transferred, number of contingent value rights</link:label>
    <link:label id="lab_lly_BusinessCombinationConsiderationTransferredNumberOfContingentValueRights_label_en-US" xlink:label="lab_lly_BusinessCombinationConsiderationTransferredNumberOfContingentValueRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Number Of Contingent Value Rights</link:label>
    <link:label id="lab_lly_BusinessCombinationConsiderationTransferredNumberOfContingentValueRights_documentation_en-US" xlink:label="lab_lly_BusinessCombinationConsiderationTransferredNumberOfContingentValueRights" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Number Of Contingent Value Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BusinessCombinationConsiderationTransferredNumberOfContingentValueRights" xlink:href="lly-20220930.xsd#lly_BusinessCombinationConsiderationTransferredNumberOfContingentValueRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_BusinessCombinationConsiderationTransferredNumberOfContingentValueRights" xlink:to="lab_lly_BusinessCombinationConsiderationTransferredNumberOfContingentValueRights" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_3c3ef0cb-f230-4366-a6aa-ab12b382594b_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible asset impairment</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Intangible Assets, Indefinite-Lived (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_13168084-526c-4268-a473-e344e4e55e43_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A1375NotesDue2061Member_23d7509c-2461-43cc-b4a5-1af4f5afd75e_terseLabel_en-US" xlink:label="lab_lly_A1375NotesDue2061Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.375% Notes due 2061</link:label>
    <link:label id="lab_lly_A1375NotesDue2061Member_label_en-US" xlink:label="lab_lly_A1375NotesDue2061Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.375% Notes Due 2061 [Member]</link:label>
    <link:label id="lab_lly_A1375NotesDue2061Member_documentation_en-US" xlink:label="lab_lly_A1375NotesDue2061Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.375% Notes Due 2061</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1375NotesDue2061Member" xlink:href="lly-20220930.xsd#lly_A1375NotesDue2061Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A1375NotesDue2061Member" xlink:to="lab_lly_A1375NotesDue2061Member" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EuropeMember_1d85f142-2c0d-4395-a479-be1f68a69d51_terseLabel_en-US" xlink:label="lab_srt_EuropeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Europe</link:label>
    <link:label id="lab_srt_EuropeMember_label_en-US" xlink:label="lab_srt_EuropeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Europe [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EuropeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EuropeMember" xlink:to="lab_srt_EuropeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_b108ae0d-6173-4d59-ba6c-776aeece9bf3_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_2cc5e23d-8b4e-432a-8135-95b5a847ab40_negatedLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected return on plan assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Return (Loss) on Plan Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_61457d8b-5223-462a-a184-a7b2ee06ebaa_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_a9806003-8431-4baf-a56b-b3b188346a46_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A3375NotesDue2029Member_4a4d1a48-2645-4744-86a6-e8c15e317cd7_terseLabel_en-US" xlink:label="lab_lly_A3375NotesDue2029Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.375% Notes Due 2029</link:label>
    <link:label id="lab_lly_A3375NotesDue2029Member_label_en-US" xlink:label="lab_lly_A3375NotesDue2029Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.375% Notes Due 2029 [Member]</link:label>
    <link:label id="lab_lly_A3375NotesDue2029Member_documentation_en-US" xlink:label="lab_lly_A3375NotesDue2029Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.375% Notes Due 2029 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A3375NotesDue2029Member" xlink:href="lly-20220930.xsd#lly_A3375NotesDue2029Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A3375NotesDue2029Member" xlink:to="lab_lly_A3375NotesDue2029Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanTypeAxis_23ae6fa3-f30c-48af-bd47-be2e89c87f7d_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Axis]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanTypeAxis_label_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanTypeAxis" xlink:to="lab_us-gaap_RetirementPlanTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_PrevailTherapeuticsIncMember_c64f4ba5-4681-462e-a04f-096cdd078aa2_terseLabel_en-US" xlink:label="lab_lly_PrevailTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prevail Therapeutics Inc.</link:label>
    <link:label id="lab_lly_PrevailTherapeuticsIncMember_label_en-US" xlink:label="lab_lly_PrevailTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prevail Therapeutics Inc. [Member]</link:label>
    <link:label id="lab_lly_PrevailTherapeuticsIncMember_documentation_en-US" xlink:label="lab_lly_PrevailTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prevail Therapeutics Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_PrevailTherapeuticsIncMember" xlink:href="lly-20220930.xsd#lly_PrevailTherapeuticsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_PrevailTherapeuticsIncMember" xlink:to="lab_lly_PrevailTherapeuticsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_HumulinMember_c67b3e93-35a5-4126-a10f-dcad4a7ab793_terseLabel_en-US" xlink:label="lab_lly_HumulinMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Humulin&#174;</link:label>
    <link:label id="lab_lly_HumulinMember_label_en-US" xlink:label="lab_lly_HumulinMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Humulin [Member]</link:label>
    <link:label id="lab_lly_HumulinMember_documentation_en-US" xlink:label="lab_lly_HumulinMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Humulin [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_HumulinMember" xlink:href="lly-20220930.xsd#lly_HumulinMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_HumulinMember" xlink:to="lab_lly_HumulinMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_d476eba1-a3f8-4ef5-a301-88212a8079fc_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_HumalogMember_2cb33133-76f7-44a4-92a8-da367d9220e6_terseLabel_en-US" xlink:label="lab_lly_HumalogMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Humalog&#174;</link:label>
    <link:label id="lab_lly_HumalogMember_label_en-US" xlink:label="lab_lly_HumalogMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Humalog [Member]</link:label>
    <link:label id="lab_lly_HumalogMember_documentation_en-US" xlink:label="lab_lly_HumalogMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Humalog [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_HumalogMember" xlink:href="lly-20220930.xsd#lly_HumalogMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_HumalogMember" xlink:to="lab_lly_HumalogMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_JardianceMember_350a7a8c-0577-48d1-83a7-95d00562171e_terseLabel_en-US" xlink:label="lab_lly_JardianceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Jardiance</link:label>
    <link:label id="lab_lly_JardianceMember_label_en-US" xlink:label="lab_lly_JardianceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Jardiance [Member]</link:label>
    <link:label id="lab_lly_JardianceMember_documentation_en-US" xlink:label="lab_lly_JardianceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Jardiance [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_JardianceMember" xlink:href="lly-20220930.xsd#lly_JardianceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_JardianceMember" xlink:to="lab_lly_JardianceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherReceivablesNetCurrent_2bbb76bd-6437-4d54-af7a-958dc2be4dc6_terseLabel_en-US" xlink:label="lab_us-gaap_OtherReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other receivables</link:label>
    <link:label id="lab_us-gaap_OtherReceivablesNetCurrent_label_en-US" xlink:label="lab_us-gaap_OtherReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Receivables, Net, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherReceivablesNetCurrent" xlink:to="lab_us-gaap_OtherReceivablesNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_9026d874-2533-4ebf-be12-a9f7866cf641_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnfavorableRegulatoryActionMember_434fec07-74f8-4ca4-b8de-e3c805261835_terseLabel_en-US" xlink:label="lab_us-gaap_UnfavorableRegulatoryActionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unfavorable Regulatory Action</link:label>
    <link:label id="lab_us-gaap_UnfavorableRegulatoryActionMember_label_en-US" xlink:label="lab_us-gaap_UnfavorableRegulatoryActionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unfavorable Regulatory Action [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnfavorableRegulatoryActionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnfavorableRegulatoryActionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnfavorableRegulatoryActionMember" xlink:to="lab_us-gaap_UnfavorableRegulatoryActionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1_4de7fb46-61f8-485c-b8ed-5d4c05992cf2_terseLabel_en-US" xlink:label="lab_us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum remaining maturity of foreign currency derivatives</link:label>
    <link:label id="lab_us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1_label_en-US" xlink:label="lab_us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Remaining Maturity of Foreign Currency Derivatives</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1" xlink:to="lab_us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_ForteoMember_0c031d97-8187-4149-9502-a082101c9e02_terseLabel_en-US" xlink:label="lab_lly_ForteoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forteo&#174;</link:label>
    <link:label id="lab_lly_ForteoMember_label_en-US" xlink:label="lab_lly_ForteoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forteo [Member]</link:label>
    <link:label id="lab_lly_ForteoMember_documentation_en-US" xlink:label="lab_lly_ForteoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forteo [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ForteoMember" xlink:href="lly-20220930.xsd#lly_ForteoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_ForteoMember" xlink:to="lab_lly_ForteoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_90fafed2-1994-45d6-b1e1-452e66945ff7_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of disaggregation of revenue</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_8b1e0ecd-9823-4d67-9aaa-a750b353fb5f_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_TrajentaBIMember_39ea7b94-7380-4f13-8998-c02634343a3d_terseLabel_en-US" xlink:label="lab_lly_TrajentaBIMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trajenta</link:label>
    <link:label id="lab_lly_TrajentaBIMember_label_en-US" xlink:label="lab_lly_TrajentaBIMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trajenta (BI) [Member]</link:label>
    <link:label id="lab_lly_TrajentaBIMember_documentation_en-US" xlink:label="lab_lly_TrajentaBIMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trajenta (BI) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_TrajentaBIMember" xlink:href="lly-20220930.xsd#lly_TrajentaBIMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_TrajentaBIMember" xlink:to="lab_lly_TrajentaBIMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DividendsPayableCurrent_5d46438b-0e92-40ef-b6e6-3dc44eaa25dd_terseLabel_en-US" xlink:label="lab_us-gaap_DividendsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends payable</link:label>
    <link:label id="lab_us-gaap_DividendsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_DividendsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsPayableCurrent" xlink:to="lab_us-gaap_DividendsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_10571fbc-2122-4dfb-9ff3-87446e75f50c_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net decrease in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_RocheMember_cea64b84-1b72-4286-9132-bf9c6b384eac_terseLabel_en-US" xlink:label="lab_lly_RocheMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Roche</link:label>
    <link:label id="lab_lly_RocheMember_label_en-US" xlink:label="lab_lly_RocheMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Roche [Member]</link:label>
    <link:label id="lab_lly_RocheMember_documentation_en-US" xlink:label="lab_lly_RocheMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Roche [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_RocheMember" xlink:href="lly-20220930.xsd#lly_RocheMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_RocheMember" xlink:to="lab_lly_RocheMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_5d802a25-d717-4c85-b655-7cc716147154_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of components of the charges included in asset impairment, restructuring, and other special charges</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Costs [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_9b28b9af-6fa4-4cff-b513-4fadffddde9f_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_b4966bd6-c110-4040-8170-cffe09d86506_negatedLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_89a200ef-51e0-4ada-8c64-0aeb24e25c98_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expenses and Acquired In-Process Research and Development (IPR&amp;D) and Developmental Milestones</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_BuyUSdollarSellJapaneseYenMember_13315c33-9f10-4124-88dc-84197fc0fd11_terseLabel_en-US" xlink:label="lab_lly_BuyUSdollarSellJapaneseYenMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buy U.S. Dollars Sell Japanese Yen</link:label>
    <link:label id="lab_lly_BuyUSdollarSellJapaneseYenMember_label_en-US" xlink:label="lab_lly_BuyUSdollarSellJapaneseYenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buy US dollar Sell Japanese Yen [Member]</link:label>
    <link:label id="lab_lly_BuyUSdollarSellJapaneseYenMember_documentation_en-US" xlink:label="lab_lly_BuyUSdollarSellJapaneseYenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buy US dollar Sell Japanese Yen [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BuyUSdollarSellJapaneseYenMember" xlink:href="lly-20220930.xsd#lly_BuyUSdollarSellJapaneseYenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_BuyUSdollarSellJapaneseYenMember" xlink:to="lab_lly_BuyUSdollarSellJapaneseYenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_BuyEuroSellUsDollarMember_5f0dfcd5-e8e8-45c9-a068-87f8ad4b2487_terseLabel_en-US" xlink:label="lab_lly_BuyEuroSellUsDollarMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buy Euros Sell U.S. Dollars</link:label>
    <link:label id="lab_lly_BuyEuroSellUsDollarMember_label_en-US" xlink:label="lab_lly_BuyEuroSellUsDollarMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buy Euro Sell Us Dollar [Member]</link:label>
    <link:label id="lab_lly_BuyEuroSellUsDollarMember_documentation_en-US" xlink:label="lab_lly_BuyEuroSellUsDollarMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Forward Commitment to Buy euro Sell US dollar</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BuyEuroSellUsDollarMember" xlink:href="lly-20220930.xsd#lly_BuyEuroSellUsDollarMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_BuyEuroSellUsDollarMember" xlink:to="lab_lly_BuyEuroSellUsDollarMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_0d6ebb50-3225-4e75-ade8-b37c112ecbe2_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborations and Other Arrangements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_BuyUsDollarSellEuroMember_625ced1c-c673-4310-b794-63aa2a7bcb8e_terseLabel_en-US" xlink:label="lab_lly_BuyUsDollarSellEuroMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buy U.S. Dollars Sell Euros</link:label>
    <link:label id="lab_lly_BuyUsDollarSellEuroMember_label_en-US" xlink:label="lab_lly_BuyUsDollarSellEuroMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buy Us Dollar Sell Euro [Member]</link:label>
    <link:label id="lab_lly_BuyUsDollarSellEuroMember_documentation_en-US" xlink:label="lab_lly_BuyUsDollarSellEuroMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Forward commitment to Buy US dollar Sell euro</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BuyUsDollarSellEuroMember" xlink:href="lly-20220930.xsd#lly_BuyUsDollarSellEuroMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_BuyUsDollarSellEuroMember" xlink:to="lab_lly_BuyUsDollarSellEuroMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_4783bec7-9f99-4d18-8e96-15d5b5dfb358_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Nature [Axis]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_label_en-US" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Nature [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:to="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityDomain_076dc267-b304-47d3-991a-d5118f231c2b_terseLabel_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_label_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_e8942894-ec01-4a0b-80f2-4c03797f227d_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_2f5316da-3cee-44c0-a1cc-b1872b497048_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_8a47fff3-5e41-4931-ac80-cdc3cdf96c76_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other changes in operating assets and liabilities, net of acquisitions and divestitures</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets and Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_9903f015-8c8e-4c03-bda1-3ab165534851_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_e2f050f2-48b0-417b-8d08-ecc0f861cd0c_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherDebtSecuritiesMember_058dd76a-575f-4cb6-a8ea-facb10e44334_terseLabel_en-US" xlink:label="lab_us-gaap_OtherDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other securities</link:label>
    <link:label id="lab_us-gaap_OtherDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_OtherDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Debt Obligations [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherDebtSecuritiesMember" xlink:to="lab_us-gaap_OtherDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_SwapU.S.DollarsToEuroMember_021b2d50-0cd6-4497-bb8d-e47e58ee13ae_terseLabel_en-US" xlink:label="lab_lly_SwapU.S.DollarsToEuroMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Swap U.S. Dollars to Euro</link:label>
    <link:label id="lab_lly_SwapU.S.DollarsToEuroMember_label_en-US" xlink:label="lab_lly_SwapU.S.DollarsToEuroMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Swap U.S. Dollars To Euro [Member]</link:label>
    <link:label id="lab_lly_SwapU.S.DollarsToEuroMember_documentation_en-US" xlink:label="lab_lly_SwapU.S.DollarsToEuroMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Swap U.S. Dollars To Euro [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_SwapU.S.DollarsToEuroMember" xlink:href="lly-20220930.xsd#lly_SwapU.S.DollarsToEuroMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_SwapU.S.DollarsToEuroMember" xlink:to="lab_lly_SwapU.S.DollarsToEuroMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_f7ee00b9-8053-4c2b-8572-eb1054335cd0_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments_79d5b22f-47ce-41d1-8cdf-850304e18384_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alternative investments, unfunded commitments</link:label>
    <link:label id="lab_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments_label_en-US" xlink:label="lab_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Investments, Entities that Calculate Net Asset Value Per Share, Unfunded Commitments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments" xlink:to="lab_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis_9162b371-b0ff-4a46-ab48-05ef4e97814f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0f9aa379-909a-466a-8c6b-5dfe6647847a_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flows from Financing Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnInvestmentsTextBlock_700da921-5b50-4098-97b9-59822194b081_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of activity related to our available-for-sale securities</link:label>
    <link:label id="lab_us-gaap_GainLossOnInvestmentsTextBlock_label_en-US" xlink:label="lab_us-gaap_GainLossOnInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Securities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestmentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnInvestmentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnInvestmentsTextBlock" xlink:to="lab_us-gaap_GainLossOnInvestmentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MortgageBackedSecuritiesMember_02cb059f-695b-445f-a84a-a04f1f6184f0_terseLabel_en-US" xlink:label="lab_us-gaap_MortgageBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage-backed securities</link:label>
    <link:label id="lab_us-gaap_MortgageBackedSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_MortgageBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collateralized Mortgage-Backed Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MortgageBackedSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MortgageBackedSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MortgageBackedSecuritiesMember" xlink:to="lab_us-gaap_MortgageBackedSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_a74b4875-934f-4bbb-9772-897afc297be5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_2270491d-b544-4ee3-9fef-d8ac847cce58_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other noncurrent liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestRateContractMember_b1ba5c4a-6dc7-4dd4-be7d-a01d8c1a799e_terseLabel_en-US" xlink:label="lab_us-gaap_InterestRateContractMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Contracts</link:label>
    <link:label id="lab_us-gaap_InterestRateContractMember_label_en-US" xlink:label="lab_us-gaap_InterestRateContractMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Contract [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateContractMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateContractMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestRateContractMember" xlink:to="lab_us-gaap_InterestRateContractMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockRetiredCostMethodAmount_8dcf9602-5f71-4e4c-b3ef-d687a2bacf80_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement of treasury shares</link:label>
    <link:label id="lab_us-gaap_TreasuryStockRetiredCostMethodAmount_label_en-US" xlink:label="lab_us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Retired, Cost Method, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockRetiredCostMethodAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:to="lab_us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_MounjaroMember_2426a9f4-a9fc-415a-9bef-6a50e009c240_terseLabel_en-US" xlink:label="lab_lly_MounjaroMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mounjaro&#174;</link:label>
    <link:label id="lab_lly_MounjaroMember_label_en-US" xlink:label="lab_lly_MounjaroMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mounjaro [Member]</link:label>
    <link:label id="lab_lly_MounjaroMember_documentation_en-US" xlink:label="lab_lly_MounjaroMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mounjaro [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MounjaroMember" xlink:href="lly-20220930.xsd#lly_MounjaroMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_MounjaroMember" xlink:to="lab_lly_MounjaroMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_8d739987-e949-4862-923d-cadb03e0418b_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_DescriptionOfDerivativeActivityVolumePercent_b0c035ce-b12b-42cf-95a7-074b9ac6644f_terseLabel_en-US" xlink:label="lab_lly_DescriptionOfDerivativeActivityVolumePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of long-term fixed-rate notes to floating rates through the use of interest rate swaps converted</link:label>
    <link:label id="lab_lly_DescriptionOfDerivativeActivityVolumePercent_label_en-US" xlink:label="lab_lly_DescriptionOfDerivativeActivityVolumePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of Derivative Activity Volume Percent</link:label>
    <link:label id="lab_lly_DescriptionOfDerivativeActivityVolumePercent_documentation_en-US" xlink:label="lab_lly_DescriptionOfDerivativeActivityVolumePercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of Derivative Activity Volume Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DescriptionOfDerivativeActivityVolumePercent" xlink:href="lly-20220930.xsd#lly_DescriptionOfDerivativeActivityVolumePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_DescriptionOfDerivativeActivityVolumePercent" xlink:to="lab_lly_DescriptionOfDerivativeActivityVolumePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_ZyprexaMember_18b6cdf7-6d55-4d65-acb8-842a77a333db_terseLabel_en-US" xlink:label="lab_lly_ZyprexaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zyprexa&#174;</link:label>
    <link:label id="lab_lly_ZyprexaMember_label_en-US" xlink:label="lab_lly_ZyprexaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zyprexa [Member]</link:label>
    <link:label id="lab_lly_ZyprexaMember_documentation_en-US" xlink:label="lab_lly_ZyprexaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zyprexa [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ZyprexaMember" xlink:href="lly-20220930.xsd#lly_ZyprexaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_ZyprexaMember" xlink:to="lab_lly_ZyprexaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_c1e3379c-21c5-4f90-95d4-7aa077773b81_terseLabel_en-US" xlink:label="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retiree Health Benefit Plans</link:label>
    <link:label id="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_label_en-US" xlink:label="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Postretirement Benefits Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:to="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilitiesNoncurrent_38ea38f4-e9f7-4f0a-9855-8f6597700075_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other noncurrent liabilities</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:to="lab_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>12
<FILENAME>lly-20220930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:1f63046d-a77a-465e-aed4-1fd7d331378a,g:f755fa79-e9ed-4360-88c0-9c62587f0bf5-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.lilly.com/role/CoverPage" xlink:type="simple" xlink:href="lly-20220930.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_80d14412-6372-473b-ac82-999c54031bd0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable_9e2376c9-79f3-409e-a1dc-5d1cdb1c2fad" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_80d14412-6372-473b-ac82-999c54031bd0" xlink:to="loc_dei_DocumentInformationTable_9e2376c9-79f3-409e-a1dc-5d1cdb1c2fad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_59ffacc9-4e66-4f3b-ae84-456dc6a05bcf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_9e2376c9-79f3-409e-a1dc-5d1cdb1c2fad" xlink:to="loc_us-gaap_StatementClassOfStockAxis_59ffacc9-4e66-4f3b-ae84-456dc6a05bcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_1dc3d308-dfe7-4e80-989b-ae75f81ff455" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_59ffacc9-4e66-4f3b-ae84-456dc6a05bcf" xlink:to="loc_us-gaap_ClassOfStockDomain_1dc3d308-dfe7-4e80-989b-ae75f81ff455" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_54cc28e9-9a15-4def-bc89-c6043a711799" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1dc3d308-dfe7-4e80-989b-ae75f81ff455" xlink:to="loc_us-gaap_CommonClassAMember_54cc28e9-9a15-4def-bc89-c6043a711799" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A718NotesDueJune12025Member_d8275590-66e2-432d-bbb5-ce1faa36d480" xlink:href="lly-20220930.xsd#lly_A718NotesDueJune12025Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1dc3d308-dfe7-4e80-989b-ae75f81ff455" xlink:to="loc_lly_A718NotesDueJune12025Member_d8275590-66e2-432d-bbb5-ce1faa36d480" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1.625NotesDueJune22026Member_a77bad25-47ed-4d64-886b-4fea83ecb9f3" xlink:href="lly-20220930.xsd#lly_A1.625NotesDueJune22026Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1dc3d308-dfe7-4e80-989b-ae75f81ff455" xlink:to="loc_lly_A1.625NotesDueJune22026Member_a77bad25-47ed-4d64-886b-4fea83ecb9f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A2.125NotesDueJune32030Member_8acd9df9-a2cf-417d-9658-21fb54d83a6d" xlink:href="lly-20220930.xsd#lly_A2.125NotesDueJune32030Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1dc3d308-dfe7-4e80-989b-ae75f81ff455" xlink:to="loc_lly_A2.125NotesDueJune32030Member_8acd9df9-a2cf-417d-9658-21fb54d83a6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A625NotesDue2031Member_bf48e6dd-4b65-489e-8e31-10b7dc77a67f" xlink:href="lly-20220930.xsd#lly_A625NotesDue2031Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1dc3d308-dfe7-4e80-989b-ae75f81ff455" xlink:to="loc_lly_A625NotesDue2031Member_bf48e6dd-4b65-489e-8e31-10b7dc77a67f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A500NotesDue2033Member_60bfe2b1-b154-4d5b-8b73-2aa25dd7e248" xlink:href="lly-20220930.xsd#lly_A500NotesDue2033Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1dc3d308-dfe7-4e80-989b-ae75f81ff455" xlink:to="loc_lly_A500NotesDue2033Member_60bfe2b1-b154-4d5b-8b73-2aa25dd7e248" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A6.77NotesDueJanuary12036Member_56652fbc-5e67-4f72-be5e-45c95b3155f1" xlink:href="lly-20220930.xsd#lly_A6.77NotesDueJanuary12036Member"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1dc3d308-dfe7-4e80-989b-ae75f81ff455" xlink:to="loc_lly_A6.77NotesDueJanuary12036Member_56652fbc-5e67-4f72-be5e-45c95b3155f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1625NotesDue2043Member_6546c0ba-f261-46c4-b3b4-dd95f412f8ee" xlink:href="lly-20220930.xsd#lly_A1625NotesDue2043Member"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1dc3d308-dfe7-4e80-989b-ae75f81ff455" xlink:to="loc_lly_A1625NotesDue2043Member_6546c0ba-f261-46c4-b3b4-dd95f412f8ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1700NotesDue2049Member_c04eacc8-e05e-4d61-b91d-4e1bcd3cc1ca" xlink:href="lly-20220930.xsd#lly_A1700NotesDue2049Member"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1dc3d308-dfe7-4e80-989b-ae75f81ff455" xlink:to="loc_lly_A1700NotesDue2049Member_c04eacc8-e05e-4d61-b91d-4e1bcd3cc1ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1125NotesDue2051Member_954a371d-9842-4e82-975a-79386b217475" xlink:href="lly-20220930.xsd#lly_A1125NotesDue2051Member"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1dc3d308-dfe7-4e80-989b-ae75f81ff455" xlink:to="loc_lly_A1125NotesDue2051Member_954a371d-9842-4e82-975a-79386b217475" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1375NotesDue2061Member_fb345301-ceb4-4798-9c1c-85f28563351d" xlink:href="lly-20220930.xsd#lly_A1375NotesDue2061Member"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1dc3d308-dfe7-4e80-989b-ae75f81ff455" xlink:to="loc_lly_A1375NotesDue2061Member_fb345301-ceb4-4798-9c1c-85f28563351d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems_663bb69d-ca95-4b75-b907-b5ccb28d5446" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_9e2376c9-79f3-409e-a1dc-5d1cdb1c2fad" xlink:to="loc_dei_DocumentInformationLineItems_663bb69d-ca95-4b75-b907-b5ccb28d5446" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_50a81e89-8691-43a2-81bb-bad2dcf26b49" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_663bb69d-ca95-4b75-b907-b5ccb28d5446" xlink:to="loc_dei_DocumentType_50a81e89-8691-43a2-81bb-bad2dcf26b49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_7f642852-70d5-4c6c-9e87-c61cdec8c84f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_663bb69d-ca95-4b75-b907-b5ccb28d5446" xlink:to="loc_dei_DocumentQuarterlyReport_7f642852-70d5-4c6c-9e87-c61cdec8c84f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_4ff9db29-c65f-4456-88e2-29c4c9dc53d0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_663bb69d-ca95-4b75-b907-b5ccb28d5446" xlink:to="loc_dei_DocumentTransitionReport_4ff9db29-c65f-4456-88e2-29c4c9dc53d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_456b6f28-4207-4b80-af52-d982ececfd88" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_663bb69d-ca95-4b75-b907-b5ccb28d5446" xlink:to="loc_dei_DocumentPeriodEndDate_456b6f28-4207-4b80-af52-d982ececfd88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_1c019e2d-62f0-408e-812c-297d326d65d2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_663bb69d-ca95-4b75-b907-b5ccb28d5446" xlink:to="loc_dei_EntityFileNumber_1c019e2d-62f0-408e-812c-297d326d65d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_6c465f87-3415-4d39-a2ae-c1bd522507e0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_663bb69d-ca95-4b75-b907-b5ccb28d5446" xlink:to="loc_dei_EntityRegistrantName_6c465f87-3415-4d39-a2ae-c1bd522507e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_b7d373af-f1e0-42ac-bd32-f50860ca174c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_663bb69d-ca95-4b75-b907-b5ccb28d5446" xlink:to="loc_dei_EntityIncorporationStateCountryCode_b7d373af-f1e0-42ac-bd32-f50860ca174c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_d72749bd-e5e6-46af-a961-a26a212afc61" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_663bb69d-ca95-4b75-b907-b5ccb28d5446" xlink:to="loc_dei_EntityTaxIdentificationNumber_d72749bd-e5e6-46af-a961-a26a212afc61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_9ed10252-eebd-440a-b316-43637819a582" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_663bb69d-ca95-4b75-b907-b5ccb28d5446" xlink:to="loc_dei_EntityAddressAddressLine1_9ed10252-eebd-440a-b316-43637819a582" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_eb7a662d-ad57-41d9-b8d7-abd82c8b529b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_663bb69d-ca95-4b75-b907-b5ccb28d5446" xlink:to="loc_dei_EntityAddressCityOrTown_eb7a662d-ad57-41d9-b8d7-abd82c8b529b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_a48d10b9-9a93-4b58-96f6-bc03a380ed03" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_663bb69d-ca95-4b75-b907-b5ccb28d5446" xlink:to="loc_dei_EntityAddressStateOrProvince_a48d10b9-9a93-4b58-96f6-bc03a380ed03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_cd1b91fd-c55a-4162-91b3-f057a666c916" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_663bb69d-ca95-4b75-b907-b5ccb28d5446" xlink:to="loc_dei_EntityAddressPostalZipCode_cd1b91fd-c55a-4162-91b3-f057a666c916" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_8d9ace8e-4245-41c2-8ab8-9f5923ab0e5a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_663bb69d-ca95-4b75-b907-b5ccb28d5446" xlink:to="loc_dei_CityAreaCode_8d9ace8e-4245-41c2-8ab8-9f5923ab0e5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_072f48b2-3e21-48c3-b7b6-59ddb078cbb9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_663bb69d-ca95-4b75-b907-b5ccb28d5446" xlink:to="loc_dei_LocalPhoneNumber_072f48b2-3e21-48c3-b7b6-59ddb078cbb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_ad02fb14-ae03-4651-a28e-eb70801a598d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_663bb69d-ca95-4b75-b907-b5ccb28d5446" xlink:to="loc_dei_Security12bTitle_ad02fb14-ae03-4651-a28e-eb70801a598d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_50ac939f-7d22-41d6-b39f-e7b718378553" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_663bb69d-ca95-4b75-b907-b5ccb28d5446" xlink:to="loc_dei_TradingSymbol_50ac939f-7d22-41d6-b39f-e7b718378553" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_f1586f9e-7ab4-4f46-b9aa-fc08a721cccd" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_663bb69d-ca95-4b75-b907-b5ccb28d5446" xlink:to="loc_dei_SecurityExchangeName_f1586f9e-7ab4-4f46-b9aa-fc08a721cccd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_910b31c0-f586-47b0-bddb-e7043238341d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_663bb69d-ca95-4b75-b907-b5ccb28d5446" xlink:to="loc_dei_EntityCurrentReportingStatus_910b31c0-f586-47b0-bddb-e7043238341d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_91a91b0e-0c78-440a-8d83-75b6f98512be" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_663bb69d-ca95-4b75-b907-b5ccb28d5446" xlink:to="loc_dei_EntityInteractiveDataCurrent_91a91b0e-0c78-440a-8d83-75b6f98512be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_579ccb8e-86dc-4934-bd6f-e43fe15e8dc7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_663bb69d-ca95-4b75-b907-b5ccb28d5446" xlink:to="loc_dei_EntityFilerCategory_579ccb8e-86dc-4934-bd6f-e43fe15e8dc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_f30c286d-fbfa-442a-8b02-cda9ee270316" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_663bb69d-ca95-4b75-b907-b5ccb28d5446" xlink:to="loc_dei_EntitySmallBusiness_f30c286d-fbfa-442a-8b02-cda9ee270316" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_5ec038ea-1e28-4bc1-a542-f1b76582d25e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_663bb69d-ca95-4b75-b907-b5ccb28d5446" xlink:to="loc_dei_EntityEmergingGrowthCompany_5ec038ea-1e28-4bc1-a542-f1b76582d25e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_77e45310-274c-4040-8706-09edaffff907" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_663bb69d-ca95-4b75-b907-b5ccb28d5446" xlink:to="loc_dei_EntityShellCompany_77e45310-274c-4040-8706-09edaffff907" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_d962d8ee-0cf6-4c50-88a9-77039364fb75" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_663bb69d-ca95-4b75-b907-b5ccb28d5446" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_d962d8ee-0cf6-4c50-88a9-77039364fb75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_1a8e26b7-e4d8-4e31-90db-62a94e8d55d4" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_663bb69d-ca95-4b75-b907-b5ccb28d5446" xlink:to="loc_dei_AmendmentFlag_1a8e26b7-e4d8-4e31-90db-62a94e8d55d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_72d5d61c-0115-46e5-82f1-496becd6839d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_663bb69d-ca95-4b75-b907-b5ccb28d5446" xlink:to="loc_dei_DocumentFiscalYearFocus_72d5d61c-0115-46e5-82f1-496becd6839d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_9f5ba0c3-e3f3-48bf-a42f-69fd1fe35f9f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_663bb69d-ca95-4b75-b907-b5ccb28d5446" xlink:to="loc_dei_DocumentFiscalPeriodFocus_9f5ba0c3-e3f3-48bf-a42f-69fd1fe35f9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_68aedcd0-c7d5-4f66-8136-6763bd167142" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_663bb69d-ca95-4b75-b907-b5ccb28d5446" xlink:to="loc_dei_EntityCentralIndexKey_68aedcd0-c7d5-4f66-8136-6763bd167142" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_6eb9c86e-df2d-4acd-bd5d-22d263f29204" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_663bb69d-ca95-4b75-b907-b5ccb28d5446" xlink:to="loc_dei_CurrentFiscalYearEndDate_6eb9c86e-df2d-4acd-bd5d-22d263f29204" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/ConsolidatedCondensedStatementsofOperationsUnaudited" xlink:type="simple" xlink:href="lly-20220930.xsd#ConsolidatedCondensedStatementsofOperationsUnaudited"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/ConsolidatedCondensedStatementsofOperationsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_b0314fc4-e6d5-4bdc-b0cf-ec110fa9053c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_d818912d-0498-4295-be93-0698576e2232" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_b0314fc4-e6d5-4bdc-b0cf-ec110fa9053c" xlink:to="loc_us-gaap_Revenues_d818912d-0498-4295-be93-0698576e2232" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_852c4e1a-8058-4c77-8718-03be1f33fcc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_b0314fc4-e6d5-4bdc-b0cf-ec110fa9053c" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_852c4e1a-8058-4c77-8718-03be1f33fcc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_86da7d82-9826-4a12-8758-c33138aabd47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_852c4e1a-8058-4c77-8718-03be1f33fcc3" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_86da7d82-9826-4a12-8758-c33138aabd47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_e52c1001-6732-4aa6-8976-e901a9863647" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_852c4e1a-8058-4c77-8718-03be1f33fcc3" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_e52c1001-6732-4aa6-8976-e901a9863647" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_0833567b-41b5-418f-804a-f37aacfed614" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_852c4e1a-8058-4c77-8718-03be1f33fcc3" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_0833567b-41b5-418f-804a-f37aacfed614" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AcquiredInProcessResearchAndDevelopmentAndDevelopmentMilestones_2020c1a6-423f-400d-8156-ef9fb764c8b3" xlink:href="lly-20220930.xsd#lly_AcquiredInProcessResearchAndDevelopmentAndDevelopmentMilestones"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_852c4e1a-8058-4c77-8718-03be1f33fcc3" xlink:to="loc_lly_AcquiredInProcessResearchAndDevelopmentAndDevelopmentMilestones_2020c1a6-423f-400d-8156-ef9fb764c8b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringSettlementAndImpairmentProvisions_8cd8dc2e-b023-4713-aaa7-5bc3c6a75895" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringSettlementAndImpairmentProvisions"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_852c4e1a-8058-4c77-8718-03be1f33fcc3" xlink:to="loc_us-gaap_RestructuringSettlementAndImpairmentProvisions_8cd8dc2e-b023-4713-aaa7-5bc3c6a75895" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_fa86f562-cd43-446e-8b88-4509cb2f6b4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_852c4e1a-8058-4c77-8718-03be1f33fcc3" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_fa86f562-cd43-446e-8b88-4509cb2f6b4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CostOfSalesOperatingExpensesAndOtherNet_7690c8c2-230c-45db-a854-5e0e1ee0ba6e" xlink:href="lly-20220930.xsd#lly_CostOfSalesOperatingExpensesAndOtherNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_852c4e1a-8058-4c77-8718-03be1f33fcc3" xlink:to="loc_lly_CostOfSalesOperatingExpensesAndOtherNet_7690c8c2-230c-45db-a854-5e0e1ee0ba6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_95d61db9-1eb5-4b69-8403-58da53dc4eb5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_b0314fc4-e6d5-4bdc-b0cf-ec110fa9053c" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_95d61db9-1eb5-4b69-8403-58da53dc4eb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_c2fc0275-5625-4316-b5e7-0e4858d98595" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_b0314fc4-e6d5-4bdc-b0cf-ec110fa9053c" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_c2fc0275-5625-4316-b5e7-0e4858d98595" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_7475148a-5482-4942-9ae1-9cc5e70e5fc7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_b0314fc4-e6d5-4bdc-b0cf-ec110fa9053c" xlink:to="loc_us-gaap_NetIncomeLoss_7475148a-5482-4942-9ae1-9cc5e70e5fc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_7aced4da-f675-4990-8d47-0b78218875f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_b0314fc4-e6d5-4bdc-b0cf-ec110fa9053c" xlink:to="loc_us-gaap_EarningsPerShareAbstract_7aced4da-f675-4990-8d47-0b78218875f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_ab00c4dd-9fe0-4667-9ea0-1789fd2ecbd0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_7aced4da-f675-4990-8d47-0b78218875f8" xlink:to="loc_us-gaap_EarningsPerShareBasic_ab00c4dd-9fe0-4667-9ea0-1789fd2ecbd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_f2e9f0cc-402a-46b8-8492-595cec01beed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_7aced4da-f675-4990-8d47-0b78218875f8" xlink:to="loc_us-gaap_EarningsPerShareDiluted_f2e9f0cc-402a-46b8-8492-595cec01beed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_f67ae5f3-9328-448d-aa53-ff0c0e959f0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_b0314fc4-e6d5-4bdc-b0cf-ec110fa9053c" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_f67ae5f3-9328-448d-aa53-ff0c0e959f0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_627eebf0-210a-4dc0-a2b2-ba94adf079d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_f67ae5f3-9328-448d-aa53-ff0c0e959f0e" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_627eebf0-210a-4dc0-a2b2-ba94adf079d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_25dddf77-b64b-4b7a-8e31-ec3056a828f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_f67ae5f3-9328-448d-aa53-ff0c0e959f0e" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_25dddf77-b64b-4b7a-8e31-ec3056a828f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/ConsolidatedCondensedStatementsofComprehensiveIncomeUnaudited" xlink:type="simple" xlink:href="lly-20220930.xsd#ConsolidatedCondensedStatementsofComprehensiveIncomeUnaudited"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/ConsolidatedCondensedStatementsofComprehensiveIncomeUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_ae3d905c-4eb9-491d-88cf-adb62daec85b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_a6ae7feb-f82e-42b4-86a9-0c72eb6cca92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_ae3d905c-4eb9-491d-88cf-adb62daec85b" xlink:to="loc_us-gaap_NetIncomeLoss_a6ae7feb-f82e-42b4-86a9-0c72eb6cca92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_73aa3b73-845c-4b36-8ef5-527a42ec4571" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_ae3d905c-4eb9-491d-88cf-adb62daec85b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_73aa3b73-845c-4b36-8ef5-527a42ec4571" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_56592743-5cbc-4187-990c-c09879a5466f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_ae3d905c-4eb9-491d-88cf-adb62daec85b" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_56592743-5cbc-4187-990c-c09879a5466f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets" xlink:type="simple" xlink:href="lly-20220930.xsd#ConsolidatedCondensedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_60861e42-f04c-4661-9901-465f542ebbe4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_7f80a943-7a6e-4686-9d0f-0684ee03dca4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_60861e42-f04c-4661-9901-465f542ebbe4" xlink:to="loc_us-gaap_AssetsAbstract_7f80a943-7a6e-4686-9d0f-0684ee03dca4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_1ec5d383-7a69-4ee6-9f2b-87ed5149fa52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_7f80a943-7a6e-4686-9d0f-0684ee03dca4" xlink:to="loc_us-gaap_AssetsCurrentAbstract_1ec5d383-7a69-4ee6-9f2b-87ed5149fa52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_896e23bc-e64f-4be8-ba00-ff443ce1cd32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1ec5d383-7a69-4ee6-9f2b-87ed5149fa52" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_896e23bc-e64f-4be8-ba00-ff443ce1cd32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_cf328e48-c424-4adc-a922-3039c8b1cfd4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1ec5d383-7a69-4ee6-9f2b-87ed5149fa52" xlink:to="loc_us-gaap_ShortTermInvestments_cf328e48-c424-4adc-a922-3039c8b1cfd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_3d62fa2a-0b5d-4662-a899-bf97b7bc4329" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1ec5d383-7a69-4ee6-9f2b-87ed5149fa52" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_3d62fa2a-0b5d-4662-a899-bf97b7bc4329" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_956faadf-2323-4753-8f52-86201ef61858" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1ec5d383-7a69-4ee6-9f2b-87ed5149fa52" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_956faadf-2323-4753-8f52-86201ef61858" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_5237ff22-a2c2-4426-a041-8df1c592724b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1ec5d383-7a69-4ee6-9f2b-87ed5149fa52" xlink:to="loc_us-gaap_InventoryNet_5237ff22-a2c2-4426-a041-8df1c592724b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_600eab76-e5b2-4a2b-a359-c2f6c8e9dae1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1ec5d383-7a69-4ee6-9f2b-87ed5149fa52" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_600eab76-e5b2-4a2b-a359-c2f6c8e9dae1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_41f020a1-d86d-4b13-889a-3abfe9fa2d95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1ec5d383-7a69-4ee6-9f2b-87ed5149fa52" xlink:to="loc_us-gaap_AssetsCurrent_41f020a1-d86d-4b13-889a-3abfe9fa2d95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments_1fc69490-9eb0-4fe6-958e-76cc22e656d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_7f80a943-7a6e-4686-9d0f-0684ee03dca4" xlink:to="loc_us-gaap_LongTermInvestments_1fc69490-9eb0-4fe6-958e-76cc22e656d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_a2bf581a-e099-4429-859c-0589266d9cbd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_7f80a943-7a6e-4686-9d0f-0684ee03dca4" xlink:to="loc_us-gaap_Goodwill_a2bf581a-e099-4429-859c-0589266d9cbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_9e1ce36f-dd85-4782-904f-f86083b494d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_7f80a943-7a6e-4686-9d0f-0684ee03dca4" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_9e1ce36f-dd85-4782-904f-f86083b494d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_9b4d2b27-00a9-4edb-9faa-8cac3b7086e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_7f80a943-7a6e-4686-9d0f-0684ee03dca4" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_9b4d2b27-00a9-4edb-9faa-8cac3b7086e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_12e54cbc-29d7-46a9-867d-5135beee1b0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_7f80a943-7a6e-4686-9d0f-0684ee03dca4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_12e54cbc-29d7-46a9-867d-5135beee1b0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_1208a57a-3c8c-4f33-b920-0d6a1a2c240a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_7f80a943-7a6e-4686-9d0f-0684ee03dca4" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_1208a57a-3c8c-4f33-b920-0d6a1a2c240a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_7b6f28de-b0b8-40d1-ba34-82e9491eb85b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_7f80a943-7a6e-4686-9d0f-0684ee03dca4" xlink:to="loc_us-gaap_Assets_7b6f28de-b0b8-40d1-ba34-82e9491eb85b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f569282f-aa84-47ee-96a5-ad6a10f81631" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_60861e42-f04c-4661-9901-465f542ebbe4" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f569282f-aa84-47ee-96a5-ad6a10f81631" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_c76bf400-93d8-40d6-ad9a-5f56bdfdb136" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f569282f-aa84-47ee-96a5-ad6a10f81631" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_c76bf400-93d8-40d6-ad9a-5f56bdfdb136" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrent_a806cfba-9807-4166-b2d2-07180d3d4771" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_c76bf400-93d8-40d6-ad9a-5f56bdfdb136" xlink:to="loc_us-gaap_DebtCurrent_a806cfba-9807-4166-b2d2-07180d3d4771" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_f8e70496-e32b-4516-889c-c1715136f197" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_c76bf400-93d8-40d6-ad9a-5f56bdfdb136" xlink:to="loc_us-gaap_AccountsPayableCurrent_f8e70496-e32b-4516-889c-c1715136f197" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_d9c270c1-c9fb-49ae-8c9e-d0eef7351263" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_c76bf400-93d8-40d6-ad9a-5f56bdfdb136" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_d9c270c1-c9fb-49ae-8c9e-d0eef7351263" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_SalesRebatesAndDiscounts_d5631cbc-251f-4bad-868c-175ab22f8287" xlink:href="lly-20220930.xsd#lly_SalesRebatesAndDiscounts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_c76bf400-93d8-40d6-ad9a-5f56bdfdb136" xlink:to="loc_lly_SalesRebatesAndDiscounts_d5631cbc-251f-4bad-868c-175ab22f8287" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableCurrent_074d14ec-e8a2-4ae0-8664-f12e4f28a13c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsPayableCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_c76bf400-93d8-40d6-ad9a-5f56bdfdb136" xlink:to="loc_us-gaap_DividendsPayableCurrent_074d14ec-e8a2-4ae0-8664-f12e4f28a13c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent_6e5fd92f-a991-4397-a185-0b608fbd7be8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_c76bf400-93d8-40d6-ad9a-5f56bdfdb136" xlink:to="loc_us-gaap_TaxesPayableCurrent_6e5fd92f-a991-4397-a185-0b608fbd7be8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_6a5884ff-528c-49ea-8de2-724574ae46c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_c76bf400-93d8-40d6-ad9a-5f56bdfdb136" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_6a5884ff-528c-49ea-8de2-724574ae46c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_86c5b447-2751-42c6-96bc-434130c36e30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_c76bf400-93d8-40d6-ad9a-5f56bdfdb136" xlink:to="loc_us-gaap_LiabilitiesCurrent_86c5b447-2751-42c6-96bc-434130c36e30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_ddff8c72-3a38-43eb-9657-0e3fdaac0312" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f569282f-aa84-47ee-96a5-ad6a10f81631" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_ddff8c72-3a38-43eb-9657-0e3fdaac0312" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_ea235d7f-385f-4ca2-9b66-37bb59f3a3d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_ddff8c72-3a38-43eb-9657-0e3fdaac0312" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_ea235d7f-385f-4ca2-9b66-37bb59f3a3d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_61bfa10a-a4c7-4263-97c8-88f0310dd0ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_ddff8c72-3a38-43eb-9657-0e3fdaac0312" xlink:to="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_61bfa10a-a4c7-4263-97c8-88f0310dd0ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesNoncurrent_f21cf63e-87c7-4689-865a-d4f9ad9e8920" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedIncomeTaxesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_ddff8c72-3a38-43eb-9657-0e3fdaac0312" xlink:to="loc_us-gaap_AccruedIncomeTaxesNoncurrent_f21cf63e-87c7-4689-865a-d4f9ad9e8920" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_eb8c3d86-2c53-4768-93b9-0e6da2cb83e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_ddff8c72-3a38-43eb-9657-0e3fdaac0312" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_eb8c3d86-2c53-4768-93b9-0e6da2cb83e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_caa094e4-d2b1-444c-95b7-daee71570317" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_ddff8c72-3a38-43eb-9657-0e3fdaac0312" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_caa094e4-d2b1-444c-95b7-daee71570317" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_86dc1fe8-a303-4362-8cc1-9155992b80c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_ddff8c72-3a38-43eb-9657-0e3fdaac0312" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_86dc1fe8-a303-4362-8cc1-9155992b80c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_55524db2-83c0-406c-9401-a324cf931cab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f569282f-aa84-47ee-96a5-ad6a10f81631" xlink:to="loc_us-gaap_CommitmentsAndContingencies_55524db2-83c0-406c-9401-a324cf931cab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_154759a0-bea3-4e63-923d-00d6a31ec86d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f569282f-aa84-47ee-96a5-ad6a10f81631" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_154759a0-bea3-4e63-923d-00d6a31ec86d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_eb2051d1-0e55-45b0-bf6d-e10b37cb8ada" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_154759a0-bea3-4e63-923d-00d6a31ec86d" xlink:to="loc_us-gaap_CommonStockValue_eb2051d1-0e55-45b0-bf6d-e10b37cb8ada" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_b63a81fb-7aa2-4cc3-a9ca-a1e221edd420" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_154759a0-bea3-4e63-923d-00d6a31ec86d" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_b63a81fb-7aa2-4cc3-a9ca-a1e221edd420" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_c45b49ef-1c70-4a4a-9c00-faa25bcf536b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_154759a0-bea3-4e63-923d-00d6a31ec86d" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_c45b49ef-1c70-4a4a-9c00-faa25bcf536b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesHeldInEmployeeTrust_30d608f1-49bf-4546-bf79-0355e3e28cef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesHeldInEmployeeTrust"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_154759a0-bea3-4e63-923d-00d6a31ec86d" xlink:to="loc_us-gaap_CommonStockSharesHeldInEmployeeTrust_30d608f1-49bf-4546-bf79-0355e3e28cef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_b5615234-f524-40ba-a6d7-0e7f5c31baa0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_154759a0-bea3-4e63-923d-00d6a31ec86d" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_b5615234-f524-40ba-a6d7-0e7f5c31baa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonValue_857d70bb-17c2-4b3f-a0a9-6a9cea62a8b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_154759a0-bea3-4e63-923d-00d6a31ec86d" xlink:to="loc_us-gaap_TreasuryStockCommonValue_857d70bb-17c2-4b3f-a0a9-6a9cea62a8b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_c6d63a10-d892-49b8-82fb-41ef9c2a3cba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_154759a0-bea3-4e63-923d-00d6a31ec86d" xlink:to="loc_us-gaap_StockholdersEquity_c6d63a10-d892-49b8-82fb-41ef9c2a3cba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_98df73c1-aa85-4b7c-91c5-8b494e8c9bcd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f569282f-aa84-47ee-96a5-ad6a10f81631" xlink:to="loc_us-gaap_MinorityInterest_98df73c1-aa85-4b7c-91c5-8b494e8c9bcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_1e2bed03-de88-4cf6-b453-ffcad9fbb463" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f569282f-aa84-47ee-96a5-ad6a10f81631" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_1e2bed03-de88-4cf6-b453-ffcad9fbb463" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_c8988b0d-5f5c-453c-be05-84f976b52d21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f569282f-aa84-47ee-96a5-ad6a10f81631" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_c8988b0d-5f5c-453c-be05-84f976b52d21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/ConsolidatedCondensedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="lly-20220930.xsd#ConsolidatedCondensedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/ConsolidatedCondensedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrentAbstract_8749706b-ab8a-4685-9721-f965aa85ffa7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesNetCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_11893f86-cead-432c-b9ad-f0492109d0aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesNetCurrentAbstract_8749706b-ab8a-4685-9721-f965aa85ffa7" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_11893f86-cead-432c-b9ad-f0492109d0aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_ab6505bf-f88c-47d1-80c7-76fac0c8f97d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesNetCurrentAbstract_8749706b-ab8a-4685-9721-f965aa85ffa7" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_ab6505bf-f88c-47d1-80c7-76fac0c8f97d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/ConsolidatedCondensedStatementsofEquity" xlink:type="simple" xlink:href="lly-20220930.xsd#ConsolidatedCondensedStatementsofEquity"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/ConsolidatedCondensedStatementsofEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_a3924b12-8fb7-40e0-81f1-b20d8c0b428b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_79369ac0-965b-4268-b9b2-584063ca3195" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_a3924b12-8fb7-40e0-81f1-b20d8c0b428b" xlink:to="loc_us-gaap_StatementTable_79369ac0-965b-4268-b9b2-584063ca3195" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_3e45009f-a686-4f63-966d-e57b78d87839" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_79369ac0-965b-4268-b9b2-584063ca3195" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_3e45009f-a686-4f63-966d-e57b78d87839" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_d695ccdf-e900-4e07-a042-f73afa72c339" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_3e45009f-a686-4f63-966d-e57b78d87839" xlink:to="loc_us-gaap_EquityComponentDomain_d695ccdf-e900-4e07-a042-f73afa72c339" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_65d02275-8b84-4417-b6c9-b595088588ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_d695ccdf-e900-4e07-a042-f73afa72c339" xlink:to="loc_us-gaap_CommonStockMember_65d02275-8b84-4417-b6c9-b595088588ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_f84e46f3-0652-4bcc-936a-3cc03cb5e9c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_d695ccdf-e900-4e07-a042-f73afa72c339" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_f84e46f3-0652-4bcc-936a-3cc03cb5e9c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_d9a9dab2-ac5d-4ed1-90a0-5f31b58db862" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_d695ccdf-e900-4e07-a042-f73afa72c339" xlink:to="loc_us-gaap_RetainedEarningsMember_d9a9dab2-ac5d-4ed1-90a0-5f31b58db862" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrustForBenefitOfEmployeesMember_14c76391-f976-46cc-804a-7d32e5e6e59d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TrustForBenefitOfEmployeesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_d695ccdf-e900-4e07-a042-f73afa72c339" xlink:to="loc_us-gaap_TrustForBenefitOfEmployeesMember_14c76391-f976-46cc-804a-7d32e5e6e59d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_fcadc3b4-5d73-4eb3-b4f8-58c1a21bdaf8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_d695ccdf-e900-4e07-a042-f73afa72c339" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_fcadc3b4-5d73-4eb3-b4f8-58c1a21bdaf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember_86a188c3-3c75-4a30-81dc-541ff1c151bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_d695ccdf-e900-4e07-a042-f73afa72c339" xlink:to="loc_us-gaap_TreasuryStockCommonMember_86a188c3-3c75-4a30-81dc-541ff1c151bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_2a68e8fe-f08f-4aee-a2ce-515d54dfe64a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_d695ccdf-e900-4e07-a042-f73afa72c339" xlink:to="loc_us-gaap_NoncontrollingInterestMember_2a68e8fe-f08f-4aee-a2ce-515d54dfe64a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_d4f5613d-6d3f-4895-a58d-4ad2339b1cd9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_79369ac0-965b-4268-b9b2-584063ca3195" xlink:to="loc_us-gaap_StatementLineItems_d4f5613d-6d3f-4895-a58d-4ad2339b1cd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f3e11bbd-91ae-4393-aca3-99c1ad0f7712" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d4f5613d-6d3f-4895-a58d-4ad2339b1cd9" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f3e11bbd-91ae-4393-aca3-99c1ad0f7712" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_c9a2508d-ed4c-4969-b4ce-e22faea04a88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f3e11bbd-91ae-4393-aca3-99c1ad0f7712" xlink:to="loc_us-gaap_CommonStockSharesIssued_c9a2508d-ed4c-4969-b4ce-e22faea04a88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_fd11850c-a80b-404f-ab4b-c87690ef909e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f3e11bbd-91ae-4393-aca3-99c1ad0f7712" xlink:to="loc_us-gaap_TreasuryStockCommonShares_fd11850c-a80b-404f-ab4b-c87690ef909e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3e334697-cb17-412a-8863-00b40cac35a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f3e11bbd-91ae-4393-aca3-99c1ad0f7712" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3e334697-cb17-412a-8863-00b40cac35a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_b7d14ff9-e415-421e-9bea-eb90d31dafa3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f3e11bbd-91ae-4393-aca3-99c1ad0f7712" xlink:to="loc_us-gaap_ProfitLoss_b7d14ff9-e415-421e-9bea-eb90d31dafa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_c97f8e46-3259-4853-9f4b-d8b3af7327bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f3e11bbd-91ae-4393-aca3-99c1ad0f7712" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_c97f8e46-3259-4853-9f4b-d8b3af7327bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Dividends_ec2d2940-c154-4c5c-8889-4182522bef2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Dividends"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f3e11bbd-91ae-4393-aca3-99c1ad0f7712" xlink:to="loc_us-gaap_Dividends_ec2d2940-c154-4c5c-8889-4182522bef2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesRetired_1e7a6536-7761-4230-b498-e70e88766626" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockSharesRetired"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f3e11bbd-91ae-4393-aca3-99c1ad0f7712" xlink:to="loc_us-gaap_TreasuryStockSharesRetired_1e7a6536-7761-4230-b498-e70e88766626" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockRetiredCostMethodAmount_68d729f2-237c-44ee-8ae4-a1df1dcab6fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockRetiredCostMethodAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f3e11bbd-91ae-4393-aca3-99c1ad0f7712" xlink:to="loc_us-gaap_TreasuryStockRetiredCostMethodAmount_68d729f2-237c-44ee-8ae4-a1df1dcab6fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_e7cda99e-083c-4086-b9b2-1e789ac1d295" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f3e11bbd-91ae-4393-aca3-99c1ad0f7712" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_e7cda99e-083c-4086-b9b2-1e789ac1d295" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_2311e70f-4963-4181-ab93-9cefb59e9f45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f3e11bbd-91ae-4393-aca3-99c1ad0f7712" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_2311e70f-4963-4181-ab93-9cefb59e9f45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_0e08ebd4-9fd4-44db-a170-8fe26aeb7283" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f3e11bbd-91ae-4393-aca3-99c1ad0f7712" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_0e08ebd4-9fd4-44db-a170-8fe26aeb7283" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_91c60a48-94fa-4663-842d-53c1b11ec663" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f3e11bbd-91ae-4393-aca3-99c1ad0f7712" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_91c60a48-94fa-4663-842d-53c1b11ec663" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_622f3ea2-c01e-4366-8efe-b52059ac05d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f3e11bbd-91ae-4393-aca3-99c1ad0f7712" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_622f3ea2-c01e-4366-8efe-b52059ac05d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOther_cb904d20-ca3e-4f05-9922-e089f2de708d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityOther"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f3e11bbd-91ae-4393-aca3-99c1ad0f7712" xlink:to="loc_us-gaap_StockholdersEquityOther_cb904d20-ca3e-4f05-9922-e089f2de708d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_a0d616d4-139e-45ba-8710-97689c77a117" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f3e11bbd-91ae-4393-aca3-99c1ad0f7712" xlink:to="loc_us-gaap_CommonStockSharesIssued_a0d616d4-139e-45ba-8710-97689c77a117" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_dafefc71-69d6-4c2f-9eaf-ba2ad1d95a7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f3e11bbd-91ae-4393-aca3-99c1ad0f7712" xlink:to="loc_us-gaap_TreasuryStockCommonShares_dafefc71-69d6-4c2f-9eaf-ba2ad1d95a7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_80bc5423-9bff-4395-870f-eb465560ebfc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f3e11bbd-91ae-4393-aca3-99c1ad0f7712" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_80bc5423-9bff-4395-870f-eb465560ebfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/ConsolidatedCondensedStatementsofEquityParenthetical" xlink:type="simple" xlink:href="lly-20220930.xsd#ConsolidatedCondensedStatementsofEquityParenthetical"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/ConsolidatedCondensedStatementsofEquityParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_24127467-325f-498d-87a0-0dc4456fe777" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared_937b737d-08e2-4668-8597-e0743e933770" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_24127467-325f-498d-87a0-0dc4456fe777" xlink:to="loc_us-gaap_CommonStockDividendsPerShareDeclared_937b737d-08e2-4668-8597-e0743e933770" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_bf312d2b-9672-4b64-91f2-7ddd52fc2421" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_24127467-325f-498d-87a0-0dc4456fe777" xlink:to="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_bf312d2b-9672-4b64-91f2-7ddd52fc2421" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_a568c3c0-ec3a-4252-ade1-6d8d303c6eff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_24127467-325f-498d-87a0-0dc4456fe777" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_a568c3c0-ec3a-4252-ade1-6d8d303c6eff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows" xlink:type="simple" xlink:href="lly-20220930.xsd#ConsolidatedCondensedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_c7ae4564-7bad-48ee-9cf9-68ea302f6ccc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_20e2ab71-c46d-46c6-983b-6477328faa56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_c7ae4564-7bad-48ee-9cf9-68ea302f6ccc" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_20e2ab71-c46d-46c6-983b-6477328faa56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_b3cbf1ee-ea54-47c1-8165-ea192ccb9fdd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_20e2ab71-c46d-46c6-983b-6477328faa56" xlink:to="loc_us-gaap_NetIncomeLoss_b3cbf1ee-ea54-47c1-8165-ea192ccb9fdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7293586a-29f8-4930-94f9-809d8755c76a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_20e2ab71-c46d-46c6-983b-6477328faa56" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7293586a-29f8-4930-94f9-809d8755c76a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_a1b85253-33ec-436e-b400-75cf396180bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7293586a-29f8-4930-94f9-809d8755c76a" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_a1b85253-33ec-436e-b400-75cf396180bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_6a54611e-e403-4332-a2a3-13c8b53dadcc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7293586a-29f8-4930-94f9-809d8755c76a" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_6a54611e-e403-4332-a2a3-13c8b53dadcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_db65d19b-57ad-4f0a-ad56-dc0f18aada68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7293586a-29f8-4930-94f9-809d8755c76a" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_db65d19b-57ad-4f0a-ad56-dc0f18aada68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_c14668a2-639b-41f1-99ba-043540856ca4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7293586a-29f8-4930-94f9-809d8755c76a" xlink:to="loc_us-gaap_ShareBasedCompensation_c14668a2-639b-41f1-99ba-043540856ca4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestments_a6f409dd-4e67-48be-9833-7f23345f8a83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7293586a-29f8-4930-94f9-809d8755c76a" xlink:to="loc_us-gaap_GainLossOnInvestments_a6f409dd-4e67-48be-9833-7f23345f8a83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AcquiredInProcessResearchAndDevelopment_ae7172c8-f148-4b8c-a44b-2ccf47648ba1" xlink:href="lly-20220930.xsd#lly_AcquiredInProcessResearchAndDevelopment"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7293586a-29f8-4930-94f9-809d8755c76a" xlink:to="loc_lly_AcquiredInProcessResearchAndDevelopment_ae7172c8-f148-4b8c-a44b-2ccf47648ba1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_570910f1-93d7-4e22-8254-8079394f72a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7293586a-29f8-4930-94f9-809d8755c76a" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_570910f1-93d7-4e22-8254-8079394f72a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_5b4ffe07-b526-4c60-a09a-ab5d72897b1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7293586a-29f8-4930-94f9-809d8755c76a" xlink:to="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_5b4ffe07-b526-4c60-a09a-ab5d72897b1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_478ca4b1-a6f2-4f4e-880a-647de8cf9e59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_20e2ab71-c46d-46c6-983b-6477328faa56" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_478ca4b1-a6f2-4f4e-880a-647de8cf9e59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_49b2051f-1830-45aa-bab1-bdb13b1f10b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_c7ae4564-7bad-48ee-9cf9-68ea302f6ccc" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_49b2051f-1830-45aa-bab1-bdb13b1f10b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets_e72f5d3b-032d-412d-8d3d-a3d4cc598113" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireProductiveAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_49b2051f-1830-45aa-bab1-bdb13b1f10b6" xlink:to="loc_us-gaap_PaymentsToAcquireProductiveAssets_e72f5d3b-032d-412d-8d3d-a3d4cc598113" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments_74081d9e-1e42-4fdf-8b7e-65a00dea55df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfShortTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_49b2051f-1830-45aa-bab1-bdb13b1f10b6" xlink:to="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments_74081d9e-1e42-4fdf-8b7e-65a00dea55df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments_d93329c6-ee15-40e8-8eb8-061ed7466341" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireShortTermInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_49b2051f-1830-45aa-bab1-bdb13b1f10b6" xlink:to="loc_us-gaap_PaymentsToAcquireShortTermInvestments_d93329c6-ee15-40e8-8eb8-061ed7466341" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfLongtermInvestments_f9d2f491-fbcf-4bbe-b8c0-68ee693ca69f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfLongtermInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_49b2051f-1830-45aa-bab1-bdb13b1f10b6" xlink:to="loc_us-gaap_ProceedsFromSaleOfLongtermInvestments_f9d2f491-fbcf-4bbe-b8c0-68ee693ca69f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireLongtermInvestments_84702405-f0e8-4376-ae3e-41e4606306dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireLongtermInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_49b2051f-1830-45aa-bab1-bdb13b1f10b6" xlink:to="loc_us-gaap_PaymentsToAcquireLongtermInvestments_84702405-f0e8-4376-ae3e-41e4606306dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_4ab8ba97-1a4f-4fc9-9056-3f90ff799e51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_49b2051f-1830-45aa-bab1-bdb13b1f10b6" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_4ab8ba97-1a4f-4fc9-9056-3f90ff799e51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_PurchasedInProcessResearchAndDevelopment_b6b7781b-6c64-4b7f-b38d-bb72dcda4da5" xlink:href="lly-20220930.xsd#lly_PurchasedInProcessResearchAndDevelopment"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_49b2051f-1830-45aa-bab1-bdb13b1f10b6" xlink:to="loc_lly_PurchasedInProcessResearchAndDevelopment_b6b7781b-6c64-4b7f-b38d-bb72dcda4da5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_a40e5ca4-18a6-402f-8091-3a784f89494d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_49b2051f-1830-45aa-bab1-bdb13b1f10b6" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_a40e5ca4-18a6-402f-8091-3a784f89494d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c4a8ce3c-0a8d-4664-8c17-c9529ac94663" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_49b2051f-1830-45aa-bab1-bdb13b1f10b6" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c4a8ce3c-0a8d-4664-8c17-c9529ac94663" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_f68a8660-5663-448a-8ffe-2b0b9cddfb41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_c7ae4564-7bad-48ee-9cf9-68ea302f6ccc" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_f68a8660-5663-448a-8ffe-2b0b9cddfb41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividends_3e838a82-8ec7-46e0-bde9-60a33772f4f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDividends"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_f68a8660-5663-448a-8ffe-2b0b9cddfb41" xlink:to="loc_us-gaap_PaymentsOfDividends_3e838a82-8ec7-46e0-bde9-60a33772f4f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromShortTermDebt_0d78b3c7-77ce-44e9-bc64-0b4bc92f7e32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromShortTermDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_f68a8660-5663-448a-8ffe-2b0b9cddfb41" xlink:to="loc_us-gaap_ProceedsFromShortTermDebt_0d78b3c7-77ce-44e9-bc64-0b4bc92f7e32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_5885d509-deea-4dbd-967a-73bdcbb46822" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_f68a8660-5663-448a-8ffe-2b0b9cddfb41" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_5885d509-deea-4dbd-967a-73bdcbb46822" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_17aea1b6-c6d8-4833-b07f-07a7c6d7bf05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_f68a8660-5663-448a-8ffe-2b0b9cddfb41" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_17aea1b6-c6d8-4833-b07f-07a7c6d7bf05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_14bcfd00-9e9e-4865-8936-fc6d9e68bae2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_f68a8660-5663-448a-8ffe-2b0b9cddfb41" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_14bcfd00-9e9e-4865-8936-fc6d9e68bae2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_a750c2c2-a706-4036-bacd-1b19596c96b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_f68a8660-5663-448a-8ffe-2b0b9cddfb41" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_a750c2c2-a706-4036-bacd-1b19596c96b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_484c85e0-335a-44dc-aa5b-ad5f954daaba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_f68a8660-5663-448a-8ffe-2b0b9cddfb41" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_484c85e0-335a-44dc-aa5b-ad5f954daaba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6a0a18a0-3867-4aca-8a19-37ea298a242f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_c7ae4564-7bad-48ee-9cf9-68ea302f6ccc" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6a0a18a0-3867-4aca-8a19-37ea298a242f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_daa85c40-0685-4cb8-8386-2875f8b8039c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_c7ae4564-7bad-48ee-9cf9-68ea302f6ccc" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_daa85c40-0685-4cb8-8386-2875f8b8039c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_84dc1c98-494f-4afd-bdfa-bdb7b8c8be29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_c7ae4564-7bad-48ee-9cf9-68ea302f6ccc" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_84dc1c98-494f-4afd-bdfa-bdb7b8c8be29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_80d0acdb-1703-4c3d-99ee-75fa42b5d830" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_c7ae4564-7bad-48ee-9cf9-68ea302f6ccc" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_80d0acdb-1703-4c3d-99ee-75fa42b5d830" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/BasisofPresentationandImplementationofNewFinancialAccountingStandard" xlink:type="simple" xlink:href="lly-20220930.xsd#BasisofPresentationandImplementationofNewFinancialAccountingStandard"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/BasisofPresentationandImplementationofNewFinancialAccountingStandard" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_bd346f61-edeb-43d0-8fde-99ed617f6ee9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_ef52e5fa-f7ab-4608-a4aa-8ca285ac868e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_bd346f61-edeb-43d0-8fde-99ed617f6ee9" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_ef52e5fa-f7ab-4608-a4aa-8ca285ac868e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/Revenue" xlink:type="simple" xlink:href="lly-20220930.xsd#Revenue"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/Revenue" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_ae94700b-3bfc-423c-94a7-1ac1f3cffc7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_6661a8e5-0a73-4c0c-922a-ad55eedc5164" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_ae94700b-3bfc-423c-94a7-1ac1f3cffc7e" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_6661a8e5-0a73-4c0c-922a-ad55eedc5164" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/Acquisitions" xlink:type="simple" xlink:href="lly-20220930.xsd#Acquisitions"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/Acquisitions" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_b9799b16-d611-432c-82ec-a17745322d77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_745ade4f-e5ff-4dea-bddd-6c9a2d1d1858" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_b9799b16-d611-432c-82ec-a17745322d77" xlink:to="loc_us-gaap_BusinessCombinationDisclosureTextBlock_745ade4f-e5ff-4dea-bddd-6c9a2d1d1858" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionTextBlock_ffce53dc-2a65-48ea-ae16-6f61360baaad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_b9799b16-d611-432c-82ec-a17745322d77" xlink:to="loc_us-gaap_AssetAcquisitionTextBlock_ffce53dc-2a65-48ea-ae16-6f61360baaad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/CollaborationsandOtherArrangements" xlink:type="simple" xlink:href="lly-20220930.xsd#CollaborationsandOtherArrangements"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/CollaborationsandOtherArrangements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_72b08612-8b46-4cab-b0cd-15307faa1f7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_d815bb59-d3bd-4f85-9b44-b57b33c50257" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_72b08612-8b46-4cab-b0cd-15307faa1f7d" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_d815bb59-d3bd-4f85-9b44-b57b33c50257" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialCharges" xlink:type="simple" xlink:href="lly-20220930.xsd#AssetImpairmentRestructuringandOtherSpecialCharges"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialCharges" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_80fff80f-4435-46cc-8a47-5c7381cb9b23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock_dfbd0305-6660-49d2-a0bc-9ac4ce0bcc58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_80fff80f-4435-46cc-8a47-5c7381cb9b23" xlink:to="loc_us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock_dfbd0305-6660-49d2-a0bc-9ac4ce0bcc58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/FinancialInstruments" xlink:type="simple" xlink:href="lly-20220930.xsd#FinancialInstruments"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/FinancialInstruments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_de049ed3-a202-48d6-8862-47fea3d2ad90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_69816381-cc39-4510-bd62-24dbba085500" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_de049ed3-a202-48d6-8862-47fea3d2ad90" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_69816381-cc39-4510-bd62-24dbba085500" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/IncomeTaxes" xlink:type="simple" xlink:href="lly-20220930.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_c4c1a936-a122-49dd-a89a-6a731bad1389" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_19706e35-48cb-479b-a167-488fd19a0151" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c4c1a936-a122-49dd-a89a-6a731bad1389" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_19706e35-48cb-479b-a167-488fd19a0151" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/RetirementBenefits" xlink:type="simple" xlink:href="lly-20220930.xsd#RetirementBenefits"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/RetirementBenefits" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract_a6d09904-e646-4a1f-8916-fcf049744573" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_b41a288c-67c9-438f-b9e8-1d03c52d1d4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract_a6d09904-e646-4a1f-8916-fcf049744573" xlink:to="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_b41a288c-67c9-438f-b9e8-1d03c52d1d4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/Contingencies" xlink:type="simple" xlink:href="lly-20220930.xsd#Contingencies"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/Contingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_9ce0a286-1b4f-4114-9ba4-13cb00b15fd5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_a360e835-2d19-4141-9858-123a37f77f8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_9ce0a286-1b4f-4114-9ba4-13cb00b15fd5" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_a360e835-2d19-4141-9858-123a37f77f8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/OtherComprehensiveIncomeLoss" xlink:type="simple" xlink:href="lly-20220930.xsd#OtherComprehensiveIncomeLoss"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/OtherComprehensiveIncomeLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_641b12e3-9014-4aef-91b2-a94d61883fb5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_2a4b34be-1fa1-43a3-a523-3271658cde87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNoteTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_641b12e3-9014-4aef-91b2-a94d61883fb5" xlink:to="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_2a4b34be-1fa1-43a3-a523-3271658cde87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/OtherNetIncomeExpense" xlink:type="simple" xlink:href="lly-20220930.xsd#OtherNetIncomeExpense"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/OtherNetIncomeExpense" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_a3135e66-01d3-453f-ab3c-94357aaecd4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_5693283b-bc98-43f2-83f7-b8710aac4935" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_a3135e66-01d3-453f-ab3c-94357aaecd4e" xlink:to="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_5693283b-bc98-43f2-83f7-b8710aac4935" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/BasisofPresentationandImplementationofNewFinancialAccountingStandardPolicies" xlink:type="simple" xlink:href="lly-20220930.xsd#BasisofPresentationandImplementationofNewFinancialAccountingStandardPolicies"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/BasisofPresentationandImplementationofNewFinancialAccountingStandardPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_76752935-43da-410c-ab0d-7a6e166563c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_a7da9760-6f19-49f8-a018-1f4138905f4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_76752935-43da-410c-ab0d-7a6e166563c9" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_a7da9760-6f19-49f8-a018-1f4138905f4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_2098332d-b7d6-4642-9e82-76e00e68efb9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_76752935-43da-410c-ab0d-7a6e166563c9" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_2098332d-b7d6-4642-9e82-76e00e68efb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy_5459f356-c264-4d16-a688-5e83dec07b9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_76752935-43da-410c-ab0d-7a6e166563c9" xlink:to="loc_us-gaap_BusinessCombinationsPolicy_5459f356-c264-4d16-a688-5e83dec07b9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock_0ba3fdd6-4380-4de3-a637-5994008d797c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_76752935-43da-410c-ab0d-7a6e166563c9" xlink:to="loc_us-gaap_DerivativesPolicyTextBlock_0ba3fdd6-4380-4de3-a637-5994008d797c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_0f1ca2dc-fcbf-43c1-b310-bd5a59b25cab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_76752935-43da-410c-ab0d-7a6e166563c9" xlink:to="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_0f1ca2dc-fcbf-43c1-b310-bd5a59b25cab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/RevenueTables" xlink:type="simple" xlink:href="lly-20220930.xsd#RevenueTables"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/RevenueTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_c5231559-4ffe-47d6-b582-f622f671800e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_d2ad9f76-ec1f-4711-ad98-5c1cd0dca0e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_c5231559-4ffe-47d6-b582-f622f671800e" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_d2ad9f76-ec1f-4711-ad98-5c1cd0dca0e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_616beb8a-f57d-4ce1-8fdc-91b00d90bc6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_c5231559-4ffe-47d6-b582-f622f671800e" xlink:to="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_616beb8a-f57d-4ce1-8fdc-91b00d90bc6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/AcquisitionsTables" xlink:type="simple" xlink:href="lly-20220930.xsd#AcquisitionsTables"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/AcquisitionsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_0ecaabda-e9a3-4f9b-8733-15bc36eaf0ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_4d47e216-3870-4727-a6f8-e0c8d5eeb636" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_0ecaabda-e9a3-4f9b-8733-15bc36eaf0ce" xlink:to="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_4d47e216-3870-4727-a6f8-e0c8d5eeb636" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock_07d6c29e-f83d-4b5f-aa04-a18a77fd4e81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_0ecaabda-e9a3-4f9b-8733-15bc36eaf0ce" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock_07d6c29e-f83d-4b5f-aa04-a18a77fd4e81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/CollaborationsandOtherArrangementsTables" xlink:type="simple" xlink:href="lly-20220930.xsd#CollaborationsandOtherArrangementsTables"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/CollaborationsandOtherArrangementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4fc31ed0-6fa9-4803-9aa3-dde004ad9c88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_fe39bbb3-fb07-48d2-8e20-3cb4282d4333" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4fc31ed0-6fa9-4803-9aa3-dde004ad9c88" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_fe39bbb3-fb07-48d2-8e20-3cb4282d4333" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialChargesTables" xlink:type="simple" xlink:href="lly-20220930.xsd#AssetImpairmentRestructuringandOtherSpecialChargesTables"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialChargesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_606aed73-b803-4a73-8e78-3efdff4d74d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_33263386-db6e-42ad-8496-43a3aded194d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_606aed73-b803-4a73-8e78-3efdff4d74d5" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_33263386-db6e-42ad-8496-43a3aded194d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/FinancialInstrumentsTables" xlink:type="simple" xlink:href="lly-20220930.xsd#FinancialInstrumentsTables"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/FinancialInstrumentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_9b836cfb-900b-41e2-8d30-474b9c862fab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_eae0d298-b6a4-4872-987a-8a529957d79c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_9b836cfb-900b-41e2-8d30-474b9c862fab" xlink:to="loc_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_eae0d298-b6a4-4872-987a-8a529957d79c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_67e08132-99c9-4c98-a21a-ecb9d71a263e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_9b836cfb-900b-41e2-8d30-474b9c862fab" xlink:to="loc_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_67e08132-99c9-4c98-a21a-ecb9d71a263e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_0c74ada8-4ff5-4ab4-8508-9db26102f4be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_9b836cfb-900b-41e2-8d30-474b9c862fab" xlink:to="loc_us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_0c74ada8-4ff5-4ab4-8508-9db26102f4be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_40a0c17e-7236-4659-987b-45fb91a84560" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_9b836cfb-900b-41e2-8d30-474b9c862fab" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_40a0c17e-7236-4659-987b-45fb91a84560" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_b9718a62-2eac-4608-9860-a6cb14014040" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_9b836cfb-900b-41e2-8d30-474b9c862fab" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_b9718a62-2eac-4608-9860-a6cb14014040" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock_c6a17135-64f0-4991-a6a9-0f47a65e7188" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByBalanceSheetGroupingTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_9b836cfb-900b-41e2-8d30-474b9c862fab" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock_c6a17135-64f0-4991-a6a9-0f47a65e7188" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_3b2a0c11-19f9-4782-9836-49b64f95fe54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_9b836cfb-900b-41e2-8d30-474b9c862fab" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_3b2a0c11-19f9-4782-9836-49b64f95fe54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_a21b0dce-427d-4a51-8b0b-58c897d1736a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_9b836cfb-900b-41e2-8d30-474b9c862fab" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_a21b0dce-427d-4a51-8b0b-58c897d1736a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestmentsTextBlock_e5bda0ba-7e22-4350-94a8-1501d8535013" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnInvestmentsTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_9b836cfb-900b-41e2-8d30-474b9c862fab" xlink:to="loc_us-gaap_GainLossOnInvestmentsTextBlock_e5bda0ba-7e22-4350-94a8-1501d8535013" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/RetirementBenefitsTables" xlink:type="simple" xlink:href="lly-20220930.xsd#RetirementBenefitsTables"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/RetirementBenefitsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract_0891d318-971c-4f1e-a30e-93a5b62bfc3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_7658fa7a-0cfe-4578-984b-cf486957a7c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNetBenefitCostsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract_0891d318-971c-4f1e-a30e-93a5b62bfc3c" xlink:to="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_7658fa7a-0cfe-4578-984b-cf486957a7c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/OtherComprehensiveIncomeLossTables" xlink:type="simple" xlink:href="lly-20220930.xsd#OtherComprehensiveIncomeLossTables"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/OtherComprehensiveIncomeLossTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_3819503b-3f08-48c9-b8dc-3a71ff315d10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_b1717de0-8e40-4d8c-9729-2e0474e6462c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_3819503b-3f08-48c9-b8dc-3a71ff315d10" xlink:to="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_b1717de0-8e40-4d8c-9729-2e0474e6462c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_9aebc671-21cc-401d-b574-5a0982082a7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_3819503b-3f08-48c9-b8dc-3a71ff315d10" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_9aebc671-21cc-401d-b574-5a0982082a7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/OtherNetIncomeExpenseTables" xlink:type="simple" xlink:href="lly-20220930.xsd#OtherNetIncomeExpenseTables"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/OtherNetIncomeExpenseTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_0ecd930f-6540-431e-aa81-6418243993e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_b950299f-0680-4f1d-b293-1ab7c1573207" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_0ecd930f-6540-431e-aa81-6418243993e6" xlink:to="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_b950299f-0680-4f1d-b293-1ab7c1573207" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/RevenueSummaryofRevenueRecognizedDetails" xlink:type="simple" xlink:href="lly-20220930.xsd#RevenueSummaryofRevenueRecognizedDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/RevenueSummaryofRevenueRecognizedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_511af67e-87a6-4e4d-9916-cbeee0d79a89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_4773a452-0c0a-4965-bc57-e72ae7c17b49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_511af67e-87a6-4e4d-9916-cbeee0d79a89" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_4773a452-0c0a-4965-bc57-e72ae7c17b49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_400ca3b4-06ce-4139-b721-aa962a33de00" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_4773a452-0c0a-4965-bc57-e72ae7c17b49" xlink:to="loc_srt_ProductOrServiceAxis_400ca3b4-06ce-4139-b721-aa962a33de00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_168fb72d-5f74-44cd-a695-b531e42b2370" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_400ca3b4-06ce-4139-b721-aa962a33de00" xlink:to="loc_srt_ProductsAndServicesDomain_168fb72d-5f74-44cd-a695-b531e42b2370" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_3f7aae95-4341-4eec-a9de-5275bfbdaaec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_168fb72d-5f74-44cd-a695-b531e42b2370" xlink:to="loc_us-gaap_ProductMember_3f7aae95-4341-4eec-a9de-5275bfbdaaec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CollaborationandOtherRevenueMember_9dbb1a70-e7c2-4bd7-8fdd-d3bf220b672a" xlink:href="lly-20220930.xsd#lly_CollaborationandOtherRevenueMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_168fb72d-5f74-44cd-a695-b531e42b2370" xlink:to="loc_lly_CollaborationandOtherRevenueMember_9dbb1a70-e7c2-4bd7-8fdd-d3bf220b672a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_386673df-59c5-47e9-96ed-f38d6d05b1ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_168fb72d-5f74-44cd-a695-b531e42b2370" xlink:to="loc_us-gaap_RoyaltyMember_386673df-59c5-47e9-96ed-f38d6d05b1ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_514b86bd-3011-4469-9181-85aa9bfed66b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_4773a452-0c0a-4965-bc57-e72ae7c17b49" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_514b86bd-3011-4469-9181-85aa9bfed66b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_79215baa-a05f-4b06-ac05-3bcc35e3b4b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_514b86bd-3011-4469-9181-85aa9bfed66b" xlink:to="loc_us-gaap_Revenues_79215baa-a05f-4b06-ac05-3bcc35e3b4b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/RevenueAdjustmentstoRevenueDetails" xlink:type="simple" xlink:href="lly-20220930.xsd#RevenueAdjustmentstoRevenueDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/RevenueAdjustmentstoRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_36112f7f-c34d-427e-8e77-e10f8a267709" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfChangeInAccountingEstimateTable_5b7aa423-a849-457b-b8df-595a2be8920d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfChangeInAccountingEstimateTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_36112f7f-c34d-427e-8e77-e10f8a267709" xlink:to="loc_us-gaap_ScheduleOfChangeInAccountingEstimateTable_5b7aa423-a849-457b-b8df-595a2be8920d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_525eb263-5de1-444c-a554-a4b36304f481" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfChangeInAccountingEstimateTable_5b7aa423-a849-457b-b8df-595a2be8920d" xlink:to="loc_srt_StatementGeographicalAxis_525eb263-5de1-444c-a554-a4b36304f481" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_83eb2484-e5cb-4f16-81c2-56e1407311e4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_525eb263-5de1-444c-a554-a4b36304f481" xlink:to="loc_srt_SegmentGeographicalDomain_83eb2484-e5cb-4f16-81c2-56e1407311e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_feec730e-4bca-4e3e-bcc7-89ac29173f74" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_83eb2484-e5cb-4f16-81c2-56e1407311e4" xlink:to="loc_country_US_feec730e-4bca-4e3e-bcc7-89ac29173f74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_f686fee8-01c8-42c4-aa90-ea60cf06c8a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInAccountingEstimateByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfChangeInAccountingEstimateTable_5b7aa423-a849-457b-b8df-595a2be8920d" xlink:to="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_f686fee8-01c8-42c4-aa90-ea60cf06c8a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_9cea77b9-d2c7-462e-89e9-85357d54370a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInAccountingEstimateTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_f686fee8-01c8-42c4-aa90-ea60cf06c8a3" xlink:to="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_9cea77b9-d2c7-462e-89e9-85357d54370a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesReturnsAndAllowancesMember_4378d874-407c-49f0-95bf-66887250f55e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesReturnsAndAllowancesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_9cea77b9-d2c7-462e-89e9-85357d54370a" xlink:to="loc_us-gaap_SalesReturnsAndAllowancesMember_4378d874-407c-49f0-95bf-66887250f55e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateLineItems_90810cfd-6d0f-48c3-a28d-245c04fe05a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInAccountingEstimateLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfChangeInAccountingEstimateTable_5b7aa423-a849-457b-b8df-595a2be8920d" xlink:to="loc_us-gaap_ChangeInAccountingEstimateLineItems_90810cfd-6d0f-48c3-a28d-245c04fe05a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent_0fb31fb1-e67e-4e04-86a0-2aa6da5ee81f" xlink:href="lly-20220930.xsd#lly_RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ChangeInAccountingEstimateLineItems_90810cfd-6d0f-48c3-a28d-245c04fe05a4" xlink:to="loc_lly_RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent_0fb31fb1-e67e-4e04-86a0-2aa6da5ee81f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/RevenueContractLiabilitiesDetails" xlink:type="simple" xlink:href="lly-20220930.xsd#RevenueContractLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/RevenueContractLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_d603cace-d502-4216-b179-249046d67e8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_45eca0e0-9ff4-41c3-92e8-3578943a3808" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_d603cace-d502-4216-b179-249046d67e8b" xlink:to="loc_us-gaap_ContractWithCustomerLiability_45eca0e0-9ff4-41c3-92e8-3578943a3808" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails" xlink:type="simple" xlink:href="lly-20220930.xsd#RevenueDisaggregationofRevenuebyProductDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_8beb618f-9c7e-4751-86a8-8c4f56117e88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_6fa2293f-f99a-48a6-8c78-bfeda3070338" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_8beb618f-9c7e-4751-86a8-8c4f56117e88" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_6fa2293f-f99a-48a6-8c78-bfeda3070338" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_6718f0ee-6631-48cb-a3e0-895c403a3d53" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_6fa2293f-f99a-48a6-8c78-bfeda3070338" xlink:to="loc_srt_ProductOrServiceAxis_6718f0ee-6631-48cb-a3e0-895c403a3d53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_e1e31312-a68d-4590-85ad-67ee5cbf776a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_6718f0ee-6631-48cb-a3e0-895c403a3d53" xlink:to="loc_srt_ProductsAndServicesDomain_e1e31312-a68d-4590-85ad-67ee5cbf776a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DiabetesMember_07f5d614-5f44-4537-8e25-580bc3f35cd4" xlink:href="lly-20220930.xsd#lly_DiabetesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e1e31312-a68d-4590-85ad-67ee5cbf776a" xlink:to="loc_lly_DiabetesMember_07f5d614-5f44-4537-8e25-580bc3f35cd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_TrulicityMember_fe5510e1-000a-4be6-9990-a787def64de0" xlink:href="lly-20220930.xsd#lly_TrulicityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_DiabetesMember_07f5d614-5f44-4537-8e25-580bc3f35cd4" xlink:to="loc_lly_TrulicityMember_fe5510e1-000a-4be6-9990-a787def64de0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_JardianceMember_9b7f8955-e9ee-4e98-818f-03eb5353bc94" xlink:href="lly-20220930.xsd#lly_JardianceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_DiabetesMember_07f5d614-5f44-4537-8e25-580bc3f35cd4" xlink:to="loc_lly_JardianceMember_9b7f8955-e9ee-4e98-818f-03eb5353bc94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_HumalogMember_9fe76c02-93a9-42db-a04b-29ddb595f98f" xlink:href="lly-20220930.xsd#lly_HumalogMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_DiabetesMember_07f5d614-5f44-4537-8e25-580bc3f35cd4" xlink:to="loc_lly_HumalogMember_9fe76c02-93a9-42db-a04b-29ddb595f98f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_HumulinMember_ce10f3ae-13a9-43f0-8cb8-1405b0e37743" xlink:href="lly-20220930.xsd#lly_HumulinMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_DiabetesMember_07f5d614-5f44-4537-8e25-580bc3f35cd4" xlink:to="loc_lly_HumulinMember_ce10f3ae-13a9-43f0-8cb8-1405b0e37743" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BasaglarMember_353c61a4-8683-4e97-b08b-3402091b4e1c" xlink:href="lly-20220930.xsd#lly_BasaglarMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_DiabetesMember_07f5d614-5f44-4537-8e25-580bc3f35cd4" xlink:to="loc_lly_BasaglarMember_353c61a4-8683-4e97-b08b-3402091b4e1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MounjaroMember_ad0bebdc-5d41-4ffe-ae2e-9059cf007f2e" xlink:href="lly-20220930.xsd#lly_MounjaroMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_DiabetesMember_07f5d614-5f44-4537-8e25-580bc3f35cd4" xlink:to="loc_lly_MounjaroMember_ad0bebdc-5d41-4ffe-ae2e-9059cf007f2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OtherDiabetesMember_827827fd-155a-40b1-9b8e-747b9d3b34b8" xlink:href="lly-20220930.xsd#lly_OtherDiabetesMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_DiabetesMember_07f5d614-5f44-4537-8e25-580bc3f35cd4" xlink:to="loc_lly_OtherDiabetesMember_827827fd-155a-40b1-9b8e-747b9d3b34b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OncologyMember_7e287428-01e4-4b27-8c8b-66f8e2a953fc" xlink:href="lly-20220930.xsd#lly_OncologyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e1e31312-a68d-4590-85ad-67ee5cbf776a" xlink:to="loc_lly_OncologyMember_7e287428-01e4-4b27-8c8b-66f8e2a953fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_VerzenioMember_8859e150-dad7-44c6-b0d1-26bb1f8d785f" xlink:href="lly-20220930.xsd#lly_VerzenioMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_OncologyMember_7e287428-01e4-4b27-8c8b-66f8e2a953fc" xlink:to="loc_lly_VerzenioMember_8859e150-dad7-44c6-b0d1-26bb1f8d785f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CyramzaMember_bd02c411-6cfb-4027-9083-506bc23a0ef6" xlink:href="lly-20220930.xsd#lly_CyramzaMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_OncologyMember_7e287428-01e4-4b27-8c8b-66f8e2a953fc" xlink:to="loc_lly_CyramzaMember_bd02c411-6cfb-4027-9083-506bc23a0ef6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ErbituxMember_f0674908-f91d-4f00-a741-d2b061f26957" xlink:href="lly-20220930.xsd#lly_ErbituxMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_OncologyMember_7e287428-01e4-4b27-8c8b-66f8e2a953fc" xlink:to="loc_lly_ErbituxMember_f0674908-f91d-4f00-a741-d2b061f26957" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AlimtaMember_bc7abe43-1b2e-4fec-9d44-d30a23dbe17d" xlink:href="lly-20220930.xsd#lly_AlimtaMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_OncologyMember_7e287428-01e4-4b27-8c8b-66f8e2a953fc" xlink:to="loc_lly_AlimtaMember_bc7abe43-1b2e-4fec-9d44-d30a23dbe17d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_TYVYTMember_e8e84b2b-962f-42e3-95db-758c09aa7e61" xlink:href="lly-20220930.xsd#lly_TYVYTMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_OncologyMember_7e287428-01e4-4b27-8c8b-66f8e2a953fc" xlink:to="loc_lly_TYVYTMember_e8e84b2b-962f-42e3-95db-758c09aa7e61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OtherOncologyMember_02a6e829-517e-4dad-ab08-6f02b9bb9aa4" xlink:href="lly-20220930.xsd#lly_OtherOncologyMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_OncologyMember_7e287428-01e4-4b27-8c8b-66f8e2a953fc" xlink:to="loc_lly_OtherOncologyMember_02a6e829-517e-4dad-ab08-6f02b9bb9aa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ImmunologyMember_1a2e23e0-39f7-456c-84d3-ea6be717a82e" xlink:href="lly-20220930.xsd#lly_ImmunologyMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e1e31312-a68d-4590-85ad-67ee5cbf776a" xlink:to="loc_lly_ImmunologyMember_1a2e23e0-39f7-456c-84d3-ea6be717a82e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_TaltzMember_31e1f3ad-9a37-47fb-9321-9f7df75b7d4e" xlink:href="lly-20220930.xsd#lly_TaltzMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_ImmunologyMember_1a2e23e0-39f7-456c-84d3-ea6be717a82e" xlink:to="loc_lly_TaltzMember_31e1f3ad-9a37-47fb-9321-9f7df75b7d4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OlumiantMember_76161c32-5546-4384-aabd-f5d8e4add712" xlink:href="lly-20220930.xsd#lly_OlumiantMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_ImmunologyMember_1a2e23e0-39f7-456c-84d3-ea6be717a82e" xlink:to="loc_lly_OlumiantMember_76161c32-5546-4384-aabd-f5d8e4add712" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OtherImmunologyMember_c61f2102-78f2-447d-93b7-a124f37eb3b5" xlink:href="lly-20220930.xsd#lly_OtherImmunologyMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_ImmunologyMember_1a2e23e0-39f7-456c-84d3-ea6be717a82e" xlink:to="loc_lly_OtherImmunologyMember_c61f2102-78f2-447d-93b7-a124f37eb3b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_NeuroscienceMember_d5a6f8c3-df3f-4b32-91d8-c868009e51d1" xlink:href="lly-20220930.xsd#lly_NeuroscienceMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e1e31312-a68d-4590-85ad-67ee5cbf776a" xlink:to="loc_lly_NeuroscienceMember_d5a6f8c3-df3f-4b32-91d8-c868009e51d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_EmgalityMember_a82efc61-3af0-482e-921d-e4f80293d679" xlink:href="lly-20220930.xsd#lly_EmgalityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_NeuroscienceMember_d5a6f8c3-df3f-4b32-91d8-c868009e51d1" xlink:to="loc_lly_EmgalityMember_a82efc61-3af0-482e-921d-e4f80293d679" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ZyprexaMember_02a0a2ca-4c9e-4fa8-8676-e557c49a5e51" xlink:href="lly-20220930.xsd#lly_ZyprexaMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_NeuroscienceMember_d5a6f8c3-df3f-4b32-91d8-c868009e51d1" xlink:to="loc_lly_ZyprexaMember_02a0a2ca-4c9e-4fa8-8676-e557c49a5e51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CymbaltaMember_38d776c9-caa5-42eb-8cef-268c74e5024c" xlink:href="lly-20220930.xsd#lly_CymbaltaMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_NeuroscienceMember_d5a6f8c3-df3f-4b32-91d8-c868009e51d1" xlink:to="loc_lly_CymbaltaMember_38d776c9-caa5-42eb-8cef-268c74e5024c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OtherNeuroscienceMember_0832a463-15ee-40f2-8868-5fcef86d4917" xlink:href="lly-20220930.xsd#lly_OtherNeuroscienceMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_NeuroscienceMember_d5a6f8c3-df3f-4b32-91d8-c868009e51d1" xlink:to="loc_lly_OtherNeuroscienceMember_0832a463-15ee-40f2-8868-5fcef86d4917" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OtherProductTotalMember_dd01e253-e4b3-431e-8e59-d994b4b8ec02" xlink:href="lly-20220930.xsd#lly_OtherProductTotalMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e1e31312-a68d-4590-85ad-67ee5cbf776a" xlink:to="loc_lly_OtherProductTotalMember_dd01e253-e4b3-431e-8e59-d994b4b8ec02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_COVID19AntibodiesMember_cdfcd4fd-026a-4772-bec3-19634d7ea501" xlink:href="lly-20220930.xsd#lly_COVID19AntibodiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_OtherProductTotalMember_dd01e253-e4b3-431e-8e59-d994b4b8ec02" xlink:to="loc_lly_COVID19AntibodiesMember_cdfcd4fd-026a-4772-bec3-19634d7ea501" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ForteoMember_fa42e216-8d6e-46eb-a326-ae478c7c2bce" xlink:href="lly-20220930.xsd#lly_ForteoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_OtherProductTotalMember_dd01e253-e4b3-431e-8e59-d994b4b8ec02" xlink:to="loc_lly_ForteoMember_fa42e216-8d6e-46eb-a326-ae478c7c2bce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CialisMember_15c41593-6f30-45d6-89d9-04348355a198" xlink:href="lly-20220930.xsd#lly_CialisMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_OtherProductTotalMember_dd01e253-e4b3-431e-8e59-d994b4b8ec02" xlink:to="loc_lly_CialisMember_15c41593-6f30-45d6-89d9-04348355a198" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OtherProductMember_af065bb4-c702-49b9-b66a-3fa37c97a221" xlink:href="lly-20220930.xsd#lly_OtherProductMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_OtherProductTotalMember_dd01e253-e4b3-431e-8e59-d994b4b8ec02" xlink:to="loc_lly_OtherProductMember_af065bb4-c702-49b9-b66a-3fa37c97a221" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_f038f5c2-a2ef-497d-83da-2b1fbb35184d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_6fa2293f-f99a-48a6-8c78-bfeda3070338" xlink:to="loc_srt_StatementGeographicalAxis_f038f5c2-a2ef-497d-83da-2b1fbb35184d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_960832e6-2d42-4555-a0a2-28b3c8105096" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_f038f5c2-a2ef-497d-83da-2b1fbb35184d" xlink:to="loc_srt_SegmentGeographicalDomain_960832e6-2d42-4555-a0a2-28b3c8105096" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_c34cea8e-50a4-470f-bd36-2c76292ce16d" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_960832e6-2d42-4555-a0a2-28b3c8105096" xlink:to="loc_country_US_c34cea8e-50a4-470f-bd36-2c76292ce16d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_fd94195a-0d67-4839-8fa3-ed0a0f3fa9b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonUsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_960832e6-2d42-4555-a0a2-28b3c8105096" xlink:to="loc_us-gaap_NonUsMember_fd94195a-0d67-4839-8fa3-ed0a0f3fa9b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_cc66c5d5-5804-40ca-ac99-28eb0d89ae7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_6fa2293f-f99a-48a6-8c78-bfeda3070338" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_cc66c5d5-5804-40ca-ac99-28eb0d89ae7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_d9287941-341c-4695-81c9-a90d841270b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_cc66c5d5-5804-40ca-ac99-28eb0d89ae7d" xlink:to="loc_us-gaap_Revenues_d9287941-341c-4695-81c9-a90d841270b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/RevenueDisaggregationofRevenuebyGeographicalAreaDetails" xlink:type="simple" xlink:href="lly-20220930.xsd#RevenueDisaggregationofRevenuebyGeographicalAreaDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/RevenueDisaggregationofRevenuebyGeographicalAreaDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_b26d3bf6-6429-49f6-8852-22f159b8458e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_a950338f-42cb-42b6-84e6-25a0ce44b0c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_b26d3bf6-6429-49f6-8852-22f159b8458e" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_a950338f-42cb-42b6-84e6-25a0ce44b0c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_2bd709b6-8e02-4814-85fb-7de3f836538a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_a950338f-42cb-42b6-84e6-25a0ce44b0c8" xlink:to="loc_srt_StatementGeographicalAxis_2bd709b6-8e02-4814-85fb-7de3f836538a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_e8456c22-0122-4601-82cd-41c8e7d40260" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_2bd709b6-8e02-4814-85fb-7de3f836538a" xlink:to="loc_srt_SegmentGeographicalDomain_e8456c22-0122-4601-82cd-41c8e7d40260" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_b68cd15e-93df-45b9-8cf4-c1ec7e90abb1" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_e8456c22-0122-4601-82cd-41c8e7d40260" xlink:to="loc_country_US_b68cd15e-93df-45b9-8cf4-c1ec7e90abb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember_2d23bee1-c4b5-47bf-b54b-eb6c55cae5d7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EuropeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_e8456c22-0122-4601-82cd-41c8e7d40260" xlink:to="loc_srt_EuropeMember_2d23bee1-c4b5-47bf-b54b-eb6c55cae5d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_JP_e26a93aa-6f45-4095-b2f7-aa7bede04ad5" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_JP"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_e8456c22-0122-4601-82cd-41c8e7d40260" xlink:to="loc_country_JP_e26a93aa-6f45-4095-b2f7-aa7bede04ad5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CN_7ab79495-a482-4645-880c-4f29018a634e" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CN"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_e8456c22-0122-4601-82cd-41c8e7d40260" xlink:to="loc_country_CN_7ab79495-a482-4645-880c-4f29018a634e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OtherForeignCountriesMember_629d9de4-93d9-417c-af48-c3fb9e1c39eb" xlink:href="lly-20220930.xsd#lly_OtherForeignCountriesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_e8456c22-0122-4601-82cd-41c8e7d40260" xlink:to="loc_lly_OtherForeignCountriesMember_629d9de4-93d9-417c-af48-c3fb9e1c39eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_ae9f083f-921d-45bb-bb43-cfb341dec8b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_a950338f-42cb-42b6-84e6-25a0ce44b0c8" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_ae9f083f-921d-45bb-bb43-cfb341dec8b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_f77b64dd-1d83-498f-bb87-310a22ea266d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_ae9f083f-921d-45bb-bb43-cfb341dec8b7" xlink:to="loc_us-gaap_Revenues_f77b64dd-1d83-498f-bb87-310a22ea266d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/AcquisitionsNarrativeDetails" xlink:type="simple" xlink:href="lly-20220930.xsd#AcquisitionsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/AcquisitionsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_73bdcb59-917c-47ca-a704-b11e5dbb6fef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_9f18d728-22fd-4459-aa14-4c34cc8fa253" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_73bdcb59-917c-47ca-a704-b11e5dbb6fef" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_9f18d728-22fd-4459-aa14-4c34cc8fa253" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_a94e5cff-c534-4db9-a801-5a3c6233f003" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_9f18d728-22fd-4459-aa14-4c34cc8fa253" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_a94e5cff-c534-4db9-a801-5a3c6233f003" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ec795f65-08ef-48b8-998e-57f0e0029a7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_a94e5cff-c534-4db9-a801-5a3c6233f003" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ec795f65-08ef-48b8-998e-57f0e0029a7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_PrevailTherapeuticsIncMember_e3422d24-6701-4b82-b7ec-d6cc6bc0b26d" xlink:href="lly-20220930.xsd#lly_PrevailTherapeuticsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ec795f65-08ef-48b8-998e-57f0e0029a7f" xlink:to="loc_lly_PrevailTherapeuticsIncMember_e3422d24-6701-4b82-b7ec-d6cc6bc0b26d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AkouosAcquisitionMember_294414aa-97aa-46b3-9c6a-c1bff14c32ff" xlink:href="lly-20220930.xsd#lly_AkouosAcquisitionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ec795f65-08ef-48b8-998e-57f0e0029a7f" xlink:to="loc_lly_AkouosAcquisitionMember_294414aa-97aa-46b3-9c6a-c1bff14c32ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_36af5a6c-c6f5-4723-a88b-7ca382d5a063" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_9f18d728-22fd-4459-aa14-4c34cc8fa253" xlink:to="loc_srt_StatementScenarioAxis_36af5a6c-c6f5-4723-a88b-7ca382d5a063" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_b28130cd-5bf1-4c48-95cd-846ae75c3cd0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_36af5a6c-c6f5-4723-a88b-7ca382d5a063" xlink:to="loc_srt_ScenarioUnspecifiedDomain_b28130cd-5bf1-4c48-95cd-846ae75c3cd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_ce4cb0da-d5c5-4931-b499-42c3012b17b1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_b28130cd-5bf1-4c48-95cd-846ae75c3cd0" xlink:to="loc_srt_ScenarioForecastMember_ce4cb0da-d5c5-4931-b499-42c3012b17b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_99321e59-a98b-4704-83dc-77613c70cbe2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_9f18d728-22fd-4459-aa14-4c34cc8fa253" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_99321e59-a98b-4704-83dc-77613c70cbe2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AcquiredInProcessResearchAndDevelopmentAndDevelopmentMilestones_93bbb501-e52b-4b1a-af59-7134d15e4902" xlink:href="lly-20220930.xsd#lly_AcquiredInProcessResearchAndDevelopmentAndDevelopmentMilestones"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_99321e59-a98b-4704-83dc-77613c70cbe2" xlink:to="loc_lly_AcquiredInProcessResearchAndDevelopmentAndDevelopmentMilestones_93bbb501-e52b-4b1a-af59-7134d15e4902" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_1f8d57ed-e749-4e19-918d-6bb0fca396d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionSharePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_99321e59-a98b-4704-83dc-77613c70cbe2" xlink:to="loc_us-gaap_BusinessAcquisitionSharePrice_1f8d57ed-e749-4e19-918d-6bb0fca396d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_8d8d78ff-1a7f-4fb7-9b4f-7dd279d125a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_99321e59-a98b-4704-83dc-77613c70cbe2" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_8d8d78ff-1a7f-4fb7-9b4f-7dd279d125a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BusinessCombinationConsiderationTransferredNumberOfContingentValueRights_9201994c-5fed-4fd4-af8e-9fc8b3fd2470" xlink:href="lly-20220930.xsd#lly_BusinessCombinationConsiderationTransferredNumberOfContingentValueRights"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_99321e59-a98b-4704-83dc-77613c70cbe2" xlink:to="loc_lly_BusinessCombinationConsiderationTransferredNumberOfContingentValueRights_9201994c-5fed-4fd4-af8e-9fc8b3fd2470" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BusinessAcquisitionContingentValueRightAdditionalPricePerShare_4aeece1d-ce31-4137-a9ab-7fccc86ebe30" xlink:href="lly-20220930.xsd#lly_BusinessAcquisitionContingentValueRightAdditionalPricePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_99321e59-a98b-4704-83dc-77613c70cbe2" xlink:to="loc_lly_BusinessAcquisitionContingentValueRightAdditionalPricePerShare_4aeece1d-ce31-4137-a9ab-7fccc86ebe30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_b26fc4e7-d055-40af-aea1-2196e7cae143" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_99321e59-a98b-4704-83dc-77613c70cbe2" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_b26fc4e7-d055-40af-aea1-2196e7cae143" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BusinessAcquisitionContingentValueRightRegulatoryApprovalDelayMonthlyReduction_70e13fce-ec58-4f95-aa5c-3f9e9532c574" xlink:href="lly-20220930.xsd#lly_BusinessAcquisitionContingentValueRightRegulatoryApprovalDelayMonthlyReduction"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_99321e59-a98b-4704-83dc-77613c70cbe2" xlink:to="loc_lly_BusinessAcquisitionContingentValueRightRegulatoryApprovalDelayMonthlyReduction_70e13fce-ec58-4f95-aa5c-3f9e9532c574" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_PaymentsForAssetAcquisitions_f176bf21-1654-4986-b627-dc14bf459409" xlink:href="lly-20220930.xsd#lly_PaymentsForAssetAcquisitions"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_99321e59-a98b-4704-83dc-77613c70cbe2" xlink:to="loc_lly_PaymentsForAssetAcquisitions_f176bf21-1654-4986-b627-dc14bf459409" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_6eb187cb-e03b-45ff-b500-fbe7276040d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_99321e59-a98b-4704-83dc-77613c70cbe2" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_6eb187cb-e03b-45ff-b500-fbe7276040d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="simple" xlink:href="lly-20220930.xsd#AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_2d22bcae-b058-4643-a190-49fd334954fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_03972954-e924-4651-89c4-03cba14c111a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_2d22bcae-b058-4643-a190-49fd334954fe" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_03972954-e924-4651-89c4-03cba14c111a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_39766ab2-2f0b-4bc5-8f12-3d05fb963083" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_03972954-e924-4651-89c4-03cba14c111a" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_39766ab2-2f0b-4bc5-8f12-3d05fb963083" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a52a759a-54e3-4c7b-ab4c-7326267cb521" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_39766ab2-2f0b-4bc5-8f12-3d05fb963083" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a52a759a-54e3-4c7b-ab4c-7326267cb521" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_PrevailTherapeuticsIncMember_39e018c8-de32-4d62-b26e-be45ab7ce49b" xlink:href="lly-20220930.xsd#lly_PrevailTherapeuticsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a52a759a-54e3-4c7b-ab4c-7326267cb521" xlink:to="loc_lly_PrevailTherapeuticsIncMember_39e018c8-de32-4d62-b26e-be45ab7ce49b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_1c898ee7-950a-40e7-823a-eeb606793986" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_03972954-e924-4651-89c4-03cba14c111a" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_1c898ee7-950a-40e7-823a-eeb606793986" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_04e50ae4-f83a-4e8c-bf92-0ca238f038f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1c898ee7-950a-40e7-823a-eeb606793986" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_04e50ae4-f83a-4e8c-bf92-0ca238f038f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_f28bec4a-7754-4fd7-be08-0623a8edb3df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1c898ee7-950a-40e7-823a-eeb606793986" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_f28bec4a-7754-4fd7-be08-0623a8edb3df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_47257f8b-d88d-4207-b8a3-fe85abc31904" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1c898ee7-950a-40e7-823a-eeb606793986" xlink:to="loc_us-gaap_Goodwill_47257f8b-d88d-4207-b8a3-fe85abc31904" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_07abbb71-e1f8-473c-ae2c-569894f0beff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1c898ee7-950a-40e7-823a-eeb606793986" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_07abbb71-e1f8-473c-ae2c-569894f0beff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet_cb403367-4114-4dfb-bbb6-3d7ebaa77d37" xlink:href="lly-20220930.xsd#lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1c898ee7-950a-40e7-823a-eeb606793986" xlink:to="loc_lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet_cb403367-4114-4dfb-bbb6-3d7ebaa77d37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_6aed2e08-48cb-494a-b977-4be0b93d9ce8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1c898ee7-950a-40e7-823a-eeb606793986" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_6aed2e08-48cb-494a-b977-4be0b93d9ce8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAcquiredFromAcquisition_19b30659-2aed-4092-af3f-645e297751cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAcquiredFromAcquisition"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1c898ee7-950a-40e7-823a-eeb606793986" xlink:to="loc_us-gaap_CashAcquiredFromAcquisition_19b30659-2aed-4092-af3f-645e297751cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability_f3151577-a9d3-4b41-88a6-4e804853d2c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1c898ee7-950a-40e7-823a-eeb606793986" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability_f3151577-a9d3-4b41-88a6-4e804853d2c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_f6800c58-a08a-47a4-9dd3-dda0667d7f14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1c898ee7-950a-40e7-823a-eeb606793986" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_f6800c58-a08a-47a4-9dd3-dda0667d7f14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/AcquisitionsAssetAcquisitionsDetails" xlink:type="simple" xlink:href="lly-20220930.xsd#AcquisitionsAssetAcquisitionsDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/AcquisitionsAssetAcquisitionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_cbdbcf3c-7f99-44b1-8ccd-6be57c6479df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionTable_e199436e-e4ec-4fe5-a5b6-ace264c825f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_cbdbcf3c-7f99-44b1-8ccd-6be57c6479df" xlink:to="loc_us-gaap_AssetAcquisitionTable_e199436e-e4ec-4fe5-a5b6-ace264c825f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_9a896f9b-d6b5-484d-8287-eed544790637" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionTable_e199436e-e4ec-4fe5-a5b6-ace264c825f3" xlink:to="loc_us-gaap_AssetAcquisitionAxis_9a896f9b-d6b5-484d-8287-eed544790637" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_72476664-ad97-4734-bd8a-8cf53b1d160e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionAxis_9a896f9b-d6b5-484d-8287-eed544790637" xlink:to="loc_us-gaap_AssetAcquisitionDomain_72476664-ad97-4734-bd8a-8cf53b1d160e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BioMarinPharmaceuticalIncMember_707271e9-9db7-4817-9993-e3761550db9d" xlink:href="lly-20220930.xsd#lly_BioMarinPharmaceuticalIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_72476664-ad97-4734-bd8a-8cf53b1d160e" xlink:to="loc_lly_BioMarinPharmaceuticalIncMember_707271e9-9db7-4817-9993-e3761550db9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_RigelPharmaceuticalsIncMember_20a8eddf-8054-4d0c-94a8-b759dcc429b5" xlink:href="lly-20220930.xsd#lly_RigelPharmaceuticalsIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_72476664-ad97-4734-bd8a-8cf53b1d160e" xlink:to="loc_lly_RigelPharmaceuticalsIncMember_20a8eddf-8054-4d0c-94a8-b759dcc429b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_PrecisionBiosciencesIncMember_d28feca0-b226-4b3f-81e5-baf9d34e422d" xlink:href="lly-20220930.xsd#lly_PrecisionBiosciencesIncMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_72476664-ad97-4734-bd8a-8cf53b1d160e" xlink:to="loc_lly_PrecisionBiosciencesIncMember_d28feca0-b226-4b3f-81e5-baf9d34e422d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_b60b8eb7-e2ee-4776-aef5-edf698d948c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionTable_e199436e-e4ec-4fe5-a5b6-ace264c825f3" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_b60b8eb7-e2ee-4776-aef5-edf698d948c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_PaymentsForAssetAcquisitions_faee0236-4c83-4abd-95c4-c23c3a8c93de" xlink:href="lly-20220930.xsd#lly_PaymentsForAssetAcquisitions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b60b8eb7-e2ee-4776-aef5-edf698d948c2" xlink:to="loc_lly_PaymentsForAssetAcquisitions_faee0236-4c83-4abd-95c4-c23c3a8c93de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/CollaborationsandOtherArrangementsDetails" xlink:type="simple" xlink:href="lly-20220930.xsd#CollaborationsandOtherArrangementsDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/CollaborationsandOtherArrangementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ac96c402-7075-48eb-bcc4-ff21e49b37db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_afb1537d-c3cb-4bbd-9f2a-4ad2df31819b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ac96c402-7075-48eb-bcc4-ff21e49b37db" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_afb1537d-c3cb-4bbd-9f2a-4ad2df31819b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_0786455d-24f1-4665-8cf1-136fb73fbe99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_afb1537d-c3cb-4bbd-9f2a-4ad2df31819b" xlink:to="loc_us-gaap_TypeOfArrangementAxis_0786455d-24f1-4665-8cf1-136fb73fbe99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b8e77768-56a8-49d6-b378-7da670854141" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_0786455d-24f1-4665-8cf1-136fb73fbe99" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b8e77768-56a8-49d6-b378-7da670854141" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember_a7b30151-22f3-4f4a-8ece-8975aedb798f" xlink:href="lly-20220930.xsd#lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b8e77768-56a8-49d6-b378-7da670854141" xlink:to="loc_lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember_a7b30151-22f3-4f4a-8ece-8975aedb798f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyAgreementTermsMember_c3b75ba4-bca1-4afb-b42d-828bf73215c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyAgreementTermsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b8e77768-56a8-49d6-b378-7da670854141" xlink:to="loc_us-gaap_RoyaltyAgreementTermsMember_c3b75ba4-bca1-4afb-b42d-828bf73215c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MilestonePaymentsCapitalizedAsIntangibleAssetsMember_575be92b-6ced-47b6-900a-8732a025e420" xlink:href="lly-20220930.xsd#lly_MilestonePaymentsCapitalizedAsIntangibleAssetsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b8e77768-56a8-49d6-b378-7da670854141" xlink:to="loc_lly_MilestonePaymentsCapitalizedAsIntangibleAssetsMember_575be92b-6ced-47b6-900a-8732a025e420" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MilestonePaymentsSalesBasedMember_2af6d978-570a-4525-be87-b58e12529ca5" xlink:href="lly-20220930.xsd#lly_MilestonePaymentsSalesBasedMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b8e77768-56a8-49d6-b378-7da670854141" xlink:to="loc_lly_MilestonePaymentsSalesBasedMember_2af6d978-570a-4525-be87-b58e12529ca5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MilestonePaymentsSuccessBasedRegulatoryAndSalesBasedMember_c8c1e098-03cf-4bf0-bcff-87d5af5262ab" xlink:href="lly-20220930.xsd#lly_MilestonePaymentsSuccessBasedRegulatoryAndSalesBasedMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b8e77768-56a8-49d6-b378-7da670854141" xlink:to="loc_lly_MilestonePaymentsSuccessBasedRegulatoryAndSalesBasedMember_c8c1e098-03cf-4bf0-bcff-87d5af5262ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MilestonePaymentsDevelopmentAndRegulatoryMember_3260e713-615b-4714-a89f-0521f1f8a27d" xlink:href="lly-20220930.xsd#lly_MilestonePaymentsDevelopmentAndRegulatoryMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b8e77768-56a8-49d6-b378-7da670854141" xlink:to="loc_lly_MilestonePaymentsDevelopmentAndRegulatoryMember_3260e713-615b-4714-a89f-0521f1f8a27d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_039cd5e0-fdb9-4a41-9869-f1c7709f3c85" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_afb1537d-c3cb-4bbd-9f2a-4ad2df31819b" xlink:to="loc_srt_ProductOrServiceAxis_039cd5e0-fdb9-4a41-9869-f1c7709f3c85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_6b5ff927-235f-4c9d-8f44-c6fe8434adea" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_039cd5e0-fdb9-4a41-9869-f1c7709f3c85" xlink:to="loc_srt_ProductsAndServicesDomain_6b5ff927-235f-4c9d-8f44-c6fe8434adea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_JardianceMember_757fbda9-52a2-42a6-b71a-9b2fcf4ea20f" xlink:href="lly-20220930.xsd#lly_JardianceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_6b5ff927-235f-4c9d-8f44-c6fe8434adea" xlink:to="loc_lly_JardianceMember_757fbda9-52a2-42a6-b71a-9b2fcf4ea20f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BasaglarMember_236944f0-b617-452e-928e-eb25c5eec4aa" xlink:href="lly-20220930.xsd#lly_BasaglarMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_6b5ff927-235f-4c9d-8f44-c6fe8434adea" xlink:to="loc_lly_BasaglarMember_236944f0-b617-452e-928e-eb25c5eec4aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_TrajentaBIMember_cb8756c1-76f5-4c4e-a2c1-22f024426ffe" xlink:href="lly-20220930.xsd#lly_TrajentaBIMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_6b5ff927-235f-4c9d-8f44-c6fe8434adea" xlink:to="loc_lly_TrajentaBIMember_cb8756c1-76f5-4c4e-a2c1-22f024426ffe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OlumiantMember_3059031e-7ee5-42f2-8fe2-0f5474c3ddf0" xlink:href="lly-20220930.xsd#lly_OlumiantMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_6b5ff927-235f-4c9d-8f44-c6fe8434adea" xlink:to="loc_lly_OlumiantMember_3059031e-7ee5-42f2-8fe2-0f5474c3ddf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_COVID19AntibodiesMember_b5a2c8ba-7d44-45e0-9285-db0988cc8a07" xlink:href="lly-20220930.xsd#lly_COVID19AntibodiesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_6b5ff927-235f-4c9d-8f44-c6fe8434adea" xlink:to="loc_lly_COVID19AntibodiesMember_b5a2c8ba-7d44-45e0-9285-db0988cc8a07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_TYVYTMember_427804ae-5071-425a-8bca-14da94f4c863" xlink:href="lly-20220930.xsd#lly_TYVYTMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_6b5ff927-235f-4c9d-8f44-c6fe8434adea" xlink:to="loc_lly_TYVYTMember_427804ae-5071-425a-8bca-14da94f4c863" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_LebrikizumabMember_89fdec69-397c-45dc-be2b-77157eefabbf" xlink:href="lly-20220930.xsd#lly_LebrikizumabMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_6b5ff927-235f-4c9d-8f44-c6fe8434adea" xlink:to="loc_lly_LebrikizumabMember_89fdec69-397c-45dc-be2b-77157eefabbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_79a61833-21d7-47aa-8247-2f994467a715" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_afb1537d-c3cb-4bbd-9f2a-4ad2df31819b" xlink:to="loc_dei_LegalEntityAxis_79a61833-21d7-47aa-8247-2f994467a715" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_71db1caa-e83e-4e5a-837a-dc9c05108fa4" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_79a61833-21d7-47aa-8247-2f994467a715" xlink:to="loc_dei_EntityDomain_71db1caa-e83e-4e5a-837a-dc9c05108fa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_InnoventBiologicsIncMember_b986ee84-811c-4659-b3b9-bf4a25f4da32" xlink:href="lly-20220930.xsd#lly_InnoventBiologicsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_71db1caa-e83e-4e5a-837a-dc9c05108fa4" xlink:to="loc_lly_InnoventBiologicsIncMember_b986ee84-811c-4659-b3b9-bf4a25f4da32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_RocheMember_72cb499e-c37a-4fd2-a118-d0dc026b3c25" xlink:href="lly-20220930.xsd#lly_RocheMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_71db1caa-e83e-4e5a-837a-dc9c05108fa4" xlink:to="loc_lly_RocheMember_72cb499e-c37a-4fd2-a118-d0dc026b3c25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_89c6607d-b434-4571-aa93-d959bb15496e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_afb1537d-c3cb-4bbd-9f2a-4ad2df31819b" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_89c6607d-b434-4571-aa93-d959bb15496e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CollaborativeArrangementRightsAndObligationsRightsObligations_d66f588f-45f2-4bd4-913f-67dc3068c62a" xlink:href="lly-20220930.xsd#lly_CollaborativeArrangementRightsAndObligationsRightsObligations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_89c6607d-b434-4571-aa93-d959bb15496e" xlink:to="loc_lly_CollaborativeArrangementRightsAndObligationsRightsObligations_d66f588f-45f2-4bd4-913f-67dc3068c62a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_5b0dd65d-48e8-41bd-9c47-f28c814c0fc9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_89c6607d-b434-4571-aa93-d959bb15496e" xlink:to="loc_us-gaap_Revenues_5b0dd65d-48e8-41bd-9c47-f28c814c0fc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CollaborativeArrangementRightsAndObligationsPercent_07674011-0cdf-4ed9-98d1-00893e7874d3" xlink:href="lly-20220930.xsd#lly_CollaborativeArrangementRightsAndObligationsPercent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_89c6607d-b434-4571-aa93-d959bb15496e" xlink:to="loc_lly_CollaborativeArrangementRightsAndObligationsPercent_07674011-0cdf-4ed9-98d1-00893e7874d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_172bf556-3607-4766-8882-b13356827efd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_89c6607d-b434-4571-aa93-d959bb15496e" xlink:to="loc_us-gaap_ContractWithCustomerLiability_172bf556-3607-4766-8882-b13356827efd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialChargesDetails" xlink:type="simple" xlink:href="lly-20220930.xsd#AssetImpairmentRestructuringandOtherSpecialChargesDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialChargesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_e87d86f9-1f50-43e7-b4e0-df5fa42a27b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1_5360a82e-9bab-4e82-a02c-a15068d67353" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeveranceCosts1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_e87d86f9-1f50-43e7-b4e0-df5fa42a27b2" xlink:to="loc_us-gaap_SeveranceCosts1_5360a82e-9bab-4e82-a02c-a15068d67353" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AssetImpairmentChargesRecoveriesAndOtherSpecialCharges_aa27b56f-0edb-4ba9-a042-4dea4e881262" xlink:href="lly-20220930.xsd#lly_AssetImpairmentChargesRecoveriesAndOtherSpecialCharges"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_e87d86f9-1f50-43e7-b4e0-df5fa42a27b2" xlink:to="loc_lly_AssetImpairmentChargesRecoveriesAndOtherSpecialCharges_aa27b56f-0edb-4ba9-a042-4dea4e881262" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringSettlementAndImpairmentProvisions_db18b265-c90e-4b90-9646-b53c787caa75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringSettlementAndImpairmentProvisions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_e87d86f9-1f50-43e7-b4e0-df5fa42a27b2" xlink:to="loc_us-gaap_RestructuringSettlementAndImpairmentProvisions_db18b265-c90e-4b90-9646-b53c787caa75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_59acbd93-7256-47bd-aeee-d3a796611bb2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_e87d86f9-1f50-43e7-b4e0-df5fa42a27b2" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_59acbd93-7256-47bd-aeee-d3a796611bb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown_282acf23-ff44-4bca-90f2-7a3f312cefca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWriteDown"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_e87d86f9-1f50-43e7-b4e0-df5fa42a27b2" xlink:to="loc_us-gaap_InventoryWriteDown_282acf23-ff44-4bca-90f2-7a3f312cefca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails" xlink:type="simple" xlink:href="lly-20220930.xsd#FinancialInstrumentsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_c5d83e65-a3d4-4903-94c6-ed57d99dbec1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_85a73397-674e-40d3-8d6b-b7658e1e5848" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_c5d83e65-a3d4-4903-94c6-ed57d99dbec1" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_85a73397-674e-40d3-8d6b-b7658e1e5848" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_4f62d6d7-04ad-46bf-99db-cc3b3e789811" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_85a73397-674e-40d3-8d6b-b7658e1e5848" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_4f62d6d7-04ad-46bf-99db-cc3b3e789811" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_8957fa1e-a3f8-4918-9d54-15c722f2ccf8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_4f62d6d7-04ad-46bf-99db-cc3b3e789811" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_8957fa1e-a3f8-4918-9d54-15c722f2ccf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BuyUsDollarSellEuroMember_ca89151e-9f6d-43b6-a161-ac27b5f9ecb8" xlink:href="lly-20220930.xsd#lly_BuyUsDollarSellEuroMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_8957fa1e-a3f8-4918-9d54-15c722f2ccf8" xlink:to="loc_lly_BuyUsDollarSellEuroMember_ca89151e-9f6d-43b6-a161-ac27b5f9ecb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BuyEuroSellUsDollarMember_3fb82bd7-472f-4564-9f17-1da899d1c962" xlink:href="lly-20220930.xsd#lly_BuyEuroSellUsDollarMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_8957fa1e-a3f8-4918-9d54-15c722f2ccf8" xlink:to="loc_lly_BuyEuroSellUsDollarMember_3fb82bd7-472f-4564-9f17-1da899d1c962" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BuyUSDollarSellChineseYuanMember_8173bf14-f84c-4ecf-be64-14e0b6b3322b" xlink:href="lly-20220930.xsd#lly_BuyUSDollarSellChineseYuanMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_8957fa1e-a3f8-4918-9d54-15c722f2ccf8" xlink:to="loc_lly_BuyUSDollarSellChineseYuanMember_8173bf14-f84c-4ecf-be64-14e0b6b3322b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BuyUSdollarSellJapaneseYenMember_8d3dc1a8-c879-4c18-899b-e258ad6347c6" xlink:href="lly-20220930.xsd#lly_BuyUSdollarSellJapaneseYenMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_8957fa1e-a3f8-4918-9d54-15c722f2ccf8" xlink:to="loc_lly_BuyUSdollarSellJapaneseYenMember_8d3dc1a8-c879-4c18-899b-e258ad6347c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BuyBritishPoundandSellUSDollarsMember_8f77e475-13c8-48e0-996e-2448531b2f39" xlink:href="lly-20220930.xsd#lly_BuyBritishPoundandSellUSDollarsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_8957fa1e-a3f8-4918-9d54-15c722f2ccf8" xlink:to="loc_lly_BuyBritishPoundandSellUSDollarsMember_8f77e475-13c8-48e0-996e-2448531b2f39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_SwapU.S.DollarsToEuroMember_77d04127-3c31-4052-8b86-349b9c789291" xlink:href="lly-20220930.xsd#lly_SwapU.S.DollarsToEuroMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_8957fa1e-a3f8-4918-9d54-15c722f2ccf8" xlink:to="loc_lly_SwapU.S.DollarsToEuroMember_77d04127-3c31-4052-8b86-349b9c789291" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_SwapSwissFrancsToU.S.DollarsMember_ad396926-911f-44ea-a0d5-031c7f535c39" xlink:href="lly-20220930.xsd#lly_SwapSwissFrancsToU.S.DollarsMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_8957fa1e-a3f8-4918-9d54-15c722f2ccf8" xlink:to="loc_lly_SwapSwissFrancsToU.S.DollarsMember_ad396926-911f-44ea-a0d5-031c7f535c39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_SellEuroMember_25416dbd-4251-49f9-a472-3a962352a819" xlink:href="lly-20220930.xsd#lly_SellEuroMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_8957fa1e-a3f8-4918-9d54-15c722f2ccf8" xlink:to="loc_lly_SellEuroMember_25416dbd-4251-49f9-a472-3a962352a819" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_36436fc6-fbd8-4d18-871b-6407ef8be4f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateSwapMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_8957fa1e-a3f8-4918-9d54-15c722f2ccf8" xlink:to="loc_us-gaap_InterestRateSwapMember_36436fc6-fbd8-4d18-871b-6407ef8be4f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_8d19370b-dbdc-4fa9-8f65-95ce93e86c3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_85a73397-674e-40d3-8d6b-b7658e1e5848" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_8d19370b-dbdc-4fa9-8f65-95ce93e86c3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_98d45780-31c9-41b9-95fb-2e927c52f395" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_8d19370b-dbdc-4fa9-8f65-95ce93e86c3b" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_98d45780-31c9-41b9-95fb-2e927c52f395" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ForeignCurrencyDenominatedDebtMember_84700694-a6f0-4f09-9389-497851db30bc" xlink:href="lly-20220930.xsd#lly_ForeignCurrencyDenominatedDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_98d45780-31c9-41b9-95fb-2e927c52f395" xlink:to="loc_lly_ForeignCurrencyDenominatedDebtMember_84700694-a6f0-4f09-9389-497851db30bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_c2329908-35ff-458a-b125-2f53fbd83203" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_85a73397-674e-40d3-8d6b-b7658e1e5848" xlink:to="loc_us-gaap_HedgingDesignationAxis_c2329908-35ff-458a-b125-2f53fbd83203" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_bb6ef92c-e459-4317-a722-5c49249ee494" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_c2329908-35ff-458a-b125-2f53fbd83203" xlink:to="loc_us-gaap_HedgingDesignationDomain_bb6ef92c-e459-4317-a722-5c49249ee494" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_570cc07b-b71b-490b-b36d-6426d3b7e5a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_bb6ef92c-e459-4317-a722-5c49249ee494" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_570cc07b-b71b-490b-b36d-6426d3b7e5a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_81648f29-8186-4148-ba5c-5c022e27706a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_85a73397-674e-40d3-8d6b-b7658e1e5848" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_81648f29-8186-4148-ba5c-5c022e27706a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_fa158429-5536-4aef-bee9-d7e5f365803b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_81648f29-8186-4148-ba5c-5c022e27706a" xlink:to="loc_us-gaap_HedgingRelationshipDomain_fa158429-5536-4aef-bee9-d7e5f365803b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_329756ee-55c0-4ac9-a0ec-ad116a463944" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_fa158429-5536-4aef-bee9-d7e5f365803b" xlink:to="loc_us-gaap_CashFlowHedgingMember_329756ee-55c0-4ac9-a0ec-ad116a463944" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_28a99abd-c4f4-4c98-a835-2cacbc153855" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_85a73397-674e-40d3-8d6b-b7658e1e5848" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_28a99abd-c4f4-4c98-a835-2cacbc153855" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_8583be1d-4a48-4134-a349-4c132eb1709b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_28a99abd-c4f4-4c98-a835-2cacbc153855" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_8583be1d-4a48-4134-a349-4c132eb1709b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MaturityDate2023Member_89f779fa-fc94-47e8-b7fe-f4dcc0f57bda" xlink:href="lly-20220930.xsd#lly_MaturityDate2023Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_8583be1d-4a48-4134-a349-4c132eb1709b" xlink:to="loc_lly_MaturityDate2023Member_89f779fa-fc94-47e8-b7fe-f4dcc0f57bda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_8a9ccf21-7104-473a-9888-088fa0b2dea7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_85a73397-674e-40d3-8d6b-b7658e1e5848" xlink:to="loc_us-gaap_DebtInstrumentAxis_8a9ccf21-7104-473a-9888-088fa0b2dea7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_b09e75b1-06e9-4124-a6d4-1272a096a2cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_8a9ccf21-7104-473a-9888-088fa0b2dea7" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_b09e75b1-06e9-4124-a6d4-1272a096a2cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A050NotesDue2033Member_725a9156-9b21-44ac-a5ce-09cf0d6715e1" xlink:href="lly-20220930.xsd#lly_A050NotesDue2033Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b09e75b1-06e9-4124-a6d4-1272a096a2cd" xlink:to="loc_lly_A050NotesDue2033Member_725a9156-9b21-44ac-a5ce-09cf0d6715e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1125NotesDue2051Member_2d85e283-eb5c-49d2-aaf2-3bb6275ca33d" xlink:href="lly-20220930.xsd#lly_A1125NotesDue2051Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b09e75b1-06e9-4124-a6d4-1272a096a2cd" xlink:to="loc_lly_A1125NotesDue2051Member_2d85e283-eb5c-49d2-aaf2-3bb6275ca33d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1375NotesDue2061Member_dfac8fc9-4016-4252-a083-15d7666e50d3" xlink:href="lly-20220930.xsd#lly_A1375NotesDue2061Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b09e75b1-06e9-4124-a6d4-1272a096a2cd" xlink:to="loc_lly_A1375NotesDue2061Member_dfac8fc9-4016-4252-a083-15d7666e50d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1625NotesDue2043Member_3c09c48d-8267-4ef8-9dd0-882142655605" xlink:href="lly-20220930.xsd#lly_A1625NotesDue2043Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b09e75b1-06e9-4124-a6d4-1272a096a2cd" xlink:to="loc_lly_A1625NotesDue2043Member_3c09c48d-8267-4ef8-9dd0-882142655605" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A395NotesDue2049Member_33a46f02-3581-4a15-9072-00ab8dcbbd21" xlink:href="lly-20220930.xsd#lly_A395NotesDue2049Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b09e75b1-06e9-4124-a6d4-1272a096a2cd" xlink:to="loc_lly_A395NotesDue2049Member_33a46f02-3581-4a15-9072-00ab8dcbbd21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A415NotesDue2059Member_036e6cda-33ec-434c-b042-632d0e1a4169" xlink:href="lly-20220930.xsd#lly_A415NotesDue2059Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b09e75b1-06e9-4124-a6d4-1272a096a2cd" xlink:to="loc_lly_A415NotesDue2059Member_036e6cda-33ec-434c-b042-632d0e1a4169" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A3375NotesDue2029Member_91ac2093-6090-4ef9-854c-d93848c949fd" xlink:href="lly-20220930.xsd#lly_A3375NotesDue2029Member"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b09e75b1-06e9-4124-a6d4-1272a096a2cd" xlink:to="loc_lly_A3375NotesDue2029Member_91ac2093-6090-4ef9-854c-d93848c949fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_42a2a3f6-0ee0-40f2-9b1a-a964cd143b00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_85a73397-674e-40d3-8d6b-b7658e1e5848" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_42a2a3f6-0ee0-40f2-9b1a-a964cd143b00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityNotionalAmount_0cbad97e-1d3d-4eb2-8f9e-97ad6b738cb7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilityNotionalAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_42a2a3f6-0ee0-40f2-9b1a-a964cd143b00" xlink:to="loc_us-gaap_DerivativeLiabilityNotionalAmount_0cbad97e-1d3d-4eb2-8f9e-97ad6b738cb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetNotionalAmount_d4cac38a-e81a-4d4c-9f82-111b8e2fc914" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetNotionalAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_42a2a3f6-0ee0-40f2-9b1a-a964cd143b00" xlink:to="loc_us-gaap_DerivativeAssetNotionalAmount_d4cac38a-e81a-4d4c-9f82-111b8e2fc914" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1_98dad97f-ba9b-497d-aeea-1f7729e71b24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_42a2a3f6-0ee0-40f2-9b1a-a964cd143b00" xlink:to="loc_us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1_98dad97f-ba9b-497d-aeea-1f7729e71b24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_728dc34e-0eeb-49be-ad03-528c49ba7e72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_42a2a3f6-0ee0-40f2-9b1a-a964cd143b00" xlink:to="loc_us-gaap_LongTermDebt_728dc34e-0eeb-49be-ad03-528c49ba7e72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTax_13292def-1386-477d-b1db-c83d548e67cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_42a2a3f6-0ee0-40f2-9b1a-a964cd143b00" xlink:to="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTax_13292def-1386-477d-b1db-c83d548e67cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_86cc7d3d-f982-4022-9279-a275813ea394" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_42a2a3f6-0ee0-40f2-9b1a-a964cd143b00" xlink:to="loc_us-gaap_DerivativeNotionalAmount_86cc7d3d-f982-4022-9279-a275813ea394" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DescriptionOfDerivativeActivityVolumePercent_7c98b834-47b6-4864-af34-4dda40b2c15d" xlink:href="lly-20220930.xsd#lly_DescriptionOfDerivativeActivityVolumePercent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_42a2a3f6-0ee0-40f2-9b1a-a964cd143b00" xlink:to="loc_lly_DescriptionOfDerivativeActivityVolumePercent_7c98b834-47b6-4864-af34-4dda40b2c15d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_ddbc3472-31dd-4821-9842-32e26f768250" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_42a2a3f6-0ee0-40f2-9b1a-a964cd143b00" xlink:to="loc_us-gaap_DebtInstrumentTerm_ddbc3472-31dd-4821-9842-32e26f768250" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_55b40cd4-6f2d-4f5a-8f33-bca3b9e030fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_42a2a3f6-0ee0-40f2-9b1a-a964cd143b00" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_55b40cd4-6f2d-4f5a-8f33-bca3b9e030fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_31a95aca-df81-4afc-ae33-4bcce27acd84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_42a2a3f6-0ee0-40f2-9b1a-a964cd143b00" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_31a95aca-df81-4afc-ae33-4bcce27acd84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_f6a95f9d-b7b1-435a-bdbf-cc161a25ca9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_42a2a3f6-0ee0-40f2-9b1a-a964cd143b00" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_f6a95f9d-b7b1-435a-bdbf-cc161a25ca9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts_4b1f72a4-7bd3-4953-bdab-2bdbaf80870b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDebtExtinguishmentCosts"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_42a2a3f6-0ee0-40f2-9b1a-a964cd143b00" xlink:to="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts_4b1f72a4-7bd3-4953-bdab-2bdbaf80870b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExtinguishmentOfDebtAmount_8e3075ca-1dbc-4748-92b1-ef9f3fbe0e63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ExtinguishmentOfDebtAmount"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_42a2a3f6-0ee0-40f2-9b1a-a964cd143b00" xlink:to="loc_us-gaap_ExtinguishmentOfDebtAmount_8e3075ca-1dbc-4748-92b1-ef9f3fbe0e63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_cdc6cc2b-ecbe-4a00-915c-19a5603f99b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_42a2a3f6-0ee0-40f2-9b1a-a964cd143b00" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_cdc6cc2b-ecbe-4a00-915c-19a5603f99b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet_9f6f1a77-7487-430c-86c3-7db2212b8739" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_42a2a3f6-0ee0-40f2-9b1a-a964cd143b00" xlink:to="loc_us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet_9f6f1a77-7487-430c-86c3-7db2212b8739" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments_468284c3-a9ca-45a1-be53-187dfe3745d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_42a2a3f6-0ee0-40f2-9b1a-a964cd143b00" xlink:to="loc_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments_468284c3-a9ca-45a1-be53-187dfe3745d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod_bcf59191-3f39-442b-b571-b99b6a15bfde" xlink:href="lly-20220930.xsd#lly_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_42a2a3f6-0ee0-40f2-9b1a-a964cd143b00" xlink:to="loc_lly_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod_bcf59191-3f39-442b-b571-b99b6a15bfde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_366e7fc7-ce64-484d-971f-00cb7ba253cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_42a2a3f6-0ee0-40f2-9b1a-a964cd143b00" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLoss_366e7fc7-ce64-484d-971f-00cb7ba253cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DebtSecuritiesAvailableForSaleUnrealizedLossPositionQualitativeDisclosureOtherPercentageOfNonperformingAssets_71a1d50a-4226-404b-92ee-6907f0ba095a" xlink:href="lly-20220930.xsd#lly_DebtSecuritiesAvailableForSaleUnrealizedLossPositionQualitativeDisclosureOtherPercentageOfNonperformingAssets"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_42a2a3f6-0ee0-40f2-9b1a-a964cd143b00" xlink:to="loc_lly_DebtSecuritiesAvailableForSaleUnrealizedLossPositionQualitativeDisclosureOtherPercentageOfNonperformingAssets_71a1d50a-4226-404b-92ee-6907f0ba095a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized_0cf229fa-54bf-4dc7-bb9a-bf984a2490df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_42a2a3f6-0ee0-40f2-9b1a-a964cd143b00" xlink:to="loc_us-gaap_TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized_0cf229fa-54bf-4dc7-bb9a-bf984a2490df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/FinancialInstrumentsEffectofRiskManagementInstrumentsDetails" xlink:type="simple" xlink:href="lly-20220930.xsd#FinancialInstrumentsEffectofRiskManagementInstrumentsDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/FinancialInstrumentsEffectofRiskManagementInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_ee3859c8-7f5a-4cb0-8f47-60173c501cff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_240f47c4-ef5d-48ce-bc34-f4d4eea1ca3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_ee3859c8-7f5a-4cb0-8f47-60173c501cff" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_240f47c4-ef5d-48ce-bc34-f4d4eea1ca3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_8efe27b1-a330-41a7-b852-6f3c24e49e15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_240f47c4-ef5d-48ce-bc34-f4d4eea1ca3f" xlink:to="loc_us-gaap_HedgingDesignationAxis_8efe27b1-a330-41a7-b852-6f3c24e49e15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_e668208e-7ec2-4bf3-b0cc-60853e45f24d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_8efe27b1-a330-41a7-b852-6f3c24e49e15" xlink:to="loc_us-gaap_HedgingDesignationDomain_e668208e-7ec2-4bf3-b0cc-60853e45f24d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_5ec22594-f48e-4f8e-acea-efb3405451b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_e668208e-7ec2-4bf3-b0cc-60853e45f24d" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_5ec22594-f48e-4f8e-acea-efb3405451b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_8d65e9c4-cbdc-4889-81ad-1f57cf20e66c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NondesignatedMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_e668208e-7ec2-4bf3-b0cc-60853e45f24d" xlink:to="loc_us-gaap_NondesignatedMember_8d65e9c4-cbdc-4889-81ad-1f57cf20e66c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_97c8413c-caf2-48c6-adf9-93aa6c53dcba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_240f47c4-ef5d-48ce-bc34-f4d4eea1ca3f" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_97c8413c-caf2-48c6-adf9-93aa6c53dcba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_4b7e9fae-50af-4375-8d68-52b9fa5a9b96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_97c8413c-caf2-48c6-adf9-93aa6c53dcba" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_4b7e9fae-50af-4375-8d68-52b9fa5a9b96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_HedgedFixedRateDebtMember_bd24cd46-02e7-4efc-aacb-feeb7f81c54f" xlink:href="lly-20220930.xsd#lly_HedgedFixedRateDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_4b7e9fae-50af-4375-8d68-52b9fa5a9b96" xlink:to="loc_lly_HedgedFixedRateDebtMember_bd24cd46-02e7-4efc-aacb-feeb7f81c54f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateContractMember_c95f789f-0d50-485e-830b-fd5e0de13da3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateContractMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_4b7e9fae-50af-4375-8d68-52b9fa5a9b96" xlink:to="loc_us-gaap_InterestRateContractMember_c95f789f-0d50-485e-830b-fd5e0de13da3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CrossCurrencyInterestRateContractMember_dd766351-c71d-4e2d-8ffc-7b5b96bad6e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CrossCurrencyInterestRateContractMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_4b7e9fae-50af-4375-8d68-52b9fa5a9b96" xlink:to="loc_us-gaap_CrossCurrencyInterestRateContractMember_dd766351-c71d-4e2d-8ffc-7b5b96bad6e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_fba979b1-8c68-4ba4-b40f-0574541a3115" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_4b7e9fae-50af-4375-8d68-52b9fa5a9b96" xlink:to="loc_us-gaap_ForeignExchangeContractMember_fba979b1-8c68-4ba4-b40f-0574541a3115" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_05fa338a-7408-43a1-9945-35fe0888e2f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateSwapMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_4b7e9fae-50af-4375-8d68-52b9fa5a9b96" xlink:to="loc_us-gaap_InterestRateSwapMember_05fa338a-7408-43a1-9945-35fe0888e2f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8ea31f4e-44f5-4f1b-9a54-30757539ba63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_240f47c4-ef5d-48ce-bc34-f4d4eea1ca3f" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8ea31f4e-44f5-4f1b-9a54-30757539ba63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_FairValueHedgeAbstract_8c568ac7-4871-40f3-b200-c1d4e4637238" xlink:href="lly-20220930.xsd#lly_FairValueHedgeAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8ea31f4e-44f5-4f1b-9a54-30757539ba63" xlink:to="loc_lly_FairValueHedgeAbstract_8c568ac7-4871-40f3-b200-c1d4e4637238" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1_105eeadb-bfd3-4cfc-b9b7-9c4ba684671a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_FairValueHedgeAbstract_8c568ac7-4871-40f3-b200-c1d4e4637238" xlink:to="loc_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1_105eeadb-bfd3-4cfc-b9b7-9c4ba684671a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_35abee40-38ea-4675-a117-5ee5ba391847" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_FairValueHedgeAbstract_8c568ac7-4871-40f3-b200-c1d4e4637238" xlink:to="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_35abee40-38ea-4675-a117-5ee5ba391847" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CashFlowHedgeAbstract_6866c12f-6936-47c2-ac13-339948483f19" xlink:href="lly-20220930.xsd#lly_CashFlowHedgeAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8ea31f4e-44f5-4f1b-9a54-30757539ba63" xlink:to="loc_lly_CashFlowHedgeAbstract_6866c12f-6936-47c2-ac13-339948483f19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_d9c781c3-9495-41b5-9304-94946a56551b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_CashFlowHedgeAbstract_6866c12f-6936-47c2-ac13-339948483f19" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_d9c781c3-9495-41b5-9304-94946a56551b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_643dfd22-5b69-448f-919f-3b517aade94f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8ea31f4e-44f5-4f1b-9a54-30757539ba63" xlink:to="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_643dfd22-5b69-448f-919f-3b517aade94f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DerivativeInstrumentsGainLossRecognized_2201d31e-10a6-4fa7-99eb-644550de3d6a" xlink:href="lly-20220930.xsd#lly_DerivativeInstrumentsGainLossRecognized"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8ea31f4e-44f5-4f1b-9a54-30757539ba63" xlink:to="loc_lly_DerivativeInstrumentsGainLossRecognized_2201d31e-10a6-4fa7-99eb-644550de3d6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_87add630-6600-4877-ab6d-d382f6cd26c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8ea31f4e-44f5-4f1b-9a54-30757539ba63" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_87add630-6600-4877-ab6d-d382f6cd26c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_edf0b470-9b30-4a53-a0d4-9742ae598ff9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8ea31f4e-44f5-4f1b-9a54-30757539ba63" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_edf0b470-9b30-4a53-a0d4-9742ae598ff9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/FinancialInstrumentsFairValueofFinancialInstrumentsDetails" xlink:type="simple" xlink:href="lly-20220930.xsd#FinancialInstrumentsFairValueofFinancialInstrumentsDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/FinancialInstrumentsFairValueofFinancialInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_d3069115-df09-4f9f-9973-3b7b754a01af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_11bc4c71-67c0-43ec-9b9a-c7cc6d929674" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_d3069115-df09-4f9f-9973-3b7b754a01af" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_11bc4c71-67c0-43ec-9b9a-c7cc6d929674" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_acd56928-a98d-48c7-ae50-68fe30601b82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_11bc4c71-67c0-43ec-9b9a-c7cc6d929674" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_acd56928-a98d-48c7-ae50-68fe30601b82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_519f5cda-316b-435b-85b0-f08b0593521c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_acd56928-a98d-48c7-ae50-68fe30601b82" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_519f5cda-316b-435b-85b0-f08b0593521c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_fbc486ab-4248-4950-93dd-909f0fbd9c32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_519f5cda-316b-435b-85b0-f08b0593521c" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_fbc486ab-4248-4950-93dd-909f0fbd9c32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_23386bcb-b55f-4ecb-b047-770bcd9249fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_519f5cda-316b-435b-85b0-f08b0593521c" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_23386bcb-b55f-4ecb-b047-770bcd9249fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember_37c885d2-60ea-463e-abd6-281073287088" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_519f5cda-316b-435b-85b0-f08b0593521c" xlink:to="loc_us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember_37c885d2-60ea-463e-abd6-281073287088" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_821c1e34-e0d8-410a-ba98-d6aabddcef65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_519f5cda-316b-435b-85b0-f08b0593521c" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_821c1e34-e0d8-410a-ba98-d6aabddcef65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_62f1229d-4b2d-453b-93d9-43dff96ec3af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_11bc4c71-67c0-43ec-9b9a-c7cc6d929674" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_62f1229d-4b2d-453b-93d9-43dff96ec3af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c92c7cc5-ff1a-4bbc-892a-c71c559b8c71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_62f1229d-4b2d-453b-93d9-43dff96ec3af" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c92c7cc5-ff1a-4bbc-892a-c71c559b8c71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_4388bcaf-4323-42a0-9d46-ac960845fe5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c92c7cc5-ff1a-4bbc-892a-c71c559b8c71" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_4388bcaf-4323-42a0-9d46-ac960845fe5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_be3a37cb-e4fd-4ed5-9e6b-5ebd7f01ed70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c92c7cc5-ff1a-4bbc-892a-c71c559b8c71" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_be3a37cb-e4fd-4ed5-9e6b-5ebd7f01ed70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_241de72f-35df-4b93-be31-8f778f01e46e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c92c7cc5-ff1a-4bbc-892a-c71c559b8c71" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_241de72f-35df-4b93-be31-8f778f01e46e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_f4029da5-e37c-4089-967c-31fe93022ddf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_11bc4c71-67c0-43ec-9b9a-c7cc6d929674" xlink:to="loc_us-gaap_FinancialInstrumentAxis_f4029da5-e37c-4089-967c-31fe93022ddf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_158334df-a401-4bdc-8185-d3a614e00d7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_f4029da5-e37c-4089-967c-31fe93022ddf" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_158334df-a401-4bdc-8185-d3a614e00d7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_40272f64-9fa8-4536-8389-1b3f4e232247" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_158334df-a401-4bdc-8185-d3a614e00d7b" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_40272f64-9fa8-4536-8389-1b3f4e232247" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_48a03932-753a-4244-ae9c-d4461d30f454" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_158334df-a401-4bdc-8185-d3a614e00d7b" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_48a03932-753a-4244-ae9c-d4461d30f454" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MortgageBackedSecuritiesMember_59f38323-1922-4cd3-ac8b-afddcfad4dac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MortgageBackedSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_158334df-a401-4bdc-8185-d3a614e00d7b" xlink:to="loc_us-gaap_MortgageBackedSecuritiesMember_59f38323-1922-4cd3-ac8b-afddcfad4dac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_780d0736-6afc-47e6-bb2d-d8ca74c8f3ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_158334df-a401-4bdc-8185-d3a614e00d7b" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_780d0736-6afc-47e6-bb2d-d8ca74c8f3ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherDebtSecuritiesMember_c23b5c1d-a8b3-47b2-8d78-0cde03a12324" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherDebtSecuritiesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_158334df-a401-4bdc-8185-d3a614e00d7b" xlink:to="loc_us-gaap_OtherDebtSecuritiesMember_c23b5c1d-a8b3-47b2-8d78-0cde03a12324" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OtherEquitySecuritiesMember_78b73ce5-0164-441e-b4b8-4a28c021fca8" xlink:href="lly-20220930.xsd#lly_OtherEquitySecuritiesMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_158334df-a401-4bdc-8185-d3a614e00d7b" xlink:to="loc_lly_OtherEquitySecuritiesMember_78b73ce5-0164-441e-b4b8-4a28c021fca8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MarketableSecuritiesMember_fbb155d4-43bc-4e45-be6b-92078dd239cd" xlink:href="lly-20220930.xsd#lly_MarketableSecuritiesMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_158334df-a401-4bdc-8185-d3a614e00d7b" xlink:to="loc_lly_MarketableSecuritiesMember_fbb155d4-43bc-4e45-be6b-92078dd239cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_EquityMethodAndOtherInvestmentsMember_d3650ca6-59f0-4561-92f1-635f18a51437" xlink:href="lly-20220930.xsd#lly_EquityMethodAndOtherInvestmentsMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_158334df-a401-4bdc-8185-d3a614e00d7b" xlink:to="loc_lly_EquityMethodAndOtherInvestmentsMember_d3650ca6-59f0-4561-92f1-635f18a51437" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_462f9b62-e494-4ed5-b670-2837457d452c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_11bc4c71-67c0-43ec-9b9a-c7cc6d929674" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_462f9b62-e494-4ed5-b670-2837457d452c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_52d5af92-c890-4c5b-af2b-15c8af38178f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_462f9b62-e494-4ed5-b670-2837457d452c" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_52d5af92-c890-4c5b-af2b-15c8af38178f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_8abffb36-0b31-4c2e-bcda-9474b2dab9b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_462f9b62-e494-4ed5-b670-2837457d452c" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_8abffb36-0b31-4c2e-bcda-9474b2dab9b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_a33c4b9d-9374-4fb5-88f7-a0428cc7ca02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_462f9b62-e494-4ed5-b670-2837457d452c" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_a33c4b9d-9374-4fb5-88f7-a0428cc7ca02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_f65bf90f-9aae-4d3e-bacc-c7434a5aed85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_462f9b62-e494-4ed5-b670-2837457d452c" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_f65bf90f-9aae-4d3e-bacc-c7434a5aed85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_91e700a3-3d4e-4ffa-8647-f56d3fe74609" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_462f9b62-e494-4ed5-b670-2837457d452c" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_91e700a3-3d4e-4ffa-8647-f56d3fe74609" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLongTermInvestments_20f434b0-62c8-4a51-967a-b2a282e886f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLongTermInvestments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_462f9b62-e494-4ed5-b670-2837457d452c" xlink:to="loc_us-gaap_OtherLongTermInvestments_20f434b0-62c8-4a51-967a-b2a282e886f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments_1491b2a5-fda3-4b6e-b223-bfde4324e9f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermInvestments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_462f9b62-e494-4ed5-b670-2837457d452c" xlink:to="loc_us-gaap_LongTermInvestments_1491b2a5-fda3-4b6e-b223-bfde4324e9f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaper_64484a5c-143b-4a00-a560-3f519c7fad1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaper"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_462f9b62-e494-4ed5-b670-2837457d452c" xlink:to="loc_us-gaap_CommercialPaper_64484a5c-143b-4a00-a560-3f519c7fad1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_d5603dae-342a-4d14-a85f-a4d7b3c4437f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_462f9b62-e494-4ed5-b670-2837457d452c" xlink:to="loc_us-gaap_LongTermDebt_d5603dae-342a-4d14-a85f-a4d7b3c4437f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/FinancialInstrumentsRiskManagementInstrumentsDetails" xlink:type="simple" xlink:href="lly-20220930.xsd#FinancialInstrumentsRiskManagementInstrumentsDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/FinancialInstrumentsRiskManagementInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_50f0419f-0280-4812-9301-78c183e6c88a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b190457a-1633-469d-ac2e-6d294c9c255a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_50f0419f-0280-4812-9301-78c183e6c88a" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b190457a-1633-469d-ac2e-6d294c9c255a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_1f7a444b-ee85-4e33-bceb-ec6043930e71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b190457a-1633-469d-ac2e-6d294c9c255a" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_1f7a444b-ee85-4e33-bceb-ec6043930e71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_5db872bd-8cc2-4bf7-aae5-e9e9e1c53210" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_1f7a444b-ee85-4e33-bceb-ec6043930e71" xlink:to="loc_us-gaap_HedgingRelationshipDomain_5db872bd-8cc2-4bf7-aae5-e9e9e1c53210" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueHedgingMember_96d73363-bca4-4167-8e14-7e0e303893c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueHedgingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_5db872bd-8cc2-4bf7-aae5-e9e9e1c53210" xlink:to="loc_us-gaap_FairValueHedgingMember_96d73363-bca4-4167-8e14-7e0e303893c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_0835ef90-361f-4342-99ed-69d786b67dd6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_5db872bd-8cc2-4bf7-aae5-e9e9e1c53210" xlink:to="loc_us-gaap_CashFlowHedgingMember_0835ef90-361f-4342-99ed-69d786b67dd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_958a15e2-0b63-47b6-b8ae-d0c4791ea5fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_5db872bd-8cc2-4bf7-aae5-e9e9e1c53210" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_958a15e2-0b63-47b6-b8ae-d0c4791ea5fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_ef86978c-826b-4ebc-ad8c-fb3b421da83d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b190457a-1633-469d-ac2e-6d294c9c255a" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_ef86978c-826b-4ebc-ad8c-fb3b421da83d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_d0b7e93f-3a43-411c-9ac7-77f98cff20cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_ef86978c-826b-4ebc-ad8c-fb3b421da83d" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_d0b7e93f-3a43-411c-9ac7-77f98cff20cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_188ab044-3b39-4345-ab4b-44d6f9253f26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_d0b7e93f-3a43-411c-9ac7-77f98cff20cc" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_188ab044-3b39-4345-ab4b-44d6f9253f26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_75938125-5d99-489f-add4-56d4debac366" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_d0b7e93f-3a43-411c-9ac7-77f98cff20cc" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_75938125-5d99-489f-add4-56d4debac366" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_49ff8af4-ed13-4bde-9dd1-378a449ff563" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_d0b7e93f-3a43-411c-9ac7-77f98cff20cc" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_49ff8af4-ed13-4bde-9dd1-378a449ff563" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_d068c9d5-ad89-4531-a712-0df2347c3c48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b190457a-1633-469d-ac2e-6d294c9c255a" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_d068c9d5-ad89-4531-a712-0df2347c3c48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_6b89593d-e838-45d6-878d-ef1c43c6b8b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_d068c9d5-ad89-4531-a712-0df2347c3c48" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_6b89593d-e838-45d6-878d-ef1c43c6b8b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateContractMember_ec3c99f3-59d7-4c8b-a785-15aaed3368f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_6b89593d-e838-45d6-878d-ef1c43c6b8b9" xlink:to="loc_us-gaap_InterestRateContractMember_ec3c99f3-59d7-4c8b-a785-15aaed3368f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CrossCurrencyInterestRateContractMember_0ba48a6b-8fca-4700-a897-16f7eb6518a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CrossCurrencyInterestRateContractMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_6b89593d-e838-45d6-878d-ef1c43c6b8b9" xlink:to="loc_us-gaap_CrossCurrencyInterestRateContractMember_0ba48a6b-8fca-4700-a897-16f7eb6518a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_bf870393-d431-4b89-84b1-74d164975dfc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_6b89593d-e838-45d6-878d-ef1c43c6b8b9" xlink:to="loc_us-gaap_ForeignExchangeContractMember_bf870393-d431-4b89-84b1-74d164975dfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_c440302f-14cd-4ff9-a6b2-a1a03c30f8d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b190457a-1633-469d-ac2e-6d294c9c255a" xlink:to="loc_us-gaap_HedgingDesignationAxis_c440302f-14cd-4ff9-a6b2-a1a03c30f8d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_a09d32cf-f87c-4224-81da-9abd5510d649" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_c440302f-14cd-4ff9-a6b2-a1a03c30f8d6" xlink:to="loc_us-gaap_HedgingDesignationDomain_a09d32cf-f87c-4224-81da-9abd5510d649" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_143018c2-8bb1-4391-9a70-f3a7c8d95e1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_a09d32cf-f87c-4224-81da-9abd5510d649" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_143018c2-8bb1-4391-9a70-f3a7c8d95e1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_26cc8d87-969a-41dd-bac1-f8b46bf4d84e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NondesignatedMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_a09d32cf-f87c-4224-81da-9abd5510d649" xlink:to="loc_us-gaap_NondesignatedMember_26cc8d87-969a-41dd-bac1-f8b46bf4d84e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5e24def9-a1c0-46ab-b4e5-115ab7ab5f10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b190457a-1633-469d-ac2e-6d294c9c255a" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5e24def9-a1c0-46ab-b4e5-115ab7ab5f10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c2628717-4e0d-48b9-acef-b8398c9c3ee0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5e24def9-a1c0-46ab-b4e5-115ab7ab5f10" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c2628717-4e0d-48b9-acef-b8398c9c3ee0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_c9249920-0447-46fe-9f30-7b190b842f8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c2628717-4e0d-48b9-acef-b8398c9c3ee0" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_c9249920-0447-46fe-9f30-7b190b842f8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_d936955e-6807-4374-bca4-9df2d4693020" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c2628717-4e0d-48b9-acef-b8398c9c3ee0" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_d936955e-6807-4374-bca4-9df2d4693020" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_d2198b9c-edf5-4289-bb66-cfacd330c9f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c2628717-4e0d-48b9-acef-b8398c9c3ee0" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_d2198b9c-edf5-4289-bb66-cfacd330c9f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b66fa097-2e16-44c4-bf80-a7a29dc8790d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b190457a-1633-469d-ac2e-6d294c9c255a" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b66fa097-2e16-44c4-bf80-a7a29dc8790d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsCurrent_ba509ab6-d100-4986-9fe1-62948870a72b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetsCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b66fa097-2e16-44c4-bf80-a7a29dc8790d" xlink:to="loc_us-gaap_DerivativeAssetsCurrent_ba509ab6-d100-4986-9fe1-62948870a72b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsNoncurrent_52dbbf42-4f87-479f-bf73-8a865e3af099" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetsNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b66fa097-2e16-44c4-bf80-a7a29dc8790d" xlink:to="loc_us-gaap_DerivativeAssetsNoncurrent_52dbbf42-4f87-479f-bf73-8a865e3af099" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent_8fa02b65-8237-43f5-9eaa-534e7146e4ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b66fa097-2e16-44c4-bf80-a7a29dc8790d" xlink:to="loc_us-gaap_DerivativeLiabilitiesCurrent_8fa02b65-8237-43f5-9eaa-534e7146e4ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_003b239c-08b9-4d03-b0ff-cc992ce76b8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b66fa097-2e16-44c4-bf80-a7a29dc8790d" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent_003b239c-08b9-4d03-b0ff-cc992ce76b8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_ed99dfa3-5839-4ab0-820d-a74758e2f189" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b66fa097-2e16-44c4-bf80-a7a29dc8790d" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_ed99dfa3-5839-4ab0-820d-a74758e2f189" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/FinancialInstrumentsContractualMaturitiesDetails" xlink:type="simple" xlink:href="lly-20220930.xsd#FinancialInstrumentsContractualMaturitiesDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/FinancialInstrumentsContractualMaturitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_5915f726-b758-4c4a-b3b5-ad433c925e0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_2d4db6de-a438-40a1-9f3c-ee3c3a7e9af9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_5915f726-b758-4c4a-b3b5-ad433c925e0c" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_2d4db6de-a438-40a1-9f3c-ee3c3a7e9af9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_e37460fe-7f81-40ce-8b67-9568a61efe09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_5915f726-b758-4c4a-b3b5-ad433c925e0c" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_e37460fe-7f81-40ce-8b67-9568a61efe09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_b8c2f30b-4269-4d87-a1b3-eaab124141ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_5915f726-b758-4c4a-b3b5-ad433c925e0c" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_b8c2f30b-4269-4d87-a1b3-eaab124141ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_8e3bec0f-b5b4-4f24-91dc-89055bdb53b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_5915f726-b758-4c4a-b3b5-ad433c925e0c" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_8e3bec0f-b5b4-4f24-91dc-89055bdb53b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue_25a788bc-fbcc-47ee-83c3-980cc5d9b0bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_5915f726-b758-4c4a-b3b5-ad433c925e0c" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue_25a788bc-fbcc-47ee-83c3-980cc5d9b0bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/FinancialInstrumentsUnrealizedGainsandLossesDetails" xlink:type="simple" xlink:href="lly-20220930.xsd#FinancialInstrumentsUnrealizedGainsandLossesDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/FinancialInstrumentsUnrealizedGainsandLossesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_8d973b95-9426-4907-b194-2bb6f869c554" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_a1258b53-9bcc-43ee-95d3-0b3395995cdc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_8d973b95-9426-4907-b194-2bb6f869c554" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_a1258b53-9bcc-43ee-95d3-0b3395995cdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_12c17879-7669-41c7-803f-b8447f2886f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_8d973b95-9426-4907-b194-2bb6f869c554" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_12c17879-7669-41c7-803f-b8447f2886f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DebtSecuritiesAvailableforsaleUnrealizedGainPosition_0f0e6577-d0f2-4202-9e9e-fca3179f3dd2" xlink:href="lly-20220930.xsd#lly_DebtSecuritiesAvailableforsaleUnrealizedGainPosition"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_8d973b95-9426-4907-b194-2bb6f869c554" xlink:to="loc_lly_DebtSecuritiesAvailableforsaleUnrealizedGainPosition_0f0e6577-d0f2-4202-9e9e-fca3179f3dd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_080455d5-c9a6-4b55-9f0c-3447a64d3a5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_8d973b95-9426-4907-b194-2bb6f869c554" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_080455d5-c9a6-4b55-9f0c-3447a64d3a5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/FinancialInstrumentsRealizedGainsandLossesDetails" xlink:type="simple" xlink:href="lly-20220930.xsd#FinancialInstrumentsRealizedGainsandLossesDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/FinancialInstrumentsRealizedGainsandLossesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_785bdd16-93bf-4674-a45d-68e80db06a98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ProceedsfromSaleofEquityandAvailableforSaleSecurities_61e4ef03-1ba3-4f5c-9a87-34c6a7e72839" xlink:href="lly-20220930.xsd#lly_ProceedsfromSaleofEquityandAvailableforSaleSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_785bdd16-93bf-4674-a45d-68e80db06a98" xlink:to="loc_lly_ProceedsfromSaleofEquityandAvailableforSaleSecurities_61e4ef03-1ba3-4f5c-9a87-34c6a7e72839" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain_093bfe54-6172-408b-9e53-4dd9e6bb2671" xlink:href="lly-20220930.xsd#lly_AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_785bdd16-93bf-4674-a45d-68e80db06a98" xlink:to="loc_lly_AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain_093bfe54-6172-408b-9e53-4dd9e6bb2671" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss_71eeb5aa-871e-4e04-842c-10e1402d6bb6" xlink:href="lly-20220930.xsd#lly_AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_785bdd16-93bf-4674-a45d-68e80db06a98" xlink:to="loc_lly_AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss_71eeb5aa-871e-4e04-842c-10e1402d6bb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/IncomeTaxesDetails" xlink:type="simple" xlink:href="lly-20220930.xsd#IncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/IncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_7c69a037-8ddf-45dc-94b1-2e33d8e834ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_443322cb-6b87-4e0f-87fb-b5beb8325309" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_7c69a037-8ddf-45dc-94b1-2e33d8e834ee" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_443322cb-6b87-4e0f-87fb-b5beb8325309" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_c73c768c-5ea9-4cf9-a68e-991a78d9dd0d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_443322cb-6b87-4e0f-87fb-b5beb8325309" xlink:to="loc_srt_StatementScenarioAxis_c73c768c-5ea9-4cf9-a68e-991a78d9dd0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_6d1d73ec-10d8-4fab-8141-58cddad03755" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_c73c768c-5ea9-4cf9-a68e-991a78d9dd0d" xlink:to="loc_srt_ScenarioUnspecifiedDomain_6d1d73ec-10d8-4fab-8141-58cddad03755" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_87737e21-accc-46be-b93a-36222807f319" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_6d1d73ec-10d8-4fab-8141-58cddad03755" xlink:to="loc_srt_ScenarioForecastMember_87737e21-accc-46be-b93a-36222807f319" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_504e981a-297d-46f6-a043-6f6c2291e26b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_443322cb-6b87-4e0f-87fb-b5beb8325309" xlink:to="loc_srt_RangeAxis_504e981a-297d-46f6-a043-6f6c2291e26b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d0da3675-212a-440e-9eb9-0e1968c715de" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_504e981a-297d-46f6-a043-6f6c2291e26b" xlink:to="loc_srt_RangeMember_d0da3675-212a-440e-9eb9-0e1968c715de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_e523e5cc-a87a-4e13-ac2f-04421f2e5d63" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_d0da3675-212a-440e-9eb9-0e1968c715de" xlink:to="loc_srt_MinimumMember_e523e5cc-a87a-4e13-ac2f-04421f2e5d63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_565b02ad-674c-4ea9-bf57-32bc5af4ae8e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_d0da3675-212a-440e-9eb9-0e1968c715de" xlink:to="loc_srt_MaximumMember_565b02ad-674c-4ea9-bf57-32bc5af4ae8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_f27e753f-9923-47a6-bc86-b5a933313b2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_443322cb-6b87-4e0f-87fb-b5beb8325309" xlink:to="loc_us-gaap_IncomeTaxContingencyLineItems_f27e753f-9923-47a6-bc86-b5a933313b2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_a39ba2e8-7d0d-473f-a863-81d2e6106a20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_f27e753f-9923-47a6-bc86-b5a933313b2f" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_a39ba2e8-7d0d-473f-a863-81d2e6106a20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/RetirementBenefitsComponentsofNetPeriodicBenefitCostDetails" xlink:type="simple" xlink:href="lly-20220930.xsd#RetirementBenefitsComponentsofNetPeriodicBenefitCostDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/RetirementBenefitsComponentsofNetPeriodicBenefitCostDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_4a1c4991-844d-4d33-9a5e-5cdc7582ac8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_59b10cb9-2224-48bb-803a-90b7a7e70eda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_4a1c4991-844d-4d33-9a5e-5cdc7582ac8d" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_59b10cb9-2224-48bb-803a-90b7a7e70eda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_ce276b6e-a2c3-46e5-93ad-3bd47a50e231" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_59b10cb9-2224-48bb-803a-90b7a7e70eda" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_ce276b6e-a2c3-46e5-93ad-3bd47a50e231" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_cfd91e2a-f022-4646-b3f8-1aa6a99317a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_ce276b6e-a2c3-46e5-93ad-3bd47a50e231" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_cfd91e2a-f022-4646-b3f8-1aa6a99317a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_ce885b37-2480-4674-b3f5-9354bc782db7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_cfd91e2a-f022-4646-b3f8-1aa6a99317a2" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_ce885b37-2480-4674-b3f5-9354bc782db7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_2ee73ae4-5c74-4b7a-b740-c40f4eb57b94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_cfd91e2a-f022-4646-b3f8-1aa6a99317a2" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_2ee73ae4-5c74-4b7a-b740-c40f4eb57b94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_2cb2af1e-5712-451f-a1eb-f9e998065b1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_59b10cb9-2224-48bb-803a-90b7a7e70eda" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_2cb2af1e-5712-451f-a1eb-f9e998065b1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_e8751cac-0f6e-4504-b28e-743c895a5e29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_2cb2af1e-5712-451f-a1eb-f9e998065b1a" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_e8751cac-0f6e-4504-b28e-743c895a5e29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_9d6e8b66-22b8-4b2e-b2f3-055fefa1ec8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_2cb2af1e-5712-451f-a1eb-f9e998065b1a" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_9d6e8b66-22b8-4b2e-b2f3-055fefa1ec8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_47070be2-1668-4c4c-a2c0-8c951f48912b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_2cb2af1e-5712-451f-a1eb-f9e998065b1a" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_47070be2-1668-4c4c-a2c0-8c951f48912b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_ea56b77c-9de6-47bb-bd7a-d5097025fe21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_2cb2af1e-5712-451f-a1eb-f9e998065b1a" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_ea56b77c-9de6-47bb-bd7a-d5097025fe21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit_4f955a86-9c9a-42bc-8756-efb48e857676" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_2cb2af1e-5712-451f-a1eb-f9e998065b1a" xlink:to="loc_us-gaap_DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit_4f955a86-9c9a-42bc-8756-efb48e857676" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_4be39af5-0974-4d52-940c-cc225d349398" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_2cb2af1e-5712-451f-a1eb-f9e998065b1a" xlink:to="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_4be39af5-0974-4d52-940c-cc225d349398" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/ContingenciesDetails" xlink:type="simple" xlink:href="lly-20220930.xsd#ContingenciesDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/ContingenciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_75c4a9c7-3078-4964-9df9-186756cf0138" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_eb28ce4c-84c5-4a40-b74c-8335ec487b15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_75c4a9c7-3078-4964-9df9-186756cf0138" xlink:to="loc_us-gaap_LossContingenciesTable_eb28ce4c-84c5-4a40-b74c-8335ec487b15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_73ff64d7-b28d-4894-acdb-a81a9232faf8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_eb28ce4c-84c5-4a40-b74c-8335ec487b15" xlink:to="loc_srt_LitigationCaseAxis_73ff64d7-b28d-4894-acdb-a81a9232faf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_d5dd8b45-9303-4083-9f3e-dc2885d43ec0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_73ff64d7-b28d-4894-acdb-a81a9232faf8" xlink:to="loc_srt_LitigationCaseTypeDomain_d5dd8b45-9303-4083-9f3e-dc2885d43ec0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_EmgalityPatentLitigationMember_3db88e87-61be-45e6-9a6b-e1bf517aa1c5" xlink:href="lly-20220930.xsd#lly_EmgalityPatentLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_d5dd8b45-9303-4083-9f3e-dc2885d43ec0" xlink:to="loc_lly_EmgalityPatentLitigationMember_3db88e87-61be-45e6-9a6b-e1bf517aa1c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_EmployeeLitigationMember_0a53c331-bac3-4bda-8c90-5e926ae98e9e" xlink:href="lly-20220930.xsd#lly_EmployeeLitigationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_d5dd8b45-9303-4083-9f3e-dc2885d43ec0" xlink:to="loc_lly_EmployeeLitigationMember_0a53c331-bac3-4bda-8c90-5e926ae98e9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_a69f1262-1bea-4709-a9a7-97560517611f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_eb28ce4c-84c5-4a40-b74c-8335ec487b15" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_a69f1262-1bea-4709-a9a7-97560517611f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_3ef83a4a-bd26-437c-979b-1f51fd2d0d3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_a69f1262-1bea-4709-a9a7-97560517611f" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_3ef83a4a-bd26-437c-979b-1f51fd2d0d3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_48c3939a-de18-4603-8448-a87b4300e35a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_3ef83a4a-bd26-437c-979b-1f51fd2d0d3b" xlink:to="loc_us-gaap_SubsequentEventMember_48c3939a-de18-4603-8448-a87b4300e35a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_45b2ca5b-575f-4636-9136-42a394abfe67" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_eb28ce4c-84c5-4a40-b74c-8335ec487b15" xlink:to="loc_srt_ProductOrServiceAxis_45b2ca5b-575f-4636-9136-42a394abfe67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_d8823e78-3372-4b78-8d8f-7e5960bc6577" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_45b2ca5b-575f-4636-9136-42a394abfe67" xlink:to="loc_srt_ProductsAndServicesDomain_d8823e78-3372-4b78-8d8f-7e5960bc6577" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ByettaMember_b088ce44-717e-4479-bb1a-b6b67b4f9bd8" xlink:href="lly-20220930.xsd#lly_ByettaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d8823e78-3372-4b78-8d8f-7e5960bc6577" xlink:to="loc_lly_ByettaMember_b088ce44-717e-4479-bb1a-b6b67b4f9bd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_HumalogHumulinAndForteoMember_beb0bb24-a7e6-4597-a677-4344240b6f42" xlink:href="lly-20220930.xsd#lly_HumalogHumulinAndForteoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d8823e78-3372-4b78-8d8f-7e5960bc6577" xlink:to="loc_lly_HumalogHumulinAndForteoMember_beb0bb24-a7e6-4597-a677-4344240b6f42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_InsulinMember_12d832fe-9a82-44c3-9cad-c0127b134c19" xlink:href="lly-20220930.xsd#lly_InsulinMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d8823e78-3372-4b78-8d8f-7e5960bc6577" xlink:to="loc_lly_InsulinMember_12d832fe-9a82-44c3-9cad-c0127b134c19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_134bab10-e3e4-4f0c-b2bf-bd26f9a346fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_eb28ce4c-84c5-4a40-b74c-8335ec487b15" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_134bab10-e3e4-4f0c-b2bf-bd26f9a346fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_f650ff05-643d-4aa1-b62b-2e44a5a99b99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_134bab10-e3e4-4f0c-b2bf-bd26f9a346fd" xlink:to="loc_us-gaap_LossContingencyNatureDomain_f650ff05-643d-4aa1-b62b-2e44a5a99b99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ProductLiabilityMember_4521f93c-d34b-46cb-bcab-5211b7b4cc7f" xlink:href="lly-20220930.xsd#lly_ProductLiabilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_f650ff05-643d-4aa1-b62b-2e44a5a99b99" xlink:to="loc_lly_ProductLiabilityMember_4521f93c-d34b-46cb-bcab-5211b7b4cc7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnfavorableRegulatoryActionMember_aa82378d-0358-47a1-b8cd-fb63e29b3531" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnfavorableRegulatoryActionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_f650ff05-643d-4aa1-b62b-2e44a5a99b99" xlink:to="loc_us-gaap_UnfavorableRegulatoryActionMember_aa82378d-0358-47a1-b8cd-fb63e29b3531" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_0e9b13cd-4ffc-467b-a9e0-39e5d2c08daa" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_eb28ce4c-84c5-4a40-b74c-8335ec487b15" xlink:to="loc_srt_StatementGeographicalAxis_0e9b13cd-4ffc-467b-a9e0-39e5d2c08daa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_2cba47d1-e42f-4d3d-9fca-f330b3175f2a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_0e9b13cd-4ffc-467b-a9e0-39e5d2c08daa" xlink:to="loc_srt_SegmentGeographicalDomain_2cba47d1-e42f-4d3d-9fca-f330b3175f2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_BR_39c34011-4d41-47c0-801a-d6a1cfff065f" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_BR"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_2cba47d1-e42f-4d3d-9fca-f330b3175f2a" xlink:to="loc_country_BR_39c34011-4d41-47c0-801a-d6a1cfff065f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_20b7d726-83ac-4226-b33d-478fac1a9789" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_eb28ce4c-84c5-4a40-b74c-8335ec487b15" xlink:to="loc_us-gaap_LossContingenciesLineItems_20b7d726-83ac-4226-b33d-478fac1a9789" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_LossContingencyNumberOfPatents_670e97d8-6a7d-45c6-ab6c-5c7ce703554b" xlink:href="lly-20220930.xsd#lly_LossContingencyNumberOfPatents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_20b7d726-83ac-4226-b33d-478fac1a9789" xlink:to="loc_lly_LossContingencyNumberOfPatents_670e97d8-6a7d-45c6-ab6c-5c7ce703554b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber_2dd4aa0f-c12e-42fb-a4dc-fd5c1d9b293d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_20b7d726-83ac-4226-b33d-478fac1a9789" xlink:to="loc_us-gaap_LossContingencyPendingClaimsNumber_2dd4aa0f-c12e-42fb-a4dc-fd5c1d9b293d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNumberOfPlaintiffs_5b811670-eb75-4ddb-bd89-1c13b8700998" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNumberOfPlaintiffs"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_20b7d726-83ac-4226-b33d-478fac1a9789" xlink:to="loc_us-gaap_LossContingencyNumberOfPlaintiffs_5b811670-eb75-4ddb-bd89-1c13b8700998" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_LossContingencyNumberOfSitesJointlyAndSeverallyLiableForCleanup_4dfcc7ce-81a0-410a-942a-1f62be715c5c" xlink:href="lly-20220930.xsd#lly_LossContingencyNumberOfSitesJointlyAndSeverallyLiableForCleanup"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_20b7d726-83ac-4226-b33d-478fac1a9789" xlink:to="loc_lly_LossContingencyNumberOfSitesJointlyAndSeverallyLiableForCleanup_4dfcc7ce-81a0-410a-942a-1f62be715c5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesAwardedValue_740fdd90-f384-40db-b24e-4f6763a02c5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyDamagesAwardedValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_20b7d726-83ac-4226-b33d-478fac1a9789" xlink:to="loc_us-gaap_LossContingencyDamagesAwardedValue_740fdd90-f384-40db-b24e-4f6763a02c5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_LitigationClaimsDismissedNumber_4b479d18-cf9b-429c-94c1-7ec08398c9ed" xlink:href="lly-20220930.xsd#lly_LitigationClaimsDismissedNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_20b7d726-83ac-4226-b33d-478fac1a9789" xlink:to="loc_lly_LitigationClaimsDismissedNumber_4b479d18-cf9b-429c-94c1-7ec08398c9ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/OtherComprehensiveIncomeLossAOCIDetails" xlink:type="simple" xlink:href="lly-20220930.xsd#OtherComprehensiveIncomeLossAOCIDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/OtherComprehensiveIncomeLossAOCIDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_5f7b80b5-0eff-499b-8fc0-5891dfadaf7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_b3fbb330-031e-47fa-a570-b9fb8f4ffd37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_5f7b80b5-0eff-499b-8fc0-5891dfadaf7e" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_b3fbb330-031e-47fa-a570-b9fb8f4ffd37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_72d270a8-de26-44ec-bfdf-6cad8232e16b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_b3fbb330-031e-47fa-a570-b9fb8f4ffd37" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_72d270a8-de26-44ec-bfdf-6cad8232e16b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_2d6613fb-7fe3-4412-94ba-2159af24ca87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_72d270a8-de26-44ec-bfdf-6cad8232e16b" xlink:to="loc_us-gaap_EquityComponentDomain_2d6613fb-7fe3-4412-94ba-2159af24ca87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_8fb886c2-7f90-46df-b0ab-507119ebcbe3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_2d6613fb-7fe3-4412-94ba-2159af24ca87" xlink:to="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_8fb886c2-7f90-46df-b0ab-507119ebcbe3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_c9f52f96-3da1-4e0f-b609-a2f5e717d7e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_8fb886c2-7f90-46df-b0ab-507119ebcbe3" xlink:to="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_c9f52f96-3da1-4e0f-b609-a2f5e717d7e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember_e2bbd132-67cd-46aa-9b47-7d92c4922f8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_8fb886c2-7f90-46df-b0ab-507119ebcbe3" xlink:to="loc_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember_e2bbd132-67cd-46aa-9b47-7d92c4922f8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_814f1855-2b16-4a0a-a469-92b8646c8f01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_8fb886c2-7f90-46df-b0ab-507119ebcbe3" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_814f1855-2b16-4a0a-a469-92b8646c8f01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember_52ae1ca3-81e9-44a6-9665-b2f5623e01b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_8fb886c2-7f90-46df-b0ab-507119ebcbe3" xlink:to="loc_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember_52ae1ca3-81e9-44a6-9665-b2f5623e01b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_061c7dac-ac39-4b7c-804a-411d5a7325f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_b3fbb330-031e-47fa-a570-b9fb8f4ffd37" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_061c7dac-ac39-4b7c-804a-411d5a7325f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_99805ae0-b1b4-422d-9790-526868b4cf59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_061c7dac-ac39-4b7c-804a-411d5a7325f8" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_99805ae0-b1b4-422d-9790-526868b4cf59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b93c4b38-0090-4961-a465-de9d7693c6d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_99805ae0-b1b4-422d-9790-526868b4cf59" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b93c4b38-0090-4961-a465-de9d7693c6d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_b4a9e65a-eeef-427a-ae76-fa164391e03c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_99805ae0-b1b4-422d-9790-526868b4cf59" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_b4a9e65a-eeef-427a-ae76-fa164391e03c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_46d138bc-eb8f-490e-9287-8982e26da634" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_99805ae0-b1b4-422d-9790-526868b4cf59" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_46d138bc-eb8f-490e-9287-8982e26da634" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_815f2711-28e6-4acb-8823-936632f5167f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_99805ae0-b1b4-422d-9790-526868b4cf59" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_815f2711-28e6-4acb-8823-936632f5167f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_72c1b9ed-aa53-47a6-bd6e-f24b97f50907" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_99805ae0-b1b4-422d-9790-526868b4cf59" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_72c1b9ed-aa53-47a6-bd6e-f24b97f50907" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/OtherComprehensiveIncomeLossTaxEffectDetails" xlink:type="simple" xlink:href="lly-20220930.xsd#OtherComprehensiveIncomeLossTaxEffectDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/OtherComprehensiveIncomeLossTaxEffectDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_82ea3958-05cc-4367-9fa2-c1daa7eb1250" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_9d705111-b4c6-4af7-bb27-608d63a6a708" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_82ea3958-05cc-4367-9fa2-c1daa7eb1250" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_9d705111-b4c6-4af7-bb27-608d63a6a708" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_caae0706-8791-4c98-b799-b649acc1b002" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_9d705111-b4c6-4af7-bb27-608d63a6a708" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_caae0706-8791-4c98-b799-b649acc1b002" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_42f8c945-2fcf-4d2f-bd57-1af4ef65a4db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_caae0706-8791-4c98-b799-b649acc1b002" xlink:to="loc_us-gaap_EquityComponentDomain_42f8c945-2fcf-4d2f-bd57-1af4ef65a4db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_840362f1-5d3d-4763-8fcd-aad558d97112" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_42f8c945-2fcf-4d2f-bd57-1af4ef65a4db" xlink:to="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_840362f1-5d3d-4763-8fcd-aad558d97112" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember_90938f9f-72c4-4688-a4b1-f491445163f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_42f8c945-2fcf-4d2f-bd57-1af4ef65a4db" xlink:to="loc_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember_90938f9f-72c4-4688-a4b1-f491445163f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_99b35180-4706-4d8d-a5f0-a676893a774e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_42f8c945-2fcf-4d2f-bd57-1af4ef65a4db" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_99b35180-4706-4d8d-a5f0-a676893a774e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember_b649192a-3e7a-4a25-8b98-17836ac73fd5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_42f8c945-2fcf-4d2f-bd57-1af4ef65a4db" xlink:to="loc_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember_b649192a-3e7a-4a25-8b98-17836ac73fd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_9d78f3b8-e99c-4d8a-9ecd-e8cea5534281" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_9d705111-b4c6-4af7-bb27-608d63a6a708" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_9d78f3b8-e99c-4d8a-9ecd-e8cea5534281" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTax_2666f2ed-596a-48d5-82f2-ab0bd0f0f9cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_9d78f3b8-e99c-4d8a-9ecd-e8cea5534281" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossTax_2666f2ed-596a-48d5-82f2-ab0bd0f0f9cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/OtherComprehensiveIncomeLossReclassificationDetails" xlink:type="simple" xlink:href="lly-20220930.xsd#OtherComprehensiveIncomeLossReclassificationDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/OtherComprehensiveIncomeLossReclassificationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_3ea26435-4967-4902-b852-6603ea1f12ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_49536301-82ab-42ad-be4e-e6323ed50e3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_3ea26435-4967-4902-b852-6603ea1f12ed" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_49536301-82ab-42ad-be4e-e6323ed50e3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_8b87a143-1252-42b2-aff1-8c2a3d5ffceb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_49536301-82ab-42ad-be4e-e6323ed50e3d" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_8b87a143-1252-42b2-aff1-8c2a3d5ffceb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_e1ded240-d0cb-4e3f-abee-d3e343b830fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_8b87a143-1252-42b2-aff1-8c2a3d5ffceb" xlink:to="loc_us-gaap_EquityComponentDomain_e1ded240-d0cb-4e3f-abee-d3e343b830fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_cc3211bd-c7ec-45d6-9bcd-624365fc211a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_e1ded240-d0cb-4e3f-abee-d3e343b830fb" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_cc3211bd-c7ec-45d6-9bcd-624365fc211a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember_4f778847-609a-4d14-9db0-5e060f45ae87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_cc3211bd-c7ec-45d6-9bcd-624365fc211a" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember_4f778847-609a-4d14-9db0-5e060f45ae87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember_5fe0b448-008c-4d0b-bcba-65cc2c97dc90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_cc3211bd-c7ec-45d6-9bcd-624365fc211a" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember_5fe0b448-008c-4d0b-bcba-65cc2c97dc90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AccumulatedGainLossNetCashFlowHedgeAndForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_6c647e1d-1ed7-44c3-a539-6a95e6fbe43f" xlink:href="lly-20220930.xsd#lly_AccumulatedGainLossNetCashFlowHedgeAndForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_e1ded240-d0cb-4e3f-abee-d3e343b830fb" xlink:to="loc_lly_AccumulatedGainLossNetCashFlowHedgeAndForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_6c647e1d-1ed7-44c3-a539-6a95e6fbe43f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_be3520b5-2399-43e8-9e6a-7e3a4b69fdc6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_49536301-82ab-42ad-be4e-e6323ed50e3d" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_be3520b5-2399-43e8-9e6a-7e3a4b69fdc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_5097c6ce-f70a-4219-a29c-10f39b879985" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_be3520b5-2399-43e8-9e6a-7e3a4b69fdc6" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_5097c6ce-f70a-4219-a29c-10f39b879985" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_4cddcc75-f895-4cca-8963-53c5c6844828" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_5097c6ce-f70a-4219-a29c-10f39b879985" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_4cddcc75-f895-4cca-8963-53c5c6844828" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_a9606c7c-0b5e-45dd-8151-83b5377d7f56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_49536301-82ab-42ad-be4e-e6323ed50e3d" xlink:to="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_a9606c7c-0b5e-45dd-8151-83b5377d7f56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_1905c47e-0197-46f6-ab3d-3e9dee8b0fd0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_a9606c7c-0b5e-45dd-8151-83b5377d7f56" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_1905c47e-0197-46f6-ab3d-3e9dee8b0fd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_f836a768-d064-4626-9d51-efe795be1b50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_a9606c7c-0b5e-45dd-8151-83b5377d7f56" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_f836a768-d064-4626-9d51-efe795be1b50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_8fa4a6e3-350b-435c-9cf0-b42de241eb0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_a9606c7c-0b5e-45dd-8151-83b5377d7f56" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_8fa4a6e3-350b-435c-9cf0-b42de241eb0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedNetLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_bc05aee7-31b0-454b-8b38-c1341ca73060" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_a9606c7c-0b5e-45dd-8151-83b5377d7f56" xlink:to="loc_us-gaap_ProfitLoss_bc05aee7-31b0-454b-8b38-c1341ca73060" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/OtherNetIncomeExpenseDetails" xlink:type="simple" xlink:href="lly-20220930.xsd#OtherNetIncomeExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/OtherNetIncomeExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_4381ce11-2428-4ef2-8a65-755858d2efe1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_8dd96411-bc89-4eda-9e15-f153f7e05b94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_4381ce11-2428-4ef2-8a65-755858d2efe1" xlink:to="loc_us-gaap_InterestExpense_8dd96411-bc89-4eda-9e15-f153f7e05b94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_b24f82d0-1eb5-4683-a57e-d9e9879768b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_4381ce11-2428-4ef2-8a65-755858d2efe1" xlink:to="loc_us-gaap_InvestmentIncomeInterest_b24f82d0-1eb5-4683-a57e-d9e9879768b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_65d0419d-1be4-4cd7-bc4f-92a406aa3e89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_4381ce11-2428-4ef2-8a65-755858d2efe1" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLoss_65d0419d-1be4-4cd7-bc4f-92a406aa3e89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent_95166158-81b3-426d-a1a5-6a2c738d569c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_4381ce11-2428-4ef2-8a65-755858d2efe1" xlink:to="loc_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent_95166158-81b3-426d-a1a5-6a2c738d569c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_bbc6c3aa-f752-4fad-88f7-4196eb58a54b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_4381ce11-2428-4ef2-8a65-755858d2efe1" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_bbc6c3aa-f752-4fad-88f7-4196eb58a54b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_39f843aa-c344-4951-b591-ea987a77f710" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_4381ce11-2428-4ef2-8a65-755858d2efe1" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_39f843aa-c344-4951-b591-ea987a77f710" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_070df020-afe8-4d78-a8b6-72b8d9151e92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_4381ce11-2428-4ef2-8a65-755858d2efe1" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_070df020-afe8-4d78-a8b6-72b8d9151e92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>a101performancelevel.jpg
<TEXT>
begin 644 a101performancelevel.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" #) H\# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH ^:O@E^SW\+/''A?Q#K?B3X:
M>#_$&M77C/Q5Y^HZIH-K<W$VW7[]%WR/&6;"JJC)X"@=!7H'_#)WP0_Z(W\/
M_P#PE['_ .-4?LT_\DZU?_L<_%G_ *D.HUZK0!Y5_P ,G?!#_HC?P_\ _"7L
M?_C5'_#)WP0_Z(W\/_\ PE['_P"-5ZK10!Y5_P ,G?!#_HC?P_\ _"7L?_C5
M'_#)WP0_Z(W\/_\ PE['_P"-5ZK10!Y5_P ,G?!#_HC?P_\ _"7L?_C5'_#)
MWP0_Z(W\/_\ PE['_P"-5ZK10!Y5_P ,G?!#_HC?P_\ _"7L?_C5'_#)WP0_
MZ(W\/_\ PE['_P"-5ZK10!Y5_P ,G?!#_HC?P_\ _"7L?_C5'_#)WP0_Z(W\
M/_\ PE['_P"-5ZK10!Y5_P ,G?!#_HC?P_\ _"7L?_C5'_#)WP0_Z(W\/_\
MPE['_P"-5ZK10!Y5_P ,G?!#_HC?P_\ _"7L?_C5'_#)WP0_Z(W\/_\ PE['
M_P"-5ZK10!Y5_P ,G?!#_HC?P_\ _"7L?_C5'_#)WP0_Z(W\/_\ PE['_P"-
M5ZK10!Y5_P ,G?!#_HC?P_\ _"7L?_C5'_#)WP0_Z(W\/_\ PE['_P"-5ZK1
M0!Y5_P ,G?!#_HC?P_\ _"7L?_C5'_#)WP0_Z(W\/_\ PE['_P"-5ZK10!Y5
M_P ,G?!#_HC?P_\ _"7L?_C5'_#)WP0_Z(W\/_\ PE['_P"-5ZK10!Y5_P ,
MG?!#_HC?P_\ _"7L?_C5'_#)WP0_Z(W\/_\ PE['_P"-5ZK10!Y5_P ,G?!#
M_HC?P_\ _"7L?_C5'_#)WP0_Z(W\/_\ PE['_P"-5ZK10!Y5_P ,G?!#_HC?
MP_\ _"7L?_C5'_#)WP0_Z(W\/_\ PE['_P"-5ZK10!Y5_P ,G?!#_HC?P_\
M_"7L?_C5'_#)WP0_Z(W\/_\ PE['_P"-5ZK10!Y5_P ,G?!#_HC?P_\ _"7L
M?_C5'_#)WP0_Z(W\/_\ PE['_P"-5ZK10!Y5_P ,G?!#_HC?P_\ _"7L?_C5
M'_#)WP0_Z(W\/_\ PE['_P"-5ZK10!Y5_P ,G?!#_HC?P_\ _"7L?_C5'_#)
MWP0_Z(W\/_\ PE['_P"-5ZK10!Y5_P ,G?!#_HC?P_\ _"7L?_C5'_#)WP0_
MZ(W\/_\ PE['_P"-5ZK10!Y5_P ,G?!#_HC?P_\ _"7L?_C5'_#)WP0_Z(W\
M/_\ PE['_P"-5ZK10!Y5_P ,G?!#_HC?P_\ _"7L?_C5'_#)WP0_Z(W\/_\
MPE['_P"-5ZK10!Y5_P ,G?!#_HC?P_\ _"7L?_C5'_#)WP0_Z(W\/_\ PE['
M_P"-5ZK10!Y5_P ,G?!#_HC?P_\ _"7L?_C5'_#)WP0_Z(W\/_\ PE['_P"-
M5ZK10!Y5_P ,G?!#_HC?P_\ _"7L?_C5'_#)WP0_Z(W\/_\ PE['_P"-5ZK1
M0!Y5_P ,G?!#_HC?P_\ _"7L?_C5'_#)WP0_Z(W\/_\ PE['_P"-5ZK10!Y5
M_P ,G?!#_HC?P_\ _"7L?_C5'_#)WP0_Z(W\/_\ PE['_P"-5ZK10!Y5_P ,
MG?!#_HC?P_\ _"7L?_C5'_#)WP0_Z(W\/_\ PE['_P"-5ZK10!Y5_P ,G?!#
M_HC?P_\ _"7L?_C5'_#)WP0_Z(W\/_\ PE['_P"-5ZK10!Y5_P ,G?!#_HC?
MP_\ _"7L?_C5'_#)WP0_Z(W\/_\ PE['_P"-5ZK10!Y5_P ,G?!#_HC?P_\
M_"7L?_C5'_#)WP0_Z(W\/_\ PE['_P"-5ZK10!Y5_P ,G?!#_HC?P_\ _"7L
M?_C5'_#)WP0_Z(W\/_\ PE['_P"-5ZK10!Y5_P ,G?!#_HC?P_\ _"7L?_C5
M'_#)WP0_Z(W\/_\ PE['_P"-5ZK10!Y5_P ,G?!#_HC?P_\ _"7L?_C5'_#)
MWP0_Z(W\/_\ PE['_P"-5ZK10!Y5_P ,G?!#_HC?P_\ _"7L?_C5'_#)WP0_
MZ(W\/_\ PE['_P"-5ZK10!Y5_P ,G?!#_HC?P_\ _"7L?_C5'_#)WP0_Z(W\
M/_\ PE['_P"-5ZK10!Y5_P ,G?!#_HC?P_\ _"7L?_C5'_#)WP0_Z(W\/_\
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MTGX#_:M_:,MO&?CSQG':^-I4N]'\!?#ZWL+MH]'CD1@]Q+<^3Y3W,B*?FW8
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M,1,XMF@65MH5CC;VZXYKZR^"<GBB;X*^"I/&P=?%[Z):MJPE14<71A7S=RJ
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MW5[J_P!ZO;L_-"UM*ZUU:7>S3M]WXJVZ9]Q6-Y+>+.9;*>Q,<SQ*)VC)E4'
MD78S?*W4;L-ZJ*R[7QE97GCC4_"T45P;_3["VU&>7:/)"3R3)&H.<[\V\A(Q
MP"O/-?%,GA?27L!X9\2_#/5O&&K:=X&M[2PTFSTJ:XLX]:OI);NXAD*KLM'5
MC:LL\WEA/F*LI!J'X@?#7QQ>>-K*]\5V<^K:!;P+I5['J7@R^\4V.J7=K9V:
MPRS65M-#(ZM+)J+)+)OB#$D[6*M3Z\O57_!M;]]$[+K)):";^Y__ &K^[5J_
M]UMZJQ]]45POP-\*ZAX)^$OAG1=5NIKN^M;;YS<0>0\2LS.D.SSY]HB5EC \
MV3A!\QZUW55)<K:0HOF284445)045Y-XT^,VHO\ $B/X>_#ZPT;Q-XLM[9K[
M61J&JFVM]&@Q'Y0G\N.5_-E\P%(]HRH9R0,9D_M+XW_]"]\/_P#P?7W_ ,A4
M >JT5Y5_:7QO_P"A>^'_ /X/K[_Y"H_M+XW_ /0O?#__ ,'U]_\ (5 'HNOZ
M#IWBK0]0T;5[.'4=*U"![6ZM+A=T<T3J5=&'<$$BN!\)_LU_#CP3JMKJ>E^'
M3_:5O%=0"\O;^YO)I4N%B283/-(YFREO"@\PMM6-57:.*@_M+XW_ /0O?#__
M ,'U]_\ (59WB*T^.?B?0[[2(X? _AHW\36S:Q::E>7<]FKC:TL436T8>102
M5!<#<!GCBEW\QW=DNQE?"WX#_!/QE\,8]4\+:#)?>&?$^GVOD3W6H7LDT5K$
M_FV\5N\LIDM$BD^9$A*!& *@$ UZ[X)\#Z)\.?#EOH7AZQ%AIL#/((S*\KO(
M[EY))))&9Y)'=F9G=BS$DDDFO'_AS\+?B1\ _#:^"O Z^&-?\$Z?-(VC-X@U
M"ZMKVT@D<R&W<QP2+($9F"OE3LV@CY<GJ?[2^-__ $+WP_\ _!]??_(55=B/
M5:*\J_M+XW_]"]\/_P#P?7W_ ,A4?VE\;_\ H7OA_P#^#Z^_^0J0'R)\-=2N
M6^(_PY\>Q+GQMX@^+'B+P_J]TD@,T^FHETJVTC#EHH5MX613PI7(QNKTG]M/
MX6:[_P )7??&:^TOP-XM\%^!O"-P4\+^+=*?4#=3&<37+("52!S%$BI*?-P=
MP,>#FNSTWX,>-=(^(4OC>T\ _#Z/Q'))-.)CXHU5H(YIE"S31VYMC#'+(J@/
M(B!V P2:P_A/^S[\,]>U36_!?B/X:VWAKQ%X7CB%S8Z7X@OKFPU73[N>:YA>
M0EHS=0F=;G,-RC*CHX *D$Q%.-.G%.SBM][>XH[=5N^FLG\ZNN><FM)/;NN9
MRWZ/9==$>%>,/%3>*-=\?_$RUMO)\6Z#X]\):?X<.]1/96$\5GNM(R/NQS+<
MS;T'RL3R#MK]):\_UCX"^!->\>VOC*^T%9M?MI89UD%U.D#S0JRP326ZN(99
M8PQ"2.C,@/RD5Z!6J:4.5+K?_P EBOO;3;\WUW,5%\W,^WZR?X)I+R70****
MDT"BBB@ HHHH ^!OVPI%\0_$CXW2ZF?](\#_  UM-:\,2F0!]/OFN9W-W >L
M<I:&)-RX)4;<X;%>W?M2:UH-I^R;?>,?&7@[0O%6L6.DPSZ?I^OZ9#?11ZI<
M(D,.$D4@?O95!(QQFO3?B%\"/ OQ4U>RU/Q1H0U*\M8Q &6[G@2>$2"40W"1
MNJW$0D4/Y<H=,C.,U2\3_LW_  Z\9:IXBU'6/#OVN\\0RZ=-J<GVVXC\][!]
M]H<+( GEMSA0 W\6ZHC!>R]E+9OIT7-)MKS:E]\5OTKFM4]JNGXZ15GY>Z^^
M^Q\X^*?V)M7TGX5_!WPWX?7P=+H'@6"_UG6M-\6:6^HVNJ:G+;$ FU0QJ4\R
M2<_?4)F/:C!=M?1G[,OCK3_B7\ / 7B;2]"M?#%AJ.DPRQ:-8HJ6]F -IBB5
M0 $!4A0 .,<5I_$CX(^#?BU<:?<^)=+FN+S3TFAMKRQU"YL+A(I0%EB,MO)&
M[1.  T;$HV!D'%=9H>B:?X:T:QTG2K.'3M+L8$MK6SMD"10Q(H5$51P%
M]*VYF^=OJT_SO^'*EV2^_/EMR)=$UZ[/\[MOK<O4445!04444 %%%% 'R#^W
M1X2U6;Q9\&?$C>*]2CT6'QYX>LH_#,(1+-YFNW9[F5L;Y&VB-54D*NTG!+<=
MC^UVR:QXE^"'A'4H8KOPQXC\9);:O97&UH;R..TN)4@E1N'1I$4E2"#L ->S
M^.?AOX=^)5OH\/B/3O[1BTC5+?6;)?/DB\J[@;=#)\C+NVD_=;*GN#7GGQ&^
M&_P4A\8S3^,;C2]&\5>.+JRC@>ZU^33[V_N;/]W;?8L3(Z31_: H-OM<^: <
M[A4K2"BU>T^;Y>YI_P"2O\/DYOFNUNX<OS][]&OFOF?&WP]5/B1J_@WX<^+8
MQJ?@/2H?'0TVUOI1+%(MG>+!:/\ -GFWC=Q&W5, J1MK[1_8]\2:QXP_9<^%
M^L:]+-<:O=Z#:O//<,6DF(0 2,3R2R@,2?6M+5OV:/AMK7@W1/"L_ASR-%T5
M98[".QOKFTFA64%9E\^*19664,WF!F(DR=^ZO1-)TFRT'2[/3--M8;'3[.%+
M>WM;= D<4:*%5%4<    #VJX>[!Q>KTU[VYKM^;YDNNVYG)7GS+1>]IVORZ+
MR5G]^Q;HHHI%A1110 4444 ?(/[='A+59O%GP9\2-XKU*/18?'GAZRC\,PA$
MLWF:[=GN96QOD;:(U520J[2<$MQZC^UWK7PK\(_":3Q1\7=/CUGPYHERMU;:
M3.SO'?7FUEBA-N&"3EMQPLH9!]\XV[AZ/XY^&_AWXE6^CP^(]._M&+2-4M]9
MLE\^2+RKN!MT,GR,N[:3]ULJ>X->??$;]COX2?%CQ9=>)O$_ABXO==N;BUNI
M+RWUF_M&\ZV1DMY (9T"LBNX!4 _,3UYJ+/V7LU_,W\FH?CHVOE\M.9<ZF^D
M4O5IR_"S7GOZGR]X7_9M^*'Q(^ GPAO]>M?"UEI^@SZUXEF\(^-K&?58(DG2
M3^SK)K<LA*112,,-(IC^3Y&VE:^N_P!F7QUI_P 2_@!X"\3:7H5KX8L-1TF&
M6+1K%%2WLP!M,42J  @*D* !QCBJ^L_LQ_#_ ,1:=IEIJEGK6HOIOGK;:A=>
M)M3DOUCG $T)NS<^>T+@ &)G,9P/EKT?0]$T_P -:-8Z3I5G#IVEV,"6UK9V
MR!(H8D4*B*HX"@   >E;77O);.UOE=.[W;MRK7MZWPL_=\D[_-I[>M_OMLB]
M1114%A1110 4444 ?+7_  44U;XC^&_V>]<UWP+XMC\(V&FVQFU.XM8W_M*<
MF:!(H[>56 A!W2%W&6X4+C)(]+_:4T_Q[KW[/?B73?AHLS^.-0LXK6PFAOA9
MR0&1T6299BR[&2,NX(.[*C )P*Z7XS_";2/CG\,M=\#:]<WMII.L1)%<3:<Z
M).H617&QG1U!R@ZJ>,UEZ[\$X]<NO%4__"<>-=._MV*R2./3]::"/26ML[9+
M-0N(S(2#*K;TDP RD9!5KQ<7W_I?U^&YIS:PDMU?\XV_4^.-'^(E_P",OC5)
M\#!>^,/!5_X>L=8O_$#6OC?5-4:XNX[:V-E)!J$SI,8@LQD,.U%W8#H0>?KS
M]E?X@:I\5/V<_AUXLUQC)K&J:-;SWDI0+YLNW:TF!P-Q!;CCYJX^Z_8G\'75
MQ<:NOB#Q+;^-KR>ZFO\ QI#+:+JMZMQ"D$T,A^S^2L1BCC4+'$FS:&3:Q+'V
MSP?X3TOP'X5T?PWH=J++1])M(K*SMU)/EQ1J%49/)X Y/)JHNT&I?%[M_5<U
MVO+6*7^'9)(P:]]..WO?<^6R?GHW\_4V****184444 %%%% 'RI\6-8^).B?
MMK?!>VN/%T=O\/\ 6KW4X+;PYIB21&81:6SM)>ONQ*?-+;$QM4*K<L>-S]N*
M1=)^%\%[IEYKUOXVU2]MO#GAR/2?$NI:7$;V[E"+))':7$:R^6N^3YP>(R.
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MLQVZ"]O8OAEX@ACFFQ\[(@L?E7.<#D@8R2<DZO\ PTMX1_Z!'Q _\-QXA_\
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M1,SLA/T_X9\+:7X/TV:PTBU^R6DU[=Z@\?F.^9[FXDN9WRQ)^:::1L=!NP
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MPM\,?%#_ (1S_A)],_M/_A'=:MO$.E_Z1+%]GO[?=Y,W[MEW;=[?*V5.>0:
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M]B9XF_\ 2[0:@9ZK1110 4444 >5?LT_\DZU?_L<_%G_ *D.HUZK7E7[-/\
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M:+8Q1?#*6Q\1W^K/I<$&J7.H:99,HLIKKSTFO--BF8#R61@+8@,1@L*9\/\
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M+XGE^)EQX;\ ZQHMVUHEK-XB22WOR;2*Z3R)IXH"[%9@I3R\AE/4$$\SX/\
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MN]_Z_KL?#_P?N[[4/B=\$[K4Y(9-1N/#GAV:Y:WMH[:+S&TC6RP2*-51%!)
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M_%7GZ=JFO6MM<0[M?OW7?&\@9<JRL,CD,#T->@?\-8_!#_HLGP__ /"HL?\
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MC_\ ':/^&L?@A_T63X?_ /A46/\ \=KU6B@#RK_AK'X(?]%D^'__ (5%C_\
M':/^&L?@A_T63X?_ /A46/\ \=KU6B@#RK_AK'X(?]%D^'__ (5%C_\ ':/^
M&L?@A_T63X?_ /A46/\ \=KU6B@#RK_AK'X(?]%D^'__ (5%C_\ ':/^&L?@
MA_T63X?_ /A46/\ \=KU6B@#RK_AK'X(?]%D^'__ (5%C_\ ':/^&L?@A_T6
M3X?_ /A46/\ \=KU6B@#RK_AK'X(?]%D^'__ (5%C_\ ':/^&L?@A_T63X?_
M /A46/\ \=KU6B@#RK_AK'X(?]%D^'__ (5%C_\ ':/^&L?@A_T63X?_ /A4
M6/\ \=KU6B@#RK_AK'X(?]%D^'__ (5%C_\ ':/^&L?@A_T63X?_ /A46/\
M\=KU6B@#RK_AK'X(?]%D^'__ (5%C_\ ':/^&L?@A_T63X?_ /A46/\ \=KU
M6B@#RK_AK'X(?]%D^'__ (5%C_\ ':/^&L?@A_T63X?_ /A46/\ \=KU6B@#
MRK_AK'X(?]%D^'__ (5%C_\ ':/^&L?@A_T63X?_ /A46/\ \=KU6B@#RK_A
MK'X(?]%D^'__ (5%C_\ ':/^&L?@A_T63X?_ /A46/\ \=KU6B@#RK_AK'X(
M?]%D^'__ (5%C_\ ':/^&L?@A_T63X?_ /A46/\ \=KU6B@#RK_AK'X(?]%D
M^'__ (5%C_\ ':/^&L?@A_T63X?_ /A46/\ \=KU6B@#RK_AK'X(?]%D^'__
M (5%C_\ ':/^&L?@A_T63X?_ /A46/\ \=KU6B@#RK_AK'X(?]%D^'__ (5%
MC_\ ':/^&L?@A_T63X?_ /A46/\ \=KU6B@#RK_AK'X(?]%D^'__ (5%C_\
M':/^&L?@A_T63X?_ /A46/\ \=KU6B@#RK_AK'X(?]%D^'__ (5%C_\ ':/^
M&L?@A_T63X?_ /A46/\ \=KU6B@#RK_AK'X(?]%D^'__ (5%C_\ ':/^&L?@
MA_T63X?_ /A46/\ \=KU6B@#RK_AK'X(?]%D^'__ (5%C_\ ':/^&L?@A_T6
M3X?_ /A46/\ \=KU6B@#RK_AK'X(?]%D^'__ (5%C_\ ':/^&L?@A_T63X?_
M /A46/\ \=KU6B@#RK_AK'X(?]%D^'__ (5%C_\ ':/^&L?@A_T63X?_ /A4
M6/\ \=KU6B@#RK_AK'X(?]%D^'__ (5%C_\ ':/^&L?@A_T63X?_ /A46/\
M\=KU6B@#RK_AK'X(?]%D^'__ (5%C_\ ':/^&L?@A_T63X?_ /A46/\ \=KU
M6B@#RK_AK'X(?]%D^'__ (5%C_\ ':/^&L?@A_T63X?_ /A46/\ \=KU6B@#
MRK_AK'X(?]%D^'__ (5%C_\ ':/^&L?@A_T63X?_ /A46/\ \=KU6B@#RK_A
MK'X(?]%D^'__ (5%C_\ ':/^&L?@A_T63X?_ /A46/\ \=KU6B@#RK_AK'X(
M?]%D^'__ (5%C_\ ':/^&L?@A_T63X?_ /A46/\ \=KU6B@#RK_AK'X(?]%D
M^'__ (5%C_\ ':/^&L?@A_T63X?_ /A46/\ \=KU6B@#RK_AK'X(?]%D^'__
M (5%C_\ ':/^&L?@A_T63X?_ /A46/\ \=KU6B@#RK_AK'X(?]%D^'__ (5%
MC_\ ':/^&L?@A_T63X?_ /A46/\ \=KU6B@#RK_AK'X(?]%D^'__ (5%C_\
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E%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>lillyfooter.jpg
<TEXT>
begin 644 lillyfooter.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" #& 6X# 2(  A$! Q$!_\0
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M%%%=Q\:%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M;NS'N:Z?4M2MM'T^XOKR9+>UMT,DLLAPJJ!DDFII)$AC:21@B*,LS'  ]:^
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MWK'Q0\56>@Z- 9;FX;!?'RQKW9CV K$T?1[S7]3M]/L('N;NX<1QQ1C)9B<
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M^;OP[_9#^(7Q :WE&EMI.GR\_:[[Y5'_  'K7UI\*?V%O!_@U8KKQ&?^$EU
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MK\)/A'H?P=\*PZ/HT"AL!KBZ8?O)W[L3_2NNU*_ATO3[B\N'6.""-I'9C@
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M[/DR.-YG"HK.S< #DFO:? '[)_C+QCX;OO$%W:MHVD6UL]RDET,-, ,X1?\
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MFZM=W'3?S_JU]S@_2N6^!OP:U7XT>-+?2+%&CM$(DN[LCY88\\G/J>PK]5?
M?@72?ASX8L]#T:W6"TMT"Y P7;'+-[FO+R[ _6)>TJ?"OQ/TGCSC)9#0^HX-
M_P"T37_@"[^KZ?>7_#OAW3O"FC6NE:5:QV=A;($BAC&  /ZUI445]HDDK(_D
M2<Y5).<W=O=A1113("BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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D*&7# $>AHHH   H  P*6BB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>lillyfooter1.jpg
<TEXT>
begin 644 lillyfooter1.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" #& 6X# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4Z*** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "D9@JDDX Y)->5
M?&?]H_PG\%[-EU"Y%[JQ!\O3;=@9"?\ :_NCW-?"'Q6_;"\=?$>YEBMKYM"T
MHDA+6R)5MI[,XY->9B<PHX;W6[OLC]#X>X'S7B!*M"/LZ7\TMGZ+=_EYGZ-^
M(?BIX2\*KG4_$%A;'^[YZEOR!KF=-_:9^&NK7*P6_BJS:1C@!B5'YD5^35U>
M37L[S7$K32N<L\AW,?Q-19KQ99U4OI!6/UZEX1X!4[5<5-R[I)+[M?S/VRL=
M0MM4MDN+.XBNK=_NRPN'4_B*L5^:'['_ ,>-5\!^/M.\/W=U)<>']2D%N;>1
MB5B=B KKZ<GFOTNZU[^#Q4<73YTK-;GXAQ3PU7X8QJPU27-&2O&6UUZ=&NHM
M%%%=Q\:%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%4-<U[3_#>ESZCJ=W%964"EI)IFP !2;MJRHQE4DHP5VR_7
M.^,/B%X<\ V1NM?UBUTR'!QY\@!;'8"OD+XW?M\/OGTKP##L7E6U6<<GT,:_
MXU\>^*/&6M^,]2EO]:U*XU&ZD;<TDSYY]AT%>#B<VIT_=I+F?X'[7D'AAC\>
MHU\SE[&#Z;S?RVC\]?(^[/'W_!0?PWHXDB\,:5-K$Z,5\RY/E1'W!&217@?B
MC]NGXDZY-)]BNK?2+=L_N[>(,1_P(C-?.ZHTC *I8DX&!7;^#O@CXW\>,1HO
MAV]NP/XO+V+^;8KPIX[%XAVBWZ(_9\+P;PSD=/VE6E'3[51I_G[OX'H_P;_:
MA\4Z5\5-(U'Q#K5U?Z=)*(+B&1_D"N=N['MG/X5^FUM<17EO%/ ZRPR*'1U.
M0RD9!%?G=X7_ ."?_CK5K=)K^^T_1VX)CF+.P_[Y%?=?PM\+ZEX+\"Z5HFJW
MRZC=V40A^T(" RCA>OM7OY8L1!2C63MNKGXGXBU,AQ4Z-?*:L'./NRC!:6W3
MT5M-4=71117NGXN%%%-=UC1G=@JJ,EF. !0 K,$4LQ"J!DD\ 5\B_M-?MG0>
M$_M/AKP1,ESJP)CN-1^\D'J$]6_E7*?M;?M<&\-UX.\&79$',=]J,1Y?U1#Z
M>IKXLDD:1BSL68G))/-?,9AF5KTJ#]7_ )']%<$^'L:D89GG,-'K&F_P<OTC
M]_8MZQK5]K^H37VH74MW=3,6>69BS$_4T:/HU]K^H0V.G6LMY=S-MCAA7<S'
MT KJOA3\(?$/Q>\21:5HEHSY(,URP_=PKW9C_2OTK^!_[./AGX+:5&+6W2^U
MIE_?ZC,H+D^B^@KRL)@:F+?-M'N?IO%'&6 X7IJBESUK:071='+LO+=]#XIT
M7]A?X@ZEX;DU:[%II16)I?LMTY\W &<$8XKYVFB,$SQM]Y3@XK]6?VI/BI#\
M+?A1J=PLJIJ=\AM+1#W9AR<>@7-?E+(YD<L>2:K,,/1PTHTZ>_4YN!<\S3B#
M#5L;CTE#FM"RMM\7KT_$Z[X0PO<?$SPU'&A=VOX0%'4_.*_8B$%8D!&#M%?F
M-^Q5\/W\9?&:PO)(F-EI2F[>3' <?<'XG-?IY7M9-!QI2F^K/R7Q9QE.MF=#
M#1WIPU_[>=_R"BBBOH#\+"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH ***AO+R'3[2:ZN9%AMX4,DDC' 50,DF@:3D[(Y[X
MC?$31_A?X6NM=UNX$-K"/E4?>D;'"J.Y-?F7\?/VD/$'QLUJ02RR6.A1M_H^
MG(WR@>K>K5<_:B^/=[\9/&TT<$S1^'K!VBM+=3\K8.#(?4G^5>+0Q//(D<:E
MW8[551DDGL*^*S#'RQ$G3IOW5^)_77 W!5'):$<?C8WQ$E?7["[+^]W?39#1
MECZFO=?@O^R)XO\ BPL=[+'_ &'HS?\ +W=H0S?[J]3]:][_ &7OV,[;3;6T
M\4^.+9;F[D59K73'Y6+N&D'<X[5]CPPQV\*11(L<: *J*,  = !73@\JYTJE
M?1=O\SP>*_$N.$G+!9+:4EHYO5)_W5U]7IZGBOPS_9%^'_PZBBE;3%UG45 )
MNKX!\-ZJ.U>TP6\5K&L<,:Q1J,!44  5)17T].E"DN6FK(_G3'9EC,SJNMC*
MKG+S=_N[?(****U/-"BBB@ KXD_;&_:HV"Y\$>$KPALF/4+V$X^L:G^==E^V
M-^TTO@#3)O"'AV?_ (G]U'BXN$/_ ![1GT_VC^E?GA--)<S/+*[22.Q9F8Y)
M)Y))KYK,\?RWH4GKU?Z']"^'G!2K<N<YE'W=Z<7U_O/R[+KN-9B[%F.2>2:]
M(^!_P/UOXU>*(M/T^)HK&-@UU>,IV1)W^I]O>H/@G\'=6^,WC*VTBPB=+4,#
M=7FW*P)ZGWK]3?AG\,]$^%/A>VT31+=8H8U'F2D?/*W=F/<UYF P#Q3YY_"O
MQ/T+C;C2GP[2^JX7WL3):=HKN_/LOF]"/X8?"W0OA/X9@T?0[58451YL^/GF
M;NS'N:Z?4M2MM'T^XOKR9+>UMT,DLLAPJJ!DDFII)$AC:21@B*,LS'  ]:^
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MWK'Q0\56>@Z- 9;FX;!?'RQKW9CV K$T?1[S7]3M]/L('N;NX<1QQ1C)9B<
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M^;OP[_9#^(7Q :WE&EMI.GR\_:[[Y5'_  'K7UI\*?V%O!_@U8KKQ&?^$EU
M ;HY!M@5@<Y ZG\:^F:6O<H99AZ.K7,_,_'<Y\1,[S9.G"?L8/I#1_.6_P!U
MBMI^GVNEVL=M9V\=K;Q@*L<2A5 'L*POB%\1-$^&/AN?6]=NEMK2/A1_%(W9
M5'<UTU?$/_!1JZU#=X7MSN&F9D=?0R8Y_'%=6+K/#T)5(K8^<X8RF&?YO1P-
M>=HR;;?6R5W;S9HS?\%&M,76L1^%[E]*SC<95$I]^N*^GOAC\4="^+7AF+6M
M"N1+"?EEB;[\+]U8>M?CG7V'_P $Z[S45\7>(+96?^S&ME>1?X?,!X/UQ7@8
M',:U2LJ=35,_;.,N \HP&45,=@(NG.E9[MJ2O;6_7M8^^*Q?&7BS3_ _AN_U
MO5)E@L[2,R,S'&2!PH]R>*VJ_/\ _;N^.+>(/$"^!]*N#_9^G/OO"AP))O[I
M]0N/S->]B\0L+2<WOT/Q7A?(*G$690P<=(;R?:*W^;V7F>!?&KXM:G\8?&UY
MK5\["$L4MK<GB*,'@?7&,US_ ('\%ZI\0/$UCH>CVS7-[=2!%51PH[L?0"L2
M""2YF2*)&DD<[551DDGM7Z7_ +(/[/<?PI\*)K>JP*?$FI1AVSR;>,\A ?4C
M&:^.PN'GCJWO/S;/ZOXBSS"<&Y3%48I2MRTX>G7T6[_X)WWP)^".D_!3PC#I
M]I&DFIRJ&O;S'S2O_@*XW]J#]IBQ^#F@RZ;IDT=SXJND(AB4@_9P>-[?T%'[
M3'[4&F?!W29M-TR6.^\4S*52!6R+?/\ $_\ A7YI^(O$6H^+-8NM4U6ZDO+Z
MY<O)-(<DD_TKW,;C886'U?#[_E_P3\;X1X1Q7$N*>=YW=TV[I/>;_P#D?SV6
MA%K6M7OB#5+G4=0N)+N\N',DLTARS,>IKTS]G7X$ZA\;/&45JJ-%HULP>^NL
M<(G]T>YK"^#_ ,'M<^,GBJ#2-(A81YS<73*?+@3NQ/\ 2OU-^%/PMT;X1^$;
M70]'@50B@SW&/GGD[LQKRLOP+Q4^>?PK\3]+XVXPI<.8;ZG@VOK$E9)?87=_
M^VKY['0>'?#^G^$]#L]*TVW2TL+.(1Q1J,!5 KX;_;0_::;7+VX\#^&;LC3X
M&VW]U"V/-<'E ?0=Z]Q_;$^.P^%?@<Z5ILP77]64QQ[3S#%T9\?F!7YF32O/
M(TDC%W8Y+,<DGUKT<TQGLU]7I?/_ "/@O#CA7ZW/^WLP7-J^1/J^LWWL]O/4
M;RS>I-?8?[)/[([^(I+7QCXRM633%(DLM.F7!N#V=Q_=]JP?V-_V:1\0]4C\
M5^(;=CH%G)F"%QQ<R _JH(K[Q\<>.-#^%_A6XUC6+B.RT^U3"J, L0.$4=S[
M5AE^!BU]8K[+;_,]KCOC*M3JO(\G;=66DI+=7^S'S[OIMN8/QD^*6D_!/P!<
MZK.(XW2,Q65HF%WR8PH ]!Q7Y.^+/%%]XR\17^LZC(9;R\E:61L]R<X'L*[G
MX^?'35?C=XOFO[EF@TN$E;*QS\L2>I_VCW-<-X3\*ZEXTUZST?2;9[N^NI!'
M'&@SU/4^@%<6/Q;Q=11A\*V\SZS@KA>'#&!EB,6U[::O-](I:VOY;M]_0]7_
M &3?@[-\5/B;9//#NT;37%S=NP^4X(*I]3_2OU+CC6&-8T&U% 4 =@*\X^ O
MP;L/@MX%MM)MT1]0E EO;E1S)(1TSZ#H*])KZ?+\+]5I6?Q/<_G3C?B3_6+,
MW.D_W-/W8>?>7S?X6"BBBO3/ST**** "BBB@ HHHH **** "BL+Q?XXT'P'I
M;ZCK^IV^F6B=7F;!/T'4U\W>,O\ @H-X3TB:>WT32KO59(SA9V*I$WTYS7-6
MQ-&A_$E8^AROA[-<YUP-"4UWMI][T/JZBO@:Z_X*.>(V8?9_"^FJO?S9)"?T
M-7=(_P""CFI^:@U+PM:^7_$;:5L_ADUQ?VIA;VYOP9]=+PWXDC'F]@O_  *-
M_P S[LHKYH\&_MZ> ?$4RPZG%=Z$^/FDN &C_-<U[UX7\<Z!XTL4N]$U:UU*
M!QD&&0$_EUKNI8BE6_AR3/C<QR+,\I?^VX>4%W:T^_;\3=HHJMJ6I6NCV,][
M>SQVUK A>2:0X55'4FN@\.,7)I)79%KFM67AW2;K4]1N$M;*UC,DLKG 517Y
M?_M._M"7?QK\6.EH[P^'+-BMG 21O_Z:,/4UU'[6/[44WQ6U%O#^@RR0>&;5
MR&93@W3#^(_[/H*^:J^.S+'^V?LJ3]U;^9_5W '!7]DP69YA']_)>[%_83_]
MN?X+S#KQ7VY^Q+^S8VZ'Q]XCMBJCG3;65>O_ $U(_E7F/[)?[--U\5M?CU[6
M(6A\+V+AB6&/M3@_<7V]:_2>SM(;"UAMK>)88(5"1QH,!5 P *URO \S5>HM
M.G^9YOB-QBL-"638"7OO^(UT7\OJ^O9:$U%%%?6'\Q!117S3^U1^U9:?"S3Y
MO#_AV>.Z\43IAI$;*V:GN?\ :]!6%:M"A!SF]#V,IRG%YUBXX/!PYI2^Y+NW
MT2/H2Q\2:7J6IW>G6NH6]Q?6A N+>.0%X\^H[5R7QH^#FD?&KPD^C:H6AD0^
M9;72#+0OZBORO\,?%+Q+X2\7#Q)I^JW$>J&4RR2LY/FDG)W#N*_2#]F?]I"W
M^.FD303V;V6MV,:M=!1F)\\94_TKR\/CZ6-O1J*S?3N?I&?<%9EPCR9I@JO/
M&%FY+1QEZ=F]ON9\U3?\$[_%8U4I'K-@UAOP)3D/M]<5]<_ KX&:/\#?"[:;
MI[M=WEP0]W>2##2L!V] *]+HKLH8&AAY<\%J?*YQQEG.>X=87&5?<ZI)*_K;
M?\C@_C?\1X/A;\-M8UV0@SQQ%+>/."TC<#'TSG\*_(S6-5N=<U.YO[R5IKJX
MD,DDC')9B<DU]E_\%$O'DK7V@^$X7_<JAO9@I_B.54'^=?%MM%Y]Q'&6"[V"
MY;H,FOF<VKNI7]FMH_F?T+X99/'+\G^O37OUW>_]U:)?FSZ>_8?^!Z>.O%[>
M*=4AWZ3I# QHZ_++-V^H7%>\_M.?M>6'PUM;CP]X5FCO/$A&QYE^:.TX_5O:
MOG[Q1^TM!\/?A?IOP_\ AVS6VV'_ (F.KC[SRM]\1^W7DU\T7%Q+>3/+-(TL
MKG+.Y))/J31];CA:/L:'Q/=_Y%1X8J\29L\WSE6HQTI4WU2V<NU][;OKH6=8
MUB]\0:E<ZAJ%Q)=7EPYDEFE;+,Q[FNP^#OP<UWXR^*8=)TB!A""#<7; ^7"F
M>23Z^U=%\!?V</$'QLU=#!&UCHD3#[1J$B_*!Z+ZFOTO^&?PPT'X4>&8-%T*
MT6&&,9DF('F3-W9CW-3@<OGBG[2II'\S7C#CC#<.TW@\%:6(M:W2'F_/M'[R
MK\)/A'H?P=\*PZ/HT"AL!KBZ8?O)W[L3_2NNU*_ATO3[B\N'6.""-I'9C@
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M[/DR.-YG"HK.S< #DFO:? '[)_C+QCX;OO$%W:MHVD6UL]RDET,-, ,X1?\
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MFZM=W'3?S_JU]S@_2N6^!OP:U7XT>-+?2+%&CM$(DN[LCY88\\G/J>PK]5?
M?@72?ASX8L]#T:W6"TMT"Y P7;'+-[FO+R[ _6)>TJ?"OQ/TGCSC)9#0^HX-
M_P"T37_@"[^KZ?>7_#OAW3O"FC6NE:5:QV=A;($BAC&  /ZUI445]HDDK(_D
M2<Y5).<W=O=A1113("BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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D*&7# $>AHHH   H  P*6BB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>lillyfooter2.jpg
<TEXT>
begin 644 lillyfooter2.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" #& 6X# 2(  A$! Q$!_\0
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M%%%=Q\:%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M;NS'N:Z?4M2MM'T^XOKR9+>UMT,DLLAPJJ!DDFII)$AC:21@B*,LS'  ]:^
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MWK'Q0\56>@Z- 9;FX;!?'RQKW9CV K$T?1[S7]3M]/L('N;NX<1QQ1C)9B<
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M^;OP[_9#^(7Q :WE&EMI.GR\_:[[Y5'_  'K7UI\*?V%O!_@U8KKQ&?^$EU
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MK\)/A'H?P=\*PZ/HT"AL!KBZ8?O)W[L3_2NNU*_ATO3[B\N'6.""-I'9C@
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M[/DR.-YG"HK.S< #DFO:? '[)_C+QCX;OO$%W:MHVD6UL]RDET,-, ,X1?\
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MFZM=W'3?S_JU]S@_2N6^!OP:U7XT>-+?2+%&CM$(DN[LCY88\\G/J>PK]5?
M?@72?ASX8L]#T:W6"TMT"Y P7;'+-[FO+R[ _6)>TJ?"OQ/TGCSC)9#0^HX-
M_P"T37_@"[^KZ?>7_#OAW3O"FC6NE:5:QV=A;($BAC&  /ZUI445]HDDK(_D
M2<Y5).<W=O=A1113("BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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D*&7# $>AHHH   H  P*6BB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140554512816816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Oct. 28, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-6351<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ELI LILLY AND COMPANY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">IN<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">35-0470950<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">Lilly Corporate Center<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Indianapolis<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">IN<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">46285<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">317<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">276-2000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">950,177,900<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000059478<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Stock (no par value)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock (no par value)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LLY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lly_A718NotesDueJune12025Member', window );">7 1/8% Notes due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">7 1/8% Notes due 2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LLY25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lly_A1.625NotesDueJune22026Member', window );">1.625% Notes due 2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">1.625% Notes due 2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LLY26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lly_A2.125NotesDueJune32030Member', window );">2.125% Notes due 2030</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">2.125% Notes due 2030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LLY30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lly_A625NotesDue2031Member', window );">0.625% Notes due 2031</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">0.625% Notes due 2031<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LLY31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lly_A500NotesDue2033Member', window );">0.500% Notes due 2033</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">0.500% Notes due 2033<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LLY33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lly_A6.77NotesDueJanuary12036Member', window );">6.77%&#160;Notes due 2036</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">6.77%&#160;Notes due 2036<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LLY36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lly_A1625NotesDue2043Member', window );">1.625% Notes due 2043</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">1.625% Notes due 2043<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LLY43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lly_A1700NotesDue2049Member', window );">1.700% Notes due 2049</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">1.700% Notes due 2049<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LLY49A<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lly_A1125NotesDue2051Member', window );">1.125% Notes due 2051</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">1.125% Notes due 2051<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LLY51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lly_A1375NotesDue2061Member', window );">1.375% Notes due 2061</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">1.375% Notes due 2061<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LLY61<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lly_A718NotesDueJune12025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lly_A718NotesDueJune12025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lly_A1.625NotesDueJune22026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lly_A1.625NotesDueJune22026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lly_A2.125NotesDueJune32030Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lly_A2.125NotesDueJune32030Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lly_A625NotesDue2031Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lly_A625NotesDue2031Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lly_A500NotesDue2033Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lly_A500NotesDue2033Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lly_A6.77NotesDueJanuary12036Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lly_A6.77NotesDueJanuary12036Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lly_A1625NotesDue2043Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lly_A1625NotesDue2043Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lly_A1700NotesDue2049Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lly_A1700NotesDue2049Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lly_A1125NotesDue2051Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lly_A1125NotesDue2051Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lly_A1375NotesDue2061Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lly_A1375NotesDue2061Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140554510327136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Condensed Statements of Operations (Unaudited) - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue (Note 2)</a></td>
<td class="nump">$ 6,941.6<span></span>
</td>
<td class="nump">$ 6,772.8<span></span>
</td>
<td class="nump">$ 21,239.6<span></span>
</td>
<td class="nump">$ 20,318.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Costs, expenses, and other:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of sales</a></td>
<td class="nump">1,579.1<span></span>
</td>
<td class="nump">1,430.8<span></span>
</td>
<td class="nump">5,081.7<span></span>
</td>
<td class="nump">5,262.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">1,802.9<span></span>
</td>
<td class="nump">1,705.3<span></span>
</td>
<td class="nump">5,194.9<span></span>
</td>
<td class="nump">5,032.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Marketing, selling, and administrative</a></td>
<td class="nump">1,614.2<span></span>
</td>
<td class="nump">1,577.9<span></span>
</td>
<td class="nump">4,797.2<span></span>
</td>
<td class="nump">4,839.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lly_AcquiredInProcessResearchAndDevelopmentAndDevelopmentMilestones', window );">Acquired in-process research and development and development milestones (Note 3)</a></td>
<td class="nump">62.4<span></span>
</td>
<td class="nump">177.6<span></span>
</td>
<td class="nump">668.4<span></span>
</td>
<td class="nump">532.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringSettlementAndImpairmentProvisions', window );">Asset impairment, restructuring, and other special charges (Note 5)</a></td>
<td class="nump">206.5<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">206.5<span></span>
</td>
<td class="nump">211.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other&#8211;net, (income) expense (Note 11)</a></td>
<td class="nump">111.0<span></span>
</td>
<td class="nump">635.9<span></span>
</td>
<td class="nump">580.9<span></span>
</td>
<td class="nump">124.3<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lly_CostOfSalesOperatingExpensesAndOtherNet', window );">Costs, expenses, and other</a></td>
<td class="nump">5,376.1<span></span>
</td>
<td class="nump">5,527.5<span></span>
</td>
<td class="nump">16,529.6<span></span>
</td>
<td class="nump">16,002.9<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income before income taxes</a></td>
<td class="nump">1,565.5<span></span>
</td>
<td class="nump">1,245.3<span></span>
</td>
<td class="nump">4,710.0<span></span>
</td>
<td class="nump">4,315.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income taxes (Note 7)</a></td>
<td class="nump">113.8<span></span>
</td>
<td class="nump">135.2<span></span>
</td>
<td class="nump">402.9<span></span>
</td>
<td class="nump">460.0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 1,451.7<span></span>
</td>
<td class="nump">$ 1,110.1<span></span>
</td>
<td class="nump">$ 4,307.1<span></span>
</td>
<td class="nump">$ 3,855.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in dollars per share)</a></td>
<td class="nump">$ 1.61<span></span>
</td>
<td class="nump">$ 1.22<span></span>
</td>
<td class="nump">$ 4.78<span></span>
</td>
<td class="nump">$ 4.25<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in dollars per share)</a></td>
<td class="nump">$ 1.61<span></span>
</td>
<td class="nump">$ 1.22<span></span>
</td>
<td class="nump">$ 4.76<span></span>
</td>
<td class="nump">$ 4.23<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Shares used in calculation of earnings per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in shares)</a></td>
<td class="nump">900.7<span></span>
</td>
<td class="nump">906.7<span></span>
</td>
<td class="nump">901.8<span></span>
</td>
<td class="nump">907.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in shares)</a></td>
<td class="nump">903.8<span></span>
</td>
<td class="nump">910.8<span></span>
</td>
<td class="nump">904.5<span></span>
</td>
<td class="nump">911.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_AcquiredInProcessResearchAndDevelopmentAndDevelopmentMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Acquired In-Process Research And Development And Development Milestones</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_AcquiredInProcessResearchAndDevelopmentAndDevelopmentMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_CostOfSalesOperatingExpensesAndOtherNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cost Of Sales, Operating Expenses, And Other-net</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_CostOfSalesOperatingExpensesAndOtherNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringSettlementAndImpairmentProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of restructuring charges, remediation cost, and asset impairment loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringSettlementAndImpairmentProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140554512737568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Condensed Statements of Comprehensive Income (Unaudited) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 1,451.7<span></span>
</td>
<td class="nump">$ 1,110.1<span></span>
</td>
<td class="nump">$ 4,307.1<span></span>
</td>
<td class="nump">$ 3,855.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax (Note 10)</a></td>
<td class="num">(8.1)<span></span>
</td>
<td class="nump">114.4<span></span>
</td>
<td class="nump">47.3<span></span>
</td>
<td class="nump">323.7<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income</a></td>
<td class="nump">$ 1,443.6<span></span>
</td>
<td class="nump">$ 1,224.5<span></span>
</td>
<td class="nump">$ 4,354.4<span></span>
</td>
<td class="nump">$ 4,179.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140554512398752">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Condensed Balance Sheets - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents (Note 6)</a></td>
<td class="nump">$ 2,617.4<span></span>
</td>
<td class="nump">$ 3,818.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments (Note 6)</a></td>
<td class="nump">124.7<span></span>
</td>
<td class="nump">90.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net of allowances of $17.7 (2022) and $22.5 (2021)</a></td>
<td class="nump">6,715.3<span></span>
</td>
<td class="nump">6,672.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Other receivables</a></td>
<td class="nump">1,609.5<span></span>
</td>
<td class="nump">1,454.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">3,831.1<span></span>
</td>
<td class="nump">3,886.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses and other</a></td>
<td class="nump">2,741.9<span></span>
</td>
<td class="nump">2,530.6<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">17,639.9<span></span>
</td>
<td class="nump">18,452.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Investments (Note 6)</a></td>
<td class="nump">2,574.6<span></span>
</td>
<td class="nump">3,212.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">3,891.6<span></span>
</td>
<td class="nump">3,892.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Other intangibles, net</a></td>
<td class="nump">7,124.1<span></span>
</td>
<td class="nump">7,691.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred tax assets</a></td>
<td class="nump">2,384.3<span></span>
</td>
<td class="nump">2,489.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net of accumulated depreciation of $10,074.0 (2022) and $9,976.7 (2021)</a></td>
<td class="nump">9,311.3<span></span>
</td>
<td class="nump">8,985.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="nump">4,535.7<span></span>
</td>
<td class="nump">4,082.7<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">47,461.5<span></span>
</td>
<td class="nump">48,806.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtCurrent', window );">Short-term borrowings and current maturities of long-term debt</a></td>
<td class="nump">1,744.6<span></span>
</td>
<td class="nump">1,538.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">1,683.2<span></span>
</td>
<td class="nump">1,670.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Employee compensation</a></td>
<td class="nump">984.1<span></span>
</td>
<td class="nump">958.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lly_SalesRebatesAndDiscounts', window );">Sales rebates and discounts</a></td>
<td class="nump">8,568.4<span></span>
</td>
<td class="nump">6,845.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsPayableCurrent', window );">Dividends payable</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">885.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxesPayableCurrent', window );">Income taxes payable</a></td>
<td class="nump">685.6<span></span>
</td>
<td class="nump">126.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">1,986.9<span></span>
</td>
<td class="nump">3,027.5<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">15,652.8<span></span>
</td>
<td class="nump">15,052.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Other Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
<td class="nump">14,143.8<span></span>
</td>
<td class="nump">15,346.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent', window );">Accrued retirement benefits (Note 8)</a></td>
<td class="nump">1,832.5<span></span>
</td>
<td class="nump">1,954.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesNoncurrent', window );">Long-term income taxes payable</a></td>
<td class="nump">3,641.7<span></span>
</td>
<td class="nump">3,920.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred tax liabilities</a></td>
<td class="nump">171.9<span></span>
</td>
<td class="nump">1,733.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other noncurrent liabilities</a></td>
<td class="nump">1,852.9<span></span>
</td>
<td class="nump">1,644.3<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total other liabilities</a></td>
<td class="nump">21,642.8<span></span>
</td>
<td class="nump">24,598.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies (Note 9)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Eli Lilly and Company Shareholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock</a></td>
<td class="nump">594.1<span></span>
</td>
<td class="nump">596.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">6,829.0<span></span>
</td>
<td class="nump">6,833.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="nump">10,006.5<span></span>
</td>
<td class="nump">8,958.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesHeldInEmployeeTrust', window );">Employee benefit trust</a></td>
<td class="num">(3,013.2)<span></span>
</td>
<td class="num">(3,013.2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss (Note 10)</a></td>
<td class="num">(4,295.8)<span></span>
</td>
<td class="num">(4,343.1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonValue', window );">Cost of common stock in treasury</a></td>
<td class="num">(50.5)<span></span>
</td>
<td class="num">(52.7)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Eli Lilly and Company shareholders' equity</a></td>
<td class="nump">10,070.1<span></span>
</td>
<td class="nump">8,979.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interests</a></td>
<td class="nump">95.8<span></span>
</td>
<td class="nump">175.6<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total equity</a></td>
<td class="nump">10,165.9<span></span>
</td>
<td class="nump">9,154.8<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and equity</a></td>
<td class="nump">$ 47,461.5<span></span>
</td>
<td class="nump">$ 48,806.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_SalesRebatesAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sales Rebates And Discounts</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_SalesRebatesAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due beyond one year or the operating cycle, whichever is longer. Alternate captions include income taxes payable, noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesHeldInEmployeeTrust">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of common stock issued to a trust (for example, but not limited to, rabbi trust) set up specifically to accumulate stock for the sole purpose of distribution to participating employees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesHeldInEmployeeTrust</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of debt and lease obligation, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1703-114919<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1731-114919<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126905020&amp;loc=d3e5879-108316<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 25: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.30)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140554515341168">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Condensed Balance Sheets (Parenthetical) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrentAbstract', window );"><strong>Receivables, Net, Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Allowances for doubtful accounts</a></td>
<td class="nump">$ 17.7<span></span>
</td>
<td class="nump">$ 22.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Property and equipment, accumulated depreciation</a></td>
<td class="nump">$ 10,074.0<span></span>
</td>
<td class="nump">$ 9,976.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5074-111524<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesNetCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesNetCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140554505654624">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Consolidated Condensed Statements of Equity - USD ($)<br> shares in Thousands, $ in Millions</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Retained Earnings</div></th>
<th class="th"><div>Employee Benefit Trust</div></th>
<th class="th"><div>Accumulated Other Comprehensive Loss</div></th>
<th class="th" colspan="2"><div>Common Stock in Treasury</div></th>
<th class="th"><div>Noncontrolling Interests</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Beginning balance (in shares) at Dec. 31, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">957,077<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Beginning balance (in shares) at Dec. 31, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">487<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 598.2<span></span>
</td>
<td class="nump">$ 6,778.5<span></span>
</td>
<td class="nump">$ 7,830.2<span></span>
</td>
<td class="num">$ (3,013.2)<span></span>
</td>
<td class="num">$ (6,496.4)<span></span>
</td>
<td class="num">$ (55.7)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 183.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Shareholders' Equity [Roll Forward]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,855.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">25.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">323.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Dividends', window );">Cash dividends declared</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,542.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesRetired', window );">Retirement of treasury shares (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,467)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,467)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockRetiredCostMethodAmount', window );">Retirement of treasury shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(498.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500.0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Purchase of treasury shares (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,467<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Purchase of treasury shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (500.0)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of stock under employee stock plans, net (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,442<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(24)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of stock under employee stock plans, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.5<span></span>
</td>
<td class="num">(287.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">267.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Other</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.9)<span></span>
</td>
<td class="num">(5.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(11.7)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ending balance (in shares) at Sep. 30, 2021</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">957,052<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Ending balance (in shares) at Sep. 30, 2021</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">463<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Sep. 30, 2021</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 598.2<span></span>
</td>
<td class="nump">6,758.0<span></span>
</td>
<td class="nump">9,639.4<span></span>
</td>
<td class="num">(3,013.2)<span></span>
</td>
<td class="num">(6,172.7)<span></span>
</td>
<td class="num">$ (52.7)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">197.1<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Beginning balance (in shares) at Jun. 30, 2021</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">957,038<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Beginning balance (in shares) at Jun. 30, 2021</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">463<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Jun. 30, 2021</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 598.1<span></span>
</td>
<td class="nump">6,669.2<span></span>
</td>
<td class="nump">8,530.1<span></span>
</td>
<td class="num">(3,013.2)<span></span>
</td>
<td class="num">(6,287.1)<span></span>
</td>
<td class="num">$ (52.7)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">219.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Shareholders' Equity [Roll Forward]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,110.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(22.6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">114.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of stock under employee stock plans, net (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of stock under employee stock plans, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="num">(1.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Other</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0.6<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ending balance (in shares) at Sep. 30, 2021</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">957,052<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Ending balance (in shares) at Sep. 30, 2021</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">463<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Sep. 30, 2021</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 598.2<span></span>
</td>
<td class="nump">6,758.0<span></span>
</td>
<td class="nump">9,639.4<span></span>
</td>
<td class="num">(3,013.2)<span></span>
</td>
<td class="num">(6,172.7)<span></span>
</td>
<td class="num">$ (52.7)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">197.1<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Beginning balance (in shares) at Dec. 31, 2021</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">954,116<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Beginning balance (in shares) at Dec. 31, 2021</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">463<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 9,154.8<span></span>
</td>
<td class="nump">$ 596.3<span></span>
</td>
<td class="nump">6,833.4<span></span>
</td>
<td class="nump">8,958.5<span></span>
</td>
<td class="num">(3,013.2)<span></span>
</td>
<td class="num">(4,343.1)<span></span>
</td>
<td class="num">$ (52.7)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">175.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Shareholders' Equity [Roll Forward]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,307.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(63.7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Dividends', window );">Cash dividends declared</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,765.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesRetired', window );">Retirement of treasury shares (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,607)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,607)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockRetiredCostMethodAmount', window );">Retirement of treasury shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (3.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,496.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500.0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Purchase of treasury shares (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,607<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Purchase of treasury shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,500.0)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of stock under employee stock plans, net (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,118<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(13)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of stock under employee stock plans, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.3<span></span>
</td>
<td class="num">(282.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.2<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">278.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Other</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(16.1)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ending balance (in shares) at Sep. 30, 2022</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">950,627<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Ending balance (in shares) at Sep. 30, 2022</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">450<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Sep. 30, 2022</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">10,165.9<span></span>
</td>
<td class="nump">$ 594.1<span></span>
</td>
<td class="nump">6,829.0<span></span>
</td>
<td class="nump">10,006.5<span></span>
</td>
<td class="num">(3,013.2)<span></span>
</td>
<td class="num">(4,295.8)<span></span>
</td>
<td class="num">$ (50.5)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">95.8<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Beginning balance (in shares) at Jun. 30, 2022</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">950,619<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Beginning balance (in shares) at Jun. 30, 2022</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">450<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Jun. 30, 2022</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 594.1<span></span>
</td>
<td class="nump">6,746.0<span></span>
</td>
<td class="nump">8,556.0<span></span>
</td>
<td class="num">(3,013.2)<span></span>
</td>
<td class="num">(4,287.7)<span></span>
</td>
<td class="num">$ (50.5)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">114.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Shareholders' Equity [Roll Forward]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,451.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(15.7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of stock under employee stock plans, net (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of stock under employee stock plans, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Other</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(3.0)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ending balance (in shares) at Sep. 30, 2022</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">950,627<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Ending balance (in shares) at Sep. 30, 2022</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">450<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Sep. 30, 2022</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 10,165.9<span></span>
</td>
<td class="nump">$ 594.1<span></span>
</td>
<td class="nump">$ 6,829.0<span></span>
</td>
<td class="nump">$ 10,006.5<span></span>
</td>
<td class="num">$ (3,013.2)<span></span>
</td>
<td class="num">$ (4,295.8)<span></span>
</td>
<td class="num">$ (50.5)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">$ 95.8<span></span>
</td>
</tr>
<tr><td colspan="10"></td></tr>
<tr><td colspan="10"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">As of September&#160;30, 2022, there was $3.25 billion remaining under our $5.00 billion share repurchase program authorized in May 2021.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">As of September&#160;30, 2022, there was $3.25 billion remaining under our $5.00 billion share repurchase program authorized in May 2021.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Dividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 405<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6957935&amp;loc=d3e64057-112817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Dividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 25: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockRetiredCostMethodAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease of par value, additional paid in capital (APIC) and retained earnings of common and preferred stock retired from treasury when treasury stock is accounted for under the cost method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockRetiredCostMethodAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesRetired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common and preferred stock retired from treasury during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesRetired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140554510206656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Condensed Statements of Equity (Parenthetical) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>May 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statement of Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareDeclared', window );">Cash dividend declared per share (in dollars per share)</a></td>
<td class="nump">$ 1.96<span></span>
</td>
<td class="nump">$ 1.70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1', window );">Stock repurchase program, remaining authorized amount</a></td>
<td class="nump">$ 3,250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Stock repurchase program, authorized amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsPerShareDeclared">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends declared during the period for each share of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsPerShareDeclared</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramAuthorizedAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount remaining of a stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140554505542144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Condensed Statements of Cash Flows - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash Flows from Operating Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 4,307.1<span></span>
</td>
<td class="nump">$ 3,855.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to Reconcile Net Income to Cash Flows from Operating Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">1,147.5<span></span>
</td>
<td class="nump">1,101.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes', window );">Change in deferred income taxes</a></td>
<td class="num">(2,195.6)<span></span>
</td>
<td class="num">(709.8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Debt extinguishment loss (Note 6)</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">405.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">278.2<span></span>
</td>
<td class="nump">267.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnInvestments', window );">Net investment (gains) losses</a></td>
<td class="nump">676.4<span></span>
</td>
<td class="num">(271.1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lly_AcquiredInProcessResearchAndDevelopment', window );">Acquired in-process research and development</a></td>
<td class="nump">252.0<span></span>
</td>
<td class="nump">498.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet', window );">Other changes in operating assets and liabilities, net of acquisitions and divestitures</a></td>
<td class="nump">821.5<span></span>
</td>
<td class="num">(548.1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOperatingActivitiesCashFlowStatement', window );">Other non-cash operating activities, net</a></td>
<td class="nump">217.6<span></span>
</td>
<td class="nump">504.7<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net Cash Provided by Operating Activities</a></td>
<td class="nump">5,504.7<span></span>
</td>
<td class="nump">5,104.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash Flows from Investing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireProductiveAssets', window );">Net purchases of property and equipment</a></td>
<td class="num">(1,353.6)<span></span>
</td>
<td class="num">(1,018.4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfShortTermInvestments', window );">Proceeds from sales and maturities of short-term investments</a></td>
<td class="nump">83.1<span></span>
</td>
<td class="nump">46.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireShortTermInvestments', window );">Purchases of short-term investments</a></td>
<td class="num">(65.0)<span></span>
</td>
<td class="num">(27.9)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfLongtermInvestments', window );">Proceeds from sales of noncurrent investments</a></td>
<td class="nump">251.6<span></span>
</td>
<td class="nump">537.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireLongtermInvestments', window );">Purchases of noncurrent investments</a></td>
<td class="num">(474.1)<span></span>
</td>
<td class="num">(710.1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Cash paid for acquisitions, net of cash acquired (Note 3)</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(747.4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lly_PurchasedInProcessResearchAndDevelopment', window );">Purchases of in-process research and development</a></td>
<td class="num">(574.8)<span></span>
</td>
<td class="num">(460.6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities', window );">Other investing activities, net</a></td>
<td class="num">(268.3)<span></span>
</td>
<td class="num">(2.7)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net Cash Used for Investing Activities</a></td>
<td class="num">(2,401.1)<span></span>
</td>
<td class="num">(2,383.3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash Flows from Financing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDividends', window );">Dividends paid</a></td>
<td class="num">(2,651.4)<span></span>
</td>
<td class="num">(2,313.5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromShortTermDebt', window );">Net change in short-term borrowings</a></td>
<td class="nump">1,741.3<span></span>
</td>
<td class="num">(1.5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from issuance of long-term debt</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">2,410.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of long-term debt</a></td>
<td class="num">(1,560.0)<span></span>
</td>
<td class="num">(1,905.3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Purchases of common stock</a></td>
<td class="num">(1,500.0)<span></span>
</td>
<td class="num">(500.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities', window );">Other financing activities, net</a></td>
<td class="num">(295.2)<span></span>
</td>
<td class="num">(295.3)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net Cash Used for Financing Activities</a></td>
<td class="num">(4,265.3)<span></span>
</td>
<td class="num">(2,604.8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash and cash equivalents</a></td>
<td class="num">(39.4)<span></span>
</td>
<td class="nump">15.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net decrease in cash and cash equivalents</a></td>
<td class="num">(1,201.1)<span></span>
</td>
<td class="nump">131.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents at January&#160;1</a></td>
<td class="nump">3,818.5<span></span>
</td>
<td class="nump">3,657.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and Cash Equivalents at September 30</a></td>
<td class="nump">$ 2,617.4<span></span>
</td>
<td class="nump">$ 3,788.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_AcquiredInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of EXPENSE related to research and development assets that are acquired in a business combination (pre-141R) and/or licensing arrangement that have no alternative future use and are therefore written off in the period of acquisition (INCOME STATEMENT)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_AcquiredInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_PurchasedInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of CASH paid for research and development assets that are acquired in a business combination (pre-141R) and/or licensing arrangement that have no alternative future use and are therefore, written off in the period of acquisition (CASH FLOWS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_PurchasedInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized and unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27405-111563<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(c),9(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingActivitiesCashFlowStatement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example, cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingActivitiesCashFlowStatement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash (inflow) outflow from investing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromOtherInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireLongtermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, beyond the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the long-term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireLongtermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126928898&amp;loc=d3e9212-128498<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126928898&amp;loc=d3e9215-128498<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=127000608&amp;loc=d3e9135-128495<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromPaymentsForOtherFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfLongtermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sales of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, beyond the current operating cycle.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfLongtermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sales of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140554505523904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Implementation of New Financial Accounting Standard<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Basis of Presentation and Implementation of New Financial Accounting Standard</a></td>
<td class="text">Basis of Presentation and Implementation of New Financial Accounting Standard <div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have prepared the accompanying unaudited consolidated condensed financial statements in accordance with the requirements of Form 10-Q and, therefore, they do not include all information and footnotes necessary for a fair presentation of financial position, results of operations, and cash flows in conformity with accounting principles generally accepted in the United States (GAAP). In our opinion, the consolidated condensed financial statements reflect all adjustments (including those that are normal and recurring) that are necessary for a fair presentation of the results of operations for the periods shown. In preparing financial statements in conformity with GAAP, we must make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, expenses, and related disclosures at the date of the financial statements and during the reporting period. Actual results could differ from those estimates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information included in this Quarterly Report on Form 10-Q should be read in conjunction with our consolidated financial statements and accompanying notes included in our Annual Report on </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="https://www.sec.gov/Archives/edgar/data/0000059478/000005947822000068/lly-20211231.htm" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Form 10-K</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the year ended December&#160;31, 2021. We issue our financial statements by filing them with the Securities and Exchange Commission and have evaluated subsequent events up to the time of the filing of this Quarterly Report on Form 10-Q.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain reclassifications have been made to prior periods in the consolidated condensed financial statements and accompanying notes to conform with the current presentation.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All per-share amounts, unless otherwise noted in the footnotes, are presented on a diluted basis; that is, based on the weighted-average number of common shares outstanding plus the effect of incremental shares from our stock-based compensation programs.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate as a single operating segment engaged in the discovery, development, manufacturing, marketing, and sales of pharmaceutical products worldwide. A global research and development organization and a supply chain organization are responsible for the discovery, development, manufacturing, and supply of our products. Regional commercial organizations market, distribute, and sell the products. The business is also supported by global corporate staff functions. Our determination that we operate as a single segment is consistent with the financial information regularly reviewed by the chief operating decision maker for purposes of evaluating performance, allocating resources, setting incentive compensation targets, and planning and forecasting for future periods.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development Expenses and Acquired In-Process Research and Development (IPR&amp;D) and Development Milestones</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are expensed as incurred. Research and development costs consist of expenses incurred in performing research and development activities, including but not limited to, compensation and benefits, facilities and overhead expense, clinical trial expense, and fees paid to contract research organizations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquired IPR&amp;D and development milestones include the initial costs of externally developed IPR&amp;D projects, acquired directly in a transaction other than a business combination, that do not have an alternative future use. Additionally, milestone payment obligations related to these transactions that are incurred prior to regulatory approval of the compound are expensed when the event triggering an obligation to pay the milestone occurs.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Implementation of New Financial Accounting Standard</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounting Standards Update 2021-01, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reference Rate Reform</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, provides for temporary optional expedients and exceptions in applying current GAAP to contracts, hedging relationships, and other transactions affected by the transition from the use of the London Interbank Offered Rate (LIBOR) to an alternative reference rate. The standard is currently applicable to contracts entered into before January 1, 2023. We adopted the standard in the first quarter of 2022. The adoption did not have a material impact on our consolidated condensed financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI https://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140554511234512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Revenue</a></td>
<td class="text">Revenue<div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our revenue recognized in our consolidated condensed statements of operations:</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.613%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.206%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,119.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,189.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">19,123.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,579.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration and other revenue</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">822.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">583.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,116.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,739.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,941.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,772.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">21,239.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,318.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><div style="margin-top:1pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Collaboration and other revenue associated with prior period transfers of intellectual property was $43.3 million and $130.9 million during the three and nine months ended September&#160;30, 2022, respectively, and $62.1 million and $136.1 million during the three and nine months ended September&#160;30, 2021, respectively.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize revenue primarily from two different types of contracts, product sales to customers (net product revenue) and collaborations and other arrangements. Revenue recognized from collaborations and other arrangements includes our share of profits from the collaborations, as well as royalties, upfront and milestone payments we receive under these types of contracts. See Note 4 for additional information related to our collaborations and other arrangements. Collaboration and other revenue disclosed above includes the revenue from the Jardiance</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trajenta</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> families of products resulting from our collaboration with Boehringer Ingelheim discussed in Note 4. Substantially all of the remainder of collaboration and other revenue is related to contracts accounted for as contracts with customers.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Adjustments to Revenue</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjustments to increase revenue recognized as a result of changes in estimates for our most significant United States (U.S.) sales returns, rebates, and discounts liability balances for products shipped in previous periods were 3 percent of U.S. revenue for the three months ended September&#160;30, 2022 and less than 1 percent of U.S. revenue during the nine months ended September&#160;30, 2022 and the three and nine months ended September&#160;30, 2021. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Contract Liabilities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our contract liabilities result from arrangements where we have received payment in advance of performance under the contract and do not include sales returns, rebates, and discounts. Changes in contract liabilities are generally due to either receipt of additional advance payments or our performance under the contract. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes contract liability balances:</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.420%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.274%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.276%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">232.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">262.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended September&#160;30, 2022 and 2021, revenue recognized from contract liabilities as of the beginning of the respective year was not material. Revenue expected to be recognized in the future from contract liabilities as the related performance obligations are satisfied is not expected to be material in any one year.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Disaggregation of Revenue</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes revenue by product for the three months ended September&#160;30, 2022 and 2021:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.133%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.577%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outside U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outside U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue&#8212;to unaffiliated customers:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diabetes:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Trulicity</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,418.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">432.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,850.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,201.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">398.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,600.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Jardiance</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">350.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">222.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">573.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">390.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Humalog</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; (2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">248.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">198.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">447.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">347.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">279.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">626.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Humulin</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">169.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">68.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">238.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">286.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Basaglar</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">124.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">68.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">193.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Mounjaro</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">97.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">90.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">187.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other diabetes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">79.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">94.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">173.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total diabetes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,488.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,174.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,662.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,143.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,131.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,274.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oncology:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Verzenio</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">414.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">202.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">617.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">335.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Cyramza</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">87.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">144.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">232.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Erbitux</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">126.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">18.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">144.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Alimta</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">64.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">54.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">119.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">297.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">457.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Tyvyt</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">76.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">76.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other oncology</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">39.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">62.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">102.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total oncology</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">732.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">560.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,293.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">730.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">675.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,406.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Immunology:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Taltz</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">493.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">186.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">679.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">422.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">593.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Olumiant</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; (3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">22.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">160.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">182.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">212.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">406.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other immunology</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total immunology</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">516.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">349.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">866.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">616.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">388.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,004.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neuroscience:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Emgality</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">114.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">54.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">168.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Zyprexa</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">73.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">81.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Cymbalta</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">54.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">62.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other neuroscience</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">16.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">44.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">60.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total neuroscience</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">145.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">227.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">373.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">450.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">COVID-19 antibodies</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">386.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">386.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Forteo</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">112.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">64.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">177.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Cialis</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">107.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">115.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">30.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">35.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">66.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">538.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">207.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">746.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">354.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">282.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">637.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,422.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,519.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,941.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,989.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,783.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,772.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Numbers may not add due to rounding.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Jardiance revenue includes Glyxambi</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Synjardy</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">and Trijardy</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> XR. </span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Humalog revenue includes insulin lispro. </span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Olumiant revenue includes sales for baricitinib that were made pursuant to Emergency Use Authorization (EUA) or similar regulatory authorizations.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">COVID-19 antibodies include sales for bamlanivimab administered alone, for bamlanivimab and etesevimab administered together, and for bebtelovimab and were made pursuant to EUAs or similar regulatory authorizations.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes revenue by product for the nine months ended September&#160;30, 2022 and 2021:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.133%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.577%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outside U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outside U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue&#8212;to unaffiliated customers:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diabetes:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Trulicity</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,162.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,341.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,503.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,465.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,122.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,588.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Humalog</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">855.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">656.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,512.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,009.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">842.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,851.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Jardiance</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">831.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">622.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,453.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">566.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">492.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,058.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Humulin</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">562.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">223.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">785.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">633.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">290.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">923.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Basaglar</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">339.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">218.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">558.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">423.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">650.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Mounjaro</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">109.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">93.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">203.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other diabetes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">195.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">276.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">472.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">302.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">488.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total diabetes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,057.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,431.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10,489.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,284.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,276.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,560.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oncology:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Verzenio</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,100.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">575.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,675.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">582.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">363.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">945.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Cyramza</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">259.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">434.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">693.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">266.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">496.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">762.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Alimta</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">490.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">200.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">691.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">911.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">714.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,626.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Erbitux</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">361.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">47.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">408.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">357.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">403.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Tyvyt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">235.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">235.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">340.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">340.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other oncology</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">124.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">186.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">310.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total oncology</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,335.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,679.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,015.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,201.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,130.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,332.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Immunology:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Taltz</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,212.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">561.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,774.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,071.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">493.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,565.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Olumiant</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">104.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">520.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">624.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">572.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">809.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other immunology</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total immunology</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,317.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,093.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,411.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,323.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,080.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,404.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neuroscience:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Emgality</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">330.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">144.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">475.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">313.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">415.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Zyprexa</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">26.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">235.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">261.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">292.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Cymbalta</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">25.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">194.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">219.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">454.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">484.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other neuroscience</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">62.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">142.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">204.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">235.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total neuroscience</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">444.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">716.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,160.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">453.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">974.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,427.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">COVID-19 antibodies</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,970.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,985.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">949.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,176.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Cialis</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">25.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">454.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">480.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">541.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">538.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Forteo</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">261.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">191.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">453.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">330.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">287.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">617.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">119.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">125.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">244.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">260.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,377.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">786.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,163.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,373.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,220.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,593.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13,531.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,708.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">21,239.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,635.1&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,683.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,318.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Numbers may not add due to rounding.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Humalog revenue includes insulin lispro.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Jardiance revenue includes Glyxambi,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Synjardy,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">and Trijardy XR.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Olumiant revenue includes sales for baricitinib that were made pursuant to EUA or similar regulatory authorizations.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">COVID-19 antibodies include sales for bamlanivimab administered alone, for bamlanivimab and etesevimab administered together, and for bebtelovimab and were made pursuant to EUAs or similar regulatory authorizations.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes revenue by geographical area:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.613%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.206%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue&#8212;to unaffiliated customers</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,422.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,989.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13,531.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,635.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,056.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,098.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,224.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,629.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">487.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">595.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,352.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,832.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">343.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,102.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,285.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other foreign countries</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">632.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">689.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,029.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,936.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,941.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,772.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">21,239.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,318.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Numbers may not add due to rounding.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Revenue is attributed to the countries based on the location of the customer.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI https://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130551-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130556-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130550-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130558-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140554511066816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination and Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">Acquisitions</a></td>
<td class="text">Acquisitions<div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We engage in various forms of business development activities to enhance our product pipeline, including acquisitions, collaborations, investments, and licensing arrangements. In connection with these arrangements, our partners may be entitled to future royalties and/or commercial milestones based on sales should products be approved for commercialization and/or milestones based on the successful progress of compounds through the development process.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, we completed the acquisition of Prevail Therapeutics Inc. (Prevail). This transaction, as further discussed below in Acquisition of a Business, was accounted for as a business combination under the acquisition method of accounting. Under this method, the assets acquired and liabilities assumed were recorded at their respective fair values as of the acquisition date in our consolidated condensed financial statements. The determination of estimated fair value required management to make significant estimates and assumptions. The excess of the purchase price over the fair value of the acquired net assets, where applicable, has been recorded as goodwill. The results of operations of this acquisition is included in our consolidated condensed financial statements from the date of acquisition.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also acquired assets in development which are further discussed below in Asset Acquisitions. Upon each acquisition, the cost allocated to acquired IPR&amp;D is immediately expensed if the compound has no alternative future use. Milestone payment obligations incurred prior to regulatory approval of the compound are expensed when the event triggering an obligation to pay the milestone occurs. We recognized acquired IPR&amp;D and development milestone charges of $62.4 million and $668.4 million for the three and nine months ended September&#160;30, 2022, respectively, and $177.6 million and $532.4 million for the three and nine months ended September&#160;30, 2021, respectively. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Acquisition of a Business</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Prevail Acquisition</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Overview of Transaction</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, we acquired all shares of Prevail for a purchase price that included $22.50 per share in cash (or an aggregate of $747.4&#160;million, net of cash acquired) plus one non-tradable contingent value right (CVR) per share. The CVR entitles Prevail stockholders up to an additional $4.00 per share in cash (or an aggregate of approximately $160&#160;million) payable, subject to certain terms and conditions, upon the first regulatory approval of a Prevail product in one of the following countries: U.S., Japan, United Kingdom, Germany, France, Italy, or Spain. To achieve the full value of the CVR, such regulatory approval must occur by December 31, 2024. If such regulatory approval occurs after December 31, 2024, the value of the CVR will be reduced by approximately 8.3 cents per month until December 1, 2028, at which point the CVR will expire without payment.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the agreement, we acquired potentially disease-modifying AAV9-based gene therapies for patients with neurodegenerative diseases. The acquisition established a new modality for drug discovery and development, extending our research efforts through the creation of a gene therapy program that is being anchored by Prevail's portfolio of assets. The lead gene therapies in clinical development that we acquired were PR001 for patients with Parkinson's disease with GBA1 mutations and neuronopathic Gaucher disease and PR006 for patients with frontotemporal dementia with GRN mutations. Both PR001 and PR006 were granted Fast Track designation from the U.S. Food and Drug Administration (FDA). </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Assets Acquired and Liabilities Assumed</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the amounts recognized for assets acquired and liabilities assumed as of the acquisition date:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:79.016%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.784%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value at January 22, 2021</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired IPR&amp;D</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">824.0</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126.8</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(106.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets and liabilities, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition date fair value of consideration transferred </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">903.8</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash acquired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(90.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of CVR liability</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(65.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid, net of cash acquired</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">747.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Acquired IPR&amp;D intangibles primarily relate to PR001. In the third quarter of 2022, we impaired the intangible asset related to PR001. See Note 5 for additional information.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The goodwill recognized from this acquisition is not deductible for tax purposes. </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">See Note 6 for a discussion on the estimation of the CVR liability. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are unable to provide the results of operations for the three and nine months ended September&#160;30, 2022 and 2021 attributable to Prevail as those operations were substantially integrated into our legacy business.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pro forma information has not been included as this acquisition did not have a material impact on our consolidated condensed statements of operations for the three and nine months ended September&#160;30, 2021.</span></div><div style="margin-top:6pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Asset Acquisitions</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our significant asset acquisitions during the nine months ended September&#160;30, 2022 and 2021:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:26.531%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:27.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.104%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.916%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Counterparty</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Compound(s), Therapy or Asset</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Acquisition Month</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Phase of Development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Acquired IPR&amp;D Expense</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BioMarin Pharmaceutical Inc.</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Priority Review Voucher</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Not applicable</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">110.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rigel Pharmaceuticals, Inc.</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R552, a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor, for the potential treatment of autoimmune and inflammatory diseases</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase I</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Precision Biosciences, Inc. </span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Potential in vivo therapies for genetic disorders</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2021</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The phase of development presented is as of the date of the arrangement and represents the phase of development of the most advanced asset acquired, where applicable. </span></div><div style="padding-left:9pt;text-indent:-9pt"><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our acquisition of Petra Pharma Corporation (Petra), we were required to make milestone payments to Petra shareholders contingent upon the occurrence of certain future events linked to the success of the mutant-selective PI3K</span><span style="color:#000000;font-family:'Book Antiqua',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#945;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> inhibitor. In the second quarter of 2022, we entered into agreements with substantially all Petra shareholders to acquire their rights to receive any future milestone payments in exchange for a one-time payment. As a result of these agreements, we recognized a charge of $333.8&#160;million as a development milestone during the nine months ended September&#160;30, 2022. Any remaining contingent milestones payments linked to the success of the mutant-selective PI3K&#945; are not expected to be material. We recognized no other significant development milestones during the three and nine months ended September&#160;30, 2022 and 2021.</span></div>Subsequent Event - Akouos, Inc. (Akouos) AcquisitionOn October 17, 2022, we entered into a definitive agreement to acquire Akouos. Pursuant to the terms of the agreement, we have commenced a tender offer to acquire all outstanding shares of Akouos for a purchase price of $12.50 per share in cash (an aggregate of approximately $487&#160;million), payable at closing, plus one non-tradable CVR per share that will entitle the holder to receive up to an additional $3.00 per CVR in cash (an aggregate of up to approximately $123&#160;million) upon the achievement of certain specified milestones. The acquisition will expand our gene therapy portfolio to include potential treatments for hearing loss and other inner ear conditions. The acquisition is not subject to any financing condition and is expected to close in the fourth quarter of 2022, subject to customary closing conditions, including receipt of required antitrust clearance and the tender of a majority of the outstanding shares of Akouos's common stock.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionTextBlock', window );">Acquisitions</a></td>
<td class="text">Acquisitions<div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We engage in various forms of business development activities to enhance our product pipeline, including acquisitions, collaborations, investments, and licensing arrangements. In connection with these arrangements, our partners may be entitled to future royalties and/or commercial milestones based on sales should products be approved for commercialization and/or milestones based on the successful progress of compounds through the development process.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, we completed the acquisition of Prevail Therapeutics Inc. (Prevail). This transaction, as further discussed below in Acquisition of a Business, was accounted for as a business combination under the acquisition method of accounting. Under this method, the assets acquired and liabilities assumed were recorded at their respective fair values as of the acquisition date in our consolidated condensed financial statements. The determination of estimated fair value required management to make significant estimates and assumptions. The excess of the purchase price over the fair value of the acquired net assets, where applicable, has been recorded as goodwill. The results of operations of this acquisition is included in our consolidated condensed financial statements from the date of acquisition.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also acquired assets in development which are further discussed below in Asset Acquisitions. Upon each acquisition, the cost allocated to acquired IPR&amp;D is immediately expensed if the compound has no alternative future use. Milestone payment obligations incurred prior to regulatory approval of the compound are expensed when the event triggering an obligation to pay the milestone occurs. We recognized acquired IPR&amp;D and development milestone charges of $62.4 million and $668.4 million for the three and nine months ended September&#160;30, 2022, respectively, and $177.6 million and $532.4 million for the three and nine months ended September&#160;30, 2021, respectively. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Acquisition of a Business</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Prevail Acquisition</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Overview of Transaction</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, we acquired all shares of Prevail for a purchase price that included $22.50 per share in cash (or an aggregate of $747.4&#160;million, net of cash acquired) plus one non-tradable contingent value right (CVR) per share. The CVR entitles Prevail stockholders up to an additional $4.00 per share in cash (or an aggregate of approximately $160&#160;million) payable, subject to certain terms and conditions, upon the first regulatory approval of a Prevail product in one of the following countries: U.S., Japan, United Kingdom, Germany, France, Italy, or Spain. To achieve the full value of the CVR, such regulatory approval must occur by December 31, 2024. If such regulatory approval occurs after December 31, 2024, the value of the CVR will be reduced by approximately 8.3 cents per month until December 1, 2028, at which point the CVR will expire without payment.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the agreement, we acquired potentially disease-modifying AAV9-based gene therapies for patients with neurodegenerative diseases. The acquisition established a new modality for drug discovery and development, extending our research efforts through the creation of a gene therapy program that is being anchored by Prevail's portfolio of assets. The lead gene therapies in clinical development that we acquired were PR001 for patients with Parkinson's disease with GBA1 mutations and neuronopathic Gaucher disease and PR006 for patients with frontotemporal dementia with GRN mutations. Both PR001 and PR006 were granted Fast Track designation from the U.S. Food and Drug Administration (FDA). </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Assets Acquired and Liabilities Assumed</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the amounts recognized for assets acquired and liabilities assumed as of the acquisition date:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:79.016%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.784%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value at January 22, 2021</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired IPR&amp;D</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">824.0</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126.8</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(106.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets and liabilities, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition date fair value of consideration transferred </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">903.8</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash acquired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(90.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of CVR liability</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(65.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid, net of cash acquired</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">747.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Acquired IPR&amp;D intangibles primarily relate to PR001. In the third quarter of 2022, we impaired the intangible asset related to PR001. See Note 5 for additional information.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The goodwill recognized from this acquisition is not deductible for tax purposes. </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">See Note 6 for a discussion on the estimation of the CVR liability. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are unable to provide the results of operations for the three and nine months ended September&#160;30, 2022 and 2021 attributable to Prevail as those operations were substantially integrated into our legacy business.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pro forma information has not been included as this acquisition did not have a material impact on our consolidated condensed statements of operations for the three and nine months ended September&#160;30, 2021.</span></div><div style="margin-top:6pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Asset Acquisitions</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our significant asset acquisitions during the nine months ended September&#160;30, 2022 and 2021:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:26.531%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:27.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.104%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.916%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Counterparty</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Compound(s), Therapy or Asset</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Acquisition Month</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Phase of Development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Acquired IPR&amp;D Expense</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BioMarin Pharmaceutical Inc.</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Priority Review Voucher</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Not applicable</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">110.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rigel Pharmaceuticals, Inc.</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R552, a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor, for the potential treatment of autoimmune and inflammatory diseases</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase I</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Precision Biosciences, Inc. </span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Potential in vivo therapies for genetic disorders</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2021</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The phase of development presented is as of the date of the arrangement and represents the phase of development of the most advanced asset acquired, where applicable. </span></div><div style="padding-left:9pt;text-indent:-9pt"><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our acquisition of Petra Pharma Corporation (Petra), we were required to make milestone payments to Petra shareholders contingent upon the occurrence of certain future events linked to the success of the mutant-selective PI3K</span><span style="color:#000000;font-family:'Book Antiqua',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#945;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> inhibitor. In the second quarter of 2022, we entered into agreements with substantially all Petra shareholders to acquire their rights to receive any future milestone payments in exchange for a one-time payment. As a result of these agreements, we recognized a charge of $333.8&#160;million as a development milestone during the nine months ended September&#160;30, 2022. Any remaining contingent milestones payments linked to the success of the mutant-selective PI3K&#945; are not expected to be material. We recognized no other significant development milestones during the three and nine months ended September&#160;30, 2022 and 2021.</span></div>Subsequent Event - Akouos, Inc. (Akouos) AcquisitionOn October 17, 2022, we entered into a definitive agreement to acquire Akouos. Pursuant to the terms of the agreement, we have commenced a tender offer to acquire all outstanding shares of Akouos for a purchase price of $12.50 per share in cash (an aggregate of approximately $487&#160;million), payable at closing, plus one non-tradable CVR per share that will entitle the holder to receive up to an additional $3.00 per CVR in cash (an aggregate of up to approximately $123&#160;million) upon the achievement of certain specified milestones. The acquisition will expand our gene therapy portfolio to include potential treatments for hearing loss and other inner ear conditions. The acquisition is not subject to any financing condition and is expected to close in the fourth quarter of 2022, subject to customary closing conditions, including receipt of required antitrust clearance and the tender of a majority of the outstanding shares of Akouos's common stock.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 15<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=6911878&amp;loc=d3e8732-128492<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI https://asc.fasb.org/topic&amp;trid=2303972<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4946-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140554511420960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborations and Other Arrangements<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaborations and Other Arrangements</a></td>
<td class="text">Collaborations and Other Arrangements<div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We often enter into collaborative and other similar arrangements to develop and commercialize drug candidates. Collaborative activities may include research and development, marketing and selling (including promotional activities and physician detailing), manufacturing, and distribution. These arrangements often require milestone as well as royalty or profit-share payments, contingent upon the occurrence of certain future events linked to the success of the asset in development, as well as expense reimbursements from or payments to the collaboration partner. See Note 2 for amounts of collaboration and other revenue recognized from these types of arrangements. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating expenses for costs incurred pursuant to these arrangements are reported in their respective expense line item, net of any payments due to or reimbursements due from our collaboration partners, with such reimbursements being recognized at the time the party becomes obligated to pay. Each collaboration is unique in nature, and our more significant arrangements are discussed below. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Boehringer Ingelheim Diabetes Collaboration</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and Boehringer Ingelheim have a global agreement to jointly develop and commercialize a portfolio of diabetes compounds. Currently included in the collaboration are Boehringer Ingelheim's oral diabetes products: Jardiance, Glyxambi, Synjardy, Trijardy XR, Trajenta, and Jentadueto</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as well as our basal insulin, Basaglar. Glyxambi, Synjardy, and Trijardy XR are included in the Jardiance product family. Jentadueto is included in the Trajenta product family. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the regulatory approvals of Jardiance, Trajenta, and Basaglar in the U.S., Europe, and Japan, milestone payments made for Jardiance and Trajenta were capitalized as intangible assets and are being amortized to cost of sales, and milestone payments received for Basaglar were recorded as contract liabilities and are being amortized to collaboration and other revenue. The milestones pertaining to Jardiance and Trajenta are being amortized through their respective term under the collaboration, which, depending on country or region, is determined based on the latest to occur of (a) a defined number of years following launch date, (b) the expiration of the compound patent, or (c) the expiration of marketing authorization exclusivity. The milestones pertaining to Basaglar are being amortized through 2029. The table below summarizes the net milestones capitalized with respect to the Jardiance and Trajenta families of products and the net milestones deferred with respect to Basaglar as of September&#160;30, 2022 and December&#160;31, 2021: </span></div><div style="margin-top:6pt;padding-left:9pt;text-indent:-9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.812%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.445%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Milestones Capitalized (Deferred)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jardiance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">121.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trajenta</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">69.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basaglar</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(135.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(149.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">This represents the amounts that have been capitalized (deferred) from the start of this collaboration through the end of the reporting period, net of amount amortized. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the Jardiance product family, we and Boehringer Ingelheim share equally the ongoing development and commercialization costs in the most significant markets, and we record our portion of the development and commercialization costs as research and development expense and marketing, selling, and administrative expense, respectively. We receive a royalty on net sales of Boehringer Ingelheim's products in the most significant markets and recognize the royalty as collaboration and other revenue. Boehringer Ingelheim is entitled to potential performance payments depending on the net sales of the Jardiance product family; therefore, our reported revenue for Jardiance may be reduced by any potential performance payments we make related to this product family. The royalty received by us related to the Jardiance product family may also be increased or decreased depending on whether net sales for this product family exceed or fall below certain thresholds. We pay to Boehringer Ingelheim a royalty on net sales for Basaglar in the U.S. We record our sales of Basaglar to third parties as net product revenue with the royalty payments made to Boehringer Ingelheim recorded as cost of sales.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our collaboration and other revenue recognized with respect to the Jardiance and Trajenta families of products and net product revenue recognized with respect to Basaglar:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.613%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.206%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jardiance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">573.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">390.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,453.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,058.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basaglar</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">193.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">558.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">650.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trajenta</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">103.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">293.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">279.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Olumiant</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a worldwide license and collaboration agreement with Incyte Corporation (Incyte), which provides us the development and commercialization rights to baricitinib, branded and trademarked as Olumiant, and certain follow-on compounds, for the treatment of inflammatory and autoimmune diseases and COVID-19. Incyte has the right to receive tiered, double digit royalty payments on worldwide net sales with rates ranging up to 20 percent. Incyte has the right to receive an additional royalty ranging up to the low teens on worldwide net sales for the treatment of COVID-19 that exceed a specified aggregate worldwide net sales threshold. The agreement calls for payments by us to Incyte associated with certain development, success-based regulatory, and sales-based milestones. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the regulatory approvals of Olumiant in the U.S., Europe, and Japan, as well as achievement of a sales-based milestone, milestone payments of $330.0 million and $260.0 million were capitalized as intangible assets as of September&#160;30, 2022 and December&#160;31, 2021, respectively, and are being amortized to cost of sales through the term of the collaboration. This represents the cumulative amounts that have been capitalized from the start of this collaboration through the end of each reporting period.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2022, Incyte is eligible to receive up to $100.0&#160;million of additional payments from us in potential sales-based milestones.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record our sales of Olumiant, including sales of baricitinib that were made pursuant to EUA or similar regulatory authorizations, to third parties as net product revenue with the royalty payments made to Incyte recorded as cost of sales. The following table summarizes our net product revenue recognized with respect to Olumiant:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.613%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.206%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Olumiant</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">182.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">406.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">624.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">809.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COVID-19 Antibodies</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a worldwide license and collaboration agreement with AbCellera Biologics Inc. (AbCellera) to co-develop therapeutic antibodies for the potential prevention and treatment of COVID-19, including bamlanivimab and bebtelovimab, for which we hold development and commercialization rights. AbCellera has the right to receive tiered royalty payments on worldwide net sales of bamlanivimab and bebtelovimab with percentages ranging in the mid-teens to mid-twenties. Royalty payments made to AbCellera are recorded as cost of sales.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a license and collaboration agreement with Shanghai Junshi Biosciences Co., Ltd. (Junshi Biosciences) to co-develop therapeutic antibodies for the potential prevention and treatment of COVID-19, including etesevimab, for which we hold development and commercialization rights outside of mainland China and the Special Administrative Regions of Hong Kong and Macau, and for which Junshi Biosciences currently maintains all rights in mainland China and the Special Administrative Regions of Hong Kong and Macau. Junshi Biosciences has the right to receive royalty payments in the mid-teens on our net sales of etesevimab. Junshi Biosciences received certain development, success-based regulatory and sales-based milestones. Capitalized regulatory and sales-based milestones were fully amortized to cost of sales as of September&#160;30, 2022. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to EUAs or similar regulatory authorizations, we recognized net product revenue associated with our sales of our COVID-19 antibodies of $386.6 million and $1.99 billion for the three and nine months ended September&#160;30, 2022, respectively, and $217.1&#160;million and $1.18 billion for the three and nine months ended September&#160;30, 2021, respectively. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Sintilimab Injection</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a collaboration agreement with Innovent Biologics, Inc. (Innovent) to jointly develop and commercialize sintilimab injection in China, where it is branded and trademarked as Tyvyt. In connection with regulatory approvals for Tyvyt in China, milestone payments of $120.0&#160;million and $40.0&#160;million were capitalized as intangible assets as of September&#160;30, 2022 and December&#160;31, 2021, respectively, and are being amortized to cost of sales through the term of the collaboration. This represents the cumulative amounts that have been capitalized from the start of this collaboration through the end of each reporting period. As of September&#160;30, 2022, Innovent is eligible to receive up to $115.0&#160;million in success-based regulatory and sales-based milestones.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record our sales of Tyvyt to third parties as net product revenue, with payments made to Innovent for its portion of the gross margin reported as cost of sales. We report as collaboration and other revenue our portion of the gross margin for Tyvyt sales made by Innovent to third parties. The following table summarizes our revenue recognized in China with respect to Tyvyt:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.613%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.206%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tyvyt</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">76.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">235.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">340.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, we obtained an exclusive license for sintilimab injection from Innovent for geographies outside of China, which was subsequently terminated and rights have reverted to Innovent in October 2022.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Lebrikizumab</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a worldwide license agreement with F. Hoffmann-La Roche Ltd and Genentech, Inc. (collectively, Roche), which provides us the worldwide development and commercialization rights to lebrikizumab. Roche has the right to receive tiered royalty payments on future worldwide net sales ranging in percentages from high single digits to high teens if the product is successfully commercialized. As of September&#160;30, 2022, Roche is eligible to receive up to $180.0&#160;million of payments from us contingent upon the achievement of success-based regulatory milestones and up to $1.03 billion in a series of sales-based milestones, contingent upon the commercial success of lebrikizumab.</span></div>We have a license agreement with Almirall, S.A. (Almirall), under which Almirall licensed the rights to develop and commercialize lebrikizumab for the treatment or prevention of dermatology indications, including, but not limited to, atopic dermatitis in Europe. We have the right to receive tiered royalty payments on future net sales in Europe ranging in percentages from low double digits to low twenties if the product is successfully commercialized. As of September&#160;30, 2022, we are eligible to receive additional payments of $85.0&#160;million from Almirall contingent upon the achievement of success-based regulatory milestones and up to $1.25&#160;billion in a series of sales-based milestones, contingent upon the commercial success of lebrikizumab. There were no remaining contract liabilities as of September&#160;30, 2022. As of December&#160;31, 2021, contract liabilities were not material. During the three and nine months ended September&#160;30, 2022 and 2021, collaboration and other revenue recognized was not material.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI https://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140554511156896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Asset Impairment, Restructuring, and Other Special Charges<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock', window );">Asset Impairment, Restructuring, and Other Special Charges</a></td>
<td class="text">Asset Impairment, Restructuring, and Other Special Charges<div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of the charges included in asset impairment, restructuring, and other special charges in our consolidated condensed statements of operations are described below. </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.613%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.206%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Severance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset impairment and other special charges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">206.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">206.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total asset impairment, restructuring, and other special charges</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">206.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">206.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Asset impairment, restructuring, and other special charges recognized during the three and nine months ended September 30, 2022 were primarily related to an intangible asset impairment for GBA1 Gene Therapy (PR001), acquired in the Prevail acquisition, as a result of changes in key assumptions used in the valuation due to delays in estimated launch timing.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Asset impairment, restructuring, and other special charges recognized during the nine months ended September&#160;30, 2021 were primarily related to an intangible asset impairment of $108.1&#160;million resulting from the sale of the rights to Qbrexza</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, as well as acquisition and integration costs associated with the acquisition of Prevail. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized a net inventory impairment charge related to our COVID-19 antibodies of $435.1&#160;million during the nine months ended September&#160;30, 2021 in cost of sales in our consolidated condensed statements of operations. As part of our response to the COVID-19 pandemic, and at the request of the U.S. and international governments, we invested in large-scale manufacturing of COVID-19 antibodies at risk, in order to ensure rapid access to patients around the world. As the COVID-19 pandemic evolved during 2021, we incurred a net inventory impairment charge primarily due to the combination of changes to demand from U.S. and international governments, including changes to our agreement with the U.S. government, and near-term expiry dates of COVID-19 antibodies.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140554511136448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Financial Instruments</a></td>
<td class="text">Financial Instruments<div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject us to credit risk consist principally of trade receivables and interest-bearing investments. Wholesale distributors of life science products account for a substantial portion of our trade receivables; collateral is generally not required. We seek to mitigate the risk associated with this concentration through our ongoing credit-review procedures and insurance. A large portion of our cash is held by a few major financial institutions. We monitor our exposures with these institutions and do not expect any of these institutions to fail to meet their obligations. In accordance with documented corporate risk-management policies, we monitor the amount of credit exposure to any one financial institution or corporate issuer. We are exposed to credit-related losses in the event of nonperformance by counterparties to risk-management instruments but do not expect any counterparties to fail to meet their obligations given their investment grade credit ratings.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider all highly liquid investments with a maturity of three months or less from the date of purchase to be cash equivalents. The cost of these investments approximates fair value.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our equity investments are accounted for using three different methods depending on the type of equity investment:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Investments in companies over which we have significant influence but not a controlling interest are accounted for using the equity method, with our share of earnings or losses reported in other-net, (income) expense. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">For equity investments that do not have readily determinable fair values, we measure these investments at cost, less any impairment, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investment of the same issuer. Any change in recorded value is recorded in other-net, (income) expense. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our public equity investments are measured and carried at fair value. Any change in fair value is recognized in other-net, (income) expense. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We review equity investments other than public equity investments for indications of impairment and observable price changes on a regular basis.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our derivative activities are initiated within the guidelines of documented corporate risk-management policies and are intended to offset losses and gains on the assets, liabilities, and transactions being hedged. Management reviews the correlation and effectiveness of our derivatives on a quarterly basis.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For derivative instruments that are designated and qualify as fair value hedges, the derivative instrument is marked to market, with gains and losses recognized currently in income to offset the respective losses and gains recognized on the underlying exposure. For derivative instruments that are designated and qualify as cash flow hedges, gains and losses are reported as a component of accumulated other comprehensive loss and reclassified into earnings in the same period the hedged transaction affects earnings. For derivative and non-derivative instruments that are designated and qualify as net investment hedges, the foreign currency translation gains or losses due to spot rate fluctuations are reported as a component of accumulated other comprehensive loss. Derivative contracts that are not designated as hedging instruments are recorded at fair value with the gain or loss recognized in earnings during the period of change.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may enter into foreign currency forward or option contracts to reduce the effect of fluctuating currency exchange rates (principally the euro, British pound, Chinese yuan, and Japanese yen). Foreign currency derivatives used for hedging are put in place using the same or like currencies and duration as the underlying exposures. Forward and option contracts are principally used to manage exposures arising from subsidiary trade and loan payables and receivables denominated in foreign currencies. These contracts are recorded at fair value with the gain or loss recognized in other&#8211;net, (income) expense. We may enter into foreign currency forward and option contracts and currency swaps as fair value hedges of firm commitments. Forward contracts generally have maturities not exceeding 12 months. At September&#160;30, 2022, we had outstanding foreign currency forward commitments to purchase 1.69 billion U.S. dollars and sell 1.71 billion euro; commitments to purchase 2.24 billion euro and sell 2.24&#160;billion U.S. dollars; commitments to purchase 239.5 million U.S. dollars and sell 1.63 billion Chinese yuan; commitments to purchase 82.1&#160;million U.S. dollars and sell 11.86 billion Japanese yen; and commitments to purchase 182.1 million British pounds and sell 206.9&#160;million U.S. dollars, which all have settlement dates within 180 days.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign currency exchange risk is also managed through the use of foreign currency debt, cross-currency interest rate swaps, and foreign currency forward contracts. Our foreign currency-denominated notes had carrying amounts of $6.23 billion and $7.90&#160;billion as of September&#160;30, 2022 and December&#160;31, 2021, respectively, of which $4.94&#160;billion and $5.79 billion have been designated as, and are effective as, economic hedges of net investments in certain of our foreign operations as of September&#160;30, 2022 and December&#160;31, 2021, respectively. At September&#160;30, 2022, we had outstanding cross-currency swaps with notional amounts of $1.56 billion swapping U.S. dollars to euro and $1.00&#160;billion swapping Swiss francs to U.S. dollars which have settlement dates ranging through 2028. Our cross-currency interest rate swaps, for which a majority convert a portion of our U.S. dollar-denominated fixed-rate debt to foreign-denominated fixed-rate debt, have also been designated as, and are effective as, economic hedges of net investments. At September&#160;30, 2022, we had outstanding foreign currency forward contracts to sell 1.34 billion euro with settlement dates ranging through 2023, which have been designated as, and are effective as, economic hedges of net investments.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, our operations are exposed to fluctuations in interest rates which can vary the costs of financing, investing, and operating. We seek to address a portion of these risks through a controlled program of risk management that includes the use of derivative financial instruments. The objective of controlling these risks is to limit the impact of fluctuations in interest rates on earnings. Our primary interest-rate risk exposure results from changes in short-term U.S. dollar interest rates. In an effort to manage interest-rate exposures, we strive to achieve an acceptable balance between fixed- and floating-rate debt and investment positions and may enter into interest rate swaps or collars to help maintain that balance.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest rate swaps or collars that convert our fixed-rate debt to a floating rate are designated as fair value hedges of the underlying instruments. Interest rate swaps or collars that convert floating-rate debt to a fixed rate are designated as cash flow hedges. Interest expense on the debt is adjusted to include the payments made or received under the swap agreements. Cash proceeds from or payments to counterparties resulting from the termination of interest rate swaps are classified as operating activities in our consolidated condensed statements of cash flows. At September&#160;30, 2022, substantially all of our total long-term debt is at a fixed rate. We have converted approximately 10 percent of our long-term fixed-rate notes to floating rates through the use of interest rate swaps.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also may enter into forward-starting interest rate swaps, which we designate as cash flow hedges, as part of any anticipated future debt issuances in order to reduce the risk of cash flow volatility from future changes in interest rates. The change in fair value of these instruments is recorded as part of other comprehensive income (loss) and, upon completion of a debt issuance and termination of the swap, is amortized to interest expense over the life of the underlying debt. As of September&#160;30, 2022, the total notional amounts of forward-starting interest rate contracts in designated cash flow hedging instruments were $1.75 billion, which have settlement dates ranging between 2023 and 2025.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective September 15, 2022, we increased our 364-day credit facility from $2.00&#160;billion to $4.00&#160;billion, which will expire in September 2023, and is available to support our commercial paper program. We have not drawn against the $4.00&#160;billion 364-day credit facility as of September 30, 2022.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2021, we issued euro-denominated notes consisting of &#8364;600.0&#160;million of 0.50 percent fixed-rate notes due in September 2033, with interest to be paid annually. The net proceeds from the offering have been, and will continue to be, used to fund, in whole or in part, eligible projects designed to advance one or more of our environmental, social, and governance objectives.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2021, we issued euro-denominated notes consisting of &#8364;500.0&#160;million of 1.125 percent fixed-rate notes due in September 2051 and &#8364;700.0&#160;million of 1.375 percent fixed-rate notes due in September 2061, with interest to be paid annually, and British pound-denominated notes consisting of &#163;250.0&#160;million of 1.625 percent fixed-rate notes due in September 2043, with interest to be paid annually. We paid $1.91&#160;billion of the net cash proceeds from the offering to purchase and redeem certain higher interest rate U.S. dollar-denominated notes with an aggregate principal amount of $1.50&#160;billion, resulting in a debt extinguishment loss of $405.2&#160;million. This loss was included in other net, (income) expense in our consolidated condensed statement of operations during the three and nine months ended September 30, 2021. The $1.50&#160;billion principal amount of higher interest rate U.S. dollar-denominated notes that were redeemed primarily included $541.8&#160;million of 3.95 percent notes due 2049, $408.7&#160;million of 4.15 percent notes due 2059, and $219.4&#160;million of 3.375 percent notes due 2029. We used the remaining net proceeds from the offering to prefund certain 2022 debt maturities and for general corporate purposes.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The Effect of Risk-Management Instruments on the Consolidated Condensed Statements of Operations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following effects of risk-management instruments were recognized in other&#8211;net, (income) expense:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.800%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.157%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.157%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.157%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.160%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value hedges:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect from hedged fixed-rate debt</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(62.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(215.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect from interest rate contracts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">62.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">215.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flow hedges:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective portion of losses on interest rate contracts reclassified from accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency interest rate swaps</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">33.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">75.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (gains) losses on foreign currency exchange contracts not designated as hedging instruments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">129.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">280.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">166.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">368.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended September&#160;30, 2022 and 2021, the amortization of losses related to the portion of our risk management hedging instruments, fair value hedges, and cash flow hedges that was excluded from the assessment of effectiveness was not material.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The Effect of Risk-Management Instruments on Other Comprehensive Income (Loss)</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective portion of risk-management instruments that was recognized in other comprehensive income (loss) is as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.613%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.206%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment hedges:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency-denominated notes</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">435.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">822.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">268.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency interest rate swaps</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">92.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">171.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forward contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">107.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">121.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flow hedges:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward-starting interest rate swaps</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">57.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">337.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency interest rate swaps</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">19.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">38.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the next 12&#160;months, we expect to reclassify $16.7&#160;million of pretax net losses on cash flow hedges from accumulated other comprehensive loss to other&#8211;net, (income) expense. During the three and nine months ended September&#160;30, 2022 and 2021, the amounts excluded from the assessment of hedge effectiveness recognized in other comprehensive income (loss) were not material.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize certain fair value information at September&#160;30, 2022 and December&#160;31, 2021 for assets and liabilities measured at fair value on a recurring basis, as well as the carrying amount and amortized cost of certain other investments:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:34.624%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.466%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.714%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices in Active Markets for Identical Assets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Other<br/>Observable Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,246.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,246.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,239.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">7.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,246.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term investments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">43.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">43.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">43.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">43.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">51.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">51.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">51.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">51.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">27.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">27.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">14.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">12.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">27.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term investments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">124.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncurrent investments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">131.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">148.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">131.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">131.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">206.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">232.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">206.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">206.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">143.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">156.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">143.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">143.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">43.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">45.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">43.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">43.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">152.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">96.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">39.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">113.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">152.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">549.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">416.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">549.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">549.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity investments without readily determinable fair values</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">583.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity method investments</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">764.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncurrent investments</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,574.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,379.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,379.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,361.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,379.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term investments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term investments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">90.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncurrent investments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">137.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">136.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">137.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">137.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">235.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">232.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">235.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">235.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">109.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">108.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">109.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">109.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">108.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">108.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">108.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,279.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">487.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,279.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,279.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity investments without readily determinable fair values</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">548.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity method investments</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">771.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncurrent investments</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,212.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">For available-for-sale debt securities, amounts disclosed represent the securities' amortized cost.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Fair value disclosures are not applicable for equity method investments and investments accounted for under the measurement alternative for equity investments.</span></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:38.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.320%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.320%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.320%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.320%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.322%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices in Active Markets for Identical Assets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Other Observable Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Short-term commercial paper borrowings</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 30, 2022</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,741.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,738.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,738.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Long-term debt, including current portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 30, 2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(14,147.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(11,848.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(11,848.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,884.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,157.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,157.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:37.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.517%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.517%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.517%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.517%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.522%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices in Active Markets for Identical Assets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Other Observable Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk-management instruments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest rate contracts designated as fair value hedges:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(140.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(140.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(140.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest rate contracts designated as cash flow hedges:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">355.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">355.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">355.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cross-currency interest rate contracts designated as net investment hedges:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">81.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">81.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">81.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">116.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">116.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">116.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cross-currency interest rate contracts designated as cash flow hedges:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">8.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">8.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">8.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(12.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(12.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(12.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign exchange contracts designated as net investment hedges:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">108.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">108.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">108.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(2.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(2.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(2.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign exchange contracts not designated as hedging instruments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">48.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">48.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">48.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(93.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(93.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(93.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent consideration liability:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(42.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(42.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(42.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk-management instruments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest rate contracts designated as fair value hedges:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other receivables</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">78.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">78.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">78.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest rate contracts designated as cash flow hedges:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(31.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(31.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(31.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cross-currency interest rate contracts designated as net investment hedges:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cross-currency interest rate contracts designated as cash flow hedges:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign exchange contracts not designated as hedging instruments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(35.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(35.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(35.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent consideration liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(70.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(70.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(70.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk-management instruments above are disclosed on a gross basis. There are various rights of setoff associated with certain of the risk-management instruments above that are subject to enforceable master netting arrangements or similar agreements. Although various rights of setoff and master netting arrangements or similar agreements may exist with the individual counterparties to the risk-management instruments above, individually, these financial rights are not material.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine our Level 1 and Level 2 fair value measurements based on a market approach using quoted market values, significant other observable inputs for identical or comparable assets or liabilities, or discounted cash flow analyses. Level 3 fair value measurements for other investment securities are determined using unobservable inputs, including the investments' cost adjusted for impairments and price changes from orderly transactions. Fair values are not readily available for certain equity investments measured under the measurement alternative. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2022, we had approximately $854 million of unfunded commitments to invest in venture capital funds, which we anticipate will be paid over a period of up to 10 years. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contingent consideration liability relates to our liability arising in connection with the CVR issued as a result of the Prevail acquisition. The fair value of the CVR liability was estimated using a discounted cash flow analysis and Level 3 inputs, including projections representative of a market participant's view of the expected cash payment associated with the first potential regulatory approval of a Prevail compound in the applicable countries based on probabilities of technical success, timing of the potential approval events for the compounds, and an estimated discount rate. See Note 3 for additional information related to the CVR arrangement. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes the contractual maturities of our investments in debt securities measured at fair value as of September&#160;30, 2022:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:40.162%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.062%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maturities by Period</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less&#160;Than<br/>1 Year</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1-5<br/>Years</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">6-10<br/>Years</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">More&#160;Than<br/>10 Years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of debt securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">622.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net gains (losses) recognized in our consolidated condensed statements of operations for equity securities were $(123.3)&#160;million and $(667.6)&#160;million for the three and nine months ended September&#160;30, 2022, respectively, and $(246.8)&#160;million and $270.1&#160;million for the three and nine months ended September&#160;30, 2021, respectively. The net gains (losses) recognized for the three and nine months ended September&#160;30, 2022 and 2021 on equity securities sold during the respective periods were not material.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We adjust our equity investments without readily determinable fair values based upon changes in the equity instruments' values resulting from observable price changes in orderly transactions for an identical or similar investment of the same issuer. Downward adjustments resulting from an impairment are recorded based upon impairment considerations, including the financial condition and near term prospects of the issuer, general market conditions, and industry specific factors. Adjustments recorded for the three and nine months ended September&#160;30, 2022 and 2021 were not material.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the amount of unrealized gains and losses in accumulated other comprehensive loss and the fair value of available-for-sale securities in an unrealized gain or loss position follows:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:66.249%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.859%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.860%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gross gains</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gross losses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">51.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of securities in an unrealized gain position</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of securities in an unrealized loss position</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">578.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">290.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We periodically assess our investment in available-for-sale securities for impairment losses and credit losses. The amount of credit losses are determined by comparing the difference between the present value of future cash flows expected to be collected on these securities and the amortized cost. Factors considered in assessing credit losses include the position in the capital structure, vintage and amount of collateral, delinquency rates, current credit support, and geographic concentration. Impairment and credit losses related to available-for-sale securities were not material for the three and nine months ended September&#160;30, 2022 and 2021.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2022, the available-for-sale securities in an unrealized loss position include primarily fixed-rate debt securities of varying maturities, which are sensitive to changes in the yield curve and other market conditions. Approximately 95 percent&#160;of the fixed-rate debt securities in a loss position are investment-grade debt securities. As of September&#160;30, 2022, we do not intend to sell, and it is not more likely than not that we will be required to sell, the securities in a loss position before the market values recover or the underlying cash flows have been received, and there is no indication of a material default on interest or principal payments for our debt securities.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Activity related to our available-for-sale securities was as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.613%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.206%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">50.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">115.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Realized gross gains on sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Realized gross losses on sales</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Realized gains and losses on sales of available-for-sale investments are computed based upon specific identification of the initial cost adjusted for any other-than-temporary declines in fair value that were recorded in earnings.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounts Receivable Factoring Arrangements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into accounts receivable factoring agreements with financial institutions to sell certain of our non-U.S. accounts receivable. These transactions are accounted for as sales and result in a reduction in accounts receivable because the agreements transfer effective control over, and risk related to, the receivables to the buyers. Our factoring agreements do not allow for recourse in the event of uncollectibility, and we do not retain any interest in the underlying accounts receivable once sold. We derecognized $356.8 million and $550.5 million&#160;of accounts receivable as of September&#160;30, 2022 and December&#160;31, 2021, respectively, under these factoring arrangements. The costs of factoring such accounts receivable on our consolidated condensed results of operations for the three and nine months ended September&#160;30, 2022 and 2021&#160;were&#160;not material.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140554511273744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes <div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective tax rates were 7.3 percent and 8.6 percent for the three and nine months ended September&#160;30, 2022, respectively, reflecting the favorable tax impact of the implementation of a provision in the Tax Cuts and Jobs Act (2017 Tax Act) that requires capitalization and amortization of research and development expenses for tax purposes starting in 2022, net investment losses on equity securities, and an intangible asset impairment charge. We expect our effective tax rate to be approximately 13 percent to 14 percent for 2022 if the capitalization and amortization of research and development expenses provision of the 2017 Tax Act is deferred or repealed by the U.S. Congress effective for 2022.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective tax rate was 10.9 percent for the three months ended September&#160;30, 2021, reflecting the favorable tax impact of a debt extinguishment loss and of net investment losses on equity securities, partially offset by a net discrete tax detriment. The effective tax rate was 10.7 percent for the nine months ended September&#160;30, 2021, reflecting the favorable tax impact of a net discrete tax benefit, a debt extinguishment loss, and a net inventory impairment charge related to our COVID-19 antibodies. </span></div>The U.S. examination of tax years 2016-2018 began in the fourth quarter of 2019 and remains ongoing. The resolution of this audit period will likely extend beyond the next 12 months.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140554511128160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Retirement Benefits<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Retirement Benefits</a></td>
<td class="text">Retirement Benefits<div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net pension and retiree health benefit (income) cost included the following components:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.613%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.206%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Defined Benefit Pension Plans</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Components of net periodic benefit cost:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">87.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">264.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">277.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">98.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">299.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(235.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(237.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(711.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(712.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of prior service cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognized actuarial loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">85.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">256.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">366.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic benefit cost</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">36.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62.4&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">110.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.613%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.206%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Retiree Health Benefit Plans</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Components of net periodic benefit income:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">35.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">28.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(38.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(114.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(109.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of prior service benefit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(13.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(41.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognized actuarial loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic benefit income</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(30.4)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30.1)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(91.1)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(90.5)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section S99<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=21916913&amp;loc=d3e273930-122802<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI https://asc.fasb.org/topic&amp;trid=2235017<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6414203&amp;loc=d3e39689-114964<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140554510991808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingencies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Contingencies</a></td>
<td class="text">Contingencies<div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are involved in various lawsuits, claims, government investigations and other legal proceedings that arise in the ordinary course of business. These claims or proceedings can involve various types of parties, including governments, competitors, customers, suppliers, service providers, licensees, employees, or shareholders, among others. These matters may involve patent infringement, antitrust, securities, pricing, sales and marketing practices, environmental, commercial, contractual rights, licensing obligations, health and safety matters, consumer fraud, employment matters, product liability and insurance coverage, among others. The resolution of these matters often develops over a long period of time and expectations can change as a result of new findings, rulings, appeals or settlement arrangements. Legal proceedings that are significant or that we believe could become significant or material are described below. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe the legal proceedings in which we are named as defendants are without merit and we are defending against them vigorously. It is not possible to determine the final outcome of these matters, and we cannot reasonably estimate the maximum potential exposure or the range of possible loss in excess of amounts accrued for any of these matters; however, we believe that the resolution of all such matters will not have a material adverse effect on our consolidated financial position or liquidity, but could possibly be material to our consolidated results of operations in any one accounting period.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Litigation accruals, environmental liabilities, and the related estimated insurance recoverables are reflected on a gross basis as liabilities and assets, respectively, on our consolidated condensed balance sheets. With respect to the product liability claims currently asserted against us, we have accrued for our estimated exposures to the extent they are both probable and reasonably estimable based on the information available to us. We accrue for certain product liability claims incurred but not filed to the extent we can formulate a reasonable estimate of their costs. We estimate these expenses based primarily on historical claims experience and data regarding product usage. Legal defense costs expected to be incurred in connection with significant product liability loss contingencies are accrued when both probable and reasonably estimable.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of the nature of pharmaceutical products, it is possible that we could become subject to large numbers of additional product liability and related claims in the future. Due to a very restrictive market for litigation liability insurance, we are self-insured for litigation liability losses for all our currently and previously marketed products. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Patent Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Alimta European Patent Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In Europe, Alimta (pemetrexed) was protected by a patent through June 2021. A number of legal proceedings that were initiated prior to patent expiration are ongoing. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Emgality Patent Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a named defendant in litigation filed by Teva Pharmaceuticals International GMBH and Teva Pharmaceuticals USA, Inc. (collectively, Teva) in the U.S. District Court for the District of Massachusetts seeking a ruling that various claims in three different Teva patents would be infringed by our launch and continued sales of Emgality for the prevention of migraine in adults. Trial began in October 2022. In June 2021, we were named as a defendant in a second litigation filed by Teva in the U.S. District Court for the District of Massachusetts seeking a ruling that two of Teva's patents, which are directed toward use of the active ingredient in Emgality to treat migraine, would be infringed by our continued sales of Emgality. We challenged these two patents by filing requests for Inter Partes Review with the Patent Trial and Appeal Board (PTAB) and in October 2022, the PTAB granted our requests.The corresponding district court litigation is stayed while this PTAB proceeding is ongoing.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Jardiance Patent Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2018, Boehringer Ingelheim, our partner in marketing and development of Jardiance, initiated U.S. patent litigation in the U.S. District Court of Delaware alleging infringement arising from submissions of Abbreviated New Drug Applications (ANDA) by a number of generic companies seeking approval to market generic versions of Jardiance, Glyxambi, and Synjardy in accordance with the procedures set out in the Drug Price Competition and Patent Term Restoration Act of 1984 (the Hatch-Waxman Act). Particularly with respect to Jardiance, the generic companies' ANDAs seek approval to market generic versions of Jardiance prior to the expiration of the relevant patents, and allege that certain patents, including in some allegations the compound patent, are invalid or would not be infringed. We are not a party to this litigation. This litigation has been stayed. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Taltz Patent Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2021, we petitioned the High Court of Ireland to declare invalid a patent that Novartis Pharma AG (Novartis) purchased from Genentech, Inc. in 2020. Novartis responded by filing a claim against us alleging patent infringement related to our commercialization of Taltz and seeking damages for past infringement and an injunction against future infringement. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2021, Novartis petitioned the Court of Rome Intellectual Property Division for a preliminary injunction (PI) against us related to our commercialization of Taltz in Italy. In May 2021, We commenced patent revocation proceedings against Novartis before the Court of Milan&#8217;s IP Division where we also sought a declaration of non-infringement. Novartis counter-claimed for patent infringement and sought a permanent injunction. A hearing on the PI request before the Court of Rome Intellectual Property Division took place in May 2022 and in July 2022, the court rejected Novartis' request.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2021, Novartis petitioned the Swiss Federal Patent Court for a PI and a permanent injunction in main infringement proceedings against us related to our commercialization of Taltz in Switzerland. We petitioned the court to revoke the patent and for a declaration of non-infringement. In April 2022, Novartis withdrew its PI request.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2022, we commenced an action in the Hague District Court asking for a judgment that a Novartis Dutch patent is not infringed by our commercialization of Taltz in the Netherlands and is invalid. In October 2022, Novartis filed a counterclaim for infringement and sought a permanent injunction.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2022, we entered into a settlement and mutual release agreement with Novartis, which resolves the above-described disputes. Without any admission of liability or wrongdoing, we and Novartis have agreed to mutual releases for past claims and mutual covenants not to sue the other in relation to Taltz and the patents Novartis purchased from Genentech. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Zyprexa Canada Patent Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in the mid-2000s, several generic companies in Canada challenged the validity of our Zyprexa compound patent. In 2012, the Canadian Federal Court of Appeals denied our appeal of a lower court's decision that certain patent claims were invalid for lack of utility. In 2013, Apotex Inc. and Apotex Pharmachem Inc. (collectively, Apotex) brought claims against us in the Ontario Superior Court of Justice at Toronto for damages related to our enforcement of the Zyprexa compound patent under Canadian regulations governing patented drugs. Apotex seeks compensation based on novel legal theories under the Statute of Monopolies, Trademark Act, and common law. In March 2021, the Ontario Superior Court granted our motion for summary judgment, thereby dismissing Apotex's case. Apotex appealed that ruling to the Court of Appeal for Ontario in April 2021. In August 2022, the Court dismissed the appeal and in October 2022, Apotex appealed the decision. This matter is ongoing.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product Liability Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Byetta&#174; Product Liability</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have been named as a defendant in over 500 Byetta product liability lawsuits in the U.S. that were first initiated in March 2009 and involved over 800 plaintiffs. These lawsuits have been filed in various state and federal jurisdictions, including California state court (coordinated in Los Angeles County Superior Court), and various federal courts, the majority of which are coordinated in a multi-district litigation (MDL) in the U.S. District Court for the Southern District of California. The majority of these suits contain allegations that Byetta caused or contributed to the plaintiffs' cancer (primarily pancreatic cancer or thyroid cancer). The federal MDL and coordinated California state trial courts granted summary judgment in our favor on claims pertaining to pancreatic cancer, and the plaintiffs have dismissed Lilly from their appeal of the MDL ruling (the parties still await the order of judgment in the Los Angeles County Superior Court). Most of the MDL and state court lawsuits have been dismissed as of November 2022.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Environmental Proceedings</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Comprehensive Environmental Response, Compensation, and Liability Act, commonly known as "Superfund," we have been designated as one of several potentially responsible parties with respect to the cleanup of fewer than 10 sites. Under Superfund, each responsible party may be jointly and severally liable for the entire amount of the cleanup.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Matters</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">340B Litigation and Investigations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are the plaintiff in a lawsuit filed in January 2021 in the U.S. District Court for the Southern District of Indiana against the U.S. Department of Health and Human Services (HHS), the Secretary of HHS, the Health Resources and Services Administration (HRSA), and the Administrator of HRSA. The lawsuit challenges the HHS's December 30, 2020 advisory opinion stating that drug manufacturers are required to deliver discounts under the 340B program to all contract pharmacies. We seek a declaratory judgment that the defendants violated the Administrative Procedures Act and the U.S. Constitution, a preliminary injunction enjoining implementation of the administrative dispute resolution process created by defendants and, with it, their application of the advisory opinion, and other related relief. In March 2021, the court entered an order preliminarily enjoining the government's enforcement of the administrative dispute resolution process against us. In May 2021, HRSA notified us that it determined that our policy was contrary to the 340B statute. In response, in May 2021, we filed a motion for preliminary injunction and temporary restraining order requesting that the U.S. District Court for the Southern District of Indiana enjoin defendants from taking any action against us relating to the 340B drug pricing program until after the court issues a final judgment on the aforementioned litigation. In May 2021, the court denied our motion for a temporary restraining order but deferred resolution of our motion for preliminary injunction. In June 2021, the defendants withdrew the HHS December 30, 2020 advisory opinion. In July 2021, the court held oral argument on the parties' cross motions for summary judgment, the defendants' motion to dismiss, and our motion for preliminary injunction related to HRSA's May 2021 enforcement letter. In October 2021, the court denied the defendants' motion to dismiss, and granted in part and denied in part the parties' cross motions for summary judgment. Both parties filed notices of appeal related to the court's summary judgment order. Oral argument took place in October 2022 in the U.S. Court of Appeals for the Seventh Circuit. This matter is ongoing.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, we, along with other pharmaceutical manufacturers, were named as a defendant in a petition currently pending before the HHS Administrative Dispute Resolution Panel. Petitioner seeks declaratory and other injunctive relief related to the 340B program. As described above, the U.S. District Court for the Southern District of Indiana has entered a preliminary injunction enjoining the government's enforcement of this administrative dispute resolution process against us. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2021, we, along with Sanofi-Aventis U.S., LLC (Sanofi), Novo Nordisk Inc. (Novo Nordisk), and AstraZeneca Pharmaceuticals LP, were named as a defendant in a purported class action lawsuit filed in the U.S. District Court for the Western District of New York by Mosaic Health, Inc. alleging antitrust and unjust enrichment claims related to the defendants' 340B distribution programs. We, with Sanofi and Novo Nordisk, filed a motion to dismiss the lawsuit, which was granted in September 2022. In October 2022, the plaintiffs filed a motion for leave to amend their complaint. This matter is ongoing.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We received a civil investigative subpoena in February 2021 from the Office of the Attorney General for the State of Vermont relating to the sale of pharmaceutical products to Vermont covered entities under the 340B program. We are cooperating with this subpoena. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Branchburg Manufacturing Facility</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, we received a subpoena from the U.S. Department of Justice requesting the production of certain documents relating to our manufacturing site in Branchburg, New Jersey. We are cooperating with the subpoena.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Brazil Litigation &#8211; Cosmopolis Facility</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Labor Attorney Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">First initiated in 2008, our subsidiary in Brazil, Eli Lilly do Brasil Limitada (Lilly Brasil), is named in a Public Civil Action brought by the Labor Public Attorney (LPA) for the 15th Region in the Labor Court of Paulinia, State of Sao Paulo, Brazil, (the Labor Court) alleging possible harm to employees and former employees caused by alleged exposure to soil and groundwater contaminants at a former Lilly Brasil manufacturing facility in Cosmopolis, Brazil, operated by the company between 1977 and 2003. In May 2014, the Labor Court judge ruled against Lilly Brasil, ordering it to undertake several remedial and compensatory actions including health coverage for a class of individuals and certain of their children. In July 2018, the appeals court (TRT) generally affirmed our appeal of the Labor Court's ruling, which included a liquidated award of 300 million Brazilian real, which, when adjusted for inflation and the addition of pre and post judgment interest using the current Central Bank of Brazil's special system of clearance and custody rate, is approximately one billion Brazilian real (approximately $185&#160;million as of September&#160;30, 2022). In August 2019, Lilly Brasil filed an appeal to the superior labor court (TST) and in June 2021, the TRT published its decision on the admissibility of Lilly Brasil's appeal, allowing the majority of the elements, which were allowed to proceed in June 2021; elements not proceeding are subject to an interlocutory appeal to the TST that was filed in June 2021. In September 2019, the TRT stayed a number of elements of its trial court decision pending the determination of Lilly Brasil's appeal to the TST.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2019 and September 2020, the LPA filed applications in the Labor Court for enforcement of certain remedies granted by the TRT in its July 2018 decision, requested restrictions on Lilly Brasil&#8217;s assets in Brazil, and required Lilly Brasil and Antibi&#243;ticos do Brasil Ltda. (ABL) to submit a list of potential beneficiaries of the Public Civil Action. In July 2019, the Labor Court issued a ruling requiring a freeze of Lilly Brasil&#8217;s immovable property or, alternatively, a security deposit or lien of 500 million Brazilian real, which ruling was subsequently limited in scope and the security was reduced to 100 million Brazilian real. ABL and LPA appealed the June 2021 Labor Court ruling to the TST, which appeal is under review. The Labor Court is currently assessing the status of Lilly Brasil&#8217;s and ABL&#8217;s compliance with such portion of the July 2018 TRT decision and an inspection in the industrial plant is expected. These matters are ongoing.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Individual Former Employee Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lilly Brasil is also named in over 20 pending lawsuits filed in the Labor Court by individual former employees making similar claims. These individual lawsuits are at various stages in the litigation process.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Puerto Rico Tax Matter</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2013, the Municipality of Carolina in Puerto Rico (Municipality) filed a lawsuit against us alleging noncompliance with respect to a contract with the Municipality and seeking a declaratory judgment. In December 2020, the Puerto Rico Appellate Court (AP) reversed the summary judgment previously granted by the Court of First Instance (CFI) in our favor, dismissing the Municipality's complaint in its entirety. The AP remanded the case to the CFI for trial on the merits. The trial began in May 2022; however, the Municipality filed a new motion requesting the CFI to award damages. The request was denied by the CFI in our favor and the Municipality filed for revision at the AP, which we opposed, staying the case. This matter is ongoing. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Eastern District of Pennsylvania Pricing (Average Manufacturer Price) Inquiry</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2014, we, along with another pharmaceutical manufacturer, were named as co-defendants in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">United States et al. ex rel. Streck v. Takeda Pharm. Am., Inc., et al.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which was filed in November 2014 and unsealed in the U.S. District Court for the Northern District of Illinois. The complaint alleges that the defendants should have treated certain credits from distributors as retroactive price increases and included such increases in calculating average manufacturer prices. Following a trial in August 2022, the jury returned a verdict in favor of the plaintiff. The case is proceeding with post-trial motions after which the court will enter final judgment in the case. This matter is ongoing.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Health Choice Alliance </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are named as a defendant in two lawsuits filed in Texas and New Jersey state courts in October 2019 seeking damages under the Texas Medicaid Fraud Prevention Act and New Jersey Medicaid False Claims Act, respectively, for certain patient support programs related to our products Humalog, Humulin, and Forteo. The Texas state court action has been stayed. The New Jersey state court action was dismissed with prejudice pending an ongoing appeal before the Appellate Division of the New Jersey Superior Court. This matter is ongoing.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Pricing Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2017 and February 2018, we, along with Sanofi and Novo Nordisk, were named as defendants in a consolidated purported class action lawsuit, In re. Insulin Pricing Litigation and in MSP Recovery Claims, Series, LLC et al. v. Sanofi Aventis U.S. LLC et al., both filed in the U.S. District Court for the District of New Jersey. The cases relate to insulin pricing and seek damages or other relief under various theories, including state consumer protection laws, common law fraud, unjust enrichment, and the Federal Racketeer Influenced and Corrupt Organization Act (federal RICO Act). In both cases, the court dismissed claims under the federal RICO Act and certain state laws. In April 2021, the plaintiffs in In re. Insulin Pricing Litigation amended their complaint to allege additional state law claims for civil conspiracy and violations of state RICO statutes. The court allowed the Arizona RICO statute and certain state civil conspiracy law claims to proceed. Additionally in 2020, we, along with Sanofi, Novo Nordisk, CVS, Express Scripts, and Optum, have been sued in a putative class action, FWK Holdings, LLC v. Novo Nordisk Inc., et al., filed in the same court, for alleged violations of the federal RICO Act as well as the New Jersey RICO Act and antitrust law. The same group of defendants, along with Medco Health and United Health Group, also have been sued in other purported class actions in the same court, Rochester Drug Co-Operative Inc. v. Eli Lilly &amp; Co. et al. and Value Drug Co. v. Eli Lilly &amp; Co. et al., which were both initiated in March 2020, with the plaintiffs seeking damages for alleged violations of the federal RICO Act. In September 2020, the U.S. District Court for the District of New Jersey granted plaintiffs' motion to consolidate FWK Holdings, LLC v. Novo Nordisk Inc., et al., Rochester Drug Co-Operative Inc. v. Eli Lilly &amp; Co. et al., and Value Drug Co. v. Eli Lilly &amp; Co. et al. In July 2021, the U.S. District Court for the District of New Jersey dismissed the three antitrust claims alleged by plaintiffs in the consolidated litigation and denied dismissal of the federal RICO Act claims.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, the Minnesota Attorney General's Office initiated litigation against us, Sanofi, and Novo Nordisk, State of Minnesota v. Sanofi-Aventis U.S. LLC et al., in the U.S. District Court for the District of New Jersey, seeking damages for unjust enrichment, violations of various Minnesota state consumer protection laws, and the federal RICO Act. In March 2021, the U.S. District Court for the District of New Jersey dismissed with prejudice the Minnesota Attorney General's federal RICO claims and false advertising claims under state law; the consumer fraud and other related state law claims remain ongoing. Additionally, in May 2019, the Kentucky Attorney General's Office filed a complaint against us, Sanofi, and Novo Nordisk, Commonwealth of Kentucky v. Novo Nordisk, Inc. et al., in Kentucky state court, alleging violations of the Kentucky consumer protection law, false advertising, and unjust enrichment.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021, the Mississippi Attorney General's Office initiated litigation against us, Sanofi, Novo Nordisk, Evernorth/ESI, CVS/Caremark, and United/Optum in the Hinds County, Mississippi Chancery Court, alleging state law consumer protection, unjust enrichment, and civil conspiracy claims. After the case was removed to federal court, we, along with the other defendants, filed a motion to dismiss the lawsuit, which was denied. This matter is ongoing.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2022, the state of Arkansas filed suit against us Sanofi, Novo Nordisk, ESI, CVS/Caremark/Aetna, and Optum, asserting state law consumer protection, civil conspiracy, and unjust enrichment claims. The case has been removed to federal court and is ongoing.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2022, the County of Albany, New York filed a suit against us, Sanofi, Novo Nordisk, Evernorth/ESI, CVS/Caremark and United/Optum asserting violations of federal RICO statute and state law claims for deceptive trade practices, unjust enrichment, and civil conspiracy. This matter is ongoing.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2022, the State of Montana filed a suit against us, Sanofi, Novo Nordisk, Evernorth/ESI, Medco Health Solutions, CVS/Caremark and Optum asserting violations of the Montana Unfair Practices and Consumer Protection Act, unjust enrichment, and civil conspiracy. This matter is ongoing.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Investigations, Subpoenas, and Inquiries</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the pricing and sale of our insulin and other products, we have been subject to various investigations and received subpoenas, civil investigative demand requests, information requests, interrogatories, and other inquiries from various governmental entities. These include subpoenas from the New York and Vermont Attorney General Offices, civil investigative demands from the Washington, New Mexico, Colorado, Illinois, Ohio Attorney General Offices, the Department of Justice and the Federal Trade Commission, as well as information requests from the Mississippi, Washington D.C., California, Florida, Hawaii, and Nevada Attorney General Offices. In January 2022, the Michigan Attorney General filed a petition in Michigan state court seeking authorization to investigate Lilly for potential violations of the Michigan Consumer Protection Act (MCPA), and a complaint seeking a declaratory judgment that the Attorney General has authority to investigate Lilly's sale of insulin under the MCPA. The court authorized the proposed investigation and the issuance of civil investigative subpoenas. In April 2022, the parties entered into a stipulation providing that the State will not issue any civil investigative subpoena to us under the MCPA until the declaratory judgment action is resolved. In July 2022, the court dismissed the case in its entirety. The Michigan Attorney General filed a notice of appeal and an application to obtain review by the Michigan Supreme Court, which remain pending. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We received a request in January 2019 from the House of Representatives' Committee on Oversight and Reform seeking commercial information and business records related to the pricing of insulin products, among other issues. We also received similar requests from the Senate Finance Committee and the Senate Committee on Health, Education, Labor, and Pensions, and separate requests from the House Committee on Energy and Commerce majority and minority members. In January 2021, the Senate Finance Committee released a report summarizing the findings of its investigation. In December 2021 the House of Representatives' Committee on Oversight and Reform majority and minority staffs released separate reports with findings from their investigations into drug pricing, including of insulin products.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are cooperating with all of the aforementioned investigations, subpoenas, and inquiries.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Research Corporation Technologies, Inc.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2016, we were named as a defendant in litigation filed by Research Corporation Technologies, Inc. (RCT) in the U.S. District Court for the District of Arizona. RCT is seeking damages for breach of contract, unjust enrichment, and conversion related to processes used to manufacture certain products, including Humalog and Humulin. In October 2021, the court issued a summary judgment decision finding in favor of RCT on certain issues, including with respect to a disputed royalty. Both parties filed motions for reconsideration, which were denied. We filed supplemental summary judgment motions. A trial date has not been set. Potential damages payable under the litigation, if finally awarded after an appeal, could be material but are not currently reasonably estimable. This matter is ongoing.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140554511170304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Comprehensive Income (Loss)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNoteTextBlock', window );">Other Comprehensive Income (Loss)</a></td>
<td class="text">Other Comprehensive Income (Loss)<div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the activity related to each component of other comprehensive income (loss) during the three months ended September&#160;30, 2022 and 2021:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.420%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.601%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Amounts presented net of taxes)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Foreign Currency Translation Gains&#160;(Losses)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Unrealized Net Gains (Losses) on&#160;Securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Defined Benefit Pension and Retiree&#160;Health Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Effective Portion of Cash&#160;Flow Hedges</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Loss</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at July 1, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,844.2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(27.9)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2,443.2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">27.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(4,287.7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(165.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(24.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">47.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">63.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(79.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net amount reclassified from accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">57.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">71.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(165.1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(11.4)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">105.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">63.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(8.1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September&#160;30, 2022</span></div></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2,009.3)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(39.3)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2,338.2)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">91.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(4,295.8)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.420%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.601%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Amounts presented net of taxes)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Foreign Currency Translation Gains&#160;(Losses)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Unrealized Net Gains (Losses) on&#160;Securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Defined Benefit Pension and Retiree&#160;Health Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Effective Portion of Cash&#160;Flow Hedges</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Loss</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at July 1, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,516.2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,569.9)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(210.1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,287.1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net amount reclassified from accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.0)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.3)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September&#160;30, 2021</span></div></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,524.2)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,465.3)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(190.0)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,172.7)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the activity related to each component of other comprehensive income (loss) during the nine months ended September&#160;30, 2022 and 2021: </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.420%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.601%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Amounts presented net of taxes)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Foreign Currency Translation Gains&#160;(Losses)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Unrealized Net Gains (Losses) on&#160;Securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Defined Benefit Pension and Retiree&#160;Health Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Effective Portion of Cash&#160;Flow Hedges</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Loss</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January 1, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,550.2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2,583.6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(213.0)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(4,343.1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(459.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(55.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">72.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">297.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(145.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net amount reclassified from accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">172.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">192.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(459.1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(43.0)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">245.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">304.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">47.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September&#160;30, 2022</span></div></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2,009.3)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(39.3)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2,338.2)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">91.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(4,295.8)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.420%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.601%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Amounts presented net of taxes)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Foreign Currency Translation Gains&#160;(Losses)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Unrealized Net Gains (Losses) on&#160;Securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Defined Benefit Pension and Retiree&#160;Health Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Effective Portion of Cash&#160;Flow Hedges</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Loss</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January 1, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,427.5)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,751.0)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(332.7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,496.4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(96.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net amount reclassified from accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">269.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(96.7)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.0)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">323.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September&#160;30, 2021</span></div></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,524.2)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,465.3)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(190.0)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,172.7)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tax effects on the net activity related to each component of other comprehensive income (loss) were as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.613%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.206%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Tax benefit (expense) </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation gains/losses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(133.3)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39.0)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(234.2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(92.3)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized net gains/losses on securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Defined benefit pension and retiree health benefit plans</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(22.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(73.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(79.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective portion of cash flow hedges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(16.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(80.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit (expense) for income taxes allocated to other comprehensive income (loss) items</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(169.2)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(71.8)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(375.1)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(206.1)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except for the tax effects of foreign currency translation gains and losses related to our foreign currency-denominated notes, cross-currency interest rate swaps, and other foreign currency exchange contracts designated as net investment hedges (see Note 6), income taxes were not provided for foreign currency translation. Generally, the assets and liabilities of foreign operations are translated into U.S. dollars using the current exchange rate. For those operations, changes in exchange rates generally do not affect cash flows; therefore, resulting translation adjustments are made in shareholders' equity rather than in the consolidated condensed statements of operations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reclassifications out of accumulated other comprehensive loss were as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.718%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.830%"/><td style="width:0.1%"/></tr><tr style="height:14pt"><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Details about Accumulated Other Comprehensive Loss Components</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Affected Line Item in the Consolidated Condensed Statements of Operations</span></td></tr><tr style="height:6pt"><td colspan="30" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of retirement benefit items:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior service benefits, net</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(13.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(39.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#8211;net, (income) expense</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actuarial losses, net</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">85.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">257.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">368.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#8211;net, (income) expense</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total before tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">72.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">218.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">327.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax benefit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(15.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(45.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(68.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net of tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">57.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">172.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net of tax</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">19.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#8211;net, (income) expense</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total reclassifications, net of tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">71.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89.4&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">192.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">269.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNoteTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -URI https://asc.fasb.org/topic&amp;trid=2134417<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNoteTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140554511124432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other&#8211;Net, (Income) Expense<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Nonoperating Income (Expense) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock', window );">Other&#8211;Net, (Income) Expense</a></td>
<td class="text">Other&#8211;Net, (Income) Expense<div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other&#8211;net, (income) expense consisted of the following:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.613%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.206%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">81.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">247.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(20.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(37.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment (gains) losses on equity securities (Note 6)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">123.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">667.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(270.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retirement benefit plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(92.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(72.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(280.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(217.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt extinguishment loss (Note 6)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">405.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">405.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (income) expense </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">18.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(17.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#8211;net, (income) expense</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">111.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">635.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">580.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other income or other expense items (both operating and nonoperating). Sources of nonoperating income or nonoperating expense that may be disclosed, include amounts earned from dividends, interest on securities, profits (losses) on securities, net and miscellaneous other income or income deductions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -URI https://asc.fasb.org/topic&amp;trid=2122503<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 610<br> -URI https://asc.fasb.org/topic&amp;trid=49130413<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140554505509104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Implementation of New Financial Accounting Standard (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses and Acquired In-Process Research and Development (IPR&amp;D) and Developmental Milestones</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development Expenses and Acquired In-Process Research and Development (IPR&amp;D) and Development Milestones</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are expensed as incurred. Research and development costs consist of expenses incurred in performing research and development activities, including but not limited to, compensation and benefits, facilities and overhead expense, clinical trial expense, and fees paid to contract research organizations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquired IPR&amp;D and development milestones include the initial costs of externally developed IPR&amp;D projects, acquired directly in a transaction other than a business combination, that do not have an alternative future use. Additionally, milestone payment obligations related to these transactions that are incurred prior to regulatory approval of the compound are expensed when the event triggering an obligation to pay the milestone occurs.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Implementation of New Financial Accounting Standard</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Implementation of New Financial Accounting Standard</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounting Standards Update 2021-01, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reference Rate Reform</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, provides for temporary optional expedients and exceptions in applying current GAAP to contracts, hedging relationships, and other transactions affected by the transition from the use of the London Interbank Offered Rate (LIBOR) to an alternative reference rate. The standard is currently applicable to contracts entered into before January 1, 2023. We adopted the standard in the first quarter of 2022. The adoption did not have a material impact on our consolidated condensed financial statements.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationsPolicy', window );">Business Combinations</a></td>
<td class="text">Under this method, the assets acquired and liabilities assumed were recorded at their respective fair values as of the acquisition date in our consolidated condensed financial statements. The determination of estimated fair value required management to make significant estimates and assumptions. The excess of the purchase price over the fair value of the acquired net assets, where applicable, has been recorded as goodwill. The results of operations of this acquisition is included in our consolidated condensed financial statements from the date of acquisition.Upon each acquisition, the cost allocated to acquired IPR&amp;D is immediately expensed if the compound has no alternative future use. Milestone payment obligations incurred prior to regulatory approval of the compound are expensed when the event triggering an obligation to pay the milestone occurs.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Description of Derivative Risk Management</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our derivative activities are initiated within the guidelines of documented corporate risk-management policies and are intended to offset losses and gains on the assets, liabilities, and transactions being hedged. Management reviews the correlation and effectiveness of our derivatives on a quarterly basis.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For derivative instruments that are designated and qualify as fair value hedges, the derivative instrument is marked to market, with gains and losses recognized currently in income to offset the respective losses and gains recognized on the underlying exposure. For derivative instruments that are designated and qualify as cash flow hedges, gains and losses are reported as a component of accumulated other comprehensive loss and reclassified into earnings in the same period the hedged transaction affects earnings. For derivative and non-derivative instruments that are designated and qualify as net investment hedges, the foreign currency translation gains or losses due to spot rate fluctuations are reported as a component of accumulated other comprehensive loss. Derivative contracts that are not designated as hedging instruments are recorded at fair value with the gain or loss recognized in earnings during the period of change.</span></div>We may enter into foreign currency forward or option contracts to reduce the effect of fluctuating currency exchange rates (principally the euro, British pound, Chinese yuan, and Japanese yen). Foreign currency derivatives used for hedging are put in place using the same or like currencies and duration as the underlying exposures. Forward and option contracts are principally used to manage exposures arising from subsidiary trade and loan payables and receivables denominated in foreign currencies. These contracts are recorded at fair value with the gain or loss recognized in other&#8211;net, (income) expense. We may enter into foreign currency forward and option contracts and currency swaps as fair value hedges of firm commitments. Forward contracts generally have maturities not exceeding 12 months.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock', window );">Contingencies</a></td>
<td class="text">Litigation accruals, environmental liabilities, and the related estimated insurance recoverables are reflected on a gross basis as liabilities and assets, respectively, on our consolidated condensed balance sheets. With respect to the product liability claims currently asserted against us, we have accrued for our estimated exposures to the extent they are both probable and reasonably estimable based on the information available to us. We accrue for certain product liability claims incurred but not filed to the extent we can formulate a reasonable estimate of their costs. We estimate these expenses based primarily on historical claims experience and data regarding product usage. Legal defense costs expected to be incurred in connection with significant product liability loss contingencies are accrued when both probable and reasonably estimable.Because of the nature of pharmaceutical products, it is possible that we could become subject to large numbers of additional product liability and related claims in the future. Due to a very restrictive market for litigation liability insurance, we are self-insured for litigation liability losses for all our currently and previously marketed products.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -Subparagraph (a)-(d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6909625&amp;loc=d3e227-128457<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126907703&amp;loc=d3e12565-110249<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 450<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6491354&amp;loc=d3e6049-115624<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41620-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41638-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41675-113959<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(n))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579240-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140554511108800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Schedule of disaggregation of revenue</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our revenue recognized in our consolidated condensed statements of operations:</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.613%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.206%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,119.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,189.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">19,123.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,579.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration and other revenue</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">822.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">583.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,116.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,739.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,941.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,772.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">21,239.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,318.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><div style="margin-top:1pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Collaboration and other revenue associated with prior period transfers of intellectual property was $43.3 million and $130.9 million during the three and nine months ended September&#160;30, 2022, respectively, and $62.1 million and $136.1 million during the three and nine months ended September&#160;30, 2021, respectively.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes revenue by product for the three months ended September&#160;30, 2022 and 2021:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.133%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.577%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outside U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outside U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue&#8212;to unaffiliated customers:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diabetes:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Trulicity</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,418.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">432.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,850.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,201.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">398.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,600.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Jardiance</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">350.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">222.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">573.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">390.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Humalog</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; (2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">248.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">198.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">447.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">347.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">279.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">626.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Humulin</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">169.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">68.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">238.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">286.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Basaglar</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">124.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">68.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">193.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Mounjaro</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">97.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">90.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">187.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other diabetes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">79.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">94.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">173.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total diabetes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,488.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,174.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,662.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,143.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,131.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,274.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oncology:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Verzenio</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">414.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">202.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">617.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">335.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Cyramza</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">87.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">144.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">232.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Erbitux</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">126.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">18.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">144.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Alimta</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">64.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">54.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">119.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">297.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">457.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Tyvyt</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">76.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">76.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other oncology</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">39.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">62.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">102.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total oncology</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">732.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">560.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,293.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">730.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">675.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,406.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Immunology:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Taltz</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">493.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">186.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">679.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">422.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">593.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Olumiant</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; (3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">22.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">160.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">182.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">212.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">406.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other immunology</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total immunology</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">516.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">349.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">866.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">616.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">388.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,004.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neuroscience:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Emgality</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">114.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">54.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">168.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Zyprexa</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">73.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">81.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Cymbalta</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">54.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">62.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other neuroscience</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">16.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">44.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">60.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total neuroscience</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">145.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">227.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">373.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">450.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">COVID-19 antibodies</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">386.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">386.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Forteo</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">112.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">64.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">177.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Cialis</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">107.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">115.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">30.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">35.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">66.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">538.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">207.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">746.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">354.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">282.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">637.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,422.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,519.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,941.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,989.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,783.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,772.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Numbers may not add due to rounding.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Jardiance revenue includes Glyxambi</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Synjardy</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">and Trijardy</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> XR. </span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Humalog revenue includes insulin lispro. </span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Olumiant revenue includes sales for baricitinib that were made pursuant to Emergency Use Authorization (EUA) or similar regulatory authorizations.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">COVID-19 antibodies include sales for bamlanivimab administered alone, for bamlanivimab and etesevimab administered together, and for bebtelovimab and were made pursuant to EUAs or similar regulatory authorizations.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes revenue by product for the nine months ended September&#160;30, 2022 and 2021:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.133%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.577%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outside U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outside U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue&#8212;to unaffiliated customers:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diabetes:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Trulicity</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,162.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,341.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,503.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,465.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,122.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,588.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Humalog</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">855.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">656.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,512.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,009.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">842.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,851.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Jardiance</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">831.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">622.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,453.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">566.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">492.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,058.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Humulin</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">562.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">223.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">785.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">633.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">290.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">923.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Basaglar</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">339.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">218.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">558.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">423.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">650.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Mounjaro</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">109.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">93.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">203.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other diabetes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">195.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">276.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">472.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">302.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">488.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total diabetes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,057.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,431.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10,489.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,284.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,276.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,560.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oncology:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Verzenio</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,100.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">575.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,675.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">582.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">363.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">945.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Cyramza</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">259.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">434.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">693.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">266.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">496.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">762.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Alimta</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">490.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">200.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">691.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">911.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">714.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,626.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Erbitux</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">361.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">47.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">408.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">357.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">403.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Tyvyt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">235.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">235.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">340.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">340.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other oncology</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">124.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">186.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">310.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total oncology</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,335.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,679.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,015.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,201.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,130.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,332.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Immunology:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Taltz</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,212.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">561.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,774.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,071.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">493.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,565.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Olumiant</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">104.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">520.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">624.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">572.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">809.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other immunology</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total immunology</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,317.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,093.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,411.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,323.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,080.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,404.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neuroscience:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Emgality</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">330.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">144.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">475.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">313.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">415.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Zyprexa</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">26.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">235.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">261.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">292.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Cymbalta</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">25.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">194.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">219.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">454.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">484.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other neuroscience</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">62.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">142.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">204.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">235.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total neuroscience</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">444.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">716.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,160.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">453.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">974.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,427.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">COVID-19 antibodies</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,970.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,985.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">949.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,176.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Cialis</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">25.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">454.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">480.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">541.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">538.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Forteo</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">261.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">191.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">453.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">330.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">287.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">617.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">119.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">125.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">244.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">260.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,377.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">786.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,163.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,373.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,220.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,593.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13,531.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,708.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">21,239.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,635.1&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,683.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,318.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Numbers may not add due to rounding.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Humalog revenue includes insulin lispro.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Jardiance revenue includes Glyxambi,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Synjardy,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">and Trijardy XR.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Olumiant revenue includes sales for baricitinib that were made pursuant to EUA or similar regulatory authorizations.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">COVID-19 antibodies include sales for bamlanivimab administered alone, for bamlanivimab and etesevimab administered together, and for bebtelovimab and were made pursuant to EUAs or similar regulatory authorizations.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes revenue by geographical area:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.613%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.206%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue&#8212;to unaffiliated customers</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,422.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,989.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13,531.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,635.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,056.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,098.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,224.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,629.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">487.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">595.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,352.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,832.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">343.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,102.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,285.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other foreign countries</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">632.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">689.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,029.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,936.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,941.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,772.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">21,239.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,318.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Numbers may not add due to rounding.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Revenue is attributed to the countries based on the location of the customer.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock', window );">Schedule of amounts recorded for contract liabilities</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes contract liability balances:</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.420%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.274%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.276%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">232.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">262.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140554511225984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination and Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">Schedule of the amounts recognized for assets acquired and liabilities assumed</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the amounts recognized for assets acquired and liabilities assumed as of the acquisition date:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:79.016%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.784%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value at January 22, 2021</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired IPR&amp;D</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">824.0</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126.8</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(106.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets and liabilities, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition date fair value of consideration transferred </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">903.8</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash acquired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(90.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of CVR liability</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(65.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid, net of cash acquired</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">747.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Acquired IPR&amp;D intangibles primarily relate to PR001. In the third quarter of 2022, we impaired the intangible asset related to PR001. See Note 5 for additional information.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The goodwill recognized from this acquisition is not deductible for tax purposes. </span></div>(3) See Note 6 for a discussion on the estimation of the CVR liability.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock', window );">Schedule of asset acquisitions</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our significant asset acquisitions during the nine months ended September&#160;30, 2022 and 2021:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:26.531%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:27.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.104%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.916%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Counterparty</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Compound(s), Therapy or Asset</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Acquisition Month</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Phase of Development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Acquired IPR&amp;D Expense</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BioMarin Pharmaceutical Inc.</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Priority Review Voucher</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Not applicable</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">110.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rigel Pharmaceuticals, Inc.</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R552, a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor, for the potential treatment of autoimmune and inflammatory diseases</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase I</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Precision Biosciences, Inc. </span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Potential in vivo therapies for genetic disorders</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2021</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span>The phase of development presented is as of the date of the arrangement and represents the phase of development of the most advanced asset acquired, where applicable.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the nature and amounts of capitalized costs of a research and development nature that were acquired in a transaction other than a business combination, the amount of such assets charged to expense during the period, and identification of the income statement caption in which the charges are included.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140554511071776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborations and Other Arrangements (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock', window );">Schedule of significant milestones and revenue recognized</a></td>
<td class="text">The table below summarizes the net milestones capitalized with respect to the Jardiance and Trajenta families of products and the net milestones deferred with respect to Basaglar as of September&#160;30, 2022 and December&#160;31, 2021: <div style="margin-top:6pt;padding-left:9pt;text-indent:-9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.812%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.445%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Milestones Capitalized (Deferred)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jardiance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">121.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trajenta</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">69.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basaglar</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(135.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(149.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">This represents the amounts that have been capitalized (deferred) from the start of this collaboration through the end of the reporting period, net of amount amortized. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our collaboration and other revenue recognized with respect to the Jardiance and Trajenta families of products and net product revenue recognized with respect to Basaglar:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.613%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.206%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jardiance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">573.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">390.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,453.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,058.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basaglar</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">193.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">558.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">650.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trajenta</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">103.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">293.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">279.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div>The following table summarizes our net product revenue recognized with respect to Olumiant:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.613%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.206%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Olumiant</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">182.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">406.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">624.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">809.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table>The following table summarizes our revenue recognized in China with respect to Tyvyt:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.613%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.206%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tyvyt</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">76.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">235.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">340.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140554511130592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Asset Impairment, Restructuring, and Other Special Charges (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock', window );">Schedule of components of the charges included in asset impairment, restructuring, and other special charges</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of the charges included in asset impairment, restructuring, and other special charges in our consolidated condensed statements of operations are described below. </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.613%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.206%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Severance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset impairment and other special charges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">206.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">206.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total asset impairment, restructuring, and other special charges</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">206.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">206.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 5.P.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140554505641296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock', window );">Schedule of effects of risk-management instruments were recognized in other&#8211;net, (income) expense</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following effects of risk-management instruments were recognized in other&#8211;net, (income) expense:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.800%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.157%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.157%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.157%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.160%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value hedges:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect from hedged fixed-rate debt</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(62.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(215.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect from interest rate contracts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">62.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">215.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flow hedges:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective portion of losses on interest rate contracts reclassified from accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency interest rate swaps</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">33.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">75.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (gains) losses on foreign currency exchange contracts not designated as hedging instruments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">129.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">280.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">166.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">368.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Schedule of effective portion of risk-management instruments that was recognized in other comprehensive income (loss), net investment hedges</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective portion of risk-management instruments that was recognized in other comprehensive income (loss) is as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.613%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.206%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment hedges:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency-denominated notes</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">435.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">822.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">268.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency interest rate swaps</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">92.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">171.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forward contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">107.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">121.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flow hedges:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward-starting interest rate swaps</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">57.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">337.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency interest rate swaps</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">19.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">38.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Schedule of effective portion of risk-management instruments that was recognized in other comprehensive income (loss), cash flow hedges</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective portion of risk-management instruments that was recognized in other comprehensive income (loss) is as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.613%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.206%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment hedges:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency-denominated notes</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">435.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">822.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">268.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency interest rate swaps</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">92.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">171.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forward contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">107.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">121.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flow hedges:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward-starting interest rate swaps</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">57.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">337.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency interest rate swaps</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">19.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">38.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Summary certain fair value information, assets</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize certain fair value information at September&#160;30, 2022 and December&#160;31, 2021 for assets and liabilities measured at fair value on a recurring basis, as well as the carrying amount and amortized cost of certain other investments:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:34.624%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.466%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.714%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices in Active Markets for Identical Assets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Other<br/>Observable Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,246.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,246.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,239.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">7.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,246.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term investments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">43.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">43.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">43.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">43.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">51.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">51.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">51.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">51.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">27.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">27.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">14.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">12.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">27.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term investments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">124.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncurrent investments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">131.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">148.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">131.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">131.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">206.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">232.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">206.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">206.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">143.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">156.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">143.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">143.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">43.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">45.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">43.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">43.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">152.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">96.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">39.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">113.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">152.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">549.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">416.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">549.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">549.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity investments without readily determinable fair values</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">583.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity method investments</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">764.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncurrent investments</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,574.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,379.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,379.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,361.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,379.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term investments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term investments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">90.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncurrent investments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">137.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">136.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">137.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">137.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">235.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">232.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">235.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">235.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">109.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">108.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">109.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">109.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">108.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">108.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">108.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,279.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">487.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,279.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,279.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity investments without readily determinable fair values</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">548.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity method investments</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">771.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncurrent investments</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,212.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">For available-for-sale debt securities, amounts disclosed represent the securities' amortized cost.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Fair value disclosures are not applicable for equity method investments and investments accounted for under the measurement alternative for equity investments.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock', window );">Summary certain fair value information, liabilities</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:38.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.320%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.320%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.320%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.320%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.322%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices in Active Markets for Identical Assets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Other Observable Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Short-term commercial paper borrowings</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 30, 2022</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,741.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,738.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,738.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Long-term debt, including current portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 30, 2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(14,147.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(11,848.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(11,848.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,884.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,157.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,157.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByBalanceSheetGroupingTextBlock', window );">Schedule of fair value, by balance sheet grouping</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:37.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.517%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.517%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.517%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.517%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.522%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices in Active Markets for Identical Assets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Other Observable Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk-management instruments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest rate contracts designated as fair value hedges:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(140.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(140.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(140.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest rate contracts designated as cash flow hedges:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">355.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">355.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">355.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cross-currency interest rate contracts designated as net investment hedges:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">81.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">81.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">81.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">116.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">116.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">116.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cross-currency interest rate contracts designated as cash flow hedges:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">8.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">8.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">8.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(12.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(12.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(12.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign exchange contracts designated as net investment hedges:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">108.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">108.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">108.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(2.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(2.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(2.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign exchange contracts not designated as hedging instruments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">48.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">48.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">48.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(93.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(93.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(93.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent consideration liability:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(42.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(42.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(42.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk-management instruments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest rate contracts designated as fair value hedges:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other receivables</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">78.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">78.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">78.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest rate contracts designated as cash flow hedges:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(31.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(31.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(31.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cross-currency interest rate contracts designated as net investment hedges:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cross-currency interest rate contracts designated as cash flow hedges:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign exchange contracts not designated as hedging instruments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(35.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(35.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(35.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent consideration liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(70.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(70.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(70.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Summary the contractual maturities of our investments in debt securities measured at fair value</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes the contractual maturities of our investments in debt securities measured at fair value as of September&#160;30, 2022:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:40.162%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.062%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maturities by Period</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less&#160;Than<br/>1 Year</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1-5<br/>Years</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">6-10<br/>Years</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">More&#160;Than<br/>10 Years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of debt securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">622.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock', window );">Summary of the fair value of available-for-sale securities in an unrealized gain or loss position</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the amount of unrealized gains and losses in accumulated other comprehensive loss and the fair value of available-for-sale securities in an unrealized gain or loss position follows:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:66.249%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.859%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.860%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gross gains</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gross losses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">51.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of securities in an unrealized gain position</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of securities in an unrealized loss position</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">578.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">290.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnInvestmentsTextBlock', window );">Schedule of activity related to our available-for-sale securities</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Activity related to our available-for-sale securities was as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.613%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.206%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">50.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">115.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Realized gross gains on sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Realized gross losses on sales</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI https://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByBalanceSheetGroupingTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13467-108611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByBalanceSheetGroupingTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnInvestmentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of realized and unrealized gain (loss) on investment in security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnInvestmentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of gain (loss) on derivative and nonderivative instruments designated and qualifying as cash flow hedge recorded in accumulated other comprehensive income (AOCI) and reclassified into earnings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of derivative instruments (including nonderivative instruments that are designated and qualify as hedging instruments) of (a) the location and amount of gains and losses reported in the statement of financial performance and (b) the location and fair value amounts of the instruments reported in the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the effective portion of gains and losses on derivative instruments (and nonderivative instruments) designated and qualifying in net investment hedges recorded in accumulated other comprehensive income (loss) during the term of the hedging relationship and reclassified into earnings during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CCC<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL109998896-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of unrealized gains and losses on investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140554511097440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Retirement Benefits (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock', window );">Schedule of net pension and retiree health benefit (income) cost</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net pension and retiree health benefit (income) cost included the following components:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.613%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.206%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Defined Benefit Pension Plans</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Components of net periodic benefit cost:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">87.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">264.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">277.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">98.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">299.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(235.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(237.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(711.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(712.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of prior service cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognized actuarial loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">85.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">256.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">366.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic benefit cost</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">36.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62.4&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">110.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.613%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.206%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Retiree Health Benefit Plans</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Components of net periodic benefit income:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">35.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">28.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(38.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(114.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(109.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of prior service benefit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(13.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(41.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognized actuarial loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic benefit income</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(30.4)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30.1)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(91.1)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(90.5)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net benefit costs for pension plans and/or other employee benefit plans including service cost, interest cost, expected return on plan assets, gain (loss), prior service cost or credit, transition asset or obligation, and gain (loss) recognized due to settlements or curtailments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNetBenefitCostsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140554511116512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Comprehensive Income (Loss) (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Schedule of components of other comprehensive income (loss)</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the activity related to each component of other comprehensive income (loss) during the three months ended September&#160;30, 2022 and 2021:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.420%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.601%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Amounts presented net of taxes)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Foreign Currency Translation Gains&#160;(Losses)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Unrealized Net Gains (Losses) on&#160;Securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Defined Benefit Pension and Retiree&#160;Health Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Effective Portion of Cash&#160;Flow Hedges</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Loss</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at July 1, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,844.2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(27.9)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2,443.2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">27.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(4,287.7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(165.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(24.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">47.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">63.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(79.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net amount reclassified from accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">57.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">71.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(165.1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(11.4)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">105.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">63.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(8.1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September&#160;30, 2022</span></div></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2,009.3)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(39.3)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2,338.2)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">91.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(4,295.8)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.420%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.601%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Amounts presented net of taxes)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Foreign Currency Translation Gains&#160;(Losses)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Unrealized Net Gains (Losses) on&#160;Securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Defined Benefit Pension and Retiree&#160;Health Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Effective Portion of Cash&#160;Flow Hedges</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Loss</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at July 1, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,516.2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,569.9)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(210.1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,287.1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net amount reclassified from accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.0)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.3)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September&#160;30, 2021</span></div></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,524.2)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,465.3)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(190.0)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,172.7)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the activity related to each component of other comprehensive income (loss) during the nine months ended September&#160;30, 2022 and 2021: </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.420%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.601%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Amounts presented net of taxes)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Foreign Currency Translation Gains&#160;(Losses)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Unrealized Net Gains (Losses) on&#160;Securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Defined Benefit Pension and Retiree&#160;Health Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Effective Portion of Cash&#160;Flow Hedges</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Loss</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January 1, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,550.2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2,583.6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(213.0)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(4,343.1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(459.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(55.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">72.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">297.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(145.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net amount reclassified from accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">172.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">192.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(459.1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(43.0)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">245.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">304.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">47.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September&#160;30, 2022</span></div></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2,009.3)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(39.3)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2,338.2)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">91.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(4,295.8)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.420%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.601%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Amounts presented net of taxes)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Foreign Currency Translation Gains&#160;(Losses)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Unrealized Net Gains (Losses) on&#160;Securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Defined Benefit Pension and Retiree&#160;Health Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Effective Portion of Cash&#160;Flow Hedges</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Loss</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January 1, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,427.5)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,751.0)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(332.7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,496.4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(96.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net amount reclassified from accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">269.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(96.7)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.0)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">323.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September&#160;30, 2021</span></div></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,524.2)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,465.3)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(190.0)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,172.7)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tax effects on the net activity related to each component of other comprehensive income (loss) were as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.613%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.206%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Tax benefit (expense) </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation gains/losses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(133.3)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39.0)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(234.2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(92.3)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized net gains/losses on securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Defined benefit pension and retiree health benefit plans</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(22.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(73.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(79.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective portion of cash flow hedges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(16.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(80.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit (expense) for income taxes allocated to other comprehensive income (loss) items</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(169.2)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(71.8)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(375.1)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(206.1)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock', window );">Schedule of reclassifications out of accumulated other comprehensive loss</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reclassifications out of accumulated other comprehensive loss were as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.718%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.830%"/><td style="width:0.1%"/></tr><tr style="height:14pt"><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Details about Accumulated Other Comprehensive Loss Components</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Affected Line Item in the Consolidated Condensed Statements of Operations</span></td></tr><tr style="height:6pt"><td colspan="30" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of retirement benefit items:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior service benefits, net</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(13.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(39.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#8211;net, (income) expense</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actuarial losses, net</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">85.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">257.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">368.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#8211;net, (income) expense</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total before tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">72.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">218.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">327.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax benefit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(15.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(45.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(68.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net of tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">57.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">172.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net of tax</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">19.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#8211;net, (income) expense</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total reclassifications, net of tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">71.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89.4&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">192.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">269.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information about items reclassified out of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140554511057296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other&#8211;Net, (Income) Expense (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Nonoperating Income (Expense) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock', window );">Schedule of other&#8211;net, (income) expense</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other&#8211;net, (income) expense consisted of the following:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.613%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.206%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">81.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">247.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(20.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(37.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment (gains) losses on equity securities (Note 6)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">123.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">667.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(270.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retirement benefit plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(92.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(72.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(280.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(217.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt extinguishment loss (Note 6)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">405.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">405.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (income) expense </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">18.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(17.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#8211;net, (income) expense</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">111.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">635.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">580.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140554512599712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue (Summary of Revenue Recognized) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">$ 6,941.6<span></span>
</td>
<td class="nump">$ 6,772.8<span></span>
</td>
<td class="nump">$ 21,239.6<span></span>
</td>
<td class="nump">$ 20,318.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Net product revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">6,119.2<span></span>
</td>
<td class="nump">6,189.0<span></span>
</td>
<td class="nump">19,123.0<span></span>
</td>
<td class="nump">18,579.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_CollaborationandOtherRevenueMember', window );">Collaboration and other revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">822.4<span></span>
</td>
<td class="nump">583.8<span></span>
</td>
<td class="nump">2,116.6<span></span>
</td>
<td class="nump">1,739.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember', window );">Collaboration and other revenue associated with prior period transfers of intellectual property</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">$ 43.3<span></span>
</td>
<td class="nump">$ 62.1<span></span>
</td>
<td class="nump">$ 130.9<span></span>
</td>
<td class="nump">$ 136.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_CollaborationandOtherRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_CollaborationandOtherRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_RoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140554512600640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue (Adjustments to Revenue) (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">U.S. | Sales returns, rebates, and discounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingEstimateLineItems', window );"><strong>Change in Accounting Estimate [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lly_RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent', window );">Revenue, information used to determine revenue recognized, change in accounting estimate, percent (less than)</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue, Information Used To Determine Revenue Recognized, Change In Accounting Estimate, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingEstimateLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingEstimateLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingEstimateByTypeAxis=us-gaap_SalesReturnsAndAllowancesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingEstimateByTypeAxis=us-gaap_SalesReturnsAndAllowancesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140554511108928">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Revenue (Contract Liabilities) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract liabilities</a></td>
<td class="nump">$ 232.5<span></span>
</td>
<td class="nump">$ 262.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140554500130368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue (Disaggregation of Revenue by Product) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">$ 6,941.6<span></span>
</td>
<td class="nump">$ 6,772.8<span></span>
</td>
<td class="nump">$ 21,239.6<span></span>
</td>
<td class="nump">$ 20,318.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">4,422.1<span></span>
</td>
<td class="nump">3,989.6<span></span>
</td>
<td class="nump">13,531.5<span></span>
</td>
<td class="nump">11,635.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">2,519.4<span></span>
</td>
<td class="nump">2,783.3<span></span>
</td>
<td class="nump">7,708.1<span></span>
</td>
<td class="nump">8,683.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_DiabetesMember', window );">Diabetes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">3,662.6<span></span>
</td>
<td class="nump">3,274.1<span></span>
</td>
<td class="nump">10,489.0<span></span>
</td>
<td class="nump">9,560.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_DiabetesMember', window );">Diabetes | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">2,488.6<span></span>
</td>
<td class="nump">2,143.0<span></span>
</td>
<td class="nump">7,057.3<span></span>
</td>
<td class="nump">6,284.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_DiabetesMember', window );">Diabetes | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">1,174.0<span></span>
</td>
<td class="nump">1,131.1<span></span>
</td>
<td class="nump">3,431.6<span></span>
</td>
<td class="nump">3,276.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_TrulicityMember', window );">Trulicity&#174;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">1,850.4<span></span>
</td>
<td class="nump">1,600.1<span></span>
</td>
<td class="nump">5,503.5<span></span>
</td>
<td class="nump">4,588.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_TrulicityMember', window );">Trulicity&#174; | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">1,418.3<span></span>
</td>
<td class="nump">1,201.4<span></span>
</td>
<td class="nump">4,162.4<span></span>
</td>
<td class="nump">3,465.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_TrulicityMember', window );">Trulicity&#174; | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">432.0<span></span>
</td>
<td class="nump">398.8<span></span>
</td>
<td class="nump">1,341.1<span></span>
</td>
<td class="nump">1,122.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_JardianceMember', window );">Jardiance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">573.3<span></span>
</td>
<td class="nump">390.4<span></span>
</td>
<td class="nump">1,453.7<span></span>
</td>
<td class="nump">1,058.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_JardianceMember', window );">Jardiance | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">350.9<span></span>
</td>
<td class="nump">221.2<span></span>
</td>
<td class="nump">831.4<span></span>
</td>
<td class="nump">566.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_JardianceMember', window );">Jardiance | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">222.4<span></span>
</td>
<td class="nump">169.2<span></span>
</td>
<td class="nump">622.4<span></span>
</td>
<td class="nump">492.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_HumalogMember', window );">Humalog&#174;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">447.0<span></span>
</td>
<td class="nump">626.7<span></span>
</td>
<td class="nump">1,512.3<span></span>
</td>
<td class="nump">1,851.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_HumalogMember', window );">Humalog&#174; | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">248.1<span></span>
</td>
<td class="nump">347.3<span></span>
</td>
<td class="nump">855.8<span></span>
</td>
<td class="nump">1,009.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_HumalogMember', window );">Humalog&#174; | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">198.8<span></span>
</td>
<td class="nump">279.4<span></span>
</td>
<td class="nump">656.4<span></span>
</td>
<td class="nump">842.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_HumulinMember', window );">Humulin&#174;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">238.2<span></span>
</td>
<td class="nump">286.7<span></span>
</td>
<td class="nump">785.4<span></span>
</td>
<td class="nump">923.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_HumulinMember', window );">Humulin&#174; | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">169.5<span></span>
</td>
<td class="nump">193.4<span></span>
</td>
<td class="nump">562.3<span></span>
</td>
<td class="nump">633.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_HumulinMember', window );">Humulin&#174; | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">68.7<span></span>
</td>
<td class="nump">93.4<span></span>
</td>
<td class="nump">223.1<span></span>
</td>
<td class="nump">290.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_BasaglarMember', window );">Basaglar&#174;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">193.0<span></span>
</td>
<td class="nump">192.8<span></span>
</td>
<td class="nump">558.7<span></span>
</td>
<td class="nump">650.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_BasaglarMember', window );">Basaglar&#174; | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">124.8<span></span>
</td>
<td class="nump">114.7<span></span>
</td>
<td class="nump">339.9<span></span>
</td>
<td class="nump">423.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_BasaglarMember', window );">Basaglar&#174; | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">68.1<span></span>
</td>
<td class="nump">78.1<span></span>
</td>
<td class="nump">218.8<span></span>
</td>
<td class="nump">226.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_MounjaroMember', window );">Mounjaro&#174;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">187.3<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">203.2<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_MounjaroMember', window );">Mounjaro&#174; | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">97.3<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">109.9<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_MounjaroMember', window );">Mounjaro&#174; | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">90.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">93.3<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_OtherDiabetesMember', window );">Other diabetes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">173.4<span></span>
</td>
<td class="nump">177.4<span></span>
</td>
<td class="nump">472.2<span></span>
</td>
<td class="nump">488.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_OtherDiabetesMember', window );">Other diabetes | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">79.7<span></span>
</td>
<td class="nump">65.0<span></span>
</td>
<td class="nump">195.6<span></span>
</td>
<td class="nump">185.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_OtherDiabetesMember', window );">Other diabetes | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">94.0<span></span>
</td>
<td class="nump">112.2<span></span>
</td>
<td class="nump">276.5<span></span>
</td>
<td class="nump">302.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_OncologyMember', window );">Oncology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">1,293.3<span></span>
</td>
<td class="nump">1,406.1<span></span>
</td>
<td class="nump">4,015.0<span></span>
</td>
<td class="nump">4,332.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_OncologyMember', window );">Oncology | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">732.7<span></span>
</td>
<td class="nump">730.9<span></span>
</td>
<td class="nump">2,335.4<span></span>
</td>
<td class="nump">2,201.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_OncologyMember', window );">Oncology | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">560.6<span></span>
</td>
<td class="nump">675.3<span></span>
</td>
<td class="nump">1,679.6<span></span>
</td>
<td class="nump">2,130.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_VerzenioMember', window );">Verzenio&#174;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">617.7<span></span>
</td>
<td class="nump">335.5<span></span>
</td>
<td class="nump">1,675.6<span></span>
</td>
<td class="nump">945.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_VerzenioMember', window );">Verzenio&#174; | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">414.8<span></span>
</td>
<td class="nump">199.6<span></span>
</td>
<td class="nump">1,100.5<span></span>
</td>
<td class="nump">582.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_VerzenioMember', window );">Verzenio&#174; | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">202.9<span></span>
</td>
<td class="nump">135.9<span></span>
</td>
<td class="nump">575.1<span></span>
</td>
<td class="nump">363.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_CyramzaMember', window );">Cyramza&#174;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">232.1<span></span>
</td>
<td class="nump">253.4<span></span>
</td>
<td class="nump">693.6<span></span>
</td>
<td class="nump">762.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_CyramzaMember', window );">Cyramza&#174; | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">87.5<span></span>
</td>
<td class="nump">84.8<span></span>
</td>
<td class="nump">259.3<span></span>
</td>
<td class="nump">266.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_CyramzaMember', window );">Cyramza&#174; | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">144.6<span></span>
</td>
<td class="nump">168.6<span></span>
</td>
<td class="nump">434.3<span></span>
</td>
<td class="nump">496.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_ErbituxMember', window );">Erbitux&#174;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">144.9<span></span>
</td>
<td class="nump">134.3<span></span>
</td>
<td class="nump">408.3<span></span>
</td>
<td class="nump">403.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_ErbituxMember', window );">Erbitux&#174; | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">126.3<span></span>
</td>
<td class="nump">114.0<span></span>
</td>
<td class="nump">361.0<span></span>
</td>
<td class="nump">357.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_ErbituxMember', window );">Erbitux&#174; | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">18.7<span></span>
</td>
<td class="nump">20.3<span></span>
</td>
<td class="nump">47.4<span></span>
</td>
<td class="nump">45.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_AlimtaMember', window );">Alimta&#174;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">119.4<span></span>
</td>
<td class="nump">457.0<span></span>
</td>
<td class="nump">691.1<span></span>
</td>
<td class="nump">1,626.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_AlimtaMember', window );">Alimta&#174; | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">64.6<span></span>
</td>
<td class="nump">297.2<span></span>
</td>
<td class="nump">490.5<span></span>
</td>
<td class="nump">911.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_AlimtaMember', window );">Alimta&#174; | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">54.8<span></span>
</td>
<td class="nump">159.8<span></span>
</td>
<td class="nump">200.5<span></span>
</td>
<td class="nump">714.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_TYVYTMember', window );">Tyvyt&#174;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">76.8<span></span>
</td>
<td class="nump">125.6<span></span>
</td>
<td class="nump">235.8<span></span>
</td>
<td class="nump">340.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_TYVYTMember', window );">Tyvyt&#174; | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_TYVYTMember', window );">Tyvyt&#174; | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">76.8<span></span>
</td>
<td class="nump">125.6<span></span>
</td>
<td class="nump">235.8<span></span>
</td>
<td class="nump">340.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_OtherOncologyMember', window );">Other oncology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">102.4<span></span>
</td>
<td class="nump">100.3<span></span>
</td>
<td class="nump">310.6<span></span>
</td>
<td class="nump">253.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_OtherOncologyMember', window );">Other oncology | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">39.5<span></span>
</td>
<td class="nump">35.3<span></span>
</td>
<td class="nump">124.1<span></span>
</td>
<td class="nump">83.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_OtherOncologyMember', window );">Other oncology | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">62.8<span></span>
</td>
<td class="nump">65.1<span></span>
</td>
<td class="nump">186.5<span></span>
</td>
<td class="nump">169.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_ImmunologyMember', window );">Immunology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">866.4<span></span>
</td>
<td class="nump">1,004.9<span></span>
</td>
<td class="nump">2,411.0<span></span>
</td>
<td class="nump">2,404.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_ImmunologyMember', window );">Immunology | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">516.7<span></span>
</td>
<td class="nump">616.2<span></span>
</td>
<td class="nump">1,317.3<span></span>
</td>
<td class="nump">1,323.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_ImmunologyMember', window );">Immunology | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">349.7<span></span>
</td>
<td class="nump">388.7<span></span>
</td>
<td class="nump">1,093.8<span></span>
</td>
<td class="nump">1,080.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_TaltzMember', window );">Taltz&#174;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">679.9<span></span>
</td>
<td class="nump">593.1<span></span>
</td>
<td class="nump">1,774.2<span></span>
</td>
<td class="nump">1,565.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_TaltzMember', window );">Taltz&#174; | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">493.8<span></span>
</td>
<td class="nump">422.2<span></span>
</td>
<td class="nump">1,212.6<span></span>
</td>
<td class="nump">1,071.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_TaltzMember', window );">Taltz&#174; | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">186.1<span></span>
</td>
<td class="nump">170.9<span></span>
</td>
<td class="nump">561.6<span></span>
</td>
<td class="nump">493.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_OlumiantMember', window );">Olumiant&#174;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">182.9<span></span>
</td>
<td class="nump">406.9<span></span>
</td>
<td class="nump">624.7<span></span>
</td>
<td class="nump">809.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_OlumiantMember', window );">Olumiant&#174; | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">22.9<span></span>
</td>
<td class="nump">194.0<span></span>
</td>
<td class="nump">104.6<span></span>
</td>
<td class="nump">236.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_OlumiantMember', window );">Olumiant&#174; | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">160.0<span></span>
</td>
<td class="nump">212.9<span></span>
</td>
<td class="nump">520.1<span></span>
</td>
<td class="nump">572.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_OtherImmunologyMember', window );">Other immunology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">3.6<span></span>
</td>
<td class="nump">4.9<span></span>
</td>
<td class="nump">12.1<span></span>
</td>
<td class="nump">29.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_OtherImmunologyMember', window );">Other immunology | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">15.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_OtherImmunologyMember', window );">Other immunology | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">3.6<span></span>
</td>
<td class="nump">4.9<span></span>
</td>
<td class="nump">12.1<span></span>
</td>
<td class="nump">14.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_NeuroscienceMember', window );">Neuroscience</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">373.2<span></span>
</td>
<td class="nump">450.2<span></span>
</td>
<td class="nump">1,160.9<span></span>
</td>
<td class="nump">1,427.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_NeuroscienceMember', window );">Neuroscience | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">145.8<span></span>
</td>
<td class="nump">144.6<span></span>
</td>
<td class="nump">444.0<span></span>
</td>
<td class="nump">453.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_NeuroscienceMember', window );">Neuroscience | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">227.4<span></span>
</td>
<td class="nump">305.5<span></span>
</td>
<td class="nump">716.9<span></span>
</td>
<td class="nump">974.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_EmgalityMember', window );">Emgality&#174;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">168.5<span></span>
</td>
<td class="nump">140.0<span></span>
</td>
<td class="nump">475.2<span></span>
</td>
<td class="nump">415.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_EmgalityMember', window );">Emgality&#174; | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">114.0<span></span>
</td>
<td class="nump">99.9<span></span>
</td>
<td class="nump">330.8<span></span>
</td>
<td class="nump">313.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_EmgalityMember', window );">Emgality&#174; | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">54.6<span></span>
</td>
<td class="nump">40.1<span></span>
</td>
<td class="nump">144.4<span></span>
</td>
<td class="nump">102.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_ZyprexaMember', window );">Zyprexa&#174;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">81.4<span></span>
</td>
<td class="nump">101.7<span></span>
</td>
<td class="nump">261.7<span></span>
</td>
<td class="nump">292.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_ZyprexaMember', window );">Zyprexa&#174; | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">8.0<span></span>
</td>
<td class="nump">13.0<span></span>
</td>
<td class="nump">26.2<span></span>
</td>
<td class="nump">28.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_ZyprexaMember', window );">Zyprexa&#174; | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">73.4<span></span>
</td>
<td class="nump">88.7<span></span>
</td>
<td class="nump">235.5<span></span>
</td>
<td class="nump">264.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_CymbaltaMember', window );">Cymbalta&#174;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">62.7<span></span>
</td>
<td class="nump">132.0<span></span>
</td>
<td class="nump">219.3<span></span>
</td>
<td class="nump">484.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_CymbaltaMember', window );">Cymbalta&#174; | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">7.8<span></span>
</td>
<td class="nump">7.0<span></span>
</td>
<td class="nump">25.0<span></span>
</td>
<td class="nump">30.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_CymbaltaMember', window );">Cymbalta&#174; | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">54.9<span></span>
</td>
<td class="nump">125.1<span></span>
</td>
<td class="nump">194.3<span></span>
</td>
<td class="nump">454.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_OtherNeuroscienceMember', window );">Other neuroscience</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">60.6<span></span>
</td>
<td class="nump">76.5<span></span>
</td>
<td class="nump">204.7<span></span>
</td>
<td class="nump">235.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_OtherNeuroscienceMember', window );">Other neuroscience | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">16.0<span></span>
</td>
<td class="nump">24.7<span></span>
</td>
<td class="nump">62.0<span></span>
</td>
<td class="nump">81.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_OtherNeuroscienceMember', window );">Other neuroscience | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">44.5<span></span>
</td>
<td class="nump">51.6<span></span>
</td>
<td class="nump">142.7<span></span>
</td>
<td class="nump">154.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_OtherProductTotalMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">746.0<span></span>
</td>
<td class="nump">637.7<span></span>
</td>
<td class="nump">3,163.7<span></span>
</td>
<td class="nump">2,593.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_OtherProductTotalMember', window );">Other | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">538.3<span></span>
</td>
<td class="nump">354.9<span></span>
</td>
<td class="nump">2,377.5<span></span>
</td>
<td class="nump">1,373.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_OtherProductTotalMember', window );">Other | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">207.8<span></span>
</td>
<td class="nump">282.7<span></span>
</td>
<td class="nump">786.2<span></span>
</td>
<td class="nump">1,220.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_COVID19AntibodiesMember', window );">COVID-19 antibodies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">386.6<span></span>
</td>
<td class="nump">217.1<span></span>
</td>
<td class="nump">1,985.5<span></span>
</td>
<td class="nump">1,176.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_COVID19AntibodiesMember', window );">COVID-19 antibodies | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">386.6<span></span>
</td>
<td class="nump">215.5<span></span>
</td>
<td class="nump">1,970.9<span></span>
</td>
<td class="nump">949.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_COVID19AntibodiesMember', window );">COVID-19 antibodies | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">1.6<span></span>
</td>
<td class="nump">14.7<span></span>
</td>
<td class="nump">226.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_ForteoMember', window );">Forteo&#174;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">177.1<span></span>
</td>
<td class="nump">200.9<span></span>
</td>
<td class="nump">453.0<span></span>
</td>
<td class="nump">617.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_ForteoMember', window );">Forteo&#174; | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">112.7<span></span>
</td>
<td class="nump">109.6<span></span>
</td>
<td class="nump">261.4<span></span>
</td>
<td class="nump">330.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_ForteoMember', window );">Forteo&#174; | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">64.4<span></span>
</td>
<td class="nump">91.3<span></span>
</td>
<td class="nump">191.7<span></span>
</td>
<td class="nump">287.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_CialisMember', window );">Cialis&#174;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">115.7<span></span>
</td>
<td class="nump">130.9<span></span>
</td>
<td class="nump">480.4<span></span>
</td>
<td class="nump">538.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_CialisMember', window );">Cialis&#174; | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">8.1<span></span>
</td>
<td class="num">(6.5)<span></span>
</td>
<td class="nump">25.8<span></span>
</td>
<td class="num">(3.1)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_CialisMember', window );">Cialis&#174; | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">107.7<span></span>
</td>
<td class="nump">137.4<span></span>
</td>
<td class="nump">454.7<span></span>
</td>
<td class="nump">541.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_OtherProductMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">66.6<span></span>
</td>
<td class="nump">88.8<span></span>
</td>
<td class="nump">244.8<span></span>
</td>
<td class="nump">260.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_OtherProductMember', window );">Other | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">30.9<span></span>
</td>
<td class="nump">36.3<span></span>
</td>
<td class="nump">119.4<span></span>
</td>
<td class="nump">96.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_OtherProductMember', window );">Other | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">$ 35.7<span></span>
</td>
<td class="nump">$ 52.4<span></span>
</td>
<td class="nump">$ 125.1<span></span>
</td>
<td class="nump">$ 164.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_NonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_DiabetesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_DiabetesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_TrulicityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_TrulicityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_JardianceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_JardianceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_HumalogMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_HumalogMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_HumulinMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_HumulinMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_BasaglarMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_BasaglarMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_MounjaroMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_MounjaroMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_OtherDiabetesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_OtherDiabetesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_OncologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_OncologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_VerzenioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_VerzenioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_CyramzaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_CyramzaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_ErbituxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_ErbituxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_AlimtaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_AlimtaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_TYVYTMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_TYVYTMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_OtherOncologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_OtherOncologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_ImmunologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_ImmunologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_TaltzMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_TaltzMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_OlumiantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_OlumiantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_OtherImmunologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_OtherImmunologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_NeuroscienceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_NeuroscienceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_EmgalityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_EmgalityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_ZyprexaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_ZyprexaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_CymbaltaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_CymbaltaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_OtherNeuroscienceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_OtherNeuroscienceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_OtherProductTotalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_OtherProductTotalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_COVID19AntibodiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_COVID19AntibodiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_ForteoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_ForteoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_CialisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_CialisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_OtherProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_OtherProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140554505598528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue (Disaggregation of Revenue by Geographical Area) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">$ 6,941.6<span></span>
</td>
<td class="nump">$ 6,772.8<span></span>
</td>
<td class="nump">$ 21,239.6<span></span>
</td>
<td class="nump">$ 20,318.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">4,422.1<span></span>
</td>
<td class="nump">3,989.6<span></span>
</td>
<td class="nump">13,531.5<span></span>
</td>
<td class="nump">11,635.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_EuropeMember', window );">Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">1,056.4<span></span>
</td>
<td class="nump">1,098.6<span></span>
</td>
<td class="nump">3,224.8<span></span>
</td>
<td class="nump">3,629.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_JP', window );">Japan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">487.7<span></span>
</td>
<td class="nump">595.0<span></span>
</td>
<td class="nump">1,352.3<span></span>
</td>
<td class="nump">1,832.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_CN', window );">China</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">343.4<span></span>
</td>
<td class="nump">400.3<span></span>
</td>
<td class="nump">1,102.0<span></span>
</td>
<td class="nump">1,285.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=lly_OtherForeignCountriesMember', window );">Other foreign countries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">$ 632.0<span></span>
</td>
<td class="nump">$ 689.4<span></span>
</td>
<td class="nump">$ 2,029.1<span></span>
</td>
<td class="nump">$ 1,936.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_EuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_EuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_JP">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_JP</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CN">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CN</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=lly_OtherForeignCountriesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=lly_OtherForeignCountriesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140554512882352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions (Narrative) (Details)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jan. 31, 2021 </div>
<div>USD ($) </div>
<div>right </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>right </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lly_AcquiredInProcessResearchAndDevelopmentAndDevelopmentMilestones', window );">Acquired in-process research and development and development milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 62.4<span></span>
</td>
<td class="nump">$ 177.6<span></span>
</td>
<td class="nump">$ 668.4<span></span>
</td>
<td class="nump">$ 532.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Cash paid, net of cash acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">$ 747.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lly_PaymentsForAssetAcquisitions', window );">Acquired IPR&amp;D Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 333.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lly_PrevailTherapeuticsIncMember', window );">Prevail Therapeutics Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionSharePrice', window );">Business acquisition, share price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 22.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Cash paid, net of cash acquired</a></td>
<td class="nump">$ 747.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lly_BusinessCombinationConsiderationTransferredNumberOfContingentValueRights', window );">Consideration transferred, number of contingent value rights | right</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lly_BusinessAcquisitionContingentValueRightAdditionalPricePerShare', window );">Contingent value right, additional price per share (up to) (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 4.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh', window );">Contingent value right, additional price per share, aggregate amount</a></td>
<td class="nump">$ 160.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lly_BusinessAcquisitionContingentValueRightRegulatoryApprovalDelayMonthlyReduction', window );">Contingent value right, monthly reduction (in cents per share) | $ / shares</a></td>
<td class="nump">$ 0.083<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lly_AkouosAcquisitionMember', window );">Akouos Acquisition | Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionSharePrice', window );">Business acquisition, share price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lly_BusinessCombinationConsiderationTransferredNumberOfContingentValueRights', window );">Consideration transferred, number of contingent value rights | right</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lly_BusinessAcquisitionContingentValueRightAdditionalPricePerShare', window );">Contingent value right, additional price per share (up to) (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh', window );">Contingent value right, additional price per share, aggregate amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 123.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Payments to acquire businesses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 487.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_AcquiredInProcessResearchAndDevelopmentAndDevelopmentMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Acquired In-Process Research And Development And Development Milestones</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_AcquiredInProcessResearchAndDevelopmentAndDevelopmentMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_BusinessAcquisitionContingentValueRightAdditionalPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Acquisition, Contingent Value Right, Additional Price Per Share</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_BusinessAcquisitionContingentValueRightAdditionalPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_BusinessAcquisitionContingentValueRightRegulatoryApprovalDelayMonthlyReduction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Acquisition, Contingent Value Right, Covenant, Regulatory Approval Occurs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_BusinessAcquisitionContingentValueRightRegulatoryApprovalDelayMonthlyReduction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_BusinessCombinationConsiderationTransferredNumberOfContingentValueRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Consideration Transferred, Number Of Contingent Value Rights</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_BusinessCombinationConsiderationTransferredNumberOfContingentValueRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_PaymentsForAssetAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments for Asset Acquisitions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_PaymentsForAssetAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=lly_PrevailTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=lly_PrevailTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=lly_AkouosAcquisitionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=lly_AkouosAcquisitionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140554509711760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions (Assets Acquired and Liabilities Assumed) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 22, 2021</div></th>
<th class="th"><div>Jan. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,891.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,892.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Cash paid, net of cash acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 747.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lly_PrevailTherapeuticsIncMember', window );">Prevail Therapeutics Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash</a></td>
<td class="nump">$ 90.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Acquired IPR&amp;D</a></td>
<td class="nump">824.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">126.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities', window );">Deferred tax liabilities</a></td>
<td class="num">(106.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet', window );">Other assets and liabilities, net</a></td>
<td class="num">(31.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet', window );">Acquisition date fair value of consideration transferred</a></td>
<td class="nump">903.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAcquiredFromAcquisition', window );">Cash acquired</a></td>
<td class="num">(90.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability', window );">Fair value of CVR liability</a></td>
<td class="num">$ (65.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Cash paid, net of cash acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 747.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Assets (Liabilities), Net</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liability arising from an inherited contingency (as defined) which has been recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI https://asc.fasb.org/extlink&amp;oid=123455525&amp;loc=d3e2207-128464<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of intangible assets, excluding goodwill, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAcquiredFromAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAcquiredFromAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=lly_PrevailTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=lly_PrevailTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140554509912704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions (Asset Acquisitions) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 28, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Jan. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lly_PaymentsForAssetAcquisitions', window );">Acquired IPR&amp;D Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 333.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=lly_BioMarinPharmaceuticalIncMember', window );">BioMarin Pharmaceutical Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lly_PaymentsForAssetAcquisitions', window );">Acquired IPR&amp;D Expense</a></td>
<td class="nump">$ 110.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=lly_RigelPharmaceuticalsIncMember', window );">Rigel Pharmaceuticals, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lly_PaymentsForAssetAcquisitions', window );">Acquired IPR&amp;D Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=lly_PrecisionBiosciencesIncMember', window );">Precision Biosciences, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lly_PaymentsForAssetAcquisitions', window );">Acquired IPR&amp;D Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 107.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_PaymentsForAssetAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments for Asset Acquisitions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_PaymentsForAssetAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=lly_BioMarinPharmaceuticalIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=lly_BioMarinPharmaceuticalIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=lly_RigelPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=lly_RigelPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=lly_PrecisionBiosciencesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=lly_PrecisionBiosciencesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140554506311008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborations and Other Arrangements (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">$ 6,941,600,000<span></span>
</td>
<td class="nump">$ 6,772,800,000<span></span>
</td>
<td class="nump">$ 21,239,600,000<span></span>
</td>
<td class="nump">$ 20,318,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Remaining contract liabilities</a></td>
<td class="nump">232,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">232,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 262,600,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_JardianceMember', window );">Jardiance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">573,300,000<span></span>
</td>
<td class="nump">390,400,000<span></span>
</td>
<td class="nump">1,453,700,000<span></span>
</td>
<td class="nump">1,058,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_BasaglarMember', window );">Basaglar</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">193,000,000.0<span></span>
</td>
<td class="nump">192,800,000<span></span>
</td>
<td class="nump">558,700,000<span></span>
</td>
<td class="nump">650,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_TrajentaBIMember', window );">Trajenta</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">103,800,000<span></span>
</td>
<td class="nump">96,100,000<span></span>
</td>
<td class="nump">293,000,000.0<span></span>
</td>
<td class="nump">279,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_OlumiantMember', window );">Olumiant&#174;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">182,900,000<span></span>
</td>
<td class="nump">406,900,000<span></span>
</td>
<td class="nump">624,700,000<span></span>
</td>
<td class="nump">809,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_COVID19AntibodiesMember', window );">COVID-19 antibodies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">386,600,000<span></span>
</td>
<td class="nump">217,100,000<span></span>
</td>
<td class="nump">1,985,500,000<span></span>
</td>
<td class="nump">1,176,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_TYVYTMember', window );">Tyvyt&#174;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">76,800,000<span></span>
</td>
<td class="nump">$ 125,600,000<span></span>
</td>
<td class="nump">235,800,000<span></span>
</td>
<td class="nump">$ 340,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_LebrikizumabMember', window );">Lebrikizumab</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Remaining contract liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember', window );">Milestone Payments, Development and Regulatory, Capitalized (Deferred), Cumulative | Jardiance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lly_CollaborativeArrangementRightsAndObligationsRightsObligations', window );">Potential achievements</a></td>
<td class="nump">121,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">121,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">136,100,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember', window );">Milestone Payments, Development and Regulatory, Capitalized (Deferred), Cumulative | Basaglar</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lly_CollaborativeArrangementRightsAndObligationsRightsObligations', window );">Potential achievements</a></td>
<td class="num">(135,300,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(135,300,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(149,300,000)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember', window );">Milestone Payments, Development and Regulatory, Capitalized (Deferred), Cumulative | Trajenta</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lly_CollaborativeArrangementRightsAndObligationsRightsObligations', window );">Potential achievements</a></td>
<td class="nump">69,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 69,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">88,500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_RoyaltyAgreementTermsMember', window );">Royalty Agreement Terms | Olumiant&#174;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lly_CollaborativeArrangementRightsAndObligationsPercent', window );">Collaborative arrangement, rights and obligations, percentage (up to)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=lly_MilestonePaymentsCapitalizedAsIntangibleAssetsMember', window );">Milestone Payments, Capitalized as Intangible Assets | Olumiant&#174;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lly_CollaborativeArrangementRightsAndObligationsRightsObligations', window );">Potential achievements</a></td>
<td class="nump">330,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 330,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">260,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=lly_MilestonePaymentsCapitalizedAsIntangibleAssetsMember', window );">Milestone Payments, Capitalized as Intangible Assets | Tyvyt&#174;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lly_CollaborativeArrangementRightsAndObligationsRightsObligations', window );">Potential achievements</a></td>
<td class="nump">120,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=lly_MilestonePaymentsSalesBasedMember', window );">Milestone Payments, Sales-based | Olumiant&#174;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lly_CollaborativeArrangementRightsAndObligationsRightsObligations', window );">Potential achievements</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=lly_MilestonePaymentsSalesBasedMember', window );">Milestone Payments, Sales-based | Lebrikizumab</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lly_CollaborativeArrangementRightsAndObligationsRightsObligations', window );">Potential achievements</a></td>
<td class="nump">1,250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=lly_MilestonePaymentsSalesBasedMember', window );">Milestone Payments, Sales-based | Lebrikizumab | Roche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lly_CollaborativeArrangementRightsAndObligationsRightsObligations', window );">Potential achievements</a></td>
<td class="nump">1,030,000,000.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,030,000,000.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=lly_MilestonePaymentsSuccessBasedRegulatoryAndSalesBasedMember', window );">Milestone Payments, Success-based Regulatory and Sales-based | Tyvyt&#174; | Innovent Biologics, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lly_CollaborativeArrangementRightsAndObligationsRightsObligations', window );">Potential achievements</a></td>
<td class="nump">115,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">115,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=lly_MilestonePaymentsDevelopmentAndRegulatoryMember', window );">Milestone Payments, Development and Regulatory | Lebrikizumab</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lly_CollaborativeArrangementRightsAndObligationsRightsObligations', window );">Potential achievements</a></td>
<td class="nump">85,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=lly_MilestonePaymentsDevelopmentAndRegulatoryMember', window );">Milestone Payments, Development and Regulatory | Lebrikizumab | Roche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lly_CollaborativeArrangementRightsAndObligationsRightsObligations', window );">Potential achievements</a></td>
<td class="nump">$ 180,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 180,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_CollaborativeArrangementRightsAndObligationsPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of rights and obligations under the collaborative arrangements, including but not limited to - percent share in various revenues and costs, percent interest earned on related party notes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_CollaborativeArrangementRightsAndObligationsPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_CollaborativeArrangementRightsAndObligationsRightsObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Terms or rights and obligations under collaborative arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_CollaborativeArrangementRightsAndObligationsRightsObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_JardianceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_JardianceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_BasaglarMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_BasaglarMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_TrajentaBIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_TrajentaBIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_OlumiantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_OlumiantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_COVID19AntibodiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_COVID19AntibodiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_TYVYTMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_TYVYTMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_LebrikizumabMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_LebrikizumabMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_RoyaltyAgreementTermsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_RoyaltyAgreementTermsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=lly_MilestonePaymentsCapitalizedAsIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=lly_MilestonePaymentsCapitalizedAsIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=lly_MilestonePaymentsSalesBasedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=lly_MilestonePaymentsSalesBasedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=lly_RocheMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=lly_RocheMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=lly_MilestonePaymentsSuccessBasedRegulatoryAndSalesBasedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=lly_MilestonePaymentsSuccessBasedRegulatoryAndSalesBasedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=lly_InnoventBiologicsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=lly_InnoventBiologicsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=lly_MilestonePaymentsDevelopmentAndRegulatoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=lly_MilestonePaymentsDevelopmentAndRegulatoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140554515363056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Asset Impairment, Restructuring, and Other Special Charges (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 11.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lly_AssetImpairmentChargesRecoveriesAndOtherSpecialCharges', window );">Asset impairment and other special charges</a></td>
<td class="nump">206.5<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">206.5<span></span>
</td>
<td class="nump">200.1<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringSettlementAndImpairmentProvisions', window );">Total asset impairment, restructuring, and other special charges</a></td>
<td class="nump">$ 206.5<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 206.5<span></span>
</td>
<td class="nump">211.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">Intangible asset impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">108.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Inventory write-down</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 435.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_AssetImpairmentChargesRecoveriesAndOtherSpecialCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Asset Impairment Charges (Recoveries) And Other Special Charges</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_AssetImpairmentChargesRecoveriesAndOtherSpecialCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4542-108314<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringSettlementAndImpairmentProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of restructuring charges, remediation cost, and asset impairment loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringSettlementAndImpairmentProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeveranceCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeveranceCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140554498745504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Narrative) (Details)<br> &#165; in Millions, &#165; in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="4"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 15, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>JPY (&#165;)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>GBP (&#163;)</div>
</th>
<th class="th">
<div>Sep. 14, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>GBP (&#163;)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1', window );">Maximum remaining maturity of foreign currency derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">180 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTax', window );">Derivatives used in net investment hedge, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,940.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,940.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,790.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lly_DescriptionOfDerivativeActivityVolumePercent', window );">Percentage of long-term fixed-rate notes to floating rates through the use of interest rate swaps converted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 405.2<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 405.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet', window );">Pretax net losses on cash flow hedges expected to be reclassified during the next 12 months</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments', window );">Alternative investments, unfunded commitments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">854.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 854.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lly_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod', window );">Alternative investments, unfunded commitments, payment period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiGainLoss', window );">Equity securities, net unrealized gains (losses)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(123.3)<span></span>
</td>
<td class="num">$ (246.8)<span></span>
</td>
<td class="num">$ (667.6)<span></span>
</td>
<td class="nump">$ 270.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lly_DebtSecuritiesAvailableForSaleUnrealizedLossPositionQualitativeDisclosureOtherPercentageOfNonperformingAssets', window );">Available-for-sale, percentage of nonperforming assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized', window );">Amount of receivable derecognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">356.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 356.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">550.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=lly_MaturityDate2023Member', window );">Maturity Date 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt instrument, term</a></td>
<td class="text">364 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of credit facility, maximum borrowing capacity</a></td>
<td class="nump">$ 4,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=lly_ForeignCurrencyDenominatedDebtMember', window );">Foreign Currency Denominated Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt, including current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,230.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,230.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,900.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtExtinguishmentCosts', window );">Payment for debt extinguishment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,910.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtAmount', window );">Extinguishment of debt, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">405.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=lly_ForeignCurrencyDenominatedDebtMember', window );">Foreign Currency Denominated Debt | 0.50% Notes Due 2033</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 600,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=lly_ForeignCurrencyDenominatedDebtMember', window );">Foreign Currency Denominated Debt | 1.125% Notes due 2051</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">112.50%<span></span>
</td>
<td class="nump">112.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=lly_ForeignCurrencyDenominatedDebtMember', window );">Foreign Currency Denominated Debt | 1.375% Notes due 2061</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 700,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">137.50%<span></span>
</td>
<td class="nump">137.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=lly_ForeignCurrencyDenominatedDebtMember', window );">Foreign Currency Denominated Debt | 1.625% Notes due 2043</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount | &#163;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 250,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">162.50%<span></span>
</td>
<td class="nump">162.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=lly_ForeignCurrencyDenominatedDebtMember', window );">Foreign Currency Denominated Debt | 3.95% Notes Due 2049</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">395.00%<span></span>
</td>
<td class="nump">395.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtAmount', window );">Extinguishment of debt, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">541.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=lly_ForeignCurrencyDenominatedDebtMember', window );">Foreign Currency Denominated Debt | 4.15% Notes Due 2059</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">415.00%<span></span>
</td>
<td class="nump">415.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtAmount', window );">Extinguishment of debt, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">408.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=lly_ForeignCurrencyDenominatedDebtMember', window );">Foreign Currency Denominated Debt | 3.375% Notes Due 2029</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">337.50%<span></span>
</td>
<td class="nump">337.50%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtAmount', window );">Extinguishment of debt, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 219.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=lly_BuyUsDollarSellEuroMember', window );">Buy U.S. Dollars Sell Euros</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityNotionalAmount', window );">Derivative liability, notional amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,690.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,690.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetNotionalAmount', window );">Derivative asset, notional amount | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,710,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=lly_BuyEuroSellUsDollarMember', window );">Buy Euros Sell U.S. Dollars</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityNotionalAmount', window );">Derivative liability, notional amount | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,240,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetNotionalAmount', window );">Derivative asset, notional amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,240.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,240.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=lly_BuyUSDollarSellChineseYuanMember', window );">Buy US Dollar Sell Chinese Yuan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityNotionalAmount', window );">Derivative liability, notional amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">239.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">239.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetNotionalAmount', window );">Derivative asset, notional amount | &#165;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 1,630<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=lly_BuyUSdollarSellJapaneseYenMember', window );">Buy U.S. Dollars Sell Japanese Yen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityNotionalAmount', window );">Derivative liability, notional amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetNotionalAmount', window );">Derivative asset, notional amount | &#165;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 11,860<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=lly_BuyBritishPoundandSellUSDollarsMember', window );">Buy British Pounds and Sell U.S. Dollars</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityNotionalAmount', window );">Derivative liability, notional amount | &#163;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 182,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetNotionalAmount', window );">Derivative asset, notional amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">206.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">206.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=lly_SwapU.S.DollarsToEuroMember', window );">Swap U.S. Dollars to Euro</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, notional amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,560.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,560.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=lly_SwapSwissFrancsToU.S.DollarsMember', window );">Swap Swiss Francs to U.S. Dollars</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, notional amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=lly_SellEuroMember', window );">Sell Euro</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetNotionalAmount', window );">Derivative asset, notional amount | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,340,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember', window );">Forward-starting interest rate swaps | Designated as Hedging Instrument | Cash Flow Hedging</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, notional amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,750.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,750.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_DebtSecuritiesAvailableForSaleUnrealizedLossPositionQualitativeDisclosureOtherPercentageOfNonperformingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt securities, available-for-sale, unrealized loss position, qualitative disclosure, other, percentage of nonperforming assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_DebtSecuritiesAvailableForSaleUnrealizedLossPositionQualitativeDisclosureOtherPercentageOfNonperformingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_DescriptionOfDerivativeActivityVolumePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of Derivative Activity Volume Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_DescriptionOfDerivativeActivityVolumePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair Value, Investments, Entities That Calculate Net Asset Value Per Share, Unfunded Commitments, Payment Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payments on the derivative asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5580258-113959<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilityNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payments on the derivative liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5580258-113959<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilityNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payment on derivative.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5580258-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126980263&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExtinguishmentOfDebtAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross amount of debt extinguished.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExtinguishmentOfDebtAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of unfunded commitments for which the entity is obligated, to those certain investments for which net asset value per share is calculated (including by unit, membership interest, or other equity (ownership interest) unit measure) (alternative investments).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=SL6742756-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated net amount of unrealized gains or losses on interest rate cash flow hedges as of the balance sheet date expected to be reclassified to earnings within the next twelve months.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121549185&amp;loc=d3e80748-113994<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum amount of time remaining before foreign currency exchange rate derivatives mature or expire, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtExtinguishmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for cost from early extinguishment and prepayment of debt. Includes, but is not limited to, third-party cost, premium paid, and other fee paid to lender directly for debt extinguishment or debt prepayment. Excludes accrued interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtExtinguishmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of derecognized financial assets from transactions which comprise an initial transfer and an agreement entered into in contemplation of the initial transfer resulting in retention of substantially all of the exposure to the economic return throughout the term of the transaction, at the date of derecognition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121570589&amp;loc=SL51823488-111719<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of cumulative translation adjustment attributable to gain (loss) on foreign currency derivatives that are designated as, and are effective as, economic hedges of a net investment in a foreign entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=lly_MaturityDate2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=lly_MaturityDate2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=lly_ForeignCurrencyDenominatedDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=lly_ForeignCurrencyDenominatedDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lly_A050NotesDue2033Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lly_A050NotesDue2033Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lly_A1125NotesDue2051Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lly_A1125NotesDue2051Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lly_A1375NotesDue2061Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lly_A1375NotesDue2061Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lly_A1625NotesDue2043Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lly_A1625NotesDue2043Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lly_A395NotesDue2049Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lly_A395NotesDue2049Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lly_A415NotesDue2059Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lly_A415NotesDue2059Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lly_A3375NotesDue2029Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lly_A3375NotesDue2029Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=lly_BuyUsDollarSellEuroMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=lly_BuyUsDollarSellEuroMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=lly_BuyEuroSellUsDollarMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=lly_BuyEuroSellUsDollarMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=lly_BuyUSDollarSellChineseYuanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=lly_BuyUSDollarSellChineseYuanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=lly_BuyUSdollarSellJapaneseYenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=lly_BuyUSdollarSellJapaneseYenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=lly_BuyBritishPoundandSellUSDollarsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=lly_BuyBritishPoundandSellUSDollarsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=lly_SwapU.S.DollarsToEuroMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=lly_SwapU.S.DollarsToEuroMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=lly_SwapSwissFrancsToU.S.DollarsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=lly_SwapSwissFrancsToU.S.DollarsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=lly_SellEuroMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=lly_SellEuroMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140554504981600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Effect of Risk-Management Instruments) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lly_CashFlowHedgeAbstract', window );"><strong>Cash flow hedges:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lly_DerivativeInstrumentsGainLossRecognized', window );">Total</a></td>
<td class="nump">$ 166.8<span></span>
</td>
<td class="nump">$ 65.0<span></span>
</td>
<td class="nump">$ 368.0<span></span>
</td>
<td class="nump">$ 181.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=lly_HedgedFixedRateDebtMember', window );">Foreign currency-denominated notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lly_CashFlowHedgeAbstract', window );"><strong>Cash flow hedges:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax', window );">Effective portion of risk-management instruments that was recognized in other comprehensive income (loss), net investment hedges</a></td>
<td class="nump">435.1<span></span>
</td>
<td class="nump">119.0<span></span>
</td>
<td class="nump">822.8<span></span>
</td>
<td class="nump">268.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CrossCurrencyInterestRateContractMember', window );">Cross-currency interest rate swaps</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lly_CashFlowHedgeAbstract', window );"><strong>Cash flow hedges:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax', window );">Effective portion of risk-management instruments that was recognized in other comprehensive income (loss), net investment hedges</a></td>
<td class="nump">92.1<span></span>
</td>
<td class="nump">66.7<span></span>
</td>
<td class="nump">171.4<span></span>
</td>
<td class="nump">170.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax', window );">Effective portion of risk-management instruments that was recognized in other comprehensive income (loss), cash flow hedges</a></td>
<td class="nump">19.9<span></span>
</td>
<td class="nump">3.1<span></span>
</td>
<td class="nump">38.4<span></span>
</td>
<td class="nump">22.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign currency exchange contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lly_CashFlowHedgeAbstract', window );"><strong>Cash flow hedges:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax', window );">Effective portion of risk-management instruments that was recognized in other comprehensive income (loss), net investment hedges</a></td>
<td class="nump">107.8<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">121.4<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember', window );">Forward-starting interest rate swaps</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lly_CashFlowHedgeAbstract', window );"><strong>Cash flow hedges:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax', window );">Effective portion of risk-management instruments that was recognized in other comprehensive income (loss), cash flow hedges</a></td>
<td class="nump">57.5<span></span>
</td>
<td class="nump">19.4<span></span>
</td>
<td class="nump">337.7<span></span>
</td>
<td class="nump">149.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as Hedging Instrument | Foreign currency-denominated notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lly_FairValueHedgeAbstract', window );"><strong>Fair value hedges:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1', window );">Effect from hedged fixed-rate debt</a></td>
<td class="num">(62.9)<span></span>
</td>
<td class="num">(10.1)<span></span>
</td>
<td class="num">(215.7)<span></span>
</td>
<td class="num">(60.5)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as Hedging Instrument | Interest Rate Contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lly_FairValueHedgeAbstract', window );"><strong>Fair value hedges:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1', window );">Effect from interest rate contracts</a></td>
<td class="nump">62.9<span></span>
</td>
<td class="nump">10.1<span></span>
</td>
<td class="nump">215.7<span></span>
</td>
<td class="nump">60.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lly_CashFlowHedgeAbstract', window );"><strong>Cash flow hedges:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax', window );">Effective portion of losses on interest rate contracts reclassified from accumulated other comprehensive loss</a></td>
<td class="nump">4.1<span></span>
</td>
<td class="nump">4.2<span></span>
</td>
<td class="nump">12.3<span></span>
</td>
<td class="nump">12.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as Hedging Instrument | Cross-currency interest rate swaps</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lly_CashFlowHedgeAbstract', window );"><strong>Cash flow hedges:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax', window );">Effective portion of losses on interest rate contracts reclassified from accumulated other comprehensive loss</a></td>
<td class="nump">33.1<span></span>
</td>
<td class="nump">10.0<span></span>
</td>
<td class="nump">75.0<span></span>
</td>
<td class="nump">58.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember', window );">Not Designated as Hedging Instrument | Foreign currency exchange contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lly_CashFlowHedgeAbstract', window );"><strong>Cash flow hedges:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments', window );">Net (gains) losses on foreign currency exchange contracts not designated as hedging instruments</a></td>
<td class="nump">$ 129.6<span></span>
</td>
<td class="nump">$ 50.8<span></span>
</td>
<td class="nump">$ 280.7<span></span>
</td>
<td class="nump">$ 110.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_CashFlowHedgeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash Flow Hedge [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_CashFlowHedgeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_DerivativeInstrumentsGainLossRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Derivative Instruments, Gain (Loss) Recognized</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_DerivativeInstrumentsGainLossRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_FairValueHedgeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair Value Hedge [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_FairValueHedgeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from the increase (decrease) in fair value of derivative and nonderivative instruments designated as fair value hedging instruments recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 25<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=121577467&amp;loc=d3e76258-113986<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the increase (decrease) in fair value of the hedged item in a fair value hedge recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 25<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=121577467&amp;loc=d3e76258-113986<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in earnings in the period from the increase (decrease) in fair value of foreign currency derivatives not designated as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=121577181&amp;loc=SL110061190-113977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e689-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and reclassification, of gain (loss) from derivative designated and qualifying as net investment hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CCC<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL109998896-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=lly_HedgedFixedRateDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=lly_HedgedFixedRateDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CrossCurrencyInterestRateContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CrossCurrencyInterestRateContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140554513017392">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments (Fair Value of Financial Instruments) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Noncurrent investments</a></td>
<td class="nump">$ 2,574.6<span></span>
</td>
<td class="nump">$ 3,212.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember', window );">Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">1,246.8<span></span>
</td>
<td class="nump">2,379.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">124.7<span></span>
</td>
<td class="nump">90.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount', window );">Equity investments without readily determinable fair values</a></td>
<td class="nump">583.7<span></span>
</td>
<td class="nump">548.1<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Noncurrent investments</a></td>
<td class="nump">2,574.6<span></span>
</td>
<td class="nump">3,212.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommercialPaper', window );">Short-term commercial paper borrowings</a></td>
<td class="num">(1,741.3)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt, including current portion</a></td>
<td class="num">(14,147.1)<span></span>
</td>
<td class="num">(16,884.7)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember', window );">Carrying Amount | U.S. government and agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">43.0<span></span>
</td>
<td class="nump">25.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Noncurrent investments</a></td>
<td class="nump">131.4<span></span>
</td>
<td class="nump">137.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember', window );">Carrying Amount | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">51.7<span></span>
</td>
<td class="nump">43.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Noncurrent investments</a></td>
<td class="nump">206.4<span></span>
</td>
<td class="nump">235.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember', window );">Carrying Amount | Mortgage-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Noncurrent investments</a></td>
<td class="nump">143.1<span></span>
</td>
<td class="nump">109.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember', window );">Carrying Amount | Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">3.0<span></span>
</td>
<td class="nump">6.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Noncurrent investments</a></td>
<td class="nump">43.6<span></span>
</td>
<td class="nump">23.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember', window );">Carrying Amount | Other securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">27.0<span></span>
</td>
<td class="nump">14.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember', window );">Carrying Amount | Other securities, noncurrent investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="nump">152.5<span></span>
</td>
<td class="nump">108.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember', window );">Carrying Amount | Marketable equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="nump">549.1<span></span>
</td>
<td class="nump">1,279.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember', window );">Carrying Amount | Equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLongTermInvestments', window );">Equity method investments</a></td>
<td class="nump">764.8<span></span>
</td>
<td class="nump">771.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember', window );">Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">1,246.8<span></span>
</td>
<td class="nump">2,379.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember', window );">Cost | U.S. government and agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">43.5<span></span>
</td>
<td class="nump">25.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Noncurrent investments</a></td>
<td class="nump">148.3<span></span>
</td>
<td class="nump">136.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember', window );">Cost | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">51.8<span></span>
</td>
<td class="nump">43.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Noncurrent investments</a></td>
<td class="nump">232.5<span></span>
</td>
<td class="nump">232.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember', window );">Cost | Mortgage-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Noncurrent investments</a></td>
<td class="nump">156.1<span></span>
</td>
<td class="nump">108.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember', window );">Cost | Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">3.0<span></span>
</td>
<td class="nump">6.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Noncurrent investments</a></td>
<td class="nump">45.5<span></span>
</td>
<td class="nump">23.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember', window );">Cost | Other securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">27.0<span></span>
</td>
<td class="nump">14.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember', window );">Cost | Other securities, noncurrent investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="nump">96.3<span></span>
</td>
<td class="nump">22.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember', window );">Cost | Marketable equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="nump">416.1<span></span>
</td>
<td class="nump">487.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">1,246.8<span></span>
</td>
<td class="nump">2,379.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommercialPaper', window );">Short-term commercial paper borrowings</a></td>
<td class="num">(1,738.0)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt, including current portion</a></td>
<td class="num">(11,848.6)<span></span>
</td>
<td class="num">(18,157.7)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | U.S. government and agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">43.0<span></span>
</td>
<td class="nump">25.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Noncurrent investments</a></td>
<td class="nump">131.4<span></span>
</td>
<td class="nump">137.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">51.7<span></span>
</td>
<td class="nump">43.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Noncurrent investments</a></td>
<td class="nump">206.4<span></span>
</td>
<td class="nump">235.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Mortgage-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Noncurrent investments</a></td>
<td class="nump">143.1<span></span>
</td>
<td class="nump">109.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">3.0<span></span>
</td>
<td class="nump">6.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Noncurrent investments</a></td>
<td class="nump">43.6<span></span>
</td>
<td class="nump">23.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Other securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">27.0<span></span>
</td>
<td class="nump">14.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Other securities, noncurrent investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="nump">152.5<span></span>
</td>
<td class="nump">108.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Marketable equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="nump">549.1<span></span>
</td>
<td class="nump">1,279.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Quoted Prices in Active Markets for Identical Assets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">1,239.2<span></span>
</td>
<td class="nump">2,361.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommercialPaper', window );">Short-term commercial paper borrowings</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt, including current portion</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Quoted Prices in Active Markets for Identical Assets (Level 1) | U.S. government and agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">43.0<span></span>
</td>
<td class="nump">25.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Noncurrent investments</a></td>
<td class="nump">131.4<span></span>
</td>
<td class="nump">137.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Quoted Prices in Active Markets for Identical Assets (Level 1) | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Noncurrent investments</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Quoted Prices in Active Markets for Identical Assets (Level 1) | Mortgage-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Noncurrent investments</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Quoted Prices in Active Markets for Identical Assets (Level 1) | Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Noncurrent investments</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Quoted Prices in Active Markets for Identical Assets (Level 1) | Other securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Quoted Prices in Active Markets for Identical Assets (Level 1) | Other securities, noncurrent investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Quoted Prices in Active Markets for Identical Assets (Level 1) | Marketable equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="nump">549.1<span></span>
</td>
<td class="nump">1,279.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Significant Other Observable Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">7.6<span></span>
</td>
<td class="nump">18.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommercialPaper', window );">Short-term commercial paper borrowings</a></td>
<td class="num">(1,738.0)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt, including current portion</a></td>
<td class="num">(11,848.6)<span></span>
</td>
<td class="num">(18,157.7)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Significant Other Observable Inputs (Level 2) | U.S. government and agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Noncurrent investments</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Significant Other Observable Inputs (Level 2) | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">51.7<span></span>
</td>
<td class="nump">43.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Noncurrent investments</a></td>
<td class="nump">206.4<span></span>
</td>
<td class="nump">235.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Significant Other Observable Inputs (Level 2) | Mortgage-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Noncurrent investments</a></td>
<td class="nump">143.1<span></span>
</td>
<td class="nump">109.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Significant Other Observable Inputs (Level 2) | Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">3.0<span></span>
</td>
<td class="nump">6.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Noncurrent investments</a></td>
<td class="nump">43.6<span></span>
</td>
<td class="nump">23.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Significant Other Observable Inputs (Level 2) | Other securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">14.8<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Significant Other Observable Inputs (Level 2) | Other securities, noncurrent investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="nump">39.5<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Significant Other Observable Inputs (Level 2) | Marketable equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Significant Unobservable Inputs (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommercialPaper', window );">Short-term commercial paper borrowings</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt, including current portion</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Significant Unobservable Inputs (Level 3) | U.S. government and agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Noncurrent investments</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Significant Unobservable Inputs (Level 3) | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Noncurrent investments</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Significant Unobservable Inputs (Level 3) | Mortgage-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Noncurrent investments</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Significant Unobservable Inputs (Level 3) | Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Noncurrent investments</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Significant Unobservable Inputs (Level 3) | Other securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">12.2<span></span>
</td>
<td class="nump">14.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Significant Unobservable Inputs (Level 3) | Other securities, noncurrent investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="nump">113.0<span></span>
</td>
<td class="nump">108.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Significant Unobservable Inputs (Level 3) | Marketable equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommercialPaper">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of short-term borrowings using unsecured obligations issued by banks, corporations and other borrowers to investors. The maturities of these money market securities generally do not exceed 270 days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommercialPaper</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=123594786&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126980263&amp;loc=SL75117539-209714<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term investments classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.1(f))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MortgageBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MortgageBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_OtherDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_OtherDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=lly_OtherEquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=lly_OtherEquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=lly_MarketableSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=lly_MarketableSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=lly_EquityMethodAndOtherInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=lly_EquityMethodAndOtherInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140554505125696">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments (Risk Management Instruments) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember', window );">Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration liability, other noncurrent liabilities</a></td>
<td class="num">$ (42.1)<span></span>
</td>
<td class="num">$ (70.5)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember', window );">Carrying Amount | Foreign currency exchange contracts | Not Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsCurrent', window );">Other receivables</a></td>
<td class="nump">48.1<span></span>
</td>
<td class="nump">9.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="num">(93.5)<span></span>
</td>
<td class="num">(35.3)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration liability, other noncurrent liabilities</a></td>
<td class="num">(42.1)<span></span>
</td>
<td class="num">(70.5)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Quoted Prices in Active Markets for Identical Assets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration liability, other noncurrent liabilities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Significant Other Observable Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration liability, other noncurrent liabilities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Significant Unobservable Inputs (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration liability, other noncurrent liabilities</a></td>
<td class="num">(42.1)<span></span>
</td>
<td class="num">(70.5)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Foreign currency exchange contracts | Not Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsCurrent', window );">Other receivables</a></td>
<td class="nump">48.1<span></span>
</td>
<td class="nump">9.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="num">(93.5)<span></span>
</td>
<td class="num">(35.3)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Foreign currency exchange contracts | Not Designated as Hedging Instrument | Quoted Prices in Active Markets for Identical Assets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsCurrent', window );">Other receivables</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Foreign currency exchange contracts | Not Designated as Hedging Instrument | Significant Other Observable Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsCurrent', window );">Other receivables</a></td>
<td class="nump">48.1<span></span>
</td>
<td class="nump">9.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="num">(93.5)<span></span>
</td>
<td class="num">(35.3)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Foreign currency exchange contracts | Not Designated as Hedging Instrument | Significant Unobservable Inputs (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsCurrent', window );">Other receivables</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember', window );">Fair Value Hedging | Carrying Amount | Interest Rate Contracts | Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsCurrent', window );">Other receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Other noncurrent liabilities</a></td>
<td class="num">(140.2)<span></span>
</td>
<td class="num">(7.6)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember', window );">Fair Value Hedging | Estimate of Fair Value Measurement | Interest Rate Contracts | Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsCurrent', window );">Other receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Other noncurrent liabilities</a></td>
<td class="num">(140.2)<span></span>
</td>
<td class="num">(7.6)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember', window );">Fair Value Hedging | Estimate of Fair Value Measurement | Interest Rate Contracts | Designated as Hedging Instrument | Quoted Prices in Active Markets for Identical Assets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsCurrent', window );">Other receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Other noncurrent liabilities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember', window );">Fair Value Hedging | Estimate of Fair Value Measurement | Interest Rate Contracts | Designated as Hedging Instrument | Significant Other Observable Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsCurrent', window );">Other receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Other noncurrent liabilities</a></td>
<td class="num">(140.2)<span></span>
</td>
<td class="num">(7.6)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember', window );">Fair Value Hedging | Estimate of Fair Value Measurement | Interest Rate Contracts | Designated as Hedging Instrument | Significant Unobservable Inputs (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsCurrent', window );">Other receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Other noncurrent liabilities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash Flow Hedging | Carrying Amount | Interest Rate Contracts | Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="nump">355.2<span></span>
</td>
<td class="nump">49.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Other noncurrent liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(31.7)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash Flow Hedging | Carrying Amount | Cross-currency interest rate swaps | Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="nump">8.3<span></span>
</td>
<td class="nump">33.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Other noncurrent liabilities</a></td>
<td class="num">(12.9)<span></span>
</td>
<td class="num">(1.3)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash Flow Hedging | Estimate of Fair Value Measurement | Interest Rate Contracts | Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="nump">355.2<span></span>
</td>
<td class="nump">49.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Other noncurrent liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(31.7)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash Flow Hedging | Estimate of Fair Value Measurement | Interest Rate Contracts | Designated as Hedging Instrument | Quoted Prices in Active Markets for Identical Assets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Other noncurrent liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash Flow Hedging | Estimate of Fair Value Measurement | Interest Rate Contracts | Designated as Hedging Instrument | Significant Other Observable Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="nump">355.2<span></span>
</td>
<td class="nump">49.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Other noncurrent liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(31.7)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash Flow Hedging | Estimate of Fair Value Measurement | Interest Rate Contracts | Designated as Hedging Instrument | Significant Unobservable Inputs (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Other noncurrent liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash Flow Hedging | Estimate of Fair Value Measurement | Cross-currency interest rate swaps | Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="nump">8.3<span></span>
</td>
<td class="nump">33.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Other noncurrent liabilities</a></td>
<td class="num">(12.9)<span></span>
</td>
<td class="num">(1.3)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash Flow Hedging | Estimate of Fair Value Measurement | Cross-currency interest rate swaps | Designated as Hedging Instrument | Quoted Prices in Active Markets for Identical Assets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Other noncurrent liabilities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash Flow Hedging | Estimate of Fair Value Measurement | Cross-currency interest rate swaps | Designated as Hedging Instrument | Significant Other Observable Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="nump">8.3<span></span>
</td>
<td class="nump">33.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Other noncurrent liabilities</a></td>
<td class="num">(12.9)<span></span>
</td>
<td class="num">(1.3)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash Flow Hedging | Estimate of Fair Value Measurement | Cross-currency interest rate swaps | Designated as Hedging Instrument | Significant Unobservable Inputs (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Other noncurrent liabilities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember', window );">Net Investment Hedges | Carrying Amount | Cross-currency interest rate swaps | Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsCurrent', window );">Other receivables</a></td>
<td class="nump">81.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="nump">116.9<span></span>
</td>
<td class="nump">31.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1.2)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember', window );">Net Investment Hedges | Carrying Amount | Foreign currency exchange contracts | Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsCurrent', window );">Other receivables</a></td>
<td class="nump">108.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="num">(2.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember', window );">Net Investment Hedges | Estimate of Fair Value Measurement | Cross-currency interest rate swaps | Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsCurrent', window );">Other receivables</a></td>
<td class="nump">81.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="nump">116.9<span></span>
</td>
<td class="nump">31.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1.2)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember', window );">Net Investment Hedges | Estimate of Fair Value Measurement | Cross-currency interest rate swaps | Designated as Hedging Instrument | Quoted Prices in Active Markets for Identical Assets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsCurrent', window );">Other receivables</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember', window );">Net Investment Hedges | Estimate of Fair Value Measurement | Cross-currency interest rate swaps | Designated as Hedging Instrument | Significant Other Observable Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsCurrent', window );">Other receivables</a></td>
<td class="nump">81.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="nump">116.9<span></span>
</td>
<td class="nump">31.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1.2)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember', window );">Net Investment Hedges | Estimate of Fair Value Measurement | Cross-currency interest rate swaps | Designated as Hedging Instrument | Significant Unobservable Inputs (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsCurrent', window );">Other receivables</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember', window );">Net Investment Hedges | Estimate of Fair Value Measurement | Foreign currency exchange contracts | Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsCurrent', window );">Other receivables</a></td>
<td class="nump">108.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="num">(2.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember', window );">Net Investment Hedges | Estimate of Fair Value Measurement | Foreign currency exchange contracts | Designated as Hedging Instrument | Quoted Prices in Active Markets for Identical Assets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsCurrent', window );">Other receivables</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember', window );">Net Investment Hedges | Estimate of Fair Value Measurement | Foreign currency exchange contracts | Designated as Hedging Instrument | Significant Other Observable Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsCurrent', window );">Other receivables</a></td>
<td class="nump">108.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="num">(2.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember', window );">Net Investment Hedges | Estimate of Fair Value Measurement | Foreign currency exchange contracts | Designated as Hedging Instrument | Significant Unobservable Inputs (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsCurrent', window );">Other receivables</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126966325&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CrossCurrencyInterestRateContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CrossCurrencyInterestRateContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140554512586256">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments (Contractual Maturities) (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total</a></td>
<td class="nump">$ 622.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Less&#160;Than 1 Year</a></td>
<td class="nump">97.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">1-5 Years</a></td>
<td class="nump">197.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue', window );">6-10 Years</a></td>
<td class="nump">121.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue', window );">More&#160;Than 10 Years</a></td>
<td class="nump">$ 205.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27198-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126980459&amp;loc=SL120269850-112803<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27198-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126980459&amp;loc=SL120269850-112803<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing after tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126980459&amp;loc=SL120269850-112803<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126980459&amp;loc=SL120269850-112803<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27198-111563<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140554500057488">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments (Unrealized Gains and Losses) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized gross gains</a></td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 9.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized gross losses</a></td>
<td class="nump">51.6<span></span>
</td>
<td class="nump">5.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lly_DebtSecuritiesAvailableforsaleUnrealizedGainPosition', window );">Fair value of securities in an unrealized gain position</a></td>
<td class="nump">13.8<span></span>
</td>
<td class="nump">250.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Fair value of securities in an unrealized loss position</a></td>
<td class="nump">$ 578.8<span></span>
</td>
<td class="nump">$ 290.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_DebtSecuritiesAvailableforsaleUnrealizedGainPosition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-for-sale, Unrealized Gain Position</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_DebtSecuritiesAvailableforsaleUnrealizedGainPosition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140554515394864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Realized Gains and Losses) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lly_ProceedsfromSaleofEquityandAvailableforSaleSecurities', window );">Proceeds from sales</a></td>
<td class="nump">$ 50.5<span></span>
</td>
<td class="nump">$ 49.6<span></span>
</td>
<td class="nump">$ 115.6<span></span>
</td>
<td class="nump">$ 137.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lly_AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain', window );">Realized gross gains on sales</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
<td class="nump">2.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lly_AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss', window );">Realized gross losses on sales</a></td>
<td class="nump">$ 7.5<span></span>
</td>
<td class="nump">$ 0.3<span></span>
</td>
<td class="nump">$ 9.0<span></span>
</td>
<td class="nump">$ 1.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Available for Sale Securities and Equity Securities, FV-NI, Realized Gain</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Available for sale Securities and Equity Securities, FV-NI, Realized Loss</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_ProceedsfromSaleofEquityandAvailableforSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from Sale of Equity and Available for Sale Securities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_ProceedsfromSaleofEquityandAvailableforSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140554513007360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate, percentage</a></td>
<td class="nump">7.30%<span></span>
</td>
<td class="nump">10.90%<span></span>
</td>
<td class="nump">8.60%<span></span>
</td>
<td class="nump">10.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember', window );">Forecast | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember', window );">Forecast | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxContingencyLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxContingencyLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140554505575968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Retirement Benefits (Components of Net Periodic Benefit Cost) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Defined Benefit Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanServiceCost', window );">Service cost</a></td>
<td class="nump">$ 87.1<span></span>
</td>
<td class="nump">$ 92.5<span></span>
</td>
<td class="nump">$ 264.4<span></span>
</td>
<td class="nump">$ 277.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanInterestCost', window );">Interest cost</a></td>
<td class="nump">98.9<span></span>
</td>
<td class="nump">84.5<span></span>
</td>
<td class="nump">299.0<span></span>
</td>
<td class="nump">253.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets', window );">Expected return on plan assets</a></td>
<td class="num">(235.1)<span></span>
</td>
<td class="num">(237.5)<span></span>
</td>
<td class="num">(711.6)<span></span>
</td>
<td class="num">(712.7)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit', window );">Amortization of prior service cost</a></td>
<td class="nump">0.6<span></span>
</td>
<td class="nump">1.0<span></span>
</td>
<td class="nump">1.9<span></span>
</td>
<td class="nump">3.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit', window );">Recognized actuarial loss</a></td>
<td class="nump">85.3<span></span>
</td>
<td class="nump">121.9<span></span>
</td>
<td class="nump">256.8<span></span>
</td>
<td class="nump">366.3<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost', window );">Net periodic benefit cost</a></td>
<td class="nump">36.8<span></span>
</td>
<td class="nump">62.4<span></span>
</td>
<td class="nump">110.5<span></span>
</td>
<td class="nump">188.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Retiree Health Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanServiceCost', window );">Service cost</a></td>
<td class="nump">11.7<span></span>
</td>
<td class="nump">12.4<span></span>
</td>
<td class="nump">35.0<span></span>
</td>
<td class="nump">37.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanInterestCost', window );">Interest cost</a></td>
<td class="nump">9.4<span></span>
</td>
<td class="nump">8.1<span></span>
</td>
<td class="nump">28.4<span></span>
</td>
<td class="nump">24.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets', window );">Expected return on plan assets</a></td>
<td class="num">(38.0)<span></span>
</td>
<td class="num">(36.5)<span></span>
</td>
<td class="num">(114.1)<span></span>
</td>
<td class="num">(109.6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit', window );">Amortization of prior service cost</a></td>
<td class="num">(13.7)<span></span>
</td>
<td class="num">(14.9)<span></span>
</td>
<td class="num">(41.1)<span></span>
</td>
<td class="num">(44.7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit', window );">Recognized actuarial loss</a></td>
<td class="nump">0.2<span></span>
</td>
<td class="nump">0.8<span></span>
</td>
<td class="nump">0.7<span></span>
</td>
<td class="nump">2.4<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost', window );">Net periodic benefit cost</a></td>
<td class="num">$ (30.4)<span></span>
</td>
<td class="num">$ (30.1)<span></span>
</td>
<td class="num">$ (91.1)<span></span>
</td>
<td class="num">$ (90.5)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss), recognized immediately as component of net periodic benefit (cost) credit, for change in value of benefit obligation or plan assets from experience different from that assumed, change in actuarial assumption, or consequence of temporarily deviating from substantive plan. Includes, but is not limited to, amount in excess of 10 percent of greater of fair value of plan assets or benefit obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of prior service cost (credit) recognized in net periodic benefit cost (credit) of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(5)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(5)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expected return (loss) recognized in net periodic benefit (cost) credit, calculated based on expected long-term rate of return and market-related value of plan assets of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanInterestCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost recognized for passage of time related to defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanInterestCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of net periodic benefit cost (credit) for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanServiceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanServiceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140554504656768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingencies (Details)<br> R$ in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">163 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jul. 31, 2021 </div>
<div>claim</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>BRL (R$) </div>
<div>patent</div>
</th>
<th class="th">
<div>Jul. 31, 2019 </div>
<div>BRL (R$)</div>
</th>
<th class="th">
<div>Jul. 31, 2018 </div>
<div>BRL (R$)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>BRL (R$) </div>
<div>patent </div>
<div>lawsuit </div>
<div>site</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($) </div>
<div>patent </div>
<div>lawsuit </div>
<div>site</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>patent </div>
<div>lawsuit </div>
<div>site </div>
<div>plaintiff</div>
</th>
<th class="th">
<div>Oct. 31, 2022 </div>
<div>patent</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=us-gaap_UnfavorableRegulatoryActionMember', window );">Unfavorable Regulatory Action</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lly_LossContingencyNumberOfSitesJointlyAndSeverallyLiableForCleanup', window );">Number of sites jointly and severally liable for cleanup (fewer than) | site</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_ByettaMember', window );">Byetta | Product Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of pending lawsuits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyNumberOfPlaintiffs', window );">Number of plaintiffs | plaintiff</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_HumalogHumulinAndForteoMember', window );">Humalog, Humulin and Forteo</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of pending lawsuits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_InsulinMember', window );">Insulin</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lly_LitigationClaimsDismissedNumber', window );">Number of claims dismissed | claim</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=lly_EmgalityPatentLitigationMember', window );">Emgality Patent Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lly_LossContingencyNumberOfPatents', window );">Number of patents | patent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=lly_EmgalityPatentLitigationMember', window );">Emgality Patent Litigation | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lly_LossContingencyNumberOfPatents', window );">Number of patents | patent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=lly_EmployeeLitigationMember', window );">Employee Litigation | Brazil</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of pending lawsuits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesAwardedValue', window );">Damages awarded, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">R$ 100<span></span>
</td>
<td class="nump">R$ 500<span></span>
</td>
<td class="nump">R$ 300<span></span>
</td>
<td class="nump">R$ 1,000<span></span>
</td>
<td class="nump">$ 185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_LitigationClaimsDismissedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Litigation, Claims Dismissed, Number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_LitigationClaimsDismissedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_LossContingencyNumberOfPatents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Number Of Patents</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_LossContingencyNumberOfPatents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_LossContingencyNumberOfSitesJointlyAndSeverallyLiableForCleanup">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Number Of Sites Jointly And Severally Liable For Cleanup</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_LossContingencyNumberOfSitesJointlyAndSeverallyLiableForCleanup</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDamagesAwardedValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of damages awarded to the plaintiff in the legal matter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDamagesAwardedValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyNumberOfPlaintiffs">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of plaintiffs that have filed claims pertaining to a loss contingency.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyNumberOfPlaintiffs</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyPendingClaimsNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of pending claims pertaining to a loss contingency.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyPendingClaimsNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=us-gaap_UnfavorableRegulatoryActionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=us-gaap_UnfavorableRegulatoryActionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_ByettaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_ByettaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=lly_ProductLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=lly_ProductLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_HumalogHumulinAndForteoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_HumalogHumulinAndForteoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_InsulinMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_InsulinMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=lly_EmgalityPatentLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=lly_EmgalityPatentLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=lly_EmployeeLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=lly_EmployeeLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_BR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_BR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140554512982032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Comprehensive Income (Loss) (AOCI) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,154.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss) before reclassifications</a></td>
<td class="num">$ (79.2)<span></span>
</td>
<td class="nump">$ 25.0<span></span>
</td>
<td class="num">(145.1)<span></span>
</td>
<td class="nump">$ 54.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Net amount reclassified from accumulated other comprehensive loss</a></td>
<td class="nump">71.1<span></span>
</td>
<td class="nump">89.4<span></span>
</td>
<td class="nump">192.4<span></span>
</td>
<td class="nump">269.2<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Net other comprehensive income (loss)</a></td>
<td class="num">(8.1)<span></span>
</td>
<td class="nump">114.4<span></span>
</td>
<td class="nump">47.3<span></span>
</td>
<td class="nump">323.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="nump">10,165.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,165.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember', window );">Accumulated Other Comprehensive Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="num">(4,287.7)<span></span>
</td>
<td class="num">(6,287.1)<span></span>
</td>
<td class="num">(4,343.1)<span></span>
</td>
<td class="num">(6,496.4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="num">(4,295.8)<span></span>
</td>
<td class="num">(6,172.7)<span></span>
</td>
<td class="num">(4,295.8)<span></span>
</td>
<td class="num">(6,172.7)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember', window );">Foreign Currency Translation Gains&#160;(Losses)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="num">(1,844.2)<span></span>
</td>
<td class="num">(1,516.2)<span></span>
</td>
<td class="num">(1,550.2)<span></span>
</td>
<td class="num">(1,427.5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss) before reclassifications</a></td>
<td class="num">(165.1)<span></span>
</td>
<td class="num">(8.0)<span></span>
</td>
<td class="num">(459.7)<span></span>
</td>
<td class="num">(96.7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Net amount reclassified from accumulated other comprehensive loss</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.6<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Net other comprehensive income (loss)</a></td>
<td class="num">(165.1)<span></span>
</td>
<td class="num">(8.0)<span></span>
</td>
<td class="num">(459.1)<span></span>
</td>
<td class="num">(96.7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="num">(2,009.3)<span></span>
</td>
<td class="num">(1,524.2)<span></span>
</td>
<td class="num">(2,009.3)<span></span>
</td>
<td class="num">(1,524.2)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember', window );">Unrealized Net Gains (Losses) on&#160;Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="num">(27.9)<span></span>
</td>
<td class="nump">9.1<span></span>
</td>
<td class="nump">3.7<span></span>
</td>
<td class="nump">14.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss) before reclassifications</a></td>
<td class="num">(24.9)<span></span>
</td>
<td class="num">(2.4)<span></span>
</td>
<td class="num">(55.5)<span></span>
</td>
<td class="num">(8.8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Net amount reclassified from accumulated other comprehensive loss</a></td>
<td class="nump">13.5<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">12.5<span></span>
</td>
<td class="nump">0.8<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Net other comprehensive income (loss)</a></td>
<td class="num">(11.4)<span></span>
</td>
<td class="num">(2.3)<span></span>
</td>
<td class="num">(43.0)<span></span>
</td>
<td class="num">(8.0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="num">(39.3)<span></span>
</td>
<td class="nump">6.8<span></span>
</td>
<td class="num">(39.3)<span></span>
</td>
<td class="nump">6.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember', window );">Defined Benefit Pension and Retiree&#160;Health Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="num">(2,443.2)<span></span>
</td>
<td class="num">(4,569.9)<span></span>
</td>
<td class="num">(2,583.6)<span></span>
</td>
<td class="num">(4,751.0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss) before reclassifications</a></td>
<td class="nump">47.8<span></span>
</td>
<td class="nump">18.6<span></span>
</td>
<td class="nump">72.9<span></span>
</td>
<td class="nump">27.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Net amount reclassified from accumulated other comprehensive loss</a></td>
<td class="nump">57.2<span></span>
</td>
<td class="nump">86.0<span></span>
</td>
<td class="nump">172.5<span></span>
</td>
<td class="nump">258.5<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Net other comprehensive income (loss)</a></td>
<td class="nump">105.0<span></span>
</td>
<td class="nump">104.6<span></span>
</td>
<td class="nump">245.4<span></span>
</td>
<td class="nump">285.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="num">(2,338.2)<span></span>
</td>
<td class="num">(4,465.3)<span></span>
</td>
<td class="num">(2,338.2)<span></span>
</td>
<td class="num">(4,465.3)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember', window );">Effective portion of cash flow hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="nump">27.6<span></span>
</td>
<td class="num">(210.1)<span></span>
</td>
<td class="num">(213.0)<span></span>
</td>
<td class="num">(332.7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss) before reclassifications</a></td>
<td class="nump">63.0<span></span>
</td>
<td class="nump">16.8<span></span>
</td>
<td class="nump">297.2<span></span>
</td>
<td class="nump">132.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Net amount reclassified from accumulated other comprehensive loss</a></td>
<td class="nump">0.4<span></span>
</td>
<td class="nump">3.3<span></span>
</td>
<td class="nump">6.8<span></span>
</td>
<td class="nump">9.9<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Net other comprehensive income (loss)</a></td>
<td class="nump">63.4<span></span>
</td>
<td class="nump">20.1<span></span>
</td>
<td class="nump">304.0<span></span>
</td>
<td class="nump">142.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="nump">$ 91.0<span></span>
</td>
<td class="num">$ (190.0)<span></span>
</td>
<td class="nump">$ 91.0<span></span>
</td>
<td class="num">$ (190.0)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 25: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140554512866960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Comprehensive Income (Loss) (Tax Effect) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTax', window );">Benefit (expense) for income taxes allocated to other comprehensive income (loss) items</a></td>
<td class="num">$ (169.2)<span></span>
</td>
<td class="num">$ (71.8)<span></span>
</td>
<td class="num">$ (375.1)<span></span>
</td>
<td class="num">$ (206.1)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember', window );">Foreign Currency Translation Gains&#160;(Losses)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTax', window );">Benefit (expense) for income taxes allocated to other comprehensive income (loss) items</a></td>
<td class="num">(133.3)<span></span>
</td>
<td class="num">(39.0)<span></span>
</td>
<td class="num">(234.2)<span></span>
</td>
<td class="num">(92.3)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember', window );">Unrealized net gains/losses on securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTax', window );">Benefit (expense) for income taxes allocated to other comprehensive income (loss) items</a></td>
<td class="nump">3.4<span></span>
</td>
<td class="nump">0.8<span></span>
</td>
<td class="nump">13.1<span></span>
</td>
<td class="nump">3.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember', window );">Defined Benefit Pension and Retiree&#160;Health Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTax', window );">Benefit (expense) for income taxes allocated to other comprehensive income (loss) items</a></td>
<td class="num">(22.4)<span></span>
</td>
<td class="num">(28.2)<span></span>
</td>
<td class="num">(73.2)<span></span>
</td>
<td class="num">(79.7)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember', window );">Effective portion of cash flow hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTax', window );">Benefit (expense) for income taxes allocated to other comprehensive income (loss) items</a></td>
<td class="num">$ (16.9)<span></span>
</td>
<td class="num">$ (5.4)<span></span>
</td>
<td class="num">$ (80.8)<span></span>
</td>
<td class="num">$ (37.9)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) allocated to other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e39076-109324<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e640-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140554504665344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Comprehensive Income (Loss) (Reclassification) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other&#8211;net, (income) expense</a></td>
<td class="num">$ (18.7)<span></span>
</td>
<td class="nump">$ 20.1<span></span>
</td>
<td class="nump">$ 17.0<span></span>
</td>
<td class="nump">$ 34.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Total before tax</a></td>
<td class="nump">1,565.5<span></span>
</td>
<td class="nump">1,245.3<span></span>
</td>
<td class="nump">4,710.0<span></span>
</td>
<td class="nump">4,315.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Tax benefit</a></td>
<td class="num">(113.8)<span></span>
</td>
<td class="num">(135.2)<span></span>
</td>
<td class="num">(402.9)<span></span>
</td>
<td class="num">(460.0)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember', window );">Reclassification out of Accumulated Other Comprehensive Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Total reclassifications, net of tax</a></td>
<td class="nump">71.1<span></span>
</td>
<td class="nump">89.4<span></span>
</td>
<td class="nump">192.4<span></span>
</td>
<td class="nump">269.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember', window );">Defined Benefit Pension and Retiree&#160;Health Benefit Plans | Reclassification out of Accumulated Other Comprehensive Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Total before tax</a></td>
<td class="nump">72.4<span></span>
</td>
<td class="nump">108.8<span></span>
</td>
<td class="nump">218.3<span></span>
</td>
<td class="nump">327.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Tax benefit</a></td>
<td class="num">(15.2)<span></span>
</td>
<td class="num">(22.8)<span></span>
</td>
<td class="num">(45.8)<span></span>
</td>
<td class="num">(68.7)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Total reclassifications, net of tax</a></td>
<td class="nump">57.2<span></span>
</td>
<td class="nump">86.0<span></span>
</td>
<td class="nump">172.5<span></span>
</td>
<td class="nump">258.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember', window );">Prior service benefits, net | Reclassification out of Accumulated Other Comprehensive Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other&#8211;net, (income) expense</a></td>
<td class="num">(13.1)<span></span>
</td>
<td class="num">(13.9)<span></span>
</td>
<td class="num">(39.2)<span></span>
</td>
<td class="num">(41.5)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember', window );">Actuarial losses, net | Reclassification out of Accumulated Other Comprehensive Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other&#8211;net, (income) expense</a></td>
<td class="nump">85.5<span></span>
</td>
<td class="nump">122.7<span></span>
</td>
<td class="nump">257.5<span></span>
</td>
<td class="nump">368.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=lly_AccumulatedGainLossNetCashFlowHedgeAndForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember', window );">Other, net of tax | Reclassification out of Accumulated Other Comprehensive Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other&#8211;net, (income) expense</a></td>
<td class="nump">$ 13.9<span></span>
</td>
<td class="nump">$ 3.4<span></span>
</td>
<td class="nump">$ 19.9<span></span>
</td>
<td class="nump">$ 10.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=lly_AccumulatedGainLossNetCashFlowHedgeAndForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=lly_AccumulatedGainLossNetCashFlowHedgeAndForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140554514938176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other&#8211;Net, (Income) Expense (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Nonoperating Income (Expense) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="nump">$ 81.5<span></span>
</td>
<td class="nump">$ 83.6<span></span>
</td>
<td class="nump">$ 247.6<span></span>
</td>
<td class="nump">$ 258.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="num">(20.1)<span></span>
</td>
<td class="num">(7.0)<span></span>
</td>
<td class="num">(37.3)<span></span>
</td>
<td class="num">(18.0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiGainLoss', window );">Net investment (gains) losses on equity securities (Note 6)</a></td>
<td class="nump">123.3<span></span>
</td>
<td class="nump">246.8<span></span>
</td>
<td class="nump">667.6<span></span>
</td>
<td class="num">(270.1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent', window );">Retirement benefit plans</a></td>
<td class="num">(92.4)<span></span>
</td>
<td class="num">(72.6)<span></span>
</td>
<td class="num">(280.0)<span></span>
</td>
<td class="num">(217.1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Debt extinguishment loss (Note 6)</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">405.2<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">405.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other (income) expense</a></td>
<td class="nump">18.7<span></span>
</td>
<td class="num">(20.1)<span></span>
</td>
<td class="num">(17.0)<span></span>
</td>
<td class="num">(34.1)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other&#8211;net, (income) expense</a></td>
<td class="nump">$ 111.0<span></span>
</td>
<td class="nump">$ 635.9<span></span>
</td>
<td class="nump">$ 580.9<span></span>
</td>
<td class="nump">$ 124.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126980263&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for net periodic benefit cost components, excluding service cost component, of defined benefit plan. Amount includes, but is not limited to, interest cost, expected (return) loss on plan asset, amortization of prior service cost (credit), amortization of (gain) loss, amortization of transition (asset) obligation, settlement (gain) loss, curtailment (gain) loss and certain termination benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>lly-20220930_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2022"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:lly="http://www.lilly.com/20220930"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="lly-20220930.xsd" xlink:type="simple"/>
    <context id="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i71f35536970d471db55131eae57d8a56_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i928ac777ff9b4d2c901021ddb94de4b4_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A718NotesDueJune12025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i47d1aafe63fc4d6a8af84bd5fc7ec42a_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A1.625NotesDueJune22026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ifbf789a7a75f4a94b1ecc8e7f5692048_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A2.125NotesDueJune32030Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i37d6cf7d3d9642f7887a8b59cb2a9056_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A625NotesDue2031Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ia2c9b0358abd4ac1849fbad87ceaf6b2_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A500NotesDue2033Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ib18e156e215841b180cc7996ffae9682_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A6.77NotesDueJanuary12036Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i80ad5b0231594dcca53dbf943886b1f2_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A1625NotesDue2043Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i8e27869f09004f868cb336c53f59bddd_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A1700NotesDue2049Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i94f283ca5ff741c39e115f9c18564a88_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A1125NotesDue2051Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i9b0db4c7708642f7a34b06aae1404242_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A1375NotesDue2061Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i465e2cbbe1e444108f9f7bdae9a93ca5_I20221028">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
        </entity>
        <period>
            <instant>2022-10-28</instant>
        </period>
    </context>
    <context id="i19fc0325c48543008ea71e1fdcf11d86_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ie4fa4f6b472a4f269297591b44aba572_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i167ed8f67bef48c49e54fa466400cdaa_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i08ccb35f6ad24d7793c9c91b74ca2ea1_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i0973ba0c1d894ceaa494709a13f814fb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3ff8d0839ef74b87b0394c920e9dfa82_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ic9a5e6caa6224a1a95516222bf3644c0_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i9fbf406305be444e87d56294647b476e_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="iab7ebbcbace541c5b7a8ee0e0e859b97_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TrustForBenefitOfEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i19336abc2d9f44a7a6562598fdd26074_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i880a0df9a6d245b9a11c009232dc11c9_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i4d264417b4674277a12ca8c8f571f6da_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ice03038a88b14398a99843ecea77cf17_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i37f1eff7c147431d9904c45abe8087de_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i28729f1c595d49408f9bc75addee5dce_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ieabf4a292fa6473cb378b3091605b996_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ia0caea5b6e2742c49986260609ac8cb2_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i5d0c3b9efde1461b8e305f2507573310_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ied5972defca747b08dfeb7847dcbf9b1_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i5e2b4f10aa894a52a243db283dd48374_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i5d24641160994798813313583b8c5313_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TrustForBenefitOfEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ib38bda0500864764be978f7cbb680740_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i7b19ed61f4414f2e89fb8677352c10c6_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i6809dd88ee6440e8b81974c0682727a5_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="id1796d16ca7c4cf0894522a6f064e12e_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ia172fdb106784793868c32f3fe4a033a_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i13cf184e02084806adfd29b238e3b85d_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i044825e6cd0d4decafdaae3baf84a330_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TrustForBenefitOfEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i9cff35c3c8c34c0fb04c18abeacebca6_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i21c6412f9d1948d19b3452207237dadd_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i28fcba67335d4eeeb35e767ac7467d7b_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ib48f338ea64a4a6ab71c4d7e3fd06673_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i55ef102ce6314f71bbad20789a340a44_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="idb26ceb80a3d4067ad9572aeb3904905_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i97b74653944e4f17928c61ac64c196ad_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i1b27ad5aed11494a84032093fe25e25c_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i5c81da162e9a42e2a66c2c1a06d48dd5_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ice411cf446b842b893447accbe09511a_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i8ebf10616d0b4419a14703502b215705_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i422ef8f62e714031b35d70b78011fe07_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TrustForBenefitOfEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i405731ae56194b5ab8d7ef0f5a2a4501_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i7890664142234b2cba495545e31cf06b_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i874cf6e76f6143ffbd4b62dbb7d9d39b_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i9e4e65510f9e48218be4e6b56cc6a8e6_I20210531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
        </entity>
        <period>
            <instant>2021-05-31</instant>
        </period>
    </context>
    <context id="id40dc90365d54458840dc95bd54da311_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i13a4d036feb14d029728aad2602198e3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i89632ef2fab645e59b17e0d04998f005_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i03ad855e73c7425c82de6d5bf47f2c5c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TrustForBenefitOfEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0f26207c7675459eb15f8af1fa1954bd_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i475ce37d989c466ca8d104299897d8b5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="idd150ac2b08f457b820ab337af8f787a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iaae84e0e259740269afbdc32023935d8_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="if4b3bbe2d1454aa7b635ddfa117d7690_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i53f6912753594605b21dd0402024a8d0_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i0f7811d1ec7f49e2b3619fe9097a5c81_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i43c09d3fa78d4c5e896029e6ef10d475_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ieb70d5cf9dee4eaa8c659c22eeb4ea9e_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i272cf8c25ebe4484a64e58f12187ad1b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibf8140dd5b59491da9ea91218accebc6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9d075318dc464943b61778b509358518_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib1b20bf098e647cbbe9a5c1797e3b7a9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TrustForBenefitOfEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i016472e8315c436a845438f1b48dc880_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i39c60ea04aef49b0830a61d60786759c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9a1a2f4319ea49c8a9891d557b01b308_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i53fe950833774c68a3cffa46aff8f74b_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i78ac3ae89d8a4e4b9b5634d9c24f6a88_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i318f185707b94171a8496548525b0a43_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i5fb9024f659a4c12b2ddd5ecc6dd8e7f_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i668d06cad6064c9488359f57b6460125_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i1e65888bb572465d96d1a55aaa12d167_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i82811f99128e46738e63b2b2f09a72ef_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5fcc694940794a94a960d8f1f9315381_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="if42877c131ac415eb21599c372b78f90_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i80d1b089c2a644458859200e15f563c8_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="id3dd0ce52c8549c58e5d29bb1bb1c197_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i1962268fe5e4415bbcb7e76b2f694425_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ie24dcfd7665d4948a6b3ea63d1979c25_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CollaborationandOtherRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i28f16eccfa8b45c9b2f74cc6235732b4_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CollaborationandOtherRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i3ebb89e75b934815a2a398afa3315ad4_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CollaborationandOtherRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i0707295b42774a95baab2b522f5925a8_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CollaborationandOtherRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i34aeabd3620f4de8ad8c2efefc863807_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ia0d2323337da484fb1444b8262ff7a7e_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i16836baff9c344308700232bb53196d6_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ib6db6b88271640b7be37a4c3c9f838c6_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i46e52d8ad0e14ebf9fa7c9ecc503bbfa_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ChangeInAccountingEstimateByTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i72b37618b2b848e48b6d7a66628d0ea0_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ChangeInAccountingEstimateByTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i19f0f8e72ada412eb34eae9afa79a051_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ChangeInAccountingEstimateByTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i7685d8873a9b40f5bab0b11fa36b225d_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ChangeInAccountingEstimateByTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i28a49a83c479441f905c7cffa76d0d1e_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrulicityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i7ce64df6d312430cadd360079f217dd5_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrulicityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i345b235e6d564f1bb6f06b9ed8319a72_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrulicityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i89ca472eabec43fd814b3653fab15181_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrulicityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i7bbccd7a5a8e4837a3a85f1a2b3d2ef1_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrulicityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i46a90cbffcd647a5801317b946ab5209_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrulicityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i5546f63545a844a085ff12b7f2497571_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:JardianceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i348983749551494ba7808729a9dd6254_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:JardianceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="idfba5b60fbbe4370bad16f003f72e3c1_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:JardianceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i669b22e2d64c487fb8bd01c345ab7f38_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:JardianceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i4ab46b2a51674189a54630451735b250_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:JardianceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ia28641f7c767406eacaa8089e13a2e77_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:JardianceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i233675fe0cc34caa880f2ae73fa95cad_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumalogMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i404df183ca794e64b829a2993c89673f_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumalogMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i6069340928544f1d98e220d601c0ccf7_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumalogMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i4b145726bc2c4ed78a3c2ec12b53c5c2_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumalogMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="id28218d7550a4cf4be526f83ae1c7332_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumalogMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ie59d14500008412ea099e2c09441a042_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumalogMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ib99bd175ff46428092a6e96c970b94c5_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumulinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i644d2f1188e14878aaa508d910b54dde_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumulinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i7cc0d4df5329427cb7da48ad36cb2efb_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumulinMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i02d6e02b9e20402bb506e5e37520efdb_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumulinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i40d7116b6c0a470195c3ab9234e5bb0e_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumulinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iec80f91e475941f1abdc131fd14d868d_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumulinMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i529518415079475fa56a8916e119480c_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:BasaglarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ie34f0db27136443ca391ec67d20f46cc_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:BasaglarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="id6f3b41d10de4dfb99b809554e15f4ca_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:BasaglarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="idcd8ed6a0f624997876200ae1a53d3ff_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:BasaglarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i1981e978a66e4861b39ec95f950a699c_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:BasaglarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ieef95d1c0c4643f8a5a104c9301c56f6_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:BasaglarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i7992fe4fc5774bd6aa8b55cf4d326364_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:MounjaroMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i47be57988ea94c92b33e106ae820b8f7_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:MounjaroMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i22fcf936becc4b56b4c435b41fdfd4c7_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:MounjaroMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i866b02b106bf4510aa3acc82ee4887a0_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:MounjaroMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i99914bb8f18546f78ea8cdcaa7af2939_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:MounjaroMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i9094ecfcbf9c4d8bbe63fc38a5f24df0_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:MounjaroMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iceaf7dbcd2d8486cb982fc3658598e56_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherDiabetesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i05fc368927fd409998e10fd8a8626ff3_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherDiabetesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="iadb96dab5219493a8a09e4ef5a30b381_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherDiabetesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i26f16b68de674d2592c2cd9ee9755295_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherDiabetesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ib4a6a3281a6e41eda8915c8ed31cf4c4_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherDiabetesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ib01598d835464cac82cecfbe826de92d_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherDiabetesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="id8862697b08648bcb4c7b9ad3dff39c3_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:DiabetesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="if00d7a9221f04fe68817babf35f51ebf_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:DiabetesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ic1a606c172db416288ba0bbd8baa9966_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:DiabetesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i9d79583b71134ad5b1affaf7d3c9e867_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:DiabetesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i74d4b85fd2a346fb93493d49de1c2bce_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:DiabetesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i42ad32bd431444b189dab3e866f14dce_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:DiabetesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i0c515dd1cd2b453686e3e31d8c9a32d3_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:VerzenioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="id154bceb5f3a4af7bf7c046f1608e110_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:VerzenioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ifb827f745b3b446f900ce979a433b71f_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:VerzenioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i1f8a0004521c4a0ab278bcec0c67c5bd_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:VerzenioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iaf75ab0eae484bb4b01f61ae25f750c5_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:VerzenioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i6b3d0e422c9640ab9313c19640d9fd90_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:VerzenioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i46e236388c73464e81b03a5d53c0dd53_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CyramzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i5b6d4e4158744aaa95ee5bf00acb80cb_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CyramzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i4c1435377d2042d39e6953c271d4585b_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CyramzaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i176af1ca7219458c851326db4f5f0e18_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CyramzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ie4ca284b63654c0bbf5fc3646e324b1b_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CyramzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i48871c7176154dbb971dc8a40b431eca_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CyramzaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ifc30105eafd9459d81eaf411eb4da357_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ErbituxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i84fe5c0fb05340ce93ab592130765d86_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ErbituxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i75db1e7f9d154c588f6bfd88b08dacf2_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ErbituxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ifb220bd49b9b4fee9a08cf2aba4811ff_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ErbituxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="if441e31221c74fb7b06ce4acda75a1ac_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ErbituxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i74ebe2d40f834c6aaed2f9503f82b5c2_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ErbituxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i51fae75c655f4c9db22deca064e1d22a_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:AlimtaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i814e9ebeca8f4359b602b1c4116691fa_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:AlimtaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i093d47ca61034ea8b9f0303b73074f6e_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:AlimtaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i5b8a2c0676cd456a958892b0fdc5f275_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:AlimtaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i01f53de517814e9fae0973ed84a89508_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:AlimtaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i91b98892233a42579bec90b2f1f07fad_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:AlimtaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i578736c37abd4751958301e188d9a111_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TYVYTMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ic105c32b09d5439ab48f1ea47e388e5c_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TYVYTMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ifc8fc5f6c1924a46b0d88ad7ea894f53_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TYVYTMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i326cec97451b4c0fa64fb496bcc0d262_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TYVYTMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="id6f0f8b1cbb14fe5bc88c77765723cdc_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TYVYTMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i9da960751fa245d8bf93fa1681ead439_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TYVYTMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i4280b008d25146138bb9937941f505ac_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherOncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ib83a82fddc51484f973f835759a83951_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherOncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i7add942c6a224625b4aa726843340e48_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherOncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i010a412d535641f895d21d4765b984db_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherOncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i9a1ab61d480a42babad1c189210b4f6f_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherOncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i3d24e8995a5a4ced9875b8b9174e8096_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherOncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="if7ca1b1b8ebc4b97a61e679591aa9aa4_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i98dec2ee927948db8ae6249a13fbc06a_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="idacb7a7257294fe689d448659352e301_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i573f860cee384e44a092723fc9aaea21_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ic45235af254e414c87819d6a61117897_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i3490b47c9d914a7a80f4c441455b8ead_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="id3ed2240ab2944e1a3695929ccce3c61_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TaltzMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="iec46bce8b1474abc9815b6e1b2d7a169_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TaltzMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i800167f3776142a4bf399d8f51830c78_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TaltzMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ia22b346dd2a54714a0f4ba483559b116_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TaltzMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i0852df9f516e48b4a9af370971f46a78_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TaltzMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ia60c521d441f43a2b5801e09809d0abe_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TaltzMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i16529d5d29744762b0746672c1ef5cbf_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i2456bc73ed7d4b8b8bc891900fd86004_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i65843c3594444a24be3c2dd715fb25e8_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="idef6b1951baa49b98d6da883dd4d89b9_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ia1eb3846894a440d9b3b08cf8304da43_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i342e7e7b465546ffa22256042c6bf573_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="id0dbce0c2a604a12ab2550f876430b73_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i32547c688b2942bb9648bd77d09fed5d_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ic666c0215c174e0da07f4d1e09afbca8_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i24578a0bb60d41509dae6c91cf840cf4_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i797465f9dcae46679ecb0c162248cdbf_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i01bedd14598d4bef97fe5433a5abe2ec_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i0bca0633651d410a8f37cdc991be5df2_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i0952e420996041498b88ed77f880c508_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i6386f383c2e5484da28e805bf356222b_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i4d8dd9cfbda345988f0d1cea4fac4546_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="icff9e13bc98e41938e743e7a4e4fd6de_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i5adbec8a8b6b48f7a5d1e48f49bf3411_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i358dff328e02486cae97aaae267517fd_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:EmgalityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i9c4b3d872761408cb58a702f02c9d3dd_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:EmgalityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i88720be3d2b447b38eacb349e966b957_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:EmgalityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i306f66892e60463a9440dd8625f955f2_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:EmgalityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i830b5f4dd99f475f892c9b95d9c74688_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:EmgalityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i04f1fa38b33d409c95edc1ca5dddc792_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:EmgalityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ib3165ffc22844091b6dfdb6536ee8f81_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ZyprexaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i93ab8179e11b4f23a7909ff2a1a2042f_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ZyprexaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ia17da4c4f6b642d596703193f6afe6b9_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ZyprexaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i870e9a03322b437eab5ad616b9b96c9f_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ZyprexaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i119d9834ae424e7fa424cf206e1fa0fa_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ZyprexaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i9028e0822d8749e59ae82cba528438af_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ZyprexaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ib6ab25c06067493bbca70a4e7597fdb8_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CymbaltaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i85be7a9452cb426a90fedddc2f455b01_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CymbaltaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i2b6eac789003419ebceebcc13f624925_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CymbaltaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ibd3368429e0140009581d9d510f8d8ff_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CymbaltaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i734fc13568954b75bd88b7375fbfa00d_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CymbaltaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i53769ba188564f8a86965473de7ac7a2_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CymbaltaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ic8c180d54e944d17bbbf0438a4c8f563_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherNeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i31bc9c1361964102bc7f26ff4a6390ee_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherNeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="icf97b2cc85a442f5bc488f333e264c43_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherNeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i7434dc344c6b4a99973bac3fef8d4f3a_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherNeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i3ed4e34eaaf642748b03cff5ec59a742_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherNeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ifdd2b94511c147b0aa78edfbd1578f35_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherNeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i75c76b5ae8b04d0694593c6b670f2a70_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="if373b9f49fe74bdbbcaeb90bdcf2de8e_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i1f4a20a3083448aabf8de47a307ae3fc_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i9aabeac82be44155a967c8ced0c3a972_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i6d31ef68d52e4c1680dc7d71063a6777_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i6cb7b465f1794abdb49eb28db9903a03_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i0fe5df95a127467ea05981672b21cdba_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:COVID19AntibodiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ib4b9aa980cc940d3870c8d9e4046840e_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:COVID19AntibodiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ic89265df487544d48f864b30c7c12762_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:COVID19AntibodiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i136c9d207de14e89bbae2b72e3112e4a_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:COVID19AntibodiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ic05b3db77dcf4e66b1e09c07f79fd579_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:COVID19AntibodiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i05b4b2fd75f8488cafa80162074dca18_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:COVID19AntibodiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i78e14fd2e59849538d2032aed3e9bb0c_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ForteoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ic73ca51c96f5471cb91194277c299762_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ForteoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i29d5f03b98014ea7af366d7dbec08cc2_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ForteoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i5b6529d5d56e42959333a8689a171264_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ForteoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i99005918fc524bff85805ac964cb5794_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ForteoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i6ec8ff4aa32b406db0037636d5d11b91_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ForteoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="id253637b6dc04f4593c5389197fd1ed5_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CialisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i9b5c45eac140477aa0acc064ef0011ea_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CialisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i57e0cd27dd3c4483afca4b02ab1ab2ea_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CialisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i71526b83a9b84d10a6e1ab1807ab8e18_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CialisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i04e727dddbbd447c91777ca002cf2367_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CialisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i01198f0de24240588ceb005e3647087b_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CialisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="if0fe66e11e054c0a85bb68ff7d7f2857_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i347c502b181c4a13a94b72d8e2a383bf_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ic32c291337714cc290c1dac418f4d40a_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i4760c4e663814ba4816919d7cf1c133d_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i0b57a14b81924b58a902d121891b42eb_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ib28a57467090415586ea5d4a46d5a6ff_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i3bfde2172ab44bdb98ffec5b7744d66c_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductTotalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i4e976e03f8b7452b97fe7c6fa5a98acb_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductTotalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ibb8a914c841d467289183242e217e8c8_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductTotalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i23b21b36e578436fa92bcc41739470c2_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductTotalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ibe9720e656b242efa27c155f58ea5690_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductTotalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i9af8cc7ddb614c4d8a4d4ce694795736_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductTotalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i5ef4c6628ee44bfaba7f2e062c3984ca_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i553eac0570bc41a68be3130cb9383387_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ib7200d1730974b7f929910230bd89187_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i8bdc66e6dc0c4330955f23ef9a18d769_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ie25d63c812ca4ba5bcb202b4ef3da925_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrulicityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i91615b3923a04f6a8fd92d711866d588_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrulicityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i9623881a23db40a3b62885fe7a43e0c9_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrulicityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i46ce2dc33fb14a94972b38a4c73c48ee_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrulicityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i9d256a84bdcc43939ac6114642c9df5a_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrulicityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="idb96fc34e7f1409fb5661213f97e7f9d_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrulicityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i29b3721d52314523b933748df1c86126_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumalogMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i50fdff0f3f64436b8220edeb6c5da6b9_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumalogMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i2bbcd6ec5faf46bc81ff607368bdd5ab_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumalogMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i5f2bb68aeed244a48b9a5b9fe2b0b039_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumalogMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ib6a78f62d5834a11a82558249ee89a7a_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumalogMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i6afc7019eb204b20bc59d3a19fef7f74_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumalogMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i1e18d072344643ada09a2e6559995804_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:JardianceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="idb016f4e6a094b91ac0aee6fd832f15c_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:JardianceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i1c01691865ed49fc84902886c99bbbdf_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:JardianceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ia2d8d981e4314247892b22b49b01d418_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:JardianceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ie65c118c7eb54da8b92e056d23b07e85_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:JardianceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i46099dfb95b0484ab5891f186d350f52_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:JardianceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i3ad9a3d1e7704c9f8a4c92e4f18248ef_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumulinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ib4c358f120c14431858d22fd921cdb1a_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumulinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i97453ba9a92b4601b70738c5fd865a63_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumulinMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i9a4be59d818242b8a5d6e29a133e78b3_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumulinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i74ac58ad376e44179242350ff8091245_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumulinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i4d442db3854641bb9c50b1533223b1bf_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumulinMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i9b84a7f78d3743f383680162b1a79677_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:BasaglarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="if1fd51de24bf4269a3f10390a0eb16b8_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:BasaglarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i1f95ba5af9c24c3eb20dc2c5a3979588_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:BasaglarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i9df6a30c7e76498dbe8e2c10556551c7_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:BasaglarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ifc6cb890a5e04ad3ab5d2c0f4a2935cb_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:BasaglarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="id065d1641c8b4bc19bda4f978edc7f70_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:BasaglarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ie9c6e93828454ef795aef5751d0352fd_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:MounjaroMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i844e2c3c4d3c4a4eb90a291b6edaa117_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:MounjaroMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i8d0e3b68ad424288aedc96a1c3c5e2d2_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:MounjaroMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ibd146a846a384a1cbb7ed3016e2cb317_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:MounjaroMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="idea0b040a90e4c93ababd4c0d4f02647_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:MounjaroMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ie993c12313da41f38573f6bc42f10868_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:MounjaroMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i1ed26a3d9a8b45559192c48d5bb034d4_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherDiabetesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i4cfbe889964e44e3a453aa644188647d_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherDiabetesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i1414ede1c78a462e95bd1b8346592f8b_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherDiabetesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i20194883f2624f82b663260d5199fa21_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherDiabetesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i820e5b799761449bbbf32e97e1e019fa_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherDiabetesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iab636b5286134cd7875bd3dfdf73353a_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherDiabetesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i1356cd272fa54029ba0f0c21fab222b4_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:DiabetesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i19fb57248d6f41d19ef8485870fa08f3_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:DiabetesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i2a4c43c5e76a47ceb09387d84fc5d358_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:DiabetesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ifc6e032f5a9d4001ba9413713acf7354_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:DiabetesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iabf6366b8c134597b8ac64603a6cb066_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:DiabetesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i44a3630aeb244ec2ab5204f6c1650459_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:DiabetesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i630ed70ef3804cddb8e7bd6a2c884284_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:VerzenioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="id50357546429495db587cbaca50bd352_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:VerzenioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i20c536a6925e49838b17da59e54c92aa_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:VerzenioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="if8fd3622c0c34f5f942c2bcf19a84b1b_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:VerzenioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i08e4bcea32b741f3ad619cb7789236d1_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:VerzenioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i6ea3180802c144d4924a8a4b8a919abd_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:VerzenioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ia0759c0458d14fac885984f8686a83c3_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CyramzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i234acbdded404fc5bcf21a6ea711e9ef_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CyramzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ib28d65608ad54ff9b7e45a5c0298b338_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CyramzaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i98867991ccbb44078d309a9dd8539a71_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CyramzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ib811fbcdfc1241359475319e63db4106_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CyramzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ieb20b9b0be4f46bfb05c7b12f39a6a9e_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CyramzaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i64bc0872b6e94aa7bf69b1268d189134_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:AlimtaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="id1a6ba9c9b6a42638bdfdbee6e6f2758_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:AlimtaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i07ddaa6f5dd549048da689638ae982f5_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:AlimtaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i9571c6749464454692162cefb3bb7738_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:AlimtaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i546701dbe3cb400c84bc62c598271f8b_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:AlimtaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i70cb0ea9b68f4680b98801d50a608b14_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:AlimtaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i40507b3da3804796ace099350f243c27_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ErbituxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i680ed22913654e2ead217f9b5989504b_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ErbituxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i0088a078fdd54003819037635cb52f70_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ErbituxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i27e99c349c3a48dcb14b9a15ed3dafe5_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ErbituxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="if0246564d9bc4f02a5441b1f2566bf51_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ErbituxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ic3c22691b22448eca997f30d1f1366e2_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ErbituxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i0302245b5cc5492d85c394bdbd9a59c3_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TYVYTMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="iab104518f25b49a4b922a68ba94e910b_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TYVYTMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i6633f1ca883b4a32962bcd825ba66bfc_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TYVYTMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i6761a6ec70464bd2bba2e8b31d7dfb55_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TYVYTMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i68cac27afeeb4c6ca2de0e2af5aeecd2_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TYVYTMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i3a42a2407e7046519687e4401e714180_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TYVYTMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ib89a61de2c8542719d727ea9b2e4d288_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherOncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ie1753f6d5c4044468226ef9a5f59457c_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherOncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="iffc444b9d88245d5a3bdb35b82ef0d55_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherOncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i85c317c4af504382b28dfedc3facb2dc_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherOncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i6290305d31574c06901b06e6eacfd414_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherOncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i7bf748b95e7a45cf9e722167434f1385_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherOncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i240fc921c5ef4622986756418d0b3d39_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i5db5d222d3da4495a3cd1481fae9b1eb_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="id3038a6b1fd04b43a1855095f482ffd4_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="idf34cf4a2aae43eda96963b778a49168_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ib71c38ea0818475aa548176344240c72_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i7cc9d1bb283d475d915f7fcb4f945c8c_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i08907695f17c4fe487c0f59792752c89_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TaltzMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i4d2d7d0cc9e04232b6d62adfc3777b93_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TaltzMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i7453a607ad674e25bbab08ef19e88d3c_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TaltzMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="iccd3059fecb04f1d94d0044c6e3c7e32_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TaltzMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i3036c3ea47bd4c89bafa4bdba1320abf_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TaltzMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ifea4d8eb21b94b0ca8248b42f02b49e9_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TaltzMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ia4036604f9c945e1a19be8b3aa38e334_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i381560b71db64644aa7adbc056fac279_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i5da2c0b8af014f4085d9e2a62f64ccc7_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i9a1215ba2eae4c7da8010b728800b4d3_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ife8cad1b8c0f45d89f7c79beb6a9506c_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i681b00cc06e740d5afd240016ce29efc_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i8cdc5308202645dfa9f06b53e46a162b_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i6010298ee7bc433e8bebac5a5efc972e_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i659d2c39bfc34df8bd9f7d944a3822a2_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i61df0f1a279148aa9e8254f5980c32dc_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i1e4c4171e5c3493aa1885a72fe4cfa14_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ic9a4f1d7373649528e8dfb81328134a4_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ibb0659e3898241ecbd83bdbf9dc59c78_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i4e251958291a42a3a1c5447458b86d15_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i8aaae8dc85e144a6a4bf886fd061d950_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i2d035bb38a454213828a14551e6edea5_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i71c9047535fe473ba6d96eba16066ad6_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i4cef6079bf0146839ee9f000bdcfe3c4_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iaf50cba6df584b358ccfd1c552ac603a_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:EmgalityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ife6ede2d6f41458f8f350cd5f6ddeb17_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:EmgalityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i0b7c20f1ff97494783d6f4579ff8f7f8_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:EmgalityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i2892d650df3349fe9ae882f6ae942d58_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:EmgalityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ibc4bdc96c6434cc8b53a24c987e9c41e_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:EmgalityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i5d73674530f248b5a702b835849253ef_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:EmgalityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ibd5454cbe2de4d0ea429015722b20f15_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ZyprexaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="id7ad299a8b764bb9813cbf2dcae42919_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ZyprexaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ic3a68db7fa3b428995899c0bf854ba94_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ZyprexaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i006ca6ec8c3c4717aef2b19d419c92a3_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ZyprexaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ib90b244e7d0040c68677396984559ec8_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ZyprexaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iedfe879bea3a496bb3766920c821c198_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ZyprexaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i3f91e524972e42a98fc9b5abba31e458_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CymbaltaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ic3c6fe2019a042c4909c317b26cdf477_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CymbaltaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="iee5d9669f4b344499cebdffb37f32030_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CymbaltaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i3f307f23d1de4f80bbe2e59ea610ff7f_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CymbaltaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i526c0b4d4b3140cfaf92e5209854bd78_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CymbaltaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i733173c6b1a342488769f27288f96647_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CymbaltaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i00d29df7fc444a888bd8f1ac7c7fcd63_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherNeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="id5a61b3abda849d981158a33cc123750_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherNeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i4894a69792984d28b5bd70bdcb925593_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherNeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i2af7293d556c4ac189783fd3d7bfa089_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherNeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="id7dd70175fc2484e9291653ca9b5bcd0_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherNeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iaffd646b91554c9fbd55b7373a9ab9f2_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherNeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i177e8ff27d1b444d8032f9fd6e71b86e_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i20063c304d1142018b211b53b3a1c50b_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i7a5789bb5ddb493385ae07bb301aa500_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i8c8cfb5bc4ac42dba8e3851f39bd2683_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ib59bf69a9b284970b3b6642f7e4b795c_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i84bebc50684e4e1b90500bbb83bb79a6_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i0e5b50746e074ddabe26161b8cf97195_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:COVID19AntibodiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i2ce72c9f883a452ca19b57204999df16_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:COVID19AntibodiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ie674d270134f4cffaff8f7a15471b73e_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:COVID19AntibodiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i62f7a17973be46d9bf4530c993775bef_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:COVID19AntibodiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ifb238d01fbaa4761a5fe7a7c91587c74_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:COVID19AntibodiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ic06f11244a5a4b88822809b3b3941ffe_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:COVID19AntibodiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ifa18b54c7e0f4330b37b5256dc5dffac_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CialisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i8a49509981cc41bbafe688a08ea538c6_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CialisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="iac7de63087cb4fa28c15d4fe01f12460_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CialisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i80c0d99bb34b42e1adce6dce3134630a_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CialisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i6dd390f6ff6a43b49662e266d7334459_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CialisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i51c31c17a15244248305698502760153_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CialisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i3c39dd39688f4abb8ddb719a2260f6bf_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ForteoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i56ac4d65faa946aaaebabc3dc7ca99f9_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ForteoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i185dafd0ab80405eb3f78281a2098c9f_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ForteoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ice1d37ac1886488088492ea4c957a118_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ForteoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i33b45d6e796b4bab93b3906f52ced571_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ForteoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i606443bf75d84de3b93c88a5d2c2a9c5_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ForteoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i62be4d98bd454dbea6bd3764ddcdacb4_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i774d30363ab447e4b7b6985e99b6de0d_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i238722e1d54440828f51f9f11854afaf_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ib4554ea5474043e5b51ccd4cca5610ae_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i1a25265d56d04bc481727001f1d55ecc_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i1fc264d1cb9b42cd927c0bbd387866cc_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i13e5988f996e48299f0ddef7dd648213_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductTotalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i3b007283f3094ae08f3a1b5eca4a7fb8_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductTotalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i5b6298a19c0a4c5da470fa7e5e3e967a_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductTotalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="idcc7138275c74437be6ca40f1474b509_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductTotalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i7efeaf621a9e448fa08571db01806cd3_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductTotalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i7fe3dcab54b44eaf90f9f242c2fe0f52_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductTotalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i60c5eb8ff51d4d9fa0a74c53c73aa0dd_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="if326645430854a2d9ac96495205c029f_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i2783a40327b64633b6abee19f7b4ca30_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i9ff1711a07ba45ffadc911d350d44f94_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i812f3d20a1af4d92924e0bbe1371c71e_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i973b61d370734fa5bcf42303b4a667df_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i4cf771cc163e44ed8acdd62a65cc8b4c_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="id0ffca9720f342dbbe64a17e04c55d84_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ib92bd7160fd94961b7bba02ffbd18490_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i25019079a8464a91a3cf96012fcc0d52_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ib37e987842e2478dab07f58a5f789a49_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="if9ff4ce3b7704faaa359e30df99f2b54_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ic678bb62bdef4faea88b4e3dfd6a7971_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ib648672815904a56b3a3874c085884b6_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="id085508ee8c24a36a655eea7d3096500_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i4b2b1ef297534a4a801da2637a1d37e4_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ib2c80ff08a384ec7a8c6dd07798b9efd_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">lly:OtherForeignCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i59dcfcfb04c94ad588f473c50147a921_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">lly:OtherForeignCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i20e09a0b7eb34ffbbc4057f306b92c3d_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">lly:OtherForeignCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i3c8b51c823f54bb1a2efb0592f5476a3_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">lly:OtherForeignCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="id1a51594b8b04df48cf5b7eff20f7e6d_I20210131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:PrevailTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-31</instant>
        </period>
    </context>
    <context id="i28f89248cda04bd08a5c9d722de7c1db_D20210101-20210131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:PrevailTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="ie6db4c7ca7af4463afc62347bd8b3a94_I20210122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:PrevailTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-22</instant>
        </period>
    </context>
    <context id="i10a5ee4bd0c64813b300c5389565a056_D20210122-20210122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:PrevailTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-22</startDate>
            <endDate>2021-01-22</endDate>
        </period>
    </context>
    <context id="i3b190c0fcac94cb9b4d37191d35b87bb_D20220201-20220228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">lly:BioMarinPharmaceuticalIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-01</startDate>
            <endDate>2022-02-28</endDate>
        </period>
    </context>
    <context id="ifa2b520f9b26403ca1dfc59f5150bb2a_D20210301-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">lly:RigelPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i2a70d59a929b499ca4d9201b21544293_D20210101-20210131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">lly:PrecisionBiosciencesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="ieacc700b698842408fe2f8c736054aa3_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:AkouosAcquisitionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7d940f045f1243808212f82e48b91487_D20221001-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:AkouosAcquisitionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="if142129c01ca4ea0b352f378c8bc9899_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:JardianceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i744124019ee24c83852d6d07406b514c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:JardianceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8a19b281bf8a4f059256a5bba91d053c_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrajentaBIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ic00807c6a67343bd9b77d66d8f53542e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrajentaBIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie2eb6b846c0e477a94f57d35ebf60943_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:BasaglarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ib6657690bf5241ba82f0d73292ac9ea7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:BasaglarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i91e1bea218144eab958a68c72b25b13d_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrajentaBIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i9fe7212a81994bafa9e83b419cfb489f_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrajentaBIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i4cbfd23e4f9c474bac8535d65c4695e8_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrajentaBIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i57c459014f2c4c2797423bd9e7eff879_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrajentaBIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="idfc0a5f22fb44537835f6510caaa9fa5_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:RoyaltyAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i46a25e2e10224815a8f7d26777b2eb48_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsCapitalizedAsIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i445e64ca4f7041e49970bead926a789e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsCapitalizedAsIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i97f0fe2e404740069df426fbe933ed1d_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsSalesBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ia361008dd9de45979f0de7611a5df845_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TYVYTMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsCapitalizedAsIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i9f82e7316ae6411ea23d0347aa8ad8db_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TYVYTMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsCapitalizedAsIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8e3c0bf77cd749d8b6fec828c354954b_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TYVYTMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsSuccessBasedRegulatoryAndSalesBasedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">lly:InnoventBiologicsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ic7d2b40b9fc943b9bfb247bb3c25f43f_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:LebrikizumabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsDevelopmentAndRegulatoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">lly:RocheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="id7f02cde7e1c419684772d2d99dda277_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:LebrikizumabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsSalesBasedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">lly:RocheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i9e48d839c4b14a2e953d735b3bb79f88_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:LebrikizumabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsDevelopmentAndRegulatoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="id39a445d06074ecaa26735263645cb4e_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:LebrikizumabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsSalesBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="iae28a429ac4b40e2a498a65c7eaaedc6_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:LebrikizumabMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="id7a3c615db604cd2baec39887078a8e2_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:BuyUsDollarSellEuroMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="icbc49bb61efe4f65ba8c0e7f0093e86a_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:BuyEuroSellUsDollarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i77c728fb616a42cc8c6b40e0bbdd95d4_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:BuyUSDollarSellChineseYuanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i80a649fe7dd9480994358ed2532d905d_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:BuyUSdollarSellJapaneseYenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i04bcb23b9ae84c9c9a64aca2a3cc4a34_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:BuyBritishPoundandSellUSDollarsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ifd62109e29474416b9bd4cb46c68e40f_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">lly:ForeignCurrencyDenominatedDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i9e675ec6e62d42a9bc9b9a5e61226095_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">lly:ForeignCurrencyDenominatedDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5b6a7a49e6b543c7a9c9f34217259d0f_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:SwapU.S.DollarsToEuroMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i5f4cbed09a8d4efbba96a84a21c4f229_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:SwapSwissFrancsToU.S.DollarsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i223b03ef72744bd2b0b10b131126e63e_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:SellEuroMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="iea65a7fd63824506a3ca41c5d51257a3_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i788cd34fd44840639efca67d73c371ff_D20220915-20220915">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">lly:MaturityDate2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-15</startDate>
            <endDate>2022-09-15</endDate>
        </period>
    </context>
    <context id="i5d53c58f4c7d459489a11fd8bfd27153_I20220914">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">lly:MaturityDate2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-14</instant>
        </period>
    </context>
    <context id="i2c071467da4c408bbfd8f27f707626e7_I20220915">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">lly:MaturityDate2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-15</instant>
        </period>
    </context>
    <context id="i17173f194d1742f38780c496d01c1177_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A050NotesDue2033Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">lly:ForeignCurrencyDenominatedDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="iff7c9802a16c4e94a8b83d2c06fbfd30_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A1125NotesDue2051Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">lly:ForeignCurrencyDenominatedDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i11a8fe2e658c49ab879c662bd320fc8e_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A1375NotesDue2061Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">lly:ForeignCurrencyDenominatedDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="iea81ed26b993414992722e426a530c04_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A1625NotesDue2043Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">lly:ForeignCurrencyDenominatedDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="icdfd3853e3eb4a398286b232426b38b1_D20210901-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">lly:ForeignCurrencyDenominatedDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i96587d4174a14444becf7821313b1347_D20210901-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A395NotesDue2049Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">lly:ForeignCurrencyDenominatedDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i750c23289e514e58bf58ede4855592f4_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A395NotesDue2049Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">lly:ForeignCurrencyDenominatedDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ice18fb651f95409d813656a157f34daf_D20210901-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A415NotesDue2059Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">lly:ForeignCurrencyDenominatedDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i50894bb5721f4dd58072e6ce75ebf15d_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A415NotesDue2059Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">lly:ForeignCurrencyDenominatedDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ice022568bdf042618c2c002393cc3c5d_D20210901-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A3375NotesDue2029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">lly:ForeignCurrencyDenominatedDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iccc6f8c08fc6454c849c681a4dbe3d01_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A3375NotesDue2029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">lly:ForeignCurrencyDenominatedDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i65012aa62d474ff8af6d08eeb55d206a_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:HedgedFixedRateDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ib627ecf64a434a6b8135da0ac7a5fdf7_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:HedgedFixedRateDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i1d213f8c24344d22ada6f016432acea5_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:HedgedFixedRateDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i41a4fdad9bd748be972c155f2f3acedf_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:HedgedFixedRateDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ic55d4cfd09d8486a8b6e1be77dcc5426_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i519d9df9a61b4cbf87c342e3496785cc_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i7bcae384fb484b6aa3e84e7d484b69e9_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i4cc8664469d846a2b0472f04c7e39442_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ic1eb1816cd7241e7af47383c68f534c0_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="if7cd0109836d43de86e2c830d47c9aec_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i5f64e83e66774562be40774b52732fd5_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i9ed2f279ccc74f238d18ee7977fea9e0_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iaaffba52583d4dd09213c45974bda81f_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="idb22c9f9ae5f42d5b5d0691a5daa1547_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i00fa96d219234882925d8b07dc0e9a2f_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i5a4ce07ee9fd474a956ccb68a6af4713_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i0803c43adcc2406c8d72a961bdbdb03a_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:HedgedFixedRateDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ifa347bfa67994dfbad7418e0ab44ad66_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:HedgedFixedRateDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i9300bb3fb0c149928c10ce50be156517_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:HedgedFixedRateDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i65cd935c26b44824a9d84d0554032fa4_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:HedgedFixedRateDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ie32852c9ac004e18a40bd3c886375fa2_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ie539446ea66443f18894fe65b477f3f2_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ieb0755f46c634be3a274f37154dcd835_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ib38ae8d2eee24da7b665b5ba4af2fc25_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iee72a06ebc24478d804a01c9c07503e0_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i847e2e726f374b8997cd2f409d0da50e_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i04964a8dc75f42aeb12d4f04a8c4b0eb_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i735c7ed5628e404298cd5de9565781a5_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i874a4fa6b8034fb7b972ede3e49e5375_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="icc403fcb68ad44ae8c3d0f5675e78f2a_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ic9cf169896e649948e7319fca615da6c_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i792ad77b79a7422690de67f74dc5988f_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ia25fb80ee7f14608ad1bc42cf7dc3d85_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ieb1b4d0ca2904d3699b0c20378d2d4de_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i909f721d549b4d17b64fd5ef7a64ed65_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ida76f129eae2411aac66cefe0c47c6fc_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ic34ce18d9ac34702bf22cdc268d8fddc_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ice641419095d40b58b1ec413657e5350_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ifab6a7669381463baa4bcac0c28cb1ec_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ic8f3a57231c145049540a666d70b036f_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i0bdbf4b6981d423b84e97332dcaf6c1a_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="if1140c058291487fa611ebff0a87770b_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i78d99dff74e3423da8f09146d5ccfac9_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i047635964deb4302a146b6e33a2497a8_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i2743696771f346c8b079973d11a7071f_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i33275a4d21e64200a487dc63563ca001_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i0a4a874cc47f46a2a264722d13461f46_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i5b78e10d989e462c8d6d0340d904cc92_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ic182ac3c1369411e8483ee598bedbe15_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ie5db88938a794a79995152d200739e71_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="if975bb8107f649de87a30d9d0518813d_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i035b6f8bf7fd4eb2ade6d5c56da79b71_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i313d32c12b5e46a3b70bb355b88d33ae_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ia62987f3e7a14b4cba45477046b24356_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i81cc2677a958476298d6e691a227d2ef_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ibafa8194f14245d092cf8e3fef7acc20_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="if5c5c6181311407dbfeb6b2bc5dabd45_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i4cd5419a2b1e4f1dae5ad80e024ffbd8_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ifa5439e6f71a449badc6db614afe1fc0_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ia7e1bfc7167249e09fd9253c7056e6a4_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i184415738c194fc89b0a1a3ae91e05f6_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i99cd69cddcd1432eb41f86a6c107e126_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i9351338d7d4b429093117dd87f8b02de_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i98487cf76fa84cba948c2fa763c08c17_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i921241c16da34890a377c6cc0f05bf9a_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ib8c508d73f5d490c991f152f357c2edc_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i4fcf6ea2160140fcb9374937bebdf459_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i5892dce618474c3397f2f21748d154da_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i839d1d25f31e4a1e8f8686d85cd27d6f_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i66f937e8eb9d439fb99fc1eaf5bb8229_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i8d540d6e9952406eae86fcb404c8aa3f_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="iac853f32fb164d5dbb16b853b6478ad8_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i4d0248c83e9f42aebdedbe45913091c1_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i1f00b6f0d7a346a0bbf8ca789b9b4986_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="id469158a1a2340c0b51dedb185916c2c_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i2330a365ee524585810c28f7dc20e39e_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="idb940b9eace84fd38c98429f0f9808ce_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ib28917d514b84c3397d29e8e54a589da_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ia4c3874a92684287bd36704e5ff16e8a_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i700bccbf1683474084361d2cee367dc8_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ib7532b4a86304eaf897b92f1ef90f733_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:EquityMethodAndOtherInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ic3b630730b424a6d8b697cf0362c83d2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0d06252e717445c989a037b2b13d0128_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6802f141d8af4b8aa65c6abe305eeed2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i124320eb89ce4dfa87c2f2083ad1e10b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2f37875c8bb94fed916b3375076f0703_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i52e3293fb124489e844061750e511c35_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i70cd211932aa44d4b6f18e4a94acaa15_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i47952f5ad6b1477c8890a2ebe950ab13_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iddfe43e26a024cd3b793575cebd70372_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic82b5cca8a0748c4ad44ff28aa5c8c63_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i19bcbbad1685404f997100cdd7ba2b51_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibb1ad2dc0cab41488bb60c7f417df54c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ifb25438d52ac455ba62e9095554c8121_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iabe3e352015e443c90f93e7aee3a5340_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4d09607d938a418caf31b9504379627d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i70c1a238fafa4e82bb91738050707531_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i94da7f9a237b4f5d92545750475e0865_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iace537990e0345b984d5d9b511dbd56b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i122e96dd9f3645a1845a400915d238b3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2193cdcf640b46f79e5eb9ee0bdb3eb2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="idb15d5720b2447969c89619f23a52bcd_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i83fbafd3b87749b69732c68f1032fe86_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if5e4829c2687480ba72b8c79c38602c5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5e0c7dd136f94803b44868029c626465_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i77a8bad9e7b643b3be999c26e7f341f3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3729e6381590490cad36d5c52a3a9a30_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i65d4f921c43e46389cd396c859835baa_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ifea7137c64a940b98bfaf9336e0de8ed_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibb1fc1f870e44eb8b489ae050e35d2ec_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5843990a9b9642e089425093f642f011_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3d4a6fcb14b84769a71beaa7fadd7543_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib55c35900e8f4879bbab1c3db2b414e6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i514a63925c814a928a17a95e4d93d7cb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4e737ad3e2234f028bf65d35bf37f064_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie8e9125bc9f34767a3e05b3c767b3498_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib0e7cf4206ef42778711f85fddbfe12c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i37d081dc80d549d0b7cf06f3dd0f097c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iebaf7a78928c429596dc216106cd2f95_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4a82bacb2ac843e1b6f6f2fe0be9b508_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iddd8d40ea4024e44853ebae245c8ff89_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iee09e9df8cb24a98b446ff1b40b49036_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i76efc9c2d361426a8fabf8f468eae443_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i900be75d24cb4d0e8aaf431324f245f7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic0829e7b5687473690dec2d117e19409_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icdba688916644cc684b154cd319074ad_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i74870f5304a445feafaa0e95c37df511_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iec666b23a81840999cae844ee05abaf5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4dddf28fc04840efa98b6944bdadf64c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i89e7fea8ea92492693f830dd7afa0d55_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:EquityMethodAndOtherInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i49af86cdb4774f6da136e21a258b9f38_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i9b96398a66a144a9aa05b43dea309d1a_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i9eb05f2daf0940029ed9c6f6079b072c_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i0cbd0bb84e934e18aa8a68f2ed4e3278_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i5e03886140d04a0f90b726a0b8cb04a2_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ie1da8e0f672e4bc390cd335a91d4cf83_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i7cba691ea8004d118d604043b64cd431_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="id1657a9a2856448687ac9aaada343dd5_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i020782910cc740779ffa9060458113ba_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i8f69ca689c7e4d23aa1cab488bb7ed65_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i1300d5f8c7d44be79cb93f333746c580_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="iaca361ecbf3749b7a324afc87754e17e_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i5ac9d317ae404d2ebdc37459bd98e0c0_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ib6a56ab1b3ed4c26b10443b11b7c0c23_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="id7268bc376574172920167043f112985_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="id872aa3055934897a2abffb3543add56_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="idfd9f0975707442aa9a203b7a16441c5_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ib2eb41ed3d014ed4b273125814f78a0d_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i79464644e1f741088bd241cb52754676_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i35a8009df6dc423f85c1ef726d565a66_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ib616e3ba735b4f66ace91c9075e315e3_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i7d14a5f5fcc44e8b974f3d717097b500_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i7cf0b43a5a854904951946bba3c063dd_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ie06f4bbec8ae497db6f7f77940abcf72_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="idd5c8623b0274f569a6e9cb890fe814d_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="id0faa86378a146a48b2256a18f02b7d5_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="iec96867cd1734fb382b9a966a90c804e_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i8d0b53a09fec472eab66541ef6214321_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i1354c03ac64d49b996ad815decc0f6d7_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ibc6aec644ba74dffa95a469f4848e6bc_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i3a65232f1fca4f95abbb3167ab435068_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i40ccf9cc0ff7401eab9722772af73854_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4aa9bedfa4ea4600ab40f4f731255ce9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6a47a49c720948c3b475ad8f3cf1ff16_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i024a1912186c40c1a4e62a542f42350c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i318612662ee348ca8f4c50e967285c42_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6b3448a25ab94a89aef263d03a2bd29a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i841d22572a894c128f4304c5a9d761b0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie51a0fafa7104530b58bfc8df0b750d4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0999361082eb4d43bc2fc7f00ef0bae3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8a94f32b7cb642279222210de17f03ed_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iab252218731740b9a75cb6728b7b9503_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5a6a92fb8f674015b49e7f493a12c723_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iee54e09047ba4b21a41fa3c8cc49cec2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icf2c03c7d41e4db1941ec3f47533b5ac_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i09f8de57c8924dc5916922a278ad4eb1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1339ff825ab84e1292a5f32205bb84fb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iddd7166aae2b440ab53a23a0b63e2aa9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic06c23f16f4443f78411fcbe2a43f013_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia6485e6d1b024de18d35df5658693713_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9674dda0210248f68699af728a2b7366_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i05396d0962d648b89a38691fab6227da_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i637a8ab6a8a7402880d7c301d82ac216_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i47903bc5967647c3ad861c42d533efb5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i22af614be29843faa74794b4926362d9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i62df949acd3f4b47ae7d10432a08e2ab_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i67750cd7b626486fa748e5b71374a667_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ifea67e1feada4a8c8d0bf25c34910e9a_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i19f7d57c42aa4dde893b82e5f134cfc1_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i0116b5022f7f41b494fd355fe823d76e_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i8a97c43966fd4f6aaf5f8dfb7bba4701_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i238afcd7e9494cbb9f4c68c1cf1dcc2d_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i6b0c929331c241cb98c2a4d85625e2e7_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i60435d86ecc44d56b9b471e301119ba4_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i146fcce3fad6486aa91cf7ba94fd98c8_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ib414aaa5a0174c7fb17ac9898d399d32_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">lly:EmgalityPatentLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="if274934ece0041f487b43797bc8de648_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">lly:EmgalityPatentLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ibcc5f2496e02449abe458e54c0a8a61f_I20221031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">lly:EmgalityPatentLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-31</instant>
        </period>
    </context>
    <context id="i58d8155218724e10a6956cdd38ca1bb1_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ByettaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i03a0a6037fc44e39af8b9a0fc87cbcbb_D20090301-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ByettaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2009-03-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="iedfe8e594f2d4534ba3f7d18996055ec_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:UnfavorableRegulatoryActionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i7b4e96e210ab4559a67ee97574922011_D20180701-20180731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">lly:EmployeeLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-07-31</endDate>
        </period>
    </context>
    <context id="i983baf60b46f4dc0ab264f727cff1fd1_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">lly:EmployeeLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="id52423032e6747898c41a944e3038420_D20190701-20190731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">lly:EmployeeLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-07-31</endDate>
        </period>
    </context>
    <context id="i098637113ce84c2f8c583d5aac35942b_D20210601-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">lly:EmployeeLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i91a11e76b2844622ba08c167af2c1bbd_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">lly:EmployeeLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i3fd1ac8f6fc9438cb71e216b3246793e_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumalogHumulinAndForteoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="if2605d2b37d747e1b5887703c18e4963_D20210701-20210731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:InsulinMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-07-31</endDate>
        </period>
    </context>
    <context id="ia44884b555f84a8bb8c051329b5b483c_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="icf1cf37660ed42919d552edbdc9ddf29_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ib07a74d7836447719291eff28ad65a22_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ia3f2ab912d2b47e7862abe56a92bb118_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ic22b2460974b4792a24b9b75e0e598d3_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ibb680e42808d41b587bffa2f35409a91_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ib423da078b9740019ae03257a6ca1320_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i0ddaa7c4639946b1a63ee163ebac9cda_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i9e78a70b50b740909d4bd5980c556e3a_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i603b413215ff4ac0860f74b6a1be9294_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i6105e19d65744395aeb2921c7555324a_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i1ec1c7b3b72549149e283cdff33abeed_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ifc51fbfd706a4f809013d42ddd4fef8c_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="iad56c44530dd4208959b336f8d1fe8b1_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i9b7795dc491c42cbb64812b2b99d2ac9_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ideb9d32d39e441f68ba01504bca2b03c_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="iec456e1ce7794922919937b65a44561f_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i2988484b109649f28736efa0418c49f9_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="id29f7d92807d4933b0fb1e960563f81f_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i3153def44849420f812d26d82e12f780_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i525ab1d53cfc40b99c19c64b4d032446_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i4b3bb220bf604c6daaf72988d3e20703_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i24f2b962044749c5a2936c59a2f25aa9_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iab4358396efe4d7f92c5aab447052434_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i5be060faaa5146e7a2bf742eb38f7bec_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i894ae4ccbe404068bbc052f007cea48c_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ic74e9458c4f44462a21bfd6f33c8c50d_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i9ed755da42e84ed28970211b57db0d80_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="if779a9c74164409ab40929f3c1a22e08_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i15e5d118ed234a2f82b7b9a362d215d8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib7546d9d8f53446e8b4f3eed0a4210c4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if2ce5c439794420c8829fd223a835cd4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic63664fe4e074a5599837d8254019a8b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i13abcd536a74422a91f0be2e859c5f11_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ieeda2eb9aa724c2eb2b08a110d5910ca_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i1c0ca46f62b245baa26e2ca939e70c30_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i698e8cd8a6e44a719d0a96611610bdf4_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i4b2bb6e433df4a26acb1d1cfbcc2ce7d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic15a6784d2e64c5b9176f90a12f6b997_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if4dbdc6b4ce3472bb83f35a58ba62009_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4084f6774b4344709f32500dfb758be3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i61189f333c704d8a9f0dffcd44fd0870_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4def4770d4c9484b9eafab55058f4c06_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="if73a641a34fe4591b395573cedb1bea4_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i71a11ec78f2242498930e393cd63658b_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i314c9492fa9044c3a8d05e0fc3ad2e63_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iaaff00acdddb497fb5b94bf8d2ff771d_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ia0716cc08360439bb971180db7de8214_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i1e81189c858b4d59b30b2380c8bf756b_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="iafe03a1322e544acb123846499dfb8f0_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iedc64e6c0ae84f6f8f6f168b1b71f00f_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i02ba7e57b97e4c15aa93cdacb3f05447_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i8d7550b247eb4a90ac3acd3ea2eab6ad_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="if8458e6a1b9b4239b31d01e183c0368d_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i14e2a21089594bfda05e2f482a1a9fdb_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="if60b1262bf5c4116ad9ba0e69b270a48_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i913335a3ccfe4b639f36db1017ae92af_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i7c947211ed8b449b9617f0791f225696_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ib98dca097ce342f1856252087101e534_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">lly:AccumulatedGainLossNetCashFlowHedgeAndForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="if20e319a4c3045b8b0693a8773446ca4_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">lly:AccumulatedGainLossNetCashFlowHedgeAndForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i06f2cc53bd804ced906cc353bccf23bd_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">lly:AccumulatedGainLossNetCashFlowHedgeAndForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i562107a932c943419a75d588f68a7ede_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">lly:AccumulatedGainLossNetCashFlowHedgeAndForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i294aedf137cf40faaba28e6d98a540dc_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="id04bc0ea75e7453daeb27bfa63e91d46_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="id8fcac86ddf342cf954cceefebfd7779_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i741049a232dc40728bbe8ee225522d87_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="right">
        <measure>lly:right</measure>
    </unit>
    <unit id="eur">
        <measure>iso4217:EUR</measure>
    </unit>
    <unit id="cny">
        <measure>iso4217:CNY</measure>
    </unit>
    <unit id="jpy">
        <measure>iso4217:JPY</measure>
    </unit>
    <unit id="gbp">
        <measure>iso4217:GBP</measure>
    </unit>
    <unit id="patent">
        <measure>lly:patent</measure>
    </unit>
    <unit id="lawsuit">
        <measure>lly:lawsuit</measure>
    </unit>
    <unit id="plaintiff">
        <measure>lly:plaintiff</measure>
    </unit>
    <unit id="site">
        <measure>lly:site</measure>
    </unit>
    <unit id="brl">
        <measure>iso4217:BRL</measure>
    </unit>
    <unit id="claim">
        <measure>lly:claim</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180L2ZyYWc6ZjA3ZDU1NzE1NmRmNGQ5N2EzYzgzZDUxMGI0NWIxNzQvdGFibGU6MDYwZDA0Mzk1MDFhNDAyNWJhODgzODY0ZDdjMDk2ZjEvdGFibGVyYW5nZTowNjBkMDQzOTUwMWE0MDI1YmE4ODM4NjRkN2MwOTZmMV8zLTEtMS0xLTE1OTU0MA_582a62c1-1ee7-48d5-940c-9bc41e37fa54">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180L2ZyYWc6ZjA3ZDU1NzE1NmRmNGQ5N2EzYzgzZDUxMGI0NWIxNzQvdGFibGU6MDYwZDA0Mzk1MDFhNDAyNWJhODgzODY0ZDdjMDk2ZjEvdGFibGVyYW5nZTowNjBkMDQzOTUwMWE0MDI1YmE4ODM4NjRkN2MwOTZmMV80LTEtMS0xLTE1OTU0MA_d1904b85-d2d2-4d0f-b9cb-92fb32c5a711">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180L2ZyYWc6ZjA3ZDU1NzE1NmRmNGQ5N2EzYzgzZDUxMGI0NWIxNzQvdGFibGU6MDYwZDA0Mzk1MDFhNDAyNWJhODgzODY0ZDdjMDk2ZjEvdGFibGVyYW5nZTowNjBkMDQzOTUwMWE0MDI1YmE4ODM4NjRkN2MwOTZmMV81LTEtMS0xLTE1OTU0MA_eb986dfe-7a49-49a0-a37d-1798f409ef8a">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180L2ZyYWc6ZjA3ZDU1NzE1NmRmNGQ5N2EzYzgzZDUxMGI0NWIxNzQvdGFibGU6MDYwZDA0Mzk1MDFhNDAyNWJhODgzODY0ZDdjMDk2ZjEvdGFibGVyYW5nZTowNjBkMDQzOTUwMWE0MDI1YmE4ODM4NjRkN2MwOTZmMV82LTEtMS0xLTE1OTU0MA_3c9cc8c2-a16e-432e-92f2-c55e9d7a051d">0000059478</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180L2ZyYWc6ZjA3ZDU1NzE1NmRmNGQ5N2EzYzgzZDUxMGI0NWIxNzQvdGFibGU6MDYwZDA0Mzk1MDFhNDAyNWJhODgzODY0ZDdjMDk2ZjEvdGFibGVyYW5nZTowNjBkMDQzOTUwMWE0MDI1YmE4ODM4NjRkN2MwOTZmMV83LTEtMS0xLTE1OTU0MA_c6179d16-4bd6-492e-8406-ea9ff242a47a">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentType
      contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xL2ZyYWc6N2FjMGRkOGIzNWQxNDhiNzlmYTVkMTUwOTYwZGFmZWIvdGV4dHJlZ2lvbjo3YWMwZGQ4YjM1ZDE0OGI3OWZhNWQxNTA5NjBkYWZlYl8yMDM2_73d5082c-d8c0-4f73-bd05-2f9a6414fe05">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xL2ZyYWc6N2FjMGRkOGIzNWQxNDhiNzlmYTVkMTUwOTYwZGFmZWIvdGV4dHJlZ2lvbjo3YWMwZGQ4YjM1ZDE0OGI3OWZhNWQxNTA5NjBkYWZlYl8yMDQx_103acb8c-ca70-4068-acc9-4530f68a6bba">true</dei:DocumentQuarterlyReport>
    <dei:DocumentTransitionReport
      contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xL2ZyYWc6N2FjMGRkOGIzNWQxNDhiNzlmYTVkMTUwOTYwZGFmZWIvdGV4dHJlZ2lvbjo3YWMwZGQ4YjM1ZDE0OGI3OWZhNWQxNTA5NjBkYWZlYl8yMDQx_87ed946d-d898-44d7-ae4d-ada2ac30381d">false</dei:DocumentTransitionReport>
    <dei:DocumentPeriodEndDate
      contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xL2ZyYWc6N2FjMGRkOGIzNWQxNDhiNzlmYTVkMTUwOTYwZGFmZWIvdGV4dHJlZ2lvbjo3YWMwZGQ4YjM1ZDE0OGI3OWZhNWQxNTA5NjBkYWZlYl8yMTA_5776ee39-678b-4d2f-9d1e-7a5c35071614">2022-09-30</dei:DocumentPeriodEndDate>
    <dei:EntityFileNumber
      contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xL2ZyYWc6N2FjMGRkOGIzNWQxNDhiNzlmYTVkMTUwOTYwZGFmZWIvdGV4dHJlZ2lvbjo3YWMwZGQ4YjM1ZDE0OGI3OWZhNWQxNTA5NjBkYWZlYl8yMDM1_22c99662-191c-4e79-9904-cd9149835d85">001-6351</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xL2ZyYWc6N2FjMGRkOGIzNWQxNDhiNzlmYTVkMTUwOTYwZGFmZWIvdGV4dHJlZ2lvbjo3YWMwZGQ4YjM1ZDE0OGI3OWZhNWQxNTA5NjBkYWZlYl8yMDQy_cc5f090c-cab8-4dc3-8289-5f068daef1f4">ELI LILLY AND COMPANY</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xL2ZyYWc6N2FjMGRkOGIzNWQxNDhiNzlmYTVkMTUwOTYwZGFmZWIvdGFibGU6ZjI0MWE4MmNiMTRkNDQwZDllNzFmMDkyMTQ1NTE5OTYvdGFibGVyYW5nZTpmMjQxYTgyY2IxNGQ0NDBkOWU3MWYwOTIxNDU1MTk5Nl8wLTAtMS0xLTE1OTU0MA_544edd58-36aa-4953-8559-944f5279d3a0">IN</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xL2ZyYWc6N2FjMGRkOGIzNWQxNDhiNzlmYTVkMTUwOTYwZGFmZWIvdGFibGU6ZjI0MWE4MmNiMTRkNDQwZDllNzFmMDkyMTQ1NTE5OTYvdGFibGVyYW5nZTpmMjQxYTgyY2IxNGQ0NDBkOWU3MWYwOTIxNDU1MTk5Nl8wLTItMS0xLTE1OTU0MA_18dc1a91-46f8-4a4b-b238-03a6332df688">35-0470950</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xL2ZyYWc6N2FjMGRkOGIzNWQxNDhiNzlmYTVkMTUwOTYwZGFmZWIvdGV4dHJlZ2lvbjo3YWMwZGQ4YjM1ZDE0OGI3OWZhNWQxNTA5NjBkYWZlYl8yMDM3_12745fad-11a6-4bd2-8050-e7644e0fb50c">Lilly Corporate Center</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xL2ZyYWc6N2FjMGRkOGIzNWQxNDhiNzlmYTVkMTUwOTYwZGFmZWIvdGV4dHJlZ2lvbjo3YWMwZGQ4YjM1ZDE0OGI3OWZhNWQxNTA5NjBkYWZlYl8yMDQz_2ab6411c-9a74-4238-948e-10e986fb63ed">Indianapolis</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xL2ZyYWc6N2FjMGRkOGIzNWQxNDhiNzlmYTVkMTUwOTYwZGFmZWIvdGV4dHJlZ2lvbjo3YWMwZGQ4YjM1ZDE0OGI3OWZhNWQxNTA5NjBkYWZlYl8yMDM4_6ef11003-a667-4a31-88b5-ad77a11e4b2b">IN</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xL2ZyYWc6N2FjMGRkOGIzNWQxNDhiNzlmYTVkMTUwOTYwZGFmZWIvdGV4dHJlZ2lvbjo3YWMwZGQ4YjM1ZDE0OGI3OWZhNWQxNTA5NjBkYWZlYl8yMDQ2_53080333-60a1-48da-96c8-abf2f245efb0">46285</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xL2ZyYWc6N2FjMGRkOGIzNWQxNDhiNzlmYTVkMTUwOTYwZGFmZWIvdGV4dHJlZ2lvbjo3YWMwZGQ4YjM1ZDE0OGI3OWZhNWQxNTA5NjBkYWZlYl8yMDQ0_d89df568-cd87-4970-a2d0-1ac793463acc">317</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xL2ZyYWc6N2FjMGRkOGIzNWQxNDhiNzlmYTVkMTUwOTYwZGFmZWIvdGV4dHJlZ2lvbjo3YWMwZGQ4YjM1ZDE0OGI3OWZhNWQxNTA5NjBkYWZlYl8yMDM5_482405d2-915b-4844-86f0-bfe33594cc69">276-2000</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i71f35536970d471db55131eae57d8a56_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xL2ZyYWc6N2FjMGRkOGIzNWQxNDhiNzlmYTVkMTUwOTYwZGFmZWIvdGFibGU6Y2UxN2EyYzQ3OWQ4NGQ0NTkyMTc5NDk3NGE2ZDJhMzUvdGFibGVyYW5nZTpjZTE3YTJjNDc5ZDg0ZDQ1OTIxNzk0OTc0YTZkMmEzNV8xLTAtMS0xLTE1OTU0MA_f71fb43d-9e49-4cda-814a-21e6f778f94e">Common Stock (no par value)</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i71f35536970d471db55131eae57d8a56_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xL2ZyYWc6N2FjMGRkOGIzNWQxNDhiNzlmYTVkMTUwOTYwZGFmZWIvdGFibGU6Y2UxN2EyYzQ3OWQ4NGQ0NTkyMTc5NDk3NGE2ZDJhMzUvdGFibGVyYW5nZTpjZTE3YTJjNDc5ZDg0ZDQ1OTIxNzk0OTc0YTZkMmEzNV8xLTEtMS0xLTE1OTU0MA_4dfed371-b10d-493b-9463-99477b5265ec">LLY</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i71f35536970d471db55131eae57d8a56_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xL2ZyYWc6N2FjMGRkOGIzNWQxNDhiNzlmYTVkMTUwOTYwZGFmZWIvdGFibGU6Y2UxN2EyYzQ3OWQ4NGQ0NTkyMTc5NDk3NGE2ZDJhMzUvdGFibGVyYW5nZTpjZTE3YTJjNDc5ZDg0ZDQ1OTIxNzk0OTc0YTZkMmEzNV8xLTItMS0xLTE1OTU0MA_97eda022-c29e-4a61-b940-00d36daaa181">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="i928ac777ff9b4d2c901021ddb94de4b4_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xL2ZyYWc6N2FjMGRkOGIzNWQxNDhiNzlmYTVkMTUwOTYwZGFmZWIvdGFibGU6Y2UxN2EyYzQ3OWQ4NGQ0NTkyMTc5NDk3NGE2ZDJhMzUvdGFibGVyYW5nZTpjZTE3YTJjNDc5ZDg0ZDQ1OTIxNzk0OTc0YTZkMmEzNV8yLTAtMS0xLTE1OTU0MA_b7df35ec-565b-4860-97d1-5bd49c0a8bac">7 1/8% Notes due 2025</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i928ac777ff9b4d2c901021ddb94de4b4_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xL2ZyYWc6N2FjMGRkOGIzNWQxNDhiNzlmYTVkMTUwOTYwZGFmZWIvdGFibGU6Y2UxN2EyYzQ3OWQ4NGQ0NTkyMTc5NDk3NGE2ZDJhMzUvdGFibGVyYW5nZTpjZTE3YTJjNDc5ZDg0ZDQ1OTIxNzk0OTc0YTZkMmEzNV8yLTEtMS0xLTE1OTU0MA_de65a88d-e01d-4fbc-84cb-fb57e15ebc31">LLY25</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i928ac777ff9b4d2c901021ddb94de4b4_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xL2ZyYWc6N2FjMGRkOGIzNWQxNDhiNzlmYTVkMTUwOTYwZGFmZWIvdGFibGU6Y2UxN2EyYzQ3OWQ4NGQ0NTkyMTc5NDk3NGE2ZDJhMzUvdGFibGVyYW5nZTpjZTE3YTJjNDc5ZDg0ZDQ1OTIxNzk0OTc0YTZkMmEzNV8yLTItMS0xLTE1OTU0MA_901b837b-1cbc-4215-87cc-22ae463a38fc">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="i47d1aafe63fc4d6a8af84bd5fc7ec42a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xL2ZyYWc6N2FjMGRkOGIzNWQxNDhiNzlmYTVkMTUwOTYwZGFmZWIvdGFibGU6Y2UxN2EyYzQ3OWQ4NGQ0NTkyMTc5NDk3NGE2ZDJhMzUvdGFibGVyYW5nZTpjZTE3YTJjNDc5ZDg0ZDQ1OTIxNzk0OTc0YTZkMmEzNV8zLTAtMS0xLTE1OTU0MA_5da37923-32d2-4be4-b5e5-2c7377898110">1.625% Notes due 2026</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i47d1aafe63fc4d6a8af84bd5fc7ec42a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xL2ZyYWc6N2FjMGRkOGIzNWQxNDhiNzlmYTVkMTUwOTYwZGFmZWIvdGFibGU6Y2UxN2EyYzQ3OWQ4NGQ0NTkyMTc5NDk3NGE2ZDJhMzUvdGFibGVyYW5nZTpjZTE3YTJjNDc5ZDg0ZDQ1OTIxNzk0OTc0YTZkMmEzNV8zLTEtMS0xLTE1OTU0MA_f4eaed6d-249f-4cef-8ee0-54629ceeff1f">LLY26</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i47d1aafe63fc4d6a8af84bd5fc7ec42a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xL2ZyYWc6N2FjMGRkOGIzNWQxNDhiNzlmYTVkMTUwOTYwZGFmZWIvdGFibGU6Y2UxN2EyYzQ3OWQ4NGQ0NTkyMTc5NDk3NGE2ZDJhMzUvdGFibGVyYW5nZTpjZTE3YTJjNDc5ZDg0ZDQ1OTIxNzk0OTc0YTZkMmEzNV8zLTItMS0xLTE1OTU0MA_7c614c28-7332-464d-9027-5e638f6cc8ba">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="ifbf789a7a75f4a94b1ecc8e7f5692048_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xL2ZyYWc6N2FjMGRkOGIzNWQxNDhiNzlmYTVkMTUwOTYwZGFmZWIvdGFibGU6Y2UxN2EyYzQ3OWQ4NGQ0NTkyMTc5NDk3NGE2ZDJhMzUvdGFibGVyYW5nZTpjZTE3YTJjNDc5ZDg0ZDQ1OTIxNzk0OTc0YTZkMmEzNV80LTAtMS0xLTE1OTU0MA_46b96503-24b6-4a19-8510-753d303f604f">2.125% Notes due 2030</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ifbf789a7a75f4a94b1ecc8e7f5692048_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xL2ZyYWc6N2FjMGRkOGIzNWQxNDhiNzlmYTVkMTUwOTYwZGFmZWIvdGFibGU6Y2UxN2EyYzQ3OWQ4NGQ0NTkyMTc5NDk3NGE2ZDJhMzUvdGFibGVyYW5nZTpjZTE3YTJjNDc5ZDg0ZDQ1OTIxNzk0OTc0YTZkMmEzNV80LTEtMS0xLTE1OTU0MA_0e404cc8-ac8c-4df3-b67c-f354b5fac456">LLY30</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ifbf789a7a75f4a94b1ecc8e7f5692048_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xL2ZyYWc6N2FjMGRkOGIzNWQxNDhiNzlmYTVkMTUwOTYwZGFmZWIvdGFibGU6Y2UxN2EyYzQ3OWQ4NGQ0NTkyMTc5NDk3NGE2ZDJhMzUvdGFibGVyYW5nZTpjZTE3YTJjNDc5ZDg0ZDQ1OTIxNzk0OTc0YTZkMmEzNV80LTItMS0xLTE1OTU0MA_aef8cbe7-ee4c-40af-8ab0-53dfe96a5193">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="i37d6cf7d3d9642f7887a8b59cb2a9056_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xL2ZyYWc6N2FjMGRkOGIzNWQxNDhiNzlmYTVkMTUwOTYwZGFmZWIvdGFibGU6Y2UxN2EyYzQ3OWQ4NGQ0NTkyMTc5NDk3NGE2ZDJhMzUvdGFibGVyYW5nZTpjZTE3YTJjNDc5ZDg0ZDQ1OTIxNzk0OTc0YTZkMmEzNV81LTAtMS0xLTE1OTU0MA_913a9fed-3e04-4e4c-807c-67eab2803549">0.625% Notes due 2031</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i37d6cf7d3d9642f7887a8b59cb2a9056_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xL2ZyYWc6N2FjMGRkOGIzNWQxNDhiNzlmYTVkMTUwOTYwZGFmZWIvdGFibGU6Y2UxN2EyYzQ3OWQ4NGQ0NTkyMTc5NDk3NGE2ZDJhMzUvdGFibGVyYW5nZTpjZTE3YTJjNDc5ZDg0ZDQ1OTIxNzk0OTc0YTZkMmEzNV81LTEtMS0xLTE1OTU0MA_ffc66a88-c114-447b-b7bc-5bf915ea4017">LLY31</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i37d6cf7d3d9642f7887a8b59cb2a9056_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xL2ZyYWc6N2FjMGRkOGIzNWQxNDhiNzlmYTVkMTUwOTYwZGFmZWIvdGFibGU6Y2UxN2EyYzQ3OWQ4NGQ0NTkyMTc5NDk3NGE2ZDJhMzUvdGFibGVyYW5nZTpjZTE3YTJjNDc5ZDg0ZDQ1OTIxNzk0OTc0YTZkMmEzNV81LTItMS0xLTE1OTU0MA_c75a01b5-50fe-43de-8a36-42a017bff4c4">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="ia2c9b0358abd4ac1849fbad87ceaf6b2_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xL2ZyYWc6N2FjMGRkOGIzNWQxNDhiNzlmYTVkMTUwOTYwZGFmZWIvdGFibGU6Y2UxN2EyYzQ3OWQ4NGQ0NTkyMTc5NDk3NGE2ZDJhMzUvdGFibGVyYW5nZTpjZTE3YTJjNDc5ZDg0ZDQ1OTIxNzk0OTc0YTZkMmEzNV82LTAtMS0xLTE1OTU0MA_9a5b992b-e8f8-4ab7-a40b-3246ba3fb5b5">0.500% Notes due 2033</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ia2c9b0358abd4ac1849fbad87ceaf6b2_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xL2ZyYWc6N2FjMGRkOGIzNWQxNDhiNzlmYTVkMTUwOTYwZGFmZWIvdGFibGU6Y2UxN2EyYzQ3OWQ4NGQ0NTkyMTc5NDk3NGE2ZDJhMzUvdGFibGVyYW5nZTpjZTE3YTJjNDc5ZDg0ZDQ1OTIxNzk0OTc0YTZkMmEzNV82LTEtMS0xLTE1OTU0MA_3606775e-049b-4974-81ad-61a808c92e70">LLY33</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ia2c9b0358abd4ac1849fbad87ceaf6b2_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xL2ZyYWc6N2FjMGRkOGIzNWQxNDhiNzlmYTVkMTUwOTYwZGFmZWIvdGFibGU6Y2UxN2EyYzQ3OWQ4NGQ0NTkyMTc5NDk3NGE2ZDJhMzUvdGFibGVyYW5nZTpjZTE3YTJjNDc5ZDg0ZDQ1OTIxNzk0OTc0YTZkMmEzNV82LTItMS0xLTE1OTU0MA_81c94f71-d34a-477c-a69c-2a7419c1d02e">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="ib18e156e215841b180cc7996ffae9682_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xL2ZyYWc6N2FjMGRkOGIzNWQxNDhiNzlmYTVkMTUwOTYwZGFmZWIvdGFibGU6Y2UxN2EyYzQ3OWQ4NGQ0NTkyMTc5NDk3NGE2ZDJhMzUvdGFibGVyYW5nZTpjZTE3YTJjNDc5ZDg0ZDQ1OTIxNzk0OTc0YTZkMmEzNV83LTAtMS0xLTE1OTU0MA_158fa2e6-e28a-47c4-ac49-d1f6607bd5ac">6.77%&#160;Notes due 2036</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ib18e156e215841b180cc7996ffae9682_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xL2ZyYWc6N2FjMGRkOGIzNWQxNDhiNzlmYTVkMTUwOTYwZGFmZWIvdGFibGU6Y2UxN2EyYzQ3OWQ4NGQ0NTkyMTc5NDk3NGE2ZDJhMzUvdGFibGVyYW5nZTpjZTE3YTJjNDc5ZDg0ZDQ1OTIxNzk0OTc0YTZkMmEzNV83LTEtMS0xLTE1OTU0MA_41257b97-39d8-456d-bc21-65ea645cf931">LLY36</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ib18e156e215841b180cc7996ffae9682_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xL2ZyYWc6N2FjMGRkOGIzNWQxNDhiNzlmYTVkMTUwOTYwZGFmZWIvdGFibGU6Y2UxN2EyYzQ3OWQ4NGQ0NTkyMTc5NDk3NGE2ZDJhMzUvdGFibGVyYW5nZTpjZTE3YTJjNDc5ZDg0ZDQ1OTIxNzk0OTc0YTZkMmEzNV83LTItMS0xLTE1OTU0MA_4a030d73-4c31-42bd-a6b9-36acfdf550a7">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="i80ad5b0231594dcca53dbf943886b1f2_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xL2ZyYWc6N2FjMGRkOGIzNWQxNDhiNzlmYTVkMTUwOTYwZGFmZWIvdGFibGU6Y2UxN2EyYzQ3OWQ4NGQ0NTkyMTc5NDk3NGE2ZDJhMzUvdGFibGVyYW5nZTpjZTE3YTJjNDc5ZDg0ZDQ1OTIxNzk0OTc0YTZkMmEzNV84LTAtMS0xLTE1OTU0MA_edba796e-a498-4abb-8935-421196db3c36">1.625% Notes due 2043</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i80ad5b0231594dcca53dbf943886b1f2_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xL2ZyYWc6N2FjMGRkOGIzNWQxNDhiNzlmYTVkMTUwOTYwZGFmZWIvdGFibGU6Y2UxN2EyYzQ3OWQ4NGQ0NTkyMTc5NDk3NGE2ZDJhMzUvdGFibGVyYW5nZTpjZTE3YTJjNDc5ZDg0ZDQ1OTIxNzk0OTc0YTZkMmEzNV84LTEtMS0xLTE1OTU0MA_922db86d-222b-42ec-835d-78124e46a67f">LLY43</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i80ad5b0231594dcca53dbf943886b1f2_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xL2ZyYWc6N2FjMGRkOGIzNWQxNDhiNzlmYTVkMTUwOTYwZGFmZWIvdGFibGU6Y2UxN2EyYzQ3OWQ4NGQ0NTkyMTc5NDk3NGE2ZDJhMzUvdGFibGVyYW5nZTpjZTE3YTJjNDc5ZDg0ZDQ1OTIxNzk0OTc0YTZkMmEzNV84LTItMS0xLTE1OTU0MA_2dcab404-05b5-4a43-a6a0-b89253fa1ac0">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="i8e27869f09004f868cb336c53f59bddd_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xL2ZyYWc6N2FjMGRkOGIzNWQxNDhiNzlmYTVkMTUwOTYwZGFmZWIvdGFibGU6Y2UxN2EyYzQ3OWQ4NGQ0NTkyMTc5NDk3NGE2ZDJhMzUvdGFibGVyYW5nZTpjZTE3YTJjNDc5ZDg0ZDQ1OTIxNzk0OTc0YTZkMmEzNV85LTAtMS0xLTE1OTU0MA_1cbfcbaf-aa17-4a52-8496-a46348ba3912">1.700% Notes due 2049</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i8e27869f09004f868cb336c53f59bddd_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xL2ZyYWc6N2FjMGRkOGIzNWQxNDhiNzlmYTVkMTUwOTYwZGFmZWIvdGFibGU6Y2UxN2EyYzQ3OWQ4NGQ0NTkyMTc5NDk3NGE2ZDJhMzUvdGFibGVyYW5nZTpjZTE3YTJjNDc5ZDg0ZDQ1OTIxNzk0OTc0YTZkMmEzNV85LTEtMS0xLTE1OTU0MA_fd675a67-017c-4ff7-98ea-cb86ef7aad4a">LLY49A</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i8e27869f09004f868cb336c53f59bddd_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xL2ZyYWc6N2FjMGRkOGIzNWQxNDhiNzlmYTVkMTUwOTYwZGFmZWIvdGFibGU6Y2UxN2EyYzQ3OWQ4NGQ0NTkyMTc5NDk3NGE2ZDJhMzUvdGFibGVyYW5nZTpjZTE3YTJjNDc5ZDg0ZDQ1OTIxNzk0OTc0YTZkMmEzNV85LTItMS0xLTE1OTU0MA_1e055b99-3d08-4167-9e0c-2384224f0417">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="i94f283ca5ff741c39e115f9c18564a88_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xL2ZyYWc6N2FjMGRkOGIzNWQxNDhiNzlmYTVkMTUwOTYwZGFmZWIvdGFibGU6Y2UxN2EyYzQ3OWQ4NGQ0NTkyMTc5NDk3NGE2ZDJhMzUvdGFibGVyYW5nZTpjZTE3YTJjNDc5ZDg0ZDQ1OTIxNzk0OTc0YTZkMmEzNV8xMC0wLTEtMS0xNTk1NDA_192914d9-d26f-4adf-9b27-0acbb8c50b5c">1.125% Notes due 2051</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i94f283ca5ff741c39e115f9c18564a88_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xL2ZyYWc6N2FjMGRkOGIzNWQxNDhiNzlmYTVkMTUwOTYwZGFmZWIvdGFibGU6Y2UxN2EyYzQ3OWQ4NGQ0NTkyMTc5NDk3NGE2ZDJhMzUvdGFibGVyYW5nZTpjZTE3YTJjNDc5ZDg0ZDQ1OTIxNzk0OTc0YTZkMmEzNV8xMC0xLTEtMS0xNTk1NDA_839eca65-ca4f-4c53-b7a0-b19ed493e5bf">LLY51</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i94f283ca5ff741c39e115f9c18564a88_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xL2ZyYWc6N2FjMGRkOGIzNWQxNDhiNzlmYTVkMTUwOTYwZGFmZWIvdGFibGU6Y2UxN2EyYzQ3OWQ4NGQ0NTkyMTc5NDk3NGE2ZDJhMzUvdGFibGVyYW5nZTpjZTE3YTJjNDc5ZDg0ZDQ1OTIxNzk0OTc0YTZkMmEzNV8xMC0yLTEtMS0xNTk1NDA_23309646-379d-4e1b-9bc4-47bb5e26f63b">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="i9b0db4c7708642f7a34b06aae1404242_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xL2ZyYWc6N2FjMGRkOGIzNWQxNDhiNzlmYTVkMTUwOTYwZGFmZWIvdGFibGU6Y2UxN2EyYzQ3OWQ4NGQ0NTkyMTc5NDk3NGE2ZDJhMzUvdGFibGVyYW5nZTpjZTE3YTJjNDc5ZDg0ZDQ1OTIxNzk0OTc0YTZkMmEzNV8xMS0wLTEtMS0xNTk1NDA_5702da64-e024-4859-9a1e-4046274ee5d2">1.375% Notes due 2061</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i9b0db4c7708642f7a34b06aae1404242_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xL2ZyYWc6N2FjMGRkOGIzNWQxNDhiNzlmYTVkMTUwOTYwZGFmZWIvdGFibGU6Y2UxN2EyYzQ3OWQ4NGQ0NTkyMTc5NDk3NGE2ZDJhMzUvdGFibGVyYW5nZTpjZTE3YTJjNDc5ZDg0ZDQ1OTIxNzk0OTc0YTZkMmEzNV8xMS0xLTEtMS0xNTk1NDA_5f72a643-8266-4c5e-9943-3d77ce8a58af">LLY61</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i9b0db4c7708642f7a34b06aae1404242_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xL2ZyYWc6N2FjMGRkOGIzNWQxNDhiNzlmYTVkMTUwOTYwZGFmZWIvdGFibGU6Y2UxN2EyYzQ3OWQ4NGQ0NTkyMTc5NDk3NGE2ZDJhMzUvdGFibGVyYW5nZTpjZTE3YTJjNDc5ZDg0ZDQ1OTIxNzk0OTc0YTZkMmEzNV8xMS0yLTEtMS0xNTk1NDA_cf504784-80e3-40fd-99b2-dd1ebd56b735">NYSE</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xL2ZyYWc6N2FjMGRkOGIzNWQxNDhiNzlmYTVkMTUwOTYwZGFmZWIvdGV4dHJlZ2lvbjo3YWMwZGQ4YjM1ZDE0OGI3OWZhNWQxNTA5NjBkYWZlYl8yMDQ1_6a7ca5a9-5562-4b8b-bf6a-c02708e9a727">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xL2ZyYWc6N2FjMGRkOGIzNWQxNDhiNzlmYTVkMTUwOTYwZGFmZWIvdGV4dHJlZ2lvbjo3YWMwZGQ4YjM1ZDE0OGI3OWZhNWQxNTA5NjBkYWZlYl8yMDQw_35d85772-cc82-4125-8aa9-bbf7cafdb834">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xL2ZyYWc6N2FjMGRkOGIzNWQxNDhiNzlmYTVkMTUwOTYwZGFmZWIvdGFibGU6M2E1NDlmYmRjZTBkNGY4OWEwZjRlMWZmMTIxZmViMWEvdGFibGVyYW5nZTozYTU0OWZiZGNlMGQ0Zjg5YTBmNGUxZmYxMjFmZWIxYV8wLTAtMS0xLTE1OTU0MA_258f7f21-3480-4d34-a73e-6e3169c3d15f">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xL2ZyYWc6N2FjMGRkOGIzNWQxNDhiNzlmYTVkMTUwOTYwZGFmZWIvdGFibGU6M2E1NDlmYmRjZTBkNGY4OWEwZjRlMWZmMTIxZmViMWEvdGFibGVyYW5nZTozYTU0OWZiZGNlMGQ0Zjg5YTBmNGUxZmYxMjFmZWIxYV8xLTctMS0xLTE1OTU0MA_b8a371c6-c7f2-470e-b1ed-82ef822c4d9a">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xL2ZyYWc6N2FjMGRkOGIzNWQxNDhiNzlmYTVkMTUwOTYwZGFmZWIvdGFibGU6M2E1NDlmYmRjZTBkNGY4OWEwZjRlMWZmMTIxZmViMWEvdGFibGVyYW5nZTozYTU0OWZiZGNlMGQ0Zjg5YTBmNGUxZmYxMjFmZWIxYV8yLTctMS0xLTE1OTU0MA_81a36563-09b5-4400-9d80-d9877eb1fe71">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xL2ZyYWc6N2FjMGRkOGIzNWQxNDhiNzlmYTVkMTUwOTYwZGFmZWIvdGV4dHJlZ2lvbjo3YWMwZGQ4YjM1ZDE0OGI3OWZhNWQxNTA5NjBkYWZlYl8yMDQ3_1270cc30-e5a9-4c62-a803-3855ce7db00a">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i465e2cbbe1e444108f9f7bdae9a93ca5_I20221028"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xL2ZyYWc6N2FjMGRkOGIzNWQxNDhiNzlmYTVkMTUwOTYwZGFmZWIvdGFibGU6ZGRhMzY1NDUzNTc0NDAyN2I5MDY1MDEyMDc5N2NkYWUvdGFibGVyYW5nZTpkZGEzNjU0NTM1NzQ0MDI3YjkwNjUwMTIwNzk3Y2RhZV8xLTItMS0xLTE1OTU0MA_05c6a09b-a3e3-437f-ac0c-7bd4b6763e01"
      unitRef="shares">950177900</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:Revenues
      contextRef="i19fc0325c48543008ea71e1fdcf11d86_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xOS9mcmFnOjI4Y2NkODJiMTEwZDQzY2Y5ZjE3OWFlZTgwNzBiYmY0L3RhYmxlOmYzNmEyNjIyOTBjMzQ3ZmRhMzU4OTA1MDE2MGM2MDhhL3RhYmxlcmFuZ2U6ZjM2YTI2MjI5MGMzNDdmZGEzNTg5MDUwMTYwYzYwOGFfMi0xLTEtMS0xNTk1NDA_84b2baed-d6a5-43c8-9b22-b1720ffd84cc"
      unitRef="usd">6941600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie4fa4f6b472a4f269297591b44aba572_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xOS9mcmFnOjI4Y2NkODJiMTEwZDQzY2Y5ZjE3OWFlZTgwNzBiYmY0L3RhYmxlOmYzNmEyNjIyOTBjMzQ3ZmRhMzU4OTA1MDE2MGM2MDhhL3RhYmxlcmFuZ2U6ZjM2YTI2MjI5MGMzNDdmZGEzNTg5MDUwMTYwYzYwOGFfMi0zLTEtMS0xNTk1NDA_2e9d205c-5646-45ea-a8f1-00dea195e123"
      unitRef="usd">6772800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xOS9mcmFnOjI4Y2NkODJiMTEwZDQzY2Y5ZjE3OWFlZTgwNzBiYmY0L3RhYmxlOmYzNmEyNjIyOTBjMzQ3ZmRhMzU4OTA1MDE2MGM2MDhhL3RhYmxlcmFuZ2U6ZjM2YTI2MjI5MGMzNDdmZGEzNTg5MDUwMTYwYzYwOGFfMi01LTEtMS0xNTk1NDA_17382a75-1af1-4741-92e1-29f6816e014e"
      unitRef="usd">21239600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i167ed8f67bef48c49e54fa466400cdaa_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xOS9mcmFnOjI4Y2NkODJiMTEwZDQzY2Y5ZjE3OWFlZTgwNzBiYmY0L3RhYmxlOmYzNmEyNjIyOTBjMzQ3ZmRhMzU4OTA1MDE2MGM2MDhhL3RhYmxlcmFuZ2U6ZjM2YTI2MjI5MGMzNDdmZGEzNTg5MDUwMTYwYzYwOGFfMi03LTEtMS0xNTk1NDA_f14d0139-fe56-4a27-8f9a-40cb6b63c480"
      unitRef="usd">20318500000</us-gaap:Revenues>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i19fc0325c48543008ea71e1fdcf11d86_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xOS9mcmFnOjI4Y2NkODJiMTEwZDQzY2Y5ZjE3OWFlZTgwNzBiYmY0L3RhYmxlOmYzNmEyNjIyOTBjMzQ3ZmRhMzU4OTA1MDE2MGM2MDhhL3RhYmxlcmFuZ2U6ZjM2YTI2MjI5MGMzNDdmZGEzNTg5MDUwMTYwYzYwOGFfNC0xLTEtMS0xNTk1NDA_613d7d37-4cb7-418c-9328-7863400be6f6"
      unitRef="usd">1579100000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ie4fa4f6b472a4f269297591b44aba572_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xOS9mcmFnOjI4Y2NkODJiMTEwZDQzY2Y5ZjE3OWFlZTgwNzBiYmY0L3RhYmxlOmYzNmEyNjIyOTBjMzQ3ZmRhMzU4OTA1MDE2MGM2MDhhL3RhYmxlcmFuZ2U6ZjM2YTI2MjI5MGMzNDdmZGEzNTg5MDUwMTYwYzYwOGFfNC0zLTEtMS0xNTk1NDA_f4d08199-fc25-4ff1-b97e-ef128b0b0d21"
      unitRef="usd">1430800000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xOS9mcmFnOjI4Y2NkODJiMTEwZDQzY2Y5ZjE3OWFlZTgwNzBiYmY0L3RhYmxlOmYzNmEyNjIyOTBjMzQ3ZmRhMzU4OTA1MDE2MGM2MDhhL3RhYmxlcmFuZ2U6ZjM2YTI2MjI5MGMzNDdmZGEzNTg5MDUwMTYwYzYwOGFfNC01LTEtMS0xNTk1NDA_10675cf5-06cf-43b2-8e6f-cb3244baaa08"
      unitRef="usd">5081700000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i167ed8f67bef48c49e54fa466400cdaa_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xOS9mcmFnOjI4Y2NkODJiMTEwZDQzY2Y5ZjE3OWFlZTgwNzBiYmY0L3RhYmxlOmYzNmEyNjIyOTBjMzQ3ZmRhMzU4OTA1MDE2MGM2MDhhL3RhYmxlcmFuZ2U6ZjM2YTI2MjI5MGMzNDdmZGEzNTg5MDUwMTYwYzYwOGFfNC03LTEtMS0xNTk1NDA_f8bcac5c-a235-4a8f-bf87-c90345e34be9"
      unitRef="usd">5262600000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i19fc0325c48543008ea71e1fdcf11d86_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xOS9mcmFnOjI4Y2NkODJiMTEwZDQzY2Y5ZjE3OWFlZTgwNzBiYmY0L3RhYmxlOmYzNmEyNjIyOTBjMzQ3ZmRhMzU4OTA1MDE2MGM2MDhhL3RhYmxlcmFuZ2U6ZjM2YTI2MjI5MGMzNDdmZGEzNTg5MDUwMTYwYzYwOGFfNS0xLTEtMS0xNTk1NDA_a8fa6aeb-cf55-4189-920d-707e4caebbe8"
      unitRef="usd">1802900000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ie4fa4f6b472a4f269297591b44aba572_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xOS9mcmFnOjI4Y2NkODJiMTEwZDQzY2Y5ZjE3OWFlZTgwNzBiYmY0L3RhYmxlOmYzNmEyNjIyOTBjMzQ3ZmRhMzU4OTA1MDE2MGM2MDhhL3RhYmxlcmFuZ2U6ZjM2YTI2MjI5MGMzNDdmZGEzNTg5MDUwMTYwYzYwOGFfNS0zLTEtMS0xNTk1NDA_d70a720b-459b-40df-9ea5-ecc8edc06707"
      unitRef="usd">1705300000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xOS9mcmFnOjI4Y2NkODJiMTEwZDQzY2Y5ZjE3OWFlZTgwNzBiYmY0L3RhYmxlOmYzNmEyNjIyOTBjMzQ3ZmRhMzU4OTA1MDE2MGM2MDhhL3RhYmxlcmFuZ2U6ZjM2YTI2MjI5MGMzNDdmZGEzNTg5MDUwMTYwYzYwOGFfNS01LTEtMS0xNTk1NDA_2a06c20f-888c-4cbc-91df-a48ea8ae00ff"
      unitRef="usd">5194900000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i167ed8f67bef48c49e54fa466400cdaa_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xOS9mcmFnOjI4Y2NkODJiMTEwZDQzY2Y5ZjE3OWFlZTgwNzBiYmY0L3RhYmxlOmYzNmEyNjIyOTBjMzQ3ZmRhMzU4OTA1MDE2MGM2MDhhL3RhYmxlcmFuZ2U6ZjM2YTI2MjI5MGMzNDdmZGEzNTg5MDUwMTYwYzYwOGFfNS03LTEtMS0xNTk1NDA_7854caa1-7b76-464d-b7f4-c4101a2e27a2"
      unitRef="usd">5032400000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i19fc0325c48543008ea71e1fdcf11d86_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xOS9mcmFnOjI4Y2NkODJiMTEwZDQzY2Y5ZjE3OWFlZTgwNzBiYmY0L3RhYmxlOmYzNmEyNjIyOTBjMzQ3ZmRhMzU4OTA1MDE2MGM2MDhhL3RhYmxlcmFuZ2U6ZjM2YTI2MjI5MGMzNDdmZGEzNTg5MDUwMTYwYzYwOGFfNi0xLTEtMS0xNTk1NDA_14213355-7ffb-439f-80f4-67242e82ed5d"
      unitRef="usd">1614200000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="ie4fa4f6b472a4f269297591b44aba572_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xOS9mcmFnOjI4Y2NkODJiMTEwZDQzY2Y5ZjE3OWFlZTgwNzBiYmY0L3RhYmxlOmYzNmEyNjIyOTBjMzQ3ZmRhMzU4OTA1MDE2MGM2MDhhL3RhYmxlcmFuZ2U6ZjM2YTI2MjI5MGMzNDdmZGEzNTg5MDUwMTYwYzYwOGFfNi0zLTEtMS0xNTk1NDA_35072b4f-0452-4d41-8273-955eed100b0f"
      unitRef="usd">1577900000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xOS9mcmFnOjI4Y2NkODJiMTEwZDQzY2Y5ZjE3OWFlZTgwNzBiYmY0L3RhYmxlOmYzNmEyNjIyOTBjMzQ3ZmRhMzU4OTA1MDE2MGM2MDhhL3RhYmxlcmFuZ2U6ZjM2YTI2MjI5MGMzNDdmZGEzNTg5MDUwMTYwYzYwOGFfNi01LTEtMS0xNTk1NDA_67f8179b-9bdd-481b-82f9-f6bcd12659f9"
      unitRef="usd">4797200000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i167ed8f67bef48c49e54fa466400cdaa_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xOS9mcmFnOjI4Y2NkODJiMTEwZDQzY2Y5ZjE3OWFlZTgwNzBiYmY0L3RhYmxlOmYzNmEyNjIyOTBjMzQ3ZmRhMzU4OTA1MDE2MGM2MDhhL3RhYmxlcmFuZ2U6ZjM2YTI2MjI5MGMzNDdmZGEzNTg5MDUwMTYwYzYwOGFfNi03LTEtMS0xNTk1NDA_05d9ca06-addd-46cf-ab12-0e16beb9b4ac"
      unitRef="usd">4839600000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <lly:AcquiredInProcessResearchAndDevelopmentAndDevelopmentMilestones
      contextRef="i19fc0325c48543008ea71e1fdcf11d86_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xOS9mcmFnOjI4Y2NkODJiMTEwZDQzY2Y5ZjE3OWFlZTgwNzBiYmY0L3RhYmxlOmYzNmEyNjIyOTBjMzQ3ZmRhMzU4OTA1MDE2MGM2MDhhL3RhYmxlcmFuZ2U6ZjM2YTI2MjI5MGMzNDdmZGEzNTg5MDUwMTYwYzYwOGFfNy0xLTEtMS0xNTk1NDA_8b459b38-3dde-4b01-86a3-b90670ef8e72"
      unitRef="usd">62400000</lly:AcquiredInProcessResearchAndDevelopmentAndDevelopmentMilestones>
    <lly:AcquiredInProcessResearchAndDevelopmentAndDevelopmentMilestones
      contextRef="ie4fa4f6b472a4f269297591b44aba572_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xOS9mcmFnOjI4Y2NkODJiMTEwZDQzY2Y5ZjE3OWFlZTgwNzBiYmY0L3RhYmxlOmYzNmEyNjIyOTBjMzQ3ZmRhMzU4OTA1MDE2MGM2MDhhL3RhYmxlcmFuZ2U6ZjM2YTI2MjI5MGMzNDdmZGEzNTg5MDUwMTYwYzYwOGFfNy0zLTEtMS0xNTk1NDA_930acb16-c7a4-46f2-b4ec-0c4ce1d82bd4"
      unitRef="usd">177600000</lly:AcquiredInProcessResearchAndDevelopmentAndDevelopmentMilestones>
    <lly:AcquiredInProcessResearchAndDevelopmentAndDevelopmentMilestones
      contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xOS9mcmFnOjI4Y2NkODJiMTEwZDQzY2Y5ZjE3OWFlZTgwNzBiYmY0L3RhYmxlOmYzNmEyNjIyOTBjMzQ3ZmRhMzU4OTA1MDE2MGM2MDhhL3RhYmxlcmFuZ2U6ZjM2YTI2MjI5MGMzNDdmZGEzNTg5MDUwMTYwYzYwOGFfNy01LTEtMS0xNTk1NDA_814d2bcb-fad1-4171-8df7-5bf614293fde"
      unitRef="usd">668400000</lly:AcquiredInProcessResearchAndDevelopmentAndDevelopmentMilestones>
    <lly:AcquiredInProcessResearchAndDevelopmentAndDevelopmentMilestones
      contextRef="i167ed8f67bef48c49e54fa466400cdaa_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xOS9mcmFnOjI4Y2NkODJiMTEwZDQzY2Y5ZjE3OWFlZTgwNzBiYmY0L3RhYmxlOmYzNmEyNjIyOTBjMzQ3ZmRhMzU4OTA1MDE2MGM2MDhhL3RhYmxlcmFuZ2U6ZjM2YTI2MjI5MGMzNDdmZGEzNTg5MDUwMTYwYzYwOGFfNy03LTEtMS0xNTk1NDA_08faa181-0763-4f6c-9031-a7e1539d6611"
      unitRef="usd">532400000</lly:AcquiredInProcessResearchAndDevelopmentAndDevelopmentMilestones>
    <us-gaap:RestructuringSettlementAndImpairmentProvisions
      contextRef="i19fc0325c48543008ea71e1fdcf11d86_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xOS9mcmFnOjI4Y2NkODJiMTEwZDQzY2Y5ZjE3OWFlZTgwNzBiYmY0L3RhYmxlOmYzNmEyNjIyOTBjMzQ3ZmRhMzU4OTA1MDE2MGM2MDhhL3RhYmxlcmFuZ2U6ZjM2YTI2MjI5MGMzNDdmZGEzNTg5MDUwMTYwYzYwOGFfOC0xLTEtMS0xNTk1NDA_871cfb58-2491-43dc-b184-34f9c6cf822b"
      unitRef="usd">206500000</us-gaap:RestructuringSettlementAndImpairmentProvisions>
    <us-gaap:RestructuringSettlementAndImpairmentProvisions
      contextRef="ie4fa4f6b472a4f269297591b44aba572_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xOS9mcmFnOjI4Y2NkODJiMTEwZDQzY2Y5ZjE3OWFlZTgwNzBiYmY0L3RhYmxlOmYzNmEyNjIyOTBjMzQ3ZmRhMzU4OTA1MDE2MGM2MDhhL3RhYmxlcmFuZ2U6ZjM2YTI2MjI5MGMzNDdmZGEzNTg5MDUwMTYwYzYwOGFfOC0zLTEtMS0xNTk1NDA_440c64be-a839-43d8-afea-b5abbee97a08"
      unitRef="usd">0</us-gaap:RestructuringSettlementAndImpairmentProvisions>
    <us-gaap:RestructuringSettlementAndImpairmentProvisions
      contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xOS9mcmFnOjI4Y2NkODJiMTEwZDQzY2Y5ZjE3OWFlZTgwNzBiYmY0L3RhYmxlOmYzNmEyNjIyOTBjMzQ3ZmRhMzU4OTA1MDE2MGM2MDhhL3RhYmxlcmFuZ2U6ZjM2YTI2MjI5MGMzNDdmZGEzNTg5MDUwMTYwYzYwOGFfOC01LTEtMS0xNTk1NDA_3d999b88-4ddd-4fb1-bbaa-a10090f42bea"
      unitRef="usd">206500000</us-gaap:RestructuringSettlementAndImpairmentProvisions>
    <us-gaap:RestructuringSettlementAndImpairmentProvisions
      contextRef="i167ed8f67bef48c49e54fa466400cdaa_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xOS9mcmFnOjI4Y2NkODJiMTEwZDQzY2Y5ZjE3OWFlZTgwNzBiYmY0L3RhYmxlOmYzNmEyNjIyOTBjMzQ3ZmRhMzU4OTA1MDE2MGM2MDhhL3RhYmxlcmFuZ2U6ZjM2YTI2MjI5MGMzNDdmZGEzNTg5MDUwMTYwYzYwOGFfOC03LTEtMS0xNTk1NDA_6408657e-186f-4757-bc29-234f3692c156"
      unitRef="usd">211600000</us-gaap:RestructuringSettlementAndImpairmentProvisions>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i19fc0325c48543008ea71e1fdcf11d86_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xOS9mcmFnOjI4Y2NkODJiMTEwZDQzY2Y5ZjE3OWFlZTgwNzBiYmY0L3RhYmxlOmYzNmEyNjIyOTBjMzQ3ZmRhMzU4OTA1MDE2MGM2MDhhL3RhYmxlcmFuZ2U6ZjM2YTI2MjI5MGMzNDdmZGEzNTg5MDUwMTYwYzYwOGFfOS0xLTEtMS0xNTk1NDA_0a080a2b-b9ee-4570-bc4c-b4a3b0d6dc9c"
      unitRef="usd">-111000000.0</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="ie4fa4f6b472a4f269297591b44aba572_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xOS9mcmFnOjI4Y2NkODJiMTEwZDQzY2Y5ZjE3OWFlZTgwNzBiYmY0L3RhYmxlOmYzNmEyNjIyOTBjMzQ3ZmRhMzU4OTA1MDE2MGM2MDhhL3RhYmxlcmFuZ2U6ZjM2YTI2MjI5MGMzNDdmZGEzNTg5MDUwMTYwYzYwOGFfOS0zLTEtMS0xNTk1NDA_bf168203-185c-4fdc-8ed2-949d74015438"
      unitRef="usd">-635900000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xOS9mcmFnOjI4Y2NkODJiMTEwZDQzY2Y5ZjE3OWFlZTgwNzBiYmY0L3RhYmxlOmYzNmEyNjIyOTBjMzQ3ZmRhMzU4OTA1MDE2MGM2MDhhL3RhYmxlcmFuZ2U6ZjM2YTI2MjI5MGMzNDdmZGEzNTg5MDUwMTYwYzYwOGFfOS01LTEtMS0xNTk1NDA_da74eabf-5727-4eaa-92ef-c61d12d89473"
      unitRef="usd">-580900000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i167ed8f67bef48c49e54fa466400cdaa_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xOS9mcmFnOjI4Y2NkODJiMTEwZDQzY2Y5ZjE3OWFlZTgwNzBiYmY0L3RhYmxlOmYzNmEyNjIyOTBjMzQ3ZmRhMzU4OTA1MDE2MGM2MDhhL3RhYmxlcmFuZ2U6ZjM2YTI2MjI5MGMzNDdmZGEzNTg5MDUwMTYwYzYwOGFfOS03LTEtMS0xNTk1NDA_0c41ebaa-dad9-4452-984b-fec846c6f7fa"
      unitRef="usd">-124300000</us-gaap:NonoperatingIncomeExpense>
    <lly:CostOfSalesOperatingExpensesAndOtherNet
      contextRef="i19fc0325c48543008ea71e1fdcf11d86_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xOS9mcmFnOjI4Y2NkODJiMTEwZDQzY2Y5ZjE3OWFlZTgwNzBiYmY0L3RhYmxlOmYzNmEyNjIyOTBjMzQ3ZmRhMzU4OTA1MDE2MGM2MDhhL3RhYmxlcmFuZ2U6ZjM2YTI2MjI5MGMzNDdmZGEzNTg5MDUwMTYwYzYwOGFfMTAtMS0xLTEtMTU5NTQw_12970031-5dbe-4849-a3f4-8ffb277f515c"
      unitRef="usd">5376100000</lly:CostOfSalesOperatingExpensesAndOtherNet>
    <lly:CostOfSalesOperatingExpensesAndOtherNet
      contextRef="ie4fa4f6b472a4f269297591b44aba572_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xOS9mcmFnOjI4Y2NkODJiMTEwZDQzY2Y5ZjE3OWFlZTgwNzBiYmY0L3RhYmxlOmYzNmEyNjIyOTBjMzQ3ZmRhMzU4OTA1MDE2MGM2MDhhL3RhYmxlcmFuZ2U6ZjM2YTI2MjI5MGMzNDdmZGEzNTg5MDUwMTYwYzYwOGFfMTAtMy0xLTEtMTU5NTQw_6cc08d87-8577-40d3-8162-b4bfa1f99ae9"
      unitRef="usd">5527500000</lly:CostOfSalesOperatingExpensesAndOtherNet>
    <lly:CostOfSalesOperatingExpensesAndOtherNet
      contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xOS9mcmFnOjI4Y2NkODJiMTEwZDQzY2Y5ZjE3OWFlZTgwNzBiYmY0L3RhYmxlOmYzNmEyNjIyOTBjMzQ3ZmRhMzU4OTA1MDE2MGM2MDhhL3RhYmxlcmFuZ2U6ZjM2YTI2MjI5MGMzNDdmZGEzNTg5MDUwMTYwYzYwOGFfMTAtNS0xLTEtMTU5NTQw_505cc220-bff5-4c8a-ba7f-c0f9d961bc6e"
      unitRef="usd">16529600000</lly:CostOfSalesOperatingExpensesAndOtherNet>
    <lly:CostOfSalesOperatingExpensesAndOtherNet
      contextRef="i167ed8f67bef48c49e54fa466400cdaa_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xOS9mcmFnOjI4Y2NkODJiMTEwZDQzY2Y5ZjE3OWFlZTgwNzBiYmY0L3RhYmxlOmYzNmEyNjIyOTBjMzQ3ZmRhMzU4OTA1MDE2MGM2MDhhL3RhYmxlcmFuZ2U6ZjM2YTI2MjI5MGMzNDdmZGEzNTg5MDUwMTYwYzYwOGFfMTAtNy0xLTEtMTU5NTQw_a69242b6-87ed-45d0-9f4f-09653dc3dd7a"
      unitRef="usd">16002900000</lly:CostOfSalesOperatingExpensesAndOtherNet>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i19fc0325c48543008ea71e1fdcf11d86_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xOS9mcmFnOjI4Y2NkODJiMTEwZDQzY2Y5ZjE3OWFlZTgwNzBiYmY0L3RhYmxlOmYzNmEyNjIyOTBjMzQ3ZmRhMzU4OTA1MDE2MGM2MDhhL3RhYmxlcmFuZ2U6ZjM2YTI2MjI5MGMzNDdmZGEzNTg5MDUwMTYwYzYwOGFfMTEtMS0xLTEtMTU5NTQw_2eef83f2-97e8-4ef0-9ec0-103a268fbf7c"
      unitRef="usd">1565500000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ie4fa4f6b472a4f269297591b44aba572_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xOS9mcmFnOjI4Y2NkODJiMTEwZDQzY2Y5ZjE3OWFlZTgwNzBiYmY0L3RhYmxlOmYzNmEyNjIyOTBjMzQ3ZmRhMzU4OTA1MDE2MGM2MDhhL3RhYmxlcmFuZ2U6ZjM2YTI2MjI5MGMzNDdmZGEzNTg5MDUwMTYwYzYwOGFfMTEtMy0xLTEtMTU5NTQw_aeb046cf-4b29-4557-8997-ab22bb920225"
      unitRef="usd">1245300000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xOS9mcmFnOjI4Y2NkODJiMTEwZDQzY2Y5ZjE3OWFlZTgwNzBiYmY0L3RhYmxlOmYzNmEyNjIyOTBjMzQ3ZmRhMzU4OTA1MDE2MGM2MDhhL3RhYmxlcmFuZ2U6ZjM2YTI2MjI5MGMzNDdmZGEzNTg5MDUwMTYwYzYwOGFfMTEtNS0xLTEtMTU5NTQw_97d34a5e-dce8-44a7-870d-73f5bcb10b3d"
      unitRef="usd">4710000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i167ed8f67bef48c49e54fa466400cdaa_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xOS9mcmFnOjI4Y2NkODJiMTEwZDQzY2Y5ZjE3OWFlZTgwNzBiYmY0L3RhYmxlOmYzNmEyNjIyOTBjMzQ3ZmRhMzU4OTA1MDE2MGM2MDhhL3RhYmxlcmFuZ2U6ZjM2YTI2MjI5MGMzNDdmZGEzNTg5MDUwMTYwYzYwOGFfMTEtNy0xLTEtMTU5NTQw_7f774311-61dc-4ef9-a174-7c15fecd6af8"
      unitRef="usd">4315600000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i19fc0325c48543008ea71e1fdcf11d86_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xOS9mcmFnOjI4Y2NkODJiMTEwZDQzY2Y5ZjE3OWFlZTgwNzBiYmY0L3RhYmxlOmYzNmEyNjIyOTBjMzQ3ZmRhMzU4OTA1MDE2MGM2MDhhL3RhYmxlcmFuZ2U6ZjM2YTI2MjI5MGMzNDdmZGEzNTg5MDUwMTYwYzYwOGFfMTItMS0xLTEtMTU5NTQw_6e1439d1-de64-4386-9f91-bcbf6791b807"
      unitRef="usd">113800000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ie4fa4f6b472a4f269297591b44aba572_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xOS9mcmFnOjI4Y2NkODJiMTEwZDQzY2Y5ZjE3OWFlZTgwNzBiYmY0L3RhYmxlOmYzNmEyNjIyOTBjMzQ3ZmRhMzU4OTA1MDE2MGM2MDhhL3RhYmxlcmFuZ2U6ZjM2YTI2MjI5MGMzNDdmZGEzNTg5MDUwMTYwYzYwOGFfMTItMy0xLTEtMTU5NTQw_6969386e-d191-4be3-9609-64ba670cddaa"
      unitRef="usd">135200000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xOS9mcmFnOjI4Y2NkODJiMTEwZDQzY2Y5ZjE3OWFlZTgwNzBiYmY0L3RhYmxlOmYzNmEyNjIyOTBjMzQ3ZmRhMzU4OTA1MDE2MGM2MDhhL3RhYmxlcmFuZ2U6ZjM2YTI2MjI5MGMzNDdmZGEzNTg5MDUwMTYwYzYwOGFfMTItNS0xLTEtMTU5NTQw_19971751-8fac-441f-a382-ebacb1652bdb"
      unitRef="usd">402900000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i167ed8f67bef48c49e54fa466400cdaa_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xOS9mcmFnOjI4Y2NkODJiMTEwZDQzY2Y5ZjE3OWFlZTgwNzBiYmY0L3RhYmxlOmYzNmEyNjIyOTBjMzQ3ZmRhMzU4OTA1MDE2MGM2MDhhL3RhYmxlcmFuZ2U6ZjM2YTI2MjI5MGMzNDdmZGEzNTg5MDUwMTYwYzYwOGFfMTItNy0xLTEtMTU5NTQw_bb0754e4-3dee-4116-b570-59f9086ff5ab"
      unitRef="usd">460000000.0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="i19fc0325c48543008ea71e1fdcf11d86_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xOS9mcmFnOjI4Y2NkODJiMTEwZDQzY2Y5ZjE3OWFlZTgwNzBiYmY0L3RhYmxlOmYzNmEyNjIyOTBjMzQ3ZmRhMzU4OTA1MDE2MGM2MDhhL3RhYmxlcmFuZ2U6ZjM2YTI2MjI5MGMzNDdmZGEzNTg5MDUwMTYwYzYwOGFfMTMtMS0xLTEtMTU5NTQw_58d9c5cb-4c5d-40be-a06d-2489d29adc4b"
      unitRef="usd">1451700000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ie4fa4f6b472a4f269297591b44aba572_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xOS9mcmFnOjI4Y2NkODJiMTEwZDQzY2Y5ZjE3OWFlZTgwNzBiYmY0L3RhYmxlOmYzNmEyNjIyOTBjMzQ3ZmRhMzU4OTA1MDE2MGM2MDhhL3RhYmxlcmFuZ2U6ZjM2YTI2MjI5MGMzNDdmZGEzNTg5MDUwMTYwYzYwOGFfMTMtMy0xLTEtMTU5NTQw_c6e26b7d-c614-4b1e-9f5b-889f1187c777"
      unitRef="usd">1110100000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xOS9mcmFnOjI4Y2NkODJiMTEwZDQzY2Y5ZjE3OWFlZTgwNzBiYmY0L3RhYmxlOmYzNmEyNjIyOTBjMzQ3ZmRhMzU4OTA1MDE2MGM2MDhhL3RhYmxlcmFuZ2U6ZjM2YTI2MjI5MGMzNDdmZGEzNTg5MDUwMTYwYzYwOGFfMTMtNS0xLTEtMTU5NTQw_6d3a5b51-fef7-4442-b0ae-e0b885eeddf5"
      unitRef="usd">4307100000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i167ed8f67bef48c49e54fa466400cdaa_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xOS9mcmFnOjI4Y2NkODJiMTEwZDQzY2Y5ZjE3OWFlZTgwNzBiYmY0L3RhYmxlOmYzNmEyNjIyOTBjMzQ3ZmRhMzU4OTA1MDE2MGM2MDhhL3RhYmxlcmFuZ2U6ZjM2YTI2MjI5MGMzNDdmZGEzNTg5MDUwMTYwYzYwOGFfMTMtNy0xLTEtMTU5NTQw_b9809708-0d2a-41f9-9bca-7ebbc7febc06"
      unitRef="usd">3855600000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="i19fc0325c48543008ea71e1fdcf11d86_D20220701-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xOS9mcmFnOjI4Y2NkODJiMTEwZDQzY2Y5ZjE3OWFlZTgwNzBiYmY0L3RhYmxlOmYzNmEyNjIyOTBjMzQ3ZmRhMzU4OTA1MDE2MGM2MDhhL3RhYmxlcmFuZ2U6ZjM2YTI2MjI5MGMzNDdmZGEzNTg5MDUwMTYwYzYwOGFfMTgtMS0xLTEtMTU5NTQw_1788c234-9267-4223-8b6d-ad74cc709e5c"
      unitRef="usdPerShare">1.61</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="ie4fa4f6b472a4f269297591b44aba572_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xOS9mcmFnOjI4Y2NkODJiMTEwZDQzY2Y5ZjE3OWFlZTgwNzBiYmY0L3RhYmxlOmYzNmEyNjIyOTBjMzQ3ZmRhMzU4OTA1MDE2MGM2MDhhL3RhYmxlcmFuZ2U6ZjM2YTI2MjI5MGMzNDdmZGEzNTg5MDUwMTYwYzYwOGFfMTgtMy0xLTEtMTU5NTQw_44d673fa-a784-49b3-9a55-f65a3ef4135c"
      unitRef="usdPerShare">1.22</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xOS9mcmFnOjI4Y2NkODJiMTEwZDQzY2Y5ZjE3OWFlZTgwNzBiYmY0L3RhYmxlOmYzNmEyNjIyOTBjMzQ3ZmRhMzU4OTA1MDE2MGM2MDhhL3RhYmxlcmFuZ2U6ZjM2YTI2MjI5MGMzNDdmZGEzNTg5MDUwMTYwYzYwOGFfMTgtNS0xLTEtMTU5NTQw_ab48a2bc-46bb-46ec-ba3a-6fced6b4efc8"
      unitRef="usdPerShare">4.78</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i167ed8f67bef48c49e54fa466400cdaa_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xOS9mcmFnOjI4Y2NkODJiMTEwZDQzY2Y5ZjE3OWFlZTgwNzBiYmY0L3RhYmxlOmYzNmEyNjIyOTBjMzQ3ZmRhMzU4OTA1MDE2MGM2MDhhL3RhYmxlcmFuZ2U6ZjM2YTI2MjI5MGMzNDdmZGEzNTg5MDUwMTYwYzYwOGFfMTgtNy0xLTEtMTU5NTQw_e2fe351d-fd87-4ba1-ab7f-45d55f23330a"
      unitRef="usdPerShare">4.25</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i19fc0325c48543008ea71e1fdcf11d86_D20220701-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xOS9mcmFnOjI4Y2NkODJiMTEwZDQzY2Y5ZjE3OWFlZTgwNzBiYmY0L3RhYmxlOmYzNmEyNjIyOTBjMzQ3ZmRhMzU4OTA1MDE2MGM2MDhhL3RhYmxlcmFuZ2U6ZjM2YTI2MjI5MGMzNDdmZGEzNTg5MDUwMTYwYzYwOGFfMjAtMS0xLTEtMTU5NTQw_a40aefd9-b793-4ede-a8b5-9ee491bc0d74"
      unitRef="usdPerShare">1.61</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ie4fa4f6b472a4f269297591b44aba572_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xOS9mcmFnOjI4Y2NkODJiMTEwZDQzY2Y5ZjE3OWFlZTgwNzBiYmY0L3RhYmxlOmYzNmEyNjIyOTBjMzQ3ZmRhMzU4OTA1MDE2MGM2MDhhL3RhYmxlcmFuZ2U6ZjM2YTI2MjI5MGMzNDdmZGEzNTg5MDUwMTYwYzYwOGFfMjAtMy0xLTEtMTU5NTQw_6489d081-a1d5-4648-aa7e-d1fde0d8b14c"
      unitRef="usdPerShare">1.22</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xOS9mcmFnOjI4Y2NkODJiMTEwZDQzY2Y5ZjE3OWFlZTgwNzBiYmY0L3RhYmxlOmYzNmEyNjIyOTBjMzQ3ZmRhMzU4OTA1MDE2MGM2MDhhL3RhYmxlcmFuZ2U6ZjM2YTI2MjI5MGMzNDdmZGEzNTg5MDUwMTYwYzYwOGFfMjAtNS0xLTEtMTU5NTQw_1cae5aec-ea4f-4289-8342-edb9c6e419be"
      unitRef="usdPerShare">4.76</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i167ed8f67bef48c49e54fa466400cdaa_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xOS9mcmFnOjI4Y2NkODJiMTEwZDQzY2Y5ZjE3OWFlZTgwNzBiYmY0L3RhYmxlOmYzNmEyNjIyOTBjMzQ3ZmRhMzU4OTA1MDE2MGM2MDhhL3RhYmxlcmFuZ2U6ZjM2YTI2MjI5MGMzNDdmZGEzNTg5MDUwMTYwYzYwOGFfMjAtNy0xLTEtMTU5NTQw_9459800a-920f-4ba4-a2ef-6c573174cb5d"
      unitRef="usdPerShare">4.23</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i19fc0325c48543008ea71e1fdcf11d86_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xOS9mcmFnOjI4Y2NkODJiMTEwZDQzY2Y5ZjE3OWFlZTgwNzBiYmY0L3RhYmxlOmYzNmEyNjIyOTBjMzQ3ZmRhMzU4OTA1MDE2MGM2MDhhL3RhYmxlcmFuZ2U6ZjM2YTI2MjI5MGMzNDdmZGEzNTg5MDUwMTYwYzYwOGFfMjQtMS0xLTEtMTU5NTQw_a342be05-e5e0-4fb9-9cf0-bf15a8143672"
      unitRef="shares">900700000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ie4fa4f6b472a4f269297591b44aba572_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xOS9mcmFnOjI4Y2NkODJiMTEwZDQzY2Y5ZjE3OWFlZTgwNzBiYmY0L3RhYmxlOmYzNmEyNjIyOTBjMzQ3ZmRhMzU4OTA1MDE2MGM2MDhhL3RhYmxlcmFuZ2U6ZjM2YTI2MjI5MGMzNDdmZGEzNTg5MDUwMTYwYzYwOGFfMjQtMy0xLTEtMTU5NTQw_45f2e109-295f-4292-b653-57a9576a5425"
      unitRef="shares">906700000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xOS9mcmFnOjI4Y2NkODJiMTEwZDQzY2Y5ZjE3OWFlZTgwNzBiYmY0L3RhYmxlOmYzNmEyNjIyOTBjMzQ3ZmRhMzU4OTA1MDE2MGM2MDhhL3RhYmxlcmFuZ2U6ZjM2YTI2MjI5MGMzNDdmZGEzNTg5MDUwMTYwYzYwOGFfMjQtNS0xLTEtMTU5NTQw_be7c3387-beae-4102-b101-6b8c58663460"
      unitRef="shares">901800000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i167ed8f67bef48c49e54fa466400cdaa_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xOS9mcmFnOjI4Y2NkODJiMTEwZDQzY2Y5ZjE3OWFlZTgwNzBiYmY0L3RhYmxlOmYzNmEyNjIyOTBjMzQ3ZmRhMzU4OTA1MDE2MGM2MDhhL3RhYmxlcmFuZ2U6ZjM2YTI2MjI5MGMzNDdmZGEzNTg5MDUwMTYwYzYwOGFfMjQtNy0xLTEtMTU5NTQw_12a33f33-8b87-4de1-a2e6-1ffbea5b8339"
      unitRef="shares">907700000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i19fc0325c48543008ea71e1fdcf11d86_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xOS9mcmFnOjI4Y2NkODJiMTEwZDQzY2Y5ZjE3OWFlZTgwNzBiYmY0L3RhYmxlOmYzNmEyNjIyOTBjMzQ3ZmRhMzU4OTA1MDE2MGM2MDhhL3RhYmxlcmFuZ2U6ZjM2YTI2MjI5MGMzNDdmZGEzNTg5MDUwMTYwYzYwOGFfMjUtMS0xLTEtMTU5NTQw_18dcdabc-0a87-4da1-97d2-dde6115ab295"
      unitRef="shares">903800000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ie4fa4f6b472a4f269297591b44aba572_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xOS9mcmFnOjI4Y2NkODJiMTEwZDQzY2Y5ZjE3OWFlZTgwNzBiYmY0L3RhYmxlOmYzNmEyNjIyOTBjMzQ3ZmRhMzU4OTA1MDE2MGM2MDhhL3RhYmxlcmFuZ2U6ZjM2YTI2MjI5MGMzNDdmZGEzNTg5MDUwMTYwYzYwOGFfMjUtMy0xLTEtMTU5NTQw_80fbbb1b-385c-462c-a772-a2b6929434e8"
      unitRef="shares">910800000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xOS9mcmFnOjI4Y2NkODJiMTEwZDQzY2Y5ZjE3OWFlZTgwNzBiYmY0L3RhYmxlOmYzNmEyNjIyOTBjMzQ3ZmRhMzU4OTA1MDE2MGM2MDhhL3RhYmxlcmFuZ2U6ZjM2YTI2MjI5MGMzNDdmZGEzNTg5MDUwMTYwYzYwOGFfMjUtNS0xLTEtMTU5NTQw_35c97634-24cf-4189-8d10-a2e1a41b8118"
      unitRef="shares">904500000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i167ed8f67bef48c49e54fa466400cdaa_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18xOS9mcmFnOjI4Y2NkODJiMTEwZDQzY2Y5ZjE3OWFlZTgwNzBiYmY0L3RhYmxlOmYzNmEyNjIyOTBjMzQ3ZmRhMzU4OTA1MDE2MGM2MDhhL3RhYmxlcmFuZ2U6ZjM2YTI2MjI5MGMzNDdmZGEzNTg5MDUwMTYwYzYwOGFfMjUtNy0xLTEtMTU5NTQw_4eb16921-f47a-45ae-9e75-e4218e04e70c"
      unitRef="shares">911700000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="i19fc0325c48543008ea71e1fdcf11d86_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yMi9mcmFnOmFkY2U4MDk2NmRlYTQzMmM4YTY4MGZlMzYxMGFmYjU2L3RhYmxlOjFhNzM4NWIwZTEyMjRhYTliM2FiNTZlY2Y3Y2VhYzUyL3RhYmxlcmFuZ2U6MWE3Mzg1YjBlMTIyNGFhOWIzYWI1NmVjZjdjZWFjNTJfMi0xLTEtMS0xNTk1NDA_58d9c5cb-4c5d-40be-a06d-2489d29adc4b"
      unitRef="usd">1451700000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ie4fa4f6b472a4f269297591b44aba572_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yMi9mcmFnOmFkY2U4MDk2NmRlYTQzMmM4YTY4MGZlMzYxMGFmYjU2L3RhYmxlOjFhNzM4NWIwZTEyMjRhYTliM2FiNTZlY2Y3Y2VhYzUyL3RhYmxlcmFuZ2U6MWE3Mzg1YjBlMTIyNGFhOWIzYWI1NmVjZjdjZWFjNTJfMi0zLTEtMS0xNTk1NDA_c6e26b7d-c614-4b1e-9f5b-889f1187c777"
      unitRef="usd">1110100000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yMi9mcmFnOmFkY2U4MDk2NmRlYTQzMmM4YTY4MGZlMzYxMGFmYjU2L3RhYmxlOjFhNzM4NWIwZTEyMjRhYTliM2FiNTZlY2Y3Y2VhYzUyL3RhYmxlcmFuZ2U6MWE3Mzg1YjBlMTIyNGFhOWIzYWI1NmVjZjdjZWFjNTJfMi01LTEtMS0xNTk1NDA_87698447-ba66-4f71-89c1-b28a71c9e82a"
      unitRef="usd">4307100000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i167ed8f67bef48c49e54fa466400cdaa_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yMi9mcmFnOmFkY2U4MDk2NmRlYTQzMmM4YTY4MGZlMzYxMGFmYjU2L3RhYmxlOjFhNzM4NWIwZTEyMjRhYTliM2FiNTZlY2Y3Y2VhYzUyL3RhYmxlcmFuZ2U6MWE3Mzg1YjBlMTIyNGFhOWIzYWI1NmVjZjdjZWFjNTJfMi03LTEtMS0xNTk1NDA_912d99b5-d76a-4c0a-b3cd-69c00d2c8eed"
      unitRef="usd">3855600000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i19fc0325c48543008ea71e1fdcf11d86_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yMi9mcmFnOmFkY2U4MDk2NmRlYTQzMmM4YTY4MGZlMzYxMGFmYjU2L3RhYmxlOjFhNzM4NWIwZTEyMjRhYTliM2FiNTZlY2Y3Y2VhYzUyL3RhYmxlcmFuZ2U6MWE3Mzg1YjBlMTIyNGFhOWIzYWI1NmVjZjdjZWFjNTJfMy0xLTEtMS0xNTk1NDA_3492514b-29f6-4a97-b4ba-d4a886cd03bd"
      unitRef="usd">-8100000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ie4fa4f6b472a4f269297591b44aba572_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yMi9mcmFnOmFkY2U4MDk2NmRlYTQzMmM4YTY4MGZlMzYxMGFmYjU2L3RhYmxlOjFhNzM4NWIwZTEyMjRhYTliM2FiNTZlY2Y3Y2VhYzUyL3RhYmxlcmFuZ2U6MWE3Mzg1YjBlMTIyNGFhOWIzYWI1NmVjZjdjZWFjNTJfMy0zLTEtMS0xNTk1NDA_6bd78490-2767-4792-8223-3f77a669bcc7"
      unitRef="usd">114400000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yMi9mcmFnOmFkY2U4MDk2NmRlYTQzMmM4YTY4MGZlMzYxMGFmYjU2L3RhYmxlOjFhNzM4NWIwZTEyMjRhYTliM2FiNTZlY2Y3Y2VhYzUyL3RhYmxlcmFuZ2U6MWE3Mzg1YjBlMTIyNGFhOWIzYWI1NmVjZjdjZWFjNTJfMy01LTEtMS0xNTk1NDA_46404f0d-dab3-4be2-8104-f9f3be52ab8b"
      unitRef="usd">47300000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i167ed8f67bef48c49e54fa466400cdaa_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yMi9mcmFnOmFkY2U4MDk2NmRlYTQzMmM4YTY4MGZlMzYxMGFmYjU2L3RhYmxlOjFhNzM4NWIwZTEyMjRhYTliM2FiNTZlY2Y3Y2VhYzUyL3RhYmxlcmFuZ2U6MWE3Mzg1YjBlMTIyNGFhOWIzYWI1NmVjZjdjZWFjNTJfMy03LTEtMS0xNTk1NDA_0cbe9d9b-064d-4c6e-9258-7ad03c8bc524"
      unitRef="usd">323700000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i19fc0325c48543008ea71e1fdcf11d86_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yMi9mcmFnOmFkY2U4MDk2NmRlYTQzMmM4YTY4MGZlMzYxMGFmYjU2L3RhYmxlOjFhNzM4NWIwZTEyMjRhYTliM2FiNTZlY2Y3Y2VhYzUyL3RhYmxlcmFuZ2U6MWE3Mzg1YjBlMTIyNGFhOWIzYWI1NmVjZjdjZWFjNTJfNC0xLTEtMS0xNTk1NDA_d0c29698-24ec-4a7b-92b3-b5188c7deeb1"
      unitRef="usd">1443600000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ie4fa4f6b472a4f269297591b44aba572_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yMi9mcmFnOmFkY2U4MDk2NmRlYTQzMmM4YTY4MGZlMzYxMGFmYjU2L3RhYmxlOjFhNzM4NWIwZTEyMjRhYTliM2FiNTZlY2Y3Y2VhYzUyL3RhYmxlcmFuZ2U6MWE3Mzg1YjBlMTIyNGFhOWIzYWI1NmVjZjdjZWFjNTJfNC0zLTEtMS0xNTk1NDA_966b1a16-2188-439b-aea5-86ccceca6fe0"
      unitRef="usd">1224500000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yMi9mcmFnOmFkY2U4MDk2NmRlYTQzMmM4YTY4MGZlMzYxMGFmYjU2L3RhYmxlOjFhNzM4NWIwZTEyMjRhYTliM2FiNTZlY2Y3Y2VhYzUyL3RhYmxlcmFuZ2U6MWE3Mzg1YjBlMTIyNGFhOWIzYWI1NmVjZjdjZWFjNTJfNC01LTEtMS0xNTk1NDA_4f365400-8e9d-4a7f-884c-23f8ba2c1acb"
      unitRef="usd">4354400000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i167ed8f67bef48c49e54fa466400cdaa_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yMi9mcmFnOmFkY2U4MDk2NmRlYTQzMmM4YTY4MGZlMzYxMGFmYjU2L3RhYmxlOjFhNzM4NWIwZTEyMjRhYTliM2FiNTZlY2Y3Y2VhYzUyL3RhYmxlcmFuZ2U6MWE3Mzg1YjBlMTIyNGFhOWIzYWI1NmVjZjdjZWFjNTJfNC03LTEtMS0xNTk1NDA_7a232746-1a31-451a-934c-5845fc79dcf3"
      unitRef="usd">4179300000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i08ccb35f6ad24d7793c9c91b74ca2ea1_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yNS9mcmFnOjhlOTlhYzhjMjM5YzRmZjg5YmQ2ZTM0YzZjMzBjM2UzL3RhYmxlOjdjMDlhN2RjNGUzNDQ5MjViNGY1Yjg3ZDBmN2Y3NzYwL3RhYmxlcmFuZ2U6N2MwOWE3ZGM0ZTM0NDkyNWI0ZjViODdkMGY3Zjc3NjBfMy0xLTEtMS0xNTk1NDA_258622be-3365-4a96-91d9-ab61a14403bd"
      unitRef="usd">2617400000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i0973ba0c1d894ceaa494709a13f814fb_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yNS9mcmFnOjhlOTlhYzhjMjM5YzRmZjg5YmQ2ZTM0YzZjMzBjM2UzL3RhYmxlOjdjMDlhN2RjNGUzNDQ5MjViNGY1Yjg3ZDBmN2Y3NzYwL3RhYmxlcmFuZ2U6N2MwOWE3ZGM0ZTM0NDkyNWI0ZjViODdkMGY3Zjc3NjBfMy0zLTEtMS0xNTk1NDA_01c2ae74-7f55-4da1-9d57-e13534decca7"
      unitRef="usd">3818500000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermInvestments
      contextRef="i08ccb35f6ad24d7793c9c91b74ca2ea1_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yNS9mcmFnOjhlOTlhYzhjMjM5YzRmZjg5YmQ2ZTM0YzZjMzBjM2UzL3RhYmxlOjdjMDlhN2RjNGUzNDQ5MjViNGY1Yjg3ZDBmN2Y3NzYwL3RhYmxlcmFuZ2U6N2MwOWE3ZGM0ZTM0NDkyNWI0ZjViODdkMGY3Zjc3NjBfNC0xLTEtMS0xNTk1NDA_ecc6984c-df33-40de-8131-7c5e04c1b75e"
      unitRef="usd">124700000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="i0973ba0c1d894ceaa494709a13f814fb_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yNS9mcmFnOjhlOTlhYzhjMjM5YzRmZjg5YmQ2ZTM0YzZjMzBjM2UzL3RhYmxlOjdjMDlhN2RjNGUzNDQ5MjViNGY1Yjg3ZDBmN2Y3NzYwL3RhYmxlcmFuZ2U6N2MwOWE3ZGM0ZTM0NDkyNWI0ZjViODdkMGY3Zjc3NjBfNC0zLTEtMS0xNTk1NDA_f11fce4a-1f0d-43a2-aac0-2a037605ca5a"
      unitRef="usd">90100000</us-gaap:ShortTermInvestments>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="i08ccb35f6ad24d7793c9c91b74ca2ea1_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yNS9mcmFnOjhlOTlhYzhjMjM5YzRmZjg5YmQ2ZTM0YzZjMzBjM2UzL3RhYmxlOjdjMDlhN2RjNGUzNDQ5MjViNGY1Yjg3ZDBmN2Y3NzYwL3RhYmxlcmFuZ2U6N2MwOWE3ZGM0ZTM0NDkyNWI0ZjViODdkMGY3Zjc3NjBfNS0wLTEtMS0xNTk1NDAvdGV4dHJlZ2lvbjoxYzg5YmU1NWM2ZWI0NWIyYjdjYjlkMGQzZWMxMmI4OF80Nw_b19a986a-77cb-4977-8e85-31f22483c306"
      unitRef="usd">17700000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="i0973ba0c1d894ceaa494709a13f814fb_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yNS9mcmFnOjhlOTlhYzhjMjM5YzRmZjg5YmQ2ZTM0YzZjMzBjM2UzL3RhYmxlOjdjMDlhN2RjNGUzNDQ5MjViNGY1Yjg3ZDBmN2Y3NzYwL3RhYmxlcmFuZ2U6N2MwOWE3ZGM0ZTM0NDkyNWI0ZjViODdkMGY3Zjc3NjBfNS0wLTEtMS0xNTk1NDAvdGV4dHJlZ2lvbjoxYzg5YmU1NWM2ZWI0NWIyYjdjYjlkMGQzZWMxMmI4OF82Mg_c63e1ac1-475f-4b86-8273-c6e2ce081463"
      unitRef="usd">22500000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i08ccb35f6ad24d7793c9c91b74ca2ea1_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yNS9mcmFnOjhlOTlhYzhjMjM5YzRmZjg5YmQ2ZTM0YzZjMzBjM2UzL3RhYmxlOjdjMDlhN2RjNGUzNDQ5MjViNGY1Yjg3ZDBmN2Y3NzYwL3RhYmxlcmFuZ2U6N2MwOWE3ZGM0ZTM0NDkyNWI0ZjViODdkMGY3Zjc3NjBfNS0xLTEtMS0xNTk1NDA_ab5f6710-3431-4d52-9859-e91ab0a14690"
      unitRef="usd">6715300000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i0973ba0c1d894ceaa494709a13f814fb_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yNS9mcmFnOjhlOTlhYzhjMjM5YzRmZjg5YmQ2ZTM0YzZjMzBjM2UzL3RhYmxlOjdjMDlhN2RjNGUzNDQ5MjViNGY1Yjg3ZDBmN2Y3NzYwL3RhYmxlcmFuZ2U6N2MwOWE3ZGM0ZTM0NDkyNWI0ZjViODdkMGY3Zjc3NjBfNS0zLTEtMS0xNTk1NDA_7bd80223-a9c3-4e22-82d9-4ae6d749a617"
      unitRef="usd">6672800000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="i08ccb35f6ad24d7793c9c91b74ca2ea1_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yNS9mcmFnOjhlOTlhYzhjMjM5YzRmZjg5YmQ2ZTM0YzZjMzBjM2UzL3RhYmxlOjdjMDlhN2RjNGUzNDQ5MjViNGY1Yjg3ZDBmN2Y3NzYwL3RhYmxlcmFuZ2U6N2MwOWE3ZGM0ZTM0NDkyNWI0ZjViODdkMGY3Zjc3NjBfNi0xLTEtMS0xNTk1NDA_0afe3dcd-2806-44d6-ae8b-0fd486f6130b"
      unitRef="usd">1609500000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="i0973ba0c1d894ceaa494709a13f814fb_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yNS9mcmFnOjhlOTlhYzhjMjM5YzRmZjg5YmQ2ZTM0YzZjMzBjM2UzL3RhYmxlOjdjMDlhN2RjNGUzNDQ5MjViNGY1Yjg3ZDBmN2Y3NzYwL3RhYmxlcmFuZ2U6N2MwOWE3ZGM0ZTM0NDkyNWI0ZjViODdkMGY3Zjc3NjBfNi0zLTEtMS0xNTk1NDA_f19b2b00-7b22-4c1f-adb3-eb30d05cebae"
      unitRef="usd">1454400000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:InventoryNet
      contextRef="i08ccb35f6ad24d7793c9c91b74ca2ea1_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yNS9mcmFnOjhlOTlhYzhjMjM5YzRmZjg5YmQ2ZTM0YzZjMzBjM2UzL3RhYmxlOjdjMDlhN2RjNGUzNDQ5MjViNGY1Yjg3ZDBmN2Y3NzYwL3RhYmxlcmFuZ2U6N2MwOWE3ZGM0ZTM0NDkyNWI0ZjViODdkMGY3Zjc3NjBfNy0xLTEtMS0xNTk1NDA_12310145-a3d9-418a-8225-fcebb251b589"
      unitRef="usd">3831100000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i0973ba0c1d894ceaa494709a13f814fb_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yNS9mcmFnOjhlOTlhYzhjMjM5YzRmZjg5YmQ2ZTM0YzZjMzBjM2UzL3RhYmxlOjdjMDlhN2RjNGUzNDQ5MjViNGY1Yjg3ZDBmN2Y3NzYwL3RhYmxlcmFuZ2U6N2MwOWE3ZGM0ZTM0NDkyNWI0ZjViODdkMGY3Zjc3NjBfNy0zLTEtMS0xNTk1NDA_e2eb9067-78a5-4492-a0c2-ff451113d3f5"
      unitRef="usd">3886000000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="i08ccb35f6ad24d7793c9c91b74ca2ea1_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yNS9mcmFnOjhlOTlhYzhjMjM5YzRmZjg5YmQ2ZTM0YzZjMzBjM2UzL3RhYmxlOjdjMDlhN2RjNGUzNDQ5MjViNGY1Yjg3ZDBmN2Y3NzYwL3RhYmxlcmFuZ2U6N2MwOWE3ZGM0ZTM0NDkyNWI0ZjViODdkMGY3Zjc3NjBfOC0xLTEtMS0xNTk1NDA_b767a778-61a5-4263-8907-6cf9f455fe1c"
      unitRef="usd">2741900000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="i0973ba0c1d894ceaa494709a13f814fb_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yNS9mcmFnOjhlOTlhYzhjMjM5YzRmZjg5YmQ2ZTM0YzZjMzBjM2UzL3RhYmxlOjdjMDlhN2RjNGUzNDQ5MjViNGY1Yjg3ZDBmN2Y3NzYwL3RhYmxlcmFuZ2U6N2MwOWE3ZGM0ZTM0NDkyNWI0ZjViODdkMGY3Zjc3NjBfOC0zLTEtMS0xNTk1NDA_f9f8c975-c9f8-48e5-8fcd-a6223da95da2"
      unitRef="usd">2530600000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i08ccb35f6ad24d7793c9c91b74ca2ea1_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yNS9mcmFnOjhlOTlhYzhjMjM5YzRmZjg5YmQ2ZTM0YzZjMzBjM2UzL3RhYmxlOjdjMDlhN2RjNGUzNDQ5MjViNGY1Yjg3ZDBmN2Y3NzYwL3RhYmxlcmFuZ2U6N2MwOWE3ZGM0ZTM0NDkyNWI0ZjViODdkMGY3Zjc3NjBfOS0xLTEtMS0xNTk1NDA_487d1f4c-a662-4d7c-bbb5-6a3584ea94a9"
      unitRef="usd">17639900000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i0973ba0c1d894ceaa494709a13f814fb_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yNS9mcmFnOjhlOTlhYzhjMjM5YzRmZjg5YmQ2ZTM0YzZjMzBjM2UzL3RhYmxlOjdjMDlhN2RjNGUzNDQ5MjViNGY1Yjg3ZDBmN2Y3NzYwL3RhYmxlcmFuZ2U6N2MwOWE3ZGM0ZTM0NDkyNWI0ZjViODdkMGY3Zjc3NjBfOS0zLTEtMS0xNTk1NDA_e25e2846-7a93-42e7-bf53-4e9483207b71"
      unitRef="usd">18452400000</us-gaap:AssetsCurrent>
    <us-gaap:LongTermInvestments
      contextRef="i08ccb35f6ad24d7793c9c91b74ca2ea1_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yNS9mcmFnOjhlOTlhYzhjMjM5YzRmZjg5YmQ2ZTM0YzZjMzBjM2UzL3RhYmxlOjdjMDlhN2RjNGUzNDQ5MjViNGY1Yjg3ZDBmN2Y3NzYwL3RhYmxlcmFuZ2U6N2MwOWE3ZGM0ZTM0NDkyNWI0ZjViODdkMGY3Zjc3NjBfMTAtMS0xLTEtMTU5NTQw_d02b5002-7f0a-4246-b2d3-adbc85598ab0"
      unitRef="usd">2574600000</us-gaap:LongTermInvestments>
    <us-gaap:LongTermInvestments
      contextRef="i0973ba0c1d894ceaa494709a13f814fb_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yNS9mcmFnOjhlOTlhYzhjMjM5YzRmZjg5YmQ2ZTM0YzZjMzBjM2UzL3RhYmxlOjdjMDlhN2RjNGUzNDQ5MjViNGY1Yjg3ZDBmN2Y3NzYwL3RhYmxlcmFuZ2U6N2MwOWE3ZGM0ZTM0NDkyNWI0ZjViODdkMGY3Zjc3NjBfMTAtMy0xLTEtMTU5NTQw_db9a907b-fd01-4b39-a4d1-6860b5de6fd9"
      unitRef="usd">3212600000</us-gaap:LongTermInvestments>
    <us-gaap:Goodwill
      contextRef="i08ccb35f6ad24d7793c9c91b74ca2ea1_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yNS9mcmFnOjhlOTlhYzhjMjM5YzRmZjg5YmQ2ZTM0YzZjMzBjM2UzL3RhYmxlOjdjMDlhN2RjNGUzNDQ5MjViNGY1Yjg3ZDBmN2Y3NzYwL3RhYmxlcmFuZ2U6N2MwOWE3ZGM0ZTM0NDkyNWI0ZjViODdkMGY3Zjc3NjBfMTEtMS0xLTEtMTU5NTQw_2449ff88-41a8-4515-bf37-fc0dcb15a504"
      unitRef="usd">3891600000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i0973ba0c1d894ceaa494709a13f814fb_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yNS9mcmFnOjhlOTlhYzhjMjM5YzRmZjg5YmQ2ZTM0YzZjMzBjM2UzL3RhYmxlOjdjMDlhN2RjNGUzNDQ5MjViNGY1Yjg3ZDBmN2Y3NzYwL3RhYmxlcmFuZ2U6N2MwOWE3ZGM0ZTM0NDkyNWI0ZjViODdkMGY3Zjc3NjBfMTEtMy0xLTEtMTU5NTQw_a9b095b2-2468-40f5-8ff3-8c40277c9562"
      unitRef="usd">3892000000</us-gaap:Goodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i08ccb35f6ad24d7793c9c91b74ca2ea1_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yNS9mcmFnOjhlOTlhYzhjMjM5YzRmZjg5YmQ2ZTM0YzZjMzBjM2UzL3RhYmxlOjdjMDlhN2RjNGUzNDQ5MjViNGY1Yjg3ZDBmN2Y3NzYwL3RhYmxlcmFuZ2U6N2MwOWE3ZGM0ZTM0NDkyNWI0ZjViODdkMGY3Zjc3NjBfMTItMS0xLTEtMTU5NTQw_7f0bb81c-6fae-484f-a08b-5bbc315de246"
      unitRef="usd">7124100000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i0973ba0c1d894ceaa494709a13f814fb_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yNS9mcmFnOjhlOTlhYzhjMjM5YzRmZjg5YmQ2ZTM0YzZjMzBjM2UzL3RhYmxlOjdjMDlhN2RjNGUzNDQ5MjViNGY1Yjg3ZDBmN2Y3NzYwL3RhYmxlcmFuZ2U6N2MwOWE3ZGM0ZTM0NDkyNWI0ZjViODdkMGY3Zjc3NjBfMTItMy0xLTEtMTU5NTQw_c53ab72a-f910-4179-8eb1-77fd6f556736"
      unitRef="usd">7691900000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="i08ccb35f6ad24d7793c9c91b74ca2ea1_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yNS9mcmFnOjhlOTlhYzhjMjM5YzRmZjg5YmQ2ZTM0YzZjMzBjM2UzL3RhYmxlOjdjMDlhN2RjNGUzNDQ5MjViNGY1Yjg3ZDBmN2Y3NzYwL3RhYmxlcmFuZ2U6N2MwOWE3ZGM0ZTM0NDkyNWI0ZjViODdkMGY3Zjc3NjBfMTMtMS0xLTEtMTU5NTQw_5b0311aa-6873-4375-a34c-678aff44af5b"
      unitRef="usd">2384300000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="i0973ba0c1d894ceaa494709a13f814fb_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yNS9mcmFnOjhlOTlhYzhjMjM5YzRmZjg5YmQ2ZTM0YzZjMzBjM2UzL3RhYmxlOjdjMDlhN2RjNGUzNDQ5MjViNGY1Yjg3ZDBmN2Y3NzYwL3RhYmxlcmFuZ2U6N2MwOWE3ZGM0ZTM0NDkyNWI0ZjViODdkMGY3Zjc3NjBfMTMtMy0xLTEtMTU5NTQw_b35d82df-9a8a-49ef-9600-44d0a3efd5ad"
      unitRef="usd">2489300000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i08ccb35f6ad24d7793c9c91b74ca2ea1_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yNS9mcmFnOjhlOTlhYzhjMjM5YzRmZjg5YmQ2ZTM0YzZjMzBjM2UzL3RhYmxlOjdjMDlhN2RjNGUzNDQ5MjViNGY1Yjg3ZDBmN2Y3NzYwL3RhYmxlcmFuZ2U6N2MwOWE3ZGM0ZTM0NDkyNWI0ZjViODdkMGY3Zjc3NjBfMTQtMC0xLTEtMTU5NTQwL3RleHRyZWdpb246MjVhYmU4OTliZDE2NDVmNjg1NzlmYzI5NzE1ZjcxN2JfNjM_37543d0e-594d-4d87-b91f-24c9527fea65"
      unitRef="usd">10074000000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i0973ba0c1d894ceaa494709a13f814fb_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yNS9mcmFnOjhlOTlhYzhjMjM5YzRmZjg5YmQ2ZTM0YzZjMzBjM2UzL3RhYmxlOjdjMDlhN2RjNGUzNDQ5MjViNGY1Yjg3ZDBmN2Y3NzYwL3RhYmxlcmFuZ2U6N2MwOWE3ZGM0ZTM0NDkyNWI0ZjViODdkMGY3Zjc3NjBfMTQtMC0xLTEtMTU5NTQwL3RleHRyZWdpb246MjVhYmU4OTliZDE2NDVmNjg1NzlmYzI5NzE1ZjcxN2JfNzc_4f13a435-2b19-460f-a2a6-d1605042b529"
      unitRef="usd">9976700000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i08ccb35f6ad24d7793c9c91b74ca2ea1_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yNS9mcmFnOjhlOTlhYzhjMjM5YzRmZjg5YmQ2ZTM0YzZjMzBjM2UzL3RhYmxlOjdjMDlhN2RjNGUzNDQ5MjViNGY1Yjg3ZDBmN2Y3NzYwL3RhYmxlcmFuZ2U6N2MwOWE3ZGM0ZTM0NDkyNWI0ZjViODdkMGY3Zjc3NjBfMTQtMS0xLTEtMTU5NTQw_213ce0f8-6fd8-4311-a364-0f5407540896"
      unitRef="usd">9311300000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i0973ba0c1d894ceaa494709a13f814fb_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yNS9mcmFnOjhlOTlhYzhjMjM5YzRmZjg5YmQ2ZTM0YzZjMzBjM2UzL3RhYmxlOjdjMDlhN2RjNGUzNDQ5MjViNGY1Yjg3ZDBmN2Y3NzYwL3RhYmxlcmFuZ2U6N2MwOWE3ZGM0ZTM0NDkyNWI0ZjViODdkMGY3Zjc3NjBfMTQtMy0xLTEtMTU5NTQw_0414288a-182c-42a7-ab08-1a91a27c5615"
      unitRef="usd">8985100000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i08ccb35f6ad24d7793c9c91b74ca2ea1_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yNS9mcmFnOjhlOTlhYzhjMjM5YzRmZjg5YmQ2ZTM0YzZjMzBjM2UzL3RhYmxlOjdjMDlhN2RjNGUzNDQ5MjViNGY1Yjg3ZDBmN2Y3NzYwL3RhYmxlcmFuZ2U6N2MwOWE3ZGM0ZTM0NDkyNWI0ZjViODdkMGY3Zjc3NjBfMTUtMS0xLTEtMTU5NTQw_5ed6a90d-7bc6-47fc-9c3f-dba9c9afb7dc"
      unitRef="usd">4535700000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i0973ba0c1d894ceaa494709a13f814fb_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yNS9mcmFnOjhlOTlhYzhjMjM5YzRmZjg5YmQ2ZTM0YzZjMzBjM2UzL3RhYmxlOjdjMDlhN2RjNGUzNDQ5MjViNGY1Yjg3ZDBmN2Y3NzYwL3RhYmxlcmFuZ2U6N2MwOWE3ZGM0ZTM0NDkyNWI0ZjViODdkMGY3Zjc3NjBfMTUtMy0xLTEtMTU5NTQw_c7d6b30f-fae9-469f-a365-4fda19a83677"
      unitRef="usd">4082700000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i08ccb35f6ad24d7793c9c91b74ca2ea1_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yNS9mcmFnOjhlOTlhYzhjMjM5YzRmZjg5YmQ2ZTM0YzZjMzBjM2UzL3RhYmxlOjdjMDlhN2RjNGUzNDQ5MjViNGY1Yjg3ZDBmN2Y3NzYwL3RhYmxlcmFuZ2U6N2MwOWE3ZGM0ZTM0NDkyNWI0ZjViODdkMGY3Zjc3NjBfMTYtMS0xLTEtMTU5NTQw_689c1831-07b9-4dbe-b846-098b7f969a0b"
      unitRef="usd">47461500000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i0973ba0c1d894ceaa494709a13f814fb_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yNS9mcmFnOjhlOTlhYzhjMjM5YzRmZjg5YmQ2ZTM0YzZjMzBjM2UzL3RhYmxlOjdjMDlhN2RjNGUzNDQ5MjViNGY1Yjg3ZDBmN2Y3NzYwL3RhYmxlcmFuZ2U6N2MwOWE3ZGM0ZTM0NDkyNWI0ZjViODdkMGY3Zjc3NjBfMTYtMy0xLTEtMTU5NTQw_b3c5f9f9-9fd3-441c-901e-bd917b861063"
      unitRef="usd">48806000000</us-gaap:Assets>
    <us-gaap:DebtCurrent
      contextRef="i08ccb35f6ad24d7793c9c91b74ca2ea1_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yNS9mcmFnOjhlOTlhYzhjMjM5YzRmZjg5YmQ2ZTM0YzZjMzBjM2UzL3RhYmxlOjdjMDlhN2RjNGUzNDQ5MjViNGY1Yjg3ZDBmN2Y3NzYwL3RhYmxlcmFuZ2U6N2MwOWE3ZGM0ZTM0NDkyNWI0ZjViODdkMGY3Zjc3NjBfMTktMS0xLTEtMTU5NTQw_ff2dfb2b-44d7-428e-a06c-ebe3af4d930e"
      unitRef="usd">1744600000</us-gaap:DebtCurrent>
    <us-gaap:DebtCurrent
      contextRef="i0973ba0c1d894ceaa494709a13f814fb_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yNS9mcmFnOjhlOTlhYzhjMjM5YzRmZjg5YmQ2ZTM0YzZjMzBjM2UzL3RhYmxlOjdjMDlhN2RjNGUzNDQ5MjViNGY1Yjg3ZDBmN2Y3NzYwL3RhYmxlcmFuZ2U6N2MwOWE3ZGM0ZTM0NDkyNWI0ZjViODdkMGY3Zjc3NjBfMTktMy0xLTEtMTU5NTQw_cf946d35-5928-4872-9b5a-0ebebcfc1f05"
      unitRef="usd">1538300000</us-gaap:DebtCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i08ccb35f6ad24d7793c9c91b74ca2ea1_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yNS9mcmFnOjhlOTlhYzhjMjM5YzRmZjg5YmQ2ZTM0YzZjMzBjM2UzL3RhYmxlOjdjMDlhN2RjNGUzNDQ5MjViNGY1Yjg3ZDBmN2Y3NzYwL3RhYmxlcmFuZ2U6N2MwOWE3ZGM0ZTM0NDkyNWI0ZjViODdkMGY3Zjc3NjBfMjAtMS0xLTEtMTU5NTQw_954fcb33-4191-48bb-99a8-4b9629c58657"
      unitRef="usd">1683200000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i0973ba0c1d894ceaa494709a13f814fb_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yNS9mcmFnOjhlOTlhYzhjMjM5YzRmZjg5YmQ2ZTM0YzZjMzBjM2UzL3RhYmxlOjdjMDlhN2RjNGUzNDQ5MjViNGY1Yjg3ZDBmN2Y3NzYwL3RhYmxlcmFuZ2U6N2MwOWE3ZGM0ZTM0NDkyNWI0ZjViODdkMGY3Zjc3NjBfMjAtMy0xLTEtMTU5NTQw_5b49cf70-0aef-416c-975b-821fbc2f8fbf"
      unitRef="usd">1670600000</us-gaap:AccountsPayableCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i08ccb35f6ad24d7793c9c91b74ca2ea1_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yNS9mcmFnOjhlOTlhYzhjMjM5YzRmZjg5YmQ2ZTM0YzZjMzBjM2UzL3RhYmxlOjdjMDlhN2RjNGUzNDQ5MjViNGY1Yjg3ZDBmN2Y3NzYwL3RhYmxlcmFuZ2U6N2MwOWE3ZGM0ZTM0NDkyNWI0ZjViODdkMGY3Zjc3NjBfMjEtMS0xLTEtMTU5NTQw_e19513ed-0f2a-422d-b91d-8b64eb3e9d40"
      unitRef="usd">984100000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i0973ba0c1d894ceaa494709a13f814fb_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yNS9mcmFnOjhlOTlhYzhjMjM5YzRmZjg5YmQ2ZTM0YzZjMzBjM2UzL3RhYmxlOjdjMDlhN2RjNGUzNDQ5MjViNGY1Yjg3ZDBmN2Y3NzYwL3RhYmxlcmFuZ2U6N2MwOWE3ZGM0ZTM0NDkyNWI0ZjViODdkMGY3Zjc3NjBfMjEtMy0xLTEtMTU5NTQw_5d192ac0-a27d-433d-b1a6-5bb5f3f2cd2b"
      unitRef="usd">958100000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <lly:SalesRebatesAndDiscounts
      contextRef="i08ccb35f6ad24d7793c9c91b74ca2ea1_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yNS9mcmFnOjhlOTlhYzhjMjM5YzRmZjg5YmQ2ZTM0YzZjMzBjM2UzL3RhYmxlOjdjMDlhN2RjNGUzNDQ5MjViNGY1Yjg3ZDBmN2Y3NzYwL3RhYmxlcmFuZ2U6N2MwOWE3ZGM0ZTM0NDkyNWI0ZjViODdkMGY3Zjc3NjBfMjItMS0xLTEtMTU5NTQw_4d908b33-c4c7-4482-9bd8-31a66f6e71fa"
      unitRef="usd">8568400000</lly:SalesRebatesAndDiscounts>
    <lly:SalesRebatesAndDiscounts
      contextRef="i0973ba0c1d894ceaa494709a13f814fb_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yNS9mcmFnOjhlOTlhYzhjMjM5YzRmZjg5YmQ2ZTM0YzZjMzBjM2UzL3RhYmxlOjdjMDlhN2RjNGUzNDQ5MjViNGY1Yjg3ZDBmN2Y3NzYwL3RhYmxlcmFuZ2U6N2MwOWE3ZGM0ZTM0NDkyNWI0ZjViODdkMGY3Zjc3NjBfMjItMy0xLTEtMTU5NTQw_8eff446a-5b64-4c73-b09e-b2abc41f0de0"
      unitRef="usd">6845800000</lly:SalesRebatesAndDiscounts>
    <us-gaap:DividendsPayableCurrent
      contextRef="i08ccb35f6ad24d7793c9c91b74ca2ea1_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yNS9mcmFnOjhlOTlhYzhjMjM5YzRmZjg5YmQ2ZTM0YzZjMzBjM2UzL3RhYmxlOjdjMDlhN2RjNGUzNDQ5MjViNGY1Yjg3ZDBmN2Y3NzYwL3RhYmxlcmFuZ2U6N2MwOWE3ZGM0ZTM0NDkyNWI0ZjViODdkMGY3Zjc3NjBfMjMtMS0xLTEtMTU5NTQw_eb03c580-9581-41db-a876-67f2d5b6a4c5"
      unitRef="usd">0</us-gaap:DividendsPayableCurrent>
    <us-gaap:DividendsPayableCurrent
      contextRef="i0973ba0c1d894ceaa494709a13f814fb_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yNS9mcmFnOjhlOTlhYzhjMjM5YzRmZjg5YmQ2ZTM0YzZjMzBjM2UzL3RhYmxlOjdjMDlhN2RjNGUzNDQ5MjViNGY1Yjg3ZDBmN2Y3NzYwL3RhYmxlcmFuZ2U6N2MwOWE3ZGM0ZTM0NDkyNWI0ZjViODdkMGY3Zjc3NjBfMjMtMy0xLTEtMTU5NTQw_effe50b6-40cd-4ead-a898-e5c73a7d302d"
      unitRef="usd">885500000</us-gaap:DividendsPayableCurrent>
    <us-gaap:TaxesPayableCurrent
      contextRef="i08ccb35f6ad24d7793c9c91b74ca2ea1_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yNS9mcmFnOjhlOTlhYzhjMjM5YzRmZjg5YmQ2ZTM0YzZjMzBjM2UzL3RhYmxlOjdjMDlhN2RjNGUzNDQ5MjViNGY1Yjg3ZDBmN2Y3NzYwL3RhYmxlcmFuZ2U6N2MwOWE3ZGM0ZTM0NDkyNWI0ZjViODdkMGY3Zjc3NjBfMjQtMS0xLTEtMTU5NTQw_91ab8558-880a-4404-b810-128448e6b45f"
      unitRef="usd">685600000</us-gaap:TaxesPayableCurrent>
    <us-gaap:TaxesPayableCurrent
      contextRef="i0973ba0c1d894ceaa494709a13f814fb_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yNS9mcmFnOjhlOTlhYzhjMjM5YzRmZjg5YmQ2ZTM0YzZjMzBjM2UzL3RhYmxlOjdjMDlhN2RjNGUzNDQ5MjViNGY1Yjg3ZDBmN2Y3NzYwL3RhYmxlcmFuZ2U6N2MwOWE3ZGM0ZTM0NDkyNWI0ZjViODdkMGY3Zjc3NjBfMjQtMy0xLTEtMTU5NTQw_fb66bc51-7140-4992-a237-cfba4951acf9"
      unitRef="usd">126900000</us-gaap:TaxesPayableCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i08ccb35f6ad24d7793c9c91b74ca2ea1_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yNS9mcmFnOjhlOTlhYzhjMjM5YzRmZjg5YmQ2ZTM0YzZjMzBjM2UzL3RhYmxlOjdjMDlhN2RjNGUzNDQ5MjViNGY1Yjg3ZDBmN2Y3NzYwL3RhYmxlcmFuZ2U6N2MwOWE3ZGM0ZTM0NDkyNWI0ZjViODdkMGY3Zjc3NjBfMjUtMS0xLTEtMTU5NTQw_6d0bd9c0-70fc-4a65-a63f-964d21b26333"
      unitRef="usd">1986900000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i0973ba0c1d894ceaa494709a13f814fb_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yNS9mcmFnOjhlOTlhYzhjMjM5YzRmZjg5YmQ2ZTM0YzZjMzBjM2UzL3RhYmxlOjdjMDlhN2RjNGUzNDQ5MjViNGY1Yjg3ZDBmN2Y3NzYwL3RhYmxlcmFuZ2U6N2MwOWE3ZGM0ZTM0NDkyNWI0ZjViODdkMGY3Zjc3NjBfMjUtMy0xLTEtMTU5NTQw_3913dbb5-0b1b-48e8-b669-9dd7fee45f64"
      unitRef="usd">3027500000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i08ccb35f6ad24d7793c9c91b74ca2ea1_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yNS9mcmFnOjhlOTlhYzhjMjM5YzRmZjg5YmQ2ZTM0YzZjMzBjM2UzL3RhYmxlOjdjMDlhN2RjNGUzNDQ5MjViNGY1Yjg3ZDBmN2Y3NzYwL3RhYmxlcmFuZ2U6N2MwOWE3ZGM0ZTM0NDkyNWI0ZjViODdkMGY3Zjc3NjBfMjYtMS0xLTEtMTU5NTQw_07f6f68b-cf9c-40a9-a102-373630c1ae79"
      unitRef="usd">15652800000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i0973ba0c1d894ceaa494709a13f814fb_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yNS9mcmFnOjhlOTlhYzhjMjM5YzRmZjg5YmQ2ZTM0YzZjMzBjM2UzL3RhYmxlOjdjMDlhN2RjNGUzNDQ5MjViNGY1Yjg3ZDBmN2Y3NzYwL3RhYmxlcmFuZ2U6N2MwOWE3ZGM0ZTM0NDkyNWI0ZjViODdkMGY3Zjc3NjBfMjYtMy0xLTEtMTU5NTQw_9952a1da-616c-4a13-b7bf-89d69b907ab8"
      unitRef="usd">15052700000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i08ccb35f6ad24d7793c9c91b74ca2ea1_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yNS9mcmFnOjhlOTlhYzhjMjM5YzRmZjg5YmQ2ZTM0YzZjMzBjM2UzL3RhYmxlOjdjMDlhN2RjNGUzNDQ5MjViNGY1Yjg3ZDBmN2Y3NzYwL3RhYmxlcmFuZ2U6N2MwOWE3ZGM0ZTM0NDkyNWI0ZjViODdkMGY3Zjc3NjBfMjgtMS0xLTEtMTU5NTQw_2375d25b-5e7c-45b6-87fb-40c0d3ff9593"
      unitRef="usd">14143800000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i0973ba0c1d894ceaa494709a13f814fb_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yNS9mcmFnOjhlOTlhYzhjMjM5YzRmZjg5YmQ2ZTM0YzZjMzBjM2UzL3RhYmxlOjdjMDlhN2RjNGUzNDQ5MjViNGY1Yjg3ZDBmN2Y3NzYwL3RhYmxlcmFuZ2U6N2MwOWE3ZGM0ZTM0NDkyNWI0ZjViODdkMGY3Zjc3NjBfMjgtMy0xLTEtMTU5NTQw_9364e45a-ca83-48de-8185-5195dd23c1f8"
      unitRef="usd">15346400000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent
      contextRef="i08ccb35f6ad24d7793c9c91b74ca2ea1_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yNS9mcmFnOjhlOTlhYzhjMjM5YzRmZjg5YmQ2ZTM0YzZjMzBjM2UzL3RhYmxlOjdjMDlhN2RjNGUzNDQ5MjViNGY1Yjg3ZDBmN2Y3NzYwL3RhYmxlcmFuZ2U6N2MwOWE3ZGM0ZTM0NDkyNWI0ZjViODdkMGY3Zjc3NjBfMjktMS0xLTEtMTU5NTQw_84f3e680-f348-4b2c-b8c0-d7d2f3a7b188"
      unitRef="usd">1832500000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent
      contextRef="i0973ba0c1d894ceaa494709a13f814fb_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yNS9mcmFnOjhlOTlhYzhjMjM5YzRmZjg5YmQ2ZTM0YzZjMzBjM2UzL3RhYmxlOjdjMDlhN2RjNGUzNDQ5MjViNGY1Yjg3ZDBmN2Y3NzYwL3RhYmxlcmFuZ2U6N2MwOWE3ZGM0ZTM0NDkyNWI0ZjViODdkMGY3Zjc3NjBfMjktMy0xLTEtMTU5NTQw_4d5b2baa-6c52-4034-8937-bf54598c3105"
      unitRef="usd">1954100000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent>
    <us-gaap:AccruedIncomeTaxesNoncurrent
      contextRef="i08ccb35f6ad24d7793c9c91b74ca2ea1_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yNS9mcmFnOjhlOTlhYzhjMjM5YzRmZjg5YmQ2ZTM0YzZjMzBjM2UzL3RhYmxlOjdjMDlhN2RjNGUzNDQ5MjViNGY1Yjg3ZDBmN2Y3NzYwL3RhYmxlcmFuZ2U6N2MwOWE3ZGM0ZTM0NDkyNWI0ZjViODdkMGY3Zjc3NjBfMzAtMS0xLTEtMTU5NTQw_3a3cec52-0ed0-44f3-8b86-18246f9232f4"
      unitRef="usd">3641700000</us-gaap:AccruedIncomeTaxesNoncurrent>
    <us-gaap:AccruedIncomeTaxesNoncurrent
      contextRef="i0973ba0c1d894ceaa494709a13f814fb_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yNS9mcmFnOjhlOTlhYzhjMjM5YzRmZjg5YmQ2ZTM0YzZjMzBjM2UzL3RhYmxlOjdjMDlhN2RjNGUzNDQ5MjViNGY1Yjg3ZDBmN2Y3NzYwL3RhYmxlcmFuZ2U6N2MwOWE3ZGM0ZTM0NDkyNWI0ZjViODdkMGY3Zjc3NjBfMzAtMy0xLTEtMTU5NTQw_8e4123d4-043f-4d9c-9faa-7c6d3f10c301"
      unitRef="usd">3920000000</us-gaap:AccruedIncomeTaxesNoncurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i08ccb35f6ad24d7793c9c91b74ca2ea1_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yNS9mcmFnOjhlOTlhYzhjMjM5YzRmZjg5YmQ2ZTM0YzZjMzBjM2UzL3RhYmxlOjdjMDlhN2RjNGUzNDQ5MjViNGY1Yjg3ZDBmN2Y3NzYwL3RhYmxlcmFuZ2U6N2MwOWE3ZGM0ZTM0NDkyNWI0ZjViODdkMGY3Zjc3NjBfMzEtMS0xLTEtMTU5NTQw_716b9b2e-60e2-4313-83e5-7c7522fc48ec"
      unitRef="usd">171900000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i0973ba0c1d894ceaa494709a13f814fb_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yNS9mcmFnOjhlOTlhYzhjMjM5YzRmZjg5YmQ2ZTM0YzZjMzBjM2UzL3RhYmxlOjdjMDlhN2RjNGUzNDQ5MjViNGY1Yjg3ZDBmN2Y3NzYwL3RhYmxlcmFuZ2U6N2MwOWE3ZGM0ZTM0NDkyNWI0ZjViODdkMGY3Zjc3NjBfMzEtMy0xLTEtMTU5NTQw_0c8cc5fd-214f-4d35-ad7c-e854c8d8ff30"
      unitRef="usd">1733700000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i08ccb35f6ad24d7793c9c91b74ca2ea1_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yNS9mcmFnOjhlOTlhYzhjMjM5YzRmZjg5YmQ2ZTM0YzZjMzBjM2UzL3RhYmxlOjdjMDlhN2RjNGUzNDQ5MjViNGY1Yjg3ZDBmN2Y3NzYwL3RhYmxlcmFuZ2U6N2MwOWE3ZGM0ZTM0NDkyNWI0ZjViODdkMGY3Zjc3NjBfMzItMS0xLTEtMTU5NTQw_17fb9f7c-9f28-4952-9bb0-3de3f0152828"
      unitRef="usd">1852900000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i0973ba0c1d894ceaa494709a13f814fb_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yNS9mcmFnOjhlOTlhYzhjMjM5YzRmZjg5YmQ2ZTM0YzZjMzBjM2UzL3RhYmxlOjdjMDlhN2RjNGUzNDQ5MjViNGY1Yjg3ZDBmN2Y3NzYwL3RhYmxlcmFuZ2U6N2MwOWE3ZGM0ZTM0NDkyNWI0ZjViODdkMGY3Zjc3NjBfMzItMy0xLTEtMTU5NTQw_7143a679-23bf-4c13-a98f-63c79fd198f9"
      unitRef="usd">1644300000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="i08ccb35f6ad24d7793c9c91b74ca2ea1_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yNS9mcmFnOjhlOTlhYzhjMjM5YzRmZjg5YmQ2ZTM0YzZjMzBjM2UzL3RhYmxlOjdjMDlhN2RjNGUzNDQ5MjViNGY1Yjg3ZDBmN2Y3NzYwL3RhYmxlcmFuZ2U6N2MwOWE3ZGM0ZTM0NDkyNWI0ZjViODdkMGY3Zjc3NjBfMzMtMS0xLTEtMTU5NTQw_5e4ffb82-2719-495f-bb32-824705e9d184"
      unitRef="usd">21642800000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="i0973ba0c1d894ceaa494709a13f814fb_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yNS9mcmFnOjhlOTlhYzhjMjM5YzRmZjg5YmQ2ZTM0YzZjMzBjM2UzL3RhYmxlOjdjMDlhN2RjNGUzNDQ5MjViNGY1Yjg3ZDBmN2Y3NzYwL3RhYmxlcmFuZ2U6N2MwOWE3ZGM0ZTM0NDkyNWI0ZjViODdkMGY3Zjc3NjBfMzMtMy0xLTEtMTU5NTQw_926495a8-349c-41e3-a1f0-0f47cf0e52af"
      unitRef="usd">24598500000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i08ccb35f6ad24d7793c9c91b74ca2ea1_I20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yNS9mcmFnOjhlOTlhYzhjMjM5YzRmZjg5YmQ2ZTM0YzZjMzBjM2UzL3RhYmxlOjdjMDlhN2RjNGUzNDQ5MjViNGY1Yjg3ZDBmN2Y3NzYwL3RhYmxlcmFuZ2U6N2MwOWE3ZGM0ZTM0NDkyNWI0ZjViODdkMGY3Zjc3NjBfMzQtMS0xLTEtMTU5NTQw_ed2c349c-8615-40f3-b30d-93b05b4cee01"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i0973ba0c1d894ceaa494709a13f814fb_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yNS9mcmFnOjhlOTlhYzhjMjM5YzRmZjg5YmQ2ZTM0YzZjMzBjM2UzL3RhYmxlOjdjMDlhN2RjNGUzNDQ5MjViNGY1Yjg3ZDBmN2Y3NzYwL3RhYmxlcmFuZ2U6N2MwOWE3ZGM0ZTM0NDkyNWI0ZjViODdkMGY3Zjc3NjBfMzQtMy0xLTEtMTU5NTQw_2ee68847-370e-4e54-94f0-08b48156ba8e"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommonStockValue
      contextRef="i08ccb35f6ad24d7793c9c91b74ca2ea1_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yNS9mcmFnOjhlOTlhYzhjMjM5YzRmZjg5YmQ2ZTM0YzZjMzBjM2UzL3RhYmxlOjdjMDlhN2RjNGUzNDQ5MjViNGY1Yjg3ZDBmN2Y3NzYwL3RhYmxlcmFuZ2U6N2MwOWE3ZGM0ZTM0NDkyNWI0ZjViODdkMGY3Zjc3NjBfMzYtMS0xLTEtMTU5NTQw_6f945256-6a20-49dc-ab4a-6f42cd913251"
      unitRef="usd">594100000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i0973ba0c1d894ceaa494709a13f814fb_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yNS9mcmFnOjhlOTlhYzhjMjM5YzRmZjg5YmQ2ZTM0YzZjMzBjM2UzL3RhYmxlOjdjMDlhN2RjNGUzNDQ5MjViNGY1Yjg3ZDBmN2Y3NzYwL3RhYmxlcmFuZ2U6N2MwOWE3ZGM0ZTM0NDkyNWI0ZjViODdkMGY3Zjc3NjBfMzYtMy0xLTEtMTU5NTQw_9d547d3c-c16e-47a8-b0d0-faaf4ba786bf"
      unitRef="usd">596300000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i08ccb35f6ad24d7793c9c91b74ca2ea1_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yNS9mcmFnOjhlOTlhYzhjMjM5YzRmZjg5YmQ2ZTM0YzZjMzBjM2UzL3RhYmxlOjdjMDlhN2RjNGUzNDQ5MjViNGY1Yjg3ZDBmN2Y3NzYwL3RhYmxlcmFuZ2U6N2MwOWE3ZGM0ZTM0NDkyNWI0ZjViODdkMGY3Zjc3NjBfMzctMS0xLTEtMTU5NTQw_30d4db3f-7b5a-4463-8464-28b1b04af3b7"
      unitRef="usd">6829000000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i0973ba0c1d894ceaa494709a13f814fb_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yNS9mcmFnOjhlOTlhYzhjMjM5YzRmZjg5YmQ2ZTM0YzZjMzBjM2UzL3RhYmxlOjdjMDlhN2RjNGUzNDQ5MjViNGY1Yjg3ZDBmN2Y3NzYwL3RhYmxlcmFuZ2U6N2MwOWE3ZGM0ZTM0NDkyNWI0ZjViODdkMGY3Zjc3NjBfMzctMy0xLTEtMTU5NTQw_0a2fce72-e720-4219-83e7-6cb98505cb5e"
      unitRef="usd">6833400000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i08ccb35f6ad24d7793c9c91b74ca2ea1_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yNS9mcmFnOjhlOTlhYzhjMjM5YzRmZjg5YmQ2ZTM0YzZjMzBjM2UzL3RhYmxlOjdjMDlhN2RjNGUzNDQ5MjViNGY1Yjg3ZDBmN2Y3NzYwL3RhYmxlcmFuZ2U6N2MwOWE3ZGM0ZTM0NDkyNWI0ZjViODdkMGY3Zjc3NjBfMzgtMS0xLTEtMTU5NTQw_4356b3df-1ebf-4a4d-83c5-97c3221e488e"
      unitRef="usd">10006500000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i0973ba0c1d894ceaa494709a13f814fb_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yNS9mcmFnOjhlOTlhYzhjMjM5YzRmZjg5YmQ2ZTM0YzZjMzBjM2UzL3RhYmxlOjdjMDlhN2RjNGUzNDQ5MjViNGY1Yjg3ZDBmN2Y3NzYwL3RhYmxlcmFuZ2U6N2MwOWE3ZGM0ZTM0NDkyNWI0ZjViODdkMGY3Zjc3NjBfMzgtMy0xLTEtMTU5NTQw_f525ed5f-f563-4f8e-ae59-f9ff003f83d0"
      unitRef="usd">8958500000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:CommonStockSharesHeldInEmployeeTrust
      contextRef="i08ccb35f6ad24d7793c9c91b74ca2ea1_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yNS9mcmFnOjhlOTlhYzhjMjM5YzRmZjg5YmQ2ZTM0YzZjMzBjM2UzL3RhYmxlOjdjMDlhN2RjNGUzNDQ5MjViNGY1Yjg3ZDBmN2Y3NzYwL3RhYmxlcmFuZ2U6N2MwOWE3ZGM0ZTM0NDkyNWI0ZjViODdkMGY3Zjc3NjBfMzktMS0xLTEtMTU5NTQw_41d7b892-cd4c-4d63-847c-8ae7104e5ff5"
      unitRef="usd">3013200000</us-gaap:CommonStockSharesHeldInEmployeeTrust>
    <us-gaap:CommonStockSharesHeldInEmployeeTrust
      contextRef="i0973ba0c1d894ceaa494709a13f814fb_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yNS9mcmFnOjhlOTlhYzhjMjM5YzRmZjg5YmQ2ZTM0YzZjMzBjM2UzL3RhYmxlOjdjMDlhN2RjNGUzNDQ5MjViNGY1Yjg3ZDBmN2Y3NzYwL3RhYmxlcmFuZ2U6N2MwOWE3ZGM0ZTM0NDkyNWI0ZjViODdkMGY3Zjc3NjBfMzktMy0xLTEtMTU5NTQw_8aa14d69-63ef-4579-b5cf-9f17a80df6c9"
      unitRef="usd">3013200000</us-gaap:CommonStockSharesHeldInEmployeeTrust>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i08ccb35f6ad24d7793c9c91b74ca2ea1_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yNS9mcmFnOjhlOTlhYzhjMjM5YzRmZjg5YmQ2ZTM0YzZjMzBjM2UzL3RhYmxlOjdjMDlhN2RjNGUzNDQ5MjViNGY1Yjg3ZDBmN2Y3NzYwL3RhYmxlcmFuZ2U6N2MwOWE3ZGM0ZTM0NDkyNWI0ZjViODdkMGY3Zjc3NjBfNDAtMS0xLTEtMTU5NTQw_be175668-fed2-4d93-b0a3-7b998489cb07"
      unitRef="usd">-4295800000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i0973ba0c1d894ceaa494709a13f814fb_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yNS9mcmFnOjhlOTlhYzhjMjM5YzRmZjg5YmQ2ZTM0YzZjMzBjM2UzL3RhYmxlOjdjMDlhN2RjNGUzNDQ5MjViNGY1Yjg3ZDBmN2Y3NzYwL3RhYmxlcmFuZ2U6N2MwOWE3ZGM0ZTM0NDkyNWI0ZjViODdkMGY3Zjc3NjBfNDAtMy0xLTEtMTU5NTQw_c48df100-2831-4414-a2d9-74efbb7b6414"
      unitRef="usd">-4343100000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:TreasuryStockCommonValue
      contextRef="i08ccb35f6ad24d7793c9c91b74ca2ea1_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yNS9mcmFnOjhlOTlhYzhjMjM5YzRmZjg5YmQ2ZTM0YzZjMzBjM2UzL3RhYmxlOjdjMDlhN2RjNGUzNDQ5MjViNGY1Yjg3ZDBmN2Y3NzYwL3RhYmxlcmFuZ2U6N2MwOWE3ZGM0ZTM0NDkyNWI0ZjViODdkMGY3Zjc3NjBfNDEtMS0xLTEtMTU5NTQw_9da404ad-22a5-41ab-acaa-fe21d3bf090b"
      unitRef="usd">50500000</us-gaap:TreasuryStockCommonValue>
    <us-gaap:TreasuryStockCommonValue
      contextRef="i0973ba0c1d894ceaa494709a13f814fb_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yNS9mcmFnOjhlOTlhYzhjMjM5YzRmZjg5YmQ2ZTM0YzZjMzBjM2UzL3RhYmxlOjdjMDlhN2RjNGUzNDQ5MjViNGY1Yjg3ZDBmN2Y3NzYwL3RhYmxlcmFuZ2U6N2MwOWE3ZGM0ZTM0NDkyNWI0ZjViODdkMGY3Zjc3NjBfNDEtMy0xLTEtMTU5NTQw_661952f6-67c9-4250-aa42-fd386e53977b"
      unitRef="usd">52700000</us-gaap:TreasuryStockCommonValue>
    <us-gaap:StockholdersEquity
      contextRef="i08ccb35f6ad24d7793c9c91b74ca2ea1_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yNS9mcmFnOjhlOTlhYzhjMjM5YzRmZjg5YmQ2ZTM0YzZjMzBjM2UzL3RhYmxlOjdjMDlhN2RjNGUzNDQ5MjViNGY1Yjg3ZDBmN2Y3NzYwL3RhYmxlcmFuZ2U6N2MwOWE3ZGM0ZTM0NDkyNWI0ZjViODdkMGY3Zjc3NjBfNDItMS0xLTEtMTU5NTQw_f5846b84-be1f-4976-ac40-6226ea648a2b"
      unitRef="usd">10070100000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i0973ba0c1d894ceaa494709a13f814fb_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yNS9mcmFnOjhlOTlhYzhjMjM5YzRmZjg5YmQ2ZTM0YzZjMzBjM2UzL3RhYmxlOjdjMDlhN2RjNGUzNDQ5MjViNGY1Yjg3ZDBmN2Y3NzYwL3RhYmxlcmFuZ2U6N2MwOWE3ZGM0ZTM0NDkyNWI0ZjViODdkMGY3Zjc3NjBfNDItMy0xLTEtMTU5NTQw_ff9c930e-a404-4170-8b92-38cbfc993039"
      unitRef="usd">8979200000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="i08ccb35f6ad24d7793c9c91b74ca2ea1_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yNS9mcmFnOjhlOTlhYzhjMjM5YzRmZjg5YmQ2ZTM0YzZjMzBjM2UzL3RhYmxlOjdjMDlhN2RjNGUzNDQ5MjViNGY1Yjg3ZDBmN2Y3NzYwL3RhYmxlcmFuZ2U6N2MwOWE3ZGM0ZTM0NDkyNWI0ZjViODdkMGY3Zjc3NjBfNDMtMS0xLTEtMTU5NTQw_1dd22c49-06ff-4fe7-ad48-6e6fc8568d67"
      unitRef="usd">95800000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="i0973ba0c1d894ceaa494709a13f814fb_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yNS9mcmFnOjhlOTlhYzhjMjM5YzRmZjg5YmQ2ZTM0YzZjMzBjM2UzL3RhYmxlOjdjMDlhN2RjNGUzNDQ5MjViNGY1Yjg3ZDBmN2Y3NzYwL3RhYmxlcmFuZ2U6N2MwOWE3ZGM0ZTM0NDkyNWI0ZjViODdkMGY3Zjc3NjBfNDMtMy0xLTEtMTU5NTQw_4d889854-6640-4a18-89bf-513e478707de"
      unitRef="usd">175600000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i08ccb35f6ad24d7793c9c91b74ca2ea1_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yNS9mcmFnOjhlOTlhYzhjMjM5YzRmZjg5YmQ2ZTM0YzZjMzBjM2UzL3RhYmxlOjdjMDlhN2RjNGUzNDQ5MjViNGY1Yjg3ZDBmN2Y3NzYwL3RhYmxlcmFuZ2U6N2MwOWE3ZGM0ZTM0NDkyNWI0ZjViODdkMGY3Zjc3NjBfNDQtMS0xLTEtMTU5NTQw_5d8111d7-420a-4d73-98fb-4648d03a68bb"
      unitRef="usd">10165900000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0973ba0c1d894ceaa494709a13f814fb_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yNS9mcmFnOjhlOTlhYzhjMjM5YzRmZjg5YmQ2ZTM0YzZjMzBjM2UzL3RhYmxlOjdjMDlhN2RjNGUzNDQ5MjViNGY1Yjg3ZDBmN2Y3NzYwL3RhYmxlcmFuZ2U6N2MwOWE3ZGM0ZTM0NDkyNWI0ZjViODdkMGY3Zjc3NjBfNDQtMy0xLTEtMTU5NTQw_dc289584-7b58-418a-b3f1-57669e605413"
      unitRef="usd">9154800000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i08ccb35f6ad24d7793c9c91b74ca2ea1_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yNS9mcmFnOjhlOTlhYzhjMjM5YzRmZjg5YmQ2ZTM0YzZjMzBjM2UzL3RhYmxlOjdjMDlhN2RjNGUzNDQ5MjViNGY1Yjg3ZDBmN2Y3NzYwL3RhYmxlcmFuZ2U6N2MwOWE3ZGM0ZTM0NDkyNWI0ZjViODdkMGY3Zjc3NjBfNDUtMS0xLTEtMTU5NTQw_a3b4d9e9-1e46-4533-bdf9-dd21360c131b"
      unitRef="usd">47461500000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i0973ba0c1d894ceaa494709a13f814fb_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yNS9mcmFnOjhlOTlhYzhjMjM5YzRmZjg5YmQ2ZTM0YzZjMzBjM2UzL3RhYmxlOjdjMDlhN2RjNGUzNDQ5MjViNGY1Yjg3ZDBmN2Y3NzYwL3RhYmxlcmFuZ2U6N2MwOWE3ZGM0ZTM0NDkyNWI0ZjViODdkMGY3Zjc3NjBfNDUtMy0xLTEtMTU5NTQw_40fb6377-8608-4b12-bf8b-d003a00a08f1"
      unitRef="usd">48806000000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:CommonStockSharesIssued
      contextRef="i3ff8d0839ef74b87b0394c920e9dfa82_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yOC9mcmFnOmEyNTBjNDBjZWQ3ZDQwZjRhNWUyMTQwZDM3MWNiYjliL3RhYmxlOjU0ZWNlYTRkMjgzZDQ4NTJiZTI1Y2QyYWEzN2M0ZDU0L3RhYmxlcmFuZ2U6NTRlY2VhNGQyODNkNDg1MmJlMjVjZDJhYTM3YzRkNTRfMy0xLTEtMS0xNTk1NDA_d99130da-dfa5-4730-b181-c58b7e189e14"
      unitRef="shares">957038000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3ff8d0839ef74b87b0394c920e9dfa82_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yOC9mcmFnOmEyNTBjNDBjZWQ3ZDQwZjRhNWUyMTQwZDM3MWNiYjliL3RhYmxlOjU0ZWNlYTRkMjgzZDQ4NTJiZTI1Y2QyYWEzN2M0ZDU0L3RhYmxlcmFuZ2U6NTRlY2VhNGQyODNkNDg1MmJlMjVjZDJhYTM3YzRkNTRfMy0zLTEtMS0xNTk1NDA_8a21183e-9e62-4214-8ea3-eaf9bfd9b255"
      unitRef="usd">598100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic9a5e6caa6224a1a95516222bf3644c0_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yOC9mcmFnOmEyNTBjNDBjZWQ3ZDQwZjRhNWUyMTQwZDM3MWNiYjliL3RhYmxlOjU0ZWNlYTRkMjgzZDQ4NTJiZTI1Y2QyYWEzN2M0ZDU0L3RhYmxlcmFuZ2U6NTRlY2VhNGQyODNkNDg1MmJlMjVjZDJhYTM3YzRkNTRfMy01LTEtMS0xNTk1NDA_d6b5ac1c-e96a-472c-bb49-c9be4b954f46"
      unitRef="usd">6669200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9fbf406305be444e87d56294647b476e_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yOC9mcmFnOmEyNTBjNDBjZWQ3ZDQwZjRhNWUyMTQwZDM3MWNiYjliL3RhYmxlOjU0ZWNlYTRkMjgzZDQ4NTJiZTI1Y2QyYWEzN2M0ZDU0L3RhYmxlcmFuZ2U6NTRlY2VhNGQyODNkNDg1MmJlMjVjZDJhYTM3YzRkNTRfMy03LTEtMS0xNTk1NDA_f4eecd7b-57d8-4ca5-8452-f0f41731dd00"
      unitRef="usd">8530100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iab7ebbcbace541c5b7a8ee0e0e859b97_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yOC9mcmFnOmEyNTBjNDBjZWQ3ZDQwZjRhNWUyMTQwZDM3MWNiYjliL3RhYmxlOjU0ZWNlYTRkMjgzZDQ4NTJiZTI1Y2QyYWEzN2M0ZDU0L3RhYmxlcmFuZ2U6NTRlY2VhNGQyODNkNDg1MmJlMjVjZDJhYTM3YzRkNTRfMy05LTEtMS0xNTk1NDA_17125689-6af3-4986-ab90-256a19eef300"
      unitRef="usd">-3013200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i19336abc2d9f44a7a6562598fdd26074_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yOC9mcmFnOmEyNTBjNDBjZWQ3ZDQwZjRhNWUyMTQwZDM3MWNiYjliL3RhYmxlOjU0ZWNlYTRkMjgzZDQ4NTJiZTI1Y2QyYWEzN2M0ZDU0L3RhYmxlcmFuZ2U6NTRlY2VhNGQyODNkNDg1MmJlMjVjZDJhYTM3YzRkNTRfMy0xMS0xLTEtMTU5NTQw_7fa55e07-b2c9-48c0-bfe6-7a08f6ccee19"
      unitRef="usd">-6287100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TreasuryStockCommonShares
      contextRef="i880a0df9a6d245b9a11c009232dc11c9_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yOC9mcmFnOmEyNTBjNDBjZWQ3ZDQwZjRhNWUyMTQwZDM3MWNiYjliL3RhYmxlOjU0ZWNlYTRkMjgzZDQ4NTJiZTI1Y2QyYWEzN2M0ZDU0L3RhYmxlcmFuZ2U6NTRlY2VhNGQyODNkNDg1MmJlMjVjZDJhYTM3YzRkNTRfMy0xMy0xLTEtMTU5NTQw_a0242d52-4853-4826-9c2a-9045ffce7d36"
      unitRef="shares">463000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i880a0df9a6d245b9a11c009232dc11c9_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yOC9mcmFnOmEyNTBjNDBjZWQ3ZDQwZjRhNWUyMTQwZDM3MWNiYjliL3RhYmxlOjU0ZWNlYTRkMjgzZDQ4NTJiZTI1Y2QyYWEzN2M0ZDU0L3RhYmxlcmFuZ2U6NTRlY2VhNGQyODNkNDg1MmJlMjVjZDJhYTM3YzRkNTRfMy0xNS0xLTEtMTU5NTQw_6d92fa6f-1acf-4170-82f2-aac697d0cb4d"
      unitRef="usd">-52700000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4d264417b4674277a12ca8c8f571f6da_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yOC9mcmFnOmEyNTBjNDBjZWQ3ZDQwZjRhNWUyMTQwZDM3MWNiYjliL3RhYmxlOjU0ZWNlYTRkMjgzZDQ4NTJiZTI1Y2QyYWEzN2M0ZDU0L3RhYmxlcmFuZ2U6NTRlY2VhNGQyODNkNDg1MmJlMjVjZDJhYTM3YzRkNTRfMy0xNy0xLTEtMTU5NTQw_a9acd5e2-5aec-4ba5-9339-48e3f1e2a6d4"
      unitRef="usd">219100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="ice03038a88b14398a99843ecea77cf17_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yOC9mcmFnOmEyNTBjNDBjZWQ3ZDQwZjRhNWUyMTQwZDM3MWNiYjliL3RhYmxlOjU0ZWNlYTRkMjgzZDQ4NTJiZTI1Y2QyYWEzN2M0ZDU0L3RhYmxlcmFuZ2U6NTRlY2VhNGQyODNkNDg1MmJlMjVjZDJhYTM3YzRkNTRfNC03LTEtMS0xNTk1NDA_9334433b-71f0-482b-b0ed-efc85667419e"
      unitRef="usd">1110100000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i37f1eff7c147431d9904c45abe8087de_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yOC9mcmFnOmEyNTBjNDBjZWQ3ZDQwZjRhNWUyMTQwZDM3MWNiYjliL3RhYmxlOjU0ZWNlYTRkMjgzZDQ4NTJiZTI1Y2QyYWEzN2M0ZDU0L3RhYmxlcmFuZ2U6NTRlY2VhNGQyODNkNDg1MmJlMjVjZDJhYTM3YzRkNTRfNC0xNy0xLTEtMTU5NTQw_b302ceb9-0483-4553-b3b0-a7bbfd98d89a"
      unitRef="usd">-22600000</us-gaap:ProfitLoss>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i28729f1c595d49408f9bc75addee5dce_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yOC9mcmFnOmEyNTBjNDBjZWQ3ZDQwZjRhNWUyMTQwZDM3MWNiYjliL3RhYmxlOjU0ZWNlYTRkMjgzZDQ4NTJiZTI1Y2QyYWEzN2M0ZDU0L3RhYmxlcmFuZ2U6NTRlY2VhNGQyODNkNDg1MmJlMjVjZDJhYTM3YzRkNTRfNS0xMS0xLTEtMTU5NTQw_b5d34ff5-fdb6-4175-bd8f-8acb0e98fca3"
      unitRef="usd">114400000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="ieabf4a292fa6473cb378b3091605b996_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yOC9mcmFnOmEyNTBjNDBjZWQ3ZDQwZjRhNWUyMTQwZDM3MWNiYjliL3RhYmxlOjU0ZWNlYTRkMjgzZDQ4NTJiZTI1Y2QyYWEzN2M0ZDU0L3RhYmxlcmFuZ2U6NTRlY2VhNGQyODNkNDg1MmJlMjVjZDJhYTM3YzRkNTRfMTAtMS0xLTEtMTU5NTQw_4a6e22e0-78b9-4cd9-9fd5-351b6a9d0265"
      unitRef="shares">14000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="ieabf4a292fa6473cb378b3091605b996_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yOC9mcmFnOmEyNTBjNDBjZWQ3ZDQwZjRhNWUyMTQwZDM3MWNiYjliL3RhYmxlOjU0ZWNlYTRkMjgzZDQ4NTJiZTI1Y2QyYWEzN2M0ZDU0L3RhYmxlcmFuZ2U6NTRlY2VhNGQyODNkNDg1MmJlMjVjZDJhYTM3YzRkNTRfMTAtMy0xLTEtMTU5NTQw_cb5228b7-d2a3-4faa-9075-9e8f7c1e1068"
      unitRef="usd">100000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="ia0caea5b6e2742c49986260609ac8cb2_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yOC9mcmFnOmEyNTBjNDBjZWQ3ZDQwZjRhNWUyMTQwZDM3MWNiYjliL3RhYmxlOjU0ZWNlYTRkMjgzZDQ4NTJiZTI1Y2QyYWEzN2M0ZDU0L3RhYmxlcmFuZ2U6NTRlY2VhNGQyODNkNDg1MmJlMjVjZDJhYTM3YzRkNTRfMTAtNS0xLTEtMTU5NTQw_5b574dac-02ce-4c68-af74-aed5fe5c9acb"
      unitRef="usd">-1300000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ia0caea5b6e2742c49986260609ac8cb2_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yOC9mcmFnOmEyNTBjNDBjZWQ3ZDQwZjRhNWUyMTQwZDM3MWNiYjliL3RhYmxlOjU0ZWNlYTRkMjgzZDQ4NTJiZTI1Y2QyYWEzN2M0ZDU0L3RhYmxlcmFuZ2U6NTRlY2VhNGQyODNkNDg1MmJlMjVjZDJhYTM3YzRkNTRfMTEtNS0xLTEtMTU5NTQw_a99ec9e9-a57b-434c-bba8-14bb40e0e4cd"
      unitRef="usd">90100000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockholdersEquityOther
      contextRef="ice03038a88b14398a99843ecea77cf17_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yOC9mcmFnOmEyNTBjNDBjZWQ3ZDQwZjRhNWUyMTQwZDM3MWNiYjliL3RhYmxlOjU0ZWNlYTRkMjgzZDQ4NTJiZTI1Y2QyYWEzN2M0ZDU0L3RhYmxlcmFuZ2U6NTRlY2VhNGQyODNkNDg1MmJlMjVjZDJhYTM3YzRkNTRfMTMtNy0xLTEtMTU5NTQw_500b1be3-576d-4c65-bf20-4f56891e467a"
      unitRef="usd">800000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="i37f1eff7c147431d9904c45abe8087de_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yOC9mcmFnOmEyNTBjNDBjZWQ3ZDQwZjRhNWUyMTQwZDM3MWNiYjliL3RhYmxlOjU0ZWNlYTRkMjgzZDQ4NTJiZTI1Y2QyYWEzN2M0ZDU0L3RhYmxlcmFuZ2U6NTRlY2VhNGQyODNkNDg1MmJlMjVjZDJhYTM3YzRkNTRfMTMtMTctMS0xLTE1OTU0MA_bc57a8e6-dc10-4b1a-b0c9-05210e9c61e2"
      unitRef="usd">-600000</us-gaap:StockholdersEquityOther>
    <us-gaap:CommonStockSharesIssued
      contextRef="i5d0c3b9efde1461b8e305f2507573310_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yOC9mcmFnOmEyNTBjNDBjZWQ3ZDQwZjRhNWUyMTQwZDM3MWNiYjliL3RhYmxlOjU0ZWNlYTRkMjgzZDQ4NTJiZTI1Y2QyYWEzN2M0ZDU0L3RhYmxlcmFuZ2U6NTRlY2VhNGQyODNkNDg1MmJlMjVjZDJhYTM3YzRkNTRfMTQtMS0xLTEtMTU5NTQw_ab54cf97-2781-4f63-b704-ce2ff1d7dbe5"
      unitRef="shares">957052000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5d0c3b9efde1461b8e305f2507573310_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yOC9mcmFnOmEyNTBjNDBjZWQ3ZDQwZjRhNWUyMTQwZDM3MWNiYjliL3RhYmxlOjU0ZWNlYTRkMjgzZDQ4NTJiZTI1Y2QyYWEzN2M0ZDU0L3RhYmxlcmFuZ2U6NTRlY2VhNGQyODNkNDg1MmJlMjVjZDJhYTM3YzRkNTRfMTQtMy0xLTEtMTU5NTQw_11f051ef-b549-4ebe-974b-408b5096316c"
      unitRef="usd">598200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ied5972defca747b08dfeb7847dcbf9b1_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yOC9mcmFnOmEyNTBjNDBjZWQ3ZDQwZjRhNWUyMTQwZDM3MWNiYjliL3RhYmxlOjU0ZWNlYTRkMjgzZDQ4NTJiZTI1Y2QyYWEzN2M0ZDU0L3RhYmxlcmFuZ2U6NTRlY2VhNGQyODNkNDg1MmJlMjVjZDJhYTM3YzRkNTRfMTQtNS0xLTEtMTU5NTQw_482df404-ec88-40d0-abc2-87feb99b0eb8"
      unitRef="usd">6758000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5e2b4f10aa894a52a243db283dd48374_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yOC9mcmFnOmEyNTBjNDBjZWQ3ZDQwZjRhNWUyMTQwZDM3MWNiYjliL3RhYmxlOjU0ZWNlYTRkMjgzZDQ4NTJiZTI1Y2QyYWEzN2M0ZDU0L3RhYmxlcmFuZ2U6NTRlY2VhNGQyODNkNDg1MmJlMjVjZDJhYTM3YzRkNTRfMTQtNy0xLTEtMTU5NTQw_1836dd86-4f61-4760-9272-7bb7b5e860ad"
      unitRef="usd">9639400000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5d24641160994798813313583b8c5313_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yOC9mcmFnOmEyNTBjNDBjZWQ3ZDQwZjRhNWUyMTQwZDM3MWNiYjliL3RhYmxlOjU0ZWNlYTRkMjgzZDQ4NTJiZTI1Y2QyYWEzN2M0ZDU0L3RhYmxlcmFuZ2U6NTRlY2VhNGQyODNkNDg1MmJlMjVjZDJhYTM3YzRkNTRfMTQtOS0xLTEtMTU5NTQw_f957e044-1a01-42c5-b1dc-fa79bc20b841"
      unitRef="usd">-3013200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib38bda0500864764be978f7cbb680740_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yOC9mcmFnOmEyNTBjNDBjZWQ3ZDQwZjRhNWUyMTQwZDM3MWNiYjliL3RhYmxlOjU0ZWNlYTRkMjgzZDQ4NTJiZTI1Y2QyYWEzN2M0ZDU0L3RhYmxlcmFuZ2U6NTRlY2VhNGQyODNkNDg1MmJlMjVjZDJhYTM3YzRkNTRfMTQtMTEtMS0xLTE1OTU0MA_93816949-4939-4059-99fa-6aa33d993e70"
      unitRef="usd">-6172700000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TreasuryStockCommonShares
      contextRef="i7b19ed61f4414f2e89fb8677352c10c6_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yOC9mcmFnOmEyNTBjNDBjZWQ3ZDQwZjRhNWUyMTQwZDM3MWNiYjliL3RhYmxlOjU0ZWNlYTRkMjgzZDQ4NTJiZTI1Y2QyYWEzN2M0ZDU0L3RhYmxlcmFuZ2U6NTRlY2VhNGQyODNkNDg1MmJlMjVjZDJhYTM3YzRkNTRfMTQtMTMtMS0xLTE1OTU0MA_5ba3cacd-6990-4cb0-813c-c9d6994bcad2"
      unitRef="shares">463000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7b19ed61f4414f2e89fb8677352c10c6_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yOC9mcmFnOmEyNTBjNDBjZWQ3ZDQwZjRhNWUyMTQwZDM3MWNiYjliL3RhYmxlOjU0ZWNlYTRkMjgzZDQ4NTJiZTI1Y2QyYWEzN2M0ZDU0L3RhYmxlcmFuZ2U6NTRlY2VhNGQyODNkNDg1MmJlMjVjZDJhYTM3YzRkNTRfMTQtMTUtMS0xLTE1OTU0MA_2900ac5b-f4af-4b04-a084-997e5a9b4ef4"
      unitRef="usd">-52700000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6809dd88ee6440e8b81974c0682727a5_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yOC9mcmFnOmEyNTBjNDBjZWQ3ZDQwZjRhNWUyMTQwZDM3MWNiYjliL3RhYmxlOjU0ZWNlYTRkMjgzZDQ4NTJiZTI1Y2QyYWEzN2M0ZDU0L3RhYmxlcmFuZ2U6NTRlY2VhNGQyODNkNDg1MmJlMjVjZDJhYTM3YzRkNTRfMTQtMTctMS0xLTE1OTU0MA_a9aff882-9ca0-4a01-a9c9-5793cd0734c9"
      unitRef="usd">197100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesIssued
      contextRef="id1796d16ca7c4cf0894522a6f064e12e_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yOC9mcmFnOmEyNTBjNDBjZWQ3ZDQwZjRhNWUyMTQwZDM3MWNiYjliL3RhYmxlOjU0ZWNlYTRkMjgzZDQ4NTJiZTI1Y2QyYWEzN2M0ZDU0L3RhYmxlcmFuZ2U6NTRlY2VhNGQyODNkNDg1MmJlMjVjZDJhYTM3YzRkNTRfMTYtMS0xLTEtMTU5NTQw_52cdcd29-2525-4ae3-b4d7-2ba5f9c69e58"
      unitRef="shares">950619000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id1796d16ca7c4cf0894522a6f064e12e_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yOC9mcmFnOmEyNTBjNDBjZWQ3ZDQwZjRhNWUyMTQwZDM3MWNiYjliL3RhYmxlOjU0ZWNlYTRkMjgzZDQ4NTJiZTI1Y2QyYWEzN2M0ZDU0L3RhYmxlcmFuZ2U6NTRlY2VhNGQyODNkNDg1MmJlMjVjZDJhYTM3YzRkNTRfMTYtMy0xLTEtMTU5NTQw_c7933550-6abf-4f37-bdc4-439f9acf1ae4"
      unitRef="usd">594100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia172fdb106784793868c32f3fe4a033a_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yOC9mcmFnOmEyNTBjNDBjZWQ3ZDQwZjRhNWUyMTQwZDM3MWNiYjliL3RhYmxlOjU0ZWNlYTRkMjgzZDQ4NTJiZTI1Y2QyYWEzN2M0ZDU0L3RhYmxlcmFuZ2U6NTRlY2VhNGQyODNkNDg1MmJlMjVjZDJhYTM3YzRkNTRfMTYtNS0xLTEtMTU5NTQw_e0dcc718-e876-40e3-865d-74e304b026f9"
      unitRef="usd">6746000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i13cf184e02084806adfd29b238e3b85d_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yOC9mcmFnOmEyNTBjNDBjZWQ3ZDQwZjRhNWUyMTQwZDM3MWNiYjliL3RhYmxlOjU0ZWNlYTRkMjgzZDQ4NTJiZTI1Y2QyYWEzN2M0ZDU0L3RhYmxlcmFuZ2U6NTRlY2VhNGQyODNkNDg1MmJlMjVjZDJhYTM3YzRkNTRfMTYtNy0xLTEtMTU5NTQw_95b3a5c3-92d3-46d8-a0f1-cd1e3723aab2"
      unitRef="usd">8556000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i044825e6cd0d4decafdaae3baf84a330_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yOC9mcmFnOmEyNTBjNDBjZWQ3ZDQwZjRhNWUyMTQwZDM3MWNiYjliL3RhYmxlOjU0ZWNlYTRkMjgzZDQ4NTJiZTI1Y2QyYWEzN2M0ZDU0L3RhYmxlcmFuZ2U6NTRlY2VhNGQyODNkNDg1MmJlMjVjZDJhYTM3YzRkNTRfMTYtOS0xLTEtMTU5NTQw_421097d9-14fe-47d2-82c0-b453d549a435"
      unitRef="usd">-3013200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9cff35c3c8c34c0fb04c18abeacebca6_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yOC9mcmFnOmEyNTBjNDBjZWQ3ZDQwZjRhNWUyMTQwZDM3MWNiYjliL3RhYmxlOjU0ZWNlYTRkMjgzZDQ4NTJiZTI1Y2QyYWEzN2M0ZDU0L3RhYmxlcmFuZ2U6NTRlY2VhNGQyODNkNDg1MmJlMjVjZDJhYTM3YzRkNTRfMTYtMTEtMS0xLTE1OTU0MA_922f799c-ed71-4cf6-873c-182b55de97e1"
      unitRef="usd">-4287700000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TreasuryStockCommonShares
      contextRef="i21c6412f9d1948d19b3452207237dadd_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yOC9mcmFnOmEyNTBjNDBjZWQ3ZDQwZjRhNWUyMTQwZDM3MWNiYjliL3RhYmxlOjU0ZWNlYTRkMjgzZDQ4NTJiZTI1Y2QyYWEzN2M0ZDU0L3RhYmxlcmFuZ2U6NTRlY2VhNGQyODNkNDg1MmJlMjVjZDJhYTM3YzRkNTRfMTYtMTMtMS0xLTE1OTU0MA_79b6e3ff-9a51-48d4-a405-02f97d7823a6"
      unitRef="shares">450000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i21c6412f9d1948d19b3452207237dadd_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yOC9mcmFnOmEyNTBjNDBjZWQ3ZDQwZjRhNWUyMTQwZDM3MWNiYjliL3RhYmxlOjU0ZWNlYTRkMjgzZDQ4NTJiZTI1Y2QyYWEzN2M0ZDU0L3RhYmxlcmFuZ2U6NTRlY2VhNGQyODNkNDg1MmJlMjVjZDJhYTM3YzRkNTRfMTYtMTUtMS0xLTE1OTU0MA_8eb7f85c-86ce-4c28-8769-6fd6765ed5b0"
      unitRef="usd">-50500000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i28fcba67335d4eeeb35e767ac7467d7b_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yOC9mcmFnOmEyNTBjNDBjZWQ3ZDQwZjRhNWUyMTQwZDM3MWNiYjliL3RhYmxlOjU0ZWNlYTRkMjgzZDQ4NTJiZTI1Y2QyYWEzN2M0ZDU0L3RhYmxlcmFuZ2U6NTRlY2VhNGQyODNkNDg1MmJlMjVjZDJhYTM3YzRkNTRfMTYtMTctMS0xLTE1OTU0MA_35553261-2932-45e5-b75b-26a9b8a401f7"
      unitRef="usd">114500000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="ib48f338ea64a4a6ab71c4d7e3fd06673_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yOC9mcmFnOmEyNTBjNDBjZWQ3ZDQwZjRhNWUyMTQwZDM3MWNiYjliL3RhYmxlOjU0ZWNlYTRkMjgzZDQ4NTJiZTI1Y2QyYWEzN2M0ZDU0L3RhYmxlcmFuZ2U6NTRlY2VhNGQyODNkNDg1MmJlMjVjZDJhYTM3YzRkNTRfMTctNy0xLTEtMTU5NTQw_14ca4ec0-2a9e-440a-b653-8d3cb5cf460a"
      unitRef="usd">1451700000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i55ef102ce6314f71bbad20789a340a44_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yOC9mcmFnOmEyNTBjNDBjZWQ3ZDQwZjRhNWUyMTQwZDM3MWNiYjliL3RhYmxlOjU0ZWNlYTRkMjgzZDQ4NTJiZTI1Y2QyYWEzN2M0ZDU0L3RhYmxlcmFuZ2U6NTRlY2VhNGQyODNkNDg1MmJlMjVjZDJhYTM3YzRkNTRfMTctMTctMS0xLTE1OTU0MA_111cfb83-128b-4931-b704-03735487bcbe"
      unitRef="usd">-15700000</us-gaap:ProfitLoss>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="idb26ceb80a3d4067ad9572aeb3904905_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yOC9mcmFnOmEyNTBjNDBjZWQ3ZDQwZjRhNWUyMTQwZDM3MWNiYjliL3RhYmxlOjU0ZWNlYTRkMjgzZDQ4NTJiZTI1Y2QyYWEzN2M0ZDU0L3RhYmxlcmFuZ2U6NTRlY2VhNGQyODNkNDg1MmJlMjVjZDJhYTM3YzRkNTRfMTgtMTEtMS0xLTE1OTU0MA_ac8af636-3dee-4504-82aa-5287e0932a31"
      unitRef="usd">-8100000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i97b74653944e4f17928c61ac64c196ad_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yOC9mcmFnOmEyNTBjNDBjZWQ3ZDQwZjRhNWUyMTQwZDM3MWNiYjliL3RhYmxlOjU0ZWNlYTRkMjgzZDQ4NTJiZTI1Y2QyYWEzN2M0ZDU0L3RhYmxlcmFuZ2U6NTRlY2VhNGQyODNkNDg1MmJlMjVjZDJhYTM3YzRkNTRfMjItMS0xLTEtMTU5NTQw_cbed6caa-260e-4cf6-bf22-4b4865463975"
      unitRef="shares">8000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i1b27ad5aed11494a84032093fe25e25c_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yOC9mcmFnOmEyNTBjNDBjZWQ3ZDQwZjRhNWUyMTQwZDM3MWNiYjliL3RhYmxlOjU0ZWNlYTRkMjgzZDQ4NTJiZTI1Y2QyYWEzN2M0ZDU0L3RhYmxlcmFuZ2U6NTRlY2VhNGQyODNkNDg1MmJlMjVjZDJhYTM3YzRkNTRfMjItNS0xLTEtMTU5NTQw_dbb85e96-a511-4c5c-b3a8-522111227c0f"
      unitRef="usd">-2100000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i1b27ad5aed11494a84032093fe25e25c_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yOC9mcmFnOmEyNTBjNDBjZWQ3ZDQwZjRhNWUyMTQwZDM3MWNiYjliL3RhYmxlOjU0ZWNlYTRkMjgzZDQ4NTJiZTI1Y2QyYWEzN2M0ZDU0L3RhYmxlcmFuZ2U6NTRlY2VhNGQyODNkNDg1MmJlMjVjZDJhYTM3YzRkNTRfMjMtNS0xLTEtMTU5NTQw_793dabe7-3c23-40ba-8b7c-01c5fbeae239"
      unitRef="usd">85100000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockholdersEquityOther
      contextRef="ib48f338ea64a4a6ab71c4d7e3fd06673_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yOC9mcmFnOmEyNTBjNDBjZWQ3ZDQwZjRhNWUyMTQwZDM3MWNiYjliL3RhYmxlOjU0ZWNlYTRkMjgzZDQ4NTJiZTI1Y2QyYWEzN2M0ZDU0L3RhYmxlcmFuZ2U6NTRlY2VhNGQyODNkNDg1MmJlMjVjZDJhYTM3YzRkNTRfMjQtNy0xLTEtMTU5NTQw_3052b3ea-5816-42a7-8c61-a84aff3ded87"
      unitRef="usd">1200000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="i55ef102ce6314f71bbad20789a340a44_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yOC9mcmFnOmEyNTBjNDBjZWQ3ZDQwZjRhNWUyMTQwZDM3MWNiYjliL3RhYmxlOjU0ZWNlYTRkMjgzZDQ4NTJiZTI1Y2QyYWEzN2M0ZDU0L3RhYmxlcmFuZ2U6NTRlY2VhNGQyODNkNDg1MmJlMjVjZDJhYTM3YzRkNTRfMjQtMTctMS0xLTE1OTU0MA_16605fdf-9003-4867-b015-ad4fd8ac69af"
      unitRef="usd">3000000.0</us-gaap:StockholdersEquityOther>
    <us-gaap:CommonStockSharesIssued
      contextRef="i5c81da162e9a42e2a66c2c1a06d48dd5_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yOC9mcmFnOmEyNTBjNDBjZWQ3ZDQwZjRhNWUyMTQwZDM3MWNiYjliL3RhYmxlOjU0ZWNlYTRkMjgzZDQ4NTJiZTI1Y2QyYWEzN2M0ZDU0L3RhYmxlcmFuZ2U6NTRlY2VhNGQyODNkNDg1MmJlMjVjZDJhYTM3YzRkNTRfMjUtMS0xLTEtMTU5NTQw_5f20c68a-bb7e-4c4b-b690-31acc3a6dc64"
      unitRef="shares">950627000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5c81da162e9a42e2a66c2c1a06d48dd5_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yOC9mcmFnOmEyNTBjNDBjZWQ3ZDQwZjRhNWUyMTQwZDM3MWNiYjliL3RhYmxlOjU0ZWNlYTRkMjgzZDQ4NTJiZTI1Y2QyYWEzN2M0ZDU0L3RhYmxlcmFuZ2U6NTRlY2VhNGQyODNkNDg1MmJlMjVjZDJhYTM3YzRkNTRfMjUtMy0xLTEtMTU5NTQw_3c594ee2-1ec7-4dfa-911c-0548180b2f69"
      unitRef="usd">594100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ice411cf446b842b893447accbe09511a_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yOC9mcmFnOmEyNTBjNDBjZWQ3ZDQwZjRhNWUyMTQwZDM3MWNiYjliL3RhYmxlOjU0ZWNlYTRkMjgzZDQ4NTJiZTI1Y2QyYWEzN2M0ZDU0L3RhYmxlcmFuZ2U6NTRlY2VhNGQyODNkNDg1MmJlMjVjZDJhYTM3YzRkNTRfMjUtNS0xLTEtMTU5NTQw_2a7f82f0-e187-410b-8956-11f19497c65e"
      unitRef="usd">6829000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8ebf10616d0b4419a14703502b215705_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yOC9mcmFnOmEyNTBjNDBjZWQ3ZDQwZjRhNWUyMTQwZDM3MWNiYjliL3RhYmxlOjU0ZWNlYTRkMjgzZDQ4NTJiZTI1Y2QyYWEzN2M0ZDU0L3RhYmxlcmFuZ2U6NTRlY2VhNGQyODNkNDg1MmJlMjVjZDJhYTM3YzRkNTRfMjUtNy0xLTEtMTU5NTQw_c293efd4-0b90-4e97-b6f9-5d3574699496"
      unitRef="usd">10006500000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i422ef8f62e714031b35d70b78011fe07_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yOC9mcmFnOmEyNTBjNDBjZWQ3ZDQwZjRhNWUyMTQwZDM3MWNiYjliL3RhYmxlOjU0ZWNlYTRkMjgzZDQ4NTJiZTI1Y2QyYWEzN2M0ZDU0L3RhYmxlcmFuZ2U6NTRlY2VhNGQyODNkNDg1MmJlMjVjZDJhYTM3YzRkNTRfMjUtOS0xLTEtMTU5NTQw_0aca80ce-bca5-4fac-9dab-71b90961a7d1"
      unitRef="usd">-3013200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i405731ae56194b5ab8d7ef0f5a2a4501_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yOC9mcmFnOmEyNTBjNDBjZWQ3ZDQwZjRhNWUyMTQwZDM3MWNiYjliL3RhYmxlOjU0ZWNlYTRkMjgzZDQ4NTJiZTI1Y2QyYWEzN2M0ZDU0L3RhYmxlcmFuZ2U6NTRlY2VhNGQyODNkNDg1MmJlMjVjZDJhYTM3YzRkNTRfMjUtMTEtMS0xLTE1OTU0MA_2e3dcb2f-de3e-4493-8c47-c1a091b32532"
      unitRef="usd">-4295800000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TreasuryStockCommonShares
      contextRef="i7890664142234b2cba495545e31cf06b_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yOC9mcmFnOmEyNTBjNDBjZWQ3ZDQwZjRhNWUyMTQwZDM3MWNiYjliL3RhYmxlOjU0ZWNlYTRkMjgzZDQ4NTJiZTI1Y2QyYWEzN2M0ZDU0L3RhYmxlcmFuZ2U6NTRlY2VhNGQyODNkNDg1MmJlMjVjZDJhYTM3YzRkNTRfMjUtMTMtMS0xLTE1OTU0MA_17f5a50e-d7d3-49ea-ac64-ce1a5539bebc"
      unitRef="shares">450000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7890664142234b2cba495545e31cf06b_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yOC9mcmFnOmEyNTBjNDBjZWQ3ZDQwZjRhNWUyMTQwZDM3MWNiYjliL3RhYmxlOjU0ZWNlYTRkMjgzZDQ4NTJiZTI1Y2QyYWEzN2M0ZDU0L3RhYmxlcmFuZ2U6NTRlY2VhNGQyODNkNDg1MmJlMjVjZDJhYTM3YzRkNTRfMjUtMTUtMS0xLTE1OTU0MA_7af684c2-0888-4891-a471-aee7fb026ebd"
      unitRef="usd">-50500000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i874cf6e76f6143ffbd4b62dbb7d9d39b_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yOC9mcmFnOmEyNTBjNDBjZWQ3ZDQwZjRhNWUyMTQwZDM3MWNiYjliL3RhYmxlOjU0ZWNlYTRkMjgzZDQ4NTJiZTI1Y2QyYWEzN2M0ZDU0L3RhYmxlcmFuZ2U6NTRlY2VhNGQyODNkNDg1MmJlMjVjZDJhYTM3YzRkNTRfMjUtMTctMS0xLTE1OTU0MA_9b67932d-c29d-44d6-9029-00b1aaa98c37"
      unitRef="usd">95800000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1
      contextRef="i08ccb35f6ad24d7793c9c91b74ca2ea1_I20220930"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yOC9mcmFnOmEyNTBjNDBjZWQ3ZDQwZjRhNWUyMTQwZDM3MWNiYjliL3RleHRyZWdpb246YTI1MGM0MGNlZDdkNDBmNGE1ZTIxNDBkMzcxY2JiOWJfMTI2_392aac4e-3a4d-409a-9955-2d5861d0f0a4"
      unitRef="usd">3250000000</us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="i9e4e65510f9e48218be4e6b56cc6a8e6_I20210531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yOC9mcmFnOmEyNTBjNDBjZWQ3ZDQwZjRhNWUyMTQwZDM3MWNiYjliL3RleHRyZWdpb246YTI1MGM0MGNlZDdkNDBmNGE1ZTIxNDBkMzcxY2JiOWJfMTQ5_7e916f3f-df34-4731-a795-e9ef2c8472bc"
      unitRef="usd">5000000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:CommonStockSharesIssued
      contextRef="id40dc90365d54458840dc95bd54da311_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfMy0xLTEtMS0xNTk1NDA_2132fa1b-70fd-4e4f-a01f-ffd6b0c714a2"
      unitRef="shares">957077000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id40dc90365d54458840dc95bd54da311_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfMy0zLTEtMS0xNTk1NDA_49513b36-23c6-4302-bc8a-3e7dce9e4f9e"
      unitRef="usd">598200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i13a4d036feb14d029728aad2602198e3_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfMy01LTEtMS0xNTk1NDA_24489339-2366-4003-a9ac-0a475443ec09"
      unitRef="usd">6778500000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i89632ef2fab645e59b17e0d04998f005_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfMy03LTEtMS0xNTk1NDA_7bf3ad30-99af-4e23-a5db-56723fa12009"
      unitRef="usd">7830200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i03ad855e73c7425c82de6d5bf47f2c5c_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfMy05LTEtMS0xNTk1NDA_97801844-2f7b-4d80-bb1b-ea229c3d9330"
      unitRef="usd">-3013200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0f26207c7675459eb15f8af1fa1954bd_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfMy0xMS0xLTEtMTU5NTQw_45563e87-5a11-412c-8815-eb21c40cb120"
      unitRef="usd">-6496400000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TreasuryStockCommonShares
      contextRef="i475ce37d989c466ca8d104299897d8b5_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfMy0xMy0xLTEtMTU5NTQw_d1cdfdda-f62e-426c-9a0c-ebd3749b728c"
      unitRef="shares">487000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i475ce37d989c466ca8d104299897d8b5_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfMy0xNS0xLTEtMTU5NTQw_0c79c58d-ca29-449b-b8c0-a4ce0f3b7eda"
      unitRef="usd">-55700000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="idd150ac2b08f457b820ab337af8f787a_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfMy0xNy0xLTEtMTU5NTQw_66e66eb1-ec42-4ada-8619-68e242132c1b"
      unitRef="usd">183600000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="iaae84e0e259740269afbdc32023935d8_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfNC03LTEtMS0xNTk1NDA_e666f04c-429b-4790-a01b-808f5cc00ecf"
      unitRef="usd">3855600000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="if4b3bbe2d1454aa7b635ddfa117d7690_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfNC0xNy0xLTEtMTU5NTQw_b6af0d50-8257-4a5b-9d1d-90d9faea180c"
      unitRef="usd">25200000</us-gaap:ProfitLoss>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i53f6912753594605b21dd0402024a8d0_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfNS0xMS0xLTEtMTU5NTQw_15e3426b-e712-410b-886e-979d782b8d05"
      unitRef="usd">323700000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="i167ed8f67bef48c49e54fa466400cdaa_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfNi0wLTEtMS0xNTk1NDAvdGV4dHJlZ2lvbjo2ZTk0NmE3YzUyMzM0ZjRkODAzOTg4ZWIyOWQ5MjkwNl8zOQ_264e7906-d7fe-4127-a93f-53fff8e375aa"
      unitRef="usdPerShare">1.70</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:Dividends
      contextRef="iaae84e0e259740269afbdc32023935d8_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfNi03LTEtMS0xNTk1NDA_20d6bbec-76c2-4d04-a885-ae1b096b0b58"
      unitRef="usd">1542900000</us-gaap:Dividends>
    <us-gaap:TreasuryStockSharesRetired
      contextRef="i0f7811d1ec7f49e2b3619fe9097a5c81_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfNy0xLTEtMS0xNTk1NDA_679f571e-3b8e-441e-b62c-bef0449b53d0"
      unitRef="shares">2467000</us-gaap:TreasuryStockSharesRetired>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="i0f7811d1ec7f49e2b3619fe9097a5c81_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfNy0zLTEtMS0xNTk1NDA_6634d471-c170-433b-892b-f6f91955369f"
      unitRef="usd">1500000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="iaae84e0e259740269afbdc32023935d8_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfNy03LTEtMS0xNTk1NDA_05ec5219-eae0-4cb0-b3bc-4e0ebcca3bdd"
      unitRef="usd">498500000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockSharesRetired
      contextRef="i43c09d3fa78d4c5e896029e6ef10d475_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfNy0xMy0xLTEtMTU5NTQw_ac6aaddd-eafb-4ec4-accf-829f59b018fb"
      unitRef="shares">2467000</us-gaap:TreasuryStockSharesRetired>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="i43c09d3fa78d4c5e896029e6ef10d475_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfNy0xNS0xLTEtMTU5NTQw_86de006e-c527-4c64-8afd-d972d9acad45"
      unitRef="usd">-500000000.0</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i43c09d3fa78d4c5e896029e6ef10d475_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfOC0xMy0xLTEtMTU5NTQw_6f9cea00-98ea-47d7-83e7-d75d6037deda"
      unitRef="shares">-2467000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i43c09d3fa78d4c5e896029e6ef10d475_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfOC0xNS0xLTEtMTU5NTQw_5b19ff46-59ca-42cb-8ec4-ec729fa0feac"
      unitRef="usd">500000000.0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i0f7811d1ec7f49e2b3619fe9097a5c81_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfOS0xLTEtMS0xNTk1NDA_ab343927-0015-46ea-b510-e6333f0c1ad8"
      unitRef="shares">2442000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i0f7811d1ec7f49e2b3619fe9097a5c81_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfOS0zLTEtMS0xNTk1NDA_522291f5-add3-4599-a7f5-cb942110c57c"
      unitRef="usd">1500000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="ieb70d5cf9dee4eaa8c659c22eeb4ea9e_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfOS01LTEtMS0xNTk1NDA_747e7374-e678-4bd6-af94-1fc5da0850ed"
      unitRef="usd">-287100000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i43c09d3fa78d4c5e896029e6ef10d475_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfOS0xMy0xLTEtMTU5NTQw_3aeef466-3c5f-4743-b85a-183e218f075e"
      unitRef="shares">-24000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i43c09d3fa78d4c5e896029e6ef10d475_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfOS0xNS0xLTEtMTU5NTQw_924c9fdc-7fe9-41c8-80cc-2c3895419a1d"
      unitRef="usd">3000000.0</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ieb70d5cf9dee4eaa8c659c22eeb4ea9e_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfMTAtNS0xLTEtMTU5NTQw_0ca3d1f2-d08b-4f97-a61b-c64ee132f2bd"
      unitRef="usd">267500000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockholdersEquityOther
      contextRef="ieb70d5cf9dee4eaa8c659c22eeb4ea9e_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfMTMtNS0xLTEtMTU5NTQw_8d18c9f1-80ac-4c14-9ad0-8db4ee8e60b0"
      unitRef="usd">900000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="iaae84e0e259740269afbdc32023935d8_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfMTMtNy0xLTEtMTU5NTQw_4462113d-c8c5-4da1-bee2-1f3244e3b67c"
      unitRef="usd">5000000.0</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="if4b3bbe2d1454aa7b635ddfa117d7690_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfMTMtMTctMS0xLTE1OTU0MA_50b230a8-b9fd-4ed9-a8d8-5d0be38f1d7b"
      unitRef="usd">11700000</us-gaap:StockholdersEquityOther>
    <us-gaap:CommonStockSharesIssued
      contextRef="i5d0c3b9efde1461b8e305f2507573310_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfMTQtMS0xLTEtMTU5NTQw_3e600aec-3f0e-47ad-a44f-0061634fd80c"
      unitRef="shares">957052000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5d0c3b9efde1461b8e305f2507573310_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfMTQtMy0xLTEtMTU5NTQw_42f8db68-04fd-4974-960b-80ceccdfe146"
      unitRef="usd">598200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ied5972defca747b08dfeb7847dcbf9b1_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfMTQtNS0xLTEtMTU5NTQw_81633402-28b7-4825-b5b7-6af580ef37f0"
      unitRef="usd">6758000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5e2b4f10aa894a52a243db283dd48374_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfMTQtNy0xLTEtMTU5NTQw_1836dd86-4f61-4760-9272-7bb7b5e860ad"
      unitRef="usd">9639400000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5d24641160994798813313583b8c5313_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfMTQtOS0xLTEtMTU5NTQw_a0d8388b-c177-44f6-87f3-6df9302cc370"
      unitRef="usd">-3013200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib38bda0500864764be978f7cbb680740_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfMTQtMTEtMS0xLTE1OTU0MA_30d30615-9381-44eb-9012-907d0f4a9c0d"
      unitRef="usd">-6172700000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TreasuryStockCommonShares
      contextRef="i7b19ed61f4414f2e89fb8677352c10c6_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfMTQtMTMtMS0xLTE1OTU0MA_96786cfe-52bc-495f-97eb-53dc1ce2f278"
      unitRef="shares">463000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7b19ed61f4414f2e89fb8677352c10c6_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfMTQtMTUtMS0xLTE1OTU0MA_47aac1d5-32f2-4222-a223-a804ecf08662"
      unitRef="usd">-52700000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6809dd88ee6440e8b81974c0682727a5_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfMTQtMTctMS0xLTE1OTU0MA_6e9724f4-a4eb-4b56-a3dc-86a277367c9a"
      unitRef="usd">197100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesIssued
      contextRef="i272cf8c25ebe4484a64e58f12187ad1b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfMTYtMS0xLTEtMTU5NTQw_002454a9-5cd6-4f01-94d5-75379d7bc199"
      unitRef="shares">954116000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i272cf8c25ebe4484a64e58f12187ad1b_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfMTYtMy0xLTEtMTU5NTQw_0b7c2b3a-07a8-4b4a-90d8-0e708bbf10f9"
      unitRef="usd">596300000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ibf8140dd5b59491da9ea91218accebc6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfMTYtNS0xLTEtMTU5NTQw_9bba381a-13d6-494e-839e-38fee9507482"
      unitRef="usd">6833400000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9d075318dc464943b61778b509358518_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfMTYtNy0xLTEtMTU5NTQw_9a0e730b-50ca-4d3b-ac16-d02e04f9bde5"
      unitRef="usd">8958500000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib1b20bf098e647cbbe9a5c1797e3b7a9_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfMTYtOS0xLTEtMTU5NTQw_2193abb6-63f7-4178-b852-58b7a88037af"
      unitRef="usd">-3013200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i016472e8315c436a845438f1b48dc880_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfMTYtMTEtMS0xLTE1OTU0MA_5ee7737e-cf3e-43c3-8600-6ff064b2d889"
      unitRef="usd">-4343100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TreasuryStockCommonShares
      contextRef="i39c60ea04aef49b0830a61d60786759c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfMTYtMTMtMS0xLTE1OTU0MA_d0839666-32d6-4ae0-946a-a4c5686bf3ad"
      unitRef="shares">463000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i39c60ea04aef49b0830a61d60786759c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfMTYtMTUtMS0xLTE1OTU0MA_535791d1-15b8-498e-a925-9f7eddc75751"
      unitRef="usd">-52700000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9a1a2f4319ea49c8a9891d557b01b308_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfMTYtMTctMS0xLTE1OTU0MA_e563bd3d-bf63-4cdb-8bdc-c615ce3a888c"
      unitRef="usd">175600000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="i53fe950833774c68a3cffa46aff8f74b_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfMTctNy0xLTEtMTU5NTQw_1488f5b1-e72b-42ae-a6a5-54c34666b7f0"
      unitRef="usd">4307100000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i78ac3ae89d8a4e4b9b5634d9c24f6a88_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfMTctMTctMS0xLTE1OTU0MA_668f5da5-cd08-4bac-bbb8-61dc5dc13db8"
      unitRef="usd">-63700000</us-gaap:ProfitLoss>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i318f185707b94171a8496548525b0a43_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfMTgtMTEtMS0xLTE1OTU0MA_2ae23a72-97f8-46ac-ac5d-bda0c1a083b7"
      unitRef="usd">47300000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfMTktMC0xLTEtMTU5NTQwL3RleHRyZWdpb246OTA0ZjZjMzVjZWM2NDE5NWI3ZjgxMjEzMTY2ZTE0YjhfMzk_04551d09-5ce0-4264-b8c4-2f3305475ce9"
      unitRef="usdPerShare">1.96</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:Dividends
      contextRef="i53fe950833774c68a3cffa46aff8f74b_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfMTktNy0xLTEtMTU5NTQw_5bea35f8-dc32-4f00-b577-3a633eb5fb8d"
      unitRef="usd">1765900000</us-gaap:Dividends>
    <us-gaap:TreasuryStockSharesRetired
      contextRef="i5fb9024f659a4c12b2ddd5ecc6dd8e7f_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfMjAtMS0xLTEtMTU5NTQw_3c5243b1-f8e1-46ea-965a-2132168277ba"
      unitRef="shares">5607000</us-gaap:TreasuryStockSharesRetired>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="i5fb9024f659a4c12b2ddd5ecc6dd8e7f_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfMjAtMy0xLTEtMTU5NTQw_2539f052-6bd7-4354-bb2d-681a9b76c79e"
      unitRef="usd">3500000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="i53fe950833774c68a3cffa46aff8f74b_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfMjAtNy0xLTEtMTU5NTQw_745a80a5-1a69-42c6-b6d4-0533f56e2900"
      unitRef="usd">1496500000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockSharesRetired
      contextRef="i668d06cad6064c9488359f57b6460125_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfMjAtMTMtMS0xLTE1OTU0MA_72afa8cd-b258-4119-8087-814775c285dd"
      unitRef="shares">5607000</us-gaap:TreasuryStockSharesRetired>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="i668d06cad6064c9488359f57b6460125_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfMjAtMTUtMS0xLTE1OTU0MA_90b2c7b9-d4d4-47cb-960d-af52cb5f093c"
      unitRef="usd">-1500000000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i668d06cad6064c9488359f57b6460125_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfMjEtMTMtMS0xLTE1OTU0MA_8e9af476-2a91-410a-81c3-a243861cdf43"
      unitRef="shares">-5607000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i668d06cad6064c9488359f57b6460125_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfMjEtMTUtMS0xLTE1OTU0MA_c8545f5f-37fb-4748-89c4-dbb910bf7e43"
      unitRef="usd">1500000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i5fb9024f659a4c12b2ddd5ecc6dd8e7f_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfMjItMS0xLTEtMTU5NTQw_fac55b76-b054-47f6-a788-aa8c5e06a9c4"
      unitRef="shares">2118000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i5fb9024f659a4c12b2ddd5ecc6dd8e7f_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfMjItMy0xLTEtMTU5NTQw_db2b2906-739a-4b47-8f3e-03022e2495d0"
      unitRef="usd">1300000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i1e65888bb572465d96d1a55aaa12d167_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfMjItNS0xLTEtMTU5NTQw_70c88f5d-6ad0-4bf4-8108-30a01e218cad"
      unitRef="usd">-282600000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i668d06cad6064c9488359f57b6460125_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfMjItMTMtMS0xLTE1OTU0MA_04bc94f9-48f3-42e4-a934-3287c4031747"
      unitRef="shares">-13000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i668d06cad6064c9488359f57b6460125_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfMjItMTUtMS0xLTE1OTU0MA_30b3cfe7-2129-4339-a61e-be4bfad21855"
      unitRef="usd">2200000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i1e65888bb572465d96d1a55aaa12d167_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfMjMtNS0xLTEtMTU5NTQw_64053464-fa17-41d1-afbf-9592f2033a17"
      unitRef="usd">278200000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockholdersEquityOther
      contextRef="i53fe950833774c68a3cffa46aff8f74b_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfMjQtNy0xLTEtMTU5NTQw_bad7e069-fcfc-431e-b524-dfc9eda39d0b"
      unitRef="usd">-3300000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="i78ac3ae89d8a4e4b9b5634d9c24f6a88_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfMjQtMTctMS0xLTE1OTU0MA_071d8009-b60e-44d6-beb2-633a460171d0"
      unitRef="usd">16100000</us-gaap:StockholdersEquityOther>
    <us-gaap:CommonStockSharesIssued
      contextRef="i5c81da162e9a42e2a66c2c1a06d48dd5_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfMjUtMS0xLTEtMTU5NTQw_ed8e396f-8fa5-483e-91c7-3849a10db72c"
      unitRef="shares">950627000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5c81da162e9a42e2a66c2c1a06d48dd5_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfMjUtMy0xLTEtMTU5NTQw_f8276910-2b59-49de-8393-db14d519ce5c"
      unitRef="usd">594100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ice411cf446b842b893447accbe09511a_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfMjUtNS0xLTEtMTU5NTQw_4fb65594-0089-4ee0-b65c-06b622fa0fed"
      unitRef="usd">6829000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8ebf10616d0b4419a14703502b215705_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfMjUtNy0xLTEtMTU5NTQw_5d85fa14-fa1e-40f8-9ad9-72d2adb9120a"
      unitRef="usd">10006500000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i422ef8f62e714031b35d70b78011fe07_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfMjUtOS0xLTEtMTU5NTQw_67618d32-1f03-47a0-8024-fce4cf6d5902"
      unitRef="usd">-3013200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i405731ae56194b5ab8d7ef0f5a2a4501_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfMjUtMTEtMS0xLTE1OTU0MA_850d9ab0-8b71-4991-b214-659011ddcdfb"
      unitRef="usd">-4295800000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TreasuryStockCommonShares
      contextRef="i7890664142234b2cba495545e31cf06b_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfMjUtMTMtMS0xLTE1OTU0MA_8ef29157-deac-4753-beeb-da0b17fe30c7"
      unitRef="shares">450000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7890664142234b2cba495545e31cf06b_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfMjUtMTUtMS0xLTE1OTU0MA_da8ad497-050f-4202-83f7-ba8bfce436f5"
      unitRef="usd">-50500000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i874cf6e76f6143ffbd4b62dbb7d9d39b_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfMjUtMTctMS0xLTE1OTU0MA_2b347a9e-dd04-46fb-8d13-754797bf19ac"
      unitRef="usd">95800000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1
      contextRef="i08ccb35f6ad24d7793c9c91b74ca2ea1_I20220930"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RleHRyZWdpb246ZTAxODE5ZTcxMTNjNGY2YzkyNjFiNDYyYzIxODNiMjFfMzE_392aac4e-3a4d-409a-9955-2d5861d0f0a4"
      unitRef="usd">3250000000</us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="i9e4e65510f9e48218be4e6b56cc6a8e6_I20210531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RleHRyZWdpb246ZTAxODE5ZTcxMTNjNGY2YzkyNjFiNDYyYzIxODNiMjFfNTQ_7e916f3f-df34-4731-a795-e9ef2c8472bc"
      unitRef="usd">5000000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:NetIncomeLoss
      contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zNC9mcmFnOmUxYWRjYjRiOGNhYTQzYTM5OWY1ZjExNzc3OTQ0YjI2L3RhYmxlOjg5MzlmNDA0NzJkMTQ2ZGViZTg3MzJlMTg4NTU5ZTE0L3RhYmxlcmFuZ2U6ODkzOWY0MDQ3MmQxNDZkZWJlODczMmUxODg1NTllMTRfMy0xLTEtMS0xNTk1NDA_87698447-ba66-4f71-89c1-b28a71c9e82a"
      unitRef="usd">4307100000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i167ed8f67bef48c49e54fa466400cdaa_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zNC9mcmFnOmUxYWRjYjRiOGNhYTQzYTM5OWY1ZjExNzc3OTQ0YjI2L3RhYmxlOjg5MzlmNDA0NzJkMTQ2ZGViZTg3MzJlMTg4NTU5ZTE0L3RhYmxlcmFuZ2U6ODkzOWY0MDQ3MmQxNDZkZWJlODczMmUxODg1NTllMTRfMy0zLTEtMS0xNTk1NDA_912d99b5-d76a-4c0a-b3cd-69c00d2c8eed"
      unitRef="usd">3855600000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zNC9mcmFnOmUxYWRjYjRiOGNhYTQzYTM5OWY1ZjExNzc3OTQ0YjI2L3RhYmxlOjg5MzlmNDA0NzJkMTQ2ZGViZTg3MzJlMTg4NTU5ZTE0L3RhYmxlcmFuZ2U6ODkzOWY0MDQ3MmQxNDZkZWJlODczMmUxODg1NTllMTRfNi0xLTEtMS0xNTk1NDA_b9cc748a-9363-4b7b-acb2-159869e22b9f"
      unitRef="usd">1147500000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i167ed8f67bef48c49e54fa466400cdaa_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zNC9mcmFnOmUxYWRjYjRiOGNhYTQzYTM5OWY1ZjExNzc3OTQ0YjI2L3RhYmxlOjg5MzlmNDA0NzJkMTQ2ZGViZTg3MzJlMTg4NTU5ZTE0L3RhYmxlcmFuZ2U6ODkzOWY0MDQ3MmQxNDZkZWJlODczMmUxODg1NTllMTRfNi0zLTEtMS0xNTk1NDA_9d7d1f9d-c79a-45eb-b5f7-11fbd7b7ea47"
      unitRef="usd">1101900000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes
      contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zNC9mcmFnOmUxYWRjYjRiOGNhYTQzYTM5OWY1ZjExNzc3OTQ0YjI2L3RhYmxlOjg5MzlmNDA0NzJkMTQ2ZGViZTg3MzJlMTg4NTU5ZTE0L3RhYmxlcmFuZ2U6ODkzOWY0MDQ3MmQxNDZkZWJlODczMmUxODg1NTllMTRfNy0xLTEtMS0xNTk1NDA_764e659f-8406-4ad2-a060-e1d8421b2f97"
      unitRef="usd">2195600000</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes
      contextRef="i167ed8f67bef48c49e54fa466400cdaa_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zNC9mcmFnOmUxYWRjYjRiOGNhYTQzYTM5OWY1ZjExNzc3OTQ0YjI2L3RhYmxlOjg5MzlmNDA0NzJkMTQ2ZGViZTg3MzJlMTg4NTU5ZTE0L3RhYmxlcmFuZ2U6ODkzOWY0MDQ3MmQxNDZkZWJlODczMmUxODg1NTllMTRfNy0zLTEtMS0xNTk1NDA_87aef963-a7a1-4268-9d2e-d9f86dec1340"
      unitRef="usd">709800000</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zNC9mcmFnOmUxYWRjYjRiOGNhYTQzYTM5OWY1ZjExNzc3OTQ0YjI2L3RhYmxlOjg5MzlmNDA0NzJkMTQ2ZGViZTg3MzJlMTg4NTU5ZTE0L3RhYmxlcmFuZ2U6ODkzOWY0MDQ3MmQxNDZkZWJlODczMmUxODg1NTllMTRfOC0xLTEtMS0xNTk1NDA_328a2c13-40c1-486c-9761-5b3e0b35c0a0"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i167ed8f67bef48c49e54fa466400cdaa_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zNC9mcmFnOmUxYWRjYjRiOGNhYTQzYTM5OWY1ZjExNzc3OTQ0YjI2L3RhYmxlOjg5MzlmNDA0NzJkMTQ2ZGViZTg3MzJlMTg4NTU5ZTE0L3RhYmxlcmFuZ2U6ODkzOWY0MDQ3MmQxNDZkZWJlODczMmUxODg1NTllMTRfOC0zLTEtMS0xNTk1NDA_569e5a6f-b822-41b5-953f-f9ef17228704"
      unitRef="usd">-405200000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:ShareBasedCompensation
      contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zNC9mcmFnOmUxYWRjYjRiOGNhYTQzYTM5OWY1ZjExNzc3OTQ0YjI2L3RhYmxlOjg5MzlmNDA0NzJkMTQ2ZGViZTg3MzJlMTg4NTU5ZTE0L3RhYmxlcmFuZ2U6ODkzOWY0MDQ3MmQxNDZkZWJlODczMmUxODg1NTllMTRfOS0xLTEtMS0xNTk1NDA_82ab231b-3959-45a5-8912-96f848fc2b13"
      unitRef="usd">278200000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i167ed8f67bef48c49e54fa466400cdaa_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zNC9mcmFnOmUxYWRjYjRiOGNhYTQzYTM5OWY1ZjExNzc3OTQ0YjI2L3RhYmxlOjg5MzlmNDA0NzJkMTQ2ZGViZTg3MzJlMTg4NTU5ZTE0L3RhYmxlcmFuZ2U6ODkzOWY0MDQ3MmQxNDZkZWJlODczMmUxODg1NTllMTRfOS0zLTEtMS0xNTk1NDA_f133a8dc-8f7b-4aca-897f-9e1c38bdc39c"
      unitRef="usd">267500000</us-gaap:ShareBasedCompensation>
    <us-gaap:GainLossOnInvestments
      contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zNC9mcmFnOmUxYWRjYjRiOGNhYTQzYTM5OWY1ZjExNzc3OTQ0YjI2L3RhYmxlOjg5MzlmNDA0NzJkMTQ2ZGViZTg3MzJlMTg4NTU5ZTE0L3RhYmxlcmFuZ2U6ODkzOWY0MDQ3MmQxNDZkZWJlODczMmUxODg1NTllMTRfMTEtMS0xLTEtMTU5NTQw_ec4b44eb-a340-48b1-b0af-46349619b1e5"
      unitRef="usd">-676400000</us-gaap:GainLossOnInvestments>
    <us-gaap:GainLossOnInvestments
      contextRef="i167ed8f67bef48c49e54fa466400cdaa_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zNC9mcmFnOmUxYWRjYjRiOGNhYTQzYTM5OWY1ZjExNzc3OTQ0YjI2L3RhYmxlOjg5MzlmNDA0NzJkMTQ2ZGViZTg3MzJlMTg4NTU5ZTE0L3RhYmxlcmFuZ2U6ODkzOWY0MDQ3MmQxNDZkZWJlODczMmUxODg1NTllMTRfMTEtMy0xLTEtMTU5NTQw_97a67122-077c-4352-ac30-90f9b59e1868"
      unitRef="usd">271100000</us-gaap:GainLossOnInvestments>
    <lly:AcquiredInProcessResearchAndDevelopment
      contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zNC9mcmFnOmUxYWRjYjRiOGNhYTQzYTM5OWY1ZjExNzc3OTQ0YjI2L3RhYmxlOjg5MzlmNDA0NzJkMTQ2ZGViZTg3MzJlMTg4NTU5ZTE0L3RhYmxlcmFuZ2U6ODkzOWY0MDQ3MmQxNDZkZWJlODczMmUxODg1NTllMTRfMTItMS0xLTEtMTU5NTQw_dcc1f7f6-af8e-4c78-aa45-9ce768437fb3"
      unitRef="usd">252000000.0</lly:AcquiredInProcessResearchAndDevelopment>
    <lly:AcquiredInProcessResearchAndDevelopment
      contextRef="i167ed8f67bef48c49e54fa466400cdaa_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zNC9mcmFnOmUxYWRjYjRiOGNhYTQzYTM5OWY1ZjExNzc3OTQ0YjI2L3RhYmxlOjg5MzlmNDA0NzJkMTQ2ZGViZTg3MzJlMTg4NTU5ZTE0L3RhYmxlcmFuZ2U6ODkzOWY0MDQ3MmQxNDZkZWJlODczMmUxODg1NTllMTRfMTItMy0xLTEtMTU5NTQw_5c23604b-5a24-410e-b04f-04d7914c0171"
      unitRef="usd">498300000</lly:AcquiredInProcessResearchAndDevelopment>
    <us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet
      contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zNC9mcmFnOmUxYWRjYjRiOGNhYTQzYTM5OWY1ZjExNzc3OTQ0YjI2L3RhYmxlOjg5MzlmNDA0NzJkMTQ2ZGViZTg3MzJlMTg4NTU5ZTE0L3RhYmxlcmFuZ2U6ODkzOWY0MDQ3MmQxNDZkZWJlODczMmUxODg1NTllMTRfMTMtMS0xLTEtMTU5NTQw_0db44160-12aa-4dd2-82a3-81f847e73113"
      unitRef="usd">-821500000</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
    <us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet
      contextRef="i167ed8f67bef48c49e54fa466400cdaa_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zNC9mcmFnOmUxYWRjYjRiOGNhYTQzYTM5OWY1ZjExNzc3OTQ0YjI2L3RhYmxlOjg5MzlmNDA0NzJkMTQ2ZGViZTg3MzJlMTg4NTU5ZTE0L3RhYmxlcmFuZ2U6ODkzOWY0MDQ3MmQxNDZkZWJlODczMmUxODg1NTllMTRfMTMtMy0xLTEtMTU5NTQw_5f6110da-05b6-4d87-afea-962318793b33"
      unitRef="usd">548100000</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
    <us-gaap:OtherOperatingActivitiesCashFlowStatement
      contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zNC9mcmFnOmUxYWRjYjRiOGNhYTQzYTM5OWY1ZjExNzc3OTQ0YjI2L3RhYmxlOjg5MzlmNDA0NzJkMTQ2ZGViZTg3MzJlMTg4NTU5ZTE0L3RhYmxlcmFuZ2U6ODkzOWY0MDQ3MmQxNDZkZWJlODczMmUxODg1NTllMTRfMTQtMS0xLTEtMTU5NTQw_288b8c65-33ef-4727-a892-c3f2cde4f247"
      unitRef="usd">217600000</us-gaap:OtherOperatingActivitiesCashFlowStatement>
    <us-gaap:OtherOperatingActivitiesCashFlowStatement
      contextRef="i167ed8f67bef48c49e54fa466400cdaa_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zNC9mcmFnOmUxYWRjYjRiOGNhYTQzYTM5OWY1ZjExNzc3OTQ0YjI2L3RhYmxlOjg5MzlmNDA0NzJkMTQ2ZGViZTg3MzJlMTg4NTU5ZTE0L3RhYmxlcmFuZ2U6ODkzOWY0MDQ3MmQxNDZkZWJlODczMmUxODg1NTllMTRfMTQtMy0xLTEtMTU5NTQw_04e1b5bd-99da-47e9-97ff-c13da12b6387"
      unitRef="usd">504700000</us-gaap:OtherOperatingActivitiesCashFlowStatement>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zNC9mcmFnOmUxYWRjYjRiOGNhYTQzYTM5OWY1ZjExNzc3OTQ0YjI2L3RhYmxlOjg5MzlmNDA0NzJkMTQ2ZGViZTg3MzJlMTg4NTU5ZTE0L3RhYmxlcmFuZ2U6ODkzOWY0MDQ3MmQxNDZkZWJlODczMmUxODg1NTllMTRfMTUtMS0xLTEtMTU5NTQw_6bb08335-ddfb-4a04-bfcc-447a014d0496"
      unitRef="usd">5504700000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i167ed8f67bef48c49e54fa466400cdaa_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zNC9mcmFnOmUxYWRjYjRiOGNhYTQzYTM5OWY1ZjExNzc3OTQ0YjI2L3RhYmxlOjg5MzlmNDA0NzJkMTQ2ZGViZTg3MzJlMTg4NTU5ZTE0L3RhYmxlcmFuZ2U6ODkzOWY0MDQ3MmQxNDZkZWJlODczMmUxODg1NTllMTRfMTUtMy0xLTEtMTU5NTQw_f383a937-0b7d-44dc-a557-f5b1f767e627"
      unitRef="usd">5104200000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zNC9mcmFnOmUxYWRjYjRiOGNhYTQzYTM5OWY1ZjExNzc3OTQ0YjI2L3RhYmxlOjg5MzlmNDA0NzJkMTQ2ZGViZTg3MzJlMTg4NTU5ZTE0L3RhYmxlcmFuZ2U6ODkzOWY0MDQ3MmQxNDZkZWJlODczMmUxODg1NTllMTRfMTctMS0xLTEtMTU5NTQw_ca5d5be9-6d35-47d9-9943-2beaa3ecad9c"
      unitRef="usd">1353600000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="i167ed8f67bef48c49e54fa466400cdaa_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zNC9mcmFnOmUxYWRjYjRiOGNhYTQzYTM5OWY1ZjExNzc3OTQ0YjI2L3RhYmxlOjg5MzlmNDA0NzJkMTQ2ZGViZTg3MzJlMTg4NTU5ZTE0L3RhYmxlcmFuZ2U6ODkzOWY0MDQ3MmQxNDZkZWJlODczMmUxODg1NTllMTRfMTctMy0xLTEtMTU5NTQw_5e9b2339-93ad-42d8-9132-14a123a8ab14"
      unitRef="usd">1018400000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:ProceedsFromSaleOfShortTermInvestments
      contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zNC9mcmFnOmUxYWRjYjRiOGNhYTQzYTM5OWY1ZjExNzc3OTQ0YjI2L3RhYmxlOjg5MzlmNDA0NzJkMTQ2ZGViZTg3MzJlMTg4NTU5ZTE0L3RhYmxlcmFuZ2U6ODkzOWY0MDQ3MmQxNDZkZWJlODczMmUxODg1NTllMTRfMTgtMS0xLTEtMTU5NTQw_40c8c0cc-1be7-4e46-a0db-c61e697604bb"
      unitRef="usd">83100000</us-gaap:ProceedsFromSaleOfShortTermInvestments>
    <us-gaap:ProceedsFromSaleOfShortTermInvestments
      contextRef="i167ed8f67bef48c49e54fa466400cdaa_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zNC9mcmFnOmUxYWRjYjRiOGNhYTQzYTM5OWY1ZjExNzc3OTQ0YjI2L3RhYmxlOjg5MzlmNDA0NzJkMTQ2ZGViZTg3MzJlMTg4NTU5ZTE0L3RhYmxlcmFuZ2U6ODkzOWY0MDQ3MmQxNDZkZWJlODczMmUxODg1NTllMTRfMTgtMy0xLTEtMTU5NTQw_a4b5ab83-a00f-416f-ae12-62df96c82992"
      unitRef="usd">46600000</us-gaap:ProceedsFromSaleOfShortTermInvestments>
    <us-gaap:PaymentsToAcquireShortTermInvestments
      contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zNC9mcmFnOmUxYWRjYjRiOGNhYTQzYTM5OWY1ZjExNzc3OTQ0YjI2L3RhYmxlOjg5MzlmNDA0NzJkMTQ2ZGViZTg3MzJlMTg4NTU5ZTE0L3RhYmxlcmFuZ2U6ODkzOWY0MDQ3MmQxNDZkZWJlODczMmUxODg1NTllMTRfMTktMS0xLTEtMTU5NTQw_62d74910-481b-40a4-8d64-e96ed1b818c8"
      unitRef="usd">65000000.0</us-gaap:PaymentsToAcquireShortTermInvestments>
    <us-gaap:PaymentsToAcquireShortTermInvestments
      contextRef="i167ed8f67bef48c49e54fa466400cdaa_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zNC9mcmFnOmUxYWRjYjRiOGNhYTQzYTM5OWY1ZjExNzc3OTQ0YjI2L3RhYmxlOjg5MzlmNDA0NzJkMTQ2ZGViZTg3MzJlMTg4NTU5ZTE0L3RhYmxlcmFuZ2U6ODkzOWY0MDQ3MmQxNDZkZWJlODczMmUxODg1NTllMTRfMTktMy0xLTEtMTU5NTQw_74557a09-80f4-473f-aa1a-6dec572a31ca"
      unitRef="usd">27900000</us-gaap:PaymentsToAcquireShortTermInvestments>
    <us-gaap:ProceedsFromSaleOfLongtermInvestments
      contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zNC9mcmFnOmUxYWRjYjRiOGNhYTQzYTM5OWY1ZjExNzc3OTQ0YjI2L3RhYmxlOjg5MzlmNDA0NzJkMTQ2ZGViZTg3MzJlMTg4NTU5ZTE0L3RhYmxlcmFuZ2U6ODkzOWY0MDQ3MmQxNDZkZWJlODczMmUxODg1NTllMTRfMjAtMS0xLTEtMTU5NTQw_3434e9b9-5b67-4077-b746-975240c17351"
      unitRef="usd">251600000</us-gaap:ProceedsFromSaleOfLongtermInvestments>
    <us-gaap:ProceedsFromSaleOfLongtermInvestments
      contextRef="i167ed8f67bef48c49e54fa466400cdaa_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zNC9mcmFnOmUxYWRjYjRiOGNhYTQzYTM5OWY1ZjExNzc3OTQ0YjI2L3RhYmxlOjg5MzlmNDA0NzJkMTQ2ZGViZTg3MzJlMTg4NTU5ZTE0L3RhYmxlcmFuZ2U6ODkzOWY0MDQ3MmQxNDZkZWJlODczMmUxODg1NTllMTRfMjAtMy0xLTEtMTU5NTQw_f4fef672-2df4-43b0-a0f7-bcd950718d5c"
      unitRef="usd">537200000</us-gaap:ProceedsFromSaleOfLongtermInvestments>
    <us-gaap:PaymentsToAcquireLongtermInvestments
      contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zNC9mcmFnOmUxYWRjYjRiOGNhYTQzYTM5OWY1ZjExNzc3OTQ0YjI2L3RhYmxlOjg5MzlmNDA0NzJkMTQ2ZGViZTg3MzJlMTg4NTU5ZTE0L3RhYmxlcmFuZ2U6ODkzOWY0MDQ3MmQxNDZkZWJlODczMmUxODg1NTllMTRfMjEtMS0xLTEtMTU5NTQw_9bf78d1b-6c1e-45bf-8e24-30fa8d8de78d"
      unitRef="usd">474100000</us-gaap:PaymentsToAcquireLongtermInvestments>
    <us-gaap:PaymentsToAcquireLongtermInvestments
      contextRef="i167ed8f67bef48c49e54fa466400cdaa_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zNC9mcmFnOmUxYWRjYjRiOGNhYTQzYTM5OWY1ZjExNzc3OTQ0YjI2L3RhYmxlOjg5MzlmNDA0NzJkMTQ2ZGViZTg3MzJlMTg4NTU5ZTE0L3RhYmxlcmFuZ2U6ODkzOWY0MDQ3MmQxNDZkZWJlODczMmUxODg1NTllMTRfMjEtMy0xLTEtMTU5NTQw_75173681-dd0d-4f28-9f64-82e68bbf1f44"
      unitRef="usd">710100000</us-gaap:PaymentsToAcquireLongtermInvestments>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zNC9mcmFnOmUxYWRjYjRiOGNhYTQzYTM5OWY1ZjExNzc3OTQ0YjI2L3RhYmxlOjg5MzlmNDA0NzJkMTQ2ZGViZTg3MzJlMTg4NTU5ZTE0L3RhYmxlcmFuZ2U6ODkzOWY0MDQ3MmQxNDZkZWJlODczMmUxODg1NTllMTRfMjItMS0xLTEtMTU5NTQw_177676c3-2202-4fa7-a902-2e4cf7a37549"
      unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i167ed8f67bef48c49e54fa466400cdaa_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zNC9mcmFnOmUxYWRjYjRiOGNhYTQzYTM5OWY1ZjExNzc3OTQ0YjI2L3RhYmxlOjg5MzlmNDA0NzJkMTQ2ZGViZTg3MzJlMTg4NTU5ZTE0L3RhYmxlcmFuZ2U6ODkzOWY0MDQ3MmQxNDZkZWJlODczMmUxODg1NTllMTRfMjItMy0xLTEtMTU5NTQw_e1fd174b-e2d1-41fc-9455-45f9c24728a3"
      unitRef="usd">747400000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <lly:PurchasedInProcessResearchAndDevelopment
      contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zNC9mcmFnOmUxYWRjYjRiOGNhYTQzYTM5OWY1ZjExNzc3OTQ0YjI2L3RhYmxlOjg5MzlmNDA0NzJkMTQ2ZGViZTg3MzJlMTg4NTU5ZTE0L3RhYmxlcmFuZ2U6ODkzOWY0MDQ3MmQxNDZkZWJlODczMmUxODg1NTllMTRfMjQtMS0xLTEtMTU5NTQw_b503ab4d-f58f-4069-9818-d2c83c572b70"
      unitRef="usd">574800000</lly:PurchasedInProcessResearchAndDevelopment>
    <lly:PurchasedInProcessResearchAndDevelopment
      contextRef="i167ed8f67bef48c49e54fa466400cdaa_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zNC9mcmFnOmUxYWRjYjRiOGNhYTQzYTM5OWY1ZjExNzc3OTQ0YjI2L3RhYmxlOjg5MzlmNDA0NzJkMTQ2ZGViZTg3MzJlMTg4NTU5ZTE0L3RhYmxlcmFuZ2U6ODkzOWY0MDQ3MmQxNDZkZWJlODczMmUxODg1NTllMTRfMjQtMy0xLTEtMTU5NTQw_1a617613-4c4d-40f3-a2fa-e891430a0c03"
      unitRef="usd">460600000</lly:PurchasedInProcessResearchAndDevelopment>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zNC9mcmFnOmUxYWRjYjRiOGNhYTQzYTM5OWY1ZjExNzc3OTQ0YjI2L3RhYmxlOjg5MzlmNDA0NzJkMTQ2ZGViZTg3MzJlMTg4NTU5ZTE0L3RhYmxlcmFuZ2U6ODkzOWY0MDQ3MmQxNDZkZWJlODczMmUxODg1NTllMTRfMjUtMS0xLTEtMTU5NTQw_3c8796b1-f1b6-4c64-a938-6142f6b5d666"
      unitRef="usd">268300000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="i167ed8f67bef48c49e54fa466400cdaa_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zNC9mcmFnOmUxYWRjYjRiOGNhYTQzYTM5OWY1ZjExNzc3OTQ0YjI2L3RhYmxlOjg5MzlmNDA0NzJkMTQ2ZGViZTg3MzJlMTg4NTU5ZTE0L3RhYmxlcmFuZ2U6ODkzOWY0MDQ3MmQxNDZkZWJlODczMmUxODg1NTllMTRfMjUtMy0xLTEtMTU5NTQw_3ee7f4b3-234c-4fba-b5fe-ee78439318dd"
      unitRef="usd">2700000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zNC9mcmFnOmUxYWRjYjRiOGNhYTQzYTM5OWY1ZjExNzc3OTQ0YjI2L3RhYmxlOjg5MzlmNDA0NzJkMTQ2ZGViZTg3MzJlMTg4NTU5ZTE0L3RhYmxlcmFuZ2U6ODkzOWY0MDQ3MmQxNDZkZWJlODczMmUxODg1NTllMTRfMjYtMS0xLTEtMTU5NTQw_a627cbdc-b668-4f21-925f-cd14613cc17d"
      unitRef="usd">-2401100000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i167ed8f67bef48c49e54fa466400cdaa_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zNC9mcmFnOmUxYWRjYjRiOGNhYTQzYTM5OWY1ZjExNzc3OTQ0YjI2L3RhYmxlOjg5MzlmNDA0NzJkMTQ2ZGViZTg3MzJlMTg4NTU5ZTE0L3RhYmxlcmFuZ2U6ODkzOWY0MDQ3MmQxNDZkZWJlODczMmUxODg1NTllMTRfMjYtMy0xLTEtMTU5NTQw_12d7c113-8444-4b2b-915e-8ef9a7e90b16"
      unitRef="usd">-2383300000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:PaymentsOfDividends
      contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zNC9mcmFnOmUxYWRjYjRiOGNhYTQzYTM5OWY1ZjExNzc3OTQ0YjI2L3RhYmxlOjg5MzlmNDA0NzJkMTQ2ZGViZTg3MzJlMTg4NTU5ZTE0L3RhYmxlcmFuZ2U6ODkzOWY0MDQ3MmQxNDZkZWJlODczMmUxODg1NTllMTRfMjgtMS0xLTEtMTU5NTQw_2daf73e0-0adb-465b-b461-da3b89a3cb06"
      unitRef="usd">2651400000</us-gaap:PaymentsOfDividends>
    <us-gaap:PaymentsOfDividends
      contextRef="i167ed8f67bef48c49e54fa466400cdaa_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zNC9mcmFnOmUxYWRjYjRiOGNhYTQzYTM5OWY1ZjExNzc3OTQ0YjI2L3RhYmxlOjg5MzlmNDA0NzJkMTQ2ZGViZTg3MzJlMTg4NTU5ZTE0L3RhYmxlcmFuZ2U6ODkzOWY0MDQ3MmQxNDZkZWJlODczMmUxODg1NTllMTRfMjgtMy0xLTEtMTU5NTQw_b734ad7f-5df0-431d-8cf8-9d7b067f6371"
      unitRef="usd">2313500000</us-gaap:PaymentsOfDividends>
    <us-gaap:ProceedsFromShortTermDebt
      contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zNC9mcmFnOmUxYWRjYjRiOGNhYTQzYTM5OWY1ZjExNzc3OTQ0YjI2L3RhYmxlOjg5MzlmNDA0NzJkMTQ2ZGViZTg3MzJlMTg4NTU5ZTE0L3RhYmxlcmFuZ2U6ODkzOWY0MDQ3MmQxNDZkZWJlODczMmUxODg1NTllMTRfMjktMS0xLTEtMTU5NTQw_0b92accc-d1a4-4611-9c38-36ef0f1c866a"
      unitRef="usd">1741300000</us-gaap:ProceedsFromShortTermDebt>
    <us-gaap:ProceedsFromShortTermDebt
      contextRef="i167ed8f67bef48c49e54fa466400cdaa_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zNC9mcmFnOmUxYWRjYjRiOGNhYTQzYTM5OWY1ZjExNzc3OTQ0YjI2L3RhYmxlOjg5MzlmNDA0NzJkMTQ2ZGViZTg3MzJlMTg4NTU5ZTE0L3RhYmxlcmFuZ2U6ODkzOWY0MDQ3MmQxNDZkZWJlODczMmUxODg1NTllMTRfMjktMy0xLTEtMTU5NTQw_9cf07f1b-dfc4-4c80-93cf-d3aac87aed91"
      unitRef="usd">-1500000</us-gaap:ProceedsFromShortTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zNC9mcmFnOmUxYWRjYjRiOGNhYTQzYTM5OWY1ZjExNzc3OTQ0YjI2L3RhYmxlOjg5MzlmNDA0NzJkMTQ2ZGViZTg3MzJlMTg4NTU5ZTE0L3RhYmxlcmFuZ2U6ODkzOWY0MDQ3MmQxNDZkZWJlODczMmUxODg1NTllMTRfMzAtMS0xLTEtMTU5NTQw_b707055a-6256-4816-aa37-c3b84c53640d"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="i167ed8f67bef48c49e54fa466400cdaa_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zNC9mcmFnOmUxYWRjYjRiOGNhYTQzYTM5OWY1ZjExNzc3OTQ0YjI2L3RhYmxlOjg5MzlmNDA0NzJkMTQ2ZGViZTg3MzJlMTg4NTU5ZTE0L3RhYmxlcmFuZ2U6ODkzOWY0MDQ3MmQxNDZkZWJlODczMmUxODg1NTllMTRfMzAtMy0xLTEtMTU5NTQw_4fbebe53-dbe3-46b7-866c-623447a9cb6d"
      unitRef="usd">2410800000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zNC9mcmFnOmUxYWRjYjRiOGNhYTQzYTM5OWY1ZjExNzc3OTQ0YjI2L3RhYmxlOjg5MzlmNDA0NzJkMTQ2ZGViZTg3MzJlMTg4NTU5ZTE0L3RhYmxlcmFuZ2U6ODkzOWY0MDQ3MmQxNDZkZWJlODczMmUxODg1NTllMTRfMzEtMS0xLTEtMTU5NTQw_fd21dd0d-8e21-4001-8765-84806aa5e6da"
      unitRef="usd">1560000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i167ed8f67bef48c49e54fa466400cdaa_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zNC9mcmFnOmUxYWRjYjRiOGNhYTQzYTM5OWY1ZjExNzc3OTQ0YjI2L3RhYmxlOjg5MzlmNDA0NzJkMTQ2ZGViZTg3MzJlMTg4NTU5ZTE0L3RhYmxlcmFuZ2U6ODkzOWY0MDQ3MmQxNDZkZWJlODczMmUxODg1NTllMTRfMzEtMy0xLTEtMTU5NTQw_50c48fb5-0621-4f3a-ba04-a0f7765632dd"
      unitRef="usd">1905300000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zNC9mcmFnOmUxYWRjYjRiOGNhYTQzYTM5OWY1ZjExNzc3OTQ0YjI2L3RhYmxlOjg5MzlmNDA0NzJkMTQ2ZGViZTg3MzJlMTg4NTU5ZTE0L3RhYmxlcmFuZ2U6ODkzOWY0MDQ3MmQxNDZkZWJlODczMmUxODg1NTllMTRfMzItMS0xLTEtMTU5NTQw_9f31c2fa-6849-4968-92d0-450b156e1d41"
      unitRef="usd">1500000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i167ed8f67bef48c49e54fa466400cdaa_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zNC9mcmFnOmUxYWRjYjRiOGNhYTQzYTM5OWY1ZjExNzc3OTQ0YjI2L3RhYmxlOjg5MzlmNDA0NzJkMTQ2ZGViZTg3MzJlMTg4NTU5ZTE0L3RhYmxlcmFuZ2U6ODkzOWY0MDQ3MmQxNDZkZWJlODczMmUxODg1NTllMTRfMzItMy0xLTEtMTU5NTQw_d85bb1cc-71a5-4c31-86ed-c2114e83e792"
      unitRef="usd">500000000.0</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zNC9mcmFnOmUxYWRjYjRiOGNhYTQzYTM5OWY1ZjExNzc3OTQ0YjI2L3RhYmxlOjg5MzlmNDA0NzJkMTQ2ZGViZTg3MzJlMTg4NTU5ZTE0L3RhYmxlcmFuZ2U6ODkzOWY0MDQ3MmQxNDZkZWJlODczMmUxODg1NTllMTRfMzQtMS0xLTEtMTU5NTQw_3b3c2ed5-5e87-44cf-8e2b-fc522b40f82f"
      unitRef="usd">-295200000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="i167ed8f67bef48c49e54fa466400cdaa_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zNC9mcmFnOmUxYWRjYjRiOGNhYTQzYTM5OWY1ZjExNzc3OTQ0YjI2L3RhYmxlOjg5MzlmNDA0NzJkMTQ2ZGViZTg3MzJlMTg4NTU5ZTE0L3RhYmxlcmFuZ2U6ODkzOWY0MDQ3MmQxNDZkZWJlODczMmUxODg1NTllMTRfMzQtMy0xLTEtMTU5NTQw_38bbeaf7-b915-436b-896c-0da49d08ba69"
      unitRef="usd">-295300000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zNC9mcmFnOmUxYWRjYjRiOGNhYTQzYTM5OWY1ZjExNzc3OTQ0YjI2L3RhYmxlOjg5MzlmNDA0NzJkMTQ2ZGViZTg3MzJlMTg4NTU5ZTE0L3RhYmxlcmFuZ2U6ODkzOWY0MDQ3MmQxNDZkZWJlODczMmUxODg1NTllMTRfMzUtMS0xLTEtMTU5NTQw_bac41b47-a144-414b-8a24-914f32a3d386"
      unitRef="usd">-4265300000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i167ed8f67bef48c49e54fa466400cdaa_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zNC9mcmFnOmUxYWRjYjRiOGNhYTQzYTM5OWY1ZjExNzc3OTQ0YjI2L3RhYmxlOjg5MzlmNDA0NzJkMTQ2ZGViZTg3MzJlMTg4NTU5ZTE0L3RhYmxlcmFuZ2U6ODkzOWY0MDQ3MmQxNDZkZWJlODczMmUxODg1NTllMTRfMzUtMy0xLTEtMTU5NTQw_4f302acd-0901-4703-a1ad-9c60a2cd4eaf"
      unitRef="usd">-2604800000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zNC9mcmFnOmUxYWRjYjRiOGNhYTQzYTM5OWY1ZjExNzc3OTQ0YjI2L3RhYmxlOjg5MzlmNDA0NzJkMTQ2ZGViZTg3MzJlMTg4NTU5ZTE0L3RhYmxlcmFuZ2U6ODkzOWY0MDQ3MmQxNDZkZWJlODczMmUxODg1NTllMTRfMzYtMS0xLTEtMTU5NTQw_2e450789-c04d-4f1c-8538-dfe6887b2591"
      unitRef="usd">-39400000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i167ed8f67bef48c49e54fa466400cdaa_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zNC9mcmFnOmUxYWRjYjRiOGNhYTQzYTM5OWY1ZjExNzc3OTQ0YjI2L3RhYmxlOjg5MzlmNDA0NzJkMTQ2ZGViZTg3MzJlMTg4NTU5ZTE0L3RhYmxlcmFuZ2U6ODkzOWY0MDQ3MmQxNDZkZWJlODczMmUxODg1NTllMTRfMzYtMy0xLTEtMTU5NTQw_1811339c-0279-44cc-a072-6fefee97a6cc"
      unitRef="usd">15000000.0</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zNC9mcmFnOmUxYWRjYjRiOGNhYTQzYTM5OWY1ZjExNzc3OTQ0YjI2L3RhYmxlOjg5MzlmNDA0NzJkMTQ2ZGViZTg3MzJlMTg4NTU5ZTE0L3RhYmxlcmFuZ2U6ODkzOWY0MDQ3MmQxNDZkZWJlODczMmUxODg1NTllMTRfMzgtMS0xLTEtMTU5NTQw_a28bb36e-7195-40e0-a77f-b14351a55465"
      unitRef="usd">-1201100000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i167ed8f67bef48c49e54fa466400cdaa_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zNC9mcmFnOmUxYWRjYjRiOGNhYTQzYTM5OWY1ZjExNzc3OTQ0YjI2L3RhYmxlOjg5MzlmNDA0NzJkMTQ2ZGViZTg3MzJlMTg4NTU5ZTE0L3RhYmxlcmFuZ2U6ODkzOWY0MDQ3MmQxNDZkZWJlODczMmUxODg1NTllMTRfMzgtMy0xLTEtMTU5NTQw_39368642-1b38-4577-a7ee-0f931466ca29"
      unitRef="usd">131100000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i0973ba0c1d894ceaa494709a13f814fb_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zNC9mcmFnOmUxYWRjYjRiOGNhYTQzYTM5OWY1ZjExNzc3OTQ0YjI2L3RhYmxlOjg5MzlmNDA0NzJkMTQ2ZGViZTg3MzJlMTg4NTU5ZTE0L3RhYmxlcmFuZ2U6ODkzOWY0MDQ3MmQxNDZkZWJlODczMmUxODg1NTllMTRfMzktMS0xLTEtMTU5NTQw_4138cde0-d05c-46d1-b55b-3ec64c5b13ec"
      unitRef="usd">3818500000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i82811f99128e46738e63b2b2f09a72ef_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zNC9mcmFnOmUxYWRjYjRiOGNhYTQzYTM5OWY1ZjExNzc3OTQ0YjI2L3RhYmxlOjg5MzlmNDA0NzJkMTQ2ZGViZTg3MzJlMTg4NTU5ZTE0L3RhYmxlcmFuZ2U6ODkzOWY0MDQ3MmQxNDZkZWJlODczMmUxODg1NTllMTRfMzktMy0xLTEtMTU5NTQw_803f4814-4572-421f-84d7-fd69fc65f552"
      unitRef="usd">3657100000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i08ccb35f6ad24d7793c9c91b74ca2ea1_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zNC9mcmFnOmUxYWRjYjRiOGNhYTQzYTM5OWY1ZjExNzc3OTQ0YjI2L3RhYmxlOjg5MzlmNDA0NzJkMTQ2ZGViZTg3MzJlMTg4NTU5ZTE0L3RhYmxlcmFuZ2U6ODkzOWY0MDQ3MmQxNDZkZWJlODczMmUxODg1NTllMTRfNDAtMS0xLTEtMTU5NTQw_eed9b77a-2738-4fbd-94c1-1605e4fd8402"
      unitRef="usd">2617400000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i5fcc694940794a94a960d8f1f9315381_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zNC9mcmFnOmUxYWRjYjRiOGNhYTQzYTM5OWY1ZjExNzc3OTQ0YjI2L3RhYmxlOjg5MzlmNDA0NzJkMTQ2ZGViZTg3MzJlMTg4NTU5ZTE0L3RhYmxlcmFuZ2U6ODkzOWY0MDQ3MmQxNDZkZWJlODczMmUxODg1NTllMTRfNDAtMy0xLTEtMTU5NTQw_9b1f9dbb-af91-4ae6-bde0-d3b4eeee6877"
      unitRef="usd">3788200000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180MC9mcmFnOjY1MTIyYTE5YjI4ZjQ1MzNhMjNhNzYyMmI4NDg4MGQ5L3RleHRyZWdpb246NjUxMjJhMTliMjhmNDUzM2EyM2E3NjIyYjg0ODgwZDlfNDE2Nw_fef486b7-2bf9-4243-b1bf-ccb3fd9bb9e8">Basis of Presentation and Implementation of New Financial Accounting Standard &lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have prepared the accompanying unaudited consolidated condensed financial statements in accordance with the requirements of Form 10-Q and, therefore, they do not include all information and footnotes necessary for a fair presentation of financial position, results of operations, and cash flows in conformity with accounting principles generally accepted in the United States (GAAP). In our opinion, the consolidated condensed financial statements reflect all adjustments (including those that are normal and recurring) that are necessary for a fair presentation of the results of operations for the periods shown. In preparing financial statements in conformity with GAAP, we must make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, expenses, and related disclosures at the date of the financial statements and during the reporting period. Actual results could differ from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The information included in this Quarterly Report on Form 10-Q should be read in conjunction with our consolidated financial statements and accompanying notes included in our Annual Report on &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="https://www.sec.gov/Archives/edgar/data/0000059478/000005947822000068/lly-20211231.htm" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Form 10-K&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for the year ended December&#160;31, 2021. We issue our financial statements by filing them with the Securities and Exchange Commission and have evaluated subsequent events up to the time of the filing of this Quarterly Report on Form 10-Q.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain reclassifications have been made to prior periods in the consolidated condensed financial statements and accompanying notes to conform with the current presentation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All per-share amounts, unless otherwise noted in the footnotes, are presented on a diluted basis; that is, based on the weighted-average number of common shares outstanding plus the effect of incremental shares from our stock-based compensation programs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We operate as a single operating segment engaged in the discovery, development, manufacturing, marketing, and sales of pharmaceutical products worldwide. A global research and development organization and a supply chain organization are responsible for the discovery, development, manufacturing, and supply of our products. Regional commercial organizations market, distribute, and sell the products. The business is also supported by global corporate staff functions. Our determination that we operate as a single segment is consistent with the financial information regularly reviewed by the chief operating decision maker for purposes of evaluating performance, allocating resources, setting incentive compensation targets, and planning and forecasting for future periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Research and Development Expenses and Acquired In-Process Research and Development (IPR&amp;amp;D) and Development Milestones&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development costs are expensed as incurred. Research and development costs consist of expenses incurred in performing research and development activities, including but not limited to, compensation and benefits, facilities and overhead expense, clinical trial expense, and fees paid to contract research organizations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Acquired IPR&amp;amp;D and development milestones include the initial costs of externally developed IPR&amp;amp;D projects, acquired directly in a transaction other than a business combination, that do not have an alternative future use. Additionally, milestone payment obligations related to these transactions that are incurred prior to regulatory approval of the compound are expensed when the event triggering an obligation to pay the milestone occurs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Implementation of New Financial Accounting Standard&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounting Standards Update 2021-01, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Reference Rate Reform&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, provides for temporary optional expedients and exceptions in applying current GAAP to contracts, hedging relationships, and other transactions affected by the transition from the use of the London Interbank Offered Rate (LIBOR) to an alternative reference rate. The standard is currently applicable to contracts entered into before January 1, 2023. We adopted the standard in the first quarter of 2022. The adoption did not have a material impact on our consolidated condensed financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180MC9mcmFnOjY1MTIyYTE5YjI4ZjQ1MzNhMjNhNzYyMmI4NDg4MGQ5L3RleHRyZWdpb246NjUxMjJhMTliMjhmNDUzM2EyM2E3NjIyYjg0ODgwZDlfNDE3NA_c48d06ff-5e0b-4653-8b6c-1453156fde1e">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Research and Development Expenses and Acquired In-Process Research and Development (IPR&amp;amp;D) and Development Milestones&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development costs are expensed as incurred. Research and development costs consist of expenses incurred in performing research and development activities, including but not limited to, compensation and benefits, facilities and overhead expense, clinical trial expense, and fees paid to contract research organizations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Acquired IPR&amp;amp;D and development milestones include the initial costs of externally developed IPR&amp;amp;D projects, acquired directly in a transaction other than a business combination, that do not have an alternative future use. Additionally, milestone payment obligations related to these transactions that are incurred prior to regulatory approval of the compound are expensed when the event triggering an obligation to pay the milestone occurs.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180MC9mcmFnOjY1MTIyYTE5YjI4ZjQ1MzNhMjNhNzYyMmI4NDg4MGQ5L3RleHRyZWdpb246NjUxMjJhMTliMjhmNDUzM2EyM2E3NjIyYjg0ODgwZDlfNDE2MA_e539ef21-51c4-4a56-93ea-59e5c9426eb5">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Implementation of New Financial Accounting Standard&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounting Standards Update 2021-01, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Reference Rate Reform&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, provides for temporary optional expedients and exceptions in applying current GAAP to contracts, hedging relationships, and other transactions affected by the transition from the use of the London Interbank Offered Rate (LIBOR) to an alternative reference rate. The standard is currently applicable to contracts entered into before January 1, 2023. We adopted the standard in the first quarter of 2022. The adoption did not have a material impact on our consolidated condensed financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerTextBlock
      contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RleHRyZWdpb246MzBhNDczMzUyMjFjNDA4Yjg4MjFiMDVmZmU0MmMzNTdfMzYxMA_932f7981-0408-4c83-94a4-8b2a8211708a">Revenue&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our revenue recognized in our consolidated condensed statements of operations:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.206%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net product revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6,119.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,189.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;19,123.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,579.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration and other revenue&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;822.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;583.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,116.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,739.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6,941.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,772.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;21,239.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,318.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Collaboration and other revenue associated with prior period transfers of intellectual property was $43.3 million and $130.9 million during the three and nine months ended September&#160;30, 2022, respectively, and $62.1 million and $136.1 million during the three and nine months ended September&#160;30, 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize revenue primarily from two different types of contracts, product sales to customers (net product revenue) and collaborations and other arrangements. Revenue recognized from collaborations and other arrangements includes our share of profits from the collaborations, as well as royalties, upfront and milestone payments we receive under these types of contracts. See Note 4 for additional information related to our collaborations and other arrangements. Collaboration and other revenue disclosed above includes the revenue from the Jardiance&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Trajenta&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; families of products resulting from our collaboration with Boehringer Ingelheim discussed in Note 4. Substantially all of the remainder of collaboration and other revenue is related to contracts accounted for as contracts with customers.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Adjustments to Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Adjustments to increase revenue recognized as a result of changes in estimates for our most significant United States (U.S.) sales returns, rebates, and discounts liability balances for products shipped in previous periods were 3 percent of U.S. revenue for the three months ended September&#160;30, 2022 and less than 1 percent of U.S. revenue during the nine months ended September&#160;30, 2022 and the three and nine months ended September&#160;30, 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Contract Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our contract liabilities result from arrangements where we have received payment in advance of performance under the contract and do not include sales returns, rebates, and discounts. Changes in contract liabilities are generally due to either receipt of additional advance payments or our performance under the contract. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes contract liability balances:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.274%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.276%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;232.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;262.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three and nine months ended September&#160;30, 2022 and 2021, revenue recognized from contract liabilities as of the beginning of the respective year was not material. Revenue expected to be recognized in the future from contract liabilities as the related performance obligations are satisfied is not expected to be material in any one year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Disaggregation of Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes revenue by product for the three months ended September&#160;30, 2022 and 2021:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.133%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.577%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Outside U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Outside U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue&#x2014;to unaffiliated customers:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diabetes:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Trulicity&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,418.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;432.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,850.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,201.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;398.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,600.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Jardiance&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;350.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;222.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;573.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;221.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;169.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;390.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Humalog&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; (2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;248.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;198.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;447.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;347.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;279.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;626.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Humulin&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;169.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;68.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;238.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;193.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;286.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Basaglar&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;124.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;68.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;193.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;192.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Mounjaro&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;97.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;90.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;187.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other diabetes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;79.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;94.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;173.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total diabetes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,488.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,174.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,662.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,143.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,131.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,274.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Oncology:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Verzenio&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;414.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;202.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;617.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;199.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;335.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Cyramza&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;87.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;144.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;232.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;168.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;253.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Erbitux&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;126.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;18.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;144.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;134.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Alimta&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;64.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;54.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;119.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;297.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;159.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;457.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Tyvyt&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;76.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;76.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other oncology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;39.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;62.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;102.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total oncology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;732.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;560.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,293.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;730.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;675.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,406.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Immunology:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Taltz&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;493.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;186.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;679.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;422.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;170.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;593.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Olumiant&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; (3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;22.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;160.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;182.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;194.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;212.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;406.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other immunology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total immunology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;516.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;349.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;866.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;616.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;388.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,004.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Neuroscience:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Emgality&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;114.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;54.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;168.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;140.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Zyprexa&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;8.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;73.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;81.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Cymbalta&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;7.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;54.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;62.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;132.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other neuroscience&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;16.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;44.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;60.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total neuroscience&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;145.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;227.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;373.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;305.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;450.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;COVID-19 antibodies&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;386.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;386.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;215.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;217.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Forteo&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;112.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;64.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;177.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Cialis&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;8.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;107.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;115.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;137.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;30.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;35.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;66.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;538.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;207.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;746.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;354.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;282.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;637.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4,422.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,519.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6,941.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,989.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,783.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,772.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Numbers may not add due to rounding.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Jardiance revenue includes Glyxambi&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Synjardy&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;and Trijardy&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; XR. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Humalog revenue includes insulin lispro. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Olumiant revenue includes sales for baricitinib that were made pursuant to Emergency Use Authorization (EUA) or similar regulatory authorizations.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(4) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;COVID-19 antibodies include sales for bamlanivimab administered alone, for bamlanivimab and etesevimab administered together, and for bebtelovimab and were made pursuant to EUAs or similar regulatory authorizations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes revenue by product for the nine months ended September&#160;30, 2022 and 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.133%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.577%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Outside U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Outside U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue&#x2014;to unaffiliated customers:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diabetes:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Trulicity&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4,162.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,341.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;5,503.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,465.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,122.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,588.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Humalog&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;855.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;656.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,512.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,009.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;842.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,851.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Jardiance&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;831.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;622.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,453.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;566.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;492.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,058.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Humulin&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;562.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;223.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;785.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;633.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;290.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;923.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Basaglar&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;339.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;218.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;558.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;423.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;226.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;650.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Mounjaro&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;109.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;93.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;203.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other diabetes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;195.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;276.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;472.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;185.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;302.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;488.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total diabetes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;7,057.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,431.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;10,489.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,284.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,276.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,560.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Oncology:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Verzenio&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,100.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;575.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,675.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;582.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;363.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;945.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Cyramza&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;259.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;434.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;693.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;266.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;496.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;762.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Alimta&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;490.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;200.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;691.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;911.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;714.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,626.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Erbitux&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;361.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;47.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;408.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;357.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;403.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Tyvyt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;235.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;235.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;340.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;340.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other oncology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;124.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;186.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;310.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;169.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;253.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total oncology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,335.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,679.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4,015.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,201.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,130.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,332.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Immunology:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Taltz&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,212.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;561.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,774.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,071.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;493.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,565.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Olumiant&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;104.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;520.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;624.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;236.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;572.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;809.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other immunology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;12.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;12.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total immunology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,317.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,093.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,411.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,323.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,080.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,404.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Neuroscience:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Emgality&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;330.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;144.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;475.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;313.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;415.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Zyprexa&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;26.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;235.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;261.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;264.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;292.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Cymbalta&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;25.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;194.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;219.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;454.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;484.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other neuroscience&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;62.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;142.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;204.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;235.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total neuroscience&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;444.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;716.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,160.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;453.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;974.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,427.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;COVID-19 antibodies&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,970.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;14.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,985.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;949.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;226.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,176.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Cialis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;25.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;454.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;480.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;541.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;538.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Forteo&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;261.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;191.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;453.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;330.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;287.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;617.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;119.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;125.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;244.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;164.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;260.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,377.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;786.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,163.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,373.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,220.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,593.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;13,531.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;7,708.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;21,239.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,635.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,683.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,318.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Numbers may not add due to rounding.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Humalog revenue includes insulin lispro.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Jardiance revenue includes Glyxambi,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Synjardy,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;and Trijardy XR.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Olumiant revenue includes sales for baricitinib that were made pursuant to EUA or similar regulatory authorizations.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(4) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;COVID-19 antibodies include sales for bamlanivimab administered alone, for bamlanivimab and etesevimab administered together, and for bebtelovimab and were made pursuant to EUAs or similar regulatory authorizations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes revenue by geographical area:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.206%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue&#x2014;to unaffiliated customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4,422.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,989.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;13,531.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,635.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,056.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,098.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,224.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,629.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Japan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;487.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;595.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,352.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,832.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;China&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;343.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;400.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,102.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,285.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other foreign countries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;632.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;689.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,029.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,936.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6,941.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,772.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;21,239.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,318.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Numbers may not add due to rounding.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Revenue is attributed to the countries based on the location of the customer.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RleHRyZWdpb246MzBhNDczMzUyMjFjNDA4Yjg4MjFiMDVmZmU0MmMzNTdfMzYyNg_6ed514c1-a15c-4ee4-b5b9-6c21ca4f5357">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our revenue recognized in our consolidated condensed statements of operations:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.206%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net product revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6,119.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,189.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;19,123.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,579.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration and other revenue&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;822.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;583.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,116.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,739.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6,941.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,772.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;21,239.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,318.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Collaboration and other revenue associated with prior period transfers of intellectual property was $43.3 million and $130.9 million during the three and nine months ended September&#160;30, 2022, respectively, and $62.1 million and $136.1 million during the three and nine months ended September&#160;30, 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes revenue by product for the three months ended September&#160;30, 2022 and 2021:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.133%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.577%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Outside U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Outside U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue&#x2014;to unaffiliated customers:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diabetes:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Trulicity&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,418.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;432.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,850.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,201.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;398.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,600.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Jardiance&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;350.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;222.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;573.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;221.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;169.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;390.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Humalog&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; (2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;248.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;198.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;447.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;347.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;279.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;626.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Humulin&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;169.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;68.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;238.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;193.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;286.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Basaglar&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;124.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;68.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;193.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;192.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Mounjaro&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;97.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;90.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;187.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other diabetes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;79.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;94.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;173.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total diabetes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,488.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,174.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,662.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,143.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,131.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,274.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Oncology:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Verzenio&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;414.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;202.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;617.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;199.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;335.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Cyramza&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;87.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;144.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;232.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;168.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;253.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Erbitux&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;126.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;18.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;144.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;134.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Alimta&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;64.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;54.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;119.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;297.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;159.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;457.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Tyvyt&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;76.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;76.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other oncology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;39.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;62.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;102.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total oncology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;732.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;560.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,293.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;730.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;675.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,406.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Immunology:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Taltz&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;493.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;186.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;679.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;422.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;170.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;593.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Olumiant&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; (3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;22.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;160.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;182.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;194.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;212.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;406.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other immunology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total immunology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;516.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;349.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;866.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;616.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;388.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,004.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Neuroscience:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Emgality&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;114.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;54.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;168.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;140.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Zyprexa&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;8.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;73.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;81.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Cymbalta&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;7.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;54.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;62.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;132.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other neuroscience&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;16.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;44.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;60.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total neuroscience&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;145.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;227.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;373.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;305.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;450.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;COVID-19 antibodies&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;386.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;386.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;215.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;217.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Forteo&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;112.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;64.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;177.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Cialis&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;8.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;107.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;115.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;137.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;30.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;35.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;66.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;538.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;207.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;746.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;354.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;282.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;637.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4,422.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,519.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6,941.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,989.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,783.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,772.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Numbers may not add due to rounding.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Jardiance revenue includes Glyxambi&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Synjardy&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;and Trijardy&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; XR. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Humalog revenue includes insulin lispro. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Olumiant revenue includes sales for baricitinib that were made pursuant to Emergency Use Authorization (EUA) or similar regulatory authorizations.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(4) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;COVID-19 antibodies include sales for bamlanivimab administered alone, for bamlanivimab and etesevimab administered together, and for bebtelovimab and were made pursuant to EUAs or similar regulatory authorizations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes revenue by product for the nine months ended September&#160;30, 2022 and 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.133%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.577%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Outside U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Outside U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue&#x2014;to unaffiliated customers:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diabetes:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Trulicity&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4,162.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,341.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;5,503.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,465.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,122.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,588.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Humalog&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;855.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;656.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,512.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,009.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;842.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,851.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Jardiance&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;831.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;622.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,453.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;566.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;492.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,058.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Humulin&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;562.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;223.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;785.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;633.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;290.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;923.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Basaglar&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;339.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;218.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;558.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;423.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;226.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;650.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Mounjaro&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;109.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;93.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;203.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other diabetes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;195.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;276.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;472.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;185.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;302.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;488.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total diabetes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;7,057.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,431.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;10,489.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,284.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,276.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,560.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Oncology:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Verzenio&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,100.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;575.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,675.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;582.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;363.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;945.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Cyramza&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;259.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;434.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;693.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;266.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;496.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;762.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Alimta&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;490.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;200.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;691.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;911.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;714.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,626.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Erbitux&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;361.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;47.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;408.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;357.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;403.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Tyvyt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;235.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;235.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;340.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;340.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other oncology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;124.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;186.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;310.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;169.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;253.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total oncology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,335.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,679.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4,015.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,201.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,130.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,332.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Immunology:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Taltz&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,212.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;561.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,774.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,071.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;493.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,565.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Olumiant&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;104.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;520.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;624.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;236.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;572.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;809.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other immunology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;12.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;12.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total immunology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,317.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,093.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,411.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,323.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,080.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,404.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Neuroscience:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Emgality&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;330.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;144.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;475.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;313.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;415.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Zyprexa&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;26.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;235.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;261.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;264.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;292.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Cymbalta&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;25.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;194.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;219.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;454.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;484.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other neuroscience&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;62.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;142.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;204.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;235.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total neuroscience&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;444.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;716.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,160.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;453.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;974.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,427.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;COVID-19 antibodies&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,970.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;14.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,985.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;949.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;226.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,176.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Cialis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;25.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;454.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;480.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;541.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;538.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Forteo&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;261.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;191.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;453.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;330.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;287.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;617.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;119.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;125.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;244.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;164.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;260.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,377.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;786.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,163.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,373.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,220.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,593.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;13,531.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;7,708.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;21,239.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,635.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,683.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,318.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Numbers may not add due to rounding.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Humalog revenue includes insulin lispro.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Jardiance revenue includes Glyxambi,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Synjardy,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;and Trijardy XR.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Olumiant revenue includes sales for baricitinib that were made pursuant to EUA or similar regulatory authorizations.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(4) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;COVID-19 antibodies include sales for bamlanivimab administered alone, for bamlanivimab and etesevimab administered together, and for bebtelovimab and were made pursuant to EUAs or similar regulatory authorizations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes revenue by geographical area:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.206%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue&#x2014;to unaffiliated customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4,422.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,989.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;13,531.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,635.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,056.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,098.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,224.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,629.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Japan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;487.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;595.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,352.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,832.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;China&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;343.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;400.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,102.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,285.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other foreign countries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;632.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;689.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,029.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,936.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6,941.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,772.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;21,239.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,318.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Numbers may not add due to rounding.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Revenue is attributed to the countries based on the location of the customer.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:Revenues
      contextRef="if42877c131ac415eb21599c372b78f90_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjA3OWI2OTMzNGFkNDQ5YTBhODFiNGY3ZGZlMDkzN2M0L3RhYmxlcmFuZ2U6MDc5YjY5MzM0YWQ0NDlhMGE4MWI0ZjdkZmUwOTM3YzRfMi0xLTEtMS0xNTk1NDA_7cb2a4c7-1716-45c9-8edc-e1709c8521c6"
      unitRef="usd">6119200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i80d1b089c2a644458859200e15f563c8_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjA3OWI2OTMzNGFkNDQ5YTBhODFiNGY3ZGZlMDkzN2M0L3RhYmxlcmFuZ2U6MDc5YjY5MzM0YWQ0NDlhMGE4MWI0ZjdkZmUwOTM3YzRfMi0zLTEtMS0xNTk1NDA_831ad7c4-6e8a-446d-90a9-8755ba774bc5"
      unitRef="usd">6189000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id3dd0ce52c8549c58e5d29bb1bb1c197_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjA3OWI2OTMzNGFkNDQ5YTBhODFiNGY3ZGZlMDkzN2M0L3RhYmxlcmFuZ2U6MDc5YjY5MzM0YWQ0NDlhMGE4MWI0ZjdkZmUwOTM3YzRfMi01LTEtMS0xNTk1NDA_7f49393a-0299-45f2-a53f-487e0e7b7fc7"
      unitRef="usd">19123000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1962268fe5e4415bbcb7e76b2f694425_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjA3OWI2OTMzNGFkNDQ5YTBhODFiNGY3ZGZlMDkzN2M0L3RhYmxlcmFuZ2U6MDc5YjY5MzM0YWQ0NDlhMGE4MWI0ZjdkZmUwOTM3YzRfMi03LTEtMS0xNTk1NDA_beeb036d-b623-4bdb-abb4-d6bf219bff19"
      unitRef="usd">18579500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie24dcfd7665d4948a6b3ea63d1979c25_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjA3OWI2OTMzNGFkNDQ5YTBhODFiNGY3ZGZlMDkzN2M0L3RhYmxlcmFuZ2U6MDc5YjY5MzM0YWQ0NDlhMGE4MWI0ZjdkZmUwOTM3YzRfMy0xLTEtMS0xNTk1NDA_91e45130-eaf7-493d-8c3f-a3da24660c94"
      unitRef="usd">822400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i28f16eccfa8b45c9b2f74cc6235732b4_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjA3OWI2OTMzNGFkNDQ5YTBhODFiNGY3ZGZlMDkzN2M0L3RhYmxlcmFuZ2U6MDc5YjY5MzM0YWQ0NDlhMGE4MWI0ZjdkZmUwOTM3YzRfMy0zLTEtMS0xNTk1NDA_f2b10dfd-d1df-4bd2-8e47-05df82f43ef9"
      unitRef="usd">583800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3ebb89e75b934815a2a398afa3315ad4_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjA3OWI2OTMzNGFkNDQ5YTBhODFiNGY3ZGZlMDkzN2M0L3RhYmxlcmFuZ2U6MDc5YjY5MzM0YWQ0NDlhMGE4MWI0ZjdkZmUwOTM3YzRfMy01LTEtMS0xNTk1NDA_7b426d53-c29a-46a8-a041-cf93af6fe19d"
      unitRef="usd">2116600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0707295b42774a95baab2b522f5925a8_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjA3OWI2OTMzNGFkNDQ5YTBhODFiNGY3ZGZlMDkzN2M0L3RhYmxlcmFuZ2U6MDc5YjY5MzM0YWQ0NDlhMGE4MWI0ZjdkZmUwOTM3YzRfMy03LTEtMS0xNTk1NDA_ac06b230-7599-445e-a758-572f515f5955"
      unitRef="usd">1739000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i19fc0325c48543008ea71e1fdcf11d86_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjA3OWI2OTMzNGFkNDQ5YTBhODFiNGY3ZGZlMDkzN2M0L3RhYmxlcmFuZ2U6MDc5YjY5MzM0YWQ0NDlhMGE4MWI0ZjdkZmUwOTM3YzRfNC0xLTEtMS0xNTk1NDA_12e03f10-98cf-4b8e-b958-bc063c635ef8"
      unitRef="usd">6941600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie4fa4f6b472a4f269297591b44aba572_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjA3OWI2OTMzNGFkNDQ5YTBhODFiNGY3ZGZlMDkzN2M0L3RhYmxlcmFuZ2U6MDc5YjY5MzM0YWQ0NDlhMGE4MWI0ZjdkZmUwOTM3YzRfNC0zLTEtMS0xNTk1NDA_159989f0-4305-48b1-9340-a92b751ddf73"
      unitRef="usd">6772800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjA3OWI2OTMzNGFkNDQ5YTBhODFiNGY3ZGZlMDkzN2M0L3RhYmxlcmFuZ2U6MDc5YjY5MzM0YWQ0NDlhMGE4MWI0ZjdkZmUwOTM3YzRfNC01LTEtMS0xNTk1NDA_c7f53c2a-97d3-40c1-8e71-3bc264a49ee2"
      unitRef="usd">21239600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i167ed8f67bef48c49e54fa466400cdaa_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjA3OWI2OTMzNGFkNDQ5YTBhODFiNGY3ZGZlMDkzN2M0L3RhYmxlcmFuZ2U6MDc5YjY5MzM0YWQ0NDlhMGE4MWI0ZjdkZmUwOTM3YzRfNC03LTEtMS0xNTk1NDA_ca22ca5b-9b12-4f38-baf1-ba66e3eb63d3"
      unitRef="usd">20318500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i34aeabd3620f4de8ad8c2efefc863807_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RleHRyZWdpb246MzBhNDczMzUyMjFjNDA4Yjg4MjFiMDVmZmU0MmMzNTdfMjM3_f0f2f02c-15ad-4db8-8741-6bed5024e2b6"
      unitRef="usd">43300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia0d2323337da484fb1444b8262ff7a7e_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RleHRyZWdpb246MzBhNDczMzUyMjFjNDA4Yjg4MjFiMDVmZmU0MmMzNTdfMjQ0_73540d04-9c94-44c7-8a94-e0acf37c1b39"
      unitRef="usd">130900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i16836baff9c344308700232bb53196d6_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RleHRyZWdpb246MzBhNDczMzUyMjFjNDA4Yjg4MjFiMDVmZmU0MmMzNTdfMjk2_74bd2027-e5ee-42ef-9a3c-077af228cbba"
      unitRef="usd">62100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib6db6b88271640b7be37a4c3c9f838c6_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RleHRyZWdpb246MzBhNDczMzUyMjFjNDA4Yjg4MjFiMDVmZmU0MmMzNTdfMzAz_cbd103f3-7e5a-4006-a81f-8fb363caa85a"
      unitRef="usd">136100000</us-gaap:Revenues>
    <lly:RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent
      contextRef="i46e52d8ad0e14ebf9fa7c9ecc503bbfa_D20220701-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RleHRyZWdpb246MzBhNDczMzUyMjFjNDA4Yjg4MjFiMDVmZmU0MmMzNTdfMzI5ODUzNDg4NzE4MA_5b451c14-f56c-4b09-ab4d-34d0986e41c2"
      unitRef="number">0.03</lly:RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent>
    <lly:RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent
      contextRef="i72b37618b2b848e48b6d7a66628d0ea0_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RleHRyZWdpb246MzBhNDczMzUyMjFjNDA4Yjg4MjFiMDVmZmU0MmMzNTdfMTQxMA_0eb796ed-9b9f-4506-8b44-40e03e988f78"
      unitRef="number">0.01</lly:RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent>
    <lly:RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent
      contextRef="i19f0f8e72ada412eb34eae9afa79a051_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RleHRyZWdpb246MzBhNDczMzUyMjFjNDA4Yjg4MjFiMDVmZmU0MmMzNTdfMTQxMA_6e78608c-d607-4a0e-84f2-ca135f08d9c7"
      unitRef="number">0.01</lly:RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent>
    <lly:RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent
      contextRef="i7685d8873a9b40f5bab0b11fa36b225d_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RleHRyZWdpb246MzBhNDczMzUyMjFjNDA4Yjg4MjFiMDVmZmU0MmMzNTdfMTQxMA_7e029b78-43ca-4f60-bc29-bad0fcf3e363"
      unitRef="number">0.01</lly:RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent>
    <us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock
      contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RleHRyZWdpb246MzBhNDczMzUyMjFjNDA4Yjg4MjFiMDVmZmU0MmMzNTdfMzYyOA_78254a29-9a46-45f0-a0cb-93d522524262">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes contract liability balances:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.274%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.276%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;232.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;262.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i08ccb35f6ad24d7793c9c91b74ca2ea1_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjQxNzkzNmNkMjI4MTQwYmU4ZWY0NWY3MjdmZjM5OGMzL3RhYmxlcmFuZ2U6NDE3OTM2Y2QyMjgxNDBiZThlZjQ1ZjcyN2ZmMzk4YzNfMS0xLTEtMS0xNTk1NDA_d65e19dc-0f22-425e-9ad6-e5dd69a060fc"
      unitRef="usd">232500000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i0973ba0c1d894ceaa494709a13f814fb_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjQxNzkzNmNkMjI4MTQwYmU4ZWY0NWY3MjdmZjM5OGMzL3RhYmxlcmFuZ2U6NDE3OTM2Y2QyMjgxNDBiZThlZjQ1ZjcyN2ZmMzk4YzNfMS0zLTEtMS0xNTk1NDA_fecc1ef7-53ac-41e6-ac8d-b31aa7ad7f68"
      unitRef="usd">262600000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:Revenues
      contextRef="i28a49a83c479441f905c7cffa76d0d1e_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfNS0xLTEtMS0xNTk1NDA_0a0e8bf5-a577-4900-b278-d7a04ee80107"
      unitRef="usd">1418300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7ce64df6d312430cadd360079f217dd5_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfNS0yLTEtMS0xNTk1NDA_1a2199b9-12bd-47bf-ae8a-6c6a69218f5a"
      unitRef="usd">432000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i345b235e6d564f1bb6f06b9ed8319a72_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfNS0zLTEtMS0xNTk1NDA_c321a335-fcb5-4a1d-9b4d-5f42b3cae5b9"
      unitRef="usd">1850400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i89ca472eabec43fd814b3653fab15181_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfNS01LTEtMS0xNTk1NDA_4dadfefb-6ae4-4196-95d1-5af313320aa4"
      unitRef="usd">1201400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7bbccd7a5a8e4837a3a85f1a2b3d2ef1_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfNS02LTEtMS0xNTk1NDA_09157d41-c628-48ef-bf42-57976969f325"
      unitRef="usd">398800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i46a90cbffcd647a5801317b946ab5209_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfNS03LTEtMS0xNTk1NDA_d980fd01-6e83-48ff-aa9c-7000ff03be32"
      unitRef="usd">1600100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5546f63545a844a085ff12b7f2497571_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfNi0xLTEtMS0xNTk1NDA_1fcf3759-c56c-4c17-831e-88fc29de45a6"
      unitRef="usd">350900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i348983749551494ba7808729a9dd6254_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfNi0yLTEtMS0xNTk1NDA_45a007c0-bd08-45bb-a63e-e154e3b3b4cc"
      unitRef="usd">222400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="idfba5b60fbbe4370bad16f003f72e3c1_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfNi0zLTEtMS0xNTk1NDA_4b4062e7-4dbf-476d-b7d9-c49ae88fb823"
      unitRef="usd">573300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i669b22e2d64c487fb8bd01c345ab7f38_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfNi01LTEtMS0xNTk1NDA_8b429d89-4e05-479b-920e-bdb91cf04f68"
      unitRef="usd">221200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4ab46b2a51674189a54630451735b250_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfNi02LTEtMS0xNTk1NDA_416e5a77-2473-428d-b4ba-9abd5f7e7ed5"
      unitRef="usd">169200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia28641f7c767406eacaa8089e13a2e77_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfNi03LTEtMS0xNTk1NDA_a6146567-ce3d-4baa-8cc0-7c8b22aba394"
      unitRef="usd">390400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i233675fe0cc34caa880f2ae73fa95cad_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfNy0xLTEtMS0xNTk1NDA_d8c05d8a-7bfe-4a08-809f-8bee6eca013b"
      unitRef="usd">248100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i404df183ca794e64b829a2993c89673f_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfNy0yLTEtMS0xNTk1NDA_a425bba8-99ae-4d14-8303-e5eea1502902"
      unitRef="usd">198800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6069340928544f1d98e220d601c0ccf7_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfNy0zLTEtMS0xNTk1NDA_5ab1e631-5e58-4f75-a0df-d43c4b15221a"
      unitRef="usd">447000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4b145726bc2c4ed78a3c2ec12b53c5c2_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfNy01LTEtMS0xNTk1NDA_ef942622-abcd-4639-8d77-6ac8e8a0402a"
      unitRef="usd">347300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id28218d7550a4cf4be526f83ae1c7332_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfNy02LTEtMS0xNTk1NDA_03219981-3fac-4a71-b859-0bf2fc9a5c4f"
      unitRef="usd">279400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie59d14500008412ea099e2c09441a042_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfNy03LTEtMS0xNTk1NDA_59269390-f54a-4272-a172-208b9ae465df"
      unitRef="usd">626700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib99bd175ff46428092a6e96c970b94c5_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfOC0xLTEtMS0xNTk1NDA_ef8255d3-ba3a-4fe4-8d53-a7c538c10f08"
      unitRef="usd">169500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i644d2f1188e14878aaa508d910b54dde_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfOC0yLTEtMS0xNTk1NDA_d767dbdb-d458-411d-9060-53fea646da55"
      unitRef="usd">68700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7cc0d4df5329427cb7da48ad36cb2efb_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfOC0zLTEtMS0xNTk1NDA_545ab11e-e529-4b1e-8c2d-d5f998327755"
      unitRef="usd">238200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i02d6e02b9e20402bb506e5e37520efdb_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfOC01LTEtMS0xNTk1NDA_704ddbb1-ea70-4a79-b949-8e824af7ebe0"
      unitRef="usd">193400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i40d7116b6c0a470195c3ab9234e5bb0e_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfOC02LTEtMS0xNTk1NDA_d73b78ed-eec6-4af8-aa8e-7aa015e64068"
      unitRef="usd">93400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iec80f91e475941f1abdc131fd14d868d_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfOC03LTEtMS0xNTk1NDA_e2256e80-7d98-4239-9df7-3cf70d782bad"
      unitRef="usd">286700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i529518415079475fa56a8916e119480c_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfOS0xLTEtMS0xNTk1NDA_0fd4e0cf-7cbe-4944-818b-8ce1563cb87e"
      unitRef="usd">124800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie34f0db27136443ca391ec67d20f46cc_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfOS0yLTEtMS0xNTk1NDA_31691ed2-0cb3-496c-9d57-42567e4ffd19"
      unitRef="usd">68100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id6f3b41d10de4dfb99b809554e15f4ca_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfOS0zLTEtMS0xNTk1NDA_f5a63c3a-96cf-4c8e-978e-398f3ff81c82"
      unitRef="usd">193000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="idcd8ed6a0f624997876200ae1a53d3ff_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfOS01LTEtMS0xNTk1NDA_117389a1-ff79-41cc-9127-c5112b157bf9"
      unitRef="usd">114700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1981e978a66e4861b39ec95f950a699c_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfOS02LTEtMS0xNTk1NDA_d6155f67-733f-4420-b723-607036c04867"
      unitRef="usd">78100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ieef95d1c0c4643f8a5a104c9301c56f6_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfOS03LTEtMS0xNTk1NDA_f749cbc3-4bf9-40a9-9045-7be859795e51"
      unitRef="usd">192800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7992fe4fc5774bd6aa8b55cf4d326364_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMTAtMS0xLTEtMTg5NTI3_8255f582-07e7-413b-8f1b-697aebc72623"
      unitRef="usd">97300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i47be57988ea94c92b33e106ae820b8f7_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMTAtMi0xLTEtMTg5NTMw_00c4b87b-fccc-4654-800e-4d61aa4fc78a"
      unitRef="usd">90000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i22fcf936becc4b56b4c435b41fdfd4c7_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMTAtMy0xLTEtMTg5NTMz_1a17e772-77e8-424a-b3a8-99bc44d20c89"
      unitRef="usd">187300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i866b02b106bf4510aa3acc82ee4887a0_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMTAtNS0xLTEtMTg5NTM2_69604ef1-fb87-4640-af77-034a6a0db5ea"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i99914bb8f18546f78ea8cdcaa7af2939_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMTAtNi0xLTEtMTg5NTQz_3ade9baa-dfc0-491a-8c02-258606dc14cc"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9094ecfcbf9c4d8bbe63fc38a5f24df0_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMTAtNy0xLTEtMTg5NTUw_fb5ffaf4-fc18-4729-9c50-d4c48f4a9343"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iceaf7dbcd2d8486cb982fc3658598e56_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMTAtMS0xLTEtMTU5NTQw_5a99f14f-a3eb-4586-a551-935e24cd4316"
      unitRef="usd">79700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i05fc368927fd409998e10fd8a8626ff3_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMTAtMi0xLTEtMTU5NTQw_34167a83-898e-4991-8e01-cda06cf1b704"
      unitRef="usd">94000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iadb96dab5219493a8a09e4ef5a30b381_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMTAtMy0xLTEtMTU5NTQw_ace0b04b-86fb-4754-8362-1ff7ca2a5ea6"
      unitRef="usd">173400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i26f16b68de674d2592c2cd9ee9755295_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMTAtNS0xLTEtMTU5NTQw_3f38029c-f3ba-449d-beb0-1c07de26c128"
      unitRef="usd">65000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib4a6a3281a6e41eda8915c8ed31cf4c4_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMTAtNi0xLTEtMTU5NTQw_a751d592-9242-4989-a1f9-324525142cd6"
      unitRef="usd">112200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib01598d835464cac82cecfbe826de92d_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMTAtNy0xLTEtMTU5NTQw_eb3e62c9-f150-41d5-8b49-0125b7996564"
      unitRef="usd">177400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id8862697b08648bcb4c7b9ad3dff39c3_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMTEtMS0xLTEtMTU5NTQw_9d99bd9f-beb1-41a1-96bb-397628572fd8"
      unitRef="usd">2488600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if00d7a9221f04fe68817babf35f51ebf_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMTEtMi0xLTEtMTU5NTQw_b425fd58-6cbf-429b-b6eb-098318981878"
      unitRef="usd">1174000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic1a606c172db416288ba0bbd8baa9966_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMTEtMy0xLTEtMTU5NTQw_50dee3e7-ab7f-476a-9f1a-44ec81c342c0"
      unitRef="usd">3662600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9d79583b71134ad5b1affaf7d3c9e867_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMTEtNS0xLTEtMTU5NTQw_b6662909-18d3-492e-a0ef-055e21944738"
      unitRef="usd">2143000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i74d4b85fd2a346fb93493d49de1c2bce_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMTEtNi0xLTEtMTU5NTQw_c983a16c-6278-49dd-b11e-d5a0cb1ee3e9"
      unitRef="usd">1131100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i42ad32bd431444b189dab3e866f14dce_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMTEtNy0xLTEtMTU5NTQw_cf24845e-71e1-48db-a723-30807d75527f"
      unitRef="usd">3274100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0c515dd1cd2b453686e3e31d8c9a32d3_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMTQtMS0xLTEtMTU5NTQw_e069ea93-cd38-4c38-b992-e533125625d9"
      unitRef="usd">414800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id154bceb5f3a4af7bf7c046f1608e110_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMTQtMi0xLTEtMTU5NTQw_2de77508-96e1-4f18-87f4-307ed27cf4a0"
      unitRef="usd">202900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ifb827f745b3b446f900ce979a433b71f_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMTQtMy0xLTEtMTU5NTQw_90b049e2-586b-47ce-9e23-2a66d21a6b97"
      unitRef="usd">617700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1f8a0004521c4a0ab278bcec0c67c5bd_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMTQtNS0xLTEtMTU5NTQw_41af130e-c1ea-4564-8900-daf733b5847d"
      unitRef="usd">199600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iaf75ab0eae484bb4b01f61ae25f750c5_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMTQtNi0xLTEtMTU5NTQw_e87e7d23-008a-4a6f-baf7-d27291162c54"
      unitRef="usd">135900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6b3d0e422c9640ab9313c19640d9fd90_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMTQtNy0xLTEtMTU5NTQw_97860e17-ba67-4bbd-bd88-851e365440b3"
      unitRef="usd">335500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i46e236388c73464e81b03a5d53c0dd53_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMTUtMS0xLTEtMTU5NTQw_a0e70550-a289-48de-9173-910bd3533c20"
      unitRef="usd">87500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5b6d4e4158744aaa95ee5bf00acb80cb_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMTUtMi0xLTEtMTU5NTQw_9a5d3133-6e39-4844-84fa-3543c50ea269"
      unitRef="usd">144600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4c1435377d2042d39e6953c271d4585b_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMTUtMy0xLTEtMTU5NTQw_547eed38-1637-4bb0-96d7-3d6b7b2b83bc"
      unitRef="usd">232100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i176af1ca7219458c851326db4f5f0e18_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMTUtNS0xLTEtMTU5NTQw_ef4c93db-fa39-455f-b988-fb25c2b566f7"
      unitRef="usd">84800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie4ca284b63654c0bbf5fc3646e324b1b_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMTUtNi0xLTEtMTU5NTQw_c2e46eb6-79f6-4e02-8130-7f4e6ae38029"
      unitRef="usd">168600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i48871c7176154dbb971dc8a40b431eca_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMTUtNy0xLTEtMTU5NTQw_35b4bdb8-c6a3-47a5-81ce-b9cccf2f2883"
      unitRef="usd">253400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ifc30105eafd9459d81eaf411eb4da357_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMTctMS0xLTEtMTg5ODM0_cbcb7a5f-830c-41ab-a693-93520437ecbe"
      unitRef="usd">126300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i84fe5c0fb05340ce93ab592130765d86_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMTctMi0xLTEtMTg5ODM0_a03d3848-0b20-4d31-8513-39008743b95f"
      unitRef="usd">18700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i75db1e7f9d154c588f6bfd88b08dacf2_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMTctMy0xLTEtMTg5ODM0_d5c0c9dd-5cfc-4f6d-9a11-c714c7907dc1"
      unitRef="usd">144900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ifb220bd49b9b4fee9a08cf2aba4811ff_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMTctNS0xLTEtMTg5ODM0_4aa752af-408e-483d-97a7-6121f91d106b"
      unitRef="usd">114000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if441e31221c74fb7b06ce4acda75a1ac_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMTctNi0xLTEtMTg5ODM0_6df77aae-22e4-46f8-ac1a-6250a2c21fe2"
      unitRef="usd">20300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i74ebe2d40f834c6aaed2f9503f82b5c2_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMTctNy0xLTEtMTg5ODM0_6a36e185-5ee4-4985-a13b-b101f56933ad"
      unitRef="usd">134300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i51fae75c655f4c9db22deca064e1d22a_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMTYtMS0xLTEtMTU5NTQw_008998d3-636a-47ac-98d6-abb4776e490a"
      unitRef="usd">64600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i814e9ebeca8f4359b602b1c4116691fa_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMTYtMi0xLTEtMTU5NTQw_2f8e2d9e-70d2-4996-99ca-902541697733"
      unitRef="usd">54800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i093d47ca61034ea8b9f0303b73074f6e_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMTYtMy0xLTEtMTU5NTQw_f5b1ff49-0ed6-42ff-82f9-9557ec1dad79"
      unitRef="usd">119400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5b8a2c0676cd456a958892b0fdc5f275_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMTYtNS0xLTEtMTU5NTQw_658bca63-6a3a-4b70-9f15-b79f6cd0632c"
      unitRef="usd">297200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i01f53de517814e9fae0973ed84a89508_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMTYtNi0xLTEtMTU5NTQw_f9ccac0c-976b-4085-a8a9-a7ed24d35244"
      unitRef="usd">159800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i91b98892233a42579bec90b2f1f07fad_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMTYtNy0xLTEtMTU5NTQw_6fff5085-50a8-400c-a933-ec49cc7f7619"
      unitRef="usd">457000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i578736c37abd4751958301e188d9a111_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMTgtMS0xLTEtMTU5NTQw_c2b50857-bdbe-42bf-b4f4-61c3da66822e"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic105c32b09d5439ab48f1ea47e388e5c_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMTgtMi0xLTEtMTU5NTQw_7cd0c5a8-1419-44f5-a7b7-bcbb4af3d433"
      unitRef="usd">76800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ifc8fc5f6c1924a46b0d88ad7ea894f53_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMTgtMy0xLTEtMTU5NTQw_dffb5a95-e891-48a9-a689-abb5c7e30b8f"
      unitRef="usd">76800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i326cec97451b4c0fa64fb496bcc0d262_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMTgtNS0xLTEtMTU5NTQw_8fe7e548-688b-46b3-a0c7-af6fa6954001"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id6f0f8b1cbb14fe5bc88c77765723cdc_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMTgtNi0xLTEtMTU5NTQw_7d371912-8da9-4688-b513-e8225a93b469"
      unitRef="usd">125600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9da960751fa245d8bf93fa1681ead439_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMTgtNy0xLTEtMTU5NTQw_c37672f7-0a32-4eec-a93a-db53ea961956"
      unitRef="usd">125600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4280b008d25146138bb9937941f505ac_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMTktMS0xLTEtMTU5NTQw_771d4ba2-7381-4a38-b5fb-9cd908d128f3"
      unitRef="usd">39500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib83a82fddc51484f973f835759a83951_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMTktMi0xLTEtMTU5NTQw_1a94ecd5-7153-462b-a9c6-0bb2bc805a21"
      unitRef="usd">62800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7add942c6a224625b4aa726843340e48_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMTktMy0xLTEtMTU5NTQw_0f863038-dd11-4964-bd8c-b8fb3ec61ba2"
      unitRef="usd">102400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i010a412d535641f895d21d4765b984db_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMTktNS0xLTEtMTU5NTQw_3b3ce568-b14b-404d-a467-e6d8521fd535"
      unitRef="usd">35300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9a1ab61d480a42babad1c189210b4f6f_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMTktNi0xLTEtMTU5NTQw_667f8e4f-545e-4583-8bf6-fdaa6d165c36"
      unitRef="usd">65100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3d24e8995a5a4ced9875b8b9174e8096_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMTktNy0xLTEtMTU5NTQw_9a0a5031-2d6f-4026-a508-b22b91f65eb3"
      unitRef="usd">100300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if7ca1b1b8ebc4b97a61e679591aa9aa4_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMjAtMS0xLTEtMTU5NTQw_baa6c5e9-cc3c-4079-ba64-1bf89df4d6e6"
      unitRef="usd">732700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i98dec2ee927948db8ae6249a13fbc06a_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMjAtMi0xLTEtMTU5NTQw_3dc52c54-71ba-4422-a2ef-751c1b81edd1"
      unitRef="usd">560600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="idacb7a7257294fe689d448659352e301_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMjAtMy0xLTEtMTU5NTQw_544235f5-6797-4de9-a4d2-b6b9a58f1718"
      unitRef="usd">1293300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i573f860cee384e44a092723fc9aaea21_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMjAtNS0xLTEtMTU5NTQw_ca75517a-c1c9-4dfe-9d59-26c6c87a57d1"
      unitRef="usd">730900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic45235af254e414c87819d6a61117897_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMjAtNi0xLTEtMTU5NTQw_9679b0de-f48b-4fb9-b293-c46ba1331ade"
      unitRef="usd">675300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3490b47c9d914a7a80f4c441455b8ead_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMjAtNy0xLTEtMTU5NTQw_589cc164-6ff6-4f93-b74f-60482aaf352e"
      unitRef="usd">1406100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id3ed2240ab2944e1a3695929ccce3c61_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMjMtMS0xLTEtMTU5NTQw_0830681a-f057-4aee-86f5-6791461a3846"
      unitRef="usd">493800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iec46bce8b1474abc9815b6e1b2d7a169_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMjMtMi0xLTEtMTU5NTQw_e2297c6f-9a44-4e35-ada7-f2e73020a633"
      unitRef="usd">186100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i800167f3776142a4bf399d8f51830c78_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMjMtMy0xLTEtMTU5NTQw_137072df-c045-4937-8754-4bd0ad4db73e"
      unitRef="usd">679900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia22b346dd2a54714a0f4ba483559b116_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMjMtNS0xLTEtMTU5NTQw_c32ea69c-4566-46a7-a983-5778aa7bb7b5"
      unitRef="usd">422200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0852df9f516e48b4a9af370971f46a78_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMjMtNi0xLTEtMTU5NTQw_dc0aaf75-cbb0-44ef-ba19-a57f93b60d8d"
      unitRef="usd">170900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia60c521d441f43a2b5801e09809d0abe_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMjMtNy0xLTEtMTU5NTQw_dadaba69-0e03-41d5-ba60-88fed39d1579"
      unitRef="usd">593100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i16529d5d29744762b0746672c1ef5cbf_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMjQtMS0xLTEtMTU5NTQw_50b999b2-f31a-41f5-8415-e5aca82bc315"
      unitRef="usd">22900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2456bc73ed7d4b8b8bc891900fd86004_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMjQtMi0xLTEtMTU5NTQw_5b4a0366-f77b-4317-8dbb-d09afc7fce7e"
      unitRef="usd">160000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i65843c3594444a24be3c2dd715fb25e8_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMjQtMy0xLTEtMTU5NTQw_257580ce-899d-4d9b-ab06-7b681acb7802"
      unitRef="usd">182900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="idef6b1951baa49b98d6da883dd4d89b9_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMjQtNS0xLTEtMTU5NTQw_26e2b0c3-c706-449d-86a1-0941b2c6e40c"
      unitRef="usd">194000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia1eb3846894a440d9b3b08cf8304da43_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMjQtNi0xLTEtMTU5NTQw_7f39255d-1753-4e20-8646-5b6010d5bb5b"
      unitRef="usd">212900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i342e7e7b465546ffa22256042c6bf573_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMjQtNy0xLTEtMTU5NTQw_64568da7-872d-4490-bbf2-bebf62cdca4f"
      unitRef="usd">406900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id0dbce0c2a604a12ab2550f876430b73_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMjUtMS0xLTEtMTU5NTQw_e5b3fd3a-aa09-4caf-90d1-51c3a7bd466c"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i32547c688b2942bb9648bd77d09fed5d_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMjUtMi0xLTEtMTU5NTQw_9fadcc39-0896-4434-bb80-61bc1bd82107"
      unitRef="usd">3600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic666c0215c174e0da07f4d1e09afbca8_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMjUtMy0xLTEtMTU5NTQw_82840e44-5947-4878-bcc6-565b79cab370"
      unitRef="usd">3600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i24578a0bb60d41509dae6c91cf840cf4_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMjUtNS0xLTEtMTU5NTQw_095cc759-d686-4964-a679-46b98946033d"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i797465f9dcae46679ecb0c162248cdbf_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMjUtNi0xLTEtMTU5NTQw_be09041e-57b0-43ee-b41b-cb85903b5a21"
      unitRef="usd">4900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i01bedd14598d4bef97fe5433a5abe2ec_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMjUtNy0xLTEtMTU5NTQw_f4b7064f-b241-48a0-b064-0e6721d8a44a"
      unitRef="usd">4900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0bca0633651d410a8f37cdc991be5df2_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMjYtMS0xLTEtMTU5NTQw_77d4aa5f-7606-426e-9162-d519fb860bf1"
      unitRef="usd">516700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0952e420996041498b88ed77f880c508_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMjYtMi0xLTEtMTU5NTQw_e9e7b637-6efc-421e-bec8-2dacd3f3521e"
      unitRef="usd">349700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6386f383c2e5484da28e805bf356222b_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMjYtMy0xLTEtMTU5NTQw_1bc8f1fc-9d20-490f-864a-30c2b71145e1"
      unitRef="usd">866400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4d8dd9cfbda345988f0d1cea4fac4546_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMjYtNS0xLTEtMTU5NTQw_b01d6266-b78a-4379-9bc0-fcfe47e68409"
      unitRef="usd">616200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="icff9e13bc98e41938e743e7a4e4fd6de_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMjYtNi0xLTEtMTU5NTQw_d4182dd0-43a7-486a-8bc1-c47dc10ad1af"
      unitRef="usd">388700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5adbec8a8b6b48f7a5d1e48f49bf3411_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMjYtNy0xLTEtMTU5NTQw_35717df8-0dcd-4782-b080-1f21092ebd04"
      unitRef="usd">1004900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i358dff328e02486cae97aaae267517fd_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMjktMS0xLTEtMTU5NTQw_8967f1e2-4625-4893-a0c4-2f543d39af2d"
      unitRef="usd">114000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9c4b3d872761408cb58a702f02c9d3dd_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMjktMi0xLTEtMTU5NTQw_befa0c0c-a1dc-40c3-8369-cffc7d5e1ee5"
      unitRef="usd">54600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i88720be3d2b447b38eacb349e966b957_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMjktMy0xLTEtMTU5NTQw_8ee494a4-a31d-4595-8d27-08873bef5193"
      unitRef="usd">168500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i306f66892e60463a9440dd8625f955f2_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMjktNS0xLTEtMTU5NTQw_c51a5040-112c-4cf6-a2e6-dea3609e2f95"
      unitRef="usd">99900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i830b5f4dd99f475f892c9b95d9c74688_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMjktNi0xLTEtMTU5NTQw_a1ce6726-10fb-41ba-aeb2-500152ff68c4"
      unitRef="usd">40100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i04f1fa38b33d409c95edc1ca5dddc792_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMjktNy0xLTEtMTU5NTQw_32a8996b-1635-4f14-9bbf-798c243c78d5"
      unitRef="usd">140000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib3165ffc22844091b6dfdb6536ee8f81_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMzAtMS0xLTEtMTU5NTQw_560db19e-bd9a-4b62-a91b-9536f09d0e72"
      unitRef="usd">8000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i93ab8179e11b4f23a7909ff2a1a2042f_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMzAtMi0xLTEtMTU5NTQw_64ae06ae-b854-405e-ad14-642010136a75"
      unitRef="usd">73400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia17da4c4f6b642d596703193f6afe6b9_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMzAtMy0xLTEtMTU5NTQw_ab5c4348-1e7e-4b8b-93a7-69d8e5158abf"
      unitRef="usd">81400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i870e9a03322b437eab5ad616b9b96c9f_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMzAtNS0xLTEtMTU5NTQw_e04efa83-7f5f-434b-9e23-a60e1458723e"
      unitRef="usd">13000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i119d9834ae424e7fa424cf206e1fa0fa_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMzAtNi0xLTEtMTU5NTQw_f3dae17b-3259-47bb-ae80-452ce0416c7a"
      unitRef="usd">88700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9028e0822d8749e59ae82cba528438af_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMzAtNy0xLTEtMTU5NTQw_b76c7e98-774b-4dc1-a816-50b4e7a108eb"
      unitRef="usd">101700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib6ab25c06067493bbca70a4e7597fdb8_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMzEtMS0xLTEtMTU5NTQw_a7af9985-6940-4b9f-9315-032dd66a34a7"
      unitRef="usd">7800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i85be7a9452cb426a90fedddc2f455b01_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMzEtMi0xLTEtMTU5NTQw_ad99c188-31f1-49d4-82c1-fd460b314ca9"
      unitRef="usd">54900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2b6eac789003419ebceebcc13f624925_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMzEtMy0xLTEtMTU5NTQw_40a7a521-b55b-430a-8278-3bf5163ad5c4"
      unitRef="usd">62700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ibd3368429e0140009581d9d510f8d8ff_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMzEtNS0xLTEtMTU5NTQw_c2357e65-39cb-435f-862c-4aa87032718d"
      unitRef="usd">7000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i734fc13568954b75bd88b7375fbfa00d_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMzEtNi0xLTEtMTU5NTQw_2737e1c9-60a5-438b-98f5-d2c8e956d29f"
      unitRef="usd">125100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i53769ba188564f8a86965473de7ac7a2_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMzEtNy0xLTEtMTU5NTQw_3caf55c9-ac07-4833-82f7-b93449a6e5d7"
      unitRef="usd">132000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic8c180d54e944d17bbbf0438a4c8f563_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMzMtMS0xLTEtMTU5NTQw_bf6d0e00-4fee-46af-b567-65b296a42b67"
      unitRef="usd">16000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i31bc9c1361964102bc7f26ff4a6390ee_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMzMtMi0xLTEtMTU5NTQw_162173ef-fc97-43b3-9c37-e122f2132b45"
      unitRef="usd">44500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="icf97b2cc85a442f5bc488f333e264c43_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMzMtMy0xLTEtMTU5NTQw_366c4be6-d347-43d9-ab7f-95b0b50139b9"
      unitRef="usd">60600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7434dc344c6b4a99973bac3fef8d4f3a_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMzMtNS0xLTEtMTU5NTQw_59d648e5-e908-4777-ba0d-d290ded228af"
      unitRef="usd">24700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3ed4e34eaaf642748b03cff5ec59a742_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMzMtNi0xLTEtMTU5NTQw_14801ce0-8a85-4c5d-b273-23b59535068c"
      unitRef="usd">51600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ifdd2b94511c147b0aa78edfbd1578f35_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMzMtNy0xLTEtMTU5NTQw_98f63d11-caca-45fb-8d9b-9b52390a9f67"
      unitRef="usd">76500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i75c76b5ae8b04d0694593c6b670f2a70_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMzQtMS0xLTEtMTU5NTQw_089e8a8d-bcbb-4507-95b5-f188b6e4da93"
      unitRef="usd">145800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if373b9f49fe74bdbbcaeb90bdcf2de8e_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMzQtMi0xLTEtMTU5NTQw_aa962b8e-92b2-4d7e-9852-fb025339841d"
      unitRef="usd">227400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1f4a20a3083448aabf8de47a307ae3fc_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMzQtMy0xLTEtMTU5NTQw_8d188003-97ae-455e-9a08-7eeb0bff9748"
      unitRef="usd">373200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9aabeac82be44155a967c8ced0c3a972_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMzQtNS0xLTEtMTU5NTQw_c96669b8-52ce-4837-9b04-7dd519f55dc0"
      unitRef="usd">144600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6d31ef68d52e4c1680dc7d71063a6777_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMzQtNi0xLTEtMTU5NTQw_d4724dbb-e2a0-4f6b-9df7-fef5c124aa39"
      unitRef="usd">305500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6cb7b465f1794abdb49eb28db9903a03_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMzQtNy0xLTEtMTU5NTQw_f4fd061b-510c-41ed-8f74-f2164e8e6c40"
      unitRef="usd">450200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0fe5df95a127467ea05981672b21cdba_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMzktMS0xLTEtMTg5ODQ0_3ac039e5-b096-4982-9fb4-378136d0ced2"
      unitRef="usd">386600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib4b9aa980cc940d3870c8d9e4046840e_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMzktMi0xLTEtMTg5ODQ0_8c158368-7148-4a58-b873-4cd8f2a2f7e2"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic89265df487544d48f864b30c7c12762_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMzktMy0xLTEtMTg5ODQ0_71e40ea7-c487-4757-9800-7bafda958193"
      unitRef="usd">386600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i136c9d207de14e89bbae2b72e3112e4a_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMzktNS0xLTEtMTg5ODQ0_d5af7875-149b-442c-8710-94ebf0d1fd20"
      unitRef="usd">215500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic05b3db77dcf4e66b1e09c07f79fd579_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMzktNi0xLTEtMTg5ODQ0_e795a3c8-c7f0-4056-9013-7c278317fa67"
      unitRef="usd">1600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i05b4b2fd75f8488cafa80162074dca18_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMzktNy0xLTEtMTg5ODQ0_68157132-4443-4e9f-95c1-d21929f2a3b7"
      unitRef="usd">217100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i78e14fd2e59849538d2032aed3e9bb0c_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfNDAtMS0xLTEtMTg5ODU2_82afa443-ae00-4d17-9ac7-bd7485cc4e11"
      unitRef="usd">112700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic73ca51c96f5471cb91194277c299762_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfNDAtMi0xLTEtMTg5ODU2_1abef22b-0ded-4d80-93c6-4c7b1c531843"
      unitRef="usd">64400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i29d5f03b98014ea7af366d7dbec08cc2_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfNDAtMy0xLTEtMTg5ODU2_c1b32467-a42b-4b3a-9ec5-d312c34430cf"
      unitRef="usd">177100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5b6529d5d56e42959333a8689a171264_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfNDAtNS0xLTEtMTg5ODU2_85c89292-5642-42e1-9658-fceb79e3828a"
      unitRef="usd">109600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i99005918fc524bff85805ac964cb5794_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfNDAtNi0xLTEtMTg5ODU2_2a89c97d-2750-4da2-b177-3640dc13e2dc"
      unitRef="usd">91300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6ec8ff4aa32b406db0037636d5d11b91_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfNDAtNy0xLTEtMTg5ODU2_facfc698-fc04-49af-bb00-5b0b2593d797"
      unitRef="usd">200900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id253637b6dc04f4593c5389197fd1ed5_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMzgtMS0xLTEtMTU5NTQw_1720fbd3-7d60-4fbf-865e-5af8fdce5f1f"
      unitRef="usd">8100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9b5c45eac140477aa0acc064ef0011ea_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMzgtMi0xLTEtMTU5NTQw_4b4840d8-4b80-415f-8dd8-32096ab164e0"
      unitRef="usd">107700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i57e0cd27dd3c4483afca4b02ab1ab2ea_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMzgtMy0xLTEtMTU5NTQw_76e3f28e-af56-4a81-be9d-ca0f83620ce0"
      unitRef="usd">115700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i71526b83a9b84d10a6e1ab1807ab8e18_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMzgtNS0xLTEtMTU5NTQw_f022107b-baf5-4b6b-bb62-e1cabad8fa34"
      unitRef="usd">-6500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i04e727dddbbd447c91777ca002cf2367_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMzgtNi0xLTEtMTU5NTQw_10342b0c-bfbf-4eb4-8b34-30977ee43ff1"
      unitRef="usd">137400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i01198f0de24240588ceb005e3647087b_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfMzgtNy0xLTEtMTU5NTQw_e24217b2-5baa-4c6b-9461-08c731010070"
      unitRef="usd">130900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if0fe66e11e054c0a85bb68ff7d7f2857_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfNDEtMS0xLTEtMTU5NTQw_2cdfa985-29ee-4f37-a429-ff25d7c6071c"
      unitRef="usd">30900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i347c502b181c4a13a94b72d8e2a383bf_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfNDEtMi0xLTEtMTU5NTQw_c16ee405-5e27-40eb-a8bb-2bb188633c30"
      unitRef="usd">35700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic32c291337714cc290c1dac418f4d40a_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfNDEtMy0xLTEtMTU5NTQw_25dec1dc-a949-44ce-b519-9f6823bdc69b"
      unitRef="usd">66600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4760c4e663814ba4816919d7cf1c133d_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfNDEtNS0xLTEtMTU5NTQw_ae0548ac-6608-4708-af7f-6160ac8b001f"
      unitRef="usd">36300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0b57a14b81924b58a902d121891b42eb_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfNDEtNi0xLTEtMTU5NTQw_fae2249b-e12d-4dc9-8c9b-46d04fe62d9d"
      unitRef="usd">52400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib28a57467090415586ea5d4a46d5a6ff_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfNDEtNy0xLTEtMTU5NTQw_c8286fcc-052e-4195-b64f-26eaeb84d91d"
      unitRef="usd">88800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3bfde2172ab44bdb98ffec5b7744d66c_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfNDItMS0xLTEtMTU5NTQw_c4c276fe-f52c-4bb8-941b-9006a1ba6cf3"
      unitRef="usd">538300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4e976e03f8b7452b97fe7c6fa5a98acb_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfNDItMi0xLTEtMTU5NTQw_ab281325-aa88-4edc-a928-62f9ee2e8ac4"
      unitRef="usd">207800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ibb8a914c841d467289183242e217e8c8_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfNDItMy0xLTEtMTU5NTQw_c1372e67-c2c5-4b5d-936e-89d76f7cc1da"
      unitRef="usd">746000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i23b21b36e578436fa92bcc41739470c2_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfNDItNS0xLTEtMTU5NTQw_3b02b59e-955c-4e54-8c30-7609a14b04b1"
      unitRef="usd">354900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ibe9720e656b242efa27c155f58ea5690_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfNDItNi0xLTEtMTU5NTQw_06ec6791-c558-4e7f-b1c3-4f6e4064dd99"
      unitRef="usd">282700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9af8cc7ddb614c4d8a4d4ce694795736_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfNDItNy0xLTEtMTU5NTQw_bd6b51b4-dfdb-4ef3-80e7-1ee168d043ed"
      unitRef="usd">637700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5ef4c6628ee44bfaba7f2e062c3984ca_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfNDMtMS0xLTEtMTU5NTQw_36d2d49b-a03a-402f-8870-b74fd2142958"
      unitRef="usd">4422100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i553eac0570bc41a68be3130cb9383387_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfNDMtMi0xLTEtMTU5NTQw_6d3f2eaa-477b-45aa-ad0b-d2e593013d29"
      unitRef="usd">2519400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i19fc0325c48543008ea71e1fdcf11d86_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfNDMtMy0xLTEtMTU5NTQw_7a6111b5-5456-4a75-b85e-f449c909d6c9"
      unitRef="usd">6941600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib7200d1730974b7f929910230bd89187_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfNDMtNS0xLTEtMTU5NTQw_930cff6b-fa4e-4b50-8808-24330c9ad2b7"
      unitRef="usd">3989600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8bdc66e6dc0c4330955f23ef9a18d769_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfNDMtNi0xLTEtMTU5NTQw_cdcf29b5-0707-4a98-a656-321aa03a343f"
      unitRef="usd">2783300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie4fa4f6b472a4f269297591b44aba572_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOmZhYTNkYzBhZjFhNjQ4NDM5ZGE3NWY1MTZlNTM2YjMyL3RhYmxlcmFuZ2U6ZmFhM2RjMGFmMWE2NDg0MzlkYTc1ZjUxNmU1MzZiMzJfNDMtNy0xLTEtMTU5NTQw_cd4c6a4e-adc6-4b3f-aa23-70ff34b66eb2"
      unitRef="usd">6772800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie25d63c812ca4ba5bcb202b4ef3da925_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfNS0xLTEtMS0xNTk1NDA_78f7c6bc-53e5-42c4-8e6f-369bee45a702"
      unitRef="usd">4162400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i91615b3923a04f6a8fd92d711866d588_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfNS0yLTEtMS0xNTk1NDA_f867169a-8cdc-4b4b-ad2e-7ae8ce771bf9"
      unitRef="usd">1341100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9623881a23db40a3b62885fe7a43e0c9_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfNS0zLTEtMS0xNTk1NDA_f9ebcd49-bc95-41e2-a637-fcd13893f83d"
      unitRef="usd">5503500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i46ce2dc33fb14a94972b38a4c73c48ee_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfNS01LTEtMS0xNTk1NDA_d9357e3f-a140-4be6-869d-6725de106ea3"
      unitRef="usd">3465700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9d256a84bdcc43939ac6114642c9df5a_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfNS02LTEtMS0xNTk1NDA_07603271-9bbc-4458-8ef3-31812afafdc4"
      unitRef="usd">1122500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="idb96fc34e7f1409fb5661213f97e7f9d_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfNS03LTEtMS0xNTk1NDA_3262ba04-7f0f-430f-88bb-cfd59fc91394"
      unitRef="usd">4588200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i29b3721d52314523b933748df1c86126_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfNi0xLTEtMS0xNTk1NDA_4e97100c-6d9e-4b42-a6b4-9281d12c89d2"
      unitRef="usd">855800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i50fdff0f3f64436b8220edeb6c5da6b9_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfNi0yLTEtMS0xNTk1NDA_191ce3f9-8adf-44ba-aa10-bafd4e89b835"
      unitRef="usd">656400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2bbcd6ec5faf46bc81ff607368bdd5ab_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfNi0zLTEtMS0xNTk1NDA_314f2181-a085-4dce-8fa0-58e41ce454f6"
      unitRef="usd">1512300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5f2bb68aeed244a48b9a5b9fe2b0b039_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfNi01LTEtMS0xNTk1NDA_9c67c148-0208-444e-89c5-563f8d84e047"
      unitRef="usd">1009000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib6a78f62d5834a11a82558249ee89a7a_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfNi02LTEtMS0xNTk1NDA_8c93613c-4e26-430f-b8e4-3fd4afd4bca6"
      unitRef="usd">842300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6afc7019eb204b20bc59d3a19fef7f74_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfNi03LTEtMS0xNTk1NDA_8191ab00-1b6f-41f9-a8d6-e7ad1136a125"
      unitRef="usd">1851300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1e18d072344643ada09a2e6559995804_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfNy0xLTEtMS0xNTk1NDA_2029b5b6-f677-46d0-8252-8915b807e55f"
      unitRef="usd">831400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="idb016f4e6a094b91ac0aee6fd832f15c_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfNy0yLTEtMS0xNTk1NDA_8a27f5df-9a0f-407d-9bfc-a282cdf5a0e1"
      unitRef="usd">622400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1c01691865ed49fc84902886c99bbbdf_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfNy0zLTEtMS0xNTk1NDA_cb373d45-18c4-40fb-bb86-e9d14a320f3a"
      unitRef="usd">1453700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia2d8d981e4314247892b22b49b01d418_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfNy01LTEtMS0xNTk1NDA_8cc9ca82-3ef7-4a0d-8bd5-5a4ea9e955e5"
      unitRef="usd">566800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie65c118c7eb54da8b92e056d23b07e85_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfNy02LTEtMS0xNTk1NDA_f26c63fc-a0e4-42b7-8a71-21244b727bb3"
      unitRef="usd">492100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i46099dfb95b0484ab5891f186d350f52_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfNy03LTEtMS0xNTk1NDA_70ca7508-c330-4dc2-95ef-5b171312bb25"
      unitRef="usd">1058900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3ad9a3d1e7704c9f8a4c92e4f18248ef_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfOC0xLTEtMS0xNTk1NDA_00d765a6-e520-48ad-9f0c-a33a20fe91ed"
      unitRef="usd">562300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib4c358f120c14431858d22fd921cdb1a_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfOC0yLTEtMS0xNTk1NDA_7348fdbe-cea7-4e55-bcad-71095de37c50"
      unitRef="usd">223100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i97453ba9a92b4601b70738c5fd865a63_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfOC0zLTEtMS0xNTk1NDA_e2811bc0-5b34-4a0f-8df4-2026c523050e"
      unitRef="usd">785400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9a4be59d818242b8a5d6e29a133e78b3_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfOC01LTEtMS0xNTk1NDA_4bf79573-94d0-4f2a-ab2e-c43f60f53746"
      unitRef="usd">633500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i74ac58ad376e44179242350ff8091245_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfOC02LTEtMS0xNTk1NDA_76a5202e-4615-4ec4-99c0-14bf221c19c5"
      unitRef="usd">290300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4d442db3854641bb9c50b1533223b1bf_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfOC03LTEtMS0xNTk1NDA_849b745e-00dd-4fb1-80df-ec298c532e4d"
      unitRef="usd">923800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9b84a7f78d3743f383680162b1a79677_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfOS0xLTEtMS0xNTk1NDA_5adc3df3-376b-4f63-8a1c-18c0eb84801f"
      unitRef="usd">339900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if1fd51de24bf4269a3f10390a0eb16b8_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfOS0yLTEtMS0xNTk1NDA_bc8b7b5b-7aba-4d58-94ed-61b1bd68e367"
      unitRef="usd">218800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1f95ba5af9c24c3eb20dc2c5a3979588_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfOS0zLTEtMS0xNTk1NDA_11a1b9ff-2de8-493b-989f-355beeaf0e2b"
      unitRef="usd">558700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9df6a30c7e76498dbe8e2c10556551c7_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfOS01LTEtMS0xNTk1NDA_a9f3c5fa-5c69-4356-88be-49889c5a8b3f"
      unitRef="usd">423300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ifc6cb890a5e04ad3ab5d2c0f4a2935cb_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfOS02LTEtMS0xNTk1NDA_423620b9-1c16-42b8-87a5-b57c86dceb50"
      unitRef="usd">226800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id065d1641c8b4bc19bda4f978edc7f70_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfOS03LTEtMS0xNTk1NDA_ce835c8b-bb9d-4ca6-af69-991834fa4bc4"
      unitRef="usd">650100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie9c6e93828454ef795aef5751d0352fd_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMTAtMS0xLTEtMTg5NTU2_b263dd4a-d009-4717-aa7c-765bc613ba3d"
      unitRef="usd">109900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i844e2c3c4d3c4a4eb90a291b6edaa117_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMTAtMi0xLTEtMTg5NTU5_ef04d445-3a87-42d9-983f-f71f06ea12cd"
      unitRef="usd">93300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8d0e3b68ad424288aedc96a1c3c5e2d2_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMTAtMy0xLTEtMTg5NTYy_fad2afec-0f97-4a73-9967-bd21e86d2bcc"
      unitRef="usd">203200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ibd146a846a384a1cbb7ed3016e2cb317_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMTAtNS0xLTEtMTg5NTY1_f1e746f9-8f1c-435d-8ea4-f56ea71f1235"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="idea0b040a90e4c93ababd4c0d4f02647_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMTAtNi0xLTEtMTg5NTcy_0e54ba4a-3ab6-433c-9362-64f9ad86d975"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie993c12313da41f38573f6bc42f10868_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMTAtNy0xLTEtMTg5NTc5_1573663c-598c-4a5a-8426-f3e528222106"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1ed26a3d9a8b45559192c48d5bb034d4_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMTAtMS0xLTEtMTU5NTQw_9eebadc7-e2dd-4ff6-9757-a1cbc244549a"
      unitRef="usd">195600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4cfbe889964e44e3a453aa644188647d_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMTAtMi0xLTEtMTU5NTQw_d91c4ecb-f2dd-4775-bcea-dd9f8913deb0"
      unitRef="usd">276500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1414ede1c78a462e95bd1b8346592f8b_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMTAtMy0xLTEtMTU5NTQw_c6c7a97f-a239-41be-9b53-faaa8ff25109"
      unitRef="usd">472200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i20194883f2624f82b663260d5199fa21_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMTAtNS0xLTEtMTU5NTQw_d86144ec-142c-4709-be8a-e49ae2a040dc"
      unitRef="usd">185700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i820e5b799761449bbbf32e97e1e019fa_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMTAtNi0xLTEtMTU5NTQw_7d9e2052-ecdb-4055-94a9-b2287dc200d6"
      unitRef="usd">302600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iab636b5286134cd7875bd3dfdf73353a_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMTAtNy0xLTEtMTU5NTQw_54996cc7-c9cc-4897-a7be-0c25eb5efb56"
      unitRef="usd">488300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1356cd272fa54029ba0f0c21fab222b4_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMTEtMS0xLTEtMTU5NTQw_68778c5e-1a3b-4eda-9cfa-9a7300b6e342"
      unitRef="usd">7057300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i19fb57248d6f41d19ef8485870fa08f3_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMTEtMi0xLTEtMTU5NTQw_95358171-7207-4b47-9a61-44cdef026f72"
      unitRef="usd">3431600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2a4c43c5e76a47ceb09387d84fc5d358_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMTEtMy0xLTEtMTU5NTQw_02a093a9-b99a-45ff-a708-0e75cc307561"
      unitRef="usd">10489000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ifc6e032f5a9d4001ba9413713acf7354_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMTEtNS0xLTEtMTU5NTQw_99e215c7-7077-4ecc-9863-46656418e352"
      unitRef="usd">6284000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iabf6366b8c134597b8ac64603a6cb066_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMTEtNi0xLTEtMTU5NTQw_b772e530-7522-4cb6-9a4b-4a45abd4bdcf"
      unitRef="usd">3276600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i44a3630aeb244ec2ab5204f6c1650459_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMTEtNy0xLTEtMTU5NTQw_83da6114-3ea7-43f6-b461-f6737d4a1efc"
      unitRef="usd">9560600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i630ed70ef3804cddb8e7bd6a2c884284_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMTQtMS0xLTEtMTU5NTQw_6d34a77f-8ec5-4c24-bc5c-7b5834e8e748"
      unitRef="usd">1100500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id50357546429495db587cbaca50bd352_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMTQtMi0xLTEtMTU5NTQw_1c68d4f4-8093-4ec0-9529-9e4e7501be18"
      unitRef="usd">575100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i20c536a6925e49838b17da59e54c92aa_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMTQtMy0xLTEtMTU5NTQw_9bede702-2b65-435e-878c-e753d652c795"
      unitRef="usd">1675600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if8fd3622c0c34f5f942c2bcf19a84b1b_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMTQtNS0xLTEtMTU5NTQw_81cfc482-4d67-4f67-9360-6b2ac4f69366"
      unitRef="usd">582100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i08e4bcea32b741f3ad619cb7789236d1_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMTQtNi0xLTEtMTU5NTQw_28a4ad81-4c7f-4a41-a9f7-03ea4c729c1b"
      unitRef="usd">363700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6ea3180802c144d4924a8a4b8a919abd_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMTQtNy0xLTEtMTU5NTQw_61a50161-29e5-4a7b-828a-56e401cb2d66"
      unitRef="usd">945800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia0759c0458d14fac885984f8686a83c3_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMTYtMS0xLTEtMTg5ODcz_09943eef-4d04-42fc-abb8-123256cf513d"
      unitRef="usd">259300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i234acbdded404fc5bcf21a6ea711e9ef_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMTYtMi0xLTEtMTg5ODcz_75d5dc1a-40bb-473e-9784-6dd0ce642bee"
      unitRef="usd">434300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib28d65608ad54ff9b7e45a5c0298b338_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMTYtMy0xLTEtMTg5ODcz_228265e0-bba2-4a9e-b79f-8950634447b6"
      unitRef="usd">693600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i98867991ccbb44078d309a9dd8539a71_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMTYtNS0xLTEtMTg5ODcz_05dedfbf-9c60-4ae2-ad1e-114c5eabeb0b"
      unitRef="usd">266300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib811fbcdfc1241359475319e63db4106_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMTYtNi0xLTEtMTg5ODcz_c7fd8e86-3aaa-428c-95f3-19abd31c4213"
      unitRef="usd">496300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ieb20b9b0be4f46bfb05c7b12f39a6a9e_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMTYtNy0xLTEtMTg5ODcz_6cfd3129-2b99-4295-bf5a-3f9cd635c1ad"
      unitRef="usd">762500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i64bc0872b6e94aa7bf69b1268d189134_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMTUtMS0xLTEtMTU5NTQw_9e452868-a984-406b-a2c7-95c8f6d4add8"
      unitRef="usd">490500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id1a6ba9c9b6a42638bdfdbee6e6f2758_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMTUtMi0xLTEtMTU5NTQw_55088cd5-938e-4b10-955f-025453af8e44"
      unitRef="usd">200500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i07ddaa6f5dd549048da689638ae982f5_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMTUtMy0xLTEtMTU5NTQw_36e6a5a1-2443-4576-a596-1070445ca1db"
      unitRef="usd">691100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9571c6749464454692162cefb3bb7738_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMTUtNS0xLTEtMTU5NTQw_384bf604-3f03-41f6-a2cd-90ceb022ef9d"
      unitRef="usd">911900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i546701dbe3cb400c84bc62c598271f8b_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMTUtNi0xLTEtMTU5NTQw_1a674613-abf5-4c24-97eb-54e01023d3d8"
      unitRef="usd">714700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i70cb0ea9b68f4680b98801d50a608b14_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMTUtNy0xLTEtMTU5NTQw_dcc8dcea-ec27-4cf4-b5df-e8e4596da607"
      unitRef="usd">1626600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i40507b3da3804796ace099350f243c27_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMTctMS0xLTEtMTU5NTQw_4655b855-be03-40a9-bfb6-55802404e5a4"
      unitRef="usd">361000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i680ed22913654e2ead217f9b5989504b_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMTctMi0xLTEtMTU5NTQw_fad0f39a-54f4-4c56-85be-3614512d2b04"
      unitRef="usd">47400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0088a078fdd54003819037635cb52f70_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMTctMy0xLTEtMTU5NTQw_cb8ab5bf-cd75-4e83-8ee2-88f9656ade25"
      unitRef="usd">408300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i27e99c349c3a48dcb14b9a15ed3dafe5_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMTctNS0xLTEtMTU5NTQw_746df41d-a5d6-479b-994c-ef88cb2a48bc"
      unitRef="usd">357700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if0246564d9bc4f02a5441b1f2566bf51_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMTctNi0xLTEtMTU5NTQw_12cf1918-9117-400f-b35f-2884cd95979d"
      unitRef="usd">45900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic3c22691b22448eca997f30d1f1366e2_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMTctNy0xLTEtMTU5NTQw_64961947-4df9-467d-a715-be43889fc82d"
      unitRef="usd">403700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0302245b5cc5492d85c394bdbd9a59c3_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMTgtMS0xLTEtMTU5NTQw_cc4c44ca-2a22-4d11-86ba-464533ca76af"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iab104518f25b49a4b922a68ba94e910b_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMTgtMi0xLTEtMTU5NTQw_af0994c6-c648-4b7d-82ee-8f1972e444a4"
      unitRef="usd">235800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6633f1ca883b4a32962bcd825ba66bfc_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMTgtMy0xLTEtMTU5NTQw_e0a86df6-6300-4357-90bd-48dc6a115ee0"
      unitRef="usd">235800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6761a6ec70464bd2bba2e8b31d7dfb55_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMTgtNS0xLTEtMTU5NTQw_b4cabb1f-f6f9-47aa-8420-70ce2b8f5a94"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i68cac27afeeb4c6ca2de0e2af5aeecd2_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMTgtNi0xLTEtMTU5NTQw_ae4c7127-fc5d-421f-beaf-c68b55cab49d"
      unitRef="usd">340200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3a42a2407e7046519687e4401e714180_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMTgtNy0xLTEtMTU5NTQw_035251c1-2596-483b-bfe5-5ec2455ef786"
      unitRef="usd">340200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib89a61de2c8542719d727ea9b2e4d288_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMTktMS0xLTEtMTU5NTQw_d1954928-0d68-436a-b652-b8f4b43c336d"
      unitRef="usd">124100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie1753f6d5c4044468226ef9a5f59457c_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMTktMi0xLTEtMTU5NTQw_d5afd4d1-6da6-496e-8e0f-2ddf9931b1ef"
      unitRef="usd">186500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iffc444b9d88245d5a3bdb35b82ef0d55_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMTktMy0xLTEtMTU5NTQw_bdfc72d6-c0a0-4d00-9cfd-5a5c91d2c5a4"
      unitRef="usd">310600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i85c317c4af504382b28dfedc3facb2dc_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMTktNS0xLTEtMTU5NTQw_27f30563-5d83-492f-9890-653dad2fdebf"
      unitRef="usd">83700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6290305d31574c06901b06e6eacfd414_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMTktNi0xLTEtMTU5NTQw_430358fb-1e2e-40f3-919d-b3d16bf185e6"
      unitRef="usd">169900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7bf748b95e7a45cf9e722167434f1385_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMTktNy0xLTEtMTU5NTQw_47730d60-9fe8-4567-ba6c-421b2883efd5"
      unitRef="usd">253600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i240fc921c5ef4622986756418d0b3d39_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMjAtMS0xLTEtMTU5NTQw_b76b1790-9c2d-4393-a4c4-1dd489a1d3f0"
      unitRef="usd">2335400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5db5d222d3da4495a3cd1481fae9b1eb_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMjAtMi0xLTEtMTU5NTQw_d98bb26f-8708-4478-859d-fc50d47e4d1e"
      unitRef="usd">1679600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id3038a6b1fd04b43a1855095f482ffd4_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMjAtMy0xLTEtMTU5NTQw_b9a08008-cef8-44af-985f-21c664d06f00"
      unitRef="usd">4015000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="idf34cf4a2aae43eda96963b778a49168_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMjAtNS0xLTEtMTU5NTQw_ed797912-125b-4f4a-aa8e-f857787ec7f2"
      unitRef="usd">2201700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib71c38ea0818475aa548176344240c72_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMjAtNi0xLTEtMTU5NTQw_4654c914-0650-4861-b47f-422d9e58cada"
      unitRef="usd">2130700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7cc9d1bb283d475d915f7fcb4f945c8c_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMjAtNy0xLTEtMTU5NTQw_dc4cf420-6e48-42d4-911d-2ecaca404342"
      unitRef="usd">4332400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i08907695f17c4fe487c0f59792752c89_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMjMtMS0xLTEtMTU5NTQw_7170280b-4102-49f8-8f6c-27a5d09a5424"
      unitRef="usd">1212600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4d2d7d0cc9e04232b6d62adfc3777b93_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMjMtMi0xLTEtMTU5NTQw_037c63eb-a53f-48a3-93e6-05c59f8fa181"
      unitRef="usd">561600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7453a607ad674e25bbab08ef19e88d3c_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMjMtMy0xLTEtMTU5NTQw_90de6c5f-36a3-491b-bf87-80b0910ab151"
      unitRef="usd">1774200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iccd3059fecb04f1d94d0044c6e3c7e32_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMjMtNS0xLTEtMTU5NTQw_4815ccb4-fc7a-4228-8bbe-81a4cdfb4d0f"
      unitRef="usd">1071600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3036c3ea47bd4c89bafa4bdba1320abf_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMjMtNi0xLTEtMTU5NTQw_3589a551-23f3-4fb5-a75e-ce83e5303093"
      unitRef="usd">493800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ifea4d8eb21b94b0ca8248b42f02b49e9_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMjMtNy0xLTEtMTU5NTQw_3af34f47-3d64-411d-aa4b-fd0846638dc8"
      unitRef="usd">1565400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia4036604f9c945e1a19be8b3aa38e334_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMjQtMS0xLTEtMTU5NTQw_f2338a2d-334b-488e-8454-5c8fa3aabc6d"
      unitRef="usd">104600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i381560b71db64644aa7adbc056fac279_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMjQtMi0xLTEtMTU5NTQw_3b095cd8-e776-41b7-83a4-56c231624b5c"
      unitRef="usd">520100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5da2c0b8af014f4085d9e2a62f64ccc7_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMjQtMy0xLTEtMTU5NTQw_0df76049-ccad-4122-b1a1-eae0338220ed"
      unitRef="usd">624700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9a1215ba2eae4c7da8010b728800b4d3_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMjQtNS0xLTEtMTU5NTQw_a3ded4d3-5609-4fa3-a38a-aa000fef4537"
      unitRef="usd">236500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ife8cad1b8c0f45d89f7c79beb6a9506c_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMjQtNi0xLTEtMTU5NTQw_8a7fef6a-7192-4e4f-bbde-8f108239dd41"
      unitRef="usd">572600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i681b00cc06e740d5afd240016ce29efc_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMjQtNy0xLTEtMTU5NTQw_0e645580-44b6-4123-bb51-2c0d05b45c34"
      unitRef="usd">809100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8cdc5308202645dfa9f06b53e46a162b_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMjUtMS0xLTEtMTU5NTQw_84eff3e8-f7a9-45e5-b5a4-7e930c0354d6"
      unitRef="usd">100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6010298ee7bc433e8bebac5a5efc972e_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMjUtMi0xLTEtMTU5NTQw_dbff1416-bdfa-4649-9dde-32101d8f32d3"
      unitRef="usd">12100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i659d2c39bfc34df8bd9f7d944a3822a2_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMjUtMy0xLTEtMTU5NTQw_a3bf93f1-ec60-48a2-88a2-911f67889c4c"
      unitRef="usd">12100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i61df0f1a279148aa9e8254f5980c32dc_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMjUtNS0xLTEtMTU5NTQw_a2d5afe6-fb45-42a9-a57b-121984acfbf8"
      unitRef="usd">15200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1e4c4171e5c3493aa1885a72fe4cfa14_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMjUtNi0xLTEtMTU5NTQw_e82df984-0ab3-4cda-932f-df2805c2afaf"
      unitRef="usd">14500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic9a4f1d7373649528e8dfb81328134a4_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMjUtNy0xLTEtMTU5NTQw_bac4c98a-62f5-44d8-b79e-864d331ebbec"
      unitRef="usd">29700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ibb0659e3898241ecbd83bdbf9dc59c78_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMjYtMS0xLTEtMTU5NTQw_322295e6-f0a1-4117-bf6c-23b22e8051fa"
      unitRef="usd">1317300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4e251958291a42a3a1c5447458b86d15_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMjYtMi0xLTEtMTU5NTQw_3b945b74-f88c-455c-b295-8cce5ce019f8"
      unitRef="usd">1093800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8aaae8dc85e144a6a4bf886fd061d950_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMjYtMy0xLTEtMTU5NTQw_2a1b4de2-78f1-4358-94f5-0e85ec10895e"
      unitRef="usd">2411000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2d035bb38a454213828a14551e6edea5_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMjYtNS0xLTEtMTU5NTQw_bf15046f-bd16-41b8-9a5f-3d03b05e718c"
      unitRef="usd">1323300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i71c9047535fe473ba6d96eba16066ad6_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMjYtNi0xLTEtMTU5NTQw_ddb39170-32cc-4211-b1c9-271ee3933363"
      unitRef="usd">1080900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4cef6079bf0146839ee9f000bdcfe3c4_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMjYtNy0xLTEtMTU5NTQw_d5844e8d-7abe-44f0-b189-b56d4ef1cc00"
      unitRef="usd">2404200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iaf50cba6df584b358ccfd1c552ac603a_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMjktMS0xLTEtMTU5NTQw_308f3405-b807-43c5-b079-9b53b9ce1c94"
      unitRef="usd">330800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ife6ede2d6f41458f8f350cd5f6ddeb17_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMjktMi0xLTEtMTU5NTQw_12a2d764-0b04-49ab-b36a-d06ff1fe8340"
      unitRef="usd">144400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0b7c20f1ff97494783d6f4579ff8f7f8_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMjktMy0xLTEtMTU5NTQw_66b2cf61-0883-49b8-8cc3-19c42c885acf"
      unitRef="usd">475200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2892d650df3349fe9ae882f6ae942d58_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMjktNS0xLTEtMTU5NTQw_f2fa058b-7488-4f61-a64a-f8fa583457e5"
      unitRef="usd">313500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ibc4bdc96c6434cc8b53a24c987e9c41e_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMjktNi0xLTEtMTU5NTQw_3454f956-24d2-48a7-8a2d-b04c804ac919"
      unitRef="usd">102200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5d73674530f248b5a702b835849253ef_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMjktNy0xLTEtMTU5NTQw_8765ed08-e070-4308-9f0f-367204ab3919"
      unitRef="usd">415700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ibd5454cbe2de4d0ea429015722b20f15_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMzAtMS0xLTEtMTU5NTQw_a45535e3-b672-4bc1-8551-d783e45a7da8"
      unitRef="usd">26200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id7ad299a8b764bb9813cbf2dcae42919_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMzAtMi0xLTEtMTU5NTQw_98b61161-64fb-4843-a541-2c35f32b06a7"
      unitRef="usd">235500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic3a68db7fa3b428995899c0bf854ba94_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMzAtMy0xLTEtMTU5NTQw_27530aab-c6b1-4264-90b9-872e0b87c681"
      unitRef="usd">261700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i006ca6ec8c3c4717aef2b19d419c92a3_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMzAtNS0xLTEtMTU5NTQw_cf9ab302-ff9b-4004-b925-3de48c55b160"
      unitRef="usd">28300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib90b244e7d0040c68677396984559ec8_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMzAtNi0xLTEtMTU5NTQw_7d00e1e3-02ca-4f0e-930f-9f409f4aa72a"
      unitRef="usd">264500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iedfe879bea3a496bb3766920c821c198_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMzAtNy0xLTEtMTU5NTQw_8323e1b4-bdca-4a0b-a930-4fc4f2df5d63"
      unitRef="usd">292800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3f91e524972e42a98fc9b5abba31e458_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMzEtMS0xLTEtMTU5NTQw_eafd4191-eaf5-4990-bdbb-aaf97378e6f1"
      unitRef="usd">25000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic3c6fe2019a042c4909c317b26cdf477_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMzEtMi0xLTEtMTU5NTQw_021cd889-11c2-4ce1-9d12-d5f5b217448c"
      unitRef="usd">194300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iee5d9669f4b344499cebdffb37f32030_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMzEtMy0xLTEtMTU5NTQw_1b415956-8aa6-4f0a-9859-2a5f0d137fec"
      unitRef="usd">219300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3f307f23d1de4f80bbe2e59ea610ff7f_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMzEtNS0xLTEtMTU5NTQw_26a269cb-9d2c-41ad-865f-dc1e3fdcb92a"
      unitRef="usd">30300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i526c0b4d4b3140cfaf92e5209854bd78_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMzEtNi0xLTEtMTU5NTQw_f184166e-77fa-41cc-a27f-2f86abde8c08"
      unitRef="usd">454000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i733173c6b1a342488769f27288f96647_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMzEtNy0xLTEtMTU5NTQw_625e4818-16b5-44e8-bf09-d39441263f9e"
      unitRef="usd">484300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i00d29df7fc444a888bd8f1ac7c7fcd63_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMzMtMS0xLTEtMTU5NTQw_c2416596-e2c0-495e-8182-f65f0142c472"
      unitRef="usd">62000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id5a61b3abda849d981158a33cc123750_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMzMtMi0xLTEtMTU5NTQw_d030dd11-a637-4d5a-99f0-d394fce76db8"
      unitRef="usd">142700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4894a69792984d28b5bd70bdcb925593_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMzMtMy0xLTEtMTU5NTQw_cc24c286-506d-4492-ab7d-1327d7c2bb52"
      unitRef="usd">204700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2af7293d556c4ac189783fd3d7bfa089_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMzMtNS0xLTEtMTU5NTQw_05c7f402-9405-4ada-9f53-5e46a10da191"
      unitRef="usd">81000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id7dd70175fc2484e9291653ca9b5bcd0_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMzMtNi0xLTEtMTU5NTQw_1ff1c493-5cbe-4f08-b556-4b3804047aac"
      unitRef="usd">154000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iaffd646b91554c9fbd55b7373a9ab9f2_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMzMtNy0xLTEtMTU5NTQw_899bd158-7165-49f4-82b2-7b6596cb6875"
      unitRef="usd">235000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i177e8ff27d1b444d8032f9fd6e71b86e_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMzQtMS0xLTEtMTU5NTQw_be398c11-6894-431e-9e28-0ee67b4475fa"
      unitRef="usd">444000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i20063c304d1142018b211b53b3a1c50b_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMzQtMi0xLTEtMTU5NTQw_8e7429f4-d1a6-47a4-b6a1-00587456c0e2"
      unitRef="usd">716900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7a5789bb5ddb493385ae07bb301aa500_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMzQtMy0xLTEtMTU5NTQw_f91f288f-acb2-4b3e-85f1-5a1d73cb38d7"
      unitRef="usd">1160900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8c8cfb5bc4ac42dba8e3851f39bd2683_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMzQtNS0xLTEtMTU5NTQw_32d83a4e-1114-4e6a-8108-d5c53edfb38a"
      unitRef="usd">453100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib59bf69a9b284970b3b6642f7e4b795c_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMzQtNi0xLTEtMTU5NTQw_431ac662-ce23-4ac6-ba0d-9f78b9786908"
      unitRef="usd">974700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i84bebc50684e4e1b90500bbb83bb79a6_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMzQtNy0xLTEtMTU5NTQw_cbd4c88d-c298-4d52-a99d-52477d083eea"
      unitRef="usd">1427800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0e5b50746e074ddabe26161b8cf97195_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMzctMS0xLTEtMTU5NTQw_5aa3a9b2-3e1c-4f33-99f7-7a72796a434b"
      unitRef="usd">1970900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2ce72c9f883a452ca19b57204999df16_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMzctMi0xLTEtMTU5NTQw_6e16a7c5-f921-4f65-a876-31902fff3d34"
      unitRef="usd">14700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie674d270134f4cffaff8f7a15471b73e_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMzctMy0xLTEtMTU5NTQw_7a9a30a8-9c8c-485a-bfb7-42874b8658e5"
      unitRef="usd">1985500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i62f7a17973be46d9bf4530c993775bef_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMzctNS0xLTEtMTU5NTQw_2d5a706e-a578-469f-a69f-6219045e347c"
      unitRef="usd">949500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ifb238d01fbaa4761a5fe7a7c91587c74_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMzctNi0xLTEtMTU5NTQw_0a7b29ef-0cbe-4090-936f-d321c82d74ed"
      unitRef="usd">226700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic06f11244a5a4b88822809b3b3941ffe_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMzctNy0xLTEtMTU5NTQw_d3fac61e-40f3-4c74-868b-7e1273c87a02"
      unitRef="usd">1176200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ifa18b54c7e0f4330b37b5256dc5dffac_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMzgtMS0xLTEtMTU5NTQw_f6758b03-d34a-4919-92eb-f2ca9590795a"
      unitRef="usd">25800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8a49509981cc41bbafe688a08ea538c6_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMzgtMi0xLTEtMTU5NTQw_86893191-cf05-42b1-8797-7d9848b02abc"
      unitRef="usd">454700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iac7de63087cb4fa28c15d4fe01f12460_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMzgtMy0xLTEtMTU5NTQw_dd613df6-183f-410e-add4-309494740e73"
      unitRef="usd">480400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i80c0d99bb34b42e1adce6dce3134630a_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMzgtNS0xLTEtMTU5NTQw_1a856c7c-f1aa-4213-b67c-03d95d46c5da"
      unitRef="usd">-3100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6dd390f6ff6a43b49662e266d7334459_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMzgtNi0xLTEtMTU5NTQw_4aed1679-c9cf-4d83-a8dc-cafbbdd71721"
      unitRef="usd">541800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i51c31c17a15244248305698502760153_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMzgtNy0xLTEtMTU5NTQw_c4884def-b052-4a85-af44-e0510efa7ce7"
      unitRef="usd">538700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3c39dd39688f4abb8ddb719a2260f6bf_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMzktMS0xLTEtMTU5NTQw_b9ad8ddb-a960-4578-b59d-fe3855a2aad9"
      unitRef="usd">261400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i56ac4d65faa946aaaebabc3dc7ca99f9_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMzktMi0xLTEtMTU5NTQw_6226f064-40a0-4192-aa5a-ad55e7c70e77"
      unitRef="usd">191700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i185dafd0ab80405eb3f78281a2098c9f_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMzktMy0xLTEtMTU5NTQw_fcf3196b-a9ea-468a-b614-74f71b8aeef3"
      unitRef="usd">453000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ice1d37ac1886488088492ea4c957a118_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMzktNS0xLTEtMTU5NTQw_52a5a948-bac9-4bd4-b974-fe6b7f9d24e8"
      unitRef="usd">330100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i33b45d6e796b4bab93b3906f52ced571_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMzktNi0xLTEtMTU5NTQw_5a4de6ff-7d0f-4a84-8e47-ddb5998f90c4"
      unitRef="usd">287700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i606443bf75d84de3b93c88a5d2c2a9c5_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfMzktNy0xLTEtMTU5NTQw_f719b0af-37e2-4069-88db-a82c09493c0d"
      unitRef="usd">617800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i62be4d98bd454dbea6bd3764ddcdacb4_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfNDAtMS0xLTEtMTU5NTQw_6ba9d7e5-aa81-4bbf-a522-9702171e5628"
      unitRef="usd">119400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i774d30363ab447e4b7b6985e99b6de0d_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfNDAtMi0xLTEtMTU5NTQw_c9d2ddfc-a807-4a7f-abd7-1682156006c5"
      unitRef="usd">125100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i238722e1d54440828f51f9f11854afaf_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfNDAtMy0xLTEtMTU5NTQw_1bf029e8-7051-40f5-bcb3-c8fd0c16f192"
      unitRef="usd">244800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib4554ea5474043e5b51ccd4cca5610ae_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfNDAtNS0xLTEtMTU5NTQw_b0efffcb-c735-4c5a-916f-72c626bc80a3"
      unitRef="usd">96500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1a25265d56d04bc481727001f1d55ecc_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfNDAtNi0xLTEtMTU5NTQw_c742b6f4-9f5d-487c-989b-9afb04d35af6"
      unitRef="usd">164300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1fc264d1cb9b42cd927c0bbd387866cc_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfNDAtNy0xLTEtMTU5NTQw_65a7826e-3d20-4a60-bf44-61163cafa545"
      unitRef="usd">260800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i13e5988f996e48299f0ddef7dd648213_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfNDEtMS0xLTEtMTU5NTQw_dfc87ea7-b2cf-4b6c-b3af-cd7054a6ca8f"
      unitRef="usd">2377500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3b007283f3094ae08f3a1b5eca4a7fb8_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfNDEtMi0xLTEtMTU5NTQw_935de9a4-b15d-4677-87ce-59467bff3f19"
      unitRef="usd">786200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5b6298a19c0a4c5da470fa7e5e3e967a_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfNDEtMy0xLTEtMTU5NTQw_b246ea30-eda0-4771-b21d-dc81c5ef75a8"
      unitRef="usd">3163700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="idcc7138275c74437be6ca40f1474b509_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfNDEtNS0xLTEtMTU5NTQw_ce57a28b-7964-4566-b132-c2a5f727a8f7"
      unitRef="usd">1373000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7efeaf621a9e448fa08571db01806cd3_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfNDEtNi0xLTEtMTU5NTQw_ac883ad5-414a-439b-939f-eceb98fb8966"
      unitRef="usd">1220500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7fe3dcab54b44eaf90f9f242c2fe0f52_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfNDEtNy0xLTEtMTU5NTQw_ba66f90c-6765-47fc-bfdb-9dca322733c0"
      unitRef="usd">2593500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i60c5eb8ff51d4d9fa0a74c53c73aa0dd_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfNDItMS0xLTEtMTU5NTQw_f7b95b53-67a9-4e1e-9d54-11edea30b950"
      unitRef="usd">13531500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if326645430854a2d9ac96495205c029f_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfNDItMi0xLTEtMTU5NTQw_d9e090eb-f8ef-4af5-9ea1-fe546ef35914"
      unitRef="usd">7708100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfNDItMy0xLTEtMTU5NTQw_5c289ad6-b9d0-4de9-a767-912454043fd8"
      unitRef="usd">21239600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2783a40327b64633b6abee19f7b4ca30_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfNDItNS0xLTEtMTU5NTQw_b734da01-1a15-4bfd-b067-7404be20971b"
      unitRef="usd">11635100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9ff1711a07ba45ffadc911d350d44f94_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfNDItNi0xLTEtMTU5NTQw_a4c93317-7d6c-410a-872b-399af12dee02"
      unitRef="usd">8683400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i167ed8f67bef48c49e54fa466400cdaa_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjI4NTk2ODI3YjI2ODQzMjI4YTI1ZGMxMzM0NzkzN2I4L3RhYmxlcmFuZ2U6Mjg1OTY4MjdiMjY4NDMyMjhhMjVkYzEzMzQ3OTM3YjhfNDItNy0xLTEtMTU5NTQw_7af87305-39ea-4021-beb7-4f04fe13d67e"
      unitRef="usd">20318500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5ef4c6628ee44bfaba7f2e062c3984ca_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjE3ZWUzZDMzZjVjNDRkMWU4ZjgxYjZkOGYxZDRkODdiL3RhYmxlcmFuZ2U6MTdlZTNkMzNmNWM0NGQxZThmODFiNmQ4ZjFkNGQ4N2JfMy0xLTEtMS0xNTk1NDA_e494795c-195e-4e17-acc0-c4d87fd013a0"
      unitRef="usd">4422100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib7200d1730974b7f929910230bd89187_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjE3ZWUzZDMzZjVjNDRkMWU4ZjgxYjZkOGYxZDRkODdiL3RhYmxlcmFuZ2U6MTdlZTNkMzNmNWM0NGQxZThmODFiNmQ4ZjFkNGQ4N2JfMy0zLTEtMS0xNTk1NDA_c1810556-5ea1-4f39-b1b4-9505f760d904"
      unitRef="usd">3989600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i60c5eb8ff51d4d9fa0a74c53c73aa0dd_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjE3ZWUzZDMzZjVjNDRkMWU4ZjgxYjZkOGYxZDRkODdiL3RhYmxlcmFuZ2U6MTdlZTNkMzNmNWM0NGQxZThmODFiNmQ4ZjFkNGQ4N2JfMy01LTEtMS0xNTk1NDA_8ed50024-bfcb-4b87-904c-5493d51273b3"
      unitRef="usd">13531500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2783a40327b64633b6abee19f7b4ca30_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjE3ZWUzZDMzZjVjNDRkMWU4ZjgxYjZkOGYxZDRkODdiL3RhYmxlcmFuZ2U6MTdlZTNkMzNmNWM0NGQxZThmODFiNmQ4ZjFkNGQ4N2JfMy03LTEtMS0xNTk1NDA_37b2118d-2c3f-47df-bac7-c96fca7f5488"
      unitRef="usd">11635100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i812f3d20a1af4d92924e0bbe1371c71e_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjE3ZWUzZDMzZjVjNDRkMWU4ZjgxYjZkOGYxZDRkODdiL3RhYmxlcmFuZ2U6MTdlZTNkMzNmNWM0NGQxZThmODFiNmQ4ZjFkNGQ4N2JfNC0xLTEtMS0xNTk1NDA_b35a54cb-bbc5-4a76-9c86-7b2a5f8b3a0a"
      unitRef="usd">1056400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i973b61d370734fa5bcf42303b4a667df_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjE3ZWUzZDMzZjVjNDRkMWU4ZjgxYjZkOGYxZDRkODdiL3RhYmxlcmFuZ2U6MTdlZTNkMzNmNWM0NGQxZThmODFiNmQ4ZjFkNGQ4N2JfNC0zLTEtMS0xNTk1NDA_04403aaa-5c93-4628-a577-8849b48afedf"
      unitRef="usd">1098600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4cf771cc163e44ed8acdd62a65cc8b4c_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjE3ZWUzZDMzZjVjNDRkMWU4ZjgxYjZkOGYxZDRkODdiL3RhYmxlcmFuZ2U6MTdlZTNkMzNmNWM0NGQxZThmODFiNmQ4ZjFkNGQ4N2JfNC01LTEtMS0xNTk1NDA_b1a7b8e1-f2d1-453c-a420-adcba0497d55"
      unitRef="usd">3224800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id0ffca9720f342dbbe64a17e04c55d84_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjE3ZWUzZDMzZjVjNDRkMWU4ZjgxYjZkOGYxZDRkODdiL3RhYmxlcmFuZ2U6MTdlZTNkMzNmNWM0NGQxZThmODFiNmQ4ZjFkNGQ4N2JfNC03LTEtMS0xNTk1NDA_1b417717-307e-4f96-9ed7-20094b2b2832"
      unitRef="usd">3629600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib92bd7160fd94961b7bba02ffbd18490_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjE3ZWUzZDMzZjVjNDRkMWU4ZjgxYjZkOGYxZDRkODdiL3RhYmxlcmFuZ2U6MTdlZTNkMzNmNWM0NGQxZThmODFiNmQ4ZjFkNGQ4N2JfNS0xLTEtMS0xNTk1NDA_2c9f2b01-887f-4033-a1da-91eb83104354"
      unitRef="usd">487700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i25019079a8464a91a3cf96012fcc0d52_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjE3ZWUzZDMzZjVjNDRkMWU4ZjgxYjZkOGYxZDRkODdiL3RhYmxlcmFuZ2U6MTdlZTNkMzNmNWM0NGQxZThmODFiNmQ4ZjFkNGQ4N2JfNS0zLTEtMS0xNTk1NDA_52023aa9-af64-4fa6-bb1e-90562938225e"
      unitRef="usd">595000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib37e987842e2478dab07f58a5f789a49_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjE3ZWUzZDMzZjVjNDRkMWU4ZjgxYjZkOGYxZDRkODdiL3RhYmxlcmFuZ2U6MTdlZTNkMzNmNWM0NGQxZThmODFiNmQ4ZjFkNGQ4N2JfNS01LTEtMS0xNTk1NDA_c5edc270-7a0d-4379-8d2e-7b30cb33a916"
      unitRef="usd">1352300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if9ff4ce3b7704faaa359e30df99f2b54_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjE3ZWUzZDMzZjVjNDRkMWU4ZjgxYjZkOGYxZDRkODdiL3RhYmxlcmFuZ2U6MTdlZTNkMzNmNWM0NGQxZThmODFiNmQ4ZjFkNGQ4N2JfNS03LTEtMS0xNTk1NDA_648df1d2-ec98-483e-9066-e540213dc338"
      unitRef="usd">1832200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic678bb62bdef4faea88b4e3dfd6a7971_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjE3ZWUzZDMzZjVjNDRkMWU4ZjgxYjZkOGYxZDRkODdiL3RhYmxlcmFuZ2U6MTdlZTNkMzNmNWM0NGQxZThmODFiNmQ4ZjFkNGQ4N2JfNi0xLTEtMS0xNTk1NDA_481185cb-e19d-4fe4-9b55-f335452f974b"
      unitRef="usd">343400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib648672815904a56b3a3874c085884b6_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjE3ZWUzZDMzZjVjNDRkMWU4ZjgxYjZkOGYxZDRkODdiL3RhYmxlcmFuZ2U6MTdlZTNkMzNmNWM0NGQxZThmODFiNmQ4ZjFkNGQ4N2JfNi0zLTEtMS0xNTk1NDA_c0605c90-d2c2-493f-ac20-eb22c98cfa57"
      unitRef="usd">400300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id085508ee8c24a36a655eea7d3096500_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjE3ZWUzZDMzZjVjNDRkMWU4ZjgxYjZkOGYxZDRkODdiL3RhYmxlcmFuZ2U6MTdlZTNkMzNmNWM0NGQxZThmODFiNmQ4ZjFkNGQ4N2JfNi01LTEtMS0xNTk1NDA_c7458d53-fe69-44d1-8ba0-43882a9d94df"
      unitRef="usd">1102000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4b2b1ef297534a4a801da2637a1d37e4_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjE3ZWUzZDMzZjVjNDRkMWU4ZjgxYjZkOGYxZDRkODdiL3RhYmxlcmFuZ2U6MTdlZTNkMzNmNWM0NGQxZThmODFiNmQ4ZjFkNGQ4N2JfNi03LTEtMS0xNTk1NDA_f8ffdb9e-a949-4c29-b9af-516ea72b450d"
      unitRef="usd">1285000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib2c80ff08a384ec7a8c6dd07798b9efd_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjE3ZWUzZDMzZjVjNDRkMWU4ZjgxYjZkOGYxZDRkODdiL3RhYmxlcmFuZ2U6MTdlZTNkMzNmNWM0NGQxZThmODFiNmQ4ZjFkNGQ4N2JfNy0xLTEtMS0xNTk1NDA_5e100b96-21c6-4c0d-a597-de4acdab4d52"
      unitRef="usd">632000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i59dcfcfb04c94ad588f473c50147a921_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjE3ZWUzZDMzZjVjNDRkMWU4ZjgxYjZkOGYxZDRkODdiL3RhYmxlcmFuZ2U6MTdlZTNkMzNmNWM0NGQxZThmODFiNmQ4ZjFkNGQ4N2JfNy0zLTEtMS0xNTk1NDA_a945ddd6-e144-4647-b9ec-0127f970c063"
      unitRef="usd">689400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i20e09a0b7eb34ffbbc4057f306b92c3d_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjE3ZWUzZDMzZjVjNDRkMWU4ZjgxYjZkOGYxZDRkODdiL3RhYmxlcmFuZ2U6MTdlZTNkMzNmNWM0NGQxZThmODFiNmQ4ZjFkNGQ4N2JfNy01LTEtMS0xNTk1NDA_e2d90996-5bac-4bb9-9b36-f894c73a19c7"
      unitRef="usd">2029100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3c8b51c823f54bb1a2efb0592f5476a3_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjE3ZWUzZDMzZjVjNDRkMWU4ZjgxYjZkOGYxZDRkODdiL3RhYmxlcmFuZ2U6MTdlZTNkMzNmNWM0NGQxZThmODFiNmQ4ZjFkNGQ4N2JfNy03LTEtMS0xNTk1NDA_6e30a109-699d-47f3-9c3d-9590872718f6"
      unitRef="usd">1936700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i19fc0325c48543008ea71e1fdcf11d86_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjE3ZWUzZDMzZjVjNDRkMWU4ZjgxYjZkOGYxZDRkODdiL3RhYmxlcmFuZ2U6MTdlZTNkMzNmNWM0NGQxZThmODFiNmQ4ZjFkNGQ4N2JfOC0xLTEtMS0xNTk1NDA_f8f0b6e6-9cba-4307-b2be-39893593c9fb"
      unitRef="usd">6941600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie4fa4f6b472a4f269297591b44aba572_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjE3ZWUzZDMzZjVjNDRkMWU4ZjgxYjZkOGYxZDRkODdiL3RhYmxlcmFuZ2U6MTdlZTNkMzNmNWM0NGQxZThmODFiNmQ4ZjFkNGQ4N2JfOC0zLTEtMS0xNTk1NDA_326ddb93-9840-4cb9-b7ef-3ca94ed85232"
      unitRef="usd">6772800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjE3ZWUzZDMzZjVjNDRkMWU4ZjgxYjZkOGYxZDRkODdiL3RhYmxlcmFuZ2U6MTdlZTNkMzNmNWM0NGQxZThmODFiNmQ4ZjFkNGQ4N2JfOC01LTEtMS0xNTk1NDA_bf893bbf-e7c6-4f13-917f-b0ac4b0ab7f0"
      unitRef="usd">21239600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i167ed8f67bef48c49e54fa466400cdaa_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180My9mcmFnOjMwYTQ3MzM1MjIxYzQwOGI4ODIxYjA1ZmZlNDJjMzU3L3RhYmxlOjE3ZWUzZDMzZjVjNDRkMWU4ZjgxYjZkOGYxZDRkODdiL3RhYmxlcmFuZ2U6MTdlZTNkMzNmNWM0NGQxZThmODFiNmQ4ZjFkNGQ4N2JfOC03LTEtMS0xNTk1NDA_a2778e51-db16-45da-907f-c4e990974baf"
      unitRef="usd">20318500000</us-gaap:Revenues>
    <us-gaap:AssetAcquisitionTextBlock
      contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180OS9mcmFnOmVkZDg1Zjg2YWYyNjQ0MGU5ZWZhMDdiM2U3YmE5ODY0L3RleHRyZWdpb246ZWRkODVmODZhZjI2NDQwZTllZmEwN2IzZTdiYTk4NjRfNTM4OA_9c9d5dc2-2183-457b-ba18-d6a3c679b6a2">Acquisitions&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We engage in various forms of business development activities to enhance our product pipeline, including acquisitions, collaborations, investments, and licensing arrangements. In connection with these arrangements, our partners may be entitled to future royalties and/or commercial milestones based on sales should products be approved for commercialization and/or milestones based on the successful progress of compounds through the development process.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2021, we completed the acquisition of Prevail Therapeutics Inc. (Prevail). This transaction, as further discussed below in Acquisition of a Business, was accounted for as a business combination under the acquisition method of accounting. Under this method, the assets acquired and liabilities assumed were recorded at their respective fair values as of the acquisition date in our consolidated condensed financial statements. The determination of estimated fair value required management to make significant estimates and assumptions. The excess of the purchase price over the fair value of the acquired net assets, where applicable, has been recorded as goodwill. The results of operations of this acquisition is included in our consolidated condensed financial statements from the date of acquisition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We also acquired assets in development which are further discussed below in Asset Acquisitions. Upon each acquisition, the cost allocated to acquired IPR&amp;amp;D is immediately expensed if the compound has no alternative future use. Milestone payment obligations incurred prior to regulatory approval of the compound are expensed when the event triggering an obligation to pay the milestone occurs. We recognized acquired IPR&amp;amp;D and development milestone charges of $62.4 million and $668.4 million for the three and nine months ended September&#160;30, 2022, respectively, and $177.6 million and $532.4 million for the three and nine months ended September&#160;30, 2021, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Acquisition of a Business&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Prevail Acquisition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Overview of Transaction&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2021, we acquired all shares of Prevail for a purchase price that included $22.50 per share in cash (or an aggregate of $747.4&#160;million, net of cash acquired) plus one non-tradable contingent value right (CVR) per share. The CVR entitles Prevail stockholders up to an additional $4.00 per share in cash (or an aggregate of approximately $160&#160;million) payable, subject to certain terms and conditions, upon the first regulatory approval of a Prevail product in one of the following countries: U.S., Japan, United Kingdom, Germany, France, Italy, or Spain. To achieve the full value of the CVR, such regulatory approval must occur by December 31, 2024. If such regulatory approval occurs after December 31, 2024, the value of the CVR will be reduced by approximately 8.3 cents per month until December 1, 2028, at which point the CVR will expire without payment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the agreement, we acquired potentially disease-modifying AAV9-based gene therapies for patients with neurodegenerative diseases. The acquisition established a new modality for drug discovery and development, extending our research efforts through the creation of a gene therapy program that is being anchored by Prevail's portfolio of assets. The lead gene therapies in clinical development that we acquired were PR001 for patients with Parkinson's disease with GBA1 mutations and neuronopathic Gaucher disease and PR006 for patients with frontotemporal dementia with GRN mutations. Both PR001 and PR006 were granted Fast Track designation from the U.S. Food and Drug Administration (FDA). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Assets Acquired and Liabilities Assumed&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the amounts recognized for assets acquired and liabilities assumed as of the acquisition date:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:79.016%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.784%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value at January 22, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired IPR&amp;amp;D&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;824.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126.8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(106.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets and liabilities, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisition date fair value of consideration transferred &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;903.8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(90.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of CVR liability&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(65.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid, net of cash acquired&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;747.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Acquired IPR&amp;amp;D intangibles primarily relate to PR001. In the third quarter of 2022, we impaired the intangible asset related to PR001. See Note 5 for additional information.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;The goodwill recognized from this acquisition is not deductible for tax purposes. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;See Note 6 for a discussion on the estimation of the CVR liability. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are unable to provide the results of operations for the three and nine months ended September&#160;30, 2022 and 2021 attributable to Prevail as those operations were substantially integrated into our legacy business.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pro forma information has not been included as this acquisition did not have a material impact on our consolidated condensed statements of operations for the three and nine months ended September&#160;30, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Asset Acquisitions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our significant asset acquisitions during the nine months ended September&#160;30, 2022 and 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.531%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:27.554%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.104%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.935%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.916%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Counterparty&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Compound(s), Therapy or Asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Acquisition Month&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Phase of Development&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Acquired IPR&amp;amp;D Expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;BioMarin Pharmaceutical Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Priority Review Voucher&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;February 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Not applicable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;110.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Rigel Pharmaceuticals, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;R552, a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor, for the potential treatment of autoimmune and inflammatory diseases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Phase I&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Precision Biosciences, Inc. &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Potential in vivo therapies for genetic disorders&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;The phase of development presented is as of the date of the arrangement and represents the phase of development of the most advanced asset acquired, where applicable. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with our acquisition of Petra Pharma Corporation (Petra), we were required to make milestone payments to Petra shareholders contingent upon the occurrence of certain future events linked to the success of the mutant-selective PI3K&lt;/span&gt;&lt;span style="color:#000000;font-family:'Book Antiqua',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x3b1;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; inhibitor. In the second quarter of 2022, we entered into agreements with substantially all Petra shareholders to acquire their rights to receive any future milestone payments in exchange for a one-time payment. As a result of these agreements, we recognized a charge of $333.8&#160;million as a development milestone during the nine months ended September&#160;30, 2022. Any remaining contingent milestones payments linked to the success of the mutant-selective PI3K&#x3b1; are not expected to be material. We recognized no other significant development milestones during the three and nine months ended September&#160;30, 2022 and 2021.&lt;/span&gt;&lt;/div&gt;Subsequent Event - Akouos, Inc. (Akouos) AcquisitionOn October 17, 2022, we entered into a definitive agreement to acquire Akouos. Pursuant to the terms of the agreement, we have commenced a tender offer to acquire all outstanding shares of Akouos for a purchase price of $12.50 per share in cash (an aggregate of approximately $487&#160;million), payable at closing, plus one non-tradable CVR per share that will entitle the holder to receive up to an additional $3.00 per CVR in cash (an aggregate of up to approximately $123&#160;million) upon the achievement of certain specified milestones. The acquisition will expand our gene therapy portfolio to include potential treatments for hearing loss and other inner ear conditions. The acquisition is not subject to any financing condition and is expected to close in the fourth quarter of 2022, subject to customary closing conditions, including receipt of required antitrust clearance and the tender of a majority of the outstanding shares of Akouos's common stock.</us-gaap:AssetAcquisitionTextBlock>
    <us-gaap:BusinessCombinationDisclosureTextBlock
      contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180OS9mcmFnOmVkZDg1Zjg2YWYyNjQ0MGU5ZWZhMDdiM2U3YmE5ODY0L3RleHRyZWdpb246ZWRkODVmODZhZjI2NDQwZTllZmEwN2IzZTdiYTk4NjRfNTM4OA_b088c754-96b4-4a83-8614-5eba5465b419">Acquisitions&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We engage in various forms of business development activities to enhance our product pipeline, including acquisitions, collaborations, investments, and licensing arrangements. In connection with these arrangements, our partners may be entitled to future royalties and/or commercial milestones based on sales should products be approved for commercialization and/or milestones based on the successful progress of compounds through the development process.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2021, we completed the acquisition of Prevail Therapeutics Inc. (Prevail). This transaction, as further discussed below in Acquisition of a Business, was accounted for as a business combination under the acquisition method of accounting. Under this method, the assets acquired and liabilities assumed were recorded at their respective fair values as of the acquisition date in our consolidated condensed financial statements. The determination of estimated fair value required management to make significant estimates and assumptions. The excess of the purchase price over the fair value of the acquired net assets, where applicable, has been recorded as goodwill. The results of operations of this acquisition is included in our consolidated condensed financial statements from the date of acquisition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We also acquired assets in development which are further discussed below in Asset Acquisitions. Upon each acquisition, the cost allocated to acquired IPR&amp;amp;D is immediately expensed if the compound has no alternative future use. Milestone payment obligations incurred prior to regulatory approval of the compound are expensed when the event triggering an obligation to pay the milestone occurs. We recognized acquired IPR&amp;amp;D and development milestone charges of $62.4 million and $668.4 million for the three and nine months ended September&#160;30, 2022, respectively, and $177.6 million and $532.4 million for the three and nine months ended September&#160;30, 2021, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Acquisition of a Business&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Prevail Acquisition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Overview of Transaction&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2021, we acquired all shares of Prevail for a purchase price that included $22.50 per share in cash (or an aggregate of $747.4&#160;million, net of cash acquired) plus one non-tradable contingent value right (CVR) per share. The CVR entitles Prevail stockholders up to an additional $4.00 per share in cash (or an aggregate of approximately $160&#160;million) payable, subject to certain terms and conditions, upon the first regulatory approval of a Prevail product in one of the following countries: U.S., Japan, United Kingdom, Germany, France, Italy, or Spain. To achieve the full value of the CVR, such regulatory approval must occur by December 31, 2024. If such regulatory approval occurs after December 31, 2024, the value of the CVR will be reduced by approximately 8.3 cents per month until December 1, 2028, at which point the CVR will expire without payment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the agreement, we acquired potentially disease-modifying AAV9-based gene therapies for patients with neurodegenerative diseases. The acquisition established a new modality for drug discovery and development, extending our research efforts through the creation of a gene therapy program that is being anchored by Prevail's portfolio of assets. The lead gene therapies in clinical development that we acquired were PR001 for patients with Parkinson's disease with GBA1 mutations and neuronopathic Gaucher disease and PR006 for patients with frontotemporal dementia with GRN mutations. Both PR001 and PR006 were granted Fast Track designation from the U.S. Food and Drug Administration (FDA). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Assets Acquired and Liabilities Assumed&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the amounts recognized for assets acquired and liabilities assumed as of the acquisition date:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:79.016%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.784%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value at January 22, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired IPR&amp;amp;D&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;824.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126.8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(106.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets and liabilities, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisition date fair value of consideration transferred &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;903.8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(90.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of CVR liability&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(65.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid, net of cash acquired&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;747.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Acquired IPR&amp;amp;D intangibles primarily relate to PR001. In the third quarter of 2022, we impaired the intangible asset related to PR001. See Note 5 for additional information.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;The goodwill recognized from this acquisition is not deductible for tax purposes. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;See Note 6 for a discussion on the estimation of the CVR liability. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are unable to provide the results of operations for the three and nine months ended September&#160;30, 2022 and 2021 attributable to Prevail as those operations were substantially integrated into our legacy business.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pro forma information has not been included as this acquisition did not have a material impact on our consolidated condensed statements of operations for the three and nine months ended September&#160;30, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Asset Acquisitions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our significant asset acquisitions during the nine months ended September&#160;30, 2022 and 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.531%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:27.554%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.104%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.935%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.916%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Counterparty&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Compound(s), Therapy or Asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Acquisition Month&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Phase of Development&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Acquired IPR&amp;amp;D Expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;BioMarin Pharmaceutical Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Priority Review Voucher&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;February 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Not applicable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;110.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Rigel Pharmaceuticals, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;R552, a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor, for the potential treatment of autoimmune and inflammatory diseases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Phase I&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Precision Biosciences, Inc. &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Potential in vivo therapies for genetic disorders&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;The phase of development presented is as of the date of the arrangement and represents the phase of development of the most advanced asset acquired, where applicable. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with our acquisition of Petra Pharma Corporation (Petra), we were required to make milestone payments to Petra shareholders contingent upon the occurrence of certain future events linked to the success of the mutant-selective PI3K&lt;/span&gt;&lt;span style="color:#000000;font-family:'Book Antiqua',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x3b1;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; inhibitor. In the second quarter of 2022, we entered into agreements with substantially all Petra shareholders to acquire their rights to receive any future milestone payments in exchange for a one-time payment. As a result of these agreements, we recognized a charge of $333.8&#160;million as a development milestone during the nine months ended September&#160;30, 2022. Any remaining contingent milestones payments linked to the success of the mutant-selective PI3K&#x3b1; are not expected to be material. We recognized no other significant development milestones during the three and nine months ended September&#160;30, 2022 and 2021.&lt;/span&gt;&lt;/div&gt;Subsequent Event - Akouos, Inc. (Akouos) AcquisitionOn October 17, 2022, we entered into a definitive agreement to acquire Akouos. Pursuant to the terms of the agreement, we have commenced a tender offer to acquire all outstanding shares of Akouos for a purchase price of $12.50 per share in cash (an aggregate of approximately $487&#160;million), payable at closing, plus one non-tradable CVR per share that will entitle the holder to receive up to an additional $3.00 per CVR in cash (an aggregate of up to approximately $123&#160;million) upon the achievement of certain specified milestones. The acquisition will expand our gene therapy portfolio to include potential treatments for hearing loss and other inner ear conditions. The acquisition is not subject to any financing condition and is expected to close in the fourth quarter of 2022, subject to customary closing conditions, including receipt of required antitrust clearance and the tender of a majority of the outstanding shares of Akouos's common stock.</us-gaap:BusinessCombinationDisclosureTextBlock>
    <us-gaap:BusinessCombinationsPolicy
      contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180OS9mcmFnOmVkZDg1Zjg2YWYyNjQ0MGU5ZWZhMDdiM2U3YmE5ODY0L3RleHRyZWdpb246ZWRkODVmODZhZjI2NDQwZTllZmEwN2IzZTdiYTk4NjRfNTM4Mg_566b54f7-348e-45d8-adfd-16d9cd26da4c">Under this method, the assets acquired and liabilities assumed were recorded at their respective fair values as of the acquisition date in our consolidated condensed financial statements. The determination of estimated fair value required management to make significant estimates and assumptions. The excess of the purchase price over the fair value of the acquired net assets, where applicable, has been recorded as goodwill. The results of operations of this acquisition is included in our consolidated condensed financial statements from the date of acquisition.Upon each acquisition, the cost allocated to acquired IPR&amp;amp;D is immediately expensed if the compound has no alternative future use. Milestone payment obligations incurred prior to regulatory approval of the compound are expensed when the event triggering an obligation to pay the milestone occurs.</us-gaap:BusinessCombinationsPolicy>
    <lly:AcquiredInProcessResearchAndDevelopmentAndDevelopmentMilestones
      contextRef="i19fc0325c48543008ea71e1fdcf11d86_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180OS9mcmFnOmVkZDg1Zjg2YWYyNjQ0MGU5ZWZhMDdiM2U3YmE5ODY0L3RleHRyZWdpb246ZWRkODVmODZhZjI2NDQwZTllZmEwN2IzZTdiYTk4NjRfMTc1NQ_8b459b38-3dde-4b01-86a3-b90670ef8e72"
      unitRef="usd">62400000</lly:AcquiredInProcessResearchAndDevelopmentAndDevelopmentMilestones>
    <lly:AcquiredInProcessResearchAndDevelopmentAndDevelopmentMilestones
      contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180OS9mcmFnOmVkZDg1Zjg2YWYyNjQ0MGU5ZWZhMDdiM2U3YmE5ODY0L3RleHRyZWdpb246ZWRkODVmODZhZjI2NDQwZTllZmEwN2IzZTdiYTk4NjRfMTc2Mg_814d2bcb-fad1-4171-8df7-5bf614293fde"
      unitRef="usd">668400000</lly:AcquiredInProcessResearchAndDevelopmentAndDevelopmentMilestones>
    <lly:AcquiredInProcessResearchAndDevelopmentAndDevelopmentMilestones
      contextRef="ie4fa4f6b472a4f269297591b44aba572_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180OS9mcmFnOmVkZDg1Zjg2YWYyNjQ0MGU5ZWZhMDdiM2U3YmE5ODY0L3RleHRyZWdpb246ZWRkODVmODZhZjI2NDQwZTllZmEwN2IzZTdiYTk4NjRfMTgxMQ_930acb16-c7a4-46f2-b4ec-0c4ce1d82bd4"
      unitRef="usd">177600000</lly:AcquiredInProcessResearchAndDevelopmentAndDevelopmentMilestones>
    <lly:AcquiredInProcessResearchAndDevelopmentAndDevelopmentMilestones
      contextRef="i167ed8f67bef48c49e54fa466400cdaa_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180OS9mcmFnOmVkZDg1Zjg2YWYyNjQ0MGU5ZWZhMDdiM2U3YmE5ODY0L3RleHRyZWdpb246ZWRkODVmODZhZjI2NDQwZTllZmEwN2IzZTdiYTk4NjRfMTgxOA_08faa181-0763-4f6c-9031-a7e1539d6611"
      unitRef="usd">532400000</lly:AcquiredInProcessResearchAndDevelopmentAndDevelopmentMilestones>
    <us-gaap:BusinessAcquisitionSharePrice
      contextRef="id1a51594b8b04df48cf5b7eff20f7e6d_I20210131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180OS9mcmFnOmVkZDg1Zjg2YWYyNjQ0MGU5ZWZhMDdiM2U3YmE5ODY0L3RleHRyZWdpb246ZWRkODVmODZhZjI2NDQwZTllZmEwN2IzZTdiYTk4NjRfMjAyMA_6f244deb-9d0b-474c-99fb-f51b8fffa448"
      unitRef="usdPerShare">22.50</us-gaap:BusinessAcquisitionSharePrice>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i28f89248cda04bd08a5c9d722de7c1db_D20210101-20210131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180OS9mcmFnOmVkZDg1Zjg2YWYyNjQ0MGU5ZWZhMDdiM2U3YmE5ODY0L3RleHRyZWdpb246ZWRkODVmODZhZjI2NDQwZTllZmEwN2IzZTdiYTk4NjRfMjA2MQ_645d971d-3cd1-4fdc-87fb-8e286f6e284c"
      unitRef="usd">747400000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <lly:BusinessCombinationConsiderationTransferredNumberOfContingentValueRights
      contextRef="i28f89248cda04bd08a5c9d722de7c1db_D20210101-20210131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180OS9mcmFnOmVkZDg1Zjg2YWYyNjQ0MGU5ZWZhMDdiM2U3YmE5ODY0L3RleHRyZWdpb246ZWRkODVmODZhZjI2NDQwZTllZmEwN2IzZTdiYTk4NjRfMjA5Mg_aa7d0c8c-64b4-4d7e-82ae-bd200b947af6"
      unitRef="right">1</lly:BusinessCombinationConsiderationTransferredNumberOfContingentValueRights>
    <lly:BusinessAcquisitionContingentValueRightAdditionalPricePerShare
      contextRef="id1a51594b8b04df48cf5b7eff20f7e6d_I20210131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180OS9mcmFnOmVkZDg1Zjg2YWYyNjQ0MGU5ZWZhMDdiM2U3YmE5ODY0L3RleHRyZWdpb246ZWRkODVmODZhZjI2NDQwZTllZmEwN2IzZTdiYTk4NjRfMjIwNg_f4c96899-c61c-4e25-9cbc-4d4b5a039966"
      unitRef="usdPerShare">4.00</lly:BusinessAcquisitionContingentValueRightAdditionalPricePerShare>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh
      contextRef="id1a51594b8b04df48cf5b7eff20f7e6d_I20210131"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180OS9mcmFnOmVkZDg1Zjg2YWYyNjQ0MGU5ZWZhMDdiM2U3YmE5ODY0L3RleHRyZWdpb246ZWRkODVmODZhZjI2NDQwZTllZmEwN2IzZTdiYTk4NjRfMjI2MQ_933609d8-ce89-48bc-a35b-0ffd528363ad"
      unitRef="usd">160000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh>
    <lly:BusinessAcquisitionContingentValueRightRegulatoryApprovalDelayMonthlyReduction
      contextRef="id1a51594b8b04df48cf5b7eff20f7e6d_I20210131"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180OS9mcmFnOmVkZDg1Zjg2YWYyNjQ0MGU5ZWZhMDdiM2U3YmE5ODY0L3RleHRyZWdpb246ZWRkODVmODZhZjI2NDQwZTllZmEwN2IzZTdiYTk4NjRfMjY3OA_690a7673-9b2f-4993-87ad-3dbbf8c0e150"
      unitRef="usdPerShare">0.083</lly:BusinessAcquisitionContingentValueRightRegulatoryApprovalDelayMonthlyReduction>
    <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock
      contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180OS9mcmFnOmVkZDg1Zjg2YWYyNjQ0MGU5ZWZhMDdiM2U3YmE5ODY0L3RleHRyZWdpb246ZWRkODVmODZhZjI2NDQwZTllZmEwN2IzZTdiYTk4NjRfNTM4Mw_44d6e0ee-dbf4-4a3a-b21c-845be5d49516">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the amounts recognized for assets acquired and liabilities assumed as of the acquisition date:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:79.016%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.784%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value at January 22, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired IPR&amp;amp;D&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;824.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126.8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(106.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets and liabilities, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisition date fair value of consideration transferred &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;903.8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(90.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of CVR liability&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(65.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid, net of cash acquired&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;747.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Acquired IPR&amp;amp;D intangibles primarily relate to PR001. In the third quarter of 2022, we impaired the intangible asset related to PR001. See Note 5 for additional information.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;The goodwill recognized from this acquisition is not deductible for tax purposes. &lt;/span&gt;&lt;/div&gt;(3) See Note 6 for a discussion on the estimation of the CVR liability.</us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
      contextRef="ie6db4c7ca7af4463afc62347bd8b3a94_I20210122"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180OS9mcmFnOmVkZDg1Zjg2YWYyNjQ0MGU5ZWZhMDdiM2U3YmE5ODY0L3RhYmxlOjNlMDE0MGU5YTIxMjQ0NWJiMzljMWI4MWY2ZWIxMGY4L3RhYmxlcmFuZ2U6M2UwMTQwZTlhMjEyNDQ1YmIzOWMxYjgxZjZlYjEwZjhfMS0xLTEtMS0xNTk1NDA_58807b48-29be-4d10-a0b2-17298c13efaa"
      unitRef="usd">90500000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="ie6db4c7ca7af4463afc62347bd8b3a94_I20210122"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180OS9mcmFnOmVkZDg1Zjg2YWYyNjQ0MGU5ZWZhMDdiM2U3YmE5ODY0L3RhYmxlOjNlMDE0MGU5YTIxMjQ0NWJiMzljMWI4MWY2ZWIxMGY4L3RhYmxlcmFuZ2U6M2UwMTQwZTlhMjEyNDQ1YmIzOWMxYjgxZjZlYjEwZjhfMi0xLTEtMS0xNTk1NDA_db4146de-1491-4d4a-bf18-705b2b325b85"
      unitRef="usd">824000000.0</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:Goodwill
      contextRef="ie6db4c7ca7af4463afc62347bd8b3a94_I20210122"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180OS9mcmFnOmVkZDg1Zjg2YWYyNjQ0MGU5ZWZhMDdiM2U3YmE5ODY0L3RhYmxlOjNlMDE0MGU5YTIxMjQ0NWJiMzljMWI4MWY2ZWIxMGY4L3RhYmxlcmFuZ2U6M2UwMTQwZTlhMjEyNDQ1YmIzOWMxYjgxZjZlYjEwZjhfMy0xLTEtMS0xNTk1NDA_7518ab8b-58df-47b7-b570-af626e5a5e5d"
      unitRef="usd">126800000</us-gaap:Goodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities
      contextRef="ie6db4c7ca7af4463afc62347bd8b3a94_I20210122"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180OS9mcmFnOmVkZDg1Zjg2YWYyNjQ0MGU5ZWZhMDdiM2U3YmE5ODY0L3RhYmxlOjNlMDE0MGU5YTIxMjQ0NWJiMzljMWI4MWY2ZWIxMGY4L3RhYmxlcmFuZ2U6M2UwMTQwZTlhMjEyNDQ1YmIzOWMxYjgxZjZlYjEwZjhfNC0xLTEtMS0xNTk1NDA_771f6ac2-5610-47c2-b998-3169ded53077"
      unitRef="usd">106000000.0</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities>
    <lly:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet
      contextRef="ie6db4c7ca7af4463afc62347bd8b3a94_I20210122"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180OS9mcmFnOmVkZDg1Zjg2YWYyNjQ0MGU5ZWZhMDdiM2U3YmE5ODY0L3RhYmxlOjNlMDE0MGU5YTIxMjQ0NWJiMzljMWI4MWY2ZWIxMGY4L3RhYmxlcmFuZ2U6M2UwMTQwZTlhMjEyNDQ1YmIzOWMxYjgxZjZlYjEwZjhfNS0xLTEtMS0xNTk1NDA_a0484e4d-414f-48da-8763-6a56fbd2d0df"
      unitRef="usd">-31500000</lly:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet
      contextRef="ie6db4c7ca7af4463afc62347bd8b3a94_I20210122"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180OS9mcmFnOmVkZDg1Zjg2YWYyNjQ0MGU5ZWZhMDdiM2U3YmE5ODY0L3RhYmxlOjNlMDE0MGU5YTIxMjQ0NWJiMzljMWI4MWY2ZWIxMGY4L3RhYmxlcmFuZ2U6M2UwMTQwZTlhMjEyNDQ1YmIzOWMxYjgxZjZlYjEwZjhfNi0xLTEtMS0xNTk1NDA_0cc12a80-9b70-4f37-bd64-ec50299eb884"
      unitRef="usd">903800000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
    <us-gaap:CashAcquiredFromAcquisition
      contextRef="i10a5ee4bd0c64813b300c5389565a056_D20210122-20210122"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180OS9mcmFnOmVkZDg1Zjg2YWYyNjQ0MGU5ZWZhMDdiM2U3YmE5ODY0L3RhYmxlOjNlMDE0MGU5YTIxMjQ0NWJiMzljMWI4MWY2ZWIxMGY4L3RhYmxlcmFuZ2U6M2UwMTQwZTlhMjEyNDQ1YmIzOWMxYjgxZjZlYjEwZjhfOC0xLTEtMS0xNTk1NDA_1a79c54a-800b-454d-8e0f-bb3d3d9cf90e"
      unitRef="usd">90500000</us-gaap:CashAcquiredFromAcquisition>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability
      contextRef="ie6db4c7ca7af4463afc62347bd8b3a94_I20210122"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180OS9mcmFnOmVkZDg1Zjg2YWYyNjQ0MGU5ZWZhMDdiM2U3YmE5ODY0L3RhYmxlOjNlMDE0MGU5YTIxMjQ0NWJiMzljMWI4MWY2ZWIxMGY4L3RhYmxlcmFuZ2U6M2UwMTQwZTlhMjEyNDQ1YmIzOWMxYjgxZjZlYjEwZjhfOS0xLTEtMS0xNTk1NDA_cca5af70-b6b3-41a5-a994-fb0e3d134546"
      unitRef="usd">65900000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i28f89248cda04bd08a5c9d722de7c1db_D20210101-20210131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180OS9mcmFnOmVkZDg1Zjg2YWYyNjQ0MGU5ZWZhMDdiM2U3YmE5ODY0L3RhYmxlOjNlMDE0MGU5YTIxMjQ0NWJiMzljMWI4MWY2ZWIxMGY4L3RhYmxlcmFuZ2U6M2UwMTQwZTlhMjEyNDQ1YmIzOWMxYjgxZjZlYjEwZjhfMTAtMS0xLTEtMTU5NTQw_645d971d-3cd1-4fdc-87fb-8e286f6e284c"
      unitRef="usd">747400000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock
      contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180OS9mcmFnOmVkZDg1Zjg2YWYyNjQ0MGU5ZWZhMDdiM2U3YmE5ODY0L3RleHRyZWdpb246ZWRkODVmODZhZjI2NDQwZTllZmEwN2IzZTdiYTk4NjRfNTM5NA_05d2cd9a-ce90-45b6-8093-3723db29a26e">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our significant asset acquisitions during the nine months ended September&#160;30, 2022 and 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.531%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:27.554%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.104%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.935%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.916%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Counterparty&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Compound(s), Therapy or Asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Acquisition Month&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Phase of Development&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Acquired IPR&amp;amp;D Expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;BioMarin Pharmaceutical Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Priority Review Voucher&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;February 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Not applicable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;110.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Rigel Pharmaceuticals, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;R552, a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor, for the potential treatment of autoimmune and inflammatory diseases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Phase I&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Precision Biosciences, Inc. &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Potential in vivo therapies for genetic disorders&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; &lt;/span&gt;The phase of development presented is as of the date of the arrangement and represents the phase of development of the most advanced asset acquired, where applicable.</us-gaap:ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock>
    <lly:PaymentsForAssetAcquisitions
      contextRef="i3b190c0fcac94cb9b4d37191d35b87bb_D20220201-20220228"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180OS9mcmFnOmVkZDg1Zjg2YWYyNjQ0MGU5ZWZhMDdiM2U3YmE5ODY0L3RhYmxlOmQzYjJkZDUwNzFlNzRiZTZhZWJmMGJhNWFlYjQ1YWQ0L3RhYmxlcmFuZ2U6ZDNiMmRkNTA3MWU3NGJlNmFlYmYwYmE1YWViNDVhZDRfMS02LTEtMS0xNTk1NDA_863e82e8-4b04-40e1-bf47-c8f31648e415"
      unitRef="usd">110000000.0</lly:PaymentsForAssetAcquisitions>
    <lly:PaymentsForAssetAcquisitions
      contextRef="ifa2b520f9b26403ca1dfc59f5150bb2a_D20210301-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180OS9mcmFnOmVkZDg1Zjg2YWYyNjQ0MGU5ZWZhMDdiM2U3YmE5ODY0L3RhYmxlOmQzYjJkZDUwNzFlNzRiZTZhZWJmMGJhNWFlYjQ1YWQ0L3RhYmxlcmFuZ2U6ZDNiMmRkNTA3MWU3NGJlNmFlYmYwYmE1YWViNDVhZDRfMy02LTEtMS0xNTk1NDA_ae271ce7-8708-4774-a62a-edc05567b11c"
      unitRef="usd">125000000.0</lly:PaymentsForAssetAcquisitions>
    <lly:PaymentsForAssetAcquisitions
      contextRef="i2a70d59a929b499ca4d9201b21544293_D20210101-20210131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180OS9mcmFnOmVkZDg1Zjg2YWYyNjQ0MGU5ZWZhMDdiM2U3YmE5ODY0L3RhYmxlOmQzYjJkZDUwNzFlNzRiZTZhZWJmMGJhNWFlYjQ1YWQ0L3RhYmxlcmFuZ2U6ZDNiMmRkNTA3MWU3NGJlNmFlYmYwYmE1YWViNDVhZDRfNC02LTEtMS0xNTk1NDA_9765f2d6-d196-430b-9962-1014523454dd"
      unitRef="usd">107800000</lly:PaymentsForAssetAcquisitions>
    <lly:PaymentsForAssetAcquisitions
      contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180OS9mcmFnOmVkZDg1Zjg2YWYyNjQ0MGU5ZWZhMDdiM2U3YmE5ODY0L3RleHRyZWdpb246ZWRkODVmODZhZjI2NDQwZTllZmEwN2IzZTdiYTk4NjRfNTA2NA_becd547d-bff8-40b6-8fcd-5b41bf6b3d7b"
      unitRef="usd">333800000</lly:PaymentsForAssetAcquisitions>
    <us-gaap:BusinessAcquisitionSharePrice
      contextRef="ieacc700b698842408fe2f8c736054aa3_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180OS9mcmFnOmVkZDg1Zjg2YWYyNjQ0MGU5ZWZhMDdiM2U3YmE5ODY0L3RleHRyZWdpb246ZWRkODVmODZhZjI2NDQwZTllZmEwN2IzZTdiYTk4NjRfMzI5ODUzNDg5NTU2MA_dea851e6-3eb9-4e84-ab22-60afe15d8fd4"
      unitRef="usdPerShare">12.50</us-gaap:BusinessAcquisitionSharePrice>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i7d940f045f1243808212f82e48b91487_D20221001-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180OS9mcmFnOmVkZDg1Zjg2YWYyNjQ0MGU5ZWZhMDdiM2U3YmE5ODY0L3RleHRyZWdpb246ZWRkODVmODZhZjI2NDQwZTllZmEwN2IzZTdiYTk4NjRfMzI5ODUzNDg5NTU2OA_48817f80-3aff-4262-bb7f-9452924fa23c"
      unitRef="usd">487000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <lly:BusinessCombinationConsiderationTransferredNumberOfContingentValueRights
      contextRef="i7d940f045f1243808212f82e48b91487_D20221001-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180OS9mcmFnOmVkZDg1Zjg2YWYyNjQ0MGU5ZWZhMDdiM2U3YmE5ODY0L3RleHRyZWdpb246ZWRkODVmODZhZjI2NDQwZTllZmEwN2IzZTdiYTk4NjRfMzI5ODUzNDg5NTYwMg_a6298565-022d-4050-befe-0451b3175c02"
      unitRef="right">1</lly:BusinessCombinationConsiderationTransferredNumberOfContingentValueRights>
    <lly:BusinessAcquisitionContingentValueRightAdditionalPricePerShare
      contextRef="ieacc700b698842408fe2f8c736054aa3_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180OS9mcmFnOmVkZDg1Zjg2YWYyNjQ0MGU5ZWZhMDdiM2U3YmE5ODY0L3RleHRyZWdpb246ZWRkODVmODZhZjI2NDQwZTllZmEwN2IzZTdiYTk4NjRfMzI5ODUzNDg5NTU4Mg_7f4c5933-1d83-45f0-bc0a-3a778944d759"
      unitRef="usdPerShare">3.00</lly:BusinessAcquisitionContingentValueRightAdditionalPricePerShare>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh
      contextRef="ieacc700b698842408fe2f8c736054aa3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN180OS9mcmFnOmVkZDg1Zjg2YWYyNjQ0MGU5ZWZhMDdiM2U3YmE5ODY0L3RleHRyZWdpb246ZWRkODVmODZhZjI2NDQwZTllZmEwN2IzZTdiYTk4NjRfMzI5ODUzNDg5NTU4OQ_428d1249-58fb-4a3b-8759-3f6d0b0315b5"
      unitRef="usd">123000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN181Mi9mcmFnOmIxNmQ0YjlkMmM5MzQ4ODZiZjM3YTgxYThjM2FiODM0L3RleHRyZWdpb246YjE2ZDRiOWQyYzkzNDg4NmJmMzdhODFhOGMzYWI4MzRfMTA3NTc_2f88cd9c-8e4f-4d20-88b6-307bd28c5de8">Collaborations and Other Arrangements&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We often enter into collaborative and other similar arrangements to develop and commercialize drug candidates. Collaborative activities may include research and development, marketing and selling (including promotional activities and physician detailing), manufacturing, and distribution. These arrangements often require milestone as well as royalty or profit-share payments, contingent upon the occurrence of certain future events linked to the success of the asset in development, as well as expense reimbursements from or payments to the collaboration partner. See Note 2 for amounts of collaboration and other revenue recognized from these types of arrangements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating expenses for costs incurred pursuant to these arrangements are reported in their respective expense line item, net of any payments due to or reimbursements due from our collaboration partners, with such reimbursements being recognized at the time the party becomes obligated to pay. Each collaboration is unique in nature, and our more significant arrangements are discussed below. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Boehringer Ingelheim Diabetes Collaboration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We and Boehringer Ingelheim have a global agreement to jointly develop and commercialize a portfolio of diabetes compounds. Currently included in the collaboration are Boehringer Ingelheim's oral diabetes products: Jardiance, Glyxambi, Synjardy, Trijardy XR, Trajenta, and Jentadueto&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; as well as our basal insulin, Basaglar. Glyxambi, Synjardy, and Trijardy XR are included in the Jardiance product family. Jentadueto is included in the Trajenta product family. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the regulatory approvals of Jardiance, Trajenta, and Basaglar in the U.S., Europe, and Japan, milestone payments made for Jardiance and Trajenta were capitalized as intangible assets and are being amortized to cost of sales, and milestone payments received for Basaglar were recorded as contract liabilities and are being amortized to collaboration and other revenue. The milestones pertaining to Jardiance and Trajenta are being amortized through their respective term under the collaboration, which, depending on country or region, is determined based on the latest to occur of (a) a defined number of years following launch date, (b) the expiration of the compound patent, or (c) the expiration of marketing authorization exclusivity. The milestones pertaining to Basaglar are being amortized through 2029. The table below summarizes the net milestones capitalized with respect to the Jardiance and Trajenta families of products and the net milestones deferred with respect to Basaglar as of September&#160;30, 2022 and December&#160;31, 2021: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.812%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.445%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Milestones Capitalized (Deferred)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Jardiance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;121.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;136.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trajenta&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;69.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basaglar&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(135.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(149.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;This represents the amounts that have been capitalized (deferred) from the start of this collaboration through the end of the reporting period, net of amount amortized. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the Jardiance product family, we and Boehringer Ingelheim share equally the ongoing development and commercialization costs in the most significant markets, and we record our portion of the development and commercialization costs as research and development expense and marketing, selling, and administrative expense, respectively. We receive a royalty on net sales of Boehringer Ingelheim's products in the most significant markets and recognize the royalty as collaboration and other revenue. Boehringer Ingelheim is entitled to potential performance payments depending on the net sales of the Jardiance product family; therefore, our reported revenue for Jardiance may be reduced by any potential performance payments we make related to this product family. The royalty received by us related to the Jardiance product family may also be increased or decreased depending on whether net sales for this product family exceed or fall below certain thresholds. We pay to Boehringer Ingelheim a royalty on net sales for Basaglar in the U.S. We record our sales of Basaglar to third parties as net product revenue with the royalty payments made to Boehringer Ingelheim recorded as cost of sales.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our collaboration and other revenue recognized with respect to the Jardiance and Trajenta families of products and net product revenue recognized with respect to Basaglar:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.206%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Jardiance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;573.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;390.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,453.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,058.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basaglar&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;193.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;192.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;558.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;650.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trajenta&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;103.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;293.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;279.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Olumiant&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have a worldwide license and collaboration agreement with Incyte Corporation (Incyte), which provides us the development and commercialization rights to baricitinib, branded and trademarked as Olumiant, and certain follow-on compounds, for the treatment of inflammatory and autoimmune diseases and COVID-19. Incyte has the right to receive tiered, double digit royalty payments on worldwide net sales with rates ranging up to 20 percent. Incyte has the right to receive an additional royalty ranging up to the low teens on worldwide net sales for the treatment of COVID-19 that exceed a specified aggregate worldwide net sales threshold. The agreement calls for payments by us to Incyte associated with certain development, success-based regulatory, and sales-based milestones. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the regulatory approvals of Olumiant in the U.S., Europe, and Japan, as well as achievement of a sales-based milestone, milestone payments of $330.0 million and $260.0 million were capitalized as intangible assets as of September&#160;30, 2022 and December&#160;31, 2021, respectively, and are being amortized to cost of sales through the term of the collaboration. This represents the cumulative amounts that have been capitalized from the start of this collaboration through the end of each reporting period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2022, Incyte is eligible to receive up to $100.0&#160;million of additional payments from us in potential sales-based milestones.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We record our sales of Olumiant, including sales of baricitinib that were made pursuant to EUA or similar regulatory authorizations, to third parties as net product revenue with the royalty payments made to Incyte recorded as cost of sales. The following table summarizes our net product revenue recognized with respect to Olumiant:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.206%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Olumiant&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;182.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;406.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;624.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;809.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;COVID-19 Antibodies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have a worldwide license and collaboration agreement with AbCellera Biologics Inc. (AbCellera) to co-develop therapeutic antibodies for the potential prevention and treatment of COVID-19, including bamlanivimab and bebtelovimab, for which we hold development and commercialization rights. AbCellera has the right to receive tiered royalty payments on worldwide net sales of bamlanivimab and bebtelovimab with percentages ranging in the mid-teens to mid-twenties. Royalty payments made to AbCellera are recorded as cost of sales.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have a license and collaboration agreement with Shanghai Junshi Biosciences Co., Ltd. (Junshi Biosciences) to co-develop therapeutic antibodies for the potential prevention and treatment of COVID-19, including etesevimab, for which we hold development and commercialization rights outside of mainland China and the Special Administrative Regions of Hong Kong and Macau, and for which Junshi Biosciences currently maintains all rights in mainland China and the Special Administrative Regions of Hong Kong and Macau. Junshi Biosciences has the right to receive royalty payments in the mid-teens on our net sales of etesevimab. Junshi Biosciences received certain development, success-based regulatory and sales-based milestones. Capitalized regulatory and sales-based milestones were fully amortized to cost of sales as of September&#160;30, 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to EUAs or similar regulatory authorizations, we recognized net product revenue associated with our sales of our COVID-19 antibodies of $386.6 million and $1.99 billion for the three and nine months ended September&#160;30, 2022, respectively, and $217.1&#160;million and $1.18 billion for the three and nine months ended September&#160;30, 2021, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Sintilimab Injection&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have a collaboration agreement with Innovent Biologics, Inc. (Innovent) to jointly develop and commercialize sintilimab injection in China, where it is branded and trademarked as Tyvyt. In connection with regulatory approvals for Tyvyt in China, milestone payments of $120.0&#160;million and $40.0&#160;million were capitalized as intangible assets as of September&#160;30, 2022 and December&#160;31, 2021, respectively, and are being amortized to cost of sales through the term of the collaboration. This represents the cumulative amounts that have been capitalized from the start of this collaboration through the end of each reporting period. As of September&#160;30, 2022, Innovent is eligible to receive up to $115.0&#160;million in success-based regulatory and sales-based milestones.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We record our sales of Tyvyt to third parties as net product revenue, with payments made to Innovent for its portion of the gross margin reported as cost of sales. We report as collaboration and other revenue our portion of the gross margin for Tyvyt sales made by Innovent to third parties. The following table summarizes our revenue recognized in China with respect to Tyvyt:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.206%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tyvyt&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;76.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;235.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;340.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2020, we obtained an exclusive license for sintilimab injection from Innovent for geographies outside of China, which was subsequently terminated and rights have reverted to Innovent in October 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Lebrikizumab&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have a worldwide license agreement with F. Hoffmann-La Roche Ltd and Genentech, Inc. (collectively, Roche), which provides us the worldwide development and commercialization rights to lebrikizumab. Roche has the right to receive tiered royalty payments on future worldwide net sales ranging in percentages from high single digits to high teens if the product is successfully commercialized. As of September&#160;30, 2022, Roche is eligible to receive up to $180.0&#160;million of payments from us contingent upon the achievement of success-based regulatory milestones and up to $1.03 billion in a series of sales-based milestones, contingent upon the commercial success of lebrikizumab.&lt;/span&gt;&lt;/div&gt;We have a license agreement with Almirall, S.A. (Almirall), under which Almirall licensed the rights to develop and commercialize lebrikizumab for the treatment or prevention of dermatology indications, including, but not limited to, atopic dermatitis in Europe. We have the right to receive tiered royalty payments on future net sales in Europe ranging in percentages from low double digits to low twenties if the product is successfully commercialized. As of September&#160;30, 2022, we are eligible to receive additional payments of $85.0&#160;million from Almirall contingent upon the achievement of success-based regulatory milestones and up to $1.25&#160;billion in a series of sales-based milestones, contingent upon the commercial success of lebrikizumab. There were no remaining contract liabilities as of September&#160;30, 2022. As of December&#160;31, 2021, contract liabilities were not material. During the three and nine months ended September&#160;30, 2022 and 2021, collaboration and other revenue recognized was not material.</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock
      contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN181Mi9mcmFnOmIxNmQ0YjlkMmM5MzQ4ODZiZjM3YTgxYThjM2FiODM0L3RleHRyZWdpb246YjE2ZDRiOWQyYzkzNDg4NmJmMzdhODFhOGMzYWI4MzRfMTA3NDk_78f77876-c203-4d20-9203-7cacc98da862">The table below summarizes the net milestones capitalized with respect to the Jardiance and Trajenta families of products and the net milestones deferred with respect to Basaglar as of September&#160;30, 2022 and December&#160;31, 2021: &lt;div style="margin-top:6pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.812%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.445%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Milestones Capitalized (Deferred)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Jardiance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;121.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;136.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trajenta&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;69.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basaglar&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(135.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(149.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;This represents the amounts that have been capitalized (deferred) from the start of this collaboration through the end of the reporting period, net of amount amortized. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our collaboration and other revenue recognized with respect to the Jardiance and Trajenta families of products and net product revenue recognized with respect to Basaglar:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.206%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Jardiance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;573.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;390.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,453.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,058.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basaglar&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;193.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;192.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;558.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;650.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trajenta&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;103.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;293.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;279.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;The following table summarizes our net product revenue recognized with respect to Olumiant:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.206%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Olumiant&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;182.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;406.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;624.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;809.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;The following table summarizes our revenue recognized in China with respect to Tyvyt:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.206%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tyvyt&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;76.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;235.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;340.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock>
    <lly:CollaborativeArrangementRightsAndObligationsRightsObligations
      contextRef="if142129c01ca4ea0b352f378c8bc9899_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN181Mi9mcmFnOmIxNmQ0YjlkMmM5MzQ4ODZiZjM3YTgxYThjM2FiODM0L3RhYmxlOjA3MjlmMmMyMWEyNDQ2MGQ5NzIwYTI0ZDgwMzVhYmYxL3RhYmxlcmFuZ2U6MDcyOWYyYzIxYTI0NDYwZDk3MjBhMjRkODAzNWFiZjFfMi0xLTEtMS0xNTk1NDA_7c5f2ab0-39c4-4a24-a141-bc0fc8e243f1"
      unitRef="usd">121200000</lly:CollaborativeArrangementRightsAndObligationsRightsObligations>
    <lly:CollaborativeArrangementRightsAndObligationsRightsObligations
      contextRef="i744124019ee24c83852d6d07406b514c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN181Mi9mcmFnOmIxNmQ0YjlkMmM5MzQ4ODZiZjM3YTgxYThjM2FiODM0L3RhYmxlOjA3MjlmMmMyMWEyNDQ2MGQ5NzIwYTI0ZDgwMzVhYmYxL3RhYmxlcmFuZ2U6MDcyOWYyYzIxYTI0NDYwZDk3MjBhMjRkODAzNWFiZjFfMi0yLTEtMS0xNTk1NDA_cfdca453-350a-48f7-982a-fcfe59c2edf4"
      unitRef="usd">136100000</lly:CollaborativeArrangementRightsAndObligationsRightsObligations>
    <lly:CollaborativeArrangementRightsAndObligationsRightsObligations
      contextRef="i8a19b281bf8a4f059256a5bba91d053c_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN181Mi9mcmFnOmIxNmQ0YjlkMmM5MzQ4ODZiZjM3YTgxYThjM2FiODM0L3RhYmxlOjA3MjlmMmMyMWEyNDQ2MGQ5NzIwYTI0ZDgwMzVhYmYxL3RhYmxlcmFuZ2U6MDcyOWYyYzIxYTI0NDYwZDk3MjBhMjRkODAzNWFiZjFfMy0xLTEtMS0xNTk1NDA_08154d56-bd1b-45a6-a7bf-04bae21e3727"
      unitRef="usd">69600000</lly:CollaborativeArrangementRightsAndObligationsRightsObligations>
    <lly:CollaborativeArrangementRightsAndObligationsRightsObligations
      contextRef="ic00807c6a67343bd9b77d66d8f53542e_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN181Mi9mcmFnOmIxNmQ0YjlkMmM5MzQ4ODZiZjM3YTgxYThjM2FiODM0L3RhYmxlOjA3MjlmMmMyMWEyNDQ2MGQ5NzIwYTI0ZDgwMzVhYmYxL3RhYmxlcmFuZ2U6MDcyOWYyYzIxYTI0NDYwZDk3MjBhMjRkODAzNWFiZjFfMy0yLTEtMS0xNTk1NDA_79a754c3-684f-4b05-a429-21d6d2e535ed"
      unitRef="usd">88500000</lly:CollaborativeArrangementRightsAndObligationsRightsObligations>
    <lly:CollaborativeArrangementRightsAndObligationsRightsObligations
      contextRef="ie2eb6b846c0e477a94f57d35ebf60943_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN181Mi9mcmFnOmIxNmQ0YjlkMmM5MzQ4ODZiZjM3YTgxYThjM2FiODM0L3RhYmxlOjA3MjlmMmMyMWEyNDQ2MGQ5NzIwYTI0ZDgwMzVhYmYxL3RhYmxlcmFuZ2U6MDcyOWYyYzIxYTI0NDYwZDk3MjBhMjRkODAzNWFiZjFfNC0xLTEtMS0xNTk1NDA_cf91d070-eef0-44fa-a9b7-0169329da805"
      unitRef="usd">-135300000</lly:CollaborativeArrangementRightsAndObligationsRightsObligations>
    <lly:CollaborativeArrangementRightsAndObligationsRightsObligations
      contextRef="ib6657690bf5241ba82f0d73292ac9ea7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN181Mi9mcmFnOmIxNmQ0YjlkMmM5MzQ4ODZiZjM3YTgxYThjM2FiODM0L3RhYmxlOjA3MjlmMmMyMWEyNDQ2MGQ5NzIwYTI0ZDgwMzVhYmYxL3RhYmxlcmFuZ2U6MDcyOWYyYzIxYTI0NDYwZDk3MjBhMjRkODAzNWFiZjFfNC0yLTEtMS0xNTk1NDA_447b4005-69d8-40b2-94f4-db759d560cf3"
      unitRef="usd">-149300000</lly:CollaborativeArrangementRightsAndObligationsRightsObligations>
    <us-gaap:Revenues
      contextRef="idfba5b60fbbe4370bad16f003f72e3c1_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN181Mi9mcmFnOmIxNmQ0YjlkMmM5MzQ4ODZiZjM3YTgxYThjM2FiODM0L3RhYmxlOmRjNWFmNjFjMDJjNTQ2NDFhYjdkNjc3ODI1N2E5YzA0L3RhYmxlcmFuZ2U6ZGM1YWY2MWMwMmM1NDY0MWFiN2Q2Nzc4MjU3YTljMDRfMi0xLTEtMS0xNTk1NDA_4b4062e7-4dbf-476d-b7d9-c49ae88fb823"
      unitRef="usd">573300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia28641f7c767406eacaa8089e13a2e77_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN181Mi9mcmFnOmIxNmQ0YjlkMmM5MzQ4ODZiZjM3YTgxYThjM2FiODM0L3RhYmxlOmRjNWFmNjFjMDJjNTQ2NDFhYjdkNjc3ODI1N2E5YzA0L3RhYmxlcmFuZ2U6ZGM1YWY2MWMwMmM1NDY0MWFiN2Q2Nzc4MjU3YTljMDRfMi0zLTEtMS0xNTk1NDA_a6146567-ce3d-4baa-8cc0-7c8b22aba394"
      unitRef="usd">390400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1c01691865ed49fc84902886c99bbbdf_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN181Mi9mcmFnOmIxNmQ0YjlkMmM5MzQ4ODZiZjM3YTgxYThjM2FiODM0L3RhYmxlOmRjNWFmNjFjMDJjNTQ2NDFhYjdkNjc3ODI1N2E5YzA0L3RhYmxlcmFuZ2U6ZGM1YWY2MWMwMmM1NDY0MWFiN2Q2Nzc4MjU3YTljMDRfMi01LTEtMS0xNTk1NDA_cb373d45-18c4-40fb-bb86-e9d14a320f3a"
      unitRef="usd">1453700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i46099dfb95b0484ab5891f186d350f52_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN181Mi9mcmFnOmIxNmQ0YjlkMmM5MzQ4ODZiZjM3YTgxYThjM2FiODM0L3RhYmxlOmRjNWFmNjFjMDJjNTQ2NDFhYjdkNjc3ODI1N2E5YzA0L3RhYmxlcmFuZ2U6ZGM1YWY2MWMwMmM1NDY0MWFiN2Q2Nzc4MjU3YTljMDRfMi03LTEtMS0xNTk1NDA_70ca7508-c330-4dc2-95ef-5b171312bb25"
      unitRef="usd">1058900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id6f3b41d10de4dfb99b809554e15f4ca_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN181Mi9mcmFnOmIxNmQ0YjlkMmM5MzQ4ODZiZjM3YTgxYThjM2FiODM0L3RhYmxlOmRjNWFmNjFjMDJjNTQ2NDFhYjdkNjc3ODI1N2E5YzA0L3RhYmxlcmFuZ2U6ZGM1YWY2MWMwMmM1NDY0MWFiN2Q2Nzc4MjU3YTljMDRfMy0xLTEtMS0xNTk1NDA_f5a63c3a-96cf-4c8e-978e-398f3ff81c82"
      unitRef="usd">193000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ieef95d1c0c4643f8a5a104c9301c56f6_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN181Mi9mcmFnOmIxNmQ0YjlkMmM5MzQ4ODZiZjM3YTgxYThjM2FiODM0L3RhYmxlOmRjNWFmNjFjMDJjNTQ2NDFhYjdkNjc3ODI1N2E5YzA0L3RhYmxlcmFuZ2U6ZGM1YWY2MWMwMmM1NDY0MWFiN2Q2Nzc4MjU3YTljMDRfMy0zLTEtMS0xNTk1NDA_f749cbc3-4bf9-40a9-9045-7be859795e51"
      unitRef="usd">192800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1f95ba5af9c24c3eb20dc2c5a3979588_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN181Mi9mcmFnOmIxNmQ0YjlkMmM5MzQ4ODZiZjM3YTgxYThjM2FiODM0L3RhYmxlOmRjNWFmNjFjMDJjNTQ2NDFhYjdkNjc3ODI1N2E5YzA0L3RhYmxlcmFuZ2U6ZGM1YWY2MWMwMmM1NDY0MWFiN2Q2Nzc4MjU3YTljMDRfMy01LTEtMS0xNTk1NDA_11a1b9ff-2de8-493b-989f-355beeaf0e2b"
      unitRef="usd">558700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id065d1641c8b4bc19bda4f978edc7f70_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN181Mi9mcmFnOmIxNmQ0YjlkMmM5MzQ4ODZiZjM3YTgxYThjM2FiODM0L3RhYmxlOmRjNWFmNjFjMDJjNTQ2NDFhYjdkNjc3ODI1N2E5YzA0L3RhYmxlcmFuZ2U6ZGM1YWY2MWMwMmM1NDY0MWFiN2Q2Nzc4MjU3YTljMDRfMy03LTEtMS0xNTk1NDA_ce835c8b-bb9d-4ca6-af69-991834fa4bc4"
      unitRef="usd">650100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i91e1bea218144eab958a68c72b25b13d_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN181Mi9mcmFnOmIxNmQ0YjlkMmM5MzQ4ODZiZjM3YTgxYThjM2FiODM0L3RhYmxlOmRjNWFmNjFjMDJjNTQ2NDFhYjdkNjc3ODI1N2E5YzA0L3RhYmxlcmFuZ2U6ZGM1YWY2MWMwMmM1NDY0MWFiN2Q2Nzc4MjU3YTljMDRfNC0xLTEtMS0xNTk1NDA_e1ddd021-8863-4d52-87c7-21043d1d2d01"
      unitRef="usd">103800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9fe7212a81994bafa9e83b419cfb489f_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN181Mi9mcmFnOmIxNmQ0YjlkMmM5MzQ4ODZiZjM3YTgxYThjM2FiODM0L3RhYmxlOmRjNWFmNjFjMDJjNTQ2NDFhYjdkNjc3ODI1N2E5YzA0L3RhYmxlcmFuZ2U6ZGM1YWY2MWMwMmM1NDY0MWFiN2Q2Nzc4MjU3YTljMDRfNC0zLTEtMS0xNTk1NDA_38c0a24d-a730-4496-b8f8-5919446b8f00"
      unitRef="usd">96100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4cbfd23e4f9c474bac8535d65c4695e8_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN181Mi9mcmFnOmIxNmQ0YjlkMmM5MzQ4ODZiZjM3YTgxYThjM2FiODM0L3RhYmxlOmRjNWFmNjFjMDJjNTQ2NDFhYjdkNjc3ODI1N2E5YzA0L3RhYmxlcmFuZ2U6ZGM1YWY2MWMwMmM1NDY0MWFiN2Q2Nzc4MjU3YTljMDRfNC01LTEtMS0xNTk1NDA_63f9b6e9-36d6-40c9-bd8d-27168e12376d"
      unitRef="usd">293000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i57c459014f2c4c2797423bd9e7eff879_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN181Mi9mcmFnOmIxNmQ0YjlkMmM5MzQ4ODZiZjM3YTgxYThjM2FiODM0L3RhYmxlOmRjNWFmNjFjMDJjNTQ2NDFhYjdkNjc3ODI1N2E5YzA0L3RhYmxlcmFuZ2U6ZGM1YWY2MWMwMmM1NDY0MWFiN2Q2Nzc4MjU3YTljMDRfNC03LTEtMS0xNTk1NDA_67e2a83d-773e-46af-90d5-440415a399aa"
      unitRef="usd">279900000</us-gaap:Revenues>
    <lly:CollaborativeArrangementRightsAndObligationsPercent
      contextRef="idfc0a5f22fb44537835f6510caaa9fa5_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN181Mi9mcmFnOmIxNmQ0YjlkMmM5MzQ4ODZiZjM3YTgxYThjM2FiODM0L3RleHRyZWdpb246YjE2ZDRiOWQyYzkzNDg4NmJmMzdhODFhOGMzYWI4MzRfNDY4NQ_52dc7c2d-ce3b-484e-8820-da8deb37ac53"
      unitRef="number">0.20</lly:CollaborativeArrangementRightsAndObligationsPercent>
    <lly:CollaborativeArrangementRightsAndObligationsRightsObligations
      contextRef="i46a25e2e10224815a8f7d26777b2eb48_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN181Mi9mcmFnOmIxNmQ0YjlkMmM5MzQ4ODZiZjM3YTgxYThjM2FiODM0L3RleHRyZWdpb246YjE2ZDRiOWQyYzkzNDg4NmJmMzdhODFhOGMzYWI4MzRfNTE5MQ_fa58c009-cddb-453c-b9ad-ccec3892dbd5"
      unitRef="usd">330000000</lly:CollaborativeArrangementRightsAndObligationsRightsObligations>
    <lly:CollaborativeArrangementRightsAndObligationsRightsObligations
      contextRef="i445e64ca4f7041e49970bead926a789e_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN181Mi9mcmFnOmIxNmQ0YjlkMmM5MzQ4ODZiZjM3YTgxYThjM2FiODM0L3RleHRyZWdpb246YjE2ZDRiOWQyYzkzNDg4NmJmMzdhODFhOGMzYWI4MzRfNTE5OA_d0840c62-9cc7-4622-b373-a0656d5f6900"
      unitRef="usd">260000000</lly:CollaborativeArrangementRightsAndObligationsRightsObligations>
    <lly:CollaborativeArrangementRightsAndObligationsRightsObligations
      contextRef="i97f0fe2e404740069df426fbe933ed1d_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN181Mi9mcmFnOmIxNmQ0YjlkMmM5MzQ4ODZiZjM3YTgxYThjM2FiODM0L3RleHRyZWdpb246YjE2ZDRiOWQyYzkzNDg4NmJmMzdhODFhOGMzYWI4MzRfNTU0MQ_dd7e39fd-0976-4f85-9a1c-db6ffbeaaf75"
      unitRef="usd">100000000</lly:CollaborativeArrangementRightsAndObligationsRightsObligations>
    <us-gaap:Revenues
      contextRef="i65843c3594444a24be3c2dd715fb25e8_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN181Mi9mcmFnOmIxNmQ0YjlkMmM5MzQ4ODZiZjM3YTgxYThjM2FiODM0L3RhYmxlOmJhZTliNGI0MzhjZjRjY2Y5MDE2NTI3M2YyOTlkNmUzL3RhYmxlcmFuZ2U6YmFlOWI0YjQzOGNmNGNjZjkwMTY1MjczZjI5OWQ2ZTNfMi0xLTEtMS0xNTk1NDA_257580ce-899d-4d9b-ab06-7b681acb7802"
      unitRef="usd">182900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i342e7e7b465546ffa22256042c6bf573_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN181Mi9mcmFnOmIxNmQ0YjlkMmM5MzQ4ODZiZjM3YTgxYThjM2FiODM0L3RhYmxlOmJhZTliNGI0MzhjZjRjY2Y5MDE2NTI3M2YyOTlkNmUzL3RhYmxlcmFuZ2U6YmFlOWI0YjQzOGNmNGNjZjkwMTY1MjczZjI5OWQ2ZTNfMi0zLTEtMS0xNTk1NDA_64568da7-872d-4490-bbf2-bebf62cdca4f"
      unitRef="usd">406900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5da2c0b8af014f4085d9e2a62f64ccc7_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN181Mi9mcmFnOmIxNmQ0YjlkMmM5MzQ4ODZiZjM3YTgxYThjM2FiODM0L3RhYmxlOmJhZTliNGI0MzhjZjRjY2Y5MDE2NTI3M2YyOTlkNmUzL3RhYmxlcmFuZ2U6YmFlOWI0YjQzOGNmNGNjZjkwMTY1MjczZjI5OWQ2ZTNfMi01LTEtMS0xNTk1NDA_0df76049-ccad-4122-b1a1-eae0338220ed"
      unitRef="usd">624700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i681b00cc06e740d5afd240016ce29efc_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN181Mi9mcmFnOmIxNmQ0YjlkMmM5MzQ4ODZiZjM3YTgxYThjM2FiODM0L3RhYmxlOmJhZTliNGI0MzhjZjRjY2Y5MDE2NTI3M2YyOTlkNmUzL3RhYmxlcmFuZ2U6YmFlOWI0YjQzOGNmNGNjZjkwMTY1MjczZjI5OWQ2ZTNfMi03LTEtMS0xNTk1NDA_0e645580-44b6-4123-bb51-2c0d05b45c34"
      unitRef="usd">809100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic89265df487544d48f864b30c7c12762_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN181Mi9mcmFnOmIxNmQ0YjlkMmM5MzQ4ODZiZjM3YTgxYThjM2FiODM0L3RleHRyZWdpb246YjE2ZDRiOWQyYzkzNDg4NmJmMzdhODFhOGMzYWI4MzRfNzE0NjgyNTU5MjY4OQ_84c24c47-9b52-4830-9028-647017123355"
      unitRef="usd">386600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie674d270134f4cffaff8f7a15471b73e_D20220101-20220930"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN181Mi9mcmFnOmIxNmQ0YjlkMmM5MzQ4ODZiZjM3YTgxYThjM2FiODM0L3RleHRyZWdpb246YjE2ZDRiOWQyYzkzNDg4NmJmMzdhODFhOGMzYWI4MzRfNzE0NjgyNTU5MjcwMg_2b20ced1-1fef-4ea4-92ae-675404e43394"
      unitRef="usd">1990000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i05b4b2fd75f8488cafa80162074dca18_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN181Mi9mcmFnOmIxNmQ0YjlkMmM5MzQ4ODZiZjM3YTgxYThjM2FiODM0L3RleHRyZWdpb246YjE2ZDRiOWQyYzkzNDg4NmJmMzdhODFhOGMzYWI4MzRfNzUyOQ_68157132-4443-4e9f-95c1-d21929f2a3b7"
      unitRef="usd">217100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic06f11244a5a4b88822809b3b3941ffe_D20210101-20210930"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN181Mi9mcmFnOmIxNmQ0YjlkMmM5MzQ4ODZiZjM3YTgxYThjM2FiODM0L3RleHRyZWdpb246YjE2ZDRiOWQyYzkzNDg4NmJmMzdhODFhOGMzYWI4MzRfNTQ5NzU1ODI2MDE4_ce62e567-a21b-4e98-8737-7351a6a6f471"
      unitRef="usd">1180000000</us-gaap:Revenues>
    <lly:CollaborativeArrangementRightsAndObligationsRightsObligations
      contextRef="ia361008dd9de45979f0de7611a5df845_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN181Mi9mcmFnOmIxNmQ0YjlkMmM5MzQ4ODZiZjM3YTgxYThjM2FiODM0L3RleHRyZWdpb246YjE2ZDRiOWQyYzkzNDg4NmJmMzdhODFhOGMzYWI4MzRfODI2Ng_4cea3fff-5730-4da4-817c-c951866d375d"
      unitRef="usd">120000000</lly:CollaborativeArrangementRightsAndObligationsRightsObligations>
    <lly:CollaborativeArrangementRightsAndObligationsRightsObligations
      contextRef="i9f82e7316ae6411ea23d0347aa8ad8db_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN181Mi9mcmFnOmIxNmQ0YjlkMmM5MzQ4ODZiZjM3YTgxYThjM2FiODM0L3RleHRyZWdpb246YjE2ZDRiOWQyYzkzNDg4NmJmMzdhODFhOGMzYWI4MzRfODI3Mw_7a723e72-ba2a-4889-8d0d-4b4545b3cbdf"
      unitRef="usd">40000000</lly:CollaborativeArrangementRightsAndObligationsRightsObligations>
    <lly:CollaborativeArrangementRightsAndObligationsRightsObligations
      contextRef="i8e3c0bf77cd749d8b6fec828c354954b_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN181Mi9mcmFnOmIxNmQ0YjlkMmM5MzQ4ODZiZjM3YTgxYThjM2FiODM0L3RleHRyZWdpb246YjE2ZDRiOWQyYzkzNDg4NmJmMzdhODFhOGMzYWI4MzRfODY2NA_897e055d-5e0a-4dcc-a5a8-c57f56ac373d"
      unitRef="usd">115000000</lly:CollaborativeArrangementRightsAndObligationsRightsObligations>
    <us-gaap:Revenues
      contextRef="ifc8fc5f6c1924a46b0d88ad7ea894f53_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN181Mi9mcmFnOmIxNmQ0YjlkMmM5MzQ4ODZiZjM3YTgxYThjM2FiODM0L3RhYmxlOjhjZDYxOTA4MTdlMjQ4NmM4ZDkyNzRhNWFjMzE5MzY0L3RhYmxlcmFuZ2U6OGNkNjE5MDgxN2UyNDg2YzhkOTI3NGE1YWMzMTkzNjRfMi0xLTEtMS0xNTk1NDA_dffb5a95-e891-48a9-a689-abb5c7e30b8f"
      unitRef="usd">76800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9da960751fa245d8bf93fa1681ead439_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN181Mi9mcmFnOmIxNmQ0YjlkMmM5MzQ4ODZiZjM3YTgxYThjM2FiODM0L3RhYmxlOjhjZDYxOTA4MTdlMjQ4NmM4ZDkyNzRhNWFjMzE5MzY0L3RhYmxlcmFuZ2U6OGNkNjE5MDgxN2UyNDg2YzhkOTI3NGE1YWMzMTkzNjRfMi0zLTEtMS0xNTk1NDA_c37672f7-0a32-4eec-a93a-db53ea961956"
      unitRef="usd">125600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6633f1ca883b4a32962bcd825ba66bfc_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN181Mi9mcmFnOmIxNmQ0YjlkMmM5MzQ4ODZiZjM3YTgxYThjM2FiODM0L3RhYmxlOjhjZDYxOTA4MTdlMjQ4NmM4ZDkyNzRhNWFjMzE5MzY0L3RhYmxlcmFuZ2U6OGNkNjE5MDgxN2UyNDg2YzhkOTI3NGE1YWMzMTkzNjRfMi01LTEtMS0xNTk1NDA_e0a86df6-6300-4357-90bd-48dc6a115ee0"
      unitRef="usd">235800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3a42a2407e7046519687e4401e714180_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN181Mi9mcmFnOmIxNmQ0YjlkMmM5MzQ4ODZiZjM3YTgxYThjM2FiODM0L3RhYmxlOjhjZDYxOTA4MTdlMjQ4NmM4ZDkyNzRhNWFjMzE5MzY0L3RhYmxlcmFuZ2U6OGNkNjE5MDgxN2UyNDg2YzhkOTI3NGE1YWMzMTkzNjRfMi03LTEtMS0xNTk1NDA_035251c1-2596-483b-bfe5-5ec2455ef786"
      unitRef="usd">340200000</us-gaap:Revenues>
    <lly:CollaborativeArrangementRightsAndObligationsRightsObligations
      contextRef="ic7d2b40b9fc943b9bfb247bb3c25f43f_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN181Mi9mcmFnOmIxNmQ0YjlkMmM5MzQ4ODZiZjM3YTgxYThjM2FiODM0L3RleHRyZWdpb246YjE2ZDRiOWQyYzkzNDg4NmJmMzdhODFhOGMzYWI4MzRfOTY3OQ_1dd06fe1-611c-4c8a-9fc1-0304b156891f"
      unitRef="usd">180000000</lly:CollaborativeArrangementRightsAndObligationsRightsObligations>
    <lly:CollaborativeArrangementRightsAndObligationsRightsObligations
      contextRef="id7f02cde7e1c419684772d2d99dda277_I20220930"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN181Mi9mcmFnOmIxNmQ0YjlkMmM5MzQ4ODZiZjM3YTgxYThjM2FiODM0L3RleHRyZWdpb246YjE2ZDRiOWQyYzkzNDg4NmJmMzdhODFhOGMzYWI4MzRfOTc4Mw_5b09a2e2-6a19-45bb-8c28-a89c6a5ad3d2"
      unitRef="usd">1030000000.00</lly:CollaborativeArrangementRightsAndObligationsRightsObligations>
    <lly:CollaborativeArrangementRightsAndObligationsRightsObligations
      contextRef="i9e48d839c4b14a2e953d735b3bb79f88_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN181Mi9mcmFnOmIxNmQ0YjlkMmM5MzQ4ODZiZjM3YTgxYThjM2FiODM0L3RleHRyZWdpb246YjE2ZDRiOWQyYzkzNDg4NmJmMzdhODFhOGMzYWI4MzRfMTAzOTY_abe0622e-8118-47c2-ae5e-fba10e22f7af"
      unitRef="usd">85000000</lly:CollaborativeArrangementRightsAndObligationsRightsObligations>
    <lly:CollaborativeArrangementRightsAndObligationsRightsObligations
      contextRef="id39a445d06074ecaa26735263645cb4e_I20220930"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN181Mi9mcmFnOmIxNmQ0YjlkMmM5MzQ4ODZiZjM3YTgxYThjM2FiODM0L3RleHRyZWdpb246YjE2ZDRiOWQyYzkzNDg4NmJmMzdhODFhOGMzYWI4MzRfMTA0OTQ_8f138dcc-b845-4cf3-b29f-ec17c2281664"
      unitRef="usd">1250000000</lly:CollaborativeArrangementRightsAndObligationsRightsObligations>
    <us-gaap:ContractWithCustomerLiability
      contextRef="iae28a429ac4b40e2a498a65c7eaaedc6_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN181Mi9mcmFnOmIxNmQ0YjlkMmM5MzQ4ODZiZjM3YTgxYThjM2FiODM0L3RleHRyZWdpb246YjE2ZDRiOWQyYzkzNDg4NmJmMzdhODFhOGMzYWI4MzRfMzI5ODUzNDg5NTkzNQ_ef166288-ac09-4915-b8a3-ff370612e89e"
      unitRef="usd">0</us-gaap:ContractWithCustomerLiability>
    <us-gaap:RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock
      contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN181OC9mcmFnOjdhMjU0OTU2YzMzNTQ1Y2Y4M2YzNGQyMTZiNzAwM2IyL3RleHRyZWdpb246N2EyNTQ5NTZjMzM1NDVjZjgzZjM0ZDIxNmI3MDAzYjJfMTQ1OQ_36fb74c1-3feb-4aa2-a9d1-776a73faf563">Asset Impairment, Restructuring, and Other Special Charges&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of the charges included in asset impairment, restructuring, and other special charges in our consolidated condensed statements of operations are described below. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.206%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Severance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset impairment and other special charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;206.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;206.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total asset impairment, restructuring, and other special charges&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;206.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;206.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;211.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Asset impairment, restructuring, and other special charges recognized during the three and nine months ended September 30, 2022 were primarily related to an intangible asset impairment for GBA1 Gene Therapy (PR001), acquired in the Prevail acquisition, as a result of changes in key assumptions used in the valuation due to delays in estimated launch timing.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Asset impairment, restructuring, and other special charges recognized during the nine months ended September&#160;30, 2021 were primarily related to an intangible asset impairment of $108.1&#160;million resulting from the sale of the rights to Qbrexza&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, as well as acquisition and integration costs associated with the acquisition of Prevail. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognized a net inventory impairment charge related to our COVID-19 antibodies of $435.1&#160;million during the nine months ended September&#160;30, 2021 in cost of sales in our consolidated condensed statements of operations. As part of our response to the COVID-19 pandemic, and at the request of the U.S. and international governments, we invested in large-scale manufacturing of COVID-19 antibodies at risk, in order to ensure rapid access to patients around the world. As the COVID-19 pandemic evolved during 2021, we incurred a net inventory impairment charge primarily due to the combination of changes to demand from U.S. and international governments, including changes to our agreement with the U.S. government, and near-term expiry dates of COVID-19 antibodies.&lt;/span&gt;&lt;/div&gt;</us-gaap:RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock
      contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN181OC9mcmFnOjdhMjU0OTU2YzMzNTQ1Y2Y4M2YzNGQyMTZiNzAwM2IyL3RleHRyZWdpb246N2EyNTQ5NTZjMzM1NDVjZjgzZjM0ZDIxNmI3MDAzYjJfMTQ2Mw_30eb621b-b403-49a9-b4f2-cf6793535fbf">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of the charges included in asset impairment, restructuring, and other special charges in our consolidated condensed statements of operations are described below. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.206%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Severance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset impairment and other special charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;206.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;206.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total asset impairment, restructuring, and other special charges&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;206.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;206.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;211.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock>
    <us-gaap:SeveranceCosts1
      contextRef="i19fc0325c48543008ea71e1fdcf11d86_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN181OC9mcmFnOjdhMjU0OTU2YzMzNTQ1Y2Y4M2YzNGQyMTZiNzAwM2IyL3RhYmxlOjMzZWJjYzY5ZmUzMzQ5Njc4OTEwNTYwMGIxODAxOTNhL3RhYmxlcmFuZ2U6MzNlYmNjNjlmZTMzNDk2Nzg5MTA1NjAwYjE4MDE5M2FfMi0xLTEtMS0xNTk1NDA_380697ba-892c-49de-98d4-b56752660ac8"
      unitRef="usd">0</us-gaap:SeveranceCosts1>
    <us-gaap:SeveranceCosts1
      contextRef="ie4fa4f6b472a4f269297591b44aba572_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN181OC9mcmFnOjdhMjU0OTU2YzMzNTQ1Y2Y4M2YzNGQyMTZiNzAwM2IyL3RhYmxlOjMzZWJjYzY5ZmUzMzQ5Njc4OTEwNTYwMGIxODAxOTNhL3RhYmxlcmFuZ2U6MzNlYmNjNjlmZTMzNDk2Nzg5MTA1NjAwYjE4MDE5M2FfMi0zLTEtMS0xNTk1NDA_2782df8a-3172-459a-a984-388835739f8e"
      unitRef="usd">0</us-gaap:SeveranceCosts1>
    <us-gaap:SeveranceCosts1
      contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN181OC9mcmFnOjdhMjU0OTU2YzMzNTQ1Y2Y4M2YzNGQyMTZiNzAwM2IyL3RhYmxlOjMzZWJjYzY5ZmUzMzQ5Njc4OTEwNTYwMGIxODAxOTNhL3RhYmxlcmFuZ2U6MzNlYmNjNjlmZTMzNDk2Nzg5MTA1NjAwYjE4MDE5M2FfMi01LTEtMS0xNTk1NDA_4961dac5-007a-46db-9323-8f4e563cee79"
      unitRef="usd">0</us-gaap:SeveranceCosts1>
    <us-gaap:SeveranceCosts1
      contextRef="i167ed8f67bef48c49e54fa466400cdaa_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN181OC9mcmFnOjdhMjU0OTU2YzMzNTQ1Y2Y4M2YzNGQyMTZiNzAwM2IyL3RhYmxlOjMzZWJjYzY5ZmUzMzQ5Njc4OTEwNTYwMGIxODAxOTNhL3RhYmxlcmFuZ2U6MzNlYmNjNjlmZTMzNDk2Nzg5MTA1NjAwYjE4MDE5M2FfMi03LTEtMS0xNTk1NDA_d03c8e32-2bdd-4e53-a743-aa601fb53597"
      unitRef="usd">11500000</us-gaap:SeveranceCosts1>
    <lly:AssetImpairmentChargesRecoveriesAndOtherSpecialCharges
      contextRef="i19fc0325c48543008ea71e1fdcf11d86_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN181OC9mcmFnOjdhMjU0OTU2YzMzNTQ1Y2Y4M2YzNGQyMTZiNzAwM2IyL3RhYmxlOjMzZWJjYzY5ZmUzMzQ5Njc4OTEwNTYwMGIxODAxOTNhL3RhYmxlcmFuZ2U6MzNlYmNjNjlmZTMzNDk2Nzg5MTA1NjAwYjE4MDE5M2FfMy0xLTEtMS0xNTk1NDA_c701641e-aa73-4776-9ea8-73bd44204eeb"
      unitRef="usd">206500000</lly:AssetImpairmentChargesRecoveriesAndOtherSpecialCharges>
    <lly:AssetImpairmentChargesRecoveriesAndOtherSpecialCharges
      contextRef="ie4fa4f6b472a4f269297591b44aba572_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN181OC9mcmFnOjdhMjU0OTU2YzMzNTQ1Y2Y4M2YzNGQyMTZiNzAwM2IyL3RhYmxlOjMzZWJjYzY5ZmUzMzQ5Njc4OTEwNTYwMGIxODAxOTNhL3RhYmxlcmFuZ2U6MzNlYmNjNjlmZTMzNDk2Nzg5MTA1NjAwYjE4MDE5M2FfMy0zLTEtMS0xNTk1NDA_38836c07-2dc0-4a68-96b1-789c0ddce6d4"
      unitRef="usd">0</lly:AssetImpairmentChargesRecoveriesAndOtherSpecialCharges>
    <lly:AssetImpairmentChargesRecoveriesAndOtherSpecialCharges
      contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN181OC9mcmFnOjdhMjU0OTU2YzMzNTQ1Y2Y4M2YzNGQyMTZiNzAwM2IyL3RhYmxlOjMzZWJjYzY5ZmUzMzQ5Njc4OTEwNTYwMGIxODAxOTNhL3RhYmxlcmFuZ2U6MzNlYmNjNjlmZTMzNDk2Nzg5MTA1NjAwYjE4MDE5M2FfMy01LTEtMS0xNTk1NDA_4a7fc6a4-00eb-48e0-9be6-7541e73b4e57"
      unitRef="usd">206500000</lly:AssetImpairmentChargesRecoveriesAndOtherSpecialCharges>
    <lly:AssetImpairmentChargesRecoveriesAndOtherSpecialCharges
      contextRef="i167ed8f67bef48c49e54fa466400cdaa_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN181OC9mcmFnOjdhMjU0OTU2YzMzNTQ1Y2Y4M2YzNGQyMTZiNzAwM2IyL3RhYmxlOjMzZWJjYzY5ZmUzMzQ5Njc4OTEwNTYwMGIxODAxOTNhL3RhYmxlcmFuZ2U6MzNlYmNjNjlmZTMzNDk2Nzg5MTA1NjAwYjE4MDE5M2FfMy03LTEtMS0xNTk1NDA_22f520ff-4c8a-4171-8bec-3ed929512e3f"
      unitRef="usd">200100000</lly:AssetImpairmentChargesRecoveriesAndOtherSpecialCharges>
    <us-gaap:RestructuringSettlementAndImpairmentProvisions
      contextRef="i19fc0325c48543008ea71e1fdcf11d86_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN181OC9mcmFnOjdhMjU0OTU2YzMzNTQ1Y2Y4M2YzNGQyMTZiNzAwM2IyL3RhYmxlOjMzZWJjYzY5ZmUzMzQ5Njc4OTEwNTYwMGIxODAxOTNhL3RhYmxlcmFuZ2U6MzNlYmNjNjlmZTMzNDk2Nzg5MTA1NjAwYjE4MDE5M2FfNC0xLTEtMS0xNTk1NDA_871cfb58-2491-43dc-b184-34f9c6cf822b"
      unitRef="usd">206500000</us-gaap:RestructuringSettlementAndImpairmentProvisions>
    <us-gaap:RestructuringSettlementAndImpairmentProvisions
      contextRef="ie4fa4f6b472a4f269297591b44aba572_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN181OC9mcmFnOjdhMjU0OTU2YzMzNTQ1Y2Y4M2YzNGQyMTZiNzAwM2IyL3RhYmxlOjMzZWJjYzY5ZmUzMzQ5Njc4OTEwNTYwMGIxODAxOTNhL3RhYmxlcmFuZ2U6MzNlYmNjNjlmZTMzNDk2Nzg5MTA1NjAwYjE4MDE5M2FfNC0zLTEtMS0xNTk1NDA_440c64be-a839-43d8-afea-b5abbee97a08"
      unitRef="usd">0</us-gaap:RestructuringSettlementAndImpairmentProvisions>
    <us-gaap:RestructuringSettlementAndImpairmentProvisions
      contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN181OC9mcmFnOjdhMjU0OTU2YzMzNTQ1Y2Y4M2YzNGQyMTZiNzAwM2IyL3RhYmxlOjMzZWJjYzY5ZmUzMzQ5Njc4OTEwNTYwMGIxODAxOTNhL3RhYmxlcmFuZ2U6MzNlYmNjNjlmZTMzNDk2Nzg5MTA1NjAwYjE4MDE5M2FfNC01LTEtMS0xNTk1NDA_3d999b88-4ddd-4fb1-bbaa-a10090f42bea"
      unitRef="usd">206500000</us-gaap:RestructuringSettlementAndImpairmentProvisions>
    <us-gaap:RestructuringSettlementAndImpairmentProvisions
      contextRef="i167ed8f67bef48c49e54fa466400cdaa_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN181OC9mcmFnOjdhMjU0OTU2YzMzNTQ1Y2Y4M2YzNGQyMTZiNzAwM2IyL3RhYmxlOjMzZWJjYzY5ZmUzMzQ5Njc4OTEwNTYwMGIxODAxOTNhL3RhYmxlcmFuZ2U6MzNlYmNjNjlmZTMzNDk2Nzg5MTA1NjAwYjE4MDE5M2FfNC03LTEtMS0xNTk1NDA_6408657e-186f-4757-bc29-234f3692c156"
      unitRef="usd">211600000</us-gaap:RestructuringSettlementAndImpairmentProvisions>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="i167ed8f67bef48c49e54fa466400cdaa_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN181OC9mcmFnOjdhMjU0OTU2YzMzNTQ1Y2Y4M2YzNGQyMTZiNzAwM2IyL3RleHRyZWdpb246N2EyNTQ5NTZjMzM1NDVjZjgzZjM0ZDIxNmI3MDAzYjJfNTUy_a6a138de-a385-482a-9695-61f4d5e3e137"
      unitRef="usd">108100000</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:InventoryWriteDown
      contextRef="i167ed8f67bef48c49e54fa466400cdaa_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN181OC9mcmFnOjdhMjU0OTU2YzMzNTQ1Y2Y4M2YzNGQyMTZiNzAwM2IyL3RleHRyZWdpb246N2EyNTQ5NTZjMzM1NDVjZjgzZjM0ZDIxNmI3MDAzYjJfMzI5ODUzNDg5MTA1NQ_588cbba9-1f4c-4fa0-bc05-1cf0e9111c12"
      unitRef="usd">435100000</us-gaap:InventoryWriteDown>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RleHRyZWdpb246OGRmOTEwZDdhYjFhNDFmMThlODU5ZTE4OTQxY2E4MDhfMTUxNjc_c5b9d29e-47f2-4819-a809-42a93bda0875">Financial Instruments&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially subject us to credit risk consist principally of trade receivables and interest-bearing investments. Wholesale distributors of life science products account for a substantial portion of our trade receivables; collateral is generally not required. We seek to mitigate the risk associated with this concentration through our ongoing credit-review procedures and insurance. A large portion of our cash is held by a few major financial institutions. We monitor our exposures with these institutions and do not expect any of these institutions to fail to meet their obligations. In accordance with documented corporate risk-management policies, we monitor the amount of credit exposure to any one financial institution or corporate issuer. We are exposed to credit-related losses in the event of nonperformance by counterparties to risk-management instruments but do not expect any counterparties to fail to meet their obligations given their investment grade credit ratings.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We consider all highly liquid investments with a maturity of three months or less from the date of purchase to be cash equivalents. The cost of these investments approximates fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our equity investments are accounted for using three different methods depending on the type of equity investment:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Investments in companies over which we have significant influence but not a controlling interest are accounted for using the equity method, with our share of earnings or losses reported in other-net, (income) expense. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;For equity investments that do not have readily determinable fair values, we measure these investments at cost, less any impairment, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investment of the same issuer. Any change in recorded value is recorded in other-net, (income) expense. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Our public equity investments are measured and carried at fair value. Any change in fair value is recognized in other-net, (income) expense. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We review equity investments other than public equity investments for indications of impairment and observable price changes on a regular basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our derivative activities are initiated within the guidelines of documented corporate risk-management policies and are intended to offset losses and gains on the assets, liabilities, and transactions being hedged. Management reviews the correlation and effectiveness of our derivatives on a quarterly basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For derivative instruments that are designated and qualify as fair value hedges, the derivative instrument is marked to market, with gains and losses recognized currently in income to offset the respective losses and gains recognized on the underlying exposure. For derivative instruments that are designated and qualify as cash flow hedges, gains and losses are reported as a component of accumulated other comprehensive loss and reclassified into earnings in the same period the hedged transaction affects earnings. For derivative and non-derivative instruments that are designated and qualify as net investment hedges, the foreign currency translation gains or losses due to spot rate fluctuations are reported as a component of accumulated other comprehensive loss. Derivative contracts that are not designated as hedging instruments are recorded at fair value with the gain or loss recognized in earnings during the period of change.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We may enter into foreign currency forward or option contracts to reduce the effect of fluctuating currency exchange rates (principally the euro, British pound, Chinese yuan, and Japanese yen). Foreign currency derivatives used for hedging are put in place using the same or like currencies and duration as the underlying exposures. Forward and option contracts are principally used to manage exposures arising from subsidiary trade and loan payables and receivables denominated in foreign currencies. These contracts are recorded at fair value with the gain or loss recognized in other&#x2013;net, (income) expense. We may enter into foreign currency forward and option contracts and currency swaps as fair value hedges of firm commitments. Forward contracts generally have maturities not exceeding 12 months. At September&#160;30, 2022, we had outstanding foreign currency forward commitments to purchase 1.69 billion U.S. dollars and sell 1.71 billion euro; commitments to purchase 2.24 billion euro and sell 2.24&#160;billion U.S. dollars; commitments to purchase 239.5 million U.S. dollars and sell 1.63 billion Chinese yuan; commitments to purchase 82.1&#160;million U.S. dollars and sell 11.86 billion Japanese yen; and commitments to purchase 182.1 million British pounds and sell 206.9&#160;million U.S. dollars, which all have settlement dates within 180 days.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Foreign currency exchange risk is also managed through the use of foreign currency debt, cross-currency interest rate swaps, and foreign currency forward contracts. Our foreign currency-denominated notes had carrying amounts of $6.23 billion and $7.90&#160;billion as of September&#160;30, 2022 and December&#160;31, 2021, respectively, of which $4.94&#160;billion and $5.79 billion have been designated as, and are effective as, economic hedges of net investments in certain of our foreign operations as of September&#160;30, 2022 and December&#160;31, 2021, respectively. At September&#160;30, 2022, we had outstanding cross-currency swaps with notional amounts of $1.56 billion swapping U.S. dollars to euro and $1.00&#160;billion swapping Swiss francs to U.S. dollars which have settlement dates ranging through 2028. Our cross-currency interest rate swaps, for which a majority convert a portion of our U.S. dollar-denominated fixed-rate debt to foreign-denominated fixed-rate debt, have also been designated as, and are effective as, economic hedges of net investments. At September&#160;30, 2022, we had outstanding foreign currency forward contracts to sell 1.34 billion euro with settlement dates ranging through 2023, which have been designated as, and are effective as, economic hedges of net investments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the normal course of business, our operations are exposed to fluctuations in interest rates which can vary the costs of financing, investing, and operating. We seek to address a portion of these risks through a controlled program of risk management that includes the use of derivative financial instruments. The objective of controlling these risks is to limit the impact of fluctuations in interest rates on earnings. Our primary interest-rate risk exposure results from changes in short-term U.S. dollar interest rates. In an effort to manage interest-rate exposures, we strive to achieve an acceptable balance between fixed- and floating-rate debt and investment positions and may enter into interest rate swaps or collars to help maintain that balance.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest rate swaps or collars that convert our fixed-rate debt to a floating rate are designated as fair value hedges of the underlying instruments. Interest rate swaps or collars that convert floating-rate debt to a fixed rate are designated as cash flow hedges. Interest expense on the debt is adjusted to include the payments made or received under the swap agreements. Cash proceeds from or payments to counterparties resulting from the termination of interest rate swaps are classified as operating activities in our consolidated condensed statements of cash flows. At September&#160;30, 2022, substantially all of our total long-term debt is at a fixed rate. We have converted approximately 10 percent of our long-term fixed-rate notes to floating rates through the use of interest rate swaps.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We also may enter into forward-starting interest rate swaps, which we designate as cash flow hedges, as part of any anticipated future debt issuances in order to reduce the risk of cash flow volatility from future changes in interest rates. The change in fair value of these instruments is recorded as part of other comprehensive income (loss) and, upon completion of a debt issuance and termination of the swap, is amortized to interest expense over the life of the underlying debt. As of September&#160;30, 2022, the total notional amounts of forward-starting interest rate contracts in designated cash flow hedging instruments were $1.75 billion, which have settlement dates ranging between 2023 and 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effective September 15, 2022, we increased our 364-day credit facility from $2.00&#160;billion to $4.00&#160;billion, which will expire in September 2023, and is available to support our commercial paper program. We have not drawn against the $4.00&#160;billion 364-day credit facility as of September 30, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2021, we issued euro-denominated notes consisting of &#x20ac;600.0&#160;million of 0.50 percent fixed-rate notes due in September 2033, with interest to be paid annually. The net proceeds from the offering have been, and will continue to be, used to fund, in whole or in part, eligible projects designed to advance one or more of our environmental, social, and governance objectives.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2021, we issued euro-denominated notes consisting of &#x20ac;500.0&#160;million of 1.125 percent fixed-rate notes due in September 2051 and &#x20ac;700.0&#160;million of 1.375 percent fixed-rate notes due in September 2061, with interest to be paid annually, and British pound-denominated notes consisting of &#xa3;250.0&#160;million of 1.625 percent fixed-rate notes due in September 2043, with interest to be paid annually. We paid $1.91&#160;billion of the net cash proceeds from the offering to purchase and redeem certain higher interest rate U.S. dollar-denominated notes with an aggregate principal amount of $1.50&#160;billion, resulting in a debt extinguishment loss of $405.2&#160;million. This loss was included in other net, (income) expense in our consolidated condensed statement of operations during the three and nine months ended September 30, 2021. The $1.50&#160;billion principal amount of higher interest rate U.S. dollar-denominated notes that were redeemed primarily included $541.8&#160;million of 3.95 percent notes due 2049, $408.7&#160;million of 4.15 percent notes due 2059, and $219.4&#160;million of 3.375 percent notes due 2029. We used the remaining net proceeds from the offering to prefund certain 2022 debt maturities and for general corporate purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;The Effect of Risk-Management Instruments on the Consolidated Condensed Statements of Operations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following effects of risk-management instruments were recognized in other&#x2013;net, (income) expense:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.800%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.157%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.157%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.157%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.160%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effect from hedged fixed-rate debt&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(62.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(215.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(60.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effect from interest rate contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;62.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;215.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash flow hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effective portion of losses on interest rate contracts reclassified from accumulated other comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;12.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;33.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;75.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net (gains) losses on foreign currency exchange contracts not designated as hedging instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;129.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;280.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;166.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;368.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;181.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three and nine months ended September&#160;30, 2022 and 2021, the amortization of losses related to the portion of our risk management hedging instruments, fair value hedges, and cash flow hedges that was excluded from the assessment of effectiveness was not material.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;The Effect of Risk-Management Instruments on Other Comprehensive Income (Loss)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The effective portion of risk-management instruments that was recognized in other comprehensive income (loss) is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.206%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net investment hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency-denominated notes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;435.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;822.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;268.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;92.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;171.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;170.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency forward contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;107.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;121.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash flow hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forward-starting interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;57.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;337.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;149.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;19.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;38.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the next 12&#160;months, we expect to reclassify $16.7&#160;million of pretax net losses on cash flow hedges from accumulated other comprehensive loss to other&#x2013;net, (income) expense. During the three and nine months ended September&#160;30, 2022 and 2021, the amounts excluded from the assessment of hedge effectiveness recognized in other comprehensive income (loss) were not material.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize certain fair value information at September&#160;30, 2022 and December&#160;31, 2021 for assets and liabilities measured at fair value on a recurring basis, as well as the carrying amount and amortized cost of certain other investments:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.466%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.714%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements Using&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted Prices in Active Markets for Identical Assets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant Other&lt;br/&gt;Observable Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,246.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,246.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,239.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;7.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,246.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Short-term investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. government and agency securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;43.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;43.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;43.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;43.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;51.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;51.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;51.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;51.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;3.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;3.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;3.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;3.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;27.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;27.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;14.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;12.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;27.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;124.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Noncurrent investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. government and agency securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;131.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;148.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;131.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;131.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;206.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;232.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;206.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;206.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;143.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;156.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;143.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;143.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;43.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;45.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;43.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;43.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;152.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;96.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;39.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;113.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;152.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;549.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;416.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;549.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;549.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Equity investments without readily determinable fair values&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;583.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Equity method investments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;764.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Noncurrent investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2,574.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,379.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,379.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,361.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,379.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Short-term investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. government and agency securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;43.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;43.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;43.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;43.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;90.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Noncurrent investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. government and agency securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;137.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;136.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;137.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;137.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;235.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;232.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;235.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;235.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;109.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;108.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;109.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;109.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;108.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;108.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;108.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,279.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;487.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,279.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,279.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Equity investments without readily determinable fair values&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;548.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Equity method investments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;771.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Noncurrent investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,212.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;For available-for-sale debt securities, amounts disclosed represent the securities' amortized cost.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Fair value disclosures are not applicable for equity method investments and investments accounted for under the measurement alternative for equity investments.&lt;/span&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.320%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.320%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.320%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.320%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.322%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements Using&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted Prices in Active Markets for Identical Assets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Other Observable Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Short-term commercial paper borrowings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(1,741.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(1,738.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(1,738.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Long-term debt, including current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(14,147.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(11,848.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(11,848.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16,884.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18,157.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18,157.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.517%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.517%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.517%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.517%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements Using&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted Prices in Active Markets for Identical Assets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Other Observable Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Risk-management instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest rate contracts designated as fair value hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other noncurrent liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(140.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(140.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(140.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest rate contracts designated as cash flow hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;355.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;355.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;355.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cross-currency interest rate contracts designated as net investment hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;81.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;81.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;81.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;116.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;116.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;116.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cross-currency interest rate contracts designated as cash flow hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;8.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;8.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;8.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other noncurrent liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(12.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(12.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(12.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts designated as net investment hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;108.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;108.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;108.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(2.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(2.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(2.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts not designated as hedging instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;48.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;48.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;48.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(93.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(93.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(93.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Contingent consideration liability:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other noncurrent liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(42.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(42.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(42.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Risk-management instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest rate contracts designated as fair value hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other receivables&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;78.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;78.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;78.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other noncurrent liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(7.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(7.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(7.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest rate contracts designated as cash flow hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;49.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;49.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;49.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other noncurrent liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(31.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(31.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(31.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cross-currency interest rate contracts designated as net investment hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;31.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;31.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;31.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cross-currency interest rate contracts designated as cash flow hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;33.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;33.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;33.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other noncurrent liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts not designated as hedging instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(35.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(35.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(35.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Contingent consideration liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other noncurrent liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(70.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(70.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(70.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Risk-management instruments above are disclosed on a gross basis. There are various rights of setoff associated with certain of the risk-management instruments above that are subject to enforceable master netting arrangements or similar agreements. Although various rights of setoff and master netting arrangements or similar agreements may exist with the individual counterparties to the risk-management instruments above, individually, these financial rights are not material.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We determine our Level 1 and Level 2 fair value measurements based on a market approach using quoted market values, significant other observable inputs for identical or comparable assets or liabilities, or discounted cash flow analyses. Level 3 fair value measurements for other investment securities are determined using unobservable inputs, including the investments' cost adjusted for impairments and price changes from orderly transactions. Fair values are not readily available for certain equity investments measured under the measurement alternative. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2022, we had approximately $854 million of unfunded commitments to invest in venture capital funds, which we anticipate will be paid over a period of up to 10 years. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contingent consideration liability relates to our liability arising in connection with the CVR issued as a result of the Prevail acquisition. The fair value of the CVR liability was estimated using a discounted cash flow analysis and Level 3 inputs, including projections representative of a market participant's view of the expected cash payment associated with the first potential regulatory approval of a Prevail compound in the applicable countries based on probabilities of technical success, timing of the potential approval events for the compounds, and an estimated discount rate. See Note 3 for additional information related to the CVR arrangement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below summarizes the contractual maturities of our investments in debt securities measured at fair value as of September&#160;30, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.162%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.060%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.060%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.060%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.060%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.062%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Maturities by Period&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Less&#160;Than&lt;br/&gt;1 Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1-5&lt;br/&gt;Years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;6-10&lt;br/&gt;Years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;More&#160;Than&lt;br/&gt;10 Years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;622.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;197.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;205.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The net gains (losses) recognized in our consolidated condensed statements of operations for equity securities were $(123.3)&#160;million and $(667.6)&#160;million for the three and nine months ended September&#160;30, 2022, respectively, and $(246.8)&#160;million and $270.1&#160;million for the three and nine months ended September&#160;30, 2021, respectively. The net gains (losses) recognized for the three and nine months ended September&#160;30, 2022 and 2021 on equity securities sold during the respective periods were not material.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We adjust our equity investments without readily determinable fair values based upon changes in the equity instruments' values resulting from observable price changes in orderly transactions for an identical or similar investment of the same issuer. Downward adjustments resulting from an impairment are recorded based upon impairment considerations, including the financial condition and near term prospects of the issuer, general market conditions, and industry specific factors. Adjustments recorded for the three and nine months ended September&#160;30, 2022 and 2021 were not material.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the amount of unrealized gains and losses in accumulated other comprehensive loss and the fair value of available-for-sale securities in an unrealized gain or loss position follows:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.249%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.859%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.860%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrealized gross gains&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrealized gross losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;51.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of securities in an unrealized gain position&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;13.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;250.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of securities in an unrealized loss position&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;578.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;290.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We periodically assess our investment in available-for-sale securities for impairment losses and credit losses. The amount of credit losses are determined by comparing the difference between the present value of future cash flows expected to be collected on these securities and the amortized cost. Factors considered in assessing credit losses include the position in the capital structure, vintage and amount of collateral, delinquency rates, current credit support, and geographic concentration. Impairment and credit losses related to available-for-sale securities were not material for the three and nine months ended September&#160;30, 2022 and 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2022, the available-for-sale securities in an unrealized loss position include primarily fixed-rate debt securities of varying maturities, which are sensitive to changes in the yield curve and other market conditions. Approximately 95 percent&#160;of the fixed-rate debt securities in a loss position are investment-grade debt securities. As of September&#160;30, 2022, we do not intend to sell, and it is not more likely than not that we will be required to sell, the securities in a loss position before the market values recover or the underlying cash flows have been received, and there is no indication of a material default on interest or principal payments for our debt securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Activity related to our available-for-sale securities was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.206%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Proceeds from sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;50.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;115.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;137.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Realized gross gains on sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;0.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Realized gross losses on sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;7.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;9.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Realized gains and losses on sales of available-for-sale investments are computed based upon specific identification of the initial cost adjusted for any other-than-temporary declines in fair value that were recorded in earnings.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accounts Receivable Factoring Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have entered into accounts receivable factoring agreements with financial institutions to sell certain of our non-U.S. accounts receivable. These transactions are accounted for as sales and result in a reduction in accounts receivable because the agreements transfer effective control over, and risk related to, the receivables to the buyers. Our factoring agreements do not allow for recourse in the event of uncollectibility, and we do not retain any interest in the underlying accounts receivable once sold. We derecognized $356.8 million and $550.5 million&#160;of accounts receivable as of September&#160;30, 2022 and December&#160;31, 2021, respectively, under these factoring arrangements. The costs of factoring such accounts receivable on our consolidated condensed results of operations for the three and nine months ended September&#160;30, 2022 and 2021&#160;were&#160;not material.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:DerivativesPolicyTextBlock
      contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RleHRyZWdpb246OGRmOTEwZDdhYjFhNDFmMThlODU5ZTE4OTQxY2E4MDhfMTUxNzM_083e67c0-6517-4e27-bc90-3f30344102df">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our derivative activities are initiated within the guidelines of documented corporate risk-management policies and are intended to offset losses and gains on the assets, liabilities, and transactions being hedged. Management reviews the correlation and effectiveness of our derivatives on a quarterly basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For derivative instruments that are designated and qualify as fair value hedges, the derivative instrument is marked to market, with gains and losses recognized currently in income to offset the respective losses and gains recognized on the underlying exposure. For derivative instruments that are designated and qualify as cash flow hedges, gains and losses are reported as a component of accumulated other comprehensive loss and reclassified into earnings in the same period the hedged transaction affects earnings. For derivative and non-derivative instruments that are designated and qualify as net investment hedges, the foreign currency translation gains or losses due to spot rate fluctuations are reported as a component of accumulated other comprehensive loss. Derivative contracts that are not designated as hedging instruments are recorded at fair value with the gain or loss recognized in earnings during the period of change.&lt;/span&gt;&lt;/div&gt;We may enter into foreign currency forward or option contracts to reduce the effect of fluctuating currency exchange rates (principally the euro, British pound, Chinese yuan, and Japanese yen). Foreign currency derivatives used for hedging are put in place using the same or like currencies and duration as the underlying exposures. Forward and option contracts are principally used to manage exposures arising from subsidiary trade and loan payables and receivables denominated in foreign currencies. These contracts are recorded at fair value with the gain or loss recognized in other&#x2013;net, (income) expense. We may enter into foreign currency forward and option contracts and currency swaps as fair value hedges of firm commitments. Forward contracts generally have maturities not exceeding 12 months.</us-gaap:DerivativesPolicyTextBlock>
    <us-gaap:DerivativeLiabilityNotionalAmount
      contextRef="id7a3c615db604cd2baec39887078a8e2_I20220930"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RleHRyZWdpb246OGRmOTEwZDdhYjFhNDFmMThlODU5ZTE4OTQxY2E4MDhfNDQyOQ_a74c6b7d-e01b-4fff-899d-93fdfa5fcc31"
      unitRef="usd">1690000000</us-gaap:DerivativeLiabilityNotionalAmount>
    <us-gaap:DerivativeAssetNotionalAmount
      contextRef="id7a3c615db604cd2baec39887078a8e2_I20220930"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RleHRyZWdpb246OGRmOTEwZDdhYjFhNDFmMThlODU5ZTE4OTQxY2E4MDhfNDQ1NA_10b3bc07-0b02-4799-8b4e-6c7ea350c6d4"
      unitRef="eur">1710000000</us-gaap:DerivativeAssetNotionalAmount>
    <us-gaap:DerivativeLiabilityNotionalAmount
      contextRef="icbc49bb61efe4f65ba8c0e7f0093e86a_I20220930"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RleHRyZWdpb246OGRmOTEwZDdhYjFhNDFmMThlODU5ZTE4OTQxY2E4MDhfNDQ4Nw_cc0d41a1-e5b0-4b89-8ece-06b439ee1596"
      unitRef="eur">2240000000</us-gaap:DerivativeLiabilityNotionalAmount>
    <us-gaap:DerivativeAssetNotionalAmount
      contextRef="icbc49bb61efe4f65ba8c0e7f0093e86a_I20220930"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RleHRyZWdpb246OGRmOTEwZDdhYjFhNDFmMThlODU5ZTE4OTQxY2E4MDhfNDUwNA_bf5baa84-61a7-4aa3-943a-cdb2b32ef617"
      unitRef="usd">2240000000</us-gaap:DerivativeAssetNotionalAmount>
    <us-gaap:DerivativeLiabilityNotionalAmount
      contextRef="i77c728fb616a42cc8c6b40e0bbdd95d4_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RleHRyZWdpb246OGRmOTEwZDdhYjFhNDFmMThlODU5ZTE4OTQxY2E4MDhfNDU0NQ_0c46b301-a1d9-4ac4-9236-2758227b2a36"
      unitRef="usd">239500000</us-gaap:DerivativeLiabilityNotionalAmount>
    <us-gaap:DerivativeAssetNotionalAmount
      contextRef="i77c728fb616a42cc8c6b40e0bbdd95d4_I20220930"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RleHRyZWdpb246OGRmOTEwZDdhYjFhNDFmMThlODU5ZTE4OTQxY2E4MDhfNDU3MA_2954e008-0049-4aed-a058-ca48833de239"
      unitRef="cny">1630000000</us-gaap:DerivativeAssetNotionalAmount>
    <us-gaap:DerivativeLiabilityNotionalAmount
      contextRef="i80a649fe7dd9480994358ed2532d905d_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RleHRyZWdpb246OGRmOTEwZDdhYjFhNDFmMThlODU5ZTE4OTQxY2E4MDhfNDYxMQ_b5308860-f970-4a43-a307-7417551accf7"
      unitRef="usd">82100000</us-gaap:DerivativeLiabilityNotionalAmount>
    <us-gaap:DerivativeAssetNotionalAmount
      contextRef="i80a649fe7dd9480994358ed2532d905d_I20220930"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RleHRyZWdpb246OGRmOTEwZDdhYjFhNDFmMThlODU5ZTE4OTQxY2E4MDhfNDYzNg_78be03b4-0d03-4ba4-9113-d2d8ea320b6c"
      unitRef="jpy">11860000000</us-gaap:DerivativeAssetNotionalAmount>
    <us-gaap:DerivativeLiabilityNotionalAmount
      contextRef="i04bcb23b9ae84c9c9a64aca2a3cc4a34_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RleHRyZWdpb246OGRmOTEwZDdhYjFhNDFmMThlODU5ZTE4OTQxY2E4MDhfNDY4MQ_0ba8459b-6759-4c70-a770-bcdcd8d741e8"
      unitRef="gbp">182100000</us-gaap:DerivativeLiabilityNotionalAmount>
    <us-gaap:DerivativeAssetNotionalAmount
      contextRef="i04bcb23b9ae84c9c9a64aca2a3cc4a34_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RleHRyZWdpb246OGRmOTEwZDdhYjFhNDFmMThlODU5ZTE4OTQxY2E4MDhfNDcwOA_cc4644b0-58d3-42a5-8ae5-aae578f05aff"
      unitRef="usd">206900000</us-gaap:DerivativeAssetNotionalAmount>
    <us-gaap:MaximumRemainingMaturityOfForeignCurrencyDerivatives1
      contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RleHRyZWdpb246OGRmOTEwZDdhYjFhNDFmMThlODU5ZTE4OTQxY2E4MDhfNDc2NA_a682fe0f-96b5-453c-9736-9aab3a483f2d">P180D</us-gaap:MaximumRemainingMaturityOfForeignCurrencyDerivatives1>
    <us-gaap:LongTermDebt
      contextRef="ifd62109e29474416b9bd4cb46c68e40f_I20220930"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RleHRyZWdpb246OGRmOTEwZDdhYjFhNDFmMThlODU5ZTE4OTQxY2E4MDhfNDk5Ng_1f3244f1-a7d5-4d3a-aae9-770af8f74064"
      unitRef="usd">6230000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i9e675ec6e62d42a9bc9b9a5e61226095_I20211231"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RleHRyZWdpb246OGRmOTEwZDdhYjFhNDFmMThlODU5ZTE4OTQxY2E4MDhfNTAwMw_b5fb8667-238a-4aba-bc32-b45eabce2aa6"
      unitRef="usd">7900000000</us-gaap:LongTermDebt>
    <us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTax
      contextRef="i08ccb35f6ad24d7793c9c91b74ca2ea1_I20220930"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RleHRyZWdpb246OGRmOTEwZDdhYjFhNDFmMThlODU5ZTE4OTQxY2E4MDhfNTA0Ng_b8b0af48-04d0-4d19-90be-7b2c8e0c91c9"
      unitRef="usd">4940000000</us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTax>
    <us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTax
      contextRef="i0973ba0c1d894ceaa494709a13f814fb_I20211231"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RleHRyZWdpb246OGRmOTEwZDdhYjFhNDFmMThlODU5ZTE4OTQxY2E4MDhfNTA1Mw_02423f90-bbe6-4b31-b670-0b1665f70c3a"
      unitRef="usd">5790000000</us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTax>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i5b6a7a49e6b543c7a9c9f34217259d0f_I20220930"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RleHRyZWdpb246OGRmOTEwZDdhYjFhNDFmMThlODU5ZTE4OTQxY2E4MDhfNTI3OA_343b1e68-7452-4b3a-844c-c8ec49513718"
      unitRef="usd">1560000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i5f4cbed09a8d4efbba96a84a21c4f229_I20220930"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RleHRyZWdpb246OGRmOTEwZDdhYjFhNDFmMThlODU5ZTE4OTQxY2E4MDhfNTMxNQ_cfa93c94-d8df-479c-aa9c-0481091d5af0"
      unitRef="usd">1000000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeAssetNotionalAmount
      contextRef="i223b03ef72744bd2b0b10b131126e63e_I20220930"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RleHRyZWdpb246OGRmOTEwZDdhYjFhNDFmMThlODU5ZTE4OTQxY2E4MDhfNTcyOQ_fa195d7c-17a4-46ce-badc-403e77c1c4af"
      unitRef="eur">1340000000</us-gaap:DerivativeAssetNotionalAmount>
    <lly:DescriptionOfDerivativeActivityVolumePercent
      contextRef="i08ccb35f6ad24d7793c9c91b74ca2ea1_I20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RleHRyZWdpb246OGRmOTEwZDdhYjFhNDFmMThlODU5ZTE4OTQxY2E4MDhfNzMxNQ_c27361a5-c64b-408f-acaa-b2836a5cc3c5"
      unitRef="number">0.10</lly:DescriptionOfDerivativeActivityVolumePercent>
    <us-gaap:DerivativeNotionalAmount
      contextRef="iea65a7fd63824506a3ca41c5d51257a3_I20220930"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RleHRyZWdpb246OGRmOTEwZDdhYjFhNDFmMThlODU5ZTE4OTQxY2E4MDhfODAxNw_0f465d2c-ee23-41d4-b53d-487c29e7e8fc"
      unitRef="usd">1750000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DebtInstrumentTerm
      contextRef="i788cd34fd44840639efca67d73c371ff_D20220915-20220915"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RleHRyZWdpb246OGRmOTEwZDdhYjFhNDFmMThlODU5ZTE4OTQxY2E4MDhfMzI5ODUzNDkwMzAxNw_ce7d2d87-4026-482f-97b8-93cb1c592998">P364D</us-gaap:DebtInstrumentTerm>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i5d53c58f4c7d459489a11fd8bfd27153_I20220914"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RleHRyZWdpb246OGRmOTEwZDdhYjFhNDFmMThlODU5ZTE4OTQxY2E4MDhfMzI5ODUzNDkwMjk1NQ_03c38822-6492-4c38-93c1-a50755127fa1"
      unitRef="usd">2000000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i2c071467da4c408bbfd8f27f707626e7_I20220915"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RleHRyZWdpb246OGRmOTEwZDdhYjFhNDFmMThlODU5ZTE4OTQxY2E4MDhfMzI5ODUzNDkwMjk3MA_59e876b1-ba17-4119-aa39-c2d44605e198"
      unitRef="usd">4000000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i2c071467da4c408bbfd8f27f707626e7_I20220915"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RleHRyZWdpb246OGRmOTEwZDdhYjFhNDFmMThlODU5ZTE4OTQxY2E4MDhfMzI5ODUzNDkwMjk4NQ_3b24ed1c-d1d4-4ebd-a28a-94b6d7e89ddc"
      unitRef="usd">4000000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentTerm
      contextRef="i788cd34fd44840639efca67d73c371ff_D20220915-20220915"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RleHRyZWdpb246OGRmOTEwZDdhYjFhNDFmMThlODU5ZTE4OTQxY2E4MDhfMzI5ODUzNDkwMzAxOA_694da09d-cb8c-4113-9beb-2dffa4b64e6f">P364D</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i17173f194d1742f38780c496d01c1177_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RleHRyZWdpb246OGRmOTEwZDdhYjFhNDFmMThlODU5ZTE4OTQxY2E4MDhfMzI5ODUzNDkwMTE5OA_fabf239f-6312-44b9-9ce8-43bbc6b59362"
      unitRef="eur">600000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i17173f194d1742f38780c496d01c1177_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RleHRyZWdpb246OGRmOTEwZDdhYjFhNDFmMThlODU5ZTE4OTQxY2E4MDhfMzI5ODUzNDkwMTIxNA_a89528c5-914f-4899-b7f3-320697f05b06"
      unitRef="number">0.50</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="iff7c9802a16c4e94a8b83d2c06fbfd30_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RleHRyZWdpb246OGRmOTEwZDdhYjFhNDFmMThlODU5ZTE4OTQxY2E4MDhfMzI5ODUzNDkwMDU5Mg_e09fb3a2-d8d3-496f-ae95-6f9d425edad8"
      unitRef="eur">500000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="iff7c9802a16c4e94a8b83d2c06fbfd30_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RleHRyZWdpb246OGRmOTEwZDdhYjFhNDFmMThlODU5ZTE4OTQxY2E4MDhfMzI5ODUzNDkwMDYwOA_ffb64c0c-3315-4943-b496-0acaf2271454"
      unitRef="number">1.125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i11a8fe2e658c49ab879c662bd320fc8e_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RleHRyZWdpb246OGRmOTEwZDdhYjFhNDFmMThlODU5ZTE4OTQxY2E4MDhfMzI5ODUzNDkwMDYxNQ_8c2421ec-6805-49f0-abfc-907a2d70ae19"
      unitRef="eur">700000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i11a8fe2e658c49ab879c662bd320fc8e_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RleHRyZWdpb246OGRmOTEwZDdhYjFhNDFmMThlODU5ZTE4OTQxY2E4MDhfMzI5ODUzNDkwMDYzMQ_95d377da-b023-432b-a5c5-3cd13eafd92a"
      unitRef="number">1.375</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="iea81ed26b993414992722e426a530c04_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RleHRyZWdpb246OGRmOTEwZDdhYjFhNDFmMThlODU5ZTE4OTQxY2E4MDhfMzI5ODUzNDkwMDYzOA_ecaafde3-786f-4832-a0d2-e47e6084fa99"
      unitRef="gbp">250000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="iea81ed26b993414992722e426a530c04_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RleHRyZWdpb246OGRmOTEwZDdhYjFhNDFmMThlODU5ZTE4OTQxY2E4MDhfMzI5ODUzNDkwMDY1NA_9bac2bf5-3734-43f3-8c9c-c37e9ed447a6"
      unitRef="number">1.625</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:PaymentsOfDebtExtinguishmentCosts
      contextRef="icdfd3853e3eb4a398286b232426b38b1_D20210901-20210930"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RleHRyZWdpb246OGRmOTEwZDdhYjFhNDFmMThlODU5ZTE4OTQxY2E4MDhfMzI5ODUzNDkwMDY2MQ_01f5fe97-07e9-40cd-a008-d0e4dd747414"
      unitRef="usd">1910000000</us-gaap:PaymentsOfDebtExtinguishmentCosts>
    <us-gaap:ExtinguishmentOfDebtAmount
      contextRef="icdfd3853e3eb4a398286b232426b38b1_D20210901-20210930"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RleHRyZWdpb246OGRmOTEwZDdhYjFhNDFmMThlODU5ZTE4OTQxY2E4MDhfMzI5ODUzNDkwMDY3Ng_77656b80-9cdf-43ef-8295-52415607ddc0"
      unitRef="usd">1500000000</us-gaap:ExtinguishmentOfDebtAmount>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="icdfd3853e3eb4a398286b232426b38b1_D20210901-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RleHRyZWdpb246OGRmOTEwZDdhYjFhNDFmMThlODU5ZTE4OTQxY2E4MDhfMzI5ODUzNDkwMDY5MQ_3f663fd6-62a2-4a6d-8eaa-a65c832b3eb8"
      unitRef="usd">-405200000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:ExtinguishmentOfDebtAmount
      contextRef="icdfd3853e3eb4a398286b232426b38b1_D20210901-20210930"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RleHRyZWdpb246OGRmOTEwZDdhYjFhNDFmMThlODU5ZTE4OTQxY2E4MDhfMzI5ODUzNDkwMDcwNw_a500e631-12ca-44b6-af36-97afec4dfb37"
      unitRef="usd">1500000000</us-gaap:ExtinguishmentOfDebtAmount>
    <us-gaap:ExtinguishmentOfDebtAmount
      contextRef="i96587d4174a14444becf7821313b1347_D20210901-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RleHRyZWdpb246OGRmOTEwZDdhYjFhNDFmMThlODU5ZTE4OTQxY2E4MDhfMzI5ODUzNDkwMDcyMg_702426dc-cd70-47c9-9146-873f2a3501c3"
      unitRef="usd">541800000</us-gaap:ExtinguishmentOfDebtAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i750c23289e514e58bf58ede4855592f4_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RleHRyZWdpb246OGRmOTEwZDdhYjFhNDFmMThlODU5ZTE4OTQxY2E4MDhfMzI5ODUzNDkwMDczOA_047fb137-f65c-4028-8748-262cfe831471"
      unitRef="number">3.95</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ExtinguishmentOfDebtAmount
      contextRef="ice18fb651f95409d813656a157f34daf_D20210901-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RleHRyZWdpb246OGRmOTEwZDdhYjFhNDFmMThlODU5ZTE4OTQxY2E4MDhfMzI5ODUzNDkwMDc0NA_bca6857f-0b81-4779-8dd1-291d63c94b48"
      unitRef="usd">408700000</us-gaap:ExtinguishmentOfDebtAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i50894bb5721f4dd58072e6ce75ebf15d_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RleHRyZWdpb246OGRmOTEwZDdhYjFhNDFmMThlODU5ZTE4OTQxY2E4MDhfMzI5ODUzNDkwMDc2MA_62d97da8-c395-40b2-b7a6-f90739a6cb1a"
      unitRef="number">4.15</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ExtinguishmentOfDebtAmount
      contextRef="ice022568bdf042618c2c002393cc3c5d_D20210901-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RleHRyZWdpb246OGRmOTEwZDdhYjFhNDFmMThlODU5ZTE4OTQxY2E4MDhfMzI5ODUzNDkwMDc2Ng_6feda03f-fc2e-4783-822a-9b435148eb37"
      unitRef="usd">219400000</us-gaap:ExtinguishmentOfDebtAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="iccc6f8c08fc6454c849c681a4dbe3d01_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RleHRyZWdpb246OGRmOTEwZDdhYjFhNDFmMThlODU5ZTE4OTQxY2E4MDhfMzI5ODUzNDkwMDc4Mg_46ae064e-e5b3-4fa2-b782-46ae301f6c8b"
      unitRef="number">3.375</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock
      contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RleHRyZWdpb246OGRmOTEwZDdhYjFhNDFmMThlODU5ZTE4OTQxY2E4MDhfMTUxMDk_30459d61-6677-4ad8-8dba-ecb15fc493c8">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following effects of risk-management instruments were recognized in other&#x2013;net, (income) expense:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.800%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.157%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.157%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.157%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.160%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effect from hedged fixed-rate debt&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(62.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(215.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(60.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effect from interest rate contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;62.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;215.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash flow hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effective portion of losses on interest rate contracts reclassified from accumulated other comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;12.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;33.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;75.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net (gains) losses on foreign currency exchange contracts not designated as hedging instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;129.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;280.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;166.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;368.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;181.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock>
    <us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1
      contextRef="i65012aa62d474ff8af6d08eeb55d206a_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOmY2M2E4OTNjOGY5MzQ0M2ViOTA2ZDYwZWNjMWRhMzJiL3RhYmxlcmFuZ2U6ZjYzYTg5M2M4ZjkzNDQzZWI5MDZkNjBlY2MxZGEzMmJfMy0xLTEtMS0xNTk1NDA_f7e28d6f-0f64-4fb1-9f5d-f00ca3de4b58"
      unitRef="usd">62900000</us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1>
    <us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1
      contextRef="ib627ecf64a434a6b8135da0ac7a5fdf7_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOmY2M2E4OTNjOGY5MzQ0M2ViOTA2ZDYwZWNjMWRhMzJiL3RhYmxlcmFuZ2U6ZjYzYTg5M2M4ZjkzNDQzZWI5MDZkNjBlY2MxZGEzMmJfMy0zLTEtMS0xNTk1NDA_40c651de-326e-477f-8354-547f965a0334"
      unitRef="usd">10100000</us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1>
    <us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1
      contextRef="i1d213f8c24344d22ada6f016432acea5_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOmY2M2E4OTNjOGY5MzQ0M2ViOTA2ZDYwZWNjMWRhMzJiL3RhYmxlcmFuZ2U6ZjYzYTg5M2M4ZjkzNDQzZWI5MDZkNjBlY2MxZGEzMmJfMy01LTEtMS0xNTk1NDA_496be9f4-9bd5-4012-8cc5-bdb0502bfaa3"
      unitRef="usd">215700000</us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1>
    <us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1
      contextRef="i41a4fdad9bd748be972c155f2f3acedf_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOmY2M2E4OTNjOGY5MzQ0M2ViOTA2ZDYwZWNjMWRhMzJiL3RhYmxlcmFuZ2U6ZjYzYTg5M2M4ZjkzNDQzZWI5MDZkNjBlY2MxZGEzMmJfMy03LTEtMS0xNTk1NDA_eb181ae3-ffba-4a20-a5f7-3c49c81ac772"
      unitRef="usd">60500000</us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1>
    <us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1
      contextRef="ic55d4cfd09d8486a8b6e1be77dcc5426_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOmY2M2E4OTNjOGY5MzQ0M2ViOTA2ZDYwZWNjMWRhMzJiL3RhYmxlcmFuZ2U6ZjYzYTg5M2M4ZjkzNDQzZWI5MDZkNjBlY2MxZGEzMmJfNC0xLTEtMS0xNTk1NDA_07fc5259-89e6-4bc6-b021-d086c6e94a2a"
      unitRef="usd">-62900000</us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1>
    <us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1
      contextRef="i519d9df9a61b4cbf87c342e3496785cc_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOmY2M2E4OTNjOGY5MzQ0M2ViOTA2ZDYwZWNjMWRhMzJiL3RhYmxlcmFuZ2U6ZjYzYTg5M2M4ZjkzNDQzZWI5MDZkNjBlY2MxZGEzMmJfNC0zLTEtMS0xNTk1NDA_751aaf20-0bb2-464e-ae8c-c294a7f06e88"
      unitRef="usd">-10100000</us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1>
    <us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1
      contextRef="i7bcae384fb484b6aa3e84e7d484b69e9_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOmY2M2E4OTNjOGY5MzQ0M2ViOTA2ZDYwZWNjMWRhMzJiL3RhYmxlcmFuZ2U6ZjYzYTg5M2M4ZjkzNDQzZWI5MDZkNjBlY2MxZGEzMmJfNC01LTEtMS0xNTk1NDA_5aeac55d-65ff-4c3d-873b-be05ab82e2dd"
      unitRef="usd">-215700000</us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1>
    <us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1
      contextRef="i4cc8664469d846a2b0472f04c7e39442_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOmY2M2E4OTNjOGY5MzQ0M2ViOTA2ZDYwZWNjMWRhMzJiL3RhYmxlcmFuZ2U6ZjYzYTg5M2M4ZjkzNDQzZWI5MDZkNjBlY2MxZGEzMmJfNC03LTEtMS0xNTk1NDA_a703e13a-35d7-422d-8d7b-a0ddbe49efc4"
      unitRef="usd">-60500000</us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="ic55d4cfd09d8486a8b6e1be77dcc5426_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOmY2M2E4OTNjOGY5MzQ0M2ViOTA2ZDYwZWNjMWRhMzJiL3RhYmxlcmFuZ2U6ZjYzYTg5M2M4ZjkzNDQzZWI5MDZkNjBlY2MxZGEzMmJfNi0xLTEtMS0xNTk1NDA_deec1bc1-e224-4ddc-b5b8-535d47d558c9"
      unitRef="usd">4100000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="i519d9df9a61b4cbf87c342e3496785cc_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOmY2M2E4OTNjOGY5MzQ0M2ViOTA2ZDYwZWNjMWRhMzJiL3RhYmxlcmFuZ2U6ZjYzYTg5M2M4ZjkzNDQzZWI5MDZkNjBlY2MxZGEzMmJfNi0zLTEtMS0xNTk1NDA_27a2de22-f375-4abb-8d67-1a70d53868dc"
      unitRef="usd">4200000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="i7bcae384fb484b6aa3e84e7d484b69e9_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOmY2M2E4OTNjOGY5MzQ0M2ViOTA2ZDYwZWNjMWRhMzJiL3RhYmxlcmFuZ2U6ZjYzYTg5M2M4ZjkzNDQzZWI5MDZkNjBlY2MxZGEzMmJfNi01LTEtMS0xNTk1NDA_2081da8d-0d6d-4f45-aaea-f2c570fcbaaf"
      unitRef="usd">12300000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="i4cc8664469d846a2b0472f04c7e39442_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOmY2M2E4OTNjOGY5MzQ0M2ViOTA2ZDYwZWNjMWRhMzJiL3RhYmxlcmFuZ2U6ZjYzYTg5M2M4ZjkzNDQzZWI5MDZkNjBlY2MxZGEzMmJfNi03LTEtMS0xNTk1NDA_2c1682bd-562f-46aa-8fc3-768ec6328ace"
      unitRef="usd">12500000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="ic1eb1816cd7241e7af47383c68f534c0_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOmY2M2E4OTNjOGY5MzQ0M2ViOTA2ZDYwZWNjMWRhMzJiL3RhYmxlcmFuZ2U6ZjYzYTg5M2M4ZjkzNDQzZWI5MDZkNjBlY2MxZGEzMmJfNy0xLTEtMS0xNTk1NDA_9d72c7a5-5f9e-4df6-ae38-aece61fa2fcb"
      unitRef="usd">33100000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="if7cd0109836d43de86e2c830d47c9aec_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOmY2M2E4OTNjOGY5MzQ0M2ViOTA2ZDYwZWNjMWRhMzJiL3RhYmxlcmFuZ2U6ZjYzYTg5M2M4ZjkzNDQzZWI5MDZkNjBlY2MxZGEzMmJfNy0zLTEtMS0xNTk1NDA_7859894c-8a1c-41e6-88d3-68b247684a74"
      unitRef="usd">10000000.0</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="i5f64e83e66774562be40774b52732fd5_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOmY2M2E4OTNjOGY5MzQ0M2ViOTA2ZDYwZWNjMWRhMzJiL3RhYmxlcmFuZ2U6ZjYzYTg5M2M4ZjkzNDQzZWI5MDZkNjBlY2MxZGEzMmJfNy01LTEtMS0xNTk1NDA_9952a76f-c00c-4375-9adf-f73464f36a14"
      unitRef="usd">75000000.0</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="i9ed2f279ccc74f238d18ee7977fea9e0_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOmY2M2E4OTNjOGY5MzQ0M2ViOTA2ZDYwZWNjMWRhMzJiL3RhYmxlcmFuZ2U6ZjYzYTg5M2M4ZjkzNDQzZWI5MDZkNjBlY2MxZGEzMmJfNy03LTEtMS0xNTk1NDA_75f0bbca-be3b-4cfb-bcc0-55d6d52f0f01"
      unitRef="usd">58100000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments
      contextRef="iaaffba52583d4dd09213c45974bda81f_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOmY2M2E4OTNjOGY5MzQ0M2ViOTA2ZDYwZWNjMWRhMzJiL3RhYmxlcmFuZ2U6ZjYzYTg5M2M4ZjkzNDQzZWI5MDZkNjBlY2MxZGEzMmJfOC0xLTEtMS0xNTk1NDA_45ad136c-ec3b-4b58-9265-6dcfcbf87432"
      unitRef="usd">-129600000</us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments>
    <us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments
      contextRef="idb22c9f9ae5f42d5b5d0691a5daa1547_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOmY2M2E4OTNjOGY5MzQ0M2ViOTA2ZDYwZWNjMWRhMzJiL3RhYmxlcmFuZ2U6ZjYzYTg5M2M4ZjkzNDQzZWI5MDZkNjBlY2MxZGEzMmJfOC0zLTEtMS0xNTk1NDA_feea260b-9edd-4420-8f6a-004a68ebd262"
      unitRef="usd">-50800000</us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments>
    <us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments
      contextRef="i00fa96d219234882925d8b07dc0e9a2f_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOmY2M2E4OTNjOGY5MzQ0M2ViOTA2ZDYwZWNjMWRhMzJiL3RhYmxlcmFuZ2U6ZjYzYTg5M2M4ZjkzNDQzZWI5MDZkNjBlY2MxZGEzMmJfOC01LTEtMS0xNTk1NDA_edd95548-5100-4323-a726-ef27ed518838"
      unitRef="usd">-280700000</us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments>
    <us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments
      contextRef="i5a4ce07ee9fd474a956ccb68a6af4713_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOmY2M2E4OTNjOGY5MzQ0M2ViOTA2ZDYwZWNjMWRhMzJiL3RhYmxlcmFuZ2U6ZjYzYTg5M2M4ZjkzNDQzZWI5MDZkNjBlY2MxZGEzMmJfOC03LTEtMS0xNTk1NDA_899dca17-35aa-4d2f-8658-642ad5f08d4f"
      unitRef="usd">-110600000</us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments>
    <lly:DerivativeInstrumentsGainLossRecognized
      contextRef="i19fc0325c48543008ea71e1fdcf11d86_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOmY2M2E4OTNjOGY5MzQ0M2ViOTA2ZDYwZWNjMWRhMzJiL3RhYmxlcmFuZ2U6ZjYzYTg5M2M4ZjkzNDQzZWI5MDZkNjBlY2MxZGEzMmJfOS0xLTEtMS0xNTk1NDA_26ee518e-1941-4c09-b6a5-0c2fe576c581"
      unitRef="usd">-166800000</lly:DerivativeInstrumentsGainLossRecognized>
    <lly:DerivativeInstrumentsGainLossRecognized
      contextRef="ie4fa4f6b472a4f269297591b44aba572_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOmY2M2E4OTNjOGY5MzQ0M2ViOTA2ZDYwZWNjMWRhMzJiL3RhYmxlcmFuZ2U6ZjYzYTg5M2M4ZjkzNDQzZWI5MDZkNjBlY2MxZGEzMmJfOS0zLTEtMS0xNTk1NDA_739481e3-e83a-4ca5-abd9-415495b69ef0"
      unitRef="usd">-65000000.0</lly:DerivativeInstrumentsGainLossRecognized>
    <lly:DerivativeInstrumentsGainLossRecognized
      contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOmY2M2E4OTNjOGY5MzQ0M2ViOTA2ZDYwZWNjMWRhMzJiL3RhYmxlcmFuZ2U6ZjYzYTg5M2M4ZjkzNDQzZWI5MDZkNjBlY2MxZGEzMmJfOS01LTEtMS0xNTk1NDA_031e8542-3748-4884-b7af-152aaaf951fe"
      unitRef="usd">-368000000.0</lly:DerivativeInstrumentsGainLossRecognized>
    <lly:DerivativeInstrumentsGainLossRecognized
      contextRef="i167ed8f67bef48c49e54fa466400cdaa_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOmY2M2E4OTNjOGY5MzQ0M2ViOTA2ZDYwZWNjMWRhMzJiL3RhYmxlcmFuZ2U6ZjYzYTg5M2M4ZjkzNDQzZWI5MDZkNjBlY2MxZGEzMmJfOS03LTEtMS0xNTk1NDA_97ebec2e-25a4-4154-8eee-716bbe3cb9b0"
      unitRef="usd">-181200000</lly:DerivativeInstrumentsGainLossRecognized>
    <us-gaap:ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock
      contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RleHRyZWdpb246OGRmOTEwZDdhYjFhNDFmMThlODU5ZTE4OTQxY2E4MDhfMTUxNjk_af7c9e84-70f2-4f2d-b46f-c00a40254ce4">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The effective portion of risk-management instruments that was recognized in other comprehensive income (loss) is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.206%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net investment hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency-denominated notes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;435.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;822.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;268.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;92.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;171.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;170.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency forward contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;107.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;121.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash flow hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forward-starting interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;57.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;337.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;149.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;19.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;38.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock
      contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RleHRyZWdpb246OGRmOTEwZDdhYjFhNDFmMThlODU5ZTE4OTQxY2E4MDhfMTUxODk_228ac172-3acf-4d55-9fbf-db92983ef792">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The effective portion of risk-management instruments that was recognized in other comprehensive income (loss) is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.206%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net investment hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency-denominated notes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;435.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;822.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;268.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;92.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;171.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;170.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency forward contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;107.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;121.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash flow hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forward-starting interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;57.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;337.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;149.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;19.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;38.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="i0803c43adcc2406c8d72a961bdbdb03a_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOmQ4YWMyOTIzMWExMjRmZTRhMzI5NWJhOGNmMTgzZGQ5L3RhYmxlcmFuZ2U6ZDhhYzI5MjMxYTEyNGZlNGEzMjk1YmE4Y2YxODNkZDlfMy0xLTEtMS0xNTk1NDA_8ada233f-b314-42ff-a8c1-c7626a18e18d"
      unitRef="usd">435100000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="ifa347bfa67994dfbad7418e0ab44ad66_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOmQ4YWMyOTIzMWExMjRmZTRhMzI5NWJhOGNmMTgzZGQ5L3RhYmxlcmFuZ2U6ZDhhYzI5MjMxYTEyNGZlNGEzMjk1YmE4Y2YxODNkZDlfMy0zLTEtMS0xNTk1NDA_dd5e03a5-f1b0-4c63-b06d-296d73176244"
      unitRef="usd">119000000.0</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="i9300bb3fb0c149928c10ce50be156517_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOmQ4YWMyOTIzMWExMjRmZTRhMzI5NWJhOGNmMTgzZGQ5L3RhYmxlcmFuZ2U6ZDhhYzI5MjMxYTEyNGZlNGEzMjk1YmE4Y2YxODNkZDlfMy01LTEtMS0xNTk1NDA_ea03d8bc-cc9d-43bc-bdbb-278a93295c5d"
      unitRef="usd">822800000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="i65cd935c26b44824a9d84d0554032fa4_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOmQ4YWMyOTIzMWExMjRmZTRhMzI5NWJhOGNmMTgzZGQ5L3RhYmxlcmFuZ2U6ZDhhYzI5MjMxYTEyNGZlNGEzMjk1YmE4Y2YxODNkZDlfMy03LTEtMS0xNTk1NDA_e0b9d6aa-0e2a-4fa9-bfb0-d102ea25b064"
      unitRef="usd">268800000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="ie32852c9ac004e18a40bd3c886375fa2_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOmQ4YWMyOTIzMWExMjRmZTRhMzI5NWJhOGNmMTgzZGQ5L3RhYmxlcmFuZ2U6ZDhhYzI5MjMxYTEyNGZlNGEzMjk1YmE4Y2YxODNkZDlfNC0xLTEtMS0xNTk1NDA_c41fbcd4-8d83-4050-9bea-1f227220f00a"
      unitRef="usd">92100000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="ie539446ea66443f18894fe65b477f3f2_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOmQ4YWMyOTIzMWExMjRmZTRhMzI5NWJhOGNmMTgzZGQ5L3RhYmxlcmFuZ2U6ZDhhYzI5MjMxYTEyNGZlNGEzMjk1YmE4Y2YxODNkZDlfNC0zLTEtMS0xNTk1NDA_048d8537-f679-4fa0-85af-c34f3f2b9be8"
      unitRef="usd">66700000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="ieb0755f46c634be3a274f37154dcd835_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOmQ4YWMyOTIzMWExMjRmZTRhMzI5NWJhOGNmMTgzZGQ5L3RhYmxlcmFuZ2U6ZDhhYzI5MjMxYTEyNGZlNGEzMjk1YmE4Y2YxODNkZDlfNC01LTEtMS0xNTk1NDA_dfdd2151-8699-4f50-a371-65c0f73a14b3"
      unitRef="usd">171400000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="ib38ae8d2eee24da7b665b5ba4af2fc25_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOmQ4YWMyOTIzMWExMjRmZTRhMzI5NWJhOGNmMTgzZGQ5L3RhYmxlcmFuZ2U6ZDhhYzI5MjMxYTEyNGZlNGEzMjk1YmE4Y2YxODNkZDlfNC03LTEtMS0xNTk1NDA_efb63077-67bf-4515-a6db-2f7fd81f422b"
      unitRef="usd">170800000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="iee72a06ebc24478d804a01c9c07503e0_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOmQ4YWMyOTIzMWExMjRmZTRhMzI5NWJhOGNmMTgzZGQ5L3RhYmxlcmFuZ2U6ZDhhYzI5MjMxYTEyNGZlNGEzMjk1YmE4Y2YxODNkZDlfNS0xLTEtMS0xNTk1NDA_0907f90c-cb5f-400a-ba6b-147a64dbdf37"
      unitRef="usd">107800000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="i847e2e726f374b8997cd2f409d0da50e_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOmQ4YWMyOTIzMWExMjRmZTRhMzI5NWJhOGNmMTgzZGQ5L3RhYmxlcmFuZ2U6ZDhhYzI5MjMxYTEyNGZlNGEzMjk1YmE4Y2YxODNkZDlfNS0zLTEtMS0xNTk1NDA_29d30dc8-c02f-451c-a952-9092e948fc6f"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="i04964a8dc75f42aeb12d4f04a8c4b0eb_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOmQ4YWMyOTIzMWExMjRmZTRhMzI5NWJhOGNmMTgzZGQ5L3RhYmxlcmFuZ2U6ZDhhYzI5MjMxYTEyNGZlNGEzMjk1YmE4Y2YxODNkZDlfNS01LTEtMS0xNTk1NDA_a5a07281-e177-4764-b709-6a94347197e5"
      unitRef="usd">121400000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="i735c7ed5628e404298cd5de9565781a5_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOmQ4YWMyOTIzMWExMjRmZTRhMzI5NWJhOGNmMTgzZGQ5L3RhYmxlcmFuZ2U6ZDhhYzI5MjMxYTEyNGZlNGEzMjk1YmE4Y2YxODNkZDlfNS03LTEtMS0xNTk1NDA_1783236e-7f89-4fb1-80e3-5d415876b230"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="i874a4fa6b8034fb7b972ede3e49e5375_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOmQ4YWMyOTIzMWExMjRmZTRhMzI5NWJhOGNmMTgzZGQ5L3RhYmxlcmFuZ2U6ZDhhYzI5MjMxYTEyNGZlNGEzMjk1YmE4Y2YxODNkZDlfNy0xLTEtMS0xNTk1NDA_8ef7bfed-ecbe-45f5-a075-60517430e066"
      unitRef="usd">57500000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="icc403fcb68ad44ae8c3d0f5675e78f2a_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOmQ4YWMyOTIzMWExMjRmZTRhMzI5NWJhOGNmMTgzZGQ5L3RhYmxlcmFuZ2U6ZDhhYzI5MjMxYTEyNGZlNGEzMjk1YmE4Y2YxODNkZDlfNy0zLTEtMS0xNTk1NDA_5bfb10b8-46fd-4378-a2fd-6705949223e7"
      unitRef="usd">19400000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="ic9cf169896e649948e7319fca615da6c_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOmQ4YWMyOTIzMWExMjRmZTRhMzI5NWJhOGNmMTgzZGQ5L3RhYmxlcmFuZ2U6ZDhhYzI5MjMxYTEyNGZlNGEzMjk1YmE4Y2YxODNkZDlfNy01LTEtMS0xNTk1NDA_50bdee4f-f2a3-415b-86e0-46b280e4ec5b"
      unitRef="usd">337700000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="i792ad77b79a7422690de67f74dc5988f_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOmQ4YWMyOTIzMWExMjRmZTRhMzI5NWJhOGNmMTgzZGQ5L3RhYmxlcmFuZ2U6ZDhhYzI5MjMxYTEyNGZlNGEzMjk1YmE4Y2YxODNkZDlfNy03LTEtMS0xNTk1NDA_ed88540e-2eda-47af-a347-b3432e3c2e17"
      unitRef="usd">149300000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="ie32852c9ac004e18a40bd3c886375fa2_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOmQ4YWMyOTIzMWExMjRmZTRhMzI5NWJhOGNmMTgzZGQ5L3RhYmxlcmFuZ2U6ZDhhYzI5MjMxYTEyNGZlNGEzMjk1YmE4Y2YxODNkZDlfOC0xLTEtMS0xNTk1NDA_881e6419-f1ab-45f1-8519-d30cc48be0d2"
      unitRef="usd">19900000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="ie539446ea66443f18894fe65b477f3f2_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOmQ4YWMyOTIzMWExMjRmZTRhMzI5NWJhOGNmMTgzZGQ5L3RhYmxlcmFuZ2U6ZDhhYzI5MjMxYTEyNGZlNGEzMjk1YmE4Y2YxODNkZDlfOC0zLTEtMS0xNTk1NDA_068058f8-7d3d-4ccc-a2aa-1bd84a03fe93"
      unitRef="usd">3100000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="ieb0755f46c634be3a274f37154dcd835_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOmQ4YWMyOTIzMWExMjRmZTRhMzI5NWJhOGNmMTgzZGQ5L3RhYmxlcmFuZ2U6ZDhhYzI5MjMxYTEyNGZlNGEzMjk1YmE4Y2YxODNkZDlfOC01LTEtMS0xNTk1NDA_556f17c3-68c7-4d1c-ab01-9229419f0ea1"
      unitRef="usd">38400000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="ib38ae8d2eee24da7b665b5ba4af2fc25_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOmQ4YWMyOTIzMWExMjRmZTRhMzI5NWJhOGNmMTgzZGQ5L3RhYmxlcmFuZ2U6ZDhhYzI5MjMxYTEyNGZlNGEzMjk1YmE4Y2YxODNkZDlfOC03LTEtMS0xNTk1NDA_6d80bf62-6bb6-4a2a-aa78-bffb042c7d8a"
      unitRef="usd">22500000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet
      contextRef="i08ccb35f6ad24d7793c9c91b74ca2ea1_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RleHRyZWdpb246OGRmOTEwZDdhYjFhNDFmMThlODU5ZTE4OTQxY2E4MDhfODc3MQ_cc02ee53-2444-4fa4-9307-1ae16614df16"
      unitRef="usd">-16700000</us-gaap:InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock
      contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RleHRyZWdpb246OGRmOTEwZDdhYjFhNDFmMThlODU5ZTE4OTQxY2E4MDhfMTUxMTg_8c519f20-07b4-4979-970c-a1817df9b732">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize certain fair value information at September&#160;30, 2022 and December&#160;31, 2021 for assets and liabilities measured at fair value on a recurring basis, as well as the carrying amount and amortized cost of certain other investments:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.466%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.714%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements Using&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted Prices in Active Markets for Identical Assets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant Other&lt;br/&gt;Observable Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,246.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,246.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,239.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;7.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,246.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Short-term investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. government and agency securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;43.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;43.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;43.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;43.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;51.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;51.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;51.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;51.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;3.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;3.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;3.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;3.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;27.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;27.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;14.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;12.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;27.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;124.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Noncurrent investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. government and agency securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;131.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;148.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;131.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;131.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;206.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;232.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;206.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;206.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;143.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;156.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;143.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;143.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;43.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;45.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;43.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;43.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;152.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;96.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;39.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;113.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;152.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;549.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;416.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;549.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;549.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Equity investments without readily determinable fair values&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;583.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Equity method investments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;764.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Noncurrent investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2,574.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,379.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,379.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,361.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,379.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Short-term investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. government and agency securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;43.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;43.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;43.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;43.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;90.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Noncurrent investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. government and agency securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;137.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;136.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;137.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;137.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;235.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;232.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;235.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;235.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;109.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;108.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;109.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;109.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;108.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;108.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;108.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,279.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;487.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,279.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,279.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Equity investments without readily determinable fair values&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;548.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Equity method investments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;771.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Noncurrent investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,212.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;For available-for-sale debt securities, amounts disclosed represent the securities' amortized cost.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Fair value disclosures are not applicable for equity method investments and investments accounted for under the measurement alternative for equity investments.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ia25fb80ee7f14608ad1bc42cf7dc3d85_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMy0xLTEtMS0xNTk1NDA_170efdd2-271a-472e-a1fd-0e5db5f1eb2c"
      unitRef="usd">1246800000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ieb1b4d0ca2904d3699b0c20378d2d4de_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMy0zLTEtMS0xNTk1NDA_cf4ac1dc-54d9-438d-a3a9-d509b2db1389"
      unitRef="usd">1246800000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i909f721d549b4d17b64fd5ef7a64ed65_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMy01LTEtMS0xNTk1NDA_76e28b35-7962-4a4d-81bb-c2a7e1b86e75"
      unitRef="usd">1239200000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ida76f129eae2411aac66cefe0c47c6fc_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMy03LTEtMS0xNTk1NDA_74cf33c2-091c-4dc6-af1d-50073c278e6b"
      unitRef="usd">7600000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ic34ce18d9ac34702bf22cdc268d8fddc_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMy05LTEtMS0xNTk1NDA_5234a2e4-073c-49a9-929c-c76431a66b80"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ice641419095d40b58b1ec413657e5350_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMy0xMS0xLTEtMTU5NTQw_4f6ca784-8d50-441e-97f9-624c2e4bddac"
      unitRef="usd">1246800000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ifab6a7669381463baa4bcac0c28cb1ec_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfNi0xLTEtMS0xNTk1NDA_30c10619-e70d-4924-8576-408b3384afd1"
      unitRef="usd">43000000.0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ic8f3a57231c145049540a666d70b036f_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfNi0zLTEtMS0xNTk1NDA_6c7e25e5-e196-4019-9910-9a46acd1fe9a"
      unitRef="usd">43500000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i0bdbf4b6981d423b84e97332dcaf6c1a_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfNi01LTEtMS0xNTk1NDA_e95852ef-2150-4460-96d5-df7dd02cd1c9"
      unitRef="usd">43000000.0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="if1140c058291487fa611ebff0a87770b_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfNi03LTEtMS0xNTk1NDA_7a8defb7-caba-4e2f-af41-4fca2c8d2dfa"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i78d99dff74e3423da8f09146d5ccfac9_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfNi05LTEtMS0xNTk1NDA_b048abc3-724b-4299-99f4-0e5db8b9110b"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i047635964deb4302a146b6e33a2497a8_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfNi0xMS0xLTEtMTU5NTQw_530f232d-70f6-446d-8429-0270e04c02dc"
      unitRef="usd">43000000.0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i2743696771f346c8b079973d11a7071f_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfNy0xLTEtMS0xNTk1NDA_052d25d3-5810-4ec2-b834-e709b357e3de"
      unitRef="usd">51700000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i33275a4d21e64200a487dc63563ca001_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfNy0zLTEtMS0xNTk1NDA_3e135d91-f69e-4dad-a13e-e2b15b3c3399"
      unitRef="usd">51800000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i0a4a874cc47f46a2a264722d13461f46_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfNy01LTEtMS0xNTk1NDA_754dc1ae-d820-4afd-8d9b-97429fd3224b"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i5b78e10d989e462c8d6d0340d904cc92_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfNy03LTEtMS0xNTk1NDA_33403580-2a0c-43fe-b168-fc6e2fbfad72"
      unitRef="usd">51700000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ic182ac3c1369411e8483ee598bedbe15_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfNy05LTEtMS0xNTk1NDA_25e41940-af39-4cb4-aee3-3a2090439889"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ie5db88938a794a79995152d200739e71_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfNy0xMS0xLTEtMTU5NTQw_bfb58401-b833-4ebe-9ed9-5cc87c5afa3d"
      unitRef="usd">51700000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="if975bb8107f649de87a30d9d0518813d_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfOS0xLTEtMS0xNTk1NDA_f5dc5b67-6257-423e-b9bb-a359f20d9c1c"
      unitRef="usd">3000000.0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i035b6f8bf7fd4eb2ade6d5c56da79b71_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfOS0zLTEtMS0xNTk1NDA_62c20e37-31ec-4725-b18a-1bac93ee5e7a"
      unitRef="usd">3000000.0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i313d32c12b5e46a3b70bb355b88d33ae_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfOS01LTEtMS0xNTk1NDA_d681c21b-5ac0-434f-9eb6-c46ce72a7632"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ia62987f3e7a14b4cba45477046b24356_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfOS03LTEtMS0xNTk1NDA_c5c302ef-e225-4bd5-84cf-2b29c818f545"
      unitRef="usd">3000000.0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i81cc2677a958476298d6e691a227d2ef_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfOS05LTEtMS0xNTk1NDA_13665a64-fc20-4dc7-a36a-7b63f395c683"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ibafa8194f14245d092cf8e3fef7acc20_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfOS0xMS0xLTEtMTU5NTQw_90b91c05-9116-449d-ad0e-8b815dffc699"
      unitRef="usd">3000000.0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="if5c5c6181311407dbfeb6b2bc5dabd45_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMTAtMS0xLTEtMTU5NTQw_655c3b21-9340-4c2d-94f0-a83cfc66d1f7"
      unitRef="usd">27000000.0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i4cd5419a2b1e4f1dae5ad80e024ffbd8_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMTAtMy0xLTEtMTU5NTQw_5362c58b-b06e-4e49-958a-e7cb4b853572"
      unitRef="usd">27000000.0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ifa5439e6f71a449badc6db614afe1fc0_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMTAtNS0xLTEtMTU5NTQw_6f85d79f-bca6-44c5-82d2-4cfd7bf4fd08"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ia7e1bfc7167249e09fd9253c7056e6a4_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMTAtNy0xLTEtMTU5NTQw_83a8514f-05a2-4242-893b-05fb9e3b34db"
      unitRef="usd">14800000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i184415738c194fc89b0a1a3ae91e05f6_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMTAtOS0xLTEtMTU5NTQw_03eee07c-6243-4f36-9b5b-1e290e847a13"
      unitRef="usd">12200000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i99cd69cddcd1432eb41f86a6c107e126_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMTAtMTEtMS0xLTE1OTU0MA_1c009b28-7a56-4655-aa0d-9dc0a09be431"
      unitRef="usd">27000000.0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ia25fb80ee7f14608ad1bc42cf7dc3d85_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMTItMS0xLTEtMTU5NTQw_8c9fa782-80ad-44f5-b3dc-09784bd399a7"
      unitRef="usd">124700000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="ifab6a7669381463baa4bcac0c28cb1ec_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMTUtMS0xLTEtMTU5NTQw_4f823aca-1097-4ad5-97ae-fdff8e8fc161"
      unitRef="usd">131400000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="ic8f3a57231c145049540a666d70b036f_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMTUtMy0xLTEtMTU5NTQw_77e928af-9068-4fa5-8b1a-69b9a853ce55"
      unitRef="usd">148300000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i0bdbf4b6981d423b84e97332dcaf6c1a_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMTUtNS0xLTEtMTU5NTQw_ddfa3ae4-10f1-44bf-85c9-d383008ad0aa"
      unitRef="usd">131400000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="if1140c058291487fa611ebff0a87770b_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMTUtNy0xLTEtMTU5NTQw_e7483636-af60-4210-9bda-9fe45a5d47c4"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i78d99dff74e3423da8f09146d5ccfac9_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMTUtOS0xLTEtMTU5NTQw_a2e639ef-7940-42d6-9901-835994db0016"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i047635964deb4302a146b6e33a2497a8_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMTUtMTEtMS0xLTE1OTU0MA_eeedb3d3-15cc-415f-8f04-751577dad833"
      unitRef="usd">131400000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i2743696771f346c8b079973d11a7071f_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMTctMS0xLTEtMTU5NTQw_3e4935bf-3fff-429c-80f9-04ca0d240a88"
      unitRef="usd">206400000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i33275a4d21e64200a487dc63563ca001_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMTctMy0xLTEtMTU5NTQw_3a8e0db3-9cd8-45a7-97f2-cfea141b3f9e"
      unitRef="usd">232500000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i0a4a874cc47f46a2a264722d13461f46_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMTctNS0xLTEtMTU5NTQw_a0e12a97-0adb-48af-9231-76f57b931744"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i5b78e10d989e462c8d6d0340d904cc92_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMTctNy0xLTEtMTU5NTQw_e4b6dce1-f351-4c15-ad3d-9ca8bda89b82"
      unitRef="usd">206400000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="ic182ac3c1369411e8483ee598bedbe15_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMTctOS0xLTEtMTU5NTQw_237d224d-90b4-4756-bce8-3a42084e7e1e"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="ie5db88938a794a79995152d200739e71_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMTctMTEtMS0xLTE1OTU0MA_f3105b3b-383d-4e1c-a067-e9dd9ece33e7"
      unitRef="usd">206400000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i9351338d7d4b429093117dd87f8b02de_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMTgtMS0xLTEtMTU5NTQw_b6810022-f21d-46cd-b78a-e1c90023a85a"
      unitRef="usd">143100000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i98487cf76fa84cba948c2fa763c08c17_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMTgtMy0xLTEtMTU5NTQw_e1b71066-7247-4bd3-9785-ff5d464a2cbd"
      unitRef="usd">156100000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i921241c16da34890a377c6cc0f05bf9a_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMTgtNS0xLTEtMTU5NTQw_91f8ac2a-d7ef-4aec-b737-64ecf554b6c7"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="ib8c508d73f5d490c991f152f357c2edc_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMTgtNy0xLTEtMTU5NTQw_bcbd68c1-7006-4713-948c-68c05b6c9c11"
      unitRef="usd">143100000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i4fcf6ea2160140fcb9374937bebdf459_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMTgtOS0xLTEtMTU5NTQw_df7a88ff-de03-4b12-95d6-30eb7d45e8be"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i5892dce618474c3397f2f21748d154da_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMTgtMTEtMS0xLTE1OTU0MA_63dc4ef0-f59a-4ac3-af4a-4efcfbefee01"
      unitRef="usd">143100000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="if975bb8107f649de87a30d9d0518813d_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMTktMS0xLTEtMTU5NTQw_00bb232e-3f9e-492d-8852-39fa209c29ec"
      unitRef="usd">43600000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i035b6f8bf7fd4eb2ade6d5c56da79b71_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMTktMy0xLTEtMTU5NTQw_78f53150-12e4-4128-8201-ce9f46292ed8"
      unitRef="usd">45500000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i313d32c12b5e46a3b70bb355b88d33ae_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMTktNS0xLTEtMTU5NTQw_90ad37c5-85a5-49b7-b7a9-2516c044a82f"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="ia62987f3e7a14b4cba45477046b24356_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMTktNy0xLTEtMTU5NTQw_337140b6-4036-4440-91a4-520f6c52cc7d"
      unitRef="usd">43600000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i81cc2677a958476298d6e691a227d2ef_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMTktOS0xLTEtMTU5NTQw_9f352256-cbf6-494b-bf6b-42fb4eadfdf7"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="ibafa8194f14245d092cf8e3fef7acc20_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMTktMTEtMS0xLTE1OTU0MA_06039997-5311-44ab-9897-d7774104aca5"
      unitRef="usd">43600000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i839d1d25f31e4a1e8f8686d85cd27d6f_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMjAtMS0xLTEtMTU5NTQw_a978486d-6469-4731-a897-bc81703c9538"
      unitRef="usd">152500000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i66f937e8eb9d439fb99fc1eaf5bb8229_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMjAtMy0xLTEtMTU5NTQw_c61d361a-f168-4771-a0a5-63f9d93e8afb"
      unitRef="usd">96300000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i8d540d6e9952406eae86fcb404c8aa3f_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMjAtNS0xLTEtMTU5NTQw_59f6c1fa-eaae-421c-baac-26a07a8a8df9"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="iac853f32fb164d5dbb16b853b6478ad8_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMjAtNy0xLTEtMTU5NTQw_66d96170-cb32-4695-aafa-ea428c262282"
      unitRef="usd">39500000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i4d0248c83e9f42aebdedbe45913091c1_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMjAtOS0xLTEtMTU5NTQw_08491453-b555-48d9-9d2c-f5bfe431e8bd"
      unitRef="usd">113000000.0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i1f00b6f0d7a346a0bbf8ca789b9b4986_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMjAtMTEtMS0xLTE1OTU0MA_ae0e8a05-1354-4c22-ba19-f8244b2dddef"
      unitRef="usd">152500000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="id469158a1a2340c0b51dedb185916c2c_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMjEtMS0xLTEtMTU5NTQw_deeb4aa8-eeb0-414b-a3a0-d86e3e1c4b05"
      unitRef="usd">549100000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i2330a365ee524585810c28f7dc20e39e_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMjEtMy0xLTEtMTU5NTQw_f4fa3e8b-597c-4675-a1ee-fa981aa22eba"
      unitRef="usd">416100000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="idb940b9eace84fd38c98429f0f9808ce_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMjEtNS0xLTEtMTU5NTQw_ca7f6c7a-476d-4396-a753-7d810ecda772"
      unitRef="usd">549100000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ib28917d514b84c3397d29e8e54a589da_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMjEtNy0xLTEtMTU5NTQw_b6f663a8-89fa-495e-ac7a-60c38a461325"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ia4c3874a92684287bd36704e5ff16e8a_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMjEtOS0xLTEtMTU5NTQw_cc1ddcd6-f30f-499d-a748-69e8cc826391"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i700bccbf1683474084361d2cee367dc8_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMjEtMTEtMS0xLTE1OTU0MA_b827dbfd-5d6f-4daf-8ebb-691b6612c340"
      unitRef="usd">549100000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
      contextRef="ia25fb80ee7f14608ad1bc42cf7dc3d85_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMjItMS0xLTEtMTU5NTQw_43cf3cab-66bc-410a-815d-0db050aa205b"
      unitRef="usd">583700000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
    <us-gaap:OtherLongTermInvestments
      contextRef="ib7532b4a86304eaf897b92f1ef90f733_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMjMtMS0xLTEtMTU5NTQw_0e8d0aab-2aca-45db-b861-610cbb6dfc1a"
      unitRef="usd">764800000</us-gaap:OtherLongTermInvestments>
    <us-gaap:LongTermInvestments
      contextRef="ia25fb80ee7f14608ad1bc42cf7dc3d85_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMjQtMS0xLTEtMTU5NTQw_ceea8f95-4c9c-473c-9381-a572a8716b92"
      unitRef="usd">2574600000</us-gaap:LongTermInvestments>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ic3b630730b424a6d8b697cf0362c83d2_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMjctMS0xLTEtMTU5NTQw_7b66aac1-5e07-4766-b62d-f2d335009b63"
      unitRef="usd">2379500000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i0d06252e717445c989a037b2b13d0128_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMjctMy0xLTEtMTU5NTQw_0dbc3d35-107a-4fb6-a6db-8ab9a1fbf94e"
      unitRef="usd">2379500000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i6802f141d8af4b8aa65c6abe305eeed2_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMjctNS0xLTEtMTU5NTQw_2467fa7e-f467-41ab-bd5c-7b6ee9e5b6cc"
      unitRef="usd">2361000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i124320eb89ce4dfa87c2f2083ad1e10b_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMjctNy0xLTEtMTU5NTQw_e9ca3d15-ce0a-4578-b6af-74402e255acc"
      unitRef="usd">18500000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i2f37875c8bb94fed916b3375076f0703_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMjctOS0xLTEtMTU5NTQw_1f815554-d81c-4187-91a3-b86b238069f3"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i52e3293fb124489e844061750e511c35_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMjctMTEtMS0xLTE1OTU0MA_e256ec1c-7bcc-436f-88d0-73c5fb6c3cb4"
      unitRef="usd">2379500000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i70cd211932aa44d4b6f18e4a94acaa15_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMzAtMS0xLTEtMTU5NTQw_c0da060b-b885-453b-ae08-f6ba6607790c"
      unitRef="usd">25700000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i47952f5ad6b1477c8890a2ebe950ab13_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMzAtMy0xLTEtMTU5NTQw_1100363e-6803-4544-976c-fb8ae6ea81cf"
      unitRef="usd">25600000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="iddfe43e26a024cd3b793575cebd70372_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMzAtNS0xLTEtMTU5NTQw_421764a3-8a3b-46f1-ace1-ae0f5ccc3cc5"
      unitRef="usd">25700000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ic82b5cca8a0748c4ad44ff28aa5c8c63_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMzAtNy0xLTEtMTU5NTQw_18bb5c48-352d-4382-961b-64103c434c69"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i19bcbbad1685404f997100cdd7ba2b51_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMzAtOS0xLTEtMTU5NTQw_a9166f0a-1aeb-4cec-8635-8f0dbc18e355"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ibb1ad2dc0cab41488bb60c7f417df54c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMzAtMTEtMS0xLTE1OTU0MA_4889383f-c53b-4aaf-a727-f8c740d6bd93"
      unitRef="usd">25700000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ifb25438d52ac455ba62e9095554c8121_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMzEtMS0xLTEtMTU5NTQw_2cad25b6-ee2b-4be4-922b-ca87f6302be4"
      unitRef="usd">43700000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="iabe3e352015e443c90f93e7aee3a5340_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMzEtMy0xLTEtMTU5NTQw_52209efd-b5d5-488f-a728-e16b4a341a5a"
      unitRef="usd">43700000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i4d09607d938a418caf31b9504379627d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMzEtNS0xLTEtMTU5NTQw_2044d514-8d2a-42b4-aaee-83dbbf2bc194"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i70c1a238fafa4e82bb91738050707531_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMzEtNy0xLTEtMTU5NTQw_48e6f4de-f6d0-48c7-8bf8-d65fb435960c"
      unitRef="usd">43700000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i94da7f9a237b4f5d92545750475e0865_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMzEtOS0xLTEtMTU5NTQw_0387427d-5688-4a9f-8513-3db44bf13f13"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="iace537990e0345b984d5d9b511dbd56b_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMzEtMTEtMS0xLTE1OTU0MA_ddb7535a-79ad-41a1-8028-5238d3eaa7e2"
      unitRef="usd">43700000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i122e96dd9f3645a1845a400915d238b3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMzItMS0xLTEtMTU5NTQw_4a9755d6-1970-4c49-a26b-2f96abe30c17"
      unitRef="usd">200000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i2193cdcf640b46f79e5eb9ee0bdb3eb2_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMzItMy0xLTEtMTU5NTQw_968a280b-6dfe-49ea-8996-8171f0ba60d2"
      unitRef="usd">200000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="idb15d5720b2447969c89619f23a52bcd_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMzItNS0xLTEtMTU5NTQw_4bb90297-c356-45c8-9a40-66fc5dc9e3d9"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i83fbafd3b87749b69732c68f1032fe86_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMzItNy0xLTEtMTU5NTQw_9431e545-5966-4707-9c0c-c892fa07d563"
      unitRef="usd">200000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="if5e4829c2687480ba72b8c79c38602c5_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMzItOS0xLTEtMTU5NTQw_53f4bbc9-a0f8-43b3-80ef-1c4747e2322f"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i5e0c7dd136f94803b44868029c626465_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMzItMTEtMS0xLTE1OTU0MA_21f0e55a-d8a9-4231-8d6b-71693a9361d2"
      unitRef="usd">200000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i77a8bad9e7b643b3be999c26e7f341f3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMzMtMS0xLTEtMTU5NTQw_6ef467e6-6bec-4457-9999-ed448e96fa78"
      unitRef="usd">6200000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i3729e6381590490cad36d5c52a3a9a30_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMzMtMy0xLTEtMTU5NTQw_bc0c326f-5d34-4b0e-8f3b-530d7b55417d"
      unitRef="usd">6200000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i65d4f921c43e46389cd396c859835baa_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMzMtNS0xLTEtMTU5NTQw_fe9752cc-d4f5-4125-9759-093427290636"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ifea7137c64a940b98bfaf9336e0de8ed_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMzMtNy0xLTEtMTU5NTQw_0cd4dba2-48f3-4ac3-a17e-a844b4aa9585"
      unitRef="usd">6200000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ibb1fc1f870e44eb8b489ae050e35d2ec_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMzMtOS0xLTEtMTU5NTQw_b34f0e66-9494-4c18-8c85-c649a7749463"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i5843990a9b9642e089425093f642f011_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMzMtMTEtMS0xLTE1OTU0MA_19f2a45a-3903-414b-bc1f-f9b46120e90b"
      unitRef="usd">6200000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i3d4a6fcb14b84769a71beaa7fadd7543_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMzQtMS0xLTEtMTU5NTQw_bbd695a7-43e1-47aa-8426-a73e14e4140d"
      unitRef="usd">14300000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ib55c35900e8f4879bbab1c3db2b414e6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMzQtMy0xLTEtMTU5NTQw_4f332b60-d353-403c-b638-2d42cbcc726e"
      unitRef="usd">14300000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i514a63925c814a928a17a95e4d93d7cb_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMzQtNS0xLTEtMTU5NTQw_6e73d3d1-890b-4ece-ba14-28fa22ac6d35"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i4e737ad3e2234f028bf65d35bf37f064_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMzQtNy0xLTEtMTU5NTQw_df349d80-9897-4b76-b9cc-7c5cfc836467"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ie8e9125bc9f34767a3e05b3c767b3498_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMzQtOS0xLTEtMTU5NTQw_9cd8843e-e6f3-44ae-acc0-4c612e6dc78b"
      unitRef="usd">14300000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ib0e7cf4206ef42778711f85fddbfe12c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMzQtMTEtMS0xLTE1OTU0MA_84661a8f-36b9-416e-8bf4-17b53ea56a91"
      unitRef="usd">14300000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ic3b630730b424a6d8b697cf0362c83d2_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMzYtMS0xLTEtMTU5NTQw_a1311ae5-10fe-420c-a7e9-178fa9e5e494"
      unitRef="usd">90100000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i70cd211932aa44d4b6f18e4a94acaa15_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMzktMS0xLTEtMTU5NTQw_15d66309-3d4f-4f49-abc4-eb1330c14607"
      unitRef="usd">137000000.0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i47952f5ad6b1477c8890a2ebe950ab13_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMzktMy0xLTEtMTU5NTQw_fe7d663f-4f6a-4d1f-9e54-34ed4130ae72"
      unitRef="usd">136800000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="iddfe43e26a024cd3b793575cebd70372_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMzktNS0xLTEtMTU5NTQw_69e75e5e-d4bb-4e0a-9c94-b5f82f911162"
      unitRef="usd">137000000.0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="ic82b5cca8a0748c4ad44ff28aa5c8c63_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMzktNy0xLTEtMTU5NTQw_ddcd1559-d70f-4d48-9409-d74db71cf56b"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i19bcbbad1685404f997100cdd7ba2b51_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMzktOS0xLTEtMTU5NTQw_6e712349-8bf7-4309-896e-f5650e62a9e7"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="ibb1ad2dc0cab41488bb60c7f417df54c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfMzktMTEtMS0xLTE1OTU0MA_b55c9a85-870a-4bd9-a2f2-0efd372b7297"
      unitRef="usd">137000000.0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="ifb25438d52ac455ba62e9095554c8121_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfNDAtMS0xLTEtMTU5NTQw_9de13d7e-0e0f-4a2f-af06-a6c84ccb4588"
      unitRef="usd">235300000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="iabe3e352015e443c90f93e7aee3a5340_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfNDAtMy0xLTEtMTU5NTQw_319ad318-d462-40de-b52f-9714e3100bd4"
      unitRef="usd">232700000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i4d09607d938a418caf31b9504379627d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfNDAtNS0xLTEtMTU5NTQw_ed893770-c64a-4eff-aa20-8542c474a054"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i70c1a238fafa4e82bb91738050707531_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfNDAtNy0xLTEtMTU5NTQw_0057f2b7-d6d0-4974-9749-e94009453be8"
      unitRef="usd">235300000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i94da7f9a237b4f5d92545750475e0865_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfNDAtOS0xLTEtMTU5NTQw_71e41d7a-b672-4263-a7a5-994a9e9f7f4c"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="iace537990e0345b984d5d9b511dbd56b_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfNDAtMTEtMS0xLTE1OTU0MA_8b3486fb-70b4-4456-8250-34073e4aa89b"
      unitRef="usd">235300000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i122e96dd9f3645a1845a400915d238b3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfNDEtMS0xLTEtMTU5NTQw_53fe74f9-f8d7-42b4-9afb-6fb9f7bbc2b6"
      unitRef="usd">109800000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i2193cdcf640b46f79e5eb9ee0bdb3eb2_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfNDEtMy0xLTEtMTU5NTQw_3aa812ff-adfc-4eb1-9951-66c05d711224"
      unitRef="usd">108100000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="idb15d5720b2447969c89619f23a52bcd_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfNDEtNS0xLTEtMTU5NTQw_c5014f5c-26e0-4957-a321-8c117536ad26"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i83fbafd3b87749b69732c68f1032fe86_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfNDEtNy0xLTEtMTU5NTQw_2a512c98-0933-4e70-80a6-666b5f66bce2"
      unitRef="usd">109800000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="if5e4829c2687480ba72b8c79c38602c5_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfNDEtOS0xLTEtMTU5NTQw_2cf65041-9992-4987-906b-efa0d10d7c05"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i5e0c7dd136f94803b44868029c626465_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfNDEtMTEtMS0xLTE1OTU0MA_7ddec577-50c1-42e6-9764-7cb61a987502"
      unitRef="usd">109800000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i77a8bad9e7b643b3be999c26e7f341f3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfNDItMS0xLTEtMTU5NTQw_c6ec8f93-6aec-4720-a531-22fb6fb38030"
      unitRef="usd">23100000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i3729e6381590490cad36d5c52a3a9a30_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfNDItMy0xLTEtMTU5NTQw_408b5c13-68ae-451f-b783-5f190843a3c5"
      unitRef="usd">23100000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i65d4f921c43e46389cd396c859835baa_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfNDItNS0xLTEtMTU5NTQw_12486ee3-0f84-4d73-a39f-011c522d1c62"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="ifea7137c64a940b98bfaf9336e0de8ed_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfNDItNy0xLTEtMTU5NTQw_d0c68b71-0a25-498b-87c8-d5d82386e23b"
      unitRef="usd">23100000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="ibb1fc1f870e44eb8b489ae050e35d2ec_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfNDItOS0xLTEtMTU5NTQw_d4c91593-5ee7-40c7-bd37-549f7fd6aede"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i5843990a9b9642e089425093f642f011_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfNDItMTEtMS0xLTE1OTU0MA_f43e31f5-5d4f-4601-90a5-6f245ac2b14a"
      unitRef="usd">23100000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i37d081dc80d549d0b7cf06f3dd0f097c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfNDMtMS0xLTEtMTU5NTQw_c27e376e-c098-4bbf-a860-8d10b104fc45"
      unitRef="usd">108100000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="iebaf7a78928c429596dc216106cd2f95_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfNDMtMy0xLTEtMTU5NTQw_6fc87c01-6efe-4949-9de4-b7ba6e85c61e"
      unitRef="usd">22200000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i4a82bacb2ac843e1b6f6f2fe0be9b508_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfNDMtNS0xLTEtMTU5NTQw_64426407-62cc-4ce5-8bd8-2e1bd520a816"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="iddd8d40ea4024e44853ebae245c8ff89_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfNDMtNy0xLTEtMTU5NTQw_461d6cc0-c4a8-4f21-ac5a-aab383791e52"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="iee09e9df8cb24a98b446ff1b40b49036_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfNDMtOS0xLTEtMTU5NTQw_1a1d9ffa-324d-46aa-98e7-b103c32ed0cb"
      unitRef="usd">108100000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i76efc9c2d361426a8fabf8f468eae443_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfNDMtMTEtMS0xLTE1OTU0MA_51023642-42a9-4daf-828d-c13b9640b9ef"
      unitRef="usd">108100000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i900be75d24cb4d0e8aaf431324f245f7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfNDQtMS0xLTEtMTU5NTQw_d6163976-f1e6-46e1-a57a-c5a5384560b5"
      unitRef="usd">1279700000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ic0829e7b5687473690dec2d117e19409_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfNDQtMy0xLTEtMTU5NTQw_37ed1f2b-2553-434a-9a38-94cf9064822d"
      unitRef="usd">487000000.0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="icdba688916644cc684b154cd319074ad_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfNDQtNS0xLTEtMTU5NTQw_66d6b23e-834a-4a90-bc92-826cf0c93afa"
      unitRef="usd">1279700000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i74870f5304a445feafaa0e95c37df511_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfNDQtNy0xLTEtMTU5NTQw_fc360f18-9e6a-4ac0-bce3-2d65f108c76e"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="iec666b23a81840999cae844ee05abaf5_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfNDQtOS0xLTEtMTU5NTQw_c07932cc-717a-49c5-be6c-d06aa60b62ac"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i4dddf28fc04840efa98b6944bdadf64c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfNDQtMTEtMS0xLTE1OTU0MA_ff317ec6-c800-44f2-8a1d-ae36d8af4ce2"
      unitRef="usd">1279700000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
      contextRef="ic3b630730b424a6d8b697cf0362c83d2_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfNDUtMS0xLTEtMTU5NTQw_6a77511b-20ea-4d06-9057-064a5f628f72"
      unitRef="usd">548100000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
    <us-gaap:OtherLongTermInvestments
      contextRef="i89e7fea8ea92492693f830dd7afa0d55_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfNDYtMS0xLTEtMTU5NTQw_5d9bcb86-8e21-4517-8e47-2fa2d674c981"
      unitRef="usd">771500000</us-gaap:OtherLongTermInvestments>
    <us-gaap:LongTermInvestments
      contextRef="ic3b630730b424a6d8b697cf0362c83d2_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjMyYWY3NWMxMWNhYTQ0ZmNiYzA4OGRkMzI3YzYzY2NmL3RhYmxlcmFuZ2U6MzJhZjc1YzExY2FhNDRmY2JjMDg4ZGQzMjdjNjNjY2ZfNDctMS0xLTEtMTU5NTQw_2102108b-a17f-4cba-ba25-7847b199c60c"
      unitRef="usd">3212600000</us-gaap:LongTermInvestments>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock
      contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RleHRyZWdpb246OGRmOTEwZDdhYjFhNDFmMThlODU5ZTE4OTQxY2E4MDhfMTUxNjQ_9cf34e74-a993-46a9-8fb7-348a8e1f7585">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.320%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.320%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.320%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.320%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.322%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements Using&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted Prices in Active Markets for Identical Assets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Other Observable Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Short-term commercial paper borrowings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(1,741.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(1,738.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(1,738.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Long-term debt, including current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(14,147.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(11,848.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(11,848.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16,884.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18,157.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18,157.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock>
    <us-gaap:CommercialPaper
      contextRef="ia25fb80ee7f14608ad1bc42cf7dc3d85_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjcyZmFiYWVlZWVhODRmZTdiN2E3NjI2ZTAwNzM2ODg2L3RhYmxlcmFuZ2U6NzJmYWJhZWVlZWE4NGZlN2I3YTc2MjZlMDA3MzY4ODZfMy0xLTEtMS0xNTk1NDA_7420c4f6-cf56-4f12-bad4-5a53445716fd"
      unitRef="usd">1741300000</us-gaap:CommercialPaper>
    <us-gaap:CommercialPaper
      contextRef="i909f721d549b4d17b64fd5ef7a64ed65_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjcyZmFiYWVlZWVhODRmZTdiN2E3NjI2ZTAwNzM2ODg2L3RhYmxlcmFuZ2U6NzJmYWJhZWVlZWE4NGZlN2I3YTc2MjZlMDA3MzY4ODZfMy0zLTEtMS0xNTk1NDA_48d1e888-4a78-41b2-8575-3184a47b5b45"
      unitRef="usd">0</us-gaap:CommercialPaper>
    <us-gaap:CommercialPaper
      contextRef="ida76f129eae2411aac66cefe0c47c6fc_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjcyZmFiYWVlZWVhODRmZTdiN2E3NjI2ZTAwNzM2ODg2L3RhYmxlcmFuZ2U6NzJmYWJhZWVlZWE4NGZlN2I3YTc2MjZlMDA3MzY4ODZfMy01LTEtMS0xNTk1NDA_b88c5560-aa75-4b1f-8c2a-232eab6d23f7"
      unitRef="usd">1738000000</us-gaap:CommercialPaper>
    <us-gaap:CommercialPaper
      contextRef="ic34ce18d9ac34702bf22cdc268d8fddc_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjcyZmFiYWVlZWVhODRmZTdiN2E3NjI2ZTAwNzM2ODg2L3RhYmxlcmFuZ2U6NzJmYWJhZWVlZWE4NGZlN2I3YTc2MjZlMDA3MzY4ODZfMy03LTEtMS0xNTk1NDA_7a4cc1b6-b1c6-495a-ae98-04e8ae4f9fae"
      unitRef="usd">0</us-gaap:CommercialPaper>
    <us-gaap:CommercialPaper
      contextRef="ice641419095d40b58b1ec413657e5350_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjcyZmFiYWVlZWVhODRmZTdiN2E3NjI2ZTAwNzM2ODg2L3RhYmxlcmFuZ2U6NzJmYWJhZWVlZWE4NGZlN2I3YTc2MjZlMDA3MzY4ODZfMy05LTEtMS0xNTk1NDA_2c2af7bf-92d5-4a21-9fa7-7fb4c3947d94"
      unitRef="usd">1738000000</us-gaap:CommercialPaper>
    <us-gaap:CommercialPaper
      contextRef="ic3b630730b424a6d8b697cf0362c83d2_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjcyZmFiYWVlZWVhODRmZTdiN2E3NjI2ZTAwNzM2ODg2L3RhYmxlcmFuZ2U6NzJmYWJhZWVlZWE4NGZlN2I3YTc2MjZlMDA3MzY4ODZfNC0xLTEtMS0xNTk1NDA_025c32dc-423b-4e5f-955e-380391d3d409"
      unitRef="usd">0</us-gaap:CommercialPaper>
    <us-gaap:CommercialPaper
      contextRef="i6802f141d8af4b8aa65c6abe305eeed2_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjcyZmFiYWVlZWVhODRmZTdiN2E3NjI2ZTAwNzM2ODg2L3RhYmxlcmFuZ2U6NzJmYWJhZWVlZWE4NGZlN2I3YTc2MjZlMDA3MzY4ODZfNC0zLTEtMS0xNTk1NDA_3a4f749f-fc88-45b4-b3e9-24998a15bb87"
      unitRef="usd">0</us-gaap:CommercialPaper>
    <us-gaap:CommercialPaper
      contextRef="i124320eb89ce4dfa87c2f2083ad1e10b_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjcyZmFiYWVlZWVhODRmZTdiN2E3NjI2ZTAwNzM2ODg2L3RhYmxlcmFuZ2U6NzJmYWJhZWVlZWE4NGZlN2I3YTc2MjZlMDA3MzY4ODZfNC01LTEtMS0xNTk1NDA_546cb3b4-8d82-4d9b-83fb-b37859df70e9"
      unitRef="usd">0</us-gaap:CommercialPaper>
    <us-gaap:CommercialPaper
      contextRef="i2f37875c8bb94fed916b3375076f0703_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjcyZmFiYWVlZWVhODRmZTdiN2E3NjI2ZTAwNzM2ODg2L3RhYmxlcmFuZ2U6NzJmYWJhZWVlZWE4NGZlN2I3YTc2MjZlMDA3MzY4ODZfNC03LTEtMS0xNTk1NDA_8ee8caf3-bdf4-4424-b31b-421b1224d2d9"
      unitRef="usd">0</us-gaap:CommercialPaper>
    <us-gaap:CommercialPaper
      contextRef="i52e3293fb124489e844061750e511c35_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjcyZmFiYWVlZWVhODRmZTdiN2E3NjI2ZTAwNzM2ODg2L3RhYmxlcmFuZ2U6NzJmYWJhZWVlZWE4NGZlN2I3YTc2MjZlMDA3MzY4ODZfNC05LTEtMS0xNTk1NDA_7df4475d-7590-4e02-b1e6-271976608ede"
      unitRef="usd">0</us-gaap:CommercialPaper>
    <us-gaap:LongTermDebt
      contextRef="ia25fb80ee7f14608ad1bc42cf7dc3d85_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjcyZmFiYWVlZWVhODRmZTdiN2E3NjI2ZTAwNzM2ODg2L3RhYmxlcmFuZ2U6NzJmYWJhZWVlZWE4NGZlN2I3YTc2MjZlMDA3MzY4ODZfNi0xLTEtMS0xNTk1NDA_d62b2cfe-dc1a-4374-bd46-a55cfcc379f3"
      unitRef="usd">14147100000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i909f721d549b4d17b64fd5ef7a64ed65_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjcyZmFiYWVlZWVhODRmZTdiN2E3NjI2ZTAwNzM2ODg2L3RhYmxlcmFuZ2U6NzJmYWJhZWVlZWE4NGZlN2I3YTc2MjZlMDA3MzY4ODZfNi0zLTEtMS0xNTk1NDA_10d5c607-7b6c-4243-b863-c2dcaae216b6"
      unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="ida76f129eae2411aac66cefe0c47c6fc_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjcyZmFiYWVlZWVhODRmZTdiN2E3NjI2ZTAwNzM2ODg2L3RhYmxlcmFuZ2U6NzJmYWJhZWVlZWE4NGZlN2I3YTc2MjZlMDA3MzY4ODZfNi01LTEtMS0xNTk1NDA_70b5fdf3-9fc1-4290-bd75-44b912f10b37"
      unitRef="usd">11848600000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="ic34ce18d9ac34702bf22cdc268d8fddc_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjcyZmFiYWVlZWVhODRmZTdiN2E3NjI2ZTAwNzM2ODg2L3RhYmxlcmFuZ2U6NzJmYWJhZWVlZWE4NGZlN2I3YTc2MjZlMDA3MzY4ODZfNi03LTEtMS0xNTk1NDA_ff95524b-e84f-4008-97ef-2a9e3c150d63"
      unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="ice641419095d40b58b1ec413657e5350_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjcyZmFiYWVlZWVhODRmZTdiN2E3NjI2ZTAwNzM2ODg2L3RhYmxlcmFuZ2U6NzJmYWJhZWVlZWE4NGZlN2I3YTc2MjZlMDA3MzY4ODZfNi05LTEtMS0xNTk1NDA_34707b5d-0cc8-4966-b228-a657e42af3b8"
      unitRef="usd">11848600000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="ic3b630730b424a6d8b697cf0362c83d2_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjcyZmFiYWVlZWVhODRmZTdiN2E3NjI2ZTAwNzM2ODg2L3RhYmxlcmFuZ2U6NzJmYWJhZWVlZWE4NGZlN2I3YTc2MjZlMDA3MzY4ODZfNy0xLTEtMS0xNTk1NDA_2b9e2e9d-7c11-4a8a-ac3a-18ac3d4dac90"
      unitRef="usd">16884700000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i6802f141d8af4b8aa65c6abe305eeed2_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjcyZmFiYWVlZWVhODRmZTdiN2E3NjI2ZTAwNzM2ODg2L3RhYmxlcmFuZ2U6NzJmYWJhZWVlZWE4NGZlN2I3YTc2MjZlMDA3MzY4ODZfNy0zLTEtMS0xNTk1NDA_09d7cbb5-d425-407d-abd5-daf856309fb4"
      unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i124320eb89ce4dfa87c2f2083ad1e10b_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjcyZmFiYWVlZWVhODRmZTdiN2E3NjI2ZTAwNzM2ODg2L3RhYmxlcmFuZ2U6NzJmYWJhZWVlZWE4NGZlN2I3YTc2MjZlMDA3MzY4ODZfNy01LTEtMS0xNTk1NDA_c8f22544-7716-4e98-a73e-0b08ced8dc96"
      unitRef="usd">18157700000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i2f37875c8bb94fed916b3375076f0703_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjcyZmFiYWVlZWVhODRmZTdiN2E3NjI2ZTAwNzM2ODg2L3RhYmxlcmFuZ2U6NzJmYWJhZWVlZWE4NGZlN2I3YTc2MjZlMDA3MzY4ODZfNy03LTEtMS0xNTk1NDA_434d68d6-5d65-4d5e-bff7-3638f8705a88"
      unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i52e3293fb124489e844061750e511c35_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjcyZmFiYWVlZWVhODRmZTdiN2E3NjI2ZTAwNzM2ODg2L3RhYmxlcmFuZ2U6NzJmYWJhZWVlZWE4NGZlN2I3YTc2MjZlMDA3MzY4ODZfNy05LTEtMS0xNTk1NDA_a78bfa23-a816-4245-b199-c78a9bd93809"
      unitRef="usd">18157700000</us-gaap:LongTermDebt>
    <us-gaap:FairValueByBalanceSheetGroupingTextBlock
      contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RleHRyZWdpb246OGRmOTEwZDdhYjFhNDFmMThlODU5ZTE4OTQxY2E4MDhfMTUxMjU_1236d36a-e08a-4940-96ed-a206440b1a5f">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.517%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.517%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.517%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.517%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements Using&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted Prices in Active Markets for Identical Assets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Other Observable Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Risk-management instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest rate contracts designated as fair value hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other noncurrent liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(140.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(140.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(140.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest rate contracts designated as cash flow hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;355.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;355.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;355.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cross-currency interest rate contracts designated as net investment hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;81.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;81.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;81.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;116.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;116.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;116.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cross-currency interest rate contracts designated as cash flow hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;8.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;8.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;8.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other noncurrent liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(12.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(12.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(12.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts designated as net investment hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;108.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;108.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;108.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(2.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(2.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(2.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts not designated as hedging instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;48.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;48.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;48.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(93.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(93.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(93.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Contingent consideration liability:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other noncurrent liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(42.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(42.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(42.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Risk-management instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest rate contracts designated as fair value hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other receivables&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;78.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;78.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;78.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other noncurrent liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(7.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(7.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(7.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest rate contracts designated as cash flow hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;49.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;49.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;49.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other noncurrent liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(31.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(31.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(31.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cross-currency interest rate contracts designated as net investment hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;31.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;31.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;31.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cross-currency interest rate contracts designated as cash flow hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;33.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;33.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;33.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other noncurrent liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts not designated as hedging instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(35.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(35.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(35.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Contingent consideration liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other noncurrent liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(70.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(70.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(70.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueByBalanceSheetGroupingTextBlock>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i49af86cdb4774f6da136e21a258b9f38_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfOC0xLTEtMS0xNTk1NDA_458a107c-8eea-400b-a657-4a0ff904219c"
      unitRef="usd">140200000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i9b96398a66a144a9aa05b43dea309d1a_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfOC0zLTEtMS0xNTk1NDA_3c2c8659-be59-40fa-b529-3cc9c6818c50"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i9eb05f2daf0940029ed9c6f6079b072c_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfOC01LTEtMS0xNTk1NDA_bd5d7c80-fb2a-4011-b95d-1b181930c010"
      unitRef="usd">140200000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i0cbd0bb84e934e18aa8a68f2ed4e3278_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfOC03LTEtMS0xNTk1NDA_8c46a2ad-b135-4b31-bfa5-f2f58be6dc64"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i5e03886140d04a0f90b726a0b8cb04a2_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfOC05LTEtMS0xNTk1NDA_8bd8e3b3-e776-4f74-9f05-dc9e9f141d1c"
      unitRef="usd">140200000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="ie1da8e0f672e4bc390cd335a91d4cf83_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfMTItMS0xLTEtMTU5NTQw_dd57b20d-a74f-471c-99f6-8a7149749b93"
      unitRef="usd">355200000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i7cba691ea8004d118d604043b64cd431_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfMTItMy0xLTEtMTU5NTQw_58e7a805-65fb-4e70-b417-727798ba8336"
      unitRef="usd">0</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="id1657a9a2856448687ac9aaada343dd5_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfMTItNS0xLTEtMTU5NTQw_57ceef84-3fe3-46de-ad91-c9b62812e074"
      unitRef="usd">355200000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i020782910cc740779ffa9060458113ba_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfMTItNy0xLTEtMTU5NTQw_242c5ee9-a6c5-47ae-bc3a-fb17e62ed2a9"
      unitRef="usd">0</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i8f69ca689c7e4d23aa1cab488bb7ed65_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfMTItOS0xLTEtMTU5NTQw_cab06653-49d3-4d64-a9d9-83ce5314f2a3"
      unitRef="usd">355200000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="i1300d5f8c7d44be79cb93f333746c580_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfMTUtMS0xLTEtMTU5NTQw_22e1f2f2-1e6c-42b2-ba3a-17acb986d6ad"
      unitRef="usd">81600000</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="iaca361ecbf3749b7a324afc87754e17e_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfMTUtMy0xLTEtMTU5NTQw_490ee643-f78c-48e4-9a9f-e0a1cbc14e98"
      unitRef="usd">0</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="i5ac9d317ae404d2ebdc37459bd98e0c0_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfMTUtNS0xLTEtMTU5NTQw_78af148b-8a72-4cc9-8391-b3bbc42f15e9"
      unitRef="usd">81600000</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="ib6a56ab1b3ed4c26b10443b11b7c0c23_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfMTUtNy0xLTEtMTU5NTQw_b54fa0cf-6abb-4ef0-a3db-ff471554b1bc"
      unitRef="usd">0</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="id7268bc376574172920167043f112985_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfMTUtOS0xLTEtMTU5NTQw_453b9670-6638-4ae0-9088-6b1158b6a484"
      unitRef="usd">81600000</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i1300d5f8c7d44be79cb93f333746c580_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfMTYtMS0xLTEtMTU5NTQw_ebdf50ae-a827-4b98-b760-613c9438eaa8"
      unitRef="usd">116900000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="iaca361ecbf3749b7a324afc87754e17e_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfMTYtMy0xLTEtMTU5NTQw_9e27aa07-70a0-44fb-a605-0e79a35b8fee"
      unitRef="usd">0</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i5ac9d317ae404d2ebdc37459bd98e0c0_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfMTYtNS0xLTEtMTU5NTQw_d79fea84-482e-413c-ba99-842ed843cfd9"
      unitRef="usd">116900000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="ib6a56ab1b3ed4c26b10443b11b7c0c23_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfMTYtNy0xLTEtMTU5NTQw_19332f46-9c44-491f-a98d-0aa5ba060b83"
      unitRef="usd">0</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="id7268bc376574172920167043f112985_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfMTYtOS0xLTEtMTU5NTQw_7e20ae77-589b-47c0-89e9-fa96c848500c"
      unitRef="usd">116900000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="id872aa3055934897a2abffb3543add56_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfMjAtMS0xLTEtMTU5NTQw_322b03c2-a902-4e01-8414-dc789221f7b3"
      unitRef="usd">8300000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="idfd9f0975707442aa9a203b7a16441c5_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfMjAtMy0xLTEtMTU5NTQw_1d3e6a0d-572b-4c76-9a66-2ed3d74705df"
      unitRef="usd">0</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="ib2eb41ed3d014ed4b273125814f78a0d_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfMjAtNS0xLTEtMTU5NTQw_aef1fa34-da10-42bb-ab0c-3951d152889e"
      unitRef="usd">8300000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i79464644e1f741088bd241cb52754676_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfMjAtNy0xLTEtMTU5NTQw_93bc179c-7728-47a6-b89c-a9105457fb44"
      unitRef="usd">0</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i35a8009df6dc423f85c1ef726d565a66_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfMjAtOS0xLTEtMTU5NTQw_42a55421-ee80-4a33-b659-64ba86119db7"
      unitRef="usd">8300000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="id872aa3055934897a2abffb3543add56_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfMjEtMS0xLTEtMTU5NTQw_c363b830-0837-4e83-a387-ed9a16b84915"
      unitRef="usd">12900000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="idfd9f0975707442aa9a203b7a16441c5_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfMjEtMy0xLTEtMTU5NTQw_aa85cf5a-507e-4e24-9be3-f79ad22f66fa"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="ib2eb41ed3d014ed4b273125814f78a0d_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfMjEtNS0xLTEtMTU5NTQw_e51dd8d9-ef2c-4045-8cf7-ff180aaef8fa"
      unitRef="usd">12900000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i79464644e1f741088bd241cb52754676_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfMjEtNy0xLTEtMTU5NTQw_27ebc35b-1998-4036-afd2-bd6b12d89ea4"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i35a8009df6dc423f85c1ef726d565a66_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfMjEtOS0xLTEtMTU5NTQw_b51103a3-95d7-424a-9274-1804e5eecfb1"
      unitRef="usd">12900000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="ib616e3ba735b4f66ace91c9075e315e3_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfMjMtMS0xLTEtMTU5NTQw_3c67fe3d-379c-49cb-b9fe-2c92be70cbee"
      unitRef="usd">108200000</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="i7d14a5f5fcc44e8b974f3d717097b500_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfMjMtMy0xLTEtMTU5NTQw_29cd5751-904d-4024-8d1e-20e27e2c3403"
      unitRef="usd">0</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="i7cf0b43a5a854904951946bba3c063dd_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfMjMtNS0xLTEtMTU5NTQw_419d7262-2984-4541-a997-45292104b17e"
      unitRef="usd">108200000</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="ie06f4bbec8ae497db6f7f77940abcf72_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfMjMtNy0xLTEtMTU5NTQw_f03efa66-b48c-4f00-a2cf-3eae3b20eee9"
      unitRef="usd">0</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="idd5c8623b0274f569a6e9cb890fe814d_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfMjMtOS0xLTEtMTU5NTQw_36bbdbae-cf70-4c04-898a-e2f63ee18621"
      unitRef="usd">108200000</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="ib616e3ba735b4f66ace91c9075e315e3_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfMjQtMS0xLTEtMTkzNDEz_076b24bf-65b5-41f5-a7c4-a3e96ec78f00"
      unitRef="usd">2900000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="i7d14a5f5fcc44e8b974f3d717097b500_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfMjQtMy0xLTEtMTkzNDI3_c51231dc-48c5-4320-957a-8698b6877907"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="i7cf0b43a5a854904951946bba3c063dd_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfMjQtNS0xLTEtMTkzNDQw_a0e929d0-4d82-4022-bdbe-6c8c242d63f8"
      unitRef="usd">2900000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="ie06f4bbec8ae497db6f7f77940abcf72_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfMjQtNy0xLTEtMTkzNDUx_acc3f89d-a9d6-45a2-99ab-1a658503186d"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="idd5c8623b0274f569a6e9cb890fe814d_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfMjQtOS0xLTEtMTkzNDU5_910d3f44-e0c1-437c-a1cc-a3d03f00f7e6"
      unitRef="usd">2900000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="id0faa86378a146a48b2256a18f02b7d5_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfMjUtMS0xLTEtMTU5NTQw_c1ce4a22-4048-4e66-958a-e5fcb6eb2431"
      unitRef="usd">48100000</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="iec96867cd1734fb382b9a966a90c804e_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfMjUtMy0xLTEtMTU5NTQw_70306229-3d77-49c6-9e24-823876c48528"
      unitRef="usd">0</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="i8d0b53a09fec472eab66541ef6214321_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfMjUtNS0xLTEtMTU5NTQw_2f215724-f9de-4e5d-86e0-08bb6dc6c70d"
      unitRef="usd">48100000</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="i1354c03ac64d49b996ad815decc0f6d7_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfMjUtNy0xLTEtMTU5NTQw_bab00712-5d23-4f4e-8bd1-afb3c3cbf3bd"
      unitRef="usd">0</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="ibc6aec644ba74dffa95a469f4848e6bc_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfMjUtOS0xLTEtMTU5NTQw_c6862c6f-4407-4d85-8438-9d3223841264"
      unitRef="usd">48100000</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="id0faa86378a146a48b2256a18f02b7d5_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfMjYtMS0xLTEtMTU5NTQw_7d2604a2-9b3d-40e6-9bd2-64e0a2c09aa7"
      unitRef="usd">93500000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="iec96867cd1734fb382b9a966a90c804e_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfMjYtMy0xLTEtMTU5NTQw_9fc9ed45-d004-4eb3-ba6a-1775e77d8531"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="i8d0b53a09fec472eab66541ef6214321_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfMjYtNS0xLTEtMTU5NTQw_053940e5-47ac-4261-adcf-247d072cfff1"
      unitRef="usd">93500000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="i1354c03ac64d49b996ad815decc0f6d7_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfMjYtNy0xLTEtMTU5NTQw_4fcf2bac-7145-46c9-8760-e4e4a03c9587"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="ibc6aec644ba74dffa95a469f4848e6bc_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfMjYtOS0xLTEtMTU5NTQw_3c8b48a8-9362-44d5-a394-3910de794eec"
      unitRef="usd">93500000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ia25fb80ee7f14608ad1bc42cf7dc3d85_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfMzEtMS0xLTEtMTU5NTQw_a454c479-b41d-4f7e-a863-9b67a1e1b97c"
      unitRef="usd">42100000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i909f721d549b4d17b64fd5ef7a64ed65_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfMzEtMy0xLTEtMTU5NTQw_dab904da-6fb0-4d2b-8e46-5ff134a993ba"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ida76f129eae2411aac66cefe0c47c6fc_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfMzEtNS0xLTEtMTU5NTQw_cbae7742-04e8-4363-a60a-a6758557c5e4"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ic34ce18d9ac34702bf22cdc268d8fddc_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfMzEtNy0xLTEtMTU5NTQw_b841238f-51cb-4aac-8384-aeff066ddc2b"
      unitRef="usd">42100000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ice641419095d40b58b1ec413657e5350_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfMzEtOS0xLTEtMTU5NTQw_337496d2-9905-448b-821d-30774d7d1d91"
      unitRef="usd">42100000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="i3a65232f1fca4f95abbb3167ab435068_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfMzYtMS0xLTEtMTU5NTQw_195b3f84-4bed-410a-8639-e544a1b13819"
      unitRef="usd">4800000</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="i40ccf9cc0ff7401eab9722772af73854_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfMzYtMy0xLTEtMTU5NTQw_b0805d62-c47a-43df-b8fb-b2f222781eb1"
      unitRef="usd">0</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="i4aa9bedfa4ea4600ab40f4f731255ce9_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfMzYtNS0xLTEtMTU5NTQw_40c5ea8c-6acb-4401-a7ed-8908804f41c9"
      unitRef="usd">4800000</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="i6a47a49c720948c3b475ad8f3cf1ff16_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfMzYtNy0xLTEtMTU5NTQw_6feccb88-17e0-4e30-a902-73b0f20dc399"
      unitRef="usd">0</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="i024a1912186c40c1a4e62a542f42350c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfMzYtOS0xLTEtMTU5NTQw_f9da8fe1-542a-44e3-86f8-c4cc8bfbf9d2"
      unitRef="usd">4800000</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i3a65232f1fca4f95abbb3167ab435068_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfMzctMS0xLTEtMTU5NTQw_702c5be3-298d-4de9-a7b6-efe750261277"
      unitRef="usd">78300000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i40ccf9cc0ff7401eab9722772af73854_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfMzctMy0xLTEtMTU5NTQw_0bd23237-d998-4adc-9bb2-7f8b45437b17"
      unitRef="usd">0</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i4aa9bedfa4ea4600ab40f4f731255ce9_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfMzctNS0xLTEtMTU5NTQw_beb31b67-0a26-4dea-b222-cf250671cfa7"
      unitRef="usd">78300000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i6a47a49c720948c3b475ad8f3cf1ff16_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfMzctNy0xLTEtMTU5NTQw_a20c48d6-e999-4249-b5e1-5de5ddab3c9f"
      unitRef="usd">0</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i024a1912186c40c1a4e62a542f42350c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfMzctOS0xLTEtMTU5NTQw_475a7dd8-a682-425c-b578-4ac9f9ee364c"
      unitRef="usd">78300000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i3a65232f1fca4f95abbb3167ab435068_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfMzktMS0xLTEtMTU5NTQw_2345edfb-29e7-40cc-8c45-9a5fb16e7a96"
      unitRef="usd">7600000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i40ccf9cc0ff7401eab9722772af73854_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfMzktMy0xLTEtMTU5NTQw_54c0ae5d-4ebd-4cdd-8771-a21ecd0debba"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i4aa9bedfa4ea4600ab40f4f731255ce9_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfMzktNS0xLTEtMTU5NTQw_00c322f4-1993-4e4c-adab-b5171fe83939"
      unitRef="usd">7600000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i6a47a49c720948c3b475ad8f3cf1ff16_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfMzktNy0xLTEtMTU5NTQw_308c6d03-3d42-43f0-91c8-464a1e037031"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i024a1912186c40c1a4e62a542f42350c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfMzktOS0xLTEtMTU5NTQw_d7a73612-0090-44cb-8650-8b6301153b76"
      unitRef="usd">7600000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i318612662ee348ca8f4c50e967285c42_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfNDEtMS0xLTEtMTU5NTQw_917b7e63-9c66-4cbe-a2ba-0a05b33173fb"
      unitRef="usd">49200000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i6b3448a25ab94a89aef263d03a2bd29a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfNDEtMy0xLTEtMTU5NTQw_00327ed6-0618-4511-8450-fd99d0855b47"
      unitRef="usd">0</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i841d22572a894c128f4304c5a9d761b0_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfNDEtNS0xLTEtMTU5NTQw_81eb4109-b8d2-478a-883d-dbb63601a4d6"
      unitRef="usd">49200000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="ie51a0fafa7104530b58bfc8df0b750d4_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfNDEtNy0xLTEtMTU5NTQw_8f4b0654-943a-4599-ad40-84f822e9c1d8"
      unitRef="usd">0</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i0999361082eb4d43bc2fc7f00ef0bae3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfNDEtOS0xLTEtMTU5NTQw_60039a2b-bdf9-42d9-995b-44b0b7308935"
      unitRef="usd">49200000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i318612662ee348ca8f4c50e967285c42_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfNDItMS0xLTEtMTU5NTQw_d47a46f8-49dd-4078-902d-2f9779a4bbd0"
      unitRef="usd">31700000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i6b3448a25ab94a89aef263d03a2bd29a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfNDItMy0xLTEtMTU5NTQw_f5fbe6a4-1584-43f3-a48d-eefc3dcef4c8"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i841d22572a894c128f4304c5a9d761b0_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfNDItNS0xLTEtMTU5NTQw_176a13ce-2a0d-4a95-8a2b-4a423e4e2f10"
      unitRef="usd">31700000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="ie51a0fafa7104530b58bfc8df0b750d4_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfNDItNy0xLTEtMTU5NTQw_219e1619-a0f5-44aa-acef-6d9e990e3d47"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i0999361082eb4d43bc2fc7f00ef0bae3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfNDItOS0xLTEtMTU5NTQw_a95a4bc5-66ef-488a-97fb-25f60cf77f9b"
      unitRef="usd">31700000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i8a94f32b7cb642279222210de17f03ed_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfNDUtMS0xLTEtMTU5NTQw_02897dc0-1425-4404-bbb3-106c18765a50"
      unitRef="usd">31300000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="iab252218731740b9a75cb6728b7b9503_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfNDUtMy0xLTEtMTU5NTQw_408933ea-01e8-48d6-9296-f809cb500bdd"
      unitRef="usd">0</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i5a6a92fb8f674015b49e7f493a12c723_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfNDUtNS0xLTEtMTU5NTQw_29d4b28f-a95b-48d2-8f91-b467d51af740"
      unitRef="usd">31300000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="iee54e09047ba4b21a41fa3c8cc49cec2_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfNDUtNy0xLTEtMTU5NTQw_73b2b14e-1ac8-43f2-a758-1317b01eee79"
      unitRef="usd">0</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="icf2c03c7d41e4db1941ec3f47533b5ac_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfNDUtOS0xLTEtMTU5NTQw_51cff681-efa0-470a-841d-615888177fcb"
      unitRef="usd">31300000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="i8a94f32b7cb642279222210de17f03ed_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfNDYtMS0xLTEtMTU5NTQw_aaf65246-76f2-4489-9052-46905345cf8e"
      unitRef="usd">1200000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="iab252218731740b9a75cb6728b7b9503_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfNDYtMy0xLTEtMTU5NTQw_a0278670-f225-4e35-b8e0-6cc186705f5a"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="i5a6a92fb8f674015b49e7f493a12c723_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfNDYtNS0xLTEtMTU5NTQw_9742dacc-dcc1-42bd-a5f3-b15ebffd65e3"
      unitRef="usd">1200000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="iee54e09047ba4b21a41fa3c8cc49cec2_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfNDYtNy0xLTEtMTU5NTQw_659aac83-3f23-4f40-b405-18d21242290e"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="icf2c03c7d41e4db1941ec3f47533b5ac_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfNDYtOS0xLTEtMTU5NTQw_83417eee-68cb-496e-b74d-5f873ab1e22a"
      unitRef="usd">1200000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i09f8de57c8924dc5916922a278ad4eb1_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfNDktMS0xLTEtMTU5NTQw_9b37ebf6-5a55-4a58-954c-cb957e1d7001"
      unitRef="usd">33200000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i1339ff825ab84e1292a5f32205bb84fb_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfNDktMy0xLTEtMTU5NTQw_a1425879-238d-4785-b0e5-50b10586d791"
      unitRef="usd">0</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="iddd7166aae2b440ab53a23a0b63e2aa9_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfNDktNS0xLTEtMTU5NTQw_92564f90-5f65-47e3-b196-c0c5d5911a29"
      unitRef="usd">33200000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="ic06c23f16f4443f78411fcbe2a43f013_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfNDktNy0xLTEtMTU5NTQw_f548e4cc-715c-4114-a162-3be09cf3f950"
      unitRef="usd">0</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="ia6485e6d1b024de18d35df5658693713_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfNDktOS0xLTEtMTU5NTQw_813e35ca-491b-4823-b2f7-d887a95854b1"
      unitRef="usd">33200000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i09f8de57c8924dc5916922a278ad4eb1_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfNTAtMS0xLTEtMTU5NTQw_e9d349c3-961b-4583-a904-0f5e3c7e0023"
      unitRef="usd">1300000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i1339ff825ab84e1292a5f32205bb84fb_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfNTAtMy0xLTEtMTU5NTQw_c8c7c961-faa8-4d2a-b814-a2461de9becb"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="iddd7166aae2b440ab53a23a0b63e2aa9_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfNTAtNS0xLTEtMTU5NTQw_1b99872b-28ce-47dd-ac6c-b82b08275635"
      unitRef="usd">1300000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="ic06c23f16f4443f78411fcbe2a43f013_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfNTAtNy0xLTEtMTU5NTQw_858eca8f-8a4d-4a7a-9b91-c65637099667"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="ia6485e6d1b024de18d35df5658693713_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfNTAtOS0xLTEtMTU5NTQw_e74e45b5-f654-460b-a5e0-91c4df806c49"
      unitRef="usd">1300000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="i9674dda0210248f68699af728a2b7366_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfNTItMS0xLTEtMTU5NTQw_a9b0cb44-1e16-4364-b2aa-dc206796df41"
      unitRef="usd">9900000</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="i05396d0962d648b89a38691fab6227da_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfNTItMy0xLTEtMTU5NTQw_42e63e7d-0796-40fe-9a02-7f231569f3d9"
      unitRef="usd">0</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="i637a8ab6a8a7402880d7c301d82ac216_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfNTItNS0xLTEtMTU5NTQw_493600d2-6bfe-4c94-8df7-31aaa9debfad"
      unitRef="usd">9900000</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="i47903bc5967647c3ad861c42d533efb5_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfNTItNy0xLTEtMTU5NTQw_97d07676-b86b-4f5b-8ca1-36c00b747282"
      unitRef="usd">0</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="i22af614be29843faa74794b4926362d9_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfNTItOS0xLTEtMTU5NTQw_d83d8859-efbb-4768-9e5f-373d7c668e82"
      unitRef="usd">9900000</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="i9674dda0210248f68699af728a2b7366_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfNTMtMS0xLTEtMTU5NTQw_f313140b-25f3-47d2-9903-34254c7891fe"
      unitRef="usd">35300000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="i05396d0962d648b89a38691fab6227da_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfNTMtMy0xLTEtMTU5NTQw_678f0086-bb4a-4545-83af-07b09c223ad8"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="i637a8ab6a8a7402880d7c301d82ac216_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfNTMtNS0xLTEtMTU5NTQw_ac2d072f-8ad2-4e4d-9bea-65d9a6fd2b2f"
      unitRef="usd">35300000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="i47903bc5967647c3ad861c42d533efb5_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfNTMtNy0xLTEtMTU5NTQw_a1828f81-f9b2-4ffd-90a9-7b0c4e2e3ac1"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="i22af614be29843faa74794b4926362d9_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfNTMtOS0xLTEtMTU5NTQw_cd7b2b48-874a-4b7b-9b88-eea51378640a"
      unitRef="usd">35300000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ic3b630730b424a6d8b697cf0362c83d2_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfNTYtMS0xLTEtMTU5NTQw_90fecfdc-c5d0-4fb1-af0a-e713a3f4d323"
      unitRef="usd">70500000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i6802f141d8af4b8aa65c6abe305eeed2_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfNTYtMy0xLTEtMTU5NTQw_7b158f4d-f4b4-4984-9a2c-6daf3b115547"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i124320eb89ce4dfa87c2f2083ad1e10b_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfNTYtNS0xLTEtMTU5NTQw_e4a927e1-ca5b-4995-a608-b10f14caf1ff"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i2f37875c8bb94fed916b3375076f0703_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfNTYtNy0xLTEtMTU5NTQw_28112ff9-cc87-4a90-92cd-2a6cd75442e2"
      unitRef="usd">70500000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i52e3293fb124489e844061750e511c35_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjk0YTA5MzRkZmM4ZTQ3ZmY4YTdmNjllZTFmYTM4YmYwL3RhYmxlcmFuZ2U6OTRhMDkzNGRmYzhlNDdmZjhhN2Y2OWVlMWZhMzhiZjBfNTYtOS0xLTEtMTU5NTQw_e816fe41-013d-4fa3-8f42-ee1697c3d840"
      unitRef="usd">70500000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments
      contextRef="i08ccb35f6ad24d7793c9c91b74ca2ea1_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RleHRyZWdpb246OGRmOTEwZDdhYjFhNDFmMThlODU5ZTE4OTQxY2E4MDhfMTA2Njc_4d1d6cb8-c65c-4dac-bd5f-f1074917dfbb"
      unitRef="usd">854000000</us-gaap:FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments>
    <lly:FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod
      contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RleHRyZWdpb246OGRmOTEwZDdhYjFhNDFmMThlODU5ZTE4OTQxY2E4MDhfMTA3ODY_c0b48292-becb-48a7-bdeb-620ef39ad735">P10Y</lly:FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock
      contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RleHRyZWdpb246OGRmOTEwZDdhYjFhNDFmMThlODU5ZTE4OTQxY2E4MDhfMTUxMDc_8195e1d3-627d-4380-a914-1bab3363b2db">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below summarizes the contractual maturities of our investments in debt securities measured at fair value as of September&#160;30, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.162%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.060%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.060%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.060%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.060%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.062%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Maturities by Period&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Less&#160;Than&lt;br/&gt;1 Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1-5&lt;br/&gt;Years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;6-10&lt;br/&gt;Years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;More&#160;Than&lt;br/&gt;10 Years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;622.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;197.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;205.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i08ccb35f6ad24d7793c9c91b74ca2ea1_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOmIyMDQ2NGYwYTg3NDRmNTE4NmY0ZTY4MmIwNmZiZWJlL3RhYmxlcmFuZ2U6YjIwNDY0ZjBhODc0NGY1MTg2ZjRlNjgyYjA2ZmJlYmVfMi0xLTEtMS0xNTk1NDA_b9dc3d8b-4db6-4ba5-b0d4-8b5002df5e24"
      unitRef="usd">622200000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="i08ccb35f6ad24d7793c9c91b74ca2ea1_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOmIyMDQ2NGYwYTg3NDRmNTE4NmY0ZTY4MmIwNmZiZWJlL3RhYmxlcmFuZ2U6YjIwNDY0ZjBhODc0NGY1MTg2ZjRlNjgyYjA2ZmJlYmVfMi0zLTEtMS0xNTk1NDA_872c587f-8a3e-4ab4-9cfb-2a4740153aa4"
      unitRef="usd">97700000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="i08ccb35f6ad24d7793c9c91b74ca2ea1_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOmIyMDQ2NGYwYTg3NDRmNTE4NmY0ZTY4MmIwNmZiZWJlL3RhYmxlcmFuZ2U6YjIwNDY0ZjBhODc0NGY1MTg2ZjRlNjgyYjA2ZmJlYmVfMi01LTEtMS0xNTk1NDA_eae1fcb3-6f93-441e-8c6e-773ba30e70a7"
      unitRef="usd">197800000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue
      contextRef="i08ccb35f6ad24d7793c9c91b74ca2ea1_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOmIyMDQ2NGYwYTg3NDRmNTE4NmY0ZTY4MmIwNmZiZWJlL3RhYmxlcmFuZ2U6YjIwNDY0ZjBhODc0NGY1MTg2ZjRlNjgyYjA2ZmJlYmVfMi03LTEtMS0xNTk1NDA_a8569ec8-bc0a-4b58-8d66-da4429ca1a33"
      unitRef="usd">121000000.0</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue
      contextRef="i08ccb35f6ad24d7793c9c91b74ca2ea1_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOmIyMDQ2NGYwYTg3NDRmNTE4NmY0ZTY4MmIwNmZiZWJlL3RhYmxlcmFuZ2U6YjIwNDY0ZjBhODc0NGY1MTg2ZjRlNjgyYjA2ZmJlYmVfMi05LTEtMS0xNTk1NDA_4a30bdbb-dee8-4fb4-a28c-7adb4d192156"
      unitRef="usd">205700000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="i19fc0325c48543008ea71e1fdcf11d86_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RleHRyZWdpb246OGRmOTEwZDdhYjFhNDFmMThlODU5ZTE4OTQxY2E4MDhfMTE2OTQ_8f0a0b99-1ff4-4ac8-8531-70c7ebd1dd6f"
      unitRef="usd">-123300000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RleHRyZWdpb246OGRmOTEwZDdhYjFhNDFmMThlODU5ZTE4OTQxY2E4MDhfMTE3MDE_eb576f1c-f504-4904-89ff-727ba1432122"
      unitRef="usd">-667600000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="ie4fa4f6b472a4f269297591b44aba572_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RleHRyZWdpb246OGRmOTEwZDdhYjFhNDFmMThlODU5ZTE4OTQxY2E4MDhfMTE3NTA_2bb44b70-0646-4de6-8b8f-88101b95cec8"
      unitRef="usd">-246800000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="i167ed8f67bef48c49e54fa466400cdaa_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RleHRyZWdpb246OGRmOTEwZDdhYjFhNDFmMThlODU5ZTE4OTQxY2E4MDhfMTE3NTc_4a4d3e33-c128-44a6-ab68-0d7e5da2a7aa"
      unitRef="usd">270100000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock
      contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RleHRyZWdpb246OGRmOTEwZDdhYjFhNDFmMThlODU5ZTE4OTQxY2E4MDhfMTUxNzg_54b52b0d-743c-45a2-b58d-52f1f154cd39">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the amount of unrealized gains and losses in accumulated other comprehensive loss and the fair value of available-for-sale securities in an unrealized gain or loss position follows:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.249%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.859%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.860%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrealized gross gains&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrealized gross losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;51.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of securities in an unrealized gain position&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;13.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;250.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of securities in an unrealized loss position&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;578.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;290.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i08ccb35f6ad24d7793c9c91b74ca2ea1_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjA4MmY3YTI1MmU1ZjRlYjRhNTZkZDU5M2YxMzEyMGZjL3RhYmxlcmFuZ2U6MDgyZjdhMjUyZTVmNGViNGE1NmRkNTkzZjEzMTIwZmNfMS0xLTEtMS0xNTk1NDA_78bb3a83-371d-4dda-8a45-2f0d8b9b1022"
      unitRef="usd">100000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i0973ba0c1d894ceaa494709a13f814fb_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjA4MmY3YTI1MmU1ZjRlYjRhNTZkZDU5M2YxMzEyMGZjL3RhYmxlcmFuZ2U6MDgyZjdhMjUyZTVmNGViNGE1NmRkNTkzZjEzMTIwZmNfMS0zLTEtMS0xNTk1NDA_d7865bfd-e2ba-4d45-8973-8bd1df337ff6"
      unitRef="usd">9700000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i08ccb35f6ad24d7793c9c91b74ca2ea1_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjA4MmY3YTI1MmU1ZjRlYjRhNTZkZDU5M2YxMzEyMGZjL3RhYmxlcmFuZ2U6MDgyZjdhMjUyZTVmNGViNGE1NmRkNTkzZjEzMTIwZmNfMi0xLTEtMS0xNTk1NDA_7716b38b-927f-4600-b2e9-a5de79a6c7b5"
      unitRef="usd">51600000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i0973ba0c1d894ceaa494709a13f814fb_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjA4MmY3YTI1MmU1ZjRlYjRhNTZkZDU5M2YxMzEyMGZjL3RhYmxlcmFuZ2U6MDgyZjdhMjUyZTVmNGViNGE1NmRkNTkzZjEzMTIwZmNfMi0zLTEtMS0xNTk1NDA_d13aca1f-0646-4b11-b367-d224022e1dd5"
      unitRef="usd">5200000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <lly:DebtSecuritiesAvailableforsaleUnrealizedGainPosition
      contextRef="i08ccb35f6ad24d7793c9c91b74ca2ea1_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjA4MmY3YTI1MmU1ZjRlYjRhNTZkZDU5M2YxMzEyMGZjL3RhYmxlcmFuZ2U6MDgyZjdhMjUyZTVmNGViNGE1NmRkNTkzZjEzMTIwZmNfMy0xLTEtMS0xNTk1NDA_e6afa47d-02f3-4ee3-bc7a-a1799604434c"
      unitRef="usd">13800000</lly:DebtSecuritiesAvailableforsaleUnrealizedGainPosition>
    <lly:DebtSecuritiesAvailableforsaleUnrealizedGainPosition
      contextRef="i0973ba0c1d894ceaa494709a13f814fb_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjA4MmY3YTI1MmU1ZjRlYjRhNTZkZDU5M2YxMzEyMGZjL3RhYmxlcmFuZ2U6MDgyZjdhMjUyZTVmNGViNGE1NmRkNTkzZjEzMTIwZmNfMy0zLTEtMS0xNTk1NDA_fe856a80-2c92-451b-9066-c79017d564cf"
      unitRef="usd">250700000</lly:DebtSecuritiesAvailableforsaleUnrealizedGainPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i08ccb35f6ad24d7793c9c91b74ca2ea1_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjA4MmY3YTI1MmU1ZjRlYjRhNTZkZDU5M2YxMzEyMGZjL3RhYmxlcmFuZ2U6MDgyZjdhMjUyZTVmNGViNGE1NmRkNTkzZjEzMTIwZmNfNC0xLTEtMS0xNTk1NDA_78b75982-8cd5-47bd-b2cb-c38c52f28428"
      unitRef="usd">578800000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i0973ba0c1d894ceaa494709a13f814fb_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjA4MmY3YTI1MmU1ZjRlYjRhNTZkZDU5M2YxMzEyMGZjL3RhYmxlcmFuZ2U6MDgyZjdhMjUyZTVmNGViNGE1NmRkNTkzZjEzMTIwZmNfNC0zLTEtMS0xNTk1NDA_005f2639-e344-435c-9630-378f3b52c417"
      unitRef="usd">290200000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <lly:DebtSecuritiesAvailableForSaleUnrealizedLossPositionQualitativeDisclosureOtherPercentageOfNonperformingAssets
      contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RleHRyZWdpb246OGRmOTEwZDdhYjFhNDFmMThlODU5ZTE4OTQxY2E4MDhfMTM1NTc_c2127107-d222-4181-bc82-39af6a9b7cb6"
      unitRef="number">0.95</lly:DebtSecuritiesAvailableForSaleUnrealizedLossPositionQualitativeDisclosureOtherPercentageOfNonperformingAssets>
    <us-gaap:GainLossOnInvestmentsTextBlock
      contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RleHRyZWdpb246OGRmOTEwZDdhYjFhNDFmMThlODU5ZTE4OTQxY2E4MDhfMTUxMjk_d53f54cd-0846-4d0c-a453-e9182f065ed0">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Activity related to our available-for-sale securities was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.206%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Proceeds from sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;50.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;115.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;137.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Realized gross gains on sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;0.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Realized gross losses on sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;7.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;9.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:GainLossOnInvestmentsTextBlock>
    <lly:ProceedsfromSaleofEquityandAvailableforSaleSecurities
      contextRef="i19fc0325c48543008ea71e1fdcf11d86_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjYxNGZlZGYwZjc2ZTQwOTc5ZDgwOTc0YmM0ODc3Y2U5L3RhYmxlcmFuZ2U6NjE0ZmVkZjBmNzZlNDA5NzlkODA5NzRiYzQ4NzdjZTlfMi0xLTEtMS0xNTk1NDA_bfcbc4cc-9a0d-4242-bd13-db7902cd263e"
      unitRef="usd">50500000</lly:ProceedsfromSaleofEquityandAvailableforSaleSecurities>
    <lly:ProceedsfromSaleofEquityandAvailableforSaleSecurities
      contextRef="ie4fa4f6b472a4f269297591b44aba572_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjYxNGZlZGYwZjc2ZTQwOTc5ZDgwOTc0YmM0ODc3Y2U5L3RhYmxlcmFuZ2U6NjE0ZmVkZjBmNzZlNDA5NzlkODA5NzRiYzQ4NzdjZTlfMi0zLTEtMS0xNTk1NDA_c69e90ca-bacd-40f8-a7fb-3b246b8d301d"
      unitRef="usd">49600000</lly:ProceedsfromSaleofEquityandAvailableforSaleSecurities>
    <lly:ProceedsfromSaleofEquityandAvailableforSaleSecurities
      contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjYxNGZlZGYwZjc2ZTQwOTc5ZDgwOTc0YmM0ODc3Y2U5L3RhYmxlcmFuZ2U6NjE0ZmVkZjBmNzZlNDA5NzlkODA5NzRiYzQ4NzdjZTlfMi01LTEtMS0xNTk1NDA_67ddab9b-d464-4e7e-a19f-c86f401e63e0"
      unitRef="usd">115600000</lly:ProceedsfromSaleofEquityandAvailableforSaleSecurities>
    <lly:ProceedsfromSaleofEquityandAvailableforSaleSecurities
      contextRef="i167ed8f67bef48c49e54fa466400cdaa_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjYxNGZlZGYwZjc2ZTQwOTc5ZDgwOTc0YmM0ODc3Y2U5L3RhYmxlcmFuZ2U6NjE0ZmVkZjBmNzZlNDA5NzlkODA5NzRiYzQ4NzdjZTlfMi03LTEtMS0xNTk1NDA_70857a31-7d04-4515-8db0-c0d9de976179"
      unitRef="usd">137300000</lly:ProceedsfromSaleofEquityandAvailableforSaleSecurities>
    <lly:AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain
      contextRef="i19fc0325c48543008ea71e1fdcf11d86_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjYxNGZlZGYwZjc2ZTQwOTc5ZDgwOTc0YmM0ODc3Y2U5L3RhYmxlcmFuZ2U6NjE0ZmVkZjBmNzZlNDA5NzlkODA5NzRiYzQ4NzdjZTlfMy0xLTEtMS0xNTk1NDA_0ee4a37b-1b18-4c7f-a4ff-f5a2ca628f81"
      unitRef="usd">0</lly:AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain>
    <lly:AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain
      contextRef="ie4fa4f6b472a4f269297591b44aba572_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjYxNGZlZGYwZjc2ZTQwOTc5ZDgwOTc0YmM0ODc3Y2U5L3RhYmxlcmFuZ2U6NjE0ZmVkZjBmNzZlNDA5NzlkODA5NzRiYzQ4NzdjZTlfMy0zLTEtMS0xNTk1NDA_181e2eff-aa2a-40ae-9cd0-87365340e6df"
      unitRef="usd">400000</lly:AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain>
    <lly:AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain
      contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjYxNGZlZGYwZjc2ZTQwOTc5ZDgwOTc0YmM0ODc3Y2U5L3RhYmxlcmFuZ2U6NjE0ZmVkZjBmNzZlNDA5NzlkODA5NzRiYzQ4NzdjZTlfMy01LTEtMS0xNTk1NDA_a4084db9-d5b2-40ab-a7e6-27ba3c7017db"
      unitRef="usd">200000</lly:AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain>
    <lly:AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain
      contextRef="i167ed8f67bef48c49e54fa466400cdaa_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjYxNGZlZGYwZjc2ZTQwOTc5ZDgwOTc0YmM0ODc3Y2U5L3RhYmxlcmFuZ2U6NjE0ZmVkZjBmNzZlNDA5NzlkODA5NzRiYzQ4NzdjZTlfMy03LTEtMS0xNTk1NDA_2e4bb8bb-6619-4ce0-986e-3d8258673716"
      unitRef="usd">2200000</lly:AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain>
    <lly:AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss
      contextRef="i19fc0325c48543008ea71e1fdcf11d86_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjYxNGZlZGYwZjc2ZTQwOTc5ZDgwOTc0YmM0ODc3Y2U5L3RhYmxlcmFuZ2U6NjE0ZmVkZjBmNzZlNDA5NzlkODA5NzRiYzQ4NzdjZTlfNC0xLTEtMS0xNTk1NDA_493453ef-6c00-4a69-afe7-7803c4f4272e"
      unitRef="usd">7500000</lly:AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss>
    <lly:AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss
      contextRef="ie4fa4f6b472a4f269297591b44aba572_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjYxNGZlZGYwZjc2ZTQwOTc5ZDgwOTc0YmM0ODc3Y2U5L3RhYmxlcmFuZ2U6NjE0ZmVkZjBmNzZlNDA5NzlkODA5NzRiYzQ4NzdjZTlfNC0zLTEtMS0xNTk1NDA_e34a78d3-71a4-45e4-910d-7771596bf60c"
      unitRef="usd">300000</lly:AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss>
    <lly:AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss
      contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjYxNGZlZGYwZjc2ZTQwOTc5ZDgwOTc0YmM0ODc3Y2U5L3RhYmxlcmFuZ2U6NjE0ZmVkZjBmNzZlNDA5NzlkODA5NzRiYzQ4NzdjZTlfNC01LTEtMS0xNTk1NDA_3da89a97-911b-4877-9510-38345ea87350"
      unitRef="usd">9000000.0</lly:AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss>
    <lly:AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss
      contextRef="i167ed8f67bef48c49e54fa466400cdaa_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RhYmxlOjYxNGZlZGYwZjc2ZTQwOTc5ZDgwOTc0YmM0ODc3Y2U5L3RhYmxlcmFuZ2U6NjE0ZmVkZjBmNzZlNDA5NzlkODA5NzRiYzQ4NzdjZTlfNC03LTEtMS0xNTk1NDA_ad957c67-3630-48eb-9e9c-e01c0c32a3df"
      unitRef="usd">1100000</lly:AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss>
    <us-gaap:TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized
      contextRef="i08ccb35f6ad24d7793c9c91b74ca2ea1_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RleHRyZWdpb246OGRmOTEwZDdhYjFhNDFmMThlODU5ZTE4OTQxY2E4MDhfMTQ4NTU_d461a7a3-cf80-45a2-b935-0ca765dd766f"
      unitRef="usd">356800000</us-gaap:TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized>
    <us-gaap:TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized
      contextRef="i0973ba0c1d894ceaa494709a13f814fb_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182MS9mcmFnOjhkZjkxMGQ3YWIxYTQxZjE4ZTg1OWUxODk0MWNhODA4L3RleHRyZWdpb246OGRmOTEwZDdhYjFhNDFmMThlODU5ZTE4OTQxY2E4MDhfMTQ4NjI_3c509b7e-cf02-4800-bc5e-abc722a8c242"
      unitRef="usd">550500000</us-gaap:TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182NC9mcmFnOmMzYjIwOWNjM2ExMjQ2OWE4NmQ5NTdhYTRkZGUyMmE4L3RleHRyZWdpb246YzNiMjA5Y2MzYTEyNDY5YTg2ZDk1N2FhNGRkZTIyYThfMTMwMw_4da865fa-c18e-49b7-bd05-bde2e642708c">Income Taxes &lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The effective tax rates were 7.3 percent and 8.6 percent for the three and nine months ended September&#160;30, 2022, respectively, reflecting the favorable tax impact of the implementation of a provision in the Tax Cuts and Jobs Act (2017 Tax Act) that requires capitalization and amortization of research and development expenses for tax purposes starting in 2022, net investment losses on equity securities, and an intangible asset impairment charge. We expect our effective tax rate to be approximately 13 percent to 14 percent for 2022 if the capitalization and amortization of research and development expenses provision of the 2017 Tax Act is deferred or repealed by the U.S. Congress effective for 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The effective tax rate was 10.9 percent for the three months ended September&#160;30, 2021, reflecting the favorable tax impact of a debt extinguishment loss and of net investment losses on equity securities, partially offset by a net discrete tax detriment. The effective tax rate was 10.7 percent for the nine months ended September&#160;30, 2021, reflecting the favorable tax impact of a net discrete tax benefit, a debt extinguishment loss, and a net inventory impairment charge related to our COVID-19 antibodies. &lt;/span&gt;&lt;/div&gt;The U.S. examination of tax years 2016-2018 began in the fourth quarter of 2019 and remains ongoing. The resolution of this audit period will likely extend beyond the next 12 months.</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i19fc0325c48543008ea71e1fdcf11d86_D20220701-20220930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182NC9mcmFnOmMzYjIwOWNjM2ExMjQ2OWE4NmQ5NTdhYTRkZGUyMmE4L3RleHRyZWdpb246YzNiMjA5Y2MzYTEyNDY5YTg2ZDk1N2FhNGRkZTIyYThfNTY_09741c81-4db5-421b-913c-1f9342c8166f"
      unitRef="number">0.073</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182NC9mcmFnOmMzYjIwOWNjM2ExMjQ2OWE4NmQ5NTdhYTRkZGUyMmE4L3RleHRyZWdpb246YzNiMjA5Y2MzYTEyNDY5YTg2ZDk1N2FhNGRkZTIyYThfNjM_204ae19b-fe42-4b04-a332-f083899a2403"
      unitRef="number">0.086</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i62df949acd3f4b47ae7d10432a08e2ab_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182NC9mcmFnOmMzYjIwOWNjM2ExMjQ2OWE4NmQ5NTdhYTRkZGUyMmE4L3RleHRyZWdpb246YzNiMjA5Y2MzYTEyNDY5YTg2ZDk1N2FhNGRkZTIyYThfNTQy_18580e2a-b740-4700-b29a-a2bb08e7e56a"
      unitRef="number">0.13</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i67750cd7b626486fa748e5b71374a667_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182NC9mcmFnOmMzYjIwOWNjM2ExMjQ2OWE4NmQ5NTdhYTRkZGUyMmE4L3RleHRyZWdpb246YzNiMjA5Y2MzYTEyNDY5YTg2ZDk1N2FhNGRkZTIyYThfNTQ4_7ceba8cc-230d-4a04-8485-1d1cf712d502"
      unitRef="number">0.14</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="ie4fa4f6b472a4f269297591b44aba572_D20210701-20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182NC9mcmFnOmMzYjIwOWNjM2ExMjQ2OWE4NmQ5NTdhYTRkZGUyMmE4L3RleHRyZWdpb246YzNiMjA5Y2MzYTEyNDY5YTg2ZDk1N2FhNGRkZTIyYThfNzYw_58733c71-1992-4699-afb8-e653abf947a3"
      unitRef="number">0.109</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i167ed8f67bef48c49e54fa466400cdaa_D20210101-20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182NC9mcmFnOmMzYjIwOWNjM2ExMjQ2OWE4NmQ5NTdhYTRkZGUyMmE4L3RleHRyZWdpb246YzNiMjA5Y2MzYTEyNDY5YTg2ZDk1N2FhNGRkZTIyYThfMjc0ODc3OTA3Mjc5NA_64cf953c-f539-4d84-a573-a47b34d0e185"
      unitRef="number">0.107</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock
      contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182Ny9mcmFnOjc2ODNiYjQ2MzFiMTQ0MTJiMDk2YzNkYmNmOTZiMTFlL3RleHRyZWdpb246NzY4M2JiNDYzMWIxNDQxMmIwOTZjM2RiY2Y5NmIxMWVfMTM3_1c8712a1-f795-4abf-992b-0ac5987fbd6a">Retirement Benefits&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net pension and retiree health benefit (income) cost included the following components:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.206%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Defined Benefit Pension Plans&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Components of net periodic benefit cost:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Service cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;87.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;264.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;277.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;98.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;299.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;253.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(235.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(237.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(711.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(712.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of prior service cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;0.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Recognized actuarial loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;85.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;256.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;366.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net periodic benefit cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;36.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;110.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;188.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.206%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Retiree Health Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Components of net periodic benefit income:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Service cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;11.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;35.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;9.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;28.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(38.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(36.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(114.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(109.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of prior service benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(13.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(41.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(44.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Recognized actuarial loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;0.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;0.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net periodic benefit income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(30.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(91.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(90.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <us-gaap:ScheduleOfNetBenefitCostsTableTextBlock
      contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182Ny9mcmFnOjc2ODNiYjQ2MzFiMTQ0MTJiMDk2YzNkYmNmOTZiMTFlL3RleHRyZWdpb246NzY4M2JiNDYzMWIxNDQxMmIwOTZjM2RiY2Y5NmIxMWVfMTQw_8042c4cc-a70c-4f01-8248-31be639cb51f">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net pension and retiree health benefit (income) cost included the following components:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.206%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Defined Benefit Pension Plans&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Components of net periodic benefit cost:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Service cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;87.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;264.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;277.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;98.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;299.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;253.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(235.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(237.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(711.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(712.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of prior service cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;0.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Recognized actuarial loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;85.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;256.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;366.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net periodic benefit cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;36.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;110.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;188.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.206%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Retiree Health Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Components of net periodic benefit income:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Service cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;11.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;35.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;9.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;28.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(38.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(36.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(114.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(109.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of prior service benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(13.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(41.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(44.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Recognized actuarial loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;0.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;0.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net periodic benefit income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(30.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(91.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(90.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfNetBenefitCostsTableTextBlock>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="ifea67e1feada4a8c8d0bf25c34910e9a_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182Ny9mcmFnOjc2ODNiYjQ2MzFiMTQ0MTJiMDk2YzNkYmNmOTZiMTFlL3RhYmxlOjdhMGMwNmMxMTE0NTRlZmU4ZTc3YWM0MDhmYTQ1NTdmL3RhYmxlcmFuZ2U6N2EwYzA2YzExMTQ1NGVmZThlNzdhYzQwOGZhNDU1N2ZfNC0xLTEtMS0xNTk1NDA_2d091511-32e1-48de-899c-0d41867dc013"
      unitRef="usd">87100000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i19f7d57c42aa4dde893b82e5f134cfc1_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182Ny9mcmFnOjc2ODNiYjQ2MzFiMTQ0MTJiMDk2YzNkYmNmOTZiMTFlL3RhYmxlOjdhMGMwNmMxMTE0NTRlZmU4ZTc3YWM0MDhmYTQ1NTdmL3RhYmxlcmFuZ2U6N2EwYzA2YzExMTQ1NGVmZThlNzdhYzQwOGZhNDU1N2ZfNC0zLTEtMS0xNTk1NDA_b0d3754d-b275-4904-bd17-baa279f27785"
      unitRef="usd">92500000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i0116b5022f7f41b494fd355fe823d76e_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182Ny9mcmFnOjc2ODNiYjQ2MzFiMTQ0MTJiMDk2YzNkYmNmOTZiMTFlL3RhYmxlOjdhMGMwNmMxMTE0NTRlZmU4ZTc3YWM0MDhmYTQ1NTdmL3RhYmxlcmFuZ2U6N2EwYzA2YzExMTQ1NGVmZThlNzdhYzQwOGZhNDU1N2ZfNC01LTEtMS0xNTk1NDA_1270c886-5b81-46b4-86d3-c161d36f5f4c"
      unitRef="usd">264400000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i8a97c43966fd4f6aaf5f8dfb7bba4701_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182Ny9mcmFnOjc2ODNiYjQ2MzFiMTQ0MTJiMDk2YzNkYmNmOTZiMTFlL3RhYmxlOjdhMGMwNmMxMTE0NTRlZmU4ZTc3YWM0MDhmYTQ1NTdmL3RhYmxlcmFuZ2U6N2EwYzA2YzExMTQ1NGVmZThlNzdhYzQwOGZhNDU1N2ZfNC03LTEtMS0xNTk1NDA_a289693d-c14d-45c1-8b22-d2b3288482fc"
      unitRef="usd">277800000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="ifea67e1feada4a8c8d0bf25c34910e9a_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182Ny9mcmFnOjc2ODNiYjQ2MzFiMTQ0MTJiMDk2YzNkYmNmOTZiMTFlL3RhYmxlOjdhMGMwNmMxMTE0NTRlZmU4ZTc3YWM0MDhmYTQ1NTdmL3RhYmxlcmFuZ2U6N2EwYzA2YzExMTQ1NGVmZThlNzdhYzQwOGZhNDU1N2ZfNS0xLTEtMS0xNTk1NDA_6af69744-5fdd-44a5-b4e7-996cae1b298a"
      unitRef="usd">98900000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i19f7d57c42aa4dde893b82e5f134cfc1_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182Ny9mcmFnOjc2ODNiYjQ2MzFiMTQ0MTJiMDk2YzNkYmNmOTZiMTFlL3RhYmxlOjdhMGMwNmMxMTE0NTRlZmU4ZTc3YWM0MDhmYTQ1NTdmL3RhYmxlcmFuZ2U6N2EwYzA2YzExMTQ1NGVmZThlNzdhYzQwOGZhNDU1N2ZfNS0zLTEtMS0xNTk1NDA_f003af34-46e5-48f2-a7ce-bb728393949f"
      unitRef="usd">84500000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i0116b5022f7f41b494fd355fe823d76e_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182Ny9mcmFnOjc2ODNiYjQ2MzFiMTQ0MTJiMDk2YzNkYmNmOTZiMTFlL3RhYmxlOjdhMGMwNmMxMTE0NTRlZmU4ZTc3YWM0MDhmYTQ1NTdmL3RhYmxlcmFuZ2U6N2EwYzA2YzExMTQ1NGVmZThlNzdhYzQwOGZhNDU1N2ZfNS01LTEtMS0xNTk1NDA_d0899d1f-4d82-4800-bb9c-d31a07cd8edf"
      unitRef="usd">299000000.0</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i8a97c43966fd4f6aaf5f8dfb7bba4701_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182Ny9mcmFnOjc2ODNiYjQ2MzFiMTQ0MTJiMDk2YzNkYmNmOTZiMTFlL3RhYmxlOjdhMGMwNmMxMTE0NTRlZmU4ZTc3YWM0MDhmYTQ1NTdmL3RhYmxlcmFuZ2U6N2EwYzA2YzExMTQ1NGVmZThlNzdhYzQwOGZhNDU1N2ZfNS03LTEtMS0xNTk1NDA_630c584b-2cc1-4279-9c6b-c4c253956a06"
      unitRef="usd">253600000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="ifea67e1feada4a8c8d0bf25c34910e9a_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182Ny9mcmFnOjc2ODNiYjQ2MzFiMTQ0MTJiMDk2YzNkYmNmOTZiMTFlL3RhYmxlOjdhMGMwNmMxMTE0NTRlZmU4ZTc3YWM0MDhmYTQ1NTdmL3RhYmxlcmFuZ2U6N2EwYzA2YzExMTQ1NGVmZThlNzdhYzQwOGZhNDU1N2ZfNi0xLTEtMS0xNTk1NDA_6ba39726-929b-48f2-9c83-872d1bc37987"
      unitRef="usd">235100000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="i19f7d57c42aa4dde893b82e5f134cfc1_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182Ny9mcmFnOjc2ODNiYjQ2MzFiMTQ0MTJiMDk2YzNkYmNmOTZiMTFlL3RhYmxlOjdhMGMwNmMxMTE0NTRlZmU4ZTc3YWM0MDhmYTQ1NTdmL3RhYmxlcmFuZ2U6N2EwYzA2YzExMTQ1NGVmZThlNzdhYzQwOGZhNDU1N2ZfNi0zLTEtMS0xNTk1NDA_1a9cf00b-7436-4fe4-bada-6e60d20b8ff0"
      unitRef="usd">237500000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="i0116b5022f7f41b494fd355fe823d76e_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182Ny9mcmFnOjc2ODNiYjQ2MzFiMTQ0MTJiMDk2YzNkYmNmOTZiMTFlL3RhYmxlOjdhMGMwNmMxMTE0NTRlZmU4ZTc3YWM0MDhmYTQ1NTdmL3RhYmxlcmFuZ2U6N2EwYzA2YzExMTQ1NGVmZThlNzdhYzQwOGZhNDU1N2ZfNi01LTEtMS0xNTk1NDA_bdd9f46a-7357-4dda-97cc-014f240b8071"
      unitRef="usd">711600000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="i8a97c43966fd4f6aaf5f8dfb7bba4701_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182Ny9mcmFnOjc2ODNiYjQ2MzFiMTQ0MTJiMDk2YzNkYmNmOTZiMTFlL3RhYmxlOjdhMGMwNmMxMTE0NTRlZmU4ZTc3YWM0MDhmYTQ1NTdmL3RhYmxlcmFuZ2U6N2EwYzA2YzExMTQ1NGVmZThlNzdhYzQwOGZhNDU1N2ZfNi03LTEtMS0xNTk1NDA_6ceeae2f-86ec-45f7-94ed-12dd3f26fd8e"
      unitRef="usd">712700000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="ifea67e1feada4a8c8d0bf25c34910e9a_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182Ny9mcmFnOjc2ODNiYjQ2MzFiMTQ0MTJiMDk2YzNkYmNmOTZiMTFlL3RhYmxlOjdhMGMwNmMxMTE0NTRlZmU4ZTc3YWM0MDhmYTQ1NTdmL3RhYmxlcmFuZ2U6N2EwYzA2YzExMTQ1NGVmZThlNzdhYzQwOGZhNDU1N2ZfNy0xLTEtMS0xNTk1NDA_79f7701a-4e75-4ad6-841e-3c300f94aad8"
      unitRef="usd">600000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="i19f7d57c42aa4dde893b82e5f134cfc1_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182Ny9mcmFnOjc2ODNiYjQ2MzFiMTQ0MTJiMDk2YzNkYmNmOTZiMTFlL3RhYmxlOjdhMGMwNmMxMTE0NTRlZmU4ZTc3YWM0MDhmYTQ1NTdmL3RhYmxlcmFuZ2U6N2EwYzA2YzExMTQ1NGVmZThlNzdhYzQwOGZhNDU1N2ZfNy0zLTEtMS0xNTk1NDA_4d01de6d-f33d-4125-b650-2465d8233962"
      unitRef="usd">1000000.0</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="i0116b5022f7f41b494fd355fe823d76e_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182Ny9mcmFnOjc2ODNiYjQ2MzFiMTQ0MTJiMDk2YzNkYmNmOTZiMTFlL3RhYmxlOjdhMGMwNmMxMTE0NTRlZmU4ZTc3YWM0MDhmYTQ1NTdmL3RhYmxlcmFuZ2U6N2EwYzA2YzExMTQ1NGVmZThlNzdhYzQwOGZhNDU1N2ZfNy01LTEtMS0xNTk1NDA_bbcd8f96-9617-4756-a8ca-93860fd077ac"
      unitRef="usd">1900000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="i8a97c43966fd4f6aaf5f8dfb7bba4701_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182Ny9mcmFnOjc2ODNiYjQ2MzFiMTQ0MTJiMDk2YzNkYmNmOTZiMTFlL3RhYmxlOjdhMGMwNmMxMTE0NTRlZmU4ZTc3YWM0MDhmYTQ1NTdmL3RhYmxlcmFuZ2U6N2EwYzA2YzExMTQ1NGVmZThlNzdhYzQwOGZhNDU1N2ZfNy03LTEtMS0xNTk1NDA_d09315bc-a246-4761-8dcf-d026058a8514"
      unitRef="usd">3200000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit
      contextRef="ifea67e1feada4a8c8d0bf25c34910e9a_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182Ny9mcmFnOjc2ODNiYjQ2MzFiMTQ0MTJiMDk2YzNkYmNmOTZiMTFlL3RhYmxlOjdhMGMwNmMxMTE0NTRlZmU4ZTc3YWM0MDhmYTQ1NTdmL3RhYmxlcmFuZ2U6N2EwYzA2YzExMTQ1NGVmZThlNzdhYzQwOGZhNDU1N2ZfOC0xLTEtMS0xNTk1NDA_b56420f5-b92a-4a74-a84f-db8f87c32552"
      unitRef="usd">-85300000</us-gaap:DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit>
    <us-gaap:DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit
      contextRef="i19f7d57c42aa4dde893b82e5f134cfc1_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182Ny9mcmFnOjc2ODNiYjQ2MzFiMTQ0MTJiMDk2YzNkYmNmOTZiMTFlL3RhYmxlOjdhMGMwNmMxMTE0NTRlZmU4ZTc3YWM0MDhmYTQ1NTdmL3RhYmxlcmFuZ2U6N2EwYzA2YzExMTQ1NGVmZThlNzdhYzQwOGZhNDU1N2ZfOC0zLTEtMS0xNTk1NDA_67aa935d-0b6b-4e66-9ab9-4385e1182ba1"
      unitRef="usd">-121900000</us-gaap:DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit>
    <us-gaap:DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit
      contextRef="i0116b5022f7f41b494fd355fe823d76e_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182Ny9mcmFnOjc2ODNiYjQ2MzFiMTQ0MTJiMDk2YzNkYmNmOTZiMTFlL3RhYmxlOjdhMGMwNmMxMTE0NTRlZmU4ZTc3YWM0MDhmYTQ1NTdmL3RhYmxlcmFuZ2U6N2EwYzA2YzExMTQ1NGVmZThlNzdhYzQwOGZhNDU1N2ZfOC01LTEtMS0xNTk1NDA_17d0dd71-107c-44a9-a8ee-8324ff5a143f"
      unitRef="usd">-256800000</us-gaap:DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit>
    <us-gaap:DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit
      contextRef="i8a97c43966fd4f6aaf5f8dfb7bba4701_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182Ny9mcmFnOjc2ODNiYjQ2MzFiMTQ0MTJiMDk2YzNkYmNmOTZiMTFlL3RhYmxlOjdhMGMwNmMxMTE0NTRlZmU4ZTc3YWM0MDhmYTQ1NTdmL3RhYmxlcmFuZ2U6N2EwYzA2YzExMTQ1NGVmZThlNzdhYzQwOGZhNDU1N2ZfOC03LTEtMS0xNTk1NDA_89bf223b-a162-4be6-9096-7103e7c89cda"
      unitRef="usd">-366300000</us-gaap:DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="ifea67e1feada4a8c8d0bf25c34910e9a_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182Ny9mcmFnOjc2ODNiYjQ2MzFiMTQ0MTJiMDk2YzNkYmNmOTZiMTFlL3RhYmxlOjdhMGMwNmMxMTE0NTRlZmU4ZTc3YWM0MDhmYTQ1NTdmL3RhYmxlcmFuZ2U6N2EwYzA2YzExMTQ1NGVmZThlNzdhYzQwOGZhNDU1N2ZfMTAtMS0xLTEtMTU5NTQw_d222aaa8-4de2-464e-ad36-89f18ffdc09e"
      unitRef="usd">36800000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i19f7d57c42aa4dde893b82e5f134cfc1_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182Ny9mcmFnOjc2ODNiYjQ2MzFiMTQ0MTJiMDk2YzNkYmNmOTZiMTFlL3RhYmxlOjdhMGMwNmMxMTE0NTRlZmU4ZTc3YWM0MDhmYTQ1NTdmL3RhYmxlcmFuZ2U6N2EwYzA2YzExMTQ1NGVmZThlNzdhYzQwOGZhNDU1N2ZfMTAtMy0xLTEtMTU5NTQw_2c71567a-37d1-44d3-a00b-549332be76a7"
      unitRef="usd">62400000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i0116b5022f7f41b494fd355fe823d76e_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182Ny9mcmFnOjc2ODNiYjQ2MzFiMTQ0MTJiMDk2YzNkYmNmOTZiMTFlL3RhYmxlOjdhMGMwNmMxMTE0NTRlZmU4ZTc3YWM0MDhmYTQ1NTdmL3RhYmxlcmFuZ2U6N2EwYzA2YzExMTQ1NGVmZThlNzdhYzQwOGZhNDU1N2ZfMTAtNS0xLTEtMTU5NTQw_b0b9ea53-a34e-4cc9-a7a2-e52a6e61d7cf"
      unitRef="usd">110500000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i8a97c43966fd4f6aaf5f8dfb7bba4701_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182Ny9mcmFnOjc2ODNiYjQ2MzFiMTQ0MTJiMDk2YzNkYmNmOTZiMTFlL3RhYmxlOjdhMGMwNmMxMTE0NTRlZmU4ZTc3YWM0MDhmYTQ1NTdmL3RhYmxlcmFuZ2U6N2EwYzA2YzExMTQ1NGVmZThlNzdhYzQwOGZhNDU1N2ZfMTAtNy0xLTEtMTU5NTQw_c3a020f8-bc63-4fc4-ab1e-08f0c7f02b32"
      unitRef="usd">188200000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i238afcd7e9494cbb9f4c68c1cf1dcc2d_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182Ny9mcmFnOjc2ODNiYjQ2MzFiMTQ0MTJiMDk2YzNkYmNmOTZiMTFlL3RhYmxlOjBhZjE5OWIyY2U1YTQ5ODA4ZTVlYThlMDdjNmE2YmZkL3RhYmxlcmFuZ2U6MGFmMTk5YjJjZTVhNDk4MDhlNWVhOGUwN2M2YTZiZmRfNC0xLTEtMS0xNTk1NDA_7b659c1c-bbe9-425c-8caa-6edcc81ad9f8"
      unitRef="usd">11700000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i6b0c929331c241cb98c2a4d85625e2e7_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182Ny9mcmFnOjc2ODNiYjQ2MzFiMTQ0MTJiMDk2YzNkYmNmOTZiMTFlL3RhYmxlOjBhZjE5OWIyY2U1YTQ5ODA4ZTVlYThlMDdjNmE2YmZkL3RhYmxlcmFuZ2U6MGFmMTk5YjJjZTVhNDk4MDhlNWVhOGUwN2M2YTZiZmRfNC0zLTEtMS0xNTk1NDA_1ee08aff-fd66-4527-b92f-171c895057f3"
      unitRef="usd">12400000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i60435d86ecc44d56b9b471e301119ba4_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182Ny9mcmFnOjc2ODNiYjQ2MzFiMTQ0MTJiMDk2YzNkYmNmOTZiMTFlL3RhYmxlOjBhZjE5OWIyY2U1YTQ5ODA4ZTVlYThlMDdjNmE2YmZkL3RhYmxlcmFuZ2U6MGFmMTk5YjJjZTVhNDk4MDhlNWVhOGUwN2M2YTZiZmRfNC01LTEtMS0xNTk1NDA_03baa210-7659-4b21-a32c-9fcb2dc8e7a1"
      unitRef="usd">35000000.0</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i146fcce3fad6486aa91cf7ba94fd98c8_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182Ny9mcmFnOjc2ODNiYjQ2MzFiMTQ0MTJiMDk2YzNkYmNmOTZiMTFlL3RhYmxlOjBhZjE5OWIyY2U1YTQ5ODA4ZTVlYThlMDdjNmE2YmZkL3RhYmxlcmFuZ2U6MGFmMTk5YjJjZTVhNDk4MDhlNWVhOGUwN2M2YTZiZmRfNC03LTEtMS0xNTk1NDA_dfaa4e37-9742-4f4d-86fb-f3f3b338ce5a"
      unitRef="usd">37000000.0</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i238afcd7e9494cbb9f4c68c1cf1dcc2d_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182Ny9mcmFnOjc2ODNiYjQ2MzFiMTQ0MTJiMDk2YzNkYmNmOTZiMTFlL3RhYmxlOjBhZjE5OWIyY2U1YTQ5ODA4ZTVlYThlMDdjNmE2YmZkL3RhYmxlcmFuZ2U6MGFmMTk5YjJjZTVhNDk4MDhlNWVhOGUwN2M2YTZiZmRfNS0xLTEtMS0xNTk1NDA_5e9dce56-a7a7-454f-8c5c-fe9a11d638ed"
      unitRef="usd">9400000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i6b0c929331c241cb98c2a4d85625e2e7_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182Ny9mcmFnOjc2ODNiYjQ2MzFiMTQ0MTJiMDk2YzNkYmNmOTZiMTFlL3RhYmxlOjBhZjE5OWIyY2U1YTQ5ODA4ZTVlYThlMDdjNmE2YmZkL3RhYmxlcmFuZ2U6MGFmMTk5YjJjZTVhNDk4MDhlNWVhOGUwN2M2YTZiZmRfNS0zLTEtMS0xNTk1NDA_4c0b4229-63c5-4de5-9668-6973b9de3436"
      unitRef="usd">8100000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i60435d86ecc44d56b9b471e301119ba4_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182Ny9mcmFnOjc2ODNiYjQ2MzFiMTQ0MTJiMDk2YzNkYmNmOTZiMTFlL3RhYmxlOjBhZjE5OWIyY2U1YTQ5ODA4ZTVlYThlMDdjNmE2YmZkL3RhYmxlcmFuZ2U6MGFmMTk5YjJjZTVhNDk4MDhlNWVhOGUwN2M2YTZiZmRfNS01LTEtMS0xNTk1NDA_79221b18-8d5e-4e89-8c41-c71302047af2"
      unitRef="usd">28400000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i146fcce3fad6486aa91cf7ba94fd98c8_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182Ny9mcmFnOjc2ODNiYjQ2MzFiMTQ0MTJiMDk2YzNkYmNmOTZiMTFlL3RhYmxlOjBhZjE5OWIyY2U1YTQ5ODA4ZTVlYThlMDdjNmE2YmZkL3RhYmxlcmFuZ2U6MGFmMTk5YjJjZTVhNDk4MDhlNWVhOGUwN2M2YTZiZmRfNS03LTEtMS0xNTk1NDA_190cdb00-ffd0-4447-9151-e314e71cbf4a"
      unitRef="usd">24400000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="i238afcd7e9494cbb9f4c68c1cf1dcc2d_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182Ny9mcmFnOjc2ODNiYjQ2MzFiMTQ0MTJiMDk2YzNkYmNmOTZiMTFlL3RhYmxlOjBhZjE5OWIyY2U1YTQ5ODA4ZTVlYThlMDdjNmE2YmZkL3RhYmxlcmFuZ2U6MGFmMTk5YjJjZTVhNDk4MDhlNWVhOGUwN2M2YTZiZmRfNi0xLTEtMS0xNTk1NDA_5e20d3b0-e504-4cd8-bbba-6febad47b954"
      unitRef="usd">38000000.0</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="i6b0c929331c241cb98c2a4d85625e2e7_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182Ny9mcmFnOjc2ODNiYjQ2MzFiMTQ0MTJiMDk2YzNkYmNmOTZiMTFlL3RhYmxlOjBhZjE5OWIyY2U1YTQ5ODA4ZTVlYThlMDdjNmE2YmZkL3RhYmxlcmFuZ2U6MGFmMTk5YjJjZTVhNDk4MDhlNWVhOGUwN2M2YTZiZmRfNi0zLTEtMS0xNTk1NDA_33531405-5355-4e13-ab49-59dfffcffecd"
      unitRef="usd">36500000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="i60435d86ecc44d56b9b471e301119ba4_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182Ny9mcmFnOjc2ODNiYjQ2MzFiMTQ0MTJiMDk2YzNkYmNmOTZiMTFlL3RhYmxlOjBhZjE5OWIyY2U1YTQ5ODA4ZTVlYThlMDdjNmE2YmZkL3RhYmxlcmFuZ2U6MGFmMTk5YjJjZTVhNDk4MDhlNWVhOGUwN2M2YTZiZmRfNi01LTEtMS0xNTk1NDA_bbe145c7-cff3-4935-881c-0d39f4e98c80"
      unitRef="usd">114100000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="i146fcce3fad6486aa91cf7ba94fd98c8_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182Ny9mcmFnOjc2ODNiYjQ2MzFiMTQ0MTJiMDk2YzNkYmNmOTZiMTFlL3RhYmxlOjBhZjE5OWIyY2U1YTQ5ODA4ZTVlYThlMDdjNmE2YmZkL3RhYmxlcmFuZ2U6MGFmMTk5YjJjZTVhNDk4MDhlNWVhOGUwN2M2YTZiZmRfNi03LTEtMS0xNTk1NDA_3aa119d3-74c2-4a5e-889e-4a61b2d3523c"
      unitRef="usd">109600000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="i238afcd7e9494cbb9f4c68c1cf1dcc2d_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182Ny9mcmFnOjc2ODNiYjQ2MzFiMTQ0MTJiMDk2YzNkYmNmOTZiMTFlL3RhYmxlOjBhZjE5OWIyY2U1YTQ5ODA4ZTVlYThlMDdjNmE2YmZkL3RhYmxlcmFuZ2U6MGFmMTk5YjJjZTVhNDk4MDhlNWVhOGUwN2M2YTZiZmRfNy0xLTEtMS0xNTk1NDA_b0039838-d99b-4511-b9ee-7d15005dd77d"
      unitRef="usd">-13700000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="i6b0c929331c241cb98c2a4d85625e2e7_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182Ny9mcmFnOjc2ODNiYjQ2MzFiMTQ0MTJiMDk2YzNkYmNmOTZiMTFlL3RhYmxlOjBhZjE5OWIyY2U1YTQ5ODA4ZTVlYThlMDdjNmE2YmZkL3RhYmxlcmFuZ2U6MGFmMTk5YjJjZTVhNDk4MDhlNWVhOGUwN2M2YTZiZmRfNy0zLTEtMS0xNTk1NDA_fced5d52-4240-4409-ac21-c381b98ddb20"
      unitRef="usd">-14900000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="i60435d86ecc44d56b9b471e301119ba4_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182Ny9mcmFnOjc2ODNiYjQ2MzFiMTQ0MTJiMDk2YzNkYmNmOTZiMTFlL3RhYmxlOjBhZjE5OWIyY2U1YTQ5ODA4ZTVlYThlMDdjNmE2YmZkL3RhYmxlcmFuZ2U6MGFmMTk5YjJjZTVhNDk4MDhlNWVhOGUwN2M2YTZiZmRfNy01LTEtMS0xNTk1NDA_42a2821c-2674-4e97-9067-c041f2b8238d"
      unitRef="usd">-41100000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="i146fcce3fad6486aa91cf7ba94fd98c8_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182Ny9mcmFnOjc2ODNiYjQ2MzFiMTQ0MTJiMDk2YzNkYmNmOTZiMTFlL3RhYmxlOjBhZjE5OWIyY2U1YTQ5ODA4ZTVlYThlMDdjNmE2YmZkL3RhYmxlcmFuZ2U6MGFmMTk5YjJjZTVhNDk4MDhlNWVhOGUwN2M2YTZiZmRfNy03LTEtMS0xNTk1NDA_9c76e13a-df82-4ce2-ae22-c31d846b7b08"
      unitRef="usd">-44700000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit
      contextRef="i238afcd7e9494cbb9f4c68c1cf1dcc2d_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182Ny9mcmFnOjc2ODNiYjQ2MzFiMTQ0MTJiMDk2YzNkYmNmOTZiMTFlL3RhYmxlOjBhZjE5OWIyY2U1YTQ5ODA4ZTVlYThlMDdjNmE2YmZkL3RhYmxlcmFuZ2U6MGFmMTk5YjJjZTVhNDk4MDhlNWVhOGUwN2M2YTZiZmRfOC0xLTEtMS0xNTk1NDA_e0784215-c079-4775-a5b2-742e92fbc4cc"
      unitRef="usd">-200000</us-gaap:DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit>
    <us-gaap:DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit
      contextRef="i6b0c929331c241cb98c2a4d85625e2e7_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182Ny9mcmFnOjc2ODNiYjQ2MzFiMTQ0MTJiMDk2YzNkYmNmOTZiMTFlL3RhYmxlOjBhZjE5OWIyY2U1YTQ5ODA4ZTVlYThlMDdjNmE2YmZkL3RhYmxlcmFuZ2U6MGFmMTk5YjJjZTVhNDk4MDhlNWVhOGUwN2M2YTZiZmRfOC0zLTEtMS0xNTk1NDA_47d99cdf-0375-4cba-b0aa-05328f552da9"
      unitRef="usd">-800000</us-gaap:DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit>
    <us-gaap:DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit
      contextRef="i60435d86ecc44d56b9b471e301119ba4_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182Ny9mcmFnOjc2ODNiYjQ2MzFiMTQ0MTJiMDk2YzNkYmNmOTZiMTFlL3RhYmxlOjBhZjE5OWIyY2U1YTQ5ODA4ZTVlYThlMDdjNmE2YmZkL3RhYmxlcmFuZ2U6MGFmMTk5YjJjZTVhNDk4MDhlNWVhOGUwN2M2YTZiZmRfOC01LTEtMS0xNTk1NDA_21e03264-275f-49f8-96ef-ab83786c7f3e"
      unitRef="usd">-700000</us-gaap:DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit>
    <us-gaap:DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit
      contextRef="i146fcce3fad6486aa91cf7ba94fd98c8_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182Ny9mcmFnOjc2ODNiYjQ2MzFiMTQ0MTJiMDk2YzNkYmNmOTZiMTFlL3RhYmxlOjBhZjE5OWIyY2U1YTQ5ODA4ZTVlYThlMDdjNmE2YmZkL3RhYmxlcmFuZ2U6MGFmMTk5YjJjZTVhNDk4MDhlNWVhOGUwN2M2YTZiZmRfOC03LTEtMS0xNTk1NDA_07011895-c6b7-4421-b55c-bceab32fdfa8"
      unitRef="usd">-2400000</us-gaap:DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i238afcd7e9494cbb9f4c68c1cf1dcc2d_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182Ny9mcmFnOjc2ODNiYjQ2MzFiMTQ0MTJiMDk2YzNkYmNmOTZiMTFlL3RhYmxlOjBhZjE5OWIyY2U1YTQ5ODA4ZTVlYThlMDdjNmE2YmZkL3RhYmxlcmFuZ2U6MGFmMTk5YjJjZTVhNDk4MDhlNWVhOGUwN2M2YTZiZmRfMTAtMS0xLTEtMTU5NTQw_7842c229-76a1-41f9-91c7-5bc773be8c6d"
      unitRef="usd">-30400000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i6b0c929331c241cb98c2a4d85625e2e7_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182Ny9mcmFnOjc2ODNiYjQ2MzFiMTQ0MTJiMDk2YzNkYmNmOTZiMTFlL3RhYmxlOjBhZjE5OWIyY2U1YTQ5ODA4ZTVlYThlMDdjNmE2YmZkL3RhYmxlcmFuZ2U6MGFmMTk5YjJjZTVhNDk4MDhlNWVhOGUwN2M2YTZiZmRfMTAtMy0xLTEtMTU5NTQw_6119dc87-bc16-4d11-a6f8-22537b1fe836"
      unitRef="usd">-30100000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i60435d86ecc44d56b9b471e301119ba4_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182Ny9mcmFnOjc2ODNiYjQ2MzFiMTQ0MTJiMDk2YzNkYmNmOTZiMTFlL3RhYmxlOjBhZjE5OWIyY2U1YTQ5ODA4ZTVlYThlMDdjNmE2YmZkL3RhYmxlcmFuZ2U6MGFmMTk5YjJjZTVhNDk4MDhlNWVhOGUwN2M2YTZiZmRfMTAtNS0xLTEtMTU5NTQw_639edd6f-88e4-4b6c-bab9-5a0e961e527c"
      unitRef="usd">-91100000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i146fcce3fad6486aa91cf7ba94fd98c8_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN182Ny9mcmFnOjc2ODNiYjQ2MzFiMTQ0MTJiMDk2YzNkYmNmOTZiMTFlL3RhYmxlOjBhZjE5OWIyY2U1YTQ5ODA4ZTVlYThlMDdjNmE2YmZkL3RhYmxlcmFuZ2U6MGFmMTk5YjJjZTVhNDk4MDhlNWVhOGUwN2M2YTZiZmRfMTAtNy0xLTEtMTU5NTQw_172a5a38-69a0-4b77-a7f5-9ff66dded603"
      unitRef="usd">-90500000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183MC9mcmFnOjNjOWJjNzRiOGMyODRlZTQ4NThjMTM0MDBiMTE4Zjk1L3RleHRyZWdpb246M2M5YmM3NGI4YzI4NGVlNDg1OGMxMzQwMGIxMThmOTVfMjU1Mjg_816570e0-3745-4ff8-b916-414dbcfea259">Contingencies&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are involved in various lawsuits, claims, government investigations and other legal proceedings that arise in the ordinary course of business. These claims or proceedings can involve various types of parties, including governments, competitors, customers, suppliers, service providers, licensees, employees, or shareholders, among others. These matters may involve patent infringement, antitrust, securities, pricing, sales and marketing practices, environmental, commercial, contractual rights, licensing obligations, health and safety matters, consumer fraud, employment matters, product liability and insurance coverage, among others. The resolution of these matters often develops over a long period of time and expectations can change as a result of new findings, rulings, appeals or settlement arrangements. Legal proceedings that are significant or that we believe could become significant or material are described below. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We believe the legal proceedings in which we are named as defendants are without merit and we are defending against them vigorously. It is not possible to determine the final outcome of these matters, and we cannot reasonably estimate the maximum potential exposure or the range of possible loss in excess of amounts accrued for any of these matters; however, we believe that the resolution of all such matters will not have a material adverse effect on our consolidated financial position or liquidity, but could possibly be material to our consolidated results of operations in any one accounting period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Litigation accruals, environmental liabilities, and the related estimated insurance recoverables are reflected on a gross basis as liabilities and assets, respectively, on our consolidated condensed balance sheets. With respect to the product liability claims currently asserted against us, we have accrued for our estimated exposures to the extent they are both probable and reasonably estimable based on the information available to us. We accrue for certain product liability claims incurred but not filed to the extent we can formulate a reasonable estimate of their costs. We estimate these expenses based primarily on historical claims experience and data regarding product usage. Legal defense costs expected to be incurred in connection with significant product liability loss contingencies are accrued when both probable and reasonably estimable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Because of the nature of pharmaceutical products, it is possible that we could become subject to large numbers of additional product liability and related claims in the future. Due to a very restrictive market for litigation liability insurance, we are self-insured for litigation liability losses for all our currently and previously marketed products. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Patent Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Alimta European Patent Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In Europe, Alimta (pemetrexed) was protected by a patent through June 2021. A number of legal proceedings that were initiated prior to patent expiration are ongoing. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Emgality Patent Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are a named defendant in litigation filed by Teva Pharmaceuticals International GMBH and Teva Pharmaceuticals USA, Inc. (collectively, Teva) in the U.S. District Court for the District of Massachusetts seeking a ruling that various claims in three different Teva patents would be infringed by our launch and continued sales of Emgality for the prevention of migraine in adults. Trial began in October 2022. In June 2021, we were named as a defendant in a second litigation filed by Teva in the U.S. District Court for the District of Massachusetts seeking a ruling that two of Teva's patents, which are directed toward use of the active ingredient in Emgality to treat migraine, would be infringed by our continued sales of Emgality. We challenged these two patents by filing requests for Inter Partes Review with the Patent Trial and Appeal Board (PTAB) and in October 2022, the PTAB granted our requests.The corresponding district court litigation is stayed while this PTAB proceeding is ongoing.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Jardiance Patent Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2018, Boehringer Ingelheim, our partner in marketing and development of Jardiance, initiated U.S. patent litigation in the U.S. District Court of Delaware alleging infringement arising from submissions of Abbreviated New Drug Applications (ANDA) by a number of generic companies seeking approval to market generic versions of Jardiance, Glyxambi, and Synjardy in accordance with the procedures set out in the Drug Price Competition and Patent Term Restoration Act of 1984 (the Hatch-Waxman Act). Particularly with respect to Jardiance, the generic companies' ANDAs seek approval to market generic versions of Jardiance prior to the expiration of the relevant patents, and allege that certain patents, including in some allegations the compound patent, are invalid or would not be infringed. We are not a party to this litigation. This litigation has been stayed. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Taltz Patent Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2021, we petitioned the High Court of Ireland to declare invalid a patent that Novartis Pharma AG (Novartis) purchased from Genentech, Inc. in 2020. Novartis responded by filing a claim against us alleging patent infringement related to our commercialization of Taltz and seeking damages for past infringement and an injunction against future infringement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2021, Novartis petitioned the Court of Rome Intellectual Property Division for a preliminary injunction (PI) against us related to our commercialization of Taltz in Italy. In May 2021, We commenced patent revocation proceedings against Novartis before the Court of Milan&#x2019;s IP Division where we also sought a declaration of non-infringement. Novartis counter-claimed for patent infringement and sought a permanent injunction. A hearing on the PI request before the Court of Rome Intellectual Property Division took place in May 2022 and in July 2022, the court rejected Novartis' request.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2021, Novartis petitioned the Swiss Federal Patent Court for a PI and a permanent injunction in main infringement proceedings against us related to our commercialization of Taltz in Switzerland. We petitioned the court to revoke the patent and for a declaration of non-infringement. In April 2022, Novartis withdrew its PI request.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2022, we commenced an action in the Hague District Court asking for a judgment that a Novartis Dutch patent is not infringed by our commercialization of Taltz in the Netherlands and is invalid. In October 2022, Novartis filed a counterclaim for infringement and sought a permanent injunction.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2022, we entered into a settlement and mutual release agreement with Novartis, which resolves the above-described disputes. Without any admission of liability or wrongdoing, we and Novartis have agreed to mutual releases for past claims and mutual covenants not to sue the other in relation to Taltz and the patents Novartis purchased from Genentech. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Zyprexa Canada Patent Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Beginning in the mid-2000s, several generic companies in Canada challenged the validity of our Zyprexa compound patent. In 2012, the Canadian Federal Court of Appeals denied our appeal of a lower court's decision that certain patent claims were invalid for lack of utility. In 2013, Apotex Inc. and Apotex Pharmachem Inc. (collectively, Apotex) brought claims against us in the Ontario Superior Court of Justice at Toronto for damages related to our enforcement of the Zyprexa compound patent under Canadian regulations governing patented drugs. Apotex seeks compensation based on novel legal theories under the Statute of Monopolies, Trademark Act, and common law. In March 2021, the Ontario Superior Court granted our motion for summary judgment, thereby dismissing Apotex's case. Apotex appealed that ruling to the Court of Appeal for Ontario in April 2021. In August 2022, the Court dismissed the appeal and in October 2022, Apotex appealed the decision. This matter is ongoing.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Product Liability Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Byetta&#xae; Product Liability&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have been named as a defendant in over 500 Byetta product liability lawsuits in the U.S. that were first initiated in March 2009 and involved over 800 plaintiffs. These lawsuits have been filed in various state and federal jurisdictions, including California state court (coordinated in Los Angeles County Superior Court), and various federal courts, the majority of which are coordinated in a multi-district litigation (MDL) in the U.S. District Court for the Southern District of California. The majority of these suits contain allegations that Byetta caused or contributed to the plaintiffs' cancer (primarily pancreatic cancer or thyroid cancer). The federal MDL and coordinated California state trial courts granted summary judgment in our favor on claims pertaining to pancreatic cancer, and the plaintiffs have dismissed Lilly from their appeal of the MDL ruling (the parties still await the order of judgment in the Los Angeles County Superior Court). Most of the MDL and state court lawsuits have been dismissed as of November 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Environmental Proceedings&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the Comprehensive Environmental Response, Compensation, and Liability Act, commonly known as "Superfund," we have been designated as one of several potentially responsible parties with respect to the cleanup of fewer than 10 sites. Under Superfund, each responsible party may be jointly and severally liable for the entire amount of the cleanup.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Other Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;340B Litigation and Investigations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are the plaintiff in a lawsuit filed in January 2021 in the U.S. District Court for the Southern District of Indiana against the U.S. Department of Health and Human Services (HHS), the Secretary of HHS, the Health Resources and Services Administration (HRSA), and the Administrator of HRSA. The lawsuit challenges the HHS's December 30, 2020 advisory opinion stating that drug manufacturers are required to deliver discounts under the 340B program to all contract pharmacies. We seek a declaratory judgment that the defendants violated the Administrative Procedures Act and the U.S. Constitution, a preliminary injunction enjoining implementation of the administrative dispute resolution process created by defendants and, with it, their application of the advisory opinion, and other related relief. In March 2021, the court entered an order preliminarily enjoining the government's enforcement of the administrative dispute resolution process against us. In May 2021, HRSA notified us that it determined that our policy was contrary to the 340B statute. In response, in May 2021, we filed a motion for preliminary injunction and temporary restraining order requesting that the U.S. District Court for the Southern District of Indiana enjoin defendants from taking any action against us relating to the 340B drug pricing program until after the court issues a final judgment on the aforementioned litigation. In May 2021, the court denied our motion for a temporary restraining order but deferred resolution of our motion for preliminary injunction. In June 2021, the defendants withdrew the HHS December 30, 2020 advisory opinion. In July 2021, the court held oral argument on the parties' cross motions for summary judgment, the defendants' motion to dismiss, and our motion for preliminary injunction related to HRSA's May 2021 enforcement letter. In October 2021, the court denied the defendants' motion to dismiss, and granted in part and denied in part the parties' cross motions for summary judgment. Both parties filed notices of appeal related to the court's summary judgment order. Oral argument took place in October 2022 in the U.S. Court of Appeals for the Seventh Circuit. This matter is ongoing.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2021, we, along with other pharmaceutical manufacturers, were named as a defendant in a petition currently pending before the HHS Administrative Dispute Resolution Panel. Petitioner seeks declaratory and other injunctive relief related to the 340B program. As described above, the U.S. District Court for the Southern District of Indiana has entered a preliminary injunction enjoining the government's enforcement of this administrative dispute resolution process against us. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2021, we, along with Sanofi-Aventis U.S., LLC (Sanofi), Novo Nordisk Inc. (Novo Nordisk), and AstraZeneca Pharmaceuticals LP, were named as a defendant in a purported class action lawsuit filed in the U.S. District Court for the Western District of New York by Mosaic Health, Inc. alleging antitrust and unjust enrichment claims related to the defendants' 340B distribution programs. We, with Sanofi and Novo Nordisk, filed a motion to dismiss the lawsuit, which was granted in September 2022. In October 2022, the plaintiffs filed a motion for leave to amend their complaint. This matter is ongoing.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We received a civil investigative subpoena in February 2021 from the Office of the Attorney General for the State of Vermont relating to the sale of pharmaceutical products to Vermont covered entities under the 340B program. We are cooperating with this subpoena. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Branchburg Manufacturing Facility&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2021, we received a subpoena from the U.S. Department of Justice requesting the production of certain documents relating to our manufacturing site in Branchburg, New Jersey. We are cooperating with the subpoena.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Brazil Litigation &#x2013; Cosmopolis Facility&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Labor Attorney Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;First initiated in 2008, our subsidiary in Brazil, Eli Lilly do Brasil Limitada (Lilly Brasil), is named in a Public Civil Action brought by the Labor Public Attorney (LPA) for the 15th Region in the Labor Court of Paulinia, State of Sao Paulo, Brazil, (the Labor Court) alleging possible harm to employees and former employees caused by alleged exposure to soil and groundwater contaminants at a former Lilly Brasil manufacturing facility in Cosmopolis, Brazil, operated by the company between 1977 and 2003. In May 2014, the Labor Court judge ruled against Lilly Brasil, ordering it to undertake several remedial and compensatory actions including health coverage for a class of individuals and certain of their children. In July 2018, the appeals court (TRT) generally affirmed our appeal of the Labor Court's ruling, which included a liquidated award of 300 million Brazilian real, which, when adjusted for inflation and the addition of pre and post judgment interest using the current Central Bank of Brazil's special system of clearance and custody rate, is approximately one billion Brazilian real (approximately $185&#160;million as of September&#160;30, 2022). In August 2019, Lilly Brasil filed an appeal to the superior labor court (TST) and in June 2021, the TRT published its decision on the admissibility of Lilly Brasil's appeal, allowing the majority of the elements, which were allowed to proceed in June 2021; elements not proceeding are subject to an interlocutory appeal to the TST that was filed in June 2021. In September 2019, the TRT stayed a number of elements of its trial court decision pending the determination of Lilly Brasil's appeal to the TST.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2019 and September 2020, the LPA filed applications in the Labor Court for enforcement of certain remedies granted by the TRT in its July 2018 decision, requested restrictions on Lilly Brasil&#x2019;s assets in Brazil, and required Lilly Brasil and Antibi&#xf3;ticos do Brasil Ltda. (ABL) to submit a list of potential beneficiaries of the Public Civil Action. In July 2019, the Labor Court issued a ruling requiring a freeze of Lilly Brasil&#x2019;s immovable property or, alternatively, a security deposit or lien of 500 million Brazilian real, which ruling was subsequently limited in scope and the security was reduced to 100 million Brazilian real. ABL and LPA appealed the June 2021 Labor Court ruling to the TST, which appeal is under review. The Labor Court is currently assessing the status of Lilly Brasil&#x2019;s and ABL&#x2019;s compliance with such portion of the July 2018 TRT decision and an inspection in the industrial plant is expected. These matters are ongoing.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Individual Former Employee Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lilly Brasil is also named in over 20 pending lawsuits filed in the Labor Court by individual former employees making similar claims. These individual lawsuits are at various stages in the litigation process.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Puerto Rico Tax Matter&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2013, the Municipality of Carolina in Puerto Rico (Municipality) filed a lawsuit against us alleging noncompliance with respect to a contract with the Municipality and seeking a declaratory judgment. In December 2020, the Puerto Rico Appellate Court (AP) reversed the summary judgment previously granted by the Court of First Instance (CFI) in our favor, dismissing the Municipality's complaint in its entirety. The AP remanded the case to the CFI for trial on the merits. The trial began in May 2022; however, the Municipality filed a new motion requesting the CFI to award damages. The request was denied by the CFI in our favor and the Municipality filed for revision at the AP, which we opposed, staying the case. This matter is ongoing. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Eastern District of Pennsylvania Pricing (Average Manufacturer Price) Inquiry&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2014, we, along with another pharmaceutical manufacturer, were named as co-defendants in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;United States et al. ex rel. Streck v. Takeda Pharm. Am., Inc., et al.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which was filed in November 2014 and unsealed in the U.S. District Court for the Northern District of Illinois. The complaint alleges that the defendants should have treated certain credits from distributors as retroactive price increases and included such increases in calculating average manufacturer prices. Following a trial in August 2022, the jury returned a verdict in favor of the plaintiff. The case is proceeding with post-trial motions after which the court will enter final judgment in the case. This matter is ongoing.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Health Choice Alliance &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are named as a defendant in two lawsuits filed in Texas and New Jersey state courts in October 2019 seeking damages under the Texas Medicaid Fraud Prevention Act and New Jersey Medicaid False Claims Act, respectively, for certain patient support programs related to our products Humalog, Humulin, and Forteo. The Texas state court action has been stayed. The New Jersey state court action was dismissed with prejudice pending an ongoing appeal before the Appellate Division of the New Jersey Superior Court. This matter is ongoing.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Pricing Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2017 and February 2018, we, along with Sanofi and Novo Nordisk, were named as defendants in a consolidated purported class action lawsuit, In re. Insulin Pricing Litigation and in MSP Recovery Claims, Series, LLC et al. v. Sanofi Aventis U.S. LLC et al., both filed in the U.S. District Court for the District of New Jersey. The cases relate to insulin pricing and seek damages or other relief under various theories, including state consumer protection laws, common law fraud, unjust enrichment, and the Federal Racketeer Influenced and Corrupt Organization Act (federal RICO Act). In both cases, the court dismissed claims under the federal RICO Act and certain state laws. In April 2021, the plaintiffs in In re. Insulin Pricing Litigation amended their complaint to allege additional state law claims for civil conspiracy and violations of state RICO statutes. The court allowed the Arizona RICO statute and certain state civil conspiracy law claims to proceed. Additionally in 2020, we, along with Sanofi, Novo Nordisk, CVS, Express Scripts, and Optum, have been sued in a putative class action, FWK Holdings, LLC v. Novo Nordisk Inc., et al., filed in the same court, for alleged violations of the federal RICO Act as well as the New Jersey RICO Act and antitrust law. The same group of defendants, along with Medco Health and United Health Group, also have been sued in other purported class actions in the same court, Rochester Drug Co-Operative Inc. v. Eli Lilly &amp;amp; Co. et al. and Value Drug Co. v. Eli Lilly &amp;amp; Co. et al., which were both initiated in March 2020, with the plaintiffs seeking damages for alleged violations of the federal RICO Act. In September 2020, the U.S. District Court for the District of New Jersey granted plaintiffs' motion to consolidate FWK Holdings, LLC v. Novo Nordisk Inc., et al., Rochester Drug Co-Operative Inc. v. Eli Lilly &amp;amp; Co. et al., and Value Drug Co. v. Eli Lilly &amp;amp; Co. et al. In July 2021, the U.S. District Court for the District of New Jersey dismissed the three antitrust claims alleged by plaintiffs in the consolidated litigation and denied dismissal of the federal RICO Act claims.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2018, the Minnesota Attorney General's Office initiated litigation against us, Sanofi, and Novo Nordisk, State of Minnesota v. Sanofi-Aventis U.S. LLC et al., in the U.S. District Court for the District of New Jersey, seeking damages for unjust enrichment, violations of various Minnesota state consumer protection laws, and the federal RICO Act. In March 2021, the U.S. District Court for the District of New Jersey dismissed with prejudice the Minnesota Attorney General's federal RICO claims and false advertising claims under state law; the consumer fraud and other related state law claims remain ongoing. Additionally, in May 2019, the Kentucky Attorney General's Office filed a complaint against us, Sanofi, and Novo Nordisk, Commonwealth of Kentucky v. Novo Nordisk, Inc. et al., in Kentucky state court, alleging violations of the Kentucky consumer protection law, false advertising, and unjust enrichment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2021, the Mississippi Attorney General's Office initiated litigation against us, Sanofi, Novo Nordisk, Evernorth/ESI, CVS/Caremark, and United/Optum in the Hinds County, Mississippi Chancery Court, alleging state law consumer protection, unjust enrichment, and civil conspiracy claims. After the case was removed to federal court, we, along with the other defendants, filed a motion to dismiss the lawsuit, which was denied. This matter is ongoing.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2022, the state of Arkansas filed suit against us Sanofi, Novo Nordisk, ESI, CVS/Caremark/Aetna, and Optum, asserting state law consumer protection, civil conspiracy, and unjust enrichment claims. The case has been removed to federal court and is ongoing.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2022, the County of Albany, New York filed a suit against us, Sanofi, Novo Nordisk, Evernorth/ESI, CVS/Caremark and United/Optum asserting violations of federal RICO statute and state law claims for deceptive trade practices, unjust enrichment, and civil conspiracy. This matter is ongoing.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2022, the State of Montana filed a suit against us, Sanofi, Novo Nordisk, Evernorth/ESI, Medco Health Solutions, CVS/Caremark and Optum asserting violations of the Montana Unfair Practices and Consumer Protection Act, unjust enrichment, and civil conspiracy. This matter is ongoing.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Investigations, Subpoenas, and Inquiries&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the pricing and sale of our insulin and other products, we have been subject to various investigations and received subpoenas, civil investigative demand requests, information requests, interrogatories, and other inquiries from various governmental entities. These include subpoenas from the New York and Vermont Attorney General Offices, civil investigative demands from the Washington, New Mexico, Colorado, Illinois, Ohio Attorney General Offices, the Department of Justice and the Federal Trade Commission, as well as information requests from the Mississippi, Washington D.C., California, Florida, Hawaii, and Nevada Attorney General Offices. In January 2022, the Michigan Attorney General filed a petition in Michigan state court seeking authorization to investigate Lilly for potential violations of the Michigan Consumer Protection Act (MCPA), and a complaint seeking a declaratory judgment that the Attorney General has authority to investigate Lilly's sale of insulin under the MCPA. The court authorized the proposed investigation and the issuance of civil investigative subpoenas. In April 2022, the parties entered into a stipulation providing that the State will not issue any civil investigative subpoena to us under the MCPA until the declaratory judgment action is resolved. In July 2022, the court dismissed the case in its entirety. The Michigan Attorney General filed a notice of appeal and an application to obtain review by the Michigan Supreme Court, which remain pending. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We received a request in January 2019 from the House of Representatives' Committee on Oversight and Reform seeking commercial information and business records related to the pricing of insulin products, among other issues. We also received similar requests from the Senate Finance Committee and the Senate Committee on Health, Education, Labor, and Pensions, and separate requests from the House Committee on Energy and Commerce majority and minority members. In January 2021, the Senate Finance Committee released a report summarizing the findings of its investigation. In December 2021 the House of Representatives' Committee on Oversight and Reform majority and minority staffs released separate reports with findings from their investigations into drug pricing, including of insulin products.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are cooperating with all of the aforementioned investigations, subpoenas, and inquiries.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Research Corporation Technologies, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2016, we were named as a defendant in litigation filed by Research Corporation Technologies, Inc. (RCT) in the U.S. District Court for the District of Arizona. RCT is seeking damages for breach of contract, unjust enrichment, and conversion related to processes used to manufacture certain products, including Humalog and Humulin. In October 2021, the court issued a summary judgment decision finding in favor of RCT on certain issues, including with respect to a disputed royalty. Both parties filed motions for reconsideration, which were denied. We filed supplemental summary judgment motions. A trial date has not been set. Potential damages payable under the litigation, if finally awarded after an appeal, could be material but are not currently reasonably estimable. This matter is ongoing.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:CommitmentsAndContingenciesPolicyTextBlock
      contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183MC9mcmFnOjNjOWJjNzRiOGMyODRlZTQ4NThjMTM0MDBiMTE4Zjk1L3RleHRyZWdpb246M2M5YmM3NGI4YzI4NGVlNDg1OGMxMzQwMGIxMThmOTVfMjU1Mjc_94d35f0a-1f1c-40a2-a374-cb9a1db87e4c">Litigation accruals, environmental liabilities, and the related estimated insurance recoverables are reflected on a gross basis as liabilities and assets, respectively, on our consolidated condensed balance sheets. With respect to the product liability claims currently asserted against us, we have accrued for our estimated exposures to the extent they are both probable and reasonably estimable based on the information available to us. We accrue for certain product liability claims incurred but not filed to the extent we can formulate a reasonable estimate of their costs. We estimate these expenses based primarily on historical claims experience and data regarding product usage. Legal defense costs expected to be incurred in connection with significant product liability loss contingencies are accrued when both probable and reasonably estimable.Because of the nature of pharmaceutical products, it is possible that we could become subject to large numbers of additional product liability and related claims in the future. Due to a very restrictive market for litigation liability insurance, we are self-insured for litigation liability losses for all our currently and previously marketed products.</us-gaap:CommitmentsAndContingenciesPolicyTextBlock>
    <lly:LossContingencyNumberOfPatents
      contextRef="ib414aaa5a0174c7fb17ac9898d399d32_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183MC9mcmFnOjNjOWJjNzRiOGMyODRlZTQ4NThjMTM0MDBiMTE4Zjk1L3RleHRyZWdpb246M2M5YmM3NGI4YzI4NGVlNDg1OGMxMzQwMGIxMThmOTVfMzI3MA_8e971b18-a9a6-4aef-8669-427d64636547"
      unitRef="patent">3</lly:LossContingencyNumberOfPatents>
    <lly:LossContingencyNumberOfPatents
      contextRef="if274934ece0041f487b43797bc8de648_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183MC9mcmFnOjNjOWJjNzRiOGMyODRlZTQ4NThjMTM0MDBiMTE4Zjk1L3RleHRyZWdpb246M2M5YmM3NGI4YzI4NGVlNDg1OGMxMzQwMGIxMThmOTVfMzYyMQ_e7472257-8527-43b9-811f-30e96ee28ad1"
      unitRef="patent">2</lly:LossContingencyNumberOfPatents>
    <lly:LossContingencyNumberOfPatents
      contextRef="ibcc5f2496e02449abe458e54c0a8a61f_I20221031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183MC9mcmFnOjNjOWJjNzRiOGMyODRlZTQ4NThjMTM0MDBiMTE4Zjk1L3RleHRyZWdpb246M2M5YmM3NGI4YzI4NGVlNDg1OGMxMzQwMGIxMThmOTVfMzI5ODUzNDkxMzc1Nw_ffd61f4e-01d0-4ed4-8e24-921cab76ceb3"
      unitRef="patent">2</lly:LossContingencyNumberOfPatents>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="i58d8155218724e10a6956cdd38ca1bb1_I20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183MC9mcmFnOjNjOWJjNzRiOGMyODRlZTQ4NThjMTM0MDBiMTE4Zjk1L3RleHRyZWdpb246M2M5YmM3NGI4YzI4NGVlNDg1OGMxMzQwMGIxMThmOTVfNzE4NA_c911cb99-3c7e-4e9d-8a5e-5f4a3ac54ad6"
      unitRef="lawsuit">500</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyNumberOfPlaintiffs
      contextRef="i03a0a6037fc44e39af8b9a0fc87cbcbb_D20090301-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183MC9mcmFnOjNjOWJjNzRiOGMyODRlZTQ4NThjMTM0MDBiMTE4Zjk1L3RleHRyZWdpb246M2M5YmM3NGI4YzI4NGVlNDg1OGMxMzQwMGIxMThmOTVfNzI5MQ_a72efacc-c27f-4e6e-8f0e-a546adfee6ab"
      unitRef="plaintiff">800</us-gaap:LossContingencyNumberOfPlaintiffs>
    <lly:LossContingencyNumberOfSitesJointlyAndSeverallyLiableForCleanup
      contextRef="iedfe8e594f2d4534ba3f7d18996055ec_I20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183MC9mcmFnOjNjOWJjNzRiOGMyODRlZTQ4NThjMTM0MDBiMTE4Zjk1L3RleHRyZWdpb246M2M5YmM3NGI4YzI4NGVlNDg1OGMxMzQwMGIxMThmOTVfOTQwMQ_5089f719-62ae-4612-80e7-43f34070b9d0"
      unitRef="site">10</lly:LossContingencyNumberOfSitesJointlyAndSeverallyLiableForCleanup>
    <us-gaap:LossContingencyDamagesAwardedValue
      contextRef="i7b4e96e210ab4559a67ee97574922011_D20180701-20180731"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183MC9mcmFnOjNjOWJjNzRiOGMyODRlZTQ4NThjMTM0MDBiMTE4Zjk1L3RleHRyZWdpb246M2M5YmM3NGI4YzI4NGVlNDg1OGMxMzQwMGIxMThmOTVfMTQyMTE_d6c1f2d4-f081-4c9e-87e4-c8521a4db76d"
      unitRef="brl">300000000</us-gaap:LossContingencyDamagesAwardedValue>
    <us-gaap:LossContingencyDamagesAwardedValue
      contextRef="i983baf60b46f4dc0ab264f727cff1fd1_D20220101-20220930"
      decimals="-9"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183MC9mcmFnOjNjOWJjNzRiOGMyODRlZTQ4NThjMTM0MDBiMTE4Zjk1L3RleHRyZWdpb246M2M5YmM3NGI4YzI4NGVlNDg1OGMxMzQwMGIxMThmOTVfMTQ0MjI_9d1ce226-be24-4fb7-88e3-a7c4b947c95a"
      unitRef="brl">1000000000</us-gaap:LossContingencyDamagesAwardedValue>
    <us-gaap:LossContingencyDamagesAwardedValue
      contextRef="i983baf60b46f4dc0ab264f727cff1fd1_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183MC9mcmFnOjNjOWJjNzRiOGMyODRlZTQ4NThjMTM0MDBiMTE4Zjk1L3RleHRyZWdpb246M2M5YmM3NGI4YzI4NGVlNDg1OGMxMzQwMGIxMThmOTVfMTQ0NjM_26784162-b13d-444b-a14d-98a5f9b6b865"
      unitRef="usd">185000000</us-gaap:LossContingencyDamagesAwardedValue>
    <us-gaap:LossContingencyDamagesAwardedValue
      contextRef="id52423032e6747898c41a944e3038420_D20190701-20190731"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183MC9mcmFnOjNjOWJjNzRiOGMyODRlZTQ4NThjMTM0MDBiMTE4Zjk1L3RleHRyZWdpb246M2M5YmM3NGI4YzI4NGVlNDg1OGMxMzQwMGIxMThmOTVfMTU0OTI_05a6deee-589b-4dc5-a6ac-d95a9c2c06f6"
      unitRef="brl">500000000</us-gaap:LossContingencyDamagesAwardedValue>
    <us-gaap:LossContingencyDamagesAwardedValue
      contextRef="i098637113ce84c2f8c583d5aac35942b_D20210601-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183MC9mcmFnOjNjOWJjNzRiOGMyODRlZTQ4NThjMTM0MDBiMTE4Zjk1L3RleHRyZWdpb246M2M5YmM3NGI4YzI4NGVlNDg1OGMxMzQwMGIxMThmOTVfMTU1OTA_a0d249b9-eaa1-45da-818b-3b500a445068"
      unitRef="brl">100000000</us-gaap:LossContingencyDamagesAwardedValue>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="i91a11e76b2844622ba08c167af2c1bbd_I20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183MC9mcmFnOjNjOWJjNzRiOGMyODRlZTQ4NThjMTM0MDBiMTE4Zjk1L3RleHRyZWdpb246M2M5YmM3NGI4YzI4NGVlNDg1OGMxMzQwMGIxMThmOTVfMTU5OTc_c00515b3-d3eb-4b3d-87f9-0186af61fd07"
      unitRef="lawsuit">20</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="i3fd1ac8f6fc9438cb71e216b3246793e_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183MC9mcmFnOjNjOWJjNzRiOGMyODRlZTQ4NThjMTM0MDBiMTE4Zjk1L3RleHRyZWdpb246M2M5YmM3NGI4YzI4NGVlNDg1OGMxMzQwMGIxMThmOTVfMTc1OTg_f42a9182-bf94-43fd-98b7-772f35b286c5"
      unitRef="lawsuit">2</us-gaap:LossContingencyPendingClaimsNumber>
    <lly:LitigationClaimsDismissedNumber
      contextRef="if2605d2b37d747e1b5887703c18e4963_D20210701-20210731"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183MC9mcmFnOjNjOWJjNzRiOGMyODRlZTQ4NThjMTM0MDBiMTE4Zjk1L3RleHRyZWdpb246M2M5YmM3NGI4YzI4NGVlNDg1OGMxMzQwMGIxMThmOTVfMjAxODI_b508d386-d4a9-4d74-8d63-16450171d9c7"
      unitRef="claim">3</lly:LitigationClaimsDismissedNumber>
    <us-gaap:ComprehensiveIncomeNoteTextBlock
      contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RleHRyZWdpb246ZTE0MjlmY2IyNjYyNDg4ZDk5MTllMTg4MGNiZTMyMTNfMTI1Ng_4177cc75-a543-4e1f-95ea-f932e4ab8da9">Other Comprehensive Income (Loss)&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize the activity related to each component of other comprehensive income (loss) during the three months ended September&#160;30, 2022 and 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Amounts presented net of taxes)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Foreign Currency Translation Gains&#160;(Losses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Unrealized Net Gains (Losses) on&#160;Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Defined Benefit Pension and Retiree&#160;Health Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Effective Portion of Cash&#160;Flow Hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Accumulated Other Comprehensive Loss&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at July 1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(1,844.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(27.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(2,443.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;27.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(4,287.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(165.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(24.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;47.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;63.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(79.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net amount reclassified from accumulated other comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;13.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;57.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;0.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;71.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(165.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(11.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;105.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;63.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(8.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at September&#160;30, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(2,009.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(39.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(2,338.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;91.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(4,295.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Amounts presented net of taxes)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Foreign Currency Translation Gains&#160;(Losses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Unrealized Net Gains (Losses) on&#160;Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Defined Benefit Pension and Retiree&#160;Health Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Effective Portion of Cash&#160;Flow Hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Accumulated Other Comprehensive Loss&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at July 1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,516.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,569.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(210.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,287.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net amount reclassified from accumulated other comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at September&#160;30, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,524.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,465.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(190.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,172.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize the activity related to each component of other comprehensive income (loss) during the nine months ended September&#160;30, 2022 and 2021: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Amounts presented net of taxes)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Foreign Currency Translation Gains&#160;(Losses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Unrealized Net Gains (Losses) on&#160;Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Defined Benefit Pension and Retiree&#160;Health Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Effective Portion of Cash&#160;Flow Hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Accumulated Other Comprehensive Loss&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at January 1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(1,550.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(2,583.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(213.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(4,343.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(459.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(55.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;72.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;297.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(145.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net amount reclassified from accumulated other comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;0.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;12.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;172.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;192.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(459.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(43.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;245.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;304.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;47.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at September&#160;30, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(2,009.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(39.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(2,338.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;91.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(4,295.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Amounts presented net of taxes)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Foreign Currency Translation Gains&#160;(Losses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Unrealized Net Gains (Losses) on&#160;Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Defined Benefit Pension and Retiree&#160;Health Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Effective Portion of Cash&#160;Flow Hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Accumulated Other Comprehensive Loss&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at January 1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,427.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,751.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(332.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,496.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(96.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;132.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net amount reclassified from accumulated other comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;258.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;269.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(96.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;285.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;142.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;323.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at September&#160;30, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,524.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,465.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(190.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,172.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The tax effects on the net activity related to each component of other comprehensive income (loss) were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.206%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Tax benefit (expense) &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency translation gains/losses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(133.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(39.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(234.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(92.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrealized net gains/losses on securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;13.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Defined benefit pension and retiree health benefit plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(22.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(28.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(73.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(79.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effective portion of cash flow hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(16.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(80.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(37.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Benefit (expense) for income taxes allocated to other comprehensive income (loss) items&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(169.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(71.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(375.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(206.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Except for the tax effects of foreign currency translation gains and losses related to our foreign currency-denominated notes, cross-currency interest rate swaps, and other foreign currency exchange contracts designated as net investment hedges (see Note 6), income taxes were not provided for foreign currency translation. Generally, the assets and liabilities of foreign operations are translated into U.S. dollars using the current exchange rate. For those operations, changes in exchange rates generally do not affect cash flows; therefore, resulting translation adjustments are made in shareholders' equity rather than in the consolidated condensed statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Reclassifications out of accumulated other comprehensive loss were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.718%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.830%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Details about Accumulated Other Comprehensive Loss Components&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Affected Line Item in the Consolidated Condensed Statements of Operations&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="30" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of retirement benefit items:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prior service benefits, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(13.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(39.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(41.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&#x2013;net, (income) expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Actuarial losses, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;85.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;257.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;368.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&#x2013;net, (income) expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total before tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;72.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;108.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;218.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;327.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(15.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(45.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(68.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income taxes&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;57.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;172.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;258.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other, net of tax&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;13.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;19.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&#x2013;net, (income) expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total reclassifications, net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;71.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;192.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;269.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomeNoteTextBlock>
    <us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock
      contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RleHRyZWdpb246ZTE0MjlmY2IyNjYyNDg4ZDk5MTllMTg4MGNiZTMyMTNfMTI1NA_1a2821d3-38b3-400c-bedd-744bdd5e1a5e">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize the activity related to each component of other comprehensive income (loss) during the three months ended September&#160;30, 2022 and 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Amounts presented net of taxes)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Foreign Currency Translation Gains&#160;(Losses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Unrealized Net Gains (Losses) on&#160;Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Defined Benefit Pension and Retiree&#160;Health Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Effective Portion of Cash&#160;Flow Hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Accumulated Other Comprehensive Loss&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at July 1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(1,844.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(27.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(2,443.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;27.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(4,287.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(165.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(24.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;47.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;63.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(79.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net amount reclassified from accumulated other comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;13.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;57.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;0.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;71.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(165.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(11.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;105.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;63.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(8.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at September&#160;30, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(2,009.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(39.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(2,338.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;91.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(4,295.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Amounts presented net of taxes)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Foreign Currency Translation Gains&#160;(Losses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Unrealized Net Gains (Losses) on&#160;Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Defined Benefit Pension and Retiree&#160;Health Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Effective Portion of Cash&#160;Flow Hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Accumulated Other Comprehensive Loss&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at July 1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,516.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,569.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(210.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,287.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net amount reclassified from accumulated other comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at September&#160;30, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,524.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,465.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(190.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,172.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize the activity related to each component of other comprehensive income (loss) during the nine months ended September&#160;30, 2022 and 2021: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Amounts presented net of taxes)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Foreign Currency Translation Gains&#160;(Losses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Unrealized Net Gains (Losses) on&#160;Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Defined Benefit Pension and Retiree&#160;Health Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Effective Portion of Cash&#160;Flow Hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Accumulated Other Comprehensive Loss&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at January 1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(1,550.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(2,583.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(213.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(4,343.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(459.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(55.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;72.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;297.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(145.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net amount reclassified from accumulated other comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;0.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;12.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;172.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;192.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(459.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(43.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;245.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;304.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;47.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at September&#160;30, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(2,009.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(39.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(2,338.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;91.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(4,295.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Amounts presented net of taxes)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Foreign Currency Translation Gains&#160;(Losses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Unrealized Net Gains (Losses) on&#160;Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Defined Benefit Pension and Retiree&#160;Health Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Effective Portion of Cash&#160;Flow Hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Accumulated Other Comprehensive Loss&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at January 1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,427.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,751.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(332.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,496.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(96.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;132.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net amount reclassified from accumulated other comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;258.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;269.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(96.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;285.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;142.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;323.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at September&#160;30, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,524.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,465.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(190.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,172.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The tax effects on the net activity related to each component of other comprehensive income (loss) were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.206%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Tax benefit (expense) &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency translation gains/losses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(133.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(39.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(234.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(92.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrealized net gains/losses on securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;13.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Defined benefit pension and retiree health benefit plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(22.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(28.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(73.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(79.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effective portion of cash flow hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(16.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(80.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(37.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Benefit (expense) for income taxes allocated to other comprehensive income (loss) items&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(169.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(71.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(375.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(206.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia44884b555f84a8bb8c051329b5b483c_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmI0OWI3ZGUzOGIzYTRjZGE4OGU1ZDkxMzcwMDI5NmJlL3RhYmxlcmFuZ2U6YjQ5YjdkZTM4YjNhNGNkYTg4ZTVkOTEzNzAwMjk2YmVfMi0xLTEtMS0xNTk1NDA_61537d92-f2a1-4b69-a3f9-24b3bc3738a2"
      unitRef="usd">-1844200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="icf1cf37660ed42919d552edbdc9ddf29_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmI0OWI3ZGUzOGIzYTRjZGE4OGU1ZDkxMzcwMDI5NmJlL3RhYmxlcmFuZ2U6YjQ5YjdkZTM4YjNhNGNkYTg4ZTVkOTEzNzAwMjk2YmVfMi0zLTEtMS0xNTk1NDA_69a279ca-9089-47c0-b87e-d86d691a3181"
      unitRef="usd">-27900000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib07a74d7836447719291eff28ad65a22_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmI0OWI3ZGUzOGIzYTRjZGE4OGU1ZDkxMzcwMDI5NmJlL3RhYmxlcmFuZ2U6YjQ5YjdkZTM4YjNhNGNkYTg4ZTVkOTEzNzAwMjk2YmVfMi01LTEtMS0xNTk1NDA_db7d1beb-6363-4f7f-a9d9-b2d18039afa9"
      unitRef="usd">-2443200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia3f2ab912d2b47e7862abe56a92bb118_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmI0OWI3ZGUzOGIzYTRjZGE4OGU1ZDkxMzcwMDI5NmJlL3RhYmxlcmFuZ2U6YjQ5YjdkZTM4YjNhNGNkYTg4ZTVkOTEzNzAwMjk2YmVfMi03LTEtMS0xNTk1NDA_343b9422-190c-462f-8ead-daf5eeaab408"
      unitRef="usd">27600000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic22b2460974b4792a24b9b75e0e598d3_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmI0OWI3ZGUzOGIzYTRjZGE4OGU1ZDkxMzcwMDI5NmJlL3RhYmxlcmFuZ2U6YjQ5YjdkZTM4YjNhNGNkYTg4ZTVkOTEzNzAwMjk2YmVfMi0xMS0xLTEtMTU5NTQw_fd980611-5e52-4a97-a798-2655f95c571e"
      unitRef="usd">-4287700000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="ibb680e42808d41b587bffa2f35409a91_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmI0OWI3ZGUzOGIzYTRjZGE4OGU1ZDkxMzcwMDI5NmJlL3RhYmxlcmFuZ2U6YjQ5YjdkZTM4YjNhNGNkYTg4ZTVkOTEzNzAwMjk2YmVfNC0xLTEtMS0xNTk1NDA_cbc2ec7d-665e-4d72-abcf-0680f8743a62"
      unitRef="usd">-165100000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="ib423da078b9740019ae03257a6ca1320_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmI0OWI3ZGUzOGIzYTRjZGE4OGU1ZDkxMzcwMDI5NmJlL3RhYmxlcmFuZ2U6YjQ5YjdkZTM4YjNhNGNkYTg4ZTVkOTEzNzAwMjk2YmVfNC0zLTEtMS0xNTk1NDA_dd7e584d-274c-4035-a1ad-3bd934deec3d"
      unitRef="usd">-24900000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i0ddaa7c4639946b1a63ee163ebac9cda_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmI0OWI3ZGUzOGIzYTRjZGE4OGU1ZDkxMzcwMDI5NmJlL3RhYmxlcmFuZ2U6YjQ5YjdkZTM4YjNhNGNkYTg4ZTVkOTEzNzAwMjk2YmVfNC01LTEtMS0xNTk1NDA_c4468f3b-2c88-45f9-a4e2-213f55b53fe2"
      unitRef="usd">47800000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i9e78a70b50b740909d4bd5980c556e3a_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmI0OWI3ZGUzOGIzYTRjZGE4OGU1ZDkxMzcwMDI5NmJlL3RhYmxlcmFuZ2U6YjQ5YjdkZTM4YjNhNGNkYTg4ZTVkOTEzNzAwMjk2YmVfNC03LTEtMS0xNTk1NDA_591568af-3056-4f1f-88f7-e568a0207664"
      unitRef="usd">63000000.0</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i19fc0325c48543008ea71e1fdcf11d86_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmI0OWI3ZGUzOGIzYTRjZGE4OGU1ZDkxMzcwMDI5NmJlL3RhYmxlcmFuZ2U6YjQ5YjdkZTM4YjNhNGNkYTg4ZTVkOTEzNzAwMjk2YmVfNC0xMS0xLTEtMTU5NTQw_c31fdf97-1486-4381-9437-328a9ca94800"
      unitRef="usd">-79200000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="ibb680e42808d41b587bffa2f35409a91_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmI0OWI3ZGUzOGIzYTRjZGE4OGU1ZDkxMzcwMDI5NmJlL3RhYmxlcmFuZ2U6YjQ5YjdkZTM4YjNhNGNkYTg4ZTVkOTEzNzAwMjk2YmVfNS0xLTEtMS0xNTk1NDA_c14fa024-aa18-4392-a0f1-db43693c837a"
      unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="ib423da078b9740019ae03257a6ca1320_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmI0OWI3ZGUzOGIzYTRjZGE4OGU1ZDkxMzcwMDI5NmJlL3RhYmxlcmFuZ2U6YjQ5YjdkZTM4YjNhNGNkYTg4ZTVkOTEzNzAwMjk2YmVfNS0zLTEtMS0xNTk1NDA_a4adb628-3aa8-4ae0-aa97-fc39db7ac531"
      unitRef="usd">-13500000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i0ddaa7c4639946b1a63ee163ebac9cda_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmI0OWI3ZGUzOGIzYTRjZGE4OGU1ZDkxMzcwMDI5NmJlL3RhYmxlcmFuZ2U6YjQ5YjdkZTM4YjNhNGNkYTg4ZTVkOTEzNzAwMjk2YmVfNS01LTEtMS0xNTk1NDA_c08f6e8b-84f8-4d36-abc4-42478db731bb"
      unitRef="usd">-57200000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i9e78a70b50b740909d4bd5980c556e3a_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmI0OWI3ZGUzOGIzYTRjZGE4OGU1ZDkxMzcwMDI5NmJlL3RhYmxlcmFuZ2U6YjQ5YjdkZTM4YjNhNGNkYTg4ZTVkOTEzNzAwMjk2YmVfNS03LTEtMS0xNTk1NDA_b3f01a8b-6d38-4402-93a0-821e676bc7a1"
      unitRef="usd">-400000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i19fc0325c48543008ea71e1fdcf11d86_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmI0OWI3ZGUzOGIzYTRjZGE4OGU1ZDkxMzcwMDI5NmJlL3RhYmxlcmFuZ2U6YjQ5YjdkZTM4YjNhNGNkYTg4ZTVkOTEzNzAwMjk2YmVfNS0xMS0xLTEtMTU5NTQw_088704fe-f523-48bf-8ae4-4b227e58c298"
      unitRef="usd">-71100000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ibb680e42808d41b587bffa2f35409a91_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmI0OWI3ZGUzOGIzYTRjZGE4OGU1ZDkxMzcwMDI5NmJlL3RhYmxlcmFuZ2U6YjQ5YjdkZTM4YjNhNGNkYTg4ZTVkOTEzNzAwMjk2YmVfNi0xLTEtMS0xNTk1NDA_3b62616a-2821-459a-a310-620633bc58e9"
      unitRef="usd">-165100000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ib423da078b9740019ae03257a6ca1320_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmI0OWI3ZGUzOGIzYTRjZGE4OGU1ZDkxMzcwMDI5NmJlL3RhYmxlcmFuZ2U6YjQ5YjdkZTM4YjNhNGNkYTg4ZTVkOTEzNzAwMjk2YmVfNi0zLTEtMS0xNTk1NDA_dc860762-cab1-407d-9227-4d943555d204"
      unitRef="usd">-11400000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i0ddaa7c4639946b1a63ee163ebac9cda_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmI0OWI3ZGUzOGIzYTRjZGE4OGU1ZDkxMzcwMDI5NmJlL3RhYmxlcmFuZ2U6YjQ5YjdkZTM4YjNhNGNkYTg4ZTVkOTEzNzAwMjk2YmVfNi01LTEtMS0xNTk1NDA_7ac26987-d230-4727-8f9c-6cc3a1627cec"
      unitRef="usd">105000000.0</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i9e78a70b50b740909d4bd5980c556e3a_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmI0OWI3ZGUzOGIzYTRjZGE4OGU1ZDkxMzcwMDI5NmJlL3RhYmxlcmFuZ2U6YjQ5YjdkZTM4YjNhNGNkYTg4ZTVkOTEzNzAwMjk2YmVfNi03LTEtMS0xNTk1NDA_fd9706f0-f0af-4046-b6c4-7bfe7b4b4acc"
      unitRef="usd">63400000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i19fc0325c48543008ea71e1fdcf11d86_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmI0OWI3ZGUzOGIzYTRjZGE4OGU1ZDkxMzcwMDI5NmJlL3RhYmxlcmFuZ2U6YjQ5YjdkZTM4YjNhNGNkYTg4ZTVkOTEzNzAwMjk2YmVfNi0xMS0xLTEtMTU5NTQw_40cb76f4-eb16-4abc-9dad-92674aae60e4"
      unitRef="usd">-8100000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i603b413215ff4ac0860f74b6a1be9294_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmI0OWI3ZGUzOGIzYTRjZGE4OGU1ZDkxMzcwMDI5NmJlL3RhYmxlcmFuZ2U6YjQ5YjdkZTM4YjNhNGNkYTg4ZTVkOTEzNzAwMjk2YmVfOC0xLTEtMS0xNTk1NDA_5d3103f5-2c11-4a4b-b0bc-675cd4e76e01"
      unitRef="usd">-2009300000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6105e19d65744395aeb2921c7555324a_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmI0OWI3ZGUzOGIzYTRjZGE4OGU1ZDkxMzcwMDI5NmJlL3RhYmxlcmFuZ2U6YjQ5YjdkZTM4YjNhNGNkYTg4ZTVkOTEzNzAwMjk2YmVfOC0zLTEtMS0xNTk1NDA_1a11a6ab-46f7-46ba-9882-ee81f6991b2d"
      unitRef="usd">-39300000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1ec1c7b3b72549149e283cdff33abeed_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmI0OWI3ZGUzOGIzYTRjZGE4OGU1ZDkxMzcwMDI5NmJlL3RhYmxlcmFuZ2U6YjQ5YjdkZTM4YjNhNGNkYTg4ZTVkOTEzNzAwMjk2YmVfOC01LTEtMS0xNTk1NDA_eb9fe125-efd8-45bc-9d1f-26432a65fe4b"
      unitRef="usd">-2338200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ifc51fbfd706a4f809013d42ddd4fef8c_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmI0OWI3ZGUzOGIzYTRjZGE4OGU1ZDkxMzcwMDI5NmJlL3RhYmxlcmFuZ2U6YjQ5YjdkZTM4YjNhNGNkYTg4ZTVkOTEzNzAwMjk2YmVfOC03LTEtMS0xNTk1NDA_fa96315f-e4ce-4976-91c5-8d39001ad233"
      unitRef="usd">91000000.0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iad56c44530dd4208959b336f8d1fe8b1_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmI0OWI3ZGUzOGIzYTRjZGE4OGU1ZDkxMzcwMDI5NmJlL3RhYmxlcmFuZ2U6YjQ5YjdkZTM4YjNhNGNkYTg4ZTVkOTEzNzAwMjk2YmVfOC0xMS0xLTEtMTU5NTQw_0792feed-da8e-462b-b629-002325c41dda"
      unitRef="usd">-4295800000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9b7795dc491c42cbb64812b2b99d2ac9_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOjU0MGYzNDkzN2Y1NDQ5NWI4YzRjZjllMzUyMjZjMjY3L3RhYmxlcmFuZ2U6NTQwZjM0OTM3ZjU0NDk1YjhjNGNmOWUzNTIyNmMyNjdfMi0xLTEtMS0xNTk1NDA_9f17f11a-0fc5-43a5-8540-fc6678ec4e5c"
      unitRef="usd">-1516200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ideb9d32d39e441f68ba01504bca2b03c_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOjU0MGYzNDkzN2Y1NDQ5NWI4YzRjZjllMzUyMjZjMjY3L3RhYmxlcmFuZ2U6NTQwZjM0OTM3ZjU0NDk1YjhjNGNmOWUzNTIyNmMyNjdfMi0zLTEtMS0xNTk1NDA_51706b6e-854b-47d9-9a42-09fa39f7bae1"
      unitRef="usd">9100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iec456e1ce7794922919937b65a44561f_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOjU0MGYzNDkzN2Y1NDQ5NWI4YzRjZjllMzUyMjZjMjY3L3RhYmxlcmFuZ2U6NTQwZjM0OTM3ZjU0NDk1YjhjNGNmOWUzNTIyNmMyNjdfMi01LTEtMS0xNTk1NDA_0e6d56b0-e95e-4911-8028-5eae3b51a9e7"
      unitRef="usd">-4569900000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2988484b109649f28736efa0418c49f9_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOjU0MGYzNDkzN2Y1NDQ5NWI4YzRjZjllMzUyMjZjMjY3L3RhYmxlcmFuZ2U6NTQwZjM0OTM3ZjU0NDk1YjhjNGNmOWUzNTIyNmMyNjdfMi03LTEtMS0xNTk1NDA_5e978c74-5638-4781-a4ff-865cc813ebaf"
      unitRef="usd">-210100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id29f7d92807d4933b0fb1e960563f81f_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOjU0MGYzNDkzN2Y1NDQ5NWI4YzRjZjllMzUyMjZjMjY3L3RhYmxlcmFuZ2U6NTQwZjM0OTM3ZjU0NDk1YjhjNGNmOWUzNTIyNmMyNjdfMi0xMS0xLTEtMTU5NTQw_37377391-9ecb-4afc-9492-6c1eadf7fe84"
      unitRef="usd">-6287100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i3153def44849420f812d26d82e12f780_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOjU0MGYzNDkzN2Y1NDQ5NWI4YzRjZjllMzUyMjZjMjY3L3RhYmxlcmFuZ2U6NTQwZjM0OTM3ZjU0NDk1YjhjNGNmOWUzNTIyNmMyNjdfNC0xLTEtMS0xNTk1NDA_bc8a8610-333e-4734-8c68-4bb9f7eac143"
      unitRef="usd">-8000000.0</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i525ab1d53cfc40b99c19c64b4d032446_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOjU0MGYzNDkzN2Y1NDQ5NWI4YzRjZjllMzUyMjZjMjY3L3RhYmxlcmFuZ2U6NTQwZjM0OTM3ZjU0NDk1YjhjNGNmOWUzNTIyNmMyNjdfNC0zLTEtMS0xNTk1NDA_69c003da-0998-4b7f-8fa6-c4c56181b78e"
      unitRef="usd">-2400000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i4b3bb220bf604c6daaf72988d3e20703_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOjU0MGYzNDkzN2Y1NDQ5NWI4YzRjZjllMzUyMjZjMjY3L3RhYmxlcmFuZ2U6NTQwZjM0OTM3ZjU0NDk1YjhjNGNmOWUzNTIyNmMyNjdfNC01LTEtMS0xNTk1NDA_db3bdeb5-0335-4d31-8f22-8dfdbf73f86c"
      unitRef="usd">18600000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i24f2b962044749c5a2936c59a2f25aa9_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOjU0MGYzNDkzN2Y1NDQ5NWI4YzRjZjllMzUyMjZjMjY3L3RhYmxlcmFuZ2U6NTQwZjM0OTM3ZjU0NDk1YjhjNGNmOWUzNTIyNmMyNjdfNC03LTEtMS0xNTk1NDA_8fcdde21-f197-47a8-bd3f-ed07e15a6bf7"
      unitRef="usd">16800000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="ie4fa4f6b472a4f269297591b44aba572_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOjU0MGYzNDkzN2Y1NDQ5NWI4YzRjZjllMzUyMjZjMjY3L3RhYmxlcmFuZ2U6NTQwZjM0OTM3ZjU0NDk1YjhjNGNmOWUzNTIyNmMyNjdfNC0xMS0xLTEtMTU5NTQw_343b68c5-27eb-4a31-b338-3ed735373f5a"
      unitRef="usd">25000000.0</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i3153def44849420f812d26d82e12f780_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOjU0MGYzNDkzN2Y1NDQ5NWI4YzRjZjllMzUyMjZjMjY3L3RhYmxlcmFuZ2U6NTQwZjM0OTM3ZjU0NDk1YjhjNGNmOWUzNTIyNmMyNjdfNS0xLTEtMS0xNTk1NDA_2a329ba9-7e50-447e-bffc-c4a69fd434f6"
      unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i525ab1d53cfc40b99c19c64b4d032446_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOjU0MGYzNDkzN2Y1NDQ5NWI4YzRjZjllMzUyMjZjMjY3L3RhYmxlcmFuZ2U6NTQwZjM0OTM3ZjU0NDk1YjhjNGNmOWUzNTIyNmMyNjdfNS0zLTEtMS0xNTk1NDA_b36cff12-8b7c-4afa-b308-583098de3ea4"
      unitRef="usd">-100000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i4b3bb220bf604c6daaf72988d3e20703_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOjU0MGYzNDkzN2Y1NDQ5NWI4YzRjZjllMzUyMjZjMjY3L3RhYmxlcmFuZ2U6NTQwZjM0OTM3ZjU0NDk1YjhjNGNmOWUzNTIyNmMyNjdfNS01LTEtMS0xNTk1NDA_7731c7aa-8612-4961-b098-63eb8bfaf2ff"
      unitRef="usd">-86000000.0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i24f2b962044749c5a2936c59a2f25aa9_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOjU0MGYzNDkzN2Y1NDQ5NWI4YzRjZjllMzUyMjZjMjY3L3RhYmxlcmFuZ2U6NTQwZjM0OTM3ZjU0NDk1YjhjNGNmOWUzNTIyNmMyNjdfNS03LTEtMS0xNTk1NDA_6e152849-6097-4be8-91ea-75fa17567af1"
      unitRef="usd">-3300000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="ie4fa4f6b472a4f269297591b44aba572_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOjU0MGYzNDkzN2Y1NDQ5NWI4YzRjZjllMzUyMjZjMjY3L3RhYmxlcmFuZ2U6NTQwZjM0OTM3ZjU0NDk1YjhjNGNmOWUzNTIyNmMyNjdfNS0xMS0xLTEtMTU5NTQw_32339359-20c1-45a6-b833-49beea1c1a68"
      unitRef="usd">-89400000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i3153def44849420f812d26d82e12f780_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOjU0MGYzNDkzN2Y1NDQ5NWI4YzRjZjllMzUyMjZjMjY3L3RhYmxlcmFuZ2U6NTQwZjM0OTM3ZjU0NDk1YjhjNGNmOWUzNTIyNmMyNjdfNi0xLTEtMS0xNTk1NDA_8d330736-566f-4748-af15-275f24a2ecc5"
      unitRef="usd">-8000000.0</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i525ab1d53cfc40b99c19c64b4d032446_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOjU0MGYzNDkzN2Y1NDQ5NWI4YzRjZjllMzUyMjZjMjY3L3RhYmxlcmFuZ2U6NTQwZjM0OTM3ZjU0NDk1YjhjNGNmOWUzNTIyNmMyNjdfNi0zLTEtMS0xNTk1NDA_974c590f-756c-4fa5-b790-400ffac0b535"
      unitRef="usd">-2300000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i4b3bb220bf604c6daaf72988d3e20703_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOjU0MGYzNDkzN2Y1NDQ5NWI4YzRjZjllMzUyMjZjMjY3L3RhYmxlcmFuZ2U6NTQwZjM0OTM3ZjU0NDk1YjhjNGNmOWUzNTIyNmMyNjdfNi01LTEtMS0xNTk1NDA_14730f10-7bc8-4e8d-835f-7b995f65368e"
      unitRef="usd">104600000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i24f2b962044749c5a2936c59a2f25aa9_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOjU0MGYzNDkzN2Y1NDQ5NWI4YzRjZjllMzUyMjZjMjY3L3RhYmxlcmFuZ2U6NTQwZjM0OTM3ZjU0NDk1YjhjNGNmOWUzNTIyNmMyNjdfNi03LTEtMS0xNTk1NDA_30b23c77-6fe2-4c9c-af28-6395045b5f29"
      unitRef="usd">20100000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ie4fa4f6b472a4f269297591b44aba572_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOjU0MGYzNDkzN2Y1NDQ5NWI4YzRjZjllMzUyMjZjMjY3L3RhYmxlcmFuZ2U6NTQwZjM0OTM3ZjU0NDk1YjhjNGNmOWUzNTIyNmMyNjdfNi0xMS0xLTEtMTU5NTQw_08c98961-b86f-4677-8189-af10d0ee5c84"
      unitRef="usd">114400000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iab4358396efe4d7f92c5aab447052434_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOjU0MGYzNDkzN2Y1NDQ5NWI4YzRjZjllMzUyMjZjMjY3L3RhYmxlcmFuZ2U6NTQwZjM0OTM3ZjU0NDk1YjhjNGNmOWUzNTIyNmMyNjdfOC0xLTEtMS0xNTk1NDA_7b757b75-7371-4b9d-ac7a-2f1cdb45fb2e"
      unitRef="usd">-1524200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5be060faaa5146e7a2bf742eb38f7bec_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOjU0MGYzNDkzN2Y1NDQ5NWI4YzRjZjllMzUyMjZjMjY3L3RhYmxlcmFuZ2U6NTQwZjM0OTM3ZjU0NDk1YjhjNGNmOWUzNTIyNmMyNjdfOC0zLTEtMS0xNTk1NDA_2b6b1d47-7f8a-468f-884d-6bf3a2292ee7"
      unitRef="usd">6800000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i894ae4ccbe404068bbc052f007cea48c_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOjU0MGYzNDkzN2Y1NDQ5NWI4YzRjZjllMzUyMjZjMjY3L3RhYmxlcmFuZ2U6NTQwZjM0OTM3ZjU0NDk1YjhjNGNmOWUzNTIyNmMyNjdfOC01LTEtMS0xNTk1NDA_b37da8f5-807c-42b1-b506-fc8dfe381b72"
      unitRef="usd">-4465300000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic74e9458c4f44462a21bfd6f33c8c50d_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOjU0MGYzNDkzN2Y1NDQ5NWI4YzRjZjllMzUyMjZjMjY3L3RhYmxlcmFuZ2U6NTQwZjM0OTM3ZjU0NDk1YjhjNGNmOWUzNTIyNmMyNjdfOC03LTEtMS0xNTk1NDA_d4efb03b-9397-40f6-bbee-979fe8e73da5"
      unitRef="usd">-190000000.0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9ed755da42e84ed28970211b57db0d80_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOjU0MGYzNDkzN2Y1NDQ5NWI4YzRjZjllMzUyMjZjMjY3L3RhYmxlcmFuZ2U6NTQwZjM0OTM3ZjU0NDk1YjhjNGNmOWUzNTIyNmMyNjdfOC0xMS0xLTEtMTU5NTQw_f375035b-ffa1-4002-b006-f4d6d33aa64c"
      unitRef="usd">-6172700000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if779a9c74164409ab40929f3c1a22e08_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmJhMWE1ZDZiZDA3YTRhN2E5MmJlMzY4ZDI1NWZkNTM3L3RhYmxlcmFuZ2U6YmExYTVkNmJkMDdhNGE3YTkyYmUzNjhkMjU1ZmQ1MzdfMS0xLTEtMS0xNTk1NDA_c57d548c-63b2-4e4c-8797-1863e9f2985c"
      unitRef="usd">-1550200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i15e5d118ed234a2f82b7b9a362d215d8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmJhMWE1ZDZiZDA3YTRhN2E5MmJlMzY4ZDI1NWZkNTM3L3RhYmxlcmFuZ2U6YmExYTVkNmJkMDdhNGE3YTkyYmUzNjhkMjU1ZmQ1MzdfMS0zLTEtMS0xNTk1NDA_e16a6b1c-4be5-4d8b-9098-1d40eec27402"
      unitRef="usd">3700000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib7546d9d8f53446e8b4f3eed0a4210c4_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmJhMWE1ZDZiZDA3YTRhN2E5MmJlMzY4ZDI1NWZkNTM3L3RhYmxlcmFuZ2U6YmExYTVkNmJkMDdhNGE3YTkyYmUzNjhkMjU1ZmQ1MzdfMS01LTEtMS0xNTk1NDA_3e788ceb-98ed-421e-a00e-fab504a1fe6d"
      unitRef="usd">-2583600000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if2ce5c439794420c8829fd223a835cd4_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmJhMWE1ZDZiZDA3YTRhN2E5MmJlMzY4ZDI1NWZkNTM3L3RhYmxlcmFuZ2U6YmExYTVkNmJkMDdhNGE3YTkyYmUzNjhkMjU1ZmQ1MzdfMS03LTEtMS0xNTk1NDA_3cc16d4d-e794-44ff-ab6d-7768cfdf83d9"
      unitRef="usd">-213000000.0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic63664fe4e074a5599837d8254019a8b_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmJhMWE1ZDZiZDA3YTRhN2E5MmJlMzY4ZDI1NWZkNTM3L3RhYmxlcmFuZ2U6YmExYTVkNmJkMDdhNGE3YTkyYmUzNjhkMjU1ZmQ1MzdfMS05LTEtMS0xNTk1NDA_7d55d54f-0b88-4df8-85ee-b72af38d492d"
      unitRef="usd">-4343100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i13abcd536a74422a91f0be2e859c5f11_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmJhMWE1ZDZiZDA3YTRhN2E5MmJlMzY4ZDI1NWZkNTM3L3RhYmxlcmFuZ2U6YmExYTVkNmJkMDdhNGE3YTkyYmUzNjhkMjU1ZmQ1MzdfMy0xLTEtMS0xNTk1NDA_4d50c7d3-123d-4020-a141-6e06010277e1"
      unitRef="usd">-459700000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="ieeda2eb9aa724c2eb2b08a110d5910ca_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmJhMWE1ZDZiZDA3YTRhN2E5MmJlMzY4ZDI1NWZkNTM3L3RhYmxlcmFuZ2U6YmExYTVkNmJkMDdhNGE3YTkyYmUzNjhkMjU1ZmQ1MzdfMy0zLTEtMS0xNTk1NDA_c6f62673-eae2-4982-b1dc-26d018ba39ac"
      unitRef="usd">-55500000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i1c0ca46f62b245baa26e2ca939e70c30_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmJhMWE1ZDZiZDA3YTRhN2E5MmJlMzY4ZDI1NWZkNTM3L3RhYmxlcmFuZ2U6YmExYTVkNmJkMDdhNGE3YTkyYmUzNjhkMjU1ZmQ1MzdfMy01LTEtMS0xNTk1NDA_1d6a8cf2-3ffa-4a8b-adbe-86525531a476"
      unitRef="usd">72900000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i698e8cd8a6e44a719d0a96611610bdf4_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmJhMWE1ZDZiZDA3YTRhN2E5MmJlMzY4ZDI1NWZkNTM3L3RhYmxlcmFuZ2U6YmExYTVkNmJkMDdhNGE3YTkyYmUzNjhkMjU1ZmQ1MzdfMy03LTEtMS0xNTk1NDA_3ee4aca4-1af3-4241-a3ad-15fa974c7eb0"
      unitRef="usd">297200000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmJhMWE1ZDZiZDA3YTRhN2E5MmJlMzY4ZDI1NWZkNTM3L3RhYmxlcmFuZ2U6YmExYTVkNmJkMDdhNGE3YTkyYmUzNjhkMjU1ZmQ1MzdfMy05LTEtMS0xNTk1NDA_f7cf9943-aa76-4bdf-b722-c3e1eaed20c4"
      unitRef="usd">-145100000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i13abcd536a74422a91f0be2e859c5f11_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmJhMWE1ZDZiZDA3YTRhN2E5MmJlMzY4ZDI1NWZkNTM3L3RhYmxlcmFuZ2U6YmExYTVkNmJkMDdhNGE3YTkyYmUzNjhkMjU1ZmQ1MzdfNC0xLTEtMS0xNTk1NDA_e23bba7b-34de-48f1-9b60-8e15a22b59f6"
      unitRef="usd">-600000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="ieeda2eb9aa724c2eb2b08a110d5910ca_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmJhMWE1ZDZiZDA3YTRhN2E5MmJlMzY4ZDI1NWZkNTM3L3RhYmxlcmFuZ2U6YmExYTVkNmJkMDdhNGE3YTkyYmUzNjhkMjU1ZmQ1MzdfNC0zLTEtMS0xNTk1NDA_9190dfd0-0744-4be9-8d39-1d232d9a7b8d"
      unitRef="usd">-12500000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i1c0ca46f62b245baa26e2ca939e70c30_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmJhMWE1ZDZiZDA3YTRhN2E5MmJlMzY4ZDI1NWZkNTM3L3RhYmxlcmFuZ2U6YmExYTVkNmJkMDdhNGE3YTkyYmUzNjhkMjU1ZmQ1MzdfNC01LTEtMS0xNTk1NDA_852c1882-c146-48a5-9450-2a666a131665"
      unitRef="usd">-172500000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i698e8cd8a6e44a719d0a96611610bdf4_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmJhMWE1ZDZiZDA3YTRhN2E5MmJlMzY4ZDI1NWZkNTM3L3RhYmxlcmFuZ2U6YmExYTVkNmJkMDdhNGE3YTkyYmUzNjhkMjU1ZmQ1MzdfNC03LTEtMS0xNTk1NDA_11893604-2bfe-48e3-81ff-2b84fa6a9b37"
      unitRef="usd">-6800000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmJhMWE1ZDZiZDA3YTRhN2E5MmJlMzY4ZDI1NWZkNTM3L3RhYmxlcmFuZ2U6YmExYTVkNmJkMDdhNGE3YTkyYmUzNjhkMjU1ZmQ1MzdfNC05LTEtMS0xNTk1NDA_43bf1dac-bccf-4c22-84b0-f7f40c953855"
      unitRef="usd">-192400000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i13abcd536a74422a91f0be2e859c5f11_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmJhMWE1ZDZiZDA3YTRhN2E5MmJlMzY4ZDI1NWZkNTM3L3RhYmxlcmFuZ2U6YmExYTVkNmJkMDdhNGE3YTkyYmUzNjhkMjU1ZmQ1MzdfNS0xLTEtMS0xNTk1NDA_9622fa05-3684-45e2-8cf0-a244e7a249f4"
      unitRef="usd">-459100000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ieeda2eb9aa724c2eb2b08a110d5910ca_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmJhMWE1ZDZiZDA3YTRhN2E5MmJlMzY4ZDI1NWZkNTM3L3RhYmxlcmFuZ2U6YmExYTVkNmJkMDdhNGE3YTkyYmUzNjhkMjU1ZmQ1MzdfNS0zLTEtMS0xNTk1NDA_a849d495-a915-48e5-9b20-7bfed9449537"
      unitRef="usd">-43000000.0</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i1c0ca46f62b245baa26e2ca939e70c30_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmJhMWE1ZDZiZDA3YTRhN2E5MmJlMzY4ZDI1NWZkNTM3L3RhYmxlcmFuZ2U6YmExYTVkNmJkMDdhNGE3YTkyYmUzNjhkMjU1ZmQ1MzdfNS01LTEtMS0xNTk1NDA_048e54b6-f1b0-4d53-91cf-412483723899"
      unitRef="usd">245400000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i698e8cd8a6e44a719d0a96611610bdf4_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmJhMWE1ZDZiZDA3YTRhN2E5MmJlMzY4ZDI1NWZkNTM3L3RhYmxlcmFuZ2U6YmExYTVkNmJkMDdhNGE3YTkyYmUzNjhkMjU1ZmQ1MzdfNS03LTEtMS0xNTk1NDA_6a7da4af-c3b0-438f-ba1d-f8da68a1e393"
      unitRef="usd">304000000.0</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmJhMWE1ZDZiZDA3YTRhN2E5MmJlMzY4ZDI1NWZkNTM3L3RhYmxlcmFuZ2U6YmExYTVkNmJkMDdhNGE3YTkyYmUzNjhkMjU1ZmQ1MzdfNS05LTEtMS0xNTk1NDA_79e6ae06-d612-4dc9-ab64-0b6d4d858ce1"
      unitRef="usd">47300000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i603b413215ff4ac0860f74b6a1be9294_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmJhMWE1ZDZiZDA3YTRhN2E5MmJlMzY4ZDI1NWZkNTM3L3RhYmxlcmFuZ2U6YmExYTVkNmJkMDdhNGE3YTkyYmUzNjhkMjU1ZmQ1MzdfNy0xLTEtMS0xNTk1NDA_e2817971-3ce0-4f62-8b72-ec9911ed1219"
      unitRef="usd">-2009300000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6105e19d65744395aeb2921c7555324a_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmJhMWE1ZDZiZDA3YTRhN2E5MmJlMzY4ZDI1NWZkNTM3L3RhYmxlcmFuZ2U6YmExYTVkNmJkMDdhNGE3YTkyYmUzNjhkMjU1ZmQ1MzdfNy0zLTEtMS0xNTk1NDA_a3b04b31-bbaf-4aa0-9a03-66bce2b7d63e"
      unitRef="usd">-39300000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1ec1c7b3b72549149e283cdff33abeed_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmJhMWE1ZDZiZDA3YTRhN2E5MmJlMzY4ZDI1NWZkNTM3L3RhYmxlcmFuZ2U6YmExYTVkNmJkMDdhNGE3YTkyYmUzNjhkMjU1ZmQ1MzdfNy01LTEtMS0xNTk1NDA_2ea540f9-5c8b-4ece-8733-2bd315bdaa84"
      unitRef="usd">-2338200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ifc51fbfd706a4f809013d42ddd4fef8c_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmJhMWE1ZDZiZDA3YTRhN2E5MmJlMzY4ZDI1NWZkNTM3L3RhYmxlcmFuZ2U6YmExYTVkNmJkMDdhNGE3YTkyYmUzNjhkMjU1ZmQ1MzdfNy03LTEtMS0xNTk1NDA_a7d3d5b8-ef0b-4c72-ac84-9259e1ecdca6"
      unitRef="usd">91000000.0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iad56c44530dd4208959b336f8d1fe8b1_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmJhMWE1ZDZiZDA3YTRhN2E5MmJlMzY4ZDI1NWZkNTM3L3RhYmxlcmFuZ2U6YmExYTVkNmJkMDdhNGE3YTkyYmUzNjhkMjU1ZmQ1MzdfNy05LTEtMS0xNTk1NDA_672abccd-1b4a-49ea-ae6b-39bf34e1fe61"
      unitRef="usd">-4295800000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4b2bb6e433df4a26acb1d1cfbcc2ce7d_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOjZkZDI3YTI5ZjA1YzQ0YjRhMWMxOWQ2MTQ5MWFiMDRiL3RhYmxlcmFuZ2U6NmRkMjdhMjlmMDVjNDRiNGExYzE5ZDYxNDkxYWIwNGJfMS0xLTEtMS0xNTk1NDA_97951402-5497-4828-9561-5cab17c2bda8"
      unitRef="usd">-1427500000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic15a6784d2e64c5b9176f90a12f6b997_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOjZkZDI3YTI5ZjA1YzQ0YjRhMWMxOWQ2MTQ5MWFiMDRiL3RhYmxlcmFuZ2U6NmRkMjdhMjlmMDVjNDRiNGExYzE5ZDYxNDkxYWIwNGJfMS0zLTEtMS0xNTk1NDA_882fb8f0-8666-4ad8-b77b-3848ee4f03b4"
      unitRef="usd">14800000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if4dbdc6b4ce3472bb83f35a58ba62009_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOjZkZDI3YTI5ZjA1YzQ0YjRhMWMxOWQ2MTQ5MWFiMDRiL3RhYmxlcmFuZ2U6NmRkMjdhMjlmMDVjNDRiNGExYzE5ZDYxNDkxYWIwNGJfMS01LTEtMS0xNTk1NDA_c2f6e5ff-e854-4806-9340-0995d612e927"
      unitRef="usd">-4751000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4084f6774b4344709f32500dfb758be3_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOjZkZDI3YTI5ZjA1YzQ0YjRhMWMxOWQ2MTQ5MWFiMDRiL3RhYmxlcmFuZ2U6NmRkMjdhMjlmMDVjNDRiNGExYzE5ZDYxNDkxYWIwNGJfMS03LTEtMS0xNTk1NDA_2da41502-b2ab-44ee-8b0f-30b72625c205"
      unitRef="usd">-332700000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i61189f333c704d8a9f0dffcd44fd0870_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOjZkZDI3YTI5ZjA1YzQ0YjRhMWMxOWQ2MTQ5MWFiMDRiL3RhYmxlcmFuZ2U6NmRkMjdhMjlmMDVjNDRiNGExYzE5ZDYxNDkxYWIwNGJfMS05LTEtMS0xNTk1NDA_0b6c8abd-2f26-4669-9d7d-4924fbdb1bf2"
      unitRef="usd">-6496400000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i4def4770d4c9484b9eafab55058f4c06_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOjZkZDI3YTI5ZjA1YzQ0YjRhMWMxOWQ2MTQ5MWFiMDRiL3RhYmxlcmFuZ2U6NmRkMjdhMjlmMDVjNDRiNGExYzE5ZDYxNDkxYWIwNGJfMy0xLTEtMS0xNTk1NDA_d44c05f9-6f7a-4c53-af68-0eda7919903d"
      unitRef="usd">-96700000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="if73a641a34fe4591b395573cedb1bea4_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOjZkZDI3YTI5ZjA1YzQ0YjRhMWMxOWQ2MTQ5MWFiMDRiL3RhYmxlcmFuZ2U6NmRkMjdhMjlmMDVjNDRiNGExYzE5ZDYxNDkxYWIwNGJfMy0zLTEtMS0xNTk1NDA_51e782a8-6f25-47c7-99d9-cdc918d27e6e"
      unitRef="usd">-8800000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i71a11ec78f2242498930e393cd63658b_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOjZkZDI3YTI5ZjA1YzQ0YjRhMWMxOWQ2MTQ5MWFiMDRiL3RhYmxlcmFuZ2U6NmRkMjdhMjlmMDVjNDRiNGExYzE5ZDYxNDkxYWIwNGJfMy01LTEtMS0xNTk1NDA_bcd0bbc9-ec9d-4c48-a74b-68fb8571e331"
      unitRef="usd">27200000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i314c9492fa9044c3a8d05e0fc3ad2e63_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOjZkZDI3YTI5ZjA1YzQ0YjRhMWMxOWQ2MTQ5MWFiMDRiL3RhYmxlcmFuZ2U6NmRkMjdhMjlmMDVjNDRiNGExYzE5ZDYxNDkxYWIwNGJfMy03LTEtMS0xNTk1NDA_8156c0cb-ba75-44a2-b9a5-dc9d6f619b07"
      unitRef="usd">132800000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i167ed8f67bef48c49e54fa466400cdaa_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOjZkZDI3YTI5ZjA1YzQ0YjRhMWMxOWQ2MTQ5MWFiMDRiL3RhYmxlcmFuZ2U6NmRkMjdhMjlmMDVjNDRiNGExYzE5ZDYxNDkxYWIwNGJfMy05LTEtMS0xNTk1NDA_b6d2e3de-b539-42d4-aadb-0ad48f908c1e"
      unitRef="usd">54500000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i4def4770d4c9484b9eafab55058f4c06_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOjZkZDI3YTI5ZjA1YzQ0YjRhMWMxOWQ2MTQ5MWFiMDRiL3RhYmxlcmFuZ2U6NmRkMjdhMjlmMDVjNDRiNGExYzE5ZDYxNDkxYWIwNGJfNC0xLTEtMS0xNTk1NDA_df117ee3-063e-4522-8a2b-590a65911b29"
      unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="if73a641a34fe4591b395573cedb1bea4_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOjZkZDI3YTI5ZjA1YzQ0YjRhMWMxOWQ2MTQ5MWFiMDRiL3RhYmxlcmFuZ2U6NmRkMjdhMjlmMDVjNDRiNGExYzE5ZDYxNDkxYWIwNGJfNC0zLTEtMS0xNTk1NDA_fc963b77-b32c-41b6-88c2-94026c36effd"
      unitRef="usd">-800000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i71a11ec78f2242498930e393cd63658b_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOjZkZDI3YTI5ZjA1YzQ0YjRhMWMxOWQ2MTQ5MWFiMDRiL3RhYmxlcmFuZ2U6NmRkMjdhMjlmMDVjNDRiNGExYzE5ZDYxNDkxYWIwNGJfNC01LTEtMS0xNTk1NDA_3a98660b-8435-4d58-a6ce-92f902d62686"
      unitRef="usd">-258500000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i314c9492fa9044c3a8d05e0fc3ad2e63_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOjZkZDI3YTI5ZjA1YzQ0YjRhMWMxOWQ2MTQ5MWFiMDRiL3RhYmxlcmFuZ2U6NmRkMjdhMjlmMDVjNDRiNGExYzE5ZDYxNDkxYWIwNGJfNC03LTEtMS0xNTk1NDA_bfaa1d27-e9e4-443a-9975-36ed67113289"
      unitRef="usd">-9900000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i167ed8f67bef48c49e54fa466400cdaa_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOjZkZDI3YTI5ZjA1YzQ0YjRhMWMxOWQ2MTQ5MWFiMDRiL3RhYmxlcmFuZ2U6NmRkMjdhMjlmMDVjNDRiNGExYzE5ZDYxNDkxYWIwNGJfNC05LTEtMS0xNTk1NDA_f029ff4d-e8ee-4af2-aa01-c0569e36d6fc"
      unitRef="usd">-269200000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i4def4770d4c9484b9eafab55058f4c06_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOjZkZDI3YTI5ZjA1YzQ0YjRhMWMxOWQ2MTQ5MWFiMDRiL3RhYmxlcmFuZ2U6NmRkMjdhMjlmMDVjNDRiNGExYzE5ZDYxNDkxYWIwNGJfNS0xLTEtMS0xNTk1NDA_f142a863-e7ef-441c-ba12-31bddcf20883"
      unitRef="usd">-96700000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="if73a641a34fe4591b395573cedb1bea4_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOjZkZDI3YTI5ZjA1YzQ0YjRhMWMxOWQ2MTQ5MWFiMDRiL3RhYmxlcmFuZ2U6NmRkMjdhMjlmMDVjNDRiNGExYzE5ZDYxNDkxYWIwNGJfNS0zLTEtMS0xNTk1NDA_fc325872-d51f-4c45-ae5b-77c883cf97bd"
      unitRef="usd">-8000000.0</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i71a11ec78f2242498930e393cd63658b_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOjZkZDI3YTI5ZjA1YzQ0YjRhMWMxOWQ2MTQ5MWFiMDRiL3RhYmxlcmFuZ2U6NmRkMjdhMjlmMDVjNDRiNGExYzE5ZDYxNDkxYWIwNGJfNS01LTEtMS0xNTk1NDA_31a06a9d-b27b-4cec-b8b2-6bbe0a72a142"
      unitRef="usd">285700000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i314c9492fa9044c3a8d05e0fc3ad2e63_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOjZkZDI3YTI5ZjA1YzQ0YjRhMWMxOWQ2MTQ5MWFiMDRiL3RhYmxlcmFuZ2U6NmRkMjdhMjlmMDVjNDRiNGExYzE5ZDYxNDkxYWIwNGJfNS03LTEtMS0xNTk1NDA_8f52c74d-d777-4d3c-9078-604c6e660b15"
      unitRef="usd">142700000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i167ed8f67bef48c49e54fa466400cdaa_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOjZkZDI3YTI5ZjA1YzQ0YjRhMWMxOWQ2MTQ5MWFiMDRiL3RhYmxlcmFuZ2U6NmRkMjdhMjlmMDVjNDRiNGExYzE5ZDYxNDkxYWIwNGJfNS05LTEtMS0xNTk1NDA_1a7b6916-95a3-4664-b1be-77f3cddfc826"
      unitRef="usd">323700000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iab4358396efe4d7f92c5aab447052434_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOjZkZDI3YTI5ZjA1YzQ0YjRhMWMxOWQ2MTQ5MWFiMDRiL3RhYmxlcmFuZ2U6NmRkMjdhMjlmMDVjNDRiNGExYzE5ZDYxNDkxYWIwNGJfNy0xLTEtMS0xNTk1NDA_df686e57-acf0-4aae-8f8d-89339b78fb83"
      unitRef="usd">-1524200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5be060faaa5146e7a2bf742eb38f7bec_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOjZkZDI3YTI5ZjA1YzQ0YjRhMWMxOWQ2MTQ5MWFiMDRiL3RhYmxlcmFuZ2U6NmRkMjdhMjlmMDVjNDRiNGExYzE5ZDYxNDkxYWIwNGJfNy0zLTEtMS0xNTk1NDA_1562e3d0-3bb8-4ee8-8ee0-5bae8ee51810"
      unitRef="usd">6800000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i894ae4ccbe404068bbc052f007cea48c_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOjZkZDI3YTI5ZjA1YzQ0YjRhMWMxOWQ2MTQ5MWFiMDRiL3RhYmxlcmFuZ2U6NmRkMjdhMjlmMDVjNDRiNGExYzE5ZDYxNDkxYWIwNGJfNy01LTEtMS0xNTk1NDA_080fc4e5-2651-4b0d-b0b2-3f8acc562924"
      unitRef="usd">-4465300000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic74e9458c4f44462a21bfd6f33c8c50d_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOjZkZDI3YTI5ZjA1YzQ0YjRhMWMxOWQ2MTQ5MWFiMDRiL3RhYmxlcmFuZ2U6NmRkMjdhMjlmMDVjNDRiNGExYzE5ZDYxNDkxYWIwNGJfNy03LTEtMS0xNTk1NDA_c699214d-26ae-4453-a649-8b55feb4304b"
      unitRef="usd">-190000000.0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9ed755da42e84ed28970211b57db0d80_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOjZkZDI3YTI5ZjA1YzQ0YjRhMWMxOWQ2MTQ5MWFiMDRiL3RhYmxlcmFuZ2U6NmRkMjdhMjlmMDVjNDRiNGExYzE5ZDYxNDkxYWIwNGJfNy05LTEtMS0xNTk1NDA_6b796905-b78a-40b3-a04d-9f8a7c2593f2"
      unitRef="usd">-6172700000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="ibb680e42808d41b587bffa2f35409a91_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmFhYWFkZDkyNDk1NzQ2NTM4ZTYyOWNhYmVmOTIyNDUwL3RhYmxlcmFuZ2U6YWFhYWRkOTI0OTU3NDY1MzhlNjI5Y2FiZWY5MjI0NTBfMi0xLTEtMS0xNTk1NDA_9288aeb5-bc35-4821-b372-845cc812a74b"
      unitRef="usd">133300000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="i3153def44849420f812d26d82e12f780_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmFhYWFkZDkyNDk1NzQ2NTM4ZTYyOWNhYmVmOTIyNDUwL3RhYmxlcmFuZ2U6YWFhYWRkOTI0OTU3NDY1MzhlNjI5Y2FiZWY5MjI0NTBfMi0zLTEtMS0xNTk1NDA_a5ffecc2-9b51-46ac-af7b-fee5b950b93f"
      unitRef="usd">39000000.0</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="i13abcd536a74422a91f0be2e859c5f11_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmFhYWFkZDkyNDk1NzQ2NTM4ZTYyOWNhYmVmOTIyNDUwL3RhYmxlcmFuZ2U6YWFhYWRkOTI0OTU3NDY1MzhlNjI5Y2FiZWY5MjI0NTBfMi01LTEtMS0xNTk1NDA_effcd36c-4bc5-413d-902e-1975903a5dbc"
      unitRef="usd">234200000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="i4def4770d4c9484b9eafab55058f4c06_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmFhYWFkZDkyNDk1NzQ2NTM4ZTYyOWNhYmVmOTIyNDUwL3RhYmxlcmFuZ2U6YWFhYWRkOTI0OTU3NDY1MzhlNjI5Y2FiZWY5MjI0NTBfMi03LTEtMS0xNTk1NDA_cf738574-2c69-4fb7-897e-f429ae685e23"
      unitRef="usd">92300000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="ib423da078b9740019ae03257a6ca1320_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmFhYWFkZDkyNDk1NzQ2NTM4ZTYyOWNhYmVmOTIyNDUwL3RhYmxlcmFuZ2U6YWFhYWRkOTI0OTU3NDY1MzhlNjI5Y2FiZWY5MjI0NTBfMy0xLTEtMS0xNTk1NDA_adc9b647-288e-4693-b5fd-7dd97abcc7c9"
      unitRef="usd">-3400000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="i525ab1d53cfc40b99c19c64b4d032446_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmFhYWFkZDkyNDk1NzQ2NTM4ZTYyOWNhYmVmOTIyNDUwL3RhYmxlcmFuZ2U6YWFhYWRkOTI0OTU3NDY1MzhlNjI5Y2FiZWY5MjI0NTBfMy0zLTEtMS0xNTk1NDA_891e3a1c-8491-4d56-a658-a73f2948d075"
      unitRef="usd">-800000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="ieeda2eb9aa724c2eb2b08a110d5910ca_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmFhYWFkZDkyNDk1NzQ2NTM4ZTYyOWNhYmVmOTIyNDUwL3RhYmxlcmFuZ2U6YWFhYWRkOTI0OTU3NDY1MzhlNjI5Y2FiZWY5MjI0NTBfMy01LTEtMS0xNTk1NDA_b1fb0281-e508-477b-bbc4-f0903d8ca148"
      unitRef="usd">-13100000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="if73a641a34fe4591b395573cedb1bea4_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmFhYWFkZDkyNDk1NzQ2NTM4ZTYyOWNhYmVmOTIyNDUwL3RhYmxlcmFuZ2U6YWFhYWRkOTI0OTU3NDY1MzhlNjI5Y2FiZWY5MjI0NTBfMy03LTEtMS0xNTk1NDA_2d52efac-cc89-410f-a00b-9f4d7f605ae7"
      unitRef="usd">-3800000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="i0ddaa7c4639946b1a63ee163ebac9cda_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmFhYWFkZDkyNDk1NzQ2NTM4ZTYyOWNhYmVmOTIyNDUwL3RhYmxlcmFuZ2U6YWFhYWRkOTI0OTU3NDY1MzhlNjI5Y2FiZWY5MjI0NTBfNC0xLTEtMS0xNTk1NDA_f3500220-7318-4848-bc45-1c25ece78cb8"
      unitRef="usd">22400000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="i4b3bb220bf604c6daaf72988d3e20703_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmFhYWFkZDkyNDk1NzQ2NTM4ZTYyOWNhYmVmOTIyNDUwL3RhYmxlcmFuZ2U6YWFhYWRkOTI0OTU3NDY1MzhlNjI5Y2FiZWY5MjI0NTBfNC0zLTEtMS0xNTk1NDA_c0679b86-78ff-4695-8681-9e8c61bd9da9"
      unitRef="usd">28200000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="i1c0ca46f62b245baa26e2ca939e70c30_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmFhYWFkZDkyNDk1NzQ2NTM4ZTYyOWNhYmVmOTIyNDUwL3RhYmxlcmFuZ2U6YWFhYWRkOTI0OTU3NDY1MzhlNjI5Y2FiZWY5MjI0NTBfNC01LTEtMS0xNTk1NDA_08c99a23-2aac-45a4-b919-842288032819"
      unitRef="usd">73200000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="i71a11ec78f2242498930e393cd63658b_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmFhYWFkZDkyNDk1NzQ2NTM4ZTYyOWNhYmVmOTIyNDUwL3RhYmxlcmFuZ2U6YWFhYWRkOTI0OTU3NDY1MzhlNjI5Y2FiZWY5MjI0NTBfNC03LTEtMS0xNTk1NDA_4e681248-c5d8-4faf-b1e8-fd0f254e2154"
      unitRef="usd">79700000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="i9e78a70b50b740909d4bd5980c556e3a_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmFhYWFkZDkyNDk1NzQ2NTM4ZTYyOWNhYmVmOTIyNDUwL3RhYmxlcmFuZ2U6YWFhYWRkOTI0OTU3NDY1MzhlNjI5Y2FiZWY5MjI0NTBfNS0xLTEtMS0xNTk1NDA_d196d5d1-d157-4ec3-a972-9a43fec9dd9d"
      unitRef="usd">16900000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="i24f2b962044749c5a2936c59a2f25aa9_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmFhYWFkZDkyNDk1NzQ2NTM4ZTYyOWNhYmVmOTIyNDUwL3RhYmxlcmFuZ2U6YWFhYWRkOTI0OTU3NDY1MzhlNjI5Y2FiZWY5MjI0NTBfNS0zLTEtMS0xNTk1NDA_2f573e2c-37b5-4711-86c5-3a6b173c0498"
      unitRef="usd">5400000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="i698e8cd8a6e44a719d0a96611610bdf4_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmFhYWFkZDkyNDk1NzQ2NTM4ZTYyOWNhYmVmOTIyNDUwL3RhYmxlcmFuZ2U6YWFhYWRkOTI0OTU3NDY1MzhlNjI5Y2FiZWY5MjI0NTBfNS01LTEtMS0xNTk1NDA_7a1f9e17-3ca1-424e-a357-8dbda5994062"
      unitRef="usd">80800000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="i314c9492fa9044c3a8d05e0fc3ad2e63_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmFhYWFkZDkyNDk1NzQ2NTM4ZTYyOWNhYmVmOTIyNDUwL3RhYmxlcmFuZ2U6YWFhYWRkOTI0OTU3NDY1MzhlNjI5Y2FiZWY5MjI0NTBfNS03LTEtMS0xNTk1NDA_f1841f57-2300-4e86-9a53-bca575b58a79"
      unitRef="usd">37900000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="i19fc0325c48543008ea71e1fdcf11d86_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmFhYWFkZDkyNDk1NzQ2NTM4ZTYyOWNhYmVmOTIyNDUwL3RhYmxlcmFuZ2U6YWFhYWRkOTI0OTU3NDY1MzhlNjI5Y2FiZWY5MjI0NTBfNi0xLTEtMS0xNTk1NDA_b0afe6a4-7541-4944-a2d7-1fe08a907f67"
      unitRef="usd">169200000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="ie4fa4f6b472a4f269297591b44aba572_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmFhYWFkZDkyNDk1NzQ2NTM4ZTYyOWNhYmVmOTIyNDUwL3RhYmxlcmFuZ2U6YWFhYWRkOTI0OTU3NDY1MzhlNjI5Y2FiZWY5MjI0NTBfNi0zLTEtMS0xNTk1NDA_54b09372-a85d-4dce-9258-21a58b740a97"
      unitRef="usd">71800000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmFhYWFkZDkyNDk1NzQ2NTM4ZTYyOWNhYmVmOTIyNDUwL3RhYmxlcmFuZ2U6YWFhYWRkOTI0OTU3NDY1MzhlNjI5Y2FiZWY5MjI0NTBfNi01LTEtMS0xNTk1NDA_95d8e0c0-f5d8-4739-a772-b658fe2818d4"
      unitRef="usd">375100000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="i167ed8f67bef48c49e54fa466400cdaa_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmFhYWFkZDkyNDk1NzQ2NTM4ZTYyOWNhYmVmOTIyNDUwL3RhYmxlcmFuZ2U6YWFhYWRkOTI0OTU3NDY1MzhlNjI5Y2FiZWY5MjI0NTBfNi03LTEtMS0xNTk1NDA_9c096cdb-f645-4bac-8c07-275cf8aa1352"
      unitRef="usd">206100000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock
      contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RleHRyZWdpb246ZTE0MjlmY2IyNjYyNDg4ZDk5MTllMTg4MGNiZTMyMTNfMTI0Ng_7fce3647-7646-46f0-b874-b42e629c05a1">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Reclassifications out of accumulated other comprehensive loss were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.718%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.830%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Details about Accumulated Other Comprehensive Loss Components&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Affected Line Item in the Consolidated Condensed Statements of Operations&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="30" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of retirement benefit items:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prior service benefits, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(13.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(39.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(41.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&#x2013;net, (income) expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Actuarial losses, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;85.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;257.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;368.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&#x2013;net, (income) expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total before tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;72.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;108.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;218.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;327.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(15.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(45.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(68.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income taxes&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;57.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;172.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;258.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other, net of tax&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;13.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;19.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&#x2013;net, (income) expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total reclassifications, net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;71.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;192.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;269.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="iaaff00acdddb497fb5b94bf8d2ff771d_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmEwNDg1MGU2OTU2MjQ2ZTg4NDNjOWQzMjQ1ZGFiZDk4L3RhYmxlcmFuZ2U6YTA0ODUwZTY5NTYyNDZlODg0M2M5ZDMyNDVkYWJkOThfNC0yLTEtMS0xNTk1NDA_75d52764-47c2-4aed-9811-e009dae7063b"
      unitRef="usd">-13100000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ia0716cc08360439bb971180db7de8214_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmEwNDg1MGU2OTU2MjQ2ZTg4NDNjOWQzMjQ1ZGFiZDk4L3RhYmxlcmFuZ2U6YTA0ODUwZTY5NTYyNDZlODg0M2M5ZDMyNDVkYWJkOThfNC00LTEtMS0xNTk1NDA_7757718b-97b7-430d-8469-2655b7c55f79"
      unitRef="usd">-13900000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i1e81189c858b4d59b30b2380c8bf756b_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmEwNDg1MGU2OTU2MjQ2ZTg4NDNjOWQzMjQ1ZGFiZDk4L3RhYmxlcmFuZ2U6YTA0ODUwZTY5NTYyNDZlODg0M2M5ZDMyNDVkYWJkOThfNC02LTEtMS0xNTk1NDA_ab068766-f7f2-4015-aca9-d0926ab6f17a"
      unitRef="usd">-39200000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="iafe03a1322e544acb123846499dfb8f0_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmEwNDg1MGU2OTU2MjQ2ZTg4NDNjOWQzMjQ1ZGFiZDk4L3RhYmxlcmFuZ2U6YTA0ODUwZTY5NTYyNDZlODg0M2M5ZDMyNDVkYWJkOThfNC04LTEtMS0xNTk1NDA_4c80be46-a6d8-4fb5-a83b-021447ab5122"
      unitRef="usd">-41500000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="iedc64e6c0ae84f6f8f6f168b1b71f00f_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmEwNDg1MGU2OTU2MjQ2ZTg4NDNjOWQzMjQ1ZGFiZDk4L3RhYmxlcmFuZ2U6YTA0ODUwZTY5NTYyNDZlODg0M2M5ZDMyNDVkYWJkOThfNS0yLTEtMS0xNTk1NDA_b8c61d10-6692-415c-acb7-4a5f3bc9cdc1"
      unitRef="usd">85500000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i02ba7e57b97e4c15aa93cdacb3f05447_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmEwNDg1MGU2OTU2MjQ2ZTg4NDNjOWQzMjQ1ZGFiZDk4L3RhYmxlcmFuZ2U6YTA0ODUwZTY5NTYyNDZlODg0M2M5ZDMyNDVkYWJkOThfNS00LTEtMS0xNTk1NDA_4aa3e2da-7c6b-4b72-b2f6-621b543f2042"
      unitRef="usd">122700000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i8d7550b247eb4a90ac3acd3ea2eab6ad_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmEwNDg1MGU2OTU2MjQ2ZTg4NDNjOWQzMjQ1ZGFiZDk4L3RhYmxlcmFuZ2U6YTA0ODUwZTY5NTYyNDZlODg0M2M5ZDMyNDVkYWJkOThfNS02LTEtMS0xNTk1NDA_acc4c432-ea31-4b2a-af8a-cd9d50eaab77"
      unitRef="usd">257500000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="if8458e6a1b9b4239b31d01e183c0368d_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmEwNDg1MGU2OTU2MjQ2ZTg4NDNjOWQzMjQ1ZGFiZDk4L3RhYmxlcmFuZ2U6YTA0ODUwZTY5NTYyNDZlODg0M2M5ZDMyNDVkYWJkOThfNS04LTEtMS0xNTk1NDA_3323a627-a909-48fd-8e7d-0bb12bf616ab"
      unitRef="usd">368700000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i14e2a21089594bfda05e2f482a1a9fdb_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmEwNDg1MGU2OTU2MjQ2ZTg4NDNjOWQzMjQ1ZGFiZDk4L3RhYmxlcmFuZ2U6YTA0ODUwZTY5NTYyNDZlODg0M2M5ZDMyNDVkYWJkOThfNi0yLTEtMS0xNTk1NDA_e4cca648-b540-4e36-bc46-c09b2a81efe5"
      unitRef="usd">72400000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="if60b1262bf5c4116ad9ba0e69b270a48_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmEwNDg1MGU2OTU2MjQ2ZTg4NDNjOWQzMjQ1ZGFiZDk4L3RhYmxlcmFuZ2U6YTA0ODUwZTY5NTYyNDZlODg0M2M5ZDMyNDVkYWJkOThfNi00LTEtMS0xNTk1NDA_753a8d8b-c928-4c94-bf34-6b0fed64423d"
      unitRef="usd">108800000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i913335a3ccfe4b639f36db1017ae92af_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmEwNDg1MGU2OTU2MjQ2ZTg4NDNjOWQzMjQ1ZGFiZDk4L3RhYmxlcmFuZ2U6YTA0ODUwZTY5NTYyNDZlODg0M2M5ZDMyNDVkYWJkOThfNi02LTEtMS0xNTk1NDA_6b167d15-d4ac-4f22-9f2f-443e5d6874be"
      unitRef="usd">218300000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i7c947211ed8b449b9617f0791f225696_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmEwNDg1MGU2OTU2MjQ2ZTg4NDNjOWQzMjQ1ZGFiZDk4L3RhYmxlcmFuZ2U6YTA0ODUwZTY5NTYyNDZlODg0M2M5ZDMyNDVkYWJkOThfNi04LTEtMS0xNTk1NDA_0350ef29-18de-4d39-86a2-c8ceb299f6e7"
      unitRef="usd">327200000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i14e2a21089594bfda05e2f482a1a9fdb_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmEwNDg1MGU2OTU2MjQ2ZTg4NDNjOWQzMjQ1ZGFiZDk4L3RhYmxlcmFuZ2U6YTA0ODUwZTY5NTYyNDZlODg0M2M5ZDMyNDVkYWJkOThfNy0yLTEtMS0xNTk1NDA_c69e305a-591a-4070-9ec3-f9a8f7a02bc0"
      unitRef="usd">15200000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="if60b1262bf5c4116ad9ba0e69b270a48_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmEwNDg1MGU2OTU2MjQ2ZTg4NDNjOWQzMjQ1ZGFiZDk4L3RhYmxlcmFuZ2U6YTA0ODUwZTY5NTYyNDZlODg0M2M5ZDMyNDVkYWJkOThfNy00LTEtMS0xNTk1NDA_2f77d614-038e-490f-b2ef-544ac03182a9"
      unitRef="usd">22800000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i913335a3ccfe4b639f36db1017ae92af_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmEwNDg1MGU2OTU2MjQ2ZTg4NDNjOWQzMjQ1ZGFiZDk4L3RhYmxlcmFuZ2U6YTA0ODUwZTY5NTYyNDZlODg0M2M5ZDMyNDVkYWJkOThfNy02LTEtMS0xNTk1NDA_202a3d38-09bf-4207-8bf8-1aff1296d1b1"
      unitRef="usd">45800000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i7c947211ed8b449b9617f0791f225696_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmEwNDg1MGU2OTU2MjQ2ZTg4NDNjOWQzMjQ1ZGFiZDk4L3RhYmxlcmFuZ2U6YTA0ODUwZTY5NTYyNDZlODg0M2M5ZDMyNDVkYWJkOThfNy04LTEtMS0xNTk1NDA_a640bf6f-a7d1-4129-81f4-869a47fac787"
      unitRef="usd">68700000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss
      contextRef="i14e2a21089594bfda05e2f482a1a9fdb_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmEwNDg1MGU2OTU2MjQ2ZTg4NDNjOWQzMjQ1ZGFiZDk4L3RhYmxlcmFuZ2U6YTA0ODUwZTY5NTYyNDZlODg0M2M5ZDMyNDVkYWJkOThfOC0yLTEtMS0xNTk1NDA_078cf349-6ae2-4264-ba2d-cc2dc7023f74"
      unitRef="usd">57200000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="if60b1262bf5c4116ad9ba0e69b270a48_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmEwNDg1MGU2OTU2MjQ2ZTg4NDNjOWQzMjQ1ZGFiZDk4L3RhYmxlcmFuZ2U6YTA0ODUwZTY5NTYyNDZlODg0M2M5ZDMyNDVkYWJkOThfOC00LTEtMS0xNTk1NDA_43f1f17d-5e6e-4e0d-9275-01fc78827701"
      unitRef="usd">86000000.0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i913335a3ccfe4b639f36db1017ae92af_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmEwNDg1MGU2OTU2MjQ2ZTg4NDNjOWQzMjQ1ZGFiZDk4L3RhYmxlcmFuZ2U6YTA0ODUwZTY5NTYyNDZlODg0M2M5ZDMyNDVkYWJkOThfOC02LTEtMS0xNTk1NDA_024f976b-b13d-4afb-a727-247f62c054ae"
      unitRef="usd">172500000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i7c947211ed8b449b9617f0791f225696_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmEwNDg1MGU2OTU2MjQ2ZTg4NDNjOWQzMjQ1ZGFiZDk4L3RhYmxlcmFuZ2U6YTA0ODUwZTY5NTYyNDZlODg0M2M5ZDMyNDVkYWJkOThfOC04LTEtMS0xNTk1NDA_ee56cd72-d540-4e2e-a6aa-7aa4b9663e61"
      unitRef="usd">258500000</us-gaap:ProfitLoss>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ib98dca097ce342f1856252087101e534_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmEwNDg1MGU2OTU2MjQ2ZTg4NDNjOWQzMjQ1ZGFiZDk4L3RhYmxlcmFuZ2U6YTA0ODUwZTY5NTYyNDZlODg0M2M5ZDMyNDVkYWJkOThfMTAtMi0xLTEtMTU5NTQw_f2d3ab8e-1b2b-4ff5-a7c3-5f627d0d4f55"
      unitRef="usd">13900000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="if20e319a4c3045b8b0693a8773446ca4_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmEwNDg1MGU2OTU2MjQ2ZTg4NDNjOWQzMjQ1ZGFiZDk4L3RhYmxlcmFuZ2U6YTA0ODUwZTY5NTYyNDZlODg0M2M5ZDMyNDVkYWJkOThfMTAtNC0xLTEtMTU5NTQw_cae01196-fe0d-48f1-a0a1-d5308a3751c6"
      unitRef="usd">3400000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i06f2cc53bd804ced906cc353bccf23bd_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmEwNDg1MGU2OTU2MjQ2ZTg4NDNjOWQzMjQ1ZGFiZDk4L3RhYmxlcmFuZ2U6YTA0ODUwZTY5NTYyNDZlODg0M2M5ZDMyNDVkYWJkOThfMTAtNi0xLTEtMTU5NTQw_0b895ae1-2a9b-4f7c-8d41-9911ac8e0f19"
      unitRef="usd">19900000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i562107a932c943419a75d588f68a7ede_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmEwNDg1MGU2OTU2MjQ2ZTg4NDNjOWQzMjQ1ZGFiZDk4L3RhYmxlcmFuZ2U6YTA0ODUwZTY5NTYyNDZlODg0M2M5ZDMyNDVkYWJkOThfMTAtOC0xLTEtMTU5NTQw_ea3bc79b-cd71-4dcc-b0cc-66f387200de8"
      unitRef="usd">10700000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:ProfitLoss
      contextRef="i294aedf137cf40faaba28e6d98a540dc_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmEwNDg1MGU2OTU2MjQ2ZTg4NDNjOWQzMjQ1ZGFiZDk4L3RhYmxlcmFuZ2U6YTA0ODUwZTY5NTYyNDZlODg0M2M5ZDMyNDVkYWJkOThfMTItMi0xLTEtMTU5NTQw_9c895380-89ef-4bd2-9085-faf91a1e9dd5"
      unitRef="usd">71100000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="id04bc0ea75e7453daeb27bfa63e91d46_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmEwNDg1MGU2OTU2MjQ2ZTg4NDNjOWQzMjQ1ZGFiZDk4L3RhYmxlcmFuZ2U6YTA0ODUwZTY5NTYyNDZlODg0M2M5ZDMyNDVkYWJkOThfMTItNC0xLTEtMTU5NTQw_dafea8ca-30c7-42dd-b875-a96517caeeaf"
      unitRef="usd">89400000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="id8fcac86ddf342cf954cceefebfd7779_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmEwNDg1MGU2OTU2MjQ2ZTg4NDNjOWQzMjQ1ZGFiZDk4L3RhYmxlcmFuZ2U6YTA0ODUwZTY5NTYyNDZlODg0M2M5ZDMyNDVkYWJkOThfMTItNi0xLTEtMTU5NTQw_a52dcf8c-cf09-42ec-bb83-f8eb0ca6ac84"
      unitRef="usd">192400000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i741049a232dc40728bbe8ee225522d87_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183My9mcmFnOmUxNDI5ZmNiMjY2MjQ4OGQ5OTE5ZTE4ODBjYmUzMjEzL3RhYmxlOmEwNDg1MGU2OTU2MjQ2ZTg4NDNjOWQzMjQ1ZGFiZDk4L3RhYmxlcmFuZ2U6YTA0ODUwZTY5NTYyNDZlODg0M2M5ZDMyNDVkYWJkOThfMTItOC0xLTEtMTU5NTQw_2d74a895-ec3d-48e4-aea1-6e52b6e3c7db"
      unitRef="usd">269200000</us-gaap:ProfitLoss>
    <us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock
      contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183OS9mcmFnOjRlODJmYzU4OGU5ZTQ1OWY4NThhZGYzYjAwN2ZhNjIxL3RleHRyZWdpb246NGU4MmZjNTg4ZTllNDU5Zjg1OGFkZjNiMDA3ZmE2MjFfMTAw_a4436a0b-790b-4f5c-89ef-5fc4fe3b6d4c">Other&#x2013;Net, (Income) Expense&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other&#x2013;net, (income) expense consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.206%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;81.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;247.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;258.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(20.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(37.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net investment (gains) losses on equity securities (Note 6)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;123.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;246.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;667.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(270.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Retirement benefit plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(92.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(72.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(280.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(217.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt extinguishment loss (Note 6)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;405.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;405.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other (income) expense &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;18.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(17.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(34.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&#x2013;net, (income) expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;111.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;635.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;580.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;124.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock>
    <us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock
      contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183OS9mcmFnOjRlODJmYzU4OGU5ZTQ1OWY4NThhZGYzYjAwN2ZhNjIxL3RleHRyZWdpb246NGU4MmZjNTg4ZTllNDU5Zjg1OGFkZjNiMDA3ZmE2MjFfMTEw_ad46a46a-9b7c-457d-899a-6c782493986f">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other&#x2013;net, (income) expense consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.206%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;81.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;247.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;258.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(20.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(37.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net investment (gains) losses on equity securities (Note 6)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;123.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;246.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;667.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(270.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Retirement benefit plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(92.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(72.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(280.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(217.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt extinguishment loss (Note 6)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;405.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;405.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other (income) expense &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;18.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(17.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(34.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&#x2013;net, (income) expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;111.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;635.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;580.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;124.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock>
    <us-gaap:InterestExpense
      contextRef="i19fc0325c48543008ea71e1fdcf11d86_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183OS9mcmFnOjRlODJmYzU4OGU5ZTQ1OWY4NThhZGYzYjAwN2ZhNjIxL3RhYmxlOjJjYTIxZTlmZWFjNzRmMWQ4ZDQ2MjEzMGY2NThlYTdkL3RhYmxlcmFuZ2U6MmNhMjFlOWZlYWM3NGYxZDhkNDYyMTMwZjY1OGVhN2RfMi0xLTEtMS0xNTk1NDA_33cda92a-e46e-4aea-842b-df4b67ecd84e"
      unitRef="usd">81500000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="ie4fa4f6b472a4f269297591b44aba572_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183OS9mcmFnOjRlODJmYzU4OGU5ZTQ1OWY4NThhZGYzYjAwN2ZhNjIxL3RhYmxlOjJjYTIxZTlmZWFjNzRmMWQ4ZDQ2MjEzMGY2NThlYTdkL3RhYmxlcmFuZ2U6MmNhMjFlOWZlYWM3NGYxZDhkNDYyMTMwZjY1OGVhN2RfMi0zLTEtMS0xNTk1NDA_1eabc783-52db-4890-bb75-8406c7ee6a31"
      unitRef="usd">83600000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183OS9mcmFnOjRlODJmYzU4OGU5ZTQ1OWY4NThhZGYzYjAwN2ZhNjIxL3RhYmxlOjJjYTIxZTlmZWFjNzRmMWQ4ZDQ2MjEzMGY2NThlYTdkL3RhYmxlcmFuZ2U6MmNhMjFlOWZlYWM3NGYxZDhkNDYyMTMwZjY1OGVhN2RfMi01LTEtMS0xNTk1NDA_ada27b2f-3ec8-422a-aed1-25eb5ee50ea0"
      unitRef="usd">247600000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i167ed8f67bef48c49e54fa466400cdaa_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183OS9mcmFnOjRlODJmYzU4OGU5ZTQ1OWY4NThhZGYzYjAwN2ZhNjIxL3RhYmxlOjJjYTIxZTlmZWFjNzRmMWQ4ZDQ2MjEzMGY2NThlYTdkL3RhYmxlcmFuZ2U6MmNhMjFlOWZlYWM3NGYxZDhkNDYyMTMwZjY1OGVhN2RfMi03LTEtMS0xNTk1NDA_54fa630a-3f4d-4f04-9577-1077a69f6f70"
      unitRef="usd">258400000</us-gaap:InterestExpense>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i19fc0325c48543008ea71e1fdcf11d86_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183OS9mcmFnOjRlODJmYzU4OGU5ZTQ1OWY4NThhZGYzYjAwN2ZhNjIxL3RhYmxlOjJjYTIxZTlmZWFjNzRmMWQ4ZDQ2MjEzMGY2NThlYTdkL3RhYmxlcmFuZ2U6MmNhMjFlOWZlYWM3NGYxZDhkNDYyMTMwZjY1OGVhN2RfMy0xLTEtMS0xNTk1NDA_75826add-d709-499e-939b-c541790eaed8"
      unitRef="usd">20100000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="ie4fa4f6b472a4f269297591b44aba572_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183OS9mcmFnOjRlODJmYzU4OGU5ZTQ1OWY4NThhZGYzYjAwN2ZhNjIxL3RhYmxlOjJjYTIxZTlmZWFjNzRmMWQ4ZDQ2MjEzMGY2NThlYTdkL3RhYmxlcmFuZ2U6MmNhMjFlOWZlYWM3NGYxZDhkNDYyMTMwZjY1OGVhN2RfMy0zLTEtMS0xNTk1NDA_f798d748-7f48-4a5f-bb59-23fd9c334244"
      unitRef="usd">7000000.0</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183OS9mcmFnOjRlODJmYzU4OGU5ZTQ1OWY4NThhZGYzYjAwN2ZhNjIxL3RhYmxlOjJjYTIxZTlmZWFjNzRmMWQ4ZDQ2MjEzMGY2NThlYTdkL3RhYmxlcmFuZ2U6MmNhMjFlOWZlYWM3NGYxZDhkNDYyMTMwZjY1OGVhN2RfMy01LTEtMS0xNTk1NDA_d3294d53-2ec1-4008-afb9-ebd49ab57ae6"
      unitRef="usd">37300000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i167ed8f67bef48c49e54fa466400cdaa_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183OS9mcmFnOjRlODJmYzU4OGU5ZTQ1OWY4NThhZGYzYjAwN2ZhNjIxL3RhYmxlOjJjYTIxZTlmZWFjNzRmMWQ4ZDQ2MjEzMGY2NThlYTdkL3RhYmxlcmFuZ2U6MmNhMjFlOWZlYWM3NGYxZDhkNDYyMTMwZjY1OGVhN2RfMy03LTEtMS0xNTk1NDA_7af8f4a4-f340-41e1-8ffc-1f0c48f342d9"
      unitRef="usd">18000000.0</us-gaap:InvestmentIncomeInterest>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="i19fc0325c48543008ea71e1fdcf11d86_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183OS9mcmFnOjRlODJmYzU4OGU5ZTQ1OWY4NThhZGYzYjAwN2ZhNjIxL3RhYmxlOjJjYTIxZTlmZWFjNzRmMWQ4ZDQ2MjEzMGY2NThlYTdkL3RhYmxlcmFuZ2U6MmNhMjFlOWZlYWM3NGYxZDhkNDYyMTMwZjY1OGVhN2RfNC0xLTEtMS0xNTk1NDA_5cd0ac3d-1d37-4f83-919d-48c80bd2ec13"
      unitRef="usd">-123300000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="ie4fa4f6b472a4f269297591b44aba572_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183OS9mcmFnOjRlODJmYzU4OGU5ZTQ1OWY4NThhZGYzYjAwN2ZhNjIxL3RhYmxlOjJjYTIxZTlmZWFjNzRmMWQ4ZDQ2MjEzMGY2NThlYTdkL3RhYmxlcmFuZ2U6MmNhMjFlOWZlYWM3NGYxZDhkNDYyMTMwZjY1OGVhN2RfNC0zLTEtMS0xNTk1NDA_8dca2ddf-db58-412d-8364-95935d1ba64c"
      unitRef="usd">-246800000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183OS9mcmFnOjRlODJmYzU4OGU5ZTQ1OWY4NThhZGYzYjAwN2ZhNjIxL3RhYmxlOjJjYTIxZTlmZWFjNzRmMWQ4ZDQ2MjEzMGY2NThlYTdkL3RhYmxlcmFuZ2U6MmNhMjFlOWZlYWM3NGYxZDhkNDYyMTMwZjY1OGVhN2RfNC01LTEtMS0xNTk1NDA_2ffa2442-aa70-42f4-b1f5-332bdd49c2c8"
      unitRef="usd">-667600000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="i167ed8f67bef48c49e54fa466400cdaa_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183OS9mcmFnOjRlODJmYzU4OGU5ZTQ1OWY4NThhZGYzYjAwN2ZhNjIxL3RhYmxlOjJjYTIxZTlmZWFjNzRmMWQ4ZDQ2MjEzMGY2NThlYTdkL3RhYmxlcmFuZ2U6MmNhMjFlOWZlYWM3NGYxZDhkNDYyMTMwZjY1OGVhN2RfNC03LTEtMS0xNTk1NDA_1ef5aaec-a5b2-49d9-b2e6-fc4bfd34c928"
      unitRef="usd">270100000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent
      contextRef="i19fc0325c48543008ea71e1fdcf11d86_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183OS9mcmFnOjRlODJmYzU4OGU5ZTQ1OWY4NThhZGYzYjAwN2ZhNjIxL3RhYmxlOjJjYTIxZTlmZWFjNzRmMWQ4ZDQ2MjEzMGY2NThlYTdkL3RhYmxlcmFuZ2U6MmNhMjFlOWZlYWM3NGYxZDhkNDYyMTMwZjY1OGVhN2RfNS0xLTEtMS0xNTk1NDA_696c9a51-3037-4c44-9707-e7a4fe5990e2"
      unitRef="usd">-92400000</us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent>
    <us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent
      contextRef="ie4fa4f6b472a4f269297591b44aba572_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183OS9mcmFnOjRlODJmYzU4OGU5ZTQ1OWY4NThhZGYzYjAwN2ZhNjIxL3RhYmxlOjJjYTIxZTlmZWFjNzRmMWQ4ZDQ2MjEzMGY2NThlYTdkL3RhYmxlcmFuZ2U6MmNhMjFlOWZlYWM3NGYxZDhkNDYyMTMwZjY1OGVhN2RfNS0zLTEtMS0xNTk1NDA_108e730a-fa82-4d4a-b646-a497cd3bfe47"
      unitRef="usd">-72600000</us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent>
    <us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent
      contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183OS9mcmFnOjRlODJmYzU4OGU5ZTQ1OWY4NThhZGYzYjAwN2ZhNjIxL3RhYmxlOjJjYTIxZTlmZWFjNzRmMWQ4ZDQ2MjEzMGY2NThlYTdkL3RhYmxlcmFuZ2U6MmNhMjFlOWZlYWM3NGYxZDhkNDYyMTMwZjY1OGVhN2RfNS01LTEtMS0xNTk1NDA_6dd8f318-1931-4704-811b-5f43ab62d832"
      unitRef="usd">-280000000.0</us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent>
    <us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent
      contextRef="i167ed8f67bef48c49e54fa466400cdaa_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183OS9mcmFnOjRlODJmYzU4OGU5ZTQ1OWY4NThhZGYzYjAwN2ZhNjIxL3RhYmxlOjJjYTIxZTlmZWFjNzRmMWQ4ZDQ2MjEzMGY2NThlYTdkL3RhYmxlcmFuZ2U6MmNhMjFlOWZlYWM3NGYxZDhkNDYyMTMwZjY1OGVhN2RfNS03LTEtMS0xNTk1NDA_ddc5eef9-547b-40ff-9889-d15cff937812"
      unitRef="usd">-217100000</us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i19fc0325c48543008ea71e1fdcf11d86_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183OS9mcmFnOjRlODJmYzU4OGU5ZTQ1OWY4NThhZGYzYjAwN2ZhNjIxL3RhYmxlOjJjYTIxZTlmZWFjNzRmMWQ4ZDQ2MjEzMGY2NThlYTdkL3RhYmxlcmFuZ2U6MmNhMjFlOWZlYWM3NGYxZDhkNDYyMTMwZjY1OGVhN2RfNi0xLTEtMS0xNTk1NDA_e112022d-6846-40ce-b958-29278337cd5d"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="ie4fa4f6b472a4f269297591b44aba572_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183OS9mcmFnOjRlODJmYzU4OGU5ZTQ1OWY4NThhZGYzYjAwN2ZhNjIxL3RhYmxlOjJjYTIxZTlmZWFjNzRmMWQ4ZDQ2MjEzMGY2NThlYTdkL3RhYmxlcmFuZ2U6MmNhMjFlOWZlYWM3NGYxZDhkNDYyMTMwZjY1OGVhN2RfNi0zLTEtMS0xNTk1NDA_94ed0a9f-b016-4c6b-8256-c4dbca145a96"
      unitRef="usd">-405200000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183OS9mcmFnOjRlODJmYzU4OGU5ZTQ1OWY4NThhZGYzYjAwN2ZhNjIxL3RhYmxlOjJjYTIxZTlmZWFjNzRmMWQ4ZDQ2MjEzMGY2NThlYTdkL3RhYmxlcmFuZ2U6MmNhMjFlOWZlYWM3NGYxZDhkNDYyMTMwZjY1OGVhN2RfNi01LTEtMS0xNTk1NDA_6bb402b6-31d7-426c-9be9-1aaec0b9e87c"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i167ed8f67bef48c49e54fa466400cdaa_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183OS9mcmFnOjRlODJmYzU4OGU5ZTQ1OWY4NThhZGYzYjAwN2ZhNjIxL3RhYmxlOjJjYTIxZTlmZWFjNzRmMWQ4ZDQ2MjEzMGY2NThlYTdkL3RhYmxlcmFuZ2U6MmNhMjFlOWZlYWM3NGYxZDhkNDYyMTMwZjY1OGVhN2RfNi03LTEtMS0xNTk1NDA_963519da-bc95-4b28-aa75-075fdb0bcf67"
      unitRef="usd">-405200000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i19fc0325c48543008ea71e1fdcf11d86_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183OS9mcmFnOjRlODJmYzU4OGU5ZTQ1OWY4NThhZGYzYjAwN2ZhNjIxL3RhYmxlOjJjYTIxZTlmZWFjNzRmMWQ4ZDQ2MjEzMGY2NThlYTdkL3RhYmxlcmFuZ2U6MmNhMjFlOWZlYWM3NGYxZDhkNDYyMTMwZjY1OGVhN2RfNy0xLTEtMS0xNTk1NDA_50be6c14-aff6-4757-847e-cfa0831e1bbb"
      unitRef="usd">-18700000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ie4fa4f6b472a4f269297591b44aba572_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183OS9mcmFnOjRlODJmYzU4OGU5ZTQ1OWY4NThhZGYzYjAwN2ZhNjIxL3RhYmxlOjJjYTIxZTlmZWFjNzRmMWQ4ZDQ2MjEzMGY2NThlYTdkL3RhYmxlcmFuZ2U6MmNhMjFlOWZlYWM3NGYxZDhkNDYyMTMwZjY1OGVhN2RfNy0zLTEtMS0xNTk1NDA_522898d9-cf62-4b08-adbb-ed7883066ea3"
      unitRef="usd">20100000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183OS9mcmFnOjRlODJmYzU4OGU5ZTQ1OWY4NThhZGYzYjAwN2ZhNjIxL3RhYmxlOjJjYTIxZTlmZWFjNzRmMWQ4ZDQ2MjEzMGY2NThlYTdkL3RhYmxlcmFuZ2U6MmNhMjFlOWZlYWM3NGYxZDhkNDYyMTMwZjY1OGVhN2RfNy01LTEtMS0xNTk1NDA_2cea1b0b-fb10-4879-86b7-123df7461cc5"
      unitRef="usd">17000000.0</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i167ed8f67bef48c49e54fa466400cdaa_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183OS9mcmFnOjRlODJmYzU4OGU5ZTQ1OWY4NThhZGYzYjAwN2ZhNjIxL3RhYmxlOjJjYTIxZTlmZWFjNzRmMWQ4ZDQ2MjEzMGY2NThlYTdkL3RhYmxlcmFuZ2U6MmNhMjFlOWZlYWM3NGYxZDhkNDYyMTMwZjY1OGVhN2RfNy03LTEtMS0xNTk1NDA_06289573-41b0-4298-95dc-9abd1048b93c"
      unitRef="usd">34100000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i19fc0325c48543008ea71e1fdcf11d86_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183OS9mcmFnOjRlODJmYzU4OGU5ZTQ1OWY4NThhZGYzYjAwN2ZhNjIxL3RhYmxlOjJjYTIxZTlmZWFjNzRmMWQ4ZDQ2MjEzMGY2NThlYTdkL3RhYmxlcmFuZ2U6MmNhMjFlOWZlYWM3NGYxZDhkNDYyMTMwZjY1OGVhN2RfOC0xLTEtMS0xNTk1NDA_f98b9603-2aa7-4cc7-9928-490f2e31db3b"
      unitRef="usd">-111000000.0</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="ie4fa4f6b472a4f269297591b44aba572_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183OS9mcmFnOjRlODJmYzU4OGU5ZTQ1OWY4NThhZGYzYjAwN2ZhNjIxL3RhYmxlOjJjYTIxZTlmZWFjNzRmMWQ4ZDQ2MjEzMGY2NThlYTdkL3RhYmxlcmFuZ2U6MmNhMjFlOWZlYWM3NGYxZDhkNDYyMTMwZjY1OGVhN2RfOC0zLTEtMS0xNTk1NDA_08fb8c9e-ea3f-490c-ae48-abadbe691982"
      unitRef="usd">-635900000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183OS9mcmFnOjRlODJmYzU4OGU5ZTQ1OWY4NThhZGYzYjAwN2ZhNjIxL3RhYmxlOjJjYTIxZTlmZWFjNzRmMWQ4ZDQ2MjEzMGY2NThlYTdkL3RhYmxlcmFuZ2U6MmNhMjFlOWZlYWM3NGYxZDhkNDYyMTMwZjY1OGVhN2RfOC01LTEtMS0xNTk1NDA_56cd7490-bc22-41e8-8cc1-e23a9679190e"
      unitRef="usd">-580900000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i167ed8f67bef48c49e54fa466400cdaa_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN183OS9mcmFnOjRlODJmYzU4OGU5ZTQ1OWY4NThhZGYzYjAwN2ZhNjIxL3RhYmxlOjJjYTIxZTlmZWFjNzRmMWQ4ZDQ2MjEzMGY2NThlYTdkL3RhYmxlcmFuZ2U6MmNhMjFlOWZlYWM3NGYxZDhkNDYyMTMwZjY1OGVhN2RfOC03LTEtMS0xNTk1NDA_dcd3636f-bd7d-474a-92e7-b4e1736f410b"
      unitRef="usd">-124300000</us-gaap:NonoperatingIncomeExpense>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yOC9mcmFnOmEyNTBjNDBjZWQ3ZDQwZjRhNWUyMTQwZDM3MWNiYjliL3RhYmxlOjU0ZWNlYTRkMjgzZDQ4NTJiZTI1Y2QyYWEzN2M0ZDU0L3RhYmxlcmFuZ2U6NTRlY2VhNGQyODNkNDg1MmJlMjVjZDJhYTM3YzRkNTRfMy0xNS0xLTEtMTU5NTQw_6d92fa6f-1acf-4170-82f2-aac697d0cb4d"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yOC9mcmFnOmEyNTBjNDBjZWQ3ZDQwZjRhNWUyMTQwZDM3MWNiYjliL3RhYmxlOjU0ZWNlYTRkMjgzZDQ4NTJiZTI1Y2QyYWEzN2M0ZDU0L3RhYmxlcmFuZ2U6NTRlY2VhNGQyODNkNDg1MmJlMjVjZDJhYTM3YzRkNTRfMy0xNS0xLTEtMTU5NTQw_6d92fa6f-1acf-4170-82f2-aac697d0cb4d"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yOC9mcmFnOmEyNTBjNDBjZWQ3ZDQwZjRhNWUyMTQwZDM3MWNiYjliL3RhYmxlOjU0ZWNlYTRkMjgzZDQ4NTJiZTI1Y2QyYWEzN2M0ZDU0L3RhYmxlcmFuZ2U6NTRlY2VhNGQyODNkNDg1MmJlMjVjZDJhYTM3YzRkNTRfMTQtMTUtMS0xLTE1OTU0MA_2900ac5b-f4af-4b04-a084-997e5a9b4ef4"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yOC9mcmFnOmEyNTBjNDBjZWQ3ZDQwZjRhNWUyMTQwZDM3MWNiYjliL3RhYmxlOjU0ZWNlYTRkMjgzZDQ4NTJiZTI1Y2QyYWEzN2M0ZDU0L3RhYmxlcmFuZ2U6NTRlY2VhNGQyODNkNDg1MmJlMjVjZDJhYTM3YzRkNTRfMTQtMTUtMS0xLTE1OTU0MA_2900ac5b-f4af-4b04-a084-997e5a9b4ef4"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yOC9mcmFnOmEyNTBjNDBjZWQ3ZDQwZjRhNWUyMTQwZDM3MWNiYjliL3RhYmxlOjU0ZWNlYTRkMjgzZDQ4NTJiZTI1Y2QyYWEzN2M0ZDU0L3RhYmxlcmFuZ2U6NTRlY2VhNGQyODNkNDg1MmJlMjVjZDJhYTM3YzRkNTRfMjUtMTUtMS0xLTE1OTU0MA_7af684c2-0888-4891-a471-aee7fb026ebd"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yOC9mcmFnOmEyNTBjNDBjZWQ3ZDQwZjRhNWUyMTQwZDM3MWNiYjliL3RhYmxlOjU0ZWNlYTRkMjgzZDQ4NTJiZTI1Y2QyYWEzN2M0ZDU0L3RhYmxlcmFuZ2U6NTRlY2VhNGQyODNkNDg1MmJlMjVjZDJhYTM3YzRkNTRfMjUtMTUtMS0xLTE1OTU0MA_7af684c2-0888-4891-a471-aee7fb026ebd"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yOC9mcmFnOmEyNTBjNDBjZWQ3ZDQwZjRhNWUyMTQwZDM3MWNiYjliL3RhYmxlOjU0ZWNlYTRkMjgzZDQ4NTJiZTI1Y2QyYWEzN2M0ZDU0L3RhYmxlcmFuZ2U6NTRlY2VhNGQyODNkNDg1MmJlMjVjZDJhYTM3YzRkNTRfMy0xMy0xLTEtMTU5NTQw_a0242d52-4853-4826-9c2a-9045ffce7d36"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yOC9mcmFnOmEyNTBjNDBjZWQ3ZDQwZjRhNWUyMTQwZDM3MWNiYjliL3RhYmxlOjU0ZWNlYTRkMjgzZDQ4NTJiZTI1Y2QyYWEzN2M0ZDU0L3RhYmxlcmFuZ2U6NTRlY2VhNGQyODNkNDg1MmJlMjVjZDJhYTM3YzRkNTRfMy0xMy0xLTEtMTU5NTQw_a0242d52-4853-4826-9c2a-9045ffce7d36"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yOC9mcmFnOmEyNTBjNDBjZWQ3ZDQwZjRhNWUyMTQwZDM3MWNiYjliL3RhYmxlOjU0ZWNlYTRkMjgzZDQ4NTJiZTI1Y2QyYWEzN2M0ZDU0L3RhYmxlcmFuZ2U6NTRlY2VhNGQyODNkNDg1MmJlMjVjZDJhYTM3YzRkNTRfMTQtMTMtMS0xLTE1OTU0MA_5ba3cacd-6990-4cb0-813c-c9d6994bcad2"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yOC9mcmFnOmEyNTBjNDBjZWQ3ZDQwZjRhNWUyMTQwZDM3MWNiYjliL3RhYmxlOjU0ZWNlYTRkMjgzZDQ4NTJiZTI1Y2QyYWEzN2M0ZDU0L3RhYmxlcmFuZ2U6NTRlY2VhNGQyODNkNDg1MmJlMjVjZDJhYTM3YzRkNTRfMTQtMTMtMS0xLTE1OTU0MA_5ba3cacd-6990-4cb0-813c-c9d6994bcad2"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yOC9mcmFnOmEyNTBjNDBjZWQ3ZDQwZjRhNWUyMTQwZDM3MWNiYjliL3RhYmxlOjU0ZWNlYTRkMjgzZDQ4NTJiZTI1Y2QyYWEzN2M0ZDU0L3RhYmxlcmFuZ2U6NTRlY2VhNGQyODNkNDg1MmJlMjVjZDJhYTM3YzRkNTRfMTYtMTMtMS0xLTE1OTU0MA_79b6e3ff-9a51-48d4-a405-02f97d7823a6"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yOC9mcmFnOmEyNTBjNDBjZWQ3ZDQwZjRhNWUyMTQwZDM3MWNiYjliL3RhYmxlOjU0ZWNlYTRkMjgzZDQ4NTJiZTI1Y2QyYWEzN2M0ZDU0L3RhYmxlcmFuZ2U6NTRlY2VhNGQyODNkNDg1MmJlMjVjZDJhYTM3YzRkNTRfMTYtMTMtMS0xLTE1OTU0MA_79b6e3ff-9a51-48d4-a405-02f97d7823a6"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yOC9mcmFnOmEyNTBjNDBjZWQ3ZDQwZjRhNWUyMTQwZDM3MWNiYjliL3RhYmxlOjU0ZWNlYTRkMjgzZDQ4NTJiZTI1Y2QyYWEzN2M0ZDU0L3RhYmxlcmFuZ2U6NTRlY2VhNGQyODNkNDg1MmJlMjVjZDJhYTM3YzRkNTRfMTYtMTUtMS0xLTE1OTU0MA_8eb7f85c-86ce-4c28-8769-6fd6765ed5b0"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yOC9mcmFnOmEyNTBjNDBjZWQ3ZDQwZjRhNWUyMTQwZDM3MWNiYjliL3RhYmxlOjU0ZWNlYTRkMjgzZDQ4NTJiZTI1Y2QyYWEzN2M0ZDU0L3RhYmxlcmFuZ2U6NTRlY2VhNGQyODNkNDg1MmJlMjVjZDJhYTM3YzRkNTRfMTYtMTUtMS0xLTE1OTU0MA_8eb7f85c-86ce-4c28-8769-6fd6765ed5b0"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yOC9mcmFnOmEyNTBjNDBjZWQ3ZDQwZjRhNWUyMTQwZDM3MWNiYjliL3RhYmxlOjU0ZWNlYTRkMjgzZDQ4NTJiZTI1Y2QyYWEzN2M0ZDU0L3RhYmxlcmFuZ2U6NTRlY2VhNGQyODNkNDg1MmJlMjVjZDJhYTM3YzRkNTRfMjUtMTMtMS0xLTE1OTU0MA_17f5a50e-d7d3-49ea-ac64-ce1a5539bebc"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yOC9mcmFnOmEyNTBjNDBjZWQ3ZDQwZjRhNWUyMTQwZDM3MWNiYjliL3RhYmxlOjU0ZWNlYTRkMjgzZDQ4NTJiZTI1Y2QyYWEzN2M0ZDU0L3RhYmxlcmFuZ2U6NTRlY2VhNGQyODNkNDg1MmJlMjVjZDJhYTM3YzRkNTRfMjUtMTMtMS0xLTE1OTU0MA_17f5a50e-d7d3-49ea-ac64-ce1a5539bebc"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yOC9mcmFnOmEyNTBjNDBjZWQ3ZDQwZjRhNWUyMTQwZDM3MWNiYjliL3RleHRyZWdpb246YTI1MGM0MGNlZDdkNDBmNGE1ZTIxNDBkMzcxY2JiOWJfMjYx_2087051d-93f9-4e3e-80d6-ea5e9c10d8dd" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yOC9mcmFnOmEyNTBjNDBjZWQ3ZDQwZjRhNWUyMTQwZDM3MWNiYjliL3RleHRyZWdpb246YTI1MGM0MGNlZDdkNDBmNGE1ZTIxNDBkMzcxY2JiOWJfMjYx_2087051d-93f9-4e3e-80d6-ea5e9c10d8dd" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">As of September&#160;30, 2022, there was $3.25 billion remaining under our $5.00 billion share repurchase program authorized in May 2021.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yOC9mcmFnOmEyNTBjNDBjZWQ3ZDQwZjRhNWUyMTQwZDM3MWNiYjliL3RhYmxlOjU0ZWNlYTRkMjgzZDQ4NTJiZTI1Y2QyYWEzN2M0ZDU0L3RhYmxlcmFuZ2U6NTRlY2VhNGQyODNkNDg1MmJlMjVjZDJhYTM3YzRkNTRfMy0xNS0xLTEtMTU5NTQw_6d92fa6f-1acf-4170-82f2-aac697d0cb4d"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yOC9mcmFnOmEyNTBjNDBjZWQ3ZDQwZjRhNWUyMTQwZDM3MWNiYjliL3RleHRyZWdpb246YTI1MGM0MGNlZDdkNDBmNGE1ZTIxNDBkMzcxY2JiOWJfMjYx_2087051d-93f9-4e3e-80d6-ea5e9c10d8dd"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yOC9mcmFnOmEyNTBjNDBjZWQ3ZDQwZjRhNWUyMTQwZDM3MWNiYjliL3RhYmxlOjU0ZWNlYTRkMjgzZDQ4NTJiZTI1Y2QyYWEzN2M0ZDU0L3RhYmxlcmFuZ2U6NTRlY2VhNGQyODNkNDg1MmJlMjVjZDJhYTM3YzRkNTRfMTQtMTUtMS0xLTE1OTU0MA_2900ac5b-f4af-4b04-a084-997e5a9b4ef4"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yOC9mcmFnOmEyNTBjNDBjZWQ3ZDQwZjRhNWUyMTQwZDM3MWNiYjliL3RleHRyZWdpb246YTI1MGM0MGNlZDdkNDBmNGE1ZTIxNDBkMzcxY2JiOWJfMjYx_2087051d-93f9-4e3e-80d6-ea5e9c10d8dd"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yOC9mcmFnOmEyNTBjNDBjZWQ3ZDQwZjRhNWUyMTQwZDM3MWNiYjliL3RhYmxlOjU0ZWNlYTRkMjgzZDQ4NTJiZTI1Y2QyYWEzN2M0ZDU0L3RhYmxlcmFuZ2U6NTRlY2VhNGQyODNkNDg1MmJlMjVjZDJhYTM3YzRkNTRfMjUtMTUtMS0xLTE1OTU0MA_7af684c2-0888-4891-a471-aee7fb026ebd"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yOC9mcmFnOmEyNTBjNDBjZWQ3ZDQwZjRhNWUyMTQwZDM3MWNiYjliL3RleHRyZWdpb246YTI1MGM0MGNlZDdkNDBmNGE1ZTIxNDBkMzcxY2JiOWJfMjYx_2087051d-93f9-4e3e-80d6-ea5e9c10d8dd"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yOC9mcmFnOmEyNTBjNDBjZWQ3ZDQwZjRhNWUyMTQwZDM3MWNiYjliL3RhYmxlOjU0ZWNlYTRkMjgzZDQ4NTJiZTI1Y2QyYWEzN2M0ZDU0L3RhYmxlcmFuZ2U6NTRlY2VhNGQyODNkNDg1MmJlMjVjZDJhYTM3YzRkNTRfMy0xMy0xLTEtMTU5NTQw_a0242d52-4853-4826-9c2a-9045ffce7d36"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yOC9mcmFnOmEyNTBjNDBjZWQ3ZDQwZjRhNWUyMTQwZDM3MWNiYjliL3RleHRyZWdpb246YTI1MGM0MGNlZDdkNDBmNGE1ZTIxNDBkMzcxY2JiOWJfMjYx_2087051d-93f9-4e3e-80d6-ea5e9c10d8dd"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yOC9mcmFnOmEyNTBjNDBjZWQ3ZDQwZjRhNWUyMTQwZDM3MWNiYjliL3RhYmxlOjU0ZWNlYTRkMjgzZDQ4NTJiZTI1Y2QyYWEzN2M0ZDU0L3RhYmxlcmFuZ2U6NTRlY2VhNGQyODNkNDg1MmJlMjVjZDJhYTM3YzRkNTRfMTQtMTMtMS0xLTE1OTU0MA_5ba3cacd-6990-4cb0-813c-c9d6994bcad2"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yOC9mcmFnOmEyNTBjNDBjZWQ3ZDQwZjRhNWUyMTQwZDM3MWNiYjliL3RleHRyZWdpb246YTI1MGM0MGNlZDdkNDBmNGE1ZTIxNDBkMzcxY2JiOWJfMjYx_2087051d-93f9-4e3e-80d6-ea5e9c10d8dd"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yOC9mcmFnOmEyNTBjNDBjZWQ3ZDQwZjRhNWUyMTQwZDM3MWNiYjliL3RhYmxlOjU0ZWNlYTRkMjgzZDQ4NTJiZTI1Y2QyYWEzN2M0ZDU0L3RhYmxlcmFuZ2U6NTRlY2VhNGQyODNkNDg1MmJlMjVjZDJhYTM3YzRkNTRfMTYtMTMtMS0xLTE1OTU0MA_79b6e3ff-9a51-48d4-a405-02f97d7823a6"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yOC9mcmFnOmEyNTBjNDBjZWQ3ZDQwZjRhNWUyMTQwZDM3MWNiYjliL3RleHRyZWdpb246YTI1MGM0MGNlZDdkNDBmNGE1ZTIxNDBkMzcxY2JiOWJfMjYx_2087051d-93f9-4e3e-80d6-ea5e9c10d8dd"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yOC9mcmFnOmEyNTBjNDBjZWQ3ZDQwZjRhNWUyMTQwZDM3MWNiYjliL3RhYmxlOjU0ZWNlYTRkMjgzZDQ4NTJiZTI1Y2QyYWEzN2M0ZDU0L3RhYmxlcmFuZ2U6NTRlY2VhNGQyODNkNDg1MmJlMjVjZDJhYTM3YzRkNTRfMTYtMTUtMS0xLTE1OTU0MA_8eb7f85c-86ce-4c28-8769-6fd6765ed5b0"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yOC9mcmFnOmEyNTBjNDBjZWQ3ZDQwZjRhNWUyMTQwZDM3MWNiYjliL3RleHRyZWdpb246YTI1MGM0MGNlZDdkNDBmNGE1ZTIxNDBkMzcxY2JiOWJfMjYx_2087051d-93f9-4e3e-80d6-ea5e9c10d8dd"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yOC9mcmFnOmEyNTBjNDBjZWQ3ZDQwZjRhNWUyMTQwZDM3MWNiYjliL3RhYmxlOjU0ZWNlYTRkMjgzZDQ4NTJiZTI1Y2QyYWEzN2M0ZDU0L3RhYmxlcmFuZ2U6NTRlY2VhNGQyODNkNDg1MmJlMjVjZDJhYTM3YzRkNTRfMjUtMTMtMS0xLTE1OTU0MA_17f5a50e-d7d3-49ea-ac64-ce1a5539bebc"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18yOC9mcmFnOmEyNTBjNDBjZWQ3ZDQwZjRhNWUyMTQwZDM3MWNiYjliL3RleHRyZWdpb246YTI1MGM0MGNlZDdkNDBmNGE1ZTIxNDBkMzcxY2JiOWJfMjYx_2087051d-93f9-4e3e-80d6-ea5e9c10d8dd"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfMTYtMTUtMS0xLTE1OTU0MA_535791d1-15b8-498e-a925-9f7eddc75751"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfMTYtMTUtMS0xLTE1OTU0MA_535791d1-15b8-498e-a925-9f7eddc75751"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfMjUtMTUtMS0xLTE1OTU0MA_da8ad497-050f-4202-83f7-ba8bfce436f5"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfMjUtMTUtMS0xLTE1OTU0MA_da8ad497-050f-4202-83f7-ba8bfce436f5"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfMjAtMTUtMS0xLTE1OTU0MA_90b2c7b9-d4d4-47cb-960d-af52cb5f093c"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfMjAtMTUtMS0xLTE1OTU0MA_90b2c7b9-d4d4-47cb-960d-af52cb5f093c"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfMjItMTUtMS0xLTE1OTU0MA_30b3cfe7-2129-4339-a61e-be4bfad21855"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfMjItMTUtMS0xLTE1OTU0MA_30b3cfe7-2129-4339-a61e-be4bfad21855"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfMy0xMy0xLTEtMTU5NTQw_d1cdfdda-f62e-426c-9a0c-ebd3749b728c"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfMy0xMy0xLTEtMTU5NTQw_d1cdfdda-f62e-426c-9a0c-ebd3749b728c"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfMy0xNS0xLTEtMTU5NTQw_0c79c58d-ca29-449b-b8c0-a4ce0f3b7eda"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfMy0xNS0xLTEtMTU5NTQw_0c79c58d-ca29-449b-b8c0-a4ce0f3b7eda"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfMTYtMTMtMS0xLTE1OTU0MA_d0839666-32d6-4ae0-946a-a4c5686bf3ad"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfMTYtMTMtMS0xLTE1OTU0MA_d0839666-32d6-4ae0-946a-a4c5686bf3ad"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfMjUtMTMtMS0xLTE1OTU0MA_8ef29157-deac-4753-beeb-da0b17fe30c7"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfMjUtMTMtMS0xLTE1OTU0MA_8ef29157-deac-4753-beeb-da0b17fe30c7"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfMjEtMTUtMS0xLTE1OTU0MA_c8545f5f-37fb-4748-89c4-dbb910bf7e43"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfMjEtMTUtMS0xLTE1OTU0MA_c8545f5f-37fb-4748-89c4-dbb910bf7e43"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfMTQtMTUtMS0xLTE1OTU0MA_47aac1d5-32f2-4222-a223-a804ecf08662"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfMTQtMTUtMS0xLTE1OTU0MA_47aac1d5-32f2-4222-a223-a804ecf08662"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfMjAtMTMtMS0xLTE1OTU0MA_72afa8cd-b258-4119-8087-814775c285dd"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfMjAtMTMtMS0xLTE1OTU0MA_72afa8cd-b258-4119-8087-814775c285dd"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfMjEtMTMtMS0xLTE1OTU0MA_8e9af476-2a91-410a-81c3-a243861cdf43"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfMjEtMTMtMS0xLTE1OTU0MA_8e9af476-2a91-410a-81c3-a243861cdf43"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfNy0xNS0xLTEtMTU5NTQw_86de006e-c527-4c64-8afd-d972d9acad45"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfNy0xNS0xLTEtMTU5NTQw_86de006e-c527-4c64-8afd-d972d9acad45"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfOS0xNS0xLTEtMTU5NTQw_924c9fdc-7fe9-41c8-80cc-2c3895419a1d"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfOS0xNS0xLTEtMTU5NTQw_924c9fdc-7fe9-41c8-80cc-2c3895419a1d"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfMjItMTMtMS0xLTE1OTU0MA_04bc94f9-48f3-42e4-a934-3287c4031747"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfMjItMTMtMS0xLTE1OTU0MA_04bc94f9-48f3-42e4-a934-3287c4031747"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfNy0xMy0xLTEtMTU5NTQw_ac6aaddd-eafb-4ec4-accf-829f59b018fb"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfNy0xMy0xLTEtMTU5NTQw_ac6aaddd-eafb-4ec4-accf-829f59b018fb"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfMTQtMTMtMS0xLTE1OTU0MA_96786cfe-52bc-495f-97eb-53dc1ce2f278"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfMTQtMTMtMS0xLTE1OTU0MA_96786cfe-52bc-495f-97eb-53dc1ce2f278"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfOC0xNS0xLTEtMTU5NTQw_5b19ff46-59ca-42cb-8ec4-ec729fa0feac"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfOC0xNS0xLTEtMTU5NTQw_5b19ff46-59ca-42cb-8ec4-ec729fa0feac"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfOC0xMy0xLTEtMTU5NTQw_6f9cea00-98ea-47d7-83e7-d75d6037deda"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfOC0xMy0xLTEtMTU5NTQw_6f9cea00-98ea-47d7-83e7-d75d6037deda"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfOS0xMy0xLTEtMTU5NTQw_3aeef466-3c5f-4743-b85a-183e218f075e"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfOS0xMy0xLTEtMTU5NTQw_3aeef466-3c5f-4743-b85a-183e218f075e"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RleHRyZWdpb246ZTAxODE5ZTcxMTNjNGY2YzkyNjFiNDYyYzIxODNiMjFfMTY0_9553bd20-e2be-4a9d-901f-d34e31f81e7e" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RleHRyZWdpb246ZTAxODE5ZTcxMTNjNGY2YzkyNjFiNDYyYzIxODNiMjFfMTY0_9553bd20-e2be-4a9d-901f-d34e31f81e7e" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">As of September&#160;30, 2022, there was $3.25 billion remaining under our $5.00 billion share repurchase program authorized in May 2021. </link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfMTYtMTUtMS0xLTE1OTU0MA_535791d1-15b8-498e-a925-9f7eddc75751"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RleHRyZWdpb246ZTAxODE5ZTcxMTNjNGY2YzkyNjFiNDYyYzIxODNiMjFfMTY0_9553bd20-e2be-4a9d-901f-d34e31f81e7e"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfMjUtMTUtMS0xLTE1OTU0MA_da8ad497-050f-4202-83f7-ba8bfce436f5"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RleHRyZWdpb246ZTAxODE5ZTcxMTNjNGY2YzkyNjFiNDYyYzIxODNiMjFfMTY0_9553bd20-e2be-4a9d-901f-d34e31f81e7e"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfMjAtMTUtMS0xLTE1OTU0MA_90b2c7b9-d4d4-47cb-960d-af52cb5f093c"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RleHRyZWdpb246ZTAxODE5ZTcxMTNjNGY2YzkyNjFiNDYyYzIxODNiMjFfMTY0_9553bd20-e2be-4a9d-901f-d34e31f81e7e"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfMjItMTUtMS0xLTE1OTU0MA_30b3cfe7-2129-4339-a61e-be4bfad21855"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RleHRyZWdpb246ZTAxODE5ZTcxMTNjNGY2YzkyNjFiNDYyYzIxODNiMjFfMTY0_9553bd20-e2be-4a9d-901f-d34e31f81e7e"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfMy0xMy0xLTEtMTU5NTQw_d1cdfdda-f62e-426c-9a0c-ebd3749b728c"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RleHRyZWdpb246ZTAxODE5ZTcxMTNjNGY2YzkyNjFiNDYyYzIxODNiMjFfMTY0_9553bd20-e2be-4a9d-901f-d34e31f81e7e"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfMy0xNS0xLTEtMTU5NTQw_0c79c58d-ca29-449b-b8c0-a4ce0f3b7eda"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RleHRyZWdpb246ZTAxODE5ZTcxMTNjNGY2YzkyNjFiNDYyYzIxODNiMjFfMTY0_9553bd20-e2be-4a9d-901f-d34e31f81e7e"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfMTYtMTMtMS0xLTE1OTU0MA_d0839666-32d6-4ae0-946a-a4c5686bf3ad"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RleHRyZWdpb246ZTAxODE5ZTcxMTNjNGY2YzkyNjFiNDYyYzIxODNiMjFfMTY0_9553bd20-e2be-4a9d-901f-d34e31f81e7e"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfMjUtMTMtMS0xLTE1OTU0MA_8ef29157-deac-4753-beeb-da0b17fe30c7"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RleHRyZWdpb246ZTAxODE5ZTcxMTNjNGY2YzkyNjFiNDYyYzIxODNiMjFfMTY0_9553bd20-e2be-4a9d-901f-d34e31f81e7e"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfMjEtMTUtMS0xLTE1OTU0MA_c8545f5f-37fb-4748-89c4-dbb910bf7e43"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RleHRyZWdpb246ZTAxODE5ZTcxMTNjNGY2YzkyNjFiNDYyYzIxODNiMjFfMTY0_9553bd20-e2be-4a9d-901f-d34e31f81e7e"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfMTQtMTUtMS0xLTE1OTU0MA_47aac1d5-32f2-4222-a223-a804ecf08662"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RleHRyZWdpb246ZTAxODE5ZTcxMTNjNGY2YzkyNjFiNDYyYzIxODNiMjFfMTY0_9553bd20-e2be-4a9d-901f-d34e31f81e7e"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfMjAtMTMtMS0xLTE1OTU0MA_72afa8cd-b258-4119-8087-814775c285dd"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RleHRyZWdpb246ZTAxODE5ZTcxMTNjNGY2YzkyNjFiNDYyYzIxODNiMjFfMTY0_9553bd20-e2be-4a9d-901f-d34e31f81e7e"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfMjEtMTMtMS0xLTE1OTU0MA_8e9af476-2a91-410a-81c3-a243861cdf43"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RleHRyZWdpb246ZTAxODE5ZTcxMTNjNGY2YzkyNjFiNDYyYzIxODNiMjFfMTY0_9553bd20-e2be-4a9d-901f-d34e31f81e7e"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfNy0xNS0xLTEtMTU5NTQw_86de006e-c527-4c64-8afd-d972d9acad45"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RleHRyZWdpb246ZTAxODE5ZTcxMTNjNGY2YzkyNjFiNDYyYzIxODNiMjFfMTY0_9553bd20-e2be-4a9d-901f-d34e31f81e7e"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfOS0xNS0xLTEtMTU5NTQw_924c9fdc-7fe9-41c8-80cc-2c3895419a1d"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RleHRyZWdpb246ZTAxODE5ZTcxMTNjNGY2YzkyNjFiNDYyYzIxODNiMjFfMTY0_9553bd20-e2be-4a9d-901f-d34e31f81e7e"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfMjItMTMtMS0xLTE1OTU0MA_04bc94f9-48f3-42e4-a934-3287c4031747"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RleHRyZWdpb246ZTAxODE5ZTcxMTNjNGY2YzkyNjFiNDYyYzIxODNiMjFfMTY0_9553bd20-e2be-4a9d-901f-d34e31f81e7e"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfNy0xMy0xLTEtMTU5NTQw_ac6aaddd-eafb-4ec4-accf-829f59b018fb"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RleHRyZWdpb246ZTAxODE5ZTcxMTNjNGY2YzkyNjFiNDYyYzIxODNiMjFfMTY0_9553bd20-e2be-4a9d-901f-d34e31f81e7e"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfMTQtMTMtMS0xLTE1OTU0MA_96786cfe-52bc-495f-97eb-53dc1ce2f278"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RleHRyZWdpb246ZTAxODE5ZTcxMTNjNGY2YzkyNjFiNDYyYzIxODNiMjFfMTY0_9553bd20-e2be-4a9d-901f-d34e31f81e7e"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfOC0xNS0xLTEtMTU5NTQw_5b19ff46-59ca-42cb-8ec4-ec729fa0feac"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RleHRyZWdpb246ZTAxODE5ZTcxMTNjNGY2YzkyNjFiNDYyYzIxODNiMjFfMTY0_9553bd20-e2be-4a9d-901f-d34e31f81e7e"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfOC0xMy0xLTEtMTU5NTQw_6f9cea00-98ea-47d7-83e7-d75d6037deda"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RleHRyZWdpb246ZTAxODE5ZTcxMTNjNGY2YzkyNjFiNDYyYzIxODNiMjFfMTY0_9553bd20-e2be-4a9d-901f-d34e31f81e7e"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RhYmxlOjZjMDVjYzRiNTlkODQ4Mjg5ODE1ODYwOWFmZTI2M2I2L3RhYmxlcmFuZ2U6NmMwNWNjNGI1OWQ4NDgyODk4MTU4NjA5YWZlMjYzYjZfOS0xMy0xLTEtMTU5NTQw_3aeef466-3c5f-4743-b85a-183e218f075e"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjVmZWQ0ODNkOWM3ZTRmM2NiYmEzYTYyYzUzMjI2Y2Q3L3NlYzo1ZmVkNDgzZDljN2U0ZjNjYmJhM2E2MmM1MzIyNmNkN18zMS9mcmFnOmUwMTgxOWU3MTEzYzRmNmM5MjYxYjQ2MmMyMTgzYjIxL3RleHRyZWdpb246ZTAxODE5ZTcxMTNjNGY2YzkyNjFiNDYyYzIxODNiMjFfMTY0_9553bd20-e2be-4a9d-901f-d34e31f81e7e"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>70
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MG_]&UH$BR9O2HF[^1\^KUX;A $V7-:?ENK'8@C*O5G^SEW5';#7 HY8&>-T
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M+IV!,\G8(T%GTRD1((&9K9#:M007EH25)>%.EG139D6!SI>U>+K6CEL#I_5
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MMO*J^5+2G$A>UI\"[KB4/*\/=XPFK-( ]?L]5\:K/=$WZ+Y7;?X%4$L#!!0
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MFSTH$J^&C&HC6:EOT3F3<"?K90IS&>'* -XO&'18O5$.FDDO^@-02P,$%
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M&A]IZ\S"F5D2P<J205GB57:CQ)X7.1+?]S;&-NUL2SN@D-#$$4IBAM?ID5#
M+*3!>D%J.DA-O5+_D)J7ACY=<.2+P3%UIS".:.JH!.P2%I*EN<;!"*_@Y&R_
M)"STW<S'*6:3<>KIX]I1@LG2>.()9;%7Z'^ES!\--4%Q&%B4*7;%86!5IF1!
MVHA [,5.OZ>+6O/ZOK![NHU4H%#B"(UM>#W>/9!=E$X7[USJB##L9]BUN!-F
M3>9(\^^>9=GW,IMMFC G1D)V+$DG=G.=([>P'UPWRJ392C^U6]RB=F^7Z$B
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M:X,"HR^6:5'^C^YK66^"XGVA958O!@29R*N_[*%V1&<!Z'$O(/4"<KS 'UA
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M@\D>W-4664"F!"^["58!=LA%WG*V< ->-( 7S[CW3B/^8%)J+XJM24B4RJ)
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MB\"QJCJ+K&ZTW)7'>7=2:YF5EUO.$JZ, /R^EK!7J&_,"YH3X=5_4$L#!!0
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MWW\_42%_],L/R;?RH6WI4_*-_&0ZI, 'L,^S9?_ "H8OKV?_ 5!+ P04
M"  %6F%5_Q*Q":(-  ! )   &0   'AL+W=O<FMS:&5E=',O<VAE970Q,"YX
M;6SM6FN/V\BQ_2N-R2*P 4;#[N9SUC8P?B39(&LO_-@$-\@'2NJ1N*%(A0^/
MM;\^YU23E&8\'H\7N??3_6":;'97U^-4U6F.GEPW[;^ZK7.]^K2KZN[IV;;O
M]Q?GY]UJZW9%MVCVKL:;JZ;=%3T>V\UYMV]=L99%N^K<A&%ROBO*^NS9$QG[
MJ7WVI!GZJJS=3ZWJAMVN: _/7=5</SW39]/ VW*S[3EP_NS)OMBX=Z[_L/^I
MQ=/Y+&5=[ES=E4VM6G?U].Q27SR/.%\F_%RZZ^[D7M&29=/\BP\_K)^>A53(
M56[54T*!_SZZ%ZZJ* AJ_'N4>39OR86G]Y/T/XKML&59=.Y%4_VM7/?;IV?9
MF5J[JV*H^K?-]9_=:$],>:NFZN2JKOW<*#U3JZ'KF]VX&!KLRMK_7WP:_7"R
M( N_L,","XSH[3<2+5\6??'L2=M<JY:S(8TW8JJLAG)ES:"\ZUN\+;&N?_;6
M?73UX)Z<]Q#&H?/5N/"Y7VB^L#!7/S9UO^W4JWKMUC?7GT.)61,S:?+<W"OP
MG=LOE T#94)C[I%G9\NLR+/W6Z:NVF:G7D#7%@B =_NM>B%^=:WZQ^6RD_%_
MWN4 +S^Z6SZSY:+;%ROW] SIT+GVHSM[]OO?Z23\_A[MHUG[Z#[I]\7E00O5
M^RU,;RHD75EO5%\L*S=F7OFKZU0SM,@I/[5UJV938WBMREK>K)JZ:ZIR7?08
MP\,:68B[KL< ,K+'^BN%PM 63*WN KNUSMU A$(\,7D)+S.HKZ'F?>\9=%[T
MR=UKU*1]VZP'Q&W2]3N5!%KG"^/OLGP1XD[G@3;6WV9!G.:+&"&OJF+9>!55
M4:]5TV_=T>I'^K'*C%E$*L[L(E,&<I-%HG206DI]>[)C'FF\X5V:&LS]3AD=
M&$SCH D#JS/L2(E?V[7HNF95BE\%BONV;%H%3Y;-6@&*=7?E6G%O6?>H52A>
M0U'1#9C3']1UT:GO(KNP* 95->WQG;;A(I^'UD,K00<$>@D,Y]2,P,Y'P'TA
M @'T[/9.*F5U"+SLQ"ST[=V2DZ'?NIN^N=M"_>T$BK/#X"!BMCKX1.ZO&[4N
MK^ DP%#UA[T39ZW&_.Z"&3%=4>%=WXQ5E%Y]5'^.J,>B[NHT;-U)W(H6,=EX
MT"]F3)QDC&CUH.6(Z*H:UF/R==NB=50=^ER5>.O-@Q-O"D,0.G4-)/#_MCD4
M55\ZC Y[+( +N!<BX6 C/+XO#GZO:U'2P;-J@/M;2N[<'0Y;(#!.O6YZIR(4
M#*B\7I?<&:@K:]_U?0.N!+5PJ*\0#W+8U])A77:KJF%MP2SH.KN(CFA/*S@'
M_E*TZ[*H5TZASJ;1]R+P?5O\@LV*:>RJ@#M*;^48ZXY 0YLF3$789Q;X9'S>
MN"VQ# 5_P+7:NG(G*@Y=YXNC]Q-\-J!Q%'5?%A60B0MW\SJ3"='AXN3[K2^[
M4[?.(0%5635#S6$)2'?R2O2<$;U0E^M?\.!C#AD30&\-PZU@;)V[J^1#?#'Z
M1W3>,GP$JP*FD'L]'J@&?;9K.B16B957Y0KFJP]U237?]3+MT8?%N\7C,?-:
MUP\M\=NZ)=_Z:D)OTK9.566Q1*!0TY9%Q:#Z;>:0==MRO_=>1W_]6#9#-]9)
MHANY8_FX8AF VMSY")BF/2E'7ZEYHA84)N:*6NDO2CVI<P^II2+WVXOBXLA5
M_CIZB&!^X[NR?U&=O!@C)["^46VNMW02ZL"V^#@7@_54(>C68OU1DHF)XEI)
M=3[.]>*XH42N47733QGZL"##F".<[E2?17#C:C ))M(:;@9<73FF"73>2R!.
MBM*D]5SJ1FS>;\+B:X3H,^V.N+RX*[HOH9P?T3YPQ[B=V@=Z8 VX ?Y''TW4
MR]_:FF7BU#6_U(7N<G WE::EVY1US=WG6C5U7W5P12O<@B%FSK>H;,=^YSYQ
MHB]3R]N$D:*N!N# W:^&W]*7N]-@-<NJW$Q]I"6R^K*[*BG<ZW-K]TD]@7!]
M4.Q[U'^A7I9=L=FTSDNCF0]DPY-'EX>9'GQ[#6%P'L"$C_Q6JLN;H>]*Y),\
MO&]ZV/6E\=&8W_\N,]I\#V<,=7%U!0][FCXUA0OXH5BZGL!]WPY5N2*8Q^X(
M@AQ$8*L6=Q&0*90YR.(0/)AW)M1R9_-,>*X.DC $V3NV7K)<&Y-N&L^>4[)1
M@\IEE$[(S&U.:7\>=D75;*:-'YG'RD091&D1'44I-K>X8C$(>Z02DRQ2+H/*
M];2,$F.59'AC;,8M<HNY<C$9%SPO$/0*\)U6F CB$[\3SP1:1YB6^@&R]Q]1
MFWXIVF9:D5,'Z(RI&6]'!W_V_QNI2NO1N0I*IRJ/N"RE.DDLFQDJF:88\%&;
MYYL@RC(Y8&!7VAXD4A)P\(A$ST!;#25M8/!>JS<U^$.S.5RHGUW[JZO+6>%(
MTT1@"$%(= HU=,ZSB+8Q1BRN./X<VF+WZ\R*8%BL=!1Q/TM"GU&$3JB0B:G^
MJW99]L.GHQL3N$+3\5R6BQM#;,I1&^%Z696[(^U**#H6H9K1-/ J'!'GC'7,
M6+\_?#STT_3)IVF"]W*91K2):8I<O<>;T1$ %K' $.J0T(.AEFY'8$/JY1T^
M3T]A:*KB)!2GFYPX3>6@E*1<B4P(>9#Y8;<;ZM'5[\&O?YW]G/-@J#-.2A#N
M7$7&AY="8KQ%E*IA5Y(*33BWP#D#HQ./*+D7F, \BL">^6A9.>\\FV^A+/]-
MSW0]_WG;3A;$FNBW$5&8)0D!B!%D7R8Q"\*0RUZ[H6VZ5>F0NA?JU6Y35"?5
MP,<T9N@(A5CE8B037D=4_W\.X%Z?CBC"D& ]8Y701*W?#54C!>1V:)E'2*1P
M7DPE$L:!$&!4(5KJCO= ?:(?=, XP(8@,V:&>1OSY V Q*,';BZ(8B:"8;99
M*&9&B-N0*1"A2AF_SX5Z\>;G'U[^0>>*K'W9K-F4'D4H95ERXFW_9#27:[E+
MH? ?F[9WS=%I- =XCR3/"3XF7ZY9R4(BXP6Z$WK7[#1.D2R%W%0]@C&/X814
M7!C.8)!;RQD)E;#,OY@PSU@O1VS+S-AFLA<=G$9TFA4_FTPTL]SK^/DB"HA:
M30H2Q)*;IY\T;)!GXW>,(,VL-(;I,\?K@5VK0\<]2",&"YLH6HL:ND8O74@_
M.':'^6@S'>3^5!T^%;ME.7DC4.\.K+[KPW'$'^/*&Z-_?[N0GC&UD<\$EW4G
MC0*>1L]>2.+-R?C9;$]7V=27Z/GHB&5=+LGX>W^8V!7HM?NA[08NAX&OT$I!
M3%<']0'GILNAWS;@"IY8/'KUX?(Q>6=7XJQ9D*EN!A";IL59\'0F"# Q=A?V
M;O)HK]@.?+/\B#/7$J[>0<,.3(='M H<)[AC$OS&UN+N6-,W&T>P>._*4K?L
M7=4<EW[!\ ^7W0-M^^VLZIL8[\4W?#W\/^54S"V=F)$ZV4A+EL5!'%JA_#:(
M$N8SWVKCCP%1$&?D,1.NY3-DS#*6Q"SB&CEJI#F%(3]#9I%_RF+6EQ,:AMS(
MK!;>9&1=A#;.=L=F&N7,>,B(,]2%B5/%B1&JQKZ59C'76FIJ<G;/W+#;S73*
M6O8"HUE\XIA5/C*>Z26B+)O$S*18 G,E'=:$K,,/Y% Z9YLW4M^C5'IK1H_9
MD,R(?,G>IE$IC")+@W,M2Y@.P:OHJ20PF>=5E(>"'/C6?P>/0CA0J&-P5^E'
M ?D V$M&I]G$"J]C2"8294!C+/@R:4^2LSV;A.4YRGE-$X9VI$-13L%&Q"<Y
M$9%K#=^DPD*QE:%N$]FRB6;+8RN(0AIK8Q;O*)8V3$4FUN3=9ZPT/+G./2MB
MF_/76X2)7%@+@8EQ3J4S,LHDJ<Z%]B6W.9,)2!\C\0G;0A2$FKS6R,D@)5E%
MGX*&F$?8?<Z=P+0T@Q<GVG]-!YDUA&+*YY%2(33<9:[7+-XZ% II"*Q$>K^Q
MB02)XC(@3'].FX2JF/D2"P402--WMSD3DE2G/KER_\T_TEJHMQ5L8SR3DPV8
M(;7^ GNR<$$F5 -A2[FGU<PCLE(#=DX$3\S)D),9H>0F$0]*[TZ\DD9 -M(F
M(P>(G" SFH"S3,LH)JBCC,-W<*:$7$I';/PFI-,R,4@6<=OP+MX417R=:C)1
MY$)"FUD^ -;4PS0R)!=?X4XZR(4)C]#.,UJ91V3I1@YS/.K0_I$0F5@. YP=
M93PC/L*6C\$1-6N,98T9J19=!1#F6I*!/),^UW >TX-GGE&Y\;3AB:6)>/[(
M"1J=B!N3\!9U KY3'H723+@R;)>$",@>B0-C)'T#DOOXA$1I&\0H-ZS@:9"&
MF>=3QS\":22,C64T"Y+,2D^8_S+T8"+U<+9C'L2ZCFSK%LL2>O5?9DP?+O^?
M$WT#)]JX9M,6^VVYXE?-UA7_2W]&?2#%$?Q=>&YT>F@X'A!.<F"&^ZN!?YD4
MIN'92YCSDP)ZL'R&L>AW7/R78E_42'IF;YS'ON3&([.QK)HOMF5=H(M9:87R
ME2%@/96DS.+YP(BHN7+#K\E#W;=$32+'R223KPY!:')IZ;E-;IR"'OI'W >G
MZMOC'W&*'IHLA_$3I?_L/&G'GXRLT5]EN&I6\Z=)F38Z?W'7+P;.3W[5(8<1
M_G:E\Z+]#SSFT?GG,9?^5R''Z?ZW-3\6[0851%7N"DO1O^,SU?K?J_B'OMG+
M;T2630^%Y';KD 4M)^#]5=/TTP,WF'\T].P_4$L#!!0    (  5:8554*A<S
M5PP  ) X   9    >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;.U;6W/;-A;^
M*QBMIVO-R+K9<IPT\8R<U%EOF];C7/JPLP\0"4E8DP0+@%;47[_?.0 I2I'=
MI-V'?=!+8I+  <[M.]\!1B]7QMZ[I5)>?,ZSPKWJ++TO7PP&+EFJ7+J^*56!
M+W-C<^GQ:!<#5UHE4YZ49X/Q<'@^R*4N.I<O^=VMO7QI*I_I0MU:X:H\EW9]
MI3*S>M49=>H7=WJQ]/1B</FRE OU7OF/Y:W%TZ"1DNI<%4Z;0E@U?]69CEY<
M36@\#_BDU<JU_A:DR<R8>WJX25]UAK0AE:G$DP2)_Q[4:Y5E) C;^"W*[#1+
MTL3VW[7T:]8=NLRD4Z]-]JM._?)5YZ(C4C675>;OS.H?*NK#&TQ,YOA?L0IC
M)V<=D53.FSQ.Q@YR783_Y>=HA]:$B^$C$\9QPICW'1;B7;Z17EZ^M&8E+(V&
M-/J#5>79V)PNR"GOO<57C7G^<IK\5FFGR4+NY<!#(KT?)''V59@]?F3V<_'.
M%'[IQ ]%JM+M^0/LI-G.N-[.U?A)@>]5V1>GPYX8#\?C)^2=-NJ=LKS31^1=
M50YOG!.O33[3A0R14*1BZAPBOJ6]^-=TYKQ%E/Q[GQW",F?[EZ',>>%*F:A7
M':2&4_9!=2Z_^]OH?/C]$TJ<-4J</27]#WWT];/%KTJH8H%L$[H0#])J4SE!
MJ>V$F8M9;:U4/2!=2R2?#WF#Z<H);S![*8M$"5-945J35HD7I2X5K=J#T"2K
M4ETL,&NS:D\@2C,Y,U;&9UT\*.=)/![('9E.*-%IHK6R6"C^UA<W!>8614SA
ME?9+X9<P\-:P7MB-M+Y0UB$[UF)&>GKM,Y72KN>5KZP2UJQEQII@S8&QD)WG
MRB9:9LBM#%LR4)^S/!58STF\$VYIJBRMM74D6Y9X>L"@^980_7L38"1]GTCL
M'@"8)+#RO,I(Z,*2Q6%]R"E-5:2P\]*::L&J;KD"HVDBF^6?LJB HI0HHYY8
M*9Z>*4\*8UK+_B3[UJH'J3/Q8:FL+%7E=>(@)>F+X_BIV\='C;5A5R?9WG -
M@J.RD&=%JAW@B+28$9)3_$RWUY"BSC;L!S-EDD ='ZU$+S8!EK32$2I#_NZF
M<^67)F6Y00Z"HR\^QK'8:!C0"Q,IFUV8;[%@""DYTUD(7'RO<KQ?*8H"E1B;
MTBA/D[7%&U<J+@]B+O'\(+.*9]'RNQM+I>?LH9A#;#J3:7J5TD.*("9]H5K!
M4>4\/L58_L#>],KFM>:0C@#1.4_?K(S]1#UR6<@0Y!3%N;Q'\.A%H><ZD7A7
M3^9X#DJ6G&%A,?4YB:%%.I25398(0T21I@1^B$9OK=O6EI8O )'!M/#HDFR'
MP$>JREF&9(<PQ((J6@9U8F%,NM)9%G8 PZ(Z\A9 (V+ZAV6TV[(J'@-X0,RW
M&U?,K<E#NI!W.&@:V7U"/9DYTXJ/$"]8J)U>JZ5.ED 6]630[Q8.&/MC"0V4
MI,F;]R$R$^-@PRPS":OA6YNXN;W[3N;E]V]8>6!(JC$F6\-O95!5SZ.,  QL
M\0(2,@01A1#%:T"VRJF^>%?C#;!PS1J96:87T>HP;V5I7?@?^8B=6+6H,ND-
M4"0 &FQJ=I8D:S3[00P$!(/1*"2M7BR49=0N6FN1;.R 1S88*$R"]1T[@P(&
M4?P[>>)+:U LM]VR$8'XM0O% 71T/NZ?T:>LKNA'Y^<7K5>$.;0!8*E2/*
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M%T$EAH@8(JE*")[7.[ZZZ)_"&U0:R-.<B8)(1+99(JQPT2,>$*"_-+KPVVL
M^Q"NS#S1TM; NB$B*OJZ+IT('BY)VWE7&D^!BO1;4TU12+.3W*1ZOB8_3J>?
MGI\$AHC 9Q> I!%OH<PL@:FL"+/?0E6("D7C;*@ 45ZL^>V:"M1$A&HTA\A\
MS%S!#BE8JE^SX-16"ZYP1 76N[#;@^K8-)-YJL;4UD@@A%!S3/;;)#6Q2FYP
MJZ7$.C!<F4<\(<80ZD6R-#8X+H;[W^$J"$9X:\-RN$8'K3(EO[ -Y2VZ#K"1
M;*M<\$)MXS/IN[T;#D=[['DK[;T&SRBP?+1D^/#V:CI"8/M8/1G4R?:%@0!$
MBW@K$=&!(_ L&D&KG.]9!?2D\(@!%%7+V\TY'.)*=S]O%NJ+*T/;XNUN1+(.
ML"/3Z6N)= /F)_>01'PPV+[A0 0&XAI$C 6\(3=/4Y!.3?TM#SV^?C,%X9\&
M&C1MT^:?6K1Y&FGSARW8\0S4X10'-=R%P,\)C%R[M ?6_W7$_'&J_4+\T%#D
M:Z*JGQ@+X..FS(U#/16O"<:/Q/-A?[+1:<,KCD==<0$T&HJWD:2*XW%7C,;G
M_0N@PEPQ._+R\]8.CT?#\_ZP*WYA0ECKLZU&*'''IZ/^I+M5I)F-;A-L8K4Z
MC5PX=%MQY>?#4VSD)Q3\%T&5QFK'I%(WJ-\((HBJ][#&XEUQ?#[I/^^&N<#U
M='_EA85"?29[[#$3(!"=M9Y14045("<#M:S*2!?4. Y-;D$#Y=$V%;_!$03?
M6"NP*.2?SK$'&]O1C=!@PB@O;0E\#^KT,W)$3$+D;"JV+L+A(W-Y<AG%8]UH
M;$5<R( O6XO">*0*%5/> O,U^!F4IS0,G62^9@/GD1%%]L^X%GEO",6(='6A
M:+P0.@VBXP7G"/%@%#FXF\?N[X;^'%'E@1SUTH,#S"I?KUBS!TF)">W::S&,
M@*^@,-3E")Y1 !;/?1>F$]9G($#)NNG6^Y!I^)1(MGT1VQ$?FL"&*O*Z.RY(
M=<HCEQ(%2PK*9DL=',4("(YYLN%KM7G_ \N-^GM:N#]".-I=N_$.,=P^XQ)I
MQ8T0[>>;_(=<YU,22^=7:SJGY,;KV'5[\;1F343MR_-*/GD5MTS989<WK1+X
M2&;_$/HX<:7-.RA6T&3X,N'C('B#SX-NJ3LD1+E3W%Y\,J',7:N9K;N*,>5)
MZRP D#(:#0&L=WJALAVQ0$<6?#>9 !@DY2NL8>P)11Z=MY+9'+61:D">-&2^
M$^2-!U,0*,ZDX$@<W]W<_@B]=+'4,XWYO<;_#;L"G(*'A,X7!*+R!FUU5838
M0.1F$AYE]EF3)O&..0TG4C#E#0K"!*H@C1+-N0]SN03%/%&U*K?-@G2*JA_,
M#F4CI@+=:14Z& &[;;=D)/JDH2ZCX3.@/GF,8K"LW;E][ ?NQ95?MP^EZJ,.
MKIJ;XU!6UJHX*53GO6+CU)Q/*-(':@W2=F0C>+X\]ME[)$OIL7O@J%#:8B0@
MJ&UI:NK!7[I<(N)Q7 S4^H0KWSW&X(/G()!;MKJ[:_6*36O%W815?$0];_JQ
M>$K"QQ8.>%W<A_5:I[&-.2K"QI-X;P2XNKTY_5%\][?G9Y/O-\'7U#^G"*CV
M%D!RF:UAM6D,(B/<!F'JR_<HN#DMJ@\JJ1EVX>PF4;0[]'6U=GOL!M759W3U
M,%*L:?A\@AJF-IW,U'%24FF*-G"M/L:Q*NT#FW@*PXW^Z2E1EN9DA"3M/[GY
M1G3$K@KB''2K&#K=QM.M0_5&S6]W:/0GU6JJ2W3"E40Z@JZRKD^[AU4%RB/3
MP'8MV*OP5CWXDY6]_\35T:2Y.IK\I:NCKY]]N#HZ7!T=KHX.5T>'JZ/#U='A
MZNAP=72X.CI<'1VNC@Y71X>KH\/5T>'JZ'!U=+@Z.EP=':Z.#E='AZNCP]71
MX>KH<'5TN#KZ?[LZ&K1^)98K^(%^"^?"44#XP5CSMOFYW33\RFPS//Q6#]"W
M0.N#:C_'U&'_V:03 JQ^\*;DWYS-C/<FYS^7:,24I0'X/C? P?A "S0_0KS\
M+U!+ P04    "  %6F%5'\:7O9X-  "C+0  &0   'AL+W=O<FMS:&5E=',O
M<VAE970Q,BYX;6SM6MERVT86_94NC6I&JJ(A+EH=VU7RDL29.'993CQ54_/0
M )I$VP":[@9$,U\_Y][&2H*4O&2>YD7"TGWWY=PF'JV,_>@2I0KQ.4MS]_@@
M*8KEPY,3%R4JDRXP2Y7CS=S83!:XM8L3M[1*QKPI2T^FX_'Y229U?O#D$3][
M8Y\\,F61ZER]L<*562;M^JE*S>KQP>2@?O!6+Y*"'IP\>;24"W6CBM^7;RSN
M3AHJL<Y4[K3)A57SQP?7DX=/3VD]+_A#JY7K7 O2)#3F(]V\C!\?C$D@E:JH
M( H2_V[5,Y6F1 AB?*IH'C0L:6/WNJ;^(^L.74+IU#.3OM=QD3P^N#P0L9K+
M,BW>FM7/JM+GC.A%)G7\5ZRJM>,#$96N,%FU&1)D.O?_Y>?*#O?9,*TV3%EN
MSXBE?"X+^>21-2MA:36HT06KRKLAG,[)*3>%Q5N-?<43:)/*T%A)-G)"YK%X
M723*BFMK9;Y0L'_A'IT48$4;3J**[%-/=KJ#[)5X9?(B<>)%'JNXO_\$(C9R
M3FLYGT[W$KQ1RT#,QB,Q'4^G>^C-&KUG3&^V@]YKNY"Y_I/5'HEGT-VD.I8^
M4F"$-U8YJ.X?F+GX4><RC[1,Q0T>>K.(?U^'KK (K/\,6<@+<#HL "7;0[>4
MD7I\L"1>]E8=//G[WR;GXQ_VJ'?:J'>ZC_K7N_4[D!7O%2Q6J%S@#N]T7A@1
MM3MO%6\TO-'I3*?2"MDE@/6QND7!6/+*R&29LF1\_:<2L2T7(L)S<I=R@7C6
M)TUIK@NM'-)D#>916L9*D(FEC1(F6!$G9B.LLA]5H?,%OT*]2.GZR&^DRZ4U
MF2&%X?P.=5J]3-9.0[ <) NI:><Q4<S+.5:6%O<CSU$C4'18$IE O$L@35]E
M;S"K/I7:*B1ZJI#Z.18YL8)(]-^:M4R+M3"61)KKXH%+)!8OY9IIC&"HG!3!
MC2B7B%M86)@H*JU5>41.$9&RD#,7\Q+2*0$[$'/(_5'%9';:X<HH4HY$XEOI
M''J#SOM6Z\BE/J-#.#*QSL+2NDJC.<S&LE;BU>2C;@SAK2UR90-QHY3XS11*
M3 5:C9"9*;U=-C:TH6-)^I+X1F:!7(8&S+-@ZQ;KI>+M73,'XO52$2&XM1+;
M,;O(.#"#S\E6\"O4*"7,Z&7>=!99W:JEL076:K:S)GG<4G&3:4Q"^2,TRL5(
MY# B29.O6XO$D!X<C-VT';WP]BOML,'@[94N$G)6LKD[5*1?QRRR8,L7Z*9\
M03366(;$(AN%J5[(P@< 9 O$"PFB?;;:B3+7GR 7],TE18^/;)(P,S"(T^ V
MUQ&9;<M:B'\T,P<>(>& 0#PU*J'T@!]?XF\*"V;BN9:A0DZ+7IVA>D*<!K<D
MDG)>+%(34GHNK&*NI,H'@\J3KO>4$BG(AW-4?D.^B6OV6+5$^,547#AYB$Q5
M26J';X8EE!P2\!^PKX5D#6VD;EQ&A7LH?I$63Y&8(_%3NOXLLU"/Q,TZ_X#G
MZY%X9S5?B7^]I1OY@=J1M_DO=(D8@9+H&!>G/W33D1P"G *>.G<E(G DGN)V
M@2H;##(BBAUFK,JFLHVLM?QB+E&D$"L=6;3;VE?+O;7M94[5*J^P&8<RK;=J
M4::R,'8MY!)[;F7*2=RQ5=\4M6HUP]^#FV D7I06L+4REEQ*V* MJ4WZ91*-
M@;*_U<[;HI)YI6")2"YUP>$2DW414HAL':958?1]@$SFLPYURQ:\F)N>XZ2'
M,Y3ST@R(@415*!HQB]+HP\PIAVWL.5-Q)ZR!HB)#M)JF">UDOK=L<A=JQ4%@
M^M9 =+![ATD&>276E(MDNPJB^6>H&C&8;B4,RE>BHV2$[$2IY#YK*"10].W:
M5\0%+T-0H;>"$DIIS  \%E5K2ZG_<ZISDR-+'\EC9#50.:_.RRQ4_'R-YD^5
M/D7Q(5ZI+'/4.$(0(W$4'C,]5&UM&\3G1?:% ,XJN.U!L*-H:'4'191%8FP%
M+;$*">$(,ZSOL'CC^7TV!OJ]\G0*23'(U;2:J+#0L634:CILNA',B5:YJ&[(
M.US-F:I]#ZV+%J\88 &#*VZ<F_1;I9@.4#R:(?FDAO),\3DRP#^=\-/)0_$;
M&+QJ&3SKZ'#TO.)V+(XFQT,TM^AU=#P4D^DDF-+_V7DP:?4]OPK.Q>5E<-8*
M?329G04S8G-ZY?\?P_::4G;IYP-O\!JL% DZ+7>D4 '-=0U_%#="UR!%N )]
MV(>:=AOYVDDJP.BX#DB/.AB5*JM-W.(*%J&-F$!@:-U;NI&!>_JJAY: HS)%
M[V,@F2\,,>[ P*V6ZF6OP11ORZ@&=K&!SY2J'*[J&L=MBW5KL^^^G @;[X#W
M#1+CVEOGZ*B&^5X(&:.X$$"77? VZI0RZECO55VI46$:+)ZS [C D]@[($"3
M/W<8A<5I@)OW>,5);D;(0$4?]"1""X;015H!/$.5C 991! ?ZG!H-)"T6X[K
M3&_4VQ=//]!;JT 2IB-O-@BY!NK]5DO364@V!0VJ[&N/C?>+MZ)]'VE76B-6
M3IY->/&N8[FFOX)%Z?I;=ZO#\@%]&!(2L,8JWWHL3%3?](RU2A1[HS78G#-P
M2SKJ"<J3FB.[JAI>3V9(?.42DQ+X?,^:<QT=\NR.,.S!B XLJB*X3K8V9NNU
MWI@VYOF T85CLK7XM1];M%:Q[R.J7>+VP4P'&7EWM<W9M[9.4]N>@O9.@=^C
MR0WIO8=%;<.'4 4C2._T:Z-#_48SX9[WW,&X:;57W?9U=C$+9O@_NQH'I]3&
M1J=GL^""K\9GE\%5Z]#)U2P8X^\TN!1G>'4ASL_&W9XW&<_PZHKZX)373B^N
M0.!U6F::RA(BIAJP5L:F\4K'---&347=<$HS?;%Y7N;1&O/\,V.7]8HC_^RX
M0G]DX5O0=)27]ZOXEDY9^2PA1'!$0,&Y#D<BQ+S)H47XQ"(*N:!RJ-7*^%K?
M'(!PM#W@'E(->Z,J81'!R.^"A4!8Z'R>2H2B'TJH792%T5E6YCS64B7P(?/L
M]1\OGS^87 6UYHGT6K',)'+=/Y!<*'O OJ:D2(_U0A?;R40UI;%ZF]X^] CZ
M"AJR*6'*)5&?CJEFPCG%W1)(>"N.=76JU53*'CV&V*A,!;#,3FD&359;P@.B
MJMQ)0=F"AD?7"X0*G3D,TFQ*H"\,;5A%*)>>96,D7],A;:4QAC*#>"GJ'*W]
MW3N\JDZX'OAIHITY?8BP$-6[%N-^\<C:)-%=DVEG=I=1HB%H;4<Y+,O@,(OE
MA[/9&#F,EVE=(P^GY]U']YQHOPBK]W'2Z-[S< _B\JC8#%V=HA(, NZHS,CF
M',EW8^^O!=Q*\ME:'W$'XGJ'>49U#!+B2K4W:2?G?%8=3L9=CY"7VT1LO,DB
MEXP76T2T*S!W]/6V\+5GV<W+3O7TIN/0X/[=/?Q\\?LUX93ZE+X;Z]TQ%[7S
M^X&'RHK?!A>^L'_7MOJ+^G=3"]"D+Z?HL(?B='S._\^GI]R\+\=7Z,)-Y;R&
MRT,3DR&_J0E?A_2+I[)2/-4F-0L=.3)P((Z:-\<^-1_4YZ0$J^12E86.0+\1
MHZ[T'83.AFWPV& +Z 9?*+-4YOI69S+D':$*"[#D![[[>E@ E$_E_]YP(.BH
M>4?3O7>;Y1S9(Z\W;]5PY:+3C>L93\</?.N$$'RS(F-1_+[=%?JM&G+K]*^7
M 6U,W#L2;A+(ET@M?BESEVB*!Q=I^F&(SMO1FGXM4-R.MM_^S^*#SL?5-P<#
MTK]PY$L^E=-YRM@LT;EL3J]N"(A P.O^X/^6CQS9]3\;R/-/4_TH^$I&LO2=
MK95KP(Q1\V,!,2;<@3*(SEX)AL#XG@(%0R+L#/^MN-\*4^I&I>VG0.N206[-
M:/U%,&LORNJ>]-UKB^]<\Y+.J?:@C5V@)A!O^OW.W;/AK7H-9:C?;&+17G>F
MFZ;:=]*(<=SE>7#>QW&3X.I*A-63!G1SK^)QE9I2YIN2VM&4AH#:X71R@;:S
MP6IR^6VL)IMG9S?(!LS95#9?YA\J!-W6L#O&R-Q0&6D;V*CJ8/6;X_O]VN=:
M(70C!&*64Y$F4HHC#&* ;WO&R7?KVW4Q. P,#@)D/][2X;0#O4^F6^C]]/_@
M_7\(WJLXNP.^3\XZ/H%3OZK*[8#L/E+N":6K+P &\'.E",6>QHN-8_6%-8Y6
M6Z"5]I!V$&/XM_<X>QXZON_Q:?/ *\O"8GAOA-U4^EXH?P#9UVFV!?&9^U^$
M[[UFA^+B/+CD7YC.4+\/Q71VQO<SY/&42@86C[ESF)#:)5>8YB?"%M7/N0,-
M5"M.AIY_%\HL@,82;ATM\&EJ&B,H^,^5H5.?2H]._,^IW)CX!P</3SC_R**V
M.AYO,R(7KZ/"D 5\R_Q5A59_U'^6)-[>^:1?RW\, &3F\TSF^8-?)7!P!!\#
M=[(8/ZF</ABC'X5]?:>8:TL3+]YY<MBR_I(SQ+2C1U")\S4#1/4YU= <T9D*
MNL,">S(!"W+THCX$9*'XJ8=DVF=2G?C:U=7&PYU>?]M;W+QJ=U2VRXV#B:W3
MB*'ORS:.K'96PPY@(Z_4/(/QK,$:,)$4#H7:%\/AVCG\E5MKB>[G:SWW#GU5
M>=+Y<!;[%_QYL/.?(?AO:)NGS1?(U_[#VW:Y_WSY%=<Y!YYS;!T'%V<'/H3J
MF\(L^3/<T!2%R?@R4:B"EA;@_=Q@<*INB$'S7?:3_P)02P,$%     @ !5IA
M56V0@[W"!   PPP  !D   !X;"]W;W)K<VAE971S+W-H965T,3,N>&ULM5?;
M<MLV%/P5#)/)M#.V)-*7.(FM&=EITCRD<>U<'CI]@,@C"6,08 !0LO/UW0-0
M$MW8GB1-7VP Q#EG=[&XZ'AEW95?$ 5Q76OC3[)%",WSX="7"ZJE']B&#+[,
MK*ME0-?-A[YQ)*L85.MA,1H=#FNI3#8^CF/G;GQLVZ"5H7,G?%O7TMV<DK:K
MDRS/U@,7:KX(/# <'S=R3I<4/C3G#KWA)DNE:C)>62,<S4ZR2?[\=)_GQPD?
M%:U\KRV8R=3:*^Z\J4ZR$0,B367@#!+_EG1&6G,BP/C<Y<PV)3FPWUYG?Q6Y
M@\M4>CJS^I.JPN(D.\I$13/9ZG!A5[]3Q^> \Y56^_A7K-+<@V>9*%L?;-T%
M T&M3/HOKSL=>@%'HWL"BBZ@B+A3H8CRI0QR?.SL2CB>C6S<B%1C-, IPXMR
M&1R^*L2%\<1[K/R;NI'*0>NP(R[(!]>6H77*S'>$-)5X%Q;DQ&5#I9):G"VD
MFY,_'@;4YRS#LJMUFFH5]]1Z)MY:$Q9>_&8JJF['#X%[ [Y8@S\M'DQX2<U
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M (4D)()85I( !M +DG3HFM=%%YAG '::2@ &$2_%1F7X$4#/<L!+_54G@")
M!+,J]05QWB55LH$>0!O%F,NRS(%RE8I!4JLM? $C 3DBP*:0-'^U+?)ZLR4@
M\FR3(\I,O.M"'5!3 3*1BHD#F4# C; @:BA>B506&]7&)9+E%D'>JC06JWM
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MUZ>MGQ?U*'!*-5AD>M3#R1@OX5U-4D7EWZ0L?NNKHKCI;&'U&+!+,1E/02*
M^\""(!<N( Y Y@R!*Q?G"-@2M^: HX'+YP$8H6".?-_9/NLFPH/1'!J2;@V?
M@<Q@9_/4535OSD@VB.D<E *9PO%XCA!-EJ JSD "^BP%:HKQ CJ'J%L\0<S
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M8C3)W)2<L!B.7;')P>O7(#/Y-YX/NNDT]0_AL#I\1MSTK^>3>?\-\I:%2.U
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MU3KYG^FL:6L(R?^.44$V>3J^"2G./YNURO1/#Z 9C:XW^L'/WWYS^H^3'^Y
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M^M"*<M*"JXZ8RU;30JF#EHH.&6)%TPHHL0:3V,,0@RN-Q0>N#*[+%"2#R=+
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M@Q6!F>^#,=7GE:)@'][K,-/^'RC;;BMZE)9_V#@"IC9ZY$C0U,Z2;F%_D\B
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MKU6N*1BG:#^UM8O5BNIF:FM#"LBU]51WD"Q.6%=5ZP(>.V_AC2FO46L829@
MUO9R8;%[2$VT1GMD1<98IL$$5U>H^@[<9M:TE0/,Q+&;.))N 6Y&7EI>MQ!8
MK;$B/9J6[T.DO:#;F%YZ-+V,^LI61=]Z2Q;K_ [&57W[S>GW3W\8>?*#[0%P
M;G"HJ,/]R>].3NQB8Q5FVU;O9="A5#@W-0?*+OTV@=TGSRTI;*^>]WJ&O1 )
MP3V8^=RWGOTF 6+Q4E%_'^E-*W9[;LW+QPYY>6XRVQ$.F=DYS +X61IEWY*
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MXA^7&D%T30_@^WD%2MI?: /_5ZA^_C]02P,$%     @ !5IA53#B?#6T!P
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MQ%ZTW7/$]J+/V;/2*A#+"KUX>.O_.)T;VX(Q_WQH^\YZ_+!UJJ)#LY:Y.A[
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M "M<Y]N*KO3N W;UC!Q?H2OKG[!KL1EG++:6=-T%LU]+U=K\MCN'O8!I_$2
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M. "_7VL^M\YQ"?K?X>(/4$L#!!0    (  5:8556?S37BPD  *8:   9
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M>P5^HF:AGA_,U='!T=$>><\'J)Z+O.>/R/OH5]J:7P6.N;IP-L#98@1L"T'
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MO'XYP] H7T72172-?(D 'Z*KY2<?+9+G%_"\="[V%ZQ@^#1U^A]02P,$%
M  @ !5IA5<>U:G)6"P  21T  !D   !X;"]W;W)K<VAE971S+W-H965T,C$N
M>&UL[5EM;]O($?XK"U]P< !6YNYR^>)+##A.VLL!EQP2YUJTZ =*6LOL4:1*
M4G&47]_G&;Y(=AS'/;3]U ^FJ>7NS.S,,S//DL]NZN:W]MK[3GU:EU7[_.BZ
MZS:G)R?MXMJO\W96;WR%)U=UL\X[_&Q6)^VF\?E2%JW+$Q.&\<DZ+ZJCLV<R
M]DMS]JS>=F51^5\:U6[7Z[S9O?!E??/\2!^- ^^*U77'@9.S9YM\Y=_[[L/F
MEP:_3B8IRV+MJ[:H*]7XJ^='Y_KTA>-\F?!KX6_:@WO%G<SK^C?^>+U\?A32
M(%_Z14<).?Y]]!>^+"D(9OQSD'DTJ>3"P_M1^A]E[]C+/&_]15W^N5AVU\^/
MTB.U]%?YMNS>U3<_^F$_8N"B+ENYJIM^KHN.U&+;=O5Z6 P+UD75_\\_#7XX
M6)"&7UE@A@5&[.X5B94O\RX_>];4-ZKA;$CCC6Q55L.XHF)0WG<-GA98UYV]
M\Q]]M?7J^#*?E[Y]^NRD@U0^.UD,$E[T$LQ7)&3JY[KJKEOUJEKZY>WU)[!F
M,LF,)KTP#PI\[S<S9<- F="8!^39:8M6Y-EO;/&JJ=?J K8V@ +<W%VK"W&P
M;]3?SN>MC/_]/@?T\J/[Y3-M3MM-OO#/CY 7K6\^^J.S[[_3<?C# ]9'D_71
M0]+/WB,-E]O2J_I*+8LV7ZT:O\H%T1AI^KW=9_3#8B^OX9"Z1$X6U4IU#/Z0
MF,5GWZIZVXRR\7]1KRH,+U51R9-%7;5U62SS#F/XL422XJ[M,("$[5J:AKK1
MB)WMJ;J\;KR_A1.%*&/R'+YGJ-_ O(>>$PJ\Z(.[-RA9FZ9>;A'-T=8G*@ZT
MSF:FOTNS68@[G07:V/XV#5R2S1R 4);YO.Y-5'FU5'5W[?>[/M9/56K,+%(N
MM;-4&<B-9['206(I]=V!QBS2>,*[)#&8^T09'1A,XZ ) ZM3:*3$;VG-V[9>
M%.)7 >BF*>I&P9-%O50 :-5>^4;<6U0=2AEJVS8OZ0;,Z7;J)F_5D\C.+&I%
M68XZGF@;SK)I:+EM).B 0">!X9R*$5CW$?!?B4  .]N-ET):[H)>=FQF^JZV
M^&#H]VK3M[7-U#<@.[IPOIM0@9YUH/<;FQ.[J/<1<-V#\,/L_4R]W79ML?3]
MC\NZ0T2^-C[ YOOO4J/-#UVMME5^=564?<P70SU"RKPL\KGO/).GV9;%HD!T
M4522Z >B.(@ *8N[R)H>UT'J0H"5=R;4<F>S5,"H@S@,$9&?\F99Y-6B![=U
MQ(3I(9X0,L9H)(Z.F3XVH[0?M^N\K%>CXF/S5)DHA2@MHJ,H@7*+*Q8CJR(5
MFWB6<!E,KL9EE.A4G.*)L2E59!9SY6)2+GB1H["5>3.M,!'$Q[TF)J[6$:8E
M_0!3[.=Z6_TC;^IQ148;8#.FIKP='/S%_[>2;LO!N0I&)RJ+N"RA.;$3989&
M)@D&^JA-\TT0I:E4 6CEWH,8^(]9'2*Q,]!6PT@;&#S7ZFV%!EVO=J?J5]]\
M]E4Q&1QI;A$80A!BG< ,G;%@:.LP8G%%C=HU^?IS/B[!QIS2441]EEF74H2.
M:9!Q-/]5,R^Z[:>]&V.X0M/Q7):)&T,HY:B-<#TOBW4W*8@IVHE0S6@:>!6.
M<!EC[1CKR]W'73=.'WV:Q'@NEW%$&\>MR+7W>#TX L B%AA"'1)ZV*BEVQ'8
MD';U#I^F)]AHHEP<BM--1IPF4LWBA"N1"2&KS>OU>EL-KK[,R^[SY.>,U5NG
MG!0CW)F*3!]>"G%XBBB5VS428]K8L07.&1CT<$&4W M,L#V*@,YLV%DQ:9ZV
M;V$L_\;?=#W_^KT=+'":Z+<149C&,0&($61?*C$+PI#+WOAM4[>+PB-U3]6K
M]2HO#ZI!'U/'T!$*3F6R22:\CFC^7W>@)9_V*,*08#UEE=!$;:\-52,!Y-9S
MN&^:G<!YCD;$C ,AP*A"M-2=W@/5@7VP >, &X+,F!GFK6-[!$#<X(';"R+'
M1##,-@O#S !Q&S(%(E0IT^LY51=O?WW]\@\Z0ZGNBGF]+)"1QQ%*61H?>+O_
M9327:[E+8# X?.?KO=.X'> ]DCPG^)A\F68E"XF,BP)>;O=.XQ3)4LA-U#$V
M\Q1.2,2%X00&N;6<$=,(R_QSA'G*>CE@6V8ZFXHN.CB)Z#0K?C:I6&:I:\\Q
MHH"HU:03@9/</.0=-LC2@6P$26JE,8Q<Y,V67:O%F6&GJKI3^7*)EHR>6*L&
M-72)7CJ3?K#O#F,G+:I%N5W"QW\J=Y_R];P8O1&H]SM6W^5N/\+N>=D4MT;_
M\FXF/6-L(U\(+JI6&@4\C9X]D\2;DO&+V6V.$XHT]3EZ/CIB415S-/<<;-XW
M:/ Y>NUFV[1;+L<&7Z&5K@"RG?K0>G6^[:YK<(6>>QV_^G#^5$%66X"IY*1@
MJVV9=W6S4_GAS'8F&+L/>X-EMPQ;EWE5?"S6^1RNQH&M:#O8ME1P0.6#>R;!
M;VPM_IXU7;WR!$OO75GJYZ!]]7[I5S;^X;Q]Y-Y^/ZMZ#&,\(%6/I_C_4T[%
MW-*Q&:B3C;1DF0M<:%$_F%M1S'SF4XT<=++"I>0Q(Z[EK.!8QF+'(JZ1HT::
M4QCRK)!&_:_4L;X<T##D1FJU\"8CZR*T<;8[-M,H8\9#ADM1%T9.Y6(C5(U]
M*TD=UUI::C)VS\RPVTUTREKV J-9?)QCE8],S_1B,99-8F)2+(&9D@YK0M;A
M1W(HG;'-&ZGO42*]-:7';$AF1+YD[]*H!)LB2X-S+4N8#L&KZ*DX,&G/JR@/
M!3GH6_\]/ KA0*%VX*[2CP+R ;"7E$ZSL15>QY",),J QECP9=*>.&-[-C'+
M<Y3QFL0,[4"'HHR"C8B/,R(BTQJ^282%0I6A;2/9LK%FRV,KB$)NUCH6[\A)
M&Z8A(VOJW6>L-#RY3CTK8IOKKW<($[FP%@+CE-5T1DJ9)-69T+[X+F<R >EC
M)#YA6XB"4)/7&CD9)"2KZ%.P$/,(NR^Y$YB69O!<K/LC+\BL(103_AXH%4)#
M+5.]9O'6H5!(0V#%TON-C25(%)<"8?I+VB14Q4P7)Q1 ($W?W>5,2%*=],F5
M]0?S2&NAWE:PC?%43C9@AK3Z*^S)P@6I4 V$+:%.JYE'9*4&[)P('IF3(2<S
M0LE-+!Z4WAWW1AH!V4";C!P@,H+,: +.,BTC1U!'*8?OX4PQN92.V/A-2*>E
MLB%91+7A?;PIBO@XT62BR(68>V;Y %B3'J:1(;GX!G?2029,>(!VEG*76426
M;N0PQZ,.]S\0(N/D,,#94<HSXC%4/@5'U*PQEC5FH%IT%4"8:4D&\DSZ7,-Y
M3 ^>>0;CAM-&3RQ-Q/-'1M#H6-P8AW>H$_"=\"B4I,*5L7=)B(#LD3@P1M(W
M(+EW!R1*V\"AW+"")T$2ICV?VK^IT4@8ZV0T#>+42D^87M\\FD@]GNV81[&N
M/=NZP[*$7OV'&=.'\_]SHG^#$ZU\O6KRS76Q #KSQN?_I7>=CZ0X@K_3GAL=
M'AKV!X2#')C@_FK+UX?"-'KV$F9\I8 >+*]A+/H=%_^4;_(*2<_L=9GK2ZX;
MF(UEU;RX+JH<7<Q**Y2W# 'KJ21EZJ8#(Z+FBU6E%LB;KB%J8CE.QJF\=0A"
MDTE+SVQ\ZQ3TV#>MCT[5433J6M[!DOFV$X@)O]U;Q\\^2_17&2[KQ?3Z7:8-
MSI\]\++?32_[W:-?]N=KZF_E]7M#E!#KB_'S!2(_1_@[F'??R_\'U=S_Q>(;
MH/]"\PYN*5FY0*?O ?!+OQA&=/\Z=__IY<!V1LWVI-K(B[3[G'AR\'E+3G3\
MB-?V\>F_=$VCTW?"\_[SV'YZ_Y'QY[Q9H0RKTE]A*4@0'-7T'^[Z'UV]D8]E
M\[I#5.7VVJ.4-)R YU=UW8T_J&#Z>GKV+U!+ P04    "  %6F%5&\.,J/ $
M   )"P  &0   'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6RM5MMNVT80_96!
M&@02X% 4;?D66X O2>NV:04Y=1^*/JS(E;@(N<OL+B6[7]\SNS(MI[)1%'V1
M>-F9.6?FS'#.UL9^<:64GN[K2KOS7NE]<SH<NKR4M7")::3&FX6QM?"XM<NA
M:ZP413"JJV&6IH?#6BC=FYR%9U,[.3.MKY264TNNK6MA'RYE9=;GO5'O\<%,
M+4O/#X:3LT8LY:WTOS53B[MAYZ50M=1.&4U6+LY[%Z/3RS&?#P?NE%R[K6MB
M)G-COO#-37'>2QF0K&3NV8/ WTI>R:IB1X#Q=>.SUX5DP^WK1^\? W=PF0LG
MKTSUNRI\>=X[[E$A%Z*M_,RL?Y ;/@%@;BH7?FD=SQZ=]"AOG3?UQA@(:J7C
MO[C?Y&'+X#A]P2#;&&0!=PP44%X++R9GUJS)\FEXXXM -5@#G-)<E%MO\5;!
MSD\N\J^M<HHSY*C_6<PKZ09G0P_7?&"8;]Q<1C?9"VY.Z)/1OG3T01>R>&X_
M!*0.5_:(ZS)[U>&M;!+:3_<H2[/L%7_['<_]X&__!7^7K<,3Y^C*U'.E192$
M+NC".4A_*PWTQ\7<>0NY_+DK#S',P>XPW$*GKA&Y/.^A1YRT*]F;O/UN=)B^
M?X7$04?BX#7ODUNT9-%6DLR"?"E)U*;5WJ$Y<K/4ZB]9$-J4!%-R$#PX63QC
MFI42<U6!H'3\OJV_K5)D]VK\W>P^ \C"5.ANI9?D64&;%@<@]S_@Q']'>*M,
MA?#RE#XXK]";./51*$MWHFIQS-./0K<8,I1E04(CNA*NI#=TDB;C6&V.>#.=
MO15U\_Z:^J,!'6<'24K?&U.L5551/QO0*#M,CNE:+J3E\U[</T/8'Z6'23J@
M7P'NB<]S&GND(;#^_B@9#Y[IC G0@E&O FIPS-&%JI VRA,BU&X3^23=!Y"?
MH>#32*7+6I\I#2+]SM'5W:S#\(#@ ^H?CI.30;1MA"HB+([YS-L;.CHX2@Y"
M/G:D26DO]%+QE*#&*BYR]8"Z5LS%&YK.TG24T(T.Y?*EL@5]12$\TH-8W,Q[
MM):D:F (&<6Q)Z<QA1M_Q9;#6RGI%X,8XZB<H@@Y%!6,XY<)=TDH&>MQ^5C#
M;<594S,B]TQ%N-7&8XX7+;X/#(']<YV;UC;&29?0*YT[[CIW_*\[-W+< N%V
M=>*K_OY3)YH6'V.%;"Q4+K3?@8.*U@93.-*(2'4<ZI*'.FK0>%G/4<G'N1RD
MSMT%37*'2]N@U \\8QO<%WTWV.-Z6-$\$-+ZSUD;OAHT+?%=Y=1<RQ76A 8?
M??^2 C_<8Q_!Z4ME/H&89F/4/Y>M!ZT*TLL3FEIE+"M_)E>\&=R9-N<._2CG
M-HX%1@]!D6B:"G:<JC<T&J48 %A,9/6-6W1Q<#P;CR%@P;I"-HQ]IY@UKQ9(
M&\J I U]::7A]+UK+"0+B%_PP0'D$?5G-].?P$OI4LT5[/>BW)#O!D>U5V#@
ML5SYD (62^N-JNL6Q>!D0^V50$5A^D"%<A)^'2$1>1G'7$SE#0;7&%2FP*G"
M_H1TN5Q)G<M'*M,N(!"NU,HP#%2*YQJ#6DH,")5S%&,QD]S33 V!K'R70Y8A
MZ:/T"-.)*[:K5X9;ZTDM[3(L80[##I*)FTKWM-OS+N)Z\W0\+HE@NE00:B47
M,$V3([2)C8M7O/&F"<O.W'BL3N&RQ*XJ+1_ ^X4![<T-!^BVW\G?4$L#!!0
M   (  5:855"&6C@\@,  ,4)   9    >&PO=V]R:W-H965T<R]S:&5E=#(S
M+GAM;+56VV[C-A#]%4(-B@0(=/6]MH$XZ:(MD$VP=MN'H@^T-);8E4B5I.S-
M?GUG*/F2K-?8A^Z+2)$S9VYG2$YW2G\T!8!EGZI2FIE76%M/@L"D!53<^*H&
MB3L;I2MN\5?G@:DU\,PI5640A^$@J+B0WGSJUI[U?*H:6PH)SYJ9IJJX?EE
MJ78S+_+V"Q]$7EA:".;3FN>P!/M[_:SQ+SB@9*(":8223,-FYMU%DT6/Y)W
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MK2Q>^VY:X#L+- G@_D8IN_\A X>7V_P_4$L#!!0    (  5:855V3V):W (
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ML4;8N=J\QRZ?<X>7*V'\$S:=;11 WABKJLZ9&%1<MF_VV-7A;QR2SB'QO-M
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M-_.LVW"VY5-0<2BJ[%N9LKKT'B-: 4R+_;BK4W;/Q[4TB-.0NNR/ASYSO0H
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M#.F:J=!X!=I?:^T.$Q]@^+M9_@502P,$%     @ !5IA5<\UE!O$!@  Z!8
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MF'<I_$<3COK[)<?(-YN]@SO0\A'"[87<LL/^C7?V&"1#"6N2I"4))Z7'!_&
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M]1P2KY0610W&# K&JW_Z5)_##@!YV@%!#0A> GH' &$-"$^-T*L!O5,C7-4
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MNF\P8UF-"]5&B]+>APNA\7:URPPG+)#& 9\OA=#;C0G0S&S1'U!+ P04
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M?Z$J<J9V5?92RR_[U=W?5\,&XPQ@[-3#X@(6%V&XK!Z:U&.V\[4K[ ';4%S
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M=KM#]X?3-_B\V__UZ7+>_3]02P,$%     @ !5IA53@P&;"%!   )AP  !D
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M0G6I%IX9U#-'T<S@:-4I<JM.[>JU>GF;CV?6M=EN1VUG)Y1&H30&I7$4S4P
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MF7SM\.'S3G)P<+3LM?G!YZ6I%Z/IT;P3.JB!:B:J6:AFHYJ#:BZJ>:CFHUJ
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MJ>1QF2C%?7Q75*FD)T5ZLZD>N:J22[&3JYMZ6V=3E/EVG>R"ZU-<W"KFJCJ
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M6])M(N_X[B.K!^05>"%/1/D_VM6VS@"%6R%Y6CNK'J1Q5OVE3W4@6@X*Q^Q
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M+)A?5&9@)$!!IL8.W%%.8WUQZ^@3<Q+6%S2A$-',6%_>!A9LZ@8.!! .;_-
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M%X;"BA4T+H0E&9MCPH4AY\(0EPM#32Y4C1ODPI!S83A)+GQ2V1XVR7@>V$#
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M;HBZ#PLF_[ZLOFW/<?I_4$L#!!0    (  5:855>5!J8< (   H&   9
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M89HU2+O!K&^$T!^!;2!M^\_^ 5!+ P04    "  %6F%52YU'C[,"  !=!P
M&0   'AL+W=O<FMS:&5E=',O<VAE970T-"YX;6RM55UKVS 4_2O"*Z.#S5^)
MW8\EAC:A6V&%TM#N8>Q!<6X245GR)#GI]NMW);O&:=RP0?,02_8]Q^?<>W4]
MVDKUJ-< ACP57.BQMS:F/ \"G:^AH-J7)0A\LI2JH :W:A7H4@%=.%#!@S@,
MTZ"@3'C9R-V[5=E(5H8S ;>*Z*HHJ/I]"5QNQU[D/=^X8ZNUL3>";%32%<S
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M)M7=:IIK55\!UP#U?<F8W'?T!&7%%OX&4$L#!!0    (  5:8578GT^380,
M !P4   9    >&PO=V]R:W-H965T<R]S:&5E=#0V+GAM;+68:V^;,!2&_XK%
MI&F3IG++I<D2I#: 5FF5JG:7#],^N'"2H(+-;.=2:3]^-A :(D+3U<V'@,UY
M'\-YG>/@R8:R![X$$&B;I81/C:40^=@T>;2$#/,SF@.15^:495C()EN8/&>
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M,+ID<3I /KZ*(O&VD*Z@N+#)[']02P,$%     @ !5IA5;0AKD$G"    #4
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M,\ I,"4@OR\I%4\ORD!S\S3_%U!+ P04    "  %6F%5;OD3 90%   \(P
M&0   'AL+W=O<FMS:&5E=',O<VAE970U,2YX;6S-6EMOVS84_BN$6Q0)T$@B
M=;&5.@822T4#M%B0K-O#L =&IF.MDNB)=)(!^_&C+M&%HK4X98#X(;'D[WP\
M'P]]>([,^0/-?[ -(1P\IDG&SB8;SK>GILFB#4DQ,^B69.*3-<U3S,5E?F>R
M;4[PJC1*$Q-9EF>F.,XFBWEY[RI?S.F.)W%&KG+ =FF*\W\N2$(?SB9P\G3C
M.K[;\.*&N9AO\1VY(?S[]BH75V;#LHI3DK&89B GZ[/).3P-D5T8E(C?8O+
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M(?3>RJ8TVIH>'%*=;(%6ME 76S^D;>\+QYO?%SW(J3FEIEY^2+/< _/E;*6
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MD;P B,_7E/*GBV* YL#,XC]02P,$%     @ !5IA52L3O+#N P  S0T  !D
M  !X;"]W;W)K<VAE971S+W-H965T-3(N>&ULK5?;;MLX$/T50BT*&VATH:Y.
M;0.)[<7F(=D@0=N'Q3[(]M@F*HDN2<?IWR])*:HLT4JP&SW8(C5SAF=F.!R.
MCY3]X#L @9[SK. 3:R?$_M)Q^&H'><IMNH="?ME0EJ="#MG6X7L&Z5HKY9F#
M73=R\I04UG2LY^[9=$P/(B,%W#/$#WF>LE_7D-'CQ/*LEXD'LMT)->%,Q_MT
M"X\@ON[OF1PY-<J:Y%!P0@O$8#.QKKS+A><J!2WQC<"1-]Z1HK*D](<:W*PG
MEJM6!!FLA()(Y=\3S"#+%))<Q\\*U*IM*L7F^POZ'YJ\)+-,.<QH]IVLQ6YB
M)19:PR8]9.*!'O^$BE"H\%8TX_H7'4O9"%MH=>""YI6R7$%.BO(_?:X<T5"0
M.&8%7"G@MD)P1L&O%/RW6@@JA>"M%L)*05-W2N[:<?-4I-,QHT?$E+1$4R_:
M^UI;^HL4*E$>!9-?B=03T[_$#MBG#PGVO"]W(#ZCP4VQHCD,T>)9)B,'-)B#
M2$G&A^@"?7V<H\''(?J(2(%N29;)6/.Q(^1"%)RSJHQ>ET;Q&:,^NJ6%V'&T
M*-:P-NC/^_5'/?J.=$#M!?SBA6O<"_@(>QOY[F>$78P-ZYF]7=TST?E_UA?_
MV?J),_PZ)7R-YY_!NZ.%K$,L%:38HC(;T*#*AB'Z^VK)!9/[^Q]3W$ODP(RL
MBMXEWZ<KF%BRJG%@3V!-/WWP(O>+R>GO"39_3[#%.X&=A">HPQ/TH4]O"@$2
M52 H0V(*0XD0:01U5#Q-$\\.Q\Y3T[T&(=\.1\WG5&/>U<!!;$>G4@N#5)C8
M02UUPCJL68=O8TUT0II(EP!QP^X%=FVOQ;J4"IM2<8NF <B/;;]%TP#D)6:2
M44TRZB4I"[#D]R1IRJ-8H,%6'O2R[F:4<^!('JOP\T#$+\1A=6!$$#DYN*,"
M4#0T.23J\/"PW^8QZTKA(+*3ED^Z4E'4#7U7Z@+'S1B<N"6NW1+WNN4!!&&@
M7;*$ C9$H'V6F@^>N+N"$;8#M_&T,\*@$N/^C1!W8X\3M^4, R[VXG/.2&IG
M)+W.F,-2;7U5G ^$[[175(+T9D+266]KL;.DL]C #6W<XOTJSN(UG!/.HYKS
MJ)>S;E+0@%2=24_A&W53/K%;^WO6%3(4BOG(L+];2 L#DA^<B[#G_N[)W-?Y
M5DU9H9NR-U"O,$=-[EX[URNA9G&._-!NY[=!+$S<MMC"(.;AH%%A2OY.HSW-
M@6WUO8"C%3T4HFQ+ZMGZ[G&E.^[6_+5W.?,,\W-U5]'M\&_X\J)SF[*MK*$H
M@XTTY=JQC"<K[P[E0-"];HZ75,A66[_NY'T+F!*0WS=4[JIJH S4-[CIOU!+
M P04    "  %6F%5AIBWZ7<#  # %P  #0   'AL+W-T>6QE<RYX;6S=6-UN
MVC 4?I4H7:=6FAI"UD!60-J0*DW:IDKMQ>XJ0QRPY#B98SK8Y5YEZMV>8H^R
M)YE/'!*@/HSV8H4%0>SS^7SG._9Q?N@5:L'I]912Y<Q3+HJ^.U4J?^-YQ7A*
M4U*<93D5&DDRF1*ENW+B%;FD)"[ *>5>N]4*O90PX0YZ8I9>IJIPQME,J+[K
MMVJ;8T[O8VT-7[N.X1MF,>V[MR<OO\PR=?'",>>C5T='K;/6[>G%)G)20:>N
M9R4^7R=NB/[F&.ZD:)LDE+JS S7*BY%V+8D>UWD>8V[1;FENS1/3U&G9R7]_
M_XFDVB!;D^WXUE5=R1<ZF'/;KNK7#T14#6S7%""T]QCM_4-:K]HN@UZ2B6;7
M!*XQZ+@DI<X=X7UW2#@;209>"4D97QAS&PSCC&?247J[:B$^6(IO!O9-#W9R
MQ9,RD<DRMHE@?D?5\ U@V0.!C/-:8-LUAD$O)TI1*2YUIQQ<&A] 3M6^6>1:
MX422A=\^=QN'\J2#C#(94]E</=RE:=#C- $YDDVF<%99[@&H5);J1LS()!.D
MU+#TJ!J:=DPYOX;+W.=DC7N>K*QH6;RB;FI!5=/0F [PK[(9[E7:SI-XG9S=
M9>K=3*<CRCY4"KV2-&'SLC]/:@$8NX^SDSSGB[><341*3?([!QSTR-+/F6:2
M?=/1H%3&VD"EZ]Q1J=AXU?)5DOR&SM6RG.8)KKE]@)K_[3Q/J*"2\%71NO;W
M>9:?K#CH/)?D\JJR*=BJL7ITV7>1YX<@,CP$D0=1D]U#$!D=@,C.LUTU'R/2
M/P21[4,0&>R_R/VL2*]Z[EUYN%Y[M*ZM#KS"]-U/\*K$FZ#.:,:X8J+J35D<
M4_'@"5O3*S+B=)U?CX]I0F9<W=1@WVW:'VG,9FE4C[J"B:A&->T/D)X?UN]/
M.A83,9W3>%AUY614-AW=T%&K QPVD<ORL".8C\'L"&!8'$P!YF.\L#C_4SY=
M-!^#8=JZ5J2+^G11'^-E0X;E!XMC]XGT8<\TBH(@#+$9'0ZM"H;8O(4A?.UL
MF#;PP.) I,?--;[:>(5LKP-L3;=5")8I7HE8IOA< V*?-_"((OMJ8W'  UL%
MK'8@OCT.U)3=)PA@53%MV [&D2C"$*A%>XV&(3([(7SLZX/MDB"((CL"F%U!
M$& ([$8<P12 !@P)@O(^N'$_\I;W*:_YSW[P!U!+ P04    "  %6F%5EXJ[
M',     3 @  "P   %]R96QS+RYR96QSG9*Y;L,P#$!_Q=">, ?0(8@S9?$6
M!/D!5J(/V!(%BD6=OZ_:I7&0"QEY/3P2W!YI0.TXI+:+J1C]$%)I6M6X 4BV
M)8]ISI%"KM0L'C6'TD!$VV-#L%HL/D N&6:WO606IW.D5XA<UYVE/=LO3T%O
M@*\Z3'%":4A+,P[PS=)_,O?S##5%Y4HCE5L:>-/E_G;@2=&A(E@6FD7)TZ(=
MI7\=Q_:0T^FO8R*T>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X 4$L#!!0    (
M  5:855[E#RV500  ,0B   /    >&PO=V]R:V)O;VLN>&ULQ9I-;]LX$$#_
M"J&3 RS6MC[2-J@+)'&S:R!- Z?-M:"EL<T-17I)*DGSZY>4XI;:VH->QCY9
MHFCIB13Y.".]?]+F8:'U WNNI;*39.W<YFPXM.4::F[_U!M0_LA2FYH[OVM6
M0[LQP"N[!G"U'*:CT>FPYD(E']YOSW5KAO&.=E ZH94O# 7W I[LS^-AEST*
M*Q9""O=]DK3;$A)6"R5J\0+5)!DES*[UT]_:B!>M')=WI=%23I)Q=^ >C!/E
M+\5W ?(+7]BVQ/'%G'N027(Z\B=<"F-=6Z,]/_>,C^ K=WN-TU=".C!3[N O
MHYN-4*MP&G\7P^@VVG;8_G:->&9^IQGU<BE*F.JRJ4&YKAT-R "H[%IL;,(4
MKV&27.I',.R6KR#<E+_*K.INT'FRJ+G,F? 'S*QJ&2EYE-525/[J%?,[%2CK
MM^X"CO]K!)DBD.D1(;^E$62&0&9'@;S@DJL26 29(Y#Y$2%[+5D@D,4QNSN+
M($\1R--C0N81Y!L$\LTQ(8L(\BT"^986\H);89E>LEL#UE=M:S"N*C:K-S*>
M)]\AD.]H(>?P"*KI3=HC;-8>T>*<E_\V_J)M><R$FH1<)5+RA3;=D;8#/[NU
MM]VY,5RM8DS,)6-BF9Q;Z\_L'RTN3*CZ!YN#=:8I76-$'Q.SR9A8)U="^2E9
M<,EF*N"%ZKVNQBPR)M;(3)6Z!O:%/T./"9/&F-@:<W#"A#6+8Q>@8"GZS86I
M8DSO"N<?+?#]V6\O3 UC8C=T8_-2USX"6'LO^/4R>^W7P;7N86)R&!/;H<7\
M=@-^G XZO!/V\7D31!8C8FH8$[L!%5AO495BSDB)G?&J,#;P89$$>Q)S8=Y(
MB;T1NVPG'!IYD(<>B-3Z?8O9(B6V!2JU/B;FC938&SNEMK//,9.DAS?)3D9,
M*2FQ4M#9N]_AF&320TAF]^P=FC3&Q"23$DOFQ]1XU]0U-]_#9+XMFT,98V*B
M20\3A+#!>?5/8UTW>IQFOP8G&2::[%"B">L>PTO'K@5O$X)^^7,29T(RS#L9
ML7=^8$Z%Y:N5@54G[M>^CS$Q V7$!D(Q^\DO-/M%;:">Q6^X"<I\],-], 7'
M18R)&2@C-E ?L]6F96VA@8K%$U*&*2@C5M .3!:5Q9B8A3+RP 9;'<69N@RS
M4$9L(7QUU,/$+)016VC/ZF@[EF),S$(9L87V8'Y<+L%/]3I.=&,6RHDMM ?S
MRC\#[)[+&!.S4$YLH3V8<V$?V"<>C_0<LU!.;*$]F%O#QYB8A?)C9,W8X*LR
MP*5XB3'1MS#'B8/F+214,29FH9S80G&:[]7CLA<"Y9A\<F+Y[ S30D2DU?]R
MI3DFGYS^'<S/Y-_N5L2DDQ\BO[8WD(S=F&/2R8FE@V/&K]L*3#H%L71PS/B%
M6X%)IR"6#AJ63^/0I\"D4[32&6Z_FJC\&%10W?A+6%]><EG>&A9^NI<^>1'2
MM,M&RDM?]EE=:UYM/\+8?D#RX3]02P,$%     @ !5IA58HQ=E_/ 0  ,Q\
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M8SYK?X5//P%02P$"% ,4    "  %6F%5!T%-8H$   "Q    $
M    @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    (  5:856:ENN_
M[@   "L"   1              "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+
M 0(4 Q0    (  5:85697)PC$ 8  )PG   3              "  <P!  !X
M;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ !5IA5=$Y!>0]"0  .T\
M !@              ("!#0@  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+
M 0(4 Q0    (  5:856!T1_)_P4  +L:   8              " @8 1  !X
M;"]W;W)K<VAE971S+W-H965T,BYX;6Q02P$"% ,4    "  %6F%5RQ)C;2 #
M  #U"0  &               @(&U%P  >&PO=V]R:W-H965T<R]S:&5E=#,N
M>&UL4$L! A0#%     @ !5IA5?>&PY7C!P  >B(  !@              ("!
M"QL  'AL+W=O<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0    (  5:854/
M^]!XC0(  /,%   8              " @20C  !X;"]W;W)K<VAE971S+W-H
M965T-2YX;6Q02P$"% ,4    "  %6F%5%W8N^7T/  !JJP  &
M    @('G)0  >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L! A0#%     @
M!5IA52$]AVWW @  6PD  !@              ("!FC4  'AL+W=O<FMS:&5E
M=',O<VAE970W+GAM;%!+ 0(4 Q0    (  5:856XHH/K)@<  !T>   8
M          " @<<X  !X;"]W;W)K<VAE971S+W-H965T."YX;6Q02P$"% ,4
M    "  %6F%5<QSKJ9((  "%%0  &               @($C0   >&PO=V]R
M:W-H965T<R]S:&5E=#DN>&UL4$L! A0#%     @ !5IA5?\2L0FB#0  0"0
M !D              ("!ZT@  'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q0
M2P$"% ,4    "  %6F%55"H7,U<,  "0.   &0              @('$5@
M>&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    (  5:854?QI>]
MG@T  *,M   9              " @5)C  !X;"]W;W)K<VAE971S+W-H965T
M,3(N>&UL4$L! A0#%     @ !5IA56V0@[W"!   PPP  !D
M ("!)W$  'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q02P$"% ,4    "  %
M6F%5H.)"A"L<  #68P  &0              @($@=@  >&PO=V]R:W-H965T
M<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    (  5:854$10&_NP,  &@)   9
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M970Q.2YX;6Q02P$"% ,4    "  %6F%55G\TUXL)  "F&@  &0
M    @(%SR   >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    (
M  5:857'M6IR5@L  $D=   9              " @372  !X;"]W;W)K<VAE
M971S+W-H965T,C$N>&UL4$L! A0#%     @ !5IA51O#C*CP!   "0L  !D
M             ("!PMT  'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q02P$"
M% ,4    "  %6F%50AEHX/(#  #%"0  &0              @('IX@  >&PO
M=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4 Q0    (  5:855V3V):W (
M !X'   9              " @1+G  !X;"]W;W)K<VAE971S+W-H965T,C0N
M>&UL4$L! A0#%     @ !5IA51UOZC;I"@  ;"P  !D              ("!
M)>H  'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q02P$"% ,4    "  %6F%5
M-ZH#]JT#  #I"   &0              @(%%]0  >&PO=V]R:W-H965T<R]S
M:&5E=#(V+GAM;%!+ 0(4 Q0    (  5:857/-90;Q 8  .@6   9
M      " @2GY  !X;"]W;W)K<VAE971S+W-H965T,C<N>&UL4$L! A0#%
M  @ !5IA5?.O--@F P  #0<  !D              ("!)  ! 'AL+W=O<FMS
M:&5E=',O<VAE970R."YX;6Q02P$"% ,4    "  %6F%56C<>!_<#  !C%
M&0              @(&! P$ >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+
M 0(4 Q0    (  5:8550,BK'Z (  +\)   9              " @:\' 0!X
M;"]W;W)K<VAE971S+W-H965T,S N>&UL4$L! A0#%     @ !5IA58N*I:HO
M @  &P4  !D              ("!S@H! 'AL+W=O<FMS:&5E=',O<VAE970S
M,2YX;6Q02P$"% ,4    "  %6F%5>'#9,2X>  !1>0$ &0
M@($T#0$ >&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4 Q0    (  5:
M854X,!FPA00  "8<   9              " @9DK 0!X;"]W;W)K<VAE971S
M+W-H965T,S,N>&UL4$L! A0#%     @ !5IA57W[3A,-!@  @2\  !D
M         ("!53 ! 'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6Q02P$"% ,4
M    "  %6F%5,'4WDK0$   %'@  &0              @(&9-@$ >&PO=V]R
M:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4 Q0    (  5:854>BFUVJ@,   @6
M   9              " @80[ 0!X;"]W;W)K<VAE971S+W-H965T,S8N>&UL
M4$L! A0#%     @ !5IA5?@2EIIA"@  %G0  !D              ("!93\!
M 'AL+W=O<FMS:&5E=',O<VAE970S-RYX;6Q02P$"% ,4    "  %6F%56I_X
M]U\#  #)#   &0              @(']20$ >&PO=V]R:W-H965T<R]S:&5E
M=#,X+GAM;%!+ 0(4 Q0    (  5:855F\9Z1LQ8  'Q^ 0 9
M  " @9-- 0!X;"]W;W)K<VAE971S+W-H965T,SDN>&UL4$L! A0#%     @
M!5IA5:IQCQ:]!@  UB\  !D              ("!?60! 'AL+W=O<FMS:&5E
M=',O<VAE970T,"YX;6Q02P$"% ,4    "  %6F%5?"@;S*L0  ".M@  &0
M            @(%Q:P$ >&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM;%!+ 0(4
M Q0    (  5:855G1[/V10T  #28   9              " @5-\ 0!X;"]W
M;W)K<VAE971S+W-H965T-#(N>&UL4$L! A0#%     @ !5IA55Y4&IAP @
M"@8  !D              ("!SXD! 'AL+W=O<FMS:&5E=',O<VAE970T,RYX
M;6Q02P$"% ,4    "  %6F%52YU'C[,"  !=!P  &0              @(%V
MC $ >&PO=V]R:W-H965T<R]S:&5E=#0T+GAM;%!+ 0(4 Q0    (  5:856R
M@@TH"P,  +T)   9              " @6"/ 0!X;"]W;W)K<VAE971S+W-H
M965T-#4N>&UL4$L! A0#%     @ !5IA5=B?3Y-A P  '!0  !D
M     ("!HI(! 'AL+W=O<FMS:&5E=',O<VAE970T-BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    (  5:855N^1,!E 4  #PC   9              "
M@9ZO 0!X;"]W;W)K<VAE971S+W-H965T-3$N>&UL4$L! A0#%     @ !5IA
M52L3O+#N P  S0T  !D              ("!:;4! 'AL+W=O<FMS:&5E=',O
M<VAE970U,BYX;6Q02P$"% ,4    "  %6F%5AIBWZ7<#  # %P  #0
M        @ &.N0$ >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    (  5:8567BKL<
MP    !,"   +              "  3"] 0!?<F5L<R\N<F5L<U!+ 0(4 Q0
M   (  5:855[E#RV500  ,0B   /              "  1F^ 0!X;"]W;W)K
M8F]O:RYX;6Q02P$"% ,4    "  %6F%5BC%V7\\!   S'P  &@
M    @ &;P@$ >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4
M"  %6F%5,N&!X<<!   2'P  $P              @ &BQ $ 6T-O;G1E;G1?
@5'EP97-=+GAM;%!+!08     /  \ %L0  ":Q@$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.2.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>803</ContextCount>
  <ElementCount>259</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>136</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>15</UnitCount>
  <MyReports>
    <Report instance="lly-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="lly-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Statement - Consolidated Condensed Statements of Operations (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/ConsolidatedCondensedStatementsofOperationsUnaudited</Role>
      <ShortName>Consolidated Condensed Statements of Operations (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="lly-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - Consolidated Condensed Statements of Comprehensive Income (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/ConsolidatedCondensedStatementsofComprehensiveIncomeUnaudited</Role>
      <ShortName>Consolidated Condensed Statements of Comprehensive Income (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="lly-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - Consolidated Condensed Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets</Role>
      <ShortName>Consolidated Condensed Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="lly-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - Consolidated Condensed Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/ConsolidatedCondensedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Condensed Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="lly-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - Consolidated Condensed Statements of Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/ConsolidatedCondensedStatementsofEquity</Role>
      <ShortName>Consolidated Condensed Statements of Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="lly-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Statement - Consolidated Condensed Statements of Equity (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/ConsolidatedCondensedStatementsofEquityParenthetical</Role>
      <ShortName>Consolidated Condensed Statements of Equity (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="lly-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Statement - Consolidated Condensed Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows</Role>
      <ShortName>Consolidated Condensed Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="lly-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Disclosure - Basis of Presentation and Implementation of New Financial Accounting Standard</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/BasisofPresentationandImplementationofNewFinancialAccountingStandard</Role>
      <ShortName>Basis of Presentation and Implementation of New Financial Accounting Standard</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="lly-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - Revenue</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/Revenue</Role>
      <ShortName>Revenue</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="lly-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - Acquisitions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/Acquisitions</Role>
      <ShortName>Acquisitions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="lly-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - Collaborations and Other Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/CollaborationsandOtherArrangements</Role>
      <ShortName>Collaborations and Other Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="lly-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - Asset Impairment, Restructuring, and Other Special Charges</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialCharges</Role>
      <ShortName>Asset Impairment, Restructuring, and Other Special Charges</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="lly-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/FinancialInstruments</Role>
      <ShortName>Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="lly-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="lly-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - Retirement Benefits</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/RetirementBenefits</Role>
      <ShortName>Retirement Benefits</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="lly-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/Contingencies</Role>
      <ShortName>Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="lly-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - Other Comprehensive Income (Loss)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/OtherComprehensiveIncomeLoss</Role>
      <ShortName>Other Comprehensive Income (Loss)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="lly-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - Other???Net, (Income) Expense</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/OtherNetIncomeExpense</Role>
      <ShortName>Other???Net, (Income) Expense</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="lly-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0000020 - Disclosure - Basis of Presentation and Implementation of New Financial Accounting Standard (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/BasisofPresentationandImplementationofNewFinancialAccountingStandardPolicies</Role>
      <ShortName>Basis of Presentation and Implementation of New Financial Accounting Standard (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.lilly.com/role/BasisofPresentationandImplementationofNewFinancialAccountingStandard</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="lly-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0000021 - Disclosure - Revenue (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/RevenueTables</Role>
      <ShortName>Revenue (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.lilly.com/role/Revenue</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="lly-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0000022 - Disclosure - Acquisitions (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/AcquisitionsTables</Role>
      <ShortName>Acquisitions (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.lilly.com/role/Acquisitions</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="lly-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0000023 - Disclosure - Collaborations and Other Arrangements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/CollaborationsandOtherArrangementsTables</Role>
      <ShortName>Collaborations and Other Arrangements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.lilly.com/role/CollaborationsandOtherArrangements</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="lly-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0000024 - Disclosure - Asset Impairment, Restructuring, and Other Special Charges (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialChargesTables</Role>
      <ShortName>Asset Impairment, Restructuring, and Other Special Charges (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialCharges</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="lly-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0000025 - Disclosure - Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/FinancialInstrumentsTables</Role>
      <ShortName>Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.lilly.com/role/FinancialInstruments</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="lly-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>0000026 - Disclosure - Retirement Benefits (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/RetirementBenefitsTables</Role>
      <ShortName>Retirement Benefits (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.lilly.com/role/RetirementBenefits</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="lly-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>0000027 - Disclosure - Other Comprehensive Income (Loss) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/OtherComprehensiveIncomeLossTables</Role>
      <ShortName>Other Comprehensive Income (Loss) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.lilly.com/role/OtherComprehensiveIncomeLoss</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="lly-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>0000028 - Disclosure - Other???Net, (Income) Expense (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/OtherNetIncomeExpenseTables</Role>
      <ShortName>Other???Net, (Income) Expense (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.lilly.com/role/OtherNetIncomeExpense</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="lly-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>0000029 - Disclosure - Revenue (Summary of Revenue Recognized) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/RevenueSummaryofRevenueRecognizedDetails</Role>
      <ShortName>Revenue (Summary of Revenue Recognized) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/RevenueTables</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="lly-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>0000030 - Disclosure - Revenue (Adjustments to Revenue) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/RevenueAdjustmentstoRevenueDetails</Role>
      <ShortName>Revenue (Adjustments to Revenue) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/RevenueTables</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="lly-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>0000031 - Disclosure - Revenue (Contract Liabilities) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/RevenueContractLiabilitiesDetails</Role>
      <ShortName>Revenue (Contract Liabilities) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/RevenueTables</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="lly-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>0000032 - Disclosure - Revenue (Disaggregation of Revenue by Product) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails</Role>
      <ShortName>Revenue (Disaggregation of Revenue by Product) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/RevenueTables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="lly-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>0000033 - Disclosure - Revenue (Disaggregation of Revenue by Geographical Area) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/RevenueDisaggregationofRevenuebyGeographicalAreaDetails</Role>
      <ShortName>Revenue (Disaggregation of Revenue by Geographical Area) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/RevenueTables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="lly-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>0000034 - Disclosure - Acquisitions (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/AcquisitionsNarrativeDetails</Role>
      <ShortName>Acquisitions (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/AcquisitionsTables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="lly-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>0000035 - Disclosure - Acquisitions (Assets Acquired and Liabilities Assumed) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails</Role>
      <ShortName>Acquisitions (Assets Acquired and Liabilities Assumed) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/AcquisitionsTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="lly-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>0000036 - Disclosure - Acquisitions (Asset Acquisitions) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/AcquisitionsAssetAcquisitionsDetails</Role>
      <ShortName>Acquisitions (Asset Acquisitions) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/AcquisitionsTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="lly-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>0000037 - Disclosure - Collaborations and Other Arrangements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/CollaborationsandOtherArrangementsDetails</Role>
      <ShortName>Collaborations and Other Arrangements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/CollaborationsandOtherArrangementsTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="lly-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>0000038 - Disclosure - Asset Impairment, Restructuring, and Other Special Charges (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialChargesDetails</Role>
      <ShortName>Asset Impairment, Restructuring, and Other Special Charges (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialChargesTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="lly-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>0000039 - Disclosure - Financial Instruments (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails</Role>
      <ShortName>Financial Instruments (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="lly-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>0000040 - Disclosure - Financial Instruments (Effect of Risk-Management Instruments) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/FinancialInstrumentsEffectofRiskManagementInstrumentsDetails</Role>
      <ShortName>Financial Instruments (Effect of Risk-Management Instruments) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="lly-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>0000041 - Disclosure - Financial Instruments (Fair Value of Financial Instruments) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/FinancialInstrumentsFairValueofFinancialInstrumentsDetails</Role>
      <ShortName>Financial Instruments (Fair Value of Financial Instruments) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="lly-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>0000042 - Disclosure - Financial Instruments (Risk Management Instruments) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/FinancialInstrumentsRiskManagementInstrumentsDetails</Role>
      <ShortName>Financial Instruments (Risk Management Instruments) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="lly-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>0000043 - Disclosure - Financial Instruments (Contractual Maturities) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/FinancialInstrumentsContractualMaturitiesDetails</Role>
      <ShortName>Financial Instruments (Contractual Maturities) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="lly-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>0000044 - Disclosure - Financial Instruments (Unrealized Gains and Losses) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/FinancialInstrumentsUnrealizedGainsandLossesDetails</Role>
      <ShortName>Financial Instruments (Unrealized Gains and Losses) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="lly-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>0000045 - Disclosure - Financial Instruments (Realized Gains and Losses) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/FinancialInstrumentsRealizedGainsandLossesDetails</Role>
      <ShortName>Financial Instruments (Realized Gains and Losses) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="lly-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>0000046 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/IncomeTaxes</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="lly-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>0000047 - Disclosure - Retirement Benefits (Components of Net Periodic Benefit Cost) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/RetirementBenefitsComponentsofNetPeriodicBenefitCostDetails</Role>
      <ShortName>Retirement Benefits (Components of Net Periodic Benefit Cost) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/RetirementBenefitsTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="lly-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>0000048 - Disclosure - Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/ContingenciesDetails</Role>
      <ShortName>Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/Contingencies</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="lly-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>0000049 - Disclosure - Other Comprehensive Income (Loss) (AOCI) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/OtherComprehensiveIncomeLossAOCIDetails</Role>
      <ShortName>Other Comprehensive Income (Loss) (AOCI) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/OtherComprehensiveIncomeLossTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="lly-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>0000050 - Disclosure - Other Comprehensive Income (Loss) (Tax Effect) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/OtherComprehensiveIncomeLossTaxEffectDetails</Role>
      <ShortName>Other Comprehensive Income (Loss) (Tax Effect) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/OtherComprehensiveIncomeLossTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="lly-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>0000051 - Disclosure - Other Comprehensive Income (Loss) (Reclassification) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/OtherComprehensiveIncomeLossReclassificationDetails</Role>
      <ShortName>Other Comprehensive Income (Loss) (Reclassification) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/OtherComprehensiveIncomeLossTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="lly-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>0000052 - Disclosure - Other???Net, (Income) Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/OtherNetIncomeExpenseDetails</Role>
      <ShortName>Other???Net, (Income) Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/OtherNetIncomeExpenseTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="lly-20220930.htm">lly-20220930.htm</File>
    <File>lly-09302022x10qxexhibit311.htm</File>
    <File>lly-09302022x10qxexhibit312.htm</File>
    <File>lly-09302022x10qxexhibit32.htm</File>
    <File>lly-093022x10qexhibit101.htm</File>
    <File>lly-093022x10qexhibit102.htm</File>
    <File>lly-093022x10qexhibit103.htm</File>
    <File>lly-20220930.xsd</File>
    <File>lly-20220930_cal.xml</File>
    <File>lly-20220930_def.xml</File>
    <File>lly-20220930_lab.xml</File>
    <File>lly-20220930_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="1442">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="59">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>75
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "lly-20220930.htm": {
   "axisCustom": 0,
   "axisStandard": 25,
   "contextCount": 803,
   "dts": {
    "calculationLink": {
     "local": [
      "lly-20220930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "lly-20220930_def.xml"
     ]
    },
    "inline": {
     "local": [
      "lly-20220930.htm"
     ]
    },
    "labelLink": {
     "local": [
      "lly-20220930_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "lly-20220930_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "lly-20220930.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 503,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 5,
    "total": 5
   },
   "keyCustom": 25,
   "keyStandard": 234,
   "memberCustom": 80,
   "memberStandard": 53,
   "nsprefix": "lly",
   "nsuri": "http://www.lilly.com/20220930",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20220930.htm",
      "contextRef": "if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover Page",
     "role": "http://www.lilly.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20220930.htm",
      "contextRef": "if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20220930.htm",
      "contextRef": "if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000010 - Disclosure - Revenue",
     "role": "http://www.lilly.com/role/Revenue",
     "shortName": "Revenue",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20220930.htm",
      "contextRef": "if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:AssetAcquisitionTextBlock",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20220930.htm",
      "contextRef": "if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000011 - Disclosure - Acquisitions",
     "role": "http://www.lilly.com/role/Acquisitions",
     "shortName": "Acquisitions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:AssetAcquisitionTextBlock",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20220930.htm",
      "contextRef": "if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20220930.htm",
      "contextRef": "if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000012 - Disclosure - Collaborations and Other Arrangements",
     "role": "http://www.lilly.com/role/CollaborationsandOtherArrangements",
     "shortName": "Collaborations and Other Arrangements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20220930.htm",
      "contextRef": "if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20220930.htm",
      "contextRef": "if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000013 - Disclosure - Asset Impairment, Restructuring, and Other Special Charges",
     "role": "http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialCharges",
     "shortName": "Asset Impairment, Restructuring, and Other Special Charges",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20220930.htm",
      "contextRef": "if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20220930.htm",
      "contextRef": "if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000014 - Disclosure - Financial Instruments",
     "role": "http://www.lilly.com/role/FinancialInstruments",
     "shortName": "Financial Instruments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20220930.htm",
      "contextRef": "if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20220930.htm",
      "contextRef": "if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000015 - Disclosure - Income Taxes",
     "role": "http://www.lilly.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20220930.htm",
      "contextRef": "if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20220930.htm",
      "contextRef": "if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000016 - Disclosure - Retirement Benefits",
     "role": "http://www.lilly.com/role/RetirementBenefits",
     "shortName": "Retirement Benefits",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20220930.htm",
      "contextRef": "if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20220930.htm",
      "contextRef": "if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000017 - Disclosure - Contingencies",
     "role": "http://www.lilly.com/role/Contingencies",
     "shortName": "Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20220930.htm",
      "contextRef": "if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20220930.htm",
      "contextRef": "if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ComprehensiveIncomeNoteTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000018 - Disclosure - Other Comprehensive Income (Loss)",
     "role": "http://www.lilly.com/role/OtherComprehensiveIncomeLoss",
     "shortName": "Other Comprehensive Income (Loss)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20220930.htm",
      "contextRef": "if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ComprehensiveIncomeNoteTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20220930.htm",
      "contextRef": "if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000019 - Disclosure - Other\u2013Net, (Income) Expense",
     "role": "http://www.lilly.com/role/OtherNetIncomeExpense",
     "shortName": "Other\u2013Net, (Income) Expense",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20220930.htm",
      "contextRef": "if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20220930.htm",
      "contextRef": "i19fc0325c48543008ea71e1fdcf11d86_D20220701-20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000002 - Statement - Consolidated Condensed Statements of Operations (Unaudited)",
     "role": "http://www.lilly.com/role/ConsolidatedCondensedStatementsofOperationsUnaudited",
     "shortName": "Consolidated Condensed Statements of Operations (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20220930.htm",
      "contextRef": "i19fc0325c48543008ea71e1fdcf11d86_D20220701-20220930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20220930.htm",
      "contextRef": "if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpensePolicy",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000020 - Disclosure - Basis of Presentation and Implementation of New Financial Accounting Standard (Policies)",
     "role": "http://www.lilly.com/role/BasisofPresentationandImplementationofNewFinancialAccountingStandardPolicies",
     "shortName": "Basis of Presentation and Implementation of New Financial Accounting Standard (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20220930.htm",
      "contextRef": "if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpensePolicy",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20220930.htm",
      "contextRef": "if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000021 - Disclosure - Revenue (Tables)",
     "role": "http://www.lilly.com/role/RevenueTables",
     "shortName": "Revenue (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20220930.htm",
      "contextRef": "if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20220930.htm",
      "contextRef": "if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000022 - Disclosure - Acquisitions (Tables)",
     "role": "http://www.lilly.com/role/AcquisitionsTables",
     "shortName": "Acquisitions (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20220930.htm",
      "contextRef": "if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20220930.htm",
      "contextRef": "if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000023 - Disclosure - Collaborations and Other Arrangements (Tables)",
     "role": "http://www.lilly.com/role/CollaborationsandOtherArrangementsTables",
     "shortName": "Collaborations and Other Arrangements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20220930.htm",
      "contextRef": "if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20220930.htm",
      "contextRef": "if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000024 - Disclosure - Asset Impairment, Restructuring, and Other Special Charges (Tables)",
     "role": "http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialChargesTables",
     "shortName": "Asset Impairment, Restructuring, and Other Special Charges (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20220930.htm",
      "contextRef": "if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20220930.htm",
      "contextRef": "if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000025 - Disclosure - Financial Instruments (Tables)",
     "role": "http://www.lilly.com/role/FinancialInstrumentsTables",
     "shortName": "Financial Instruments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20220930.htm",
      "contextRef": "if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20220930.htm",
      "contextRef": "if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000026 - Disclosure - Retirement Benefits (Tables)",
     "role": "http://www.lilly.com/role/RetirementBenefitsTables",
     "shortName": "Retirement Benefits (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20220930.htm",
      "contextRef": "if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20220930.htm",
      "contextRef": "if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000027 - Disclosure - Other Comprehensive Income (Loss) (Tables)",
     "role": "http://www.lilly.com/role/OtherComprehensiveIncomeLossTables",
     "shortName": "Other Comprehensive Income (Loss) (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20220930.htm",
      "contextRef": "if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20220930.htm",
      "contextRef": "if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000028 - Disclosure - Other\u2013Net, (Income) Expense (Tables)",
     "role": "http://www.lilly.com/role/OtherNetIncomeExpenseTables",
     "shortName": "Other\u2013Net, (Income) Expense (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20220930.htm",
      "contextRef": "if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20220930.htm",
      "contextRef": "i19fc0325c48543008ea71e1fdcf11d86_D20220701-20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000029 - Disclosure - Revenue (Summary of Revenue Recognized) (Details)",
     "role": "http://www.lilly.com/role/RevenueSummaryofRevenueRecognizedDetails",
     "shortName": "Revenue (Summary of Revenue Recognized) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20220930.htm",
      "contextRef": "if42877c131ac415eb21599c372b78f90_D20220701-20220930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20220930.htm",
      "contextRef": "i19fc0325c48543008ea71e1fdcf11d86_D20220701-20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000003 - Statement - Consolidated Condensed Statements of Comprehensive Income (Unaudited)",
     "role": "http://www.lilly.com/role/ConsolidatedCondensedStatementsofComprehensiveIncomeUnaudited",
     "shortName": "Consolidated Condensed Statements of Comprehensive Income (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20220930.htm",
      "contextRef": "i19fc0325c48543008ea71e1fdcf11d86_D20220701-20220930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:ComprehensiveIncomeNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20220930.htm",
      "contextRef": "i46e52d8ad0e14ebf9fa7c9ecc503bbfa_D20220701-20220930",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "lly:RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000030 - Disclosure - Revenue (Adjustments to Revenue) (Details)",
     "role": "http://www.lilly.com/role/RevenueAdjustmentstoRevenueDetails",
     "shortName": "Revenue (Adjustments to Revenue) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20220930.htm",
      "contextRef": "i46e52d8ad0e14ebf9fa7c9ecc503bbfa_D20220701-20220930",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "lly:RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20220930.htm",
      "contextRef": "i08ccb35f6ad24d7793c9c91b74ca2ea1_I20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerLiability",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000031 - Disclosure - Revenue (Contract Liabilities) (Details)",
     "role": "http://www.lilly.com/role/RevenueContractLiabilitiesDetails",
     "shortName": "Revenue (Contract Liabilities) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20220930.htm",
      "contextRef": "i19fc0325c48543008ea71e1fdcf11d86_D20220701-20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000032 - Disclosure - Revenue (Disaggregation of Revenue by Product) (Details)",
     "role": "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails",
     "shortName": "Revenue (Disaggregation of Revenue by Product) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20220930.htm",
      "contextRef": "i553eac0570bc41a68be3130cb9383387_D20220701-20220930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20220930.htm",
      "contextRef": "i19fc0325c48543008ea71e1fdcf11d86_D20220701-20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000033 - Disclosure - Revenue (Disaggregation of Revenue by Geographical Area) (Details)",
     "role": "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyGeographicalAreaDetails",
     "shortName": "Revenue (Disaggregation of Revenue by Geographical Area) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20220930.htm",
      "contextRef": "i812f3d20a1af4d92924e0bbe1371c71e_D20220701-20220930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20220930.htm",
      "contextRef": "i19fc0325c48543008ea71e1fdcf11d86_D20220701-20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "lly:AcquiredInProcessResearchAndDevelopmentAndDevelopmentMilestones",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000034 - Disclosure - Acquisitions (Narrative) (Details)",
     "role": "http://www.lilly.com/role/AcquisitionsNarrativeDetails",
     "shortName": "Acquisitions (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20220930.htm",
      "contextRef": "id1a51594b8b04df48cf5b7eff20f7e6d_I20210131",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:BusinessAcquisitionSharePrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20220930.htm",
      "contextRef": "i08ccb35f6ad24d7793c9c91b74ca2ea1_I20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000035 - Disclosure - Acquisitions (Assets Acquired and Liabilities Assumed) (Details)",
     "role": "http://www.lilly.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails",
     "shortName": "Acquisitions (Assets Acquired and Liabilities Assumed) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20220930.htm",
      "contextRef": "ie6db4c7ca7af4463afc62347bd8b3a94_I20210122",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20220930.htm",
      "contextRef": "if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "lly:PaymentsForAssetAcquisitions",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000036 - Disclosure - Acquisitions (Asset Acquisitions) (Details)",
     "role": "http://www.lilly.com/role/AcquisitionsAssetAcquisitionsDetails",
     "shortName": "Acquisitions (Asset Acquisitions) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20220930.htm",
      "contextRef": "i3b190c0fcac94cb9b4d37191d35b87bb_D20220201-20220228",
      "decimals": "-5",
      "lang": "en-US",
      "name": "lly:PaymentsForAssetAcquisitions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20220930.htm",
      "contextRef": "i19fc0325c48543008ea71e1fdcf11d86_D20220701-20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000037 - Disclosure - Collaborations and Other Arrangements (Details)",
     "role": "http://www.lilly.com/role/CollaborationsandOtherArrangementsDetails",
     "shortName": "Collaborations and Other Arrangements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20220930.htm",
      "contextRef": "i91e1bea218144eab958a68c72b25b13d_D20220701-20220930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20220930.htm",
      "contextRef": "i19fc0325c48543008ea71e1fdcf11d86_D20220701-20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SeveranceCosts1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000038 - Disclosure - Asset Impairment, Restructuring, and Other Special Charges (Details)",
     "role": "http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialChargesDetails",
     "shortName": "Asset Impairment, Restructuring, and Other Special Charges (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20220930.htm",
      "contextRef": "i19fc0325c48543008ea71e1fdcf11d86_D20220701-20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SeveranceCosts1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20220930.htm",
      "contextRef": "if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MaximumRemainingMaturityOfForeignCurrencyDerivatives1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000039 - Disclosure - Financial Instruments (Narrative) (Details)",
     "role": "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails",
     "shortName": "Financial Instruments (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20220930.htm",
      "contextRef": "if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MaximumRemainingMaturityOfForeignCurrencyDerivatives1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20220930.htm",
      "contextRef": "i08ccb35f6ad24d7793c9c91b74ca2ea1_I20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000004 - Statement - Consolidated Condensed Balance Sheets",
     "role": "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets",
     "shortName": "Consolidated Condensed Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20220930.htm",
      "contextRef": "i08ccb35f6ad24d7793c9c91b74ca2ea1_I20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20220930.htm",
      "contextRef": "i19fc0325c48543008ea71e1fdcf11d86_D20220701-20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "lly:DerivativeInstrumentsGainLossRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000040 - Disclosure - Financial Instruments (Effect of Risk-Management Instruments) (Details)",
     "role": "http://www.lilly.com/role/FinancialInstrumentsEffectofRiskManagementInstrumentsDetails",
     "shortName": "Financial Instruments (Effect of Risk-Management Instruments) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20220930.htm",
      "contextRef": "i19fc0325c48543008ea71e1fdcf11d86_D20220701-20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "lly:DerivativeInstrumentsGainLossRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20220930.htm",
      "contextRef": "i08ccb35f6ad24d7793c9c91b74ca2ea1_I20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermInvestments",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000041 - Disclosure - Financial Instruments (Fair Value of Financial Instruments) (Details)",
     "role": "http://www.lilly.com/role/FinancialInstrumentsFairValueofFinancialInstrumentsDetails",
     "shortName": "Financial Instruments (Fair Value of Financial Instruments) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20220930.htm",
      "contextRef": "ia25fb80ee7f14608ad1bc42cf7dc3d85_I20220930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueByBalanceSheetGroupingTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20220930.htm",
      "contextRef": "ia25fb80ee7f14608ad1bc42cf7dc3d85_I20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000042 - Disclosure - Financial Instruments (Risk Management Instruments) (Details)",
     "role": "http://www.lilly.com/role/FinancialInstrumentsRiskManagementInstrumentsDetails",
     "shortName": "Financial Instruments (Risk Management Instruments) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueByBalanceSheetGroupingTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20220930.htm",
      "contextRef": "ia25fb80ee7f14608ad1bc42cf7dc3d85_I20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20220930.htm",
      "contextRef": "i08ccb35f6ad24d7793c9c91b74ca2ea1_I20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000043 - Disclosure - Financial Instruments (Contractual Maturities) (Details)",
     "role": "http://www.lilly.com/role/FinancialInstrumentsContractualMaturitiesDetails",
     "shortName": "Financial Instruments (Contractual Maturities) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20220930.htm",
      "contextRef": "i08ccb35f6ad24d7793c9c91b74ca2ea1_I20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20220930.htm",
      "contextRef": "i08ccb35f6ad24d7793c9c91b74ca2ea1_I20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000044 - Disclosure - Financial Instruments (Unrealized Gains and Losses) (Details)",
     "role": "http://www.lilly.com/role/FinancialInstrumentsUnrealizedGainsandLossesDetails",
     "shortName": "Financial Instruments (Unrealized Gains and Losses) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20220930.htm",
      "contextRef": "i08ccb35f6ad24d7793c9c91b74ca2ea1_I20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:GainLossOnInvestmentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20220930.htm",
      "contextRef": "i19fc0325c48543008ea71e1fdcf11d86_D20220701-20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "lly:ProceedsfromSaleofEquityandAvailableforSaleSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000045 - Disclosure - Financial Instruments (Realized Gains and Losses) (Details)",
     "role": "http://www.lilly.com/role/FinancialInstrumentsRealizedGainsandLossesDetails",
     "shortName": "Financial Instruments (Realized Gains and Losses) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:GainLossOnInvestmentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20220930.htm",
      "contextRef": "i19fc0325c48543008ea71e1fdcf11d86_D20220701-20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "lly:ProceedsfromSaleofEquityandAvailableforSaleSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20220930.htm",
      "contextRef": "i19fc0325c48543008ea71e1fdcf11d86_D20220701-20220930",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000046 - Disclosure - Income Taxes (Details)",
     "role": "http://www.lilly.com/role/IncomeTaxesDetails",
     "shortName": "Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20220930.htm",
      "contextRef": "i19fc0325c48543008ea71e1fdcf11d86_D20220701-20220930",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20220930.htm",
      "contextRef": "ifea67e1feada4a8c8d0bf25c34910e9a_D20220701-20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanServiceCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000047 - Disclosure - Retirement Benefits (Components of Net Periodic Benefit Cost) (Details)",
     "role": "http://www.lilly.com/role/RetirementBenefitsComponentsofNetPeriodicBenefitCostDetails",
     "shortName": "Retirement Benefits (Components of Net Periodic Benefit Cost) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20220930.htm",
      "contextRef": "ifea67e1feada4a8c8d0bf25c34910e9a_D20220701-20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanServiceCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20220930.htm",
      "contextRef": "iedfe8e594f2d4534ba3f7d18996055ec_I20220930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "lly:LossContingencyNumberOfSitesJointlyAndSeverallyLiableForCleanup",
      "reportCount": 1,
      "unitRef": "site",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000048 - Disclosure - Contingencies (Details)",
     "role": "http://www.lilly.com/role/ContingenciesDetails",
     "shortName": "Contingencies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20220930.htm",
      "contextRef": "i03a0a6037fc44e39af8b9a0fc87cbcbb_D20090301-20220930",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:LossContingencyNumberOfPlaintiffs",
      "reportCount": 1,
      "unique": true,
      "unitRef": "plaintiff",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20220930.htm",
      "contextRef": "i0973ba0c1d894ceaa494709a13f814fb_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000049 - Disclosure - Other Comprehensive Income (Loss) (AOCI) (Details)",
     "role": "http://www.lilly.com/role/OtherComprehensiveIncomeLossAOCIDetails",
     "shortName": "Other Comprehensive Income (Loss) (AOCI) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20220930.htm",
      "contextRef": "i19fc0325c48543008ea71e1fdcf11d86_D20220701-20220930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20220930.htm",
      "contextRef": "i08ccb35f6ad24d7793c9c91b74ca2ea1_I20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000005 - Statement - Consolidated Condensed Balance Sheets (Parenthetical)",
     "role": "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheetsParenthetical",
     "shortName": "Consolidated Condensed Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20220930.htm",
      "contextRef": "i08ccb35f6ad24d7793c9c91b74ca2ea1_I20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20220930.htm",
      "contextRef": "i19fc0325c48543008ea71e1fdcf11d86_D20220701-20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000050 - Disclosure - Other Comprehensive Income (Loss) (Tax Effect) (Details)",
     "role": "http://www.lilly.com/role/OtherComprehensiveIncomeLossTaxEffectDetails",
     "shortName": "Other Comprehensive Income (Loss) (Tax Effect) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20220930.htm",
      "contextRef": "i19fc0325c48543008ea71e1fdcf11d86_D20220701-20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20220930.htm",
      "contextRef": "i19fc0325c48543008ea71e1fdcf11d86_D20220701-20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherNonoperatingIncomeExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000051 - Disclosure - Other Comprehensive Income (Loss) (Reclassification) (Details)",
     "role": "http://www.lilly.com/role/OtherComprehensiveIncomeLossReclassificationDetails",
     "shortName": "Other Comprehensive Income (Loss) (Reclassification) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20220930.htm",
      "contextRef": "i294aedf137cf40faaba28e6d98a540dc_D20220701-20220930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20220930.htm",
      "contextRef": "i19fc0325c48543008ea71e1fdcf11d86_D20220701-20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InterestExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000052 - Disclosure - Other\u2013Net, (Income) Expense (Details)",
     "role": "http://www.lilly.com/role/OtherNetIncomeExpenseDetails",
     "shortName": "Other\u2013Net, (Income) Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20220930.htm",
      "contextRef": "i19fc0325c48543008ea71e1fdcf11d86_D20220701-20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InterestExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20220930.htm",
      "contextRef": "id40dc90365d54458840dc95bd54da311_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000006 - Statement - Consolidated Condensed Statements of Equity",
     "role": "http://www.lilly.com/role/ConsolidatedCondensedStatementsofEquity",
     "shortName": "Consolidated Condensed Statements of Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20220930.htm",
      "contextRef": "id40dc90365d54458840dc95bd54da311_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20220930.htm",
      "contextRef": "if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockDividendsPerShareDeclared",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000007 - Statement - Consolidated Condensed Statements of Equity (Parenthetical)",
     "role": "http://www.lilly.com/role/ConsolidatedCondensedStatementsofEquityParenthetical",
     "shortName": "Consolidated Condensed Statements of Equity (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20220930.htm",
      "contextRef": "if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockDividendsPerShareDeclared",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20220930.htm",
      "contextRef": "if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000008 - Statement - Consolidated Condensed Statements of Cash Flows",
     "role": "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows",
     "shortName": "Consolidated Condensed Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20220930.htm",
      "contextRef": "if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20220930.htm",
      "contextRef": "if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000009 - Disclosure - Basis of Presentation and Implementation of New Financial Accounting Standard",
     "role": "http://www.lilly.com/role/BasisofPresentationandImplementationofNewFinancialAccountingStandard",
     "shortName": "Basis of Presentation and Implementation of New Financial Accounting Standard",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20220930.htm",
      "contextRef": "if8dcfbea11824c45a6c960ab0a956d04_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 136,
   "tag": {
    "country_BR": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "BRAZIL",
        "terseLabel": "Brazil"
       }
      }
     },
     "localname": "BR",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_CN": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CHINA",
        "terseLabel": "China"
       }
      }
     },
     "localname": "CN",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyGeographicalAreaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_JP": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "JAPAN",
        "terseLabel": "Japan"
       }
      }
     },
     "localname": "JP",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyGeographicalAreaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "U.S."
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.lilly.com/role/RevenueAdjustmentstoRevenueDetails",
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyGeographicalAreaDetails",
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Document Information [Line Items]",
        "terseLabel": "Document Information [Line Items]"
       }
      }
     },
     "localname": "DocumentInformationLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentInformationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.",
        "label": "Document Information [Table]",
        "terseLabel": "Document Information [Table]"
       }
      }
     },
     "localname": "DocumentInformationTable",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r654"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r655"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r652"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]",
        "terseLabel": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r652"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r652"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r663"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r652"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r652"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r652"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r652"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]",
        "terseLabel": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r651"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r653"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "lly_A050NotesDue2033Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "0.50% Notes Due 2033 [Member]",
        "label": "0.50% Notes Due 2033 [Member]",
        "terseLabel": "0.50% Notes Due 2033"
       }
      }
     },
     "localname": "A050NotesDue2033Member",
     "nsuri": "http://www.lilly.com/20220930",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A1.625NotesDueJune22026Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1.625% Notes Due June 2, 2026 [Member]",
        "label": "1.625% Notes Due June 2, 2026 [Member]",
        "terseLabel": "1.625% Notes due 2026"
       }
      }
     },
     "localname": "A1.625NotesDueJune22026Member",
     "nsuri": "http://www.lilly.com/20220930",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A1125NotesDue2051Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1.125% Notes Due 2051",
        "label": "1.125% Notes Due 2051 [Member]",
        "terseLabel": "1.125% Notes due 2051"
       }
      }
     },
     "localname": "A1125NotesDue2051Member",
     "nsuri": "http://www.lilly.com/20220930",
     "presentation": [
      "http://www.lilly.com/role/CoverPage",
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A1375NotesDue2061Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1.375% Notes Due 2061",
        "label": "1.375% Notes Due 2061 [Member]",
        "terseLabel": "1.375% Notes due 2061"
       }
      }
     },
     "localname": "A1375NotesDue2061Member",
     "nsuri": "http://www.lilly.com/20220930",
     "presentation": [
      "http://www.lilly.com/role/CoverPage",
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A1625NotesDue2043Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1.625% Notes Due 2043",
        "label": "1.625% Notes Due 2043 [Member]",
        "terseLabel": "1.625% Notes due 2043"
       }
      }
     },
     "localname": "A1625NotesDue2043Member",
     "nsuri": "http://www.lilly.com/20220930",
     "presentation": [
      "http://www.lilly.com/role/CoverPage",
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A1700NotesDue2049Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1.700% Notes due 2049 [Member]",
        "label": "1.700% Notes Due 2049 [Member]",
        "terseLabel": "1.700% Notes due 2049"
       }
      }
     },
     "localname": "A1700NotesDue2049Member",
     "nsuri": "http://www.lilly.com/20220930",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A2.125NotesDueJune32030Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.125% Notes Due June 3, 2030 [Member]",
        "label": "2.125% Notes Due June 3, 2030 [Member]",
        "terseLabel": "2.125% Notes due 2030"
       }
      }
     },
     "localname": "A2.125NotesDueJune32030Member",
     "nsuri": "http://www.lilly.com/20220930",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A3375NotesDue2029Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "3.375% Notes Due 2029 [Member]",
        "label": "3.375% Notes Due 2029 [Member]",
        "terseLabel": "3.375% Notes Due 2029"
       }
      }
     },
     "localname": "A3375NotesDue2029Member",
     "nsuri": "http://www.lilly.com/20220930",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A395NotesDue2049Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "3.95% Notes Due 2049 [Member]",
        "label": "3.95% Notes Due 2049 [Member]",
        "terseLabel": "3.95% Notes Due 2049"
       }
      }
     },
     "localname": "A395NotesDue2049Member",
     "nsuri": "http://www.lilly.com/20220930",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A415NotesDue2059Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "4.15% Notes Due 2059 [Member]",
        "label": "4.15% Notes Due 2059 [Member]",
        "terseLabel": "4.15% Notes Due 2059"
       }
      }
     },
     "localname": "A415NotesDue2059Member",
     "nsuri": "http://www.lilly.com/20220930",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A500NotesDue2033Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": ".500% Notes Due 2033 [Member]",
        "label": ".500% Notes Due 2033 [Member]",
        "terseLabel": "0.500% Notes due 2033"
       }
      }
     },
     "localname": "A500NotesDue2033Member",
     "nsuri": "http://www.lilly.com/20220930",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A6.77NotesDueJanuary12036Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "6.77%\u00a0Notes Due January\u00a01, 2036 [Member]",
        "label": "6.77%\u00a0Notes Due January\u00a01, 2036 [Member]",
        "terseLabel": "6.77%\u00a0Notes due 2036"
       }
      }
     },
     "localname": "A6.77NotesDueJanuary12036Member",
     "nsuri": "http://www.lilly.com/20220930",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A625NotesDue2031Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": ".625% Notes due 2031 [Member]",
        "label": ".625% Notes Due 2031 [Member]",
        "terseLabel": "0.625% Notes due 2031"
       }
      }
     },
     "localname": "A625NotesDue2031Member",
     "nsuri": "http://www.lilly.com/20220930",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A718NotesDueJune12025Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "7 1/8% Notes Due June\u00a01, 2025 [Member]",
        "label": "7 1/8% Notes Due June\u00a01, 2025 [Member]",
        "terseLabel": "7 1/8% Notes due 2025"
       }
      }
     },
     "localname": "A718NotesDueJune12025Member",
     "nsuri": "http://www.lilly.com/20220930",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_AccumulatedGainLossNetCashFlowHedgeAndForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated Gain (Loss), Net, Cash Flow Hedge And Foreign Currency Adjustment, Including Portion Attributable To Noncontrolling Interest",
        "label": "Accumulated Gain (Loss), Net, Cash Flow Hedge And Foreign Currency Adjustment, Including Portion Attributable To Noncontrolling Interest [Member]",
        "terseLabel": "Other, net of tax"
       }
      }
     },
     "localname": "AccumulatedGainLossNetCashFlowHedgeAndForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember",
     "nsuri": "http://www.lilly.com/20220930",
     "presentation": [
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossReclassificationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_AcquiredInProcessResearchAndDevelopment": {
     "auth_ref": [],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of EXPENSE related to research and development assets that are acquired in a business combination (pre-141R) and/or licensing arrangement that have no alternative future use and are therefore written off in the period of acquisition (INCOME STATEMENT)",
        "label": "Acquired In-process Research And Development",
        "terseLabel": "Acquired in-process research and development"
       }
      }
     },
     "localname": "AcquiredInProcessResearchAndDevelopment",
     "nsuri": "http://www.lilly.com/20220930",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lly_AcquiredInProcessResearchAndDevelopmentAndDevelopmentMilestones": {
     "auth_ref": [],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofOperationsUnaudited": {
       "order": 1.0,
       "parentTag": "lly_CostOfSalesOperatingExpensesAndOtherNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Acquired In-Process Research And Development And Development Milestones",
        "label": "Acquired In-Process Research And Development And Development Milestones",
        "terseLabel": "Acquired in-process research and development and development milestones (Note 3)",
        "verboseLabel": "Acquired in-process research and development and development milestones"
       }
      }
     },
     "localname": "AcquiredInProcessResearchAndDevelopmentAndDevelopmentMilestones",
     "nsuri": "http://www.lilly.com/20220930",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsNarrativeDetails",
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lly_AkouosAcquisitionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Akouos Acquisition [Member]",
        "label": "Akouos Acquisition [Member]",
        "terseLabel": "Akouos Acquisition"
       }
      }
     },
     "localname": "AkouosAcquisitionMember",
     "nsuri": "http://www.lilly.com/20220930",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_AlimtaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Alimta [Member]",
        "label": "Alimta [Member]",
        "terseLabel": "Alimta\u00ae"
       }
      }
     },
     "localname": "AlimtaMember",
     "nsuri": "http://www.lilly.com/20220930",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_AssetImpairmentChargesRecoveriesAndOtherSpecialCharges": {
     "auth_ref": [],
     "calculation": {
      "http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialChargesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_RestructuringSettlementAndImpairmentProvisions",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset Impairment Charges (Recoveries) And Other Special Charges",
        "label": "Asset Impairment Charges (Recoveries) And Other Special Charges",
        "terseLabel": "Asset impairment and other special charges"
       }
      }
     },
     "localname": "AssetImpairmentChargesRecoveriesAndOtherSpecialCharges",
     "nsuri": "http://www.lilly.com/20220930",
     "presentation": [
      "http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialChargesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lly_AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Available for Sale Securities and Equity Securities, FV-NI, Realized Gain",
        "label": "Available for Sale Securities and Equity Securities, FV-NI, Realized Gain",
        "terseLabel": "Realized gross gains on sales"
       }
      }
     },
     "localname": "AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain",
     "nsuri": "http://www.lilly.com/20220930",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsRealizedGainsandLossesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lly_AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Available for sale Securities and Equity Securities, FV-NI, Realized Loss",
        "label": "Available for sale Securities and Equity Securities, FV-NI, Realized Loss",
        "terseLabel": "Realized gross losses on sales"
       }
      }
     },
     "localname": "AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss",
     "nsuri": "http://www.lilly.com/20220930",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsRealizedGainsandLossesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lly_BasaglarMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Basaglar [Member]",
        "label": "Basaglar [Member]",
        "terseLabel": "Basaglar\u00ae",
        "verboseLabel": "Basaglar"
       }
      }
     },
     "localname": "BasaglarMember",
     "nsuri": "http://www.lilly.com/20220930",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsDetails",
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_BioMarinPharmaceuticalIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "BioMarin Pharmaceutical Inc",
        "label": "BioMarin Pharmaceutical Inc [Member]",
        "terseLabel": "BioMarin Pharmaceutical Inc."
       }
      }
     },
     "localname": "BioMarinPharmaceuticalIncMember",
     "nsuri": "http://www.lilly.com/20220930",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsAssetAcquisitionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_BusinessAcquisitionContingentValueRightAdditionalPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Acquisition, Contingent Value Right, Additional Price Per Share",
        "label": "Business Acquisition, Contingent Value Right, Additional Price Per Share",
        "terseLabel": "Contingent value right, additional price per share (up to) (in dollars per share)"
       }
      }
     },
     "localname": "BusinessAcquisitionContingentValueRightAdditionalPricePerShare",
     "nsuri": "http://www.lilly.com/20220930",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "lly_BusinessAcquisitionContingentValueRightRegulatoryApprovalDelayMonthlyReduction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Acquisition, Contingent Value Right, Covenant, Regulatory Approval Occurs",
        "label": "Business Acquisition, Contingent Value Right, Regulatory Approval Delay, Monthly Reduction",
        "terseLabel": "Contingent value right, monthly reduction (in cents per share)"
       }
      }
     },
     "localname": "BusinessAcquisitionContingentValueRightRegulatoryApprovalDelayMonthlyReduction",
     "nsuri": "http://www.lilly.com/20220930",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "lly_BusinessCombinationConsiderationTransferredNumberOfContingentValueRights": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Consideration Transferred, Number Of Contingent Value Rights",
        "label": "Business Combination, Consideration Transferred, Number Of Contingent Value Rights",
        "terseLabel": "Consideration transferred, number of contingent value rights"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferredNumberOfContingentValueRights",
     "nsuri": "http://www.lilly.com/20220930",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.lilly.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Assets (Liabilities), Net",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Assets (Liabilities), Net",
        "terseLabel": "Other assets and liabilities, net"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet",
     "nsuri": "http://www.lilly.com/20220930",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lly_BuyBritishPoundandSellUSDollarsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Buy British Pound and Sell US Dollars [Member]",
        "label": "Buy British Pound and Sell US Dollars [Member]",
        "terseLabel": "Buy British Pounds and Sell U.S. Dollars"
       }
      }
     },
     "localname": "BuyBritishPoundandSellUSDollarsMember",
     "nsuri": "http://www.lilly.com/20220930",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_BuyEuroSellUsDollarMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Foreign Currency Forward Commitment to Buy euro Sell US dollar",
        "label": "Buy Euro Sell Us Dollar [Member]",
        "terseLabel": "Buy Euros Sell U.S. Dollars"
       }
      }
     },
     "localname": "BuyEuroSellUsDollarMember",
     "nsuri": "http://www.lilly.com/20220930",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_BuyUSDollarSellChineseYuanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Buy US Dollar Sell Chinese Yuan",
        "label": "Buy US Dollar Sell Chinese Yuan [Member]",
        "terseLabel": "Buy US Dollar Sell Chinese Yuan"
       }
      }
     },
     "localname": "BuyUSDollarSellChineseYuanMember",
     "nsuri": "http://www.lilly.com/20220930",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_BuyUSdollarSellJapaneseYenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Buy US dollar Sell Japanese Yen [Member]",
        "label": "Buy US dollar Sell Japanese Yen [Member]",
        "terseLabel": "Buy U.S. Dollars Sell Japanese Yen"
       }
      }
     },
     "localname": "BuyUSdollarSellJapaneseYenMember",
     "nsuri": "http://www.lilly.com/20220930",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_BuyUsDollarSellEuroMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Foreign Currency Forward commitment to Buy US dollar Sell euro",
        "label": "Buy Us Dollar Sell Euro [Member]",
        "terseLabel": "Buy U.S. Dollars Sell Euros"
       }
      }
     },
     "localname": "BuyUsDollarSellEuroMember",
     "nsuri": "http://www.lilly.com/20220930",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_ByettaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Byetta",
        "label": "Byetta [Member]",
        "terseLabel": "Byetta"
       }
      }
     },
     "localname": "ByettaMember",
     "nsuri": "http://www.lilly.com/20220930",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_COVID19AntibodiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "COVID-19 Antibodies",
        "label": "COVID-19 Antibodies [Member]",
        "terseLabel": "COVID-19 antibodies"
       }
      }
     },
     "localname": "COVID19AntibodiesMember",
     "nsuri": "http://www.lilly.com/20220930",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsDetails",
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_CashFlowHedgeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash Flow Hedge [Abstract]",
        "label": "Cash Flow Hedge [Abstract]",
        "terseLabel": "Cash flow hedges:"
       }
      }
     },
     "localname": "CashFlowHedgeAbstract",
     "nsuri": "http://www.lilly.com/20220930",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsEffectofRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "lly_CialisMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cialis [Member]",
        "label": "Cialis [Member]",
        "terseLabel": "Cialis\u00ae"
       }
      }
     },
     "localname": "CialisMember",
     "nsuri": "http://www.lilly.com/20220930",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_CollaborationandOtherRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration and Other Revenue [Member]",
        "label": "Collaboration and Other Revenue [Member]",
        "verboseLabel": "Collaboration and other revenue"
       }
      }
     },
     "localname": "CollaborationandOtherRevenueMember",
     "nsuri": "http://www.lilly.com/20220930",
     "presentation": [
      "http://www.lilly.com/role/RevenueSummaryofRevenueRecognizedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_CollaborativeArrangementRightsAndObligationsPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of rights and obligations under the collaborative arrangements, including but not limited to - percent share in various revenues and costs, percent interest earned on related party notes.",
        "label": "Collaborative Arrangement, Rights and Obligations Percent",
        "terseLabel": "Collaborative arrangement, rights and obligations, percentage (up to)"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsPercent",
     "nsuri": "http://www.lilly.com/20220930",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "lly_CollaborativeArrangementRightsAndObligationsRightsObligations": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Terms or rights and obligations under collaborative arrangements.",
        "label": "Collaborative Arrangement, Rights and Obligations, Rights (Obligations)",
        "terseLabel": "Potential achievements"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsRightsObligations",
     "nsuri": "http://www.lilly.com/20220930",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lly_CostOfSalesOperatingExpensesAndOtherNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofOperationsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost Of Sales, Operating Expenses, And Other-net",
        "label": "Cost Of Sales, Operating Expenses, And Other-net",
        "totalLabel": "Costs, expenses, and other"
       }
      }
     },
     "localname": "CostOfSalesOperatingExpensesAndOtherNet",
     "nsuri": "http://www.lilly.com/20220930",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lly_CymbaltaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cymbalta [Member]",
        "label": "Cymbalta [Member]",
        "terseLabel": "Cymbalta\u00ae"
       }
      }
     },
     "localname": "CymbaltaMember",
     "nsuri": "http://www.lilly.com/20220930",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_CyramzaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cyramza [Member]",
        "label": "Cyramza [Member]",
        "terseLabel": "Cyramza\u00ae"
       }
      }
     },
     "localname": "CyramzaMember",
     "nsuri": "http://www.lilly.com/20220930",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_DebtSecuritiesAvailableForSaleUnrealizedLossPositionQualitativeDisclosureOtherPercentageOfNonperformingAssets": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities, available-for-sale, unrealized loss position, qualitative disclosure, other, percentage of nonperforming assets.",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Qualitative Disclosure, Other, Percentage of Nonperforming Assets",
        "terseLabel": "Available-for-sale, percentage of nonperforming assets"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionQualitativeDisclosureOtherPercentageOfNonperformingAssets",
     "nsuri": "http://www.lilly.com/20220930",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "lly_DebtSecuritiesAvailableforsaleUnrealizedGainPosition": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Securities, Available-for-sale, Unrealized Gain Position",
        "label": "Debt Securities, Available-for-sale, Unrealized Gain Position",
        "terseLabel": "Fair value of securities in an unrealized gain position"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableforsaleUnrealizedGainPosition",
     "nsuri": "http://www.lilly.com/20220930",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsUnrealizedGainsandLossesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lly_DerivativeInstrumentsGainLossRecognized": {
     "auth_ref": [],
     "calculation": {
      "http://www.lilly.com/role/FinancialInstrumentsEffectofRiskManagementInstrumentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative Instruments, Gain (Loss) Recognized",
        "label": "Derivative Instruments, Gain (Loss) Recognized",
        "negatedTotalLabel": "Total"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossRecognized",
     "nsuri": "http://www.lilly.com/20220930",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsEffectofRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lly_DescriptionOfDerivativeActivityVolumePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of Derivative Activity Volume Percent",
        "label": "Description of Derivative Activity Volume Percent",
        "terseLabel": "Percentage of long-term fixed-rate notes to floating rates through the use of interest rate swaps converted"
       }
      }
     },
     "localname": "DescriptionOfDerivativeActivityVolumePercent",
     "nsuri": "http://www.lilly.com/20220930",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "lly_DiabetesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Diabetes [Member]",
        "label": "Diabetes [Member]",
        "terseLabel": "Diabetes"
       }
      }
     },
     "localname": "DiabetesMember",
     "nsuri": "http://www.lilly.com/20220930",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_EmgalityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Emgality [Member]",
        "label": "Emgality [Member]",
        "terseLabel": "Emgality\u00ae"
       }
      }
     },
     "localname": "EmgalityMember",
     "nsuri": "http://www.lilly.com/20220930",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_EmgalityPatentLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Emgality Patent Litigation [Member]",
        "label": "Emgality Patent Litigation [Member]",
        "terseLabel": "Emgality Patent Litigation"
       }
      }
     },
     "localname": "EmgalityPatentLitigationMember",
     "nsuri": "http://www.lilly.com/20220930",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_EmployeeLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee Litigation [Member]",
        "label": "Employee Litigation [Member]",
        "terseLabel": "Employee Litigation"
       }
      }
     },
     "localname": "EmployeeLitigationMember",
     "nsuri": "http://www.lilly.com/20220930",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_EquityMethodAndOtherInvestmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Method and Other Investments [Member]",
        "label": "Equity Method And Other Investments [Member]",
        "verboseLabel": "Equity method investments"
       }
      }
     },
     "localname": "EquityMethodAndOtherInvestmentsMember",
     "nsuri": "http://www.lilly.com/20220930",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsFairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_ErbituxMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Erbitux [Member]",
        "label": "Erbitux [Member]",
        "terseLabel": "Erbitux\u00ae"
       }
      }
     },
     "localname": "ErbituxMember",
     "nsuri": "http://www.lilly.com/20220930",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_FairValueHedgeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair Value Hedge [Abstract]",
        "label": "Fair Value Hedge [Abstract]",
        "terseLabel": "Fair value hedges:"
       }
      }
     },
     "localname": "FairValueHedgeAbstract",
     "nsuri": "http://www.lilly.com/20220930",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsEffectofRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "lly_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair Value, Investments, Entities That Calculate Net Asset Value Per Share, Unfunded Commitments, Payment Period",
        "label": "Fair Value, Investments, Entities That Calculate Net Asset Value Per Share, Unfunded Commitments, Payment Period",
        "terseLabel": "Alternative investments, unfunded commitments, payment period"
       }
      }
     },
     "localname": "FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod",
     "nsuri": "http://www.lilly.com/20220930",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "lly_ForeignCurrencyDenominatedDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Foreign Currency Denominated Debt [Member]",
        "label": "Foreign Currency Denominated Debt [Member]",
        "terseLabel": "Foreign Currency Denominated Debt"
       }
      }
     },
     "localname": "ForeignCurrencyDenominatedDebtMember",
     "nsuri": "http://www.lilly.com/20220930",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_ForteoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Forteo [Member]",
        "label": "Forteo [Member]",
        "terseLabel": "Forteo\u00ae"
       }
      }
     },
     "localname": "ForteoMember",
     "nsuri": "http://www.lilly.com/20220930",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_HedgedFixedRateDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hedged Fixed-Rate Debt [Member]",
        "label": "Hedged Fixed Rate Debt [Member]",
        "terseLabel": "Foreign currency-denominated notes"
       }
      }
     },
     "localname": "HedgedFixedRateDebtMember",
     "nsuri": "http://www.lilly.com/20220930",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsEffectofRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_HumalogHumulinAndForteoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Humalog, Humulin, And Forteo",
        "label": "Humalog, Humulin, And Forteo [Member]",
        "terseLabel": "Humalog, Humulin and Forteo"
       }
      }
     },
     "localname": "HumalogHumulinAndForteoMember",
     "nsuri": "http://www.lilly.com/20220930",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_HumalogMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Humalog [Member]",
        "label": "Humalog [Member]",
        "terseLabel": "Humalog\u00ae"
       }
      }
     },
     "localname": "HumalogMember",
     "nsuri": "http://www.lilly.com/20220930",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_HumulinMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Humulin [Member]",
        "label": "Humulin [Member]",
        "terseLabel": "Humulin\u00ae"
       }
      }
     },
     "localname": "HumulinMember",
     "nsuri": "http://www.lilly.com/20220930",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_ImmunologyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Immunology [Member]",
        "label": "Immunology [Member]",
        "terseLabel": "Immunology"
       }
      }
     },
     "localname": "ImmunologyMember",
     "nsuri": "http://www.lilly.com/20220930",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_InnoventBiologicsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Innovent Biologics, Inc.",
        "label": "Innovent Biologics, Inc. [Member]",
        "terseLabel": "Innovent Biologics, Inc."
       }
      }
     },
     "localname": "InnoventBiologicsIncMember",
     "nsuri": "http://www.lilly.com/20220930",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_InsulinMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Insulin",
        "label": "Insulin [Member]",
        "terseLabel": "Insulin"
       }
      }
     },
     "localname": "InsulinMember",
     "nsuri": "http://www.lilly.com/20220930",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_JardianceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Jardiance [Member]",
        "label": "Jardiance [Member]",
        "terseLabel": "Jardiance"
       }
      }
     },
     "localname": "JardianceMember",
     "nsuri": "http://www.lilly.com/20220930",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsDetails",
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_LebrikizumabMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lebrikizumab [Member]",
        "label": "Lebrikizumab [Member]",
        "terseLabel": "Lebrikizumab"
       }
      }
     },
     "localname": "LebrikizumabMember",
     "nsuri": "http://www.lilly.com/20220930",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_LitigationClaimsDismissedNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Litigation, Claims Dismissed, Number",
        "label": "Litigation, Claims Dismissed, Number",
        "terseLabel": "Number of claims dismissed"
       }
      }
     },
     "localname": "LitigationClaimsDismissedNumber",
     "nsuri": "http://www.lilly.com/20220930",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "lly_LossContingencyNumberOfPatents": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Number Of Patents",
        "label": "Loss Contingency, Number Of Patents",
        "terseLabel": "Number of patents"
       }
      }
     },
     "localname": "LossContingencyNumberOfPatents",
     "nsuri": "http://www.lilly.com/20220930",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "lly_LossContingencyNumberOfSitesJointlyAndSeverallyLiableForCleanup": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Number Of Sites Jointly And Severally Liable For Cleanup",
        "label": "Loss Contingency, Number Of Sites Jointly And Severally Liable For Cleanup",
        "terseLabel": "Number of sites jointly and severally liable for cleanup (fewer than)"
       }
      }
     },
     "localname": "LossContingencyNumberOfSitesJointlyAndSeverallyLiableForCleanup",
     "nsuri": "http://www.lilly.com/20220930",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "lly_MarketableSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Marketable Securities [Member]",
        "label": "Marketable Securities [Member]",
        "terseLabel": "Marketable equity securities"
       }
      }
     },
     "localname": "MarketableSecuritiesMember",
     "nsuri": "http://www.lilly.com/20220930",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsFairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_MaturityDate2023Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maturity Date 2023 [Member]",
        "label": "Maturity Date 2023 [Member]",
        "terseLabel": "Maturity Date 2023"
       }
      }
     },
     "localname": "MaturityDate2023Member",
     "nsuri": "http://www.lilly.com/20220930",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_MilestonePaymentsCapitalizedAsIntangibleAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Payments, Capitalized As Intangible Assets",
        "label": "Milestone Payments, Capitalized As Intangible Assets [Member]",
        "terseLabel": "Milestone Payments, Capitalized as Intangible Assets"
       }
      }
     },
     "localname": "MilestonePaymentsCapitalizedAsIntangibleAssetsMember",
     "nsuri": "http://www.lilly.com/20220930",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_MilestonePaymentsDevelopmentAndRegulatoryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Payments, Development and Regulatory [Member]",
        "label": "Milestone Payments, Development and Regulatory [Member]",
        "terseLabel": "Milestone Payments, Development and Regulatory"
       }
      }
     },
     "localname": "MilestonePaymentsDevelopmentAndRegulatoryMember",
     "nsuri": "http://www.lilly.com/20220930",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Payments, Development and Regulatory, Capitalized, Cumulative [Member]",
        "label": "Milestone Payments, Development and Regulatory, Capitalized (Deferred), Cumulative [Member]",
        "terseLabel": "Milestone Payments, Development and Regulatory, Capitalized (Deferred), Cumulative"
       }
      }
     },
     "localname": "MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember",
     "nsuri": "http://www.lilly.com/20220930",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_MilestonePaymentsSalesBasedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Payments, Sales-based [Member]",
        "label": "Milestone Payments, Sales-based [Member]",
        "terseLabel": "Milestone Payments, Sales-based"
       }
      }
     },
     "localname": "MilestonePaymentsSalesBasedMember",
     "nsuri": "http://www.lilly.com/20220930",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_MilestonePaymentsSuccessBasedRegulatoryAndSalesBasedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Payments, Success-based Regulatory And Sales-based",
        "label": "Milestone Payments, Success-based Regulatory And Sales-based [Member]",
        "terseLabel": "Milestone Payments, Success-based Regulatory and Sales-based"
       }
      }
     },
     "localname": "MilestonePaymentsSuccessBasedRegulatoryAndSalesBasedMember",
     "nsuri": "http://www.lilly.com/20220930",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_MounjaroMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Mounjaro [Member]",
        "label": "Mounjaro [Member]",
        "terseLabel": "Mounjaro\u00ae"
       }
      }
     },
     "localname": "MounjaroMember",
     "nsuri": "http://www.lilly.com/20220930",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_NeuroscienceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue to unaffiliated customers, Neuroscience",
        "label": "Neuroscience [Member]",
        "terseLabel": "Neuroscience"
       }
      }
     },
     "localname": "NeuroscienceMember",
     "nsuri": "http://www.lilly.com/20220930",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_OlumiantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Olumiant [Member]",
        "label": "Olumiant [Member]",
        "terseLabel": "Olumiant\u00ae"
       }
      }
     },
     "localname": "OlumiantMember",
     "nsuri": "http://www.lilly.com/20220930",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsDetails",
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_OncologyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue to unaffiliated customers, Oncology",
        "label": "Oncology [Member]",
        "terseLabel": "Oncology"
       }
      }
     },
     "localname": "OncologyMember",
     "nsuri": "http://www.lilly.com/20220930",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_OtherDiabetesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Diabetes [Member]",
        "label": "Other Diabetes [Member]",
        "terseLabel": "Other diabetes"
       }
      }
     },
     "localname": "OtherDiabetesMember",
     "nsuri": "http://www.lilly.com/20220930",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_OtherEquitySecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Equity Securities [Member]",
        "label": "Other Equity Securities [Member]",
        "terseLabel": "Other securities, noncurrent investments"
       }
      }
     },
     "localname": "OtherEquitySecuritiesMember",
     "nsuri": "http://www.lilly.com/20220930",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsFairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_OtherForeignCountriesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Foreign Countries [Member]",
        "label": "Other Foreign Countries [Member]",
        "terseLabel": "Other foreign countries"
       }
      }
     },
     "localname": "OtherForeignCountriesMember",
     "nsuri": "http://www.lilly.com/20220930",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyGeographicalAreaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_OtherImmunologyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Immunology [Member]",
        "label": "Other Immunology [Member]",
        "terseLabel": "Other immunology"
       }
      }
     },
     "localname": "OtherImmunologyMember",
     "nsuri": "http://www.lilly.com/20220930",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_OtherNeuroscienceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Neuroscience [Member]",
        "label": "Other Neuroscience [Member]",
        "terseLabel": "Other neuroscience"
       }
      }
     },
     "localname": "OtherNeuroscienceMember",
     "nsuri": "http://www.lilly.com/20220930",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_OtherOncologyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Oncology [Member]",
        "label": "Other Oncology [Member]",
        "terseLabel": "Other oncology"
       }
      }
     },
     "localname": "OtherOncologyMember",
     "nsuri": "http://www.lilly.com/20220930",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_OtherProductMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Product [Member]",
        "label": "Other Product [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherProductMember",
     "nsuri": "http://www.lilly.com/20220930",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_OtherProductTotalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Product, Total [Member]",
        "label": "Other Product, Total [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherProductTotalMember",
     "nsuri": "http://www.lilly.com/20220930",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_PaymentsForAssetAcquisitions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments for Asset Acquisitions",
        "label": "Payments for Asset Acquisitions",
        "terseLabel": "Acquired IPR&amp;D Expense"
       }
      }
     },
     "localname": "PaymentsForAssetAcquisitions",
     "nsuri": "http://www.lilly.com/20220930",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsAssetAcquisitionsDetails",
      "http://www.lilly.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lly_PrecisionBiosciencesIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Precision Biosciences, Inc.",
        "label": "Precision Biosciences, Inc. [Member]",
        "terseLabel": "Precision Biosciences, Inc."
       }
      }
     },
     "localname": "PrecisionBiosciencesIncMember",
     "nsuri": "http://www.lilly.com/20220930",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsAssetAcquisitionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_PrevailTherapeuticsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prevail Therapeutics Inc.",
        "label": "Prevail Therapeutics Inc. [Member]",
        "terseLabel": "Prevail Therapeutics Inc."
       }
      }
     },
     "localname": "PrevailTherapeuticsIncMember",
     "nsuri": "http://www.lilly.com/20220930",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.lilly.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_ProceedsfromSaleofEquityandAvailableforSaleSecurities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from Sale of Equity and Available for Sale Securities",
        "label": "Proceeds from Sale of Equity and Available for Sale Securities",
        "terseLabel": "Proceeds from sales"
       }
      }
     },
     "localname": "ProceedsfromSaleofEquityandAvailableforSaleSecurities",
     "nsuri": "http://www.lilly.com/20220930",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsRealizedGainsandLossesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lly_ProductLiabilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product Liability",
        "label": "Product Liability [Member]",
        "terseLabel": "Product Liability"
       }
      }
     },
     "localname": "ProductLiabilityMember",
     "nsuri": "http://www.lilly.com/20220930",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_PurchasedInProcessResearchAndDevelopment": {
     "auth_ref": [],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of CASH paid for research and development assets that are acquired in a business combination (pre-141R) and/or licensing arrangement that have no alternative future use and are therefore, written off in the period of acquisition (CASH FLOWS).",
        "label": "Purchased In-process Research And Development",
        "negatedTerseLabel": "Purchases of in-process research and development"
       }
      }
     },
     "localname": "PurchasedInProcessResearchAndDevelopment",
     "nsuri": "http://www.lilly.com/20220930",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lly_RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue, Information Used To Determine Revenue Recognized, Change In Accounting Estimate, Percent",
        "label": "Revenue, Information Used To Determine Revenue Recognized, Change In Accounting Estimate, Percent",
        "terseLabel": "Revenue, information used to determine revenue recognized, change in accounting estimate, percent (less than)"
       }
      }
     },
     "localname": "RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent",
     "nsuri": "http://www.lilly.com/20220930",
     "presentation": [
      "http://www.lilly.com/role/RevenueAdjustmentstoRevenueDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "lly_RigelPharmaceuticalsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rigel Pharmaceuticals, Inc.",
        "label": "Rigel Pharmaceuticals, Inc. [Member]",
        "terseLabel": "Rigel Pharmaceuticals, Inc."
       }
      }
     },
     "localname": "RigelPharmaceuticalsIncMember",
     "nsuri": "http://www.lilly.com/20220930",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsAssetAcquisitionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_RocheMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Roche [Member]",
        "label": "Roche [Member]",
        "terseLabel": "Roche"
       }
      }
     },
     "localname": "RocheMember",
     "nsuri": "http://www.lilly.com/20220930",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_SalesRebatesAndDiscounts": {
     "auth_ref": [],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales Rebates And Discounts",
        "label": "Sales Rebates And Discounts",
        "terseLabel": "Sales rebates and discounts"
       }
      }
     },
     "localname": "SalesRebatesAndDiscounts",
     "nsuri": "http://www.lilly.com/20220930",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lly_SellEuroMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sell Euro [Member]",
        "label": "Sell Euro [Member]",
        "terseLabel": "Sell Euro"
       }
      }
     },
     "localname": "SellEuroMember",
     "nsuri": "http://www.lilly.com/20220930",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_SwapSwissFrancsToU.S.DollarsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Swap Swiss Francs To U.S. Dollars [Member]",
        "label": "Swap Swiss Francs To U.S. Dollars [Member]",
        "terseLabel": "Swap Swiss Francs to U.S. Dollars"
       }
      }
     },
     "localname": "SwapSwissFrancsToU.S.DollarsMember",
     "nsuri": "http://www.lilly.com/20220930",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_SwapU.S.DollarsToEuroMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Swap U.S. Dollars To Euro [Member]",
        "label": "Swap U.S. Dollars To Euro [Member]",
        "terseLabel": "Swap U.S. Dollars to Euro"
       }
      }
     },
     "localname": "SwapU.S.DollarsToEuroMember",
     "nsuri": "http://www.lilly.com/20220930",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_TYVYTMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "TYVYT",
        "label": "TYVYT [Member]",
        "terseLabel": "Tyvyt\u00ae"
       }
      }
     },
     "localname": "TYVYTMember",
     "nsuri": "http://www.lilly.com/20220930",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsDetails",
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_TaltzMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Taltz [Member]",
        "label": "Taltz [Member]",
        "terseLabel": "Taltz\u00ae"
       }
      }
     },
     "localname": "TaltzMember",
     "nsuri": "http://www.lilly.com/20220930",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_TrajentaBIMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trajenta (BI) [Member]",
        "label": "Trajenta (BI) [Member]",
        "terseLabel": "Trajenta"
       }
      }
     },
     "localname": "TrajentaBIMember",
     "nsuri": "http://www.lilly.com/20220930",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_TrulicityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trulicity [Member]",
        "label": "Trulicity [Member]",
        "terseLabel": "Trulicity\u00ae"
       }
      }
     },
     "localname": "TrulicityMember",
     "nsuri": "http://www.lilly.com/20220930",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_VerzenioMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Verzenio [Member]",
        "label": "Verzenio [Member]",
        "terseLabel": "Verzenio\u00ae"
       }
      }
     },
     "localname": "VerzenioMember",
     "nsuri": "http://www.lilly.com/20220930",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_ZyprexaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Zyprexa [Member]",
        "label": "Zyprexa [Member]",
        "terseLabel": "Zyprexa\u00ae"
       }
      }
     },
     "localname": "ZyprexaMember",
     "nsuri": "http://www.lilly.com/20220930",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_EuropeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Europe [Member]",
        "terseLabel": "Europe"
       }
      }
     },
     "localname": "EuropeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyGeographicalAreaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_LitigationCaseAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Axis]",
        "terseLabel": "Litigation Case [Axis]"
       }
      }
     },
     "localname": "LitigationCaseAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_LitigationCaseTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Domain]",
        "terseLabel": "Litigation Case Type [Domain]"
       }
      }
     },
     "localname": "LitigationCaseTypeDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r235",
      "r237",
      "r238",
      "r239",
      "r259",
      "r283",
      "r396",
      "r402",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r573",
      "r625",
      "r628",
      "r648",
      "r649"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r235",
      "r237",
      "r238",
      "r239",
      "r259",
      "r283",
      "r396",
      "r402",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r573",
      "r625",
      "r628",
      "r648",
      "r649"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r168",
      "r237",
      "r238",
      "r302",
      "r305",
      "r575",
      "r624",
      "r626"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsDetails",
      "http://www.lilly.com/role/ContingenciesDetails",
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails",
      "http://www.lilly.com/role/RevenueSummaryofRevenueRecognizedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r168",
      "r237",
      "r238",
      "r302",
      "r305",
      "r575",
      "r624",
      "r626"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsDetails",
      "http://www.lilly.com/role/ContingenciesDetails",
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails",
      "http://www.lilly.com/role/RevenueSummaryofRevenueRecognizedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r225",
      "r235",
      "r237",
      "r238",
      "r239",
      "r259",
      "r283",
      "r340",
      "r396",
      "r402",
      "r405",
      "r406",
      "r407",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r573",
      "r625",
      "r628",
      "r648",
      "r649"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r225",
      "r235",
      "r237",
      "r238",
      "r239",
      "r259",
      "r283",
      "r340",
      "r396",
      "r402",
      "r405",
      "r406",
      "r407",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r573",
      "r625",
      "r628",
      "r648",
      "r649"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioForecastMember": {
     "auth_ref": [
      "r130",
      "r397"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forecast [Member]",
        "terseLabel": "Forecast"
       }
      }
     },
     "localname": "ScenarioForecastMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsNarrativeDetails",
      "http://www.lilly.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r130",
      "r135",
      "r233",
      "r397"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]",
        "terseLabel": "Scenario [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsNarrativeDetails",
      "http://www.lilly.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r169",
      "r170",
      "r302",
      "r306",
      "r627",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails",
      "http://www.lilly.com/role/RevenueAdjustmentstoRevenueDetails",
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyGeographicalAreaDetails",
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r169",
      "r170",
      "r302",
      "r306",
      "r627",
      "r636",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails",
      "http://www.lilly.com/role/RevenueAdjustmentstoRevenueDetails",
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyGeographicalAreaDetails",
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r130",
      "r135",
      "r233",
      "r397",
      "r541"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]",
        "terseLabel": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsNarrativeDetails",
      "http://www.lilly.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r41",
      "r539"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r172",
      "r173"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable, net of allowances of $17.7 (2022) and $22.5 (2021)"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedIncomeTaxesNoncurrent": {
     "auth_ref": [
      "r26",
      "r581",
      "r608"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due beyond one year or the operating cycle, whichever is longer. Alternate captions include income taxes payable, noncurrent.",
        "label": "Accrued Income Taxes, Noncurrent",
        "terseLabel": "Long-term income taxes payable"
       }
      }
     },
     "localname": "AccruedIncomeTaxesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember": {
     "auth_ref": [
      "r61",
      "r67",
      "r75",
      "r76",
      "r77",
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive (income) loss related to defined benefit plans including the portion attributable to the noncontrolling interest.",
        "label": "Accumulated Defined Benefit Plans Adjustment Including Portion Attributable to Noncontrolling Interest [Member]",
        "terseLabel": "Defined Benefit Pension and Retiree\u00a0Health Benefit Plans"
       }
      }
     },
     "localname": "AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossAOCIDetails",
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossReclassificationDetails",
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossTaxEffectDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember": {
     "auth_ref": [
      "r60",
      "r67",
      "r75",
      "r76",
      "r77",
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) related to gain (loss) component of defined benefit plans including the portion attributable to the noncontrolling interest.",
        "label": "Accumulated Defined Benefit Plans Adjustment, Net Gain (Loss) Including Portion Attributable to Noncontrolling Interest [Member]",
        "terseLabel": "Actuarial losses, net"
       }
      }
     },
     "localname": "AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossReclassificationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember": {
     "auth_ref": [
      "r62",
      "r67",
      "r75",
      "r76",
      "r77",
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive (income) loss related to prior service cost (credit) component of defined benefit plans including the portion attributable to the noncontrolling interest.",
        "label": "Accumulated Defined Benefit Plans Adjustment, Net Prior Service Including Portion Attributable to Noncontrolling Interest [Member]",
        "terseLabel": "Prior service benefits, net"
       }
      }
     },
     "localname": "AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossReclassificationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r15",
      "r223"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "terseLabel": "Property and equipment, accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheetsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember": {
     "auth_ref": [
      "r55",
      "r67",
      "r75",
      "r76",
      "r77",
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, including the portion attributable to the noncontrolling interest.",
        "label": "Accumulated Foreign Currency Adjustment Including Portion Attributable to Noncontrolling Interest [Member]",
        "terseLabel": "Foreign Currency Translation Gains\u00a0(Losses)"
       }
      }
     },
     "localname": "AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossAOCIDetails",
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossTaxEffectDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember": {
     "auth_ref": [
      "r67",
      "r75",
      "r76",
      "r77",
      "r466"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, including portion attributable to noncontrolling interest.",
        "label": "Accumulated Gain (Loss), Cash Flow Hedge, Including Noncontrolling Interest [Member]",
        "terseLabel": "Effective portion of cash flow hedges"
       }
      }
     },
     "localname": "AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossAOCIDetails",
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossTaxEffectDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember": {
     "auth_ref": [
      "r57",
      "r58",
      "r59",
      "r67",
      "r75",
      "r76",
      "r77"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), including portion attributable to noncontrolling interest.",
        "label": "AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Including Noncontrolling Interest [Member]",
        "terseLabel": "Unrealized net gains/losses on securities",
        "verboseLabel": "Unrealized Net Gains (Losses) on\u00a0Securities"
       }
      }
     },
     "localname": "AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossAOCIDetails",
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossTaxEffectDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossAOCIDetails",
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossTaxEffectDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r32",
      "r64",
      "r66",
      "r67",
      "r610",
      "r633",
      "r634"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss (Note 10)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": {
     "auth_ref": [
      "r75",
      "r76",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r526"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).",
        "label": "Accumulated Other Comprehensive Income (Loss) [Table]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossAOCIDetails",
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossTaxEffectDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r63",
      "r67",
      "r75",
      "r76",
      "r77",
      "r122",
      "r123",
      "r124",
      "r467",
      "r533",
      "r629",
      "r630"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r30"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r122",
      "r123",
      "r124",
      "r408",
      "r409",
      "r410",
      "r504"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to Reconcile Net Income to Cash Flows from Operating Activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": {
     "auth_ref": [
      "r36",
      "r174",
      "r199"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.",
        "label": "Accounts Receivable, Allowance for Credit Loss, Current",
        "terseLabel": "Allowances for doubtful accounts"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheetsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember": {
     "auth_ref": [
      "r63",
      "r67",
      "r75",
      "r76",
      "r77",
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, including the portion attributable to the noncontrolling interest. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Including Portion Attributable to Noncontrolling Interest [Member]",
        "terseLabel": "Accumulated Other Comprehensive Loss"
       }
      }
     },
     "localname": "AociIncludingPortionAttributableToNoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossAOCIDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangements and Non-collaborative Arrangement Transactions [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetAcquisitionAxis": {
     "auth_ref": [
      "r450"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by asset acquisition.",
        "label": "Asset Acquisition [Axis]",
        "terseLabel": "Asset Acquisition [Axis]"
       }
      }
     },
     "localname": "AssetAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsAssetAcquisitionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetAcquisitionDomain": {
     "auth_ref": [
      "r450"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset acquisition.",
        "label": "Asset Acquisition [Domain]",
        "terseLabel": "Asset Acquisition [Domain]"
       }
      }
     },
     "localname": "AssetAcquisitionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsAssetAcquisitionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetAcquisitionTable": {
     "auth_ref": [
      "r450"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset acquisition.",
        "label": "Asset Acquisition [Table]",
        "terseLabel": "Asset Acquisition [Table]"
       }
      }
     },
     "localname": "AssetAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsAssetAcquisitionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetAcquisitionTextBlock": {
     "auth_ref": [
      "r450"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for asset acquisition.",
        "label": "Asset Acquisition [Text Block]",
        "terseLabel": "Acquisitions"
       }
      }
     },
     "localname": "AssetAcquisitionTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/Acquisitions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AssetBackedSecuritiesMember": {
     "auth_ref": [
      "r188",
      "r341"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities that are primarily serviced by the cash flows of a discrete pool of receivables or other financial assets for example, but not limited to, credit card receivables, car loans, recreational vehicle loans, and mobile home loans.",
        "label": "Asset-Backed Securities [Member]",
        "terseLabel": "Asset-backed securities"
       }
      }
     },
     "localname": "AssetBackedSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsFairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r18",
      "r116",
      "r158",
      "r161",
      "r166",
      "r197",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r462",
      "r468",
      "r518",
      "r537",
      "r539",
      "r578",
      "r607"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r8",
      "r40",
      "r116",
      "r197",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r462",
      "r468",
      "r518",
      "r537",
      "r539"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current Assets"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r181"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Unrealized gross gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsUnrealizedGainsandLossesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r182"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "terseLabel": "Unrealized gross losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsUnrealizedGainsandLossesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue": {
     "auth_ref": [
      "r183",
      "r186",
      "r600"
     ],
     "calculation": {
      "http://www.lilly.com/role/FinancialInstrumentsContractualMaturitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10",
        "terseLabel": "6-10 Years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsContractualMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": {
     "auth_ref": [
      "r183",
      "r185",
      "r599"
     ],
     "calculation": {
      "http://www.lilly.com/role/FinancialInstrumentsContractualMaturitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five",
        "terseLabel": "1-5 Years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsContractualMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue": {
     "auth_ref": [
      "r183",
      "r187",
      "r601"
     ],
     "calculation": {
      "http://www.lilly.com/role/FinancialInstrumentsContractualMaturitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing after tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 10",
        "terseLabel": "More\u00a0Than 10 Years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsContractualMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": {
     "auth_ref": [
      "r183",
      "r184",
      "r598"
     ],
     "calculation": {
      "http://www.lilly.com/role/FinancialInstrumentsContractualMaturitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One",
        "terseLabel": "Less\u00a0Than 1 Year"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsContractualMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r176",
      "r180",
      "r205",
      "r587"
     ],
     "calculation": {
      "http://www.lilly.com/role/FinancialInstrumentsContractualMaturitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsContractualMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "auth_ref": [
      "r177",
      "r205"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities, Available-for-Sale, Current",
        "verboseLabel": "Short-term investments"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsFairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent": {
     "auth_ref": [
      "r14",
      "r177",
      "r205"
     ],
     "calculation": {
      "http://www.lilly.com/role/FinancialInstrumentsFairValueofFinancialInstrumentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LongTermInvestments",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.",
        "label": "Debt Securities, Available-for-Sale, Noncurrent",
        "verboseLabel": "Noncurrent investments"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsFairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r392",
      "r398",
      "r443"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.lilly.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r392",
      "r398",
      "r438",
      "r439",
      "r443"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.lilly.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]",
        "terseLabel": "Business Acquisition [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsAssetAcquisitionsDetails",
      "http://www.lilly.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.lilly.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionSharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.",
        "label": "Business Acquisition, Share Price",
        "terseLabel": "Business acquisition, share price (in dollars per share)"
       }
      }
     },
     "localname": "BusinessAcquisitionSharePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination and Asset Acquisition [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationAndAssetAcquisitionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh": {
     "auth_ref": [
      "r449"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid.",
        "label": "Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High",
        "terseLabel": "Contingent value right, additional price per share, aggregate amount"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "auth_ref": [
      "r445",
      "r446",
      "r448"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.",
        "label": "Business Combination, Contingent Consideration, Liability",
        "negatedLabel": "Contingent consideration liability, other noncurrent liabilities"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "auth_ref": [
      "r444",
      "r454"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).",
        "label": "Business Combination Disclosure [Text Block]",
        "terseLabel": "Acquisitions"
       }
      }
     },
     "localname": "BusinessCombinationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/Acquisitions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": {
     "auth_ref": [
      "r441"
     ],
     "calculation": {
      "http://www.lilly.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents",
        "terseLabel": "Cash"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability": {
     "auth_ref": [
      "r440",
      "r441"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of liability arising from an inherited contingency (as defined) which has been recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Contingent Liability",
        "negatedTerseLabel": "Fair value of CVR liability"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities": {
     "auth_ref": [
      "r441"
     ],
     "calculation": {
      "http://www.lilly.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities",
        "negatedTerseLabel": "Deferred tax liabilities"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill": {
     "auth_ref": [
      "r441"
     ],
     "calculation": {
      "http://www.lilly.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of intangible assets, excluding goodwill, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill",
        "terseLabel": "Acquired IPR&amp;D"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": {
     "auth_ref": [
      "r441"
     ],
     "calculation": {
      "http://www.lilly.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net",
        "totalLabel": "Acquisition date fair value of consideration transferred"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationsPolicy": {
     "auth_ref": [
      "r437"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.",
        "label": "Business Combinations Policy [Policy Text Block]",
        "terseLabel": "Business Combinations"
       }
      }
     },
     "localname": "BusinessCombinationsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/BasisofPresentationandImplementationofNewFinancialAccountingStandardPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CarryingReportedAmountFairValueDisclosureMember": {
     "auth_ref": [
      "r516",
      "r517"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured as reported on the statement of financial position (balance sheet).",
        "label": "Reported Value Measurement [Member]",
        "terseLabel": "Carrying Amount"
       }
      }
     },
     "localname": "CarryingReportedAmountFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsFairValueofFinancialInstrumentsDetails",
      "http://www.lilly.com/role/FinancialInstrumentsRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashAcquiredFromAcquisition": {
     "auth_ref": [
      "r95"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business).",
        "label": "Cash Acquired from Acquisition",
        "negatedTerseLabel": "Cash acquired"
       }
      }
     },
     "localname": "CashAcquiredFromAcquisition",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r4",
      "r13",
      "r112"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "verboseLabel": "Cash and cash equivalents (Note 6)"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsFairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "auth_ref": [
      "r107",
      "r112",
      "r113"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "periodEndLabel": "Cash and Cash Equivalents at September 30",
        "periodStartLabel": "Cash and cash equivalents at January\u00a01"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r107",
      "r519"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net decrease in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowHedgingMember": {
     "auth_ref": [
      "r480"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hedge of the exposure to variability in the cash flows of a recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk.",
        "label": "Cash Flow Hedging [Member]",
        "terseLabel": "Cash Flow Hedging"
       }
      }
     },
     "localname": "CashFlowHedgingMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.lilly.com/role/FinancialInstrumentsRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ChangeInAccountingEstimateByTypeAxis": {
     "auth_ref": [
      "r130",
      "r147"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of change in accounting estimate.",
        "label": "Change in Accounting Estimate by Type [Axis]",
        "terseLabel": "Change in Accounting Estimate by Type [Axis]"
       }
      }
     },
     "localname": "ChangeInAccountingEstimateByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/RevenueAdjustmentstoRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ChangeInAccountingEstimateLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Change in Accounting Estimate [Line Items]",
        "terseLabel": "Change in Accounting Estimate [Line Items]"
       }
      }
     },
     "localname": "ChangeInAccountingEstimateLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/RevenueAdjustmentstoRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ChangeInAccountingEstimateTypeDomain": {
     "auth_ref": [
      "r130",
      "r147"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the accounting estimate that was changed that had the effect of adjusting the carrying amount of an existing asset or liability, or that will alter the subsequent accounting for existing or future assets or liabilities.",
        "label": "Change in Accounting Estimate, Type [Domain]",
        "terseLabel": "Change in Accounting Estimate, Type [Domain]"
       }
      }
     },
     "localname": "ChangeInAccountingEstimateTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/RevenueAdjustmentstoRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1": {
     "auth_ref": [
      "r501"
     ],
     "calculation": {
      "http://www.lilly.com/role/FinancialInstrumentsEffectofRiskManagementInstrumentsDetails": {
       "order": 3.0,
       "parentTag": "lly_DerivativeInstrumentsGainLossRecognized",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) from the increase (decrease) in fair value of derivative and nonderivative instruments designated as fair value hedging instruments recognized in the income statement.",
        "label": "Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments",
        "negatedLabel": "Effect from interest rate contracts"
       }
      }
     },
     "localname": "ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsEffectofRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1": {
     "auth_ref": [
      "r501"
     ],
     "calculation": {
      "http://www.lilly.com/role/FinancialInstrumentsEffectofRiskManagementInstrumentsDetails": {
       "order": 4.0,
       "parentTag": "lly_DerivativeInstrumentsGainLossRecognized",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the increase (decrease) in fair value of the hedged item in a fair value hedge recognized in the income statement.",
        "label": "Change in Unrealized Gain (Loss) on Hedged Item in Fair Value Hedge",
        "negatedLabel": "Effect from hedged fixed-rate debt"
       }
      }
     },
     "localname": "ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsEffectofRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r27",
      "r28",
      "r29",
      "r114",
      "r116",
      "r138",
      "r139",
      "r140",
      "r142",
      "r144",
      "r149",
      "r150",
      "r151",
      "r197",
      "r245",
      "r249",
      "r250",
      "r251",
      "r254",
      "r255",
      "r281",
      "r282",
      "r284",
      "r285",
      "r287",
      "r518",
      "r656"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r455",
      "r456",
      "r458"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "Collaborations and Other Arrangements"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommercialPaper": {
     "auth_ref": [
      "r19",
      "r579",
      "r609"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of short-term borrowings using unsecured obligations issued by banks, corporations and other borrowers to investors. The maturities of these money market securities generally do not exceed 270 days.",
        "label": "Commercial Paper",
        "negatedTerseLabel": "Short-term commercial paper borrowings"
       }
      }
     },
     "localname": "CommercialPaper",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsFairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r49",
      "r588",
      "r615"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and Contingencies (Note 9)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r229",
      "r230",
      "r231",
      "r240",
      "r637"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/Contingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommitmentsAndContingenciesPolicyTextBlock": {
     "auth_ref": [
      "r243",
      "r638"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.",
        "label": "Commitments and Contingencies, Policy [Policy Text Block]",
        "terseLabel": "Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/BasisofPresentationandImplementationofNewFinancialAccountingStandardPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonClassAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Classification of common stock representing ownership interest in a corporation.",
        "label": "Common Class A [Member]",
        "terseLabel": "Common Stock (no par value)"
       }
      }
     },
     "localname": "CommonClassAMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockDividendsPerShareDeclared": {
     "auth_ref": [
      "r288"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding.",
        "label": "Common Stock, Dividends, Per Share, Declared",
        "terseLabel": "Cash dividend declared per share (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockDividendsPerShareDeclared",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofEquityParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r122",
      "r123",
      "r504"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockSharesHeldInEmployeeTrust": {
     "auth_ref": [],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of common stock issued to a trust (for example, but not limited to, rabbi trust) set up specifically to accumulate stock for the sole purpose of distribution to participating employees.",
        "label": "Common Stock, Shares Held in Employee Trust",
        "negatedLabel": "Employee benefit trust"
       }
      }
     },
     "localname": "CommonStockSharesHeldInEmployeeTrust",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r29"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r29",
      "r539"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]",
        "terseLabel": "Retirement Benefits [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r71",
      "r73",
      "r74",
      "r85",
      "r593",
      "r620"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofComprehensiveIncomeUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive income"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofComprehensiveIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r71",
      "r73",
      "r84",
      "r461",
      "r472",
      "r592",
      "r619"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Other comprehensive income (loss), net of tax"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNoteTextBlock": {
     "auth_ref": [
      "r83",
      "r94",
      "r591",
      "r618"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.",
        "label": "Comprehensive Income (Loss) Note [Text Block]",
        "terseLabel": "Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "ComprehensiveIncomeNoteTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/OtherComprehensiveIncomeLoss"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": {
     "auth_ref": [
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.",
        "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]",
        "terseLabel": "Schedule of amounts recorded for contract liabilities"
       }
      }
     },
     "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/RevenueTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r292",
      "r293",
      "r303"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract with Customer, Liability",
        "terseLabel": "Remaining contract liabilities",
        "verboseLabel": "Contract liabilities"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsDetails",
      "http://www.lilly.com/role/RevenueContractLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r341",
      "r386",
      "r635"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate debt securities"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsFairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r87",
      "r575"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofOperationsUnaudited": {
       "order": 3.0,
       "parentTag": "lly_CostOfSalesOperatingExpensesAndOtherNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of sales"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Costs and Expenses [Abstract]",
        "terseLabel": "Costs, expenses, and other:"
       }
      }
     },
     "localname": "CostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CrossCurrencyInterestRateContractMember": {
     "auth_ref": [
      "r341",
      "r496"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument whose primary underlying risk is tied to interest rates and foreign exchange rates.",
        "label": "Cross Currency Interest Rate Contract [Member]",
        "terseLabel": "Cross-currency interest rate swaps"
       }
      }
     },
     "localname": "CrossCurrencyInterestRateContractMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsEffectofRiskManagementInstrumentsDetails",
      "http://www.lilly.com/role/FinancialInstrumentsRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtCurrent": {
     "auth_ref": [
      "r23"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of debt and lease obligation, classified as current.",
        "label": "Debt, Current",
        "terseLabel": "Short-term borrowings and current maturities of long-term debt"
       }
      }
     },
     "localname": "DebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r20",
      "r22",
      "r24",
      "r115",
      "r121",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r275",
      "r276",
      "r277",
      "r278",
      "r531",
      "r580",
      "r582",
      "r605"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r256",
      "r275",
      "r276",
      "r529",
      "r531",
      "r532"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Debt instrument, face amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r46",
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Stated interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r47",
      "r115",
      "r121",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r275",
      "r276",
      "r277",
      "r278",
      "r531"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodAxis": {
     "auth_ref": [
      "r604"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about timing of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period [Axis]",
        "terseLabel": "Debt Instrument, Redemption, Period [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodDomain": {
     "auth_ref": [
      "r604"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period as defined under terms of the debt agreement for debt redemption features.",
        "label": "Debt Instrument, Redemption, Period [Domain]",
        "terseLabel": "Debt Instrument, Redemption, Period [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Debt Instrument, Term",
        "terseLabel": "Debt instrument, term"
       }
      }
     },
     "localname": "DebtInstrumentTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "auth_ref": [
      "r192"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale [Table Text Block]",
        "terseLabel": "Summary the contractual maturities of our investments in debt securities measured at fair value"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition": {
     "auth_ref": [
      "r191",
      "r207",
      "r211"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position",
        "terseLabel": "Fair value of securities in an unrealized loss position"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsUnrealizedGainsandLossesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "auth_ref": [
      "r415",
      "r416"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.",
        "label": "Deferred Income Tax Assets, Net",
        "verboseLabel": "Deferred tax assets"
       }
      }
     },
     "localname": "DeferredIncomeTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r415",
      "r416"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred Income Tax Liabilities, Net",
        "terseLabel": "Deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit": {
     "auth_ref": [
      "r318",
      "r356",
      "r380"
     ],
     "calculation": {
      "http://www.lilly.com/role/RetirementBenefitsComponentsofNetPeriodicBenefitCostDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss), recognized immediately as component of net periodic benefit (cost) credit, for change in value of benefit obligation or plan assets from experience different from that assumed, change in actuarial assumption, or consequence of temporarily deviating from substantive plan. Includes, but is not limited to, amount in excess of 10 percent of greater of fair value of plan assets or benefit obligation.",
        "label": "Defined Benefit Plan, Actuarial Gain (Loss), Immediate Recognition as Component in Net Periodic Benefit (Cost) Credit",
        "negatedLabel": "Recognized actuarial loss"
       }
      }
     },
     "localname": "DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit": {
     "auth_ref": [
      "r318",
      "r357",
      "r381",
      "r386",
      "r387"
     ],
     "calculation": {
      "http://www.lilly.com/role/RetirementBenefitsComponentsofNetPeriodicBenefitCostDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of prior service cost (credit) recognized in net periodic benefit cost (credit) of defined benefit plan.",
        "label": "Defined Benefit Plan, Amortization of Prior Service Cost (Credit)",
        "terseLabel": "Amortization of prior service cost"
       }
      }
     },
     "localname": "DefinedBenefitPlanAmortizationOfPriorServiceCostCredit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Defined Benefit Plan Disclosure [Line Items]",
        "terseLabel": "Defined Benefit Plan Disclosure [Line Items]"
       }
      }
     },
     "localname": "DefinedBenefitPlanDisclosureLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets": {
     "auth_ref": [
      "r318",
      "r355",
      "r379",
      "r386",
      "r387"
     ],
     "calculation": {
      "http://www.lilly.com/role/RetirementBenefitsComponentsofNetPeriodicBenefitCostDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expected return (loss) recognized in net periodic benefit (cost) credit, calculated based on expected long-term rate of return and market-related value of plan assets of defined benefit plan.",
        "label": "Defined Benefit Plan, Expected Return (Loss) on Plan Assets",
        "negatedLabel": "Expected return on plan assets"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedReturnOnPlanAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanInterestCost": {
     "auth_ref": [
      "r318",
      "r322",
      "r354",
      "r378",
      "r386",
      "r387"
     ],
     "calculation": {
      "http://www.lilly.com/role/RetirementBenefitsComponentsofNetPeriodicBenefitCostDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost recognized for passage of time related to defined benefit plan.",
        "label": "Defined Benefit Plan, Interest Cost",
        "terseLabel": "Interest cost"
       }
      }
     },
     "localname": "DefinedBenefitPlanInterestCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost": {
     "auth_ref": [
      "r352",
      "r376",
      "r386",
      "r387"
     ],
     "calculation": {
      "http://www.lilly.com/role/RetirementBenefitsComponentsofNetPeriodicBenefitCostDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of net periodic benefit cost (credit) for defined benefit plan.",
        "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit)",
        "totalLabel": "Net periodic benefit cost"
       }
      }
     },
     "localname": "DefinedBenefitPlanNetPeriodicBenefitCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanServiceCost": {
     "auth_ref": [
      "r320",
      "r353",
      "r377",
      "r386",
      "r387"
     ],
     "calculation": {
      "http://www.lilly.com/role/RetirementBenefitsComponentsofNetPeriodicBenefitCostDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.",
        "label": "Defined Benefit Plan, Service Cost",
        "terseLabel": "Service cost"
       }
      }
     },
     "localname": "DefinedBenefitPlanServiceCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Abstract]",
        "terseLabel": "Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Abstract]"
       }
      }
     },
     "localname": "DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r110",
      "r156"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssetNotionalAmount": {
     "auth_ref": [
      "r475",
      "r476",
      "r478"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nominal or face amount used to calculate payments on the derivative asset.",
        "label": "Derivative Asset, Notional Amount",
        "terseLabel": "Derivative asset, notional amount"
       }
      }
     },
     "localname": "DerivativeAssetNotionalAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssetsCurrent": {
     "auth_ref": [
      "r53"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Asset, Current",
        "terseLabel": "Other receivables"
       }
      }
     },
     "localname": "DerivativeAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssetsNoncurrent": {
     "auth_ref": [
      "r53"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Asset, Noncurrent",
        "terseLabel": "Other noncurrent assets"
       }
      }
     },
     "localname": "DerivativeAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Contract [Domain]",
        "terseLabel": "Derivative Contract [Domain]"
       }
      }
     },
     "localname": "DerivativeContractTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsEffectofRiskManagementInstrumentsDetails",
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.lilly.com/role/FinancialInstrumentsRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "auth_ref": [
      "r54",
      "r484",
      "r487",
      "r491",
      "r497"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of derivative contract.",
        "label": "Derivative Instrument [Axis]",
        "terseLabel": "Derivative Instrument [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentRiskAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsEffectofRiskManagementInstrumentsDetails",
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.lilly.com/role/FinancialInstrumentsRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": {
     "auth_ref": [
      "r482",
      "r484",
      "r491"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of hedging relationship.",
        "label": "Hedging Relationship [Axis]",
        "terseLabel": "Hedging Relationship [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.lilly.com/role/FinancialInstrumentsRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeLiabilitiesCurrent": {
     "auth_ref": [
      "r53"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Liability, Current",
        "negatedTerseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "DerivativeLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilitiesNoncurrent": {
     "auth_ref": [
      "r53"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Liability, Noncurrent",
        "negatedTerseLabel": "Other noncurrent liabilities"
       }
      }
     },
     "localname": "DerivativeLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilityNotionalAmount": {
     "auth_ref": [
      "r475",
      "r476",
      "r478"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nominal or face amount used to calculate payments on the derivative liability.",
        "label": "Derivative Liability, Notional Amount",
        "terseLabel": "Derivative liability, notional amount"
       }
      }
     },
     "localname": "DerivativeLiabilityNotionalAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeNotionalAmount": {
     "auth_ref": [
      "r476",
      "r478"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nominal or face amount used to calculate payment on derivative.",
        "label": "Derivative, Notional Amount",
        "terseLabel": "Derivative, notional amount"
       }
      }
     },
     "localname": "DerivativeNotionalAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativesPolicyTextBlock": {
     "auth_ref": [
      "r120",
      "r474",
      "r477",
      "r482",
      "r483",
      "r499"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities.",
        "label": "Derivatives, Policy [Policy Text Block]",
        "terseLabel": "Description of Derivative Risk Management"
       }
      }
     },
     "localname": "DerivativesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/BasisofPresentationandImplementationofNewFinancialAccountingStandardPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DesignatedAsHedgingInstrumentMember": {
     "auth_ref": [
      "r482"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Designated as Hedging Instrument [Member]",
        "terseLabel": "Designated as Hedging Instrument"
       }
      }
     },
     "localname": "DesignatedAsHedgingInstrumentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsEffectofRiskManagementInstrumentsDetails",
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.lilly.com/role/FinancialInstrumentsRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyGeographicalAreaDetails",
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails",
      "http://www.lilly.com/role/RevenueSummaryofRevenueRecognizedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r302",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]",
        "terseLabel": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyGeographicalAreaDetails",
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails",
      "http://www.lilly.com/role/RevenueSummaryofRevenueRecognizedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r302"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "terseLabel": "Schedule of disaggregation of revenue"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/RevenueTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Dividends": {
     "auth_ref": [
      "r288",
      "r603"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock.",
        "label": "Dividends",
        "negatedLabel": "Cash dividends declared"
       }
      }
     },
     "localname": "Dividends",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DividendsPayableCurrent": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Dividends Payable, Current",
        "terseLabel": "Dividends payable"
       }
      }
     },
     "localname": "DividendsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings per share:"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r86",
      "r127",
      "r128",
      "r129",
      "r130",
      "r131",
      "r136",
      "r138",
      "r142",
      "r143",
      "r144",
      "r145",
      "r146",
      "r505",
      "r506",
      "r594",
      "r621"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r86",
      "r127",
      "r128",
      "r129",
      "r130",
      "r131",
      "r138",
      "r142",
      "r143",
      "r144",
      "r145",
      "r146",
      "r505",
      "r506",
      "r594",
      "r621"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r519"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations",
        "terseLabel": "Effect of exchange rate changes on cash and cash equivalents"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "terseLabel": "Effective income tax rate, percentage"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Employee compensation"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r75",
      "r76",
      "r77",
      "r122",
      "r123",
      "r124",
      "r126",
      "r132",
      "r134",
      "r148",
      "r198",
      "r287",
      "r288",
      "r408",
      "r409",
      "r410",
      "r426",
      "r427",
      "r504",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r526",
      "r533",
      "r629",
      "r630",
      "r631"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofEquity",
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossAOCIDetails",
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossReclassificationDetails",
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossTaxEffectDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquitySecuritiesFvNi": {
     "auth_ref": [
      "r6",
      "r21",
      "r513"
     ],
     "calculation": {
      "http://www.lilly.com/role/FinancialInstrumentsFairValueofFinancialInstrumentsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LongTermInvestments",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.",
        "label": "Equity Securities, FV-NI, Current",
        "terseLabel": "Equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesFvNi",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsFairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiGainLoss": {
     "auth_ref": [
      "r196"
     ],
     "calculation": {
      "http://www.lilly.com/role/OtherNetIncomeExpenseDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Gain (Loss)",
        "negatedLabel": "Net investment (gains) losses on equity securities (Note 6)",
        "terseLabel": "Equity securities, net unrealized gains (losses)"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.lilly.com/role/OtherNetIncomeExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount": {
     "auth_ref": [
      "r193"
     ],
     "calculation": {
      "http://www.lilly.com/role/FinancialInstrumentsFairValueofFinancialInstrumentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermInvestments",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity security without readily determinable fair value.",
        "label": "Equity Securities without Readily Determinable Fair Value, Amount",
        "terseLabel": "Equity investments without readily determinable fair values"
       }
      }
     },
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsFairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EstimateOfFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r265",
      "r275",
      "r276",
      "r515"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured as an estimate of fair value.",
        "label": "Estimate of Fair Value Measurement [Member]",
        "terseLabel": "Estimate of Fair Value Measurement"
       }
      }
     },
     "localname": "EstimateOfFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsFairValueofFinancialInstrumentsDetails",
      "http://www.lilly.com/role/FinancialInstrumentsRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ExtinguishmentOfDebtAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross amount of debt extinguished.",
        "label": "Extinguishment of Debt, Amount",
        "terseLabel": "Extinguishment of debt, amount"
       }
      }
     },
     "localname": "ExtinguishmentOfDebtAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsEffectofRiskManagementInstrumentsDetails",
      "http://www.lilly.com/role/FinancialInstrumentsFairValueofFinancialInstrumentsDetails",
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.lilly.com/role/FinancialInstrumentsRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r507",
      "r508",
      "r510"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsEffectofRiskManagementInstrumentsDetails",
      "http://www.lilly.com/role/FinancialInstrumentsFairValueofFinancialInstrumentsDetails",
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.lilly.com/role/FinancialInstrumentsRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "auth_ref": [
      "r507",
      "r508"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Summary certain fair value information, assets"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByBalanceSheetGroupingTextBlock": {
     "auth_ref": [
      "r507",
      "r516"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.",
        "label": "Fair Value, by Balance Sheet Grouping [Table Text Block]",
        "terseLabel": "Schedule of fair value, by balance sheet grouping"
       }
      }
     },
     "localname": "FairValueByBalanceSheetGroupingTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r265",
      "r275",
      "r276",
      "r341",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r386",
      "r508",
      "r545",
      "r546",
      "r547"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsFairValueofFinancialInstrumentsDetails",
      "http://www.lilly.com/role/FinancialInstrumentsRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementBasisAxis": {
     "auth_ref": [
      "r265",
      "r275",
      "r276",
      "r507",
      "r511"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement basis.",
        "label": "Measurement Basis [Axis]",
        "terseLabel": "Measurement Basis [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementBasisAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsFairValueofFinancialInstrumentsDetails",
      "http://www.lilly.com/role/FinancialInstrumentsRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosureItemAmountsDomain": {
     "auth_ref": [
      "r265",
      "r275",
      "r276"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value.",
        "label": "Fair Value Measurement [Domain]",
        "terseLabel": "Fair Value Measurement [Domain]"
       }
      }
     },
     "localname": "FairValueDisclosureItemAmountsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsFairValueofFinancialInstrumentsDetails",
      "http://www.lilly.com/role/FinancialInstrumentsRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Financial Instruments"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstruments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueHedgingMember": {
     "auth_ref": [
      "r479"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A hedge of the exposure to changes in the fair value of a recognized asset or liability, or of an unrecognized firm commitment, that are attributable to a particular risk.",
        "label": "Fair Value Hedging [Member]",
        "terseLabel": "Fair Value Hedging"
       }
      }
     },
     "localname": "FairValueHedgingMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r265",
      "r341",
      "r343",
      "r348",
      "r386",
      "r508",
      "r545"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Quoted Prices in Active Markets for Identical Assets (Level 1)"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsFairValueofFinancialInstrumentsDetails",
      "http://www.lilly.com/role/FinancialInstrumentsRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r265",
      "r275",
      "r276",
      "r341",
      "r343",
      "r348",
      "r386",
      "r508",
      "r546"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Significant Other Observable Inputs (Level 2)"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsFairValueofFinancialInstrumentsDetails",
      "http://www.lilly.com/role/FinancialInstrumentsRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r265",
      "r275",
      "r276",
      "r341",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r386",
      "r508",
      "r547"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Significant Unobservable Inputs (Level 3)"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsFairValueofFinancialInstrumentsDetails",
      "http://www.lilly.com/role/FinancialInstrumentsRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments": {
     "auth_ref": [
      "r512"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of unfunded commitments for which the entity is obligated, to those certain investments for which net asset value per share is calculated (including by unit, membership interest, or other equity (ownership interest) unit measure) (alternative investments).",
        "label": "Fair Value, Investments, Entities that Calculate Net Asset Value Per Share, Unfunded Commitments",
        "terseLabel": "Alternative investments, unfunded commitments"
       }
      }
     },
     "localname": "FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock": {
     "auth_ref": [
      "r507",
      "r508"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Summary certain fair value information, liabilities"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r265",
      "r275",
      "r276",
      "r341",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r386",
      "r545",
      "r546",
      "r547"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsFairValueofFinancialInstrumentsDetails",
      "http://www.lilly.com/role/FinancialInstrumentsRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r188",
      "r189",
      "r193",
      "r194",
      "r195",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r208",
      "r209",
      "r210",
      "r211",
      "r273",
      "r286",
      "r503",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsFairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ForeignExchangeContractMember": {
     "auth_ref": [
      "r54",
      "r341",
      "r495"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument whose primary underlying risk is tied to foreign exchange rates.",
        "label": "Foreign Exchange Contract [Member]",
        "terseLabel": "Foreign currency exchange contracts"
       }
      }
     },
     "localname": "ForeignExchangeContractMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsEffectofRiskManagementInstrumentsDetails",
      "http://www.lilly.com/role/FinancialInstrumentsRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments": {
     "auth_ref": [
      "r484",
      "r490"
     ],
     "calculation": {
      "http://www.lilly.com/role/FinancialInstrumentsEffectofRiskManagementInstrumentsDetails": {
       "order": 1.0,
       "parentTag": "lly_DerivativeInstrumentsGainLossRecognized",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in earnings in the period from the increase (decrease) in fair value of foreign currency derivatives not designated as hedging instruments.",
        "label": "Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments",
        "negatedLabel": "Net (gains) losses on foreign currency exchange contracts not designated as hedging instruments"
       }
      }
     },
     "localname": "GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsEffectofRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnInvestments": {
     "auth_ref": [
      "r91",
      "r110",
      "r178"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized and unrealized gain (loss) on investment.",
        "label": "Gain (Loss) on Investments",
        "negatedLabel": "Net investment (gains) losses"
       }
      }
     },
     "localname": "GainLossOnInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnInvestmentsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of realized and unrealized gain (loss) on investment in security.",
        "label": "Gain (Loss) on Securities [Table Text Block]",
        "terseLabel": "Schedule of activity related to our available-for-sale securities"
       }
      }
     },
     "localname": "GainLossOnInvestmentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "auth_ref": [
      "r110",
      "r279",
      "r280"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.lilly.com/role/OtherNetIncomeExpenseDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "negatedLabel": "Loss on extinguishment of debt",
        "negatedTerseLabel": "Debt extinguishment loss (Note 6)"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows",
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.lilly.com/role/OtherNetIncomeExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r16",
      "r215",
      "r216",
      "r217",
      "r218",
      "r539",
      "r577"
     ],
     "calculation": {
      "http://www.lilly.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0
      },
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HedgingDesignationAxis": {
     "auth_ref": [
      "r482",
      "r498"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Axis]",
        "terseLabel": "Hedging Designation [Axis]"
       }
      }
     },
     "localname": "HedgingDesignationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsEffectofRiskManagementInstrumentsDetails",
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.lilly.com/role/FinancialInstrumentsRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HedgingDesignationDomain": {
     "auth_ref": [
      "r482"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Domain]",
        "terseLabel": "Hedging Designation [Domain]"
       }
      }
     },
     "localname": "HedgingDesignationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsEffectofRiskManagementInstrumentsDetails",
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.lilly.com/role/FinancialInstrumentsRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_HedgingRelationshipDomain": {
     "auth_ref": [
      "r482"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nature or intent of a hedge.",
        "label": "Hedging Relationship [Domain]",
        "terseLabel": "Hedging Relationship [Domain]"
       }
      }
     },
     "localname": "HedgingRelationshipDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.lilly.com/role/FinancialInstrumentsRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill": {
     "auth_ref": [
      "r110",
      "r222"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.",
        "label": "Impairment of Intangible Assets, Indefinite-Lived (Excluding Goodwill)",
        "terseLabel": "Intangible asset impairment"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialChargesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r81",
      "r158",
      "r160",
      "r162",
      "r165",
      "r167",
      "r576",
      "r589",
      "r596",
      "r622"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofOperationsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "terseLabel": "Total before tax",
        "totalLabel": "Income before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofOperationsUnaudited",
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossReclassificationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxContingencyLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Income Tax Contingency [Line Items]",
        "terseLabel": "Income Tax Contingency [Line Items]"
       }
      }
     },
     "localname": "IncomeTaxContingencyLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxContingencyTable": {
     "auth_ref": [
      "r420",
      "r421",
      "r423",
      "r425"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.",
        "label": "Income Tax Contingency [Table]",
        "terseLabel": "Income Tax Contingency [Table]"
       }
      }
     },
     "localname": "IncomeTaxContingencyTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r117",
      "r419",
      "r422",
      "r424",
      "r428",
      "r430",
      "r434",
      "r435",
      "r436"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r118",
      "r133",
      "r134",
      "r157",
      "r417",
      "r429",
      "r432",
      "r623"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofOperationsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedNetLabel": "Tax benefit",
        "terseLabel": "Income taxes (Note 7)"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofOperationsUnaudited",
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossReclassificationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDeferredIncomeTaxes": {
     "auth_ref": [
      "r109"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.",
        "label": "Increase (Decrease) in Deferred Income Taxes",
        "negatedTerseLabel": "Change in deferred income taxes"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet": {
     "auth_ref": [
      "r109"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets and Liabilities, Net",
        "negatedTerseLabel": "Other changes in operating assets and liabilities, net of acquisitions and divestitures"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingCapitalNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Shareholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r219",
      "r221"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "Other intangibles, net"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r79",
      "r155",
      "r528",
      "r530",
      "r595"
     ],
     "calculation": {
      "http://www.lilly.com/role/OtherNetIncomeExpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "terseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/OtherNetIncomeExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet": {
     "auth_ref": [
      "r502"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated net amount of unrealized gains or losses on interest rate cash flow hedges as of the balance sheet date expected to be reclassified to earnings within the next twelve months.",
        "label": "Interest Rate Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net",
        "negatedLabel": "Pretax net losses on cash flow hedges expected to be reclassified during the next 12 months"
       }
      }
     },
     "localname": "InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestRateContractMember": {
     "auth_ref": [
      "r54",
      "r341",
      "r494"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument whose primary underlying risk is tied to the right to receive or pay a sum of money at a given interest rate.",
        "label": "Interest Rate Contract [Member]",
        "terseLabel": "Interest Rate Contracts"
       }
      }
     },
     "localname": "InterestRateContractMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsEffectofRiskManagementInstrumentsDetails",
      "http://www.lilly.com/role/FinancialInstrumentsRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InterestRateSwapMember": {
     "auth_ref": [
      "r494"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period.",
        "label": "Interest Rate Swap [Member]",
        "terseLabel": "Forward-starting interest rate swaps"
       }
      }
     },
     "localname": "InterestRateSwapMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsEffectofRiskManagementInstrumentsDetails",
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r5",
      "r37",
      "r539"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWriteDown": {
     "auth_ref": [
      "r212"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.",
        "label": "Inventory Write-down",
        "terseLabel": "Inventory write-down"
       }
      }
     },
     "localname": "InventoryWriteDown",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialChargesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r90",
      "r154"
     ],
     "calculation": {
      "http://www.lilly.com/role/OtherNetIncomeExpenseDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "negatedLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/OtherNetIncomeExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r35",
      "r116",
      "r197",
      "r518",
      "r539",
      "r584",
      "r613"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r9",
      "r45",
      "r116",
      "r197",
      "r245",
      "r246",
      "r247",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r463",
      "r468",
      "r469",
      "r518",
      "r537",
      "r538",
      "r539"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current Liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "auth_ref": [
      "r10",
      "r11",
      "r12",
      "r24",
      "r25",
      "r116",
      "r197",
      "r245",
      "r246",
      "r247",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r463",
      "r468",
      "r469",
      "r518",
      "r537",
      "r538"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.",
        "label": "Liabilities, Noncurrent",
        "totalLabel": "Total other liabilities"
       }
      }
     },
     "localname": "LiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Noncurrent [Abstract]",
        "terseLabel": "Other Liabilities"
       }
      }
     },
     "localname": "LiabilitiesNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r42"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Line of credit facility, maximum borrowing capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r24",
      "r264",
      "r274",
      "r275",
      "r276",
      "r582",
      "r609"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.",
        "label": "Long-Term Debt",
        "negatedTerseLabel": "Long-term debt, including current portion",
        "terseLabel": "Long-term debt, including current portion"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsFairValueofFinancialInstrumentsDetails",
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r24"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.",
        "label": "Long-Term Debt, Excluding Current Maturities",
        "terseLabel": "Long-term debt"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermInvestments": {
     "auth_ref": [
      "r14"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.lilly.com/role/FinancialInstrumentsFairValueofFinancialInstrumentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).",
        "label": "Long-Term Investments",
        "terseLabel": "Investments (Note 6)",
        "totalLabel": "Noncurrent investments"
       }
      }
     },
     "localname": "LongTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets",
      "http://www.lilly.com/role/FinancialInstrumentsFairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r47"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-Term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r47",
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-Term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingenciesByNatureOfContingencyAxis": {
     "auth_ref": [
      "r232",
      "r234",
      "r235",
      "r236",
      "r237",
      "r241",
      "r242"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur.",
        "label": "Loss Contingency Nature [Axis]",
        "terseLabel": "Loss Contingency Nature [Axis]"
       }
      }
     },
     "localname": "LossContingenciesByNatureOfContingencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Loss Contingencies [Line Items]",
        "terseLabel": "Loss Contingencies [Line Items]"
       }
      }
     },
     "localname": "LossContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesTable": {
     "auth_ref": [
      "r232",
      "r234",
      "r235",
      "r236",
      "r237",
      "r241",
      "r242"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
        "label": "Loss Contingencies [Table]",
        "terseLabel": "Loss Contingencies [Table]"
       }
      }
     },
     "localname": "LossContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingencyDamagesAwardedValue": {
     "auth_ref": [
      "r232",
      "r234",
      "r236"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of damages awarded to the plaintiff in the legal matter.",
        "label": "Loss Contingency, Damages Awarded, Value",
        "terseLabel": "Damages awarded, value"
       }
      }
     },
     "localname": "LossContingencyDamagesAwardedValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyNatureDomain": {
     "auth_ref": [
      "r232",
      "r234",
      "r235",
      "r236",
      "r237",
      "r241",
      "r242"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur. Resolution of the uncertainty may confirm the incurrence of a loss or impairment of an asset or the incurrence of a liability.",
        "label": "Loss Contingency, Nature [Domain]",
        "terseLabel": "Loss Contingency, Nature [Domain]"
       }
      }
     },
     "localname": "LossContingencyNatureDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingencyNumberOfPlaintiffs": {
     "auth_ref": [
      "r234",
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of plaintiffs that have filed claims pertaining to a loss contingency.",
        "label": "Loss Contingency, Number of Plaintiffs",
        "terseLabel": "Number of plaintiffs"
       }
      }
     },
     "localname": "LossContingencyNumberOfPlaintiffs",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_LossContingencyPendingClaimsNumber": {
     "auth_ref": [
      "r234",
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of pending claims pertaining to a loss contingency.",
        "label": "Loss Contingency, Pending Claims, Number",
        "terseLabel": "Number of pending lawsuits"
       }
      }
     },
     "localname": "LossContingencyPendingClaimsNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum amount of time remaining before foreign currency exchange rate derivatives mature or expire, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Maximum Remaining Maturity of Foreign Currency Derivatives",
        "terseLabel": "Maximum remaining maturity of foreign currency derivatives"
       }
      }
     },
     "localname": "MaximumRemainingMaturityOfForeignCurrencyDerivatives1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_MinorityInterest": {
     "auth_ref": [
      "r52",
      "r116",
      "r197",
      "r245",
      "r249",
      "r250",
      "r251",
      "r254",
      "r255",
      "r518",
      "r583",
      "r612"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).",
        "label": "Stockholders' Equity Attributable to Noncontrolling Interest",
        "terseLabel": "Noncontrolling interests"
       }
      }
     },
     "localname": "MinorityInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MortgageBackedSecuritiesMember": {
     "auth_ref": [
      "r179",
      "r341",
      "r343",
      "r386",
      "r635"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities collateralized by mortgage loans.",
        "label": "Collateralized Mortgage-Backed Securities [Member]",
        "terseLabel": "Mortgage-backed securities"
       }
      }
     },
     "localname": "MortgageBackedSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsFairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r107"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net Cash Used for Financing Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash Flows from Financing Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r107"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net Cash Used for Investing Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash Flows from Investing Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r107",
      "r108",
      "r111"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net Cash Provided by Operating Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash Flows from Operating Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r2",
      "r69",
      "r72",
      "r77",
      "r82",
      "r111",
      "r116",
      "r125",
      "r127",
      "r128",
      "r129",
      "r130",
      "r133",
      "r134",
      "r141",
      "r158",
      "r160",
      "r162",
      "r165",
      "r167",
      "r197",
      "r245",
      "r246",
      "r247",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r506",
      "r518",
      "r590",
      "r617"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofComprehensiveIncomeUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofOperationsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net income",
        "totalLabel": "Net income",
        "verboseLabel": "Net income"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows",
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofComprehensiveIncomeUnaudited",
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetInvestmentHedgingMember": {
     "auth_ref": [
      "r481"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hedges of a net investment in a foreign operation.",
        "label": "Net Investment Hedging [Member]",
        "terseLabel": "Net Investment Hedges"
       }
      }
     },
     "localname": "NetInvestmentHedgingMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent": {
     "auth_ref": [
      "r318"
     ],
     "calculation": {
      "http://www.lilly.com/role/OtherNetIncomeExpenseDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (reversal of expense) for net periodic benefit cost components, excluding service cost component, of defined benefit plan. Amount includes, but is not limited to, interest cost, expected (return) loss on plan asset, amortization of prior service cost (credit), amortization of (gain) loss, amortization of transition (asset) obligation, settlement (gain) loss, curtailment (gain) loss and certain termination benefits.",
        "label": "Net Periodic Defined Benefits Expense (Reversal of Expense), Excluding Service Cost Component",
        "terseLabel": "Retirement benefit plans"
       }
      }
     },
     "localname": "NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/OtherNetIncomeExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Implementation of New Financial Accounting Standard"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/BasisofPresentationandImplementationofNewFinancialAccountingStandardPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonUsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Countries excluding the United States of America (US).",
        "label": "Non-US [Member]",
        "terseLabel": "Outside U.S."
       }
      }
     },
     "localname": "NonUsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NoncontrollingInterestMember": {
     "auth_ref": [
      "r122",
      "r123",
      "r124",
      "r288",
      "r459"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
        "label": "Noncontrolling Interest [Member]",
        "terseLabel": "Noncontrolling Interests"
       }
      }
     },
     "localname": "NoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NondesignatedMember": {
     "auth_ref": [
      "r482"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Not Designated as Hedging Instrument [Member]",
        "terseLabel": "Not Designated as Hedging Instrument"
       }
      }
     },
     "localname": "NondesignatedMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsEffectofRiskManagementInstrumentsDetails",
      "http://www.lilly.com/role/FinancialInstrumentsRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r92"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofOperationsUnaudited": {
       "order": 4.0,
       "parentTag": "lly_CostOfSalesOperatingExpensesAndOtherNet",
       "weight": -1.0
      },
      "http://www.lilly.com/role/OtherNetIncomeExpenseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "negatedLabel": "Other\u2013net, (income) expense (Note 11)",
        "negatedTotalLabel": "Other\u2013net, (income) expense"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofOperationsUnaudited",
      "http://www.lilly.com/role/OtherNetIncomeExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Nonoperating Income (Expense) [Abstract]"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r3",
      "r473"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Basis of Presentation and Implementation of New Financial Accounting Standard"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/BasisofPresentationandImplementationofNewFinancialAccountingStandard"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r17"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other noncurrent assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax": {
     "auth_ref": [
      "r67",
      "r75",
      "r76",
      "r78",
      "r520",
      "r522",
      "r526"
     ],
     "calculation": {
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossAOCIDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax, before reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), before Reclassifications, Net of Tax",
        "terseLabel": "Other comprehensive income (loss) before reclassifications"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossAOCIDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax": {
     "auth_ref": [
      "r56",
      "r64",
      "r485",
      "r488",
      "r500"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax",
        "terseLabel": "Effective portion of risk-management instruments that was recognized in other comprehensive income (loss), cash flow hedges"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsEffectofRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax": {
     "auth_ref": [
      "r64",
      "r68",
      "r489"
     ],
     "calculation": {
      "http://www.lilly.com/role/FinancialInstrumentsEffectofRiskManagementInstrumentsDetails": {
       "order": 2.0,
       "parentTag": "lly_DerivativeInstrumentsGainLossRecognized",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax",
        "terseLabel": "Effective portion of losses on interest rate contracts reclassified from accumulated other comprehensive loss"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsEffectofRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax": {
     "auth_ref": [
      "r492"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative designated and qualifying as net investment hedge.",
        "label": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax",
        "terseLabel": "Effective portion of risk-management instruments that was recognized in other comprehensive income (loss), net investment hedges"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsEffectofRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r70",
      "r73",
      "r75",
      "r76",
      "r78",
      "r83",
      "r287",
      "r520",
      "r525",
      "r526",
      "r591",
      "r618"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofComprehensiveIncomeUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossAOCIDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Other comprehensive income (loss), net of tax (Note 10)",
        "totalLabel": "Net other comprehensive income (loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofComprehensiveIncomeUnaudited",
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossAOCIDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossTax": {
     "auth_ref": [
      "r65",
      "r75",
      "r83",
      "r417",
      "r431",
      "r433",
      "r520",
      "r523",
      "r526",
      "r591",
      "r618"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax expense (benefit) allocated to other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Tax",
        "negatedTerseLabel": "Benefit (expense) for income taxes allocated to other comprehensive income (loss) items"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossTaxEffectDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherDebtSecuritiesMember": {
     "auth_ref": [
      "r190",
      "r206",
      "r341",
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investments in debt securities classified as other.",
        "label": "Other Debt Obligations [Member]",
        "terseLabel": "Other securities"
       }
      }
     },
     "localname": "OtherDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsFairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock": {
     "auth_ref": [
      "r313",
      "r411"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for other income or other expense items (both operating and nonoperating). Sources of nonoperating income or nonoperating expense that may be disclosed, include amounts earned from dividends, interest on securities, profits (losses) on securities, net and miscellaneous other income or income deductions.",
        "label": "Other Income and Other Expense Disclosure [Text Block]",
        "terseLabel": "Other\u2013Net, (Income) Expense"
       }
      }
     },
     "localname": "OtherIncomeAndOtherExpenseDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/OtherNetIncomeExpense"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r44",
      "r539"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "terseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other noncurrent liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLongTermInvestments": {
     "auth_ref": [
      "r14",
      "r616"
     ],
     "calculation": {
      "http://www.lilly.com/role/FinancialInstrumentsFairValueofFinancialInstrumentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermInvestments",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term investments classified as other.",
        "label": "Other Long-Term Investments",
        "verboseLabel": "Equity method investments"
       }
      }
     },
     "localname": "OtherLongTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsFairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r93"
     ],
     "calculation": {
      "http://www.lilly.com/role/OtherNetIncomeExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "negatedLabel": "Other (income) expense",
        "terseLabel": "Other\u2013net, (income) expense"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossReclassificationDetails",
      "http://www.lilly.com/role/OtherNetIncomeExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherOperatingActivitiesCashFlowStatement": {
     "auth_ref": [],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example, cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities).",
        "label": "Other Operating Activities, Cash Flow Statement",
        "terseLabel": "Other non-cash operating activities, net"
       }
      }
     },
     "localname": "OtherOperatingActivitiesCashFlowStatement",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember": {
     "auth_ref": [
      "r315",
      "r316",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r366",
      "r369",
      "r373",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan designed to provide other postretirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes pension benefits.",
        "label": "Other Postretirement Benefits Plan [Member]",
        "terseLabel": "Retiree Health Benefit Plans"
       }
      }
     },
     "localname": "OtherPostretirementBenefitPlansDefinedBenefitMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherReceivablesNetCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.",
        "label": "Other Receivables, Net, Current",
        "terseLabel": "Other receivables"
       }
      }
     },
     "localname": "OtherReceivablesNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": {
     "auth_ref": [
      "r96",
      "r99"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash (inflow) outflow from investing activities classified as other.",
        "label": "Payments for (Proceeds from) Other Investing Activities",
        "negatedLabel": "Other investing activities, net"
       }
      }
     },
     "localname": "PaymentsForProceedsFromOtherInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "auth_ref": [
      "r102"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to reacquire common stock during the period.",
        "label": "Payments for Repurchase of Common Stock",
        "negatedTerseLabel": "Purchases of common stock"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDebtExtinguishmentCosts": {
     "auth_ref": [
      "r104"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for cost from early extinguishment and prepayment of debt. Includes, but is not limited to, third-party cost, premium paid, and other fee paid to lender directly for debt extinguishment or debt prepayment. Excludes accrued interest.",
        "label": "Payment for Debt Extinguishment or Debt Prepayment Cost",
        "terseLabel": "Payment for debt extinguishment"
       }
      }
     },
     "localname": "PaymentsOfDebtExtinguishmentCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDividends": {
     "auth_ref": [
      "r102"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests.",
        "label": "Payments of Dividends",
        "negatedLabel": "Dividends paid"
       }
      }
     },
     "localname": "PaymentsOfDividends",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesGross": {
     "auth_ref": [
      "r97",
      "r447"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.",
        "label": "Payments to Acquire Businesses, Gross",
        "terseLabel": "Payments to acquire businesses"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": {
     "auth_ref": [
      "r97"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.",
        "label": "Payments to Acquire Businesses, Net of Cash Acquired",
        "negatedLabel": "Cash paid for acquisitions, net of cash acquired (Note 3)",
        "terseLabel": "Cash paid, net of cash acquired"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.lilly.com/role/AcquisitionsNarrativeDetails",
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireLongtermInvestments": {
     "auth_ref": [
      "r99"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, beyond the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the long-term.",
        "label": "Payments to Acquire Long-Term Investments",
        "negatedTerseLabel": "Purchases of noncurrent investments"
       }
      }
     },
     "localname": "PaymentsToAcquireLongtermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireProductiveAssets": {
     "auth_ref": [
      "r98",
      "r451",
      "r452",
      "r453"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.",
        "label": "Payments to Acquire Productive Assets",
        "negatedLabel": "Net purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquireProductiveAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireShortTermInvestments": {
     "auth_ref": [
      "r99"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.",
        "label": "Payments to Acquire Short-Term Investments",
        "negatedTerseLabel": "Purchases of short-term investments"
       }
      }
     },
     "localname": "PaymentsToAcquireShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "auth_ref": [
      "r340",
      "r342",
      "r348",
      "r365",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r386",
      "r388",
      "r389",
      "r390",
      "r403"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for retirement benefits.",
        "label": "Retirement Benefits [Text Block]",
        "terseLabel": "Retirement Benefits"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefits"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent": {
     "auth_ref": [
      "r26",
      "r316",
      "r317",
      "r339",
      "r386"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans, classified as noncurrent.",
        "label": "Liability, Defined Benefit Plan, Noncurrent",
        "terseLabel": "Accrued retirement benefits (Note 8)"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionPlansDefinedBenefitMember": {
     "auth_ref": [
      "r314",
      "r316",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r366",
      "r369",
      "r373",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r390",
      "r391",
      "r398",
      "r399",
      "r400",
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan designed to provide participant with pension benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes other postretirement benefits.",
        "label": "Pension Plan [Member]",
        "verboseLabel": "Defined Benefit Pension Plans"
       }
      }
     },
     "localname": "PensionPlansDefinedBenefitMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PortionAtFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r514"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured at fair value for financial reporting purposes.",
        "label": "Portion at Fair Value Measurement [Member]",
        "terseLabel": "Portion at Fair Value Measurement"
       }
      }
     },
     "localname": "PortionAtFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsFairValueofFinancialInstrumentsDetails",
      "http://www.lilly.com/role/FinancialInstrumentsRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r514"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Not measured at fair value.",
        "label": "Portion at Other than Fair Value Measurement [Member]",
        "terseLabel": "Cost"
       }
      }
     },
     "localname": "PortionAtOtherThanFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsFairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "auth_ref": [
      "r7",
      "r38",
      "r213",
      "r214"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense, Current",
        "terseLabel": "Prepaid expenses and other"
       }
      }
     },
     "localname": "PrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
     "auth_ref": [
      "r100"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.",
        "label": "Proceeds from Issuance of Long-Term Debt",
        "terseLabel": "Proceeds from issuance of long-term debt"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": {
     "auth_ref": [
      "r101",
      "r105"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities classified as other.",
        "label": "Proceeds from (Payments for) Other Financing Activities",
        "terseLabel": "Other financing activities, net"
       }
      }
     },
     "localname": "ProceedsFromPaymentsForOtherFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfLongtermInvestments": {
     "auth_ref": [
      "r96"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from sales of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, beyond the current operating cycle.",
        "label": "Proceeds from Sale of Long-Term Investments",
        "terseLabel": "Proceeds from sales of noncurrent investments"
       }
      }
     },
     "localname": "ProceedsFromSaleOfLongtermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfShortTermInvestments": {
     "auth_ref": [
      "r96"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from sales of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.",
        "label": "Proceeds from Sale of Short-Term Investments",
        "terseLabel": "Proceeds from sales and maturities of short-term investments"
       }
      }
     },
     "localname": "ProceedsFromSaleOfShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromShortTermDebt": {
     "auth_ref": [
      "r100"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.",
        "label": "Proceeds from Short-Term Debt",
        "terseLabel": "Net change in short-term borrowings"
       }
      }
     },
     "localname": "ProceedsFromShortTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product [Member]",
        "terseLabel": "Net product revenue"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/RevenueSummaryofRevenueRecognizedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r2",
      "r69",
      "r72",
      "r77",
      "r106",
      "r116",
      "r125",
      "r133",
      "r134",
      "r158",
      "r160",
      "r162",
      "r165",
      "r167",
      "r197",
      "r245",
      "r246",
      "r247",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r461",
      "r464",
      "r465",
      "r471",
      "r472",
      "r506",
      "r518",
      "r596"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net income (loss)",
        "verboseLabel": "Total reclassifications, net of tax"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofEquity",
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossReclassificationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r224",
      "r539",
      "r602",
      "r614"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net of accumulated depreciation of $10,074.0 (2022) and $9,976.7 (2021)"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReceivablesNetCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Receivables, Net, Current [Abstract]",
        "terseLabel": "Receivables, Net, Current [Abstract]"
       }
      }
     },
     "localname": "ReceivablesNetCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]",
        "terseLabel": "Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]"
       }
      }
     },
     "localname": "ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossReclassificationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax": {
     "auth_ref": [
      "r67",
      "r75",
      "r76",
      "r78",
      "r520",
      "r524",
      "r526"
     ],
     "calculation": {
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossAOCIDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss).",
        "label": "Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax",
        "negatedTerseLabel": "Net amount reclassified from accumulated other comprehensive loss"
       }
      }
     },
     "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossAOCIDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]",
        "terseLabel": "AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]"
       }
      }
     },
     "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossAOCIDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis": {
     "auth_ref": [
      "r77"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by item reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Axis]",
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Axis]"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossReclassificationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain": {
     "auth_ref": [
      "r77"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Item reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Domain]",
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Domain]"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossReclassificationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r77"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies item reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Member]",
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossReclassificationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable": {
     "auth_ref": [
      "r77"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about items reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Table]",
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Table]"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossReclassificationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information about items reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Table Text Block]",
        "terseLabel": "Schedule of reclassifications out of accumulated other comprehensive loss"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "auth_ref": [
      "r103"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.",
        "label": "Repayments of Long-Term Debt",
        "negatedTerseLabel": "Repayments of long-term debt"
       }
      }
     },
     "localname": "RepaymentsOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r412",
      "r574",
      "r650"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofOperationsUnaudited": {
       "order": 6.0,
       "parentTag": "lly_CostOfSalesOperatingExpensesAndOtherNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Expenses and Acquired In-Process Research and Development (IPR&amp;D) and Developmental Milestones"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/BasisofPresentationandImplementationofNewFinancialAccountingStandardPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestructuringAndRelatedActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Activities [Abstract]",
        "terseLabel": "Restructuring and Related Activities [Abstract]"
       }
      }
     },
     "localname": "RestructuringAndRelatedActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.",
        "label": "Restructuring, Impairment, and Other Activities Disclosure [Text Block]",
        "terseLabel": "Asset Impairment, Restructuring, and Other Special Charges"
       }
      }
     },
     "localname": "RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialCharges"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestructuringSettlementAndImpairmentProvisions": {
     "auth_ref": [
      "r88"
     ],
     "calculation": {
      "http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialChargesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofOperationsUnaudited": {
       "order": 2.0,
       "parentTag": "lly_CostOfSalesOperatingExpensesAndOtherNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of restructuring charges, remediation cost, and asset impairment loss.",
        "label": "Restructuring, Settlement and Impairment Provisions",
        "terseLabel": "Asset impairment, restructuring, and other special charges (Note 5)",
        "totalLabel": "Total asset impairment, restructuring, and other special charges"
       }
      }
     },
     "localname": "RestructuringSettlementAndImpairmentProvisions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialChargesDetails",
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r31",
      "r288",
      "r539",
      "r611",
      "r632",
      "r634"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Retained earnings"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r122",
      "r123",
      "r124",
      "r126",
      "r132",
      "r134",
      "r198",
      "r408",
      "r409",
      "r410",
      "r426",
      "r427",
      "r504",
      "r629",
      "r631"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Retained Earnings"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetirementPlanTypeAxis": {
     "auth_ref": [
      "r314",
      "r315",
      "r316",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r366",
      "r369",
      "r373",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r398",
      "r399",
      "r400",
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of retirement benefit plan. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.",
        "label": "Retirement Plan Type [Axis]",
        "terseLabel": "Retirement Plan Type [Axis]"
       }
      }
     },
     "localname": "RetirementPlanTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetirementPlanTypeDomain": {
     "auth_ref": [
      "r314",
      "r315",
      "r316",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r366",
      "r369",
      "r373",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r398",
      "r399",
      "r400",
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of plan designed to provide participants with retirement benefits. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.",
        "label": "Retirement Plan Type [Domain]",
        "terseLabel": "Retirement Plan Type [Domain]"
       }
      }
     },
     "localname": "RetirementPlanTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]",
        "terseLabel": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r304",
      "r312"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "Revenue from Contract with Customer [Text Block]",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/Revenue"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r80",
      "r116",
      "r152",
      "r153",
      "r159",
      "r163",
      "r164",
      "r168",
      "r169",
      "r171",
      "r197",
      "r245",
      "r246",
      "r247",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r518",
      "r596"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofOperationsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "terseLabel": "Revenue",
        "verboseLabel": "Revenue (Note 2)"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsDetails",
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofOperationsUnaudited",
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyGeographicalAreaDetails",
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails",
      "http://www.lilly.com/role/RevenueSummaryofRevenueRecognizedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RoyaltyAgreementTermsMember": {
     "auth_ref": [
      "r413",
      "r414"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Terms of the royalty agreement under research and development arrangements.",
        "label": "Royalty Agreement Terms [Member]",
        "terseLabel": "Royalty Agreement Terms"
       }
      }
     },
     "localname": "RoyaltyAgreementTermsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RoyaltyMember": {
     "auth_ref": [
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Money for usage-based right to asset.",
        "label": "Royalty [Member]",
        "terseLabel": "Collaboration and other revenue associated with prior period transfers of intellectual property"
       }
      }
     },
     "localname": "RoyaltyMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/RevenueSummaryofRevenueRecognizedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SalesReturnsAndAllowancesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A revision in the estimated reserve needed for product returns and price or other concessions granted to customers.",
        "label": "Sales Returns and Allowances [Member]",
        "terseLabel": "Sales returns, rebates, and discounts"
       }
      }
     },
     "localname": "SalesReturnsAndAllowancesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/RevenueAdjustmentstoRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
     "auth_ref": [
      "r67",
      "r525",
      "r526"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).",
        "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
        "terseLabel": "Schedule of components of other comprehensive income (loss)"
       }
      }
     },
     "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r438",
      "r439",
      "r443"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.lilly.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
     "auth_ref": [
      "r489"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of gain (loss) on derivative and nonderivative instruments designated and qualifying as cash flow hedge recorded in accumulated other comprehensive income (AOCI) and reclassified into earnings.",
        "label": "Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
        "terseLabel": "Schedule of effective portion of risk-management instruments that was recognized in other comprehensive income (loss), cash flow hedges"
       }
      }
     },
     "localname": "ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfChangeInAccountingEstimateTable": {
     "auth_ref": [
      "r130",
      "r147"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A summarization of the nature of changes in accounting estimates, including changes that occur in interim periods. Changes in accounting estimate have the effect of adjusting the carrying amounts of existing assets or liabilities or altering the subsequent accounting for existing or future assets or liabilities. Changes in accounting estimates are a necessary consequence of assessments, in conjunction with the periodic presentation of financial statements, of the present status and expected future benefits and obligations associated with assets and liabilities. Changes in accounting estimates result from new or better information. Examples of items for which estimates are necessary are uncollectible receivables, inventory obsolescence, service lives and salvage values of depreciable assets, warranty obligations, and regulatory reviews.",
        "label": "Schedule of Change in Accounting Estimate [Table]",
        "terseLabel": "Schedule of Change in Accounting Estimate [Table]"
       }
      }
     },
     "localname": "ScheduleOfChangeInAccountingEstimateTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/RevenueAdjustmentstoRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r457"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock": {
     "auth_ref": [
      "r457"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block]",
        "terseLabel": "Schedule of significant milestones and revenue recognized"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": {
     "auth_ref": [
      "r372",
      "r373",
      "r374",
      "r375",
      "r386"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosures about an individual defined benefit pension plan or an other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Defined Benefit Plans Disclosures [Table]",
        "terseLabel": "Schedule of Defined Benefit Plans Disclosures [Table]"
       }
      }
     },
     "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock": {
     "auth_ref": [
      "r486"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of derivative instruments (including nonderivative instruments that are designated and qualify as hedging instruments) of (a) the location and amount of gains and losses reported in the statement of financial performance and (b) the location and fair value amounts of the instruments reported in the statement of financial position.",
        "label": "Schedule of Derivatives Instruments Statements of Financial Performance and Financial Position, Location [Table Text Block]",
        "terseLabel": "Schedule of effects of risk-management instruments were recognized in other\u2013net, (income) expense"
       }
      }
     },
     "localname": "ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNetBenefitCostsTableTextBlock": {
     "auth_ref": [
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net benefit costs for pension plans and/or other employee benefit plans including service cost, interest cost, expected return on plan assets, gain (loss), prior service cost or credit, transition asset or obligation, and gain (loss) recognized due to settlements or curtailments.",
        "label": "Schedule of Net Benefit Costs [Table Text Block]",
        "terseLabel": "Schedule of net pension and retiree health benefit (income) cost"
       }
      }
     },
     "localname": "ScheduleOfNetBenefitCostsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
     "auth_ref": [
      "r493"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the effective portion of gains and losses on derivative instruments (and nonderivative instruments) designated and qualifying in net investment hedges recorded in accumulated other comprehensive income (loss) during the term of the hedging relationship and reclassified into earnings during the current period.",
        "label": "Schedule of Net Investment Hedges in Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
        "terseLabel": "Schedule of effective portion of risk-management instruments that was recognized in other comprehensive income (loss), net investment hedges"
       }
      }
     },
     "localname": "ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.",
        "label": "Schedule of Other Nonoperating Income (Expense) [Table Text Block]",
        "terseLabel": "Schedule of other\u2013net, (income) expense"
       }
      }
     },
     "localname": "ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/OtherNetIncomeExpenseTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": {
     "auth_ref": [
      "r442"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.",
        "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]",
        "terseLabel": "Schedule of the amounts recognized for assets acquired and liabilities assumed"
       }
      }
     },
     "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock": {
     "auth_ref": [
      "r220"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the nature and amounts of capitalized costs of a research and development nature that were acquired in a transaction other than a business combination, the amount of such assets charged to expense during the period, and identification of the income statement caption in which the charges are included.",
        "label": "Schedule of Research and Development Assets Acquired Other than Through Business Combination [Table Text Block]",
        "terseLabel": "Schedule of asset acquisitions"
       }
      }
     },
     "localname": "ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": {
     "auth_ref": [
      "r226",
      "r227",
      "r228"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.",
        "label": "Restructuring and Related Costs [Table Text Block]",
        "terseLabel": "Schedule of components of the charges included in asset impairment, restructuring, and other special charges"
       }
      }
     },
     "localname": "ScheduleOfRestructuringAndRelatedCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialChargesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofOperationsUnaudited": {
       "order": 5.0,
       "parentTag": "lly_CostOfSalesOperatingExpensesAndOtherNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Marketing, selling, and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SeveranceCosts1": {
     "auth_ref": [
      "r110"
     ],
     "calculation": {
      "http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialChargesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_RestructuringSettlementAndImpairmentProvisions",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.",
        "label": "Severance Costs",
        "terseLabel": "Severance"
       }
      }
     },
     "localname": "SeveranceCosts1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialChargesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r109"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShortTermInvestments": {
     "auth_ref": [
      "r39",
      "r585",
      "r586",
      "r606"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.",
        "label": "Short-Term Investments",
        "terseLabel": "Short-term investments (Note 6)"
       }
      }
     },
     "localname": "ShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r27",
      "r28",
      "r29",
      "r114",
      "r116",
      "r138",
      "r139",
      "r140",
      "r142",
      "r144",
      "r149",
      "r150",
      "r151",
      "r197",
      "r245",
      "r249",
      "r250",
      "r251",
      "r254",
      "r255",
      "r281",
      "r282",
      "r284",
      "r285",
      "r287",
      "r518",
      "r656"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r50",
      "r75",
      "r76",
      "r77",
      "r122",
      "r123",
      "r124",
      "r126",
      "r132",
      "r134",
      "r148",
      "r198",
      "r287",
      "r288",
      "r408",
      "r409",
      "r410",
      "r426",
      "r427",
      "r504",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r526",
      "r533",
      "r629",
      "r630",
      "r631"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofEquity",
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossAOCIDetails",
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossReclassificationDetails",
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossTaxEffectDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r122",
      "r123",
      "r124",
      "r148",
      "r575"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r28",
      "r29",
      "r287",
      "r288"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Issuance of stock under employee stock plans, net (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "auth_ref": [
      "r28",
      "r29",
      "r287",
      "r288"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "terseLabel": "Issuance of stock under employee stock plans, net"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r28",
      "r29",
      "r288",
      "r404"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramAuthorizedAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stock repurchase plan authorized.",
        "label": "Stock Repurchase Program, Authorized Amount",
        "terseLabel": "Stock repurchase program, authorized amount"
       }
      }
     },
     "localname": "StockRepurchaseProgramAuthorizedAmount1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofEquityParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount remaining of a stock repurchase plan authorized.",
        "label": "Stock Repurchase Program, Remaining Authorized Repurchase Amount",
        "terseLabel": "Stock repurchase program, remaining authorized amount"
       }
      }
     },
     "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofEquityParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r29",
      "r33",
      "r34",
      "r116",
      "r175",
      "r197",
      "r518",
      "r539"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Total Eli Lilly and Company shareholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r0",
      "r1",
      "r76",
      "r116",
      "r122",
      "r123",
      "r124",
      "r126",
      "r132",
      "r197",
      "r198",
      "r288",
      "r408",
      "r409",
      "r410",
      "r426",
      "r427",
      "r459",
      "r460",
      "r470",
      "r504",
      "r518",
      "r520",
      "r521",
      "r526",
      "r533",
      "r630",
      "r631"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets",
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofEquity",
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossAOCIDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]",
        "terseLabel": "Eli Lilly and Company Shareholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityOther": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy.",
        "label": "Stockholders' Equity, Other",
        "negatedLabel": "Other"
       }
      }
     },
     "localname": "StockholdersEquityOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r527",
      "r540"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r527",
      "r540"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r527",
      "r540"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TaxesPayableCurrent": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Taxes Payable, Current",
        "terseLabel": "Income taxes payable"
       }
      }
     },
     "localname": "TaxesPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized": {
     "auth_ref": [
      "r555"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of derecognized financial assets from transactions which comprise an initial transfer and an agreement entered into in contemplation of the initial transfer resulting in retention of substantially all of the exposure to the economic return throughout the term of the transaction, at the date of derecognition.",
        "label": "Transfer of Financial Assets Accounted for as Sales, Amount Derecognized",
        "terseLabel": "Amount of receivable derecognized"
       }
      }
     },
     "localname": "TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r188",
      "r189",
      "r193",
      "r194",
      "r195",
      "r273",
      "r286",
      "r503",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsFairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTax": {
     "auth_ref": [
      "r521"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax, of cumulative translation adjustment attributable to gain (loss) on foreign currency derivatives that are designated as, and are effective as, economic hedges of a net investment in a foreign entity.",
        "label": "Derivatives used in Net Investment Hedge, Net of Tax",
        "terseLabel": "Derivatives used in net investment hedge, net of tax"
       }
      }
     },
     "localname": "TranslationAdjustmentForNetInvestmentHedgeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TreasuryStockCommonMember": {
     "auth_ref": [
      "r290"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury.",
        "label": "Treasury Stock, Common [Member]",
        "terseLabel": "Common Stock in Treasury"
       }
      }
     },
     "localname": "TreasuryStockCommonMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockCommonShares": {
     "auth_ref": [
      "r290"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury.",
        "label": "Treasury Stock, Common, Shares",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "TreasuryStockCommonShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockCommonValue": {
     "auth_ref": [
      "r51",
      "r290",
      "r291"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury.",
        "label": "Treasury Stock, Common, Value",
        "negatedLabel": "Cost of common stock in treasury"
       }
      }
     },
     "localname": "TreasuryStockCommonValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TreasuryStockRetiredCostMethodAmount": {
     "auth_ref": [
      "r29",
      "r287",
      "r289"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease of par value, additional paid in capital (APIC) and retained earnings of common and preferred stock retired from treasury when treasury stock is accounted for under the cost method.",
        "label": "Treasury Stock, Retired, Cost Method, Amount",
        "negatedTerseLabel": "Retirement of treasury shares"
       }
      }
     },
     "localname": "TreasuryStockRetiredCostMethodAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TreasuryStockSharesAcquired": {
     "auth_ref": [
      "r29",
      "r287",
      "r288"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased during the period and are being held in treasury.",
        "label": "Treasury Stock, Shares, Acquired",
        "negatedTerseLabel": "Purchase of treasury shares (in shares)"
       }
      }
     },
     "localname": "TreasuryStockSharesAcquired",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockSharesRetired": {
     "auth_ref": [
      "r29",
      "r287",
      "r288"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common and preferred stock retired from treasury during the period.",
        "label": "Treasury Stock, Shares, Retired",
        "negatedTerseLabel": "Retirement of treasury shares (in shares)"
       }
      }
     },
     "localname": "TreasuryStockSharesRetired",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockValueAcquiredCostMethod": {
     "auth_ref": [
      "r287",
      "r288",
      "r290"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.",
        "label": "Treasury Stock, Value, Acquired, Cost Method",
        "negatedTerseLabel": "Purchase of treasury shares"
       }
      }
     },
     "localname": "TreasuryStockValueAcquiredCostMethod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TrustForBenefitOfEmployeesMember": {
     "auth_ref": [
      "r366",
      "r534",
      "r535",
      "r536"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trust created by the entity that exists for the benefit of its employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management.",
        "label": "Trust for Benefit of Employees [Member]",
        "terseLabel": "Employee Benefit Trust"
       }
      }
     },
     "localname": "TrustForBenefitOfEmployeesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r457"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangements and Non-collaborative Arrangements [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": {
     "auth_ref": [
      "r119",
      "r341",
      "r597"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB).",
        "label": "US Government Agencies Debt Securities [Member]",
        "terseLabel": "U.S. government and agency securities"
       }
      }
     },
     "localname": "USGovernmentAgenciesDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsFairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnfavorableRegulatoryActionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A enacted or proposed action, ruling or regulation that is likely to or possibly will have an adverse effect on the entity's financial position or results of operations, excluding tax matters.",
        "label": "Unfavorable Regulatory Action [Member]",
        "terseLabel": "Unfavorable Regulatory Action"
       }
      }
     },
     "localname": "UnfavorableRegulatoryActionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of unrealized gains and losses on investments.",
        "label": "Unrealized Gain (Loss) on Investments [Table Text Block]",
        "terseLabel": "Summary of the fair value of available-for-sale securities in an unrealized gain or loss position"
       }
      }
     },
     "localname": "UnrealizedGainLossOnInvestmentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r137",
      "r144"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "terseLabel": "Shares used in calculation of earnings per share:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r136",
      "r144"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 15
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(24))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(25))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(26))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(n))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(12))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "270",
   "URI": "https://asc.fasb.org/extlink&oid=126900757&loc=d3e777-108305"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(15))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26626-111562"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27405-111563"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL6283291-111563"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27290-111563"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27290-111563"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org/topic&trid=2196928"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117546-209714"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(2))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4542-108314"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.3)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.4)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(21))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=126907703&loc=d3e12565-110249"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(23))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(24))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12317-112629"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12355-112629"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130532-203044"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130558-203045"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130550-203045"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "https://asc.fasb.org/topic&trid=49130388"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "610",
   "URI": "https://asc.fasb.org/topic&trid=49130413"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "712",
   "URI": "https://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "712",
   "URI": "https://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123453770&loc=d3e1703-114919"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123453770&loc=d3e1731-114919"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123453770&loc=SL108413299-114919"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(10)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(8)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(9)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(8)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(j)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(l)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(o)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(p)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(q)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2410-114920"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2439-114920"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2919-114920"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4587-114921"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "60",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=29639808&loc=d3e29008-114946"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450691-114947"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "https://asc.fasb.org/topic&trid=2235017"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "720",
   "URI": "https://asc.fasb.org/topic&trid=2122503"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "217",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126976462&loc=d3e36027-109320"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e39076-109324"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=6909625&loc=d3e227-128457"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "37",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123455525&loc=d3e2207-128464"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4845-128472"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4845-128472"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966325&loc=d3e6819-128478"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(1)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(1)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(3)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=6911878&loc=d3e8732-128492"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=127000608&loc=d3e9135-128495"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126928898&loc=d3e9212-128498"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126928898&loc=d3e9215-128498"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "805",
   "URI": "https://asc.fasb.org/topic&trid=2303972"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "https://asc.fasb.org/topic&trid=5833765"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568447-111683"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568740-111683"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org/topic&trid=2197479"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5580258-113959"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)(i)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)(ii)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)(iii)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4CCC",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL109998896-113959"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4CCC",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL109998896-113959"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(6)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624181-113959"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41675-113959"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=121577181&loc=SL110061190-113977"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "25",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=121549185&loc=d3e80748-113994"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.30)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594786&loc=SL75136599-209740"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594809&loc=d3e13220-108610"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13467-108611"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13476-108611"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a),(b),(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=SL51823488-111719"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(4))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(5))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(24))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(a)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=SL120269850-112803"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=SL120269850-112803"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(c)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=SL120269850-112803"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(d)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=SL120269850-112803"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Subparagraph": "e",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(g))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(i),(j),(k)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.1(f))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(20))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(j)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "450",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491354&loc=d3e6049-115624"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e640-108580"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r651": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r652": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r653": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r654": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r655": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r656": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r657": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)"
  },
  "r658": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)"
  },
  "r659": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580"
  },
  "r660": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)"
  },
  "r661": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)"
  },
  "r662": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)"
  },
  "r663": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e689-108580"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(22))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.3)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(c),9(a))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "220",
   "URI": "https://asc.fasb.org/topic&trid=2134417"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>76
<FILENAME>0000059478-22-000250-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000059478-22-000250-xbrl.zip
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M9ON0;2^\;7UWL/ST;S*Z=RI/_PM02P,$%     @ !5IA57,_=!@2"   IRD
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MU3S+5\]^^)#-=1V]T<OH73E7Q0]Q#5MQK]95-N4;Z^Q_];.C8Y@A_;GD63^
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M69@SX!7MXKF6+'5SLBD+29H0<1H1MY3"V^EQUV5R1+'Y1655])NJ/NHF^M>
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M-),/%:P98Z7U>B?Q/OY.31HJ;]>N<RFCZ(W@$PQV'RDDC5M9D()!+U7W,<=
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MLQ8,-B2]LJU0L_9[I-P*2,=+RM?Q.LZ;(/_7JBP:SY65(6(?W819DRGT\RJ
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MB F/#,X88<\4&T=F'@-?8._".5H(Y5O.:\>#G=TP5U>TFJ0'M!"Y -V#10R
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MNZD2*,KWWQT_X?_-E_K?;=8L]P@08R\IY[<_Y0<_FJTX.G[!4'S1KW8+S<[
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M\F"X7QQQ(&XD(^6DIA489=>;\E76PK^% Y>OX^:FK+ R1_W!UD%+WW(0DUC
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M/H$$[H=_O"E ?2Q4'&'UZ^F>-0"Y3H?@ O V9B#$5!/56H8JKD=^4M^KMJA
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MN&YK.DS^,_"MR(V-X?Y?6N$J?\40?LDZX+RLK/4Q$)$?=8E*!T]RL8(*G]M
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M-P.TAL'ESM@"!AV8YDW%PJ8H2^H3(]GPBP;FI JGX-?.=\>?I!9\YQ7&"M&
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M W;<*QUO/&GAGE'J/W.X2=625Y9?*\R!L?(M,O@\!0+2N',#(RS(]-2*,V!
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M[<388=U!AZ.#@[,.E^BC1JPNHF_0PN1JX)H_:@*8E6)GM&0PT-U7Z;X;"02
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M2&:0NQ_N\*Y"?A;4'XYX<@T&BWENKTYH:!&."S/C7#(-:@,?[8DO$O4J>MV
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MS-!ZRD?+>P#H]P^BZO>MRB\;</[O,"O2G^0;6UAYGA&#-?34*L.$^SJ_I'1
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M\>"#G5]V^?Y^7Y?;$$)R]+YI=3A]P3Z@#9')[ ]3CUF6!)5)5_7S]T:R[T6
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M[D_[\"I-Q_S.O<?SUWYQ+_1-$/S3(,@_$@1>YV(.J/?(8OXE,PB84KW75<9
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MY*&-@[STZ> 32J];&EQ,17L\0&]$O>X/;+>6HOB0Z)VZ*GLMXHB]V[PI_7C
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MJ4?;>D!AWQJ.E.S%<7D"/PP%[%-[B]LHO6BE)"4?9+U@'9RU@[><WX3'[:.
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M@1(!'FA4<N7:<\\0[*(98Q4O\/?!^U._^+:?G1S@VO$^><90:&[V5D96FNK
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M4GHX^#0%$=[DSFPD2X)G&6H9PQ%Y[O\"5F.$U9)K[SQX_?KBSY]]==&_.<!
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M_V)/;3094=KZ$S*.3!#[:,\R106.V(K:B=EU*">H<Z^A<(7U*]MOFB#VN<K
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M94D J=7D6PI(9B!38J@"$LT'^(1U_?XTQV*$G6:BEJ8S.A@$:1ML(PD#$%C
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M%$ZT/'W_1B_B1 \QR&$7C1"6H&ZM6&=DD FHIZD7Z@C..*#XFP"YA32P2Z2
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M?(!L[>9A_6SQX[# +BHA<2?SKAFM;8DA&A7$K6V]J'*-]2\C'9 %]I&3,T:
M$R?<>I $"9*RTM4,9U%;?_# #;' /HX_M2(^+1L'T-#I (HP#:Y<E;.O<N[[
M]\'[X-F%/OY6UR>!?11>)G6+Z$%I.^&=^@!!YXIO %T.T'[J9L+C\$[ D*.6
MFEBCT!ABK5/1X@F%+>?UKPJ\7IPLB9TPUR8"[F9$:6LRD40E@DN6N="7Y^_#
M4, ^<P<88)C'<$""O&%6,DBOV\!!2*M<$]@[/ YO [9>$B:6K-,V>F98*MX,
M<,Q-I*JL/\KP9BA@'PLWG7[BAE:[D&JS465"5Z<I8(&\_A6!]T]/'E\>@ 'V
MN1XP%;^IN%A5PIK98H3U7GL=V Z0\G$CT7%X#Y!:A&H=):8'D$0<6EEFN&@7
MQK'^4//7"I,EH9/2P&LCH4I4J I"1>_#LEEK>?TBP*/L_[NH@QD0+<'<\;,;
MI>0\U<(,CS)7=8.7)4%OHN,6[?_[-*)-;JGK5 D\#0!/,\ \PZ8DK8D-5DDN
MW'G_WR>=*Y74+(=N&4%-JGI/(EL78:3LN'[/F \O[.3RZ3?K$\ N\F NYAZ(
MTPG60AV[!D(;8I,!I"1:OR;T9L+C^ X@,6MJ/#8'D%)FD)1;W7H/%GS95^[X
M<;(D=MBZB&>:?W1:-Y^$;:)0>DQ:&'W]-O*'H8!]>HLFI%HJA9AO+82T$('!
MP%*KC;+^1:+C4< N<>)3+F(5,$0B[JXB;>04,*9XJ'W]:6,W0P'[9/SE22A4
MK+@7$@PNGH4L+$2+'" 7Z-//_O39I^L3P#X320T2%>"YXQMM(XD$42MO%81=
M(*WO 6XB. [O &K->8 K<S;2C%+1/'C&C&XZ8?WYU*\3)6LBU^J6V.<M49U[
M/IHI=K8,T6)865__'V3SWR<_@%T=V_2!W<BK*T9/'744[=UC?55WM,U_IUFU
MA(J46M\VD0)2N76B!+T! :\_5N F-O^=<OQ$ZS8_RKD0-I!HV+9+.=@I\ !C
M@:[Z.WU\YN>GYX^>K4\"NRB$#JWD4:,X)2*J/(U^'],:C@EB:>MKNYL,DL,[
M@3%\!HE),".5*)HM+!=C["-%63\;Z*=$RY((;L<_T)RFRDN4&;<:C]'#\U W
M#%^>S@]&"OLX Y244XD,I9&G*@DLU5Z[^@@Z0-+'44EAGQ0A&XW8I/2F5'Q(
M;XA0&V4:D'G]0X:;)(5=$)SV;K@@>.F#*J)P;:5.=Q?)<F19G]8/PP>[B(:M
M6U @XI8U0"13]GD ,0SM8M#7OTQP0"K8IZ@DI\Q:#48D,LH*7$J2,HAQC".,
M+CFP-8B1R;>YLJJ=<@^5*C5OO6&4! XP-.@X++#/>6(#S]PU,3"UHEHF!;2:
MB:9^\+;^]8(#LL ^AL!= LR0<\Q "8$RVG"C(=,?\ '.& [L!1)+:G52]G9*
M-#IQ\S2*-,%6T'E]+_"IGEY^NSX%[#-U+#!:I+F^>R+,:#4J:@S/K363 R23
MW4!P'-X%M&T674U-HS;J6,S4$O<!TIDCKW]-Z76B9$GDW*>#*S*Z6Z(!(10I
M$7GMV5O/ZTN\@VS^^V2"I%P]=Z6V#1UF,1VZ)1(K9$QJXTUPW++-?Y^:DAD@
MP=T03,B2*R.Q$8Z$1M+7'R)P$YO_/EU#:2[P.O=]\>G3.BB(;<FBJM/UYP/T
M"_KX].GC$SV[7'__WT4<9(92DS4(JUM+$=6I\,Q3J6/+(UW%&5[3YGPSL;AD
MH)10]&2L(P$-2EQ".FK%4<G=UV\\<&3P1 &A;'4"VLE;*$^@K"%S2D:1E^?O
MX[# 3OJ.7;?AX9X&E6 9S=L4"E952JJK'.[>*1;8J;P$+"7W5'NC%$5'X#:>
ML'I'Z6.50+F;X+&'EYQX/FF=JWRHC%2MY$Y5H>(J&1__VO[\K\;'EC;VT>/'
M3\\.FS)09P2@<._-G'*>;K&;>M$RU[<T[.N'R4V2P1V(ER*!GL6&9XK!%E,^
MA&R#)QE1UQ]"=Q<PA!AI@$['#\2JTAD+C2*</*]307"'J&$7!0'3/1(TZ&7K
M/Y55@;EHPS&_/W29&H*[2 W[]!@2W:XXMMQR)2G(G6,80\;YAW25>+G3&)JE
MR? ]LS 2=+?@K4!PR#03XFW]BN/7AN\&*&A)\;"E@X 41H&MKT!6\$+4J+!Q
M#5B_@/3&(N3P64136NKD .?281J$JF2#N8Y(4X%*6;_OZ+%M D;*Q2RS4B&$
MZ>]XJKY2H-<>7=>O"CP2%^R3)@XN:9L[5J8G:-FTAM1N"C75JK'^#+)#<L$^
MK>R]CYJ:V'9%N7*6WF5,("U\].SKFX-C^X*MV81OZWL4)LN%W4=,Y5=0O::L
MRU/YAX\?Z>E\F>LSP3YM9:XT 48=-"4"#QYY!DR442.ZP?H)(S<4'X?W!,F:
M8QHPAFQSK1KG+69*DS%CIHWU#QA>,U"6! ]9YA(O*4;.)*/+M'>,HVH7PBCK
MUQ<?AP7V.3UTFGI.JE?*Y,Y6LB*Y<.OB!.O/FCT@"^PSNBY:KEN1V3;):H:)
MMH3&4U:28,E]_4*4&V*!?59Y%"KD-N5>ITA="25!:8BV,?OZ)\"?/_OJHG]S
M@+&4^S0A:1HHHFRMDIDP9+>!X=IGH, J109[A\?AG8!GK1S6AF:CJ2RES#^>
M;'"A;7S%'8F3);%+J?HVE8 ].S5HV@<:2!"("^KZ)0:'H8!]%((D0Z+>MMKS
MY)5K:UFJ,)4B,VK>A,>MHX!=XJ3'Z+R5GFA6DFJ66ZV"R1G!0>Y*G"R)71X"
MO2!M2>*$*CQ<II$STPR=ROH'>1\\>VQZ>H3I]#O).Z^CSP 0381.DF3K6VY8
M/0:U]:\(W%!\'-X']%Y"YK8_R#(130_0+<:87# RIKQ^EM!K!LJ2X.614QN8
M Z+3X&36L4^-IQ72&&W]@[SCL, ^![USN]^*SN?:AND$A@Z9\3$7\6;RHZVO
M\ [( ONDDN4I#J9D,-!,2,QM,@)N30O&) =J=R50E@0OI4")K4/L)'!E9@L>
MH-Y\?BOJ^DTEKRH_'O:G%^=/_*2?>5^?#O:Y-E"F,+"L%LHD(0Q06'-V!\QM
MF8SP6U12]A."<LF((1;2NC4O%MYF'EJ9LF'+&C7!4@[0K_9.H(@Z&DJ.4JJ3
M.K TSB-R-!N:>/V6@@<DB%V41+28RQM:&3Y%(/6Y[*&6["ISX7NL,JOV;A+$
M3IGI(RI5$RB%7(;-3<:V&F05M6DA%HF8.XXBM-9Y3,,78--#!*>,0R:RO8%Q
M7:4-S=]'\5C<L(^(2*EFSXD"@&8LL"& E6Q7-<AIE8Y6MR)&#G]5H6EI+&8E
MPDARYJ(]-;.<0+6D59SFM03+D@"RLX]-]$V_0!BFW">(,+)88.7U4XR.Q0C[
MY!D5L5%EF@-DDI8L6ZV$HW6R)F651E:W(D8.?X6!R;I-G5"GK:0.)FG2@)EQ
MMADLNGZQ^M$]0NK%2FI4)Y%3A%K'"G7K8SRD@:Q?=_#!QW_ZZ#[(^_/I[3Q.
M^K4<#]Q%H^"]H<M@SDH%?1N#41HF$I$84-\$RBWFAGURD.K<4; ER#3(Q]"K
M:F2%0@VLY?6/'WYJQ"R)8L4-LR8M6Z<:4QMN%88NDELK=H"JP@,2Q#X3$ PS
M1X)AJM0J:!F]:7.!PLW;^LUHCDP0^_0V374 ()$6)6-F1$XR_686@C'6KVR_
M:8+89]TKL!7RUM.@G)/E9@5+#2\Q27_]L:8?G.CIR0%88:=VE20EB3"X$YCI
MZ)59$W<MF7T5VW [KCV_5B0N&2;J+7K-:2H%HZ'(#B5H]"DG)D'4]:\L'!<Z
M3IY"Q"R3$7;0\#XW_YZG[YN(ZOHL?I#]?Y]Q5Q%9TJAC5*5L)+5BQUJCY4Q4
M5DE2NT/[_SXE+> 9'+;3H>D'D#BG4H5+PE83E/4O3!X7NNQ9MD4^9=T@->,(
M:R"*6.>Z?S'_?&7J_M7YQ64_7W__WV?H;56GJ&6H"M6M=[VI>0YOKB)C_<9%
M-Q(=A[]6 %Q"1R0U3I1*MSP:(X-N58TN=V0361(Z[Q"Y;?4'7(DY\=9OL"NY
ME$GGL'XUZE'V_WW4P=3\9<LXEFHTMW[93G=3'06]1VGP)CINV_Z_CTU,E:8]
M'*T$4_0\X\29M00ZJOCZ8U%N9/_?!SJT3B%L087"NE:;?% IPD/=UF\Y>%4K
M\N+N]5E@G\3Q1I%3KEF-Z"J1U#9WWT6L1D_Q)D9N)Q?LDVF6N2%.55F(*$T7
M, H,&5-*%M*AZWN!GQ L2P(X%5^AKH4:)<I;@BFX![EKJ9!T_>OZQV*$?6H3
M%0O6$J5&(G-B:-C2=KDO2NF^?I7!01EAGV 9CE-0@IL8H8=@\V139G+C6N]6
ML*P)X&0!V;I.2>W$*#)21!\MHLZ;<)"&(R_N_O3\4D_7IX5]6A]:2@UYZX H
MI#WQR HV"4%)V[!5&N#>CLO%/S4HEXR88A6%%<23DI=0:FEHZZ7G+K6M/T3Q
M3J 8[FT;AMR*-Z+<K->YY-. Z2&LI%721.X40>S3TK*/KJ,BJ'0BWAI=E09A
M"3A5CU421>XF0>P3,:/G<+5"1C1C1]*0@=-&X.AIE(/T,CHZBC5YZ<9C% @*
MF>M>VZ3[["VK3C.Q",W?04D_,M9*A7+:SF\Q1%TJ2<%4/.$RJ1VWY/QEGQ/Y
MMA5]IXS-*M6<K:KU#C*:D6L^0 /!H\HE&0,:@*9F2F4,#1> R"4%T9!5BC)O
MR>+;I\4*X,B!24''9#X4I+Z-A(#<8)JFEV7T;=W]<[O[PZ<7YU_=0,^M=N.;
MYU8Y7[<4N=0R#2WF@S"G;*2UMGA90-_678(WAA^\/G[7M_[(1YLKS:'FZ3A[
ML'I$1:UE&\9-J]2WW@;\]CE:2F.X2L,T\M;SSGHEA=;3M ];MMGZ%'B3ZV^/
MN9=HT:"F$4)2P9J9)AS# I@DK<]_+\7G;WYW+.;#DD!2$V6:2TY LP^I:>H9
M]Q3?G;PLS'PW@-PNG&>Y=>'&A!WG)QEJJ8W"6D9C45JE:F?W-;?#:<MT?.0]
M6VMIJDW57*3G%$-DH)4#L-W-K+D=NN'4QF9UDET?$[FN/-5ESS&B:I,7E1*'
MX+D/'AZ+YZP2UX8,11)IJ98U<R-/7)C)ZG%X[M^(W"X\%Q.BDKAW=B3-=9JZ
MTKNVR$GJ.@W-=U]S.XRP,C3H Z653$K*"4*QYJ;;44L_$,_]>]?<#GX.G:<E
M3SPW2>K>E+U&I-:$3?J(]7GNNXNROSJ_Z">/SCZX0O)&^H/>//D5"1\^+)$+
M:92M"T3+/JT?-16$]<EO+SAW841,/8DF:]TRC6'FE$H;.543]'R Z^P[KLX=
M\FF=M^H;QCP*F8%BGTNU",Z;K>H!TJ5V7)T[3/(#+=-ED/'<;V,0^RASJ8Z!
M:;1>XS\_>@YGAMN&XLO+M+]\^N3DK#]Y\K[_U].3)R>7\\[O<?S=1?]:3TX_
MG6CJ5_WIY8D_^>C,KQ_(D[,)UWSL2QCS=S"^O.=_LG/R8,$)26@BF\Y"BTLT
MQ.C-(>QOE]H;D/YMJ^V'B/ZTU?;T[.0YG!<GC[ZX_ Z?QUV?/+WH5^__ZIZ7
M/_[RCI>WMY__T>B8B]-H:WK4=!#5K,,K9FH6;%F%7JY<Q#=!\1-6+N(UK%Q(
M.EW_MF:]$D.VG)*7S%)JT52^&V(S>?D-2/^CE?L]3/]TY7[_T'^IC @D>1JN
MTY1<50U&;B!;XI-QLY=3#?&EBD7DVXKH^T^>],L?A?.7)^</].+D['=?Z,5C
M]2M ]?3?C^A4I_CZ0G:N&;X&1(>BE:ERQ+!2RJX0PXN,*8>2&;[L,IM?LFN^
MO>SZ]Q']P\FC?OHJG#>S0O/K<VO^'W/KJVI)6XHB*C@7IXCKEMJ6P! *$<I_
M,R:W6"W]?3SGANLGVX/G4GTQ0^Q 6NE5?:/N+:6MK0L34N+1<;"W7%,AG49S
MTS<(>'MA_(?4^?Y?SI^>__"N:RW?^L3[V=S)S[]/YWGYG<W4NC[Y-Q2%_T!)
MX3W Z_% +8322%2VKNV9$T_$!V,G-@'B]IQW(;W@W3?A<&O"X6\8'M)K,_PK
ML?.O,#S0# CQ!),,NB;+!4=N[&PN+/)\![FM)U1_OSSK-WH1)WH-LT9?1N:G
MS[[J'X_W+R[T[-%5O'S_NQZ<G/8GE^=G_7?Z;+OGR?W^=3\]_VK[6L_B#_W1
MTU.]/+]X]H%^=7*IIR??]KC?1[^XZ/'_L_?MSU$<R;K_BL(GSCW>B&VV'EF/
M])[K" S8RP82-@C[BE\<6559,"!IM"/)(/[ZFS62>$DVKQ'3W6ICQ&BZIZ>[
M\LO,+[.J,F\=[[6#LS^N8!7A.\;FG638EQ@; +$R2B.S@1QM=*;XH@(HGYR&
M?!I2]]'&3(#YI#A_5=ZI50E()NI4(T%M67#GR:5$$A@J9W-_+4Q?)/F%R-Y>
MT+-V.S_<'8B)R4I%%;(G'RS85#"%4+POL3KKP'!_3<R$F/78&#:<?(K@LV((
M@1"J"\4Z3M4K!-M?&_/7@OB!#NG)+BTFG[1:"Y.\=\&C2M49T(FBJ:H$:]!0
M1J;07PLSX64=]@4UZ\1D=-2MFD5"%\G''$PR+FD[E-53Z['XZU\MA96#1+D4
M-2(DJH0<;0*-N2:(.)3-H#T0WYKV@J9:C&6HF%ME*LI1B&#Q+H-'QT,I3]<#
M\:VG5ES(X%!IJ"9#-@$#F,;JN2VAB6'X5<:^IO:M8?53S8I<-49L)3@;HG75
M.ZTR$6$E-WCMN[][O#<38G#%I.G\\(/Y">T>G=Q\LN#ET6U>[(UR%21X,DXB
M,RT7A:@=Q1J*\2&$).$:Q/X&99]#?]^BN3</[S8._&26=GDY37G5!>4^#L!]
M";[$BK"'3%"# LV &)20ZX+&4X@XLO3.V'&QPB K5%7%7H!J+0R4QU+!^)H8
MK>6BR[CLQ4.2-R1>YS("$*S..)#U6JE8"A86UAA:S7(.7FMRI49P_07!!SCB
MSJ\[V^M(RWR)_>D+*+"M9@A6>Q+'H363L459"$212BRIOQYC L65N8O(-JM4
M0\@E ):8?.4<3<S6 3I(_;44G^4NCG/FPU.'\2:W>G._?"T_LA*L%IY]=X^?
MT.Z=I23>7/WN_O[\#WG.'V;SW?F3K[".?86SE1+4)% ):T:P"5--!D)*-AM7
MP=;^XO!/I?%@+O=QM7"ZQVDQ>SY[=;Q':<VS%3??GJT8".B*<&63A1FQSJ#1
M1PC!%%,02R$3P@2Z/H+NHVUU7V"&#+%$BQF2!C*,SI9@7;(I"3.//4[A]!L(
M0[<^%@G %>55 ,Y$Q@LJC+<>7$[ $RRNB7T@-I' ((F! ,6& &,KT1J8B$OV
MUP (?1%%"62SUZXDKR +)27.%F,,*D2*;/HKBG--N2T/^\=R5<A=&8;%<?OX
M@]GA\[>6MQR?/#J\/=_=)1'9[FZKOMI?Z;S>U,S'BPM;FF>'<S Z?'?GT8/S
MCW_TIN:<,F!*7G-EJ-XEBEFQ$$(1+D=/(Y%TDVZ3\KG$^ROI]YINYV!B%?%X
ML8PYQ^R;:6R-,PNZ B.1SJ.';_3PUM.V9X=WCNE#.W+ZH(YY_^1/U?'6ULXG
MJV-4Y*&M,!+Y0E2(8%WD8IR5<$RY 4Q;?*3 RVN!_YL.:"EQ'H+ GQW\N<#_
M_?.G"[QU3D[&)B2.D#&CR)\R&?&_&<B.1<-_6,R.9H=/?YX?[Q?:+TM3?*;T
M/9XW>"WU)^G@3Z7^TP\_?[+4:_%M;1(;$0: ]@E3 0EV?/:10?4XS7<N]7OS
M_2='O-B[S>FH125OI'U>Q.EXL>#]?'*;]^=[LWTZ:BMVTU!F#I%]<)P]>U/
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M&+: /D27\T2T1H*NM;"MD#*QC= JK4/R1)8C<"C+WY!Q8ELC0==Z*%?.T7L
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MJI!3/#IO?)TRZ( >*)8<VI0,<=*F0!7EC1F2XC0Z'WR-DMG!MK9AQ7G3VBF
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MJ(1,F2/48F/&" :KJAA5S&,"3H_8U6< 9@IM+T%O,A%U*$Y#BJ<S",4@1W9
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MS@<BE6HDNBPFV5#$K[-.+L80E,TZ,J"W[T]9]]2O_[EX[NX?-KGT:@IZ!7%
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M-8#A9&,-B?,8Y=QC?G E,HX(Q)!S8E"@?$PIBQ)7I4)F@CA*&0_ TU^)K',
M1G Q0^N2ZPT9G6KQU=H<LU-EC++NA\^^$G$BE^!<(;'($;B8B*&U1TDNE*2*
M1/FC$6=/LS6KFI,. 0E%.;6'MC@YR0^#U69-QK"*_6][,VXZM:IF,=JQ*UI'
M454+$C!%DT)":JV-C'9EE'(>"IU:E8Q3<. +EEB=%1?+,4&US$6)E=8JPQAE
M/#0ZM2I95Y/9M98! 0&,RC&*U2[&6(K6Y3)*6?>03JU*G-E;[Z$RL I SB%&
M&THT#MK^D)C&(\Y^TJF5N5E+*1=G/0512T.HJTHL'-EA=E4/H:#6:'G5^LMH
MB2\FPT*[*!C(\LHD%4EK51R*@Z91HZ/';&S]R-!9Q ^^^K8!V"4BX]ED0HL<
M5+9JU,@8 (=;/T(\1HZY1/(,0$&CT'KT7FNO52IU2!U'ALK\U@\"$(^1! #6
MBL3%1E!.NNA<4\X2#X33)*H: TT<#*MXBT:JU84#VI$/$8IA#]DEU,%75*1-
M]0DQC%'./>8'5R+C"JWNDD^0V4(0O8ZV6D<N)O*MLOD893P 3W\EL@85H?K0
MRKK8ME(!JS5.J=;A4>3-=HRR[H?/OA)Q"NN*(D)K<U @E RKB++F E"+BD&-
M1YQ]S-:L4"W;.N405(&,;2<!,E5*SBD7*V3E!]39;72\ZOV59E^_%UP-ECQH
MLBTOZU GB\X%F[DDG?BLQ^-8T=%C-K9^9(1E^>H<8C4&#& 4T;-%FXNW7ASZ
MJ)$Q  ZW?H18W5P*FDJH +*E6)1C5>55B^GLJ!'2#^:W?A 0U:H4Y5)* @PU
M22 /J<9B:@U!#ZOY=]ZEPT.Y2EY6G;]_?'2_OB7R9>/8!HT%/VV?_:/)>[[W
M7@O$S[W*!\"Q+F,G/O)G <-YU?$>VKZUE*<B%;3/647;NF1C2A@D7E(EA<+1
M:!C0-HT)]H.$_5HVIFB.+2V0HQ! **T6C$K&1I5CJL'Y-* )F@GV@X3]6J:D
MJ+*RK6ZM80?0)J0$]. !L=04JQH0TYU@/TC8KX7;<\D>V&=%W%+[M74VTCXF
MG8(6TE\G;C]XV/<XZ[6>ZM0F46 7A,\SM!EJ:ADOL?BV*C']8>+U$^1'QNEC
MV^0F-!X")R!4E"WE8ID,4_)4)DX_07YD?+Y&<)%;+7%LC2HDC-5%:=;19F5]
M+!.?GR _,BZO@=MV]&4%7TBUD')L*D1#FK"6-" NW__IO'%H[R )?/4J:>--
MJBZ#UL)?,)%BC\D$11 '1. GG \#YVMA[:BMM8YLSI4A>8O5^I*$L01B-%0'
MQ-HGG \#YVNAZB$+W(S67&("P(1>AZH"ZFJ,\SCNY8L3SM=DS[\^/T\82R:%
MH>V4,%5'YXTS*@9!-CL+X^'GK8/[)0NI)&9[9RW5S?VONGIW@O[Z*+M1;#42
M9*O I9B41TLQA%;@)=.0UM),T!\L]-?"XI6O)F=G4XD*,A=4/F<KOPNM-_+N
M>%C\!/W^0G\MQ%[XC=AT0FN$X5L0^Q]<<3%6'REPX?$0^PGZ_87^6KB^:26!
M2]4VY JM_',B$]D7C.1 E3P@KC]J<*R%#9?6K$VQ6$,.X&QI#7%#JJU-.NHR
MJ.8AHP;'6OABB353CKZ4:L'DB@YR9J[<.JZ&@ /BBZ,&QWI2I: 5(!EK2@85
M3$R)([,QSAE38A@0HQHU.*Z><\Q>?K?@W>4S'SZ='6S0(@LY?%>*[2,WYHLG
M_S!*V7^<G?&/2OFHJ_/YT?[\B+_9J(OYW@.NA\WTV%]/TNWY'_?,@S]V[.9Q
M>7;GC\<_X;/[SW[=>_S;+^K^[:WG]W_;M(^W'^QMFJW9SMZ=5SO;.R<[KQZ]
MVGQVU^R87^P]N[6[\VJN'^_]^GSK]I-7CV_O/MLRC]3C9UO/=O;^_733W#&;
M>YMZ\]7=DZV]K>=;.I[<OX5[>>_'_?M[=TZVMG]XMG7[AV?R??;Q[5]>/'[V
MX.G6;X].-K?E]>U-N_F;?.^SW=D]^^#ISM[+W?O/Y-J_R7=N/WB^^:Q]WR^P
MM?WOV>/MNUKNYV3GMSNOMLRF>GS[D3K_C'S7\6/SR&]M/]C=,;\^W?KIEY/V
M;'*_>G/OW[N;SWY]]OCVOY_N;&_:G5</GLMY=?-$O=QZJ%[>V[YSM+G]R&W)
M_?PN?,Z(VZZ=IEP[T$%UT533$66/H:B<H&Q,P_I7P[K]2QO.H\W3H=7WMQ^I
MS9N_&VP;3EWJ*I ,;%+0D8K0(09VA FXPC2P?SVP.S*PF^\/;,#DV=;:(3G=
M02PRL*!<ITP5P(9H+/EI8/]R8)\]NFQ@=:B.G.*NA&([0*9.C !TF34Y9S%Q
MRM/ ?LC"MK_O6%A2!DQQ1J#J9%BC\1UF0QTJ<+6V6H%VPNM'&((+%C9R"C6Z
MW$6?N8-L8A>#Q\[7XH-W7%Q2T\!^V'5=, 0ND94 KG0>4<G )N$$VN8N8Y%W
M6I?V8J:!_;"%O8#80-5' 6JG8HQB"E"+ZPKR@SG4I(SG5+[9V)WM/W_PUT1X
MR8+;>=]L',V'27UW^5\/3A[_5@Z2 ;\CX[_YTZ;:_&EK]_'M(M_]P][63W>T
MR.6EO'Z^^2J_W#'_GMW_[=\RMCLO?V]K#I33I4-;L0.VW$55?,?D&+-6)189
MR?FB\.+_?M-JO_WCO6AC5.''J\V'YS)X]&)S^\G+^[\]LIO;<NU7#_:V]C9=
M&[.=9[^TSXDLGKS:>7;WY1N=>/QL\_:OS^3<V=;V[O/[HA.B&^[^;<'M[9T7
M]W_[<4_D8#;-77-!)_8V7VS]MO5LZZ>[^OYOHDNWGXAN/ ?!/FP]N^EV?GLL
M^K$CW_=8Y';S,IU E4P.";L"PN0@Y-2A5Z6CZDQ.KBJTZV,= QG8NY=9\9:A
M16C:$:OP#L/"D]%"9TT,&935 <(TL'\UL/<?7A(PHX&,M>0N5):QU5E8A\JY
M,]E&=&V&4*\O8![$L/Z)<RP4J0"&3CDE ;-1IHNVABY13$*3P?KJIH']RX&]
M+,&C<L#L8NDR&<$K8.I2S$J(1V95;0I<:!K6#^/U@GV-7 UJ%[K"E,5Q27"7
MF%-72"4)I=G*R$\#^U<#NW5IN)P]42E%J%Q-PNRRN*V<:]>Z:CE,2L>:IF']
M2[Q>GI"$0)1U<4( JA'[:DQ'QMB.HI)1KBIZO[ZH;A@#NR1:%P;6JF1SY= 9
MW2RLM=B1URS6 %*54%E'-SFN#SJN"X:@Z%QJ*=15;UCPZG.'I'(G,;(-XL:"
MB5-@\!&&X(+C0A^B%\!VSB1Q7.AJAT$<E[,EZ\QB'4*<!O8O X-;E^#55\Q,
M2G48F80/E"#\5:Q"":YX94.9B-8'\7IIGM=9%U 7W6F7HN UL@2RQG58A;N6
M'%QP>AK8#P_L!4-05+3HO1=&4'P'Q()=\-1" ^>C3]72%,I^T!!<B+A<TE@K
M^,YA%D-@<NIBH[&<@W!84E7BA6E8/Q087!C6Z LKY;G+SH0.VLQDI%JZ@L$4
MI$P%)IKUP7S6!;=EB5G *D8@"Q&  !+&1D>=%N<EU+6JX'@:UK\."^Y<GA]
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MY)P3K)-)R@4;C34Y</.?O;Q-$DSU!E!]WSJQ[?[_;NPU?Y_C %TMG<KK?R1
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MXV5SI_'J[?X?+YNCS^\__/9^;V?OY;N]W?>UZ96^W7SL=-MMV^MGGQUX9AL
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MM<('/$]P3'/?PY;Z >""CDQJ!( //OC 1C%GL2=!&^ZCM=QPA8TE+&G"DZL
MD!#*2 ' >@'@C%\1)I[:J#A228AQH;T@%(J$"<9AE+U55;X HA?F5U2CE #U
MYI?OC[J] 0+=^*31ZGR)_<')C>1RQ0./:L/+JF$_@%'?NQST C1W )IYCNJ
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M,5M:L+RTQ_:4\8O'JWZK6O53F\3H&N5;4NIK+^,M<NVUFQXKM@Q5]WKJS=<
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M1Y9C@3#,FPI*@PHF04!%4;X*D2E$YMZ@5B)&:@>%,Q$C.CJ5M/!(RZH@*-7
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M&!F5@\%,,<&U<MY%V#?$@XYW%@C?:QMR-RHP"RK#:2\>Q4Z_]24VLNJPV>B
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M'(:O$B+'F/90&IY,,)<^'>"#,>*I 7(R1,SLB5@<9\.,F#?N;+@GX!5GPX)
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ML(,6(PA$138O&LN<Q)W -&2) )2TK5ZG>G+-!0&Y!\,"*O"X4TT<K-@$IL&
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M8ZQLQE9*\/"V4PXB!:,,!W[.^:)D2E"DN!QB&!S:'%T^IQCLZV!Z&ES>5:8
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M5+2542)58,P*HRA(HBA2Q,NKK3C[G=X^?7Y35Y5R$.FC> 6=(^QJ9FE GCL
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MO4@+(64)$:<1(PPG1=R1SNG\&A+W/[3W/9O4?3PD=?^NN[EGF# (/5#S)2:
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M>/#.$<8T1\-=$*URX8X ;E&=33&Z5!L.YB@M :X "SH5ELD:);66[ YNNRQ
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M%<FTU-SK DZ6DM;IB='H88/TL.1]]\@=)V:(N51ZP.ISJ]G8(AH#B9O"27N
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MDDDK<E9>*6549TLXOGX/[0;6W0 KQ%P,MS[4U$[CE,_9%WJFD&+)*JYS%-'
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MP:E :,36WWQ'H+H4WQ(21.=H_TKO:I2:9.A]8EJ"M8D[E3-6W1RD7;^.S;;
MNI&6R?O0 K6-L=MM97>W97*7'W&W7LDWS=]N8^S.&!O* ;KQ1D[]-Y=CSX=@
M]?N/E.F>Z5Z+@7W_[Z=/F/ ]'$[[893Z>;)!%Y,YTC? WU=GHTF_2M!'XSS
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M26M)TML#Z>(8/8.0@ 5O@;1R$VSQ24)V!\=*\?4K6#7INDE,*15 UQK41.-
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M<.S-^L4^FG#=)*0$2BV-3MHD#B&"$U:2Q!9%U B!V/HC; ]22RJR!1E,@=I
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M&8J*(:!"(Z-64IJ8[._@#U;LY:UT9U\R"68[=S3-,W)0C^8D,:,.VM(T8MR
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M^N1W\2$__,2Y6#&?/^#X=7\X&0WI]O.9G'WPW3\?"^+9Z?PTNO-PUKD?CF@
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M7]XPXY.5OVZ.P2,W.X_MWD_;O*US](>O>V&OW_-KWBZG.55X;GB0SQ%^ZG#
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M12B"I1X[;5-.3.8X=ZJ*U$J:)/?>JY^]+N')\&RI+@&'I$"Q&.2]!3PC.?.
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M^\OP+9,$8QV""9%G$OV$0U22$ LFK.:BJ9]\%K3**+5W](7[:%E*"8G"D!C
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M1EK-+26>)TI-(PZ/(P[M;WL?OOADL\7"4= A\V,:#Y8V_,!<@\=#@K )9W'
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M/#5119U\*=-:D7-?QRRV;Q42'/M4.6I1=@;\(C;2M7D["95,&\X0,1.R S0
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MHSA9>?Q3K_S[;[FN1AM!M1<(W)T$OI@QR*G$$*-8&I6P<%ANO<([XIJ(_5*
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MDV=(21V]9%1;'PN2_(#APDT.K;P9@-@C/QH,8L]?+H12AA?V['[QD-NFG[Y
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MQ%:N  $GR%T&Y-9*#A.6!E"\L>R*P5JBD>:J"=:F_G(BC?G.W;0?)\!-@)L
M5P"+.JHL_;=D?6[>EUI\I$JMUJL N)L\!.+3 5]8:]S@ <4KFH%S!KF;MNRY
MF)(B@I,X>I*_>PC$!+\)?K</_$9#-'3=S T5;0Z4G19T$$/2 ,%.^W;)"/BO
M!Z\';S[^+CQ\_+=?_HDM%DF$AFJP!M&IX=381(^E(V.N56:0XZW ].OO>G56
MK^J=/OV$E;<BZ_Y*0O=SC;G&M:QQ8S- OGUZ='QJ3O7X^85UG=LD6G.-N<;B
MU]AF1^UTUL]A<3+_W?ZW^WM/COIY'*XZCJR*OI^LVFN?C'KQ55GYQW3LNA%F
MTD77M=MF4I,<)<7(0 XC9!',18HMGLJPF#8UD^[]+ ?/1O+]5T?'WW9+Y]O?
M-\U]S:=O_OIBU;3]=-I#E["''AZLYWR!+<Y&QT:3K0;9=\,HI&C04@8@E%;=
MG;L(^W;G;*'E=?*<.+?S.%>H@83DP16'P2('M!)CK,EF"[%-G%L$SJUE=L62
MU <-1AT/=.N(Q^RL8<$HI;JF+"N<N]*IC!/G)L[M!L[97'/#')E<10^94#D!
M^%JDQ>)DXMPB<&XM?TLY4/#:C'<K]W;L$!=K,+6E6JWO2%=X\KF)<Q/G7MFM
MSJ$M-I!GAY2:1.<TMV:%4NJ<[LIP;F8X; /_UE.[A*JVG$R1+ ;5-R,-G<%6
MQ)=1E=%D=S,<)@1."-PZ!":JS+6UA J=ZE6A9CL8=M902I/"$P(7#8%K25[9
M(DDN8)+';-#S,'4;GI5Q4F;G;)X0."%P0N ;:Q=3A, 1JV8$ZZ7#7XX*(!ZY
M4XII[2X"ZM:SN0+8YL%7DVR+P]RMACKB&>N358O%^EJFN;NE#)-%!YZ_.#I^
M<;0:W-QE^/0]P>;?;\#[QJEMFI^[>U#G$T+DF))K@+%0MHDY075.DNTO3JA;
M -1=T)S#!E]]J& ".=L-V^)-)L 1M^4,(2E4O7,WN O&W2P=Z9:7MW_+,0+
MIR!8_9@&[JT5I%1+9T@1BEC[GG%8$R,^(4:L!3E!'83*SK3(:K!*->) C?KL
M0H8"P+S"B%N=V#XQ8BLFDZ!0PE(P-8SBQ4=,WE?7687KKTROT:*Q8[WQPYC-
M[41-)=_YA;1N257.AE.WIUH%[W&'O483/A8&'R$G4F<K$RO&$9F)U0+V%[K5
M7MA/BK$(F%B+KT%_1A#(&B^V&(2F)KM(II6HON4F-?EIADR,V$JN99<3*5 <
M1$;GE)! -3!EK5G=QJVE)L6X%NQ8"TSYH.@8K9$&;+!D-*(*!J0_1(O -+KK
M38HQX6,[O3E'N),82!)C_X\YN.%$&TU^6-/T8BP#)M:#.KGE0&C=<'""0<UJ
M6"N;4 JE$J0)U,DQ_D-0Y_6PT7YW]/VX,H_<S2-O0SGI:GJ4&9>B]6-C>INF
M8^R>IFN<0L[D;!H#V:M2$NB6=+7!$3FH4]-=OZ9[].UZ3*^%6D*.R40?DD$/
MW9CFG(U &./+*Q=7[MR]Y<D+VV[3<3LAPD+?:(UR2ZUV1N6EZDCP#+%V9IPG
M&5X(1*S7+?KBK4(RX+2,F1S!9$=B7-^\/+PAFF1"Q(2(;43].U, 7YS/03$*
MY&1SAA"Z$5T!9.-9%M/==BW0L1;1JY%<\2Z;(,4:!&S=C,[1%(Q%DY<4P>^N
MNVW"Q\+@0Z)G2@VZ0G*8L63!@"E9C-DCA*M+")@P<1F86(OHE5# CHIA]9U<
M8*[!$)9F?/9<R%$+&";#F!"Q!8CH^JCXF))P($P#+VK4R$Z\3[5OP<DP%@T=
M:P$]!S$&B6A:&3E#M20C$,6D'*$!AQ())L.8\+$E^,C2A!QC<^@Q5,N^-%)H
M8]A4!Y:-6W%/AG&U;LZU@![;S*[88-BY4:7%U4BU:BB3"[6U$D=>\BVG&+>A
M2.O1Z5,]GK59[XSCA$[&HR,'HRM)JKEU>SW[7$*57/'J$IXFP&T^5.#QO=,U
M@(NA&U'9.\. G0@57TU74]8(0>GH%JMKZ<Y=GW80X69:T\)  DL-Z%A\=MJI
M4!4-4LFJ]=A:KK-6?2D@\>M:K7KT)5 VV48UJ,BFV\%B-)6,F0*$D3H]06*"
MQ#;:<0<$UMB2D\ZWL]02:XX.I:EKY>I,I>EIV0IX/%QC&(U"3=Q,+C),J!(,
M^>H[UV@UY8:M6MI=5\O$CX7AQVK8<RO)Q>21U7*K[ .49$/4*#A)QD)PXCS)
M(! *#INQ03HZ>/2&&'+_LV56R( UW[GK<): 3Y#X6)!PA.A" BK#*5N(LQ4G
M(,I.^WZ;$=^%@,2C\V3"@JK:5,;00S#8(!K.(1NGGJT2)G'00<+O^PD2$R0^
M#B282XW]OUJJ0_":T36*$HNSG6/X"1(+ 8D'KV*['2C<H\??V0?W_NF*M9P]
MF22AVQPQ!"-BJ^%:K/1W%,%-A\6LP[KE1]Z&.JR+1WE>-DSZU@Q?]\X9OC>M
M3>[F%[W;BEY\-S')JJ;F,%J2ZG)!7UJJ!2K-X.4B%/W7Z\%+*MPDD3=DI1K$
M%DR&6HSE1)@K,$L:U@#N8+WU965P*0E><XVYQA7.&G_]X5>B%5<'7,.8Y+?D
MTK]3+A<YRWFN,==XWQI;,@J69PD\/#HL9\SK;4O@\W=F\NTZ8LXUYAH;:-0;
MG;;[W?ZW^WM/COIY' YIWY/#NB=/]+#\^IY<WH_V=>^:O7_1=>VV2=\D1TDQ
M,E WZ2&+8"Y2;/%4LM.R;9/^C6Z95OVEK/KOUJUZ;.1!BAC7[7B#4H/A)&I:
M;8V46G'1=:L>W#[NG%6_O"#?!+N=![M"#20D#ZXX#!8YH)488TTV6XA;+TZ=
M8/?A8'<^ZRDE94_2#-M(!IL$0]F)B9Q9*$#1$$;6$^W#!+L)=A/L;*ZY88Y,
MKJ*'3*B< 'PMTF)Q,L%N,6"WE@I>:QM)=MB977,&,3=#H;"I0&!'W,V*3&8W
MP6Z"W6LS=E33%AO(<Z< J4ET3G-K5BBESNZN$NQF/<QV0/ \X].$!!&BZ?K*
M&O3.&LY5##?%(*%B*CCK828,3AC\'0835>;:6D*%SOFJ4+,=$$<;V-*D\(3!
MQ</@6B:_>(W VDP:<U70UVB8K3,$@1EKMM;%"8,3!B<,OC%],<4N'1&K9@3K
MI4-@C@H@'CG)UOLG3-/WP_U\ZS4)JEHS5#"N:RV#+G3CMUDT*;B04I5* -/X
MG44)M_W(VU"4\,71\8NC8SG5CM/Y=(Z'>9?&\PDA<DS)-<!8*-O$G* Z)\GV
M%Z?&6XC&*^MA?%!D"+D9Z*JA$WPNAFQC8[&(K1ZM$-VYZVW<07TW&ZPN#"@
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M)W:IALX]Z:PS2/6LI $E$&_>&60&3*\2(M;ZC\46(W3#@;AUG."@1@9B1%N
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MUV#SSD@)8D0R$"1V&K87F9HRNS"95;6L7!MU58O"E!%C:RZ/TDNVL'&%QR3
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M)\XZ+#'ZC,5*9ZRM68H87;)6VQG9[9_1>F_PT);Z,3AFG2DC)15.32,+DV=
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MT:P?'<\*&ADU# PIFOO 1\TYE@1X-@I"/+OVC6KAV;OGV>52(IK(%#E!F+
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M#/O=9:NV?:XL[9K'=9WLF!K),\[G2]5AOP-VXV196[!5QWTPB*^3)7:==?X
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M6V*>6,0\#GJ="\ZA$*/.Q;0XLE1[I&QP/!!#B9 [>Q2++;%XKR8"UKED"^F
MFQ.'UHNCUJEM]X:MGSK]X3 .?\Y-Q/NG/1BGBN[,,6<Y!#?O414?";^$V,N1
MG<,1?- D1:56_[R)T:UC-)L$D+G0M(N<,/8_-ZD*0$SRF%'AN1:<8:RC503L
M@^ 3(4'+)I)278FDO,KI.04(?EID^6?5[&:,_MO'H_9SV(;_P!YL.T/?(K3R
M&87?W^F$+7;&()(21]R".J(%(TAAKZ(+) 29LA+"5A5?KCERDMB00W-O=.3?
M%3Q;COP61\X.#YZ]BTXHF8A'2>!<!0W^ITU*2%'E+.&,$DIW]J14N_);1SX)
MT!Z=#6*L"*"74_ZZ<,IGPU:L<ER^F$0UB,,<LPXF1LYWO#'U1)XL3])Q1>%?
M*@TU2H!&P+EU5BA:40^9  8IU'-[ZCDZWG]''>RP4QAAR27B(4JDG4Y(:^!3
M9X0'BP8D.)<KG#:K .,F(D*J&'22RL7$M><FBDP#4H+(\\':YL3)5T[\)@==
M\N"^1 4>]#@>6&0,>4)!C^-6(NND1CBH*(*E5ED+5*#P+OF"'G=[""%7(:1.
MW?FZCG,+O*J>SF_-22[+"@_H3*$5X+<F.W<VLR89K]&)MB%WN\XCKK3!%:F]
M.9&H/Y[E!$]RE^NTX+GDX3HE:'P.^S5).VXRB*:C3G/@_S7Y4IVAE7>Q3E&>
M94%?36#.VNJ*].4ZZ:=W-<M[DL(_EW_=I!X- 0[J!+'!;NN@?]&[L(/0K+]>
M[<)\\M#3Q.HJ/3I3UR#3S=QRYQZYDM&VE,,]2^_/FG:5J513)5B=K;RM.9VJ
M(J3A9,KU;)^T3F,/1NU,,L.FWV]RI-J] &L8 (W"MW->/!R-'_5S#N#^E>4U
MLU\+9WR+PN\VD>I-#TBRD_E\@N$O>W-)J3]\)M71Y]-W@CM!'0Y(<>81;#-%
M3NB !$TD$<%]8&9#,ZGVF]RIRPDGV&Z5]U?E4T].OL'^3)$U_&>@L-Z/N^,Z
MXZ^NQ) 3"@?Q#$S;#-#YR>HKHZ7<SVG! P0,@H8V)T3-0#^/W5M\>U5"(H\X
MJ<(#O-7I]"]FK4VNN6?'[2Z\XRA>M%[WN[;WO?7YZ(IDB<W+_0*C\WMROZ3<
MI=RL/X^&PX2^;]AO)?W<0:(:3/::&4KKRR+9@ACJJ;AJ3235-0+0']<6'$3?
M[ "I5>8?/GC\S1Q85R6N*H'QF*/&5U/&X[QF6KW6#;AF6DCRGRDDSS,17M5<
M?XV@:\1C^VG;O0Q-M=I]?M@]82?'+\AA]PW)-T4G[U^?'1V__? 6--5#>O+I
M\/.SR\/G;]\OWC8='IQ>OGT?S@[?O[E\>_QW]^CYW^VCY\_(4??UAZ/C#Y_A
MW9\/CU]<O.T>I6G?EKG;)J6=8U8SQ!0)B(=@D;9<()IPT,XX@K.G<Y6/XH:J
MVIVELY8;_6V"VG*C?Q.H-3G,#WL2M.$^6LL-5]A8PI(F/%V['4>!V@> VJ5(
M]J"T%"X%%*FS +6 LAH.&.E\AY@84RG)G3VS3=?ZM^_&NFE(M*3\UCZ2[VK7
MMV+%UV]04#3 +\)2]EL66/HN6%J15*A4;@BC'3)4)<0EQLC1:) 5(2ICI5=.
M[.P)LN*J>^-5P*]T@+X3+>^Z372W$#6V7IDIJ'$+U%A69@BSWI+4Q#@X0I!C
M4J% *0?PCR2$C!JW3T1>%PNOJ=WPINDK5RL]?//B97+A<O_MAQ^Q/I-K_'ZA
M1"7 3;X1NVI2O6H.H8#034#H<EEUB=(FRU5 F":&>(P,.:\LLD09(S'GC/N=
M/<)6Q%EMO.IRJP9/W^^@>KB.;(]8=2D <3\ L:2EI*B%M!HCZ@U%7!"P<K"4
MR"N#B0I"<I]V]JC :W.Z%+_*;?64*X$AQ>]R!WZ7KY?3OFHQ%2CZ#B@Z>KKR
MHDT)HRG2/@C$E0O(4>^09]H+FJCF5(/!I/0V*BO%S_)XE)6"$O>'$DL*"\8B
M4<D,BHQSQ)GPR$B&$5,Z,2>HYT2!PF+PACE6MB&_\Y])GD%>1^[4E2]VA@M=
M!"I]Y*L1K5<[ATUB:'-LK!_$T)Y\4N=:S )PK_QQL:.9NVSZK$VBWD,[I3B(
M/9^;(HPN8JRS IJN)S-%*HV;'DA-,Y7AK,O)J)];'N5 U/KW?J]IF#??6*V)
MZ(5IPO%^KM)9AZ/<X*P*A)^&YM>YK_6&Y2E>74P=L!^;3B5-1&^3QS#ISI33
M&'R>ZY/6QW9O9$_K"/JY_<D1LZ,<K_\$=@9.[[]C6/YEU;-D^*0%4QY4R0+U
MFX?C\W.8<AW(?QK[IP-[?E8'S.? PCJ78+?U8BX18?& YCN<?/W$EV+VUY(*
ML!#XO]P2]<?L=ZHVO]_I]?J7;@#B?:-%7\7Y-XO>OQJU/V'\\T$[=VP!3$WM
M3S&@S+-+K5A@)A_MX#+#QZR-RZ1?6]75-.<:5.E@P)$+Z5"7[=@)&00^UNQ6
MYR@L)?;LMO:O]!O\HMK4&^<-66^R-;V&N^>KVM.?8_BL;FEU4+>:!;Q\F5?Z
M*@XR+P+5OTQ'_1Z(L9QY"5M9M8N[9B(FHMNIE-TBH^>0Y$Q,3PE5!%>74Q1Q
MH@ER'BPQ9BS8TL8I[W+@C5AN2'A>[WO-.$U.S5=(/+/+ HMDPIYI%PCD5%CZ
M'E#M-WMIAGXE@4!TQEXELH:QTVGRV.#C82V?^O"V3OM#)OT1,%#U8=4U^&+6
M!'&04PL'<6Z0*LWOJZMPU;UIW:-TOJ=LE1R7^RDV\K!J9=JI>'Q.)3FS'[,:
M$W-3,1^!NL.3B>:1=R?/O>KLZVN,;;JY-:(VQ&2KAG2]:O&#W/T1W@:0T\M=
MWCJ31FY-%UE0YA9W]SX3[%:GU?W &76'[S^\"X*EG#>'L*[RX;%'E@N&HH%)
M)2Q%#'A3,^IR?O*LO6*8M%?\AL*8.RD.EY+:-BVG#-2@75RK0C=N*$9W)6'K
MS].BNQ1_7\^GK_]-TS+9+9NLW((>7=?+/UU,1/NN9EUFFY+JCBN[^+ VAY]=
M-8=SJN$ZL@RW:D..LGO@FOM1^IA-=NV:":FE(])TNTC9KD)=]T1=FY ;_0!-
M-5\-^K".,*RKW635?P-RH^]T'S8O/?H!EGN_=3IGCL0)N65JRZ[#?JI+LME>
MF \BNUJH]Y'<PYY\.GK^MO/V^<G%V_>>OCW^\^+EL1=O#T[SO_BD>PCS]NR$
MOA&+][!'[Y_A/,^W[W_M'GU^VSDZV!='GSL?7E;_OFZ??/Z3'WT.[]\>=U9W
MVDK>>>X],A8'Q"FGR 7"4'#*8.H#E2SN[ F\N^PTW/A@C;M+#YRRY2-.C7X
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MF^U:K1WF[\\:$_@SD!:QLJ3KW@V5:KF,X4U#!WN+ N>2AF2XL3ZPQ!U7-JI
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M^B1S499M;1"$P(:K>!=^"5E7 ;EA.]6KAV<Q9J'U#V#L9(#,HGG*RP*[T;E
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MB7+8"$PYJ,>@8PL=!??8:BM)JG&<8$8*;:X9Q\7+@S>?CPX^P-\\.;IXEU*
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M/\:]CI[4-&)O7S\[KOH;O:XZTA>K,%6'/,*6JMQIC,"SMYE*C2WGFN8UW4L
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M]WI*M#!567,J-ZL3MT=W?W=QG@J>:X.Y[O!<.':J5(BU<> MP$]8IZA/-4U
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M1%]U!TSO!&-.4^PE]0Y+)2*"(\.$,]!)F#7N[8?[9G0Z$,$@80:$H%'*:,7
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M]^W7>!T>G[PG1\\_QG&==HZ^O&8?\<OVIP\?69P7/#KY/1RVFXF?"DNIO6'
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M]OPJ%9[>>7(L"1$ P</N=80LVSV>U[8ULJ?[Q?ZS40"*)-HX.#@DTY]^,[,
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M'\WO?__;L&N]A@%//-M+8:*$8=@T PP,MIW6@%W%7A1[Z0S0\8TG;MD?4>8
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M6X@0]_,#+TWSI+X5JI</@\X7'@85*X_0:M] PSGE,5+78N^S.)H"2\&;_^1
M/QEYF,^-DI&AF9%/JT:^"@# +,F]%1@U3F\A2)B30]ZE4.&7A"4>Y1$ NU^$
MR.#@1D\CC 6'[!YS/1KMVUR3/G?!.$KGX!5QLG1D?N5K+8'X04D+KY]I6 SL
M_@@,89I.DU?GY[>WMQJ,3AM'-^<7 /M@O9-SX8YY? Y2R\^)\ZUAMS^H_&D8
M^&=O< ZZI8U66C=,79NDP8LW'R)03GJG_=^_GO,WAW?B2H Q$R0\B"S> 1M7
M@(6^.["0[%LB 0S?XS$!GT\3\:KXXW5QIM,+:5STTNM%A;/&\:65DC_/[:?6
MD38T/PV:]YS_K-%/2^<N\M\&FMGM;OP98-OF5Y^A65,S^^;>F^U:FF4.MVWV
MJ0[GN@/\_]<YM^3KCP=?R"]F* #%CQ+JK_T)>7#IESH=]UU_8.PR"J9(B@>=
ML#MANGT$J.20OE:4VXUR7R68>$:RQ7(TQT/2R@[DYJNK'J S]<IQR&>F:N"Y
MKB\.2U6/VR*]XS*PK2BZ%,TP+8E2%IN)HUOYM[4#P6M.U/7G'[]Y\4^!21.N
M8&?%B9VM"M ?*3UF4\$,<(JWYK4C)<0%.:MWE!S9A0(-UD5W4Z?JRA=_@TL8
MA2[[3\;C5(9<RF-!\(1T]^D3N?O%6^G$BU=>T@Z@ZXZ;C?\A,--MQ#T?L\5H
MMW&*UZ#'N'@" V&T[1S+%(O3%?<R_*7D_4[R%$%!C"5&X3A:R.;?AY!V3U!(
MO]@B\=*9DKY&2=^^"F-L2:/?8AYBW/W#NPOV@2<I^P9*^SMS@77&X8+G?Y@L
MG<Z#LW3.])<'C>X2^1!G?''2"'>!"%K@!@#@?6<.8C8 %SJ=B+][H8?G&-F2
M,F2!P%/5;9F(-9/[3K[/OHM9WB1^*T)W"MHR3;3E]S<H4[G7N0^5:G1/4:7*
M[$C<ADQ\(::,3T/!E8IME(I]-H"3RWHZ5PX'\$].44X_XV$/)YK F!WH4? T
MFE \)O6VB\D>)UD*=E3">A=U"EE-2NNY#<L\9(ON.+GL+4^ ?!_#)(/?VA^<
MTY4W"GOJLG2-"GXJL+!C-&0%+5!%L58._UMYL;D*@$A*!/%(C;4$(?2[MW-V
MV3]KY,I\B4=1//:]:1R%[.RWWZ_:^C7[?'5QPCLZ6P27'L0?1RO5BE*[X:\G
M# :O5V>G2_C==V>5Z=B6MM<BY6F<R4R WW[[C7V+O?;%.,+2ILI\/$PIUC,C
MJG&V19%Q"\-S"""MEN7IS9)*^:MD]09!%D(/XVWVANL>USK<?JENX=$\8<?>
M=^]G%G#[L#NCT/U#=T:-EUOO_QTIWKB 47L.@_$'<A>@SM!KX]4?3\O:7XM#
M>$T*SZETB2:E2VBL9+)U.9YK=T.74CQ7$B[NS'M@!TM\.!V7]I.W8@'KJ$6?
ME@C_]AV17TT"'=7=HCPM+93AV(%&RWI/WA*S8UK[^IRRI\CR>F2LM)'\?!E'
MD_"_$O;.2_!>GM,5;+5A^_#T=94SLI-_]OFWJV^_FRSQKC]?G*[ 7?+8]:(;
MGLA2*ZY20"IA;?N$M4,DEYX8 [[]]OL%^W3QEN5;=J<KBE]G24IUW?ULFB5,
MQ#-@L8"G49*=L.NC%-1C%-1];HS24%M AO^YO-;/#?:[-^98=N]3%$:.3Y<=
M7,B[!T[X!. _/#?FK@@I[S_)IM.,8C;JP(Y26%LIK&1/"6BGPV2TDW0E8H$#
M#KC-SJ[>M?4JA#K-K">BR_5$9 B98,1@\2;QR8:-)9<H5;0%=?:MBAZYF?5\
M1=R>)7GSYU2,N>^*Q!?9=T"M9Q]_;QOL,@K_RL: 9$]3ERE_4,&K6NFT75YY
MWB=IP.=4B/>-N@M@J51RM].8NP!4_655?_EQ]9>?U/(UN\3RL9%FKU64CXTX
M^RN4_&Q(2M5";AP^7:$JX=//(HN+2SWWZF5;)YXR^BX*>2A..F'T/8_]&;OP
M?\*W@8C_*U'9'2IO=+<#!V_1Z4DG8 +'D_P*SUDCCQZ8]3MZL&$KFET7-TY=
MQ5X4XT5FU_)*J@K=\\O"Y'VKCO Q,1ROO"PNIIKR= (NJBK1>) (7"S*J\:4
MME7)O \NU:CV?A^X9Q*  @U%FHU/5]84V%/JIP&58D^,!;]&/GBA)WYP4>$C
MI:#VC(_44:>=//JW%SK[382B=.'/KJX['?V$<TFN>/S="Y,HG.LA5:6[47I(
ME>%H5AF.;6J=/R(.=6(2^]OUYS4:O7?"&OU##(]$J0BF40S\Y0K<J?34N0NE
MU)525TJ]$1+[I?V;[WR^<(BFX>1T59>*$C1<CQ^>.FH/Y7&!RJ_?KKNJY, 5
M]]3=P4K3;*%I]GE9Q(FQV;?KJPL=2P5PI6Z4NE'J1JF;IR7DQ>7%E3EX0&V2
MDSIY_,D;QZ".=G"T3HH\[[S$@8>\,-LE>;A!-VL<O@1\?E+ICCK<&-]R0>O1
M([%(,C^E"P?QXZ)^;+%;@:&"<HV8.S^OLE=]>;+G562(*G3V<(W'4M)PKY8W
M=AVZ7+/PIR+&0WNA9[.S:Y&*FR!J2OSY[W_3^]W7AP]!G_PU([]GX9@Y/'1$
M7#=/XL "=$&''^;6N>XB<];=)_,>YP;=W?6N[\(.+?H)-_;&^2;?VH,RF.J:
M!5'<YN,P2F#*[/K]-S;*$EC.MES7&\&X>X,2!E D9H%(>9)R?%32D]Y/Y-7(
M,7>)$Z#E:A=^!*3T9YO:6=<E6,UV$L!;#$;M,W\NYJKF_I["4)-9C'71E/)4
MRK.Y,/W 1XN6]$;W;N1^]#KDRHO3R,;+=@FT__[E?[ZTS8YUPFE8G\#8^B(W
M6K-@.HF"$\[!4N?-=Z#1\B'IYS@@O593JN/1CRH7/HFC$*LVDC9P9HAXL;:E
M"%1VICK[\Q#'[^ 79!\;\[UMDWT.: #@_GA;W75]I,10V] US*\[J;W%CX&?
MA2)),5"EME_7DNC]]?_^Q_MKHUT-FV%%UB3=.7YS4G1[ ,QHT)YU(X,H&VLQ
MYQ21-!X6)/' D0G35^TAP90]S-[2C/NF;VR.RQG:X)YS*&R/,<3!%B-]\6;]
MT1U<+_D1'+\T8B/N>+X'JD.06UC)#Z#8O?@Q%:Z7_QA+AQ)<S@"^=*#'!)M(
M0>, $\,@HRQAZ)T2B63P?^0!I.+H>8*.DN\!TX1"N$N>Y+$MN?$,2_XQ1)GS
M.>@7N=BW7CIA%W[@Q=SW6^RK=J'-KS->/HUT;"NPU^IVVRW O:4!E\5O0;Z6
MA6\N;],HI7.;?E7R)B!UZ !Z(?SHRO:D+/)5:62W,!C!ID!"+_!"'L]867X$
MNG&QU"JT1 62B\9I&Q$;I!$%'&<2@&"G&#9B268#Y)"C\@+:**'GX+\QXS?<
M\ZDV>YH3 8; RR[]&4,:>"/X *_ \*=@0=)CY\CN,W#D99G[58;Y<"5MP616
MV)C6+&0WV'Q>'INX#]C4B;TI?086++G%%J$8>2GJ$6AAY,5XV0BPTW)PXO'Z
M?=V5 .J6AF)ENWIC;FDX'%&^9#&;>E,2. 9,&!&7<P_02 +:-2;L<5LH.F1M
M>A(64H28:L#./G_\_?W_O 1%&;F9DR8::G$V JL:W7J8;0#"#<TQ>JQ\"AZ(
M69:((EA?:5^*D8WR!_K7R>(86 7T'SQ91A'@Y;GTE(*6Q_C@QPF_$2!W(D2E
MFV\+8(^Q&&>^E+["5N0/Q\5N0.61A?2.?$>AE6.!%K[Y3P[KM#QA><-&+$:^
MP(E2C599*EZFG,*H%VG1@O8=/W.KU(K0"E3M&RR'AQ8G@O6Z",,,1G4MIE%,
MJN@>)3D:[9EMI""[PLEATRO:)I$Z^U>^5@6('Q//]M+7SS0L-H$% 0V8IM/D
MU?GY[>VM!J/3QM'-^47L3&#EDW/ACGE\[O*4GY.L6<-N?U#YTS#PS][@'*QQ
MV^@8NFZ8NC9) W =HCA@>J?]W[^>\S=[-%E;"C'Q-C+:3/"826SS#A@ZL$7\
M][_IO<YK4V_AMI=^!V!05\6<RE4Q^[\ YLX8S0/"-,V^!F;7T-<14&^O-\6<
M(/WD93+/0+O3NVA&'<=9<RJ-VR(5:^FTY#R:)W[(AJ[;>1^ E^A[(S_ZB5>K
M_I/'KL<K5^\<)NT5AM*<8S9$MWU&<YZ40)4Z6*=Z(N@?X$JD;,0]/P,WG.+B
MTQB<UQB=9/$7^+;HK(_0N=O2ZA\GG993WIN0]_%,IP(6,C,Q8BI#*<77(R].
MTI7#N_@</$"AEGONO%DCLKODFY_P_GZ17/G=<T,QV[U8VDD1Z_B2(52]S(?B
M!.-9ZF5^O$MAXB_@CHNIH/TA]HZGG'T"\4ZC&$/,EU% $7&*></?,ER8P'2G
M%+ZN%$4H4E8$W0KC9@)W3!T?@XSE"4,QPDTP9W:']E6N5C5)+\C"U=H'N^3Y
MGXZS);.,>>PY7GXTZHN?!5XEO_%)%,2ZE6N.IZ4*&LC:KX L'8_C)B(H0.6?
M*/]D)_]DOL^+#L@VWL>Z4M4//RMR4HCZ\LL?']^U]6&C'(YG/EJ_K6*ON>OQ
MS%&(+0,*"LRN)>G:,EZ-.9ESX$V#"UL$W/$<'W'L'R+^*4+O:0MSK2Q:@W<,
MGEK=-9>OKN(HH>,(2R>8FD.P ])*A>X.<:!Z"0"KHTK[3E)??V[E;20F&.(#
M!/,1_O7Q\I-C/R'P'*>&FGM0K)+CJ=,1@,.PP/UP4N:B4]+S)YX"!D^VF<,3
M),M3.Z]@V7S/V8(5KCB>,WKF,=\YPC^1]7 O !/%IS1<2I&7&>:C* XH,1W/
M1/F8L8Z9Y5.,?,3I#/](BYU^+#8(2 ,?QB1T8%D19J(%L".9L)$?W28R5B)X
M' )/);ND&A^.'!_F>?H@=__,0D%YT<R/$J*#I!!(I^-GB7>#98%PYA>^%\RC
MB(?9EKI#*]8/K<L\]/*HY#QJ1B6U01<*MU7J/2>EC:1('K3*E26PTEB$T+$#
MOP13D<IC>'2P#E 'B_G4<['Z)31"1U,$?!!QY-*AC9P9\<=;471RBRJRV@T]
M7CS-1G$4% =,F(_Z.:&]-52*V#<T!ZHVKQA>% R'9^,9:6KXTIOZHAAULA!8
M&"WPV1)WX2A1^_,49UOE-6CB$Y_EI4=O\0S+&!8/34DXOI]^Q<!!A.\DY8Y4
MVTSYNTGY;4(FT:$30S"SXF$<PH2[LEOLC$[@<!8 =6B_D;O024)[BS@@/$\'
M&@>&1("92G!5RKBCKN)SNSC71QK[*@3[#"J,#<F<3L1B(VA118C%X4<>%;"!
MOLF7DB=N4/#Y\K$^'U:$-*0#EA;U7.6($JI97/(8GHD7S_-(I9GKWZT,]'.<
M!'/R)/C24" )_I$%W(_&2OG=H_S.O!!X$NOT>@GPQTO)UB!47KPF]RG@?P%M
MT>S&$C_2.=/XNTB34B"E7."A/'B.3HM!0\#9X$).0;CA \H)<3XP6+Y.J+2F
MF+N7\UPQ*CZ"Q72YC:!TQNCX)KZIL8M22=!A.%1YB0=DX7'1O 0(U<FM3 </
MM^:\+BT D#V?CL;>23U"!_V"*7=H;%7-1 H1MWE!9##+,,EBL=)%$@5B$\'F
MVHN4'-&HU#=YX@* :1_64_8D2L6TJ.[H,';J!:*V,HJ0#4\H%G3#4Y15<?T0
MQ:DX<,7_!DKKLG!*>2Q9]L^2H499G!_&7#%D=\&#P@#C$ME>5$A4E>O=N5C<
M 3]7Q]8,UPCX$#Z&[)+,HS-C[W\X$QZ.!;OFU;,&-1*O"US/L1_9W*>%XN&L
MA*\H6S0?IYA/["7?D4DBTE:$@$9^AAY42J:_>$X4\\8J$*"K0/W '&',<_7F
M8C 'P,88#U[+.A("M&A+0F@\,CP3H30+EQ-/?I'AT>,_)QX@T%O<P1+?D9D"
M'O(Q@BD\&YRK;GGHN!@I'DF6Y38FPAWC2+%9Z0[2E&03%*@ YV\2>O_)<-C5
M^A/E/-'T>%6:4#$,>&8%TTG%WV+"HY[*_#%@[!#@$O[=V@'IH4$+9VP,KX%;
MBQ$2%^U,7"!NF*.07DB(0AO VD^2_&CL5S%-JV=C.ZT<<!=R?0N"G84C?A/%
MW,:CYS1V>-.>L2[VYA0HWBP^X<L)Z@L8D ]<D\MVP32+/%"L6THE1CSL+#>>
M4MXIN2]+D:V"O$H(S7A]:ZV5Y9 ++M<"UZ$$%'.HFBNWO+,0G/8V+%10=(M&
ML57@\)("#X3AJB#%AH(41LT+4N1D!C7\NE:FY1LPL9NP"W(/4>*O)CP.0$EG
M!#*PHK-TF*^%%]@9L'! (HI\>>$X@"_OM:$'F_J=$_VML$6H'\*\4I"< "@7
MG,XBJD<$L4B*LN!&@7#I33?VJ.;%O-0%- 6>K9=(P0.P8V/@FGIPREC(+99[
MQ?]&L>\">Z$[C:43(ZH80A9#X'B@.]"48QPN?8LN?99.L,JVA]KO:^9,6""X
M-$>R^H4,A".8Q=@*=$SZA>YBR\)4FDT'QTR&C9SL_V0 WD@YMN9OQ&(D8BK.
M1"\DI)@QSD+SRL%S[.$/4HE*4I;EE^X+A"8+E)!F,Y\T!8\NLG$&-)E?'D,&
M?DX+L$'2EL@\[5&.Y*\%+A/^=0%Z]NSC]<5+\,S ;(WS/@IRR4;A=^FX< PS
MS?MY)]#UDV6EP",$CR>=T"JB<QB"Y8MOD"@4"Y/2@^8*T$.:DXM<B,*32X#.
MOF@GH/;188JS<5+@67 T,>05%P+FYJ72/]$^!%B0*W1!W]+C].<[C?V&D!AK
M6;5R"U6A2MX[GTYA.&2RS^9;(;Q(W9%]</99W+)W,!QV <_G!\]?,BJ"X8'W
M Y#@KK??EL/_'3H-82 +S6 1C:02P/-"CVIVX7&%LB1,&;O"NE#P+9:KH3IB
M>)";1,H1()/DSR+?DEL*EM[WOB/!R1VE\W0AO57!5@7+2T3)L0;/N&!F?.]V
M$ODBX;[(;PMR00B 9::P1K@Y&R,;4E=I%('/C'$_\#&07R=53JG0GN:!+"!7
MI5@*6;O&Y[<,@0T,#[]<G%:+V5G*P@CG !;("[( 5P',/OQ+3VCL2T@@+P#L
MLC#/WSVL:E;JI[S&%J -@>(!N'OB@9:XC3+?E6"24'$>$1S-Z_%+72"!FX@C
MBE=,L:0_SKOTI\#/F\E*/?,F8I2Y<BY)7D*N8C$6A*$(X<T5*HZL,J-%F&2#
M_Q:BHB8P="]FNC?<4 ^#)+?H<E\7E-#?_S8P]/[K!,ERX\E0%/WIDJ[%B"BH
M(.0<]'=18D$-9>!/(<J,\[)Y8 "P!F_)>1@<RHF^69U4=DI)\*C$WA@W3.G"
M!I[?]HG?4O1J5 F9@.CYW)$<E;?F1+F@C?ET+H(PE7', [F]SJD25G7\Y8.2
MB>A9C7U:G2$>HY4A^P#U&S57J/&"\3/[KSRP?\/EAF])O(4*4=X-M 6&0:18
MD[!\1C(W-ICR[T"4G,UI5,"&N9Z'=U*IT]!"F:WY4.1AHHI6J-B$TE3D[_7F
MG>'HP33ACM\H\ZE,%W@CHBA518&]143BA2X82!AZ*2&R/N*8)O$QI."EYZ"5
M9IZLHDB"*I>+IX3@T>T32;YS>0,&GH:,)HLN.PM 14(+.-X0U#4NO :HL&31
M.0.O(;^,\(,R!1A ^*#<+05L$6'U/HF'0C=WU*##N5(IVLU=V04U@+]MH@8@
M&:JZ5KJ"8/[GVSE3T!Z.)]',.(_^P8<2LN& (BS]! -T<K0[YQF 7B1=$;A+
M@O9=SE$V0<UETJDMK<(E (ZX&*[X 42D9;=C'H(RSJ<G([(N*GQ:ND*L"B+-
M4>4<],TQ8RO7G&N=RUVUYBJ./Z0VO"P'F$=:0%YN4.-,^0PO\ZM&L"FPCJ'\
M=18CAX,RPB<5YP*;$)[.U23I&FR?]ME(9T$_H1A'@%)(N!=4E(0?Y$$D2>F=
MY\W/ENQ='IWX($.>:+(7X3,6[2OC(J((V;=*[4E,N-BD*S"NX(5Y: #GA@L]
MU]Y1:5,Q;N32<B_Y#W.V)ZX:BU#* C!2C#]*L%%0'KBJ!?(,_)I#F$MR[67?
MI4'Y.P^FK_./GELBX_]BGXO-A<O")+RK3B%/A @CQY<7-,K[X+T<.B^6@ 66
MN/!_8AZ6B/\K8>_DN>H6*9W]\/^?BQL?$L%)ETUB*BIVFWBC6=XDBMY<P^*N
MKE1=A<6=5R4L2)CO_)#?4UF3,M2(F@+F-\YCH$3Q_$ '] 28._"< LXMBW[>
M>77J2UOPMX)R#$$30V<4J0=/UQO/M8[4__DWZ)'X1"]0Y-BJV>V\+<VX=&<+
M][G8T4+"@;9$/ CD1D=A/CYX+$L*C57$*1^Y9!*=(VBN[!Q'()Q4_3?"#3!@
M2AD%)A;T_4H]XV)O/!\!#9#EC#>6#M9&&T.[;D5UVXVN>ZFIZYG!\_X&%BG?
M92]4PE1>X>7E\<YRSY0XWX/)+L0B$H>NVIL5D'XI<BDW327)JE:4H%(>Y24P
MEZ<[_!9%;@7T43R*, I%'_Z3<0K-<-S4Q QMB1R*_: %<R[968)A+%CJ9(2;
M2PX#^&B7FM0+%T8*<"&<56GB08<B*6)'>5P\02-#N6HY3_N"N](;78X%(:\5
M$8]"08.G"=R8Y)D@WD\9D!A)%$Y)+17$"KW$V71N&J,BPH%]TGBBLN$$<$(*
M HXO!E36U.8A\;4K0EG5=53\@IJJK+P,+[@@\;.%9W.[6SCK]#)B]])W@V>3
M#'Q^442GJD\6ZUH^/4_K*';-"R0D:4QC!IF5:K%,- &H+XJ'URYAJW!&LK2P
M.2BX+=K9@)>J'O#=*K..<HJY-R_>%O-NL^LYITLW+K?85VBQ,>I%OSPBION"
M2@2C._>Q!4I6!$RG7U]<XZ[6!V!FP&1K'KHH]("JJZOJZCZXKBZR.YF=!^>;
MJ7VR3?MD9LWWR6JR*\9_U#P1'8%\)= "4 =3NE+^(X</1>!+!A+D]VL2S0*T
MC\5>^%^ N!+$RV@^7LLM]1$YKL7V#KP!<C!A+G26I'E*SF(>&72%@>Z$10N(
M+ >39))DW$1Z;G,+/(^,81/H/K?6P_[62F[J1PREZ?W*)E%U9P@7\S)+)5W^
M&=F)W!?"G_ M^AV^>3EWK/*J_7P>BI4N8;Y/AED94^*EGW/?B0>XF?:SC%_@
MA@2/G4E^G\7\Q KZF*"X<A\7^IYF,0:3DN60HH%Q-G&#RSC?YRG?EIC3QOU%
MA%;SM$A2L, /"+U<&5WT@@*?S1&75PDT4T2E1,LY>$YR;U@Z@-4DYN+)%JT;
M54JBU9CRF<1M%$I<8DB\L@7()WTT,( R3$U9$'>^&T0N714,;\F$0@JPWH@V
MS7.!ZD7N2M61WV+R.*.Y#[K%=.P9RZ;XVB^Z9G68[?D^144_%$&+AR3,;#74
M-7DTI8 S#QK.@^0%?=T-DH53(*#^PPLD;<M<'-HAPPMQ4*Y6!I"#]:K<R,-:
M(X'L)H5^*KB_*1@Z'PNR?YF<GZ_7AM$"J6VQ-&"]S!?"G_5Y+E'1;BV1_+>J
M_J7]CICV JD,-9&+0@:DWGFQI8S QP,I*!+,2+G)^S%(UQ;J6:,ED;%I=,#F
M5W=4<IXWAJ@WA:-S=8C]5?<<\SZK7GVA%TK'K5A VE>2RG75?!36)Q<QX# :
MA4P:E.'N7-.A]+E+,2WLHAH;7[9Q4CP6+!L^D_N#H#VCN4,)BP!DI1,9/V#)
M0ZF>:!(BS>+<V2JOO<)(8!X+\.)Y)$2&^_D\3BL]=KRV"#,,G,)OHX2$A8&5
MT>)6&7;$#:AP)5P"0VH7P;DB!F%37"1RO,)(5L.V7^(QT#*91UW?PZI& :S
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MV\W04P'R,$&H^YZ0)5W(\8$TP?NID,>!4/_[_*;%*^QR!AVA:"80!_<^!-F
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M@0QHR:/^<79B/CA5>>45Y :8<D_LI2)FDR,QH,C<$18+2^G]QHM-I>=<Q6"
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M,[+-VG N2_6&<06.Z6B1BA4R<X6K)(S@4*BSF;= &5.&BI@%%)-/9Q$@K38
MN)+)A%9WRQ-2$61$DP3XPT9\2P(WY)M?EQZ_B\3=MRGQAT[R$'%M.]QV,RW#
M><#@W&+\H;EA.O'*?)6.04)+%#QX&X!8]%_#-$ L#PYC*UX%4Q8XT]D8EHR3
M#&I2(@E;JWKL6'XTL>[^O+C.^CT%, 3Y6^)JLPX+2)>*8<5QA.)-8EZGS&+*
MIMGDY!-U">I6(".-;@>EPP/%,+;M%X@0I'*6<>\SAG#HM872[$)-E1<MM0G4
MZF2([9?1Q-KTG'L"09.6&DQ7_8$%G)BS4RF',,\X41.,"ZLN*3"5'#HC*4H6
ML\)5$[(2@(ZDUM2GBNZ ,]*8G9Y.5"*AJTSH.EAU$VW <U\-,T4HC!R,95%5
MQS@WSBA0'F,)ZCQ^_V0:_!OOH*(CS:/7C!L96K.MR#PDM K&B:0-VH9$[81>
M 3 FS^P!DKVQ\_#@R:5SO1;SPX^P/#Z8?T(]VB^<B:C2>VXK4T(@$%,5"ZA%
MF8J.JUJ]SHDZU[@%QIC<+@)9[SO19!)O#53^FLYFDV2$\UX4AJ1+R#>7\.E%
M,OS/0$!OOY+OFVZ>/2;WAD"V#YI2PL/1JS@_G*)[=#:4WV'UYO/:ASI'9B4'
MJ"(SR-&C%X]F,$0)++N(OA&R3I,7(NV":TR."0$1R$5!F$6LL.R[O*U/2)\#
MG&2CLL+PGM5<^WR78%XB,JFMQ<FP2I$7R-Z.9DQ["P2$()IVVFV%-8:+$-\F
M@52TG&$8A1ZW:-%]"(55D-;I()N=&F)3X3J0,6TI$ A__\DFD_N[9>N+M?KR
M;A;[3GLMU.I;U30FUIB$T44S"4*V0J[:[VRB5U)D2 A0.FKQWX5G3-L,!"P@
MF_J!TZU&YFR-MRS;8A$*HH@I628DNJA"5*4*N=?_]73K@RKIEJ>7-.ZU008P
MN,I8@EC0XY::^9@B:TU,@[&\9$4]R+OPC"F>W9\56PKK:"1!'NVV[;Y+6(*W
MT@D9F9.Y,EV]8\%6#,MR#@ID06=^J(#W*I(QQ;ST?""8?3J#V(Z;X+RN^\"]
M6W2K):RFR[[_3#LK/8>R;GG5%'>W?380.6BM.9,1YT#7B &\SS@Y(@4O?<@^
M46=Y28"/*?ZFY]GCRW:PLI]+>&3A7BGN6:FQ3P]RAD X$]%**;S,1E/7?MV.
M9DQQ.SV!B*0P7/!^&1OT)S&$TAA%*B_1BZS%L%0<!A>*0Y1.B:0&C^"O0AI3
M&$_/#TIY$.\T710M5L.A;YA>.-/:NG;_E6'%EY!M,EXGZGS?'3LU#]A;C5UK
MJMK^UP*F3W'6[^FM7L?E\LMT?GAVV-@4FR0 !DW.\=80R:'_*"SC46N9,"R3
M]&>[=P$V)K_^X;RXL;E*+A.Z>I&CQ7)U?7O%:1]=Q.<[T3H[ZBPPQ B9U> A
M*L13@;H-^S8<8W+JZ<BP]XQ3'O[O#VR\1QV.I$RSUGIM,\2<8JD2V0@83:"]
M+CA$%PI+,:CB T_545?,WH5G3(XW'1?()$#K1U_ Z2[AB6B"BXPX1LLST]Q%
M%I25+>9T(F1T"02U9;P=S9C\:#H^$,T^X0[I)WSV8OFE;_<NBX6:,O.Z.N2C
M0"KJ9J1<5CAOU4OR$N/+SQ^39TPG\0?/,.$.!YS$:5EW*S\O9Q9!08R5U5)M
MJ_D*+( *S&:)4@HU>O*@>2N0\>UL44A]_SE_RH;:Z,;^,EO\1=:M=/N7/T*K
M[.T#(>I>VG0W/J"_D N_[=67/[H6^)[?J/$RKZ:?^L@7USW74H;$M "U3ND7
MY1EW'.D@BL^2NH'C[NAH>Q]7K[TJ+F.0DW'II-"2@WWB.G*9J[&@-/U0[]?[
M^+$"S($8<G<KY/L(@# /=[*$/.TG!?\]@]59FOGE<2M5_U?_^D0&Y8(-E:G2
M/)RV5YP"2!RC==D9C(<4_1F]K^,:4Q3Z2(PA%Q?E?2:MOR;\#&?_/YC?2"GB
MV%W*T0HEF:JM 4$C>N358"#%I:E6QPC4SLM.P$;5]_21N$0O,<+<5US"*\14
M6B<]= _.B"UX#6"Y8$J8BAHRMQ.LHA47!U=JE498:FN\'<F88MQ'8@N!2$A:
MQ>QXMR_RUF4/&(9;+1$8M":M!95@SDJ;*AU7U_>Q][EQ>4PA\,"$&$H( UJB
M/GES/OYU6]^S@E5A54V2>6Z;<A.9I:0Q9E1%:8B^W>,TN#FZ#=T] ^SOU":1
MR(XV";MET)N ]3R(G0B+FL]D=,*@;9,:WNZU"86%#/B.\QS\( 7(NX ;4SGJ
M(Q%K&,'1G6"*TWD+ M_.+^\]M;.<@-XZ<[4&)+9SS">5F=%!):[ %/+VLEN!
M[,(7_YUIHOTE0DJ.KF$!1//F<QODZ;0[:HC>UE9Y. $1<:PR,:/:?4S2919]
MT,P*GK(J+@GR0N>O@MJ%-.$[) V=I"@O.=LV^E^F\SC/5T</.45=*J#'5G *
MC$9\( L37IMBA,[T13:[HR,X,I(!2G_CYKOXI5_2ORR6O6W8-ADQ6P!K+2LR
MX61$M <^0<4AN+/M(+#4%W#<$^(WD#3=EV5;#I\,)D3*PTGG(,_+2GH%D*I&
M%5(3$]IJIGFL+'*P#$KFF9LB7:5.L]\*YAM(H [)GH<+AHPG[^%D3>&W]?)9
M@HGQU04%A;4+S!H:CFA*?SE%-+*""9G:HM^&Y5O(C5+3A$0N=-KD0LTAL--E
M/L+0^&V]?#&1 ^>LS(FAJL-HV+>CM\%HQKV H+Q44E&'"E]'=<\TZ7?!'&)9
MD7,(_=!-2^!)"5D[FQR3-4>,9GSH;\!C$+PJ*?D2%+E_<Q/&/7.GWQ5+'BJ-
M01R5@ZX[;1?'7E-Y[1Y[H3UG2N2,N&1F25;$Y7VU5B+:3!T2?!W5F*J/GL!U
M(1#5T-'E6=KDZO"YQ* ZYLJ\=$AQKR2+1G,6(M<^J!R+I+92NZ,C]?GC#&6S
MM:"\HI\0,"9A'EK/MF B"T4)EDS 0"47I2VYI=X)V3<02^[+J3NC 1J1D1OL
MCXOU;MM6:. ESZ@X&(:TK8]_Z[90364B)JZ4XU)4\FK078"-ZHKAQV(3N<2&
MR4?T1&]V8W4#FM' @V4J@FXM1Q-+7AG$5T6R1;=V3H.KIBW QG3$Y,DTT[X"
M&R(:O8RR3\!MFX::BRVN)E:,]DR#*2S&4IFV5BGK7,F)O!?/_2!^"W'J4,IJ
M""D.9P.W+0*!EEE:GUB-7C'-M6EW,AL&-?M0M*TI4U>G[H+K6PAK![> ^\J+
MI&3LW3H+\]5R)73O$H]1,#3%:)ISNP(8H3(9G.!>H5;-U\Y>;ZT9V_5YWT*!
M#Q5#!I/#<+KFU6DWG4/;R^WO;>Z/BJ_KWB8RRJ!,U,RW!@O:FG9]EO4,PVYN
M=(E).SFTSKD#WST+?+YI9@TNO^$8AE-23MOHU[U5)[R5&*CD6:ZQ76:K(DNQ
MBM;+P[6Z!"CD]8A?!?4M%/\,SJ6])$5W.P,._5JK"M2@J^4TMX-T9ZTLKKYP
MZ9/O8#E=E)L%ENM>OF\^HVZ>'\+[N((WM4)>35+)LEH9F:FM$D;C#":'@:NO
M/OO4YM"27_CPJ"/<^VK;_EO>ULO?_':^UQ@F HHJHFIFC6H-U'V;;RN0MLYS
MX\!%\NX. PQC3+G$$:^:&U?S/C&AGJ+BK'*KBM1M#T1@8-E*;7T&SB0HKKR)
MW 3J.[$>6G'VM!4RWQ"/!Q+_4VQ9@=:B8LS!C"SJK"8TMGODP.7B98G!1.IK
M;AZZ9?6TB=%OGY[[BG]H>FZK5M:A6A7 8ZA<$].J_Y=0S'&>>74VZ43=+NZA
M#0J>]ICDMT_/?<4_7&.2/DCJINT[NK/X:!-HQWFY?#E:A]*"\C.LXG3VD"8E
M#WS0W@U+* 9(U+QDD]5XO3A.:$X;I/>0%X?SZ;^0) 79.JW3>'Y=RP;GYJJ6
ME]OPMN-T4&15N+"8\\HQ79QCJ4B.K W.!V&T$M0%IP,-95_M^T!86^%<OSVG
MWU[YB,KB_.H<B#9970T3NEV,%J1GJ8;6C#<%"SZ85*F#[$<=X)@BP3&LG>O*
M?KQL(W-G*(>X:5%QM4/QI(4)EBO-P"C>=B<E\U%%)@J:1*\--^3'EH8?U:AJ
M:+[WM4- K%$NF+5K>SDC9'&" ;AFP9G(=.6!)=.N%ZXJ&P&Z^E$OEILC&E,8
M_+VODSWY1+*A3SF>2S>:76MY'Z2QCF.L[Z!=:NAR8-%'S:2"HDO1-L2OQ2N/
M!G9,D?:85L XV4)_\6W-^/AB"CY.:J:]4"S&E%@HVH1H8]6">M?H/@[^8[4^
M&A/U]I+1@+F:-O*#XY,X7;8M[C[E=9I7I\OI_#"NKQ?Z<-)Z#,Y>'\7E(71[
MI&L>_*S],S8TPR1*VEQY_ =8K69]KQGDVP7$/MW7+GGJ)DHI+1QZF=8B7;3&
M'\DDA>YGNU&S0"KD71+OAW#O_G[P"9;M_-+K1;?JQ 3')9S+CG%C$GH006-8
MFBTK.<08DJS64R>?KD$84YIB0+;<Z.JWAR!HVOE=7:?KM=B4-@)K2GCK6IUH
MK[1N*0S%*S"=4BN_21;!"E]52,;ZNH-O]K"GCVE3^!&X\DAB&L[DK;>=X^Q@
MWB:KK^PZVZ99U/?3[L_?XCP>]M-VZ0,/MWI[/6YOPT<WV#UM7Z/-STB.3[&5
MS5UZV*:SUH5G-HFBA.RB96"X9)ISI BZ6DSJ=CMQ5@DUSP[+><?'T35K^V6Q
MQ$4^/[LF('_9^OS?%ZN?H<-/M6[W+[O_A'*(2_72!R;29TA0 JM-WVKE#8NN
M1J94XM(8'3WYB5#B(8S!>@[%M]L;PSV^]&G[6+9&ODLX:E>+-LR;1O2;EH@-
M*UR:O%GL.@R?<B^$5U!Q]!_CYXD0*1?@D0F5,#:JU;.8,< I%:+.#GPEOVF8
M#OTH4NR/Q=PG$CI=^7-?9'$P_V.^A#AKTW%I+:)GTE_6=W.%B8F7W.OB4ZOV
M;\7:I6+XCM%\*4[C.\D&1UUB^%"L8TAE/Q8?'T6>C\*^?M64 YS-@ZO(04Q2
M\4KV5RU+W_H4&\Z2U/W)[Q!Y29EG:NO^0*AC2"*/@7M4TGS<B.8<Z:)N>YLV
MGMGQ88-$,P\9*%$>;]-LY_)Q5F.Y\RAV9E1$4VA;1]>,EM$FRY44UECRR_>V
MP*"YI7W+\-J%,25 ZW,,[>+G&EA0VC,C30I1XJI3U+;S-BQCB#*HF+#]?O8]
MYY_,UK7=W=67#Y!/E_U6R#^GJZ/%Z>H]Q#*=8:#3CG3CTDLS.%^,+X_;?:F3
MG"48CX/FQ0:F@Q;,6\0<1:HA!N]3)#^^]%"P8\KC4?/I<21(=^'Q)]39/9K%
MLK4[N0#>^II=_';IMGOG6WSL*I.^W?I0'>),"!9]P,(=AB'B^F']_:]!OC?*
M,;CS0U%L8)D-ILQ^^?3[=&*"5V"+9,EF]-[:W9XIULQ :"F\L$I(ZK+;;3C&
MX'(_E@JZ][P_KO_\>C%?+6->G<;9;W%USF1*K_G.1PSB*^\^*"(/>5>E, %=
MHVO76Z(?@T202(006E.A6HL),CE)WNI@5VS#&K,+.32;/)V_G</_A[@\-\,3
M83"2Y!I#3!,RTT)8YB, <R"$SA"5(K_@>3_$8_++!^'?_2P?J8 ?R<.ZP/RR
MHFN(D#\>+1>GAT>_3#_UZ"^B[DFHVJ/:MRT.:?V;6@-#SPLKVAL;HHI)4R>T
MR,"/R>4?%55IQ?XTK&V@U_@_POP:_ H"XQHMF5 <PYIL,O.M]Z9U&$-;C>/1
MU&D:,O!CBB+&QUHRL3\-:V]BSE&8*'QA CWBEEGF+"D#+%=OG"S@1:5.N>V'
M>$Q1S/CXN9^ APN"WL-JNNPK@5[!'.JT10O')XMYBQL6]7=8G9UZG^;UVZU$
M\.'QT#Y/VSLT(ALJ493T,SYD#F7]M'>S.-^.8>)X3MI#9,HDP[3#(#QEJ1C4
ME(QURFI!W6=P5VS[*LF;S_D RT_3LU+4B>*I-2U*C&>KSNZ5]E*V*0C<:).-
M4=1GU.X$-*889Q#V7%=Q=.(A,ZLW(1W,4;]"=S;:I#(O,E26DM--H2OF4S:,
M2U."UEDE1WV;S=V(QA1L/!%G'BR@ 4GSYO,)M!XO:!1.EQB=M]?671UKM:8F
ME]KN/@Y>5(7N )?,:ZND"S;E3-WLZ3[X1G43VQ,QBDAZ _+KY?%BN9K^JY_#
MM_4=3LCRDNI\O80R74V$%!8"<%:\\DQK;5BT7#!005O07.@PO'W;!>F8?/LG
MHARY0(<D7\OU+Z=QMBEG.C@^1GQQ!>O"J5YT%^[OP2U3N!Y5EL[79"U.GP.F
M3<TL1&-Q7J/0 G+4COI&D*''-*J^_$_%Z*=CR7#Q[%WES2_?OCYX>.RZZS?O
M':<^: A$,>E=S^X;J/=UW\%%B0)FL6\F*W)B$1TW%FJ.L5CI*_E=@+O@&O(X
MQ%G1^_52^(LIL:'@Y/<WH=2"H5#P+*0 +/FJ(D0^0"7!'G#'%,>2,^X^!QXH
MQ4IX'?15..U&GI<YGQXW(:V[3VP9S]D)I+6"/A^!=\)FF3R3->9VSPIG4>;,
M2M60("7%,_6.!R7^41S->32J/IGD![;'B.D,:8O;YJUWZEY&^+:OH[&\.X$E
M,K>_+^:+34/7*P^=!*&"K"!:.R6+WE3*S+OL&7<.L@XE<D^=\[T5#(EAO7VH
M(EE72JSHQ@:%7JU0+&$$SYP7U?" ;BUY[_>[$8W)/-(P9*M-I)$(F=G;9 DW
M(&RQE1?I6"TFMU@:6%"6LRI+Q)#"F2"H+=<U"*,R/L,089])'[0V=Q.33G@!
M44O!2%<";V$EFM*,/W0MR2J0/D;JA/Y=>,94A3$,)<BD0:@9-K7(9Z/<D'9B
MK1)%>,N$+NB>"VZ8SPF8<1)$"59E;\E5Q'8L8\J0#J4J"*1 >3O")A5U-;/5
MK<?ZOC4UZN*LW:/3O_#F\[I1_^6T[2:W-9&R*!%U8JH=<]'*%Q9$#BPK8ZI(
M!IR@5C/$0QA52G,8"CZET.G:-:(N[9HRA>[M_,WG-D.GT^ZH+:RWM54.3;2/
MF1N;VF5-"8UP$2P6 /3&%+=)Z<@=M>?S55#WO*;T&R07K5QVC*C7K[<?*7;P
MC[_]#U!+ P04    "  %6F%5U"7#1DA?  "F_@, %    &QL>2TR,#(R,#DS
M,%]D968N>&UL[+U;=UM'DB;Z/K_"Q^?UA)WW2ZVNGB5+=K5J;$DCJ:JGY@4K
M+Y$DND! #8"R6+_^1(($KP"Y >0&2=!=O6B"I'9^&5_LS(C(R(A_^Y_?3D;?
M?<7I;#@9__E[_@/[_CL<ITD>CH_^_/W?/O\"[OO_^>__XW_\V_\#\']^^OCK
M=V\FZ?0$Q_/O7D\QS#%_]_MP?OS=?V:<_?.[,IV<?/>?D^D_AU\#P+\O_M'K
MR9>SZ?#H>/Z=8$+<_NWT3[P8R93)$*P-H(Q&")@5\))MEI)+Z\+_=_2G8K4N
MP7I CQF4- R<2PQ\,D([6U@L>O'0T7#\SS_5+S',\#N:W'BV^/CG[X_G\R]_
M^O''WW___8=O<3KZ83(]^E$P)G]<_O7W%W_^[<[?_RX7?\V]]S\N?GOYI[/A
MJC^DQ_(?_\]OOWY*QW@28#B>S<,X70U P^?YY3^\CD;_>/Y+^M/9\$^SQ;__
M=9+"?$'/@U/X;NU?U$^P_#.H/P(N0/(?OLWR]__^/[[[[EQR89JFDQ%^Q/+=
MQ;=_^_CV+M+A>/YC'I[\>/$W/X;1B! OGC _^X)__GXV//DRPN7/CJ=8UJ)?
M3KF"TA7._UN?]N/.F(X)R#2=1@3Z*8ZK@C?$N.KINV.^?!9D+.%T-&^(^.ZS
MF^*=G(1A2P'?>70#M(L'P0F>1)RVA'KCN==P+D'>1E@?.1J.1F<_I,G)CPML
MKR>T"'\(1_@P+OIW4!=3YB5;C'_U;Z^-320/Q\.Z;OQ*'R\>4(?: @5^F^,X
M8_[^NV'^\_=#9353Z*,T(:K 2A E,V]31,LX,V)P]9B*9XEH-$DWGCJJZ]KD
MDHA1B#A:_'20<3A8;C1OQV4R/0D7$\&W<SR9#8R1,1J?(06O046K(7IF(>J4
MHG!9*V7NDCE;*L<,TP]'DZ\_TC@_5DG6;Q8B/:?S@='/I;S;K#[3WPXT"XZC
M\^",Y[2I!0&.QP@Q9)%3$28JWV06=;2;J*^TX]5TB?_B-=GR/:J;?P_LS2<-
MA'?.#,'__KO)-./TS]^S%B3^[],PG>-T=/81OTRF\X$M1@FG!5B6:5[))/#H
M+"3#4\;DDE.E"9^W!CX@:G<1Z5V6>9-7=1IH'ZK3O,"D2O$Y"D\@= &EM"%;
M% 4(GU3R.6F969O7]M;(!\3S3D*]2[1H0?0'G XG^>=Q?D..S8 01%.$ R5H
M7BHZ!J&0(F;O!"9,)3O7A.4;PQX0Q=N+\RZ_<A=^?Q[/A_.S7X8C?'=:93'@
MB7&/(H,1A8%B#FGK$(ETC5Q.8;+16>Q$[>T1#X#5G81XEU"U.Z$?\6@XF],Z
M,G\73G!@DJ*5@[8&J3A-+$L/002$Q&/60FAF<;=5>=6H!T/L#L*\2Z[>G=RW
MXS29TL:PF.2G.:T@KR>GX_GT[/4DXR"2BED9"A2.I'LB)(BD=% T<X:EP*U*
M#;B^%\3!4-].U'<UP>RN"9_#M[>99CXLP_,PV,7ZDZVPRL<,J-& ,@0Q>,-)
M3TT07(1")F(#'5@S_,&PWT*\=WFWN_/^*N<ISF87_ZG3Y0./F3-!5@,B(5.*
M!8B2FQH/EM9Q'[1KL7&O&/I@^-Y5K'>Y=LVX?DW?OI]^GOP^'F"TP1BR+D+6
M9"[R["&Z;"'$[$1R40L?VS%]-?"A\;RE2.^R[)NQO-ABWD\_3"=?A^.$@Z <
MJ5_TX(.7-$_MP)MB("8F@W0,,Y/MJ+XU^J'QO8MP5\1/=@J3W0#V83*;A]'_
M'7Y96!4I\^AYH;EJ'4@7C0#/HX3"=%52DSS?+7Z[?NQ#8WQ[P:[@>Z> 65UK
M7DTQ+("X[$-"<@J54#0WG@2X$$G[BO9"ALA0AYT8OC[: 7"ZM?!6L+A3-*R>
M-H\^'$_&2T>?65&4BP(D"@[*)0G11@/:YQR9=2G&W4XI;H]X &SN),05C.X4
M__J$Z71*ZL5%_#R<CVA3R$R4R!4$9++F7%2SGK2-+ 3F& _:N[P3H[='/ !&
M=Q+B"D9W"H!]GH::H//I["1.1O4D+'GI"]@L1#7L:'NO']%&RQU9\%KO9D#=
M&.X N-Q>?"N(W"G8M=2JG[^EXS ^PD7PK7#M3/$(-D0%JB@"Y$. DI@+5O"4
M4IO7\_JH!T#KSL)<P6Z# -;KT^F4IGI^SE75CDSTT]G DUDN>6)0"" H&QE$
MV@M([9B20CI)FMC !%X]^@&PW4RX*UAO$+YZ.Y[C-*3Y\"N^"?-P@9. !;+'
M&0)+UIV'6EQV$JR.I*5.T_:R(@MIB\CUJM$/AO4&PEW!>H- 5CT?F[XF%_QH
M,CT;:.MI-O5@S.0$RDM%6FAH9U&R(-?H<K*-SADO!ST8CK<7Y0IJ&T2O/IV$
MT>BGTQE-;S8;%,F2("Q08B$_6PE2M<@$I!P\HK!,-@E@W!CT8*C=7I0K,C\:
MA*A^/L'I$6T>?YE.?I\?OYZ<? EC4CE,3#H,P+&F+<1$!KY6 @J/UF@GLM M
MENJ5@Q\,U;N+=@7E.T6I+E3P&$>C)1QK46G)&0BK:'%ABH&SS #SF$.A_Z/Y
MMGB9KXUY, 1O+<@5O.X4M[JP!R<G)_44>Y+^^>DX3''V_G1>+U]4?V^0O1'9
M8;4/"EF%2==+),&#I37&2Z,*S;V%R7T/AH/AO9F@5^C!3M&N5S3A7"?]RR@<
M#7AP*$RT9"AD6FE0<O",' $C@E=D-6B=U4Z4WQCN -C=7GPKB-PIR+6<WB_#
M60JC?V"8_D(_F0VLR#H;GH#QFIMD4(,3A9-1:"*F;)STNSG.:P8^ ');B'0%
MS3N%P&YB.D\:/4?EBXZ!)0DHBP3E8H&@1 'C2^8%I2Z^33K]G:$/CNIMQ;J"
M[!81,<(U#:.WXXS?_A>>#8P+F%-FD&Q-\B_&@./2@+$T^<R-Y:I%6L^M80^
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M:$W26D.-4(!P42;'F6;>/#_JMRK#UI[Y383;3QFV)%7"X! T"XK,;E8@9DF
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MD9%M4Y!.9!V8:=&_>.7@!VT3MA%YZXH4%SC^-IY]P30L0\P7BMX%5,L;(NN
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M0&Z&2$X2)">S5@Z-;=Y_;G.4+UF_>N:TAY:=5ZODK0W<F91L-0&+IVU;D5Z
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M%#B> _@0L]:<95KEGK4R/."M[%,7-I%U+Y[K.2#,KV87&*\\M.5!@Y*,NR3
M1=KEE/2<T%D&10:;7/8:>?N;Q@_">K0$F!TYO./ MB6@!]>%=LE\B7)9;-LD
M&ME9\,:39<QSAA@2)PE$96)1V:G6)<]7P#@0'=A5P'VF%=S?0$2C4"1V6@AY
M+<A=NS]&A>14DU<=;8BZ-,^9?BF]I!JE0K5BKV&MJ#LH.[4-Z +VCUY2+1G?
MJ>'/-G0]?B\I882SW()"5GLM1X*?L$!TTCMZYR1B;\O9<^\EM3_5VH2E/?>2
M2K4EK1<,F%*$SQ0$7R0#6U?SZ)0HS:L:/.=>4IL0N4$OJ4U8V',OJ>RE\5K3
M-NY8K<IAU?D5%Y^+R+3)DW_Y1R^IWA1D&Q;VW$LJ"^YIG@DP%TU^A/,0HS&0
M2DA92I9\Z:V=X3/L)=580;9A86V(OUU)Q+=C^A8_AV^X0\'#%0_9M9SA0[AN
M%2NL1_NJ2"Y4[>@74G36\<1MBNB*=&FPXGF['L%?//"RL$@Z^_6R(D01%JV6
M!6BSJ!>,@J%EP-$7';R4DLLH6K?FNA?0SNF3I6 Z3[*X&&5YICD<G];RHU\N
MZJG,!D'Z& 0ZL+F^.):$$)R1-68AT'!F0O-]J#NZ_:\Z[?3D3LYD/YST8+:L
MDL%Y*$(I*85($4QTBZ6V@+.%['L=D59:H25KGZVR!LR^:L_TIQ%MY/S8M6%F
MT_G@TYQ4N3[D4\)QF XGY\<D5B9K7 *-P8-*BV,21R:XY\&Z['/N5K"51KBF
M*?3I2DO6#OY88;]&G$Y:RK:AX;H =('C;^/9%TS#,L2\-,(Z@-HD,O<0\>N
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M4+).//LH?/-A7[M17;QH=&) !VUUDP 31/K+4J8C'1WG),B T6I0.=<(B?/
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M(P.]2I[X:85/I8IWW-'W^)FM/F7EJJA6BKIJ!/,#SD@"I3EL1I)Q2 .?0"]
ME"&F39[ REE[>HBY<415_&4G8J]:$4> M".'R^ 9F10<D>EQJ'Q*^<$.DP\&
MF/@0^92"AX?')Z_L]VF_N]<S*3]E?\L*29?I/Z78[9:VE6?^0XJ[-+O;#5SZ
M"R)\*8.(0<&C "+""=0#A# 2B!))L%": )R<'7U%F9\_Y(-2DJ_JQ-RTR1H
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M4N4"$2HCD?@P3&(%4:2-P82%/F0AD4F,J$+,R1@\.^+<:*?5+V8KXT4GPD=
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MFYW>R847)V;J-3]*@;29J7]*M-D):2BD'W,9R,BI++K]T'.CT%J^ER5-+RF
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M3U.(J?M 8G/*CF%,J0\CQ&.B:!(S05VHY=1 <V.51D[0$K3G*=M):.U(8PC
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M9@Z]2A,77?5E-T6B3">_$BC]RG\2FJ2K%MM5S% )WE0: =_QT+=K"NS,C8&
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M,35%UC?;4^ZIR$N8#Y&'$42^PI F0D 5A8KZ7B)4%+DPC>W <V.<]EY4:1W
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MBK[Y@([\Q;W@P8=_K/47^(M<W>?B.A/5P4>KQV)CP7&?ZFVSHMH>1J'IR1%
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M$AA1'>)N.Q ];ZX,A-/(!/ "(BTI,*(V_N&K"J\^ <L=P#G$+P\#X$0VSQ!
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M/ Q)XG1*:#_VW+BQ$=U$J+1J>/XBJ1&Y1_$!AUFP/%@<!]NQCQO/P3H@:UR
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M6Y9KRY\I"J#^J-,,\;3(K)9ZSQA36^G[N@&5G)$1-"HE=:^K< IG_RH/!-+
MB]P#'Z_""AT(W%18X?29HQ=6Z%#J4F&%KDO]''P3*:";Q\_KU?>YD.*GEU\W
M4GQ87HAN[LL%("ABI2 'B3)5%]), !)+I/]9Q 5.<2RP4^31782I4<,^>E^?
M6;P4XW<+"WA,BUVL8%BP!Z88+7RU4]*('[&7Z(W1()HO?[@(^R!E(/Q!#!1[
M\!!@U("$/T"G48H;GG1CQ/.7^5)^T#]N9JFI@0>% +R0B3GED0$JX@P44$ N
M.4H)=&R%?#K$U BM5<?1R!B50OI&-@] .H8SO> 9.F;AAHQ_!/-,^=!AR\,
MKQ.K/%.P,T!Y?J5[V<N6;[2@\Z?-N_GF:;[17/)Q5V9MQ6FJB%0,9"B/ 6)0
M II(#!A+XX)CE MJU:[$8JRI+?9*JK*Q;RFNR>JMY+6O^7@-WOZ5'QBTT:(9
M=U$E:[07]BZJQ V'G'W9S( (CE0_\R8DG4IJ6F+34UOSVA-&*[)IJ4J[VJ;M
M+>ZT>O^=SA=FQUFMUB:)^JODNW5ICM&EJ#:6#K]Z_X^/'[Y(NIC_CQ1_+3>$
M",4LA0ID(B?:DV3FM#Y.@8 *IRH5,DZL,IMOEF1JE-S(%CVL5YM-]*!%W$2F
MY;K)4[?GEMMFYSIGCX;YP(R^UZ/,:BDK#AWD+M.&ZJWKPV_OHO?_ !\_W$7[
MJ3(ZC34U]A^%T:9HI$_&\%/E]%T) F_/5^>VYX_V30H"0_N+%>:!GB'1U7*?
M]5R=9J[[)LXHR[DB1'^J1$)-S8?8)#!D($DADE"1!"'45)>QC'UVC66U]([+
MR@S\32JS7O_\)YS$\5^6<GMGRL@8@7]HNM)&;SZNMC**71,KN_%.4(QP(J7V
MPDQM0<J8=LI2JLV%-$E%@1*4IOMJ/M?[_PX!^K<1FO]>13X4WI8AY)O@&RE2
MW)*Q*5;QIA8SX+'NJU"$BO=VCC-N6/>:NF?1VZLW^%'T>SI?_X,N=O*GE_V/
M?YOK@=;\\>47^5VC8-(G1:+_D\809*GI-TG-H4EB?DJ+ D&:QP19[5*[#3LU
M9\*(&I6R1GMA2TOIX_T_O')6+=&W8Y/PF Y,+;? Z4PP;N@$8AO+04>E'C<@
M3GG(\6[/G2-9'F#\JUSJ!R_,,7+Q-%_.S:[4=OY]_Y&-$T:4R9)/9&Z:%D@"
M&"+:J($4$HZARAS;HUD-.S52^CM=_U.:S\)=M*D4J"I*T"/A'7><["; <A<J
M.*Q#[TPU,-8B5W4FCH2.?KYB+[IO5SFA%&H+RV[0<;>UG( XV^IRN]N/G\PQ
MK;>KI5ET<LFUWURU'$1YEC$*$="N5@:09-JIU:X&2--,I3E%$MOM?/4/,S7^
M,5)&1V+Z]6_L -6.8VZ':NBM+G>4G"FD'X1 E-$QR*@4T:_H*25<N=KS1'$3
M5GM?A=7>2;8]Q-%:I53^:O8=?EVNZZB:$>8G$XN3W^@?LR1G6!:" <PT3R"9
M2L (9/HG',=9*E"!I=/1XQ!238U@#F+6FS@+_5^N:8!AYLN.C$:?A8&YR\A_
MM NP5Q!H88%1\>ZHSFFI5]2:M^I<,RMUB[1R 8\VA\0ZU!GH(#*->U@Z)(QG
MIZJ#/MR[&8]ID]D4(DP+P@CG0&:QYEULJDV33/\S(3*6!6()=0IG'3U]:OQI
M<GV?Z_ZJ:^VA+W>.WN Q=G8<Z(W(P%S6-)H-7RWKHL;A^MNTGCUV'YMSM2[T
MJ[EPD7>MEFLUD>LW$>(TYXSF&B_M:J$4)8 I(4'"%6&(%H5,K3K2.H\\M14^
M0.4^ZTFP-(F&@'9@JBCK\9U6W_M,JY:8X8OMN2(4KF"+Y;AC5V]Q@^-"*1?'
M!_C1U87GFLW[;_*/[4]:H7_.D$@93E0*:!*;OMD, <9$!F!J&FG3%!7$*2IT
M;<"ID5-/TX,WAI@<<QRNXFU'2"%1')B'>J"+RCR1WXS442EV0$*R12@0#UT=
M;E3ZL57^E'6L[W-/$"[746UHE;DR]0=8QESD><%!J@@%*(NA.4 .0<%%C&1&
MLU1:U=OL&6.2E&*?(=J%7#]3!,)C8'*HV+46\2XJA;QNG5A#9)\>&P"JD1)?
M_2!S2F:] D9/FFK7G:,EH%X1O9U:>NU2ST@-?2G;FWY;U9W)ZA$TH58-TF<I
M3+#D, 62)0E E I .!< %PSF*6<J(<HM>?3JF%:O\:A)I&54IVY-6!;H?%Z;
M!+%ME4$CM1;/O;5O/;&WC/X$P7.DB% MJ_'N:FFC@[A1)6_ ,)$M-*%"1U?'
M&S><9*O^68C)^D;_VCS?UG19M5?](I]7:U.@0R8HP1043"KMNV4%8(4TQ?8(
MDDP5,*%6^W-]@TS-N-I7GSD(&E62NE?G.0.TGSY"P33T?I@[0E[U>;H@N*E
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M=2J[K*T[O;FV<VZF,8,#&T3F6-/)<6VM7GV@X"ZR.NR]!R(Z5CIJM![V@-1
MDQ/^1%5H05_K"-9 @/><V1IJ1'?G]JU^'F6KJG[0_7JMUU*Y ?AE_O"XW=PO
MQ2>VJ&O";SY+O4B7VQEF.!:%]F4S*3* &&;:HI ,9#D4D,&L4-*Z!X;'^%/[
M7ARI$-&##G?1NM2B-/Q7!SWNHN=*$_H@HS>[YVB[LCPFYCMCUQWA@>=A8-8_
MGH+[]A1\.4Q!2X6HUF%8V.W]WX'A'\G[?2<W?#U_;O)T+K_]T6ZIJ2G:/LJ(
M=ZT<O43F^X^PIL!HN=I&B_G3W'S0MZL(-"LHVCS2M=071]]-^^+=IJD!40W+
M5YOM8;GIR^KOMZ3KI7Z2%G,M*ROAF9K#!7H8N?DQC!M^PY3V..$^3QW-!;]!
MY;8#?LMC/-UO\5^[.G_BV^J+-*K.%[+\2IM#CN;K_&WEVFA1IBK+32)?+&(*
M4)QD ,.$:S\\R;,\IXAQ[.2!#2#DU+ZE+1W-.M]K63K?]>%@_7N;1IK_U]$]
M&^(5L'3,7GEBAW;)+.:T/O#=3.TK]^T<<D)"N6%#B#BN S8@R&>NUY!C^7UR
MJI&_T3_JHJT_R:54\^TL9ACGJ%!FRU!_-3 E *M<@8)B7N"<PH(Y%>_J&&=J
MQ-]P._U#K^FJ04CA6#NC"]$T8XDD&0,\S[6[6H@"L%AFH$ %CHL,8LYH<Z!6
MOQ+#PWI\DK89<CALM901J^0+@ZC=9RW FS?PEZE^Z0P^/S>]:6HI S;_N()#
MH ]"URBC<OH554]I^=KE;LRZ66]G7^5#&5*3JX<U?7Z<<[IXMWHRK= 2Q7&:
M%A2D:9IK<I4,$,X4$ 064,DD%]BJG%KO*%-CU;:$T6^5C);IC_UH]C- ,(P&
M7O]N\%@O?"OU^Y:]?D!KR>M_'99[_[-'6>Q6ZC5+W>YBST8:_%&*W4)^4ET1
M Q,L* /GE_]<GK_5IIP))%1YO5D",YIC!)32GCI*> X8I P@B@M(DT1F@CHU
MW0@NXM0HIC/T6J6[M/Y=5:;9/M)E='R35T'] 2;?SJQYW2E]K4!ZN-ET[QTR
M&."A^HR$%W#<GB2# 7S6OV2XD?P^(>^DDNNU\?1K2_27.67S1>GH:\=LI@A.
M4J0X$%1I;SS5#B033 "4*4P5S!"2A<OWX,IX4R/W1ESCET>+@ZAN5'T-9#O>
M#0C=P"2Z1ZWE7[:$O3.!SW#T:(E+(*Z[-MJHQ&6I^BD+V=[F78N_3!]];])'
M'U?K[3>Y?C)Y1S.)%4Q-@24H,J2-2R4!A8P!3BD1B.4HBW/'NOR71YH:C9A
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MR 7RXEU'']6U]X3FU-_W?8R[-76?_!@GF2G$L'FWD_^^6\HT@2FLOY88)U1
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M.=WT_/$.086 X>B05) '^I:I>WI:+;]N5_R?_Z"+G9SEBB=,) C$&9$ D5@
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M-KT&A(G$[I4LKVJK&95Z1K\93:-25<? 4MB7P([D7FUJ!R;'5YE59WH=!/U
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M=M_\_/M\(3?;U5(VY[W>TN?YM@J;W6\^++=ZRN=[1JHWNU("<4PH!7E,3?5
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M$4SB.'$J/=,WV-2LDTK6(]8Q[85:+/.@)=>.G"$;N7%TY'IAU^:D+&0B05Q
M"1 5"<"0):"0)$%Y@@G)'.L&W@S\J$4;3';!?/E=;K9EXN.;$N@?H@IHTR%.
MGLZ-ISO=.PMV7G2H5WI@&ZQ^F]M6V/M_@(\?[B(C;)W7$; SG@4JH5K<]0TU
M;J\Z"Z7/FL[9W..9?59^'IKB544<IVF<4,WB* =(*@(H4C'(%>)448:T1SO;
MKK9T8<<H1T]WXN[]&,.][=_,&/OZ BY^XV7P[*C &Y*!UWXEUQ 5NRXI'"H?
MZ^C9XV9;75+K+)?JXD6^94HW\X>E^;#>;_XFQ4-9V*6I0%COA&<,LDP6&&2P
MT.N7%0)@GFO_![&4H23E6>K80NWJF%.SR XBZR4=U4*W*FRZ%B:]#KK=N@\,
MY>#1F'X4!\A0<  H6$G2ZR..7)'4&H+S@J3VM_KQSS?ZA]Q\IB_M8I<X%Q1F
M$ *DA#8:,H0 02H'F&BBT=:#RG+LPC<7QI@:O]0YSELC:?1<B>K&*9> M..0
M&^$9F#-*Z:):O $,B1[M Q'"I1%&)8 >%4\7?-^E[IMC5>N#IZ?=<K58/;PT
M18RTS8^2+ 6T2 5 (F;ZIR(!*=.Z09Q(A:PWL2Z.,+7%71UJF.^EM-\4N S@
M]>V>FV$9>%'7_4[V GJD8%^&QGY?XV:(1MI_<(?*:5^@%X:>^/WE^T:+L_>*
MW8Z']U]X6\?!5G[3+_H7'[;R:3/CJ"A@0A&@2"" I,A-:])$&R\""BES2'#F
MTS_PTF!3([I+R7[1;T;<J)37,;.R%V<[VR84>@/SH3]PWLWT^A )W!KOXE"O
MTNBN3^FNMG6]][@1B)#SV<_+K8FZ/M'%HAEA!B$E(I84Q*GD *6YIHM$QH P
MGD%6I 6TLX@ZGC\UFJA$C$H9]PG"=M30A6 _&P3 9>@]$B=(K!?]%<4OK/.-
MY#\^K+[_F[ZS6N+ZA\/*[GK>*(OYBC+-^KUVF=\W_SV=K\M<P9^T#4'-!GG9
M_IQNYIO[/^:;&4U(P9@I<B],NY0<:_<FBSF(\X+"#*>4)TZ?_2OC36U)MV2,
M2B&CWXR8CA_\:R#;??,#0C?PJG=&S?EK;XE%H _^M=%&_>9;JG[ZV;>][=9#
M71_E]B>YE&J^?;O:;#?E 8E#NU-*(*5,* !13#6=%!!0(AD@LJ!8"D8(=>I"
M;CGNU&BE?9+(9,"87@/&-#:I^&NYG:^EC!XE76P?(U8I=>BWP;5ZOB>Y^B?'
MCH8&@'Q@.FJC;?)@:J&C4NKZC%8T2/]91ZR"G]+J'_65#F=90=%])LON]EL.
MGY?'KO?],C_+]=='NI;OZNZK,Y:D..6Q!#(1,4!)E@'*BA@414P*P1)1%%;E
MOEP&G1J!'76FW3>F-6F_T<;(;>@J$JN%_O7F\%NOP^M79L..M$)C/#!CM<__
MWT5[B<O,_*@46O_V6C=@SU/O=B %/0=_9<A7.!EO!\+EL_*6]][HKU7),K4I
M)SXMOYA\M_5\^5":=(>/.N$LYP0R$*<I!H@6.6","9#"A))$I3F3T,N!LQ1@
M:LSU=??T1-<O$9?KK4G35%J?JK1&-%^:+'!:'7#PR7!SGAQ'QV\ R <F,B-Z
M=7STKCXY%#7BFZ3CO0*-FSB@+>:+8F@?TG;XUW$J'<'I]#)=G^/32RA/LE:?
MCGVQ*HZQ*.(8*(490$6F !.$ 1$GG*88)QA;50OJ&6-JG!;_J,4\:?[B4!2M
M"\E^=@J$S\ $= 1-W4O(IS):Y]OFT$OH9JQ&ZR5T ;-0+81Z0>AM(73YSA%;
M"/6*?MQ"J/]2WY3F]?Q[>9JM)%?]?/T6T,7]DVDY/,MB!67"<E!(*  BE&C:
MRP4@(L\3C'+(A%-DK7>TJ1'@0=C*;KN+EK6\$2T%=LUC[D/:SF@+AM_ !-F"
M[KZ"KA$UNN^'SB-GV0*28-G*?6.-G*=LH?9YAK+-33=T$V\Z.G[8'PK<S%B:
MPY01"/(,YN9L*M0<$G.0Q23F>0SS.$[<:@QU#>6R ,8I*U2?YGN2V\>5:!V5
M='0!.[&U8XT0> U,&%7BWJ'#Z@<+J/R:6/?@$+)]]:5AQF]<W:/LQ9;5?=>[
M.U-O/_WCP[N8W"^W<[82<[EI6EM(F$"9*L 3Q4WM10D(2R1(N&)<*$4PD[;.
M5,<84[,E2C%!3"*Z%]3>3>C"\;HK%0"=H8/2#3 '&3T<J2Z$[!VI $B-Y$A=
M0"R,&W4%@AXWJNO.T=RH*Z*WW:AKE[K3W$_SU=_I>K[\_$C73WK.=MLYIXL/
M2]Z\A*+(8R$QX"Q3 $$2 U:(&-",$:I-H((3JV"YQ5A3H[U&W.A87M.EHKM4
MCS/ UWDP(&P#\V$/8AZ\>/75M.;'@ B.Q),]2(;A2TM(>GCSVA-&XT]+5=H\
M:GN+>])W763C)4[8M_EV(6<)I:K 1 &I)QT@+A@P)8U @F*:9 HC1JRZD5QZ
M^-08LQ3*Y!3%R1OV0U,'QO(4W$7T^MGQ5DP&ID-7.)R2O;OT]LKT/GO8:&G>
M76JT<[P[K[DU,_.=5/.E%'7RU&<]>9M#6;1-76L_+CB2<0)88O(S69$#6F0<
M"(Z@R*3*69SXY6=:C#ZU!=[.&ZS%W^<.E@JT:F=N;BVR;S,[=C&DP3 ?F$#"
MPGU#KJ8#;,$S-FW&?J6\30=8NK,W71[B&=U>/]#E_']*D_7M:KE9+>:B_,?]
M4GS68S3F["?U?KZD2SZGBWWCV)8LAR0=D1/&,($@8<J4"5(,,)0CD#*J!$LE
M5IF533.4@%.CS2J51R_BMC)E:ON'I^>%W/L353KV[]%>R^B><[.]8?*!M,9+
M0=?=V8WCS+UEU/X59W3H:']+M;OH2+ER2H_F6$_H83(/&K9X6]/V$+E=0TU
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M'<XK1:T##.!NK/[\]$#U@"^?M5V\W/ZBAWXHO^6U+:%R7&3Z?0=$$9.GPC+
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MI?U0].V5=MPYWF9IO^A'NZ57+O4S0FI_;_.9OIC(_=NZ9D">0Q$358 TA0E
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M5A0 )9@ DN4$T)SS5"">PL3)<>D=;6JTT]2LXBM77Z4?5%O[(A!4@QL9YU7
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M3-=FW]N9I//UTX-,,Y)(K(""A:8U_4]0Y$R!G$M.."(\1M;5\B^4Y=J(;EM
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M/B?*@'8V"Y!#F'+($,ND54'9XZ&O[3W32>=:4O( L.&W@3\,(S-\)Y@'6Q^
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M%0BUB?PN;_2<'#$+3'K\LKZ[)W/3+%38]=IL+K^XG5%[=O @,<YE@@A@0L8
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M0&QXH3"3,F<8X Y9-M"HGHS,^7(M15/X^IY^E]7'C4_VD,H$4I2D("4I ;A
M&# %"Y 6 HH4LCCE3BF;?9-=&YMN:ZZ638WYE9$W>J(O9JD<2;4/9$O*# 3=
MR(38BMG5Y:\%O8FVH@8D,0M 0E%4WU33$I"%TD?T8G./QX'^MHO-8JY?8;5#
M^%D^R_FZZTM(<T0YUVZ;I@I#'PD&E)C ;2P93Y#@-!,/SW+)%E8'_8,3NCP'
MN]..>.J[*W/]HE_4^Q'+1FR'0_%AM(?WN\(B.#*3'$/7;.6T\OH$%@QCZ!!N
M$!3+J8(0+L74+3K!&J*^F(7A0::+9+!6:"^^P?XNSS8CB^63&5X:<_%H8[=
M2A)8%$ J@@'.6 (8)0PHS'(B4T@E=RJ:W3O;M1EQ&V'K>MD[1P^.74)Z$;8S
MX(+A-CKO=I =.+<C9,M881*J;4?O7-,VY[!1^Z@%A]5-WK4?%D_2,-3\L;$3
MWWU_DO-*;HJZQ"A3/$\Y2+EA$5+D@$AMSXF$"9)2A1+LQ"*#,UX;D^P*W'DW
MKUJ9?_*NN#,,O!VY!(5S9(*Y&$F?DA%VZ(0K(#$PW]3E).S4/U%<PO)&SQ::
MBQ<Z6[V\?EQ*V77Z[5ZJ2*6")#$$19IG ,M, "94!A"%F/."<&X7(F$QU[51
M32MJM)&U[C3M:++T86O'*8$0&YE-SH U@K%B@4>H[HX],TW;K7%8Y:/NBQ:W
MN*?VOINO2CVH$/JK4[5_?2CG$CW$<8Y$BE(@8:%,<0#-$W&6@D+%(A$9%IA(
MV]S>L[-<&T,T@D:MB#?=#Y$1-KJ;.R3XG@>VGR2"P34R/7@CY93F.XB$5Y[O
M^5$G2_0=5&PWTW?X8L_RH^?:M"ZJZIY^?Z!I1F*:QH"(NDI=IO1/"0<)TA00
M8REB/5B79>M07[1_6JLO^4&*[P34\$;.I2I7T2O96=2F$M7>$1;=G#RO%NU^
M--]KJMQ>_6I69V"6IA.N8R'1@16S,T!"+,"4(9HG.U,W::PWYB0L8$U/.V1"
M5>L<F&W:.IQVJA]5V+2\S;-FWG+!I135+UK<KFC2+XME/6E;L7/^^)JORN=Z
MS^8!,\H@E^8X3#* B<@ RU-L3M@%R@H"4>Q4T<AQ_FLS9YK'1W6"1G0CJ4=:
MFNM:V''1B B/S$V=Y$W/[%>;4FWZM?!3>_RS42#::A"P/)L?=*$JM#G./FV1
M-C]HCNJT>0[C>]PTKS=__KM<?7V[KE::19==H.C+ Z$RSUC.@1*Q )BC I X
MY8!@3(N,IKE,J-V9O]5\UWCDWXCK'[3=#W"6Q2R7B@,IJ6F"RYC&5A& 1,)8
MD0A.D97#&QS>2;;&-IT/^<@PVQ[J!0)O]$.]%JT_M:!1)^E-M)$UY)F>!23!
MSO3ZYIKX3,]"[>,S/9N;W&.SNCJ=VN!EFO^[LO*ED$T4POV2SBLEETLI/J[-
MUMR=,J+HYTJ_.NJHTL_EX]=5]4!%D>"XB('D, 4X1PHP$6MKE:1)#N,T)YEU
MH9900ET;)^TI$:VV6FCCM=:C+C.\T21Z-JI$RUH7^^"E8$O:3VP_:J%&YK].
MI6A'IZ9+QW;E[G=7KE$LNE/15K4FAC_Z_*-6SCXX[4>LX$0A;!.NI%.P6VC(
M>T+B@DTU6>!<:'!VP^N"C^U9>NC;$RV738/[PTHC[^="*FVVKN2L?);BN$I.
MPA.I(&= Q0D$.,DR0#-* 64H9HGVGPK,G$H272#,M;U>=XKM4*- 5&Z4<ZQ7
M=,D*V;D#4^$^\MMRJX8Q74Y4.]KJ CX89<8N?10 UE ED2X19=I220% .RJA
M%&),-WZMEBNSOR76?'6W_"*7SR67K[^7U0-*4$8@P2"-,PYPG!% <9X F6 L
ML4Q3B1,;SCPWP;7Q8"MCDRW:B!G];@2U##D\"V0_M86 9_P=;E=DK"EH2/T^
M6M'W[E"*_M>63LX..PE%#"G5/?:#U[GO3+Q&29YVK=-CF*&N(E(B\A06',0X
M0Z;"!P<,TQ0@JK!*J=*?6NUJ]LQQ;0\T^EF+^1]1+6@DM#MB1+5W*\\A.>S?
M!\!GY"=Z#YK;%AJ/C*]S&-E[T@&PFL@Q/HE9&-]V (0>5_7<G9-YG@.B[SJ2
M0Y>ZVRWOULO%4Y=:B 1)%<(QB#D4FN&*U-@K!6 2J8S0K! ILK57=@>^-EIK
M9+.W2?9 &K9%?%4?F;$:L0)&'9_3]0*#8V^XR0R-4TKL&A@G/_<\F9[1JKI3
M7U8+_L?MPIP4/C $"97Z@<N0]@VP2/4#1[6_D.<9E9++@BDK+^'\%-?V_-42
M&K^]EC'ZO9'2,2_I!)*6!Z(7X3/V*:@C-.YGGV>U#W7@>3S!M*><9Q4\.MH\
M?Z7?PWUK=A>D:.-;/^F%-<E(?"7%9[E:+^=W<_.[9B_B(>8\E:9Q-6%8ZI=M
M3 $Q=6R*U)1<QCEE&+KUI769WNHK/VE?VD[6:%D+&RWFT9.^H-E1=8R;<%H(
M.]8(#NY4U;]JL:,NYMH(>1-ML&YD[QK9:,C-Y^T>:CC.\<$N$!LY33TI3_F
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M'XV^(Y$S=TYW)-(O^MZ1R,"EGF5?Y*I<UL4AC -UKP>IXQ#BA,I,T02H!'*
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M=Z^>S"L_(>*N0W[J8S]+O#L^-.<EFN#6W$2/S!]KPIN9FO=O%]6JVI[ZI8+
M6'OB0.0H!YB35/OH:0IRSG.4(9RC%+OXZ([S7QL[[9Z^\L6WI\7<O!+,OU;Z
M:ZN9?_DH*VTDFY>!MH[*^5%[U)MHN:MX8U MZAR8ZDGRDLZZ8=S,:=>%M;.'
M1URNT<]+=N1MK=9:XJ@6>=3C74_4 MF/KK-/:@!Z0G-HP?D.XYN]]%:: YN9
M::?Z_?_(EX>"Q8055(%,4:QI42G 4I0 K*A02@@A"ZL#W[,S7!OQM;DWK91U
MK^'OD9;3-4OI$,A^&@H"S\A$XXR,1S;2&>TOR$(Z'''B[*,S"AUG'9V[T+<B
M_[.F"_,:UO[:XIOL"H<_,%QD&1,9X A!@"&&@* < OU@2U@(DJ4P<VM-=&XJ
MJV_NI&V(-I7IRUI0US+]9Q"ULR\N0FFJPOV=B%$CH]G&:J0,6<._'X=@Q?S/
M3#-Q5?]^98_+^P]<[QO<54E]D]GLN97/<K9X,E.T/00^+68E?WD@!=4:2@52
M)#4O4$$!X1D&D$H68QFGO"!N@5V#<U[;F[\3N;:A=X3N&EE4]0>O^?];ETMI
M]GW!I^6"RZJ*SM[YZOVGSW^AWY[^>OO3X6?Z#?IK.=.+JSTK1P_(9CWM6"GP
M*HWOZ?0NT$W4B!S]WOX]BL_C@%FP&+'A&2>.#[.&X#@VS/Y6]VWD-^N7W[Z(
MQ6Q&EU_D;/8/^D3UTR7_1W99ORA)4,J3!!3*F#\HQH 0P0'!J,@5ATH@JR(,
M-I-=&[]I>:/??O[R<W1;RUQ%1NJH$SO2<MOOR X"/;Q%'1*^D8FG1NY+U A[
M#)O'CO8@?O;;W"%QG&CO^V(\G7;%;0'JV2H?'&*R_7-;978WU:WO\2)<TT';
M#/M;U?!*^P5.%12*BQ1((@G VGX$%&8$D%P1*K V*HEU(ZFSLUPCQ1I)6V[=
M95LG;CB#J16I7H[4!&QJA&PQJEJ$_%CT#%).]'DY8M.E:.XGN^M?_$F79J?_
MV[>R<=U7B\@ ++< =T0;C$W[\>JGT3/W3LF?_>(?$.? Q9Y1@F8HMEC62>NO
METL31F$6;]N9<WM\!44F&4LA2.(X!5CF*:!",RI+<HY0+#F33G4Y'.:^-G;=
M$7TQ;[SQIJ;>CAJNL7D.*V'G4H^$[\B<O"?U+IX[_7NCWT?QIST "Q5_YC#S
MM,%C[I <17YY#.'G;[?$:$C2D&7[ L[BE$N!..!9G@"<:&^;Y04&64)I3'/&
M&;$NSGQVEFLCJ-,>=FT0NKF&IS&U\ZDO1FH*9WIC]&T0\G2B3R/EYCU?C-B/
M-O_XD?EWX%T;:S"<,]V+UX 7??K>2=WG7O$/_>;^B_W,OP^+JC*)L:7FY#DO
M9?7FY:,I;B3OU/;7+W7_3)R3A$F>@T(5!< ":0=:%AE J4A9*A1+4J=C&?NI
MKXU;C>31CHQ1([=7LU*'!; S^L:!=60B]D34V<!S!R>0?><P\:3FG3L@A]:=
MQPB^ 6&W"U-_[0'FF>!QEFN_$V* <Y& HD 4B!0AHN($\9BYQ8$U U\;S;1!
M3K\WTEGRRA%:_:QQ"08C<X*M^AZA7?NZ7A#1U0XT<2#7OOC'\5L'G[L_;F]-
M3ZZEI&\70CY(4N!8_P<DAPA@"AD@4,4 <YCD1:[BV*X;^>' U_:X&=DB(UQD
MI+-_VO; &G[:?"$8>]?%3GNGA^V4JEX/V]Y DSULI\3??=A.?NYGAK\V"0O5
MIIY2K-($98*"A$L)L'[2 $6< X9('C-<Y! [F=K[PU_;@]=(YV8V'P!F9QK[
MPS#RP]<(-DHIJ=,Z![)J#P:?U'(]K=BA=7KF*M](YL/\TWK/_^Y)FKW-^>-;
M^E2NZ.RC7#T0BG-ERA^D$NN79I$@0#F!@ N><*&*C.>;V.9[^P?97@*K;_=^
MR//]!,]Z<TC29.N:G*UHT8G>)&TU1RFSDK)R5JY*TYAH+E<FUXN:8,>JW)ZW
M"%-E69L[VM5P) ^'=;0CEL#+,E6,]5&Q +,@S0IM1(]>;Y?EP^ZR:&5"AF*[
M A@L.-MZXHG#M5T!.0[@=A[!]P3YFXF8K#><ZURP5;D\.-_9O*>+ B8*HA00
M3F3M00 F* ()92A+TP23U"KFT6/N:[-ZMK)&;^1<JM+. +AX">P8;21@1Z8T
M3TP]SHF=T0EV3FP_\\3GQ,Z0')\3NP_A>^HQ?]3/^+=;R5;W>HAVJTS&"J;U
MU@9A)B([9X (2(#D'"J2(2Z@5;6/_FFNC8B,E,"(&1DY;R(CJ>.FXP"NM@<7
MEZ(U^B&%!NK>%2B/,XH^'(*=1YR<9.*SASY%C\\9>J^^H(.N&?&+Y*:CB[9L
MNZXK*1$BSRA(\U1I2X5E@!))@:*<(2@Q3A*G&AQG9[HV.FCL_VHCI4?[W).
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M(VU68 Y88LR*C.0TUCZ^(M"C>H'-W%;/P_1U"W8R2TW?V5:1J#+VGB.96*V
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M'\UG9_-P\0'K RNRX*\NE^>S^?COF&]^YNK:DH]BD5QD4:>/VMJEP"@Z88H
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MW:?#^BCPZ+30$J3$5&^]$:)B#*Q.17K#'8NM.V3O0U>_1K=_]-Q]>M):E0.
MY_U;@S=K0JZD_"E\Q<7(T,EC.*<C2#%)3$D*R420P&5R4<L<<G-?>R_"^K6F
M@P-H>V4.I^#V3V$\7521XN+=].>O57J7X\7YE6__!N-RE*/1F?L(VE9WOK
M(6L#.;'"70@YF-9M0YXDJM^<SN  VE:)PP'G \5LB==$?Q!@I*^S0PL'[V,
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M1Y+6.F]YS9%V3F?-/&3$ "K7UFG&!K RYA2C,DYT";+=5 WR?N,YT-9 20.
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M1<Y/$M5D>N?U/EK];KW"KO-9&R]%G=H75P\?91% ^\="=):S$)+RLK4]/HC
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M:$!R'DHA7X+3UO2"W&)R4)ROS:<=:]TSZ5&"7D8._A"T[#,][SA]-"QFZ<!
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MO2<0'*JU65,1C@T"SH6^9D'S3597=AJ%DX!1ISKI5D (18",T0BK4Y!REVG
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ML=@TBGF$K5Q[)$O-(=DZ/ 1%!E?(2&S4)*<8LL'6);<[DC9V]^J!(#:$8CK
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M%=8!'O?JBJU\*2X4!9AYS5C("#YG#M*ZH.HOM6F=4]*\@?FX_?2/0>)@JNH
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M,<E$ :Y2KC4]'LA*! 0>F$R2%=?\=7,[)2^_H/!X3[Z!CKI$VMH6 _-9BE2
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M8,"4(GY,0?!%,K#5I*-3HKC!TH5>^#3'?4"PQS3'?332*;@VLP.SE\9K3>>
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MI3;O(_4.H#-P#J!33!I1..B\*K,SLI:[5/\R:^VRIX"K]>[V,R>+-H#<\^:
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M1[2IE+X4S7737Z&*$YD!':JZ5CW7%S&*D;)'[ZPGGR^VSAMZB)9QW?BAX=-
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M+3(P,C(P.3,P7V1E9BYX;6Q02P$"% ,4    "  &6F%5CX;1@P?L  "SBPD
M%               @ $0R00 ;&QY+3(P,C(P.3,P7VQA8BYX;6Q02P$"% ,4
M    "  &6F%5,.%8PUV)  !V% 8 %               @ %)M04 ;&QY+3(P
D,C(P.3,P7W!R92YX;6Q02P4&      P # !( P  V#X&

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
